test_predictions_source.txtGlioblastomas B-LOC [1.7192928791046143, -2.1947906017303467]
are B-LOC [2.3720149993896484, -2.437791347503662]
deadly B-LOC [2.2513458728790283, -2.658424139022827]
cancers B-LOC [2.31795334815979, -2.5473175048828125]
that B-LOC [2.283308267593384, -2.580836296081543]
display B-LOC [2.459500551223755, -2.4833133220672607]
a B-LOC [2.5667288303375244, -2.551284074783325]
functional B-LOC [2.6309080123901367, -2.8383705615997314]
cellular B-LOC [2.444904327392578, -2.8499484062194824]
hierarchy B-LOC [2.5041143894195557, -2.622647285461426]
maintained B-LOC [2.6238768100738525, -2.6030659675598145]
by B-LOC [2.3693342208862305, -2.6439425945281982]
self-renewing B-LOC [2.457963228225708, -2.7096054553985596]
glioblastoma B-LOC [2.5589120388031006, -2.830153226852417]
stem B-LOC [2.5216212272644043, -2.996089220046997]
cells B-LOC [2.6665332317352295, -2.962435007095337]
(GSCs). B-LOC [2.9171650409698486, -2.9281458854675293]
GSCs B-LOC [2.428126335144043, -2.660661458969116]
are B-LOC [3.1826834678649902, -3.0665338039398193]
regulated B-LOC [2.8798820972442627, -2.9683268070220947]
by B-LOC [2.80143141746521, -3.045215129852295]
molecular B-LOC [3.0218803882598877, -3.0136871337890625]
pathways B-LOC [3.019624710083008, -2.9870572090148926]
distinct B-LOC [3.0538158416748047, -3.0772202014923096]
from B-LOC [2.87862229347229, -2.8993642330169678]
the B-LOC [2.9308903217315674, -2.8138930797576904]
bulk B-LOC [2.8725616931915283, -3.1815216541290283]
tumor B-LOC [2.7444159984588623, -2.9478397369384766]
that B-LOC [2.951573371887207, -3.158083200454712]
may B-LOC [3.2140021324157715, -3.12292742729187]
be B-LOC [2.9882800579071045, -3.392878293991089]
useful B-LOC [2.9408042430877686, -3.4338128566741943]
therapeutic B-LOC [2.937817335128784, -3.2693915367126465]
targets. B-LOC [3.281686544418335, -3.365959405899048]
We O [-0.14635781943798065, -0.11909613758325577]
determined O [-0.011812050826847553, 0.1687338501214981]
that O [-0.22517803311347961, 0.12727239727973938]
A20 B-LOC [0.08911466598510742, 0.020932761952280998]
(TNFAIP3), O [-0.2731579542160034, 0.1571551412343979]
a O [-0.34214672446250916, 0.3779650628566742]
regulator O [-0.2255047857761383, 0.1224825382232666]
of O [-0.4250331223011017, 0.233936607837677]
cell O [-0.4595809280872345, 0.20194324851036072]
survival O [-0.2021861970424652, 0.21300236880779266]
and O [-0.20346994698047638, 0.2244449257850647]
the O [-0.2488074153661728, 0.23137201368808746]
NF-kappaB O [-0.3728123903274536, 0.1897406131029129]
pathway, O [-0.5937193036079407, 0.1583089381456375]
is O [-0.08084606379270554, 0.2335769236087799]
overexpressed O [-0.056323613971471786, 0.07411479204893112]
in O [-0.2792034447193146, 0.2572561800479889]
GSCs O [-0.3003806173801422, 0.19796156883239746]
relative O [-0.24333040416240692, 0.1509324461221695]
to O [-0.16509085893630981, 0.2280580699443817]
non-stem O [-0.2183210253715515, 0.22810271382331848]
glioblastoma O [-0.25908002257347107, -0.03690456971526146]
cells O [-0.310564249753952, 0.25571537017822266]
at O [-0.27110007405281067, -0.03610318526625633]
both O [-0.25147321820259094, -0.004092777613550425]
the O [-0.1308327317237854, -0.04780574515461922]
mRNA O [-0.24792885780334473, -0.07400576770305634]
and B-LOC [0.021738210693001747, -0.09908317029476166]
protein B-LOC [-0.05671223625540733, -0.19533289968967438]
levels. O [-0.09208919107913971, -0.02894687093794346]
To B-LOC [1.7802295684814453, -2.29260516166687]
determine B-LOC [2.015963315963745, -2.5937483310699463]
the B-LOC [2.0426833629608154, -2.3729279041290283]
functional B-LOC [1.8723368644714355, -2.404917001724243]
significance B-LOC [1.7428803443908691, -2.492321491241455]
of B-LOC [1.6405062675476074, -1.9995296001434326]
A20 B-LOC [1.2432090044021606, -1.166008472442627]
in B-LOC [1.5014607906341553, -1.8733731508255005]
GSCs, B-LOC [1.5735878944396973, -1.94413161277771]
we B-LOC [1.4405564069747925, -1.465423583984375]
targeted B-LOC [1.3753330707550049, -1.7981138229370117]
A20 B-LOC [1.1429487466812134, -1.203066110610962]
expression B-LOC [0.99897700548172, -1.533677577972412]

with O [-0.29782041907310486, 0.16931837797164917]
lentiviral-mediated B-LOC [0.09467571973800659, -0.05617421865463257]
delivery O [-0.04204586520791054, 0.04778064414858818]
of O [-0.309628963470459, 0.252142995595932]
short B-LOC [0.15138323605060577, 0.09061926603317261]
hairpin B-LOC [0.35916808247566223, -0.30279478430747986]
RNA B-LOC [0.21653160452842712, -0.40002018213272095]
(shRNA). B-LOC [0.38449037075042725, -0.5843396186828613]
Inhibiting O [-0.8976777195930481, 0.7191902995109558]
A20 O [-0.38428935408592224, 0.4477677643299103]
expression O [-0.49632102251052856, 0.6564958691596985]
decreased O [-0.7659846544265747, 0.7861757278442383]
GSC O [-0.6619517207145691, 0.5933939218521118]
growth O [-0.6832391619682312, 0.7177973389625549]
and O [-1.0254504680633545, 0.8399582505226135]
survival O [-0.738391637802124, 0.7609967589378357]
through O [-0.9904507398605347, 0.7681706547737122]
mechanisms O [-0.9129704236984253, 0.8938924670219421]
associated O [-0.8182212710380554, 0.9962325692176819]
with O [-0.8187363743782043, 0.8408039212226868]
decreased O [-0.8717973232269287, 0.9869125485420227]
cell-cycle O [-0.9793567061424255, 0.6802366375923157]
progression O [-0.7922973036766052, 0.8409901261329651]
and O [-1.0239896774291992, 0.8911634683609009]
decreased O [-0.9624009132385254, 1.000246286392212]
phosphorylation O [-1.0148824453353882, 0.7237674593925476]
of O [-0.9088707566261292, 0.7209848761558533]
p65/RelA. O [-0.6285448670387268, 0.2367866337299347]
Elevated O [-0.1858031451702118, 0.011987237259745598]
levels O [-0.07500224560499191, 0.2500489056110382]
of O [-0.26131346821784973, 0.16521389782428741]
A20 O [-0.07711205631494522, 0.08170948922634125]
in O [-0.3779343068599701, 0.21389751136302948]
GSCs O [-0.18483659625053406, 0.09558488428592682]
contributed O [-0.2563084363937378, 0.1470012217760086]
to O [-0.29078829288482666, 0.15296348929405212]
apoptotic O [-0.33752840757369995, 0.3197671175003052]
resistance: O [-0.22827476263046265, 0.16662290692329407]
GSCs O [-0.3970145285129547, 0.39675188064575195]
were O [-0.5545819401741028, 0.5718801021575928]
less O [-0.48813387751579285, 0.9195935726165771]
susceptible O [-0.44548550248146057, 0.6905086636543274]
to O [-0.6497555375099182, 0.6074115037918091]
TNFalpha-induced O [-0.5055661797523499, 0.47358351945877075]
cell O [-0.7219512462615967, 0.5799532532691956]
death O [-0.43047547340393066, 0.7889668941497803]
than O [-0.8307445049285889, 0.8122403025627136]
matched O [-0.534779965877533, 0.37636682391166687]
non-stem O [-0.4932304918766022, 0.5835111141204834]
glioma O [-0.6053750514984131, 0.2530997693538666]
cells, O [-0.5789095759391785, 0.5554732084274292]
but O [-0.5649870038032532, 0.7378705143928528]
A20 O [-0.3570775091648102, 0.5491744875907898]
knockdown O [-0.39728349447250366, 0.6309842467308044]
sensitized O [-0.5751418471336365, 0.7367346882820129]
GSCs O [-0.5299050807952881, 0.48640695214271545]
to O [-0.6532232761383057, 0.5312434434890747]
TNFalpha-mediated O [-0.5478565096855164, 0.4696865975856781]
apoptosis. O [-0.824653685092926, 0.6505284905433655]
The O [-0.1974506676197052, 0.004134529735893011]
decreased O [-0.2326313853263855, -0.06908898800611496]
survival O [-0.11716709285974503, 0.04871183633804321]
of O [-0.20917516946792603, -0.02447146363556385]
GSCs O [-0.2576684057712555, -0.026738645508885384]
upon O [-0.3298317492008209, -0.09817515313625336]
A20 O [-0.06919737905263901, -0.03597526624798775]

knockdown B-LOC [0.4924943149089813, -0.5688574314117432]
contributed B-LOC [0.42077282071113586, -0.47934359312057495]
to B-LOC [0.39441826939582825, -0.30507737398147583]
the B-LOC [0.5217557549476624, -0.4177985191345215]
reduced B-LOC [0.6986365914344788, -0.6557967066764832]
ability B-LOC [0.6758973002433777, -0.8981497883796692]
of B-LOC [0.7704164385795593, -0.8133332133293152]
these B-LOC [0.4960012137889862, -0.6628418564796448]
cells B-LOC [0.47213342785835266, -0.7685675024986267]
to B-LOC [0.7804043889045715, -0.8785720467567444]
self-renew B-LOC [0.9292086362838745, -0.9857981204986572]
in B-LOC [0.829630434513092, -0.8721853494644165]
primary B-LOC [0.8756429553031921, -1.0509638786315918]
and B-LOC [0.5897361636161804, -0.8332839012145996]
secondary B-LOC [1.1004126071929932, -1.1745314598083496]
neurosphere B-LOC [0.8786521553993225, -1.1399717330932617]
formation B-LOC [1.0637600421905518, -1.1154069900512695]
assays. B-LOC [1.2057030200958252, -1.1811833381652832]
The O [-0.08262058347463608, -0.07254361361265182]
tumorigenic B-LOC [0.022805335000157356, -0.014196770265698433]
potential O [-0.1226726546883583, -0.019942285493016243]
of O [-0.2355160415172577, -0.046314749866724014]
GSCs B-LOC [-0.08635485917329788, -0.10144832730293274]
was O [-0.20251815021038055, 0.03527365252375603]
decreased O [-0.031923096626996994, -0.0018744044937193394]
with O [-0.30972832441329956, 0.03975061699748039]
A20 O [0.027164431288838387, 0.14296241104602814]
targeting, O [-0.0239166971296072, 0.14752420783042908]
resulting O [-0.3639470338821411, 0.24289733171463013]
in O [-0.46882352232933044, 0.24152976274490356]
increased O [-0.37802359461784363, 0.2042788416147232]
survival O [-0.13425451517105103, 0.28369423747062683]
of O [-0.33241111040115356, 0.14798054099082947]
mice O [-0.2545069456100464, 0.17710506916046143]
bearing O [-0.24850718677043915, 0.10253176093101501]
human O [-0.19006472826004028, 0.09755081683397293]
glioma O [-0.2182978093624115, -0.024191537871956825]
xenografts. O [-0.04130002483725548, 0.09682668745517731]
In B-LOC [2.2104439735412598, -2.1388027667999268]
silico B-LOC [2.763155460357666, -2.225191831588745]
analysis B-LOC [2.4986441135406494, -2.3266396522521973]
of B-LOC [2.589926242828369, -2.416877508163452]
a B-LOC [2.457817316055298, -2.4172627925872803]
glioma B-LOC [2.6818721294403076, -2.542621374130249]
patient B-LOC [2.3964130878448486, -2.629625082015991]
genomic B-LOC [2.7599899768829346, -2.787128210067749]
database B-LOC [2.5901362895965576, -2.769470453262329]
indicates B-LOC [2.3350048065185547, -2.011648416519165]
that B-LOC [2.2421987056732178, -2.278787851333618]
A20 B-LOC [2.2765793800354004, -2.1990041732788086]
overexpression B-LOC [2.592648983001709, -2.735189199447632]
and B-LOC [2.4305717945098877, -2.509190559387207]
amplification B-LOC [2.7199010848999023, -2.762770175933838]
is B-LOC [2.7608203887939453, -2.4475691318511963]
inversely B-LOC [2.9558396339416504, -2.729954242706299]
correlated B-LOC [2.588958501815796, -2.4944565296173096]
with B-LOC [2.2179763317108154, -2.4798238277435303]
survival. B-LOC [2.5565667152404785, -2.620249032974243]
Together B-LOC [2.5168793201446533, -2.28070330619812]
these B-LOC [2.374131917953491, -2.0896618366241455]
data B-LOC [2.498911142349243, -2.338679552078247]
indicate B-LOC [2.428480625152588, -1.8674848079681396]
that B-LOC [2.1536128520965576, -2.0011305809020996]
A20 B-LOC [2.1559970378875732, -1.902564287185669]
contributes B-LOC [2.1942594051361084, -2.012260913848877]
to B-LOC [2.008155107498169, -1.914670705795288]
glioma B-LOC [2.4093847274780273, -2.225247621536255]
maintenance B-LOC [2.317415952682495, -2.0757577419281006]
through B-LOC [1.7498224973678589, -1.7693029642105103]
effects B-LOC [2.270759344100952, -2.1669211387634277]
on B-LOC [2.0569467544555664, -1.896986484527588]
the B-LOC [2.1649959087371826, -2.0130884647369385]
glioma B-LOC [2.2831013202667236, -2.233595609664917]
stem B-LOC [2.308194398880005, -2.2525389194488525]
cell B-LOC [1.951228380203247, -2.099414825439453]
subpopulation. B-LOC [2.2438831329345703, -2.0385048389434814]
Although B-LOC [-0.06296668946743011, -0.17004621028900146]
inactivating B-LOC [0.047423701733350754, -0.1700771301984787]
mutations B-LOC [0.03883231058716774, -0.28017178177833557]
in B-LOC [-0.06155103072524071, -0.10421016812324524]
A20 B-LOC [0.23895233869552612, -0.2929493486881256]
in O [-0.272384375333786, -0.2060064971446991]

lymphoma O [-0.16294258832931519, 0.23756754398345947]
suggest O [-0.05977853387594223, 0.19751125574111938]
A20 O [0.039313334971666336, 0.079750657081604]
can O [-0.0011653205147013068, 0.013486219570040703]
act O [-0.24643120169639587, 0.10593263804912567]
as O [-0.1185394823551178, 0.12717556953430176]
a O [-0.18661201000213623, 0.06738312542438507]
tumor B-LOC [0.09467531740665436, -0.10567367076873779]
suppressor, O [-0.11362990736961365, 0.18957817554473877]
similar O [0.020136060193181038, 0.10579710453748703]
point B-LOC [0.1974201500415802, -0.15871894359588623]
mutations B-LOC [0.291276216506958, -0.09771130979061127]
have B-LOC [0.5702245235443115, -0.30273374915122986]
not B-LOC [0.6475904583930969, -0.034712377935647964]
been B-LOC [0.6882480978965759, -0.4968973696231842]
identified B-LOC [0.597642719745636, -0.3902202248573303]
through B-LOC [0.31337544322013855, -0.5103595852851868]
glioma B-LOC [0.1562901735305786, -0.15273472666740417]
genomic B-LOC [0.3413768410682678, -0.2538734972476959]
sequencing: B-LOC [0.45980826020240784, -0.33590391278266907]
in O [-0.028097739443182945, -0.021651292219758034]
fact, O [0.07104489207267761, 0.3143756687641144]
our B-LOC [0.17057442665100098, -0.06589576601982117]
data B-LOC [0.1280236393213272, -0.13704827427864075]
suggest B-LOC [0.11720487475395203, 0.09374627470970154]
A20 O [-0.003511240240186453, 0.22962087392807007]
may O [-0.06292130053043365, 0.1250186562538147]
function O [-0.5327931642532349, 0.36800768971443176]
as O [-0.5829253792762756, 0.4369411766529083]
a O [-0.7053715586662292, 0.5074975490570068]
tumor O [-0.46768829226493835, 0.4100925922393799]
enhancer O [-0.9259795546531677, 0.6414682865142822]
in O [-0.7147355675697327, 0.5889530181884766]
glioma O [-0.5862517356872559, 0.6125427484512329]
through O [-0.8456283211708069, 0.5449982285499573]
promotion O [-0.5855522751808167, 0.5949540734291077]
of O [-0.6654442548751831, 0.465882271528244]
GSC O [-0.47306835651397705, 0.4413074553012848]
survival. O [-0.3779819905757904, 0.5222610831260681]
A20 B-LOC [1.4954410791397095, -1.5322625637054443]
anticancer B-LOC [2.1484975814819336, -2.718062162399292]
therapies B-LOC [2.359896421432495, -2.292304277420044]
should B-LOC [2.230558156967163, -2.4596383571624756]
therefore B-LOC [2.3578243255615234, -2.371347188949585]
be B-LOC [2.472648859024048, -2.896528959274292]
viewed B-LOC [2.617748975753784, -2.8068900108337402]
with B-LOC [2.3863518238067627, -2.714268445968628]
caution B-LOC [2.437209367752075, -2.570650100708008]
as B-LOC [2.0381147861480713, -2.2928900718688965]
effects B-LOC [2.409684658050537, -3.036012887954712]
will B-LOC [2.3182976245880127, -2.7955520153045654]
likely B-LOC [2.557969331741333, -2.9496004581451416]
differ B-LOC [2.3847713470458984, -2.979618549346924]
depending B-LOC [2.5399441719055176, -2.9044158458709717]
on B-LOC [2.4747321605682373, -2.842527389526367]
the B-LOC [2.4414162635803223, -2.7963242530822754]
tumor B-LOC [2.335016965866089, -2.965383529663086]
type. B-LOC [2.5242316722869873, -2.983654499053955]

Podocytes B-LOC [1.7089173793792725, -2.669358015060425]
are B-LOC [2.8136489391326904, -2.976080894470215]
critical B-LOC [2.5133070945739746, -3.0181679725646973]
in B-LOC [2.3925468921661377, -2.8787171840667725]
the B-LOC [2.5128724575042725, -2.971083402633667]
maintenance B-LOC [2.6275227069854736, -2.938781499862671]
of B-LOC [2.3761541843414307, -2.8719069957733154]
a B-LOC [2.4350593090057373, -2.94317889213562]
healthy B-LOC [2.3510220050811768, -2.872413158416748]
glomerular B-LOC [2.5256736278533936, -2.9653289318084717]
filter; B-LOC [2.3035054206848145, -2.849330186843872]
however, B-LOC [2.8360636234283447, -3.0046467781066895]
they B-LOC [2.840257406234741, -3.2190616130828857]
have B-LOC [3.052814245223999, -3.09810733795166]
been B-LOC [2.806184768676758, -3.288329601287842]
difficult B-LOC [2.995702028274536, -3.354670763015747]
to B-LOC [2.7864153385162354, -3.342155933380127]
study B-LOC [2.6472904682159424, -3.1208860874176025]
in B-LOC [2.6879827976226807, -3.055142879486084]
the B-LOC [2.6688802242279053, -3.029179811477661]
intact B-LOC [2.6431901454925537, -3.1348085403442383]
kidney B-LOC [2.283823013305664, -3.007988691329956]
because B-LOC [3.2164530754089355, -2.8908114433288574]
of B-LOC [3.0903494358062744, -3.1810827255249023]
technical B-LOC [2.902960777282715, -3.1608498096466064]
limitations. B-LOC [3.3397345542907715, -3.3665220737457275]
Here B-LOC [1.440687894821167, -1.5951131582260132]
we B-LOC [1.4437048435211182, -1.4787496328353882]
report B-LOC [1.505692481994629, -1.686295986175537]
the B-LOC [1.6894221305847168, -1.9269059896469116]
development B-LOC [1.9895565509796143, -2.011935234069824]
of B-LOC [1.9028452634811401, -2.0220448970794678]
serial B-LOC [2.1715171337127686, -2.4962751865386963]
multiphoton B-LOC [2.284529447555542, -2.455054521560669]
microscopy B-LOC [2.4553418159484863, -2.145962953567505]
(MPM) B-LOC [2.3852407932281494, -2.5996932983398438]
of B-LOC [2.0681984424591064, -2.3022639751434326]
the B-LOC [2.172743082046509, -2.134406328201294]
same B-LOC [1.7656108140945435, -2.129120349884033]
glomeruli B-LOC [2.2437784671783447, -2.2851548194885254]
over B-LOC [1.798464059829712, -1.973042368888855]
several B-LOC [2.076218843460083, -2.1916863918304443]
days B-LOC [2.002683162689209, -2.1561412811279297]
to B-LOC [2.008929967880249, -2.2877562046051025]
visualize B-LOC [2.111762762069702, -2.399557590484619]
the B-LOC [2.17558217048645, -2.403057336807251]
motility B-LOC [2.448565721511841, -2.64029598236084]
of B-LOC [2.0790326595306396, -2.37778639793396]
podocytes B-LOC [1.7932606935501099, -2.4125616550445557]
and B-LOC [2.182906150817871, -2.461668014526367]
parietal B-LOC [1.9974291324615479, -2.4518368244171143]
epithelial B-LOC [2.285454034805298, -2.5417253971099854]
cells B-LOC [2.151944875717163, -2.525496244430542]
(PECs) B-LOC [2.3634092807769775, -2.6142120361328125]
in B-LOC [2.0651395320892334, -1.9439492225646973]
vivo. B-LOC [1.8086603879928589, -2.3446044921875]
In O [-0.17407886683940887, 0.08213227987289429]
podocin-GFP O [-0.15096132457256317, -0.14496555924415588]
mice, O [-0.3367180824279785, -0.1657281368970871]
podocytes B-LOC [-0.20837220549583435, -0.30363574624061584]
formed B-LOC [0.02781503088772297, -0.3503415882587433]
sporadic B-LOC [0.0854448527097702, -0.3709254264831543]
multicellular B-LOC [0.1569269895553589, -0.3951980173587799]
clusters B-LOC [0.1256917268037796, -0.18982988595962524]
after B-LOC [-0.08190959692001343, -0.2228357046842575]
unilateral B-LOC [-0.08504201471805573, -0.28167760372161865]
ureteral B-LOC [-0.10137954354286194, -0.12926387786865234]

ligation B-LOC [0.08261542022228241, -0.5879738926887512]
and B-LOC [0.3451676666736603, -0.5127297639846802]
migrated B-LOC [0.29119694232940674, -0.6024414896965027]
into B-LOC [0.2575218975543976, -0.5037733912467957]
the B-LOC [0.35235676169395447, -0.5005360841751099]
parietal B-LOC [0.05291435495018959, -0.8804693222045898]
Bowman's B-LOC [0.24422496557235718, -0.8709395527839661]
capsule. B-LOC [0.2896031439304352, -0.7668803334236145]
The B-LOC [0.6217312216758728, -0.5408374667167664]
tracking B-LOC [0.6437119245529175, -0.6294695138931274]
of B-LOC [0.6883172392845154, -0.7252569794654846]
single B-LOC [0.9495754837989807, -0.8962027430534363]
cells B-LOC [0.6443101763725281, -0.7680110335350037]
in B-LOC [0.5768163800239563, -0.5039240717887878]
podocin-confetti B-LOC [0.5288419723510742, -0.7185969948768616]
mice B-LOC [0.49122366309165955, -0.6496113538742065]
featuring B-LOC [0.5424991846084595, -0.7383579611778259]
cell-specific B-LOC [0.6354794502258301, -0.7710612416267395]
expression B-LOC [0.6797507405281067, -0.48513689637184143]
of B-LOC [0.5860384702682495, -0.7459484338760376]
CFP, B-LOC [0.4275508224964142, -0.6448994278907776]
GFP, B-LOC [0.5118287205696106, -0.6783915162086487]
YFP B-LOC [0.497700959444046, -0.6211245656013489]
or B-LOC [0.6635395884513855, -0.7625865936279297]
RFP B-LOC [0.5820090770721436, -0.8251336216926575]
revealed B-LOC [0.6221426129341125, -0.4754319190979004]
the B-LOC [0.7495772242546082, -0.7268722653388977]
simultaneous B-LOC [0.6410430073738098, -0.9214204549789429]
migration B-LOC [0.7022975087165833, -0.841314971446991]
of B-LOC [0.7225461602210999, -0.9366164803504944]
multiple B-LOC [0.6880877614021301, -1.0642832517623901]
podocytes. B-LOC [0.5107724070549011, -0.9007102847099304]
In B-LOC [0.24789811670780182, -0.130164235830307]
phosphoenolpyruvate B-LOC [0.36981040239334106, -0.5581929683685303]
carboxykinase B-LOC [0.3506828546524048, -0.6617180109024048]
(PEPCK)-GFP B-LOC [0.5504984259605408, -0.5558698177337646]
mice, B-LOC [0.21533198654651642, -0.2975104749202728]
serial B-LOC [0.33787426352500916, -0.4837419092655182]
MPM B-LOC [0.3376851975917816, -0.3324463665485382]
found B-LOC [0.15750940144062042, -0.31104007363319397]
PEC-to-podocyte B-LOC [0.3019869327545166, -0.4803954064846039]
migration B-LOC [0.20146939158439636, -0.31514671444892883]
and B-LOC [0.2558347284793854, -0.34925320744514465]
nanotubule B-LOC [0.2696632444858551, -0.6030981540679932]
connections. B-LOC [0.25386473536491394, -0.5057717561721802]
Our B-LOC [0.700903594493866, -0.7495056986808777]
data B-LOC [0.9324018955230713, -1.0984487533569336]
support B-LOC [0.8975459933280945, -0.9485053420066833]
a B-LOC [0.8285083770751953, -1.003941535949707]
highly B-LOC [0.8781285881996155, -1.036940336227417]
dynamic B-LOC [1.0026065111160278, -1.406064748764038]
rather B-LOC [0.7813702821731567, -1.0957915782928467]
than B-LOC [0.8528686165809631, -0.8415336012840271]
a B-LOC [1.0736521482467651, -1.2511799335479736]
static B-LOC [0.9502277970314026, -1.4360320568084717]
nature B-LOC [1.0785378217697144, -1.39254891872406]
of B-LOC [1.1815775632858276, -1.5910041332244873]
the B-LOC [1.1853502988815308, -1.464691400527954]
glomerular B-LOC [1.2661643028259277, -1.4547334909439087]

environment B-LOC [0.9306346774101257, -1.5111286640167236]
and B-LOC [1.2067795991897583, -1.7308931350708008]
cellular B-LOC [0.9341834783554077, -1.5223290920257568]
composition. B-LOC [1.4209461212158203, -1.6593594551086426]
Future B-LOC [1.3866149187088013, -1.758151888847351]
application B-LOC [1.5583077669143677, -1.9459755420684814]
of B-LOC [1.388454556465149, -1.8391566276550293]
this B-LOC [1.2182657718658447, -1.3823051452636719]
new B-LOC [1.3657890558242798, -1.8601641654968262]
approach B-LOC [1.0930466651916504, -1.6345911026000977]
should B-LOC [1.3570215702056885, -1.581449270248413]
advance B-LOC [1.754705548286438, -2.096574544906616]
our B-LOC [1.2533187866210938, -1.8171751499176025]
understanding B-LOC [1.7482120990753174, -2.1436729431152344]
of B-LOC [1.7232264280319214, -2.199105739593506]
the B-LOC [1.695056438446045, -2.0209524631500244]
mechanisms B-LOC [1.5155848264694214, -2.073632001876831]
of B-LOC [1.3888750076293945, -2.070305347442627]
glomerular B-LOC [1.1604199409484863, -1.3296765089035034]
injury B-LOC [0.9558093547821045, -1.323707103729248]
and B-LOC [1.5109386444091797, -1.903305172920227]
regeneration. B-LOC [1.0617176294326782, -1.4576048851013184]

T B-LOC [1.4304301738739014, -2.025632858276367]
cell B-LOC [1.267998456954956, -2.0472748279571533]
activation B-LOC [1.5828256607055664, -1.9063074588775635]
is B-LOC [2.0648417472839355, -1.9800245761871338]
predicated B-LOC [1.851656198501587, -1.9252140522003174]
on B-LOC [1.7017028331756592, -1.9983899593353271]
the B-LOC [1.8566856384277344, -2.074589490890503]
interaction B-LOC [1.7511571645736694, -2.0110411643981934]
between B-LOC [1.9480061531066895, -2.3308751583099365]
the B-LOC [1.7470613718032837, -1.9864190816879272]
T B-LOC [1.676114797592163, -2.001554489135742]
cell B-LOC [1.194677710533142, -1.8883693218231201]
receptor B-LOC [1.3305842876434326, -1.7821074724197388]
and B-LOC [1.9872252941131592, -2.3316948413848877]
peptide-major B-LOC [1.8325697183609009, -2.199260950088501]
histocompatibility B-LOC [1.9059959650039673, -2.1754331588745117]
(pMHC) B-LOC [2.109825849533081, -2.3689944744110107]
ligands. B-LOC [2.4010510444641113, -2.690131425857544]
The B-LOC [3.08355975151062, -2.885838747024536]
factors B-LOC [2.960397481918335, -2.928556203842163]
that B-LOC [3.1634976863861084, -2.732477903366089]
determine B-LOC [3.0325441360473633, -2.763547420501709]
the B-LOC [2.9662187099456787, -2.9143271446228027]
stimulatory B-LOC [2.8051350116729736, -2.982872724533081]
potency B-LOC [2.7619574069976807, -2.6698896884918213]
of B-LOC [2.631007432937622, -2.7382776737213135]
a B-LOC [2.6713125705718994, -2.7512705326080322]
pMHC B-LOC [2.354165554046631, -2.951894521713257]
molecule B-LOC [2.03713059425354, -2.399916887283325]
remain B-LOC [3.2826976776123047, -2.692676305770874]
unclear. B-LOC [3.18638014793396, -2.6743667125701904]
We B-LOC [0.5488808155059814, -0.3789326846599579]
describe B-LOC [0.9322587847709656, -0.49912330508232117]
results B-LOC [0.7504674792289734, -0.5300478339195251]
showing B-LOC [0.5755364298820496, -0.5629534125328064]
that B-LOC [0.2207736074924469, -0.42681458592414856]
a B-LOC [0.4403567910194397, -0.39722898602485657]
peptide B-LOC [0.43412625789642334, -0.44492682814598083]
exhibiting B-LOC [0.6760770678520203, -0.740664005279541]
many B-LOC [0.742443859577179, -0.6268681287765503]
hallmarks B-LOC [1.2015471458435059, -0.8466705679893494]
of B-LOC [0.5534728765487671, -0.41329213976860046]
a B-LOC [0.44463127851486206, -0.5898966789245605]
weak B-LOC [0.6923481225967407, -0.7052883505821228]
agonist B-LOC [0.41688960790634155, -0.6887363195419312]
stimulates B-LOC [0.3504841923713684, -0.27571555972099304]
T B-LOC [0.48704633116722107, -0.5241748690605164]
cells B-LOC [0.19462887942790985, -0.3805840015411377]
to B-LOC [0.6359257102012634, -0.29623135924339294]
proliferate B-LOC [0.3839990794658661, -0.4113185703754425]
more B-LOC [0.4629906117916107, -0.24557319283485413]
than B-LOC [0.5280881524085999, -0.34092265367507935]
the B-LOC [0.7192015647888184, -0.6891694664955139]
wild-type B-LOC [0.8973914980888367, -1.0828593969345093]
agonist B-LOC [0.6095656156539917, -0.6816147565841675]
ligand. B-LOC [0.9139544367790222, -0.8803896307945251]
An B-LOC [0.3197116553783417, -0.48455068469047546]
in B-LOC [0.4609502851963043, -0.5063324570655823]
silico B-LOC [0.5738551616668701, -0.4262143075466156]
approach B-LOC [0.4329428970813751, -0.5214467644691467]
suggested B-LOC [0.19213606417179108, -0.20740200579166412]
that B-LOC [0.15970581769943237, -0.135969877243042]
the B-LOC [0.5248539447784424, -0.2110476791858673]
inability B-LOC [0.4448889195919037, -0.3220944404602051]
to B-LOC [0.6313519477844238, -0.2847277820110321]
form B-LOC [0.4966229200363159, -0.473488986492157]
the B-LOC [0.5098676085472107, -0.5304539799690247]
central B-LOC [0.23836764693260193, -0.6388787627220154]
supramolecular B-LOC [0.23948484659194946, -0.4880709946155548]
activation B-LOC [0.1861284226179123, -0.47996634244918823]
cluster B-LOC [0.31759563088417053, -0.5175473690032959]
(cSMAC) B-LOC [0.4823511242866516, -0.5161479115486145]
could B-LOC [0.33244767785072327, -0.31043708324432373]
underlie B-LOC [0.5457035899162292, -0.22184836864471436]
the B-LOC [0.4162783622741699, -0.25681272149086]
increased B-LOC [0.01911880262196064, -0.44178929924964905]

proliferation. O [-0.5361456274986267, 0.16893631219863892]
This O [-0.3206103444099426, 0.12291915714740753]
conclusion O [-0.28308942914009094, 0.17887431383132935]
was O [-0.3926444947719574, 0.06437891721725464]
supported B-LOC [0.16062253713607788, -0.10517549514770508]
by O [-0.2473321557044983, 0.20009830594062805]
experiments O [-0.4467964768409729, 0.380736380815506]
that O [-0.48212411999702454, 0.21745100617408752]
showed O [-0.4152859151363373, 0.3955516517162323]
that O [-0.63386470079422, 0.4490167796611786]
enhancing O [-0.9144478440284729, 0.8800593018531799]
cSMAC O [-0.7275872826576233, 0.748701274394989]
formation O [-0.5417941212654114, 1.02950119972229]
reduced O [-0.8256130814552307, 0.9718994498252869]
stimulatory O [-0.9522051215171814, 0.9661890864372253]
capacity O [-0.666340172290802, 0.8676195740699768]
of O [-0.8347876667976379, 0.9530097842216492]
the O [-0.8019486665725708, 0.7120372653007507]
weak O [-0.5752387642860413, 0.5381084084510803]
peptide. O [-0.8145838379859924, 0.619772732257843]
Our B-LOC [0.8005797863006592, -1.1090315580368042]
studies B-LOC [1.1763840913772583, -1.317169427871704]
highlight B-LOC [1.3013073205947876, -1.3093533515930176]
the B-LOC [1.3454936742782593, -1.440711498260498]
fact B-LOC [1.1128475666046143, -1.2832590341567993]
that B-LOC [0.8793633580207825, -1.427044153213501]
a B-LOC [1.1009587049484253, -1.3665366172790527]
complex B-LOC [1.176783561706543, -1.7239646911621094]
interplay B-LOC [1.312501072883606, -1.6909221410751343]
of B-LOC [1.2970304489135742, -1.7469466924667358]
factors B-LOC [1.212905764579773, -1.7822750806808472]
determines B-LOC [1.3880577087402344, -1.7848949432373047]
the B-LOC [1.447396159172058, -1.92347252368927]
quality B-LOC [1.1735882759094238, -1.9321773052215576]
of B-LOC [1.217081069946289, -1.7767002582550049]
a B-LOC [1.109442949295044, -1.832763671875]
T B-LOC [1.0074023008346558, -1.536618947982788]
cell B-LOC [0.55292147397995, -1.4297850131988525]
antigen. B-LOC [1.0825395584106445, -1.5663161277770996]

Genetically B-LOC [1.8995517492294312, -2.6203596591949463]
identical B-LOC [2.158198595046997, -3.0173914432525635]
cells B-LOC [1.976660132408142, -2.6494128704071045]
sharing B-LOC [2.1968655586242676, -2.9185593128204346]
an B-LOC [2.1905176639556885, -2.777987480163574]
environment B-LOC [2.087449073791504, -2.665971517562866]
can B-LOC [2.0879504680633545, -2.6370811462402344]
display B-LOC [2.040914297103882, -2.6859238147735596]
markedly B-LOC [2.1156129837036133, -2.7633166313171387]
different B-LOC [2.144325017929077, -3.1991922855377197]
phenotypes. B-LOC [2.3389766216278076, -3.041473627090454]
It B-LOC [2.84900164604187, -2.9636666774749756]
is B-LOC [3.026872158050537, -2.998059034347534]
often B-LOC [2.9446349143981934, -3.019324541091919]
unclear B-LOC [2.945129871368408, -3.058345317840576]
how B-LOC [2.7691242694854736, -3.4048211574554443]
much B-LOC [2.771048069000244, -3.32908034324646]
of B-LOC [2.6630449295043945, -3.1461238861083984]
this B-LOC [2.6506617069244385, -3.0455124378204346]
variation B-LOC [2.499191999435425, -3.2988388538360596]
derives B-LOC [2.7700679302215576, -3.1261403560638428]
from B-LOC [2.5629584789276123, -3.2188644409179688]
chance, B-LOC [2.657890558242798, -3.21036696434021]
external B-LOC [2.727592706680298, -3.456935167312622]
signals, B-LOC [2.4874026775360107, -3.250720977783203]
or B-LOC [2.728428363800049, -3.2376911640167236]
attempts B-LOC [2.430676221847534, -3.0517194271087646]
by B-LOC [2.6198766231536865, -3.373736619949341]
individual B-LOC [2.5806002616882324, -3.3933074474334717]
cells B-LOC [2.462657928466797, -3.269831657409668]
to B-LOC [2.5766422748565674, -3.1897034645080566]
exert B-LOC [2.4965250492095947, -3.213743209838867]
autonomous B-LOC [2.5351169109344482, -3.2410831451416016]
phenotypic B-LOC [2.7317917346954346, -3.3418023586273193]
programs. B-LOC [2.416269063949585, -3.069441318511963]
By B-LOC [0.9426108598709106, -1.0055170059204102]
observing B-LOC [1.3606808185577393, -1.3319169282913208]
thousands B-LOC [1.577148199081421, -1.671217918395996]
of B-LOC [1.484687328338623, -1.7171952724456787]
cells B-LOC [1.4790500402450562, -1.618870496749878]
for B-LOC [1.6059186458587646, -1.683708906173706]
hundreds B-LOC [1.7475838661193848, -1.8855981826782227]
of B-LOC [1.5766921043395996, -1.8356287479400635]
consecutive B-LOC [1.5719252824783325, -2.131014585494995]
generations B-LOC [2.114086389541626, -2.2665884494781494]
under B-LOC [1.9539506435394287, -2.1233291625976562]
constant B-LOC [1.7558034658432007, -2.291949510574341]
conditions, B-LOC [1.858870029449463, -1.8898842334747314]
we B-LOC [1.0715510845184326, -1.1978522539138794]
dissect B-LOC [1.5698506832122803, -1.4625847339630127]
the B-LOC [1.6666522026062012, -1.421238660812378]
stochastic B-LOC [1.7566426992416382, -1.8938319683074951]
decision B-LOC [1.1704484224319458, -1.5567368268966675]
between B-LOC [1.5365550518035889, -1.7878832817077637]
a B-LOC [1.4760723114013672, -1.559586763381958]
solitary, B-LOC [1.521059513092041, -1.5114701986312866]
motile B-LOC [1.4940226078033447, -1.7843797206878662]
state B-LOC [1.174961805343628, -1.3931267261505127]
and B-LOC [1.6017787456512451, -1.6587443351745605]
a B-LOC [1.473515272140503, -1.3717082738876343]
chained, B-LOC [1.254806637763977, -1.569770097732544]
sessile B-LOC [1.345620036125183, -1.4295448064804077]
state B-LOC [1.1414296627044678, -1.311434268951416]
in B-LOC [1.2192533016204834, -1.3502304553985596]
Bacillus B-LOC [1.3303766250610352, -1.5844535827636719]
subtilis. B-LOC [1.4291326999664307, -1.5048253536224365]
We B-LOC [0.027390452101826668, -0.1272985190153122]
show B-LOC [0.13476668298244476, 0.06742829829454422]
that O [-0.1430480182170868, 0.04648579657077789]
the B-LOC [0.26199761033058167, -0.21650907397270203]
motile B-LOC [0.11955037713050842, -0.3708343505859375]
state B-LOC [0.1241203248500824, -0.14119312167167664]
is B-LOC [0.11173371225595474, 0.1011391133069992]
'memoryless', O [0.14206458628177643, 0.2476470172405243]
exhibiting O [-0.12574924528598785, 0.21073396503925323]
no O [0.09731405973434448, 0.147931769490242]
autonomous B-LOC [0.06461555510759354, -0.048080895096063614]
control B-LOC [0.17023040354251862, -0.21707133948802948]
over B-LOC [0.20278069376945496, -0.31778964400291443]
the B-LOC [0.2593006193637848, -0.44950416684150696]
time B-LOC [0.12065107375383377, -0.2995583415031433]
spent B-LOC [0.30723077058792114, -0.5205829739570618]
in B-LOC [0.43344804644584656, -0.46357831358909607]
the B-LOC [0.41527196764945984, -0.6052678823471069]
state. B-LOC [0.3093954622745514, -0.5450997352600098]
In B-LOC [0.095626100897789, -0.18316888809204102]
contrast, O [0.0506414994597435, 0.15657348930835724]

the B-LOC [0.6391293406486511, -0.8730026483535767]
time B-LOC [0.825838565826416, -1.274909496307373]
spent B-LOC [0.9630416035652161, -1.41780686378479]
as B-LOC [0.9077152609825134, -1.4127153158187866]
connected B-LOC [1.170846700668335, -1.470374345779419]
chains B-LOC [1.1243075132369995, -1.4443424940109253]
of B-LOC [1.170133352279663, -1.6036698818206787]
cells B-LOC [0.9226320385932922, -1.4116556644439697]
is B-LOC [1.0097676515579224, -1.141619324684143]
tightly B-LOC [1.0685672760009766, -1.208091378211975]
controlled, B-LOC [1.1532127857208252, -1.2731842994689941]
enforcing B-LOC [1.1817114353179932, -1.3924578428268433]
coordination B-LOC [1.0076518058776855, -1.2034876346588135]
among B-LOC [1.0788776874542236, -1.595163345336914]
related B-LOC [1.1565001010894775, -1.5482898950576782]
cells B-LOC [1.04435133934021, -1.401151180267334]
in B-LOC [1.1671228408813477, -1.3206901550292969]
the B-LOC [1.156791090965271, -1.326811671257019]
multicellular B-LOC [0.9804354310035706, -1.5644557476043701]
state. B-LOC [1.0353050231933594, -1.473616600036621]
We B-LOC [0.19303742051124573, -0.36464205384254456]
show B-LOC [0.26223212480545044, -0.12699274718761444]
that B-LOC [0.21487218141555786, -0.4715215265750885]
the B-LOC [0.9017066359519958, -0.7824827432632446]
three-protein B-LOC [1.0132331848144531, -1.3268849849700928]
regulatory B-LOC [0.8380284905433655, -1.087770700454712]
circuit B-LOC [0.7691037654876709, -1.2509428262710571]
governing B-LOC [1.0475444793701172, -1.2827575206756592]
the B-LOC [1.091383457183838, -1.1979944705963135]
decision B-LOC [0.8712933659553528, -1.2827050685882568]
is B-LOC [0.7321595549583435, -0.6573382019996643]
modular, B-LOC [1.0019640922546387, -0.8610048890113831]
as B-LOC [0.4091716706752777, -0.377566933631897]
initiation B-LOC [0.8724198341369629, -1.171987771987915]
and B-LOC [0.9633030295372009, -0.919690728187561]
maintenance B-LOC [0.9912769198417664, -1.1589064598083496]
of B-LOC [0.8858864307403564, -1.2819575071334839]
chaining B-LOC [0.9994556307792664, -1.2637996673583984]
are B-LOC [0.7909120321273804, -0.8219282031059265]
genetically B-LOC [0.6500653028488159, -0.7323641180992126]
separable B-LOC [0.8449733257293701, -0.7449705004692078]
functions. B-LOC [0.8967763781547546, -1.0433274507522583]
As B-LOC [0.26589763164520264, -0.3204296827316284]
stimulation B-LOC [0.3484194278717041, -0.46108508110046387]
of B-LOC [0.4883666932582855, -0.4926963448524475]
the B-LOC [0.5631092190742493, -0.44475555419921875]
same B-LOC [0.5007943511009216, -0.5326153039932251]
initiating B-LOC [0.08973009884357452, -0.4298715889453888]
pathway B-LOC [0.12970802187919617, -0.428566038608551]
triggers B-LOC [0.30362391471862793, -0.4521327018737793]
biofilm B-LOC [0.170903742313385, -0.6105323433876038]
formation, B-LOC [0.43855613470077515, -0.40297427773475647]
we B-LOC [0.20363448560237885, -0.33711954951286316]
argue B-LOC [0.49358299374580383, -0.1584988832473755]
that B-LOC [0.1914057433605194, -0.289528489112854]
autonomous B-LOC [0.4996541738510132, -0.46180620789527893]
timing B-LOC [0.4400579631328583, -0.6997271776199341]
allows B-LOC [0.29748815298080444, -0.22153382003307343]
a B-LOC [0.3390248715877533, -0.24110130965709686]
trial B-LOC [0.3107979893684387, -0.4126817584037781]
commitment B-LOC [0.42932644486427307, -0.48557618260383606]
to B-LOC [0.49434494972229004, -0.5661348104476929]
multicellularity B-LOC [0.5465489029884338, -0.7409012913703918]
that B-LOC [0.43120142817497253, -0.5964176654815674]
external B-LOC [0.4063773453235626, -0.7986010313034058]
signals B-LOC [0.42460837960243225, -0.7272326350212097]
could B-LOC [0.47108104825019836, -0.4560016095638275]
extend. B-LOC [0.4880807101726532, -0.6284427046775818]

OBJECTIVE B-LOC [3.2582294940948486, -3.642169237136841]
To B-LOC [3.6232709884643555, -3.7178938388824463]
determine B-LOC [3.7460756301879883, -3.648348093032837]
whether B-LOC [3.6698713302612305, -3.807939052581787]
higher B-LOC [3.325352191925049, -3.924410104751587]
past B-LOC [3.646742343902588, -3.906616449356079]
exposure B-LOC [3.8322184085845947, -3.7467901706695557]
to B-LOC [3.5972044467926025, -3.4518115520477295]
particulate B-LOC [3.575650453567505, -3.6985137462615967]
air B-LOC [3.4768824577331543, -3.7296440601348877]
pollution B-LOC [3.7209744453430176, -3.719935417175293]
is B-LOC [3.620797634124756, -3.7946293354034424]
associated B-LOC [3.6587064266204834, -3.918722152709961]
with B-LOC [3.443863868713379, -3.885072708129883]
prevalent B-LOC [3.5283656120300293, -3.899927854537964]
high B-LOC [3.4350388050079346, -3.8830673694610596]
symptoms B-LOC [3.9038450717926025, -3.716989278793335]
of B-LOC [3.4383704662323, -3.720344305038452]
anxiety. B-LOC [3.62243914604187, -3.7388932704925537]
DESIGN B-LOC [3.451441526412964, -3.4213006496429443]
Observational B-LOC [3.1708157062530518, -2.929990530014038]
cohort B-LOC [3.4462718963623047, -3.212275266647339]
study. B-LOC [3.295638084411621, -3.47281551361084]
SETTING B-LOC [3.075542688369751, -3.3174846172332764]
Nurses' B-LOC [3.367750644683838, -3.330974817276001]
Health B-LOC [3.4465205669403076, -3.514446973800659]
Study. B-LOC [3.4611589908599854, -3.372682809829712]
PARTICIPANTS B-LOC [3.130974054336548, -3.002485513687134]
71,271 B-LOC [3.7506983280181885, -2.9403345584869385]
women B-LOC [3.4956982135772705, -2.978715658187866]
enrolled B-LOC [3.5339601039886475, -3.0756773948669434]
in B-LOC [3.3291122913360596, -2.691878080368042]
the B-LOC [3.3614718914031982, -2.7863101959228516]
Nurses' B-LOC [3.3704721927642822, -3.104421377182007]
Health B-LOC [3.416569471359253, -3.2473793029785156]
Study B-LOC [3.434772491455078, -2.955402135848999]
residing B-LOC [3.5026144981384277, -3.0643184185028076]
throughout B-LOC [3.6744954586029053, -3.029503583908081]
the B-LOC [3.651287317276001, -2.723712682723999]
contiguous B-LOC [3.5590577125549316, -2.960568904876709]
United B-LOC [3.3575799465179443, -3.039996862411499]
States B-LOC [3.583103895187378, -2.828577756881714]
who B-LOC [3.4408082962036133, -2.9952046871185303]
had B-LOC [3.4660229682922363, -3.0564939975738525]
valid B-LOC [3.5042495727539062, -3.0974953174591064]
estimates B-LOC [3.543329954147339, -3.086773633956909]
on B-LOC [3.438544750213623, -3.1269123554229736]
exposure B-LOC [3.7676122188568115, -3.011112928390503]
to B-LOC [3.43595552444458, -2.7021214962005615]
particulate B-LOC [3.376451253890991, -3.015094518661499]
matter B-LOC [3.360555410385132, -2.7927258014678955]
for B-LOC [3.5317113399505615, -3.0225110054016113]
at B-LOC [3.1919214725494385, -2.678262948989868]
least B-LOC [3.242729425430298, -2.8563075065612793]
one B-LOC [3.1996591091156006, -3.010486125946045]
exposure B-LOC [3.546510696411133, -3.2581467628479004]
period B-LOC [3.5858263969421387, -2.9564406871795654]
of B-LOC [3.2291927337646484, -2.8321049213409424]
interest B-LOC [3.3880913257598877, -3.1399102210998535]
and B-LOC [3.421151876449585, -3.0104644298553467]
data B-LOC [3.588168144226074, -3.203934907913208]
on B-LOC [3.558439016342163, -3.1479222774505615]
anxiety B-LOC [3.5389487743377686, -3.2850260734558105]
symptoms. B-LOC [3.818415403366089, -3.2711355686187744]
MAIN B-LOC [2.9260618686676025, -2.8289194107055664]
OUTCOME B-LOC [2.748445510864258, -2.67901873588562]
MEASURES B-LOC [2.694171667098999, -2.5477724075317383]
Meaningfully B-LOC [2.3062808513641357, -2.5441908836364746]
high B-LOC [2.471015691757202, -2.8442325592041016]
symptoms B-LOC [2.8311774730682373, -2.4071104526519775]
of B-LOC [1.8750667572021484, -2.375877618789673]
anxiety, B-LOC [2.8067219257354736, -2.8760783672332764]
defined B-LOC [3.308743715286255, -2.707350492477417]
as B-LOC [2.8238651752471924, -2.507721185684204]

a B-LOC [2.5420706272125244, -3.0510172843933105]
score B-LOC [3.0730788707733154, -3.4606213569641113]
of B-LOC [2.8393898010253906, -3.333904266357422]
6 B-LOC [3.1922123432159424, -3.282181739807129]
points B-LOC [3.064070463180542, -3.506324052810669]
or B-LOC [3.001103162765503, -3.3840975761413574]
greater B-LOC [3.1504690647125244, -3.1936943531036377]
on B-LOC [3.0671494007110596, -3.3530044555664062]
the B-LOC [3.199471950531006, -3.1613285541534424]
phobic B-LOC [3.231407642364502, -3.557904005050659]
anxiety B-LOC [2.9949586391448975, -3.5804555416107178]
subscale B-LOC [3.379753351211548, -3.198312520980835]
of B-LOC [3.25485897064209, -3.226491689682007]
the B-LOC [3.2028119564056396, -3.215710401535034]
Crown-Crisp B-LOC [2.666839361190796, -3.5229058265686035]
index, B-LOC [3.143824338912964, -3.577005386352539]
administered B-LOC [3.321601152420044, -3.4502127170562744]
in B-LOC [3.2038943767547607, -3.127863645553589]
2004. B-LOC [3.313800573348999, -3.3352224826812744]
RESULTS B-LOC [2.7057032585144043, -3.1445271968841553]
The B-LOC [3.1125149726867676, -3.2063841819763184]
71,271 B-LOC [3.3830158710479736, -3.4687278270721436]
eligible B-LOC [3.02103328704834, -3.499868392944336]
women B-LOC [3.0704925060272217, -3.515103816986084]
were B-LOC [3.1387124061584473, -3.4046030044555664]
aged B-LOC [3.3061254024505615, -3.4700138568878174]
between B-LOC [3.3295066356658936, -3.511035919189453]
57 B-LOC [3.2160706520080566, -3.4614462852478027]
and B-LOC [2.98861026763916, -3.173388957977295]
85 B-LOC [3.0443427562713623, -3.356844425201416]
years B-LOC [3.2373225688934326, -3.559333086013794]
(mean B-LOC [3.1427109241485596, -3.286092758178711]
70 B-LOC [3.1792690753936768, -3.3742430210113525]
years) B-LOC [3.1844208240509033, -3.506909132003784]
at B-LOC [3.0626304149627686, -3.3933217525482178]
the B-LOC [3.0263519287109375, -3.2556536197662354]
time B-LOC [3.0631136894226074, -3.551567316055298]
of B-LOC [2.8547589778900146, -3.2570462226867676]
assessment B-LOC [3.123821496963501, -3.506300687789917]
of B-LOC [3.0008413791656494, -3.421309471130371]
anxiety B-LOC [3.0080325603485107, -3.533132553100586]
symptoms, B-LOC [3.1999034881591797, -3.66166353225708]
with B-LOC [2.9311368465423584, -3.066192388534546]
a B-LOC [3.0207746028900146, -3.2912721633911133]
prevalence B-LOC [3.1545352935791016, -3.5505282878875732]
of B-LOC [2.956860303878784, -3.346450090408325]
high B-LOC [2.853910207748413, -3.4982972145080566]
anxiety B-LOC [2.706254720687866, -3.440028190612793]
symptoms B-LOC [3.0247714519500732, -3.496910333633423]
of B-LOC [2.6001603603363037, -3.277500867843628]
15%. B-LOC [3.059424638748169, -3.2244391441345215]
Exposure B-LOC [1.0649434328079224, -1.0773608684539795]
to B-LOC [1.3087468147277832, -1.0774199962615967]
particulate B-LOC [1.1138675212860107, -1.2827409505844116]
matter B-LOC [0.9558247327804565, -1.104712963104248]
was B-LOC [1.3353716135025024, -1.1757910251617432]
characterized B-LOC [1.5102148056030273, -1.2987874746322632]
using B-LOC [1.024012565612793, -1.1100994348526]
estimated B-LOC [1.1359914541244507, -0.9279404282569885]
average B-LOC [1.0218255519866943, -1.1263630390167236]
exposure B-LOC [1.0784032344818115, -1.0203531980514526]
to B-LOC [1.112525463104248, -0.8331498503684998]
particulate B-LOC [0.9463461637496948, -1.0776830911636353]
matter B-LOC [0.8332064747810364, -0.9158012866973877]
<2.5 B-LOC [1.02542245388031, -0.9800942540168762]
μm B-LOC [1.2393300533294678, -0.9401077032089233]
in B-LOC [1.1383328437805176, -1.0547783374786377]
diameter B-LOC [1.2704753875732422, -1.0294705629348755]
(PM2.5) B-LOC [1.1451694965362549, -0.8564363121986389]
and B-LOC [0.7634532451629639, -0.9754102826118469]
2.5 B-LOC [0.7894229292869568, -0.22208024561405182]
to B-LOC [0.46222636103630066, -0.9306899905204773]
10 B-LOC [0.776028573513031, -0.624231219291687]
μm B-LOC [1.1268857717514038, -0.8463948965072632]
in B-LOC [0.9566854238510132, -1.0855001211166382]
diameter B-LOC [1.1804230213165283, -0.9639014005661011]
(PM2.5-10) B-LOC [1.075363039970398, -0.9988299608230591]

in B-LOC [0.899787425994873, -1.5642292499542236]
the B-LOC [1.5794589519500732, -2.041811943054199]
one B-LOC [1.4831781387329102, -2.167607545852661]
month, B-LOC [2.0832130908966064, -2.0209643840789795]
three B-LOC [1.7568049430847168, -2.3055851459503174]
months, B-LOC [2.466200828552246, -2.1111414432525635]
six B-LOC [1.976115345954895, -2.4168500900268555]
months, B-LOC [2.648369550704956, -2.2241456508636475]
one B-LOC [1.8091822862625122, -2.22015380859375]
year, B-LOC [2.4967844486236572, -2.401978015899658]
and B-LOC [1.822584867477417, -2.4828755855560303]
15 B-LOC [1.9750558137893677, -2.3089418411254883]
years B-LOC [2.198474645614624, -2.4602322578430176]
prior B-LOC [2.034752130508423, -2.2208282947540283]
to B-LOC [1.8476524353027344, -2.262583017349243]
assessment B-LOC [1.6952080726623535, -2.21954607963562]
of B-LOC [1.7754206657409668, -2.2687032222747803]
anxiety B-LOC [1.6860623359680176, -2.137085199356079]
symptoms, B-LOC [1.715818166732788, -2.309788703918457]
and B-LOC [1.6903634071350098, -2.2681827545166016]
residential B-LOC [1.790949821472168, -2.115462303161621]
distance B-LOC [1.6946675777435303, -2.259472370147705]
to B-LOC [1.6855753660202026, -2.171870470046997]
the B-LOC [1.9088681936264038, -2.092604160308838]
nearest B-LOC [1.8378217220306396, -2.3278305530548096]
major B-LOC [1.5988346338272095, -2.3432796001434326]
road B-LOC [1.4270901679992676, -2.352818727493286]
two B-LOC [1.7514039278030396, -2.4225075244903564]
years B-LOC [2.223095655441284, -2.5643930435180664]
prior B-LOC [2.1845548152923584, -2.3278305530548096]
to B-LOC [1.884521484375, -2.3599307537078857]
assessment. B-LOC [1.8558909893035889, -2.421443223953247]
Significantly O [-1.0998793840408325, 1.1273574829101562]
increased O [-1.2064307928085327, 1.1948174238204956]
odds O [-1.3244481086730957, 1.348265290260315]
of O [-1.2860064506530762, 1.2097610235214233]
high O [-1.196314811706543, 1.2183113098144531]
anxiety O [-0.9353522658348083, 1.2829419374465942]
symptoms O [-1.115547776222229, 1.2556357383728027]
were O [-1.1492642164230347, 1.1157445907592773]
observed O [-1.2636499404907227, 1.298007607460022]
with O [-1.2053022384643555, 1.2989857196807861]
higher O [-1.155759572982788, 1.3652421236038208]
exposure O [-1.1675549745559692, 1.3253748416900635]
to O [-1.0918779373168945, 1.4017364978790283]
PM2.5 O [-0.9098767638206482, 1.1865403652191162]
for O [-1.300466537475586, 1.3797801733016968]
multiple O [-1.1306676864624023, 1.3592344522476196]
averaging O [-1.2096517086029053, 1.323212742805481]
periods O [-1.247768521308899, 1.3942475318908691]
(for O [-1.1365854740142822, 1.3337690830230713]
example, O [-1.1223176717758179, 1.312436819076538]
odds O [-1.2741734981536865, 1.4639170169830322]
ratio O [-1.165799617767334, 1.2983784675598145]
per O [-1.228881597518921, 1.2950009107589722]
10 O [-0.991239607334137, 1.3185203075408936]
µg/m(3) O [-1.0686228275299072, 1.317182183265686]
increase O [-1.0594992637634277, 1.3217542171478271]
in O [-1.2405946254730225, 1.2860236167907715]
prior O [-1.337435007095337, 1.2230864763259888]
one O [-1.0421513319015503, 1.2386703491210938]
month O [-1.1484434604644775, 1.481421709060669]
average O [-1.2528241872787476, 1.3302991390228271]
PM2.5: O [-0.9396498799324036, 1.1968560218811035]
1.12, O [-0.8484597206115723, 1.2461191415786743]
95% O [-1.25334632396698, 1.4955406188964844]
confidence O [-1.2620147466659546, 1.3284201622009277]
interval O [-1.210428237915039, 1.21504545211792]
1.06 O [-1.0912874937057495, 1.3305070400238037]
to O [-1.2514994144439697, 0.9949661493301392]
1.19; O [-0.9186064600944519, 1.0731260776519775]
in O [-1.1652415990829468, 1.1905661821365356]
prior O [-1.1856855154037476, 1.0898833274841309]
12 O [-0.9308783411979675, 0.9318086504936218]
month O [-1.093287467956543, 1.3385257720947266]
average O [-1.149129033088684, 1.0362029075622559]
PM2.5: O [-0.9700782299041748, 1.1020270586013794]
1.15, O [-0.7925205826759338, 0.859986424446106]

1.06 B-LOC [0.03612663969397545, -0.701871931552887]
to B-LOC [0.35131600499153137, -0.8465228080749512]
1.26). B-LOC [0.4088585376739502, -0.9460045695304871]
Models B-LOC [0.7070007920265198, -0.8397274017333984]
including B-LOC [0.9719228148460388, -1.0106854438781738]
multiple B-LOC [0.948775589466095, -1.1020300388336182]
exposure B-LOC [0.7934321165084839, -1.2134559154510498]
windows B-LOC [0.8662528991699219, -1.1903640031814575]
suggested B-LOC [0.6577911972999573, -0.8264716863632202]
short B-LOC [0.7538045644760132, -0.8043673038482666]
term B-LOC [0.8782642483711243, -1.1610374450683594]
averaging B-LOC [0.7811673879623413, -1.2255895137786865]
periods B-LOC [0.7475577592849731, -1.047292947769165]
were B-LOC [0.8787317276000977, -1.1795259714126587]
more B-LOC [0.812195897102356, -0.9557018876075745]
relevant B-LOC [1.0137174129486084, -1.2850940227508545]
than B-LOC [0.8247503638267517, -0.9475108981132507]
long B-LOC [0.7905746102333069, -0.9134422540664673]
term B-LOC [0.9177114367485046, -1.2799941301345825]
averaging B-LOC [0.8265806436538696, -1.2681187391281128]
periods. B-LOC [0.8907135128974915, -1.1262636184692383]
There B-LOC [1.2120897769927979, -1.600365161895752]
was B-LOC [1.123460054397583, -1.6567221879959106]
no B-LOC [1.264426589012146, -1.70383882522583]
association B-LOC [1.1887311935424805, -1.7616463899612427]
between B-LOC [1.4422214031219482, -2.221912384033203]
anxiety B-LOC [1.259273886680603, -1.6845483779907227]
and B-LOC [1.7694296836853027, -2.244986057281494]
exposure B-LOC [1.489778995513916, -1.8653377294540405]
to B-LOC [1.1772682666778564, -1.7020392417907715]
PM2.5-10. B-LOC [1.0505623817443848, -1.6533401012420654]
Residential B-LOC [1.4783068895339966, -1.857128381729126]
proximity B-LOC [1.4101109504699707, -1.7983644008636475]
to B-LOC [1.4933147430419922, -1.9039280414581299]
major B-LOC [1.4619777202606201, -2.227799654006958]
roads B-LOC [1.4914271831512451, -2.1793956756591797]
was B-LOC [1.1564018726348877, -1.6944682598114014]
not B-LOC [1.2963416576385498, -1.6889702081680298]
related B-LOC [1.5106828212738037, -1.8687454462051392]
to B-LOC [1.433931589126587, -2.062878370285034]
anxiety B-LOC [1.5732005834579468, -2.021742582321167]
symptoms B-LOC [1.398026943206787, -2.069673776626587]
in B-LOC [1.1268433332443237, -1.7247782945632935]
a B-LOC [1.2950856685638428, -1.8288583755493164]
dose B-LOC [1.2948498725891113, -1.7439515590667725]
dependent B-LOC [1.3300594091415405, -2.086519956588745]
manner. B-LOC [0.9066914319992065, -1.816878080368042]
CONCLUSIONS O [-0.6095239520072937, 0.3371315002441406]
Exposure O [-0.21826918423175812, 0.2076919972896576]
to O [-0.06809558719396591, 0.11934791505336761]
fine B-LOC [0.16460321843624115, -0.3219950199127197]
particulate B-LOC [0.17504528164863586, -0.5185895562171936]
matter B-LOC [0.057268161326646805, -0.0017337375320494175]
(PM2.5) O [-0.035708826035261154, 0.04560444876551628]
was O [-0.45268699526786804, 0.11276792734861374]
associated O [-0.3934966027736664, 0.37622764706611633]
with O [-0.5269788503646851, 0.2154161036014557]
high O [-0.29340311884880066, 0.18451595306396484]
symptoms O [-0.1993274688720703, 0.29176029562950134]
of O [-0.5459295511245728, 0.36435452103614807]
anxiety, O [0.1121339499950409, 0.12130187451839447]
with O [-0.13305440545082092, 0.144021138548851]
more O [-0.2242812216281891, 0.4291001260280609]
recent O [-0.06641042232513428, 0.04212919995188713]
exposures B-LOC [0.2483263462781906, -0.12299972772598267]
potentially B-LOC [0.009594838134944439, -0.022099735215306282]
more O [-0.09377647191286087, 0.32216712832450867]
relevant B-LOC [0.1281847357749939, 0.00019493470608722419]
than O [-0.08968540281057358, 0.27596765756607056]
more O [-0.06853677332401276, 0.22110548615455627]
distant B-LOC [0.1767290234565735, -0.3219301700592041]
exposures. B-LOC [0.3032326102256775, -0.2673540413379669]
Research B-LOC [0.9219376444816589, -0.8614261150360107]
evaluating B-LOC [1.4097598791122437, -1.3546197414398193]
whether B-LOC [1.529976725578308, -1.4852309226989746]
reductions B-LOC [0.7749987244606018, -1.1067918539047241]
in B-LOC [1.0123176574707031, -1.3669259548187256]
exposure B-LOC [0.6730709075927734, -0.7899096608161926]
to B-LOC [0.7769297361373901, -0.9576048254966736]
ambient B-LOC [0.5984516739845276, -0.9644132256507874]

PM2.5 O [-0.31688806414604187, 0.05522897467017174]
would O [-0.29073020815849304, 0.07744134962558746]
reduce O [-0.2879449427127838, 0.32525601983070374]
the O [-0.23614078760147095, -0.020023854449391365]
population O [-0.22922606766223907, 0.0663866400718689]
level O [-0.18233194947242737, -0.11035265028476715]
burden O [-0.14921948313713074, -0.012292483821511269]
of B-LOC [-0.1485203206539154, -0.2039940357208252]
clinically O [-0.09159723669290543, -0.007273415569216013]
relevant B-LOC [0.019871225580573082, -0.28348758816719055]
symptoms B-LOC [0.03633568808436394, -0.10787650942802429]
of B-LOC [-0.020250024273991585, -0.29067137837409973]
anxiety B-LOC [0.13321751356124878, -0.10927416384220123]
is B-LOC [0.05895939841866493, -0.344948410987854]
warranted. B-LOC [0.08014009892940521, -0.3538345396518707]

Chaperone-mediated B-LOC [0.0935053750872612, -0.7942001223564148]
autophagy B-LOC [0.4108206629753113, -0.817869246006012]
(CMA), B-LOC [0.4709091782569885, -0.7483846545219421]
a B-LOC [0.22283443808555603, -0.538568913936615]
selective B-LOC [0.3449139893054962, -0.5768876075744629]
mechanism B-LOC [0.3064509928226471, -0.7405198216438293]
for B-LOC [0.22840054333209991, -0.597275972366333]
degradation B-LOC [0.46967777609825134, -0.4173991084098816]
of B-LOC [0.29680630564689636, -0.6388593316078186]
cytosolic B-LOC [0.37010762095451355, -0.6902019381523132]
proteins B-LOC [0.43910980224609375, -0.6765133142471313]
in B-LOC [0.2880135476589203, -0.6034039855003357]
lysosomes, B-LOC [0.5221720933914185, -0.7532440423965454]
contributes B-LOC [0.464198499917984, -0.5825961828231812]
to B-LOC [0.348631888628006, -0.5464009642601013]
the B-LOC [0.4385046362876892, -0.5562185645103455]
removal B-LOC [0.606648862361908, -0.6814828515052795]
of B-LOC [0.5613260865211487, -0.7140555381774902]
altered B-LOC [0.3973277807235718, -0.7788007259368896]
proteins B-LOC [0.5395765900611877, -0.8083458542823792]
as B-LOC [0.47989311814308167, -0.6885698437690735]
part B-LOC [0.5981866121292114, -0.6804288029670715]
of B-LOC [0.547184407711029, -0.7510625720024109]
the B-LOC [0.5899162888526917, -0.7092152237892151]
cellular B-LOC [0.41036930680274963, -0.9735519886016846]
quality-control B-LOC [0.6392641067504883, -0.9787639379501343]
systems. B-LOC [0.4993404448032379, -0.7996793389320374]
We B-LOC [0.06267592310905457, -0.19711418449878693]
have B-LOC [0.4371553957462311, 0.05654806271195412]
previously B-LOC [0.16553547978401184, -0.06126949191093445]
found O [0.08155661821365356, 0.16757604479789734]
that O [-0.3017942011356354, 0.18208327889442444]
CMA O [-0.43073493242263794, 0.03628053516149521]
activity O [-0.4210110306739807, 0.3197060227394104]
declines O [-0.005859782453626394, 0.09141000360250473]
in O [-0.17752321064472198, 0.1700376570224762]
aged B-LOC [0.13801458477973938, 0.10726924240589142]
organisms O [-0.10927489399909973, 0.002902728971093893]
and O [-0.17769357562065125, -0.02261604554951191]
have B-LOC [0.4198877215385437, -0.17242935299873352]
proposed B-LOC [0.2427223175764084, -0.12736199796199799]
that O [-0.06620598584413528, -0.023505406454205513]
this O [-0.25964534282684326, 0.24564926326274872]
failure O [-0.3129229247570038, -0.06249966099858284]
in O [-0.4733053147792816, 0.1155928522348404]
cellular O [-0.5104092359542847, 0.23110564053058624]
clearance O [-0.3189454972743988, 0.195542111992836]
could O [-0.17829065024852753, 0.0019141859374940395]
contribute O [-0.31568577885627747, 0.043660204857587814]
to O [-0.29694664478302, 0.18251296877861023]
the O [-0.39735546708106995, 0.30607861280441284]
accumulation O [-0.1455129086971283, 0.3065299391746521]
of O [-0.25250205397605896, 0.20567546784877777]
altered O [-0.260309100151062, -0.017273830249905586]
proteins, O [-0.18059778213500977, 0.039928849786520004]
the O [-0.3451281487941742, 0.30558738112449646]
abnormal O [-0.26333585381507874, -0.1049240306019783]
cellular O [-0.35510966181755066, -0.013252081349492073]
homeostasis O [-0.22988851368427277, 0.22604480385780334]
and, O [-0.1631728708744049, 0.3255201578140259]
eventually, O [-0.008176249451935291, 0.07481076568365097]
the O [-0.2022695243358612, 0.2249058336019516]
functional B-LOC [-0.0004512941522989422, -0.08587859570980072]
loss B-LOC [0.07109641283750534, -0.07313994318246841]
characteristic B-LOC [0.1139453798532486, -0.18604248762130737]
of B-LOC [0.09775111079216003, -0.3595221936702728]
aged B-LOC [0.2714187800884247, -0.32696211338043213]
organisms. B-LOC [0.15540416538715363, -0.4637760818004608]
To B-LOC [1.315903902053833, -1.366256833076477]
determine B-LOC [1.5904585123062134, -1.7906219959259033]
whether B-LOC [1.6838617324829102, -1.8654886484146118]
these B-LOC [1.1336199045181274, -1.266987919807434]
negative B-LOC [1.213489294052124, -1.6552878618240356]
features B-LOC [1.0196640491485596, -1.545204758644104]
of B-LOC [0.7378136515617371, -1.2865376472473145]
aging B-LOC [0.8074764609336853, -1.0958130359649658]
can B-LOC [1.3986029624938965, -1.7044466733932495]
be B-LOC [1.3611928224563599, -1.8319066762924194]
prevented B-LOC [1.1539509296417236, -1.5681227445602417]
by B-LOC [0.5559423565864563, -1.2340795993804932]
maintaining B-LOC [0.8303666710853577, -1.150357961654663]
efficient B-LOC [0.7859398722648621, -1.399977445602417]
autophagic B-LOC [0.7799981236457825, -1.3197124004364014]
activity B-LOC [0.6182032227516174, -0.8518376350402832]
until B-LOC [1.3849072456359863, -1.4582629203796387]

late B-LOC [0.664930522441864, -1.0160406827926636]
in B-LOC [1.3432807922363281, -1.4792680740356445]
life, B-LOC [1.4246159791946411, -1.5529475212097168]
in B-LOC [1.3011354207992554, -1.3922741413116455]
this B-LOC [1.3055856227874756, -1.3204050064086914]
work B-LOC [1.3515231609344482, -1.4137585163116455]
we B-LOC [1.015507459640503, -1.3229858875274658]
have B-LOC [1.3902239799499512, -1.182957410812378]
corrected B-LOC [1.4264017343521118, -1.3700270652770996]
the B-LOC [1.3394458293914795, -1.425809383392334]
CMA B-LOC [0.8782106041908264, -1.2687692642211914]
defect B-LOC [0.9618887305259705, -1.3545297384262085]
in B-LOC [1.2951120138168335, -1.5194387435913086]
aged B-LOC [1.5692753791809082, -1.5156068801879883]
rodents. B-LOC [1.3268826007843018, -1.804659366607666]
We B-LOC [1.1300972700119019, -1.4165817499160767]
have B-LOC [1.4807279109954834, -1.2842864990234375]
generated B-LOC [1.6912487745285034, -1.4285387992858887]
a B-LOC [1.304841160774231, -1.4178913831710815]
double B-LOC [1.2954450845718384, -1.3936636447906494]
transgenic B-LOC [1.3434019088745117, -1.5315501689910889]
mouse B-LOC [1.199583649635315, -1.4776290655136108]
model B-LOC [1.1180789470672607, -1.5024983882904053]
in B-LOC [1.0544852018356323, -1.2371833324432373]
which B-LOC [1.0880000591278076, -1.6252076625823975]
the B-LOC [1.2178254127502441, -1.4484970569610596]
amount B-LOC [1.0431249141693115, -1.203730583190918]
of B-LOC [1.0250682830810547, -1.287665605545044]
the B-LOC [1.0143632888793945, -1.2621561288833618]
lysosomal B-LOC [0.8603531718254089, -1.0966911315917969]
receptor B-LOC [0.622904360294342, -1.0986661911010742]
for B-LOC [0.8580541014671326, -1.2294795513153076]
CMA, B-LOC [0.6297323107719421, -1.1829386949539185]
previously B-LOC [0.543698251247406, -0.7455126047134399]
shown B-LOC [0.7478910684585571, -0.9535725116729736]
to B-LOC [1.0079302787780762, -1.030040979385376]
decrease B-LOC [1.0222786664962769, -1.3180317878723145]
in B-LOC [0.6661149859428406, -1.2461053133010864]
abundance B-LOC [1.1581707000732422, -1.0987014770507812]
with B-LOC [0.4395858645439148, -0.9880767464637756]
age, B-LOC [1.2775466442108154, -0.959956705570221]
can B-LOC [1.298995018005371, -1.409280776977539]
be B-LOC [1.4376225471496582, -1.667027235031128]
modulated. B-LOC [1.4109692573547363, -1.6409008502960205]
We B-LOC [2.0216729640960693, -2.13651967048645]
have B-LOC [2.5540268421173096, -2.09067702293396]
analyzed B-LOC [2.732248067855835, -2.499568223953247]
in B-LOC [2.622788190841675, -2.369957685470581]
this B-LOC [2.5342485904693604, -2.387596607208252]
model B-LOC [2.435877799987793, -2.623352289199829]
the B-LOC [2.6512091159820557, -2.393040418624878]
consequences B-LOC [2.430835008621216, -2.539947271347046]
of B-LOC [2.0278196334838867, -1.9221161603927612]
preventing B-LOC [2.2324225902557373, -2.3834779262542725]
the B-LOC [2.3038599491119385, -2.2028448581695557]
age-dependent B-LOC [2.3171684741973877, -2.3732750415802]
decrease B-LOC [1.7055938243865967, -2.374058485031128]
in B-LOC [1.9428926706314087, -2.5322558879852295]
receptor B-LOC [1.7453317642211914, -2.298866033554077]
abundance B-LOC [1.9224854707717896, -2.0923709869384766]
in B-LOC [2.039931297302246, -2.2691457271575928]
aged B-LOC [2.3107361793518066, -2.4404914379119873]
rodents B-LOC [1.7823845148086548, -2.5190372467041016]
at B-LOC [2.175915002822876, -2.4833385944366455]
the B-LOC [2.283721685409546, -2.577744960784912]
cellular B-LOC [1.8736679553985596, -2.6083123683929443]
and B-LOC [2.170701026916504, -2.435420513153076]
organ B-LOC [1.9685901403427124, -2.620529890060425]
levels. B-LOC [2.063232660293579, -2.66902756690979]
We O [-0.7978596091270447, 0.508888304233551]
show O [-0.6742768883705139, 0.4919146001338959]
here O [-0.415659636259079, 0.3592453896999359]
that O [-0.9006469249725342, 0.49703100323677063]
CMA O [-0.4679435193538666, 0.3440854847431183]
activity O [-0.4546511471271515, 0.584313690662384]
is O [-0.41607508063316345, 0.4594930112361908]
maintained O [-0.36863306164741516, 0.3084867000579834]
until O [-0.3619225323200226, 0.3457138240337372]
advanced O [-0.6386571526527405, 0.3201541602611542]
ages O [-0.4254039525985718, 0.561420738697052]
if O [-0.6172383427619934, 0.25728073716163635]
the O [-0.38491326570510864, 0.39054182171821594]
decrease O [-0.39565590023994446, 0.17552384734153748]
in O [-0.46403422951698303, 0.25447407364845276]
the O [-0.6273366808891296, 0.4116252064704895]
receptor O [-0.49787649512290955, 0.266290545463562]
abundance O [-0.4157056510448456, 0.5672509074211121]
is O [-0.27191850543022156, 0.32190877199172974]
prevented O [-0.3043802082538605, 0.41263988614082336]
and O [-0.7500116229057312, 0.5895623564720154]
that O [-0.7163174748420715, 0.49225643277168274]
preservation O [-0.4394071400165558, 0.4440995752811432]
of O [-0.6346412897109985, 0.47155722975730896]
autophagic O [-0.621655285358429, 0.5610213875770569]
activity O [-0.4319581985473633, 0.4528732895851135]

is O [-0.9837160110473633, 1.1038024425506592]
associated O [-1.0868853330612183, 1.301492691040039]
with O [-1.11929452419281, 1.2298502922058105]
lower O [-0.9275273680686951, 1.3287832736968994]
intracellular O [-1.049295425415039, 1.1455830335617065]
accumulation O [-0.5431113243103027, 1.1266194581985474]
of O [-0.9304124712944031, 1.0418808460235596]
damaged O [-0.5832744240760803, 0.822170078754425]
proteins, O [-0.5351701378822327, 0.866580069065094]
better O [-0.8337901830673218, 1.2500423192977905]
ability O [-0.7616997361183167, 1.0803524255752563]
to O [-0.7096117734909058, 1.0502089262008667]
handle O [-0.5221852660179138, 0.7953561544418335]
protein O [-0.6063571572303772, 0.6571248173713684]
damage O [-0.570311963558197, 0.8204429149627686]
and O [-1.0196142196655273, 1.228360891342163]
improved O [-0.9045936465263367, 1.137284755706787]
organ O [-0.8169615864753723, 0.7664602398872375]
function. O [-0.6770561933517456, 0.975426971912384]

BACKGROUND B-LOC [0.4988691806793213, -0.7914344668388367]
Endothelium-dependent B-LOC [0.0444863885641098, -0.3418029844760895]
modulation B-LOC [-0.0767015889286995, -0.4286494553089142]
of B-LOC [-0.04838017374277115, -0.23287126421928406]
coronary B-LOC [0.016528600826859474, -0.01812138594686985]
tone B-LOC [0.1794695109128952, -0.3970930874347687]
is B-LOC [0.2722378969192505, -0.4891897737979889]
impaired B-LOC [0.33474263548851013, -0.4336005747318268]
in B-LOC [0.08204951882362366, -0.29643699526786804]
the B-LOC [0.07969052344560623, -0.26381003856658936]
collateral-dependent B-LOC [0.023111507296562195, -0.0780462846159935]
coronary B-LOC [0.07801257073879242, -0.10099278390407562]
microcirculation. B-LOC [-0.03703929856419563, -0.21542343497276306]
We B-LOC [2.34348726272583, -2.0881550312042236]
used B-LOC [2.699389696121216, -2.3718831539154053]
a B-LOC [2.699180841445923, -2.549628973007202]
porcine B-LOC [2.7817981243133545, -2.542846441268921]
model B-LOC [2.643174886703491, -2.5977470874786377]
of B-LOC [2.3303844928741455, -2.6142256259918213]
chronic B-LOC [2.739158868789673, -2.729492664337158]
coronary B-LOC [2.7216637134552, -2.2425472736358643]
occlusion B-LOC [2.395397901535034, -2.336110830307007]
and B-LOC [2.4923462867736816, -2.4001224040985107]
collateral B-LOC [2.6318352222442627, -2.32891583442688]
development B-LOC [1.9236979484558105, -1.8797276020050049]
to B-LOC [3.0099704265594482, -2.757518768310547]
evaluate B-LOC [2.9489858150482178, -2.7284162044525146]
the B-LOC [2.9176323413848877, -2.6179797649383545]
hypothesis B-LOC [2.680973768234253, -2.593155860900879]
that B-LOC [2.0360963344573975, -2.3471145629882812]
exercise B-LOC [2.0049080848693848, -2.1025640964508057]
training B-LOC [2.025167465209961, -2.126115083694458]
enhances B-LOC [1.9175997972488403, -1.9178768396377563]
endothelium-mediated B-LOC [2.0659101009368896, -1.9440388679504395]
relaxation B-LOC [1.5476776361465454, -1.4372947216033936]
and B-LOC [1.0130245685577393, -1.1041722297668457]
increases B-LOC [2.1706762313842773, -2.2377817630767822]
endothelial B-LOC [2.049539804458618, -1.9051337242126465]
nitric B-LOC [2.361024856567383, -2.2595038414001465]
oxide B-LOC [2.44736385345459, -2.2803187370300293]
synthase B-LOC [2.24367094039917, -1.8293098211288452]
(ecNOS) B-LOC [2.3353934288024902, -2.051945924758911]
mRNA B-LOC [2.1274235248565674, -2.1284682750701904]
levels B-LOC [2.0319530963897705, -1.9297655820846558]
of B-LOC [2.025721788406372, -1.8756786584854126]
collateral-dependent B-LOC [2.1634488105773926, -2.09358286857605]
microvasculature. B-LOC [2.269486665725708, -2.10906720161438]
METHODS B-LOC [0.5270208716392517, -0.9467164278030396]
AND B-LOC [0.8307144045829773, -1.4228236675262451]
RESULTS B-LOC [0.5098251104354858, -1.0867033004760742]
Adult B-LOC [0.5982666611671448, -0.9451858401298523]
female B-LOC [0.824255645275116, -1.0967612266540527]
miniature B-LOC [0.5699213147163391, -0.9993337392807007]
swine B-LOC [0.39269593358039856, -0.7438119053840637]

were B-LOC [1.034995436668396, -1.4360530376434326]
subjected B-LOC [1.4350918531417847, -1.525126576423645]
to B-LOC [1.0350555181503296, -1.0574928522109985]
chronic, B-LOC [0.8924326300621033, -1.217334270477295]
progressive B-LOC [0.8055136799812317, -1.2113142013549805]
ameroid B-LOC [0.892852246761322, -1.260425090789795]
occlusion B-LOC [0.9129632115364075, -1.1791372299194336]
of B-LOC [0.5305467247962952, -0.7803575396537781]
the B-LOC [0.9015569686889648, -0.9029094576835632]
proximal B-LOC [0.8920629620552063, -1.2373493909835815]
left B-LOC [0.8562038540840149, -1.192099690437317]
circumflex B-LOC [0.9297337532043457, -1.317229986190796]
coronary B-LOC [0.9230992197990417, -1.4127702713012695]
artery B-LOC [0.5411328673362732, -1.4176230430603027]
(LCx); B-LOC [1.319570779800415, -1.6200244426727295]
after B-LOC [1.6780906915664673, -2.105703592300415]
2 B-LOC [1.7475368976593018, -1.9428832530975342]
months, B-LOC [2.2036306858062744, -2.005127429962158]
animals B-LOC [1.9551186561584473, -2.4374468326568604]
were B-LOC [2.047672986984253, -1.9946815967559814]
randomly B-LOC [2.316267967224121, -2.3584816455841064]
exposed B-LOC [2.1175432205200195, -2.0540735721588135]
to B-LOC [2.0014865398406982, -2.199190378189087]
16-week B-LOC [2.3054418563842773, -2.5532102584838867]
exercise-training B-LOC [2.0621566772460938, -2.363318681716919]
(EX B-LOC [2.1837775707244873, -2.5750527381896973]
group; B-LOC [1.9597289562225342, -2.3100509643554688]
treadmill B-LOC [2.294337272644043, -2.550567865371704]
running) B-LOC [1.7741588354110718, -2.2617838382720947]
or B-LOC [2.2497284412384033, -2.301001787185669]
sedentary B-LOC [2.3334429264068604, -2.2824928760528564]
(SED B-LOC [2.2578649520874023, -2.687307119369507]
group; B-LOC [2.102119207382202, -2.238184928894043]
cage B-LOC [2.053816318511963, -2.4504735469818115]
confinement) B-LOC [2.0329480171203613, -2.3193819522857666]
protocols. B-LOC [2.054021120071411, -2.114950180053711]
After B-LOC [1.0052306652069092, -1.3523280620574951]
completion B-LOC [1.7745118141174316, -1.427124261856079]
of B-LOC [1.5124236345291138, -1.6187474727630615]
EX B-LOC [1.7857378721237183, -1.6370928287506104]
or B-LOC [1.801397681236267, -1.9978300333023071]
SED B-LOC [1.9162850379943848, -1.5558316707611084]
programs, B-LOC [1.603410243988037, -1.5552716255187988]
coronary B-LOC [0.9371516704559326, -1.2528014183044434]
arterioles B-LOC [1.0398261547088623, -1.3485713005065918]
( B-LOC [1.5046555995941162, -1.5593962669372559]
approximately B-LOC [1.6098453998565674, -1.6381698846817017]
100 B-LOC [1.5006777048110962, -1.3485406637191772]
microm B-LOC [1.2414352893829346, -1.550281286239624]
in B-LOC [1.7480831146240234, -1.7127807140350342]
diameter) B-LOC [1.965578556060791, -1.8716528415679932]
were B-LOC [1.676954746246338, -1.4748878479003906]
isolated B-LOC [1.33744478225708, -1.4067559242248535]
from B-LOC [1.0865775346755981, -1.211452603340149]
collateral-dependent B-LOC [0.8151502013206482, -0.9609270691871643]
LCx B-LOC [0.9075321555137634, -1.0470911264419556]
(distal B-LOC [0.8092929720878601, -1.2006670236587524]
to B-LOC [0.4928787648677826, -0.8757665753364563]
occlusion) B-LOC [0.7258450388908386, -0.9040128588676453]
and B-LOC [1.0167381763458252, -1.196915864944458]
nonoccluded B-LOC [0.8199061155319214, -0.926354169845581]
left B-LOC [0.5671483278274536, -0.9481655955314636]
anterior B-LOC [0.438479483127594, -1.0773558616638184]
descending B-LOC [0.25854843854904175, -1.206910252571106]
coronary B-LOC [0.22165127098560333, -0.59977787733078]

artery B-LOC [1.8110740184783936, -2.8778393268585205]
(LAD) B-LOC [2.927199125289917, -3.3257229328155518]
regions B-LOC [2.275735855102539, -2.810467481613159]
of B-LOC [2.391040563583374, -2.7470943927764893]
each B-LOC [2.4764177799224854, -2.947737216949463]
heart. B-LOC [2.5242130756378174, -3.5576627254486084]
Arterioles B-LOC [3.3917434215545654, -3.738065481185913]
were B-LOC [3.372699022293091, -3.628080368041992]
studied B-LOC [3.404296398162842, -3.859745502471924]
by B-LOC [3.233855724334717, -3.9965827465057373]
in B-LOC [3.256420135498047, -3.706695318222046]
vitro B-LOC [3.094078302383423, -3.3926279544830322]
videomicroscopy B-LOC [3.3308956623077393, -3.9447104930877686]
or B-LOC [3.4145097732543945, -3.659740924835205]
frozen B-LOC [3.5201125144958496, -3.7016913890838623]
for B-LOC [3.3748581409454346, -3.8203084468841553]
ecNOS B-LOC [3.276366949081421, -3.708576202392578]
mRNA B-LOC [3.35628342628479, -3.6796329021453857]
analysis B-LOC [3.4027481079101562, -3.9400808811187744]
(RT-PCR B-LOC [3.4923415184020996, -3.8626654148101807]
techniques). B-LOC [3.4655001163482666, -3.824660539627075]
Relaxation B-LOC [0.4028843939304352, -0.46520331501960754]
to B-LOC [0.24834345281124115, -0.2829875648021698]
the B-LOC [0.28447654843330383, -0.26540306210517883]
endothelium-dependent B-LOC [0.19661685824394226, -0.25585076212882996]
vasodilator B-LOC [0.201848104596138, -0.41580837965011597]
bradykinin B-LOC [0.35002073645591736, -0.2707046568393707]
was B-LOC [0.35071536898612976, -0.45976996421813965]
decreased B-LOC [0.5764731764793396, -0.4613257944583893]
(P<0.05) B-LOC [0.5473963618278503, -0.5019646286964417]
in B-LOC [0.5548104643821716, -0.6319887638092041]
arterioles B-LOC [0.7812911868095398, -0.6992884874343872]
isolated B-LOC [0.8038964867591858, -0.5528032779693604]
from B-LOC [0.7333299517631531, -0.5551125407218933]
collateral-dependent B-LOC [0.6003584265708923, -0.4442242681980133]
LCx B-LOC [0.5290251970291138, -0.44697460532188416]
versus B-LOC [0.517873227596283, -0.5954272150993347]
nonoccluded B-LOC [0.7309325933456421, -0.5523540377616882]
LAD B-LOC [0.6250925660133362, -0.35954341292381287]
regions B-LOC [0.3422143757343292, -0.4076268672943115]
of B-LOC [0.8115909695625305, -0.6154276728630066]
SED B-LOC [0.8448955416679382, -0.5049378275871277]
animals. B-LOC [0.330427348613739, -0.584820568561554]
Bradykinin-mediated B-LOC [0.2619970142841339, -0.3533829152584076]
relaxation, B-LOC [0.31236857175827026, -0.46878930926322937]
however, B-LOC [0.2968478500843048, -0.5449402332305908]
was B-LOC [0.27555471658706665, -0.5360420346260071]
not B-LOC [0.5004277229309082, -0.5012791156768799]
different B-LOC [0.42422497272491455, -0.7412164211273193]
in B-LOC [0.45332232117652893, -0.4855753779411316]
LCx B-LOC [0.325051873922348, -0.4175562560558319]
versus B-LOC [0.35970738530158997, -0.5912590622901917]
LAD B-LOC [0.3833138048648834, -0.31030207872390747]
arterioles B-LOC [0.38413766026496887, -0.48661166429519653]
isolated B-LOC [0.5675802826881409, -0.4222504794597626]
from B-LOC [0.5225601196289062, -0.39888688921928406]
EX B-LOC [0.375478059053421, -0.31322893500328064]
animals. B-LOC [0.10610449314117432, -0.5637839436531067]

Nitroprusside-induced B-LOC [0.5594581961631775, -1.036720633506775]
relaxation B-LOC [0.6358933448791504, -0.8060784935951233]
was B-LOC [0.5616422891616821, -0.7630565166473389]
unaffected B-LOC [0.8249656558036804, -0.8361989259719849]
by B-LOC [0.7598410248756409, -1.0378899574279785]
either B-LOC [0.9868386387825012, -1.1876801252365112]
chronic B-LOC [0.7141024470329285, -1.0025709867477417]
occlusion B-LOC [0.9204086661338806, -1.1223340034484863]
or B-LOC [0.9210536479949951, -1.0060291290283203]
exercise. B-LOC [0.638605535030365, -0.8618676662445068]
Importantly, B-LOC [0.5444650650024414, -0.4857570230960846]
ecNOS B-LOC [0.31150051951408386, -0.6039764285087585]
mRNA B-LOC [0.27791059017181396, -0.5379734635353088]
expression B-LOC [0.333004891872406, -0.5312997102737427]
was B-LOC [0.30538955330848694, -0.532381534576416]
significantly B-LOC [0.34541162848472595, -0.4913835823535919]
decreased B-LOC [0.49254468083381653, -0.4997251331806183]
in B-LOC [0.4130600392818451, -0.5097383260726929]
arterioles B-LOC [0.8110861778259277, -0.847963273525238]
isolated B-LOC [0.5780681371688843, -0.5363834500312805]
from B-LOC [0.6398017406463623, -0.4978645443916321]
LCx B-LOC [0.4643538296222687, -0.5193673372268677]
versus B-LOC [0.3700551688671112, -0.4859791100025177]
LAD B-LOC [0.4788510203361511, -0.441719114780426]
regions B-LOC [0.3754182755947113, -0.5459062457084656]
of B-LOC [0.5914755463600159, -0.6196211576461792]
SED B-LOC [0.7495059967041016, -0.5827891826629639]
animals. B-LOC [0.2839891016483307, -0.6153705716133118]
After B-LOC [1.1207714080810547, -1.3192546367645264]
training, B-LOC [1.1221133470535278, -1.316115140914917]
ecNOS B-LOC [1.0907392501831055, -1.2924705743789673]
mRNA B-LOC [1.1802427768707275, -1.3382172584533691]
expression B-LOC [1.127210259437561, -1.3751182556152344]
was B-LOC [1.2148380279541016, -1.3773424625396729]
not B-LOC [1.4086055755615234, -1.3548035621643066]
different B-LOC [1.472435474395752, -1.8558913469314575]
between B-LOC [1.6871458292007446, -1.8715746402740479]
LAD B-LOC [1.3432059288024902, -1.328476905822754]
and B-LOC [1.5471141338348389, -1.7679791450500488]
LCx B-LOC [1.2396140098571777, -1.4699177742004395]
arterioles. B-LOC [1.7136211395263672, -1.6470763683319092]
CONCLUSIONS O [-0.6799001693725586, 0.35506734251976013]
These O [-0.21051236987113953, 0.29097864031791687]
data O [-0.3304935395717621, 0.2549593150615692]
indicate O [-0.3195895254611969, 0.3133489787578583]
that O [-0.647845447063446, 0.36794620752334595]
exercise O [-0.46057698130607605, 0.39384275674819946]
training O [-0.5031945109367371, 0.37776005268096924]
enhances O [-0.6140525937080383, 0.5841930508613586]
bradykinin-mediated O [-0.670312762260437, 0.6496815085411072]
relaxation O [-0.40740978717803955, 0.6577864289283752]
of O [-0.4088268280029297, 0.4982934296131134]
collateral-dependent O [-0.6530803442001343, 0.7909382581710815]
LCx O [-0.4941476583480835, 0.4756276607513428]
arterioles O [-0.6254516243934631, 0.46736010909080505]
isolated O [-0.4214392900466919, 0.3890955150127411]
after O [-0.4333454668521881, 0.3619484007358551]
chronic O [-0.6730472445487976, 0.42629340291023254]
coronary O [-0.7460147738456726, 0.7018721699714661]
occlusion, O [-0.5809556245803833, 0.5408155918121338]
most O [-0.4506379961967468, 0.360713928937912]
likely O [-0.5168652534484863, 0.2584175169467926]
because O [-0.630071222782135, 0.3288893699645996]
of O [-0.4570349156856537, 0.22277775406837463]
effects O [-0.6340355277061462, 0.5909309983253479]

on O [-1.1495180130004883, 0.9766269326210022]
ecNOS O [-0.9263185858726501, 0.929523766040802]
mRNA O [-1.0525633096694946, 0.920710027217865]
expression O [-0.6613608002662659, 0.852819561958313]
and O [-1.1395533084869385, 0.97733473777771]
increased O [-1.07664954662323, 0.8519307374954224]
production O [-0.8194525837898254, 0.7771101593971252]
of O [-0.9926057457923889, 0.8000187277793884]
NO. O [-0.6354148983955383, 0.5509028434753418]

An B-LOC [1.9299840927124023, -2.719702959060669]
adoption B-LOC [1.8694074153900146, -2.368645668029785]
study B-LOC [2.2908544540405273, -2.910770893096924]
of B-LOC [2.366795301437378, -3.0978801250457764]
genetic B-LOC [2.491800308227539, -3.0000011920928955]
effects B-LOC [2.4853148460388184, -2.8693747520446777]
on B-LOC [2.3279197216033936, -2.9332189559936523]
obesity B-LOC [1.9597060680389404, -2.400752305984497]
in B-LOC [2.1761834621429443, -2.4302022457122803]
adulthood B-LOC [2.4205236434936523, -2.316863775253296]
was B-LOC [2.3200533390045166, -2.9832937717437744]
carried B-LOC [2.6741034984588623, -3.1865744590759277]
out B-LOC [2.638554811477661, -3.3133673667907715]
in B-LOC [2.121976852416992, -2.7312421798706055]
which B-LOC [1.8195081949234009, -2.549420118331909]
adoptees B-LOC [1.8815175294876099, -1.8263617753982544]
separated B-LOC [1.8758769035339355, -1.9111511707305908]
from B-LOC [1.649146318435669, -1.8466306924819946]
their B-LOC [1.7574713230133057, -2.1004514694213867]
natural B-LOC [1.5204768180847168, -2.126507043838501]
parents B-LOC [1.565070390701294, -1.6593562364578247]
very B-LOC [1.8382325172424316, -2.321528196334839]
early B-LOC [1.5872710943222046, -1.914008378982544]
in B-LOC [1.590461254119873, -1.667479157447815]
life B-LOC [1.9903486967086792, -2.1334948539733887]
were B-LOC [1.8178846836090088, -2.3864471912384033]
compared B-LOC [2.0430123805999756, -2.486438035964966]
with B-LOC [1.763588309288025, -2.2424535751342773]
their B-LOC [1.8501346111297607, -2.3431689739227295]
biological B-LOC [1.8296148777008057, -2.4227335453033447]
full B-LOC [1.5119833946228027, -1.756588101387024]
and B-LOC [1.6249935626983643, -2.28004789352417]
half B-LOC [1.9073364734649658, -2.1466052532196045]
siblings B-LOC [2.005674123764038, -2.1116526126861572]
reared B-LOC [2.006988286972046, -2.103020668029785]
by B-LOC [1.8329873085021973, -2.3641462326049805]
their B-LOC [2.0058417320251465, -2.4565794467926025]
natural B-LOC [1.9527041912078857, -2.6026084423065186]
parents. B-LOC [2.020339012145996, -2.1757664680480957]
The B-LOC [2.737285852432251, -3.081637144088745]
adoptees B-LOC [2.553630828857422, -2.694399118423462]
represented B-LOC [2.931148052215576, -3.1146767139434814]
four B-LOC [2.9974749088287354, -3.228780508041382]
groups B-LOC [3.0393636226654053, -3.1607298851013184]
who B-LOC [2.794940710067749, -3.226682662963867]
by B-LOC [2.876908540725708, -3.4257924556732178]
sampling B-LOC [2.978503465652466, -3.254462480545044]
from B-LOC [3.1013543605804443, -3.406696081161499]
a B-LOC [3.108833074569702, -3.340137243270874]
larger B-LOC [2.9771478176116943, -3.471384286880493]
population B-LOC [3.058814764022827, -3.351982355117798]
were B-LOC [2.9198811054229736, -3.180881977081299]
categorised B-LOC [3.276057720184326, -3.402531862258911]
as B-LOC [2.9967195987701416, -3.1825711727142334]
either B-LOC [2.9636495113372803, -3.4340169429779053]
thin, B-LOC [3.032909870147705, -3.3421902656555176]
medium B-LOC [2.7243659496307373, -3.467942953109741]
weight, B-LOC [2.70546555519104, -3.166642427444458]
overweight, B-LOC [2.8103415966033936, -3.3315370082855225]
or B-LOC [2.7208898067474365, -3.2279562950134277]
obese. B-LOC [3.003554105758667, -3.2958834171295166]
Weight B-LOC [2.766052007675171, -2.508577585220337]
and B-LOC [2.6581430435180664, -2.475480794906616]
height B-LOC [2.6170132160186768, -2.763079881668091]
were B-LOC [2.709184169769287, -2.4102094173431396]
obtained B-LOC [2.81249737739563, -2.8387372493743896]
for B-LOC [2.7718160152435303, -2.594089984893799]
115 B-LOC [2.9760851860046387, -2.754060745239258]
full B-LOC [2.9147212505340576, -2.684361457824707]
siblings B-LOC [2.950340986251831, -2.749458074569702]
of B-LOC [2.902160406112671, -2.606151819229126]
57 B-LOC [3.110854387283325, -2.800875186920166]
adoptees B-LOC [2.9480762481689453, -2.7110912799835205]
and B-LOC [2.8113768100738525, -2.5499048233032227]
for B-LOC [2.856351137161255, -2.497774362564087]
850 B-LOC [2.9921486377716064, -2.875863790512085]
half B-LOC [2.9667766094207764, -2.921488046646118]
siblings B-LOC [3.0132973194122314, -2.6838059425354004]
of B-LOC [2.9912469387054443, -2.5943665504455566]
341 B-LOC [3.3119051456451416, -2.7799768447875977]
adoptees. B-LOC [2.849379301071167, -2.560396671295166]
In B-LOC [0.263692706823349, -0.6534887552261353]
full B-LOC [0.8330315947532654, -0.7931616306304932]
siblings B-LOC [0.6666436791419983, -0.7015490531921387]
body B-LOC [0.4395572245121002, -0.6261046528816223]
mass B-LOC [0.4469529390335083, -0.6219329833984375]
index B-LOC [0.45333728194236755, -0.7756960391998291]
(kg/m2) B-LOC [0.9644818902015686, -0.8893122673034668]
significantly B-LOC [0.7674635052680969, -0.8677842617034912]
increased B-LOC [0.6472746729850769, -0.8735910058021545]
with B-LOC [0.35635659098625183, -0.8767657279968262]
weight B-LOC [0.8110904097557068, -0.7197420597076416]
of B-LOC [0.5261663198471069, -0.8828086256980896]
the B-LOC [0.7874969244003296, -0.8780304193496704]
adoptees. B-LOC [0.9884770512580872, -0.9026287794113159]
Body B-LOC [0.44125989079475403, -0.6601777672767639]
mass B-LOC [0.4520721137523651, -0.5670035481452942]
index B-LOC [0.44103822112083435, -0.6740137934684753]
of B-LOC [0.43182674050331116, -0.6903966069221497]

the B-LOC [0.2309078574180603, -0.2918245494365692]
half B-LOC [0.6526165008544922, -0.76109379529953]
siblings B-LOC [0.48078200221061707, -0.6712391972541809]
showed B-LOC [0.33272048830986023, -0.4286354184150696]
a B-LOC [0.3725533187389374, -0.3665364384651184]
steady B-LOC [0.44205331802368164, -0.6157172918319702]
but B-LOC [0.6151869893074036, -0.83409184217453]
weaker B-LOC [0.7066510915756226, -0.5251955389976501]
increase B-LOC [0.5213718414306641, -0.7271508574485779]
across B-LOC [0.6131339073181152, -0.7756800055503845]
the B-LOC [0.6820595860481262, -0.707451581954956]
four B-LOC [0.8993375897407532, -1.0338571071624756]
weight B-LOC [0.7323325872421265, -0.6057973504066467]
groups B-LOC [0.9777239561080933, -0.9653645157814026]
of B-LOC [0.8443096876144409, -1.0354466438293457]
adoptees. B-LOC [0.8623008728027344, -0.6485665440559387]
There B-LOC [0.5165312886238098, -0.5303259491920471]
were B-LOC [0.49376869201660156, -0.6779322028160095]
no B-LOC [0.6151723265647888, -0.6744819283485413]
significant B-LOC [0.6071389317512512, -0.9759775996208191]
interactions B-LOC [0.5805595517158508, -0.8375594615936279]
with B-LOC [0.8181937336921692, -1.2849360704421997]
sex B-LOC [0.7717942595481873, -0.9568575024604797]
of B-LOC [0.7889050841331482, -1.2309165000915527]
the B-LOC [0.7930397391319275, -0.9192891120910645]
adoptees, B-LOC [0.814738929271698, -0.6747688055038452]
sex B-LOC [0.8018079400062561, -0.9760220050811768]
of B-LOC [0.7771832346916199, -1.2411658763885498]
the B-LOC [0.8849918246269226, -1.0138241052627563]
siblings, B-LOC [0.748136579990387, -0.9797160029411316]
or B-LOC [1.0338091850280762, -1.150151014328003]
(for B-LOC [0.9056696891784668, -0.6798173189163208]
the B-LOC [0.8410434126853943, -1.0519049167633057]
half B-LOC [0.8443182706832886, -0.8902991414070129]
siblings) B-LOC [0.7503698468208313, -0.9795297384262085]
sex B-LOC [0.8432058691978455, -1.0718618631362915]
of B-LOC [0.7751912474632263, -1.3036457300186157]
the B-LOC [0.8938557505607605, -1.190292239189148]
common B-LOC [0.7715267539024353, -1.1659809350967407]
parent. B-LOC [0.7022327780723572, -1.023769497871399]
In B-LOC [0.4150497615337372, -0.5603811144828796]
contrast B-LOC [0.6021274924278259, -0.4574604332447052]
with B-LOC [0.5536466240882874, -0.6244939565658569]
the B-LOC [0.5651160478591919, -0.6029900908470154]
findings B-LOC [0.3949863612651825, -0.6891513466835022]
in B-LOC [0.505344033241272, -0.8209725618362427]
half B-LOC [0.7789062857627869, -0.806503176689148]
siblings B-LOC [0.5687279105186462, -0.6937004923820496]
and B-LOC [0.595687747001648, -0.5693653225898743]
(previously) B-LOC [0.8792865872383118, -0.3999134302139282]
the B-LOC [0.5996742844581604, -0.6090986728668213]
natural B-LOC [0.39098456501960754, -0.8223747611045837]
parents B-LOC [0.5898619294166565, -0.7092978358268738]
there B-LOC [0.370989054441452, -0.43598484992980957]
was B-LOC [0.5128212571144104, -0.6285932064056396]
a B-LOC [0.5345904231071472, -0.6043760180473328]
striking, B-LOC [0.7340971231460571, -0.73076993227005]
significant B-LOC [0.5099123120307922, -0.7179078459739685]
increase B-LOC [0.5298987627029419, -0.8293442130088806]
in B-LOC [0.48553237318992615, -0.8514131307601929]
body B-LOC [0.5540450215339661, -0.6130726933479309]
mass B-LOC [0.5063676238059998, -0.5451983213424683]
index B-LOC [0.5988401174545288, -0.60043865442276]
between B-LOC [0.5214571356773376, -0.6890025734901428]
full B-LOC [0.5827582478523254, -0.5499448776245117]
siblings B-LOC [0.7706198692321777, -0.8119417428970337]
of B-LOC [0.7324901223182678, -0.7991431355476379]
overweight B-LOC [0.6085155010223389, -0.6522608399391174]
and B-LOC [0.6013878583908081, -0.7948969006538391]
obese B-LOC [0.7522650957107544, -0.800643265247345]
adoptees. B-LOC [0.6505306363105774, -0.584729015827179]
The B-LOC [0.7501912713050842, -1.2312297821044922]
degree B-LOC [0.7827656865119934, -1.2886775732040405]
of B-LOC [0.7625001072883606, -1.3698410987854004]
fatness B-LOC [0.5992591381072998, -0.8250702023506165]
in B-LOC [0.7198517322540283, -1.0214680433273315]
adults B-LOC [0.5597609281539917, -0.8003020882606506]
living B-LOC [0.6632511615753174, -0.8377454876899719]
in B-LOC [0.8114699721336365, -0.8821396231651306]
the B-LOC [0.9791786670684814, -0.9538817405700684]
same B-LOC [0.8457654714584351, -1.3237372636795044]
environment B-LOC [0.5965023040771484, -0.9914738535881042]
appears B-LOC [0.9097740650177002, -0.9849412441253662]
to B-LOC [1.2340004444122314, -1.2910364866256714]
be B-LOC [1.0742077827453613, -1.2787176370620728]
influenced B-LOC [0.8298432230949402, -1.1427081823349]
by B-LOC [0.6583382487297058, -1.0145916938781738]
genetic B-LOC [0.6928285360336304, -1.1625137329101562]
factors B-LOC [0.6513729691505432, -1.220881462097168]
independent B-LOC [0.7644824385643005, -1.145772933959961]
of B-LOC [0.7123887538909912, -1.2654626369476318]
sex, B-LOC [0.653773844242096, -1.2259924411773682]
which B-LOC [0.517670750617981, -1.0170828104019165]
may B-LOC [0.8861924409866333, -1.0979199409484863]
include B-LOC [0.849350094795227, -1.040116548538208]
polygenic B-LOC [0.6960088014602661, -0.9928110241889954]
as B-LOC [0.5586968064308167, -0.8255126476287842]
well B-LOC [0.6020621061325073, -0.980481743812561]
as B-LOC [0.8349682688713074, -1.2297331094741821]
major B-LOC [0.6303399205207825, -1.1499786376953125]
gene B-LOC [0.5451070666313171, -1.197290062904358]
effects B-LOC [0.5527819991111755, -1.2708975076675415]
on B-LOC [0.4709511697292328, -1.0245893001556396]

obesity. O [-0.37629586458206177, 0.20499971508979797]

Currently, B-LOC [3.074115753173828, -3.0943496227264404]
major B-LOC [3.0285017490386963, -3.2835817337036133]
concerns B-LOC [3.0827672481536865, -3.385540246963501]
about B-LOC [2.9758269786834717, -3.511568546295166]
the B-LOC [3.075998067855835, -3.634401559829712]
safety B-LOC [3.1987574100494385, -3.6604044437408447]
and B-LOC [3.074037790298462, -3.685424566268921]
efficacy B-LOC [3.109424352645874, -3.7802882194519043]
of B-LOC [2.864889621734619, -3.5852882862091064]
RNA B-LOC [2.9235544204711914, -3.2861080169677734]
interference B-LOC [2.6849451065063477, -3.0986716747283936]
(RNAi)-based B-LOC [3.0299136638641357, -3.5191357135772705]
bone B-LOC [2.6941604614257812, -3.1726584434509277]
anabolic B-LOC [3.1389551162719727, -3.4137985706329346]
strategies B-LOC [3.022557020187378, -3.205228090286255]
still B-LOC [3.362377166748047, -3.170881986618042]
exist B-LOC [3.192293405532837, -3.187152147293091]
because B-LOC [3.1183271408081055, -2.952991247177124]
of B-LOC [2.987574577331543, -3.119966745376587]
the B-LOC [3.0458669662475586, -3.165644884109497]
lack B-LOC [3.061042308807373, -3.2518885135650635]
of B-LOC [2.8270678520202637, -3.3638458251953125]
direct B-LOC [2.7250735759735107, -3.382920026779175]
osteoblast-specific B-LOC [2.8007633686065674, -3.373960018157959]
delivery B-LOC [2.6863961219787598, -3.1384737491607666]
systems B-LOC [2.8221166133880615, -3.18951416015625]
for B-LOC [2.8293726444244385, -3.242927074432373]
osteogenic B-LOC [2.8389365673065186, -3.2687180042266846]
siRNAs. B-LOC [2.3322577476501465, -3.0240485668182373]
Here B-LOC [0.3019644320011139, -0.5880486369132996]
we B-LOC [0.5332248210906982, -0.6729044318199158]
screened B-LOC [0.5523548126220703, -0.6231172680854797]
the B-LOC [0.6322766542434692, -0.5384728908538818]
aptamer B-LOC [0.44366398453712463, -0.46734684705734253]
CH6 B-LOC [0.5083714127540588, -0.5068278312683105]
by B-LOC [0.4834010899066925, -0.7272983193397522]
cell-SELEX, B-LOC [0.42724451422691345, -0.7104594111442566]
specifically B-LOC [0.24319829046726227, -0.2859848439693451]
targeting B-LOC [0.3094373047351837, -0.247468501329422]
both B-LOC [0.28350117802619934, -0.12205024063587189]
rat B-LOC [0.26542502641677856, -0.6080595850944519]
and B-LOC [0.20945234596729279, -0.31722453236579895]
human B-LOC [0.17888537049293518, -0.4721373915672302]
osteoblasts, B-LOC [0.1253969520330429, -0.30254730582237244]
and B-LOC [0.6126486659049988, -0.6340439915657043]
then B-LOC [0.7252689003944397, -0.3865050673484802]
we B-LOC [0.7067663073539734, -0.7979142069816589]
developed B-LOC [0.7331393361091614, -0.5731734037399292]
CH6 B-LOC [0.8073991537094116, -0.5266419053077698]
aptamer–functionalized B-LOC [0.8324677348136902, -0.5670978426933289]
lipid B-LOC [0.9238149523735046, -0.7924955487251282]
nanoparticles B-LOC [1.1614384651184082, -0.8324074745178223]
(LNPs) B-LOC [1.3046677112579346, -1.0955601930618286]
encapsulating B-LOC [0.9750041365623474, -0.6310145854949951]
osteogenic B-LOC [0.6373190879821777, -0.7281242609024048]
pleckstrin B-LOC [0.6324496865272522, -0.7962375283241272]
homology B-LOC [0.6779714822769165, -0.4306076169013977]
domain-containing B-LOC [0.7044721245765686, -0.6084977388381958]
family B-LOC [0.8682683110237122, -0.537955105304718]
O B-LOC [0.7975562214851379, -0.7227807641029358]
member B-LOC [0.7631117701530457, -0.6149109601974487]
1 B-LOC [0.8370369672775269, -0.962019145488739]

(Plekho1) B-LOC [0.20849448442459106, -0.7057492136955261]
siRNA B-LOC [0.1151847243309021, -0.6074619889259338]
(CH6-LNPs-siRNA). B-LOC [0.26220253109931946, -0.6439068913459778]
Our O [-0.8962580561637878, 0.5977940559387207]
results O [-0.6430532336235046, 0.529819905757904]
showed O [-0.9999932646751404, 0.9033277630805969]
that O [-1.5539860725402832, 1.182654857635498]
CH6 O [-0.9107866287231445, 1.2372453212738037]
facilitated O [-1.5275678634643555, 1.4745274782180786]
in O [-1.4973126649856567, 1.4219322204589844]
vitro O [-1.095967411994934, 1.3373512029647827]
osteoblast-selective O [-1.6326172351837158, 1.6506752967834473]
uptake O [-1.5276212692260742, 1.669402003288269]
of O [-1.4235479831695557, 1.5865609645843506]
Plekho1 O [-1.4262590408325195, 1.4165316820144653]
siRNA, O [-1.2737854719161987, 1.4364842176437378]
mainly O [-1.5207899808883667, 1.625359296798706]
via O [-1.752302885055542, 1.592301845550537]
macropinocytosis, O [-1.297132134437561, 1.5352113246917725]
and O [-1.4862127304077148, 1.5611239671707153]
boosted O [-1.5251133441925049, 1.6042063236236572]
in O [-1.6570345163345337, 1.5741708278656006]
vivo O [-1.4752806425094604, 1.7725934982299805]
osteoblast-specific O [-1.5897213220596313, 1.687896490097046]
Plekho1 O [-1.3794035911560059, 1.3231050968170166]
gene O [-1.515768051147461, 1.50931715965271]
silencing, O [-1.3359131813049316, 1.425370693206787]
which O [-1.4921696186065674, 1.4344666004180908]
promoted O [-1.4150586128234863, 1.41375732421875]
bone O [-1.0367751121520996, 1.2547630071640015]
formation, O [-1.0130767822265625, 1.399362325668335]
improved O [-1.4411438703536987, 1.3852897882461548]
bone O [-0.9803045988082886, 1.1006046533584595]
microarchitecture, O [-1.1377333402633667, 1.2747316360473633]
increased O [-1.3675204515457153, 1.3643368482589722]
bone O [-0.9117540717124939, 0.9980683922767639]
mass O [-0.9667556881904602, 0.9471333622932434]
and O [-1.4190795421600342, 1.3896689414978027]
enhanced O [-1.2972002029418945, 1.3045458793640137]
mechanical O [-0.830295741558075, 0.6462071537971497]
properties O [-0.9113535284996033, 0.8722050786018372]
in O [-1.056209683418274, 0.9422865509986877]
both O [-1.0140528678894043, 1.0270024538040161]
osteopenic O [-0.9897186160087585, 1.0613805055618286]
and O [-1.0037434101104736, 0.7998621463775635]
healthy O [-0.9983336329460144, 0.9504563212394714]
rodents. O [-0.696096658706665, 0.637367844581604]
These B-LOC [0.10884352028369904, -0.13322055339813232]
results B-LOC [0.21646858751773834, -0.06622306257486343]
indicate B-LOC [0.1617695540189743, -0.017789063975214958]
that B-LOC [0.2527513802051544, -0.31478556990623474]
osteoblast-specific B-LOC [0.07688681781291962, -0.06204191595315933]
aptamer-functionalized B-LOC [0.10828058421611786, -0.11135102808475494]
LNPs B-LOC [0.13233104348182678, -0.2918177843093872]
could B-LOC [0.054397132247686386, -0.22247803211212158]

act O [-0.1559871882200241, -0.027070822194218636]
as O [-0.2733156681060791, 0.23533307015895844]
a O [-0.33023932576179504, 0.20062874257564545]
new O [-0.1351137012243271, 0.06016768887639046]
RNAi-based B-LOC [-0.020361987873911858, -0.30183109641075134]
bone B-LOC [-0.03294068202376366, -0.2135891616344452]
anabolic O [-0.15443173050880432, 0.05008089169859886]
strategy, O [-0.23866869509220123, 0.05491665378212929]
advancing O [-0.30154862999916077, -0.011088626459240913]
the O [-0.1554458886384964, -0.11844570934772491]
targeted O [-0.24559712409973145, -0.03339172899723053]
delivery B-LOC [-0.09958843141794205, -0.1146441176533699]
selectivity O [-0.07510983943939209, -0.01971939392387867]
of B-LOC [-0.07125145941972733, -0.24028396606445312]
osteogenic O [-0.19512371718883514, -0.10722542554140091]
siRNAs B-LOC [-0.13857673108577728, -0.3375498354434967]
from B-LOC [0.12415135651826859, -0.26904574036598206]
the B-LOC [0.07026788592338562, -0.24379786849021912]
tissue B-LOC [-0.2060188502073288, -0.2412397563457489]
level B-LOC [-0.2501739263534546, -0.2868647575378418]
to B-LOC [0.17203643918037415, -0.3701748549938202]
the B-LOC [0.12060807645320892, -0.33129867911338806]
cellular B-LOC [-0.23485136032104492, -0.46018746495246887]
level. B-LOC [-0.2040952742099762, -0.38930532336235046]

The B-LOC [2.667914628982544, -3.409173011779785]
interest B-LOC [2.877995729446411, -3.373643636703491]
in B-LOC [3.0157630443573, -3.4910740852355957]
brown B-LOC [2.611884355545044, -3.355583906173706]
adipose B-LOC [2.4361660480499268, -3.086472988128662]
tissue B-LOC [2.467118740081787, -3.1462230682373047]
(BAT) B-LOC [2.950615644454956, -3.4305579662323]
as B-LOC [3.1360371112823486, -3.5730974674224854]
a B-LOC [3.1209638118743896, -3.5759520530700684]
target B-LOC [3.2073662281036377, -3.6567251682281494]
to B-LOC [3.1392128467559814, -3.5777363777160645]
combat B-LOC [3.184201955795288, -3.3914692401885986]
metabolic B-LOC [2.9639439582824707, -3.4653937816619873]
disease B-LOC [3.171236753463745, -3.4324982166290283]
has B-LOC [3.2333898544311523, -3.119136095046997]
recently B-LOC [3.1750640869140625, -3.1372411251068115]
been B-LOC [3.1759774684906006, -3.3494837284088135]
renewed B-LOC [3.223773956298828, -3.3218424320220947]
with B-LOC [2.9578475952148438, -3.1591877937316895]
the B-LOC [3.0015275478363037, -3.135831594467163]
discovery B-LOC [3.0265071392059326, -3.2370660305023193]
of B-LOC [2.926100969314575, -3.4728305339813232]
functional B-LOC [2.912479877471924, -3.289438486099243]
BAT B-LOC [2.5722224712371826, -3.3326499462127686]
in B-LOC [2.834151029586792, -3.452368974685669]
humans. B-LOC [3.1858808994293213, -3.4121172428131104]
In O [-0.3772057890892029, 0.1370135247707367]
rodents, B-LOC [-0.08682546019554138, -0.3311615288257599]
BAT B-LOC [-0.16484525799751282, -0.17156118154525757]
can O [-0.3372862935066223, -0.03301885351538658]
be O [-0.39030835032463074, 0.08473028987646103]
activated O [-0.37640640139579773, 0.2866213023662567]
by O [-0.530697762966156, 0.36088696122169495]
bile O [-0.3577525317668915, 0.17530813813209534]
acids, O [-0.17995405197143555, 0.19245749711990356]
which O [-0.47842344641685486, 0.1382068544626236]
activate O [-0.51449054479599, 0.3908655345439911]
type O [-0.30259883403778076, 0.3386249244213104]
2 O [-0.3685154616832733, 0.15623752772808075]
iodothyronine O [-0.36908748745918274, 0.1632920205593109]
deiodinase O [-0.5831890106201172, 0.10929512977600098]
(D2) O [-0.2823216915130615, 0.2601967453956604]
in O [-0.7909064888954163, 0.38223162293434143]
BAT O [-0.33244338631629944, 0.04836811497807503]
via O [-0.7164002060890198, 0.36677107214927673]
the O [-0.2654315233230591, 0.23578038811683655]
G-coupled O [-0.2714116871356964, 0.2276846170425415]
protein O [-0.3056168556213379, -0.022718803957104683]
receptor O [-0.5130550861358643, 0.1065015122294426]
TGR5, O [-0.42579805850982666, 0.15071573853492737]
resulting O [-0.6459718346595764, 0.32123929262161255]
in O [-0.6710482239723206, 0.30740734934806824]
increased O [-0.6403663754463196, 0.29853740334510803]
oxygen O [-0.3958830237388611, 0.005610908847302198]
consumption O [-0.3281426727771759, 0.38521337509155273]
and O [-0.6343704462051392, 0.4983096420764923]
energy O [-0.4972083568572998, 0.22897909581661224]
expenditure. O [-0.3270595967769623, 0.30657246708869934]
Here B-LOC [1.6820181608200073, -1.7268656492233276]
we B-LOC [1.7975789308547974, -1.6053733825683594]
examined B-LOC [2.296813726425171, -2.1133549213409424]
the B-LOC [2.698800802230835, -2.369950771331787]
effects B-LOC [2.497671365737915, -2.4721062183380127]
of B-LOC [2.2625601291656494, -2.1224629878997803]
oral B-LOC [2.1426360607147217, -2.2819833755493164]
supplementation B-LOC [2.3827340602874756, -2.641815423965454]
of B-LOC [2.2308692932128906, -2.1809704303741455]
the B-LOC [2.3494603633880615, -2.158221483230591]
bile B-LOC [2.477665662765503, -2.4845924377441406]
acid B-LOC [2.1475651264190674, -2.3985519409179688]
chenodeoxycholic B-LOC [2.325395345687866, -2.303454875946045]
acid B-LOC [1.917021632194519, -2.177501678466797]
(CDCA) B-LOC [2.4381163120269775, -2.1763617992401123]
on B-LOC [2.1343395709991455, -2.5020835399627686]
human B-LOC [2.2651402950286865, -2.605189085006714]
BAT B-LOC [1.7969615459442139, -2.396946668624878]
activity. B-LOC [2.1071200370788574, -2.4550020694732666]
Treatment B-LOC [1.2478578090667725, -1.548397421836853]
of B-LOC [1.0819461345672607, -1.4174206256866455]
12 B-LOC [1.257655143737793, -1.6334500312805176]
healthy B-LOC [1.13800847530365, -1.7621445655822754]
female B-LOC [0.8963436484336853, -1.6209049224853516]

subjects O [-0.2759656012058258, 0.2921317219734192]
with O [-0.2520082890987396, 0.04877639189362526]
CDCA O [-0.1005205512046814, -0.008735479786992073]
for O [-0.3004298806190491, 0.07228211313486099]
2 O [-0.09828902781009674, 0.04621480777859688]
days O [-0.16475528478622437, 0.1439884603023529]
resulted O [-0.2817383110523224, 0.09045669436454773]
in O [-0.3076527416706085, 0.13426679372787476]
increased O [-0.25319674611091614, 0.08281824737787247]
BAT B-LOC [-0.08642223477363586, -0.304618775844574]
activity. O [-0.07937124371528625, 0.04427974298596382]
Whole-body B-LOC [0.01828230731189251, -0.3397546112537384]
energy B-LOC [0.18733075261116028, -0.4854802191257477]
expenditure B-LOC [0.25419875979423523, -0.4829622209072113]
was B-LOC [0.0844033882021904, -0.4789600372314453]
also B-LOC [0.13666003942489624, -0.36905625462532043]
increased B-LOC [0.20264363288879395, -0.5221548080444336]
upon B-LOC [0.13994577527046204, -0.501514196395874]
CDCA B-LOC [0.29277220368385315, -0.40535059571266174]
treatment. B-LOC [0.10961969941854477, -0.3954661190509796]
In O [-0.6983981728553772, 0.49534720182418823]
vitro O [-0.40047746896743774, 0.5886169075965881]
treatment O [-0.3093146085739136, 0.6944701075553894]
of O [-0.4229639172554016, 0.75364750623703]
primary O [-0.667305052280426, 0.5430585741996765]
human O [-0.6673216223716736, 0.7615494132041931]
brown O [-0.2634703814983368, 0.4119841754436493]
adipocytes O [-0.6208943724632263, 0.5490018725395203]
derived O [-0.46678081154823303, 0.6431718468666077]
with O [-0.39327606558799744, 0.6362224221229553]
CDCA O [-0.5031580328941345, 0.5966424345970154]
or O [-0.45591065287590027, 0.5535651445388794]
specific O [-0.6102607846260071, 0.5879227519035339]
TGR5 O [-0.45147740840911865, 0.6086189150810242]
agonists O [-0.4462411105632782, 0.759242594242096]
increased O [-0.6109001636505127, 0.5214142799377441]
mitochondrial O [-0.7008365988731384, 0.43067243695259094]
uncoupling O [-0.6762027144432068, 0.7482897043228149]
and O [-0.6365815997123718, 0.5479287505149841]
D2 O [-0.552015483379364, 0.447813481092453]
expression, O [-0.49074429273605347, 0.6178463697433472]
an O [-0.4936864674091339, 0.12124533951282501]
effect O [-0.5238989591598511, 0.2891750931739807]
that O [-0.2763960063457489, 0.05658921226859093]
was O [-0.2516178786754608, 0.024034691974520683]
absent O [-0.1196582019329071, 0.09821249544620514]
in O [-0.25139209628105164, 0.05767377093434334]
human O [-0.19867466390132904, 0.0007129940786398947]
primary O [-0.39106521010398865, 0.07704155892133713]
white O [-0.25606971979141235, 0.08222047239542007]
adipocytes. O [-0.471271812915802, 0.06290632486343384]
These B-LOC [0.682464063167572, -0.717681884765625]
findings B-LOC [0.7193241715431213, -0.5849232077598572]
identify B-LOC [0.9752323031425476, -0.9272131323814392]
bile B-LOC [0.8528907895088196, -1.0541051626205444]
acids B-LOC [0.9604306221008301, -1.1296639442443848]
as B-LOC [1.1758992671966553, -1.3827006816864014]
a B-LOC [1.090565800666809, -1.295663833618164]
target B-LOC [1.0017708539962769, -1.497320294380188]
to B-LOC [1.1229002475738525, -1.26465904712677]
activate B-LOC [0.7209808230400085, -1.1095892190933228]
BAT B-LOC [0.44199472665786743, -1.2433748245239258]
in B-LOC [0.9338062405586243, -1.297616958618164]
humans. B-LOC [0.9870533347129822, -1.4484755992889404]

CONTEXT B-LOC [2.592998743057251, -3.5666840076446533]
Many B-LOC [3.4587466716766357, -3.6025636196136475]
observational B-LOC [3.588149309158325, -3.84218692779541]
studies B-LOC [3.6009552478790283, -3.68803334236145]
have B-LOC [3.6834514141082764, -3.541809320449829]
shown B-LOC [3.468498706817627, -3.538435697555542]
that B-LOC [3.0790209770202637, -3.483896255493164]
physical B-LOC [3.4818849563598633, -3.8425376415252686]
activity B-LOC [3.449979543685913, -3.764887571334839]
reduces B-LOC [3.3466718196868896, -3.6350715160369873]
the B-LOC [3.384657621383667, -3.6438865661621094]
risk B-LOC [3.4879534244537354, -3.928164482116699]
of B-LOC [3.2589163780212402, -3.62712025642395]
cognitive B-LOC [3.5704970359802246, -3.764838457107544]
decline; B-LOC [3.413102388381958, -3.735917329788208]
however, B-LOC [3.47758150100708, -3.686666250228882]
evidence B-LOC [3.513596296310425, -3.7888576984405518]
from B-LOC [3.613793134689331, -3.804780960083008]
randomized B-LOC [3.709212064743042, -3.8789103031158447]
trials B-LOC [3.6830809116363525, -3.8443961143493652]
is B-LOC [3.74889874458313, -3.610567331314087]
lacking. B-LOC [3.725446939468384, -3.68894100189209]
OBJECTIVE B-LOC [3.356365919113159, -3.6537129878997803]
To B-LOC [3.5766091346740723, -3.775160074234009]
determine B-LOC [3.624826431274414, -3.6890923976898193]
whether B-LOC [3.4572408199310303, -3.753120183944702]
physical B-LOC [3.444718599319458, -3.9321603775024414]
activity B-LOC [3.551255702972412, -3.834826707839966]
reduces B-LOC [3.311638116836548, -3.863933801651001]
the B-LOC [3.5886101722717285, -3.782348155975342]
rate B-LOC [3.4526307582855225, -3.911221742630005]
of B-LOC [3.3806004524230957, -3.772251605987549]
cognitive B-LOC [3.5563175678253174, -3.710623264312744]
decline B-LOC [3.4931423664093018, -3.708505868911743]
among B-LOC [3.3639979362487793, -3.7538578510284424]
older B-LOC [3.707341432571411, -3.724466323852539]
adults B-LOC [3.754566192626953, -3.626293659210205]
at B-LOC [3.6723415851593018, -3.669098377227783]
risk. B-LOC [3.7904298305511475, -3.784998655319214]
DESIGN B-LOC [3.7226665019989014, -3.3309266567230225]
AND B-LOC [3.745375394821167, -3.5175893306732178]
SETTING B-LOC [3.6410598754882812, -3.418036460876465]
Randomized B-LOC [3.7983338832855225, -3.2612361907958984]
controlled B-LOC [3.929645299911499, -3.489640712738037]
trial B-LOC [3.8697509765625, -3.3646368980407715]
of B-LOC [3.842116594314575, -3.1723110675811768]
a B-LOC [3.724879503250122, -3.248436212539673]
24-week B-LOC [3.7581191062927246, -3.0885074138641357]
physical B-LOC [3.779714584350586, -3.5756161212921143]
activity B-LOC [3.7857308387756348, -3.4871809482574463]
intervention B-LOC [3.557769298553467, -3.5192952156066895]
conducted B-LOC [3.879535436630249, -3.19435715675354]
between B-LOC [3.699660062789917, -2.9709372520446777]
2004 B-LOC [3.864607572555542, -3.0812418460845947]
and B-LOC [3.7239668369293213, -2.952049970626831]
2007 B-LOC [3.889019727706909, -3.2444827556610107]
in B-LOC [3.81492280960083, -3.0332820415496826]
metropolitan B-LOC [3.85337495803833, -3.4071435928344727]
Perth, B-LOC [3.710622549057007, -3.4932987689971924]
Western B-LOC [3.5812652111053467, -3.515230894088745]
Australia. B-LOC [3.8187921047210693, -3.475294828414917]
Assessors B-LOC [3.740771532058716, -3.5135087966918945]
of B-LOC [3.7294111251831055, -3.371889114379883]
cognitive B-LOC [3.8574562072753906, -3.621713399887085]
function B-LOC [3.8302557468414307, -3.405885696411133]
were B-LOC [3.6812264919281006, -3.1960299015045166]
blinded B-LOC [3.9510014057159424, -3.1506917476654053]
to B-LOC [3.6042401790618896, -3.28373384475708]
group B-LOC [3.8113420009613037, -3.5150539875030518]
membership. B-LOC [3.838477373123169, -3.4667274951934814]
PARTICIPANTS B-LOC [1.9956947565078735, -2.8202717304229736]
We B-LOC [1.9991523027420044, -2.2182371616363525]
recruited B-LOC [2.564944267272949, -2.618990182876587]
volunteers B-LOC [2.678014039993286, -2.830681085586548]
who B-LOC [2.5328805446624756, -2.5802106857299805]
reported B-LOC [2.1010987758636475, -2.2537314891815186]
memory B-LOC [2.6712961196899414, -2.778052568435669]
problems B-LOC [2.67543625831604, -2.462143659591675]
but B-LOC [2.1287190914154053, -2.411302089691162]
did B-LOC [2.32454776763916, -2.2485499382019043]
not B-LOC [2.671529769897461, -2.222135543823242]
meet B-LOC [2.8032140731811523, -2.8274593353271484]
criteria B-LOC [3.180422306060791, -3.066237211227417]
for B-LOC [2.806330680847168, -2.8066461086273193]
dementia. B-LOC [3.149879217147827, -2.84110951423645]
Three B-LOC [2.183095693588257, -2.147343397140503]

hundred B-LOC [2.523872137069702, -2.7452120780944824]
eleven B-LOC [2.9980154037475586, -3.3154122829437256]
individuals B-LOC [2.891028642654419, -3.425065755844116]
aged B-LOC [3.27506422996521, -3.188338279724121]
50 B-LOC [3.384390115737915, -2.822859048843384]
years B-LOC [3.2319138050079346, -2.9643967151641846]
or B-LOC [2.837315320968628, -2.8971049785614014]
older B-LOC [3.303621530532837, -2.789252281188965]
were B-LOC [2.9222283363342285, -3.2582836151123047]
screened B-LOC [3.3085241317749023, -3.3674190044403076]
for B-LOC [3.137883424758911, -3.33024001121521]
eligibility, B-LOC [3.0836119651794434, -3.2589664459228516]
89 B-LOC [3.033031940460205, -3.277360200881958]
were B-LOC [2.9704113006591797, -3.205254316329956]
not B-LOC [3.2930119037628174, -3.0659396648406982]
eligible, B-LOC [3.2196638584136963, -3.297048330307007]
and B-LOC [2.8005878925323486, -3.0409328937530518]
52 B-LOC [3.20003342628479, -3.2915852069854736]
refused B-LOC [3.243713140487671, -3.1374380588531494]
to B-LOC [3.02129864692688, -2.8777964115142822]
participate. B-LOC [3.11966609954834, -3.1888067722320557]
A B-LOC [3.1025612354278564, -3.061734199523926]
total B-LOC [3.424461603164673, -2.9542124271392822]
of B-LOC [3.1389172077178955, -2.8448355197906494]
170 B-LOC [3.3912580013275146, -3.2125613689422607]
participants B-LOC [3.3013429641723633, -3.4766454696655273]
were B-LOC [3.3157479763031006, -3.0514817237854004]
randomized B-LOC [3.389103889465332, -3.172358751296997]
and B-LOC [2.8532791137695312, -3.0438225269317627]
138 B-LOC [3.3215694427490234, -3.1110188961029053]
participants B-LOC [3.4030802249908447, -3.465235471725464]
completed B-LOC [3.552868366241455, -3.107449769973755]
the B-LOC [3.232154607772827, -3.0793323516845703]
18-month B-LOC [3.208976984024048, -3.1326234340667725]
assessment. B-LOC [3.2967112064361572, -3.4685165882110596]
INTERVENTION B-LOC [2.9330146312713623, -3.024390935897827]
Participants B-LOC [3.015192747116089, -3.068718671798706]
were B-LOC [3.187208890914917, -2.714012384414673]
randomly B-LOC [3.24765944480896, -3.055732488632202]
allocated B-LOC [3.4398066997528076, -3.101182460784912]
to B-LOC [3.2449944019317627, -2.9012935161590576]
an B-LOC [3.1826016902923584, -2.9729702472686768]
education B-LOC [3.063059091567993, -3.3514888286590576]
and B-LOC [3.058882474899292, -3.1938066482543945]
usual B-LOC [3.0535542964935303, -3.021834373474121]
care B-LOC [3.321894884109497, -3.135347604751587]
group B-LOC [3.3539695739746094, -3.04640793800354]
or B-LOC [3.259370803833008, -2.8645784854888916]
to B-LOC [3.175774097442627, -3.006319761276245]
a B-LOC [3.1623764038085938, -2.871140718460083]
24-week B-LOC [3.1858108043670654, -2.777808427810669]
home-based B-LOC [2.8795745372772217, -3.0542972087860107]
program B-LOC [3.179332971572876, -2.992685079574585]
of B-LOC [2.936542272567749, -2.668919324874878]
physical B-LOC [3.0917770862579346, -3.2486000061035156]
activity. B-LOC [2.995035171508789, -3.096881151199341]
MAIN B-LOC [3.0574629306793213, -2.840207576751709]
OUTCOME B-LOC [2.807269334793091, -2.6379783153533936]
MEASURE B-LOC [2.8524272441864014, -2.7454144954681396]
Change B-LOC [2.9109508991241455, -3.1128904819488525]
in B-LOC [3.0772063732147217, -2.8408777713775635]
Alzheimer B-LOC [3.223586320877075, -3.021026372909546]
Disease B-LOC [3.282562255859375, -3.1310112476348877]
Assessment B-LOC [3.269371747970581, -3.0796926021575928]
Scale-Cognitive B-LOC [2.9310824871063232, -2.920050859451294]
Subscale B-LOC [3.1280152797698975, -2.9035422801971436]
(ADAS-Cog) B-LOC [3.0389511585235596, -2.779684066772461]
scores B-LOC [3.1673591136932373, -2.8887836933135986]
(possible B-LOC [3.2618188858032227, -2.651766777038574]
range, B-LOC [3.1104307174682617, -2.9544460773468018]
0-70) B-LOC [3.224837064743042, -2.706690549850464]
over B-LOC [2.783794403076172, -2.6930038928985596]
18 B-LOC [3.237236261367798, -2.762415647506714]
months. B-LOC [3.1220853328704834, -2.7578012943267822]
RESULTS B-LOC [0.933351457118988, -1.683084487915039]
In B-LOC [0.9833968877792358, -1.0567892789840698]
an B-LOC [0.5886486172676086, -1.1254674196243286]

intent-to-treat O [-0.7257949709892273, 0.622532308101654]
analysis, O [-0.8371666073799133, 0.8586863279342651]
participants O [-0.6978629231452942, 0.7093358039855957]
in O [-0.6673237085342407, 0.8099753260612488]
the O [-0.7006117105484009, 0.7945287227630615]
intervention O [-0.7166271805763245, 0.5777942538261414]
group O [-0.6643807291984558, 1.002310872077942]
improved O [-0.8182469010353088, 0.7232306599617004]
0.26 O [-0.6148653626441956, 0.774094820022583]
points O [-0.7471471428871155, 0.6985309720039368]
(95% O [-0.7692816257476807, 0.6738154292106628]
confidence O [-0.7765247225761414, 0.8137523531913757]
interval, O [-0.9463663101196289, 0.8046184182167053]
-0.89 O [-0.9285969138145447, 0.5356380343437195]
to O [-0.9542784094810486, 0.43501660227775574]
0.54) O [-0.5580397844314575, 0.7295244336128235]
and O [-0.8373463749885559, 0.6832456588745117]
those O [-0.6781058311462402, 0.7622703909873962]
in O [-0.834195077419281, 0.7913722395896912]
the O [-0.8619592189788818, 0.875428318977356]
usual O [-0.8980321288108826, 0.6966509222984314]
care O [-0.7763936519622803, 0.737815797328949]
group O [-0.9449135065078735, 0.8856968283653259]
deteriorated O [-0.7516629099845886, 0.7586852312088013]
1.04 O [-0.7483564019203186, 0.8166576623916626]
points O [-0.7933793067932129, 0.6641407608985901]
(95% O [-0.7651801705360413, 0.5450118780136108]
confidence O [-0.8082067370414734, 0.8386139273643494]
interval, O [-0.9701860547065735, 0.7691676020622253]
0.32 O [-0.6473944187164307, 0.7951980233192444]
to O [-0.8016189932823181, 0.33295226097106934]
1.82) O [-0.6565843820571899, 0.6583570837974548]
on O [-0.7845350503921509, 0.7655819654464722]
the O [-0.7588525414466858, 0.706334114074707]
ADAS-Cog O [-0.6684889197349548, 0.7001417279243469]
at O [-0.7767632603645325, 0.6562575101852417]
the O [-0.6948749423027039, 0.8165962100028992]
end O [-0.6236501336097717, 0.7382695078849792]
of O [-0.7771722674369812, 0.7348921895027161]
the O [-0.6529626250267029, 0.7734450697898865]
intervention. O [-0.7961109280586243, 0.5346645712852478]
The B-LOC [1.7747700214385986, -1.739741563796997]
absolute B-LOC [2.1145966053009033, -2.0518441200256348]
difference B-LOC [1.8953174352645874, -2.0898120403289795]
of B-LOC [2.214118719100952, -1.9265412092208862]
the B-LOC [2.1605961322784424, -2.096968412399292]
outcome B-LOC [1.817897081375122, -2.0933525562286377]
measure B-LOC [1.9544999599456787, -1.9996733665466309]
between B-LOC [2.0240635871887207, -2.0267274379730225]
the B-LOC [2.001816987991333, -2.121803045272827]
intervention B-LOC [1.2169753313064575, -1.8912622928619385]
and B-LOC [1.840058445930481, -1.993380069732666]
control B-LOC [2.0157456398010254, -2.250558376312256]
groups B-LOC [2.006089925765991, -1.905375599861145]
was B-LOC [1.626772165298462, -1.7189583778381348]
-1.3 B-LOC [1.3401163816452026, -1.5733426809310913]
points B-LOC [1.6386679410934448, -2.298058271408081]
(95% B-LOC [1.6296815872192383, -1.5981228351593018]
confidence B-LOC [1.6426445245742798, -2.0503461360931396]
interval,-2.38 B-LOC [1.5624343156814575, -2.041112184524536]
to B-LOC [1.3712100982666016, -1.735363483428955]
-0.22) B-LOC [1.0699642896652222, -1.4354660511016846]
at B-LOC [2.015770435333252, -1.9532033205032349]
the B-LOC [2.0822207927703857, -1.958899974822998]
end B-LOC [2.0334091186523438, -1.8829760551452637]
of B-LOC [2.0744330883026123, -1.855189561843872]
the B-LOC [2.009516716003418, -1.8957788944244385]
intervention. B-LOC [1.2503280639648438, -2.0549490451812744]
At B-LOC [0.3196263909339905, -0.7902864813804626]
18 B-LOC [1.0128991603851318, -0.937608540058136]
months, B-LOC [0.974679172039032, -0.9648240208625793]
participants B-LOC [0.5909081697463989, -0.8089125752449036]
in B-LOC [0.6141989827156067, -0.7353660464286804]
the B-LOC [0.8744800686836243, -0.7866938710212708]
intervention B-LOC [0.49304941296577454, -1.0007020235061646]
group B-LOC [0.49005672335624695, -0.5282479524612427]

improved O [-0.5365034937858582, 0.3641504943370819]
0.73 O [-0.33079442381858826, 0.39683765172958374]
points O [-0.5214934945106506, 0.2518933415412903]
(95% O [-0.5776148438453674, 0.2803124189376831]
confidence O [-0.5578979849815369, 0.45968860387802124]
interval, O [-0.6716793179512024, 0.42659881711006165]
-1.27 O [-0.7176334857940674, 0.18358628451824188]
to O [-0.6997728943824768, 0.18344834446907043]
0.03) O [-0.4479745924472809, 0.20848365128040314]
on O [-0.4926084578037262, 0.4815311133861542]
the O [-0.4718075394630432, 0.38465461134910583]
ADAS-Cog, O [-0.436605840921402, 0.3979960083961487]
and O [-0.5445835590362549, 0.39582905173301697]
those O [-0.3526325523853302, 0.3737392723560333]
in O [-0.38993075489997864, 0.3136005103588104]
the O [-0.3965928256511688, 0.41203299164772034]
usual O [-0.6041339635848999, 0.3113529086112976]
care O [-0.5338847041130066, 0.4852561056613922]
group O [-0.49624115228652954, 0.5637509226799011]
improved O [-0.4306834936141968, 0.37637272477149963]
0.04 O [-0.23164035379886627, 0.34037959575653076]
points O [-0.4368531107902527, 0.17861242592334747]
(95% O [-0.4663369357585907, 0.13154028356075287]
confidence O [-0.46086183190345764, 0.3765012323856354]
interval, O [-0.6217129826545715, 0.3188888132572174]
-0.46 O [-0.6429217457771301, 0.14385131001472473]
to O [-0.57896488904953, 0.05010916665196419]
0.88). O [-0.3022878170013428, 0.13908842206001282]
Word B-LOC [1.4940528869628906, -2.287304162979126]
list B-LOC [1.349597454071045, -2.126638412475586]
delayed B-LOC [1.1512970924377441, -1.8057007789611816]
recall B-LOC [1.2356021404266357, -1.8427311182022095]
and B-LOC [1.2278416156768799, -1.95364511013031]
Clinical B-LOC [1.7501096725463867, -2.233013391494751]
Dementia B-LOC [1.4305269718170166, -2.2130649089813232]
Rating B-LOC [1.56516432762146, -2.4797260761260986]
sum B-LOC [1.5062974691390991, -2.0710549354553223]
of B-LOC [1.5912712812423706, -2.0481369495391846]
boxes B-LOC [1.5412733554840088, -2.228100538253784]
improved B-LOC [1.0244979858398438, -1.8268554210662842]
modestly B-LOC [1.1543552875518799, -1.562805414199829]
as B-LOC [0.6656817197799683, -1.0307085514068604]
well, B-LOC [0.7533173561096191, -1.0664597749710083]
whereas B-LOC [0.8356475234031677, -1.239306092262268]
word B-LOC [1.6379718780517578, -2.5043785572052]
list B-LOC [1.5722192525863647, -2.3312833309173584]
total B-LOC [1.4293897151947021, -2.1394102573394775]
immediate B-LOC [1.484923243522644, -2.2966225147247314]
recall, B-LOC [1.4650001525878906, -2.087815046310425]
digit B-LOC [1.807687759399414, -2.6630189418792725]
symbol B-LOC [1.858046293258667, -2.467038631439209]
coding, B-LOC [1.4572389125823975, -2.2234957218170166]
verbal B-LOC [1.738722801208496, -2.371752977371216]
fluency, B-LOC [1.9711508750915527, -2.774029493331909]
Beck B-LOC [1.4164286851882935, -2.1351146697998047]
depression B-LOC [1.8708343505859375, -2.4221625328063965]
score, B-LOC [1.7839727401733398, -2.372622013092041]
and B-LOC [1.6646678447723389, -2.424849510192871]
Medical B-LOC [1.8010778427124023, -2.5809803009033203]
Outcomes B-LOC [2.203230381011963, -2.6458818912506104]
36-Item B-LOC [1.9741878509521484, -2.379025459289551]
Short-Form B-LOC [1.8167065382003784, -2.2690012454986572]
physical B-LOC [1.7663614749908447, -2.3496055603027344]
and B-LOC [1.6644692420959473, -2.280198097229004]
mental B-LOC [1.9883334636688232, -2.3450019359588623]
component B-LOC [1.6557812690734863, -2.527941942214966]
summaries B-LOC [2.185725212097168, -2.35514235496521]
did B-LOC [1.2948583364486694, -1.74078369140625]
not B-LOC [1.2132742404937744, -1.416077733039856]
change B-LOC [1.3313331604003906, -2.2705094814300537]
significantly. B-LOC [1.319079041481018, -2.0447728633880615]

CONCLUSIONS O [-1.165696382522583, 0.7200996279716492]
In O [-1.1703959703445435, 0.949070394039154]
this O [-0.8786039352416992, 0.8213040232658386]
study O [-0.9673829674720764, 0.8085259199142456]
of O [-0.9037905335426331, 0.9085476994514465]
adults O [-0.6707329154014587, 0.6256951093673706]
with O [-0.9522795081138611, 0.8064528107643127]
subjective O [-0.9639731049537659, 0.9832056164741516]
memory O [-0.5545758605003357, 0.7612878680229187]
impairment, O [-0.9055138826370239, 0.9414018392562866]
a O [-1.1599775552749634, 1.0550909042358398]
6-month O [-0.887755274772644, 1.0438544750213623]
program O [-1.2633038759231567, 1.018910527229309]
of O [-1.4721598625183105, 1.1357903480529785]
physical O [-1.2696551084518433, 1.0700953006744385]
activity O [-1.0626286268234253, 1.1574792861938477]
provided O [-1.253316044807434, 1.058621883392334]
a O [-1.1972886323928833, 1.13431978225708]
modest O [-1.0683473348617554, 1.2049860954284668]
improvement O [-1.1161527633666992, 1.1582807302474976]
in O [-1.2399033308029175, 1.224814772605896]
cognition O [-1.3054919242858887, 1.2216076850891113]
over O [-1.0740565061569214, 1.17287015914917]
an O [-1.1437482833862305, 0.9198673367500305]
18-month O [-0.9286313056945801, 1.0046578645706177]
follow-up O [-1.2261544466018677, 0.9904354214668274]
period. O [-1.1256601810455322, 0.9590515494346619]
TRIAL B-LOC [2.107301950454712, -2.190661907196045]
REGISTRATION B-LOC [1.8798549175262451, -1.9922431707382202]
anzctr.org.au B-LOC [1.8842709064483643, -1.8560328483581543]
Identifier: B-LOC [2.2129030227661133, -1.9314663410186768]
ACTRN12605000136606. B-LOC [2.2414419651031494, -2.136042356491089]

BACKGROUND B-LOC [0.39643290638923645, -0.6881781220436096]
Artemisinin B-LOC [0.26528260111808777, -0.12444117665290833]
derivatives O [0.07418400049209595, 0.30889883637428284]
used B-LOC [0.1108192652463913, 0.04989490658044815]
in B-LOC [0.129313662648201, -0.1386665552854538]
recently B-LOC [0.16322794556617737, -0.11713121831417084]
introduced B-LOC [0.3190777003765106, -0.17056941986083984]
combination B-LOC [0.27668604254722595, -0.16628682613372803]
therapies B-LOC [0.847716748714447, -0.2641817629337311]
(ACTs) B-LOC [0.2546803653240204, -0.31398239731788635]
for O [-0.0811159759759903, 0.12579578161239624]
Plasmodium O [-0.20166827738285065, 0.2557094693183899]
falciparum O [-0.4120309054851532, 0.33033886551856995]
malaria O [-0.2818291485309601, 0.608394980430603]
significantly O [-0.5007341504096985, 0.5634120106697083]
lower O [-0.5202476382255554, 0.6835731267929077]
patient O [-0.4016219675540924, 0.04380663111805916]
infectiousness B-LOC [0.08146579563617706, 0.03908893093466759]
and O [-0.6848941445350647, 0.546737015247345]
have O [-0.08115409314632416, 0.18093831837177277]
the O [-0.488519549369812, 0.3061387240886688]
potential B-LOC [0.11639299988746643, 0.05095283314585686]
to O [-0.2777281701564789, 0.21352839469909668]
reduce O [-0.2807773947715759, 0.22777625918388367]
population-level B-LOC [0.0006778562092222273, -0.20438428223133087]
transmission O [-0.08670522272586823, -0.019164210185408592]
of O [-0.03755461797118187, -0.03740949556231499]
the O [-0.1942983865737915, -0.0381229892373085]
parasite. B-LOC [0.19332006573677063, -0.38948333263397217]
With B-LOC [2.3349015712738037, -2.7685277462005615]
the B-LOC [2.615321397781372, -2.516333818435669]
increased B-LOC [2.652465581893921, -3.0450708866119385]
interest B-LOC [2.91059947013855, -3.0801119804382324]
in B-LOC [2.930243730545044, -3.2963364124298096]
malaria B-LOC [2.8345301151275635, -3.078871965408325]
elimination, B-LOC [3.1397271156311035, -3.398460626602173]
understanding B-LOC [3.0958759784698486, -3.2560782432556152]
the B-LOC [3.248438835144043, -3.4247500896453857]
impact B-LOC [3.051687240600586, -3.600816011428833]
on B-LOC [2.845269203186035, -3.3207712173461914]
transmission B-LOC [3.175468683242798, -3.463001012802124]
of B-LOC [2.970557928085327, -3.34080171585083]
ACT B-LOC [2.7335550785064697, -3.047928810119629]
and B-LOC [3.048516035079956, -3.217750072479248]
other B-LOC [3.38187837600708, -3.301706552505493]
antimalarial B-LOC [3.1657278537750244, -3.381321668624878]
drugs B-LOC [3.124418020248413, -3.376711845397949]
with B-LOC [3.2074005603790283, -3.458261489868164]
different B-LOC [2.996617555618286, -3.5707597732543945]
pharmacodynamics B-LOC [3.293558359146118, -3.3891029357910156]
becomes B-LOC [3.2077956199645996, -3.2487454414367676]
a B-LOC [3.1171605587005615, -3.348376989364624]
key B-LOC [3.05895733833313, -3.3333659172058105]
issue. B-LOC [3.026376962661743, -3.3721983432769775]
This B-LOC [2.9285576343536377, -3.1659176349639893]
study B-LOC [2.8210151195526123, -3.040247917175293]
estimates B-LOC [3.0838661193847656, -2.9744226932525635]
the B-LOC [3.169806480407715, -2.955645799636841]
reduction B-LOC [3.045030355453491, -3.3053603172302246]
in B-LOC [2.8676042556762695, -3.029667854309082]
transmission B-LOC [3.135394811630249, -3.204298257827759]
that B-LOC [3.0759012699127197, -3.0371415615081787]
may B-LOC [3.2015841007232666, -2.8974955081939697]
be B-LOC [3.2110984325408936, -3.1287314891815186]
achieved B-LOC [3.3553121089935303, -3.254624128341675]
by B-LOC [3.0463621616363525, -2.677558183670044]
introducing B-LOC [3.207036256790161, -3.089595079421997]
different B-LOC [3.0748531818389893, -3.153867483139038]
types B-LOC [3.4532430171966553, -3.044888734817505]
of B-LOC [3.1487488746643066, -3.033656358718872]
treatment B-LOC [3.1940701007843018, -3.2528903484344482]
for B-LOC [3.113158941268921, -2.957296848297119]
symptomatic B-LOC [3.1771984100341797, -2.8097407817840576]
P. B-LOC [2.5226686000823975, -2.6651647090911865]
falciparum B-LOC [2.5679500102996826, -2.484760284423828]
malaria B-LOC [2.689633369445801, -2.892017126083374]
in B-LOC [3.099797487258911, -2.845357656478882]
endemic B-LOC [3.283729314804077, -3.2813127040863037]
areas. B-LOC [3.2853872776031494, -3.017869234085083]
METHODS B-LOC [1.2176332473754883, -1.7553671598434448]
AND B-LOC [1.3724431991577148, -2.0570123195648193]

FINDINGS B-LOC [0.9911159873008728, -1.6544153690338135]
We B-LOC [1.6565418243408203, -2.2433204650878906]
developed B-LOC [2.051283121109009, -2.400660753250122]
a B-LOC [2.1803317070007324, -2.5053117275238037]
mathematical B-LOC [2.383897542953491, -2.6203553676605225]
model B-LOC [2.3687241077423096, -2.8613333702087402]
to B-LOC [2.1509816646575928, -2.7262520790100098]
predict B-LOC [2.3097031116485596, -2.796734571456909]
the B-LOC [2.448014497756958, -2.811419725418091]
potential B-LOC [2.1959168910980225, -2.5698931217193604]
impact B-LOC [2.114121437072754, -2.4828827381134033]
on B-LOC [2.146434783935547, -2.6412534713745117]
transmission B-LOC [1.8146917819976807, -2.201568365097046]
outcomes B-LOC [2.0851991176605225, -2.1651649475097656]
of B-LOC [1.6528156995773315, -2.014361619949341]
introducing B-LOC [1.5428324937820435, -1.7928811311721802]
ACT B-LOC [1.496739387512207, -1.6227980852127075]
as B-LOC [1.307335376739502, -1.800752878189087]
first-line B-LOC [1.7056200504302979, -2.0661213397979736]
treatment B-LOC [1.5348541736602783, -1.6264188289642334]
for B-LOC [1.7533321380615234, -1.9670627117156982]
uncomplicated B-LOC [2.110241174697876, -2.25407338142395]
malaria B-LOC [1.694261074066162, -1.7601079940795898]
in B-LOC [1.8591722249984741, -2.0008304119110107]
six B-LOC [2.145547389984131, -2.16576886177063]
areas B-LOC [1.7366058826446533, -1.734447717666626]
of B-LOC [1.8219304084777832, -1.9691877365112305]
varying B-LOC [1.8974210023880005, -2.6203932762145996]
transmission B-LOC [1.6165742874145508, -1.8088725805282593]
intensity B-LOC [1.7023957967758179, -1.7361608743667603]
in B-LOC [1.9126944541931152, -2.04007625579834]
Tanzania. B-LOC [1.9114317893981934, -1.9496259689331055]
We B-LOC [1.9150885343551636, -2.597576856613159]
also B-LOC [2.2008495330810547, -2.5953872203826904]
estimated B-LOC [2.206953287124634, -2.69891357421875]
the B-LOC [2.3653926849365234, -2.675478935241699]
impact B-LOC [2.169527053833008, -2.575242042541504]
that B-LOC [2.256727933883667, -2.6881906986236572]
could B-LOC [2.2459661960601807, -2.424592971801758]
be B-LOC [2.276041269302368, -2.6435210704803467]
achieved B-LOC [2.129037857055664, -2.4096696376800537]
by B-LOC [1.9043031930923462, -2.2310831546783447]
antimalarials B-LOC [2.0520989894866943, -2.182269811630249]
with B-LOC [2.0854856967926025, -2.500070333480835]
different B-LOC [2.0726046562194824, -2.7437140941619873]
efficacy, B-LOC [1.888397216796875, -2.01898455619812]
prophylactic B-LOC [2.0761706829071045, -2.561859369277954]
time, B-LOC [1.64323091506958, -1.7218217849731445]
and B-LOC [2.063218116760254, -2.589973211288452]
gametocytocidal B-LOC [1.9720489978790283, -2.0656425952911377]
effects. B-LOC [2.059861421585083, -2.244619131088257]
Rates B-LOC [2.8959286212921143, -3.2692365646362305]
of B-LOC [2.54003643989563, -3.0228850841522217]
treatment, B-LOC [2.802668571472168, -3.049034357070923]
asymptomatic B-LOC [2.8421003818511963, -3.374298334121704]
infection, B-LOC [2.4970438480377197, -2.8645761013031006]
and B-LOC [2.598228693008423, -3.222425937652588]
symptomatic B-LOC [3.050119161605835, -3.452697515487671]
infection B-LOC [2.4260714054107666, -2.7438836097717285]
in B-LOC [2.953295946121216, -3.0000782012939453]
the B-LOC [3.0713179111480713, -3.071450710296631]
six B-LOC [2.955603837966919, -3.16808819770813]
study B-LOC [2.9206197261810303, -3.2964680194854736]
areas B-LOC [3.220473051071167, -3.096806526184082]
were B-LOC [2.83390212059021, -2.8734235763549805]
estimated B-LOC [3.126873016357422, -3.4276697635650635]
using B-LOC [2.632716655731201, -3.3155367374420166]
the B-LOC [3.1359658241271973, -3.08319091796875]
model B-LOC [2.7670555114746094, -3.2824299335479736]
together B-LOC [2.843005418777466, -2.9615156650543213]
with B-LOC [2.9594531059265137, -3.1374495029449463]
data B-LOC [2.852538824081421, -3.0263631343841553]
from B-LOC [2.717557191848755, -3.03509259223938]
a B-LOC [2.983766555786133, -2.8977577686309814]
cross-sectional B-LOC [3.064649820327759, -2.8239693641662598]
survey B-LOC [2.7298476696014404, -2.7037405967712402]
of B-LOC [2.7744429111480713, -2.7778255939483643]
5,667 B-LOC [3.2509682178497314, -2.90738844871521]
individuals B-LOC [2.8922598361968994, -3.0527732372283936]
conducted B-LOC [3.0187718868255615, -3.16814923286438]
prior B-LOC [3.1036643981933594, -3.00400447845459]
to B-LOC [3.031564950942993, -3.066500186920166]
policy B-LOC [2.5984113216400146, -3.0624020099639893]
change B-LOC [2.3881185054779053, -2.909214973449707]

from B-LOC [1.2847529649734497, -1.449763536453247]
sulfadoxine-pyrimethamine B-LOC [1.4301033020019531, -1.6219381093978882]
to B-LOC [1.6810033321380615, -1.8526232242584229]
ACT. B-LOC [1.4116933345794678, -1.6346969604492188]
The B-LOC [3.0379106998443604, -3.53635311126709]
effects B-LOC [3.080167293548584, -3.5740244388580322]
of B-LOC [2.8849027156829834, -3.1875672340393066]
ACT B-LOC [2.163480043411255, -2.63199782371521]
and B-LOC [3.080002546310425, -3.576319932937622]
other B-LOC [3.3005166053771973, -3.4678256511688232]
drug B-LOC [3.1260409355163574, -3.6817829608917236]
types B-LOC [3.3337206840515137, -3.4683971405029297]
on B-LOC [2.916909694671631, -3.6447956562042236]
gametocytaemia B-LOC [2.8769447803497314, -3.390794515609741]
and B-LOC [3.1451034545898438, -3.6353495121002197]
infectiousness B-LOC [3.4245450496673584, -3.7667171955108643]
to B-LOC [3.1141302585601807, -3.6002564430236816]
mosquitoes B-LOC [3.3437116146087646, -3.636272430419922]
were B-LOC [3.3385040760040283, -3.7946550846099854]
independently B-LOC [3.3595240116119385, -3.9156606197357178]
estimated B-LOC [3.3520314693450928, -3.8038816452026367]
from B-LOC [3.256542205810547, -3.78698468208313]
clinical B-LOC [3.399433135986328, -3.7775042057037354]
trial B-LOC [3.449284553527832, -3.90101957321167]
data. B-LOC [3.3731539249420166, -3.8565902709960938]
Predicted B-LOC [2.452251672744751, -2.6235034465789795]
percentage B-LOC [2.177278518676758, -2.5761756896972656]
reductions B-LOC [2.4683949947357178, -2.8227245807647705]
in B-LOC [2.2191145420074463, -2.630131244659424]
prevalence B-LOC [2.583322763442993, -2.798215389251709]
of B-LOC [2.3888909816741943, -2.5346872806549072]
infection B-LOC [2.6271865367889404, -2.9937422275543213]
and B-LOC [2.3473470211029053, -2.596933126449585]
incidence B-LOC [2.4379725456237793, -2.817824125289917]
of B-LOC [2.388690710067749, -2.592437982559204]
clinical B-LOC [2.6778345108032227, -2.968052625656128]
episodes B-LOC [2.5261282920837402, -2.928206205368042]
achieved B-LOC [2.6943633556365967, -2.8926165103912354]
by B-LOC [2.5617010593414307, -2.6722989082336426]
ACT B-LOC [2.124793767929077, -2.4687979221343994]
were B-LOC [2.308711528778076, -2.6020750999450684]
highest B-LOC [2.711677074432373, -2.828450918197632]
in B-LOC [2.604741334915161, -2.6173806190490723]
the B-LOC [2.5293452739715576, -2.656359910964966]
areas B-LOC [2.6556050777435303, -2.7192094326019287]
with B-LOC [2.598738431930542, -2.507768154144287]
low B-LOC [2.7249276638031006, -2.944338083267212]
initial B-LOC [2.208402156829834, -2.817256212234497]
transmission. B-LOC [2.543134927749634, -2.9836225509643555]
A O [-0.17590659856796265, -0.0420774482190609]
53% O [0.03136994317173958, 0.3199314773082733]
reduction B-LOC [0.05103754624724388, -0.2613922655582428]
in B-LOC [0.006936045829206705, -0.32350391149520874]
prevalence B-LOC [0.044035654515028, -0.1177588403224945]
of B-LOC [-0.00296580558642745, -0.1550835222005844]
infection B-LOC [0.2212456315755844, -0.3034074604511261]
was B-LOC [0.15394799411296844, -0.15704604983329773]
seen B-LOC [0.14420738816261292, -0.04268550127744675]
if B-LOC [-0.009942364878952503, -0.1422746777534485]
100% B-LOC [0.15911102294921875, 0.04576485976576805]
of B-LOC [0.1780685931444168, -0.059761907905340195]
current B-LOC [0.30846646428108215, -0.09297365695238113]
treatment B-LOC [0.11545103043317795, -0.16078829765319824]
was B-LOC [0.3270312249660492, -0.21595102548599243]
switched B-LOC [0.35858288407325745, -0.29077979922294617]
to B-LOC [0.40635308623313904, -0.13961359858512878]
ACT B-LOC [0.2670935094356537, -0.20169873535633087]
in B-LOC [0.19398750364780426, 0.048187416046857834]
the B-LOC [0.17619149386882782, 0.03890300169587135]
area B-LOC [0.33354341983795166, -0.2659851014614105]
where B-LOC [-0.0957125574350357, -0.15775658190250397]
baseline B-LOC [-0.020983723923563957, -0.03926973044872284]
slide-prevalence B-LOC [0.151334747672081, -0.10848931223154068]
of O [-0.1347654163837433, 0.014415161684155464]
parasitaemia O [-0.14271871745586395, -0.010114485397934914]
was B-LOC [0.08361812680959702, -0.21957266330718994]
lowest B-LOC [0.34707221388816833, -0.145029217004776]
(3.7%), B-LOC [0.17766903340816498, -0.18639498949050903]
compared O [-0.27187415957450867, 0.13574504852294922]
to O [-0.13593704998493195, 0.10188200324773788]
an O [-0.35138189792633057, -0.13759660720825195]
11% O [-0.07388211786746979, 0.19812926650047302]
reduction O [-0.2020910382270813, -0.12632989883422852]

in B-LOC [1.043257474899292, -1.6167904138565063]
the B-LOC [1.5570101737976074, -1.7404452562332153]
highest-transmission B-LOC [1.7701241970062256, -2.2862281799316406]
setting B-LOC [1.365343451499939, -2.1843760013580322]
(baseline B-LOC [1.6222188472747803, -1.7449742555618286]
slide B-LOC [1.7721630334854126, -2.162531852722168]
prevalence B-LOC [1.3990461826324463, -2.0777499675750732]
= B-LOC [1.0449910163879395, -1.7105512619018555]
57.1%). B-LOC [1.6954846382141113, -2.0800867080688477]
Estimated B-LOC [2.0803449153900146, -2.536939859390259]
percentage B-LOC [1.9930081367492676, -2.549630880355835]
reductions B-LOC [1.9924780130386353, -2.558575391769409]
in B-LOC [1.8765513896942139, -2.4412009716033936]
incidence B-LOC [1.8404407501220703, -2.4155967235565186]
of B-LOC [1.7638049125671387, -2.3030948638916016]
clinical B-LOC [2.028062105178833, -2.5900771617889404]
episodes B-LOC [1.76903235912323, -2.426748514175415]
were B-LOC [1.9788827896118164, -2.380861520767212]
similar. B-LOC [2.131157875061035, -2.6659743785858154]
The B-LOC [2.210862159729004, -2.628002405166626]
absolute B-LOC [2.589381456375122, -2.912693738937378]
size B-LOC [2.409576416015625, -2.7889232635498047]
of B-LOC [2.542786121368408, -2.83249831199646]
the B-LOC [2.33659291267395, -2.7623798847198486]
public B-LOC [2.4192841053009033, -2.9025895595550537]
health B-LOC [2.332176446914673, -2.9809396266937256]
impact, B-LOC [2.0131702423095703, -2.8756649494171143]
however, B-LOC [2.2424800395965576, -2.5435636043548584]
was B-LOC [1.9399781227111816, -2.4664499759674072]
greater B-LOC [2.4922640323638916, -2.74200701713562]
in B-LOC [2.2204105854034424, -2.370781660079956]
the B-LOC [2.3782567977905273, -2.437694787979126]
highest-transmission B-LOC [2.5470163822174072, -2.8926403522491455]
area, B-LOC [2.321782350540161, -2.9120404720306396]
with B-LOC [2.13102650642395, -2.374112606048584]
54 B-LOC [2.2863528728485107, -2.6574130058288574]
clinical B-LOC [2.2841062545776367, -2.9806578159332275]
episodes B-LOC [2.1856186389923096, -2.7441678047180176]
per B-LOC [2.6137313842773438, -2.7858636379241943]
100 B-LOC [2.466435670852661, -2.8553993701934814]
persons B-LOC [2.15352725982666, -2.865454912185669]
per B-LOC [2.585881471633911, -2.7928450107574463]
year B-LOC [2.548821210861206, -3.0909390449523926]
averted B-LOC [2.5980935096740723, -2.7513537406921387]
compared B-LOC [1.8981283903121948, -2.140176773071289]
to B-LOC [2.3856444358825684, -2.544875383377075]
five B-LOC [2.267319440841675, -2.6571481227874756]
per B-LOC [2.275472640991211, -2.736518621444702]
100 B-LOC [2.3713390827178955, -2.639012098312378]
persons B-LOC [2.122572898864746, -2.8466179370880127]
per B-LOC [2.50003981590271, -2.79986834526062]
year B-LOC [2.4842777252197266, -3.031158924102783]
in B-LOC [2.2149128913879395, -2.500576972961426]
the B-LOC [2.403320789337158, -2.4554030895233154]
lowest-transmission B-LOC [2.6130683422088623, -2.841845750808716]
area. B-LOC [2.4265224933624268, -2.9852988719940186]
High B-LOC [1.2244691848754883, -2.1986892223358154]
coverage B-LOC [1.107849359512329, -1.85304594039917]
was B-LOC [1.3768178224563599, -2.11810564994812]
important. B-LOC [1.4108738899230957, -2.0378823280334473]
Reducing B-LOC [0.4921153485774994, -0.5290865898132324]
presumptive B-LOC [0.7018828988075256, -0.9685269594192505]
treatment B-LOC [0.7492886185646057, -1.1132245063781738]
through B-LOC [0.3524082601070404, -0.5129734873771667]
improved B-LOC [0.14330491423606873, -0.4768693149089813]
diagnosis B-LOC [0.8518075942993164, -1.1350347995758057]
substantially B-LOC [0.33713579177856445, -0.20988506078720093]
reduced B-LOC [0.3120866119861603, -0.40040215849876404]
the B-LOC [0.3408174216747284, -0.7826585173606873]
number B-LOC [0.48987823724746704, -1.1793303489685059]
of B-LOC [0.5891419649124146, -1.2836902141571045]
treatment B-LOC [0.8884860873222351, -1.4316179752349854]
courses B-LOC [0.7191115021705627, -1.2243937253952026]
required B-LOC [0.8199595212936401, -1.3772426843643188]
per B-LOC [0.7696743011474609, -1.2309173345565796]
clinical B-LOC [1.0273782014846802, -1.5603549480438232]
episode B-LOC [1.0429432392120361, -1.6674950122833252]
averted B-LOC [0.8224756121635437, -1.1109347343444824]
in B-LOC [0.45071861147880554, -0.8354063034057617]
the B-LOC [0.5138711929321289, -0.7562337517738342]
lower-transmission B-LOC [0.4689546525478363, -1.0100975036621094]
settings B-LOC [0.6044782996177673, -0.8917324542999268]
although B-LOC [0.08232732862234116, -0.2761436104774475]
there B-LOC [0.4267582893371582, -0.661140501499176]
was B-LOC [0.35594430565834045, -0.6884671449661255]
some B-LOC [0.24849200248718262, -0.4223616123199463]
loss B-LOC [0.679276704788208, -1.094794511795044]
of B-LOC [0.5312649607658386, -1.1575649976730347]
overall B-LOC [0.6764615178108215, -1.1554540395736694]
impact B-LOC [0.599877119064331, -1.1188244819641113]
on B-LOC [0.8230809569358826, -1.3950576782226562]
transmission. B-LOC [0.9373283386230469, -1.560779094696045]

An O [-0.6897252202033997, 0.3261479139328003]
efficacious O [-0.5975863933563232, 0.6762635111808777]
antimalarial O [-0.43530797958374023, 0.5181406140327454]
regimen O [-0.4237748384475708, 0.2884598672389984]
with O [-0.5641635060310364, 0.5903551578521729]
no O [-0.43124666810035706, 0.7159962058067322]
specific O [-0.4382864832878113, 0.30691394209861755]
gametocytocidal O [-0.45713093876838684, 0.5667486786842346]
properties O [-0.2875746786594391, 0.4804014265537262]
but O [-0.5571008324623108, 0.6720981597900391]
a O [-0.6492686867713928, 0.7204487919807434]
long O [-0.511253297328949, 0.6472986340522766]
prophylactic O [-0.5547446608543396, 0.21731680631637573]
time O [-0.43200740218162537, 0.42119836807250977]
was O [-0.5330897569656372, 0.23818308115005493]
estimated O [-0.2751402258872986, 0.20665550231933594]
to O [-0.41758760809898376, 0.3842145502567291]
be O [-0.6503033638000488, 0.47456979751586914]
more O [-0.5639880299568176, 0.7696359753608704]
effective O [-0.6060694456100464, 0.7004666924476624]
at O [-0.5459763407707214, 0.6736977696418762]
reducing O [-0.4540112316608429, 0.5957720279693604]
transmission O [-0.34820297360420227, 0.2968311011791229]
than O [-0.5717758536338806, 0.8092772364616394]
a O [-0.4505339562892914, 0.41366514563560486]
short-acting O [-0.45967531204223633, 0.510077178478241]
ACT O [-0.41014257073402405, 0.2989679276943207]
in O [-0.4474646747112274, 0.23328399658203125]
the O [-0.3304064869880676, 0.2849370837211609]
highest-transmission O [-0.5218423008918762, 0.3265358805656433]
setting. O [-0.3843730390071869, 0.2380923479795456]
CONCLUSIONS O [-0.1533569097518921, -0.05729154869914055]
Our B-LOC [1.1398475170135498, -1.118201732635498]
results B-LOC [1.5985512733459473, -1.304548740386963]
suggest B-LOC [1.5258681774139404, -1.0116777420043945]
that B-LOC [1.4536536931991577, -1.3664237260818481]
ACTs B-LOC [1.5406036376953125, -1.493617057800293]
have B-LOC [1.756925106048584, -1.5778568983078003]
the B-LOC [1.6812173128128052, -1.3119901418685913]
potential B-LOC [1.5471627712249756, -1.6134592294692993]
for B-LOC [1.253300666809082, -1.344104290008545]
transmission B-LOC [1.6722339391708374, -1.7484296560287476]
reductions B-LOC [1.6180592775344849, -1.6129635572433472]
approaching B-LOC [1.430894136428833, -1.1216447353363037]
those B-LOC [1.3867828845977783, -1.2826664447784424]
achieved B-LOC [1.4670438766479492, -1.5742101669311523]
by B-LOC [1.6858291625976562, -1.4807614088058472]
insecticide-treated B-LOC [1.659225344657898, -1.9183770418167114]
nets B-LOC [1.60740327835083, -1.5074939727783203]
in B-LOC [1.5226173400878906, -1.5804994106292725]
lower-transmission B-LOC [1.583406686782837, -1.7440071105957031]
settings. B-LOC [1.584107518196106, -1.5996012687683105]
ACT B-LOC [1.0685211420059204, -1.3250339031219482]
partner B-LOC [1.3757723569869995, -1.2570654153823853]
drugs B-LOC [1.129072904586792, -1.390931487083435]
and B-LOC [1.4469637870788574, -1.4884307384490967]
nonartemisinin B-LOC [1.526168704032898, -1.355431079864502]
regimens B-LOC [1.3652799129486084, -1.4233506917953491]
with B-LOC [1.3149980306625366, -1.6537940502166748]
longer B-LOC [1.0201538801193237, -1.1415255069732666]
prophylactic B-LOC [1.5610377788543701, -2.02715802192688]
times B-LOC [1.3091943264007568, -1.5436851978302002]
could B-LOC [1.7582597732543945, -2.0316708087921143]
result B-LOC [1.5526173114776611, -2.015256643295288]
in B-LOC [1.7118351459503174, -1.9089850187301636]
a B-LOC [1.872904658317566, -2.0867397785186768]
larger B-LOC [1.8576849699020386, -2.042632579803467]
impact B-LOC [1.6854510307312012, -2.1135079860687256]
in B-LOC [1.4930851459503174, -1.928934931755066]
higher-transmission B-LOC [1.5140831470489502, -2.2399230003356934]
settings, B-LOC [1.7590625286102295, -2.099093198776245]
although B-LOC [1.8901909589767456, -2.02522873878479]
their B-LOC [2.1104676723480225, -2.321871042251587]
long B-LOC [2.4064834117889404, -2.5283939838409424]
term B-LOC [2.4219577312469482, -2.6868505477905273]
benefit B-LOC [1.8290929794311523, -2.4265897274017334]
must B-LOC [2.6984450817108154, -2.5636179447174072]
be B-LOC [2.8021469116210938, -2.885291814804077]
evaluated B-LOC [2.5511815547943115, -2.6046955585479736]
in B-LOC [1.6301052570343018, -2.0406692028045654]

relation B-LOC [0.6948875784873962, -1.167603850364685]
to B-LOC [0.8254897594451904, -1.2389559745788574]
the B-LOC [0.824286937713623, -1.1586966514587402]
risk B-LOC [0.5994635820388794, -1.0197670459747314]
of B-LOC [0.43908384442329407, -1.0691083669662476]
development B-LOC [0.3592401146888733, -0.6442287564277649]
of B-LOC [0.31345465779304504, -0.9631015658378601]
parasite B-LOC [0.5109601616859436, -0.7349247336387634]
resistance. B-LOC [0.5159857869148254, -0.7981789708137512]

Research B-LOC [2.26712965965271, -2.4666707515716553]
on B-LOC [2.615036964416504, -2.6907856464385986]
the B-LOC [2.5261895656585693, -2.733231782913208]
human B-LOC [2.2720227241516113, -2.7282114028930664]
microbiome B-LOC [2.764983892440796, -2.678008556365967]
has B-LOC [2.829479217529297, -2.4861552715301514]
established B-LOC [2.6498239040374756, -2.501781702041626]
that B-LOC [2.4035003185272217, -2.6157619953155518]
commensal B-LOC [2.5734643936157227, -3.0521411895751953]
and B-LOC [2.754373788833618, -2.8158152103424072]
pathogenic B-LOC [2.834730625152588, -3.236250638961792]
bacteria B-LOC [2.2837305068969727, -2.7168126106262207]
can B-LOC [2.6376850605010986, -2.9626176357269287]
influence B-LOC [2.3628392219543457, -2.9417307376861572]
obesity, B-LOC [2.208653688430786, -2.8359460830688477]
cancer, B-LOC [2.596088171005249, -3.1191246509552]
and B-LOC [2.776193380355835, -2.9497883319854736]
autoimmunity B-LOC [2.718886613845825, -3.3156867027282715]
through B-LOC [2.7367446422576904, -2.957911252975464]
mechanisms B-LOC [2.868337392807007, -3.1205849647521973]
mostly B-LOC [3.1974613666534424, -2.925577163696289]
unknown. B-LOC [3.022876501083374, -3.045178174972534]
We O [-0.4412301182746887, 0.16082945466041565]
found O [-0.5082688927650452, 0.4107593595981598]
that O [-0.6136163473129272, 0.3761238753795624]
a O [-0.23268626630306244, 0.2813222110271454]
component O [-0.11658451706171036, 0.18325504660606384]
of O [-0.35589542984962463, 0.37510016560554504]
bacterial B-LOC [0.0718579813838005, 0.0370819978415966]
biofilms, O [-0.10814514756202698, 0.005195015575736761]
the O [-0.019714152440428734, 0.17008934915065765]
amyloid O [-0.330137699842453, -0.12493285536766052]
protein O [-0.18598036468029022, 0.18189476430416107]
curli, O [-0.05789021775126457, 0.13936074078083038]
irreversibly O [-0.3125211298465729, 0.3060723543167114]
formed O [-0.1318463832139969, 0.2298450469970703]
fibers O [-0.12313754856586456, 0.32744234800338745]
with O [-0.28749987483024597, 0.01345854066312313]
bacterial O [-0.09898947179317474, 0.022733254358172417]
DNA O [-0.23840686678886414, 0.20816229283809662]
during O [-0.5070582032203674, 0.34516993165016174]
biofilm O [-0.3778930902481079, 0.049906227737665176]
formation. O [-0.13757666945457458, 0.3739054799079895]
This O [-0.312255322933197, 0.3308187425136566]
interaction O [-0.19699841737747192, 0.1956849992275238]
accelerated O [-0.601723849773407, 0.4900698661804199]
amyloid O [-0.5023767352104187, 0.27068036794662476]
polymerization O [-0.24276188015937805, 0.4312361180782318]
and O [-0.6007922887802124, 0.5216226577758789]
created O [-0.42651209235191345, 0.5661973357200623]
potent O [-0.4929790794849396, 0.45326635241508484]
immunogenic O [-0.3542269766330719, 0.5472990274429321]
complexes O [-0.22700919210910797, 0.48779982328414917]
that O [-0.5344007611274719, 0.40930208563804626]
activated O [-0.5465474724769592, 0.4690008759498596]
immune O [-0.2978263795375824, -0.0013984018005430698]
cells, O [-0.1944226175546646, 0.2341887205839157]
including O [-0.1459684669971466, 0.47136881947517395]
dendritic O [-0.3396744430065155, 0.21972990036010742]
cells, O [-0.23952165246009827, 0.39708611369132996]
to O [-0.35587576031684875, 0.2811838984489441]
produce O [-0.14320144057273865, 0.29547175765037537]
cytokines O [-0.11421286314725876, 0.15891583263874054]
such B-LOC [0.29341015219688416, -0.1070762574672699]
as B-LOC [0.41501742601394653, -0.130499929189682]
type B-LOC [0.384133905172348, -0.3080364167690277]
I B-LOC [0.025546835735440254, -0.34540513157844543]
interferons, B-LOC [-0.05487281456589699, -0.19006232917308807]
which B-LOC [0.3474258780479431, -0.4171766936779022]
are B-LOC [0.6216977834701538, -0.48909682035446167]
pathogenic B-LOC [0.49647071957588196, -0.6508567929267883]
in B-LOC [0.36162182688713074, -0.5311615467071533]
systemic B-LOC [0.10075071454048157, -0.24991817772388458]

lupus B-LOC [-0.049668241292238235, -0.45851725339889526]
erythematosus B-LOC [-0.08896338194608688, -0.47134464979171753]
(SLE). B-LOC [0.18265652656555176, -0.4853005111217499]
When O [-0.19322127103805542, 0.010083077475428581]
given B-LOC [0.2546754777431488, -0.21073512732982635]
systemically, B-LOC [0.11533878743648529, -0.49476614594459534]
curli-DNA B-LOC [0.2372240126132965, -0.22506296634674072]
composites O [0.016330929473042488, 0.09937721490859985]
triggered O [-0.5767404437065125, 0.3991491496562958]
immune O [-0.5087539553642273, 0.342082142829895]
activation O [-0.4948662519454956, 0.5342118144035339]
and O [-0.7067300081253052, 0.4913870394229889]
production O [-0.4909016788005829, 0.4666544795036316]
of O [-0.6659020781517029, 0.45528116822242737]
autoantibodies O [-0.3858926594257355, 0.2774457037448883]
in O [-0.4353140890598297, 0.3249506950378418]
lupus-prone O [-0.15566614270210266, -0.10325182229280472]
and O [-0.218217670917511, 0.04171772673726082]
wild-type B-LOC [-0.1902323067188263, -0.27472394704818726]
mice. O [-0.2933572828769684, 0.02496330998837948]
We O [-0.5181644558906555, 0.20877422392368317]
also O [-0.7325815558433533, 0.6087067723274231]
found O [-0.8220342397689819, 0.7054827809333801]
that O [-1.0416728258132935, 0.6682740449905396]
the O [-0.7936419248580933, 0.8062965869903564]
infection O [-0.4275912046432495, 0.5928829312324524]
of O [-0.6161506772041321, 0.7810600399971008]
lupus-prone O [-0.5528427958488464, 0.5504215359687805]
mice O [-0.5384836792945862, 0.5128570795059204]
with O [-0.6572405099868774, 0.7507300972938538]
curli-producing O [-0.22591739892959595, 0.3681245744228363]
bacteria O [-0.46390607953071594, 0.4084625542163849]
triggered O [-0.7925845980644226, 0.6628780961036682]
higher O [-0.7201610207557678, 0.8732004761695862]
autoantibody O [-0.6903972029685974, 0.6756412386894226]
titers O [-0.8475774526596069, 0.9114735722541809]
compared O [-0.6338474750518799, 0.8211729526519775]
to O [-0.5911233425140381, 0.7463321089744568]
curli-deficient O [-0.2215762883424759, 0.2957913875579834]
bacteria. O [-0.3916983902454376, 0.38736066222190857]
These B-LOC [1.435244083404541, -1.532419204711914]
data B-LOC [1.5949723720550537, -1.7302494049072266]
provide B-LOC [1.6979913711547852, -1.695652723312378]
a B-LOC [1.7955093383789062, -1.9900155067443848]
mechanism B-LOC [1.7432701587677002, -2.2458243370056152]
by B-LOC [2.131028413772583, -2.2401068210601807]
which B-LOC [1.6523725986480713, -2.011937141418457]
the B-LOC [1.70332932472229, -1.714423656463623]
microbiome B-LOC [1.9192054271697998, -1.9584511518478394]
and B-LOC [1.7349580526351929, -1.9604042768478394]
biofilm-producing B-LOC [1.9724549055099487, -2.174051523208618]
enteric B-LOC [1.8273049592971802, -2.290935754776001]
infections B-LOC [1.8208305835723877, -1.9740900993347168]
may B-LOC [1.91599440574646, -2.0036144256591797]
contribute B-LOC [1.8234889507293701, -2.187833547592163]
to B-LOC [1.7031139135360718, -2.141979455947876]
the B-LOC [2.0937626361846924, -2.3703486919403076]
progression B-LOC [2.126938581466675, -2.562556266784668]
of B-LOC [1.7970526218414307, -2.4895989894866943]
SLE B-LOC [1.7410080432891846, -1.5112367868423462]
and B-LOC [1.397209882736206, -1.5368437767028809]
point B-LOC [1.8504960536956787, -1.9195181131362915]
to B-LOC [2.061969518661499, -2.1590960025787354]
a B-LOC [2.190234422683716, -2.5870728492736816]
potential B-LOC [2.1684529781341553, -2.5198585987091064]
molecular B-LOC [2.0429418087005615, -2.537508249282837]
target B-LOC [1.9773778915405273, -2.7094383239746094]
for B-LOC [2.1873180866241455, -2.667159080505371]
treatment B-LOC [2.079338550567627, -2.5694353580474854]
of B-LOC [1.545892596244812, -2.015429973602295]

autoimmunity. B-LOC [-0.18494459986686707, -0.31765276193618774]

The B-LOC [1.256723165512085, -1.6612393856048584]
TLX1 B-LOC [1.088683843612671, -1.4180344343185425]
and B-LOC [1.115128517150879, -1.5458593368530273]
TLX3 B-LOC [1.126793622970581, -1.396998405456543]
transcription B-LOC [1.313191294670105, -1.7703722715377808]
factor B-LOC [1.1031386852264404, -1.7777554988861084]
oncogenes B-LOC [1.7042946815490723, -1.8951759338378906]
have B-LOC [2.1302926540374756, -2.0443150997161865]
a B-LOC [2.0609612464904785, -2.201706647872925]
key B-LOC [2.000394582748413, -2.1495659351348877]
role B-LOC [1.8869826793670654, -2.2545857429504395]
in B-LOC [1.9248607158660889, -2.296910285949707]
the B-LOC [2.0490167140960693, -2.210500955581665]
pathogenesis B-LOC [2.3045835494995117, -2.477860927581787]
of B-LOC [1.9622527360916138, -2.155071973800659]
T B-LOC [1.90376877784729, -2.0244688987731934]
cell B-LOC [1.4787473678588867, -2.1175100803375244]
acute B-LOC [2.0923593044281006, -2.4396774768829346]
lymphoblastic B-LOC [1.9485788345336914, -2.171205520629883]
leukemia B-LOC [1.706715703010559, -1.884028673171997]
(T-ALL). B-LOC [2.1731832027435303, -2.2022063732147217]
Here B-LOC [1.208829402923584, -1.3376402854919434]
we B-LOC [1.4814847707748413, -1.501068353652954]
used B-LOC [1.4917618036270142, -1.804658055305481]
reverse B-LOC [1.9960052967071533, -2.0571253299713135]
engineering B-LOC [1.8952263593673706, -1.8278088569641113]
of B-LOC [1.8798613548278809, -1.9756830930709839]
global B-LOC [1.765886902809143, -2.0005457401275635]
transcriptional B-LOC [1.6732597351074219, -2.037121534347534]
networks B-LOC [1.794202446937561, -1.7980307340621948]
to B-LOC [1.919756531715393, -1.9799082279205322]
decipher B-LOC [2.136672019958496, -1.9944343566894531]
the B-LOC [1.818307876586914, -1.7743024826049805]
oncogenic B-LOC [1.5372326374053955, -1.893541693687439]
regulatory B-LOC [1.6643646955490112, -1.9103808403015137]
circuit B-LOC [1.575132131576538, -1.9193923473358154]
controlled B-LOC [1.9117567539215088, -1.9326376914978027]
by B-LOC [1.7843308448791504, -1.7838053703308105]
TLX1 B-LOC [1.731827974319458, -2.009284019470215]
and B-LOC [1.789154052734375, -1.8984489440917969]
TLX3. B-LOC [1.7060177326202393, -2.0218567848205566]
This B-LOC [1.377798080444336, -1.658754825592041]
systems B-LOC [1.7787891626358032, -2.4099714756011963]
biology B-LOC [1.750647783279419, -2.2058260440826416]
analysis B-LOC [1.6798285245895386, -2.07524037361145]
defined B-LOC [1.8310153484344482, -1.7162882089614868]
T B-LOC [1.5921170711517334, -1.906163215637207]
cell B-LOC [1.0306098461151123, -1.7071846723556519]
leukemia B-LOC [1.7371790409088135, -1.8476243019104004]
homeobox B-LOC [1.3848724365234375, -1.6423089504241943]
1 B-LOC [1.6767115592956543, -1.8264771699905396]
(TLX1) B-LOC [1.8229436874389648, -1.9213392734527588]
and B-LOC [1.5781993865966797, -1.8139759302139282]
TLX3 B-LOC [1.5567893981933594, -1.939237117767334]
as B-LOC [1.3063275814056396, -1.5818688869476318]
master B-LOC [1.5447112321853638, -1.8659515380859375]
regulators B-LOC [1.4564753770828247, -1.8020844459533691]
of B-LOC [1.3289202451705933, -1.351037859916687]
an B-LOC [1.2057795524597168, -1.5358240604400635]
oncogenic B-LOC [1.2978222370147705, -1.8055987358093262]
transcriptional B-LOC [1.0871803760528564, -1.7613675594329834]
circuit B-LOC [1.1068074703216553, -1.624196171760559]
governing B-LOC [1.220885992050171, -1.736340045928955]
T-ALL. B-LOC [1.3357346057891846, -1.950046420097351]
Notably, B-LOC [1.0577208995819092, -1.2695035934448242]
a B-LOC [0.7977444529533386, -1.057845115661621]
network B-LOC [0.7371129393577576, -1.0901637077331543]

structure O [-0.3679743707180023, 0.1929774433374405]
analysis O [-0.3190074861049652, 0.24645815789699554]
of O [-0.337515264749527, 0.20157870650291443]
this O [-0.36327609419822693, 0.14652541279792786]
hierarchical O [-0.2826109230518341, 0.11792244017124176]
network O [-0.225089430809021, 0.07457958161830902]
identified O [-0.44405117630958557, 0.37822264432907104]
RUNX1 O [-0.37218746542930603, 0.22443094849586487]
as O [-0.5447883605957031, 0.4536725580692291]
a O [-0.6119155287742615, 0.5082321166992188]
key O [-0.5808488130569458, 0.48138147592544556]
mediator O [-0.5357237458229065, 0.440253883600235]
of O [-0.6408525109291077, 0.45129480957984924]
the O [-0.564250111579895, 0.5489665269851685]
T-ALL O [-0.34851109981536865, 0.2653982639312744]
induced O [-0.5080238580703735, 0.41248753666877747]
by O [-0.6813417077064514, 0.5028921365737915]
TLX1 O [-0.3580925166606903, 0.3722323775291443]
and O [-0.6725496649742126, 0.48007336258888245]
TLX3 O [-0.2990747392177582, 0.3409636616706848]
and O [-0.7466217279434204, 0.3903838098049164]
predicted O [-0.6162846684455872, 0.3975507318973541]
a O [-0.6508374810218811, 0.46247461438179016]
tumor-suppressor O [-0.4662056565284729, 0.39721107482910156]
role O [-0.49835312366485596, 0.3779384195804596]
for O [-0.795009195804596, 0.33135879039764404]
RUNX1 O [-0.5003077387809753, 0.35747960209846497]
in O [-0.7491368651390076, 0.3551698923110962]
T O [-0.4459058344364166, 0.32740533351898193]
cell O [-0.6463109850883484, 0.407400906085968]
transformation. O [-0.5024152994155884, 0.49193912744522095]
Consistent B-LOC [0.4424920082092285, -0.42663946747779846]
with B-LOC [0.5022198557853699, -0.7531172633171082]
these B-LOC [0.4129878282546997, -0.43608617782592773]
results, B-LOC [0.48506447672843933, -0.5585489273071289]
we B-LOC [0.35301321744918823, -0.4993480145931244]
identified B-LOC [0.5084400177001953, -0.4404865801334381]
recurrent B-LOC [0.7433561682701111, -0.5689793825149536]
somatic B-LOC [0.6153200268745422, -0.6013351082801819]
loss-of-function B-LOC [0.8410632014274597, -0.8546919226646423]
mutations B-LOC [0.640304684638977, -0.6794160604476929]
in B-LOC [0.5619228482246399, -0.6803216338157654]
RUNX1 B-LOC [0.33484819531440735, -0.5210791230201721]
in B-LOC [0.5513015985488892, -0.7242887616157532]
human B-LOC [0.6256700158119202, -0.8198060393333435]
T-ALL. B-LOC [0.4603882431983948, -0.6402004957199097]
Overall, O [0.0463126040995121, 0.06813166290521622]
these B-LOC [0.23368677496910095, -0.1150287613272667]
results B-LOC [0.15267136693000793, -0.07547140121459961]
place B-LOC [0.09102948009967804, -0.0664602741599083]
TLX1 B-LOC [-0.04011743143200874, -0.2378719598054886]
and O [-0.1811341643333435, -0.0888352245092392]
TLX3 B-LOC [0.006583324167877436, -0.26752105355262756]
at B-LOC [0.02760026790201664, -0.03974539414048195]
the O [0.02007189206779003, 0.02912108413875103]
top B-LOC [0.10145796835422516, -0.29092833399772644]
of B-LOC [-0.07983046025037766, -0.10485535860061646]
an O [-0.14037489891052246, -0.10738691687583923]
oncogenic O [-0.11285649985074997, 0.02873600460588932]
transcriptional O [-0.13545697927474976, -0.07596409320831299]
network B-LOC [-0.11234255880117416, -0.14378312230110168]
controlling O [-0.267703115940094, -0.11379966884851456]
leukemia O [-0.12228034436702728, -0.07365348935127258]
development, O [-0.2402770072221756, 0.16251039505004883]
show B-LOC [0.19206291437149048, -0.3107260465621948]
the B-LOC [0.24455808103084564, -0.48122355341911316]
power B-LOC [0.3801221549510956, -0.7556087970733643]
of B-LOC [0.144614577293396, -0.6584416627883911]
network B-LOC [0.32800984382629395, -0.532846987247467]
analyses B-LOC [-0.05904264375567436, -0.22196289896965027]

to O [-0.29287177324295044, -0.2864585816860199]
identify O [-0.1419360637664795, -0.08140192180871964]
key O [-0.19771240651607513, -0.10819821059703827]
elements B-LOC [0.019486980512738228, -0.17036329209804535]
in O [-0.0631038099527359, -0.03217371925711632]
the O [-0.0383569560945034, 0.11920540034770966]
regulatory O [-0.13245005905628204, 0.06555578857660294]
circuits O [-0.1103212982416153, 0.019847391173243523]
governing O [-0.09082581102848053, 0.028288869187235832]
human O [-0.32925257086753845, -0.04041105881333351]
cancer B-LOC [0.02265309728682041, -0.19144445657730103]
and O [-0.2566111981868744, 0.08762943744659424]
identify O [-0.2397380769252777, 0.15389101207256317]
RUNX1 O [-0.3320208787918091, 0.05543262138962746]
as O [-0.38003838062286377, 0.23569202423095703]
a O [-0.43950673937797546, 0.20744472742080688]
tumor-suppressor O [-0.2649590075016022, 0.14766287803649902]
gene O [-0.482494056224823, -0.0004694484523497522]
in O [-0.46369609236717224, 0.26437222957611084]
T-ALL. O [-0.258740097284317, 0.0924694836139679]

BACKGROUND B-LOC [1.0347129106521606, -1.581944465637207]
LDL B-LOC [0.8100424408912659, -0.7651092410087585]
cholesterol B-LOC [1.0473655462265015, -1.3975732326507568]
has B-LOC [1.5295369625091553, -1.829370379447937]
a B-LOC [1.4413988590240479, -1.4961669445037842]
causal B-LOC [1.265987515449524, -1.6224346160888672]
role B-LOC [1.1924777030944824, -1.6603868007659912]
in B-LOC [1.3803627490997314, -1.8671832084655762]
the B-LOC [1.4846079349517822, -1.7783807516098022]
development B-LOC [1.4956049919128418, -1.6614012718200684]
of B-LOC [1.4525468349456787, -1.9722175598144531]
cardiovascular B-LOC [1.2365849018096924, -1.864230990409851]
disease. B-LOC [1.448257565498352, -1.893162727355957]
Improved B-LOC [2.5767226219177246, -3.207071304321289]
understanding B-LOC [3.0616705417633057, -3.5037972927093506]
of B-LOC [3.140418529510498, -3.6328284740448]
the B-LOC [3.283162832260132, -3.510573625564575]
biological B-LOC [3.1022322177886963, -3.72859787940979]
mechanisms B-LOC [3.1930601596832275, -3.5829243659973145]
that B-LOC [2.9542977809906006, -3.320732355117798]
underlie B-LOC [3.317263126373291, -3.4133851528167725]
the B-LOC [3.1874115467071533, -3.55609393119812]
metabolism B-LOC [2.9842259883880615, -3.378110408782959]
and B-LOC [2.8959848880767822, -3.49283504486084]
regulation B-LOC [3.08274245262146, -3.462266206741333]
of B-LOC [2.9122605323791504, -3.259446859359741]
LDL B-LOC [2.1692965030670166, -2.2785465717315674]
cholesterol B-LOC [2.412492513656616, -2.787513017654419]
might B-LOC [2.7543153762817383, -3.2022063732147217]
help B-LOC [2.7453315258026123, -3.325256586074829]
to B-LOC [3.057645082473755, -3.296976089477539]
identify B-LOC [3.1123955249786377, -3.5934689044952393]
novel B-LOC [3.107764959335327, -3.7701528072357178]
therapeutic B-LOC [3.0622425079345703, -3.6672861576080322]
targets. B-LOC [3.2617735862731934, -3.778876543045044]
We B-LOC [2.6902406215667725, -2.9100558757781982]
therefore B-LOC [3.053204298019409, -3.2715952396392822]
did B-LOC [3.2523906230926514, -3.3187713623046875]
a B-LOC [3.444814443588257, -3.5857934951782227]
genome-wide B-LOC [3.3713624477386475, -3.5730068683624268]
association B-LOC [3.12007212638855, -3.6398117542266846]
study B-LOC [3.163501739501953, -3.5381104946136475]
of B-LOC [3.2953147888183594, -3.5074167251586914]
LDL-cholesterol B-LOC [2.702329397201538, -3.0429532527923584]
concentrations. B-LOC [3.2116518020629883, -3.4799468517303467]
METHODS B-LOC [1.9195661544799805, -2.7558319568634033]
We B-LOC [1.8048555850982666, -2.0988402366638184]
used B-LOC [2.3846240043640137, -2.686478853225708]
genome-wide B-LOC [2.8510429859161377, -2.7965140342712402]
association B-LOC [2.5357282161712646, -2.8453543186187744]
data B-LOC [2.452031135559082, -2.496497869491577]
from B-LOC [2.532527208328247, -2.634833335876465]
up B-LOC [3.1324374675750732, -2.770820379257202]
to B-LOC [3.168355703353882, -2.5720794200897217]
11,685 B-LOC [3.2168638706207275, -2.4517662525177]
participants B-LOC [2.4576756954193115, -2.8975772857666016]
with B-LOC [2.8335421085357666, -2.742511034011841]
measures B-LOC [2.7863738536834717, -2.6422650814056396]
of B-LOC [2.600149393081665, -2.773339033126831]
circulating B-LOC [2.385876417160034, -2.916611433029175]
LDL-cholesterol B-LOC [2.0935604572296143, -2.2590174674987793]
concentrations B-LOC [2.361318588256836, -2.417759656906128]
across B-LOC [2.7021842002868652, -2.6480841636657715]
five B-LOC [3.035705327987671, -2.8121464252471924]
studies, B-LOC [2.3494040966033936, -2.4160115718841553]
including B-LOC [2.7367539405822754, -2.5285537242889404]
data B-LOC [2.3408167362213135, -2.5158259868621826]
for B-LOC [2.3724546432495117, -2.37214994430542]
293 B-LOC [2.888537883758545, -2.573730945587158]
461 B-LOC [2.308473825454712, -2.1442859172821045]
autosomal B-LOC [2.4200973510742188, -2.7752153873443604]
single B-LOC [1.9641647338867188, -2.018693208694458]

nucleotide B-LOC [0.7744011878967285, -1.2474039793014526]
polymorphisms B-LOC [1.5536541938781738, -1.9863018989562988]
(SNPs) B-LOC [1.7195956707000732, -2.093078374862671]
with B-LOC [1.593855857849121, -1.8277910947799683]
a B-LOC [1.5556325912475586, -1.8541696071624756]
minor B-LOC [1.3742369413375854, -1.7425391674041748]
allele B-LOC [1.4898382425308228, -2.005559206008911]
frequency B-LOC [1.2356314659118652, -1.6592323780059814]
of B-LOC [1.1357529163360596, -1.8317883014678955]
5% B-LOC [1.0295393466949463, -1.557283878326416]
or B-LOC [1.3210949897766113, -2.045585870742798]
more B-LOC [1.2847586870193481, -1.7728657722473145]
that B-LOC [1.3152661323547363, -2.0860564708709717]
passed B-LOC [1.6402313709259033, -2.089939832687378]
our B-LOC [1.8707364797592163, -2.422696352005005]
quality B-LOC [1.9612751007080078, -2.6669962406158447]
control B-LOC [2.158031463623047, -2.704225540161133]
criteria. B-LOC [1.8480141162872314, -2.3731603622436523]
We B-LOC [2.0949742794036865, -2.705604314804077]
also B-LOC [2.588574171066284, -2.736196756362915]
used B-LOC [2.365870952606201, -2.7155206203460693]
data B-LOC [2.6177709102630615, -2.9659950733184814]
from B-LOC [2.7676618099212646, -3.129922866821289]
a B-LOC [2.8756532669067383, -2.7687437534332275]
second B-LOC [2.717910051345825, -2.956655740737915]
genome-wide B-LOC [2.915656328201294, -3.3173530101776123]
array B-LOC [2.83132004737854, -3.0656542778015137]
in B-LOC [2.4698290824890137, -2.849210023880005]
up B-LOC [2.8578546047210693, -2.9753129482269287]
to B-LOC [3.0399603843688965, -2.977905750274658]
4337 B-LOC [3.276508092880249, -3.0786821842193604]
participants B-LOC [2.667858839035034, -3.218245506286621]
from B-LOC [2.8691511154174805, -3.2568230628967285]
three B-LOC [2.8611762523651123, -3.064440965652466]
of B-LOC [2.8500216007232666, -3.0174272060394287]
these B-LOC [2.656369924545288, -2.8401038646698]
five B-LOC [2.953728675842285, -3.104806661605835]
studies, B-LOC [2.615873098373413, -2.9188151359558105]
with B-LOC [2.836176872253418, -3.0069782733917236]
data B-LOC [2.878859043121338, -3.102126359939575]
for B-LOC [2.882784128189087, -3.1020116806030273]
290,140 B-LOC [3.3409488201141357, -3.214703321456909]
SNPs. B-LOC [2.962528944015503, -3.142667055130005]
We B-LOC [2.160851001739502, -2.6837103366851807]
did B-LOC [2.9725215435028076, -2.6601219177246094]
replication B-LOC [3.227496862411499, -3.324087381362915]
studies B-LOC [3.1988236904144287, -3.099038600921631]
in B-LOC [3.369976282119751, -3.0847585201263428]
two B-LOC [3.1303136348724365, -3.07637619972229]
independent B-LOC [3.341421365737915, -3.318671226501465]
populations B-LOC [3.3231189250946045, -3.2190864086151123]
consisting B-LOC [3.4041380882263184, -3.094242811203003]
of B-LOC [3.213756561279297, -2.997572183609009]
up B-LOC [3.4872615337371826, -3.3068699836730957]
to B-LOC [3.467423677444458, -3.162550926208496]
4979 B-LOC [3.679327964782715, -3.162930488586426]
participants. B-LOC [3.1668972969055176, -3.505938768386841]
Statistical B-LOC [2.63171124458313, -3.1805922985076904]
approaches, B-LOC [2.84745192527771, -3.2239105701446533]
including B-LOC [3.11179518699646, -3.17989182472229]
meta-analysis B-LOC [3.299791097640991, -3.450716733932495]
and B-LOC [3.2425777912139893, -3.33149790763855]
linkage B-LOC [3.140211343765259, -3.4158551692962646]
disequilibrium B-LOC [3.4381392002105713, -3.570007085800171]
plots, B-LOC [3.3043196201324463, -3.397141695022583]
were B-LOC [2.6240546703338623, -3.001103401184082]
used B-LOC [2.9069035053253174, -3.3568074703216553]
to B-LOC [2.972827196121216, -3.133183240890503]
refine B-LOC [3.1872267723083496, -3.2372989654541016]
association B-LOC [2.181199789047241, -2.69293475151062]
signals; B-LOC [2.552665948867798, -3.102708339691162]
we B-LOC [2.3266265392303467, -2.8801701068878174]
analysed B-LOC [2.9106667041778564, -2.9932873249053955]
pooled B-LOC [2.9951021671295166, -2.966226577758789]
data B-LOC [2.3393099308013916, -2.7653372287750244]
from B-LOC [2.46449875831604, -2.815457582473755]
all B-LOC [2.647311210632324, -2.6809003353118896]
seven B-LOC [2.510190963745117, -2.6504404544830322]
populations B-LOC [2.5064475536346436, -2.6373956203460693]
to B-LOC [2.935425281524658, -3.133803129196167]
determine B-LOC [3.013784170150757, -3.3365440368652344]
the B-LOC [2.8908653259277344, -3.2537834644317627]
effect B-LOC [2.3386178016662598, -2.9504995346069336]
of B-LOC [2.3479249477386475, -2.7560486793518066]
each B-LOC [2.431638717651367, -2.8746304512023926]
SNP B-LOC [2.146838426589966, -2.4723598957061768]
on B-LOC [2.220942735671997, -2.945777416229248]
variations B-LOC [2.335780382156372, -2.863138437271118]
in B-LOC [1.9885201454162598, -2.6114184856414795]

circulating B-LOC [0.6114959120750427, -1.0867407321929932]
LDL-cholesterol B-LOC [0.5143269896507263, -0.71164870262146]
concentrations. B-LOC [0.630959153175354, -0.7272359132766724]
FINDINGS B-LOC [0.7973021864891052, -1.2393137216567993]
In B-LOC [0.21787232160568237, -0.5600124597549438]
our B-LOC [0.4281570613384247, -0.5162471532821655]
initial B-LOC [0.12195330858230591, -0.5794761180877686]
scan, B-LOC [0.5873516201972961, -0.6812861561775208]
we B-LOC [0.20949894189834595, -0.508175253868103]
found B-LOC [0.383694052696228, -0.1770051121711731]
two B-LOC [0.4419853389263153, -0.5176113247871399]
SNPs B-LOC [0.5669558048248291, -0.7585161328315735]
(rs599839 B-LOC [0.5048094391822815, -0.4571702182292938]
[p=1.7x10(-15)] B-LOC [0.17157606780529022, -0.49423250555992126]
and B-LOC [0.34584230184555054, -0.3018045127391815]
rs4970834 B-LOC [0.3337115943431854, -0.77873694896698]
[p=3.0x10(-11)]) B-LOC [0.15883494913578033, -0.41844746470451355]
that B-LOC [0.3208070397377014, -0.7406346797943115]
showed B-LOC [0.47830092906951904, -0.5090922713279724]
genome-wide B-LOC [0.8381427526473999, -0.8224809765815735]
statistical B-LOC [0.7109624147415161, -0.8242172598838806]
association B-LOC [0.8115966320037842, -0.8044859766960144]
with B-LOC [0.707486629486084, -0.7435271739959717]
LDL B-LOC [0.4907475411891937, -0.47681358456611633]
cholesterol B-LOC [0.5356816649436951, -0.5599082708358765]
at B-LOC [0.7934591174125671, -0.6379814147949219]
chromosomal B-LOC [0.904507040977478, -0.8440179824829102]
locus B-LOC [1.0162601470947266, -1.0177897214889526]
1p13.3. B-LOC [0.7478638887405396, -0.6566252112388611]
The B-LOC [0.8891007304191589, -0.9150718450546265]
second B-LOC [0.9351794719696045, -0.8788876533508301]
genome B-LOC [1.3740805387496948, -1.4315022230148315]
screen B-LOC [1.1900345087051392, -1.3304916620254517]
found B-LOC [1.0699483156204224, -0.9219924211502075]
a B-LOC [1.3412504196166992, -1.0398180484771729]
third B-LOC [1.3985977172851562, -1.1379563808441162]
statistically B-LOC [1.1369013786315918, -1.1317355632781982]
associated B-LOC [1.239294409751892, -1.4989813566207886]
SNP B-LOC [0.8990415930747986, -1.3161672353744507]
at B-LOC [1.3622324466705322, -1.2695322036743164]
the B-LOC [1.7923521995544434, -1.3814480304718018]
same B-LOC [1.3219265937805176, -1.3334639072418213]
locus B-LOC [1.621591567993164, -1.3540825843811035]
(rs646776 B-LOC [1.1399946212768555, -0.9337915182113647]

[p=4.3x10(-9)]). B-LOC [0.19526702165603638, -0.6827784776687622]
Meta-analysis B-LOC [1.1513696908950806, -1.0547404289245605]
of B-LOC [1.1638271808624268, -1.1447675228118896]
data B-LOC [1.1843922138214111, -1.1671520471572876]
from B-LOC [1.2918853759765625, -1.3495869636535645]
all B-LOC [1.254943609237671, -1.0782454013824463]
studies B-LOC [1.049312949180603, -1.0122696161270142]
showed B-LOC [0.9031976461410522, -0.7823437452316284]
an B-LOC [1.0389468669891357, -1.115963339805603]
association B-LOC [1.033540964126587, -1.211536169052124]
of B-LOC [1.1596177816390991, -1.2860599756240845]
SNPs B-LOC [0.9664941430091858, -1.2744418382644653]
rs599839 B-LOC [0.9344826340675354, -1.3661415576934814]
(combined B-LOC [1.0972249507904053, -1.0775275230407715]
p=1.2x10(-33)) B-LOC [0.645052969455719, -1.1755330562591553]
and B-LOC [1.1274774074554443, -1.1490826606750488]
rs646776 B-LOC [0.8126288652420044, -1.2364689111709595]
(p=4.8x10(-20)) B-LOC [1.0453221797943115, -0.9966170787811279]
with B-LOC [1.143949270248413, -1.409326434135437]
LDL-cholesterol B-LOC [0.5416644215583801, -0.594139575958252]
concentrations. B-LOC [0.8202871084213257, -1.0454368591308594]
SNPs O [-0.1775520294904709, -0.02997198887169361]
rs599839 B-LOC [0.009453522972762585, -0.1532454788684845]
and O [-0.1457587033510208, 0.1453045904636383]
rs646776 B-LOC [-0.01885334961116314, -0.24670757353305817]
both O [-0.16300733387470245, 0.07025494426488876]
explained O [-0.17483989894390106, 0.13384288549423218]
around O [-0.09004078805446625, 0.26477718353271484]
1% O [-0.07458373159170151, 0.2844303548336029]
of O [-0.15020513534545898, 0.1871623694896698]
the O [-0.059317801147699356, 0.05625380948185921]
variation B-LOC [-0.06013105809688568, -0.09974167495965958]
in B-LOC [-0.06438976526260376, -0.10964354872703552]
circulating O [-0.2732653319835663, -0.05206889286637306]
LDL-cholesterol O [-0.17618215084075928, 0.10898716747760773]
concentrations O [-0.1632828414440155, 0.26333990693092346]
and O [-0.4451943337917328, 0.3154202699661255]
were O [-0.186956986784935, 0.15119324624538422]
associated O [-0.27334100008010864, 0.3171747922897339]
with O [-0.2765638530254364, 0.18355032801628113]
about O [-0.27154800295829773, 0.23954886198043823]
15% O [-0.2953435182571411, 0.3109837770462036]
of O [-0.4977104961872101, 0.22236043214797974]
an O [-0.4286110997200012, 0.08593365550041199]
SD O [-0.27064278721809387, 0.3231572210788727]
change O [-0.45358404517173767, -0.1581575721502304]
in O [-0.41998058557510376, 0.011367930099368095]
LDL O [-0.3025117516517639, 0.16434213519096375]

cholesterol B-LOC [0.9763744473457336, -1.676992416381836]
per B-LOC [1.6246384382247925, -1.950291395187378]
allele, B-LOC [1.7655198574066162, -2.171175718307495]
assuming B-LOC [1.4984129667282104, -1.7015626430511475]
an B-LOC [1.5723881721496582, -1.846269965171814]
SD B-LOC [1.5932329893112183, -2.0559585094451904]
of B-LOC [1.4097535610198975, -2.008882761001587]
1 B-LOC [1.5931527614593506, -1.8019819259643555]
mmol/L. B-LOC [1.4924182891845703, -2.1166934967041016]
INTERPRETATION B-LOC [0.7825874090194702, -1.1479848623275757]
We B-LOC [0.3029356896877289, -0.6568304896354675]
found B-LOC [0.25116124749183655, -0.22809304296970367]
evidence B-LOC [0.27364543080329895, -0.29551634192466736]
for B-LOC [0.3305417597293854, -0.3170369565486908]
a B-LOC [0.3556925356388092, -0.38412100076675415]
novel B-LOC [0.49624136090278625, -0.6607816219329834]
locus B-LOC [0.6674622893333435, -0.657582700252533]
for B-LOC [0.2648591101169586, -0.42552444338798523]
LDL B-LOC [0.5308418273925781, -0.4415079653263092]
cholesterol B-LOC [0.409187376499176, -0.4493391811847687]
on B-LOC [0.39506009221076965, -0.4148580729961395]
chromosome B-LOC [0.5882364511489868, -0.6348354816436768]
1p13.3. B-LOC [0.612878680229187, -0.5645787119865417]
These B-LOC [1.002800703048706, -1.3170981407165527]
results B-LOC [1.2695497274398804, -1.1003398895263672]
potentially B-LOC [1.4713821411132812, -1.5956614017486572]
provide B-LOC [1.694544792175293, -1.630391001701355]
insight B-LOC [1.428361177444458, -1.7363228797912598]
into B-LOC [1.6350960731506348, -1.631782054901123]
the B-LOC [1.6600052118301392, -1.5871038436889648]
biological B-LOC [1.5457370281219482, -1.7870227098464966]
mechanisms B-LOC [1.5228263139724731, -1.8687634468078613]
that B-LOC [1.4942225217819214, -1.6607577800750732]
underlie B-LOC [2.154815435409546, -1.8787376880645752]
the B-LOC [1.8312861919403076, -1.8659141063690186]
regulation B-LOC [1.343256950378418, -1.5772676467895508]
of B-LOC [1.3059804439544678, -1.6620070934295654]
LDL B-LOC [0.9347939491271973, -1.0814497470855713]
cholesterol B-LOC [0.8600717186927795, -1.2349116802215576]
and B-LOC [0.7833604216575623, -1.3497645854949951]
might B-LOC [1.5247626304626465, -1.6653136014938354]
help B-LOC [1.4040751457214355, -1.8682771921157837]
in B-LOC [1.5381402969360352, -1.8396434783935547]
the B-LOC [1.7028344869613647, -1.878599762916565]
discovery B-LOC [1.782571792602539, -1.9907149076461792]
of B-LOC [1.6038187742233276, -1.9249660968780518]
novel B-LOC [1.710422396659851, -2.1644155979156494]
therapeutic B-LOC [1.798658847808838, -2.2330973148345947]
targets B-LOC [1.9831764698028564, -2.3153188228607178]
for B-LOC [1.8550392389297485, -2.268230676651001]
cardiovascular B-LOC [1.6153020858764648, -2.1630403995513916]
disease. B-LOC [1.699784517288208, -2.116560459136963]

Methyl-CpG B-LOC [0.9350937008857727, -1.5519230365753174]
binding B-LOC [1.046173334121704, -1.44610595703125]
protein B-LOC [1.1981302499771118, -1.589147925376892]
1 B-LOC [1.0469251871109009, -1.2549841403961182]
(MBD1) B-LOC [1.0342124700546265, -1.2984610795974731]
regulates B-LOC [1.35047447681427, -1.578761100769043]
gene B-LOC [1.449493646621704, -1.8582274913787842]
expression B-LOC [1.4265830516815186, -1.6874239444732666]
via B-LOC [1.244887113571167, -1.6138107776641846]
a B-LOC [1.5404764413833618, -1.5667505264282227]
DNA B-LOC [1.3191678524017334, -1.7142095565795898]
methylation-mediated B-LOC [1.7742745876312256, -2.0461761951446533]
epigenetic B-LOC [1.8997360467910767, -2.2002909183502197]
mechanism. B-LOC [1.2251884937286377, -1.8873387575149536]
We B-LOC [1.6282531023025513, -1.5500221252441406]
have B-LOC [1.7448160648345947, -1.287854790687561]
previously B-LOC [1.6149424314498901, -1.467320203781128]
demonstrated B-LOC [1.404491901397705, -1.1390186548233032]
that B-LOC [1.2984278202056885, -1.3264331817626953]
MBD1 B-LOC [1.312394380569458, -1.3538191318511963]
deficiency B-LOC [1.5705705881118774, -1.4614695310592651]
impairs B-LOC [1.5492680072784424, -1.4477289915084839]
adult B-LOC [1.6459338665008545, -1.7077205181121826]
neural B-LOC [1.6316759586334229, -2.0532031059265137]
stem/progenitor B-LOC [1.966404676437378, -2.370063543319702]
cell B-LOC [1.448622703552246, -1.9019893407821655]
(aNSC) B-LOC [1.7288378477096558, -1.762629747390747]
differentiation B-LOC [1.1406934261322021, -1.3812028169631958]
and B-LOC [1.6113179922103882, -1.648451566696167]
neurogenesis, B-LOC [1.8599742650985718, -2.1164891719818115]
but B-LOC [2.653298854827881, -2.5226213932037354]
the B-LOC [2.8054254055023193, -2.837892770767212]
underlying B-LOC [2.715179681777954, -2.8148152828216553]
mechanism B-LOC [2.4501430988311768, -2.697312116622925]
was B-LOC [2.461538076400757, -2.619434356689453]
unclear. B-LOC [2.8749706745147705, -2.71118426322937]
Here, O [-0.48524031043052673, 0.20008584856987]
we O [-0.5387584567070007, 0.23750784993171692]
show O [-0.4450170695781708, 0.2705787420272827]
that O [-0.720711886882782, 0.22467359900474548]
MBD1 O [-0.0977841168642044, -0.029091449454426765]
regulates O [-0.3645017147064209, 0.16578271985054016]
the O [-0.3592032492160797, 0.19055821001529694]
expression O [-0.1805761456489563, 0.30293896794319153]
of O [-0.27538537979125977, 0.18506218492984772]
several O [-0.20656216144561768, -0.04148605465888977]
microRNAs O [-0.2557241916656494, -0.04049858823418617]
in O [-0.3584766089916229, 0.1768217831850052]
aNSCs O [-0.16394390165805817, -0.14123809337615967]
and, O [-0.2925008237361908, 0.34760260581970215]
specifically, O [-0.3783707916736603, 0.36380839347839355]
that O [-0.3679198920726776, 0.22668713331222534]
miR-184 O [-0.2482033520936966, -0.03839519992470741]
is O [-0.05528201535344124, 0.051057394593954086]
directly O [-0.1706867814064026, -0.16247433423995972]
repressed O [-0.07233361899852753, 0.028474388644099236]
by O [-0.17027027904987335, 0.007704415824264288]
MBD1. O [-0.09594210237264633, -0.00888204388320446]
High B-LOC [-0.10336557030677795, -0.15079744160175323]
levels B-LOC [0.0049465917982161045, -0.05711926519870758]
of B-LOC [0.01376680564135313, -0.17616140842437744]
miR-184 O [-0.15424761176109314, -0.1298471987247467]
promoted B-LOC [-0.14735926687717438, -0.31357184052467346]

proliferation O [-0.5534188747406006, 0.34038597345352173]
but O [-0.710765540599823, 0.7525876760482788]
inhibited O [-0.7764216065406799, 0.7317327857017517]
differentiation O [-0.44517993927001953, 0.37975695729255676]
of O [-0.6594975590705872, 0.3968243896961212]
aNSCs, O [-0.45614147186279297, 0.3059544861316681]
whereas O [-0.6168435215950012, 0.7687590718269348]
inhibition O [-0.6809856295585632, 0.5814674496650696]
of O [-0.45337435603141785, 0.43482643365859985]
miR-184 O [-0.25359785556793213, 0.17731736600399017]
rescued O [-0.3386041224002838, 0.3335449993610382]
the O [-0.32842469215393066, 0.17392577230930328]
phenotypes O [-0.3514246642589569, 0.050192587077617645]
associated O [-0.12429216504096985, 0.1681937873363495]
with O [-0.24485017359256744, 0.009268814697861671]
MBD1 O [-0.20258218050003052, -0.04807358980178833]
deficiency. O [-0.09624151885509491, 0.2517651617527008]
We O [-0.7090311646461487, 0.29382362961769104]
further O [-0.6691812872886658, 0.598377525806427]
found O [-0.8376703262329102, 0.7799424529075623]
that O [-1.0778099298477173, 0.7647821307182312]
miR-184 O [-0.6573637127876282, 0.440094918012619]
regulates O [-0.7244635820388794, 0.757175087928772]
the O [-0.7259896993637085, 0.7878632545471191]
expression O [-0.5902340412139893, 0.8687537312507629]
of O [-0.7864871025085449, 0.8009042143821716]
Numblike O [-0.568304717540741, 0.4406445324420929]
(Numbl), O [-0.7548709511756897, 0.6277872920036316]
a O [-0.8266486525535583, 0.8336091041564941]
known O [-0.6441865563392639, 0.6193955540657043]
regulator O [-0.676098644733429, 0.6600866913795471]
of O [-0.7628186345100403, 0.7335695624351501]
brain O [-0.7549628615379333, 0.6175652742385864]
development, O [-0.770428478717804, 0.7534276247024536]
by O [-1.0249314308166504, 1.0366880893707275]
binding O [-0.6183632612228394, 0.7817119359970093]
to O [-0.5405123829841614, 0.5957070589065552]
the O [-0.6051439642906189, 0.7376226186752319]
3'-UTR O [-0.47957730293273926, 0.5973634719848633]
of O [-0.573386549949646, 0.4838624894618988]
Numbl O [-0.3651045858860016, 0.2847989499568939]
mRNA O [-0.8339277505874634, 0.5167208313941956]
and O [-0.6844423413276672, 0.8628709316253662]
affecting O [-0.7105169892311096, 0.7502397298812866]
its O [-0.5276530981063843, 0.4866926074028015]
translation. O [-0.6093016862869263, 0.4918932616710663]
Expression B-LOC [0.8439880013465881, -0.6186525225639343]
of B-LOC [0.9229747653007507, -0.7606112360954285]
exogenous B-LOC [1.0202456712722778, -0.8632964491844177]
Numbl B-LOC [0.6072565317153931, -0.8105370998382568]
could B-LOC [0.6255108118057251, -0.9071634411811829]
rescue B-LOC [0.5330154299736023, -0.8927198052406311]
the B-LOC [0.7127366662025452, -0.7516483664512634]
aNSC B-LOC [0.18337011337280273, -0.6501116752624512]
defects B-LOC [0.5551180243492126, -0.7222316265106201]
that B-LOC [0.6234111189842224, -0.8591567277908325]
result B-LOC [0.5894955992698669, -0.8230934143066406]
from B-LOC [0.37513330578804016, -0.5565664768218994]
either B-LOC [0.4158126711845398, -0.6967450976371765]
miR-184 B-LOC [0.2357580065727234, -0.5632700324058533]
overexpression B-LOC [0.34022819995880127, -0.6474164128303528]
or B-LOC [0.42500942945480347, -0.4997718632221222]
MBD1 B-LOC [0.17471802234649658, -0.6508496999740601]
deficiency. B-LOC [0.32550564408302307, -0.4959101378917694]

Therefore, B-LOC [-0.05436982586979866, -0.08234450221061707]
MBD1, B-LOC [-0.23981350660324097, -0.2774868607521057]
miR-184, B-LOC [-0.06531393527984619, -0.18930940330028534]
and B-LOC [0.1778305470943451, -0.05364396050572395]
Numbl B-LOC [0.0004243651346769184, -0.20119935274124146]
form B-LOC [0.4033893942832947, -0.15033170580863953]
a B-LOC [0.20657911896705627, -0.2079586684703827]
regulatory B-LOC [0.08661671727895737, -0.26948103308677673]
network B-LOC [0.009534667246043682, -0.27753812074661255]
that B-LOC [0.06462514400482178, -0.41525283455848694]
helps B-LOC [0.20981907844543457, -0.21212507784366608]
control B-LOC [0.23358911275863647, -0.5131320953369141]
the B-LOC [0.2544260323047638, -0.3859979212284088]
balance B-LOC [0.19242392480373383, -0.3581976294517517]
between B-LOC [0.2304745614528656, -0.5451542735099792]
proliferation B-LOC [0.2226521372795105, -0.42167994379997253]
and B-LOC [0.4508126378059387, -0.5668846368789673]
differentiation B-LOC [0.14659908413887024, -0.4052310287952423]
of B-LOC [0.173997700214386, -0.47985419631004333]
aNSCs. B-LOC [-0.11368454992771149, -0.29693517088890076]

OBJECTIVE B-LOC [3.3539276123046875, -3.5169928073883057]
To B-LOC [3.5595593452453613, -3.592517137527466]
assess B-LOC [3.783048391342163, -3.433656692504883]
the B-LOC [3.8537721633911133, -3.324960470199585]
effect B-LOC [3.837083578109741, -3.50748610496521]
of B-LOC [3.7159454822540283, -3.432009696960449]
25-hydroxyvitamin B-LOC [3.6085824966430664, -3.4206502437591553]
D B-LOC [3.4550538063049316, -3.4749436378479004]
(25-OHD) B-LOC [3.658674478530884, -3.294947385787964]
levels B-LOC [3.8635730743408203, -3.393820285797119]
on B-LOC [3.5684683322906494, -3.595024824142456]
pregnancy B-LOC [3.7976131439208984, -3.5953757762908936]
outcomes B-LOC [4.08762788772583, -3.656235456466675]
and B-LOC [3.651811361312866, -3.5336802005767822]
birth B-LOC [3.8210320472717285, -3.704434633255005]
variables. B-LOC [3.8597710132598877, -3.6272454261779785]
DESIGN B-LOC [3.6878509521484375, -3.4872353076934814]
Systematic B-LOC [3.4138479232788086, -3.1316568851470947]
review B-LOC [3.4968652725219727, -3.181520938873291]
and B-LOC [3.408400058746338, -3.2084453105926514]
meta-analysis. B-LOC [3.6682348251342773, -3.451990842819214]
DATA B-LOC [3.567288637161255, -3.18180251121521]
SOURCES B-LOC [3.3040096759796143, -2.8763294219970703]
Medline B-LOC [3.1542229652404785, -2.821955919265747]
(1966 B-LOC [3.102289915084839, -2.651176929473877]
to B-LOC [3.3556478023529053, -2.972968578338623]
August B-LOC [3.3758208751678467, -3.240464210510254]
2012), B-LOC [3.2382681369781494, -3.028596878051758]
PubMed B-LOC [3.1771366596221924, -3.077545404434204]
(2008 B-LOC [3.0634267330169678, -2.611377477645874]
to B-LOC [3.3426225185394287, -2.7880213260650635]
August B-LOC [3.209010124206543, -2.906374216079712]
2012), B-LOC [3.1594769954681396, -2.7656915187835693]
Embase B-LOC [3.1547327041625977, -2.8929619789123535]
(1980 B-LOC [3.0859358310699463, -2.558065176010132]
to B-LOC [3.406162977218628, -2.8175270557403564]
August B-LOC [3.218013286590576, -2.8638722896575928]
2012), B-LOC [3.1775567531585693, -2.763789653778076]
CINAHL B-LOC [3.1782424449920654, -3.004227876663208]
(1981 B-LOC [3.1516149044036865, -2.6757984161376953]
to B-LOC [3.4937591552734375, -2.8647725582122803]
August B-LOC [3.3991200923919678, -2.94653058052063]
2012), B-LOC [3.3061516284942627, -2.8851354122161865]
the B-LOC [3.3735764026641846, -3.054389238357544]
Cochrane B-LOC [3.4398629665374756, -3.422353744506836]
database B-LOC [3.418807029724121, -3.0561978816986084]
of B-LOC [3.3092033863067627, -2.701870918273926]
systematic B-LOC [3.670480966567993, -3.1329870223999023]
reviews, B-LOC [3.7700424194335938, -3.170856475830078]
and B-LOC [3.319489002227783, -3.13197922706604]
the B-LOC [3.5376336574554443, -3.108471632003784]
Cochrane B-LOC [3.6317684650421143, -3.4343438148498535]
database B-LOC [3.5653905868530273, -3.0006539821624756]
of B-LOC [3.435434341430664, -2.884868860244751]
registered B-LOC [3.709338903427124, -3.19026255607605]
clinical B-LOC [3.9118812084198, -3.3788204193115234]
trials. B-LOC [3.8001186847686768, -3.391138792037964]
STUDY B-LOC [1.353921890258789, -1.9974908828735352]
SELECTION B-LOC [1.360642671585083, -1.8198637962341309]
Studies B-LOC [1.3659120798110962, -1.8764079809188843]
reporting B-LOC [1.492233395576477, -1.9446353912353516]
on B-LOC [2.1006200313568115, -2.2021610736846924]
the B-LOC [2.1842334270477295, -2.3348677158355713]
association B-LOC [1.821507215499878, -2.152101755142212]
between B-LOC [1.5352535247802734, -2.24629807472229]
serum B-LOC [1.420974612236023, -2.298189401626587]
25-OHD B-LOC [1.4275883436203003, -1.555910348892212]
levels B-LOC [1.7052143812179565, -2.0887985229492188]
during B-LOC [1.28620183467865, -1.8342612981796265]
pregnancy B-LOC [1.5544052124023438, -1.9580867290496826]

and B-LOC [2.648024559020996, -3.420718193054199]
the B-LOC [2.790506601333618, -3.5981712341308594]
outcomes B-LOC [3.072957754135132, -3.5979743003845215]
of B-LOC [2.8991124629974365, -3.7472941875457764]
interest B-LOC [2.6915252208709717, -3.5667243003845215]
(pre-eclampsia, B-LOC [2.3922977447509766, -3.3610892295837402]
gestational B-LOC [2.6686861515045166, -3.139936685562134]
diabetes, B-LOC [2.168010950088501, -2.911881685256958]
bacterial B-LOC [2.2826478481292725, -3.2301506996154785]
vaginosis, B-LOC [2.4238617420196533, -3.044844388961792]
caesarean B-LOC [2.3873651027679443, -3.1450717449188232]
section, B-LOC [1.711193323135376, -2.6613097190856934]
small B-LOC [2.574355125427246, -3.135331153869629]
for B-LOC [2.0181357860565186, -2.9710335731506348]
gestational B-LOC [2.4545459747314453, -3.0378496646881104]
age B-LOC [2.465465784072876, -3.0466830730438232]
infants, B-LOC [2.2522475719451904, -2.9213707447052]
birth B-LOC [2.3039450645446777, -2.9580602645874023]
weight, B-LOC [2.7510263919830322, -3.191359758377075]
birth B-LOC [2.269115686416626, -2.827716588973999]
length, B-LOC [2.252640962600708, -3.0189545154571533]
and B-LOC [2.7555696964263916, -3.649005174636841]
head B-LOC [2.675410032272339, -3.3943917751312256]
circumference). B-LOC [2.8068768978118896, -3.392422914505005]
DATA B-LOC [3.223266363143921, -3.5307061672210693]
EXTRACTION B-LOC [2.8523080348968506, -2.960660219192505]
Two B-LOC [3.1556236743927, -3.666903018951416]
authors B-LOC [3.40698504447937, -3.621843099594116]
independently B-LOC [3.5410208702087402, -3.549657106399536]
extracted B-LOC [3.4269859790802, -3.565880060195923]
data B-LOC [3.688633918762207, -3.7139875888824463]
from B-LOC [3.461219072341919, -3.6291263103485107]
original B-LOC [3.2560181617736816, -3.6117565631866455]
research B-LOC [3.375490427017212, -3.6691505908966064]
articles, B-LOC [3.538966417312622, -3.651165723800659]
including B-LOC [3.675476312637329, -3.5539326667785645]
key B-LOC [3.4816935062408447, -3.7014286518096924]
indicators B-LOC [3.656226396560669, -3.6129939556121826]
of B-LOC [3.34899640083313, -3.6070282459259033]
study B-LOC [3.41044020652771, -3.6799044609069824]
quality. B-LOC [3.36332106590271, -3.779576301574707]
We B-LOC [3.346876382827759, -3.637766122817993]
pooled B-LOC [3.6964080333709717, -3.434410572052002]
the B-LOC [3.583280324935913, -3.5297489166259766]
most B-LOC [3.4751975536346436, -3.7724363803863525]
adjusted B-LOC [3.5519678592681885, -3.806417226791382]
odds B-LOC [3.6263487339019775, -3.7171170711517334]
ratios B-LOC [3.517547845840454, -3.6415998935699463]
and B-LOC [3.438852071762085, -3.5355799198150635]
weighted B-LOC [3.6559383869171143, -3.727358102798462]
mean B-LOC [3.495439291000366, -3.8398709297180176]
differences. B-LOC [3.5145230293273926, -3.7092490196228027]
Associations B-LOC [3.691150665283203, -3.6969728469848633]
were B-LOC [3.514507293701172, -3.6914167404174805]
tested B-LOC [3.8344266414642334, -3.707537889480591]
in B-LOC [3.579066038131714, -3.510319471359253]
subgroups B-LOC [3.8779380321502686, -3.461841344833374]
representing B-LOC [3.5578668117523193, -3.754518747329712]
different B-LOC [3.4824185371398926, -3.853745937347412]
patient B-LOC [3.724095344543457, -3.8702425956726074]
characteristics B-LOC [3.738252878189087, -3.8728244304656982]
and B-LOC [3.4769928455352783, -3.7195160388946533]
study B-LOC [3.6488821506500244, -3.9051361083984375]
quality. B-LOC [3.6566810607910156, -3.859649419784546]
RESULTS B-LOC [2.377370595932007, -2.884732484817505]
3357 B-LOC [3.3378348350524902, -3.1372108459472656]
studies B-LOC [3.19187068939209, -3.6110148429870605]
were B-LOC [3.464545249938965, -3.5925068855285645]
identified B-LOC [3.8805503845214844, -3.6493141651153564]
and B-LOC [3.0867350101470947, -3.382760763168335]
reviewed B-LOC [3.9035582542419434, -3.6018424034118652]
for B-LOC [3.484651803970337, -3.6214077472686768]
eligibility. B-LOC [3.628354072570801, -3.686431884765625]
31 B-LOC [3.1881277561187744, -3.38440203666687]
eligible B-LOC [2.298848867416382, -2.9733517169952393]

studies B-LOC [2.1054275035858154, -2.6939799785614014]
were B-LOC [2.62050199508667, -2.937269926071167]
included B-LOC [2.8517582416534424, -3.204706907272339]
in B-LOC [2.569427728652954, -3.157663583755493]
the B-LOC [2.5374934673309326, -2.9072299003601074]
final B-LOC [2.6650359630584717, -2.6890180110931396]
analysis. B-LOC [2.4603993892669678, -2.871469259262085]
Insufficient B-LOC [1.1119637489318848, -1.293724775314331]
serum B-LOC [0.5850797295570374, -0.8974477052688599]
levels B-LOC [1.099359393119812, -0.9555773735046387]
of B-LOC [0.6897253394126892, -0.6171517968177795]
25-OHD B-LOC [0.5558944344520569, -0.7519063353538513]
were B-LOC [0.8040412664413452, -0.8524366021156311]
associated B-LOC [0.8219192624092102, -0.7863548398017883]
with B-LOC [0.685928225517273, -0.7907700538635254]
gestational B-LOC [0.9817392230033875, -1.0751733779907227]
diabetes B-LOC [0.5389083027839661, -0.8120943903923035]
(pooled B-LOC [0.5674765706062317, -0.590006411075592]
odds B-LOC [0.28587719798088074, -0.6510298848152161]
ratio B-LOC [0.29768112301826477, -0.7670084834098816]
1.49, B-LOC [0.4341365694999695, -0.537079930305481]
95% B-LOC [0.4274064898490906, -0.7275153994560242]
confidence B-LOC [0.039535123854875565, -0.579928994178772]
interval B-LOC [0.08519980311393738, -0.7533818483352661]
1.18 B-LOC [0.34145763516426086, -0.5010936856269836]
to B-LOC [0.15281307697296143, -0.7927947640419006]
1.89), B-LOC [0.41811642050743103, -0.3839857280254364]
pre-eclampsia B-LOC [0.5640022158622742, -0.7719343304634094]
(1.79, B-LOC [0.5796288847923279, -0.6883569359779358]
1.25 B-LOC [0.4990064799785614, -0.43841707706451416]
to B-LOC [0.29710566997528076, -0.7920554280281067]
2.58), B-LOC [0.4261169731616974, -0.44514766335487366]
and B-LOC [0.6201596260070801, -0.5979166626930237]
small B-LOC [0.7379674315452576, -0.7231677770614624]
for B-LOC [0.4975415766239166, -0.7198591828346252]
gestational B-LOC [0.9344324469566345, -1.0512323379516602]
age B-LOC [0.9175670742988586, -0.9338789582252502]
infants B-LOC [0.4633667767047882, -0.8579052090644836]
(1.85, B-LOC [0.5488271117210388, -0.6708551645278931]
1.52 B-LOC [0.46217140555381775, -0.47062692046165466]
to B-LOC [0.2966756820678711, -0.8743849396705627]
2.26). B-LOC [0.1728512942790985, -0.4658440053462982]
Pregnant O [-1.0408446788787842, 0.8054378628730774]
women O [-0.7830062508583069, 0.6746817231178284]
with O [-1.1699535846710205, 0.6431892514228821]
low O [-0.9866614937782288, 0.7983863353729248]
serum O [-1.1506906747817993, 0.7554751038551331]
25-OHD O [-0.5699400901794434, 0.4939357042312622]
levels O [-0.8648632168769836, 0.9450722932815552]
had O [-1.3768457174301147, 0.8095074892044067]
an O [-1.31034255027771, 0.8709320425987244]
increased O [-1.2938616275787354, 0.8876440525054932]
risk O [-1.2070460319519043, 0.9074956774711609]
of O [-1.388504981994629, 1.0074489116668701]
bacterial O [-1.169112205505371, 0.9238879084587097]
vaginosis O [-1.1436476707458496, 0.9267169833183289]
and O [-1.424450397491455, 0.9393899440765381]
low O [-1.2859184741973877, 0.9844790101051331]
birthweight O [-0.9472880959510803, 0.8251934051513672]
infants O [-0.8483725190162659, 0.8439843058586121]
but O [-1.472080945968628, 0.9566106200218201]
not O [-1.2833529710769653, 1.1358662843704224]
delivery O [-0.7427572011947632, 0.7313504219055176]
by O [-1.4379721879959106, 0.9181033968925476]

caesarean B-LOC [-0.14645686745643616, -0.18960228562355042]
section. O [-0.2150547206401825, -0.1679518073797226]
CONCLUSION O [-0.6580958962440491, 0.3618374764919281]
Vitamin O [-0.1830681711435318, 0.25242891907691956]
D O [-0.4511529505252838, 0.45490527153015137]
insufficiency O [-0.2768629491329193, 0.5123171210289001]
is O [-0.33875635266304016, 0.0028591579757630825]
associated O [-0.41888687014579773, 0.2579161524772644]
with O [-0.4216090440750122, 0.15789790451526642]
an O [-0.4861522912979126, 0.17996862530708313]
increased O [-0.5007710456848145, 0.19108936190605164]
risk O [-0.40235674381256104, 0.11240851879119873]
of O [-0.5719441175460815, 0.11380262672901154]
gestational O [-0.2149721384048462, 0.11801476776599884]
diabetes, O [-0.1670851856470108, 0.10208705812692642]
pre-eclampsia, O [-0.3861573338508606, 0.1705203354358673]
and O [-0.33836492896080017, 0.1773376762866974]
small O [-0.34609392285346985, 0.28853490948677063]
for O [-0.29969319701194763, -0.14190638065338135]
gestational B-LOC [0.03274596109986305, -0.0629906952381134]
age O [-0.04744555801153183, 0.03261442109942436]
infants. O [-0.25190839171409607, -0.013664254918694496]
Pregnant O [-1.0338611602783203, 0.8719886541366577]
women O [-0.7653129696846008, 0.6219463348388672]
with O [-1.162853479385376, 0.6513012051582336]
low O [-1.0733261108398438, 0.8619911074638367]
25-OHD O [-0.6350874900817871, 0.6412095427513123]
levels O [-0.8994559049606323, 0.9142230153083801]
had O [-1.2711946964263916, 0.7403967976570129]
an O [-1.2319737672805786, 0.8308054208755493]
increased O [-1.1911522150039673, 0.8192256093025208]
risk O [-1.1754083633422852, 0.9020056128501892]
of O [-1.3094838857650757, 0.9949559569358826]
bacterial O [-0.9864359498023987, 0.7816731333732605]
vaginosis O [-1.016133427619934, 0.9034284949302673]
and O [-1.3294553756713867, 0.8898563981056213]
lower O [-1.1974279880523682, 0.9018033146858215]
birth O [-0.8850757479667664, 0.8090682625770569]
weight O [-0.7748857140541077, 0.9147160649299622]
infants, O [-0.7423253655433655, 0.6487500071525574]
but O [-1.3553696870803833, 0.8219935297966003]
not O [-1.040418267250061, 0.9743825793266296]
delivery O [-0.7227835655212402, 0.5773845314979553]
by O [-1.060544490814209, 0.571691632270813]
caesarean O [-0.8387640714645386, 0.6041259169578552]
section. O [-0.714971125125885, 0.32468181848526]

Lysine B-LOC [0.370140016078949, -1.0290515422821045]
acetylation B-LOC [0.6433400511741638, -1.4624521732330322]
is B-LOC [1.0092779397964478, -1.287275791168213]
a B-LOC [0.823136031627655, -1.1912569999694824]
reversible B-LOC [0.8298018574714661, -1.257588505744934]
posttranslational B-LOC [0.7126867175102234, -1.1734658479690552]
modifcation, B-LOC [0.7106776237487793, -1.280295968055725]
an B-LOC [0.8767003417015076, -1.3583086729049683]
epigenetic B-LOC [1.0824949741363525, -1.487153172492981]
phenomenon, B-LOC [0.7741823792457581, -1.385948896408081]
referred B-LOC [1.057902455329895, -1.2530968189239502]
to B-LOC [1.272623896598816, -1.3064430952072144]
as B-LOC [1.0414087772369385, -1.2334861755371094]
transfer B-LOC [0.754831850528717, -1.105799913406372]
of B-LOC [0.7623411417007446, -1.2805149555206299]
an B-LOC [0.6804899573326111, -1.1053836345672607]
acetyl B-LOC [0.6382659077644348, -1.408231496810913]
group B-LOC [0.5876830816268921, -0.9352474808692932]
from B-LOC [0.4467563033103943, -0.7970998287200928]
acetyl B-LOC [0.6230883002281189, -1.4165637493133545]
CoA B-LOC [0.4226089417934418, -0.8836910724639893]
to B-LOC [0.5905280113220215, -1.0085647106170654]
lysine B-LOC [0.5739920735359192, -1.0569790601730347]
e- B-LOC [0.4322050213813782, -0.8214744329452515]
amino B-LOC [0.9128304719924927, -1.4263771772384644]
group B-LOC [0.5605244040489197, -0.9484702944755554]
of B-LOC [0.8506947755813599, -1.3918101787567139]
targeted B-LOC [1.0513226985931396, -1.3279550075531006]
protein, B-LOC [0.9313939213752747, -1.3547008037567139]
which B-LOC [1.2587298154830933, -1.6518242359161377]
is B-LOC [1.846002459526062, -1.5457615852355957]
modulated B-LOC [2.040475606918335, -1.5473616123199463]
by B-LOC [1.8057618141174316, -1.7209949493408203]
acetyltransferases B-LOC [1.4222426414489746, -1.9442694187164307]
(histone/ B-LOC [1.7329652309417725, -1.657217025756836]
lysine B-LOC [0.7073120474815369, -0.9208555817604065]
(K) B-LOC [1.046377182006836, -1.4085373878479004]
acetyltransferases, B-LOC [1.020431637763977, -1.6496191024780273]
HATs/KATs) B-LOC [0.7597691416740417, -1.176018476486206]
and B-LOC [1.6596369743347168, -1.509443998336792]
deacetylases B-LOC [1.4055339097976685, -1.4685875177383423]
(histone/lysine B-LOC [1.6182453632354736, -1.4824351072311401]
(K) B-LOC [0.8150192499160767, -1.2493873834609985]
deacetylases, B-LOC [0.9025614857673645, -1.12297523021698]
HDACs/KDACs). B-LOC [1.1248468160629272, -0.8605613708496094]
Lysine B-LOC [0.24008896946907043, -0.5330727100372314]
acetylation B-LOC [0.2291584014892578, -1.0909147262573242]
regulates B-LOC [0.35943078994750977, -0.7240379452705383]
various B-LOC [0.533115565776825, -0.9421826004981995]
metabolic B-LOC [0.24850106239318848, -0.9646596312522888]

processes, B-LOC [0.3242815434932709, -1.1912306547164917]
such B-LOC [0.7728151082992554, -1.230143666267395]
as B-LOC [0.7277930974960327, -1.1642460823059082]
fatty B-LOC [0.6644988059997559, -0.9786220192909241]
acid B-LOC [0.5774409174919128, -1.0551412105560303]
oxidation, B-LOC [0.6001399755477905, -0.8986225128173828]
Krebs B-LOC [0.3705808222293854, -0.8763084411621094]
cycle, B-LOC [0.2984509766101837, -0.8079723119735718]
oxidative B-LOC [0.44617801904678345, -0.9911625981330872]
phosphorylation, B-LOC [0.5409387946128845, -1.0236576795578003]
angiogenesis B-LOC [0.3782520592212677, -1.1175706386566162]
and B-LOC [0.8793005347251892, -1.2000482082366943]
so B-LOC [0.8891217112541199, -0.9565236568450928]
on. B-LOC [0.9021150469779968, -1.0816516876220703]
Thus B-LOC [1.620114803314209, -1.8593076467514038]
disorders B-LOC [1.6846497058868408, -2.151611566543579]
of B-LOC [1.4332497119903564, -2.168520212173462]
lysine B-LOC [1.1227302551269531, -1.5223240852355957]
acetylation B-LOC [1.1448850631713867, -2.0683796405792236]
may B-LOC [1.8858070373535156, -2.3267998695373535]
be B-LOC [1.9449920654296875, -2.4338228702545166]
correlated B-LOC [1.659168004989624, -2.1390798091888428]
with B-LOC [1.642855167388916, -2.2784993648529053]
obesity, B-LOC [1.35044264793396, -2.1487014293670654]
diabetes B-LOC [1.586914300918579, -2.2222683429718018]
and B-LOC [1.7685524225234985, -2.2125258445739746]
cardiovascular B-LOC [1.4816741943359375, -2.3595635890960693]
disease, B-LOC [1.7051105499267578, -2.4915361404418945]
which B-LOC [1.6462035179138184, -2.272768974304199]
are B-LOC [2.0393316745758057, -2.2341115474700928]
termed B-LOC [1.9165306091308594, -2.17734694480896]
as B-LOC [1.8562464714050293, -2.24491548538208]
the B-LOC [1.5397778749465942, -2.1450231075286865]
metabolic B-LOC [1.499099612236023, -2.302821636199951]
complication. B-LOC [1.5770037174224854, -2.2624549865722656]
With B-LOC [1.2695400714874268, -1.4775917530059814]
accumulating B-LOC [1.8935439586639404, -1.636420726776123]
studies B-LOC [1.624993085861206, -1.6588776111602783]
on B-LOC [1.7222906351089478, -2.0546252727508545]
proteomic B-LOC [1.5669070482254028, -1.8375282287597656]
acetylation, B-LOC [1.660304307937622, -2.07572603225708]
lysine B-LOC [1.3074464797973633, -1.4878406524658203]
acetylation B-LOC [1.3996531963348389, -1.8721479177474976]
also B-LOC [1.7979927062988281, -1.757321834564209]
involves B-LOC [1.5924053192138672, -1.656614065170288]
in B-LOC [1.5120470523834229, -1.705567479133606]
cell B-LOC [1.4899168014526367, -1.8999006748199463]
immune B-LOC [2.0189626216888428, -1.9690176248550415]
status B-LOC [1.6842045783996582, -1.5653431415557861]
and B-LOC [1.838021993637085, -1.855421543121338]
degenerative B-LOC [2.0540401935577393, -1.8969848155975342]
diseases, B-LOC [2.0609235763549805, -1.9443057775497437]
for B-LOC [2.065877914428711, -1.9048631191253662]
example, B-LOC [2.009053945541382, -1.8291432857513428]
Alzheimer’s B-LOC [1.9230096340179443, -1.8980581760406494]
disease B-LOC [1.7615983486175537, -2.0015156269073486]
and B-LOC [1.5776622295379639, -1.4362175464630127]
Huntington’s B-LOC [1.5995666980743408, -1.668820858001709]
disease. B-LOC [1.7554805278778076, -1.9236407279968262]
This B-LOC [1.2531867027282715, -1.6233911514282227]
review B-LOC [1.5933876037597656, -1.8799488544464111]
primarily B-LOC [1.4219038486480713, -1.6162924766540527]
summarizes B-LOC [1.9818463325500488, -1.8521617650985718]
the B-LOC [1.730534315109253, -1.8461840152740479]
current B-LOC [1.6473031044006348, -1.8467453718185425]
studies B-LOC [1.548552393913269, -1.943031668663025]
of B-LOC [1.5589382648468018, -1.873927116394043]
lysine B-LOC [1.2161706686019897, -1.3510276079177856]

acetylation B-LOC [0.0016893992433324456, -0.40772122144699097]
in B-LOC [0.04381255805492401, -0.3722732365131378]
metabolism B-LOC [0.01850159280002117, -0.2535730004310608]
modulation B-LOC [0.18063008785247803, -0.28242969512939453]
and B-LOC [0.2864968478679657, -0.502848207950592]
in B-LOC [0.1277046501636505, -0.5249876379966736]
metabolism-related B-LOC [0.12536293268203735, -0.35036906599998474]
diseases, B-LOC [0.42757168412208557, -0.6173834204673767]
such B-LOC [0.7532346248626709, -0.5696120858192444]
as B-LOC [0.7895912528038025, -0.6424646973609924]
cardiovascular B-LOC [0.16874012351036072, -0.5612695813179016]
disease B-LOC [0.276080459356308, -0.4548664093017578]
and B-LOC [0.4957104027271271, -0.4190221130847931]
fat B-LOC [0.10699496418237686, -0.4024263024330139]
metabolism B-LOC [0.05662768706679344, -0.273696631193161]
disorder. B-LOC [0.1855776160955429, -0.3532505929470062]

Local B-LOC [1.053330898284912, -1.8353148698806763]
translation B-LOC [0.9137544631958008, -1.3803794384002686]
mediates B-LOC [1.0030255317687988, -1.3791351318359375]
axonal B-LOC [1.2466578483581543, -1.65762460231781]
responses B-LOC [1.2428479194641113, -1.5221806764602661]
to B-LOC [1.0147595405578613, -1.5511516332626343]
Semaphorin3A B-LOC [1.210702657699585, -1.6281217336654663]
(Sema3A) B-LOC [1.1080156564712524, -1.3546782732009888]
and B-LOC [1.2055319547653198, -1.6097344160079956]
other B-LOC [1.3389447927474976, -1.5750941038131714]
guidance B-LOC [1.317169189453125, -1.7882752418518066]
cues. B-LOC [1.1629921197891235, -1.6851351261138916]
However, B-LOC [1.889164924621582, -2.2269413471221924]
only B-LOC [1.9412760734558105, -2.1683833599090576]
a B-LOC [1.9971529245376587, -2.2697155475616455]
subset B-LOC [1.8893768787384033, -2.42263126373291]
of B-LOC [1.7340246438980103, -2.4053561687469482]
the B-LOC [1.9312801361083984, -2.3174853324890137]
axonal B-LOC [2.0312514305114746, -2.6290388107299805]
proteome B-LOC [1.6307607889175415, -2.441256046295166]
is B-LOC [1.9213531017303467, -2.1993370056152344]
locally B-LOC [1.945068359375, -2.4108824729919434]
synthesized, B-LOC [1.8907999992370605, -2.298635721206665]
whereas B-LOC [1.7736828327178955, -2.0719738006591797]
most B-LOC [1.9342796802520752, -2.3840668201446533]
proteins B-LOC [2.1021926403045654, -2.62575364112854]
are B-LOC [2.079963445663452, -2.3978769779205322]
trafficked B-LOC [1.8996241092681885, -2.467113971710205]
from B-LOC [1.8212239742279053, -2.208087682723999]
the B-LOC [1.8493738174438477, -2.183729648590088]
soma. B-LOC [1.917549729347229, -2.4136102199554443]
The B-LOC [2.802375078201294, -2.9309945106506348]
reason B-LOC [2.5132973194122314, -2.8703105449676514]
why B-LOC [2.5433528423309326, -3.0198333263397217]
only B-LOC [2.692885398864746, -2.8911619186401367]
specific B-LOC [2.6253392696380615, -3.171112060546875]
proteins B-LOC [2.60671067237854, -2.92997670173645]
are B-LOC [2.718268394470215, -2.9240753650665283]
locally B-LOC [2.438647508621216, -2.8596701622009277]
synthesized B-LOC [2.6707537174224854, -2.842432975769043]
is B-LOC [3.110239267349243, -2.9242513179779053]
unknown. B-LOC [2.905791759490967, -2.913902997970581]
Here B-LOC [-0.029559804126620293, -0.3006005883216858]
we O [-0.23135675489902496, -0.17429450154304504]
show B-LOC [0.1822597235441208, -0.2592396140098572]
that B-LOC [-0.21546390652656555, -0.5722324252128601]
local B-LOC [0.38570788502693176, -0.9275434613227844]
protein B-LOC [0.3865344226360321, -0.7437060475349426]
synthesis B-LOC [0.5219342708587646, -0.6988129615783691]
and B-LOC [0.8770492672920227, -1.164873480796814]
degradation B-LOC [0.8803926706314087, -1.2146934270858765]
are B-LOC [1.1988226175308228, -1.2662665843963623]
linked B-LOC [0.9237784743309021, -1.314333200454712]
events B-LOC [0.6882992386817932, -1.1791951656341553]
in B-LOC [0.6702912449836731, -1.100048303604126]
growth B-LOC [0.30954962968826294, -0.6114539504051208]
cones. B-LOC [0.47570255398750305, -0.9045876264572144]
We O [-0.47749063372612, 0.22062227129936218]
find O [-0.42961186170578003, 0.2780424654483795]
that O [-0.7929195761680603, 0.30958279967308044]
growth O [-0.2029258906841278, 0.2140326052904129]
cones O [-0.1743260771036148, 0.2240827977657318]
exhibit O [-0.2662835419178009, 0.22503739595413208]
high O [-0.19646134972572327, 0.1770675629377365]
levels O [-0.0850536972284317, 0.17181220650672913]
of O [-0.27652260661125183, -0.005160915199667215]
ubiquitination O [-0.13139019906520844, -0.03857792913913727]
and O [-0.5163638591766357, 0.3404557406902313]
that O [-0.7733427286148071, 0.3664267957210541]
local O [-0.395060658454895, 0.10678406059741974]
signalling O [-0.4731593132019043, 0.3730006217956543]
pathways O [-0.47425568103790283, 0.31322500109672546]
trigger O [-0.5748276114463806, 0.24836261570453644]
the O [-0.45569470524787903, 0.32728490233421326]
ubiquitination O [-0.39326417446136475, 0.357586532831192]
and O [-0.4815903604030609, 0.3435433506965637]
degradation O [-0.17898136377334595, 0.2318563312292099]
of O [-0.45643994212150574, 0.24702665209770203]
RhoA, O [-0.5151428580284119, 0.12674164772033691]

a B-LOC [0.1308317929506302, -0.3969869911670685]
mediator B-LOC [0.1743757426738739, -0.48121318221092224]
of B-LOC [0.15110936760902405, -0.4631315767765045]
Sema3A-induced B-LOC [0.4984472692012787, -0.6168538928031921]
growth B-LOC [0.22316212952136993, -0.5343899726867676]
cone B-LOC [0.15175026655197144, -0.5446166396141052]
collapse. B-LOC [0.3382006585597992, -0.4426015317440033]
Inhibition B-LOC [0.4655391275882721, -0.6507291793823242]
of B-LOC [0.4149457812309265, -0.6459680199623108]
RhoA B-LOC [0.3687165081501007, -0.765428364276886]
degradation B-LOC [0.4987660050392151, -0.5577937960624695]
is B-LOC [0.7083123326301575, -0.8046643137931824]
sufficient B-LOC [0.7194418907165527, -0.6002095937728882]
to B-LOC [0.6919366717338562, -0.6095950603485107]
remove B-LOC [0.7583939433097839, -0.5682148933410645]
the B-LOC [0.5985057950019836, -0.5735229253768921]
protein-synthesis B-LOC [0.4056380093097687, -0.7907403707504272]
requirement B-LOC [0.19774982333183289, -0.5026872754096985]
for B-LOC [0.3400358259677887, -0.6419277787208557]
Sema3A-induced B-LOC [0.6112118363380432, -0.6116477847099304]
growth B-LOC [0.29441556334495544, -0.650152325630188]
cone B-LOC [0.25836512446403503, -0.7206013798713684]
collapse. B-LOC [0.3884476125240326, -0.425718754529953]
In O [-0.4319889545440674, 0.26940497756004333]
addition O [-0.2298952341079712, 0.4999776780605316]
to O [-0.15959560871124268, 0.2823329269886017]
RhoA, O [-0.1056138426065445, -0.009178336709737778]
we O [-0.5301633477210999, 0.1688401997089386]
find O [-0.4335591793060303, 0.32190850377082825]
that O [-0.4782291650772095, 0.33579710125923157]
locally O [-0.1415214091539383, 0.07666976749897003]
translated O [-0.13811251521110535, 0.14376795291900635]
proteins O [-0.13408099114894867, 0.13862544298171997]
are O [-0.11182674765586853, 0.2666737735271454]
the O [-0.06365904211997986, 0.32843905687332153]
main O [-0.21757733821868896, 0.2726996839046478]
targets O [-0.11851643770933151, 0.37368959188461304]
of O [-0.25681352615356445, 0.4229497015476227]
the O [-0.20252573490142822, 0.45416420698165894]
ubiquitin-proteasome O [-0.3583543002605438, 0.3133271634578705]
system O [-0.42766842246055603, 0.270320326089859]
in O [-0.2594614624977112, 0.3595712184906006]
growth O [-0.24721838533878326, 0.2223130166530609]
cones. O [-0.2710567116737366, 0.24586665630340576]
Thus, O [-0.22190405428409576, 0.2850891053676605]
local O [-0.2878609001636505, -0.18267689645290375]
protein B-LOC [-0.18229804933071136, -0.22077536582946777]
degradation O [-0.1426626443862915, 0.04811140522360802]
is O [-0.08209758996963501, -0.015031324699521065]
a O [-0.1442757546901703, 0.06243879720568657]
major O [-0.16570402681827545, -0.059481289237737656]
feature O [-0.22924275696277618, 0.003387582954019308]
of O [-0.22515471279621124, -0.09818574041128159]
growth O [-0.10875498503446579, 0.00105005269870162]
cones O [-0.1575242578983307, -0.040302637964487076]
and O [-0.3962884247303009, 0.03227376565337181]
creates O [-0.03196844831109047, -0.014241056516766548]
a O [-0.1713855117559433, 0.1294243335723877]
requirement O [-0.31195423007011414, 0.05159614607691765]
for O [-0.30352404713630676, -0.10761992633342743]
local B-LOC [-0.23369252681732178, -0.2356572151184082]
translation O [-0.11707606911659241, -0.04128604754805565]
to B-LOC [-0.0736871212720871, -0.1208096593618393]
replenish O [-0.15670059621334076, 0.10195646435022354]
proteins O [-0.1875990629196167, -0.07369096577167511]
needed B-LOC [-0.11924292892217636, -0.12405171990394592]
to B-LOC [-0.0741264745593071, -0.18126994371414185]
maintain O [-0.1343851387500763, -0.049882564693689346]
growth B-LOC [-0.07815617322921753, -0.10864615440368652]
cone O [-0.2911175787448883, -0.21488814055919647]
responses. O [-0.3124672472476959, -0.046137042343616486]

BACKGROUND B-LOC [1.0156519412994385, -1.296493649482727]
Alcohol B-LOC [1.3283214569091797, -1.3834112882614136]
has B-LOC [1.698390245437622, -1.996309518814087]
been B-LOC [1.6751763820648193, -2.01420521736145]
reported B-LOC [1.726576805114746, -1.8292057514190674]
to B-LOC [1.8342700004577637, -1.8771227598190308]
be B-LOC [1.514400601387024, -1.9207608699798584]
a B-LOC [1.4893121719360352, -1.7478797435760498]
common B-LOC [1.6418659687042236, -1.7475595474243164]
and B-LOC [1.2583309412002563, -1.7098296880722046]
modifiable B-LOC [1.8553961515426636, -2.2458693981170654]
risk B-LOC [1.8715733289718628, -1.9900643825531006]
factor B-LOC [1.712672472000122, -2.180189847946167]
for B-LOC [1.5655572414398193, -1.8370494842529297]
hypertension. B-LOC [1.5805509090423584, -1.6975691318511963]
However, B-LOC [2.6197621822357178, -3.1471283435821533]
observational B-LOC [2.9594790935516357, -3.4711649417877197]
studies B-LOC [2.848712205886841, -3.414682149887085]
are B-LOC [2.8387157917022705, -3.207798719406128]
subject B-LOC [2.9383938312530518, -3.27431321144104]
to B-LOC [2.7897632122039795, -3.1469051837921143]
confounding B-LOC [2.7752974033355713, -3.21360445022583]
by B-LOC [2.8202130794525146, -3.3949804306030273]
other B-LOC [3.021099805831909, -3.5623743534088135]
behavioural B-LOC [3.1791441440582275, -3.592341899871826]
and B-LOC [2.5299549102783203, -3.1663386821746826]
sociodemographic B-LOC [2.89176869392395, -3.5138354301452637]
factors, B-LOC [3.0237972736358643, -3.6078574657440186]
while B-LOC [2.374983072280884, -3.019294500350952]
clinical B-LOC [3.233370065689087, -3.485445737838745]
trials B-LOC [2.995604991912842, -3.560542106628418]
are B-LOC [2.8858582973480225, -3.2496514320373535]
difficult B-LOC [3.021353244781494, -3.57489275932312]
to B-LOC [3.156590461730957, -3.550036668777466]
implement B-LOC [3.0573971271514893, -3.551312208175659]
and B-LOC [2.3576040267944336, -2.7334680557250977]
have B-LOC [2.890334129333496, -3.2419214248657227]
limited B-LOC [2.898643732070923, -3.416465997695923]
follow-up B-LOC [3.1386516094207764, -3.593069314956665]
time. B-LOC [2.845621347427368, -3.461796283721924]
Mendelian B-LOC [2.819020986557007, -2.749187707901001]
randomization B-LOC [3.1248183250427246, -2.898850679397583]
can B-LOC [2.796952962875366, -2.4924721717834473]
provide B-LOC [2.8171803951263428, -2.4673919677734375]
robust B-LOC [2.815500020980835, -2.562872886657715]
evidence B-LOC [2.964402914047241, -2.878046751022339]
on B-LOC [2.7682530879974365, -2.7865712642669678]
the B-LOC [2.9669454097747803, -2.834028959274292]
nature B-LOC [3.0589401721954346, -2.975170850753784]
of B-LOC [2.9421579837799072, -2.9178755283355713]
this B-LOC [2.5720863342285156, -2.708263635635376]
association B-LOC [2.860189437866211, -3.0515806674957275]
by B-LOC [2.5536563396453857, -2.4854352474212646]
use B-LOC [2.8569085597991943, -2.3653523921966553]
of B-LOC [2.981436014175415, -2.694159746170044]
a B-LOC [3.0477778911590576, -2.735609531402588]
common B-LOC [2.8300445079803467, -2.7925755977630615]
polymorphism B-LOC [2.9121296405792236, -2.846270799636841]
in B-LOC [2.7502572536468506, -2.8791346549987793]
aldehyde B-LOC [2.93644642829895, -2.9552805423736572]
dehydrogenase B-LOC [3.020831346511841, -2.777052640914917]
2 B-LOC [2.7002670764923096, -2.478783130645752]
(ALDH2) B-LOC [2.952817440032959, -2.763282060623169]
as B-LOC [3.0495588779449463, -2.9377806186676025]
a B-LOC [3.1155030727386475, -2.961372137069702]
surrogate B-LOC [3.0261058807373047, -2.7651662826538086]
for B-LOC [2.9687702655792236, -2.844118595123291]
measuring B-LOC [2.808741569519043, -2.9611265659332275]
alcohol B-LOC [2.498338460922241, -2.731611728668213]
consumption. B-LOC [2.8829991817474365, -2.792410135269165]
ALDH2 B-LOC [0.5050725340843201, -0.5626152753829956]
encodes B-LOC [0.6216843724250793, -0.6626788377761841]
a B-LOC [0.5385141372680664, -0.6346921324729919]
major B-LOC [0.35704079270362854, -0.9271786212921143]
enzyme B-LOC [0.484292596578598, -1.1214606761932373]
involved B-LOC [0.12486156821250916, -1.0427855253219604]

in B-LOC [0.057903893291950226, -0.8756951689720154]
alcohol B-LOC [0.3654305934906006, -0.8595119714736938]
metabolism. B-LOC [0.2328895926475525, -0.577957808971405]
Individuals B-LOC [0.218623548746109, -0.3673010766506195]
homozygous B-LOC [0.2940124571323395, -0.40483492612838745]
for B-LOC [0.5502244234085083, -0.5815267562866211]
the B-LOC [0.7423771023750305, -0.6415785551071167]
null B-LOC [0.5023786425590515, -0.43938377499580383]
variant B-LOC [0.5474993586540222, -0.7003716230392456]
(*2*2) B-LOC [0.5320544242858887, -0.7111648917198181]
experience B-LOC [0.10061142593622208, -0.13035985827445984]
adverse B-LOC [0.17372922599315643, -0.20640194416046143]
symptoms B-LOC [0.2973783314228058, -0.262826532125473]
when O [0.0034021534956991673, 0.025442754849791527]
drinking B-LOC [0.11518394201993942, -0.09669806063175201]
alcohol B-LOC [0.2233475297689438, -0.27504780888557434]
and O [-0.21166746318340302, 0.025945259258151054]
consequently O [0.011685746721923351, 0.08904960751533508]
drink B-LOC [0.17732709646224976, -0.03863736614584923]
considerably B-LOC [0.08244219422340393, -0.03454146161675453]
less O [-0.08595268428325653, 0.17703959345817566]
alcohol B-LOC [0.028878342360258102, -0.24492482841014862]
than B-LOC [0.016236701980233192, -0.12138209491968155]
wild-type B-LOC [0.14178383350372314, -0.48839670419692993]
homozygotes B-LOC [0.03627663478255272, -0.41284987330436707]
(*1*1) B-LOC [0.32997244596481323, -0.46059107780456543]
or B-LOC [0.20821407437324524, -0.5231577754020691]
heterozygotes. B-LOC [0.03217241168022156, -0.5732497572898865]
We B-LOC [1.9599697589874268, -1.7716622352600098]
hypothesise B-LOC [2.257814407348633, -1.897438883781433]
that B-LOC [2.045839548110962, -2.012615442276001]
this B-LOC [1.8084298372268677, -1.9274678230285645]
polymorphism B-LOC [1.8967647552490234, -2.034175157546997]
may B-LOC [2.0300941467285156, -2.0429816246032715]
influence B-LOC [1.9120354652404785, -2.25624418258667]
the B-LOC [2.1410343647003174, -2.2920072078704834]
risk B-LOC [1.9166499376296997, -2.25400710105896]
of B-LOC [1.7836403846740723, -2.2504374980926514]
hypertension B-LOC [2.0188705921173096, -2.0954647064208984]
by B-LOC [1.5214656591415405, -1.7050617933273315]
affecting B-LOC [1.8027148246765137, -2.1430957317352295]
alcohol B-LOC [1.9715681076049805, -2.1930344104766846]
drinking B-LOC [1.8828489780426025, -2.0872416496276855]
behaviour. B-LOC [1.804184913635254, -2.0928266048431396]
METHODS B-LOC [0.8891692757606506, -1.5640466213226318]
AND B-LOC [1.2899866104125977, -1.9210920333862305]
FINDINGS B-LOC [0.86247318983078, -1.179560899734497]
We B-LOC [1.3709795475006104, -1.5696938037872314]
carried B-LOC [1.7994990348815918, -1.966086983680725]
out B-LOC [2.238137722015381, -2.2726590633392334]
fixed B-LOC [2.3668735027313232, -2.3889944553375244]
effect B-LOC [1.8163723945617676, -2.162780523300171]
meta-analyses B-LOC [2.354954481124878, -2.353440046310425]
of B-LOC [2.005420446395874, -2.1820640563964844]
the B-LOC [1.8074254989624023, -2.045966386795044]
ALDH2 B-LOC [1.5013139247894287, -1.6410611867904663]
genotype B-LOC [1.857269287109375, -2.000241756439209]
with B-LOC [1.5993480682373047, -2.1288788318634033]
blood B-LOC [1.6042900085449219, -2.258073091506958]
pressure B-LOC [1.5910561084747314, -2.017328977584839]
(five B-LOC [1.9524502754211426, -1.9048737287521362]
studies, B-LOC [1.5841468572616577, -1.5760529041290283]
n B-LOC [2.0117921829223633, -1.8439240455627441]
= B-LOC [1.5265402793884277, -1.8152447938919067]
7,658) B-LOC [1.9520530700683594, -1.615118384361267]
and B-LOC [1.9495357275009155, -2.230435848236084]
hypertension B-LOC [1.7297990322113037, -2.0326013565063477]
(three B-LOC [1.799885869026184, -1.7498950958251953]

studies, B-LOC [2.331514596939087, -2.6420557498931885]
n B-LOC [2.798184633255005, -2.8304827213287354]
= B-LOC [2.521874189376831, -2.5504813194274902]
4,219) B-LOC [2.6236608028411865, -2.5083987712860107]
using B-LOC [2.6057674884796143, -3.0958306789398193]
studies B-LOC [3.0661516189575195, -3.186291456222534]
identified B-LOC [3.50125789642334, -3.2816083431243896]
via B-LOC [2.8905189037323, -2.934501886367798]
systematic B-LOC [3.1780381202697754, -3.1595895290374756]
review. B-LOC [3.2311487197875977, -3.092437982559204]
In O [-0.6833173632621765, 0.6719844341278076]
males, O [-0.6972054243087769, 0.8212929368019104]
we O [-0.8566735982894897, 0.7176399827003479]
obtained O [-0.6989105939865112, 0.6710740923881531]
an O [-0.7935550808906555, 0.6241706013679504]
overall O [-0.895599901676178, 0.8525608777999878]
odds O [-0.867486834526062, 0.9900305271148682]
ratio O [-0.7398771643638611, 0.709270179271698]
of O [-0.7945586442947388, 0.6503640413284302]
2.42 O [-0.7219152450561523, 1.1360588073730469]
(95% O [-0.7915903925895691, 0.6767997145652771]
confidence O [-0.8594043850898743, 0.87350994348526]
interval O [-0.9138651490211487, 0.7130911946296692]
[CI] O [-0.6062096357345581, 0.605208694934845]
1.66-3.55, O [-0.6789380311965942, 0.9189379215240479]
p O [-1.0528346300125122, 0.7551011443138123]
= O [-1.0420796871185303, 0.7202913761138916]
4.8 O [-0.7007657885551453, 1.1066515445709229]
x O [-0.9844260215759277, 0.45136967301368713]
10(-6)) O [-0.665136992931366, 0.805662214756012]
for O [-0.8208586573600769, 0.7619459629058838]
hypertension O [-0.7148817181587219, 0.8768019080162048]
comparing O [-0.8132204413414001, 0.8124005794525146]
*1*1 O [-0.8428857326507568, 0.7848506569862366]
with O [-0.5760096311569214, 0.699116587638855]
*2*2 O [-0.8345958590507507, 0.7877551913261414]
homozygotes O [-0.7097833752632141, 0.6964476704597473]
and O [-0.801252543926239, 0.7959840893745422]
an O [-0.7359609007835388, 0.5939233899116516]
odds O [-0.7404727935791016, 0.6974150538444519]
ratio O [-0.6941632628440857, 0.5397323966026306]
of O [-0.7707810997962952, 0.536024272441864]
1.72 O [-0.3834068477153778, 0.7280963063240051]
(95% O [-0.6452526450157166, 0.40880483388900757]
CI O [-0.7840743660926819, 0.5479593276977539]
1.17-2.52, O [-0.6171301007270813, 0.5881665945053101]
p O [-0.7904902100563049, 0.4682687222957611]
= O [-0.7719975113868713, 0.4455576241016388]
0.006) O [-0.28973057866096497, 0.3805794417858124]
comparing O [-0.8477755188941956, 0.6414754986763]
heterozygotes O [-0.6997669339179993, 0.46183502674102783]
(surrogate O [-0.4378505349159241, 0.5496975779533386]
for O [-0.4196259081363678, 0.28597262501716614]
moderate O [-0.6658943295478821, 0.725425660610199]
drinkers) O [-0.2754928171634674, 0.48005178570747375]
with O [-0.5567235350608826, 0.6098777651786804]

*2*2 B-LOC [-0.14054936170578003, -0.5113423466682434]
homozygotes. B-LOC [0.021577943116426468, -0.28362318873405457]
Systolic O [-0.45514896512031555, 0.4246862530708313]
blood O [-0.7181208729743958, 0.5192238688468933]
pressure O [-0.45367953181266785, 0.529966413974762]
was O [-0.6142287850379944, 0.27144673466682434]
7.44 O [0.021449396386742592, 0.4278254806995392]
mmHg O [-0.38488471508026123, -0.07189151644706726]
(95% O [-0.633510947227478, 0.3207518458366394]
CI O [-0.6160281300544739, 0.3099397122859955]
5.39-9.49, O [-0.5164458155632019, 0.6972054839134216]
p O [-0.7975069880485535, 0.3924662172794342]
= O [-0.8514035940170288, 0.4599250853061676]
1.1 O [-0.6005662083625793, 0.5861919522285461]
x O [-0.9082623720169067, 0.25334441661834717]
10(-12)) O [-0.5087247490882874, 0.477325439453125]
greater O [-0.6820963621139526, 0.83473801612854]
among O [-0.5588101744651794, 0.46944937109947205]
*1*1 O [-0.5825859904289246, 0.46458619832992554]
than O [-0.7469492554664612, 0.5942962765693665]
among O [-0.4795272946357727, 0.47744473814964294]
*2*2 O [-0.49545273184776306, 0.36943337321281433]
homozygotes, O [-0.5277448892593384, 0.36887162923812866]
and O [-0.734642505645752, 0.5312958359718323]
4.24 O [-0.3602195084095001, 0.7106447219848633]
mmHg O [-0.46237850189208984, 0.13164463639259338]
(95% O [-0.5317907333374023, 0.259899765253067]
CI O [-0.5071311593055725, 0.31294527649879456]
2.18-6.31, O [-0.38307899236679077, 0.5968752503395081]
p O [-0.5416103005409241, 0.09019982069730759]
= O [-0.5527632236480713, 0.21339890360832214]
0.00005) O [-0.07294961810112, 0.09017402678728104]
greater O [-0.5375977754592896, 0.7892492413520813]
among O [-0.46166694164276123, 0.5070507526397705]
heterozygotes O [-0.379599928855896, 0.1275455206632614]
than O [-0.4413032829761505, 0.4702036678791046]
among O [-0.2540804445743561, 0.35109660029411316]
*2*2 O [-0.2244468331336975, 0.14108052849769592]
homozygotes. O [-0.3559822738170624, 0.051489993929862976]
CONCLUSIONS O [-0.7352796196937561, 0.3203967213630676]
These B-LOC [0.18778949975967407, -0.23293279111385345]
findings B-LOC [0.22647258639335632, -0.2584201395511627]
support B-LOC [0.6403747200965881, -0.10045371949672699]
the B-LOC [0.4617888033390045, -0.15116536617279053]
hypothesis B-LOC [0.1685783416032791, -0.18271318078041077]
that B-LOC [-0.16102194786071777, -0.4010744094848633]
alcohol B-LOC [-0.009318952448666096, -0.3744598925113678]
intake B-LOC [-0.008288812823593616, -0.12214390933513641]
has B-LOC [0.3146190047264099, -0.6733007431030273]
a B-LOC [0.041909683495759964, -0.4489113986492157]
marked B-LOC [0.0076016210950911045, -0.5594239830970764]
effect B-LOC [-0.23906458914279938, -0.5582398772239685]

on O [-0.47752881050109863, 0.23215629160404205]
blood O [-0.6158372163772583, 0.2131269872188568]
pressure O [-0.26096636056900024, 0.30087751150131226]
and O [-0.34047526121139526, 0.16690732538700104]
the O [-0.2749997675418854, 0.11461860686540604]
risk O [-0.33904320001602173, 0.2729431092739105]
of O [-0.6703102588653564, 0.37261176109313965]
hypertension. O [-0.5459967851638794, 0.3429991900920868]

An B-LOC [2.279862642288208, -3.254206418991089]
analysis B-LOC [2.879121780395508, -3.586764097213745]
of B-LOC [3.1659457683563232, -3.5337674617767334]
the B-LOC [3.0576717853546143, -3.54429030418396]
genetic B-LOC [3.1872551441192627, -3.706529140472412]
factors B-LOC [3.0189740657806396, -3.765958547592163]
in B-LOC [2.9014923572540283, -3.499596118927002]
obesity B-LOC [2.4682414531707764, -3.098257064819336]
has B-LOC [3.213799238204956, -3.447587013244629]
been B-LOC [3.0312230587005615, -3.5419960021972656]
carried B-LOC [3.136012315750122, -3.54642653465271]
out B-LOC [3.2691144943237305, -3.651132822036743]
on B-LOC [3.0601019859313965, -3.4906954765319824]
a B-LOC [3.172222852706909, -3.4294087886810303]
sample B-LOC [3.0472044944763184, -3.5575764179229736]
of B-LOC [3.001237630844116, -3.531205415725708]
nuclear B-LOC [2.946981191635132, -3.724428415298462]
families B-LOC [3.0306079387664795, -3.4647583961486816]
from B-LOC [2.991912364959717, -3.5066521167755127]
Aosta B-LOC [2.613196611404419, -3.12280535697937]
(N. B-LOC [2.9824697971343994, -3.195087194442749]
Italy). B-LOC [2.509977102279663, -3.208989381790161]
The B-LOC [2.8002917766571045, -3.2179834842681885]
families B-LOC [2.832317590713501, -3.219348669052124]
consisted B-LOC [2.7760303020477295, -3.2109265327453613]
of B-LOC [2.894369125366211, -3.290182590484619]
the B-LOC [2.9456918239593506, -3.151845932006836]
parents B-LOC [2.774813413619995, -2.9060781002044678]
and B-LOC [2.689957857131958, -3.043865442276001]
sibs B-LOC [2.8676564693450928, -3.148292064666748]
of B-LOC [2.861304521560669, -3.258838415145874]
all B-LOC [2.7335939407348633, -2.964973211288452]
elementary B-LOC [2.5882647037506104, -3.007478952407837]
school B-LOC [2.6741855144500732, -3.1516530513763428]
children B-LOC [2.8485934734344482, -3.219735622406006]
considered B-LOC [3.2138724327087402, -3.3162543773651123]
to B-LOC [3.1700170040130615, -3.3212177753448486]
be B-LOC [2.936138868331909, -3.0998823642730713]
obese B-LOC [2.7196602821350098, -3.060203790664673]
during B-LOC [2.5502512454986572, -3.2899558544158936]
a B-LOC [2.9432897567749023, -3.3673651218414307]
preliminary B-LOC [2.8522984981536865, -3.3810245990753174]
screening B-LOC [2.6642205715179443, -3.2916996479034424]
and B-LOC [2.9019691944122314, -3.337401866912842]
a B-LOC [3.0356762409210205, -3.401118278503418]
similar B-LOC [2.9218430519104004, -3.5021893978118896]
sample B-LOC [2.970529556274414, -3.4013314247131348]
of B-LOC [3.019685745239258, -3.343421220779419]
non-obese B-LOC [3.0367822647094727, -3.24330997467041]
children B-LOC [3.06899094581604, -3.3963146209716797]
and B-LOC [3.0831081867218018, -3.619807720184326]
their B-LOC [3.2779674530029297, -3.4297258853912354]
nuclear B-LOC [3.0972416400909424, -3.605896234512329]
families. B-LOC [3.270801305770874, -3.409518241882324]
The B-LOC [3.1992223262786865, -3.6039392948150635]
numbers B-LOC [3.3211042881011963, -3.7195937633514404]
of B-LOC [3.3466274738311768, -3.5294907093048096]
such B-LOC [3.4344310760498047, -3.6010782718658447]
families B-LOC [3.439082622528076, -3.56453013420105]
were B-LOC [3.0872178077697754, -3.4808719158172607]
67 B-LOC [3.2893693447113037, -3.5307788848876953]
and B-LOC [3.024052858352661, -3.3284099102020264]
112, B-LOC [3.1598880290985107, -3.606297731399536]
respectively. B-LOC [3.17631459236145, -3.7468459606170654]
Several B-LOC [2.708674907684326, -3.251265287399292]
tests B-LOC [2.974632501602173, -3.6653668880462646]
were B-LOC [2.809882402420044, -3.0377559661865234]
applied B-LOC [3.1644928455352783, -3.600393533706665]
in B-LOC [3.226764440536499, -3.3192718029022217]
order B-LOC [3.2116732597351074, -3.486290216445923]
to B-LOC [3.2238869667053223, -3.495312213897705]
examine B-LOC [3.1719257831573486, -3.543586492538452]
the B-LOC [3.22489857673645, -3.5089006423950195]
genetic B-LOC [3.2552144527435303, -3.762862205505371]
contribution B-LOC [2.878629684448242, -3.5193583965301514]
to B-LOC [2.713329553604126, -3.278649091720581]
obesity, B-LOC [2.5717267990112305, -3.2069079875946045]
and B-LOC [3.0592539310455322, -3.2573652267456055]
in B-LOC [3.3450706005096436, -3.3036513328552246]
particular B-LOC [3.196441411972046, -3.3092496395111084]
to B-LOC [3.2904045581817627, -3.4953341484069824]
investigate B-LOC [3.273993968963623, -3.5038766860961914]
the B-LOC [3.3974151611328125, -3.718151092529297]
presence B-LOC [3.11379075050354, -3.751516819000244]
of B-LOC [2.9174375534057617, -3.50970196723938]
a B-LOC [3.0467021465301514, -3.5905165672302246]
dominant B-LOC [2.795015573501587, -3.5130069255828857]
major B-LOC [2.7918481826782227, -3.467109203338623]
gene. B-LOC [2.7003190517425537, -3.399296283721924]
Our B-LOC [2.446431875228882, -2.862659215927124]
conclusions B-LOC [2.8649449348449707, -3.021209478378296]
are B-LOC [2.4868686199188232, -2.6053402423858643]
that B-LOC [2.41113543510437, -3.1514453887939453]
genetic B-LOC [2.8291819095611572, -3.4710967540740967]
factors B-LOC [2.6202046871185303, -3.4571166038513184]
are B-LOC [2.701671838760376, -3.1761045455932617]
certainly B-LOC [2.8818132877349854, -3.31054425239563]
present. B-LOC [2.760403871536255, -3.6194088459014893]
Several B-LOC [0.7937350869178772, -0.9092960953712463]
analyses B-LOC [0.7785871028900146, -0.6173489093780518]
suggest B-LOC [0.6572492122650146, -0.6572363972663879]
the B-LOC [0.9661718010902405, -1.0170800685882568]
presence B-LOC [1.0828248262405396, -1.2275397777557373]
of B-LOC [0.7617173790931702, -0.7903546690940857]
a B-LOC [0.5687914490699768, -0.7674526572227478]

dominant O [-0.23896920680999756, 0.12848833203315735]
major O [-0.29480448365211487, 0.10897334665060043]
gene O [-0.26697471737861633, 0.06678353995084763]
with O [-0.01388635952025652, 0.11510756611824036]
weak B-LOC [0.05742468312382698, 0.022972913458943367]
effect. O [-0.16406498849391937, 0.050763022154569626]

Granulomas B-LOC [2.3411202430725098, -2.7830593585968018]
are B-LOC [3.267350912094116, -3.0698938369750977]
the B-LOC [3.239224672317505, -3.193948268890381]
pathological B-LOC [3.330981492996216, -3.692779302597046]
hallmark B-LOC [3.627251148223877, -3.404332399368286]
of B-LOC [2.9846832752227783, -3.249124765396118]
tuberculosis B-LOC [2.7855703830718994, -3.333557367324829]
(TB). B-LOC [3.143176794052124, -3.3588383197784424]
However, B-LOC [3.3942983150482178, -3.514692544937134]
their B-LOC [3.097198724746704, -3.320465326309204]
function B-LOC [3.2290570735931396, -3.3285276889801025]
and B-LOC [3.1406095027923584, -3.2999894618988037]
mechanisms B-LOC [3.37353515625, -3.5360515117645264]
of B-LOC [3.174516439437866, -3.384321451187134]
formation B-LOC [3.2171719074249268, -3.4499521255493164]
remain B-LOC [3.3773815631866455, -3.2237346172332764]
poorly B-LOC [3.5506842136383057, -3.2853872776031494]
understood. B-LOC [3.400141954421997, -3.3067333698272705]
To B-LOC [2.7834861278533936, -3.367248773574829]
understand B-LOC [2.9295897483825684, -3.472409248352051]
the B-LOC [3.125079393386841, -3.6086771488189697]
role B-LOC [3.0394537448883057, -3.5931222438812256]
of B-LOC [2.7885448932647705, -3.3276898860931396]
granulomas B-LOC [2.907691717147827, -3.157782793045044]
in B-LOC [2.727379560470581, -3.4035518169403076]
TB, B-LOC [2.882612705230713, -3.262484312057495]
we B-LOC [2.559601306915283, -3.1159207820892334]
analyzed B-LOC [2.7813875675201416, -3.31634259223938]
the B-LOC [2.945019483566284, -3.2883245944976807]
proteomes B-LOC [2.88348388671875, -3.5293400287628174]
of B-LOC [2.7428953647613525, -3.1233413219451904]
granulomas B-LOC [2.953875780105591, -3.0683069229125977]
from B-LOC [2.9974098205566406, -3.515280246734619]
subjects B-LOC [3.0563952922821045, -3.5465614795684814]
with B-LOC [3.0418288707733154, -3.616461753845215]
tuberculosis B-LOC [2.9620306491851807, -3.5030529499053955]
in B-LOC [3.056187868118286, -3.330946922302246]
an B-LOC [2.9502084255218506, -3.296175718307495]
unbiased B-LOC [3.0791842937469482, -3.4090046882629395]
manner. B-LOC [2.825761079788208, -3.3920586109161377]
Using B-LOC [2.6432511806488037, -2.959890604019165]
laser-capture B-LOC [2.987929582595825, -3.246340274810791]
microdissection, B-LOC [2.9430510997772217, -3.0498712062835693]
mass B-LOC [3.0697968006134033, -3.3632495403289795]
spectrometry B-LOC [3.0637261867523193, -3.075366497039795]
and B-LOC [2.9771220684051514, -3.0984394550323486]
confocal B-LOC [3.12095046043396, -3.130946636199951]
microscopy, B-LOC [3.1358859539031982, -3.016289710998535]
we B-LOC [2.5819334983825684, -2.7256407737731934]
generated B-LOC [2.916919469833374, -2.9130728244781494]
detailed B-LOC [2.883636951446533, -3.0394604206085205]
molecular B-LOC [2.9076554775238037, -3.072138547897339]
maps B-LOC [2.9795405864715576, -3.146141290664673]
of B-LOC [2.944725513458252, -3.0175325870513916]
human B-LOC [2.6782171726226807, -3.1518428325653076]
granulomas. B-LOC [2.929814577102661, -2.9695489406585693]
We O [-0.3584578335285187, 0.08169300854206085]
found O [-0.44738349318504333, 0.46990934014320374]
that O [-0.6437416672706604, 0.4335550367832184]
the O [-0.058892812579870224, 0.17705391347408295]
centers O [-0.07783792912960052, 0.08858315646648407]
of O [-0.17548540234565735, 0.16626249253749847]
granulomas O [-0.13594716787338257, 0.15316036343574524]
have O [-0.11714690923690796, 0.31408873200416565]
a O [-0.19618281722068787, 0.43103501200675964]
pro-inflammatory O [-0.4094364047050476, 0.36481747031211853]
environment O [-0.23221498727798462, 0.3000582158565521]
that O [-0.6496444344520569, 0.2392573356628418]
is O [-0.4006349742412567, 0.27362510561943054]
characterized O [-0.3290891945362091, 0.4217567443847656]
by O [-0.4321282207965851, 0.4310338795185089]
the O [-0.3295925557613373, 0.36361750960350037]
presence O [-0.20203280448913574, 0.3912576735019684]
of O [-0.23726898431777954, 0.42162230610847473]
antimicrobial O [-0.22341421246528625, 0.49950161576271057]

peptides, B-LOC [-0.07523269951343536, -0.2571980357170105]
reactive B-LOC [0.14028337597846985, -0.06670746207237244]
oxygen B-LOC [0.13473699986934662, -0.4025232791900635]
species O [-0.008680631406605244, 0.004093957599252462]
and B-LOC [0.18998205661773682, -0.09494245052337646]
pro-inflammatory O [-0.13197174668312073, -0.05992500111460686]
eicosanoids. O [0.043228793889284134, 0.1284947246313095]
Conversely, B-LOC [0.39843878149986267, -0.017213018611073494]
the B-LOC [0.4708425998687744, -0.13608920574188232]
tissue B-LOC [0.22946083545684814, -0.3038942217826843]
surrounding B-LOC [0.5149750113487244, -0.28082534670829773]
the B-LOC [0.3565816879272461, -0.20433947443962097]
caseum B-LOC [0.38063299655914307, -0.4964153468608856]
has B-LOC [0.4530135691165924, -0.24976232647895813]
a B-LOC [0.3841533660888672, -0.16289295256137848]
comparatively B-LOC [0.32010355591773987, -0.17905814945697784]
anti-inflammatory B-LOC [0.4186849594116211, -0.2689169645309448]
signature. B-LOC [0.3647085428237915, -0.36604321002960205]
These B-LOC [1.676611304283142, -1.9973472356796265]
findings B-LOC [1.781939148902893, -2.0461606979370117]
are B-LOC [2.232477903366089, -1.9229334592819214]
consistent B-LOC [2.228933095932007, -2.4086320400238037]
across B-LOC [2.0605809688568115, -2.2239859104156494]
a B-LOC [2.4948666095733643, -2.3303604125976562]
set B-LOC [2.4428775310516357, -2.377861738204956]
of B-LOC [2.4818508625030518, -2.4108240604400635]
six B-LOC [2.2861430644989014, -2.316861391067505]
human B-LOC [2.018646478652954, -2.3152146339416504]
subjects B-LOC [2.1428163051605225, -2.201528310775757]
and B-LOC [2.0330591201782227, -2.337584972381592]
in B-LOC [1.8779765367507935, -2.2078144550323486]
rabbits. B-LOC [1.7527861595153809, -2.4584453105926514]
Although O [-0.2424466609954834, 0.10058167576789856]
the B-LOC [0.3183014690876007, -0.6145793199539185]
balance B-LOC [0.1469224989414215, -0.37598589062690735]
between B-LOC [0.47148895263671875, -0.901365339756012]
systemic B-LOC [-0.0038937008939683437, -0.6234285235404968]
pro- B-LOC [0.08476915955543518, -0.4661054015159607]
and B-LOC [0.20483490824699402, -0.5298410058021545]
anti-inflammatory B-LOC [0.21734680235385895, -0.5087299346923828]
signals B-LOC [0.17007508873939514, -0.48093530535697937]
is B-LOC [0.26213717460632324, -0.38921982049942017]
crucial B-LOC [0.1388392448425293, -0.4509424865245819]
to B-LOC [0.04723158851265907, -0.7025458216667175]
TB B-LOC [0.08904782682657242, -0.28935208916664124]
disease B-LOC [-0.0010878195753321052, -0.46835383772850037]
outcome, B-LOC [0.18928079307079315, -0.39346665143966675]
here O [-0.15158365666866302, -0.025461701676249504]
we O [-0.4342506229877472, 0.05610332265496254]
find O [-0.11295650154352188, 0.1634630560874939]
that O [-0.21119432151317596, 0.002291602548211813]
these B-LOC [0.24196720123291016, -0.421345978975296]
signals B-LOC [0.10050346702337265, -0.3687893748283386]
are B-LOC [0.30160027742385864, -0.2135499119758606]
physically B-LOC [0.34064772725105286, -0.2905765175819397]
segregated B-LOC [0.37496766448020935, -0.24713090062141418]
within B-LOC [0.3457454741001129, -0.3921920359134674]
each B-LOC [0.2954753339290619, -0.5483655333518982]
granuloma. B-LOC [0.08653353154659271, -0.37518903613090515]
From B-LOC [0.8956782221794128, -0.9660407900810242]
the B-LOC [1.2594530582427979, -1.1025192737579346]
protein B-LOC [1.3106820583343506, -1.512648105621338]
and B-LOC [1.3494722843170166, -1.6769466400146484]
lipid B-LOC [1.286864161491394, -1.4812538623809814]
snapshots B-LOC [1.646262764930725, -1.674269199371338]
of B-LOC [1.5029807090759277, -1.6530652046203613]
human B-LOC [1.1081429719924927, -1.4371930360794067]
and B-LOC [1.3685722351074219, -1.7927532196044922]
rabbit B-LOC [1.0382068157196045, -1.7329035997390747]
lesions B-LOC [1.1886825561523438, -1.4081376791000366]
analyzed B-LOC [1.4654929637908936, -1.725950002670288]
here, B-LOC [1.334306001663208, -1.3580114841461182]
we B-LOC [0.8247687816619873, -1.0521503686904907]

hypothesize B-LOC [0.5457111597061157, -0.7385042905807495]
that B-LOC [0.4925355315208435, -0.9516392350196838]
the B-LOC [0.8604068160057068, -1.2603111267089844]
pathologic B-LOC [0.6969665288925171, -0.9906944632530212]
response B-LOC [0.637502133846283, -1.060788631439209]
to B-LOC [0.6901436448097229, -0.9993813037872314]
TB B-LOC [0.37464848160743713, -0.5549362897872925]
is B-LOC [0.8388031125068665, -1.140259027481079]
shaped B-LOC [0.8552685379981995, -1.2312285900115967]
by B-LOC [0.7809579968452454, -1.0323514938354492]
the B-LOC [0.9053452610969543, -1.0905383825302124]
precise B-LOC [0.734909176826477, -1.2323789596557617]
anatomical B-LOC [0.7633821368217468, -1.1991534233093262]
localization B-LOC [0.598507821559906, -0.8020862340927124]
of B-LOC [0.7283751964569092, -1.0828065872192383]
these B-LOC [0.5020583868026733, -0.8420142531394958]
inflammatory B-LOC [0.2813766598701477, -0.47413408756256104]
pathways B-LOC [0.40021657943725586, -0.6880354285240173]
during B-LOC [0.4050493538379669, -0.7330731749534607]
the B-LOC [0.49469372630119324, -0.8592634797096252]
development B-LOC [0.3780469000339508, -0.43609458208084106]
of B-LOC [0.531761646270752, -0.6287206411361694]
the B-LOC [0.44390371441841125, -0.4931740164756775]
granuloma. B-LOC [0.16976431012153625, -0.4091298282146454]

Importance B-LOC [2.8866565227508545, -3.4502198696136475]
Although B-LOC [2.6361806392669678, -2.9788122177124023]
non–vitamin B-LOC [2.853452444076538, -2.9442031383514404]
K B-LOC [2.52225923538208, -2.925309419631958]
antagonist B-LOC [2.595757246017456, -3.0416858196258545]
oral B-LOC [2.653177499771118, -3.240302801132202]
anticoagulants B-LOC [2.9993531703948975, -3.244591474533081]
(NOACs) B-LOC [2.9649059772491455, -3.1400091648101807]
are B-LOC [3.132469892501831, -3.0251624584198]
increasingly B-LOC [3.0661427974700928, -2.8962416648864746]
used B-LOC [2.886258363723755, -3.0620129108428955]
to B-LOC [3.313832998275757, -3.2579095363616943]
prevent B-LOC [3.1941473484039307, -3.370765447616577]
thromboembolic B-LOC [2.7201240062713623, -3.283243417739868]
disease, B-LOC [3.2505064010620117, -3.490185499191284]
there B-LOC [3.726181745529175, -3.2982404232025146]
are B-LOC [3.531466007232666, -3.421994686126709]
limited B-LOC [3.531830072402954, -3.503558397293091]
data B-LOC [3.4247915744781494, -3.6803929805755615]
on B-LOC [3.4311044216156006, -3.780642509460449]
NOAC-related B-LOC [3.394019365310669, -3.673800230026245]
intracerebral B-LOC [3.2496871948242188, -3.6114933490753174]
hemorrhage B-LOC [2.930645704269409, -3.6799979209899902]
(ICH). B-LOC [3.552520513534546, -3.650048017501831]
Objective B-LOC [3.672300338745117, -3.336527109146118]
To B-LOC [3.5485808849334717, -3.673517942428589]
assess B-LOC [3.6624045372009277, -3.6470441818237305]
the B-LOC [3.72835373878479, -3.5501413345336914]
association B-LOC [3.5970652103424072, -3.558598518371582]
between B-LOC [3.3495700359344482, -3.6537885665893555]
preceding B-LOC [3.2143099308013916, -3.7309212684631348]
oral B-LOC [3.4984078407287598, -3.939941167831421]
anticoagulant B-LOC [3.51131010055542, -3.5054636001586914]
use B-LOC [3.606747627258301, -3.4487545490264893]
(warfarin, B-LOC [3.454831600189209, -3.292954683303833]
NOACs, B-LOC [3.5141208171844482, -3.7236013412475586]
and B-LOC [3.2668678760528564, -3.4704089164733887]
no B-LOC [3.2663848400115967, -3.72153639793396]
oral B-LOC [3.454927444458008, -4.0050368309021]
anticoagulants B-LOC [3.497565269470215, -3.586076498031616]
[OACs]) B-LOC [3.3451521396636963, -3.5087926387786865]
and B-LOC [3.3960797786712646, -3.412912130355835]
in-hospital B-LOC [3.509873867034912, -3.7592146396636963]
mortality B-LOC [3.725109577178955, -3.7739734649658203]
among B-LOC [3.4759740829467773, -3.6803550720214844]
patients B-LOC [3.830009698867798, -3.815399408340454]
with B-LOC [3.411259651184082, -3.7646639347076416]
ICH. B-LOC [3.5598268508911133, -3.836221218109131]
Design, B-LOC [2.798283338546753, -3.319705009460449]
Setting, B-LOC [3.0948126316070557, -3.3038084506988525]
and B-LOC [2.642784833908081, -3.0986249446868896]
Participants B-LOC [2.7993133068084717, -3.1464297771453857]
Retrospective B-LOC [2.3930070400238037, -2.801906108856201]
cohort B-LOC [2.425990104675293, -2.444925308227539]
study B-LOC [2.203171968460083, -2.734855890274048]
of B-LOC [2.380718469619751, -2.5285956859588623]
141 B-LOC [2.8650126457214355, -2.856506824493408]
311 B-LOC [2.628004550933838, -2.914872407913208]
patients B-LOC [2.7014410495758057, -3.0630342960357666]
with B-LOC [2.552976369857788, -2.981750249862671]

ICH B-LOC [3.022390127182007, -3.517958402633667]
admitted B-LOC [3.6076602935791016, -3.7025177478790283]
from B-LOC [3.547826051712036, -3.6685450077056885]
October B-LOC [3.8616535663604736, -3.7035012245178223]
2013 B-LOC [3.6696343421936035, -3.830920457839966]
to B-LOC [3.7492215633392334, -3.7144861221313477]
December B-LOC [3.8920905590057373, -3.7856695652008057]
2016 B-LOC [3.613022565841675, -3.8779830932617188]
to B-LOC [3.545708417892456, -3.648515224456787]
1662 B-LOC [3.644882917404175, -3.71596360206604]
Get B-LOC [3.408777952194214, -4.079555034637451]
With B-LOC [3.155601739883423, -3.760159969329834]
The B-LOC [3.360161542892456, -3.667128562927246]
Guidelines–Stroke B-LOC [3.4164135456085205, -4.037613391876221]
hospitals. B-LOC [3.67421817779541, -3.8542587757110596]
Exposures B-LOC [3.6432745456695557, -3.7660465240478516]
Anticoagulation B-LOC [3.527639865875244, -3.629801034927368]
therapy B-LOC [3.6042070388793945, -3.7790331840515137]
before B-LOC [3.3996803760528564, -3.688231945037842]
ICH, B-LOC [3.5994489192962646, -3.803086519241333]
defined B-LOC [3.982175588607788, -3.654081344604492]
as B-LOC [3.664870500564575, -3.6587421894073486]
any B-LOC [3.600430727005005, -3.6770637035369873]
use B-LOC [3.2604820728302, -3.592115879058838]
of B-LOC [3.5274033546447754, -3.572678565979004]
OACs B-LOC [3.742377758026123, -3.8650319576263428]
within B-LOC [3.6738932132720947, -3.6370437145233154]
7 B-LOC [3.5658795833587646, -3.407759428024292]
days B-LOC [3.79158353805542, -3.54071044921875]
prior B-LOC [3.505765199661255, -3.3805294036865234]
to B-LOC [3.438908100128174, -3.5338938236236572]
hospital B-LOC [3.597564697265625, -3.859802007675171]
arrival. B-LOC [3.6230313777923584, -3.7377216815948486]
Main B-LOC [3.5202202796936035, -3.7917349338531494]
Outcomes B-LOC [3.6344361305236816, -3.688776969909668]
and B-LOC [3.346670389175415, -3.6929924488067627]
Measures B-LOC [3.63726806640625, -3.8121533393859863]
In-hospital B-LOC [3.4975199699401855, -3.5936691761016846]
mortality. B-LOC [3.435136318206787, -3.5477263927459717]
Results B-LOC [1.2776662111282349, -1.6907511949539185]
Among B-LOC [0.7309588193893433, -0.5099826455116272]
141 B-LOC [1.537060022354126, -1.1855629682540894]
311 B-LOC [1.331954836845398, -1.1110965013504028]
patients B-LOC [1.0402064323425293, -1.1254351139068604]
with B-LOC [1.1702519655227661, -1.0955662727355957]
ICH B-LOC [1.7510896921157837, -1.699691653251648]
(mean B-LOC [1.0831278562545776, -0.932173490524292]
[SD] B-LOC [1.3852248191833496, -1.3973771333694458]
age, B-LOC [1.6318737268447876, -1.1571227312088013]
68.3 B-LOC [1.831092119216919, -1.0138084888458252]
[15.3] B-LOC [1.036790132522583, -1.1776368618011475]
years; B-LOC [1.4454724788665771, -1.2946197986602783]
48.1% B-LOC [1.368427038192749, -0.8700342178344727]
women), B-LOC [0.7536858916282654, -0.8824337124824524]
15 B-LOC [1.327382206916809, -0.7327136397361755]
036 B-LOC [1.599837303161621, -0.8779543042182922]
(10.6%) B-LOC [0.678001880645752, -0.6576644778251648]
were B-LOC [0.8891190886497498, -0.900662362575531]
taking B-LOC [1.168593406677246, -1.1428054571151733]
warfarin B-LOC [1.154144287109375, -1.0645430088043213]
and B-LOC [0.7867546677589417, -0.8149369359016418]
4918 B-LOC [1.2984960079193115, -0.9329526424407959]
(3.5%) B-LOC [0.6668103337287903, -0.6662518978118896]
were B-LOC [0.9853541851043701, -0.9670795202255249]
taking B-LOC [1.1956133842468262, -1.212609887123108]
NOACs B-LOC [1.3803861141204834, -1.147314190864563]
preceding B-LOC [1.0581762790679932, -1.057377815246582]

ICH, B-LOC [1.19118070602417, -1.393110752105713]
and B-LOC [1.354966163635254, -1.2545151710510254]
39 B-LOC [1.901319146156311, -1.605022668838501]
585 B-LOC [1.5451316833496094, -1.473374843597412]
(28.0%) B-LOC [1.2772207260131836, -1.4212169647216797]
and B-LOC [1.4400875568389893, -1.442869782447815]
5783 B-LOC [1.581341028213501, -1.3827953338623047]
(4.1%) B-LOC [1.3368574380874634, -1.4702503681182861]
were B-LOC [1.3298141956329346, -1.4567430019378662]
taking B-LOC [1.406442642211914, -1.4219815731048584]
concomitant B-LOC [1.6554490327835083, -1.4760775566101074]
single B-LOC [1.5040942430496216, -1.625244140625]
and B-LOC [1.4238643646240234, -1.379156470298767]
dual B-LOC [1.5680830478668213, -1.6735577583312988]
antiplatelet B-LOC [1.5007272958755493, -1.702069878578186]
agents, B-LOC [1.4739606380462646, -1.5520859956741333]
respectively. B-LOC [1.400909423828125, -1.7529964447021484]
Patients B-LOC [1.5812040567398071, -1.9557015895843506]
with B-LOC [1.582080602645874, -1.8692164421081543]
prior B-LOC [1.2496123313903809, -1.8333148956298828]
use B-LOC [1.5135445594787598, -1.6783374547958374]
of B-LOC [1.6711399555206299, -1.6097956895828247]
warfarin B-LOC [1.546181559562683, -1.9444465637207031]
or B-LOC [1.4892332553863525, -1.9842135906219482]
NOACs B-LOC [1.6056392192840576, -1.9562647342681885]
were B-LOC [1.4988679885864258, -1.8945764303207397]
older B-LOC [1.5359435081481934, -1.7328516244888306]
and B-LOC [0.8864430785179138, -1.3144187927246094]
had B-LOC [1.3675687313079834, -1.6848119497299194]
higher B-LOC [1.2604109048843384, -1.644493818283081]
prevalence B-LOC [1.661498785018921, -1.6924002170562744]
of B-LOC [1.4323980808258057, -1.521641492843628]
atrial B-LOC [1.5123891830444336, -1.915225863456726]
fibrillation B-LOC [1.3620266914367676, -1.6789641380310059]
and B-LOC [1.101136565208435, -1.3096232414245605]
prior B-LOC [1.1712838411331177, -1.5942155122756958]
stroke. B-LOC [1.4254751205444336, -1.9706735610961914]
Acute B-LOC [1.8364284038543701, -2.286208152770996]
ICH B-LOC [1.9689571857452393, -2.63036847114563]
stroke B-LOC [1.9083585739135742, -2.4186933040618896]
severity B-LOC [2.228055715560913, -2.463620901107788]
(measured B-LOC [2.3668763637542725, -2.2083723545074463]
by B-LOC [2.429270029067993, -2.636378526687622]
the B-LOC [2.490819215774536, -2.5143558979034424]
National B-LOC [2.3051083087921143, -2.8130557537078857]
Institutes B-LOC [2.4522483348846436, -3.095916509628296]
of B-LOC [2.52089524269104, -2.7459633350372314]
Health B-LOC [2.4161293506622314, -2.9957196712493896]
Stroke B-LOC [2.2889068126678467, -2.698014497756958]
Scale) B-LOC [2.0732262134552, -2.739655017852783]
was B-LOC [2.003859043121338, -2.2212703227996826]
not B-LOC [1.6113450527191162, -1.7390658855438232]
significantly B-LOC [1.9840078353881836, -2.093557357788086]
different B-LOC [1.873564600944519, -2.3263843059539795]
across B-LOC [1.6829864978790283, -1.9046275615692139]
the B-LOC [1.8377163410186768, -1.6965084075927734]
3 B-LOC [1.7773594856262207, -1.5804224014282227]
groups B-LOC [2.0631697177886963, -1.693946361541748]
(median, B-LOC [1.556868314743042, -1.4419136047363281]
9 B-LOC [1.7626514434814453, -2.018632650375366]
[interquartile B-LOC [1.434685230255127, -1.6287204027175903]
range, B-LOC [1.5272997617721558, -1.8676486015319824]
2-21] B-LOC [1.7464500665664673, -1.4288179874420166]
for B-LOC [1.2724711894989014, -1.5114779472351074]
warfarin, B-LOC [1.436828851699829, -1.455237865447998]
8 B-LOC [1.5291736125946045, -1.6696971654891968]
[2-20] B-LOC [1.4457664489746094, -1.6850080490112305]
for B-LOC [1.1681101322174072, -1.5014780759811401]

NOACs, B-LOC [0.2219942957162857, -0.6013931632041931]
and B-LOC [0.35496947169303894, -0.27919164299964905]
8 B-LOC [0.5499964356422424, -0.4387999475002289]
[2-19] B-LOC [0.19805732369422913, -0.396889865398407]
for B-LOC [0.1382400095462799, -0.4301705062389374]
no B-LOC [0.31215932965278625, -0.3883085548877716]
OACs). B-LOC [0.23481881618499756, -0.6754951477050781]
The O [-0.2541915774345398, -0.13053224980831146]
unadjusted B-LOC [-0.13735398650169373, -0.16542157530784607]
in-hospital O [-0.33059823513031006, -0.17177769541740417]
mortality O [-0.3300244212150574, -0.1873510330915451]
rates O [-0.3566475212574005, -0.15682753920555115]
were O [-0.3450799584388733, -0.2848534882068634]
32.6% O [-0.1550375521183014, 0.19511094689369202]
for O [-0.2474818378686905, -0.09564569592475891]
warfarin, O [-0.10369028896093369, -0.07073093205690384]
26.5% O [-0.2163698375225067, 0.2679510712623596]
for O [-0.22662055492401123, -0.1445682793855667]
NOACs, B-LOC [-0.09052704274654388, -0.22231121361255646]
and O [-0.2896464467048645, 0.045207735151052475]
22.5% O [-0.1615319848060608, 0.22285667061805725]
for O [-0.2582798898220062, -0.17382119596004486]
no O [-0.07293936610221863, -0.05670802667737007]
OACs. B-LOC [-0.10007284581661224, -0.24826781451702118]
Compared O [-0.7951751351356506, 0.7594682574272156]
with O [-0.5604265928268433, 0.5935994982719421]
patients O [-0.843095600605011, 0.566528856754303]
without O [-0.5909936428070068, 0.48608919978141785]
prior O [-0.8465188145637512, 0.38922902941703796]
use O [-0.5963860750198364, 0.288911908864975]
of O [-0.6269558668136597, 0.44808533787727356]
OACs, O [-0.4409119188785553, 0.3060198128223419]
the O [-0.5580059885978699, 0.3920741379261017]
risk O [-0.6837920546531677, 0.48246175050735474]
of O [-0.8651295304298401, 0.5649703145027161]
in-hospital O [-0.7720564007759094, 0.4257076680660248]
mortality O [-0.613857090473175, 0.48380187153816223]
was O [-0.628487765789032, 0.17736263573169708]
higher O [-0.59303218126297, 0.4751506745815277]
among O [-0.5935872793197632, 0.574485182762146]
patients O [-0.8593645095825195, 0.5657121539115906]
with O [-0.7797339558601379, 0.524916410446167]
prior O [-0.9071952104568481, 0.485100120306015]
use O [-0.6690331101417542, 0.5280192494392395]
of O [-0.7577070593833923, 0.6565032601356506]
warfarin O [-0.522767961025238, 0.41872236132621765]
(adjusted O [-0.7282490730285645, 0.47591185569763184]
risk O [-0.7503008246421814, 0.6674274802207947]
difference O [-0.8447847962379456, 0.5541794896125793]
[ARD], O [-0.6749235987663269, 0.47517862915992737]
9.0% O [-0.702340304851532, 0.7641861438751221]
[97.5% O [-0.7637109160423279, 0.46363240480422974]
CI, O [-0.8078625798225403, 0.5435481667518616]
7.9% O [-0.7517262101173401, 0.8216412663459778]
to O [-0.8770037889480591, 0.33814558386802673]
10.1%]; O [-0.7233836054801941, 0.5876656174659729]
adjusted O [-0.8141034245491028, 0.4583928883075714]
odds O [-0.7981927990913391, 0.5622837543487549]

ratio O [-0.6205124855041504, 0.08751429617404938]
[AOR], O [-0.45587578415870667, 0.16658692061901093]
1.62 O [-0.2809423506259918, 0.38842150568962097]
[97.5% O [-0.5337561964988708, 0.11147376894950867]
CI, O [-0.536902666091919, 0.21592627465724945]
1.53 O [-0.4436788856983185, 0.39512741565704346]
to O [-0.6419476270675659, -0.018958570435643196]
1.71]) O [-0.3065713346004486, 0.2463371306657791]
and O [-0.3809022605419159, 0.3471774458885193]
higher O [-0.3446643650531769, 0.3523203134536743]
among O [-0.4079572260379791, 0.37697073817253113]
patients O [-0.5160458087921143, 0.3940075933933258]
with O [-0.3695897161960602, 0.3822031319141388]
prior O [-0.6667371392250061, 0.3553299307823181]
use O [-0.5722352862358093, 0.5272170901298523]
of O [-0.6214017271995544, 0.6172764897346497]
NOACs O [-0.44067075848579407, 0.4420774281024933]
(ARD, O [-0.48565438389778137, 0.32647114992141724]
3.3% O [-0.6434231400489807, 0.7450194358825684]
[97.5% O [-0.6583130955696106, 0.3657010495662689]
CI, O [-0.6373252272605896, 0.3819243013858795]
1.7% O [-0.7130715250968933, 0.6118389964103699]
to O [-0.8038581013679504, 0.2865986227989197]
4.8%]; O [-0.6336954236030579, 0.8382824063301086]
AOR, O [-0.6461798548698425, 0.23236364126205444]
1.21 O [-0.5935171246528625, 0.6075754761695862]
[97.5% O [-0.7238357663154602, 0.2761532962322235]
CI, O [-0.6501933932304382, 0.3449030816555023]
1.11-1.32]). O [-0.6000126600265503, 0.6118414998054504]
Compared O [-1.0862663984298706, 1.113403558731079]
with O [-0.8147874474525452, 0.8774322867393494]
patients O [-0.9844576120376587, 0.9023141264915466]
with O [-1.018639326095581, 0.8237684369087219]
prior O [-0.9373258352279663, 0.7231596112251282]
use O [-0.6933877468109131, 0.7911830544471741]
of O [-0.7500972151756287, 0.8954359889030457]
warfarin, O [-0.5801953077316284, 0.6545925140380859]
patients O [-1.026806354522705, 0.8922267556190491]
with O [-1.0862561464309692, 0.7391076683998108]
prior O [-0.9773341417312622, 0.6948674321174622]
use O [-0.7213757038116455, 0.7986244559288025]
of O [-0.834645688533783, 0.8748335838317871]
NOACs O [-0.5856866836547852, 0.6155532598495483]
had O [-1.0266704559326172, 0.9114417433738708]
a O [-0.9903603792190552, 0.8928924202919006]
lower O [-0.8592466711997986, 0.8986861705780029]
risk O [-0.9323115944862366, 0.8673965334892273]
of O [-1.1593852043151855, 0.9601750373840332]
in-hospital O [-0.9950507879257202, 0.8460946679115295]
mortality O [-0.7703894376754761, 0.707378089427948]
(ARD, O [-0.9673476815223694, 0.7445068955421448]
−5.7% O [-1.0736563205718994, 0.8297153115272522]

[97.5% O [-0.297972172498703, -0.12335511296987534]
CI, O [-0.3179795444011688, -0.032295968383550644]
−7.3% O [-0.27420902252197266, 0.08776940405368805]
to O [-0.4333285391330719, -0.12148644030094147]
−4.2%]; O [-0.29336777329444885, 0.13804921507835388]
AOR, O [-0.26838794350624084, -0.14456750452518463]
0.75 O [-0.1070505678653717, 0.09824776649475098]
[97.5% O [-0.353772908449173, -0.034874122589826584]
CI, O [-0.3400954604148865, -0.04274643585085869]
0.69 O [-0.09203936159610748, 0.09824568778276443]
to O [-0.3391610383987427, -0.08825767040252686]
0.81]). O [-0.057801056653261185, 0.017463168129324913]
The B-LOC [0.15794119238853455, -0.5608430504798889]
difference B-LOC [-0.048006702214479446, -0.5716388821601868]
in B-LOC [0.19496390223503113, -0.4726777970790863]
mortality B-LOC [0.16106849908828735, -0.31541362404823303]
between B-LOC [0.25234854221343994, -0.5607377290725708]
NOAC-treated B-LOC [0.2649505138397217, -0.4049510955810547]
patients B-LOC [0.1050553247332573, -0.3027714192867279]
and B-LOC [0.4004308879375458, -0.5822705626487732]
warfarin-treated B-LOC [0.26362064480781555, -0.42868778109550476]
patients B-LOC [0.10886076837778091, -0.24968558549880981]
was B-LOC [0.324184387922287, -0.6488634943962097]
numerically B-LOC [0.17462021112442017, -0.3607838451862335]
greater B-LOC [0.3303309381008148, -0.45713815093040466]
among B-LOC [0.2710210978984833, -0.27740541100502014]
patients B-LOC [-0.019906213507056236, -0.1732902079820633]
with B-LOC [0.05458449199795723, -0.1858121007680893]
prior B-LOC [-0.06965631246566772, -0.2266235649585724]
use B-LOC [0.14715643227100372, -0.15320628881454468]
of B-LOC [0.11413934081792831, -0.12345153838396072]
dual B-LOC [0.04324990138411522, -0.3265354335308075]
antiplatelet B-LOC [0.11474999785423279, -0.20544996857643127]
agents B-LOC [0.10201029479503632, -0.1604345440864563]
(32.7% B-LOC [-0.0835082158446312, -0.2559395134449005]
vs B-LOC [-0.12317775934934616, -0.3900454640388489]
47.1%; O [0.12147162854671478, 0.19409629702568054]
ARD, O [-0.11524948477745056, -0.02384052984416485]
−15.0% B-LOC [-0.0734880194067955, -0.10621711611747742]
[95.5% O [-0.3223412334918976, -0.0209085363894701]
CI, O [-0.31962236762046814, 0.008551279082894325]
−26.3% O [-0.274187296628952, 0.06646348536014557]
to O [-0.33863365650177, -0.07829178869724274]
−3.8%]; O [-0.23971107602119446, 0.0783071517944336]
AOR, O [-0.27057918906211853, -0.10635857284069061]
0.50 O [-0.009726111777126789, 0.016757985576987267]

[97.5% O [-0.4748375117778778, 0.06406468898057938]
CI, O [-0.43977275490760803, 0.12674865126609802]
0.29 O [-0.14408737421035767, 0.27906161546707153]
to O [-0.5002716183662415, 0.03356201574206352]
0.86]) O [-0.0053696236573159695, 0.08738692104816437]
than O [-0.5131667256355286, 0.4320816695690155]
among O [-0.21244707703590393, 0.5108242630958557]
those O [-0.3050821125507355, 0.49871888756752014]
taking O [-0.35216403007507324, 0.38131240010261536]
these O [-0.24144092202186584, 0.2871858775615692]
agents O [-0.3817507326602936, 0.258686900138855]
without O [-0.23426668345928192, 0.45812827348709106]
prior O [-0.4893477261066437, 0.17184099555015564]
antiplatelet O [-0.3696715831756592, 0.2967464029788971]
therapy O [-0.36246445775032043, 0.38370537757873535]
(26.4% O [-0.34049734473228455, 0.1648385226726532]
vs O [-0.45413801074028015, 0.08030261099338531]
31.7%; O [-0.16496923565864563, 0.4629828631877899]
ARD, O [-0.41747310757637024, 0.35065218806266785]
−5.0% O [-0.4582079350948334, 0.4658851623535156]
[97.5% O [-0.40955764055252075, 0.13661283254623413]
CI, O [-0.4558309316635132, 0.17061203718185425]
−6.8% O [-0.4662351906299591, 0.4185184836387634]
to O [-0.4922630488872528, 0.10638021677732468]
−3.2%]; O [-0.429686039686203, 0.32632356882095337]
AOR, O [-0.29807063937187195, -0.10793039202690125]
0.77 O [-0.10994897037744522, 0.11501872539520264]
[97.5% O [-0.30797308683395386, -0.15018868446350098]
CI, O [-0.29296499490737915, -0.0929722785949707]
0.70 O [-0.003956583794206381, 0.018531469628214836]
to O [-0.23513157665729523, -0.040078599005937576]
0.85]), B-LOC [0.10401344299316406, -0.13145644962787628]
although B-LOC [-0.0562765896320343, -0.24230548739433289]
the B-LOC [0.811290979385376, -0.9298179745674133]
interaction B-LOC [0.4817386269569397, -0.792708694934845]
P B-LOC [0.7388109564781189, -1.1317861080169678]
value B-LOC [0.47453081607818604, -0.8778928518295288]
(.07) B-LOC [0.8823503851890564, -0.8860419988632202]
was B-LOC [1.0545313358306885, -1.5107784271240234]
not B-LOC [1.5559251308441162, -1.5549088716506958]
statistically B-LOC [0.9074650406837463, -1.1026747226715088]
significant. B-LOC [1.4478007555007935, -1.822188377380371]
Conclusions B-LOC [0.4370538890361786, -0.8032329678535461]
and B-LOC [0.5232213735580444, -1.1304261684417725]
Relevance B-LOC [0.41994670033454895, -0.8055856823921204]
Among B-LOC [0.34538254141807556, -0.38908854126930237]
patients B-LOC [0.31435200572013855, -0.45629438757896423]
with B-LOC [0.35073164105415344, -0.45712175965309143]
ICH, B-LOC [0.3117114007472992, -0.40655234456062317]
prior B-LOC [0.21040722727775574, -0.5529547929763794]
use B-LOC [0.29765185713768005, -0.4819397032260895]
of B-LOC [0.24540139734745026, -0.4487617015838623]

NOACs O [-0.17198196053504944, -0.03241633251309395]
or O [-0.25593024492263794, 0.3327043950557709]
warfarin O [-0.18429476022720337, 0.20459046959877014]
was O [-0.5240444540977478, 0.2001437246799469]
associated O [-0.4493333399295807, 0.46392622590065]
with O [-0.5371106863021851, 0.2892351448535919]
higher O [-0.32945507764816284, 0.4004746377468109]
in-hospital O [-0.47513386607170105, 0.22609767317771912]
mortality O [-0.24824455380439758, 0.1812324970960617]
compared O [-0.3456757962703705, 0.4470670521259308]
with O [-0.2491987943649292, 0.03718574717640877]
no O [-0.19714918732643127, 0.24460947513580322]
OACs. O [-0.11734499037265778, -0.020155461505055428]
Prior O [-0.8918840289115906, 0.7112193703651428]
use O [-0.5718761086463928, 0.704508364200592]
of O [-0.6806401610374451, 0.6954753398895264]
NOACs, O [-0.38793984055519104, 0.39183878898620605]
compared O [-0.8654240965843201, 0.9828681349754333]
with O [-0.7145878672599792, 0.7819632887840271]
prior O [-0.8225053548812866, 0.6699516773223877]
use O [-0.5251991152763367, 0.6575568318367004]
of O [-0.6969860196113586, 0.7568766474723816]
warfarin, O [-0.5306131839752197, 0.6352229714393616]
was O [-0.8652141690254211, 0.7240651249885559]
associated O [-0.8703698515892029, 0.8954269289970398]
with O [-0.920391857624054, 0.8334550261497498]
lower O [-0.6390223503112793, 0.7450848817825317]
risk O [-0.7147473692893982, 0.6491868495941162]
of O [-1.0284366607666016, 0.7569295763969421]
in-hospital O [-0.8326268196105957, 0.469999223947525]
mortality. O [-0.5925615429878235, 0.5116996765136719]

Viral B-LOC [2.2839250564575195, -3.3614931106567383]
replication B-LOC [2.5624730587005615, -2.956611156463623]
usually B-LOC [2.799954891204834, -3.048278570175171]
requires B-LOC [2.5911524295806885, -2.8973758220672607]
that B-LOC [2.5207455158233643, -2.9062490463256836]
innate B-LOC [2.552563428878784, -3.3637778759002686]
intracellular B-LOC [2.7083070278167725, -3.302884817123413]
lines B-LOC [2.8570098876953125, -3.3403782844543457]
of B-LOC [2.7361347675323486, -3.4513556957244873]
defence B-LOC [2.670060873031616, -3.1086771488189697]
be B-LOC [2.59895658493042, -3.098031759262085]
overcome, B-LOC [2.8869645595550537, -3.300335168838501]
a B-LOC [2.8971927165985107, -3.19197678565979]
task B-LOC [2.9435694217681885, -3.384728193283081]
usually B-LOC [3.1738245487213135, -3.432366132736206]
accomplished B-LOC [3.1915383338928223, -3.3027026653289795]
by B-LOC [2.911062240600586, -3.403236150741577]
specialized B-LOC [2.766319990158081, -3.3365423679351807]
viral B-LOC [2.6038997173309326, -3.382370710372925]
gene B-LOC [2.7504775524139404, -3.5309805870056152]
products. B-LOC [3.1244935989379883, -3.390803575515747]
The B-LOC [0.696861743927002, -0.710300624370575]
virion B-LOC [0.6544837355613708, -1.1509780883789062]
infectivity B-LOC [0.8325551748275757, -1.1386879682540894]
factor B-LOC [0.45776256918907166, -0.9302018284797668]
(Vif) B-LOC [1.037771463394165, -1.094237208366394]
protein B-LOC [0.5817422866821289, -0.8964497447013855]
of B-LOC [0.50212162733078, -0.7621729373931885]
human B-LOC [0.6127265095710754, -0.9100019335746765]
immunodeficiency B-LOC [0.8818833827972412, -1.1010526418685913]
virus B-LOC [0.8343059420585632, -1.074173927307129]
(HIV) B-LOC [1.2663993835449219, -1.2787678241729736]
is B-LOC [0.7004945874214172, -0.7587099075317383]
required B-LOC [0.4552890360355377, -0.6630297303199768]
during B-LOC [0.282325804233551, -0.45943745970726013]
the B-LOC [0.4699830412864685, -0.39723241329193115]
late B-LOC [0.3434872627258301, -0.4007302522659302]
stages B-LOC [0.2780629098415375, -0.5495107769966125]
of B-LOC [0.2627244293689728, -0.5184324979782104]
viral B-LOC [0.5720916390419006, -0.7216344475746155]
production B-LOC [0.4938681721687317, -0.37618160247802734]
to B-LOC [0.5384958386421204, -0.5579347610473633]
counter B-LOC [0.4883815348148346, -0.6612406969070435]
the B-LOC [0.4131699502468109, -0.27042922377586365]
antiviral B-LOC [0.45112496614456177, -0.5098847150802612]
activity B-LOC [0.4278828799724579, -0.4297657907009125]
of B-LOC [0.2713290750980377, -0.3666926920413971]
APOBEC3G B-LOC [0.39725640416145325, -0.6486954092979431]
(apolipoprotein B-LOC [0.29940152168273926, -0.5817343592643738]
B B-LOC [0.4140079915523529, -0.4901317059993744]
mRNA-editing B-LOC [0.13932228088378906, -0.5894601941108704]
enzyme, B-LOC [0.16857555508613586, -0.5753441452980042]
catalytic B-LOC [0.33959513902664185, -0.6850142478942871]
polypeptide-like B-LOC [0.286141961812973, -0.633549153804779]
3G; B-LOC [0.4656822979450226, -0.5077764987945557]
also B-LOC [0.6053858399391174, -0.8494053483009338]
known B-LOC [0.6197062730789185, -0.6656099557876587]
as B-LOC [0.4357202351093292, -0.7488817572593689]
CEM15), B-LOC [0.2249222844839096, -0.4792609214782715]
a B-LOC [0.2894246280193329, -0.5690459609031677]
protein B-LOC [0.2392856776714325, -0.684554398059845]
expressed B-LOC [0.29651138186454773, -0.4131363332271576]
notably B-LOC [0.3634240925312042, -0.6167978644371033]
in B-LOC [0.23004543781280518, -0.3956369459629059]
human B-LOC [0.35323408246040344, -0.7969119548797607]
T B-LOC [0.3087465763092041, -0.6026223301887512]
lymphocytes. B-LOC [0.3253880441188812, -0.5588071346282959]
When B-LOC [0.29487842321395874, -0.5517781972885132]
produced B-LOC [0.5552929043769836, -0.48178112506866455]
in B-LOC [0.4700820744037628, -0.6514226198196411]
the B-LOC [0.5144668221473694, -0.7054577469825745]
presence B-LOC [0.5129370093345642, -0.5028618574142456]
of B-LOC [0.40879303216934204, -0.5594503283500671]

APOBEC3G, B-LOC [1.3820990324020386, -1.8586866855621338]
vif-defective B-LOC [1.4032491445541382, -1.7043571472167969]
virus B-LOC [1.3769689798355103, -2.042663812637329]
is B-LOC [1.8699884414672852, -1.8846274614334106]
non-infectious. B-LOC [1.9177746772766113, -2.021320104598999]
APOBEC3G B-LOC [0.24321000277996063, -0.6998603940010071]
is B-LOC [0.395377516746521, -0.5183431506156921]
closely B-LOC [0.4409097135066986, -0.5328273773193359]
related B-LOC [0.5316576361656189, -0.5354339480400085]
to B-LOC [0.25869500637054443, -0.4631604254245758]
APOBEC1, B-LOC [-0.03694913163781166, -0.5504149198532104]
the B-LOC [-0.09067339450120926, -0.22829115390777588]
central B-LOC [-0.09952971339225769, -0.21583880484104156]
component B-LOC [0.05837083235383034, -0.39239445328712463]
of B-LOC [0.0361480750143528, -0.17004184424877167]
an B-LOC [0.003517771605402231, -0.21407516300678253]
RNA-editing B-LOC [0.033666837960481644, -0.5220221281051636]
complex B-LOC [0.058968398720026016, -0.35813844203948975]
that B-LOC [-0.17980463802814484, -0.34009408950805664]
deaminates O [-0.01688285730779171, -0.012769879773259163]
a B-LOC [0.09894172847270966, -0.13352617621421814]
cytosine B-LOC [-0.0979355052113533, -0.24675121903419495]
residue B-LOC [-0.009578329510986805, -0.30206844210624695]
in B-LOC [-0.12410180270671844, -0.22683186829090118]
apoB B-LOC [-0.12443505227565765, -0.3392338752746582]
messenger B-LOC [-0.04584898427128792, -0.48176008462905884]
RNA. B-LOC [0.17836572229862213, -0.586558997631073]
APOBEC B-LOC [2.1446518898010254, -2.0658371448516846]
family B-LOC [2.7268588542938232, -2.3689122200012207]
members B-LOC [2.637472629547119, -2.3654019832611084]
also B-LOC [2.569196939468384, -2.432663679122925]
have B-LOC [2.5589749813079834, -2.4238929748535156]
potent B-LOC [2.5635197162628174, -2.604550361633301]
DNA B-LOC [2.592289924621582, -2.8899543285369873]
mutator B-LOC [2.78202223777771, -2.644324541091919]
activity B-LOC [2.468151807785034, -2.2677090167999268]
through B-LOC [2.459984302520752, -2.373211145401001]
dC B-LOC [2.432400941848755, -2.2841579914093018]
deamination; B-LOC [2.793926239013672, -2.6047990322113037]
however, B-LOC [3.0248758792877197, -2.7482359409332275]
whether B-LOC [2.884765863418579, -3.1170670986175537]
the B-LOC [2.945631742477417, -2.9260079860687256]
editing B-LOC [2.758591890335083, -3.029813528060913]
potential B-LOC [2.7694621086120605, -2.9852633476257324]
of B-LOC [2.699167013168335, -2.589491128921509]
APOBEC3G B-LOC [2.3675379753112793, -2.291754961013794]
has B-LOC [3.1679022312164307, -3.1648144721984863]
any B-LOC [2.9716126918792725, -2.9803662300109863]
relevance B-LOC [3.018022298812866, -2.989328622817993]
to B-LOC [2.8771984577178955, -3.0672495365142822]
HIV B-LOC [2.591249704360962, -2.821326494216919]
inhibition B-LOC [2.9374148845672607, -3.0136797428131104]
is B-LOC [3.291686534881592, -2.878786325454712]
unknown. B-LOC [3.108934164047241, -2.837615728378296]
Here, O [-0.3609527349472046, 0.08199743181467056]
we O [-0.4602923095226288, 0.25563862919807434]
demonstrate O [-0.16669638454914093, 0.14173360168933868]
that O [-0.48700612783432007, 0.11891695111989975]
it B-LOC [-0.11178978532552719, -0.1531696319580078]
does, O [-0.16122007369995117, -0.08632811903953552]
as O [-0.4688476622104645, -0.057663995772600174]
APOBEC3G O [-0.16851159930229187, -0.13914474844932556]
exerts O [-0.3197295367717743, 0.06499898433685303]

its O [-0.29361972212791443, -0.0741499811410904]
antiviral O [-0.2093532234430313, 0.09624568372964859]
effect O [-0.3061325252056122, 0.13244423270225525]
during O [-0.35812872648239136, 0.17456884682178497]
reverse O [-0.2223633974790573, 0.14593179523944855]
transcription O [-0.1672588288784027, 0.18411919474601746]
to O [-0.2693500816822052, 0.14383715391159058]
trigger O [-0.3913666307926178, 0.18709330260753632]
G-to-A O [-0.292770653963089, 0.052171144634485245]
hypermutation O [-0.23262420296669006, -0.038666982203722]
in O [-0.2760123908519745, 0.0019236630760133266]
the O [-0.09887155145406723, 0.014739828184247017]
nascent B-LOC [-0.05340460315346718, -0.2195555418729782]
retroviral B-LOC [-0.1682104766368866, -0.33424288034439087]
DNA. O [-0.20027878880500793, -0.126198872923851]
We O [-0.3408788740634918, 0.05928465351462364]
also O [-0.09792470932006836, 0.039371307939291]
find O [-0.2918943166732788, 0.2624835669994354]
that O [-0.4466269612312317, 0.19799987971782684]
APOBEC3G O [-0.2684520184993744, -0.04544161260128021]
can O [-0.026525413617491722, 0.05576152727007866]
act O [-0.15226969122886658, 0.1223628893494606]
on O [0.09615932404994965, 0.1998925507068634]
a O [0.15413762629032135, 0.2222139537334442]
broad B-LOC [0.1172560602426529, -0.18983115255832672]
range B-LOC [0.3341623842716217, -0.17205213010311127]
of B-LOC [0.18159234523773193, -0.055409494787454605]
retroviruses O [-0.06279796361923218, -0.015518615022301674]
in O [-0.09276822209358215, -0.05081046000123024]
addition O [-0.08701509237289429, 0.10653794556856155]
to B-LOC [0.08708309382200241, -0.0356452651321888]
HIV, B-LOC [0.17406079173088074, -0.40685996413230896]
suggesting B-LOC [-0.024773942306637764, -0.13383910059928894]
that B-LOC [0.005855145398527384, -0.3427930474281311]
hypermutation B-LOC [0.03237178176641464, -0.3443211317062378]
by B-LOC [-0.1631762534379959, -0.2116735279560089]
editing B-LOC [0.06472417712211609, -0.4213602840900421]
is B-LOC [0.38996055722236633, -0.5339369177818298]
a B-LOC [0.29460588097572327, -0.5004945397377014]
general B-LOC [0.27231889963150024, -0.7607564330101013]
innate B-LOC [0.2718636095523834, -0.46083864569664]
defence B-LOC [0.2768976092338562, -0.527928352355957]
mechanism B-LOC [0.12795311212539673, -0.6005122661590576]
against B-LOC [0.45718035101890564, -0.6869327425956726]
this B-LOC [0.2823779582977295, -0.6608601808547974]
important B-LOC [0.2624361515045166, -0.753635585308075]
group B-LOC [0.4703315496444702, -0.8098557591438293]
of B-LOC [0.4090452790260315, -0.7903215885162354]
pathogens. B-LOC [0.34736350178718567, -0.748454213142395]

Stem B-LOC [0.9720734357833862, -1.251078486442566]
cells B-LOC [1.0628249645233154, -1.2712398767471313]
are B-LOC [1.7524389028549194, -1.3086915016174316]
proposed B-LOC [1.4652804136276245, -1.0739864110946655]
to B-LOC [1.4175875186920166, -1.1884982585906982]
segregate B-LOC [0.9346936345100403, -0.8407539129257202]
chromosomes B-LOC [0.8196535110473633, -1.2781007289886475]
asymmetrically B-LOC [0.8314281105995178, -1.0178008079528809]
during B-LOC [0.7589426636695862, -1.0530327558517456]
self-renewing B-LOC [0.753379225730896, -0.8749011158943176]
divisions B-LOC [0.9863579869270325, -1.168112874031067]
so B-LOC [0.6610560417175293, -0.46338480710983276]
that B-LOC [0.31370359659194946, -0.5006387233734131]
older B-LOC [0.3150184452533722, -0.5268282294273376]
(‘immortal’) B-LOC [0.5770372152328491, -0.6968283653259277]
DNA B-LOC [0.4613633453845978, -0.5585715174674988]
strands B-LOC [0.5375981330871582, -0.45996469259262085]
are B-LOC [0.331714391708374, -0.19287219643592834]
retained B-LOC [0.3452272117137909, -0.18341436982154846]
in B-LOC [0.344946026802063, -0.5740436315536499]
daughter B-LOC [0.36147043108940125, -0.4940212070941925]
stem B-LOC [0.45860418677330017, -0.7965672612190247]
cells B-LOC [0.49898383021354675, -0.5415287613868713]
whereas B-LOC [0.31923583149909973, -0.04062703624367714]
newly B-LOC [0.35513031482696533, -0.5376128554344177]
synthesized B-LOC [0.5092224478721619, -0.572381317615509]
strands B-LOC [0.6647177934646606, -0.5373225808143616]
segregate B-LOC [0.5841799378395081, -0.21382920444011688]
to B-LOC [0.3316616117954254, -0.6149419546127319]
differentiating B-LOC [0.5377278923988342, -0.6229696273803711]
cells. B-LOC [0.6838024854660034, -0.7542668581008911]
Stem B-LOC [1.2090320587158203, -1.1386641263961792]
cells B-LOC [1.0545521974563599, -1.227919101715088]
are B-LOC [1.7013630867004395, -1.313706874847412]
also B-LOC [1.8028292655944824, -1.3097381591796875]
proposed B-LOC [1.6135165691375732, -1.174670696258545]
to B-LOC [1.6874816417694092, -1.260040044784546]
retain B-LOC [1.109163761138916, -1.0450351238250732]
DNA B-LOC [1.0610692501068115, -1.3265929222106934]
labels, B-LOC [1.1766674518585205, -1.051193118095398]
such B-LOC [1.4946863651275635, -1.3185780048370361]
as B-LOC [1.2895549535751343, -1.1740963459014893]
5-bromo-2-deoxyuridine B-LOC [0.8697379231452942, -0.8565198183059692]
(BrdU), B-LOC [1.396538496017456, -1.332360029220581]
either B-LOC [1.0520100593566895, -1.1608158349990845]
because B-LOC [0.8460927605628967, -0.7942599654197693]
they B-LOC [0.9419246315956116, -0.812214195728302]
segregate B-LOC [0.9463561177253723, -0.6767816543579102]
chromosomes B-LOC [0.7965146899223328, -1.0318433046340942]
asymmetrically B-LOC [0.7214487195014954, -0.6707510948181152]
or B-LOC [1.1227020025253296, -0.9715763926506042]
because B-LOC [0.7647050619125366, -0.6207583546638489]
they B-LOC [0.966834545135498, -0.8636594414710999]
divide B-LOC [0.8333228230476379, -0.8349844217300415]
slowly. B-LOC [0.7218634486198425, -0.7007933259010315]
However, B-LOC [2.144019603729248, -1.9166295528411865]
the B-LOC [2.0051679611206055, -2.2508137226104736]
purity B-LOC [1.822513222694397, -2.0597832202911377]
of B-LOC [1.9088022708892822, -2.1959707736968994]
stem B-LOC [1.8766212463378906, -1.8381911516189575]
cells B-LOC [1.8601168394088745, -1.768760085105896]
among B-LOC [1.9977672100067139, -1.8762145042419434]
BrdU-label-retaining B-LOC [1.3654019832611084, -1.3908441066741943]
cells B-LOC [1.7582885026931763, -1.615776538848877]
has B-LOC [2.6027512550354004, -2.1559019088745117]
not B-LOC [2.4580562114715576, -2.1050055027008057]
been B-LOC [2.497645378112793, -2.5449604988098145]
documented B-LOC [2.1055121421813965, -2.2459523677825928]
in B-LOC [1.9575867652893066, -2.1004974842071533]
any B-LOC [1.427417278289795, -1.6128731966018677]

tissue, B-LOC [2.1313724517822266, -3.1617252826690674]
and B-LOC [2.5600085258483887, -3.082277774810791]
the B-LOC [2.930596113204956, -3.0557873249053955]
‘immortal B-LOC [2.0816709995269775, -2.7219748497009277]
strand B-LOC [2.4723289012908936, -3.3755099773406982]
hypothesis’ B-LOC [2.6800005435943604, -3.2387917041778564]
has B-LOC [3.1433918476104736, -3.3926379680633545]
not B-LOC [3.1331136226654053, -3.3385822772979736]
been B-LOC [3.030071496963501, -3.5845837593078613]
tested B-LOC [3.084012985229492, -3.656625986099243]
in B-LOC [3.0606887340545654, -3.6466968059539795]
a B-LOC [2.9168202877044678, -3.2992851734161377]
system B-LOC [2.885197639465332, -3.738131284713745]
with B-LOC [2.9921720027923584, -3.6406893730163574]
definitive B-LOC [3.00500226020813, -3.596266746520996]
stem B-LOC [2.958235025405884, -3.7318904399871826]
cell B-LOC [2.795907974243164, -3.7266430854797363]
markers. B-LOC [2.9760587215423584, -3.683042049407959]
Here B-LOC [2.7734317779541016, -3.2411787509918213]
we B-LOC [2.7233059406280518, -3.1485934257507324]
tested B-LOC [3.0062758922576904, -3.4426443576812744]
these B-LOC [2.9484994411468506, -3.2446954250335693]
hypotheses B-LOC [3.1857268810272217, -3.379361391067505]
in B-LOC [3.0854973793029785, -3.440793991088867]
haematopoietic B-LOC [3.12960147857666, -3.4452004432678223]
stem B-LOC [3.005768060684204, -3.5982825756073]
cells B-LOC [2.967568874359131, -3.600064516067505]
(HSCs), B-LOC [3.1556146144866943, -3.500699758529663]
which B-LOC [3.119295358657837, -3.4690754413604736]
can B-LOC [3.215428113937378, -3.485684394836426]
be B-LOC [3.1102612018585205, -3.5101213455200195]
highly B-LOC [3.1928789615631104, -3.5268824100494385]
purified B-LOC [3.206273317337036, -3.4889864921569824]
using B-LOC [3.1862757205963135, -3.5556232929229736]
well B-LOC [3.2402379512786865, -3.4310905933380127]
characterized B-LOC [3.1480860710144043, -3.47794508934021]
markers. B-LOC [3.063422441482544, -3.629729986190796]
We B-LOC [0.3968304395675659, -0.6767876744270325]
administered B-LOC [0.6297866702079773, -0.5591779947280884]
BrdU B-LOC [0.5003893971443176, -0.6642022132873535]
to B-LOC [0.5288161039352417, -0.531437337398529]
newborn B-LOC [0.4451890289783478, -0.49628281593322754]
mice, B-LOC [0.47008198499679565, -0.7053993940353394]
mice B-LOC [0.416419118642807, -0.6963377594947815]
treated B-LOC [0.730616569519043, -0.6311246752738953]
with B-LOC [0.710730254650116, -0.5766732692718506]
cyclophosphamide B-LOC [0.4160013794898987, -0.4216654896736145]
and B-LOC [0.39576947689056396, -0.5809797048568726]
granulocyte B-LOC [0.5418941974639893, -0.39633843302726746]
colony-stimulating B-LOC [0.2941638231277466, -0.3129686117172241]
factor, B-LOC [0.358864426612854, -0.4476880431175232]
and B-LOC [0.7983869910240173, -0.7837206721305847]
normal B-LOC [0.40472906827926636, -0.7520419359207153]
adult B-LOC [0.38001975417137146, -0.5394219160079956]
mice B-LOC [0.3868121802806854, -0.7034946084022522]
for B-LOC [0.8075290322303772, -0.6490328907966614]
4 B-LOC [0.6718523502349854, -0.6746354103088379]
to B-LOC [0.5661687254905701, -0.6992278099060059]
10 B-LOC [0.8360292315483093, -0.7949203848838806]
days, B-LOC [0.7387176752090454, -0.6348319053649902]
followed B-LOC [0.67142254114151, -0.7577992677688599]
by B-LOC [0.6543187499046326, -0.7613145709037781]
70 B-LOC [0.750494658946991, -0.7161936163902283]
days B-LOC [0.6930790543556213, -0.6774614453315735]
without B-LOC [0.6846479177474976, -0.7291808724403381]
BrdU. B-LOC [0.36047086119651794, -0.6474370360374451]
In B-LOC [0.3738618493080139, -0.23917286098003387]
each B-LOC [0.6128283143043518, -0.3414994776248932]
case, B-LOC [0.5162732005119324, -0.4982074499130249]
less B-LOC [0.3873015344142914, -0.23521706461906433]
than B-LOC [0.32355454564094543, -0.38852450251579285]
6% B-LOC [0.5381407737731934, -0.28505754470825195]
of B-LOC [0.2692704498767853, -0.21849742531776428]
HSCs B-LOC [0.3956519365310669, -0.8139013051986694]

retained O [-0.17990979552268982, 0.3469652235507965]
BrdU O [-0.2937000095844269, 0.1273157000541687]
and O [-0.3281531035900116, 0.4019196629524231]
less O [-0.1390267014503479, 0.38816091418266296]
than O [-0.13472409546375275, 0.2631744146347046]
0.5% O [-0.0675901472568512, 0.23968897759914398]
of O [-0.17519459128379822, 0.28103020787239075]
all O [-0.06893754005432129, 0.22733646631240845]
BrdU-retaining O [-0.23752644658088684, 0.12894566357135773]
haematopoietic O [-0.21586039662361145, 0.17186239361763]
cells O [-0.2525087296962738, 0.22977440059185028]
were O [-0.31287238001823425, 0.32130393385887146]
HSCs, O [-0.24418415129184723, 0.06169707700610161]
revealing O [-0.2085532397031784, 0.42699483036994934]
that O [-0.24957430362701416, 0.15966366231441498]
BrdU O [-0.17502540349960327, 0.04931681230664253]
has O [-0.09165292978286743, 0.17157992720603943]
poor O [0.00926292221993208, 0.17944510281085968]
specificity O [0.041769493371248245, 0.08437059819698334]
and O [-0.3574523329734802, 0.4418835937976837]
poor O [0.06776639074087143, 0.21325194835662842]
sensitivity O [-0.005550993140786886, 0.03348803147673607]
as O [-0.3128631114959717, 0.09378640353679657]
an O [-0.30453503131866455, 0.01761612854897976]
HSC B-LOC [-0.013671991415321827, -0.09804283827543259]
marker. O [-0.1425396203994751, 0.04234158247709274]
Sequential B-LOC [1.5072205066680908, -1.5449326038360596]
administration B-LOC [1.4376394748687744, -1.5331697463989258]
of B-LOC [1.3725855350494385, -1.5008753538131714]
5-chloro-2-deoxyuridine B-LOC [1.1527886390686035, -1.0087252855300903]
and B-LOC [1.4851510524749756, -1.593982219696045]
5-iodo-2-deoxyuridine B-LOC [1.3502839803695679, -1.1453977823257446]
indicated B-LOC [1.364467740058899, -1.640606164932251]
that B-LOC [1.3546123504638672, -1.7123792171478271]
all B-LOC [1.5757179260253906, -1.9026535749435425]
HSCs B-LOC [1.373378872871399, -1.8022925853729248]
segregate B-LOC [1.417646050453186, -1.7609443664550781]
their B-LOC [1.5830210447311401, -1.8385056257247925]
chromosomes B-LOC [1.5104166269302368, -1.985508680343628]
randomly. B-LOC [1.6674166917800903, -1.959560513496399]
Division B-LOC [1.8150286674499512, -2.155648708343506]
of B-LOC [2.0368077754974365, -2.488645553588867]
individual B-LOC [2.1586906909942627, -2.571598768234253]
HSCs B-LOC [1.7264758348464966, -2.1230108737945557]
in B-LOC [2.0713961124420166, -2.2892391681671143]
culture B-LOC [2.0644478797912598, -2.1679067611694336]
revealed B-LOC [1.8057074546813965, -1.9469186067581177]
no B-LOC [2.0648677349090576, -2.117981195449829]
asymmetric B-LOC [2.2354867458343506, -2.2195382118225098]
segregation B-LOC [1.9922094345092773, -2.303391695022583]
of B-LOC [2.1139414310455322, -2.44867205619812]
the B-LOC [2.0498850345611572, -2.331554889678955]
label. B-LOC [1.9588109254837036, -2.486133337020874]
Thus, B-LOC [1.4745934009552002, -1.6608235836029053]
HSCs B-LOC [1.2612758874893188, -1.734992265701294]
cannot B-LOC [1.9706591367721558, -1.9043842554092407]
be B-LOC [2.039999485015869, -2.1943774223327637]
identified B-LOC [1.8439533710479736, -2.194422721862793]
on B-LOC [1.8108398914337158, -2.036264657974243]
the B-LOC [1.9240798950195312, -1.9707434177398682]
basis B-LOC [1.599226474761963, -1.8013896942138672]

of O [-0.3039678633213043, 0.35441750288009644]
BrdU-label O [-0.28142374753952026, 0.056242141872644424]
retention O [0.015260751359164715, 0.32366061210632324]
and O [-0.2903306186199188, 0.5095920562744141]
do O [-0.14101064205169678, 0.4270224869251251]
not O [-0.2012031078338623, 0.5908664464950562]
retain O [-0.104933962225914, 0.13680385053157806]
older O [-0.2513173520565033, 0.0415148101747036]
DNA O [-0.19488248229026794, -0.13660478591918945]
strands O [-0.08633847534656525, 0.05755843594670296]
during O [-0.45874401926994324, 0.18098315596580505]
division, B-LOC [0.021981270983815193, -0.07042944431304932]
indicating B-LOC [0.0020450674928724766, -0.005042436067014933]
that B-LOC [-0.09738977998495102, -0.17106418311595917]
these B-LOC [0.08827349543571472, -0.14855968952178955]
are B-LOC [0.2192150503396988, -0.42343080043792725]
not B-LOC [0.1926477998495102, -0.21397604048252106]
general B-LOC [0.17184723913669586, -0.6552369594573975]
properties B-LOC [0.25307977199554443, -0.39047542214393616]
of B-LOC [0.11241478472948074, -0.573432207107544]
stem B-LOC [-0.08864521980285645, -0.35522034764289856]
cells. B-LOC [0.07973527908325195, -0.39997291564941406]

In B-LOC [1.4701582193374634, -2.051689386367798]
the B-LOC [2.2032394409179688, -2.2822341918945312]
mammalian B-LOC [2.0884344577789307, -2.3975908756256104]
model B-LOC [2.0109870433807373, -2.560866594314575]
of B-LOC [2.1021111011505127, -2.7854015827178955]
sex B-LOC [2.0035135746002197, -2.7031397819519043]
determination, B-LOC [1.8192957639694214, -2.5383903980255127]
embryos B-LOC [1.688293695449829, -2.3089654445648193]
are B-LOC [1.78385329246521, -2.21746563911438]
considered B-LOC [1.8090357780456543, -2.015990972518921]
to B-LOC [1.8181500434875488, -2.1085197925567627]
be B-LOC [1.5967626571655273, -1.9888719320297241]
sexually B-LOC [1.6139999628067017, -2.1643974781036377]
indifferent B-LOC [1.558290719985962, -1.9911987781524658]
until B-LOC [1.8310341835021973, -2.2264039516448975]
the B-LOC [1.815826177597046, -2.11468243598938]
transient B-LOC [2.073971748352051, -2.6459290981292725]
action B-LOC [1.5898759365081787, -2.4654030799865723]
of B-LOC [1.724111557006836, -2.4141287803649902]
a B-LOC [2.007784128189087, -2.4138543605804443]
sex-determining B-LOC [2.3251564502716064, -2.977652072906494]
gene B-LOC [1.4638903141021729, -2.33620548248291]
initiates B-LOC [1.9524438381195068, -2.3516204357147217]
gonadal B-LOC [2.5175907611846924, -2.9392147064208984]
differentiation. B-LOC [1.7743945121765137, -2.558483123779297]
Although B-LOC [2.9599416255950928, -3.236497163772583]
this B-LOC [2.934217691421509, -3.269819498062134]
model B-LOC [2.8701350688934326, -3.394146680831909]
is B-LOC [3.046011447906494, -3.1508476734161377]
thought B-LOC [3.187316656112671, -3.3556318283081055]
to B-LOC [3.123298406600952, -3.359506607055664]
apply B-LOC [2.9824068546295166, -3.319847583770752]
to B-LOC [2.864842176437378, -3.273958206176758]
all B-LOC [2.9995243549346924, -3.261183023452759]
vertebrates, B-LOC [2.9465057849884033, -3.253166437149048]
this B-LOC [3.0011579990386963, -3.392277717590332]
has B-LOC [3.134122133255005, -3.3538870811462402]
yet B-LOC [3.115943193435669, -3.3861947059631348]
to B-LOC [3.231673240661621, -3.524251699447632]
be B-LOC [3.054917573928833, -3.332029342651367]
established. B-LOC [3.1152102947235107, -3.4665277004241943]
Here B-LOC [0.7485466599464417, -0.7317009568214417]
we B-LOC [0.8144291043281555, -0.892533004283905]
have B-LOC [1.3442881107330322, -1.0822815895080566]
examined B-LOC [1.2796525955200195, -1.1881858110427856]
three B-LOC [1.2110247611999512, -1.0948857069015503]
lateral B-LOC [0.9774638414382935, -1.3884457349777222]
gynandromorph B-LOC [0.863315224647522, -1.0733684301376343]
chickens B-LOC [0.8418704271316528, -1.1298118829727173]
(a B-LOC [0.8145455121994019, -0.9388377666473389]
rare, B-LOC [1.2174253463745117, -1.2519553899765015]
naturally B-LOC [1.0847703218460083, -1.4211019277572632]
occurring B-LOC [1.0951751470565796, -1.4241182804107666]
phenomenon B-LOC [0.7741816639900208, -1.203403115272522]
in B-LOC [0.8304399251937866, -0.9865522384643555]
which B-LOC [0.7498410940170288, -1.2410961389541626]
one B-LOC [0.48270687460899353, -1.047308087348938]
side B-LOC [0.6312180161476135, -0.9522865414619446]
of B-LOC [0.6767500042915344, -0.9742271304130554]
the B-LOC [0.7999290823936462, -1.1671793460845947]
animal B-LOC [0.6148043274879456, -1.405705213546753]
appears B-LOC [0.6360824108123779, -0.8754013776779175]
male B-LOC [0.7182255387306213, -0.9146606922149658]
and B-LOC [0.3734826147556305, -0.872226893901825]
the B-LOC [0.7902585864067078, -0.9210104942321777]
other B-LOC [0.750127911567688, -0.6218037605285645]
female) B-LOC [1.0168508291244507, -0.8306273818016052]
to B-LOC [1.5603234767913818, -1.5477499961853027]
investigate B-LOC [1.6781482696533203, -1.3928302526474]
the B-LOC [1.6101486682891846, -1.504462480545044]
sex-determining B-LOC [1.130768060684204, -1.3643087148666382]
mechanism B-LOC [1.1295313835144043, -1.5825681686401367]
in B-LOC [1.247732162475586, -1.483230710029602]
birds. B-LOC [0.9056121706962585, -1.1957298517227173]
These B-LOC [0.5735023021697998, -0.5843954086303711]
studies B-LOC [0.638888418674469, -0.5594479441642761]
demonstrated B-LOC [0.2560778856277466, -0.35534796118736267]
that B-LOC [0.331144243478775, -0.612191915512085]
gynandromorph B-LOC [0.38177892565727234, -0.44370463490486145]
birds B-LOC [0.43064966797828674, -0.45580458641052246]
are B-LOC [0.42538490891456604, -0.5106421709060669]
genuine B-LOC [0.23408789932727814, -0.4727834463119507]

male:female B-LOC [-1.2738084478769451e-05, -0.27403655648231506]
chimaeras, B-LOC [-0.11786413937807083, -0.33992788195610046]
and B-LOC [0.1344725340604782, -0.13996833562850952]
indicated B-LOC [0.0748916044831276, -0.19593271613121033]
that B-LOC [0.10072988271713257, -0.23367679119110107]
male B-LOC [0.11781050264835358, -0.06437936425209045]
and B-LOC [-0.07075932621955872, -0.42064300179481506]
female B-LOC [0.12352257966995239, -0.2098141610622406]
avian B-LOC [-0.05964640900492668, -0.2593233585357666]
somatic B-LOC [0.05142210051417351, -0.08639368414878845]
cells B-LOC [0.03828330710530281, -0.3208085596561432]
may B-LOC [0.4024816155433655, -0.39126986265182495]
have B-LOC [0.3554255962371826, -0.35019955039024353]
an B-LOC [0.32481756806373596, -0.39985421299934387]
inherent B-LOC [0.21009129285812378, -0.6021470427513123]
sex B-LOC [0.39512529969215393, -0.6847538948059082]
identity. B-LOC [0.38871249556541443, -0.5119393467903137]
To B-LOC [1.095912218093872, -1.5216596126556396]
test B-LOC [1.4211829900741577, -1.727278232574463]
this B-LOC [1.2122795581817627, -1.5099565982818604]
hypothesis, B-LOC [1.327458143234253, -1.5805659294128418]
we B-LOC [0.9630809426307678, -1.0769063234329224]
transplanted B-LOC [0.9381171464920044, -0.9733389019966125]
presumptive B-LOC [0.8987480998039246, -1.1559289693832397]
mesoderm B-LOC [0.7066698670387268, -1.0741554498672485]
between B-LOC [0.8315097689628601, -1.1351772546768188]
embryos B-LOC [0.7278737425804138, -0.9548208117485046]
of B-LOC [0.720989465713501, -1.2051129341125488]
reciprocal B-LOC [0.6993218660354614, -0.8727192282676697]
sexes B-LOC [0.7740060687065125, -0.9758055806159973]
to B-LOC [0.9681559205055237, -0.9851841330528259]
generate B-LOC [0.9285218119621277, -0.9089025259017944]
embryos B-LOC [0.9060015082359314, -1.010535717010498]
containing B-LOC [0.9616209864616394, -1.0661132335662842]
male:female B-LOC [0.7897409200668335, -1.0707893371582031]
chimaeric B-LOC [0.7317906022071838, -1.1537890434265137]
gonads. B-LOC [0.7465539574623108, -1.0741780996322632]
In B-LOC [1.1336015462875366, -1.2601298093795776]
contrast B-LOC [0.8560556769371033, -0.8605520129203796]
to B-LOC [0.8717745542526245, -0.9787001013755798]
the B-LOC [0.9283317923545837, -1.2172174453735352]
outcome B-LOC [0.902908205986023, -1.2449915409088135]
for B-LOC [0.9579625725746155, -1.074291467666626]
mammalian B-LOC [1.2754783630371094, -1.2285869121551514]
mixed-sex B-LOC [1.0779446363449097, -1.4911298751831055]
chimaeras, B-LOC [0.6972957253456116, -1.1542377471923828]
in B-LOC [0.8372288942337036, -0.9356808066368103]
chicken B-LOC [0.904127836227417, -1.1648095846176147]
mixed-sex B-LOC [1.1859675645828247, -1.3989360332489014]
chimaeras B-LOC [0.6810941696166992, -1.1148993968963623]
the B-LOC [0.9220238327980042, -1.0554803609848022]
donor B-LOC [0.8362395167350769, -1.2536195516586304]
cells B-LOC [0.8407353162765503, -1.0944328308105469]
were B-LOC [0.8871369957923889, -1.0825424194335938]
excluded B-LOC [1.153890609741211, -1.0867688655853271]
from B-LOC [1.0511500835418701, -1.14436936378479]
the B-LOC [1.0139621496200562, -1.2404825687408447]
functional B-LOC [0.9862368702888489, -1.2846723794937134]
structures B-LOC [1.0723812580108643, -1.1976417303085327]
of B-LOC [0.9334566593170166, -1.2263922691345215]
the B-LOC [0.8809120655059814, -1.2229474782943726]
host B-LOC [0.5965059995651245, -1.2017536163330078]
gonad. B-LOC [0.8116489052772522, -1.2450848817825317]
In B-LOC [0.08744639158248901, -0.4060173034667969]
an B-LOC [0.06236117705702782, -0.5477343201637268]
example B-LOC [0.28305014967918396, -0.6414217352867126]
where B-LOC [-0.08920846879482269, -0.48170578479766846]
female B-LOC [0.28475406765937805, -0.4634517431259155]
tissue B-LOC [0.0372176356613636, -0.559929609298706]
was B-LOC [0.3222018778324127, -0.49548080563545227]
transplanted B-LOC [0.33784720301628113, -0.478261798620224]
into B-LOC [0.08705037832260132, -0.4367007911205292]
a B-LOC [0.3686438798904419, -0.5530751347541809]
male B-LOC [0.27707719802856445, -0.5941082239151001]
host, B-LOC [0.011125023476779461, -0.6811735033988953]

donor O [-0.29134079813957214, 0.022263435646891594]
cells O [-0.32286596298217773, 0.2851453125476837]
contributing O [-0.39064261317253113, 0.2592043876647949]
to O [-0.44007086753845215, 0.38009247183799744]
the O [-0.43590250611305237, 0.3709166347980499]
developing O [-0.3514006733894348, 0.29849773645401]
testis O [-0.3363937735557556, 0.11243365705013275]
retained O [-0.3948821723461151, 0.29882311820983887]
a O [-0.4141683578491211, 0.38005372881889343]
female O [-0.23249277472496033, 0.15957634150981903]
identity O [-0.24922432005405426, 0.26406338810920715]
and O [-0.42814943194389343, 0.2982628643512726]
expressed O [-0.37964290380477905, 0.2575685381889343]
a O [-0.38264361023902893, 0.3107585310935974]
marker O [-0.3405422866344452, 0.03297353908419609]
of O [-0.5124208927154541, 0.03983149304986]
female O [-0.1960374116897583, 0.03015078417956829]
function. O [-0.3549560606479645, 0.018698066473007202]
Our O [-0.4243539869785309, 0.3572040796279907]
study O [-0.3588642179965973, 0.31797894835472107]
demonstrates O [-0.265216588973999, 0.3990326225757599]
that O [-0.7403083443641663, 0.45798423886299133]
avian O [-0.5861684679985046, 0.5538651347160339]
somatic O [-0.48965761065483093, 0.5418728590011597]
cells O [-0.46651750802993774, 0.32540157437324524]
possess O [-0.48977240920066833, 0.5698503851890564]
an O [-0.4902905523777008, 0.6490777134895325]
inherent O [-0.5529298186302185, 0.3094766139984131]
sex O [-0.428690105676651, 0.23505035042762756]
identity O [-0.3171694576740265, 0.3634392321109772]
and O [-0.6590060591697693, 0.5856645703315735]
that, O [-0.6994401216506958, 0.48699554800987244]
in O [-0.6100584864616394, 0.43109485507011414]
birds, O [-0.4334082007408142, 0.2833288311958313]
sexual O [-0.4789159893989563, 0.22148939967155457]
differentiation O [-0.5495312213897705, 0.2227940857410431]
is O [-0.3498847186565399, 0.3451601564884186]
substantively O [-0.2757774591445923, 0.26879021525382996]
cell O [-0.3888264000415802, 0.2359689176082611]
autonomous. O [-0.3901903033256531, 0.15592125058174133]

The B-LOC [1.7799184322357178, -2.267460584640503]
bacterial B-LOC [1.8048015832901, -2.0553677082061768]
type B-LOC [2.1297996044158936, -2.269538164138794]
VI B-LOC [2.093088388442993, -2.4355032444000244]
secretion B-LOC [2.0406100749969482, -2.1348865032196045]
system B-LOC [1.6390876770019531, -2.2147605419158936]
(T6SS) B-LOC [2.024101734161377, -2.226112127304077]
is B-LOC [2.2066633701324463, -2.2083075046539307]
a B-LOC [2.0753114223480225, -2.191293954849243]
large B-LOC [2.1943271160125732, -2.1931838989257812]
multicomponent, B-LOC [2.2443273067474365, -2.3804214000701904]
dynamic B-LOC [2.211707592010498, -2.459416151046753]
macromolecular B-LOC [2.264944076538086, -2.251636028289795]
machine B-LOC [1.8338425159454346, -2.2712342739105225]
that B-LOC [1.8067231178283691, -2.2437024116516113]
has B-LOC [2.606320381164551, -2.380155324935913]
an B-LOC [2.434293746948242, -2.4142298698425293]
important B-LOC [2.246412992477417, -2.2145793437957764]
role B-LOC [2.2201178073883057, -2.3799188137054443]
in B-LOC [2.299084424972534, -2.3879776000976562]
the B-LOC [2.2140493392944336, -2.09684419631958]
ecology B-LOC [2.37109112739563, -2.3093578815460205]
of B-LOC [2.2868149280548096, -2.2775356769561768]
many B-LOC [2.383452892303467, -2.282184600830078]
Gram-negative B-LOC [2.568711996078491, -2.4547884464263916]
bacteria. B-LOC [2.146162271499634, -2.3192384243011475]
T6SS B-LOC [1.463670253753662, -1.4033725261688232]
is B-LOC [1.6024781465530396, -1.3322386741638184]
responsible B-LOC [1.490553379058838, -1.1400924921035767]
for B-LOC [1.240234613418579, -1.0203291177749634]
translocation B-LOC [1.4230037927627563, -1.1906747817993164]
of B-LOC [1.5232188701629639, -1.0985615253448486]
a B-LOC [1.7792668342590332, -1.350279688835144]
wide B-LOC [1.7755811214447021, -1.6406810283660889]
range B-LOC [1.7313328981399536, -1.5525516271591187]
of B-LOC [1.5285903215408325, -1.2850353717803955]
toxic B-LOC [1.6019978523254395, -1.6077747344970703]
effector B-LOC [1.4521772861480713, -1.360068440437317]
molecules, B-LOC [1.2690587043762207, -1.2857143878936768]
allowing B-LOC [1.0223687887191772, -1.0574473142623901]
predatory B-LOC [1.3613178730010986, -1.4711462259292603]
cells B-LOC [1.130263328552246, -1.2637512683868408]
to B-LOC [1.2014529705047607, -1.0163201093673706]
kill B-LOC [1.359938383102417, -1.2184245586395264]
both B-LOC [0.6971949934959412, -0.7850210070610046]
prokaryotic B-LOC [1.0040420293807983, -1.1745359897613525]
as B-LOC [0.9821441769599915, -0.7459772825241089]
well B-LOC [0.9801798462867737, -0.9614428877830505]
as B-LOC [1.3087096214294434, -1.1722939014434814]
eukaryotic B-LOC [1.3037368059158325, -1.1481465101242065]
prey B-LOC [1.5101268291473389, -1.4953382015228271]
cells. B-LOC [1.1267130374908447, -1.419633388519287]
The B-LOC [0.5876708626747131, -0.5679352879524231]
T6SS B-LOC [0.5007333755493164, -0.5991454720497131]
organelle B-LOC [0.39475274085998535, -0.88776695728302]
is B-LOC [0.5506102442741394, -0.5499451756477356]
functionally B-LOC [0.7739256620407104, -0.7267870903015137]
analogous B-LOC [0.6562628149986267, -0.7952489256858826]
to B-LOC [0.4414568245410919, -0.7027178406715393]
contractile B-LOC [0.4136519432067871, -0.6289194822311401]
tails B-LOC [0.48083803057670593, -0.7291067242622375]
of B-LOC [0.5382444858551025, -0.696133017539978]
bacteriophages B-LOC [0.47430670261383057, -0.7704853415489197]
and B-LOC [0.08347609639167786, -0.47584885358810425]
is B-LOC [0.7126965522766113, -0.7137592434883118]
thought B-LOC [0.665052592754364, -0.6821733117103577]
to B-LOC [0.46194592118263245, -0.7081271409988403]
attack B-LOC [0.415789395570755, -0.5432940721511841]
cells B-LOC [0.32234880328178406, -0.7377627491950989]
by B-LOC [0.1492825299501419, -0.24369622766971588]
initially B-LOC [0.1431281566619873, -0.1591961532831192]
penetrating B-LOC [0.2248649150133133, -0.4084133207798004]
them B-LOC [0.3886951506137848, -0.5071138739585876]
with B-LOC [0.23421120643615723, -0.3858085870742798]
a B-LOC [0.5030763745307922, -0.2607382535934448]
trimeric B-LOC [0.3779487907886505, -0.348093718290329]
protein B-LOC [0.297664612531662, -0.47706085443496704]
complex B-LOC [0.2440890073776245, -0.38500887155532837]
called B-LOC [0.6751661896705627, -0.33452633023262024]
the B-LOC [0.3584037125110626, -0.39652907848358154]

VgrG B-LOC [0.9135636687278748, -1.6656537055969238]
spike. B-LOC [1.2005970478057861, -1.8762654066085815]
Neither B-LOC [2.4437544345855713, -2.486720561981201]
the B-LOC [2.6291916370391846, -2.6016314029693604]
exact B-LOC [2.7603437900543213, -2.4545862674713135]
protein B-LOC [2.227534532546997, -2.5431840419769287]
composition B-LOC [2.396580696105957, -2.267648935317993]
of B-LOC [2.3602049350738525, -2.4179818630218506]
the B-LOC [2.2298648357391357, -1.9897462129592896]
T6SS B-LOC [1.3653039932250977, -1.9072811603546143]
organelle B-LOC [2.134681463241577, -2.4758055210113525]
nor B-LOC [2.491180181503296, -2.438117265701294]
the B-LOC [2.618673086166382, -2.701805830001831]
mechanisms B-LOC [2.321561574935913, -2.4325788021087646]
of B-LOC [2.2784712314605713, -2.544700860977173]
effector B-LOC [2.026616334915161, -2.5350534915924072]
selection B-LOC [1.9708266258239746, -2.548161745071411]
and B-LOC [2.296912431716919, -2.4624836444854736]
delivery B-LOC [2.046982526779175, -2.4878203868865967]
are B-LOC [2.8000032901763916, -2.7299299240112305]
known. B-LOC [2.6994221210479736, -2.6686837673187256]
Here O [-0.39099204540252686, 0.1736283153295517]
we O [-0.601572573184967, 0.32017993927001953]
report O [-0.5988801121711731, 0.44621944427490234]
that O [-0.8841050267219543, 0.5153698921203613]
proteins O [-0.2574692964553833, 0.2853364646434784]
from O [-0.22988976538181305, 0.44721922278404236]
the O [-0.3103141486644745, 0.36844488978385925]
PAAR O [-0.3779388964176178, 0.17004042863845825]
(proline-alanine-alanine-arginine) O [-0.32573631405830383, 0.2559385597705841]
repeat O [-0.28545916080474854, 0.411686509847641]
superfamily O [-0.3701470196247101, 0.11232473701238632]
form O [-0.3372689187526703, 0.41018053889274597]
a O [-0.4188259243965149, 0.3724934160709381]
sharp O [-0.3365029990673065, 0.17460601031780243]
conical O [-0.41810113191604614, 0.21042758226394653]
extension O [-0.31852400302886963, 0.2127557396888733]
on O [-0.3468783497810364, 0.3350278437137604]
the O [-0.3163128197193146, 0.4009314179420471]
VgrG O [-0.5921271443367004, 0.2817264497280121]
spike, O [-0.3568769693374634, 0.29617759585380554]
which O [-0.5917043089866638, 0.3146536946296692]
is O [-0.5793169140815735, 0.32906413078308105]
further O [-0.5483280420303345, 0.34917008876800537]
involved O [-0.6098319292068481, 0.27656832337379456]
in O [-0.6214972734451294, 0.5106310248374939]
attaching O [-0.3101505637168884, 0.326605886220932]
effector O [-0.21560344099998474, 0.27551859617233276]
domains O [-0.24922595918178558, 0.3564443290233612]
to O [-0.16506658494472504, 0.1616755574941635]
the O [-0.19744691252708435, 0.17661899328231812]
spike. O [-0.1115044504404068, 0.08705716580152512]
The B-LOC [0.9217959046363831, -0.886474072933197]
crystal B-LOC [1.7152879238128662, -1.1394915580749512]
structures B-LOC [1.6840839385986328, -1.167412281036377]
of B-LOC [1.3671663999557495, -1.0919063091278076]
two B-LOC [1.162420630455017, -0.976378321647644]
PAAR-repeat B-LOC [0.8600156307220459, -0.9150082468986511]
proteins B-LOC [1.107851266860962, -1.0203092098236084]
bound B-LOC [1.3717252016067505, -0.9677936434745789]
to B-LOC [1.081491470336914, -1.007699728012085]
VgrG-like B-LOC [0.33070313930511475, -0.7478681206703186]
partners B-LOC [1.1693410873413086, -1.1207548379898071]
show B-LOC [1.024430751800537, -0.7958611845970154]
that B-LOC [0.7025370001792908, -0.8276588320732117]
these B-LOC [1.0285100936889648, -1.0188751220703125]
proteins B-LOC [1.1715455055236816, -1.016505479812622]
sharpen B-LOC [0.9650713801383972, -1.1357557773590088]
the B-LOC [1.190329909324646, -1.3299026489257812]
tip B-LOC [0.9010192155838013, -1.4580224752426147]
of B-LOC [0.9626017212867737, -1.1695574522018433]
the B-LOC [1.1344740390777588, -1.1242284774780273]
T6SS B-LOC [0.7373080849647522, -1.0247448682785034]
spike B-LOC [0.8201170563697815, -1.0750575065612793]
complex. B-LOC [0.9548322558403015, -1.2363897562026978]
We O [-0.23029495775699615, 0.035270195454359055]
demonstrate B-LOC [0.08106628060340881, 0.042694129049777985]
that O [-0.14578358829021454, -0.08342708647251129]
PAAR B-LOC [0.3461301326751709, -0.4089822471141815]

proteins B-LOC [0.1855345517396927, -0.6123409867286682]
are B-LOC [0.35212442278862, -0.5071893930435181]
essential B-LOC [0.2234635055065155, -0.34933751821517944]
for B-LOC [0.06799814105033875, -0.4160672128200531]
T6SS-mediated B-LOC [0.30299097299575806, -0.3991880714893341]
secretion B-LOC [0.5287826657295227, -0.18363451957702637]
and B-LOC [0.22081613540649414, -0.3675864338874817]
target B-LOC [0.5173376202583313, -0.6171230673789978]
cell B-LOC [0.023115530610084534, -0.6348037123680115]
killing B-LOC [0.41030561923980713, -0.3466765880584717]
by B-LOC [0.3145260512828827, -0.4252071678638458]
Vibrio B-LOC [-0.030429599806666374, -0.42247745394706726]
cholerae B-LOC [0.19334277510643005, -0.29704341292381287]
and B-LOC [0.2264401912689209, -0.26035210490226746]
Acinetobacter B-LOC [0.31353580951690674, -0.6514024138450623]
baylyi. B-LOC [0.16144013404846191, -0.6540514230728149]
Our B-LOC [0.4602956771850586, -0.5556396245956421]
results B-LOC [0.790406346321106, -0.5800806879997253]
indicate B-LOC [0.6296995282173157, -0.46429476141929626]
a B-LOC [0.685893177986145, -0.7977012991905212]
new B-LOC [0.8726730346679688, -0.8910285830497742]
model B-LOC [0.7827140688896179, -0.9805596470832825]
of B-LOC [0.7233196496963501, -0.9113926291465759]
the B-LOC [0.907466471195221, -0.9254969954490662]
T6SS B-LOC [0.6382240653038025, -1.0117024183273315]
organelle B-LOC [0.7352619767189026, -1.1474835872650146]
in B-LOC [0.5621041655540466, -0.7874144315719604]
which B-LOC [0.535601019859314, -0.9680067896842957]
the B-LOC [0.7499390244483948, -0.8555757999420166]
VgrG-PAAR B-LOC [0.16456454992294312, -0.6526978611946106]
spike B-LOC [0.35972860455513, -0.8343687653541565]
complex B-LOC [0.4053760766983032, -0.927856981754303]
is B-LOC [0.8891047835350037, -0.9678544402122498]
decorated B-LOC [0.8260582089424133, -0.8231714963912964]
with B-LOC [0.6347551345825195, -0.9217303395271301]
multiple B-LOC [0.656406819820404, -0.9962337017059326]
effectors B-LOC [0.41084012389183044, -0.8826428651809692]
that B-LOC [0.6221405863761902, -1.0108929872512817]
are B-LOC [0.7881502509117126, -1.0006046295166016]
delivered B-LOC [0.5427661538124084, -0.7205867171287537]
simultaneously B-LOC [0.47123071551322937, -1.0300911664962769]
into B-LOC [0.1422213613986969, -0.6681179404258728]
target B-LOC [0.6347292065620422, -1.01587975025177]
cells B-LOC [0.2583378255367279, -0.8020130395889282]
in B-LOC [0.2964182198047638, -0.7195665240287781]
a B-LOC [0.6312620639801025, -0.716894805431366]
single B-LOC [0.7590427994728088, -1.1608550548553467]
contraction-driven B-LOC [0.5470096468925476, -0.8737116456031799]
translocation B-LOC [0.4433707594871521, -0.7937068343162537]
event. B-LOC [0.22796224057674408, -0.6768864989280701]

Improved B-LOC [2.4779248237609863, -2.961045026779175]
sequencing B-LOC [3.003612756729126, -3.3391332626342773]
technologies B-LOC [3.080263614654541, -3.1057982444763184]
offer B-LOC [2.9738590717315674, -2.864342451095581]
unprecedented B-LOC [2.9968128204345703, -3.2235004901885986]
opportunities B-LOC [3.137205123901367, -3.4249069690704346]
for B-LOC [2.943202257156372, -3.137852907180786]
investigating B-LOC [3.1980888843536377, -3.349867820739746]
the B-LOC [3.4212217330932617, -3.4941980838775635]
role B-LOC [3.371394395828247, -3.6483371257781982]
of B-LOC [3.17345929145813, -3.5298731327056885]
rare B-LOC [3.114802122116089, -3.488715887069702]
genetic B-LOC [3.1874115467071533, -3.630702257156372]
variation B-LOC [3.0834343433380127, -3.5229146480560303]
in B-LOC [2.931720018386841, -3.4636266231536865]
common B-LOC [3.0088908672332764, -3.6161727905273438]
disease. B-LOC [3.196955680847168, -3.51613187789917]
However, B-LOC [3.2546308040618896, -3.197338581085205]
there B-LOC [3.2069079875946045, -3.004842519760132]
are B-LOC [3.2505040168762207, -3.089432954788208]
considerable B-LOC [3.247478723526001, -3.132704496383667]
challenges B-LOC [3.3850393295288086, -3.494154691696167]
with B-LOC [3.203306198120117, -3.1245453357696533]
respect B-LOC [3.1693623065948486, -3.253154754638672]
to B-LOC [3.1676881313323975, -3.453343152999878]
study B-LOC [3.298877239227295, -3.580089807510376]
design, B-LOC [3.3987863063812256, -3.5601806640625]
data B-LOC [3.320934772491455, -3.673053741455078]
analysis B-LOC [3.262110471725464, -3.6327993869781494]
and B-LOC [3.238966226577759, -3.4376628398895264]
replication. B-LOC [3.471158504486084, -3.6676433086395264]
Using B-LOC [1.591120719909668, -2.296093463897705]
pooled B-LOC [2.877065896987915, -2.6190521717071533]
next-generation B-LOC [2.419658899307251, -2.533121347427368]
sequencing B-LOC [2.455535650253296, -2.4840941429138184]
of B-LOC [2.2599709033966064, -2.5897767543792725]
507 B-LOC [2.819777727127075, -2.4971001148223877]
genes B-LOC [2.101912260055542, -2.3833935260772705]
implicated B-LOC [2.1464645862579346, -2.2605538368225098]
in B-LOC [2.0357916355133057, -2.268808126449585]
the B-LOC [2.607494592666626, -2.514634132385254]
repair B-LOC [2.2758429050445557, -2.3604955673217773]
of B-LOC [2.1655404567718506, -2.549654960632324]
DNA B-LOC [2.404432535171509, -2.76519513130188]
in B-LOC [2.3080201148986816, -2.4871747493743896]
1,150 B-LOC [3.0511763095855713, -2.5886595249176025]
samples, B-LOC [2.410517454147339, -2.6676113605499268]
an B-LOC [2.2248032093048096, -2.3006410598754883]
analytical B-LOC [2.416457414627075, -2.550719976425171]
strategy B-LOC [2.500887393951416, -2.3502988815307617]
focused B-LOC [2.587534189224243, -2.4282820224761963]
on B-LOC [2.618929147720337, -2.4379541873931885]
protein-truncating B-LOC [2.0642483234405518, -2.396836757659912]
variants B-LOC [2.494770050048828, -2.4974148273468018]
(PTVs) B-LOC [3.003161668777466, -2.9023232460021973]
and B-LOC [2.4627199172973633, -2.43503999710083]
a B-LOC [2.302151679992676, -2.2439756393432617]
large-scale B-LOC [2.529942512512207, -2.4195072650909424]
sequencing B-LOC [2.314060926437378, -2.3819925785064697]
case–control B-LOC [2.5306637287139893, -2.545644760131836]
replication B-LOC [2.2701001167297363, -2.287370443344116]
experiment B-LOC [1.8723437786102295, -2.3208084106445312]
in B-LOC [2.0387179851531982, -2.2921929359436035]
13,642 B-LOC [2.729059934616089, -2.1699917316436768]
individuals, B-LOC [1.8829302787780762, -2.155684471130371]
here B-LOC [1.0118032693862915, -1.137374758720398]
we B-LOC [0.545756995677948, -0.6400208473205566]
show B-LOC [0.357347697019577, -0.3987240493297577]
that B-LOC [0.18525424599647522, -0.3698095977306366]
rare B-LOC [1.1480783224105835, -1.3268389701843262]
PTVs B-LOC [1.2927610874176025, -1.25499427318573]
in B-LOC [0.24540966749191284, -0.15946567058563232]
the B-LOC [0.45243725180625916, -0.3934782147407532]
p53-inducible B-LOC [0.6269257664680481, -0.9131839871406555]
protein B-LOC [0.2210291028022766, -0.8016110062599182]

phosphatase B-LOC [1.3269612789154053, -1.785682201385498]
PPM1D B-LOC [1.3319854736328125, -1.5617789030075073]
are B-LOC [1.696070671081543, -1.8014237880706787]
associated B-LOC [1.655531406402588, -1.722083568572998]
with B-LOC [1.4733606576919556, -1.8336663246154785]
predisposition B-LOC [2.003774642944336, -2.0850000381469727]
to B-LOC [1.641758680343628, -1.9679332971572876]
breast B-LOC [1.671351671218872, -1.8849461078643799]
cancer B-LOC [1.7951021194458008, -2.203422784805298]
and B-LOC [1.6926121711730957, -1.8349477052688599]
ovarian B-LOC [1.7392808198928833, -2.271968364715576]
cancer. B-LOC [1.7311033010482788, -2.1228652000427246]
PPM1D B-LOC [0.6967085599899292, -0.9174888730049133]
PTV B-LOC [0.8319018483161926, -0.8229447603225708]
mutations B-LOC [1.0612996816635132, -0.9737064838409424]
were B-LOC [1.1166750192642212, -1.0156981945037842]
present B-LOC [1.0939558744430542, -1.051818609237671]
in B-LOC [1.0568866729736328, -1.0541572570800781]
25 B-LOC [1.8066039085388184, -0.8938449621200562]
out B-LOC [1.4566943645477295, -0.7562652826309204]
of B-LOC [1.462446928024292, -0.7940230369567871]
7,781 B-LOC [1.9838606119155884, -0.8444530963897705]
cases B-LOC [1.0901622772216797, -1.0081171989440918]
versus B-LOC [1.1407296657562256, -1.1324049234390259]
1 B-LOC [1.9180901050567627, -0.8352325558662415]
out B-LOC [1.632942795753479, -0.7098701596260071]
of B-LOC [1.5762799978256226, -0.8861225247383118]
5,861 B-LOC [1.9972115755081177, -0.8460134267807007]
controls B-LOC [1.010361671447754, -1.1132700443267822]
(P B-LOC [1.3086295127868652, -1.1470139026641846]
= B-LOC [0.8036016821861267, -0.9815324544906616]
1.12 B-LOC [1.6715776920318604, -1.1026016473770142]
× B-LOC [1.057660460472107, -1.342307209968567]
10−5), B-LOC [1.6370723247528076, -1.29715895652771]
including B-LOC [1.3513848781585693, -1.0953866243362427]
18 B-LOC [1.5239112377166748, -1.0571939945220947]
mutations B-LOC [1.1891483068466187, -1.1763179302215576]
in B-LOC [1.1699817180633545, -1.1719701290130615]
6,912 B-LOC [1.9609038829803467, -0.9980853199958801]
individuals B-LOC [0.912530243396759, -1.1290613412857056]
with B-LOC [1.2346811294555664, -1.1302692890167236]
breast B-LOC [0.8838071823120117, -0.9874655604362488]
cancer B-LOC [1.0570087432861328, -1.1107439994812012]
(P B-LOC [1.0932326316833496, -1.153496503829956]
= B-LOC [0.5446867346763611, -0.9570068717002869]
2.42 B-LOC [1.194024682044983, -0.9226958751678467]
× B-LOC [0.7974294424057007, -1.2840733528137207]
10−4) B-LOC [1.4548020362854004, -1.3079688549041748]
and B-LOC [1.2443424463272095, -1.1152783632278442]
12 B-LOC [1.6170397996902466, -1.3523503541946411]
mutations B-LOC [1.148844838142395, -1.2508478164672852]
in B-LOC [1.0760380029678345, -1.2731080055236816]
1,121 B-LOC [1.8216105699539185, -1.2896530628204346]
individuals B-LOC [1.0221227407455444, -1.3344889879226685]
with B-LOC [1.098448395729065, -1.2927134037017822]
ovarian B-LOC [0.9948375821113586, -1.3917756080627441]
cancer B-LOC [1.02730393409729, -1.2689018249511719]
(P B-LOC [1.1615912914276123, -1.2279999256134033]
= B-LOC [0.6610180735588074, -0.9670568108558655]
3.10 B-LOC [1.144529104232788, -1.0017017126083374]
× B-LOC [0.9449609518051147, -1.0084134340286255]
10−9). B-LOC [1.2956205606460571, -1.288346529006958]
Notably, B-LOC [1.0503203868865967, -0.998586118221283]
all B-LOC [1.0229663848876953, -1.059709072113037]
of B-LOC [1.078705072402954, -0.9394426941871643]
the B-LOC [0.9563223719596863, -0.8504553437232971]
identified B-LOC [1.0252982378005981, -1.0566926002502441]
PPM1D B-LOC [0.5771563649177551, -0.8039164543151855]
PTVs B-LOC [0.5866662859916687, -0.76408451795578]
were B-LOC [0.9732136130332947, -0.9837308526039124]
mosaic B-LOC [1.1954505443572998, -1.2176791429519653]
in B-LOC [0.5570421814918518, -0.8105509281158447]

lymphocyte B-LOC [0.36315101385116577, -0.7128911018371582]
DNA B-LOC [0.6436780691146851, -0.9157837629318237]
and B-LOC [0.6114179491996765, -0.6492099165916443]
clustered B-LOC [0.8523129820823669, -0.7818920016288757]
within B-LOC [0.7072862982749939, -0.8101515769958496]
a B-LOC [0.7212814092636108, -0.6838589310646057]
370-base-pair B-LOC [0.6892117857933044, -0.7531751990318298]
region B-LOC [0.532779335975647, -0.917238175868988]
in B-LOC [0.5514808893203735, -0.8163885474205017]
the B-LOC [0.7610272169113159, -0.8836309909820557]
final B-LOC [0.7411743402481079, -0.9176048040390015]
exon B-LOC [0.623113214969635, -0.885138213634491]
of B-LOC [0.6250213980674744, -1.0291242599487305]
the B-LOC [0.7969937920570374, -0.9188044667243958]
gene, B-LOC [0.5305898189544678, -0.9497538805007935]
carboxy-terminal B-LOC [0.6524572968482971, -0.9155659675598145]
to B-LOC [0.5759013295173645, -0.8831762075424194]
the B-LOC [0.8023896813392639, -0.8552331328392029]
phosphatase B-LOC [0.43931058049201965, -0.9179704785346985]
catalytic B-LOC [0.7648935914039612, -1.172982931137085]
domain. B-LOC [0.5233590006828308, -0.9444977641105652]
Functional O [0.1878797709941864, 0.24876844882965088]
studies O [-0.07012158632278442, 0.35735026001930237]
demonstrate O [-0.1720363199710846, 0.3681739270687103]
that O [-0.5614377856254578, 0.2755250036716461]
the O [0.04768062382936478, 0.2913314402103424]
mutations O [-0.012562711723148823, 0.25436416268348694]
result O [-0.4590723216533661, 0.6083282232284546]
in O [-0.7007372379302979, 0.6785394549369812]
enhanced O [-0.6587244272232056, 0.6991235613822937]
suppression O [-0.5847575664520264, 0.7555097341537476]
of O [-0.6669589877128601, 0.765926718711853]
p53 O [-0.5284786820411682, 0.3703666627407074]
in O [-0.710798978805542, 0.6175286173820496]
response O [-0.30258363485336304, 0.5738763809204102]
to O [-0.28795191645622253, 0.5251646637916565]
ionizing O [-0.24921146035194397, 0.4303162395954132]
radiation O [-0.2751241624355316, 0.2872268855571747]
exposure, O [-0.19188974797725677, 0.4157971441745758]
suggesting O [0.015947038307785988, 0.19909153878688812]
that O [-0.20143088698387146, -0.09844320267438889]
the B-LOC [0.11047780513763428, 0.061061277985572815]
mutant B-LOC [-0.03256513550877571, -0.11077480018138885]
alleles B-LOC [0.22231367230415344, -0.2359972596168518]
encode B-LOC [0.34396907687187195, -0.2351996898651123]
hyperactive B-LOC [0.0008531795465387404, -0.004141754005104303]
PPM1D B-LOC [-0.007010442670434713, -0.023706825450062752]
isoforms. B-LOC [-0.0030093989335000515, -0.2885783016681671]
Thus, O [-0.09580682963132858, 0.06829184293746948]
although O [-0.16379281878471375, 0.005896953400224447]
the B-LOC [0.5141618251800537, -0.39334729313850403]
mutations B-LOC [0.2316916435956955, -0.3230924606323242]
cause B-LOC [0.13307762145996094, -0.20833037793636322]
premature B-LOC [-0.09234859049320221, -0.16659390926361084]
protein B-LOC [0.15172892808914185, -0.6296460032463074]
truncation, B-LOC [0.19047893583774567, -0.38946494460105896]
they B-LOC [0.4209773540496826, -0.4447874128818512]
do B-LOC [0.4309985637664795, -0.2781958281993866]
not B-LOC [0.16756653785705566, 0.07081759721040726]
result B-LOC [0.09679809212684631, -0.25726252794265747]
in O [-0.10318675637245178, -0.09332595765590668]
the B-LOC [0.15695041418075562, -0.32815173268318176]
simple B-LOC [0.05355338379740715, -0.45477592945098877]
loss-of-function B-LOC [0.22503556311130524, -0.5617541670799255]
effect B-LOC [-0.021733982488512993, -0.509614884853363]
typically B-LOC [0.5640774369239807, -0.6522493958473206]
associated B-LOC [0.28108811378479004, -0.5534871220588684]
with B-LOC [0.49909985065460205, -0.6810599565505981]
this B-LOC [0.43609604239463806, -0.7051629424095154]
class B-LOC [0.573093593120575, -0.9433020353317261]
of B-LOC [0.3917545974254608, -0.6787415742874146]
variant, B-LOC [0.24927127361297607, -0.772404134273529]
but O [-0.0720900148153305, 0.036488424986600876]
instead B-LOC [0.062050167471170425, -0.03365880623459816]
probably B-LOC [0.2735796272754669, -0.4339337646961212]
have B-LOC [0.22211375832557678, -0.38742655515670776]
a B-LOC [0.1290774643421173, -0.3874571919441223]

gain-of-function B-LOC [0.3113939166069031, -0.823443591594696]
effect. B-LOC [0.5239399671554565, -0.8418670296669006]
Our B-LOC [1.0594385862350464, -1.3388140201568604]
results B-LOC [1.1613798141479492, -1.4314807653427124]
have B-LOC [1.7512153387069702, -1.9771451950073242]
implications B-LOC [1.9941624402999878, -2.240994691848755]
for B-LOC [1.8094359636306763, -2.141871213912964]
the B-LOC [1.7355961799621582, -2.102079153060913]
detection B-LOC [1.670999526977539, -1.9754843711853027]
and B-LOC [1.778709888458252, -2.2463021278381348]
management B-LOC [1.9927093982696533, -2.304887056350708]
of B-LOC [1.6860034465789795, -2.2696423530578613]
breast B-LOC [1.4469839334487915, -1.8197903633117676]
and B-LOC [1.5091464519500732, -1.9966247081756592]
ovarian B-LOC [1.423370599746704, -2.0295369625091553]
cancer B-LOC [1.4509913921356201, -2.0261127948760986]
risk. B-LOC [1.7839970588684082, -2.010106325149536]
More B-LOC [1.4032891988754272, -1.6733903884887695]
generally, B-LOC [1.6418015956878662, -1.3621771335601807]
these B-LOC [1.357839822769165, -1.4784717559814453]
data B-LOC [1.28291916847229, -1.656632423400879]
provide B-LOC [1.4753527641296387, -1.655107021331787]
new B-LOC [1.5576837062835693, -1.8463518619537354]
insights B-LOC [1.6234400272369385, -1.8281667232513428]
into B-LOC [1.6549930572509766, -1.8402769565582275]
the B-LOC [1.805314302444458, -1.9917411804199219]
role B-LOC [1.8899719715118408, -2.008415937423706]
of B-LOC [1.5428807735443115, -1.9710237979888916]
rare B-LOC [1.59928560256958, -1.532109022140503]
and B-LOC [1.5643205642700195, -1.599132776260376]
of B-LOC [1.4493024349212646, -1.974511742591858]
mosaic B-LOC [1.3805603981018066, -1.7492902278900146]
genetic B-LOC [1.4620519876480103, -1.8234107494354248]
variants B-LOC [1.4893100261688232, -1.6541482210159302]
in B-LOC [1.4743046760559082, -2.1467530727386475]
common B-LOC [1.6337852478027344, -2.100400686264038]
conditions, B-LOC [1.7105995416641235, -2.0047452449798584]
and B-LOC [1.6834166049957275, -1.8905664682388306]
the B-LOC [1.881699562072754, -2.090276002883911]
use B-LOC [1.7404935359954834, -2.116729497909546]
of B-LOC [1.7601145505905151, -2.226288080215454]
sequencing B-LOC [1.6530120372772217, -2.070415735244751]
in B-LOC [1.7117730379104614, -2.3342597484588623]
their B-LOC [1.8392333984375, -1.9080997705459595]
identification. B-LOC [1.6844282150268555, -1.9727014303207397]

The B-LOC [0.6126532554626465, -1.2282907962799072]
functional B-LOC [1.03694486618042, -1.4215466976165771]
heart B-LOC [0.751755952835083, -1.2753783464431763]
is B-LOC [1.2007501125335693, -1.2540069818496704]
comprised B-LOC [1.0839365720748901, -1.2107257843017578]
of B-LOC [0.9947867393493652, -1.1122616529464722]
distinct B-LOC [1.109773874282837, -1.4777354001998901]
mesoderm-derived B-LOC [0.8531983494758606, -1.40126633644104]
lineages B-LOC [0.8192335963249207, -1.1335387229919434]
including B-LOC [0.8258230090141296, -1.0226635932922363]
cardiomyocytes, B-LOC [0.5209436416625977, -1.0434174537658691]
endothelial B-LOC [0.4081067740917206, -0.7777919173240662]
cells B-LOC [0.41737282276153564, -0.9060185551643372]
and B-LOC [0.9923712611198425, -1.0530576705932617]
vascular B-LOC [0.5492634773254395, -1.2023942470550537]
smooth B-LOC [0.6869428753852844, -1.0740747451782227]
muscle B-LOC [0.6866125464439392, -1.0371934175491333]
cells. B-LOC [0.6268366575241089, -1.0862945318222046]
Studies B-LOC [0.4104873836040497, -0.29493585228919983]
in B-LOC [0.7667065262794495, -0.728770911693573]
the B-LOC [0.7793528437614441, -0.5935409665107727]
mouse B-LOC [0.3539448082447052, -0.7730365991592407]
embryo B-LOC [0.32169076800346375, -0.5572327971458435]
and B-LOC [0.660372793674469, -0.7869215607643127]
the B-LOC [1.1115385293960571, -0.8733793497085571]
mouse B-LOC [0.4523278474807739, -0.7681287527084351]
embryonic B-LOC [0.3638146221637726, -0.6738280653953552]
stem B-LOC [0.847140908241272, -1.024472951889038]
cell B-LOC [0.37937358021736145, -0.8558932542800903]
differentiation B-LOC [0.3632276952266693, -0.7458838820457458]
model B-LOC [0.5462973713874817, -0.8732801079750061]
have B-LOC [0.6366899609565735, -0.4176955819129944]
provided B-LOC [0.6949871182441711, -0.5753077864646912]
evidence B-LOC [0.3252151906490326, -0.18305742740631104]
indicating B-LOC [0.32746246457099915, -0.2285756915807724]
that B-LOC [0.04020179435610771, -0.20140883326530457]
these B-LOC [0.33351755142211914, -0.3412947356700897]
three B-LOC [0.3604486286640167, -0.5214630961418152]
lineages B-LOC [0.05056903883814812, -0.2851320803165436]
develop B-LOC [0.12415510416030884, -0.20810171961784363]
from B-LOC [0.10078772902488708, 0.07530255615711212]
a B-LOC [0.10521522164344788, -0.09379454702138901]
common B-LOC [0.040158867835998535, -0.2703971266746521]
Flk-1+ B-LOC [-0.1569218933582306, -0.16255345940589905]
(kinase B-LOC [-0.05959760770201683, -0.26258236169815063]
insert B-LOC [0.04344360902905464, -0.04022625461220741]
domain O [-0.11267050355672836, -0.07534562051296234]
protein B-LOC [-0.18209362030029297, -0.2990688979625702]
receptor, B-LOC [-0.22836308181285858, -0.30139654874801636]
also B-LOC [0.21977011859416962, -0.5199298858642578]
known B-LOC [0.3407655358314514, -0.29601219296455383]
as B-LOC [0.15129411220550537, -0.28555211424827576]
Kdr) B-LOC [-0.03246303275227547, -0.2404842972755432]
cardiovascular O [-0.30196166038513184, -0.15385490655899048]
progenitor O [-0.21581050753593445, -0.18191130459308624]
that B-LOC [-0.19387859106063843, -0.3933368921279907]
represents B-LOC [0.10281549394130707, -0.16847877204418182]
one B-LOC [-0.0393003486096859, -0.07243375480175018]
of O [-0.055479392409324646, 0.0364336334168911]
the B-LOC [0.11059167981147766, -0.10476063191890717]
earliest B-LOC [-0.006573272403329611, -0.06996925175189972]
stages B-LOC [-0.07906420528888702, -0.10597574710845947]
in B-LOC [-0.13292214274406433, -0.3321835696697235]
mesoderm B-LOC [0.038607362657785416, -0.40927281975746155]
specification B-LOC [-0.04274282976984978, -0.1726159155368805]
to B-LOC [0.06532147526741028, -0.38618233799934387]
the B-LOC [0.2777567505836487, -0.37189343571662903]
cardiovascular B-LOC [-0.06261628866195679, -0.5352484583854675]
lineages. B-LOC [0.020873041823506355, -0.49289265275001526]
To B-LOC [1.2103517055511475, -1.4215586185455322]
determine B-LOC [1.7907873392105103, -1.8646154403686523]
whether B-LOC [1.8220114707946777, -2.083669900894165]
a B-LOC [1.557081699371338, -1.6643812656402588]
comparable B-LOC [1.2785710096359253, -1.6266577243804932]
progenitor B-LOC [0.9276868104934692, -1.4028884172439575]
is B-LOC [1.7629163265228271, -1.9422101974487305]
present B-LOC [1.2650772333145142, -1.3069956302642822]
during B-LOC [0.992114245891571, -1.521250605583191]
human B-LOC [0.9789756536483765, -1.4694490432739258]

cardiogenesis, B-LOC [1.7817565202713013, -2.5580499172210693]
we B-LOC [1.9967594146728516, -2.3197124004364014]
analysed B-LOC [2.8538994789123535, -2.806809663772583]
the B-LOC [2.455584764480591, -2.5943591594696045]
development B-LOC [2.454007625579834, -2.7628889083862305]
of B-LOC [2.4944326877593994, -2.8224542140960693]
the B-LOC [2.416534185409546, -2.609032154083252]
cardiovascular B-LOC [2.1122629642486572, -2.8735601902008057]
lineages B-LOC [2.5456154346466064, -2.9745898246765137]
in B-LOC [2.390216588973999, -2.845409870147705]
human B-LOC [2.354135751724243, -2.872581720352173]
embryonic B-LOC [2.3574113845825195, -2.8308682441711426]
stem B-LOC [2.5740807056427, -3.1187350749969482]
cell B-LOC [2.2395756244659424, -2.9189364910125732]
differentiation B-LOC [2.2478346824645996, -2.876917600631714]
cultures. B-LOC [2.756856918334961, -2.8137400150299072]
Here O [-0.34021899104118347, -0.05084269866347313]
we O [-0.5812657475471497, 0.10879350453615189]
show O [-0.4668336808681488, 0.2524198293685913]
that O [-0.7173715233802795, 0.20328527688980103]
after O [-0.6779585480690002, 0.22969184815883636]
induction O [-0.3429206311702728, 0.06499391049146652]
with O [-0.37075576186180115, 0.03777344897389412]
combinations O [-0.32584694027900696, 0.1671103835105896]
of O [-0.21466520428657532, 0.07734963297843933]
activin O [-0.32158592343330383, -0.050117816776037216]
A, O [-0.350196897983551, 0.25956282019615173]
bone O [-0.28431323170661926, -0.0294055063277483]
morphogenetic O [-0.31606563925743103, 0.03327252343297005]
protein O [-0.3551495373249054, 0.05373789742588997]
4 O [-0.1081860214471817, 0.044810328632593155]
(BMP4), O [-0.11853142082691193, -0.016160795465111732]
basic O [-0.33143922686576843, 0.042782265692949295]
fibroblast O [-0.31520846486091614, 0.1963595747947693]
growth O [-0.45703306794166565, 0.1839558482170105]
factor O [-0.3453175723552704, 0.060331448912620544]
(bFGF, O [-0.27145951986312866, 0.06840517371892929]
also B-LOC [0.19445210695266724, -0.5336783528327942]
known B-LOC [-0.0035756020806729794, -0.23313261568546295]
as B-LOC [0.023915359750390053, -0.44251206517219543]
FGF2), O [-0.2127765417098999, 0.0489046648144722]
vascular O [-0.3417750895023346, -0.07567354291677475]
endothelial O [-0.44393447041511536, 0.13224169611930847]
growth O [-0.4010401666164398, 0.21733829379081726]
factor O [-0.3575626313686371, 0.1262190341949463]
(VEGF, O [-0.22379422187805176, -0.028199953958392143]
also B-LOC [0.5335366129875183, -0.7144818305969238]
known B-LOC [0.3529839813709259, -0.4712381064891815]
as B-LOC [0.28076961636543274, -0.4793238639831543]
VEGFA) O [-0.3506998121738434, -0.1331474483013153]
and O [-0.08879825472831726, 0.08475009351968765]
dickkopf O [-0.22717741131782532, -0.15734881162643433]
homolog O [-0.2774265706539154, 0.14066478610038757]
1 O [-0.21861785650253296, 0.04768901318311691]
(DKK1) O [-0.24997171759605408, 0.04263802617788315]
in O [-0.29961180686950684, 0.26036444306373596]
serum-free O [-0.21664497256278992, -0.012067170813679695]
media, O [-0.2663504481315613, 0.028248634189367294]
human O [-0.534236490726471, 0.09078013151884079]

embryonic-stem-cell-derived B-LOC [0.10457495599985123, -0.4651050865650177]
embryoid B-LOC [0.2523730993270874, -0.36014917492866516]
bodies B-LOC [0.26839861273765564, -0.3977110683917999]
generate B-LOC [0.45106789469718933, -0.24663576483726501]
a B-LOC [0.43870607018470764, -0.3286390006542206]
KDRlow/C-KIT(CD117)neg B-LOC [0.5892452597618103, -0.43695181608200073]
population B-LOC [0.0903797522187233, -0.33208951354026794]
that B-LOC [0.07079455256462097, -0.6648127436637878]
displays B-LOC [0.17779675126075745, -0.5064932107925415]
cardiac, B-LOC [0.13628140091896057, -0.4515317380428314]
endothelial B-LOC [0.011405731551349163, -0.12747709453105927]
and B-LOC [0.1392284482717514, -0.3968544900417328]
vascular B-LOC [0.10681667923927307, -0.6027936339378357]
smooth B-LOC [0.21681734919548035, -0.2739103138446808]
muscle B-LOC [0.1956373155117035, -0.48381754755973816]
potential B-LOC [0.112535260617733, -0.4589585065841675]
in B-LOC [-0.07242785394191742, -0.2683062255382538]
vitro B-LOC [0.13246382772922516, -0.385223925113678]
and, B-LOC [0.42523249983787537, -0.4265536367893219]
after B-LOC [0.1680150330066681, -0.5646661520004272]
transplantation, B-LOC [0.38491854071617126, -0.3797164857387543]
in B-LOC [0.09718979895114899, -0.34226977825164795]
vivo. B-LOC [0.20605787634849548, -0.540851891040802]
When B-LOC [1.212531566619873, -1.0603411197662354]
plated B-LOC [1.5537500381469727, -1.3057390451431274]
in B-LOC [1.3157038688659668, -1.0730897188186646]
monolayer B-LOC [1.7483975887298584, -1.4014661312103271]
cultures, B-LOC [1.4653804302215576, -1.2164520025253296]
these B-LOC [0.9194691777229309, -0.8217571973800659]
KDRlow/C-KITneg B-LOC [0.9800022840499878, -0.9016667008399963]
cells B-LOC [1.117942452430725, -0.972791850566864]
differentiate B-LOC [1.4320346117019653, -1.190122365951538]
to B-LOC [1.598815679550171, -1.1684319972991943]
generate B-LOC [1.4928154945373535, -1.1101717948913574]
populations B-LOC [1.4566503763198853, -1.1052356958389282]
consisting B-LOC [1.7324717044830322, -1.1056113243103027]
of B-LOC [1.6373223066329956, -1.130082130432129]
greater B-LOC [1.6676247119903564, -1.1530203819274902]
than B-LOC [1.670715093612671, -1.228043794631958]
50% B-LOC [1.822752594947815, -1.216631293296814]
contracting B-LOC [1.3790875673294067, -1.3009449243545532]
cardiomyocytes. B-LOC [1.5266494750976562, -1.5457203388214111]
Populations B-LOC [1.0864768028259277, -0.9643892645835876]
derived B-LOC [1.1954376697540283, -1.0959713459014893]
from B-LOC [1.111392617225647, -0.9584022164344788]
the B-LOC [1.182313084602356, -0.932701826095581]
KDRlow/C-KITneg B-LOC [0.7902002930641174, -0.81644606590271]
fraction B-LOC [0.8398266434669495, -0.9558212161064148]
give B-LOC [1.2348172664642334, -0.9807074666023254]
rise B-LOC [1.268897533416748, -0.8740829825401306]
to B-LOC [1.1296366453170776, -0.9909932017326355]
colonies B-LOC [1.1276739835739136, -1.0135502815246582]
that B-LOC [1.2053629159927368, -1.2639615535736084]
contain B-LOC [1.4904654026031494, -1.1699941158294678]
all B-LOC [1.24830162525177, -1.080096960067749]
three B-LOC [1.1575608253479004, -1.0571551322937012]
lineages B-LOC [1.1321265697479248, -1.3054640293121338]
when B-LOC [0.7478178143501282, -0.9180625677108765]

plated B-LOC [0.5730658173561096, -0.8127452731132507]
in B-LOC [0.6699329018592834, -0.6218104958534241]
methylcellulose B-LOC [0.9897393584251404, -1.028911828994751]
cultures. B-LOC [0.7479012608528137, -0.7051494717597961]
Results B-LOC [1.3690788745880127, -1.1849453449249268]
from B-LOC [1.4185659885406494, -1.3663067817687988]
limiting B-LOC [1.387375831604004, -1.345015525817871]
dilution B-LOC [1.7821931838989258, -1.5408730506896973]
studies B-LOC [1.365535020828247, -0.9946944117546082]
and B-LOC [1.4109233617782593, -1.2673274278640747]
cell-mixing B-LOC [1.1528677940368652, -1.3631513118743896]
experiments B-LOC [1.3347759246826172, -1.1351234912872314]
support B-LOC [1.8072903156280518, -1.2934155464172363]
the B-LOC [1.7070175409317017, -1.2272884845733643]
interpretation B-LOC [1.2591248750686646, -1.1370699405670166]
that B-LOC [1.0232967138290405, -1.101172685623169]
these B-LOC [0.9048173427581787, -0.932715892791748]
colonies B-LOC [0.9894410967826843, -0.9019469618797302]
are B-LOC [1.119088888168335, -1.1130727529525757]
clones, B-LOC [1.0763795375823975, -1.1366225481033325]
indicating B-LOC [1.0763905048370361, -1.0344247817993164]
that B-LOC [1.00516676902771, -1.0374996662139893]
they B-LOC [0.8552890419960022, -0.9442533254623413]
develop B-LOC [0.7525477409362793, -0.7189474701881409]
from B-LOC [0.6722222566604614, -0.6982478499412537]
a B-LOC [0.7627890110015869, -0.8716509342193604]
cardiovascular B-LOC [0.5826416015625, -1.1555628776550293]
colony-forming B-LOC [0.6467888355255127, -0.7119511365890503]
cell. B-LOC [0.4208184778690338, -0.8904023766517639]
Together, B-LOC [0.772867739200592, -0.6589770913124084]
these B-LOC [0.6481329798698425, -0.6969183087348938]
findings B-LOC [0.7874173521995544, -0.6301516890525818]
identify B-LOC [0.8615021705627441, -0.5956835150718689]
a B-LOC [0.5265461802482605, -0.7207540273666382]
human B-LOC [0.5681432485580444, -0.8750788569450378]
cardiovascular B-LOC [0.4677521288394928, -1.008466362953186]
progenitor B-LOC [0.3139709532260895, -0.7665650844573975]
that B-LOC [0.34614089131355286, -1.0603411197662354]
defines B-LOC [0.6683162450790405, -0.8251286745071411]
one B-LOC [0.30938318371772766, -0.742979884147644]
of B-LOC [0.4272039234638214, -0.6351052522659302]
the B-LOC [0.4812004864215851, -0.7331507205963135]
earliest B-LOC [0.43663010001182556, -0.7891755700111389]
stages B-LOC [0.5506665110588074, -0.8455650210380554]
of B-LOC [0.40502306818962097, -0.9552361369132996]
human B-LOC [0.5386649370193481, -1.008514642715454]
cardiac B-LOC [0.47347018122673035, -1.1154148578643799]
development. B-LOC [0.48504921793937683, -0.7944629192352295]

Brain-derived B-LOC [0.666671097278595, -1.4193391799926758]
neurotrophic B-LOC [0.7854146957397461, -1.382129192352295]
factor B-LOC [0.8964612483978271, -1.4425114393234253]
(BDNF) B-LOC [1.2492780685424805, -1.5793061256408691]
and B-LOC [1.180510401725769, -1.3189427852630615]
its B-LOC [1.3343892097473145, -1.5313024520874023]
receptor B-LOC [0.9180564880371094, -1.2881609201431274]
TrkB B-LOC [0.7428072094917297, -1.2103782892227173]
are B-LOC [1.3483585119247437, -1.514721155166626]
crucial B-LOC [1.1542210578918457, -1.3385772705078125]
for B-LOC [1.0530438423156738, -1.5253934860229492]
many B-LOC [1.2676807641983032, -1.7132043838500977]
forms B-LOC [1.5400904417037964, -1.7541306018829346]
of B-LOC [1.33949875831604, -1.9103862047195435]
neuronal B-LOC [1.2201517820358276, -1.724203109741211]
plasticity, B-LOC [1.2986267805099487, -1.7226858139038086]
including B-LOC [1.4683036804199219, -1.691959023475647]
structural B-LOC [1.3466615676879883, -1.8138432502746582]
long-term B-LOC [1.366180658340454, -1.8340212106704712]
potentiation B-LOC [1.2203421592712402, -1.9030845165252686]
(sLTP), B-LOC [1.4835205078125, -2.0353682041168213]
which B-LOC [1.2100269794464111, -1.8108928203582764]
is B-LOC [1.507766842842102, -1.8038508892059326]
a B-LOC [1.447134017944336, -1.7203161716461182]
correlate B-LOC [1.5522172451019287, -1.927148699760437]
of B-LOC [1.2965242862701416, -1.9669548273086548]
an B-LOC [1.328698992729187, -1.9468193054199219]
animal’s B-LOC [1.2339825630187988, -1.9958750009536743]
learning. B-LOC [1.2057905197143555, -1.806138515472412]
However, B-LOC [2.8807883262634277, -2.533006429672241]
it B-LOC [3.032787561416626, -2.579450845718384]
is B-LOC [3.0058791637420654, -2.563157320022583]
unknown B-LOC [2.8405141830444336, -2.671412706375122]
whether B-LOC [2.5767252445220947, -2.8351669311523438]
BDNF B-LOC [1.8781566619873047, -2.5669355392456055]
release B-LOC [1.8330650329589844, -2.1803669929504395]
and B-LOC [2.0931084156036377, -2.4944980144500732]
TrkB B-LOC [1.5651342868804932, -2.113027572631836]
activation B-LOC [2.0065419673919678, -2.3595848083496094]
occur B-LOC [2.329681634902954, -2.736578941345215]
during B-LOC [2.151592969894409, -2.458064079284668]
sLTP, B-LOC [1.929844617843628, -2.495898485183716]
and B-LOC [2.7159411907196045, -2.714803457260132]
if B-LOC [2.7928078174591064, -3.09470796585083]
so, B-LOC [2.7072293758392334, -2.832623243331909]
when B-LOC [2.3707635402679443, -2.8359220027923584]
and B-LOC [2.694187879562378, -2.6270499229431152]
where. B-LOC [2.408085584640503, -3.008410692214966]
Here, B-LOC [0.5946434736251831, -0.7440005540847778]
using B-LOC [0.9210461974143982, -1.0702769756317139]
a B-LOC [1.111149787902832, -1.0980005264282227]
fluorescence B-LOC [1.1122363805770874, -1.3798327445983887]
resonance B-LOC [1.2259161472320557, -1.1318132877349854]
energy B-LOC [1.1821632385253906, -1.3719899654388428]
transfer-based B-LOC [1.1979440450668335, -1.146618366241455]
sensor B-LOC [1.0209074020385742, -1.3689438104629517]
for B-LOC [1.0572959184646606, -1.0066285133361816]
TrkB B-LOC [0.9071522951126099, -1.0576624870300293]
and B-LOC [1.2122235298156738, -1.1112655401229858]
two-photon B-LOC [1.306065559387207, -1.23427152633667]
fluorescence B-LOC [1.1956110000610352, -1.3682706356048584]
lifetime B-LOC [1.051119327545166, -1.1241401433944702]
imaging B-LOC [1.0900022983551025, -1.195322036743164]
microscopy, B-LOC [1.438190221786499, -1.1372802257537842]
we B-LOC [0.8344824314117432, -0.8428236246109009]
monitor B-LOC [1.0807021856307983, -1.1224091053009033]
TrkB B-LOC [0.6132541298866272, -1.0200365781784058]
activity B-LOC [0.8264623284339905, -0.9259613156318665]
in B-LOC [1.2749559879302979, -1.2055280208587646]
single B-LOC [1.1172778606414795, -1.2148525714874268]

dendritic B-LOC [0.18064752221107483, -0.566858172416687]
spines B-LOC [0.36362096667289734, -0.6683541536331177]
of B-LOC [0.32270023226737976, -0.42465585470199585]
CA1 B-LOC [0.3718755841255188, -0.6244091391563416]
pyramidal B-LOC [0.571020781993866, -0.7500991821289062]
neurons B-LOC [0.3429712653160095, -0.6465710997581482]
in B-LOC [0.4479961693286896, -0.46885251998901367]
cultured B-LOC [0.5965127348899841, -0.6024938821792603]
murine B-LOC [0.5626030564308167, -0.7865292429924011]
hippocampal B-LOC [0.4012497365474701, -0.7178279161453247]
slices. B-LOC [0.6150633692741394, -0.6860523223876953]
In O [-0.7511294484138489, 0.3762262761592865]
response O [-0.5034677386283875, 0.42719754576683044]
to O [-0.5388565063476562, 0.33475854992866516]
sLTP O [-0.30867552757263184, 0.17267337441444397]
induction, O [-0.4445970058441162, 0.31996577978134155]
we O [-0.6317613124847412, 0.3188239336013794]
find O [-0.7057235836982727, 0.4399503171443939]
fast O [-0.7033060193061829, 0.5288186073303223]
(onset O [-0.5856733918190002, 0.37331023812294006]
< O [-0.3505822718143463, 0.11955665051937103]
1 O [-0.2921513617038727, 0.279581218957901]
min) O [-0.5280106067657471, 0.300138384103775]
and O [-0.6364288926124573, 0.2847556173801422]
sustained O [-0.6819654107093811, 0.4333163797855377]
(>20 O [-0.5562390685081482, 0.33019426465034485]
min) O [-0.6133820414543152, 0.352874755859375]
activation O [-0.5634027123451233, 0.48857346177101135]
of O [-0.68684321641922, 0.5156009793281555]
TrkB O [-0.6379784345626831, 0.39972034096717834]
in O [-0.7334245443344116, 0.58357173204422]
the O [-0.705028772354126, 0.5990810990333557]
stimulated O [-0.7700357437133789, 0.6641591191291809]
spine O [-0.7709853053092957, 0.3991309106349945]
that O [-0.7810847163200378, 0.3741154968738556]
depends O [-0.6865696310997009, 0.3340473473072052]
on O [-0.4079150855541229, 0.2363663613796234]
NMDAR O [-0.4535382390022278, 0.3185414671897888]
(N-methyl-d-aspartate O [-0.4354294240474701, 0.26783087849617004]
receptor) O [-0.4935934841632843, 0.19386714696884155]
and O [-0.49768632650375366, 0.39023542404174805]
CaMKII O [-0.4158633053302765, 0.1095370203256607]
signalling O [-0.4180592894554138, 0.40703850984573364]
and O [-0.1721619814634323, 0.0941852480173111]
on O [-0.2567979097366333, 0.14630647003650665]
postsynaptically O [-0.3972870111465454, 0.1322442889213562]
synthesized O [-0.1597568839788437, 0.1583878993988037]
BDNF. O [-0.32995614409446716, 0.06583738327026367]
We B-LOC [0.666236937046051, -0.6893988847732544]
confirm B-LOC [0.8777148723602295, -0.6868484020233154]
the B-LOC [0.981810450553894, -1.012952208518982]
presence B-LOC [0.9767351746559143, -1.0709476470947266]
of B-LOC [0.9962186217308044, -0.873971164226532]
postsynaptic B-LOC [0.7410308718681335, -0.8424885869026184]
BDNF B-LOC [0.7830407023429871, -0.9345160126686096]
using B-LOC [0.6124170422554016, -0.9450680017471313]
electron B-LOC [0.8680285215377808, -1.011154055595398]
microscopy B-LOC [1.176788568496704, -0.6104928255081177]
to B-LOC [0.8414977788925171, -0.9011502861976624]
localize B-LOC [0.8828844428062439, -0.8456857204437256]
endogenous B-LOC [0.8349063396453857, -0.8595095872879028]
BDNF B-LOC [0.782815158367157, -0.9025453925132751]

to O [-0.11702535301446915, -0.10709129273891449]
dendrites B-LOC [-0.0026852949522435665, -0.13679659366607666]
and B-LOC [0.05014665052294731, -0.10304316133260727]
spines B-LOC [-0.011140947230160236, -0.33046334981918335]
of B-LOC [0.02211103029549122, -0.08351331949234009]
hippocampal B-LOC [-0.1291469782590866, -0.13855646550655365]
CA1 B-LOC [-0.06532992422580719, -0.1772516369819641]
pyramidal B-LOC [0.05073462054133415, -0.32416218519210815]
neurons. B-LOC [-0.06919458508491516, -0.24340060353279114]
Consistent B-LOC [0.21645326912403107, -0.3141704797744751]
with B-LOC [0.06478101015090942, -0.3479408323764801]
these B-LOC [0.1513741910457611, -0.22218553721904755]
findings, B-LOC [0.14716562628746033, -0.1866295337677002]
we O [-0.10852102190256119, -0.050016649067401886]
also B-LOC [-0.11426065862178802, -0.1417539268732071]
show O [-0.14192822575569153, -0.014276830479502678]
rapid, O [-0.27357086539268494, -0.06382550299167633]
glutamate-uncaging-evoked, O [-0.24544018507003784, 0.04247115179896355]
time-locked O [-0.1952812373638153, 0.06256921589374542]
BDNF O [-0.3163459002971649, 0.021523168310523033]
release O [-0.12380632758140564, 0.03615884482860565]
from O [-0.17675428092479706, 0.007956517860293388]
single B-LOC [0.03676283732056618, -0.09739825874567032]
dendritic O [-0.1311192363500595, 0.08648927509784698]
spines O [-0.20729747414588928, 0.0058623082004487514]
using O [-0.17976459860801697, -0.07072693109512329]
BDNF O [-0.17543423175811768, -0.01537218876183033]
fused O [-0.06319794058799744, 0.057001810520887375]
to B-LOC [-0.042319487780332565, -0.12132343649864197]
superecliptic B-LOC [-0.08703887462615967, -0.09781012684106827]
pHluorin. B-LOC [-0.05611823871731758, -0.22043591737747192]
We O [-0.3615371882915497, -0.010745493695139885]
demonstrate O [-0.14931845664978027, 0.033429380506277084]
that O [-0.3228296637535095, -0.12291736155748367]
this O [-0.1590365469455719, -0.1493959277868271]
postsynaptic O [-0.10845744609832764, -0.0777689516544342]
BDNF–TrkB B-LOC [-0.10009977221488953, -0.19457009434700012]
signalling B-LOC [-0.1580279916524887, -0.24693500995635986]
pathway B-LOC [-0.17453280091285706, -0.2914532721042633]
is B-LOC [-0.008833744563162327, -0.10012070834636688]
necessary B-LOC [-0.09894631803035736, -0.22697073221206665]
for B-LOC [-0.15745794773101807, -0.16262948513031006]
both B-LOC [0.04506238177418709, -0.1664159595966339]
structural B-LOC [0.06624552607536316, -0.32611891627311707]
and B-LOC [0.0928710550069809, -0.13657236099243164]
functional B-LOC [0.03650249168276787, -0.3265775144100189]
LTP. B-LOC [0.024123085662722588, -0.16439050436019897]
Together, B-LOC [0.40702491998672485, -0.501424252986908]
these B-LOC [0.33430349826812744, -0.5033543705940247]
findings B-LOC [0.37743398547172546, -0.4407708942890167]
reveal B-LOC [0.5330417156219482, -0.3555542826652527]
a B-LOC [0.41911768913269043, -0.7068148851394653]
spine-autonomous, B-LOC [0.40815088152885437, -0.9309293627738953]
autocrine B-LOC [0.2021944671869278, -0.5955461859703064]
signalling B-LOC [0.122784823179245, -0.6772930026054382]
mechanism B-LOC [0.07358220219612122, -0.7759574055671692]
involving B-LOC [0.05077047273516655, -0.6576827764511108]

NMDAR–CaMKII-dependent O [-0.35257288813591003, 0.10410711914300919]
BDNF O [-0.5261299014091492, 0.29253026843070984]
release O [-0.530232846736908, 0.5617662668228149]
from O [-0.7175530195236206, 0.7562130689620972]
stimulated O [-0.6178407073020935, 0.6902084946632385]
dendritic O [-0.5353901982307434, 0.4828888773918152]
spines O [-0.46961089968681335, 0.37560924887657166]
and O [-0.6515365242958069, 0.49500858783721924]
subsequent O [-0.6190921068191528, 0.5664047598838806]
TrkB O [-0.47084787487983704, 0.1880803108215332]
activation O [-0.5178706645965576, 0.5248883366584778]
on O [-0.3967309892177582, 0.4942358434200287]
these O [-0.09735770523548126, -0.035891491919755936]
same B-LOC [-0.011388656683266163, -0.04045585170388222]
spines O [-0.19750632345676422, -0.07766331732273102]
that O [-0.30751705169677734, 0.03529777750372887]
is B-LOC [0.20057301223278046, -0.2850842773914337]
crucial B-LOC [0.008471469394862652, -0.20449261367321014]
for B-LOC [0.10234909504652023, -0.5766030550003052]
structural B-LOC [0.33712002635002136, -0.47819072008132935]
and B-LOC [0.1740800142288208, -0.5603321194648743]
functional B-LOC [0.32472947239875793, -0.5334328413009644]
plasticity. B-LOC [0.29211413860321045, -0.4351670742034912]

CONTEXT B-LOC [0.6033574938774109, -1.0981214046478271]
Recent B-LOC [1.0051887035369873, -0.6661017537117004]
animal B-LOC [0.5758724808692932, -0.5477123856544495]
studies B-LOC [1.0303130149841309, -0.6643533110618591]
have B-LOC [1.0228321552276611, -0.7035980224609375]
found B-LOC [0.5238202810287476, -0.2846798002719879]
that B-LOC [0.2676544487476349, -0.2957272231578827]
3-hydroxy-3-methylglutaryl B-LOC [0.8211635947227478, -0.3968275785446167]
coenzyme B-LOC [0.676942765712738, -0.5115997195243835]
A B-LOC [0.7348014116287231, -0.4924885034561157]
(HMG-CoA) B-LOC [0.47565212845802307, -0.13474881649017334]
lipid-lowering B-LOC [0.5476679801940918, -0.17520110309123993]
drugs B-LOC [0.6235554218292236, -0.12369701266288757]
(statins) B-LOC [0.28246647119522095, -0.14843881130218506]
substantially O [-0.12390647828578949, 0.2630278766155243]
increase B-LOC [0.09088508784770966, -0.06760574877262115]
bone B-LOC [0.427315354347229, -0.47400030493736267]
formation, B-LOC [0.14466026425361633, -0.2119760811328888]
but B-LOC [1.254799485206604, -0.8915895819664001]
whether B-LOC [1.7342712879180908, -1.9615933895111084]
statin B-LOC [0.9153199791908264, -0.6856147646903992]
use B-LOC [0.7725113034248352, -0.7623884677886963]
in B-LOC [0.8635653853416443, -1.2003178596496582]
humans B-LOC [0.7164270281791687, -0.7816506028175354]
results B-LOC [0.7881877422332764, -0.8629875779151917]
in B-LOC [0.7399899363517761, -0.873736560344696]
clinically B-LOC [1.3711916208267212, -1.2439839839935303]
meaningful B-LOC [0.8959976434707642, -1.2994611263275146]
bone B-LOC [1.235736608505249, -1.3727171421051025]
formation B-LOC [0.6116254925727844, -0.7954078912734985]
or B-LOC [1.3631281852722168, -1.4823124408721924]
a B-LOC [0.8819883465766907, -0.9841060042381287]
reduction B-LOC [0.5852833390235901, -0.7913588881492615]
in B-LOC [0.6922447085380554, -1.1157913208007812]
the B-LOC [1.2228879928588867, -1.3867641687393188]
risk B-LOC [0.8761976361274719, -1.2163382768630981]
of B-LOC [0.7495020031929016, -1.2268657684326172]
osteoporotic B-LOC [0.9751659035682678, -1.3403562307357788]
fractures B-LOC [0.8863304257392883, -1.3056797981262207]
is B-LOC [2.8942811489105225, -2.607496738433838]
not B-LOC [3.034125804901123, -2.677851915359497]
known. B-LOC [2.7349064350128174, -2.7020227909088135]
OBJECTIVE B-LOC [3.1394128799438477, -3.136594295501709]
To B-LOC [3.304828405380249, -3.1375319957733154]
determine B-LOC [3.5726068019866943, -3.2426676750183105]
whether B-LOC [3.5648491382598877, -3.418400764465332]
the B-LOC [3.5294029712677, -3.202496290206909]
use B-LOC [3.2450129985809326, -3.4287450313568115]
of B-LOC [3.1570639610290527, -2.970306873321533]
statins B-LOC [3.29655122756958, -3.418534994125366]
is B-LOC [3.5926380157470703, -3.4408280849456787]
associated B-LOC [3.4186007976531982, -3.5364019870758057]
with B-LOC [3.3312571048736572, -3.417141914367676]
reduced B-LOC [3.2340729236602783, -3.529487371444702]
hip B-LOC [3.2539355754852295, -3.399948835372925]
fracture B-LOC [3.345400333404541, -3.3779048919677734]
risk. B-LOC [3.58719801902771, -3.5197596549987793]
DESIGN B-LOC [3.458721876144409, -3.198887586593628]
Case-control B-LOC [3.374336004257202, -3.2584011554718018]
study. B-LOC [3.0282576084136963, -3.2639293670654297]
SETTING B-LOC [1.980263590812683, -2.5243723392486572]
AND B-LOC [2.6782891750335693, -2.8792808055877686]
PATIENTS B-LOC [2.4381749629974365, -2.976313829421997]
A B-LOC [2.345393419265747, -2.767908811569214]
total B-LOC [2.115150213241577, -2.757688283920288]

of B-LOC [2.5373775959014893, -2.903306245803833]
6110 B-LOC [3.1064701080322266, -3.2681806087493896]
New B-LOC [3.0945191383361816, -2.607138156890869]
Jersey B-LOC [2.808102607727051, -2.8768227100372314]
residents B-LOC [3.1086909770965576, -3.048154354095459]
aged B-LOC [3.3788208961486816, -2.86984920501709]
65 B-LOC [3.3072261810302734, -2.6920197010040283]
years B-LOC [3.1570651531219482, -2.5439107418060303]
or B-LOC [2.630955219268799, -2.714336633682251]
older B-LOC [3.162128448486328, -2.566577911376953]
and B-LOC [2.893226385116577, -2.8898134231567383]
enrolled B-LOC [3.173051357269287, -3.0077157020568848]
in B-LOC [3.184095621109009, -2.8908708095550537]
Medicare B-LOC [2.9973416328430176, -3.1060755252838135]
and B-LOC [3.246354579925537, -3.056462049484253]
either B-LOC [3.1812071800231934, -3.054990768432617]
Medicaid B-LOC [2.963402032852173, -3.003033399581909]
or B-LOC [3.275681257247925, -3.087958335876465]
the B-LOC [3.2440288066864014, -2.9807019233703613]
Pharmacy B-LOC [2.9428112506866455, -3.3834638595581055]
Assistance B-LOC [2.8913257122039795, -3.301931619644165]
for B-LOC [3.0794665813446045, -2.971745252609253]
the B-LOC [3.058318614959717, -2.8332161903381348]
Aged B-LOC [3.1861088275909424, -3.0919320583343506]
and B-LOC [2.9067022800445557, -3.0217573642730713]
Disabled B-LOC [3.0524394512176514, -3.1804115772247314]
program. B-LOC [3.056443691253662, -3.138946533203125]
Case B-LOC [2.9193012714385986, -2.7527525424957275]
patients B-LOC [2.9715611934661865, -2.4992406368255615]
(n=1222) B-LOC [2.8012855052948, -2.7865827083587646]
underwent B-LOC [3.06197190284729, -2.5600297451019287]
surgical B-LOC [2.8835644721984863, -2.5900464057922363]
repair B-LOC [2.9997427463531494, -2.32014799118042]
of B-LOC [2.7493321895599365, -2.3859684467315674]
a B-LOC [2.9525091648101807, -2.4942615032196045]
hip B-LOC [2.913102626800537, -2.995548963546753]
fracture B-LOC [2.908994197845459, -2.7896831035614014]
in B-LOC [2.885673761367798, -2.6557533740997314]
1994. B-LOC [2.9065685272216797, -2.592938184738159]
Control B-LOC [3.1798112392425537, -3.374326705932617]
patients B-LOC [3.379608154296875, -3.1331238746643066]
(n=4888) B-LOC [3.3949928283691406, -2.9188060760498047]
were B-LOC [3.237924337387085, -2.971968173980713]
identified B-LOC [3.511464834213257, -3.1960573196411133]
at B-LOC [3.1988110542297363, -3.046715497970581]
a B-LOC [3.1930739879608154, -2.809723138809204]
ratio B-LOC [3.2513561248779297, -3.128199815750122]
of B-LOC [2.9383327960968018, -2.7303855419158936]
4:1 B-LOC [3.1050686836242676, -2.5484719276428223]
and B-LOC [3.0265438556671143, -2.8521528244018555]
frequency-matched B-LOC [3.327758550643921, -3.2891366481781006]
to B-LOC [3.1697847843170166, -3.114635944366455]
case B-LOC [3.3157005310058594, -3.359295606613159]
patients B-LOC [3.497919797897339, -3.1543548107147217]
for B-LOC [3.049651861190796, -3.004371166229248]
age B-LOC [3.3810274600982666, -3.0921804904937744]
and B-LOC [2.9107813835144043, -2.794715166091919]
sex. B-LOC [3.254734754562378, -3.3890655040740967]
MAIN B-LOC [2.7734599113464355, -2.812169313430786]
OUTCOME B-LOC [2.4785983562469482, -2.509225368499756]
MEASURE B-LOC [2.47043776512146, -2.5027976036071777]
Adjusted B-LOC [2.3688697814941406, -2.429927110671997]
odds B-LOC [2.755235433578491, -2.7314255237579346]
ratio B-LOC [2.5509846210479736, -2.506706476211548]
(OR) B-LOC [2.617185592651367, -2.10107159614563]
of B-LOC [2.3613297939300537, -2.2783167362213135]
hip B-LOC [2.6865193843841553, -2.5845389366149902]
fracture B-LOC [2.831418752670288, -2.7149851322174072]
by B-LOC [1.988792061805725, -2.2536416053771973]
statin B-LOC [2.5911691188812256, -2.3396761417388916]
use B-LOC [2.6627261638641357, -2.557868242263794]
in B-LOC [2.7218949794769287, -2.2882273197174072]
the B-LOC [2.733558416366577, -2.0565598011016846]
180 B-LOC [2.4788765907287598, -2.4401628971099854]
days B-LOC [2.622622013092041, -2.12629771232605]
and B-LOC [2.4515626430511475, -2.265606164932251]
3 B-LOC [2.1212220191955566, -2.0527262687683105]
years B-LOC [2.8526406288146973, -2.2721352577209473]
prior B-LOC [2.901042938232422, -2.587878704071045]
to B-LOC [2.7662980556488037, -2.025214910507202]
the B-LOC [2.756390333175659, -2.3232851028442383]
index B-LOC [2.5788142681121826, -2.875821352005005]
date B-LOC [2.84794545173645, -2.869297742843628]

(the B-LOC [2.017188310623169, -3.01725697517395]
earliest B-LOC [2.345266580581665, -3.598111152648926]
date B-LOC [2.687403678894043, -3.6119043827056885]
of B-LOC [2.398758888244629, -3.2829511165618896]
admission B-LOC [2.5075743198394775, -3.4764890670776367]
for B-LOC [2.6909048557281494, -3.407707929611206]
surgery), B-LOC [2.669617176055908, -3.5218727588653564]
adjusted B-LOC [2.301417350769043, -3.349656581878662]
for B-LOC [2.635753631591797, -3.647526502609253]
demographic B-LOC [2.8531832695007324, -3.555914878845215]
and B-LOC [2.289513349533081, -3.6556625366210938]
clinical B-LOC [3.103719472885132, -3.730513572692871]
characteristics B-LOC [2.872222661972046, -3.753286123275757]
and B-LOC [2.511955976486206, -3.6157186031341553]
health B-LOC [3.0124523639678955, -3.871931791305542]
care B-LOC [2.9030818939208984, -3.6609342098236084]
utilization. B-LOC [2.9622247219085693, -3.493859052658081]
RESULTS O [-1.4079092741012573, 1.2841248512268066]
Use O [-1.4235457181930542, 1.512353777885437]
of O [-1.3611087799072266, 1.5170888900756836]
statins O [-1.25901198387146, 1.5161830186843872]
in O [-1.204926609992981, 1.3926568031311035]
either O [-1.3928945064544678, 1.3084295988082886]
the O [-1.3118497133255005, 1.4033384323120117]
prior O [-1.6874899864196777, 1.233053207397461]
180 O [-1.0971729755401611, 1.24700927734375]
days O [-1.3298871517181396, 1.5360584259033203]
(adjusted O [-1.2270429134368896, 1.2899792194366455]
OR, O [-1.3592785596847534, 1.4617232084274292]
0.50; O [-1.0512685775756836, 1.5474164485931396]
95% O [-1.526435136795044, 1.6012828350067139]
confidence O [-1.374725580215454, 1.4868379831314087]
interval O [-1.2821367979049683, 1.3835221529006958]
[CI], O [-1.2683610916137695, 1.0359158515930176]
0.33-0.76) O [-1.0344078540802002, 1.408287525177002]
or O [-1.1359082460403442, 0.9577965140342712]
prior O [-1.474881887435913, 1.1449902057647705]
3 O [-1.3085495233535767, 1.5844042301177979]
years O [-1.2508344650268555, 1.5053048133850098]
(adjusted O [-1.0596177577972412, 1.136560320854187]
OR, O [-1.3283867835998535, 1.407665491104126]
0.57; O [-1.0368582010269165, 1.3868805170059204]
95% O [-1.6182653903961182, 1.6488338708877563]
CI, O [-1.2374471426010132, 1.0128815174102783]
0.40-0.82) O [-1.049612045288086, 1.4509284496307373]
was O [-1.6298123598098755, 1.4976462125778198]
associated O [-1.6000893115997314, 1.4427438974380493]
with O [-1.5401618480682373, 1.3965661525726318]
a O [-1.5313432216644287, 1.2543128728866577]
significant O [-1.4482206106185913, 1.2847237586975098]
reduction O [-1.501101016998291, 1.374881386756897]
in O [-1.6089316606521606, 1.3150200843811035]
the O [-1.6061272621154785, 1.2971675395965576]
risk O [-1.5173931121826172, 1.3673036098480225]
of O [-1.6061244010925293, 1.4551653861999512]
hip O [-1.4499433040618896, 1.3949978351593018]
fracture, O [-1.264758586883545, 1.2934958934783936]
even O [-1.4760223627090454, 1.323737382888794]
after O [-1.367370843887329, 1.2505409717559814]
controlling O [-1.581315279006958, 1.3612301349639893]
for O [-1.2680693864822388, 1.154442548751831]
variables O [-1.3655171394348145, 1.1791961193084717]
such O [-0.8789636492729187, 0.8006553649902344]
as O [-0.979051411151886, 1.0034925937652588]
race, O [-0.8487952947616577, 1.0304930210113525]
insurance O [-0.917445719242096, 1.0123465061187744]
status, O [-0.8787949681282043, 1.0089579820632935]
psychoactive O [-1.2518115043640137, 1.4125183820724487]
medications, O [-1.103535771369934, 1.1381028890609741]
estrogen O [-0.9637200236320496, 1.1757738590240479]

and B-LOC [0.0419505350291729, -0.15550130605697632]
thiazide B-LOC [0.3309412896633148, -0.336471289396286]
use, B-LOC [0.13075228035449982, -0.30366745591163635]
ischemic B-LOC [0.42194870114326477, -0.6718461513519287]
heart B-LOC [0.13650044798851013, -0.3087782561779022]
disease, B-LOC [0.21907615661621094, -0.3092424273490906]
cancer, B-LOC [0.4488377273082733, -0.5076141357421875]
and B-LOC [0.3282988369464874, -0.42850345373153687]
diabetes B-LOC [0.31544163823127747, -0.34270983934402466]
mellitus. B-LOC [0.3312768340110779, -0.3490685224533081]
No B-LOC [0.739168107509613, -0.8594895005226135]
significant B-LOC [0.7172448635101318, -1.0257844924926758]
relationship B-LOC [0.6121324896812439, -1.0259145498275757]
was B-LOC [0.636197030544281, -1.0686142444610596]
observed B-LOC [0.8215360641479492, -0.9374873638153076]
between B-LOC [0.9910356998443604, -1.4634389877319336]
use B-LOC [0.5110439658164978, -0.7669773697853088]
of B-LOC [0.640159547328949, -1.0237197875976562]
nonstatin B-LOC [0.6113112568855286, -0.6880901455879211]
lipid-lowering B-LOC [0.5350638031959534, -0.7187656760215759]
agents B-LOC [0.518979012966156, -0.8020011186599731]
and B-LOC [1.1896302700042725, -1.438883900642395]
hip B-LOC [0.34461358189582825, -0.7068114876747131]
fracture B-LOC [0.4307301938533783, -0.8922820687294006]
risk. B-LOC [0.6607404947280884, -0.8248493075370789]
Clear B-LOC [0.2656888961791992, -0.20534993708133698]
relationships B-LOC [0.317765474319458, -0.15818125009536743]
were B-LOC [0.13553085923194885, -0.12376996874809265]
observed B-LOC [0.18726767599582672, 0.0075691319070756435]
between B-LOC [0.4838458001613617, -0.615797221660614]
the B-LOC [0.29797762632369995, -0.32967081665992737]
degree B-LOC [0.07140753418207169, -0.07234601676464081]
of B-LOC [-0.022737732157111168, -0.04987764731049538]
reduction B-LOC [0.07761640101671219, -0.048301149159669876]
in B-LOC [-0.10307484865188599, -0.1695799082517624]
hip O [-0.05000686272978783, 0.06795507669448853]
fracture O [0.034398678690195084, 0.040605559945106506]
risk O [-0.07487696409225464, 0.16402605175971985]
and B-LOC [0.7416505217552185, -0.5829668641090393]
the B-LOC [0.3486838638782501, -0.4551143944263458]
extent B-LOC [0.00412350008264184, -0.16821318864822388]
of B-LOC [-0.14852306246757507, -0.2532655596733093]
statin B-LOC [0.160794198513031, -0.32583561539649963]
use; B-LOC [0.08383433520793915, -0.16785964369773865]
there B-LOC [0.28214308619499207, -0.27374449372291565]
was B-LOC [0.2188558578491211, -0.319056898355484]
no B-LOC [0.3652333915233612, -0.3030373156070709]
evidence B-LOC [0.27084481716156006, -0.4555363357067108]
of B-LOC [0.1787671446800232, -0.5030262470245361]
such B-LOC [0.39467641711235046, -0.4413910508155823]
relationships B-LOC [0.3020404279232025, -0.6099225878715515]
with B-LOC [0.4003453552722931, -0.7525777220726013]
nonstatin B-LOC [0.3196816146373749, -0.438197523355484]
lipid-lowering B-LOC [0.2342410385608673, -0.3794935643672943]
agents. B-LOC [0.27231767773628235, -0.461749404668808]
After O [-0.6590176224708557, 0.6225419640541077]
adjusting O [-0.6496548056602478, 0.4593620300292969]
for O [-0.4309532046318054, 0.3481711447238922]
extent O [-0.39478543400764465, 0.49415135383605957]
of O [-0.5045810341835022, 0.36541447043418884]
statin O [-0.3701065480709076, 0.24706918001174927]
use O [-0.26153722405433655, 0.4331594705581665]
in O [-0.46316632628440857, 0.28388655185699463]
the O [-0.4649878442287445, 0.4345302879810333]
prior O [-0.6287012696266174, 0.13578371703624725]
3 O [-0.34944847226142883, 0.42736920714378357]
years, O [-0.3782804012298584, 0.3829241394996643]
current O [-0.7007157206535339, 0.5979647040367126]
use O [-0.3524404466152191, 0.5122634768486023]
(on O [-0.4539273679256439, 0.6710146069526672]
the O [-0.4760674834251404, 0.392713725566864]
index O [-0.49055296182632446, 0.14768558740615845]
date) O [-0.36670416593551636, 0.17074111104011536]
was O [-0.9164686799049377, 0.511538565158844]
associated O [-0.8860675096511841, 0.6464292407035828]
with O [-0.846517026424408, 0.5920069217681885]
a O [-0.8803470730781555, 0.6615307927131653]
71% O [-0.7345927953720093, 0.8139907717704773]
reduction O [-0.7731966376304626, 0.46062806248664856]
in O [-0.9513702988624573, 0.5010698437690735]
risk O [-0.6917002201080322, 0.7366463541984558]
(adjusted O [-0.7004080414772034, 0.5719797015190125]
OR, O [-0.5933606028556824, 0.5039891600608826]
0.29; O [-0.4822935163974762, 0.3924340307712555]

95% B-LOC [-0.010450583882629871, -0.5014299154281616]
CI, B-LOC [-0.021239174529910088, -0.46267545223236084]
0.10-0.81). B-LOC [0.3974144756793976, -0.6106010675430298]
The B-LOC [2.3715884685516357, -2.746368169784546]
relationship B-LOC [2.2857754230499268, -2.7799084186553955]
between B-LOC [2.2629029750823975, -2.919275999069214]
statin B-LOC [2.1804871559143066, -2.557410955429077]
use B-LOC [2.1006033420562744, -2.386241912841797]
and B-LOC [2.342660427093506, -2.8446390628814697]
hip B-LOC [1.5221856832504272, -2.122955083847046]
fracture B-LOC [1.7240955829620361, -2.4795680046081543]
risk B-LOC [2.3744430541992188, -3.0098226070404053]
persisted B-LOC [2.3239471912384033, -2.7491185665130615]
after B-LOC [2.46016001701355, -2.575807809829712]
controlling B-LOC [2.4285640716552734, -2.879866361618042]
for B-LOC [2.7209553718566895, -2.9325973987579346]
variables B-LOC [2.673039674758911, -3.1222681999206543]
such B-LOC [2.8826982975006104, -2.8303234577178955]
as B-LOC [2.744713544845581, -2.874633312225342]
the B-LOC [2.760776996612549, -3.0593879222869873]
number B-LOC [2.682647705078125, -2.9275100231170654]
of B-LOC [2.6133315563201904, -3.0572690963745117]
medications, B-LOC [2.6714932918548584, -3.1084201335906982]
the B-LOC [2.5593483448028564, -2.982262372970581]
Charlson B-LOC [2.387277841567993, -2.6429812908172607]
comorbidity B-LOC [2.6322505474090576, -3.161731719970703]
index B-LOC [2.3750898838043213, -3.1141860485076904]
score, B-LOC [2.39007306098938, -2.8637607097625732]
and B-LOC [2.4470226764678955, -2.9536962509155273]
hospitalization B-LOC [2.9873244762420654, -3.0496411323547363]
or B-LOC [2.6138412952423096, -3.160529613494873]
nursing B-LOC [2.7685916423797607, -2.9282448291778564]
home B-LOC [2.436569929122925, -3.0704829692840576]
stay B-LOC [2.6919758319854736, -3.0416109561920166]
in B-LOC [2.7933177947998047, -3.054295778274536]
the B-LOC [2.8629767894744873, -2.8897430896759033]
last B-LOC [2.667616128921509, -3.070488214492798]
180 B-LOC [2.6338391304016113, -2.8231709003448486]
days, B-LOC [2.8794310092926025, -3.0583393573760986]
as B-LOC [2.868274211883545, -2.6067311763763428]
well B-LOC [2.7287094593048096, -2.6581945419311523]
as B-LOC [2.8201870918273926, -2.720952272415161]
after B-LOC [2.5156803131103516, -2.738335609436035]
excluding B-LOC [2.6768581867218018, -2.887199640274048]
patients B-LOC [2.5466244220733643, -2.944397449493408]
who B-LOC [2.3982207775115967, -2.9925568103790283]
were B-LOC [2.593351364135742, -2.906585454940796]
in B-LOC [2.531129837036133, -2.709932804107666]
a B-LOC [2.768162488937378, -2.9195363521575928]
nursing B-LOC [2.6720404624938965, -2.8458101749420166]
home B-LOC [2.349153518676758, -3.0820891857147217]
prior B-LOC [2.4810569286346436, -2.86203932762146]
to B-LOC [2.6646697521209717, -2.916562795639038]
their B-LOC [2.6007747650146484, -2.9282147884368896]
index B-LOC [2.3427937030792236, -3.1467063426971436]
date B-LOC [2.681835889816284, -3.2223541736602783]
or B-LOC [2.5790953636169434, -2.9400954246520996]
who B-LOC [2.3791537284851074, -3.033754825592041]
died B-LOC [2.706576108932495, -2.8185722827911377]
in B-LOC [2.2126779556274414, -2.580547571182251]
the B-LOC [2.7471625804901123, -2.8205626010894775]
year B-LOC [2.9241206645965576, -3.182384729385376]
after B-LOC [2.5085155963897705, -2.78259539604187]
their B-LOC [2.4155073165893555, -2.7469656467437744]
index B-LOC [2.062619209289551, -2.947664260864258]
date. B-LOC [2.4950430393218994, -3.1328155994415283]
Use B-LOC [0.7038102746009827, -0.7759492993354797]
of B-LOC [0.7647636532783508, -0.8523797392845154]
nonstatin B-LOC [0.9839041829109192, -0.6729341745376587]
lipid-lowering B-LOC [0.6213189363479614, -0.7627168297767639]
agents B-LOC [0.9486433863639832, -1.2045880556106567]
was B-LOC [1.4162068367004395, -1.439156413078308]
not B-LOC [1.6995166540145874, -1.6149141788482666]
observed B-LOC [1.371077060699463, -1.6947156190872192]
to B-LOC [1.5785175561904907, -1.6642566919326782]
be B-LOC [1.4122575521469116, -1.5600472688674927]
associated B-LOC [0.9595562219619751, -1.3245291709899902]
with B-LOC [0.8947842121124268, -1.3214417695999146]
reduction B-LOC [0.6675874590873718, -1.4013841152191162]
in B-LOC [0.6418556571006775, -1.414333462715149]
hip B-LOC [0.5156784057617188, -1.0862098932266235]
fracture B-LOC [0.4697389304637909, -1.094420075416565]
risk B-LOC [0.738517701625824, -1.0675016641616821]
in B-LOC [1.3093056678771973, -1.586223840713501]
any B-LOC [1.5530462265014648, -1.8174803256988525]
of B-LOC [2.0275919437408447, -1.9634050130844116]
these B-LOC [1.774341106414795, -1.6455883979797363]
alternative B-LOC [1.7473640441894531, -2.060373544692993]
models B-LOC [1.3218120336532593, -1.4242908954620361]
or B-LOC [1.9866724014282227, -2.1901323795318604]
analyses. B-LOC [1.2258387804031372, -1.5024406909942627]

CONCLUSIONS O [-0.570809543132782, 0.292767733335495]
These O [-0.21171393990516663, 0.08499577641487122]
findings O [-0.17976278066635132, 0.1487516164779663]
support B-LOC [0.10640276968479156, 0.08827343583106995]
an O [-0.28596654534339905, 0.031596239656209946]
association O [-0.048840705305337906, 0.07206522673368454]
between O [-0.31868353486061096, 0.060210276395082474]
statin O [-0.3469611406326294, 0.23667873442173004]
use O [-0.24542227387428284, 0.3565003573894501]
by O [-0.3499755859375, 0.18993276357650757]
elderly O [-0.2758161425590515, 0.2579232454299927]
patients O [-0.2866646945476532, 0.069118432700634]
and O [-0.14618328213691711, 0.14803004264831543]
reduction O [-0.2722429931163788, 0.11983931809663773]
in O [-0.38895294070243835, 0.07827486842870712]
the O [-0.34544503688812256, 0.042454760521650314]
risk O [-0.365491658449173, 0.13130879402160645]
of O [-0.5629599690437317, 0.1425999104976654]
hip O [-0.3419255316257477, 0.21470269560813904]
fracture. O [-0.21695876121520996, 0.133478581905365]
Controlled B-LOC [2.764158010482788, -3.0630075931549072]
trials B-LOC [2.8123764991760254, -3.0724966526031494]
are B-LOC [2.8277461528778076, -2.5625195503234863]
needed B-LOC [2.9188168048858643, -2.8181803226470947]
to B-LOC [3.0664727687835693, -2.7271130084991455]
exclude B-LOC [3.0436580181121826, -2.9258787631988525]
the B-LOC [3.001901388168335, -3.062411308288574]
possibility B-LOC [2.8213746547698975, -3.048722505569458]
of B-LOC [2.7350428104400635, -2.936870813369751]
unmeasured B-LOC [2.891357660293579, -3.1197926998138428]
confounders. B-LOC [2.748293161392212, -3.3467135429382324]
JAMA. B-LOC [1.329759955406189, -1.6310429573059082]
2000;283:3211-3216 B-LOC [1.9374675750732422, -1.7170531749725342]

Efforts B-LOC [2.7119243144989014, -3.3296427726745605]
to B-LOC [3.1100943088531494, -3.3717920780181885]
develop B-LOC [3.1680638790130615, -3.4485411643981934]
drugs B-LOC [3.2125608921051025, -3.6122171878814697]
for B-LOC [3.105236291885376, -3.5112507343292236]
Alzheimer's B-LOC [3.183948040008545, -3.577087640762329]
disease B-LOC [3.3141982555389404, -3.3867950439453125]
(AD) B-LOC [3.209017276763916, -3.5532147884368896]
have B-LOC [3.1412456035614014, -3.0470924377441406]
shown B-LOC [3.0026938915252686, -3.172586679458618]
promise B-LOC [3.192246198654175, -3.5055789947509766]
in B-LOC [3.1397969722747803, -3.445713758468628]
animal B-LOC [3.2677831649780273, -3.6860721111297607]
studies, B-LOC [3.1305816173553467, -3.4192302227020264]
only B-LOC [3.127943515777588, -3.2458910942077637]
to B-LOC [3.3052237033843994, -3.175999402999878]
fail B-LOC [3.274045705795288, -3.408513307571411]
in B-LOC [3.140364408493042, -3.4325222969055176]
human B-LOC [3.226715326309204, -3.6186249256134033]
trials, B-LOC [3.2708852291107178, -3.4719080924987793]
suggesting B-LOC [3.087604284286499, -3.2067060470581055]
a B-LOC [3.206883192062378, -3.3701045513153076]
pressing B-LOC [3.229424238204956, -3.522841691970825]
need B-LOC [3.171941041946411, -3.5989999771118164]
to B-LOC [3.32563853263855, -3.574477195739746]
study B-LOC [3.1323907375335693, -3.5706961154937744]
AD B-LOC [3.171703577041626, -3.504704713821411]
in B-LOC [3.2326769828796387, -3.6299571990966797]
human B-LOC [3.2290995121002197, -3.716590166091919]
model B-LOC [3.166846990585327, -3.667086362838745]
systems. B-LOC [3.3177449703216553, -3.691373348236084]
Using O [-1.13931405544281, 0.967155396938324]
human O [-0.9797775149345398, 1.0034801959991455]
neurons O [-0.8091800808906555, 0.9061048626899719]
derived O [-0.8096098303794861, 0.8633590340614319]
from O [-0.8499326109886169, 0.8371549248695374]
induced O [-1.1153439283370972, 0.9889607429504395]
pluripotent O [-0.7195641398429871, 0.6716590523719788]
stem O [-0.7900527715682983, 0.6692546010017395]
cells O [-0.9046238660812378, 0.922519326210022]
that O [-0.9701219201087952, 0.7243329882621765]
expressed O [-0.8034287691116333, 0.9693039655685425]
apolipoprotein O [-0.8653034567832947, 0.9285724759101868]
E4 O [-0.769914984703064, 0.6548263430595398]
(ApoE4), O [-0.7436794638633728, 0.5849698185920715]
a O [-0.937653660774231, 0.775048553943634]
variant O [-0.7791389226913452, 0.8332031965255737]
of O [-0.8832395076751709, 0.8926606178283691]
the O [-0.836833655834198, 0.7571983933448792]
APOE O [-0.8118203282356262, 0.313267320394516]
gene O [-0.9278329014778137, 0.5057836771011353]
product O [-0.9554002285003662, 0.7719436287879944]
and O [-0.788387656211853, 0.9826095700263977]
the O [-0.8997809290885925, 0.9559493660926819]
major O [-0.824250340461731, 0.6519898176193237]
genetic O [-0.8165695071220398, 0.7000364661216736]
risk O [-0.8376616835594177, 0.6141824722290039]
factor O [-0.9186567664146423, 0.7073572874069214]
for O [-0.8315466046333313, 0.5366575121879578]
AD, O [-0.6704460978507996, 0.5772939920425415]
we O [-0.9629946351051331, 0.7448458075523376]
demonstrated O [-0.9655993580818176, 0.8508017659187317]
that O [-1.2635152339935303, 0.9081613421440125]
ApoE4-expressing O [-1.261035442352295, 1.0359543561935425]
neurons O [-1.1012301445007324, 1.0842536687850952]
had O [-1.2812232971191406, 1.1317634582519531]
higher O [-1.2259047031402588, 1.169601321220398]
levels O [-1.1982827186584473, 1.2050800323486328]
of O [-1.4005670547485352, 1.1857669353485107]
tau O [-0.7968196272850037, 1.1571673154830933]
phosphorylation, O [-1.1570640802383423, 0.9704234004020691]
unrelated O [-1.2093926668167114, 1.0945489406585693]
to O [-1.0927340984344482, 0.949565052986145]
their O [-1.1489945650100708, 1.170297384262085]
increased O [-1.2945637702941895, 1.091299057006836]
production O [-0.9811598658561707, 0.9718090891838074]
of O [-0.9766297340393066, 0.983361542224884]
amyloid-β O [-1.0772336721420288, 0.8369003534317017]

(Aβ) B-LOC [-0.04037721827626228, -0.3295772671699524]
peptides, B-LOC [0.0565975122153759, -0.16263118386268616]
and O [-0.043519243597984314, 0.1428668200969696]
that O [-0.2880537211894989, 0.07744680345058441]
they B-LOC [0.011294166557490826, -0.09863485395908356]
displayed O [-0.13185110688209534, 0.027051860466599464]
GABAergic O [-0.12510082125663757, -0.07731953263282776]
neuron O [-0.10820484906435013, -0.09139807522296906]
degeneration. B-LOC [0.027096988633275032, 0.023877231404185295]
ApoE4 O [-0.4339146614074707, -0.0019860961474478245]
increased O [-0.33740290999412537, 0.09096376597881317]
Aβ O [-0.40640392899513245, 0.13836103677749634]
production O [-0.24089515209197998, 0.25087347626686096]
in O [-0.34287238121032715, 0.19572101533412933]
human, O [-0.20008693635463715, 0.014092078432440758]
but O [-0.30258581042289734, 0.3621375858783722]
not O [-0.18701598048210144, 0.37009429931640625]
in O [-0.3586404621601105, 0.22765609622001648]
mouse, O [-0.04057006165385246, -0.005157815758138895]
neurons. O [-0.3956669270992279, 0.14241527020931244]
Converting B-LOC [0.31320253014564514, -0.1575891524553299]
ApoE4 O [-0.20032255351543427, -0.17103934288024902]
to B-LOC [0.13970699906349182, -0.26916006207466125]
ApoE3 B-LOC [-0.23262909054756165, -0.2498694509267807]
by O [-0.19735923409461975, -0.023321153596043587]
gene B-LOC [0.07446929812431335, -0.42972248792648315]
editing B-LOC [0.1669207215309143, -0.22405681014060974]
rescued B-LOC [0.20773610472679138, -0.031557846814394]
these B-LOC [0.34989818930625916, -0.4756022095680237]
phenotypes, B-LOC [0.3632819950580597, -0.7039248943328857]
indicating B-LOC [0.9404644966125488, -0.9471493363380432]
the B-LOC [0.9824292063713074, -1.035333514213562]
specific B-LOC [0.9537455439567566, -1.361261010169983]
effects B-LOC [0.8506128787994385, -1.139270544052124]
of B-LOC [0.8877847790718079, -1.0283650159835815]
ApoE4. B-LOC [0.5589224100112915, -1.0074503421783447]
Neurons B-LOC [0.9931871891021729, -1.0420572757720947]
that B-LOC [0.9585036039352417, -1.1024130582809448]
lacked B-LOC [0.7128632664680481, -0.8852540850639343]
APOE B-LOC [0.5049355626106262, -0.8536112308502197]
behaved B-LOC [0.9304859042167664, -0.9617829918861389]
similarly B-LOC [0.8449999690055847, -0.9733853936195374]
to B-LOC [0.6712270379066467, -0.915812075138092]
those B-LOC [0.8515398502349854, -0.8523510098457336]
expressing B-LOC [0.635136067867279, -0.6947067379951477]
ApoE3, B-LOC [0.3484336733818054, -0.8488700985908508]
and B-LOC [0.537735641002655, -0.7854820489883423]
the B-LOC [0.7341467142105103, -0.87281334400177]
introduction B-LOC [0.6128707528114319, -0.9122980237007141]
of B-LOC [0.621141791343689, -0.7818611264228821]
ApoE4 B-LOC [0.3358049988746643, -0.9039881825447083]
expression B-LOC [0.7697755694389343, -0.7082707285881042]
recapitulated B-LOC [0.8839272856712341, -1.0144034624099731]
the B-LOC [0.9096375107765198, -1.1462219953536987]
pathological B-LOC [1.055818796157837, -1.4527024030685425]
phenotypes, B-LOC [0.9328770041465759, -1.4317567348480225]
suggesting B-LOC [0.7721204161643982, -0.997726321220398]
a B-LOC [0.9189561009407043, -1.2770838737487793]
gain B-LOC [0.9045950174331665, -1.3647775650024414]
of B-LOC [0.778718888759613, -1.4233522415161133]
toxic B-LOC [1.1886472702026367, -1.5989227294921875]
effects B-LOC [1.0717437267303467, -1.316295862197876]
from B-LOC [0.6233046054840088, -0.9777469038963318]

ApoE4. B-LOC [-0.2061750888824463, -0.35303446650505066]
Treatment O [-0.18236619234085083, 0.40299317240715027]
of O [-0.4101558327674866, 0.5278468728065491]
ApoE4-expressing O [-0.4302683174610138, 0.40913355350494385]
neurons O [-0.29116490483283997, 0.3800252676010132]
with O [-0.18959593772888184, 0.49792245030403137]
a O [-0.27020779252052307, 0.5046350955963135]
small-molecule O [-0.08950013667345047, 0.6064168810844421]
structure O [0.0018600808689370751, 0.2709183394908905]
corrector O [0.008098679594695568, 0.4327195882797241]
ameliorated O [-0.503963053226471, 0.5946606993675232]
the O [-0.10464946925640106, 0.31355950236320496]
detrimental O [0.11739607900381088, 0.1796863079071045]
effects, O [-0.07618340849876404, 0.2587797939777374]
thus O [0.046024490147829056, 0.3649996221065521]
showing O [-0.15456075966358185, 0.22280113399028778]
that O [-0.015137930400669575, 0.035952042788267136]
correcting O [-0.04933507367968559, 0.036854300647974014]
the B-LOC [0.21140003204345703, -0.1635996252298355]
pathogenic B-LOC [0.04198263958096504, -0.13251526653766632]
conformation B-LOC [0.2848553955554962, -0.2069343775510788]
of O [-0.07641920447349548, 0.059125252068042755]
ApoE4 O [-0.21713349223136902, -0.0518481470644474]
is B-LOC [0.2798962891101837, -0.264934778213501]
a B-LOC [0.33479681611061096, -0.360142320394516]
viable B-LOC [0.4139677584171295, -0.5647440552711487]
therapeutic B-LOC [0.1224549263715744, -0.4456233084201813]
approach B-LOC [0.14168930053710938, -0.5439804792404175]
for B-LOC [0.22944684326648712, -0.4928576946258545]
ApoE4-related O [-0.23128777742385864, -0.10621578246355057]
AD. B-LOC [-0.006436919327825308, -0.19921207427978516]

BACKGROUND B-LOC [1.6736526489257812, -2.21573805809021]
Human B-LOC [2.354170083999634, -2.826855182647705]
immunodeficiency B-LOC [2.892049551010132, -2.8733227252960205]
virus B-LOC [2.792091131210327, -2.8817555904388428]
(HIV) B-LOC [2.8916611671447754, -2.78440523147583]
infection B-LOC [2.7498931884765625, -2.6711103916168213]
is B-LOC [2.653730630874634, -2.601006269454956]
the B-LOC [2.5846405029296875, -2.4931344985961914]
strongest B-LOC [2.4691479206085205, -2.5940558910369873]
risk B-LOC [2.816399335861206, -2.857694625854492]
factor B-LOC [2.6207797527313232, -3.024554967880249]
for B-LOC [2.495710611343384, -2.5885956287384033]
developing B-LOC [2.5425827503204346, -2.5398752689361572]
tuberculosis B-LOC [2.6966023445129395, -2.9024088382720947]
and B-LOC [2.072097063064575, -2.446126937866211]
has B-LOC [2.7272088527679443, -2.7044548988342285]
fuelled B-LOC [2.7820818424224854, -2.8592238426208496]
its B-LOC [2.482570171356201, -2.7667489051818848]
resurgence, B-LOC [2.595899820327759, -2.7852942943573]
especially B-LOC [2.687666654586792, -2.7338857650756836]
in B-LOC [2.598594903945923, -2.4686570167541504]
sub-Saharan B-LOC [2.7800610065460205, -2.935560464859009]
Africa. B-LOC [2.5793280601501465, -2.7410168647766113]
In B-LOC [2.8464958667755127, -3.0339672565460205]
2010, B-LOC [3.1480872631073, -3.0840535163879395]
there B-LOC [3.1288862228393555, -2.8528969287872314]
were B-LOC [2.9056479930877686, -2.855942964553833]
an B-LOC [2.9596145153045654, -3.0417070388793945]
estimated B-LOC [2.9339146614074707, -3.06792950630188]
1.1 B-LOC [3.237931489944458, -3.0558180809020996]
million B-LOC [3.108994722366333, -3.186152219772339]
incident B-LOC [3.0916569232940674, -3.3294758796691895]
cases B-LOC [3.2609987258911133, -3.033149242401123]
of B-LOC [3.030482292175293, -3.1313889026641846]
tuberculosis B-LOC [3.1140339374542236, -3.3008382320404053]
among B-LOC [3.188411235809326, -2.9540321826934814]
the B-LOC [3.1714606285095215, -3.0043046474456787]
34 B-LOC [3.390035390853882, -3.0374515056610107]
million B-LOC [3.3381876945495605, -3.241006374359131]
people B-LOC [3.197871685028076, -3.0522987842559814]
living B-LOC [3.247229814529419, -3.0556576251983643]
with B-LOC [3.2014410495758057, -3.0765135288238525]
HIV B-LOC [3.161036252975464, -3.259861469268799]
worldwide. B-LOC [3.1308178901672363, -3.0455520153045654]
Antiretroviral B-LOC [3.1863420009613037, -3.113133192062378]
therapy B-LOC [3.080904483795166, -3.503873825073242]
has B-LOC [3.300975799560547, -3.104161024093628]
substantial B-LOC [3.2076666355133057, -3.199585437774658]
potential B-LOC [3.413916826248169, -3.43845534324646]
to B-LOC [3.3219029903411865, -3.204364538192749]
prevent B-LOC [3.3093974590301514, -3.325798511505127]
HIV-associated B-LOC [3.3660285472869873, -3.484128475189209]
tuberculosis. B-LOC [3.2386739253997803, -3.542773962020874]
We B-LOC [3.2370855808258057, -3.060032367706299]
conducted B-LOC [3.532780885696411, -3.2294459342956543]
a B-LOC [3.523043155670166, -3.254042387008667]
systematic B-LOC [3.6969168186187744, -3.4120097160339355]
review B-LOC [3.5433847904205322, -3.3414173126220703]
of B-LOC [3.4270598888397217, -3.1843411922454834]
studies B-LOC [3.56108021736145, -3.4834251403808594]
that B-LOC [3.463270425796509, -3.3273398876190186]
analysed B-LOC [3.531978130340576, -3.2144033908843994]
the B-LOC [3.5580060482025146, -3.176424264907837]
impact B-LOC [3.5463526248931885, -3.4956114292144775]
of B-LOC [3.467883586883545, -3.3723459243774414]
antiretroviral B-LOC [3.589114189147949, -3.492844820022583]
therapy B-LOC [3.568392753601074, -3.6132569313049316]
on B-LOC [3.29715895652771, -3.407262086868286]
the B-LOC [3.5338330268859863, -3.2698371410369873]
incidence B-LOC [3.640247106552124, -3.7041890621185303]
of B-LOC [3.4137017726898193, -3.3823416233062744]
tuberculosis B-LOC [3.5681540966033936, -3.751547336578369]
in B-LOC [3.3712174892425537, -3.459653854370117]
adults B-LOC [3.697558879852295, -3.456800699234009]
with B-LOC [3.5305423736572266, -3.72538161277771]
HIV B-LOC [3.5778086185455322, -3.646341562271118]
infection. B-LOC [3.7042272090911865, -3.6497747898101807]
METHODS B-LOC [0.8803640007972717, -1.6324371099472046]
AND B-LOC [1.3930988311767578, -2.175022602081299]
FINDINGS B-LOC [0.8711057305335999, -1.1703510284423828]

PubMed, B-LOC [3.322909116744995, -4.085974216461182]
Embase, B-LOC [3.480743169784546, -3.822540521621704]
African B-LOC [3.5624098777770996, -4.164175033569336]
Index B-LOC [3.269385814666748, -4.092611312866211]
Medicus, B-LOC [3.5870559215545654, -3.7194316387176514]
LILACS, B-LOC [3.686009645462036, -3.9683589935302734]
and B-LOC [3.392102003097534, -3.84474515914917]
clinical B-LOC [3.839495897293091, -4.018835544586182]
trial B-LOC [3.599919080734253, -4.17103385925293]
registries B-LOC [3.644695997238159, -3.8508780002593994]
were B-LOC [3.54850172996521, -3.9853291511535645]
systematically B-LOC [3.7203805446624756, -3.9885809421539307]
searched. B-LOC [3.7618134021759033, -3.88932204246521]
Randomised B-LOC [3.4036056995391846, -3.8247368335723877]
controlled B-LOC [3.5505573749542236, -3.92248797416687]
trials, B-LOC [3.6257364749908447, -3.8450710773468018]
prospective B-LOC [3.4654762744903564, -3.848574638366699]
cohort B-LOC [3.367902994155884, -3.633058786392212]
studies, B-LOC [3.560025215148926, -4.000294208526611]
and B-LOC [3.2449910640716553, -3.7543423175811768]
retrospective B-LOC [3.637028455734253, -3.9614717960357666]
cohort B-LOC [3.437319278717041, -3.745063066482544]
studies B-LOC [3.54606556892395, -3.949179172515869]
were B-LOC [3.447319269180298, -3.7687695026397705]
included B-LOC [3.6596107482910156, -3.8657357692718506]
if B-LOC [3.511904001235962, -3.810403823852539]
they B-LOC [3.4284958839416504, -3.785757541656494]
compared B-LOC [3.4452903270721436, -3.9571871757507324]
tuberculosis B-LOC [3.4434945583343506, -3.9241983890533447]
incidence B-LOC [3.5406434535980225, -3.837061643600464]
by B-LOC [3.3806746006011963, -3.8689000606536865]
antiretroviral B-LOC [3.551069974899292, -3.9027953147888184]
therapy B-LOC [3.4567525386810303, -3.950448513031006]
status B-LOC [3.5738816261291504, -3.7448461055755615]
in B-LOC [3.4347903728485107, -3.672363519668579]
HIV-infected B-LOC [3.430021286010742, -4.043054580688477]
adults B-LOC [3.592193126678467, -3.8249218463897705]
for B-LOC [3.5004899501800537, -3.7390260696411133]
a B-LOC [3.476797103881836, -3.5596959590911865]
median B-LOC [3.5445022583007812, -3.851580858230591]
of B-LOC [3.2877237796783447, -3.4948809146881104]
over B-LOC [3.463576555252075, -3.721423864364624]
6 B-LOC [3.4089515209198, -3.5339925289154053]
mo B-LOC [3.260348320007324, -3.711581230163574]
in B-LOC [3.4120535850524902, -3.6812217235565186]
developing B-LOC [3.5650596618652344, -3.854605197906494]
countries. B-LOC [3.6149117946624756, -3.851670742034912]
For B-LOC [1.43979012966156, -1.671366572380066]
the B-LOC [1.9886443614959717, -1.6624003648757935]
meta-analyses B-LOC [1.9820327758789062, -1.7279647588729858]
there B-LOC [2.3131470680236816, -1.6674600839614868]
were B-LOC [2.2397282123565674, -1.628110647201538]
four B-LOC [2.183483123779297, -1.7976877689361572]
categories B-LOC [2.131324052810669, -1.7871556282043457]
based B-LOC [2.2004523277282715, -2.179828643798828]
on B-LOC [1.9199649095535278, -1.950528621673584]
CD4 B-LOC [1.2552560567855835, -1.1687288284301758]
counts B-LOC [1.790875792503357, -1.5648335218429565]
at B-LOC [1.6954820156097412, -1.8054654598236084]
antiretroviral B-LOC [1.907902717590332, -1.652361273765564]
therapy B-LOC [1.3759407997131348, -1.4007227420806885]
initiation: B-LOC [1.6414169073104858, -1.4740984439849854]
(1) B-LOC [1.6094369888305664, -1.3957968950271606]
less B-LOC [1.3347631692886353, -1.0953283309936523]
than B-LOC [1.2619647979736328, -1.3758854866027832]
200 B-LOC [1.0313693284988403, -1.032928705215454]
cells/µl, B-LOC [0.947865903377533, -1.4441463947296143]
(2) B-LOC [1.6816867589950562, -1.396178126335144]
200 B-LOC [1.0474305152893066, -0.9260316491127014]
to B-LOC [0.895077109336853, -1.5718653202056885]
350 B-LOC [0.9264928698539734, -1.0791435241699219]
cells/µl, B-LOC [0.790252149105072, -1.300917387008667]

(3) B-LOC [2.0663564205169678, -2.156644105911255]
greater B-LOC [2.2178351879119873, -2.260862112045288]
than B-LOC [2.1407225131988525, -2.185875415802002]
350 B-LOC [2.4841153621673584, -2.585930824279785]
cells/µl, B-LOC [1.7752128839492798, -2.3808300495147705]
and B-LOC [2.1088531017303467, -2.1110315322875977]
(4) B-LOC [2.302701711654663, -1.9931824207305908]
any B-LOC [2.2854013442993164, -2.3745033740997314]
CD4 B-LOC [2.569981813430786, -2.488154888153076]
count. B-LOC [2.3120265007019043, -2.6500585079193115]
Eleven B-LOC [3.171032190322876, -3.122568130493164]
studies B-LOC [2.8124301433563232, -2.9425785541534424]
met B-LOC [3.1578662395477295, -3.1380622386932373]
the B-LOC [3.0851423740386963, -2.807180166244507]
inclusion B-LOC [3.162609338760376, -3.0981252193450928]
criteria. B-LOC [3.0832018852233887, -3.206718921661377]
Antiretroviral O [-1.0992152690887451, 1.4269055128097534]
therapy O [-1.147028923034668, 1.2772406339645386]
is O [-1.2087280750274658, 1.1772348880767822]
strongly O [-1.1297669410705566, 1.1603907346725464]
associated O [-1.3201053142547607, 1.2633520364761353]
with O [-1.1775695085525513, 1.2653522491455078]
a O [-1.2846802473068237, 1.2426514625549316]
reduction O [-1.347275733947754, 1.3384946584701538]
in O [-1.395873785018921, 1.2480099201202393]
the O [-1.4076822996139526, 1.2996320724487305]
incidence O [-1.3388161659240723, 1.4058802127838135]
of O [-1.4186352491378784, 1.402966022491455]
tuberculosis O [-1.066356897354126, 1.2628123760223389]
in O [-1.372480034828186, 1.3079020977020264]
all O [-1.2243592739105225, 1.277966856956482]
baseline O [-1.1899709701538086, 1.4550132751464844]
CD4 O [-1.0603891611099243, 1.4825174808502197]
count O [-1.2386765480041504, 1.2836642265319824]
categories: O [-1.2324142456054688, 1.3474125862121582]
(1) O [-1.3471556901931763, 1.604339838027954]
less O [-1.270894169807434, 1.3722906112670898]
than O [-1.4473013877868652, 1.3862733840942383]
200 O [-1.2307897806167603, 1.2764081954956055]
cells/µl O [-1.2722218036651611, 1.0888969898223877]
(hazard O [-1.2996160984039307, 1.1679654121398926]
ratio O [-1.3668383359909058, 1.0913043022155762]
[HR] O [-1.3153704404830933, 1.267146348953247]
0.16, O [-1.2845985889434814, 1.3516499996185303]
95% O [-1.469792366027832, 1.516399621963501]
confidence O [-1.3530983924865723, 1.2531154155731201]
interval O [-1.379852533340454, 1.1692575216293335]
[CI] O [-1.2377456426620483, 1.1485040187835693]
0.07 O [-1.191992163658142, 1.2602354288101196]
to O [-1.4412485361099243, 0.7075781226158142]
0.36), O [-1.0672065019607544, 1.1806886196136475]
(2) O [-1.2203290462493896, 1.3595492839813232]
200 O [-0.9517804384231567, 0.9810948371887207]
to O [-1.4473462104797363, 0.7969098687171936]
350 O [-0.7626292109489441, 0.9921826124191284]
cells/µl O [-1.1439166069030762, 0.7994066476821899]
(HR O [-1.1758188009262085, 1.0092328786849976]
0.34, O [-0.8308528065681458, 0.7669862508773804]
95% O [-1.3490517139434814, 1.2443621158599854]
CI O [-1.1275138854980469, 0.8499804139137268]
0.19 O [-0.969179093837738, 0.7445558309555054]
to O [-1.3002557754516602, 0.7638420462608337]
0.60), O [-0.8030747771263123, 0.8311352133750916]
(3) O [-1.0944328308105469, 1.2272053956985474]
greater O [-1.3858616352081299, 1.4717695713043213]
than O [-1.411669373512268, 1.3786499500274658]

350 B-LOC [0.005986424628645182, -0.32686272263526917]
cells/µl B-LOC [-0.12557977437973022, -0.402601033449173]
(HR B-LOC [0.06369951367378235, -0.31091371178627014]
0.43, B-LOC [0.15976722538471222, -0.3688693344593048]
95% O [-0.2491874396800995, -0.02662588842213154]
CI O [-0.24910423159599304, -0.1410045325756073]
0.30 B-LOC [-0.05807477608323097, -0.27111414074897766]
to O [-0.31616124510765076, -0.22848083078861237]
0.63), B-LOC [0.08294373750686646, -0.22745491564273834]
and B-LOC [0.12355548143386841, -0.26747599244117737]
(4) B-LOC [0.15868079662322998, -0.010760227218270302]
any B-LOC [0.06044619157910347, -0.2754230797290802]
CD4 B-LOC [0.20800717175006866, -0.12070353329181671]
count B-LOC [-0.029849795624613762, -0.29747217893600464]
(HR B-LOC [0.28782588243484497, -0.6097899079322815]
0.35, B-LOC [0.21609075367450714, -0.5149431228637695]
95% B-LOC [0.44524458050727844, -0.9786943197250366]
CI B-LOC [-0.07003702223300934, -0.3445235788822174]
0.28 B-LOC [0.10192281007766724, -0.5202588438987732]
to B-LOC [-0.0338381789624691, -0.48770174384117126]
0.44). B-LOC [0.305309921503067, -0.6754626631736755]
There B-LOC [1.548041820526123, -1.7562131881713867]
was B-LOC [1.4099421501159668, -1.9379308223724365]
no B-LOC [1.7297728061676025, -1.9754482507705688]
evidence B-LOC [1.8345335721969604, -2.2009594440460205]
of B-LOC [1.760122299194336, -2.262993812561035]
hazard B-LOC [1.9889370203018188, -2.424844980239868]
ratio B-LOC [1.7839348316192627, -2.379422426223755]
modification B-LOC [1.711478590965271, -2.4477663040161133]
with B-LOC [2.067718744277954, -1.979961633682251]
respect B-LOC [2.2501935958862305, -2.0137572288513184]
to B-LOC [2.092942953109741, -2.23302960395813]
baseline B-LOC [2.0846965312957764, -2.5284266471862793]
CD4 B-LOC [1.9476759433746338, -2.062969446182251]
count B-LOC [2.011133909225464, -2.439227342605591]
category B-LOC [1.934497594833374, -2.3864662647247314]
(p B-LOC [1.8673371076583862, -1.8098039627075195]
= B-LOC [1.401092767715454, -1.8952546119689941]
0.20). B-LOC [1.6645090579986572, -1.8767833709716797]
CONCLUSIONS O [-0.5664606690406799, 0.2921046316623688]
Antiretroviral B-LOC [0.09087938070297241, -0.20123381912708282]
therapy B-LOC [0.09673567116260529, -0.32794150710105896]
is B-LOC [0.3554746210575104, -0.5077440738677979]
strongly B-LOC [0.3605051338672638, -0.39477959275245667]
associated B-LOC [0.0847376137971878, -0.17756783962249756]
with B-LOC [0.03335198387503624, -0.24059700965881348]
a B-LOC [0.01671578176319599, -0.14797399938106537]
reduction B-LOC [0.10897967219352722, -0.34652814269065857]
in B-LOC [-0.04432503506541252, -0.4818894863128662]
the B-LOC [0.24255861341953278, -0.4180615544319153]
incidence B-LOC [0.119113989174366, -0.4015168249607086]
of B-LOC [0.10860823094844818, -0.38379576802253723]
tuberculosis B-LOC [0.38179337978363037, -0.6796761751174927]
across B-LOC [0.33762526512145996, -0.5229421257972717]
all B-LOC [0.49613305926322937, -0.6146075129508972]
CD4 B-LOC [0.4564925730228424, -0.1310548186302185]
count B-LOC [0.3987046480178833, -0.6300716996192932]
strata. B-LOC [0.6342067718505859, -0.7930601239204407]
Earlier B-LOC [0.51264888048172, -0.849862277507782]
initiation B-LOC [0.6975645422935486, -0.8076428771018982]
of B-LOC [0.7063990235328674, -0.9051410555839539]
antiretroviral B-LOC [0.8283427953720093, -0.8132205009460449]
therapy B-LOC [0.7782921195030212, -0.9326509237289429]
may B-LOC [1.1338227987289429, -1.0921764373779297]
be B-LOC [1.0178313255310059, -1.1811259984970093]
a B-LOC [0.8762298226356506, -1.0204373598098755]
key B-LOC [0.7926315665245056, -1.1036593914031982]
component B-LOC [0.8349463939666748, -1.1115083694458008]
of B-LOC [0.7438530325889587, -1.1432089805603027]
global B-LOC [0.6384915113449097, -1.0211787223815918]

and B-LOC [1.6457937955856323, -2.0873262882232666]
national B-LOC [1.77402663230896, -2.2075235843658447]
strategies B-LOC [2.2469875812530518, -2.1425254344940186]
to B-LOC [2.2297112941741943, -2.2847020626068115]
control B-LOC [2.200827121734619, -2.3216609954833984]
the B-LOC [2.1531002521514893, -2.1818361282348633]
HIV-associated B-LOC [2.0710601806640625, -2.486151933670044]
tuberculosis B-LOC [1.8943495750427246, -2.3881330490112305]
syndemic. B-LOC [2.3565735816955566, -2.377804756164551]
REVIEW B-LOC [1.6730647087097168, -2.1037583351135254]
REGISTRATION B-LOC [1.2445327043533325, -1.628962516784668]
International B-LOC [2.1233818531036377, -2.5411503314971924]
Prospective B-LOC [2.529456377029419, -2.6341054439544678]
Register B-LOC [2.2929437160491943, -2.5305731296539307]
of B-LOC [2.364567995071411, -2.368661642074585]
Systematic B-LOC [2.580965757369995, -2.698967933654785]
Reviews B-LOC [2.024104595184326, -2.3530075550079346]
CRD42011001209 B-LOC [2.2817699909210205, -2.1284682750701904]
Please B-LOC [1.8933336734771729, -2.2968451976776123]
see B-LOC [1.9217638969421387, -2.5450587272644043]
later B-LOC [1.7918508052825928, -2.623765230178833]
in B-LOC [1.9953231811523438, -2.1965596675872803]
the B-LOC [2.051579236984253, -2.379706621170044]
article B-LOC [2.1017634868621826, -2.6635584831237793]
for B-LOC [1.9725894927978516, -2.409405469894409]
the B-LOC [2.2287323474884033, -2.586599826812744]
Editors' B-LOC [2.1682214736938477, -3.0947628021240234]
Summary. B-LOC [2.0501129627227783, -2.4581034183502197]

Somatic B-LOC [1.6708756685256958, -1.9452883005142212]
mutations B-LOC [2.1232187747955322, -2.0533859729766846]
that B-LOC [1.886274814605713, -2.261737108230591]
activate B-LOC [1.8294663429260254, -2.0972788333892822]
phosphoinositide B-LOC [1.5175604820251465, -1.987606406211853]
3-kinase B-LOC [1.5271270275115967, -1.4191992282867432]
(PI3K) B-LOC [1.9896879196166992, -2.145167827606201]
have B-LOC [2.6375341415405273, -2.328251361846924]
been B-LOC [2.700754404067993, -2.5379257202148438]
identified B-LOC [2.4216957092285156, -2.441567897796631]
in B-LOC [2.140216112136841, -2.4188342094421387]
the B-LOC [2.157588005065918, -2.1592180728912354]
p110-alpha B-LOC [1.0351276397705078, -1.83510422706604]
catalytic B-LOC [2.056964159011841, -2.3260726928710938]
subunit B-LOC [1.8145995140075684, -2.170133352279663]
(encoded B-LOC [2.447052240371704, -2.2736711502075195]
by B-LOC [2.0886199474334717, -2.1256518363952637]
PIK3CA). B-LOC [1.467401385307312, -2.1172127723693848]
They B-LOC [2.307326078414917, -2.274338483810425]
are B-LOC [2.5711166858673096, -2.1766293048858643]
most B-LOC [2.697676420211792, -2.374816656112671]
frequently B-LOC [2.482779026031494, -2.319411516189575]
observed B-LOC [2.3287298679351807, -2.1521553993225098]
in B-LOC [2.280456304550171, -2.120659589767456]
two B-LOC [2.2101900577545166, -2.456977367401123]
hotspots: B-LOC [2.494394540786743, -2.401945114135742]
the B-LOC [2.3301870822906494, -2.2878520488739014]
helical B-LOC [1.9351017475128174, -2.3457655906677246]
domain B-LOC [2.055969715118408, -2.4981689453125]
(E545K B-LOC [2.238936185836792, -2.1484758853912354]
and B-LOC [1.608309268951416, -2.005966901779175]
E542K) B-LOC [1.8420038223266602, -1.9609856605529785]
and B-LOC [2.305290937423706, -2.324078321456909]
the B-LOC [2.2525887489318848, -2.3631017208099365]
kinase B-LOC [1.9284924268722534, -2.40674090385437]
domain B-LOC [1.9684443473815918, -2.502305746078491]
(H1047R). B-LOC [2.1024606227874756, -2.1986911296844482]
Although B-LOC [2.3658082485198975, -2.2322309017181396]
the B-LOC [2.155670642852783, -1.9977983236312866]
p110-alpha B-LOC [1.0129872560501099, -1.6923131942749023]
mutants B-LOC [1.9162631034851074, -2.299701690673828]
are B-LOC [2.6271231174468994, -2.222371816635132]
transforming B-LOC [2.5965657234191895, -2.69447660446167]
in B-LOC [2.3427507877349854, -2.451251983642578]
vitro, B-LOC [2.1585042476654053, -2.2243340015411377]
their B-LOC [2.4435455799102783, -2.3593344688415527]
oncogenic B-LOC [2.399916887283325, -2.6488091945648193]
potential B-LOC [2.5558688640594482, -2.7971932888031006]
has B-LOC [3.1444904804229736, -2.7050721645355225]
not B-LOC [3.1841163635253906, -2.679871082305908]
been B-LOC [3.073514223098755, -2.970346689224243]
assessed B-LOC [2.8675107955932617, -3.1009514331817627]
in B-LOC [2.6731226444244385, -2.876770496368408]
genetically B-LOC [2.8881359100341797, -3.0140812397003174]
engineered B-LOC [2.7041852474212646, -3.089561700820923]
mouse B-LOC [2.325749635696411, -2.6334116458892822]
models. B-LOC [2.622976303100586, -2.914236068725586]
Furthermore, B-LOC [2.3611855506896973, -2.3225855827331543]
clinical B-LOC [2.1238131523132324, -2.297292947769165]
trials B-LOC [2.056583881378174, -2.1752777099609375]
with B-LOC [1.8497867584228516, -1.785970687866211]

PI3K B-LOC [2.5876762866973877, -3.3477635383605957]
inhibitors B-LOC [3.2238996028900146, -3.5186684131622314]
have B-LOC [3.4732825756073, -3.3769538402557373]
recently B-LOC [3.5939064025878906, -3.5545718669891357]
been B-LOC [3.4454469680786133, -3.5929667949676514]
initiated, B-LOC [3.4208245277404785, -3.6626625061035156]
and B-LOC [3.1109273433685303, -3.503448724746704]
it B-LOC [3.5160555839538574, -3.4771299362182617]
is B-LOC [3.451932191848755, -3.3714916706085205]
unknown B-LOC [3.4088289737701416, -3.5963504314422607]
if B-LOC [3.173184394836426, -3.853529214859009]
their B-LOC [3.4932749271392822, -3.48842453956604]
efficacy B-LOC [3.360621213912964, -3.5812909603118896]
will B-LOC [3.4710805416107178, -3.530451536178589]
be B-LOC [3.396892547607422, -3.6174404621124268]
restricted B-LOC [3.470334053039551, -3.7618205547332764]
to B-LOC [3.340033531188965, -3.5390734672546387]
specific, B-LOC [3.2612197399139404, -3.885969877243042]
genetically B-LOC [3.61159348487854, -3.791931390762329]
defined B-LOC [3.1763031482696533, -3.8546652793884277]
malignancies. B-LOC [3.4222629070281982, -3.5546610355377197]
In B-LOC [2.4861855506896973, -2.8608009815216064]
this B-LOC [2.628092050552368, -2.766605854034424]
study, B-LOC [2.677039384841919, -3.018174409866333]
we B-LOC [2.382106065750122, -2.6476266384124756]
engineered B-LOC [2.7613117694854736, -2.832151412963867]
a B-LOC [2.733325958251953, -2.970841646194458]
mouse B-LOC [2.8682596683502197, -3.035335063934326]
model B-LOC [2.7985851764678955, -3.1557891368865967]
of B-LOC [2.7041680812835693, -2.8785364627838135]
lung B-LOC [2.6423447132110596, -3.000324010848999]
adenocarcinomas B-LOC [2.854116201400757, -2.8857076168060303]
initiated B-LOC [2.766838312149048, -2.9034197330474854]
and B-LOC [2.5641512870788574, -2.6401541233062744]
maintained B-LOC [2.7338576316833496, -2.9447414875030518]
by B-LOC [2.606703519821167, -2.7104392051696777]
expression B-LOC [2.737060070037842, -2.688479423522949]
of B-LOC [2.5836877822875977, -2.8101806640625]
p110-alpha B-LOC [2.4590818881988525, -2.9030792713165283]
H1047R. B-LOC [2.547942876815796, -2.9772675037384033]
Treatment B-LOC [1.2632265090942383, -1.2830781936645508]
of B-LOC [1.4631152153015137, -1.168297290802002]
these B-LOC [1.1802418231964111, -1.084613561630249]
tumors B-LOC [1.1541502475738525, -1.222421646118164]
with B-LOC [1.1088838577270508, -1.123255729675293]
NVP-BEZ235, B-LOC [0.9938600063323975, -1.0021531581878662]
a B-LOC [1.0215011835098267, -0.7931704521179199]
dual B-LOC [1.0482707023620605, -1.190500020980835]
pan-PI3K B-LOC [0.9681481122970581, -1.3129215240478516]
and B-LOC [0.8040999174118042, -0.8279735445976257]
mammalian B-LOC [1.2851295471191406, -1.3125940561294556]
target B-LOC [1.0203968286514282, -1.0527632236480713]
of B-LOC [0.9082128405570984, -0.7081997990608215]
rapamycin B-LOC [0.8207476735115051, -0.9239475131034851]
(mTOR) B-LOC [1.2601399421691895, -1.0014216899871826]
inhibitor B-LOC [1.0352280139923096, -1.1300472021102905]
in B-LOC [1.232580304145813, -1.3084065914154053]
clinical B-LOC [1.5696382522583008, -1.4529504776000977]
development, B-LOC [1.2334785461425781, -0.9121080040931702]
led B-LOC [0.9046021103858948, -1.3445730209350586]
to B-LOC [1.0325887203216553, -1.2081694602966309]
marked B-LOC [1.0236272811889648, -1.4179394245147705]
tumor B-LOC [1.1810426712036133, -1.539608359336853]
regression B-LOC [1.3304929733276367, -1.6978486776351929]
as B-LOC [1.0985281467437744, -1.3280234336853027]
shown B-LOC [1.4188895225524902, -1.5501601696014404]
by B-LOC [1.3649373054504395, -1.3963990211486816]
positron B-LOC [1.4731491804122925, -1.5706686973571777]
emission B-LOC [1.247243046760559, -1.2423298358917236]

tomography-computed B-LOC [1.5517524480819702, -2.1363425254821777]
tomography, B-LOC [2.1181139945983887, -2.5120303630828857]
magnetic B-LOC [2.074462413787842, -2.2800183296203613]
resonance B-LOC [2.1660213470458984, -2.330690622329712]
imaging B-LOC [1.8535183668136597, -1.9443888664245605]
and B-LOC [1.715688705444336, -2.0645124912261963]
microscopic B-LOC [2.1418516635894775, -2.211653470993042]
examination. B-LOC [1.7330877780914307, -1.9803385734558105]
In B-LOC [0.3129919469356537, -0.3950813114643097]
contrast, B-LOC [0.45123714208602905, -0.3920397460460663]
mouse B-LOC [0.1180557906627655, -0.21900855004787445]
lung B-LOC [0.3007291257381439, -0.5460168123245239]
cancers B-LOC [0.26148340106010437, -0.3298582136631012]
driven B-LOC [0.33748963475227356, -0.4911710023880005]
by B-LOC [0.0894898995757103, -0.11283138394355774]
mutant B-LOC [0.29188480973243713, -0.4037468135356903]
Kras B-LOC [0.43079784512519836, -0.6334399580955505]
did B-LOC [0.2287413477897644, -0.29584455490112305]
not B-LOC [0.4191746413707733, -0.21718202531337738]
substantially B-LOC [0.3374076783657074, -0.3041991889476776]
respond B-LOC [0.3940373361110687, -0.47868508100509644]
to B-LOC [0.2241998016834259, -0.364266037940979]
single-agent B-LOC [0.5842105746269226, -0.5153428912162781]
NVP-BEZ235. B-LOC [0.2797853946685791, -0.4233689308166504]
However, O [-0.20631143450737, 0.13979017734527588]
when O [-0.3104475438594818, 0.09770046174526215]
NVP-BEZ235 O [-0.2209978699684143, 0.18128296732902527]
was O [-0.030570054426789284, 0.2354286164045334]
combined O [-0.0038361004553735256, 0.2384297251701355]
with O [0.037901271134614944, 0.13221213221549988]
a O [0.0071302675642073154, 0.16372370719909668]
mitogen-activated O [-0.18624380230903625, 0.4115416705608368]
protein O [-0.23887300491333008, 0.11479762941598892]
kinase O [0.05333076789975166, 0.15553875267505646]
kinase O [-0.008648973889648914, 0.17074662446975708]
(MEK) B-LOC [0.0982072725892067, 0.020960649475455284]
inhibitor, O [-0.1848173290491104, 0.06719361990690231]
ARRY-142886, O [-0.14013725519180298, 0.23747161030769348]
there O [-0.5199553370475769, 0.2824220657348633]
was O [-0.5354994535446167, 0.1542493999004364]
marked O [-0.3248284161090851, 0.2566838264465332]
synergy O [-0.34213677048683167, 0.17167097330093384]
in O [-0.41426464915275574, 0.351725697517395]
shrinking O [-0.01819559745490551, 0.40445417165756226]
these O [-0.13985788822174072, 0.0937211811542511]
Kras-mutant B-LOC [-0.04200107231736183, -0.1046743094921112]
cancers. O [-0.12659093737602234, 0.001620789524167776]
These B-LOC [0.24879735708236694, -0.19022053480148315]
in B-LOC [0.11630332469940186, -0.2934532165527344]
vivo B-LOC [0.009968745522201061, -0.1103982999920845]
studies B-LOC [0.2254866361618042, -0.195730522274971]
suggest B-LOC [0.216824471950531, -0.2623613476753235]
that B-LOC [0.3382548391819, -0.4832216501235962]
inhibitors B-LOC [0.49022117257118225, -0.34149783849716187]
of B-LOC [0.20155183970928192, -0.19202201068401337]
the B-LOC [0.36462756991386414, -0.3971025049686432]
PI3K-mTOR B-LOC [0.09902763366699219, -0.39191049337387085]
pathway B-LOC [-0.11413145810365677, -0.25888174772262573]

may O [-0.3938327133655548, 0.19981727004051208]
be O [-0.5115810036659241, 0.21383686363697052]
active O [-0.4241359531879425, 0.4724980294704437]
in O [-0.49614855647087097, 0.5067028999328613]
cancers O [-0.14273783564567566, 0.14192767441272736]
with O [-0.3242245614528656, 0.2709587812423706]
PIK3CA O [-0.441619873046875, 0.31391313672065735]
mutations O [-0.3198651373386383, 0.4608219265937805]
and, O [-0.7523367404937744, 0.5654699206352234]
when O [-0.46809104084968567, 0.24911926686763763]
combined O [-0.1472601294517517, 0.36129826307296753]
with O [-0.07194457203149796, 0.3898884356021881]
MEK O [-0.2799140214920044, 0.46303287148475647]
inhibitors, O [-0.21383659541606903, 0.2837364375591278]
may O [-0.3925606608390808, 0.5769860744476318]
effectively O [-0.40972113609313965, 0.44483521580696106]
treat O [-0.3986265957355499, 0.5534239411354065]
KRAS O [-0.3205183744430542, 0.2684830129146576]
mutated O [-0.40972721576690674, 0.5801698565483093]
lung O [-0.3417668640613556, 0.24655213952064514]
cancers. O [-0.2792466878890991, 0.2329566925764084]

In B-LOC [1.4952361583709717, -1.94886314868927]
this B-LOC [1.9447379112243652, -2.1095216274261475]
study, B-LOC [1.9406434297561646, -2.350426197052002]
we B-LOC [1.784712553024292, -1.7967610359191895]
describe B-LOC [2.2218315601348877, -2.2312939167022705]
the B-LOC [2.3771145343780518, -2.4953038692474365]
3D B-LOC [2.3432457447052, -2.57283878326416]
chromosome B-LOC [2.0631978511810303, -2.5726468563079834]
regulatory B-LOC [2.2126047611236572, -2.6225709915161133]
landscape B-LOC [2.329648733139038, -2.5481536388397217]
of B-LOC [2.1225461959838867, -2.538665771484375]
human B-LOC [2.067857027053833, -2.5442187786102295]
naive B-LOC [2.0293664932250977, -2.2730648517608643]
and B-LOC [2.2388529777526855, -2.662635087966919]
primed B-LOC [2.452493190765381, -2.9668447971343994]
embryonic B-LOC [2.236360549926758, -2.5319478511810303]
stem B-LOC [2.2608721256256104, -2.687283754348755]
cells. B-LOC [2.143141746520996, -2.51161789894104]
To B-LOC [1.9337533712387085, -2.560628652572632]
devise B-LOC [2.5620644092559814, -2.886537551879883]
this B-LOC [2.1074740886688232, -2.639328956604004]
map, B-LOC [2.114206314086914, -3.022329807281494]
we B-LOC [1.953916311264038, -2.3132336139678955]
identified B-LOC [2.030256748199463, -2.3869259357452393]
transcriptional B-LOC [1.8775951862335205, -2.4215285778045654]
enhancers B-LOC [1.9628899097442627, -2.2539010047912598]
and B-LOC [1.9798634052276611, -2.279953956604004]
insulators B-LOC [1.9280164241790771, -2.3549046516418457]
in B-LOC [1.5598088502883911, -2.0525269508361816]
these B-LOC [2.0047523975372314, -2.222513198852539]
cells B-LOC [1.8133738040924072, -2.2694084644317627]
and B-LOC [2.1484432220458984, -2.535951852798462]
placed B-LOC [2.2966196537017822, -2.481473922729492]
them B-LOC [2.2125627994537354, -2.5030758380889893]
within B-LOC [2.7251217365264893, -2.7552952766418457]
the B-LOC [2.57031512260437, -2.646045684814453]
context B-LOC [2.473602294921875, -2.594658136367798]
of B-LOC [2.1158831119537354, -2.5416786670684814]
cohesin-associated B-LOC [1.8065505027770996, -2.385286569595337]
CTCF-CTCF B-LOC [1.8316457271575928, -2.1291086673736572]
loops B-LOC [1.876908779144287, -2.142544984817505]
using B-LOC [2.3572568893432617, -2.714590549468994]
cohesin B-LOC [1.8788931369781494, -2.3318943977355957]
ChIA-PET B-LOC [2.186467409133911, -2.4433445930480957]
data. B-LOC [2.315953254699707, -2.4806337356567383]
The B-LOC [0.8259036540985107, -0.7863561511039734]
CTCF-CTCF B-LOC [0.7758476138114929, -0.9154241681098938]
loops B-LOC [0.8859911561012268, -0.8780129551887512]
we B-LOC [0.6436085104942322, -0.9346395134925842]
identified B-LOC [0.9393828511238098, -0.7976763248443604]
form B-LOC [1.1309831142425537, -0.8058432340621948]
a B-LOC [1.0656628608703613, -0.8542704582214355]
chromosomal B-LOC [1.023854374885559, -1.0155022144317627]
framework B-LOC [0.934013307094574, -0.9742048382759094]
of B-LOC [0.9056260585784912, -0.9851984977722168]
insulated B-LOC [0.9599366784095764, -0.9205772876739502]
neighborhoods, B-LOC [1.0679658651351929, -0.8780962824821472]
which B-LOC [0.8395223021507263, -0.9740508794784546]
in B-LOC [1.0999393463134766, -0.793561577796936]
turn B-LOC [1.1293447017669678, -0.6129950284957886]
form B-LOC [1.1426589488983154, -0.995102047920227]
topologically B-LOC [1.461203932762146, -1.3112365007400513]
associating B-LOC [0.9609752893447876, -1.2619860172271729]
domains B-LOC [0.9472833275794983, -1.0676829814910889]
(TADs) B-LOC [1.315947413444519, -1.2703484296798706]
that B-LOC [0.9226769804954529, -1.0408552885055542]
are B-LOC [1.3926126956939697, -1.209069013595581]
largely B-LOC [1.082926869392395, -1.0438965559005737]
preserved B-LOC [1.0728440284729004, -1.10422682762146]
during B-LOC [0.9504463076591492, -0.9475429058074951]
the B-LOC [1.1447514295578003, -1.044264316558838]
transition B-LOC [0.8575851321220398, -1.1142730712890625]
between B-LOC [1.0725574493408203, -1.353265643119812]
the B-LOC [0.8059912323951721, -1.0116251707077026]

naive B-LOC [0.6015393137931824, -1.1259851455688477]
and B-LOC [0.8341837525367737, -1.2219533920288086]
primed B-LOC [1.085375428199768, -1.5159894227981567]
states. B-LOC [0.8934381008148193, -1.2091236114501953]
Regulatory B-LOC [1.0957762002944946, -1.6417597532272339]
changes B-LOC [1.0905367136001587, -1.582254409790039]
in B-LOC [1.0812697410583496, -1.7294855117797852]
enhancer-promoter B-LOC [1.049033522605896, -1.3125879764556885]
interactions B-LOC [1.1671664714813232, -1.3506171703338623]
occur B-LOC [1.2464430332183838, -1.675325870513916]
within B-LOC [1.333092212677002, -1.5851234197616577]
insulated B-LOC [1.6007094383239746, -1.4578434228897095]
neighborhoods B-LOC [1.29596745967865, -1.3844120502471924]
during B-LOC [1.127766489982605, -1.5363816022872925]
cell B-LOC [0.7183840870857239, -1.3551549911499023]
state B-LOC [1.1532173156738281, -1.432253122329712]
transition. B-LOC [1.1944611072540283, -1.5923278331756592]
The B-LOC [0.7883400321006775, -0.679374635219574]
CTCF B-LOC [0.7346572875976562, -0.8344610929489136]
anchor B-LOC [0.808006227016449, -0.6645663380622864]
regions B-LOC [0.7967643141746521, -0.7353092432022095]
we B-LOC [0.6581137776374817, -0.8852481245994568]
identified B-LOC [0.7585996985435486, -0.6320237517356873]
are B-LOC [0.972602903842926, -0.8740898966789246]
conserved B-LOC [0.9464328289031982, -0.8738726377487183]
across B-LOC [0.8579227328300476, -1.279788613319397]
species, B-LOC [0.8837172389030457, -1.122186541557312]
influence B-LOC [0.5108065009117126, -1.0350985527038574]
gene B-LOC [0.513918936252594, -1.1062936782836914]
expression, B-LOC [0.646841824054718, -0.6683482527732849]
and B-LOC [0.6571740508079529, -0.4899607002735138]
are B-LOC [0.7118061184883118, -0.7480356097221375]
a B-LOC [0.6867198348045349, -0.6518577337265015]
frequent B-LOC [0.6874784231185913, -0.776739776134491]
site B-LOC [0.8270809054374695, -0.875858724117279]
of B-LOC [0.8888291120529175, -1.0646569728851318]
mutations B-LOC [0.8967466950416565, -1.0353509187698364]
in B-LOC [0.7630874514579773, -0.9688159227371216]
cancer B-LOC [0.9768149256706238, -1.0334874391555786]
cells, B-LOC [0.8408403992652893, -1.0040160417556763]
underscoring B-LOC [1.1512118577957153, -0.9827613830566406]
their B-LOC [1.2810701131820679, -1.4403736591339111]
functional B-LOC [1.3465218544006348, -1.2326966524124146]
importance B-LOC [1.185807228088379, -1.2667827606201172]
in B-LOC [1.1192827224731445, -1.5639653205871582]
cellular B-LOC [0.9528524875640869, -1.2308595180511475]
regulation. B-LOC [1.1828057765960693, -1.2003790140151978]
These B-LOC [1.1040427684783936, -1.1891659498214722]
3D B-LOC [1.2731008529663086, -1.4766530990600586]
regulatory B-LOC [1.505092740058899, -1.832374930381775]
maps B-LOC [1.394041657447815, -1.6228324174880981]
of B-LOC [1.3867254257202148, -1.8215080499649048]
human B-LOC [1.276773452758789, -1.7471463680267334]
pluripotent B-LOC [1.60637629032135, -1.9404644966125488]
cells B-LOC [1.43619966506958, -1.7555748224258423]
therefore B-LOC [1.6141998767852783, -1.4342834949493408]
provide B-LOC [1.7147318124771118, -1.707960605621338]
a B-LOC [1.682629108428955, -1.731675148010254]
foundation B-LOC [1.6564059257507324, -1.7991211414337158]
for B-LOC [1.68791663646698, -1.6984344720840454]
future B-LOC [1.623239517211914, -1.9033650159835815]
interrogation B-LOC [1.596126914024353, -1.7760558128356934]
of B-LOC [1.5854694843292236, -1.9656527042388916]
the B-LOC [1.7231359481811523, -1.9658719301223755]
relationships B-LOC [1.6616380214691162, -1.9972857236862183]
between B-LOC [1.7654821872711182, -2.203690767288208]
chromosome B-LOC [1.491382122039795, -2.0031192302703857]
structure B-LOC [1.7411222457885742, -1.9111316204071045]
and B-LOC [1.8082349300384521, -2.144310235977173]
gene B-LOC [1.6272770166397095, -2.2629857063293457]
control B-LOC [1.6945302486419678, -2.09488844871521]
in B-LOC [1.4984124898910522, -2.072003126144409]
development B-LOC [1.6275511980056763, -1.878259301185608]
and B-LOC [1.8144664764404297, -2.031079053878784]
disease. B-LOC [1.9728367328643799, -2.226983070373535]

One B-LOC [1.9410784244537354, -2.275891065597534]
hypothesis B-LOC [1.9417186975479126, -2.1882174015045166]
that B-LOC [2.1167232990264893, -2.481031894683838]
couples B-LOC [2.1320090293884277, -2.3866755962371826]
infection B-LOC [2.017707109451294, -2.401867151260376]
with B-LOC [1.9711761474609375, -2.6979215145111084]
autoimmune B-LOC [2.279928207397461, -2.932939291000366]
disease B-LOC [2.234975576400757, -2.637037754058838]
is B-LOC [2.261901617050171, -2.377936601638794]
molecular B-LOC [1.9335185289382935, -2.3946292400360107]
mimicry. B-LOC [1.6750702857971191, -2.179567813873291]
Molecular B-LOC [0.9607468247413635, -1.2549772262573242]
mimicry B-LOC [0.9359884262084961, -1.1212574243545532]
is B-LOC [1.0510156154632568, -1.2933104038238525]
characterized B-LOC [0.9168381094932556, -1.055598497390747]
by B-LOC [0.792323887348175, -1.1499581336975098]
an B-LOC [0.8162134289741516, -1.243399977684021]
immune B-LOC [0.9534390568733215, -1.1795856952667236]
response B-LOC [0.7900665402412415, -0.9548672437667847]
to B-LOC [0.7260304093360901, -1.141709804534912]
an B-LOC [0.9011795520782471, -1.2058179378509521]
environmental B-LOC [0.9435297250747681, -1.1141705513000488]
agent B-LOC [0.6825467944145203, -1.0886530876159668]
that B-LOC [0.6346959471702576, -1.273596167564392]
cross-reacts B-LOC [0.4926339387893677, -0.8388412594795227]
with B-LOC [0.7938547134399414, -1.0529454946517944]
a B-LOC [1.013904333114624, -1.2311749458312988]
host B-LOC [0.8572227954864502, -1.3381329774856567]
antigen, B-LOC [0.9999616146087646, -1.230380654335022]
resulting B-LOC [0.8565977215766907, -1.130834698677063]
in B-LOC [0.726942777633667, -1.244079828262329]
disease. B-LOC [1.6076223850250244, -1.9318816661834717]
This B-LOC [2.4982974529266357, -2.7622368335723877]
hypothesis B-LOC [2.500808000564575, -2.6929123401641846]
has B-LOC [2.7637851238250732, -2.5744731426239014]
been B-LOC [2.754437208175659, -2.71834397315979]
implicated B-LOC [2.5508055686950684, -2.6435561180114746]
in B-LOC [2.4948294162750244, -2.7061350345611572]
the B-LOC [2.530508279800415, -2.4644813537597656]
pathogenesis B-LOC [2.697749376296997, -2.8567099571228027]
of B-LOC [2.523914337158203, -2.584843873977661]
diabetes, B-LOC [2.6730101108551025, -2.7950661182403564]
lupus B-LOC [2.352891683578491, -2.5976600646972656]
and B-LOC [2.632964849472046, -2.445084810256958]
multiple B-LOC [2.799368381500244, -2.7992217540740967]
sclerosis B-LOC [2.636153221130371, -2.8714652061462402]
(MS). B-LOC [2.7895681858062744, -2.839170217514038]
There B-LOC [2.7794811725616455, -2.338540554046631]
is B-LOC [2.9914543628692627, -2.487034559249878]
limited B-LOC [2.8707447052001953, -2.6776814460754395]
direct B-LOC [2.850729465484619, -2.8186757564544678]
evidence B-LOC [2.6554996967315674, -2.641306161880493]
linking B-LOC [2.739133358001709, -2.86891770362854]
causative B-LOC [2.879542350769043, -2.914095163345337]
agents B-LOC [2.8538129329681396, -3.0860559940338135]
with B-LOC [2.666982650756836, -3.048085927963257]
pathogenic B-LOC [2.9410502910614014, -3.0918359756469727]
immune B-LOC [2.9511606693267822, -3.1471827030181885]
reactions B-LOC [2.7202742099761963, -3.0194904804229736]
in B-LOC [2.8189656734466553, -3.000483989715576]
these B-LOC [2.7898573875427246, -2.798638105392456]
diseases. B-LOC [2.9894461631774902, -2.955270767211914]
Our B-LOC [2.434349298477173, -2.260470390319824]
study B-LOC [2.479402542114258, -2.5249319076538086]
establishes B-LOC [2.9822797775268555, -2.588867664337158]
a B-LOC [2.868859052658081, -2.9300267696380615]
clear B-LOC [2.90480637550354, -2.881063222885132]
link B-LOC [2.7012150287628174, -2.8424313068389893]
between B-LOC [2.7611231803894043, -2.898771286010742]
viral B-LOC [2.5558087825775146, -2.9155514240264893]
infection, B-LOC [2.7058072090148926, -2.8911397457122803]
autoimmunity B-LOC [2.749335527420044, -3.2685797214508057]
and B-LOC [2.80794620513916, -2.799243211746216]
neurological B-LOC [2.6597142219543457, -3.0885818004608154]
disease B-LOC [2.7573933601379395, -3.053673505783081]
in B-LOC [2.659320592880249, -2.883344888687134]
humans. B-LOC [2.7071726322174072, -2.7985012531280518]
As B-LOC [1.2247790098190308, -1.6041717529296875]
a B-LOC [1.344293236732483, -1.8814111948013306]
model B-LOC [1.3451875448226929, -1.7741847038269043]
for B-LOC [1.2666884660720825, -1.6661310195922852]
molecular B-LOC [1.4384078979492188, -1.9517128467559814]
mimicry, B-LOC [1.3511022329330444, -1.7278766632080078]
we B-LOC [0.9037088751792908, -1.187537670135498]
studied B-LOC [1.1227210760116577, -1.3603699207305908]
patients B-LOC [1.050689935684204, -1.26628839969635]

with B-LOC [1.2670241594314575, -1.6290212869644165]
human B-LOC [1.7514231204986572, -2.034977436065674]
T-lymphotropic B-LOC [1.5181353092193604, -2.010256052017212]
virus B-LOC [1.7481576204299927, -2.1793229579925537]
type B-LOC [2.085721731185913, -1.9879049062728882]
1 B-LOC [1.7678300142288208, -1.8940064907073975]
(HTLV-1)-associated B-LOC [1.8185234069824219, -2.03576922416687]
myelopathy/tropical B-LOC [1.6911811828613281, -2.028230667114258]
spastic B-LOC [1.7024377584457397, -1.993729591369629]
paraparesis B-LOC [1.635756015777588, -2.0142738819122314]
(HAM/TSP), B-LOC [1.9970853328704834, -2.120234251022339]
a B-LOC [1.8523415327072144, -1.9297587871551514]
disease B-LOC [1.7882575988769531, -2.0626296997070312]
that B-LOC [1.850399374961853, -2.155001163482666]
can B-LOC [2.1893904209136963, -2.229978322982788]
be B-LOC [2.3041188716888428, -2.4647276401519775]
indistinguishable B-LOC [2.326831102371216, -2.2291266918182373]
from B-LOC [1.9764420986175537, -2.094407320022583]
MS B-LOC [1.817901849746704, -2.074805974960327]
(refs. B-LOC [1.910095453262329, -2.1113197803497314]
5,6,7). B-LOC [1.765744924545288, -1.9734044075012207]
HAM/TSP B-LOC [1.8070363998413086, -2.3184964656829834]
patients B-LOC [1.8378342390060425, -1.964908242225647]
develop B-LOC [1.8228263854980469, -1.829761266708374]
antibodies B-LOC [2.1007630825042725, -2.251164197921753]
to B-LOC [1.7410012483596802, -2.064150333404541]
neurons. B-LOC [1.6255676746368408, -2.2345831394195557]
We B-LOC [2.131308078765869, -2.396066188812256]
hypothesized B-LOC [3.169180154800415, -2.8905272483825684]
these B-LOC [2.509267568588257, -2.7506978511810303]
antibodies B-LOC [2.4432969093322754, -2.8035261631011963]
would B-LOC [2.4693171977996826, -2.6594154834747314]
identify B-LOC [2.3923444747924805, -2.8209638595581055]
a B-LOC [2.618532419204712, -2.975187063217163]
central B-LOC [2.4058845043182373, -3.208510160446167]
nervous B-LOC [2.4113552570343018, -2.9452593326568604]
system B-LOC [2.0733704566955566, -2.8093745708465576]
(CNS) B-LOC [2.684370994567871, -2.74748158454895]
autoantigen. B-LOC [2.5885279178619385, -3.0908496379852295]
Immunoglobulin B-LOC [1.2733240127563477, -1.2724297046661377]
G B-LOC [1.189693570137024, -1.0112059116363525]
isolated B-LOC [1.3737387657165527, -1.305942416191101]
from B-LOC [0.9773539900779724, -0.9440759420394897]
HAM/TSP B-LOC [0.9345006942749023, -1.4186887741088867]
patients B-LOC [0.9784310460090637, -1.0093566179275513]
identified B-LOC [1.1661851406097412, -1.1546127796173096]
heterogeneous B-LOC [1.2994506359100342, -1.5252962112426758]
nuclear B-LOC [0.9538319706916809, -1.3513038158416748]

ribonuclear B-LOC [0.896496593952179, -1.4545713663101196]
protein-A1 B-LOC [1.2263023853302002, -1.7690942287445068]
(hnRNP-A1) B-LOC [1.1507421731948853, -1.4509813785552979]
as B-LOC [1.1063532829284668, -1.4712210893630981]
the B-LOC [1.151144027709961, -1.3224643468856812]
autoantigen. B-LOC [1.2449824810028076, -1.6113576889038086]
Antibodies B-LOC [2.047614336013794, -2.1226723194122314]
to B-LOC [1.786928653717041, -1.9415502548217773]
hnRNP-A1 B-LOC [1.381734848022461, -2.003711462020874]
cross-reacted B-LOC [1.9262804985046387, -2.129915475845337]
with B-LOC [2.0491321086883545, -2.1840574741363525]
HTLV-1-tax, B-LOC [1.7165074348449707, -2.33866548538208]
the B-LOC [1.8458712100982666, -2.119318962097168]
immune B-LOC [1.9104077816009521, -2.3108060359954834]
response B-LOC [1.6156814098358154, -2.0944674015045166]
to B-LOC [2.016998767852783, -2.3689308166503906]
which B-LOC [1.8226152658462524, -2.058529853820801]
is B-LOC [2.071052312850952, -2.095527410507202]
associated B-LOC [1.9159108400344849, -1.968748688697815]
with B-LOC [1.9863758087158203, -2.141000986099243]
HAM/TSP B-LOC [1.8566392660140991, -2.345322370529175]
(refs. B-LOC [1.9536045789718628, -2.090052366256714]
5,9). B-LOC [1.8812696933746338, -2.042583703994751]
Immunoglobulin B-LOC [1.843191385269165, -1.5583107471466064]
G B-LOC [1.7939629554748535, -1.5948697328567505]
specifically B-LOC [2.008674383163452, -1.9387904405593872]
stained B-LOC [1.8477563858032227, -1.764934778213501]
human B-LOC [1.7929472923278809, -1.9621567726135254]
Betz B-LOC [1.1799204349517822, -1.6355952024459839]
cells, B-LOC [1.403530478477478, -1.9968147277832031]
whose B-LOC [2.06245756149292, -2.115108013153076]
axons B-LOC [2.032419204711914, -1.9336552619934082]
are B-LOC [2.420038938522339, -2.161125421524048]
preferentially B-LOC [2.3321774005889893, -2.2646000385284424]
damaged. B-LOC [2.2776684761047363, -2.1517820358276367]
Infusion B-LOC [1.1196060180664062, -0.8381908535957336]
of B-LOC [1.1012259721755981, -0.7732948660850525]
autoantibodies B-LOC [1.1974456310272217, -1.2386773824691772]
in B-LOC [0.9074035882949829, -0.9639071822166443]
brain B-LOC [0.9121567606925964, -1.3526389598846436]
sections B-LOC [0.9487536549568176, -1.1132441759109497]
inhibited B-LOC [1.0096955299377441, -1.0802631378173828]
neuronal B-LOC [0.9035121202468872, -1.4626245498657227]
firing, B-LOC [0.6228789687156677, -1.2957203388214111]
indicative B-LOC [1.375319242477417, -1.0978810787200928]
of B-LOC [1.1204441785812378, -1.3744101524353027]
their B-LOC [1.3675901889801025, -1.5050286054611206]
pathogenic B-LOC [1.5004745721817017, -1.851689338684082]
nature. B-LOC [1.437186360359192, -1.7507779598236084]
These B-LOC [1.2683676481246948, -1.4310603141784668]
data B-LOC [1.3343886137008667, -1.6064748764038086]
demonstrate B-LOC [1.4613847732543945, -1.572447657585144]
the B-LOC [1.6077780723571777, -1.7972991466522217]
importance B-LOC [1.3425624370574951, -1.8075296878814697]

of B-LOC [-0.13751907646656036, -0.2761043310165405]
molecular B-LOC [-0.1246546283364296, -0.3200072646141052]
mimicry B-LOC [0.06663939356803894, -0.27203842997550964]
between B-LOC [0.03513512387871742, -0.4013291299343109]
an B-LOC [-0.0018023973098024726, -0.23955056071281433]
infecting B-LOC [0.06201561912894249, -0.21333813667297363]
agent B-LOC [-0.1485254168510437, -0.2755472660064697]
and B-LOC [0.22399768233299255, -0.2353915572166443]
hnRNP-A1 B-LOC [-0.04708753153681755, -0.42424073815345764]
in B-LOC [-0.01673702709376812, -0.25961917638778687]
autoimmune B-LOC [-0.04793863371014595, -0.2961038649082184]
disease B-LOC [0.028838107362389565, -0.2955871820449829]
of B-LOC [-0.06159006431698799, -0.1336759328842163]
the O [-0.11141087114810944, -0.00257545942440629]
CNS. O [-0.4337950348854065, -0.1750614047050476]

Antigen-specific B-LOC [1.1575523614883423, -1.5026417970657349]
CD8+ B-LOC [1.2674319744110107, -1.2929449081420898]
T-cell B-LOC [1.3341795206069946, -1.7558627128601074]
tolerance, B-LOC [1.438525915145874, -1.7065937519073486]
induced B-LOC [1.6233739852905273, -1.855109453201294]
by B-LOC [1.5615181922912598, -1.899217128753662]
myeloid-derived B-LOC [1.9262185096740723, -1.957869291305542]
suppressor B-LOC [1.7333945035934448, -2.025240182876587]
cells B-LOC [1.3871049880981445, -1.6263935565948486]
(MDSCs), B-LOC [1.992728590965271, -2.055706024169922]
is B-LOC [2.0312745571136475, -2.0872085094451904]
one B-LOC [2.136245012283325, -2.2443976402282715]
of B-LOC [2.0987393856048584, -2.206141710281372]
the B-LOC [2.2008469104766846, -2.0387284755706787]
main B-LOC [2.0950939655303955, -2.2127749919891357]
mechanisms B-LOC [2.1199355125427246, -2.285759687423706]
of B-LOC [1.6805925369262695, -2.1446125507354736]
tumor B-LOC [1.5712945461273193, -1.8555221557617188]
escape. B-LOC [1.6620255708694458, -1.9118386507034302]
Using B-LOC [0.24462337791919708, -0.6365553736686707]
in B-LOC [0.7489019632339478, -0.9477872252464294]
vivo B-LOC [0.43981388211250305, -0.6696256995201111]
models, B-LOC [0.5826404690742493, -0.5522419810295105]
we O [-0.2950472831726074, 0.07152151316404343]
show O [-0.07789209485054016, 0.006154248025268316]
here O [-0.050450291484594345, 0.018367839977145195]
that O [-0.4975840747356415, 0.03275183215737343]
MDSCs B-LOC [0.029860595241189003, -0.16047993302345276]
directly O [-0.5731269717216492, 0.19637003540992737]
disrupt O [-0.42887935042381287, 0.19088909029960632]
the O [-0.5318490862846375, 0.30665236711502075]
binding O [-0.3296007812023163, 0.35714229941368103]
of O [-0.38176384568214417, 0.25009211897850037]
specific O [-0.31942081451416016, -0.01168488897383213]
peptide–major O [-0.5317035913467407, 0.18857163190841675]
histocompatibility O [-0.19706013798713684, -0.13440380990505219]
complex O [-0.1319417953491211, -0.00402359152212739]
(pMHC) B-LOC [0.0945959985256195, -0.07080882787704468]
dimers O [-0.04305652901530266, 0.015420792624354362]
to O [-0.2921237349510193, 0.05369599908590317]
CD8-expressing O [-0.3315638303756714, 0.34064343571662903]
T O [-0.2768110930919647, 0.19822391867637634]
cells O [-0.47435957193374634, 0.332506388425827]
through O [-0.6776166558265686, 0.3425275385379791]
nitration O [-0.43304237723350525, 0.36330345273017883]
of O [-0.3442632555961609, 0.1574247032403946]
tyrosines O [-0.4211560785770416, 0.27647626399993896]
in O [-0.33895665407180786, 0.206211656332016]
a O [-0.3340054750442505, 0.25264695286750793]
T-cell O [-0.3521994650363922, 0.11236333847045898]
receptor O [-0.4127127230167389, -0.044181231409311295]
(TCR)-CD8 B-LOC [0.0522981621325016, -0.2063407301902771]
complex. O [-0.46890789270401, -0.01435469277203083]
This O [-0.31844162940979004, 0.1784699261188507]
process O [-0.22198757529258728, 0.1387978345155716]
makes O [-0.18708287179470062, 0.2547561526298523]
CD8-expressing O [-0.29686132073402405, 0.39303091168403625]
T O [-0.3641970455646515, 0.25315678119659424]
cells O [-0.5442131161689758, 0.27714934945106506]
unable O [-0.36819249391555786, 0.22464227676391602]
to O [-0.34153735637664795, 0.17757096886634827]
bind O [-0.32151302695274353, 0.055522773414850235]
pMHC O [-0.2963344156742096, -0.07649509608745575]
and O [-0.350279837846756, 0.24276742339134216]
to O [-0.5256363749504089, 0.10231005400419235]

respond B-LOC [0.929842472076416, -1.4321179389953613]
to B-LOC [0.8279631733894348, -1.284853219985962]
the B-LOC [1.0458729267120361, -1.3194279670715332]
specific B-LOC [0.9379772543907166, -1.7197926044464111]
peptide, B-LOC [1.018817663192749, -1.5227301120758057]
although B-LOC [0.8502938151359558, -1.2477399110794067]
they B-LOC [0.8340691924095154, -1.1430306434631348]
retain B-LOC [1.0867786407470703, -1.2931526899337769]
their B-LOC [0.8934426307678223, -1.2185776233673096]
ability B-LOC [0.7543391585350037, -1.300671935081482]
to B-LOC [0.9553564190864563, -1.2826178073883057]
respond B-LOC [1.2056972980499268, -1.6142646074295044]
to B-LOC [1.0463058948516846, -1.4195951223373413]
nonspecific B-LOC [1.1537096500396729, -1.458351731300354]
stimulation. B-LOC [1.1020705699920654, -1.5282868146896362]
Nitration B-LOC [0.06389378756284714, -0.2477380633354187]
of O [-0.09994667768478394, -0.07091286778450012]
TCR-CD8 B-LOC [0.09098856896162033, -0.19634737074375153]
is O [-0.2682502567768097, 0.0806807279586792]
induced O [-0.2934342324733734, 0.16698986291885376]
by O [-0.39743420481681824, 0.18082313239574432]
MDSCs O [-0.3919278085231781, 0.06074390187859535]
through O [-0.49360209703445435, 0.17157390713691711]
hyperproduction O [-0.3586830794811249, 0.15661735832691193]
of O [-0.4020117223262787, 0.16637778282165527]
reactive O [-0.2384357452392578, 0.09399852156639099]
oxygen O [-0.33013415336608887, -0.07345718145370483]
species O [-0.29650792479515076, 0.26118195056915283]
and O [-0.4779614210128784, 0.24344751238822937]
peroxynitrite O [-0.3638092577457428, 0.16397547721862793]
during O [-0.4517242908477783, 0.22183506190776825]
direct O [-0.395052433013916, -0.05590518191456795]
cell-cell O [-0.5038148164749146, -0.07570376992225647]
contact. O [-0.23372499644756317, 0.1737115979194641]
Molecular B-LOC [1.8660297393798828, -2.04069447517395]
modeling B-LOC [1.901717185974121, -2.100660800933838]
suggests B-LOC [1.9176321029663086, -1.711721420288086]
specific B-LOC [1.9318513870239258, -2.190096616744995]
sites B-LOC [1.8927505016326904, -2.345773458480835]
of B-LOC [1.766343355178833, -2.1143569946289062]
nitration B-LOC [1.766829252243042, -2.129240036010742]
that B-LOC [1.972374439239502, -2.1414401531219482]
might B-LOC [2.163536787033081, -2.2497451305389404]
affect B-LOC [1.8763318061828613, -2.2223503589630127]
the B-LOC [2.0099356174468994, -2.227536201477051]
conformational B-LOC [2.0525426864624023, -2.2453722953796387]
flexibility B-LOC [1.761712670326233, -2.272199869155884]
of B-LOC [1.9361319541931152, -2.1289875507354736]
TCR-CD8 B-LOC [1.5574342012405396, -1.8525007963180542]
and B-LOC [2.062589645385742, -2.279811382293701]
its B-LOC [2.2290780544281006, -2.200528860092163]
interaction B-LOC [1.9374313354492188, -2.3164007663726807]
with B-LOC [1.8300539255142212, -2.1714749336242676]
pMHC. B-LOC [1.8265495300292969, -2.272315263748169]
These B-LOC [1.0820484161376953, -1.181650996208191]
data B-LOC [0.9105005264282227, -1.174906849861145]
identify B-LOC [0.9794083833694458, -0.9370533227920532]
a B-LOC [0.7688655257225037, -1.1242988109588623]
previously B-LOC [1.0598108768463135, -1.1828333139419556]
unknown B-LOC [0.9690369963645935, -1.2895276546478271]
mechanism B-LOC [0.5601672530174255, -1.3722493648529053]
of B-LOC [0.716130793094635, -1.495535135269165]
T-cell B-LOC [0.5707532167434692, -1.0431817770004272]
tolerance B-LOC [0.5829153060913086, -1.1052088737487793]
in B-LOC [0.800303041934967, -1.164760708808899]
cancer B-LOC [0.7470410466194153, -1.1263107061386108]
that B-LOC [0.6004260778427124, -1.1478352546691895]
is B-LOC [0.994543194770813, -1.1369059085845947]
also B-LOC [0.734611451625824, -1.0665466785430908]
pertinent B-LOC [1.0071420669555664, -0.8836683630943298]
to B-LOC [0.714931070804596, -1.0703833103179932]
many B-LOC [0.7259434461593628, -1.0866953134536743]
pathological B-LOC [1.0576956272125244, -1.380440592765808]
conditions B-LOC [0.659067690372467, -1.1439520120620728]
associated B-LOC [0.7735640406608582, -1.0765571594238281]
with B-LOC [0.6089471578598022, -1.2271140813827515]
accumulation B-LOC [1.0428329706192017, -1.0696380138397217]
of B-LOC [0.4486195743083954, -0.9112449884414673]

MDSCs. B-LOC [0.15744449198246002, -0.5937135815620422]

Neutrophils B-LOC [1.6798546314239502, -2.5473008155822754]
rapidly B-LOC [2.071044445037842, -2.531794548034668]
undergo B-LOC [2.2675697803497314, -2.7003257274627686]
polarization B-LOC [2.272002696990967, -2.982253074645996]
and B-LOC [1.930229663848877, -2.5451924800872803]
directional B-LOC [2.21794056892395, -2.931504964828491]
movement B-LOC [2.1316335201263428, -2.7069313526153564]
to B-LOC [1.970458745956421, -2.531433343887329]
infiltrate B-LOC [2.4557182788848877, -2.8098649978637695]
the B-LOC [2.387190580368042, -2.8518757820129395]
sites B-LOC [2.3742685317993164, -2.874194383621216]
of B-LOC [2.0893964767456055, -3.0281171798706055]
infection B-LOC [2.3618147373199463, -2.842395782470703]
and B-LOC [2.2422938346862793, -2.8293251991271973]
inflammation. B-LOC [2.4097816944122314, -2.672917127609253]
Here, O [-0.4028439223766327, 0.41121912002563477]
we O [-0.6695155501365662, 0.4184757173061371]
show O [-0.5855546593666077, 0.4550318419933319]
that O [-1.0370125770568848, 0.49479547142982483]
an O [-0.5502578020095825, 0.34773626923561096]
inhibitory O [-0.22101137042045593, 0.41540101170539856]
MHC O [-0.34285199642181396, 0.31288883090019226]
I O [-0.33551448583602905, 0.4178732633590698]
receptor, O [-0.49800199270248413, 0.3453206419944763]
Ly49Q, O [-0.32893332839012146, 0.3693702816963196]
was O [-0.7353804111480713, 0.5791347622871399]
crucial O [-0.5490334033966064, 0.49239349365234375]
for O [-0.8773948550224304, 0.5232211351394653]
the O [-0.7136157751083374, 0.6228770613670349]
swift O [-0.5435866713523865, 0.46579936146736145]
polarization O [-0.2606229782104492, 0.43556278944015503]
of O [-0.04832543060183525, 0.4143899083137512]
and O [-0.5297562479972839, 0.5792614221572876]
tissue O [-0.4885074198246002, 0.2775282561779022]
infiltration O [-0.3356274366378784, 0.37223219871520996]
by O [-0.35464173555374146, 0.3217661380767822]
neutrophils. O [-0.33896955847740173, 0.4929230511188507]
During O [-0.5754426717758179, 0.5524073839187622]
the O [-0.4159368574619293, 0.5167941451072693]
steady O [-0.4040336310863495, 0.3462089002132416]
state, O [-0.5006791949272156, 0.4162624180316925]
Ly49Q O [-0.31102174520492554, 0.3744911253452301]
inhibited O [-0.8109023571014404, 0.5985013842582703]
neutrophil O [-0.6201982498168945, 0.8314874768257141]
adhesion O [-0.6493123173713684, 0.6117343306541443]
by O [-0.8444724082946777, 0.8233743906021118]
preventing O [-0.627291738986969, 0.5908629894256592]
focal-complex O [-0.4908957779407501, 0.4458265006542206]
formation, O [-0.4147823750972748, 0.678848922252655]
likely O [-0.5169764757156372, 0.49049514532089233]
by O [-0.8636725544929504, 0.8042352795600891]
inhibiting O [-0.8693790435791016, 0.6615412831306458]
Src O [-0.4420962333679199, 0.4843844473361969]
and O [-0.5931775569915771, 0.5369600057601929]
PI3 O [-0.6445479989051819, 0.4583531320095062]
kinases. O [-0.47410085797309875, 0.4801933169364929]
However, O [-0.32094088196754456, 0.34259703755378723]
in O [-0.20954257249832153, -0.0222290251404047]
the O [-0.07493244111537933, 0.12855105102062225]
presence B-LOC [0.13871678709983826, -0.035496875643730164]
of B-LOC [0.08784377574920654, -0.12807053327560425]
inflammatory O [-0.14627516269683838, 0.0058475336991250515]
stimuli, B-LOC [-0.1546037793159485, -0.21143092215061188]

Ly49Q B-LOC [0.5892453193664551, -0.851496696472168]
mediated B-LOC [0.4548092484474182, -0.6760602593421936]
rapid B-LOC [0.3269864022731781, -0.6074032783508301]
neutrophil B-LOC [0.48004645109176636, -0.6455289125442505]
polarization B-LOC [0.5709869265556335, -0.8036386370658875]
and B-LOC [0.4093758761882782, -0.43045198917388916]
tissue B-LOC [0.4126797020435333, -0.8888810276985168]
infiltration B-LOC [0.7211118340492249, -0.774091899394989]
in B-LOC [0.618588387966156, -0.6921877264976501]
an B-LOC [0.5441797971725464, -0.6010887026786804]
ITIM-domain-dependent B-LOC [1.0143425464630127, -1.2847503423690796]
manner. B-LOC [0.30535706877708435, -0.5945029854774475]
These B-LOC [2.1033713817596436, -2.5540072917938232]
opposite B-LOC [2.183767557144165, -2.976699113845825]
functions B-LOC [2.26838755607605, -2.679245710372925]
appeared B-LOC [2.514004707336426, -2.7142984867095947]
to B-LOC [2.7591793537139893, -2.87266206741333]
be B-LOC [2.7075865268707275, -2.9565131664276123]
mediated B-LOC [2.596189260482788, -2.8708584308624268]
by B-LOC [2.6103765964508057, -2.758751153945923]
distinct B-LOC [2.5051586627960205, -2.9531962871551514]
use B-LOC [2.467751979827881, -2.6183865070343018]
of B-LOC [2.3221218585968018, -2.737401008605957]
effector B-LOC [2.3772640228271484, -2.66084623336792]
phosphatase B-LOC [2.4974899291992188, -2.7489302158355713]
SHP-1 B-LOC [1.6347038745880127, -2.2586262226104736]
and B-LOC [2.369903326034546, -2.536604166030884]
SHP-2. B-LOC [1.9147412776947021, -2.354464292526245]
Ly49Q-dependent B-LOC [0.6038327813148499, -0.6839297413825989]
polarization B-LOC [0.8882901668548584, -1.1306015253067017]
and B-LOC [0.6028664112091064, -0.7213547229766846]
migration B-LOC [0.8122056126594543, -0.9094759821891785]
were B-LOC [0.6818190217018127, -0.8176400661468506]
affected B-LOC [0.6926388144493103, -0.8326594829559326]
by B-LOC [0.5141651034355164, -0.7367261648178101]
Ly49Q B-LOC [0.4634062349796295, -0.5475022196769714]
regulation B-LOC [0.5415529012680054, -0.7097266316413879]
of B-LOC [0.5601500272750854, -0.9265887141227722]
membrane B-LOC [0.6697328686714172, -0.9234111309051514]
raft B-LOC [0.6905263662338257, -0.8527170419692993]
functions. B-LOC [0.7768252491950989, -0.8543811440467834]
We O [-0.5114821791648865, 0.10964031517505646]
propose O [-0.2608235776424408, 0.3441854417324066]
that O [-0.7344896197319031, 0.21976356208324432]
Ly49Q O [-0.3263666331768036, 0.20177701115608215]
is O [-0.4939046800136566, 0.1578977406024933]
pivotal O [-0.6422541737556458, 0.2281520664691925]
in O [-0.8912433981895447, 0.3729960024356842]
switching O [-0.7480266094207764, 0.37016743421554565]
neutrophils O [-0.44800207018852234, 0.47638270258903503]
to O [-0.7527797818183899, 0.5441041588783264]
their O [-0.5138867497444153, 0.43931809067726135]
polarized O [-0.5259886384010315, 0.2733466327190399]
morphology O [-0.30584263801574707, 0.26492786407470703]
and O [-0.8867078423500061, 0.6763483285903931]
rapid O [-0.8144362568855286, 0.6188642978668213]
migration O [-0.37506964802742004, 0.46781280636787415]
upon O [-0.8411145210266113, 0.5922629833221436]
inflammation, O [-0.29803892970085144, 0.3069520592689514]
through O [-0.9379714727401733, 0.5768331289291382]
its O [-0.7044143080711365, 0.5006521344184875]
spatiotemporal O [-0.706751823425293, 0.42995893955230713]
regulation O [-0.5809556841850281, 0.541424572467804]
of O [-0.5151606202125549, 0.4301967918872833]
membrane O [-0.41717445850372314, 0.28894782066345215]
rafts O [-0.4786621034145355, 0.3472670018672943]
and O [-0.7143514752388, 0.4754326045513153]

raft-associated O [-0.22815974056720734, -0.22044557332992554]
signaling B-LOC [-0.16787493228912354, -0.17747056484222412]
molecules. B-LOC [0.035280875861644745, -0.2798268496990204]

BACKGROUND B-LOC [1.295983910560608, -1.861572504043579]
Although B-LOC [2.3684439659118652, -2.761554002761841]
unstable B-LOC [2.3997926712036133, -2.9230000972747803]
coronary B-LOC [2.403306245803833, -2.8203213214874268]
artery B-LOC [2.521965265274048, -3.289797782897949]
disease B-LOC [2.49653959274292, -2.9479832649230957]
is B-LOC [2.7358522415161133, -3.050424098968506]
the B-LOC [2.692944288253784, -3.0030791759490967]
most B-LOC [2.9146475791931152, -3.2565953731536865]
common B-LOC [2.7857611179351807, -3.269228935241699]
reason B-LOC [2.5016822814941406, -3.4070916175842285]
for B-LOC [2.554373025894165, -3.263829231262207]
admission B-LOC [2.707897186279297, -3.452514171600342]
to B-LOC [2.7013845443725586, -3.154987335205078]
a B-LOC [2.74755859375, -3.2599241733551025]
coronary B-LOC [2.8362042903900146, -3.041171073913574]
care B-LOC [2.8812289237976074, -3.402371883392334]
unit, B-LOC [2.5675370693206787, -3.5468356609344482]
the B-LOC [2.9523136615753174, -3.3449978828430176]
long-term B-LOC [3.1802587509155273, -3.346323013305664]
prognosis B-LOC [2.9476027488708496, -3.494861364364624]
of B-LOC [2.980454683303833, -3.382699966430664]
patients B-LOC [3.253960371017456, -3.542701482772827]
with B-LOC [3.015894889831543, -3.4843766689300537]
this B-LOC [2.880614995956421, -3.277346611022949]
diagnosis B-LOC [2.894338846206665, -3.4061853885650635]
is B-LOC [3.3144969940185547, -3.233631134033203]
unknown. B-LOC [3.0728964805603027, -3.394766092300415]
This B-LOC [2.7785861492156982, -2.9711902141571045]
is B-LOC [2.998782157897949, -2.906217336654663]
particularly B-LOC [2.9740102291107178, -2.9715898036956787]
true B-LOC [2.7272117137908936, -2.999431610107422]
for B-LOC [2.998779773712158, -2.931062936782837]
patients B-LOC [3.1695716381073, -2.901272773742676]
with B-LOC [2.934781551361084, -2.9128057956695557]
diabetes B-LOC [2.920250177383423, -3.0012147426605225]
mellitus, B-LOC [2.984337091445923, -2.709141731262207]
who B-LOC [2.9395439624786377, -2.8049802780151367]
are B-LOC [3.006582498550415, -2.791677951812744]
known B-LOC [2.966918468475342, -2.9449474811553955]
to B-LOC [3.133589506149292, -2.8401708602905273]
have B-LOC [2.8690316677093506, -2.8283612728118896]
a B-LOC [2.894765615463257, -2.8853607177734375]
high B-LOC [2.659313917160034, -3.0713934898376465]
morbidity B-LOC [2.949409246444702, -2.9499127864837646]
and B-LOC [2.260938882827759, -2.6432993412017822]
mortality B-LOC [3.0789268016815186, -3.1052587032318115]
after B-LOC [2.7601206302642822, -2.8359744548797607]
an B-LOC [2.871922254562378, -2.793720006942749]
acute B-LOC [3.0133495330810547, -2.9894347190856934]
myocardial B-LOC [2.6349849700927734, -2.7986347675323486]
infarction. B-LOC [3.0035037994384766, -2.836440324783325]
METHODS B-LOC [1.5225703716278076, -2.460040807723999]
AND B-LOC [2.791684865951538, -3.0574891567230225]
RESULTS B-LOC [1.6539031267166138, -2.3070406913757324]
Prospectively B-LOC [3.0240962505340576, -3.304718255996704]
collected B-LOC [2.9668190479278564, -3.1953980922698975]
data B-LOC [3.0274250507354736, -3.2631139755249023]
from B-LOC [3.024521589279175, -3.3395869731903076]
6 B-LOC [3.165703296661377, -3.444767475128174]
different B-LOC [3.1049630641937256, -3.5474565029144287]
countries B-LOC [3.4707982540130615, -3.324022054672241]
in B-LOC [3.363940954208374, -3.2624008655548096]
the B-LOC [3.4360625743865967, -3.1223623752593994]
Organization B-LOC [3.2954981327056885, -3.267000913619995]
to B-LOC [2.976104497909546, -3.0076122283935547]
Assess B-LOC [3.035186529159546, -3.1448614597320557]
Strategies B-LOC [3.2441818714141846, -3.194901704788208]
for B-LOC [3.0862200260162354, -3.24792742729187]
Ischemic B-LOC [2.7679216861724854, -3.337230682373047]
Syndromes B-LOC [3.156987428665161, -3.087453842163086]
(OASIS) B-LOC [3.0144333839416504, -2.9981634616851807]
registry B-LOC [3.228059768676758, -3.37331223487854]
were B-LOC [3.1367223262786865, -2.9399805068969727]
analyzed B-LOC [3.450965166091919, -3.5575244426727295]

to B-LOC [2.770277261734009, -3.178630828857422]
determine B-LOC [3.1133873462677, -3.523853302001953]
the B-LOC [3.1543219089508057, -3.4284512996673584]
2-year B-LOC [2.9342753887176514, -3.4729342460632324]
prognosis B-LOC [3.187016487121582, -3.725135326385498]
of B-LOC [3.015530586242676, -3.3913941383361816]
diabetic B-LOC [3.162376642227173, -3.6072750091552734]
and B-LOC [2.8632216453552246, -3.3805739879608154]
nondiabetic B-LOC [3.1982710361480713, -3.635570764541626]
patients B-LOC [3.104402780532837, -3.507749080657959]
who B-LOC [3.1075520515441895, -3.397489547729492]
were B-LOC [3.1832115650177, -3.466952085494995]
hospitalized B-LOC [3.1678075790405273, -3.6864335536956787]
with B-LOC [3.0299980640411377, -3.316751480102539]
unstable B-LOC [2.7002551555633545, -3.302100896835327]
angina B-LOC [2.644796848297119, -3.27038836479187]
or B-LOC [2.6935675144195557, -3.1982181072235107]
non-Q-wave B-LOC [2.5704476833343506, -3.0345041751861572]
myocardial B-LOC [2.3215925693511963, -2.853729724884033]
infarction. B-LOC [2.7818758487701416, -3.1611523628234863]
Overall, B-LOC [2.6033666133880615, -2.49033260345459]
1718 B-LOC [2.6025774478912354, -2.6676199436187744]
of B-LOC [2.2714383602142334, -2.267171859741211]
8013 B-LOC [2.821286201477051, -2.5173678398132324]
registry B-LOC [2.4500486850738525, -2.704084634780884]
patients B-LOC [2.6695687770843506, -2.749497175216675]
(21%) B-LOC [2.5319838523864746, -2.4515299797058105]
had B-LOC [2.5028598308563232, -2.3284995555877686]
diabetes. B-LOC [2.5626633167266846, -2.8751957416534424]
Diabetic B-LOC [1.0704745054244995, -0.7022255063056946]
patients B-LOC [0.8900263905525208, -0.7249193787574768]
had B-LOC [0.5556955337524414, -0.5539361834526062]
a B-LOC [0.4940183162689209, -0.5213021636009216]
higher B-LOC [0.4820093810558319, -0.32468727231025696]
rate B-LOC [0.4450225532054901, -0.6064760684967041]
of B-LOC [0.31248998641967773, -0.2911924421787262]
coronary B-LOC [0.5607290863990784, -0.4168173372745514]
bypass B-LOC [0.6588786244392395, -0.5913450121879578]
surgery B-LOC [0.2887904942035675, -0.4436917304992676]
than B-LOC [0.32151710987091064, -0.3491767942905426]
nondiabetic B-LOC [0.9507143497467041, -0.6040694117546082]
patients B-LOC [0.5830455422401428, -0.5858500003814697]
(23% B-LOC [0.6423158049583435, -0.5814042687416077]
versus B-LOC [0.4782968759536743, -0.707027018070221]
20%, B-LOC [0.5547959208488464, -0.5536864995956421]
P:<0.001) B-LOC [0.2894642651081085, -0.5539880394935608]
but B-LOC [0.484939306974411, -0.5329717993736267]
had B-LOC [0.6043517589569092, -0.7629284262657166]
similar B-LOC [0.595766007900238, -0.6480871438980103]
rates B-LOC [0.5266483426094055, -0.7039451599121094]
of B-LOC [0.4261808693408966, -0.6629430651664734]
catheterization B-LOC [0.6878432035446167, -0.9368740320205688]
and B-LOC [0.5852471590042114, -0.6363517045974731]
angioplasty. B-LOC [0.6277411580085754, -0.9043465852737427]
Diabetes B-LOC [0.28740227222442627, -0.44874414801597595]
independently B-LOC [0.32284805178642273, -0.5388582944869995]
predicted B-LOC [0.2451830804347992, -0.4353761374950409]
mortality B-LOC [0.19543182849884033, -0.5567922592163086]
(relative B-LOC [0.17932714521884918, -0.21891307830810547]
risk B-LOC [0.10599464178085327, -0.4756341278553009]
[RR], B-LOC [0.2407667636871338, -0.47606587409973145]
1.57; B-LOC [0.3043244779109955, -0.34864306449890137]

95% O [-0.8195430040359497, 0.48250290751457214]
CI, O [-0.7927426695823669, 0.2936840355396271]
1.38 O [-0.7402138113975525, 0.4973783791065216]
to O [-0.7911321520805359, 0.139075368642807]
1.81; O [-0.41031697392463684, 0.2698797285556793]
P:<0.001), O [-0.8395035862922668, 0.4496113359928131]
as O [-0.7833938002586365, 0.5756969451904297]
well O [-1.0003305673599243, 0.68610018491745]
as O [-0.9709514379501343, 0.6580333113670349]
cardiovascular O [-0.8877386450767517, 0.7039076089859009]
death, O [-0.8411527872085571, 0.5726873278617859]
new O [-1.0987231731414795, 0.7973760962486267]
myocardial O [-0.9226413369178772, 0.7112943530082703]
infarction, O [-0.95396488904953, 0.6140164732933044]
stroke, O [-0.7277796864509583, 0.592667818069458]
and O [-0.8615992069244385, 0.6335576176643372]
new O [-1.0156370401382446, 0.8037086129188538]
congestive O [-0.974736750125885, 0.6389850974082947]
heart O [-0.7142140865325928, 0.5853592753410339]
failure. O [-0.8094274997711182, 0.6688178181648254]
Moreover, O [-0.36992576718330383, 0.29492875933647156]
compared O [-0.15122294425964355, 0.05395541712641716]
with B-LOC [0.20733508467674255, -0.15256313979625702]
their B-LOC [0.2506280839443207, -0.09987975656986237]
nondiabetic B-LOC [0.006188931409269571, -0.03949340432882309]
counterparts, B-LOC [0.13208019733428955, -0.31822794675827026]
women B-LOC [0.13191315531730652, -0.22850921750068665]
had B-LOC [-0.17810210585594177, -0.24942049384117126]
a B-LOC [-0.025892267003655434, -0.27914610505104065]
significantly B-LOC [0.020750978961586952, -0.30516716837882996]
higher B-LOC [0.057517193257808685, -0.22864045202732086]
risk B-LOC [-0.1476670205593109, -0.20702916383743286]
than B-LOC [-0.12872940301895142, -0.30611470341682434]
men B-LOC [-0.019848627969622612, -0.3926970362663269]
(RR, B-LOC [0.25939512252807617, -0.4204111397266388]
1.98; B-LOC [0.25520697236061096, -0.0578824020922184]
95% O [-0.04811443015933037, 0.012838422320783138]
CI, O [-0.3694128096103668, -0.10927078127861023]
1.60 O [-0.017959168180823326, 0.077886663377285]
to B-LOC [-0.3395163118839264, -0.38521477580070496]
2.44; B-LOC [0.06616920977830887, 0.05688856169581413]
and B-LOC [0.03737149015069008, -0.2839007079601288]
RR, O [-0.21803511679172516, -0.10436911135911942]
1.28; B-LOC [-0.0133053595200181, -0.050062354654073715]
95% B-LOC [0.01992728002369404, -0.1401873528957367]
CI, O [-0.3306236267089844, -0.037213798612356186]
1.06 O [-0.06733556091785431, -0.04989062249660492]
to B-LOC [-0.10654115676879883, -0.31203213334083557]
1.56, B-LOC [0.13836908340454102, -0.314227432012558]
respectively). B-LOC [-0.11219644546508789, -0.4758341610431671]
Interestingly, B-LOC [0.3386160135269165, -0.5417875647544861]
diabetic B-LOC [0.4364784061908722, -0.41605862975120544]
patients B-LOC [0.4509369432926178, -0.5068778395652771]
without B-LOC [0.3036712408065796, -0.20685985684394836]
prior B-LOC [0.04898575320839882, -0.40291228890419006]
cardiovascular B-LOC [0.3765003979206085, -0.6598805785179138]
disease B-LOC [0.20329280197620392, -0.5753877758979797]

had B-LOC [0.7078672647476196, -1.3246822357177734]
the B-LOC [1.0391666889190674, -1.350928783416748]
same B-LOC [1.0639456510543823, -1.571334958076477]
event B-LOC [1.1259208917617798, -1.802613377571106]
rates B-LOC [1.2585384845733643, -1.8135945796966553]
for B-LOC [1.2149436473846436, -1.7895481586456299]
all B-LOC [1.176137924194336, -1.727529525756836]
outcomes B-LOC [1.2117931842803955, -1.585254192352295]
as B-LOC [1.0829780101776123, -1.6137655973434448]
nondiabetic B-LOC [1.2681169509887695, -1.4861668348312378]
patients B-LOC [1.1608222723007202, -1.607261061668396]
with B-LOC [1.1870911121368408, -1.6644048690795898]
previous B-LOC [0.9262828826904297, -1.4867417812347412]
vascular B-LOC [1.0587586164474487, -1.813007116317749]
disease. B-LOC [1.299649953842163, -1.589416742324829]
CONCLUSIONS O [-0.42945513129234314, 0.025746723636984825]
Hospitalization B-LOC [1.157778024673462, -1.0952097177505493]
for B-LOC [1.0504792928695679, -1.0498218536376953]
unstable B-LOC [0.831494152545929, -0.9592876434326172]
angina B-LOC [0.7471941113471985, -0.9396792054176331]
or B-LOC [0.6987150311470032, -0.9158496856689453]
non-Q-wave B-LOC [0.6990588307380676, -0.8080251812934875]
myocardial B-LOC [0.6015438437461853, -0.9743775725364685]
infarction B-LOC [0.7777464985847473, -0.91908198595047]
predicts B-LOC [1.0695189237594604, -1.0255470275878906]
a B-LOC [1.0285333395004272, -1.142316460609436]
high B-LOC [1.1291484832763672, -1.319901704788208]
2-year B-LOC [1.1922953128814697, -1.0641353130340576]
morbidity B-LOC [1.3004274368286133, -1.661022424697876]
and B-LOC [0.8485018014907837, -1.3466105461120605]
mortality; B-LOC [1.4155774116516113, -1.4909353256225586]
this B-LOC [1.0839749574661255, -1.3970296382904053]
is B-LOC [1.3985273838043213, -1.491807460784912]
especially B-LOC [1.3811627626419067, -1.54427969455719]
evident B-LOC [1.3143935203552246, -1.3805009126663208]
for B-LOC [1.3170493841171265, -1.397510290145874]
patients B-LOC [1.5640068054199219, -1.5509902238845825]
with B-LOC [1.5423760414123535, -1.7177817821502686]
diabetes. B-LOC [1.5770665407180786, -1.6227645874023438]
Diabetic B-LOC [1.2237573862075806, -1.412087321281433]
patients B-LOC [1.0289714336395264, -1.3115148544311523]
with B-LOC [0.8933475017547607, -1.2633206844329834]
no B-LOC [1.0241069793701172, -1.2295472621917725]
previous B-LOC [0.9078779816627502, -1.4358891248703003]
cardiovascular B-LOC [1.236067295074463, -1.675502896308899]
disease B-LOC [1.3760240077972412, -1.6291108131408691]
have B-LOC [0.9364164471626282, -1.323462724685669]
the B-LOC [1.2096989154815674, -1.4386073350906372]
same B-LOC [1.2140305042266846, -1.4489233493804932]
long-term B-LOC [1.3298509120941162, -1.54720139503479]
morbidity B-LOC [1.1849615573883057, -1.7712733745574951]
and B-LOC [1.046187400817871, -1.513681173324585]
mortality B-LOC [1.4214411973953247, -1.52663254737854]
as B-LOC [1.0292549133300781, -1.396801471710205]
nondiabetic B-LOC [1.1480987071990967, -1.3790051937103271]
patients B-LOC [1.1264264583587646, -1.407496452331543]
with B-LOC [0.9000994563102722, -1.2663849592208862]
established B-LOC [0.9629839658737183, -1.2404134273529053]
cardiovascular B-LOC [1.203823208808899, -1.6413973569869995]
disease B-LOC [1.3183517456054688, -1.5157033205032349]
after B-LOC [1.0130972862243652, -1.1962757110595703]
hospitalization B-LOC [1.1412289142608643, -1.5187461376190186]
for B-LOC [0.8921930193901062, -1.2377187013626099]
unstable B-LOC [0.9452682733535767, -1.2130526304244995]
coronary B-LOC [0.6527382731437683, -1.0213133096694946]
artery B-LOC [0.6726841330528259, -1.433032751083374]
disease. B-LOC [1.1525278091430664, -1.292618751525879]

CONTEXT B-LOC [1.1594277620315552, -2.056307077407837]
Insomnia B-LOC [2.0946898460388184, -2.6834828853607178]
is B-LOC [2.4799606800079346, -2.9205386638641357]
a B-LOC [2.4291388988494873, -2.8260562419891357]
common B-LOC [2.1581108570098877, -2.741122245788574]
condition B-LOC [2.5453686714172363, -3.0596745014190674]
in B-LOC [1.7448745965957642, -2.5026795864105225]
older B-LOC [2.599182367324829, -2.7302355766296387]
adults B-LOC [2.666069746017456, -2.612748384475708]
and B-LOC [2.0059456825256348, -2.800651788711548]
is B-LOC [2.629105806350708, -3.0034587383270264]
associated B-LOC [2.654237985610962, -3.118825912475586]
with B-LOC [2.6012990474700928, -3.1013906002044678]
a B-LOC [2.637643337249756, -2.9618189334869385]
number B-LOC [2.6300203800201416, -2.887068510055542]
of B-LOC [2.5982911586761475, -3.132312297821045]
adverse B-LOC [3.031709909439087, -3.5273213386535645]
medical, B-LOC [2.8937509059906006, -3.5130226612091064]
social, B-LOC [2.711186170578003, -3.1268951892852783]
and B-LOC [2.559495210647583, -3.2162866592407227]
psychological B-LOC [3.2671072483062744, -3.5643179416656494]
consequences. B-LOC [3.1559793949127197, -3.4906535148620605]
Previous B-LOC [2.8019251823425293, -3.398792028427124]
research B-LOC [3.040168285369873, -3.3483173847198486]
has B-LOC [3.2805702686309814, -3.2587802410125732]
suggested B-LOC [2.9801909923553467, -3.149199962615967]
beneficial B-LOC [3.2612245082855225, -3.582796335220337]
outcomes B-LOC [3.359758138656616, -3.6072258949279785]
of B-LOC [3.0424325466156006, -3.5206477642059326]
both B-LOC [2.7035012245178223, -3.3618009090423584]
psychological B-LOC [3.3068439960479736, -3.737659215927124]
and B-LOC [2.90910267829895, -3.2369706630706787]
pharmacological B-LOC [3.390911102294922, -3.6629905700683594]
treatments, B-LOC [3.263502836227417, -3.5601184368133545]
but B-LOC [3.2823097705841064, -3.2020859718322754]
blinded B-LOC [3.2222697734832764, -3.112537145614624]
placebo-controlled B-LOC [3.391162395477295, -3.3603310585021973]
trials B-LOC [3.3895537853240967, -3.4510042667388916]
comparing B-LOC [3.3862814903259277, -3.729092597961426]
the B-LOC [3.494713068008423, -3.4033472537994385]
effects B-LOC [3.5456528663635254, -3.6301472187042236]
of B-LOC [3.4832026958465576, -3.3908560276031494]
these B-LOC [3.329439401626587, -3.480330467224121]
treatments B-LOC [3.4189345836639404, -3.4106900691986084]
are B-LOC [3.3577897548675537, -3.0823214054107666]
lacking. B-LOC [3.402517795562744, -3.4065494537353516]
OBJECTIVE B-LOC [3.2288405895233154, -3.2442266941070557]
To B-LOC [3.2603936195373535, -3.280259847640991]
examine B-LOC [3.4466445446014404, -3.298166513442993]
short- B-LOC [3.562201976776123, -3.2379605770111084]
and B-LOC [3.355095624923706, -3.17486834526062]
long-term B-LOC [3.5084774494171143, -3.185516595840454]
clinical B-LOC [3.778041362762451, -3.574847936630249]
efficacy B-LOC [3.658611536026001, -3.6519391536712646]
of B-LOC [3.4221031665802, -3.168135404586792]
cognitive B-LOC [3.59714674949646, -3.5018532276153564]
behavioral B-LOC [3.5164754390716553, -3.5803797245025635]
therapy B-LOC [3.5193116664886475, -3.4443671703338623]
(CBT) B-LOC [3.4791579246520996, -3.222736120223999]
and B-LOC [3.3958792686462402, -3.228069543838501]
pharmacological B-LOC [3.599241018295288, -3.6942496299743652]
treatment B-LOC [3.6988298892974854, -3.4498064517974854]
in B-LOC [3.562622308731079, -3.2293026447296143]
older B-LOC [3.7303593158721924, -3.151594400405884]
adults B-LOC [3.759490489959717, -3.0381782054901123]
experiencing B-LOC [3.6736226081848145, -3.324239492416382]
chronic B-LOC [3.6850481033325195, -3.2470903396606445]
primary B-LOC [3.280299186706543, -3.3443076610565186]
insomnia. B-LOC [3.399333953857422, -3.151344060897827]
DESIGN, B-LOC [3.4466116428375244, -3.2008864879608154]

SETTING, B-LOC [2.671808958053589, -3.31624436378479]
AND B-LOC [3.1940057277679443, -3.493699789047241]
PARTICIPANTS B-LOC [3.1557648181915283, -3.2658798694610596]
A B-LOC [3.090582847595215, -3.1297872066497803]
randomized, B-LOC [3.3193399906158447, -3.1041364669799805]
double-blinded, B-LOC [3.4484758377075195, -2.82474946975708]
placebo-controlled B-LOC [3.3270556926727295, -3.0156056880950928]
trial B-LOC [3.4006223678588867, -3.2063815593719482]
of B-LOC [3.314772844314575, -2.916713237762451]
46 B-LOC [3.285297155380249, -3.112030267715454]
adults B-LOC [3.2520880699157715, -2.9984147548675537]
(mean B-LOC [3.2857565879821777, -3.0307459831237793]
age, B-LOC [3.23193097114563, -2.677048444747925]
60.8 B-LOC [3.141284942626953, -2.706207036972046]
y; B-LOC [3.213691473007202, -2.9370510578155518]
22 B-LOC [3.2800421714782715, -2.9728524684906006]
women) B-LOC [3.4756462574005127, -3.12218976020813]
with B-LOC [3.4980757236480713, -2.9832544326782227]
chronic B-LOC [3.3708336353302, -3.00547456741333]
primary B-LOC [3.3323299884796143, -3.115212917327881]
insomnia B-LOC [3.451446771621704, -3.0850753784179688]
conducted B-LOC [3.3896262645721436, -3.0459482669830322]
between B-LOC [3.3323817253112793, -2.8360164165496826]
January B-LOC [3.3187215328216553, -2.98162579536438]
2004 B-LOC [3.225417375564575, -2.913963556289673]
and B-LOC [3.2709925174713135, -2.7269558906555176]
December B-LOC [3.2722809314727783, -2.900158166885376]
2005 B-LOC [3.1875336170196533, -3.0577552318573]
in B-LOC [3.3619744777679443, -2.8293962478637695]
a B-LOC [3.225999355316162, -2.7212929725646973]
single B-LOC [3.148329257965088, -2.89434552192688]
Norwegian B-LOC [3.4354865550994873, -3.511948585510254]
university-based B-LOC [3.2853822708129883, -3.1141750812530518]
outpatient B-LOC [3.4504969120025635, -3.00178599357605]
clinic B-LOC [3.377962350845337, -3.167376756668091]
for B-LOC [3.491589069366455, -3.0029489994049072]
adults B-LOC [3.3299455642700195, -2.890697717666626]
and B-LOC [3.2488389015197754, -2.936109781265259]
elderly B-LOC [3.352557897567749, -3.0442025661468506]
patients. B-LOC [3.5441668033599854, -3.098191738128662]
INTERVENTION B-LOC [1.9869332313537598, -2.3660085201263428]
CBT B-LOC [2.149137258529663, -2.4859771728515625]
(sleep B-LOC [2.1141436100006104, -2.218256711959839]
hygiene, B-LOC [2.4537620544433594, -2.3929736614227295]
sleep B-LOC [2.3844103813171387, -2.1922237873077393]
restriction, B-LOC [2.2270452976226807, -2.352243185043335]
stimulus B-LOC [2.128567934036255, -2.561300039291382]
control, B-LOC [2.3784987926483154, -2.6308789253234863]
cognitive B-LOC [2.4713950157165527, -2.352245330810547]
therapy, B-LOC [1.9400721788406372, -2.209988832473755]
and B-LOC [2.8453314304351807, -2.7647340297698975]
relaxation; B-LOC [2.1490671634674072, -2.2475152015686035]
n B-LOC [2.548421859741211, -2.3474414348602295]
= B-LOC [1.9716928005218506, -2.557250738143921]
18), B-LOC [2.503183603286743, -2.5146169662475586]
sleep B-LOC [2.038748025894165, -1.9146244525909424]
medication B-LOC [2.004312038421631, -2.3261749744415283]
(7.5-mg B-LOC [2.2193028926849365, -1.961500644683838]
zopiclone B-LOC [2.151779890060425, -2.362097978591919]
each B-LOC [2.03444242477417, -2.225196123123169]
night; B-LOC [2.4659297466278076, -2.440997838973999]
n B-LOC [2.475327730178833, -2.0627691745758057]
= B-LOC [1.963928461074829, -2.4402201175689697]

16), B-LOC [3.0326507091522217, -3.2675065994262695]
or B-LOC [3.5592076778411865, -3.3686304092407227]
placebo B-LOC [3.771364688873291, -3.5456478595733643]
medication B-LOC [3.429316759109497, -3.5711450576782227]
(n B-LOC [3.577347993850708, -3.3827197551727295]
= B-LOC [3.2297799587249756, -3.4254493713378906]
12). B-LOC [3.6018543243408203, -3.264331579208374]
All B-LOC [3.4961259365081787, -3.3320775032043457]
treatment B-LOC [3.5341923236846924, -3.309142827987671]
duration B-LOC [3.373290777206421, -2.9219892024993896]
was B-LOC [3.337291955947876, -3.030644416809082]
6 B-LOC [3.5500919818878174, -3.056525230407715]
weeks, B-LOC [3.781061887741089, -3.1850943565368652]
and B-LOC [3.188680410385132, -3.0095596313476562]
the B-LOC [3.6839993000030518, -3.0524680614471436]
2 B-LOC [3.51045560836792, -3.1548285484313965]
active B-LOC [3.554565906524658, -3.3475043773651123]
treatments B-LOC [3.706131935119629, -3.3718340396881104]
were B-LOC [3.708664655685425, -3.151001214981079]
followed B-LOC [3.726445436477661, -3.555783987045288]
up B-LOC [3.5632247924804688, -3.2648043632507324]
at B-LOC [3.518472671508789, -3.2535345554351807]
6 B-LOC [3.6756207942962646, -3.149945020675659]
months. B-LOC [3.8118669986724854, -3.155566453933716]
MAIN B-LOC [3.406013011932373, -3.110030174255371]
OUTCOME B-LOC [3.3695566654205322, -3.0214905738830566]
MEASURES B-LOC [3.419513463973999, -3.0841453075408936]
Ambulant B-LOC [3.3517372608184814, -2.9578144550323486]
clinical B-LOC [3.7740485668182373, -3.270057439804077]
polysomnographic B-LOC [3.3051750659942627, -3.093414306640625]
data B-LOC [3.517483711242676, -3.226564884185791]
and B-LOC [3.156982421875, -3.115525960922241]
sleep B-LOC [3.5052573680877686, -3.209364414215088]
diaries B-LOC [3.398855447769165, -3.026075839996338]
were B-LOC [3.4073140621185303, -3.0904247760772705]
used B-LOC [3.440048933029175, -3.26902174949646]
to B-LOC [3.470991373062134, -3.0817782878875732]
determine B-LOC [3.5113604068756104, -3.2866992950439453]
total B-LOC [3.618537664413452, -3.3568837642669678]
wake B-LOC [3.357137680053711, -3.3447747230529785]
time, B-LOC [3.527750015258789, -3.3912394046783447]
total B-LOC [3.6930994987487793, -3.447864294052124]
sleep B-LOC [3.469407081604004, -3.163494348526001]
time, B-LOC [3.549743413925171, -3.362213373184204]
sleep B-LOC [3.5377774238586426, -3.2296698093414307]
efficiency, B-LOC [3.5453131198883057, -3.4437687397003174]
and B-LOC [3.3709592819213867, -3.2549784183502197]
slow-wave B-LOC [3.504690647125244, -3.311262369155884]
sleep B-LOC [3.638883113861084, -3.1592822074890137]
(only B-LOC [3.589327573776245, -3.017644166946411]
assessed B-LOC [3.675795316696167, -3.3190977573394775]
using B-LOC [3.3424956798553467, -3.2225852012634277]
polysomnography) B-LOC [3.39670729637146, -3.1724016666412354]
on B-LOC [3.469578266143799, -3.338165760040283]
all B-LOC [3.6646668910980225, -3.1991846561431885]
3 B-LOC [3.4642868041992188, -3.0560386180877686]
assessment B-LOC [3.537743330001831, -3.6021347045898438]
points. B-LOC [3.6060073375701904, -3.4364757537841797]
RESULTS O [-0.6407415270805359, 0.5581762194633484]
CBT O [-0.3545239567756653, 0.5261815190315247]
resulted O [-0.7327578663825989, 0.6922038793563843]
in O [-0.8237912654876709, 0.7556607127189636]
improved O [-0.6738476157188416, 0.6701181530952454]
short- O [-0.5875378251075745, 0.9357843399047852]
and O [-0.6619002819061279, 0.6018497943878174]
long-term O [-0.6355841755867004, 0.7948412299156189]
outcomes O [-0.59100741147995, 0.7469260096549988]
compared O [-0.7170008420944214, 0.785603940486908]
with O [-0.6569117903709412, 0.836811363697052]
zopiclone O [-0.41645655035972595, 0.9609832167625427]
on O [-0.7823917865753174, 0.8742070198059082]
3 O [-0.42346030473709106, 0.897072970867157]
out O [-0.6739647388458252, 0.9926947951316833]
of O [-0.7328044772148132, 0.8136640191078186]
4 O [-0.21893912553787231, 0.6829409599304199]
outcome O [-0.5326562523841858, 0.5571304559707642]
measures. O [-0.5220610499382019, 0.658195436000824]
For O [-0.3362923860549927, 0.4622173607349396]
most O [-0.17081035673618317, 0.49717843532562256]

outcomes, B-LOC [1.0430901050567627, -1.348337173461914]
zopiclone B-LOC [1.0634222030639648, -1.0926017761230469]
did B-LOC [1.0181920528411865, -1.1842925548553467]
not B-LOC [1.5389200448989868, -1.3933701515197754]
differ B-LOC [1.5179216861724854, -1.9107964038848877]
from B-LOC [1.3469631671905518, -1.5673041343688965]
placebo. B-LOC [1.2745347023010254, -1.4461513757705688]
Participants O [-0.6864802241325378, 0.6696920990943909]
receiving O [-0.6628808975219727, 0.5308480262756348]
CBT O [-0.32099443674087524, 0.3284524083137512]
improved O [-0.8777557015419006, 0.7153059840202332]
their O [-0.8200839161872864, 0.820786714553833]
sleep O [-0.5476379990577698, 0.8611693978309631]
efficiency O [-0.7557015419006348, 0.7116925716400146]
from O [-1.124351978302002, 0.7408366799354553]
81.4% O [-0.9952254295349121, 1.0433783531188965]
at O [-1.0701837539672852, 0.7821589708328247]
pretreatment O [-0.9953430891036987, 0.9039822220802307]
to O [-1.126723289489746, 0.8408432602882385]
90.1% O [-0.9561997056007385, 1.0125417709350586]
at O [-1.0579149723052979, 0.7207129597663879]
6-month O [-0.8127543330192566, 0.8940804600715637]
follow-up O [-0.9448521733283997, 0.7726675271987915]
compared O [-0.9899153709411621, 0.905328094959259]
with O [-0.8557335138320923, 0.7985844016075134]
a O [-0.8062725067138672, 0.7174015641212463]
decrease O [-0.6625484824180603, 0.7255810499191284]
from O [-1.0407949686050415, 0.5745729804039001]
82.3% O [-0.8598576188087463, 0.9354183673858643]
to O [-0.9950911402702332, 0.5565653443336487]
81.9% O [-0.9031581878662109, 0.8465596437454224]
in O [-0.9568799138069153, 0.5921728014945984]
the O [-0.9690788388252258, 0.6994895935058594]
zopiclone O [-0.5453504920005798, 0.6253250241279602]
group. O [-0.9750425815582275, 0.9168345928192139]
Participants O [-0.4603824317455292, 0.38900044560432434]
in O [-0.24886493384838104, 0.45047610998153687]
the O [-0.34533846378326416, 0.6321949362754822]
CBT O [-0.3707672655582428, 0.12526807188987732]
group O [-0.47501251101493835, 0.7610355019569397]
spent O [-0.5126211047172546, 0.5392360091209412]
much O [-0.3628956079483032, 0.5746587514877319]
more O [-0.42037227749824524, 0.7738487124443054]
time O [-0.3982333242893219, 0.6118854284286499]
in O [-0.4815150201320648, 0.6467522978782654]
slow-wave O [-0.4443223178386688, 0.459473192691803]
sleep O [-0.2451622635126114, 0.5712055563926697]
(stages O [-0.3434589207172394, 0.35726603865623474]
3 O [-0.37837329506874084, 0.5821449160575867]
and O [-0.5191280841827393, 0.19206248223781586]
4) O [-0.14820560812950134, 0.27279552817344666]
compared O [-0.593952476978302, 0.6977868676185608]
with O [-0.36425361037254333, 0.623476505279541]
those O [-0.33107098937034607, 0.5218502879142761]
in O [-0.2910003662109375, 0.2118653655052185]
other O [-0.25165945291519165, 0.23474037647247314]
groups, O [-0.22496727108955383, 0.3978155553340912]
and O [-0.5500195622444153, 0.6448076367378235]
spent O [-0.41972336173057556, 0.4716201722621918]
less O [-0.31346186995506287, 0.7369629144668579]
time O [-0.26810672879219055, 0.4246661961078644]
awake O [-0.20594441890716553, 0.4253528416156769]
during O [-0.289110392332077, 0.3375209867954254]
the O [-0.3851388990879059, 0.5933318734169006]
night. O [-0.018975062295794487, 0.18241651356220245]
Total B-LOC [0.36569225788116455, -0.8164533972740173]
sleep B-LOC [0.3508633077144623, -0.4256819188594818]
time B-LOC [0.15024176239967346, -0.5920934081077576]
was B-LOC [0.3766024708747864, -0.8546844720840454]
similar B-LOC [0.3901533782482147, -1.0009596347808838]
in B-LOC [0.3179258108139038, -0.827917218208313]
all B-LOC [0.48113295435905457, -0.6801437735557556]
3 B-LOC [0.5628373622894287, -0.5214880704879761]
groups; B-LOC [0.598992109298706, -0.6262684464454651]
at O [-0.12943340837955475, -0.056850384920835495]
6 B-LOC [0.16517001390457153, -0.09765490144491196]
months, B-LOC [0.14536520838737488, -0.17534299194812775]
patients O [-0.23275905847549438, -0.11322727054357529]
receiving B-LOC [-0.12931054830551147, -0.24231654405593872]
CBT B-LOC [0.13391166925430298, -0.2608965039253235]
had O [-0.03076607547700405, 0.03283863514661789]
better O [-0.18637815117835999, 0.13312184810638428]

sleep O [-0.024010391905903816, 0.03483607992529869]
efficiency B-LOC [0.08296622335910797, -0.08038945496082306]
using B-LOC [0.029441608116030693, -0.02252248115837574]
polysomnography B-LOC [-0.015674730762839317, -0.13535946607589722]
than O [-0.08028984069824219, 0.14392833411693573]
those B-LOC [0.08012507110834122, -0.02244148962199688]
taking B-LOC [-0.06787027418613434, -0.16857972741127014]
zopiclone. B-LOC [0.08075901865959167, 0.013990780338644981]
CONCLUSION O [-0.739143431186676, 0.684814989566803]
These O [-0.6084364652633667, 0.8375415205955505]
results O [-0.7720614671707153, 0.9215276837348938]
suggest O [-0.6648312211036682, 0.7742056846618652]
that O [-1.0068168640136719, 0.8147137761116028]
interventions O [-1.101515293121338, 1.149343490600586]
based O [-1.2244417667388916, 1.266951084136963]
on O [-0.9848286509513855, 1.1947513818740845]
CBT O [-0.9632702469825745, 1.1117948293685913]
are O [-0.843293309211731, 1.050133466720581]
superior O [-0.8191105127334595, 1.0161099433898926]
to O [-0.9134642481803894, 1.0368938446044922]
zopiclone O [-0.8431442975997925, 1.487300992012024]
treatment O [-1.1803648471832275, 1.2429444789886475]
both O [-1.143661618232727, 1.0605037212371826]
in O [-1.2720032930374146, 1.0496320724487305]
short- O [-1.1206436157226562, 1.4405674934387207]
and O [-0.96298748254776, 1.034400463104248]
long-term O [-1.041979432106018, 1.3269723653793335]
management O [-0.9348757863044739, 1.063836693763733]
of O [-1.0014846324920654, 1.1181449890136719]
insomnia O [-0.9007050395011902, 1.1359269618988037]
in O [-0.753328263759613, 0.8041065335273743]
older O [-0.8280813097953796, 0.9467430710792542]
adults. O [-0.6447597146034241, 0.7468343377113342]
TRIAL B-LOC [2.302365303039551, -2.4902119636535645]
REGISTRATION B-LOC [2.0204904079437256, -2.331533670425415]
clinicaltrials.gov B-LOC [2.541830539703369, -2.583383798599243]
Identifier: B-LOC [2.3015472888946533, -2.2638437747955322]
NCT00295386. B-LOC [2.6324312686920166, -2.678770065307617]

Adenosine B-LOC [0.7046918272972107, -1.1462950706481934]
deaminases B-LOC [0.5388652086257935, -0.8186044096946716]
acting B-LOC [0.76661616563797, -0.861915647983551]
on B-LOC [0.812121570110321, -0.8377887606620789]
RNA B-LOC [1.3414478302001953, -1.3633167743682861]
(ADARs) B-LOC [1.03130042552948, -1.1628360748291016]
are B-LOC [1.0870383977890015, -1.1488516330718994]
involved B-LOC [0.859968364238739, -0.9698430895805359]
in B-LOC [0.9217415452003479, -0.9318517446517944]
RNA B-LOC [1.220033884048462, -1.3074172735214233]
editing B-LOC [0.878181517124176, -0.9407253861427307]
that B-LOC [0.713865339756012, -1.1290303468704224]
converts B-LOC [0.7634861469268799, -0.9349934458732605]
adenosine B-LOC [0.977375864982605, -0.9523010849952698]
residues B-LOC [0.7102231383323669, -0.8201500177383423]
to B-LOC [0.5889855623245239, -0.8964659571647644]
inosine B-LOC [0.7943127751350403, -1.0586310625076294]
specifically B-LOC [0.8003224730491638, -1.1221781969070435]
in B-LOC [0.7621356248855591, -0.9570638537406921]
double-stranded B-LOC [1.4946510791778564, -1.0691896677017212]
RNAs. B-LOC [1.197774887084961, -1.5056802034378052]
In B-LOC [0.702540934085846, -0.9135947823524475]
this B-LOC [1.0107661485671997, -0.9936239719390869]
study, B-LOC [1.0667588710784912, -1.1381330490112305]
we B-LOC [0.7373145818710327, -0.7553932070732117]
investigated B-LOC [1.3821948766708374, -1.1591745615005493]
the B-LOC [1.7208893299102783, -1.5367457866668701]
interaction B-LOC [1.45342218875885, -1.4760032892227173]
of B-LOC [1.532996416091919, -1.6143555641174316]
the B-LOC [1.6751505136489868, -1.5561339855194092]
RNA B-LOC [1.3642202615737915, -1.4934062957763672]
editing B-LOC [1.2324730157852173, -1.2148016691207886]
mechanism B-LOC [1.3922317028045654, -1.594980001449585]
with B-LOC [1.4441157579421997, -1.7091643810272217]
the B-LOC [1.6815807819366455, -1.4598417282104492]
RNA B-LOC [1.5260167121887207, -1.6207650899887085]
interference B-LOC [1.3021162748336792, -1.444526195526123]
(RNAi) B-LOC [1.6520780324935913, -1.7301092147827148]
machinery B-LOC [1.3714396953582764, -1.4637304544448853]
and B-LOC [0.8364487886428833, -0.9400656223297119]
found B-LOC [0.5485216379165649, -0.33124682307243347]
that B-LOC [0.5661212205886841, -0.6154937148094177]
ADAR1 B-LOC [0.7982547879219055, -0.8661537170410156]
forms B-LOC [0.8913049697875977, -0.635360062122345]
a B-LOC [0.7953349947929382, -0.762520432472229]
complex B-LOC [0.9865133762359619, -0.9194563031196594]
with B-LOC [0.8536197543144226, -0.8753883838653564]
Dicer B-LOC [0.9731813073158264, -1.2044355869293213]
through B-LOC [0.5897055268287659, -0.8821897506713867]
direct B-LOC [0.8282080888748169, -1.0823456048965454]
protein-protein B-LOC [0.9792205691337585, -1.189171314239502]
interaction. B-LOC [0.9006524682044983, -0.8927077054977417]
Most O [-0.37101224064826965, 0.3831564486026764]
importantly, O [-0.4860796630382538, 0.4696560204029083]
ADAR1 O [-0.3913748562335968, 0.47292473912239075]
increases O [-0.659496009349823, 0.6599594950675964]
the O [-0.6133612990379333, 0.5802189111709595]
maximum O [-0.6540713906288147, 0.5633878111839294]
rate O [-0.5940269827842712, 0.38587307929992676]
(Vmax) O [-0.3543899953365326, 0.3522433340549469]
of O [-0.7129239439964294, 0.37189748883247375]
pre-microRNA O [-0.5007473826408386, 0.30735281109809875]
(miRNA) O [-0.2634306252002716, 0.23084570467472076]
cleavage O [-0.2594006657600403, 0.4145472049713135]
by O [-0.5498522520065308, 0.3332577645778656]
Dicer O [-0.3698098361492157, 0.3361031711101532]
and O [-0.9479981660842896, 0.824637234210968]
facilitates O [-0.6395358443260193, 0.7950553297996521]
loading O [-0.3416554033756256, 0.3424122631549835]
of O [-0.43735116720199585, 0.35935306549072266]
miRNA O [-0.26358214020729065, 0.2509770095348358]
onto O [-0.3371855616569519, 0.39915183186531067]
RNA-induced O [-0.15261025726795197, 0.1292702853679657]
silencing O [-0.29036054015159607, 0.2641489803791046]

complexes, B-LOC [2.059349298477173, -2.3068687915802]
identifying B-LOC [1.959105372428894, -2.243602991104126]
a B-LOC [2.072052001953125, -2.5137829780578613]
new B-LOC [2.122586488723755, -2.4416005611419678]
role B-LOC [2.166231870651245, -2.5396173000335693]
of B-LOC [1.8840465545654297, -2.481835126876831]
ADAR1 B-LOC [1.7331939935684204, -2.0804965496063232]
in B-LOC [1.918764352798462, -2.5642569065093994]
miRNA B-LOC [2.0082714557647705, -2.3657541275024414]
processing B-LOC [2.0307910442352295, -2.255190372467041]
and B-LOC [2.045916795730591, -2.3032679557800293]
RNAi B-LOC [2.21728253364563, -2.544257879257202]
mechanisms. B-LOC [2.340646743774414, -2.5201895236968994]
ADAR1 B-LOC [1.588320255279541, -1.8393081426620483]
differentiates B-LOC [1.955076813697815, -2.227717399597168]
its B-LOC [1.8720202445983887, -2.255833387374878]
functions B-LOC [1.8316259384155273, -2.153393030166626]
in B-LOC [1.7911909818649292, -2.2674410343170166]
RNA B-LOC [2.0357298851013184, -2.238327980041504]
editing B-LOC [1.9113616943359375, -2.0584094524383545]
and B-LOC [1.9125137329101562, -2.148200750350952]
RNAi B-LOC [2.1239421367645264, -2.2209794521331787]
by B-LOC [2.120723009109497, -2.1956350803375244]
the B-LOC [1.8825721740722656, -2.1855456829071045]
formation B-LOC [2.022951602935791, -2.0674726963043213]
of B-LOC [1.9411736726760864, -2.209742784500122]
either B-LOC [1.8944286108016968, -2.299819231033325]
ADAR1/ADAR1 B-LOC [1.578528642654419, -1.723085641860962]
homodimer B-LOC [1.7909812927246094, -1.9868528842926025]
or B-LOC [1.9530541896820068, -2.076949119567871]
Dicer/ADAR1 B-LOC [1.4887417554855347, -1.7398505210876465]
heterodimer B-LOC [1.883201241493225, -2.151411533355713]
complexes, B-LOC [2.0765464305877686, -2.01967716217041]
respectively. B-LOC [1.9885144233703613, -2.4364237785339355]
As B-LOC [0.11928131431341171, -0.48286911845207214]
expected, B-LOC [0.2810393273830414, -0.42668482661247253]
the B-LOC [0.1307147890329361, -0.479511022567749]
expression B-LOC [0.04385395720601082, -0.3888603746891022]
of B-LOC [0.030978115275502205, -0.3606579899787903]
miRNAs B-LOC [0.14444369077682495, -0.6223448514938354]
is B-LOC [0.3431917726993561, -0.5574418902397156]
globally B-LOC [0.18342998623847961, -0.5604128837585449]
inhibited B-LOC [0.14071255922317505, -0.4996660351753235]
in B-LOC [-0.17452594637870789, -0.25569555163383484]
ADAR1(-/-) B-LOC [-0.07753609865903854, -0.4772390127182007]
mouse B-LOC [0.01454568188637495, -0.6030005812644958]
embryos, B-LOC [0.027025563642382622, -0.3818529546260834]
which, O [-0.4284200966358185, 0.08978921175003052]
in O [-0.30802616477012634, -0.07477301359176636]
turn, O [-0.34971269965171814, 0.08038317412137985]
alters B-LOC [-0.22916364669799805, -0.2584663927555084]
the B-LOC [-0.10480964183807373, -0.1625872254371643]
expression O [-0.020444391295313835, 0.15394330024719238]
of O [-0.04925091192126274, -0.03643826022744179]
their B-LOC [0.44964638352394104, -0.6170359253883362]
target B-LOC [0.2389725297689438, -0.651827335357666]
genes B-LOC [-0.14525912702083588, -0.30227699875831604]
and O [-0.2416505515575409, -0.034767989069223404]
might B-LOC [0.1020042821764946, -0.3363451659679413]
contribute O [-0.1773126721382141, -0.08460377901792526]
to O [-0.12436627596616745, -0.08027668297290802]
their B-LOC [0.16578686237335205, -0.4714479446411133]
embryonic B-LOC [0.005518140736967325, -0.32006242871284485]
lethal B-LOC [-0.09745397418737411, -0.5751166939735413]
phenotype. B-LOC [-0.18023306131362915, -0.26380303502082825]

Gliomas B-LOC [2.0149238109588623, -2.454073190689087]
arising B-LOC [2.6918842792510986, -2.8935000896453857]
in B-LOC [2.5146191120147705, -2.859524965286255]
the B-LOC [2.6355011463165283, -2.7964487075805664]
brainstem B-LOC [2.949986219406128, -3.2621991634368896]
and B-LOC [2.668034076690674, -2.7810516357421875]
thalamus B-LOC [2.9208486080169678, -3.2659804821014404]
are B-LOC [2.955010175704956, -2.8302619457244873]
devastating B-LOC [2.802978754043579, -3.1630444526672363]
tumors B-LOC [3.0049831867218018, -3.114103078842163]
that B-LOC [3.171327590942383, -3.2274982929229736]
are B-LOC [3.401089668273926, -3.2793819904327393]
difficult B-LOC [3.3719239234924316, -3.4902966022491455]
to B-LOC [3.3102617263793945, -3.2709333896636963]
surgically B-LOC [3.3331034183502197, -3.4405744075775146]
resect. B-LOC [3.3695147037506104, -3.3951594829559326]
To B-LOC [2.990539073944092, -3.462315559387207]
determine B-LOC [3.3014867305755615, -3.5667359828948975]
the B-LOC [3.39821720123291, -3.684382200241089]
genetic B-LOC [3.393569231033325, -3.614062547683716]
and B-LOC [3.0832183361053467, -3.5215024948120117]
epigenetic B-LOC [3.4568352699279785, -3.626192092895508]
landscape B-LOC [3.3774659633636475, -3.6218838691711426]
of B-LOC [3.329231023788452, -3.3858678340911865]
these B-LOC [2.99682879447937, -3.2620913982391357]
tumors, B-LOC [3.195078134536743, -3.3675670623779297]
we B-LOC [3.0339620113372803, -3.0604031085968018]
performed B-LOC [3.017822027206421, -3.3110783100128174]
exomic B-LOC [3.1870524883270264, -3.394585132598877]
sequencing B-LOC [3.273759603500366, -3.3897759914398193]
of B-LOC [3.1710543632507324, -3.268819570541382]
14 B-LOC [3.2164804935455322, -3.5008130073547363]
brainstem B-LOC [3.171056032180786, -3.3378288745880127]
gliomas B-LOC [3.141200304031372, -3.261556386947632]
(BSGs) B-LOC [3.233896017074585, -3.456549882888794]
and B-LOC [3.232884645462036, -3.1822526454925537]
12 B-LOC [3.2976162433624268, -3.5029566287994385]
thalamic B-LOC [3.3081562519073486, -3.4367380142211914]
gliomas. B-LOC [2.987332344055176, -3.062088966369629]
We B-LOC [2.851168394088745, -2.968193769454956]
also B-LOC [3.2524282932281494, -3.005880355834961]
performed B-LOC [2.982301950454712, -3.016265630722046]
targeted B-LOC [3.230388879776001, -3.3340654373168945]
mutational B-LOC [3.072705030441284, -3.536320924758911]
analysis B-LOC [3.1475255489349365, -3.1775002479553223]
of B-LOC [3.276897430419922, -3.1200830936431885]
an B-LOC [3.404017925262451, -3.228337049484253]
additional B-LOC [3.187286615371704, -3.239698648452759]
24 B-LOC [3.346317768096924, -3.2500977516174316]
such B-LOC [3.3736608028411865, -3.2447948455810547]
tumors B-LOC [3.118211030960083, -3.130345582962036]
and B-LOC [3.0567688941955566, -3.2200896739959717]
genome-wide B-LOC [3.5207560062408447, -3.3755743503570557]
methylation B-LOC [3.4484446048736572, -3.351884603500366]
profiling B-LOC [3.358644723892212, -3.4136664867401123]
of B-LOC [3.2542219161987305, -3.1443674564361572]
45 B-LOC [3.296654224395752, -3.2090656757354736]
gliomas. B-LOC [2.865326166152954, -2.825575590133667]
This B-LOC [0.8317238688468933, -0.9793024063110352]
study B-LOC [0.8157903552055359, -0.8682148456573486]
led B-LOC [0.6641771793365479, -0.48700353503227234]
to B-LOC [0.4145403504371643, -0.34871944785118103]
the B-LOC [0.6435111165046692, -0.4797786772251129]
discovery B-LOC [0.48852068185806274, -0.18951982259750366]
of B-LOC [0.289682000875473, -0.2225753366947174]
tumor-specific B-LOC [0.44851526618003845, -0.4083981513977051]
mutations B-LOC [0.35690829157829285, -0.33137455582618713]
in B-LOC [0.0880921483039856, -0.287837415933609]
PPM1D, B-LOC [0.17133525013923645, -0.1085093766450882]
encoding B-LOC [0.28389596939086914, -0.03869275376200676]
wild-type B-LOC [0.31867632269859314, -0.3624548017978668]
p53-induced B-LOC [-0.09604952484369278, -0.2692263722419739]
protein B-LOC [-0.05325746163725853, -0.3285099267959595]

phosphatase B-LOC [1.4125691652297974, -1.5001649856567383]
1D B-LOC [1.4295196533203125, -1.1216224431991577]
(WIP1), B-LOC [1.4040262699127197, -1.1471326351165771]
in B-LOC [1.2159528732299805, -1.0864626169204712]
37.5% B-LOC [1.9493088722229004, -1.3417295217514038]
of B-LOC [1.6564035415649414, -1.224574327468872]
the B-LOC [1.6750637292861938, -1.0798078775405884]
BSGs B-LOC [1.813126802444458, -1.5051918029785156]
that B-LOC [1.6529935598373413, -1.33233642578125]
harbored B-LOC [1.993399739265442, -1.4181818962097168]
hallmark B-LOC [2.080889940261841, -1.5478705167770386]
H3F3A B-LOC [1.9577609300613403, -1.7146978378295898]
mutations B-LOC [1.7383157014846802, -1.36287522315979]
encoding B-LOC [1.9321026802062988, -1.3238738775253296]
p. B-LOC [1.8330411911010742, -1.5977485179901123]
Lys27Met B-LOC [1.928922176361084, -1.6127865314483643]
substitutions. B-LOC [1.7379076480865479, -1.5940595865249634]
PPM1D B-LOC [0.13067716360092163, -0.4113427996635437]
mutations O [-0.17171761393547058, 0.043820034712553024]
were B-LOC [-0.0555209256708622, -0.13388828933238983]
mutually B-LOC [0.21550384163856506, -0.27531448006629944]
exclusive B-LOC [0.06435081362724304, -0.3475305140018463]
with B-LOC [-0.09168033301830292, -0.2593859136104584]
TP53 B-LOC [-0.02737109176814556, -0.2148495316505432]
mutations O [-0.3722458481788635, 0.1797959804534912]
in B-LOC [-0.1746358573436737, -0.22446466982364655]
BSG B-LOC [0.166374072432518, -0.18623411655426025]
and O [-0.5495093464851379, 0.3237611651420593]
attenuated O [-0.5205023884773254, 0.3118549883365631]
p53 O [-0.23724989593029022, -0.19666151702404022]
activation O [-0.38099172711372375, 0.22221168875694275]
in O [-0.3650602102279663, 0.0505073256790638]
vitro. O [-0.17365242540836334, 0.10429806262254715]
PPM1D O [-0.2971888780593872, 0.10933474451303482]
mutations O [-0.37926891446113586, 0.40174898505210876]
were O [-0.6155180931091309, 0.45937058329582214]
truncating O [-0.4926033020019531, 0.580705463886261]
alterations O [-0.483789324760437, 0.5172948837280273]
in O [-0.5114933848381042, 0.5035317540168762]
exon O [-0.35446444153785706, 0.3919113576412201]
6 O [-0.3247848153114319, 0.5119045972824097]
that O [-0.5536817312240601, 0.46466901898384094]
enhanced O [-0.6402509212493896, 0.5074920058250427]
the O [-0.5849608182907104, 0.5005695819854736]
ability O [-0.6277756094932556, 0.6131535172462463]
of O [-0.5310550332069397, 0.4604552686214447]
PPM1D O [-0.38386043906211853, 0.17540118098258972]
to O [-0.5786349177360535, 0.5330278277397156]
suppress O [-0.48123443126678467, 0.5217158198356628]
the O [-0.6556715369224548, 0.5625590085983276]
activation O [-0.5186453461647034, 0.6428650617599487]
of O [-0.5808874368667603, 0.5906020998954773]
the O [-0.42771679162979126, 0.40481504797935486]
DNA O [-0.3253135681152344, 0.20101583003997803]
damage O [-0.28357353806495667, 0.2548926770687103]
response O [-0.3816360533237457, 0.22305908799171448]
checkpoint O [-0.29850712418556213, 0.21723881363868713]
protein O [-0.4222160577774048, 0.1371535211801529]
CHK2. O [-0.21498727798461914, -0.05349726974964142]
These B-LOC [0.5887631177902222, -0.6511922478675842]
results B-LOC [0.545224130153656, -0.5615939497947693]
define B-LOC [1.215027093887329, -0.9825983643531799]
PPM1D B-LOC [0.22239533066749573, -0.5181931853294373]
as B-LOC [1.2214117050170898, -1.0819865465164185]
a B-LOC [0.975996196269989, -1.0672807693481445]
frequent B-LOC [0.9488744139671326, -1.1167092323303223]
target B-LOC [0.916778028011322, -1.3029834032058716]
of B-LOC [0.7593334317207336, -0.8797311186790466]

somatic B-LOC [0.106051504611969, -0.4231153428554535]
mutation B-LOC [0.2500751316547394, -0.6210571527481079]
and B-LOC [0.6668198704719543, -0.6965903639793396]
as B-LOC [0.7962695956230164, -0.8689215779304504]
a B-LOC [0.8037941455841064, -0.7766847014427185]
potential B-LOC [1.0812437534332275, -1.2037876844406128]
therapeutic B-LOC [0.7952558398246765, -1.262401819229126]
target B-LOC [0.6354795694351196, -1.091135025024414]
in B-LOC [0.35886135697364807, -0.6078356504440308]
brainstem B-LOC [0.32656070590019226, -0.590706467628479]
gliomas. B-LOC [0.21153539419174194, -0.4564487934112549]

Angiotensin B-LOC [2.2025325298309326, -2.8721923828125]
converting B-LOC [2.709951400756836, -2.8927793502807617]
enzyme B-LOC [2.8803322315216064, -3.2300169467926025]
(ACE) B-LOC [3.2057716846466064, -3.0921452045440674]
inhibitors B-LOC [3.121840238571167, -2.969136953353882]
are B-LOC [3.1878674030303955, -2.9930338859558105]
now B-LOC [3.2855517864227295, -2.938228130340576]
one B-LOC [3.3397765159606934, -3.033703565597534]
of B-LOC [3.2770063877105713, -3.047377586364746]
the B-LOC [3.222625970840454, -2.9731831550598145]
most B-LOC [3.250189781188965, -3.21002459526062]
frequently B-LOC [3.336998701095581, -3.1371405124664307]
used B-LOC [3.232581853866577, -3.2171175479888916]
classes B-LOC [3.428403615951538, -3.1917941570281982]
of B-LOC [2.9837276935577393, -3.3550615310668945]
antihypertensive B-LOC [3.2479138374328613, -3.18212628364563]
drugs. B-LOC [3.021169662475586, -3.1452200412750244]
Beyond B-LOC [3.0881621837615967, -3.0494496822357178]
their B-LOC [3.0428197383880615, -3.040168046951294]
utility B-LOC [2.7574846744537354, -3.0765981674194336]
in B-LOC [2.838381052017212, -3.229379177093506]
the B-LOC [2.823335647583008, -3.2213258743286133]
management B-LOC [2.9440128803253174, -3.2552168369293213]
of B-LOC [2.836111068725586, -3.3385472297668457]
hypertension, B-LOC [2.8363301753997803, -3.330361843109131]
their B-LOC [3.121187448501587, -3.1220788955688477]
use B-LOC [2.9026880264282227, -3.0666496753692627]
has B-LOC [3.1541895866394043, -2.926905393600464]
been B-LOC [3.1957240104675293, -3.1190807819366455]
extended B-LOC [3.1727607250213623, -2.9800381660461426]
to B-LOC [3.093600273132324, -3.060109853744507]
the B-LOC [2.993556261062622, -3.1144955158233643]
long-term B-LOC [3.1803977489471436, -3.1495373249053955]
management B-LOC [3.053605556488037, -3.2514700889587402]
of B-LOC [2.945399045944214, -3.2141807079315186]
patients B-LOC [3.12026309967041, -3.137199640274048]
with B-LOC [2.9209659099578857, -3.290586233139038]
congestive B-LOC [2.944746255874634, -3.3863742351531982]
heart B-LOC [2.7477197647094727, -3.359373092651367]
failure B-LOC [3.00498366355896, -3.1780622005462646]
(CHF), B-LOC [3.1512820720672607, -3.3689584732055664]
as B-LOC [3.276028871536255, -3.071681261062622]
well B-LOC [3.035763740539551, -2.91463041305542]
as B-LOC [3.087885856628418, -2.9200944900512695]
diabetic B-LOC [3.042961359024048, -3.387845754623413]
and B-LOC [2.908968210220337, -3.107724189758301]
nondiabetic B-LOC [2.8698999881744385, -3.20206356048584]
nephropathies. B-LOC [2.9550302028656006, -3.3268187046051025]
Although O [-1.0296998023986816, 1.3071123361587524]
ACE O [-0.4248233735561371, 0.6936030387878418]
inhibitor O [-0.6444085240364075, 0.7170712351799011]
therapy O [-0.7936398983001709, 0.9381230473518372]
usually O [-0.9584983587265015, 1.1590641736984253]
improves O [-1.044108271598816, 1.265052318572998]
renal O [-0.8454397916793823, 1.0554156303405762]
blood O [-1.0911587476730347, 0.9077049493789673]
flow O [-0.8751866221427917, 1.0152050256729126]
(RBF) O [-0.82587069272995, 0.9493356347084045]
and O [-1.3038662672042847, 1.2147823572158813]
sodium O [-0.902601420879364, 0.9336431622505188]
excretion O [-1.0830492973327637, 1.1636545658111572]
rates O [-0.9402613639831543, 1.0436491966247559]
in O [-1.0468202829360962, 1.0786391496658325]
CHF O [-0.7165525555610657, 0.8596577644348145]
and O [-1.1765495538711548, 1.2886807918548584]
reduces O [-0.9516808986663818, 1.3007495403289795]
the O [-1.0910104513168335, 1.0858489274978638]
rate O [-1.113950252532959, 1.0507019758224487]
of O [-1.28373384475708, 1.0970804691314697]
progressive O [-1.162489891052246, 1.0668261051177979]
renal O [-1.0396533012390137, 1.0094913244247437]
injury O [-0.9090095162391663, 0.8043126463890076]
in O [-1.0731836557388306, 1.107934832572937]
chronic O [-1.0288386344909668, 1.028300166130066]
renal O [-0.9397670030593872, 0.8851991295814514]
disease, O [-0.8757915496826172, 0.8315644860267639]
its O [-0.7396525144577026, 0.926534116268158]

use B-LOC [-0.13367678225040436, -0.27098432183265686]
can B-LOC [0.06756043434143066, -0.5862818956375122]
also B-LOC [0.06772878021001816, -0.49984440207481384]
be B-LOC [-0.011620399542152882, -0.5815636515617371]
associated B-LOC [0.09478184580802917, -0.39383986592292786]
with B-LOC [-0.006907319184392691, -0.47126808762550354]
a B-LOC [0.1211116686463356, -0.41947394609451294]
syndrome B-LOC [0.268757164478302, -0.6305121779441833]
of B-LOC [-0.14345897734165192, -0.38122498989105225]
“functional B-LOC [-0.14218589663505554, -0.2152765393257141]
renal B-LOC [-0.13913732767105103, -0.3693789839744568]
insufficiency” B-LOC [0.052977632731199265, -0.28088489174842834]
and/or B-LOC [-0.16387435793876648, -0.31393566727638245]
hyperkalemia. B-LOC [0.07890915870666504, -0.5194658637046814]
This B-LOC [1.42633855342865, -1.5767625570297241]
form B-LOC [1.3463516235351562, -1.893334150314331]
of B-LOC [1.5170280933380127, -1.811588168144226]
acute B-LOC [1.771190881729126, -2.1235949993133545]
renal B-LOC [1.6969772577285767, -2.0774009227752686]
failure B-LOC [1.6527900695800781, -1.9124250411987305]
(ARF) B-LOC [1.894396185874939, -2.112088918685913]
most B-LOC [1.6050713062286377, -1.8529945611953735]
commonly B-LOC [1.792029619216919, -1.8222689628601074]
develops B-LOC [1.6427958011627197, -1.6368013620376587]
shortly B-LOC [1.4661004543304443, -1.5859729051589966]
after B-LOC [1.5593726634979248, -1.5396045446395874]
initiation B-LOC [1.5755946636199951, -1.8147673606872559]
of B-LOC [1.556915521621704, -1.791750431060791]
ACE B-LOC [1.4355170726776123, -1.6634936332702637]
inhibitor B-LOC [1.666198968887329, -1.9525066614151]
therapy B-LOC [1.5622673034667969, -1.8468527793884277]
but B-LOC [1.4843641519546509, -1.6179225444793701]
can B-LOC [1.7519344091415405, -1.8833461999893188]
be B-LOC [1.8845748901367188, -2.1298091411590576]
observed B-LOC [1.630993127822876, -1.7535344362258911]
after B-LOC [1.5401098728179932, -1.6981468200683594]
months B-LOC [2.1733510494232178, -1.9775258302688599]
or B-LOC [1.5516953468322754, -2.122746229171753]
years B-LOC [2.039794683456421, -2.167015314102173]
of B-LOC [1.5343966484069824, -1.8859963417053223]
therapy, B-LOC [1.6883257627487183, -1.8474570512771606]
even B-LOC [1.6232086420059204, -2.0369718074798584]
in B-LOC [1.4937214851379395, -1.709728479385376]
the B-LOC [1.5083928108215332, -1.7619457244873047]
absence B-LOC [1.5501362085342407, -1.6449874639511108]
of B-LOC [1.4681150913238525, -1.7265074253082275]
prior B-LOC [1.3870890140533447, -1.8406381607055664]
ill B-LOC [1.8726656436920166, -2.2380402088165283]
effects. B-LOC [1.5180479288101196, -1.7560210227966309]
ARF B-LOC [0.028555752709507942, -0.36304566264152527]
is B-LOC [-0.026153041049838066, -0.5759052634239197]
most B-LOC [0.19783608615398407, -0.4233316481113434]
likely B-LOC [0.06376217305660248, -0.4163878262042999]
to B-LOC [0.4165668785572052, -0.5862443447113037]
occur B-LOC [-0.23688331246376038, -0.5128897428512573]
when O [-0.27704718708992004, -0.22806140780448914]
renal O [-0.23197969794273376, -0.0860910415649414]
perfusion O [-0.33174842596054077, -0.11139708757400513]
pressure O [-0.24036365747451782, -0.1021520346403122]
cannot O [-0.019383756443858147, 0.05748043209314346]
be O [-0.12719380855560303, -0.10955646634101868]
sustained O [-0.24375298619270325, -0.08790384232997894]
because O [-0.1820315718650818, 0.06087269261479378]
of O [-0.1405925750732422, 0.014509214088320732]
substantial O [-0.20966990292072296, 0.11758358776569366]
decreases O [-0.19706006348133087, -0.07904963940382004]
in O [-0.42469069361686707, -0.14566639065742493]
mean O [-0.38332265615463257, 0.02161797322332859]
arterial B-LOC [-0.22647503018379211, -0.3299057185649872]
pressure O [-0.20329296588897705, 0.0008126269676722586]
(MAP) B-LOC [0.1540544331073761, -0.31312018632888794]
or B-LOC [-0.04221075400710106, -0.08661350607872009]
when B-LOC [-0.27408555150032043, -0.29320240020751953]
glomerular O [-0.09470231831073761, -0.039643365889787674]
filtration B-LOC [0.048157501965761185, -0.20075565576553345]
rate O [-0.3345619738101959, 0.08739034831523895]
(GFR) B-LOC [0.09086544811725616, -0.2127629518508911]
is O [-0.16615401208400726, -0.14788438379764557]
highly O [-0.10418862104415894, -0.030981997027993202]
angiotensin B-LOC [-0.11744171380996704, -0.3796873986721039]
II O [0.045387379825115204, 0.053746577352285385]
(Ang B-LOC [0.00664679566398263, -0.09118586778640747]
II) O [-0.18634119629859924, -0.11863234639167786]

dependent. B-LOC [0.9979994297027588, -1.2917622327804565]
Conditions B-LOC [1.7082085609436035, -1.8556678295135498]
that B-LOC [1.7420525550842285, -1.7026705741882324]
predict B-LOC [1.416236162185669, -1.6201162338256836]
an B-LOC [1.43668532371521, -1.9479327201843262]
adverse B-LOC [1.7183434963226318, -2.100613832473755]
hemodynamic B-LOC [1.504486083984375, -2.030461072921753]
effect B-LOC [1.5800861120224, -2.0484554767608643]
of B-LOC [1.2805627584457397, -1.5614032745361328]
ACE B-LOC [0.9558106064796448, -1.2030539512634277]
inhibitors B-LOC [1.2604061365127563, -1.400260090827942]
in B-LOC [1.4609267711639404, -1.5347065925598145]
patients B-LOC [1.451948642730713, -1.562063217163086]
with B-LOC [1.212477684020996, -1.4937021732330322]
CHF B-LOC [1.116552710533142, -1.1805329322814941]
are B-LOC [1.4126659631729126, -1.412302851676941]
preexisting B-LOC [1.0976423025131226, -1.2634806632995605]
hypotension B-LOC [1.4252891540527344, -1.461161732673645]
and B-LOC [1.0171582698822021, -0.9111295342445374]
low B-LOC [1.1183595657348633, -1.2131288051605225]
cardiac B-LOC [0.40467292070388794, -1.0090608596801758]
filling B-LOC [0.8866072297096252, -1.1908389329910278]
pressures. B-LOC [1.2076104879379272, -1.2376067638397217]
The B-LOC [0.20336881279945374, -0.4221411645412445]
GFR B-LOC [0.1426045000553131, -0.4378370940685272]
is B-LOC [0.2578163146972656, -0.5119537711143494]
especially B-LOC [0.4226871430873871, -0.6450105905532837]
dependent B-LOC [0.30012014508247375, -0.6573554873466492]
on B-LOC [0.3740536868572235, -0.5531031489372253]
Ang B-LOC [0.05925978347659111, -0.20395170152187347]
II B-LOC [-0.0842578336596489, -0.11033465713262558]
during B-LOC [-0.018602335825562477, -0.29540422558784485]
extracellular B-LOC [0.02480674348771572, -0.3342890739440918]
fluid B-LOC [-0.0889437198638916, -0.24350687861442566]
(ECF) B-LOC [0.32684341073036194, -0.36476075649261475]
volume B-LOC [-0.13878515362739563, -0.1924516260623932]
depletion, B-LOC [0.10290166735649109, -0.19494232535362244]
high-grade B-LOC [-0.0021965759806334972, -0.22583016753196716]
bilateral B-LOC [-0.16223756968975067, -0.20642311871051788]
renal B-LOC [-0.18381129205226898, -0.310464084148407]
artery O [-0.3634602129459381, -0.20689384639263153]
stenosis, B-LOC [0.0064589292742311954, -0.2857523262500763]
or B-LOC [0.33856087923049927, -0.5211830139160156]
stenosis B-LOC [0.021102333441376686, -0.29718509316444397]
of B-LOC [0.07065366208553314, -0.289776086807251]
a B-LOC [0.27327460050582886, -0.512863039970398]
dominant B-LOC [-0.023394891992211342, -0.16647276282310486]
or B-LOC [0.35191673040390015, -0.8742263317108154]
single B-LOC [0.22124263644218445, -0.4414478540420532]
kidney, B-LOC [-0.0836598128080368, -0.2949390411376953]
as B-LOC [0.2346493899822235, -0.721045196056366]
in B-LOC [0.27931690216064453, -0.4945867955684662]
a B-LOC [0.3820047080516815, -0.6548904180526733]
renal B-LOC [-0.010875840671360493, -0.41557207703590393]
transplant B-LOC [0.037631805986166, -0.48691102862358093]
recipient. B-LOC [0.03545749932527542, -0.3778735399246216]
Understanding B-LOC [1.7653462886810303, -1.7936116456985474]
the B-LOC [2.02817702293396, -1.8714359998703003]
pathophysiological B-LOC [2.020846128463745, -2.038341760635376]
mechanisms B-LOC [1.651125192642212, -2.0863072872161865]
and B-LOC [2.041378974914551, -2.094592332839966]
the B-LOC [2.0545732975006104, -1.9399176836013794]
common B-LOC [1.920656442642212, -2.1112725734710693]
risk B-LOC [1.646042823791504, -1.9083397388458252]
factors B-LOC [1.6614856719970703, -2.1753878593444824]
for B-LOC [1.3303498029708862, -1.563664436340332]
ACE B-LOC [1.1646703481674194, -1.084909200668335]
inhibitor–induced B-LOC [1.276924729347229, -1.4061055183410645]
functional B-LOC [1.4029121398925781, -1.640681266784668]
ARF B-LOC [0.8596742749214172, -1.0582993030548096]
is B-LOC [1.6058902740478516, -1.754058837890625]

critical, B-LOC [0.5270639061927795, -0.7313490509986877]
because B-LOC [0.6445809602737427, -0.6291027665138245]
preventive B-LOC [0.8456645607948303, -1.025522232055664]
strategies B-LOC [0.8860422372817993, -0.8086796402931213]
for B-LOC [0.6601162552833557, -0.9931818842887878]
ARF B-LOC [0.6216810345649719, -0.9466326832771301]
exist, B-LOC [0.8541740775108337, -0.8447966575622559]
and B-LOC [0.7978766560554504, -0.619437575340271]
if B-LOC [0.5325931906700134, -1.1892809867858887]
effectively B-LOC [0.7056207656860352, -0.9874542355537415]
used, B-LOC [0.8792416453361511, -1.1692166328430176]
they B-LOC [0.868235170841217, -0.9133113026618958]
may B-LOC [0.8115920424461365, -1.04051673412323]
permit B-LOC [0.5901023745536804, -0.9137511849403381]
use B-LOC [0.7722724080085754, -0.9461325407028198]
of B-LOC [0.7444977760314941, -1.0596133470535278]
these B-LOC [0.7422601580619812, -0.9762064814567566]
compounds B-LOC [0.6452141404151917, -0.924125611782074]
in B-LOC [0.7681524157524109, -0.9571231007575989]
a B-LOC [0.8336668610572815, -0.9742775559425354]
less B-LOC [0.608672022819519, -0.8386361002922058]
restricted B-LOC [0.8127181529998779, -1.2258390188217163]
fashion. B-LOC [0.666370689868927, -1.1228331327438354]
Under B-LOC [1.1543083190917969, -1.2173806428909302]
normal B-LOC [1.2788143157958984, -1.2646522521972656]
physiological B-LOC [1.323425531387329, -1.4369231462478638]
conditions, B-LOC [1.3083806037902832, -1.2417993545532227]
renal B-LOC [0.6693242788314819, -0.9513659477233887]
autoregulation B-LOC [1.1210594177246094, -1.2797260284423828]
adjusts B-LOC [0.9372384548187256, -0.9865997433662415]
renal B-LOC [0.803754985332489, -1.0970491170883179]
vascular B-LOC [0.9049798846244812, -1.2881850004196167]
resistance, B-LOC [1.0785382986068726, -1.1515120267868042]
so B-LOC [0.9785513281822205, -0.9309393167495728]
that B-LOC [0.8097125887870789, -0.9907227754592896]
RBF B-LOC [1.050013780593872, -1.0061769485473633]
and B-LOC [0.9080984592437744, -0.9986143708229065]
GFR B-LOC [0.9540446996688843, -1.031320333480835]
remain B-LOC [1.1370713710784912, -1.019496202468872]
constant B-LOC [1.0686380863189697, -1.1832998991012573]
over B-LOC [1.1877601146697998, -1.2193294763565063]
a B-LOC [1.4428534507751465, -1.3323887586593628]
wide B-LOC [1.5577867031097412, -1.5154318809509277]
range B-LOC [1.5283563137054443, -1.5761082172393799]
of B-LOC [1.3872573375701904, -1.3931949138641357]
MAPs.1 B-LOC [1.1704390048980713, -1.369800090789795]
The B-LOC [1.5028642416000366, -1.9559552669525146]
intrinsic B-LOC [1.4592335224151611, -2.0909647941589355]
renal B-LOC [1.2671210765838623, -1.9643133878707886]
autoregulation B-LOC [1.6504226922988892, -2.4495761394500732]
mechanism B-LOC [1.4302020072937012, -2.080456256866455]
is B-LOC [2.0122854709625244, -1.8829596042633057]
adjusted B-LOC [1.880344033241272, -2.3286149501800537]
by B-LOC [1.6098783016204834, -1.8976705074310303]
Ang B-LOC [1.588897705078125, -2.0328452587127686]
II B-LOC [1.5752298831939697, -1.8074129819869995]
and B-LOC [1.7824890613555908, -2.1527132987976074]
the B-LOC [1.9757366180419922, -2.2500202655792236]
sympathetic B-LOC [1.312016487121582, -2.2572860717773438]
nervous B-LOC [1.50406813621521, -2.2555229663848877]
system. B-LOC [1.520108699798584, -2.156186103820801]
When B-LOC [0.40353313088417053, -0.6704210638999939]
renal B-LOC [0.21534180641174316, -0.7651174664497375]
perfusion B-LOC [0.1379391849040985, -0.7976815700531006]
pressure B-LOC [0.35239264369010925, -0.6495904326438904]
falls B-LOC [0.6317475438117981, -0.7332505583763123]
(as B-LOC [0.7070401310920715, -0.6434056162834167]
in B-LOC [0.7034327387809753, -0.652517557144165]
… B-LOC [0.40555480122566223, -0.594545304775238]

CONTEXT B-LOC [1.3061342239379883, -2.3018798828125]
Exogenous B-LOC [1.8463584184646606, -2.677586317062378]
estrogen B-LOC [2.7075746059417725, -2.8540031909942627]
use B-LOC [2.0479493141174316, -2.4276912212371826]
may B-LOC [2.11745285987854, -2.7675883769989014]
lower B-LOC [1.8336920738220215, -2.8633038997650146]
risk B-LOC [2.4087884426116943, -3.093862771987915]
of B-LOC [2.1591336727142334, -3.095059394836426]
dementia B-LOC [2.394235134124756, -3.1015655994415283]
in B-LOC [1.879819631576538, -2.652247667312622]
postmenopausal B-LOC [1.8527565002441406, -2.714996099472046]
women. B-LOC [2.2731540203094482, -2.7656073570251465]
A B-LOC [3.063283920288086, -3.8146064281463623]
relationship B-LOC [3.0631422996520996, -3.874676465988159]
between B-LOC [2.951551675796509, -3.90675950050354]
long-term B-LOC [3.1648919582366943, -3.6227893829345703]
exposure B-LOC [3.2714900970458984, -3.712238311767578]
to B-LOC [3.0419976711273193, -3.6603682041168213]
endogenous B-LOC [3.111124038696289, -3.8425638675689697]
estrogens B-LOC [3.3788998126983643, -3.622746229171753]
and B-LOC [3.0879080295562744, -3.768233299255371]
incident B-LOC [3.180384635925293, -3.9614899158477783]
dementia B-LOC [3.2032625675201416, -3.602034330368042]
has B-LOC [3.377031087875366, -3.5542068481445312]
been B-LOC [3.2812559604644775, -3.7351205348968506]
hypothesized B-LOC [3.394674301147461, -3.5987889766693115]
but B-LOC [2.981510877609253, -3.6311185359954834]
not B-LOC [3.320242166519165, -3.582120180130005]
studied. B-LOC [3.4331600666046143, -3.5772528648376465]
OBJECTIVE B-LOC [2.9827566146850586, -3.3550913333892822]
To B-LOC [3.346198797225952, -3.3405535221099854]
determine B-LOC [3.5239455699920654, -3.4208669662475586]
whether B-LOC [3.401094913482666, -3.3942036628723145]
a B-LOC [3.3373191356658936, -3.247819185256958]
longer B-LOC [3.112544536590576, -3.5056064128875732]
reproductive B-LOC [3.28609299659729, -3.348721742630005]
period, B-LOC [3.2542226314544678, -3.5089006423950195]
as B-LOC [3.354649543762207, -3.2842938899993896]
an B-LOC [3.332346200942993, -3.4358737468719482]
indicator B-LOC [3.3524599075317383, -3.5155014991760254]
of B-LOC [3.112281560897827, -3.3530611991882324]
longer B-LOC [3.06569504737854, -3.5060417652130127]
exposure B-LOC [3.572861909866333, -3.4120500087738037]
to B-LOC [3.1836698055267334, -3.2018442153930664]
endogenous B-LOC [3.3816394805908203, -3.393754720687866]
estrogens, B-LOC [3.6284890174865723, -3.237591028213501]
is B-LOC [3.443789482116699, -3.4975128173828125]
associated B-LOC [3.2842671871185303, -3.612255811691284]
with B-LOC [3.1723992824554443, -3.468418836593628]
lower B-LOC [3.054797887802124, -3.591822385787964]
risk B-LOC [3.562530755996704, -3.5906295776367188]
of B-LOC [3.167424201965332, -3.238219976425171]
dementia B-LOC [3.3929808139801025, -3.2802634239196777]
and B-LOC [3.1280109882354736, -3.284935474395752]
Alzheimer B-LOC [3.4324023723602295, -3.444345474243164]
disease B-LOC [3.4248743057250977, -3.270846366882324]
(AD) B-LOC [3.3457772731781006, -3.2826969623565674]
in B-LOC [3.2187130451202393, -3.5608692169189453]
women B-LOC [3.5656158924102783, -3.418195962905884]
who B-LOC [3.259617328643799, -3.3707382678985596]
have B-LOC [3.3966517448425293, -3.4799606800079346]
natural B-LOC [3.294013261795044, -3.6090543270111084]
menopause. B-LOC [3.2040042877197266, -3.2947075366973877]
DESIGN B-LOC [2.5071334838867188, -2.638784646987915]
AND B-LOC [2.5202760696411133, -2.737126111984253]
SETTING B-LOC [1.995925784111023, -2.3240103721618652]
The B-LOC [2.0769174098968506, -2.30332612991333]
Rotterdam B-LOC [2.170196294784546, -2.58170485496521]
Study, B-LOC [2.4148666858673096, -2.6999402046203613]
a B-LOC [2.7083539962768555, -2.5565993785858154]
population-based B-LOC [2.66020131111145, -2.7918179035186768]

prospective B-LOC [3.321629524230957, -3.7677009105682373]
cohort B-LOC [3.451225757598877, -3.827923059463501]
study B-LOC [3.3577358722686768, -3.7538599967956543]
conducted B-LOC [3.5846168994903564, -3.6814630031585693]
in B-LOC [3.5838000774383545, -3.4617040157318115]
the B-LOC [3.5310962200164795, -3.6222355365753174]
Netherlands. B-LOC [3.5615837574005127, -3.86767840385437]
PARTICIPANTS B-LOC [2.6857106685638428, -3.3598365783691406]
A B-LOC [3.3887839317321777, -3.7098817825317383]
total B-LOC [3.7756495475769043, -3.3228681087493896]
of B-LOC [3.3983194828033447, -3.2353930473327637]
3601 B-LOC [3.4882819652557373, -3.4412858486175537]
women B-LOC [3.2967514991760254, -3.5731139183044434]
aged B-LOC [3.4234397411346436, -3.424834728240967]
55 B-LOC [3.6354589462280273, -3.412379026412964]
years B-LOC [3.518357515335083, -3.3096179962158203]
or B-LOC [3.0558669567108154, -3.0919926166534424]
older B-LOC [3.476767063140869, -3.167292594909668]
who B-LOC [3.209821939468384, -3.4096109867095947]
did B-LOC [3.110135078430176, -3.2579567432403564]
not B-LOC [3.3763837814331055, -3.3144078254699707]
have B-LOC [3.2552638053894043, -3.4943251609802246]
dementia B-LOC [3.408081293106079, -3.440918445587158]
at B-LOC [3.354641914367676, -3.7559139728546143]
baseline B-LOC [3.3156487941741943, -3.824875831604004]
(1990-1993) B-LOC [3.4685351848602295, -3.485046625137329]
and B-LOC [2.8895442485809326, -3.2330081462860107]
had B-LOC [3.2961490154266357, -3.636624813079834]
information B-LOC [3.50485897064209, -3.843224048614502]
on B-LOC [3.406280279159546, -3.9607245922088623]
age B-LOC [3.6889452934265137, -3.711564540863037]
at B-LOC [3.384639024734497, -3.83345365524292]
menarche, B-LOC [3.2036168575286865, -3.746602773666382]
age B-LOC [3.674595594406128, -3.7548115253448486]
at B-LOC [3.2796833515167236, -3.7639992237091064]
menopause, B-LOC [3.1717641353607178, -3.5872504711151123]
and B-LOC [3.528779983520508, -3.751429319381714]
type B-LOC [3.7435715198516846, -3.643998622894287]
of B-LOC [3.6316721439361572, -3.8034043312072754]
menopause. B-LOC [3.269249200820923, -3.7662832736968994]
Participants B-LOC [3.372760534286499, -3.7305727005004883]
were B-LOC [3.4349513053894043, -3.5333008766174316]
reexamined B-LOC [3.6476433277130127, -3.535721778869629]
in B-LOC [3.3236701488494873, -3.5117990970611572]
1993-1994 B-LOC [3.2544476985931396, -3.5560123920440674]
and B-LOC [3.206041097640991, -3.384047746658325]
1997-1999 B-LOC [3.32849383354187, -3.495305299758911]
and B-LOC [3.3387598991394043, -3.4709341526031494]
were B-LOC [3.540531873703003, -3.465686559677124]
continuously B-LOC [3.5635712146759033, -3.544039487838745]
monitored B-LOC [3.691457509994507, -3.5312917232513428]
for B-LOC [3.5602505207061768, -3.512006998062134]
development B-LOC [3.5851542949676514, -3.751539707183838]
of B-LOC [3.5563924312591553, -3.660966396331787]
dementia. B-LOC [3.6124107837677, -3.5512912273406982]
MAIN B-LOC [2.989590644836426, -3.1374943256378174]
OUTCOME B-LOC [2.8297760486602783, -2.98358154296875]
MEASURES B-LOC [2.7595155239105225, -2.8556110858917236]
Incidence B-LOC [2.690984010696411, -3.1875739097595215]
of B-LOC [2.955493211746216, -2.9391982555389404]
dementia, B-LOC [3.1818201541900635, -3.0507404804229736]
based B-LOC [2.624356269836426, -3.0548205375671387]
on B-LOC [2.6644957065582275, -2.930377960205078]
Diagnostic B-LOC [2.787022113800049, -3.145610809326172]
and B-LOC [2.4441230297088623, -2.6465842723846436]
Statistical B-LOC [3.095195770263672, -3.0266926288604736]
Manual B-LOC [2.8383116722106934, -3.2419674396514893]
of B-LOC [2.9371917247772217, -3.1013238430023193]
Mental B-LOC [3.0621325969696045, -3.1458518505096436]
Disorders, B-LOC [2.7325878143310547, -3.0351150035858154]
Revised B-LOC [2.8725075721740723, -2.9266245365142822]
Third B-LOC [2.473996162414551, -2.7956221103668213]

Edition B-LOC [3.0834031105041504, -3.672515392303467]
criteria, B-LOC [3.408099412918091, -3.716613531112671]
and B-LOC [3.0469491481781006, -3.428025960922241]
AD, B-LOC [3.349252700805664, -3.8706703186035156]
based B-LOC [3.5200767517089844, -3.6279895305633545]
on B-LOC [3.4185826778411865, -3.5979301929473877]
National B-LOC [3.3445539474487305, -3.754537343978882]
Institute B-LOC [3.390892744064331, -3.7944746017456055]
of B-LOC [3.003960609436035, -3.2408030033111572]
Neurological B-LOC [3.2527048587799072, -3.573042154312134]
Disorders B-LOC [3.316859483718872, -3.5241479873657227]
and B-LOC [3.351989269256592, -3.4683778285980225]
Stroke/Alzheimer's B-LOC [3.5017685890197754, -3.5028271675109863]
Disease B-LOC [3.5532338619232178, -3.4539525508880615]
and B-LOC [3.332298994064331, -3.3866519927978516]
Related B-LOC [3.3364641666412354, -3.3620855808258057]
Disorders B-LOC [3.371188163757324, -3.450287342071533]
Association B-LOC [3.5182032585144043, -3.5435590744018555]
criteria, B-LOC [3.6725540161132812, -3.7058286666870117]
compared B-LOC [3.601665496826172, -3.6626460552215576]
by B-LOC [3.302009105682373, -3.370964288711548]
quartiles B-LOC [3.536572217941284, -3.5519769191741943]
of B-LOC [3.384183406829834, -3.565720319747925]
reproductive B-LOC [3.4782943725585938, -3.7433393001556396]
period B-LOC [3.3744900226593018, -3.7792789936065674]
among B-LOC [3.325403928756714, -3.670549154281616]
women B-LOC [3.490987539291382, -3.599308967590332]
with B-LOC [3.4308245182037354, -3.7587201595306396]
natural B-LOC [3.2935826778411865, -3.903272867202759]
menopause. B-LOC [3.2190754413604736, -3.651573896408081]
RESULTS B-LOC [1.6724634170532227, -2.2698776721954346]
During B-LOC [1.9515310525894165, -2.201165199279785]
21 B-LOC [2.7120823860168457, -2.6756808757781982]
046 B-LOC [3.0110020637512207, -2.634654998779297]
person-years B-LOC [2.1128625869750977, -2.589329481124878]
of B-LOC [2.4848945140838623, -2.4440276622772217]
follow-up B-LOC [2.411222219467163, -2.723759889602661]
(median B-LOC [2.3040812015533447, -2.364234685897827]
follow-up, B-LOC [2.4893250465393066, -2.8552324771881104]
6.3 B-LOC [2.923851728439331, -2.679008722305298]
years), B-LOC [2.7948365211486816, -2.8158228397369385]
199 B-LOC [2.485574722290039, -2.3975794315338135]
women B-LOC [2.203706741333008, -2.4480788707733154]
developed B-LOC [2.161672353744507, -2.2616488933563232]
dementia, B-LOC [2.745866298675537, -2.9472625255584717]
including B-LOC [2.8164451122283936, -2.491837978363037]
159 B-LOC [2.716503858566284, -2.5677144527435303]
who B-LOC [2.496368646621704, -2.6112382411956787]
developed B-LOC [2.326690912246704, -2.398873805999756]
AD. B-LOC [2.456782341003418, -2.6887710094451904]
After B-LOC [0.9038102626800537, -1.3901240825653076]
adjusting B-LOC [0.8894967436790466, -1.5389145612716675]
for B-LOC [0.979655385017395, -1.7563834190368652]
age, B-LOC [1.154474139213562, -1.5351613759994507]
dementia B-LOC [1.1412841081619263, -1.6237869262695312]
was B-LOC [0.9721066355705261, -1.5816850662231445]
not B-LOC [1.250494360923767, -1.4985511302947998]
clearly B-LOC [1.057244062423706, -1.6767072677612305]
associated B-LOC [1.004867434501648, -1.6315467357635498]
with B-LOC [0.849371612071991, -1.7554352283477783]
length B-LOC [1.0847058296203613, -1.9292256832122803]
of B-LOC [1.0819876194000244, -2.132608652114868]
reproductive B-LOC [0.9684242010116577, -1.5395097732543945]
period. B-LOC [0.8500098586082458, -1.7944421768188477]
However, B-LOC [0.6900352835655212, -1.1297682523727417]
after B-LOC [0.4324502646923065, -0.9005577564239502]
adjusting B-LOC [0.47673919796943665, -0.9242531061172485]
for B-LOC [0.5336282849311829, -0.9359757304191589]
multiple B-LOC [0.6089923977851868, -1.176855444908142]
covariates, B-LOC [0.6655003428459167, -1.0798907279968262]
women B-LOC [0.6349667310714722, -0.9110733866691589]
with B-LOC [0.4379514157772064, -0.9288495182991028]
natural B-LOC [0.07742136716842651, -0.920957624912262]

menopause O [-0.36821016669273376, 0.43188926577568054]
and O [-0.7725553512573242, 0.5112523436546326]
more O [-0.6696751713752747, 0.6147379279136658]
reproductive O [-0.3781433701515198, 0.31064122915267944]
years O [-0.5578246116638184, 0.6078751683235168]
had O [-0.7896742224693298, 0.4830220937728882]
an O [-0.8117185831069946, 0.4625679850578308]
increased O [-0.7259604930877686, 0.45181629061698914]
risk O [-0.6011979579925537, 0.46669337153434753]
of O [-0.8192588686943054, 0.45706507563591003]
dementia O [-0.37532535195350647, 0.24105174839496613]
(adjusted O [-0.45505329966545105, 0.24854975938796997]
rate B-LOC [-0.23217064142227173, -0.24024750292301178]
ratio B-LOC [-0.06499333679676056, -0.238384410738945]
[RR] B-LOC [-0.02993510477244854, -0.22051884233951569]
for O [-0.18159516155719757, 0.04411937668919563]
women O [-0.17300117015838623, 0.09791287779808044]
with O [-0.21184495091438293, -0.0290690828114748]
>39 O [-0.21555402874946594, 0.04023661091923714]
reproductive B-LOC [-0.021456366404891014, -0.17451097071170807]
years B-LOC [-0.026038585230708122, -0.060043688863515854]
[highest B-LOC [0.12829795479774475, -0.024671921506524086]
quartile] B-LOC [0.15764731168746948, -0.22701340913772583]
compared O [-0.33537599444389343, 0.4063850939273834]
with O [-0.09397442638874054, -0.009843574836850166]
<34 O [-0.07850358635187149, -0.015307297930121422]
reproductive B-LOC [-0.04397301375865936, -0.17010559141635895]
years B-LOC [-0.0674223005771637, -0.08942447602748871]
[lowest B-LOC [0.07109257578849792, -0.13245399296283722]
quartile], B-LOC [0.18052907288074493, -0.1937074512243271]
1.78; O [-0.04454228654503822, 0.16824091970920563]
95% O [-0.3739708364009857, 0.317642480134964]
confidence O [-0.3531520664691925, 0.0049852835945785046]
interval O [-0.3918067514896393, -0.044407740235328674]
[CI], B-LOC [-0.002106448169797659, -0.12656615674495697]
1.12-2.84). O [-0.27363187074661255, 0.2485012263059616]
The B-LOC [0.4694961607456207, -0.7327759861946106]
adjusted B-LOC [0.3003748655319214, -0.8016179203987122]
RR B-LOC [0.34881484508514404, -0.7948614954948425]
per B-LOC [0.15442529320716858, -0.7091495394706726]
year B-LOC [0.3113310635089874, -0.988082230091095]
of B-LOC [0.5257431864738464, -0.7265956997871399]
increase B-LOC [0.21866142749786377, -0.712353527545929]
was B-LOC [0.30364617705345154, -0.6420201659202576]
1.04 B-LOC [0.2215365469455719, -0.5421730875968933]
(95% B-LOC [0.25929614901542664, -0.5910527110099792]
CI, B-LOC [-0.16120651364326477, -0.3631281554698944]
1.01-1.08). B-LOC [0.060910824686288834, -0.3255278766155243]
For O [-0.1856907606124878, -0.13756075501441956]
risk O [-0.19924107193946838, 0.05705966427922249]
of O [-0.4923901855945587, -0.016622526571154594]
AD, O [-0.2835417091846466, -0.0029301573522388935]
the B-LOC [0.0952749252319336, -0.2145226001739502]
adjusted B-LOC [-0.06721191108226776, -0.2781733274459839]
RRs B-LOC [-0.08534716069698334, -0.30365559458732605]
were B-LOC [0.017838062718510628, -0.14962488412857056]
1.51 O [-0.08813701570034027, 0.053644925355911255]
(95% B-LOC [-0.11884340643882751, -0.12025383114814758]
CI, O [-0.3917142450809479, -0.05294487252831459]

0.91-2.50) B-LOC [0.04614685848355293, -0.4062356948852539]
and B-LOC [0.08971918374300003, -0.34831860661506653]
1.03 B-LOC [0.048806872218847275, -0.40049222111701965]
(95% B-LOC [0.07251115143299103, -0.5320211052894592]
CI, O [-0.31207284331321716, -0.3025236427783966]
1.00-1.07), B-LOC [-0.04353040084242821, -0.36441880464553833]
respectively. B-LOC [0.23347100615501404, -0.5486192107200623]
Risk O [-0.5904358625411987, 0.5632252097129822]
of O [-0.8092758059501648, 0.7165189385414124]
dementia O [-0.4842340052127838, 0.5604010224342346]
associated O [-0.7625256180763245, 0.7100136876106262]
with O [-0.7714521288871765, 0.6680389046669006]
a O [-0.70900958776474, 0.712528645992279]
longer O [-0.7497087121009827, 0.8012859225273132]
reproductive O [-0.5841028690338135, 0.6337936520576477]
period O [-0.6272568106651306, 0.5696386694908142]
was O [-0.6068606972694397, 0.3198431730270386]
most O [-0.41671082377433777, 0.32624551653862]
pronounced O [-0.4624439775943756, 0.44695180654525757]
in O [-0.5759669542312622, 0.6266204118728638]
APOE O [-0.659145176410675, 0.45419177412986755]
epsilon4 O [-0.7197503447532654, 0.873627781867981]
carriers O [-0.6201063990592957, 0.6104231476783752]
(adjusted O [-0.5966476798057556, 0.6711881756782532]
RR O [-0.5383548140525818, 0.6213263869285583]
for O [-0.6546358466148376, 0.43425729870796204]
>39 O [-0.5735087990760803, 0.5476003885269165]
reproductive O [-0.5984768271446228, 0.57085782289505]
years O [-0.6579733490943909, 0.6818564534187317]
compared O [-0.7988414764404297, 0.7849530577659607]
with O [-0.5545870661735535, 0.568461000919342]
<34 O [-0.6000221371650696, 0.542094349861145]
reproductive O [-0.6083205342292786, 0.5261883735656738]
years, O [-0.6707327961921692, 0.68326336145401]
4.20 O [-0.6642487049102783, 0.9718562960624695]
[95% O [-0.652044951915741, 0.3778908848762512]
CI, O [-0.6888114809989929, 0.508539617061615]
1.97-8.92] O [-0.4722011983394623, 0.7192427515983582]
for O [-0.8537167906761169, 0.3969508707523346]
dementia O [-0.589594304561615, 0.6603103876113892]
and O [-0.6442638039588928, 0.4619585871696472]
3.42 O [-0.6506499648094177, 0.8264392018318176]
[95% O [-0.6074457168579102, 0.22393564879894257]
CI, O [-0.6619428992271423, 0.3911084830760956]
1.51-7.75] O [-0.46805867552757263, 0.47788456082344055]
for O [-0.5673295855522156, 0.3424999415874481]
AD), O [-0.686790406703949, 0.513859748840332]
whereas O [-0.6606413722038269, 0.5428645610809326]
in O [-0.5428846478462219, 0.49996641278266907]
noncarriers, O [-0.694758415222168, 0.6687466502189636]
no O [-0.18204540014266968, 0.2769998013973236]
clear B-LOC [-0.08626363426446915, -0.14598557353019714]
association O [-0.2938652038574219, 0.1098523885011673]
with O [-0.375177264213562, 0.18869422376155853]

dementia B-LOC [0.16996750235557556, -0.4959413707256317]
or B-LOC [0.3249562382698059, -0.8333503603935242]
AD B-LOC [0.10539621859788895, -0.779390275478363]
was B-LOC [0.3035230040550232, -0.6738564372062683]
observed. B-LOC [0.37695300579071045, -0.6070023775100708]
CONCLUSION O [-0.6595114469528198, 0.3569418489933014]
Our B-LOC [0.15063820779323578, -0.30854135751724243]
findings B-LOC [0.3676466643810272, -0.30289164185523987]
do B-LOC [0.9780206084251404, -0.28121593594551086]
not B-LOC [0.8251595497131348, -0.2393062263727188]
support B-LOC [1.0669667720794678, -0.6169115900993347]
the B-LOC [0.9128108620643616, -0.6045275330543518]
hypothesis B-LOC [0.6716636419296265, -0.6703571081161499]
that B-LOC [0.15738895535469055, -0.460021048784256]
a O [-0.24351578950881958, 0.17966079711914062]
longer O [-0.34732088446617126, 0.06588129699230194]
reproductive O [-0.16131491959095, -0.11550882458686829]
period O [-0.39317572116851807, 0.025224288925528526]
reduces B-LOC [-0.0810580626130104, -0.10100964456796646]
risk B-LOC [-0.1308821439743042, -0.19264322519302368]
of B-LOC [-0.23693254590034485, -0.27512168884277344]
dementia B-LOC [-0.03089163266122341, -0.23844075202941895]
in B-LOC [-0.08595873415470123, -0.18914061784744263]
women B-LOC [0.11826156079769135, -0.28608396649360657]
who B-LOC [-0.1450841724872589, -0.3186453580856323]
have B-LOC [-0.05618274211883545, -0.20902633666992188]
natural B-LOC [-0.3132263720035553, -0.3279029130935669]
menopause. B-LOC [0.12215431034564972, -0.12685754895210266]

Antibiotics B-LOC [0.8151089549064636, -1.262121558189392]
can B-LOC [1.360332727432251, -1.6801164150238037]
have B-LOC [1.4605348110198975, -1.6913701295852661]
significant B-LOC [1.222344994544983, -1.5861116647720337]
and B-LOC [1.0641584396362305, -1.2696343660354614]
long-lasting B-LOC [1.5795180797576904, -1.8154038190841675]
effects B-LOC [1.311142921447754, -1.5375628471374512]
on B-LOC [1.1417747735977173, -1.6392405033111572]
the B-LOC [1.0297613143920898, -1.4774621725082397]
gastrointestinal B-LOC [1.0392229557037354, -1.7379872798919678]
tract B-LOC [1.2703046798706055, -1.7679020166397095]
microbiota, B-LOC [1.3748692274093628, -1.7458134889602661]
reducing B-LOC [1.276662826538086, -1.5682342052459717]
colonization B-LOC [1.2331268787384033, -1.5241904258728027]
resistance B-LOC [1.4154775142669678, -1.7499070167541504]
against B-LOC [1.5578542947769165, -1.8183621168136597]
pathogens B-LOC [1.6587826013565063, -1.9214454889297485]
including B-LOC [1.6008753776550293, -1.6933190822601318]
Clostridium B-LOC [0.9807607531547546, -1.4746290445327759]
difficile. B-LOC [1.3362658023834229, -1.6612046957015991]
Here O [-0.39884284138679504, 0.09896862506866455]
we O [-0.4220734238624573, 0.06317871809005737]
show O [-0.3297259509563446, 0.1973685920238495]
that O [-0.7019320130348206, 0.18572154641151428]
antibiotic B-LOC [0.08421915769577026, -0.01085486076772213]
treatment O [-0.03355579078197479, -0.007814774289727211]
induces O [-0.10231766104698181, 0.15452001988887787]
substantial O [-0.16430073976516724, -0.008608700707554817]
changes B-LOC [-0.08023246377706528, -0.1672741323709488]
in O [-0.1268845796585083, 0.026292799040675163]
the O [-0.056859005242586136, 0.12330479174852371]
gut O [-0.11282987147569656, -0.10458262264728546]
microbial O [0.03194156661629677, 0.039399515837430954]
community O [-0.011978344060480595, 0.006649804767221212]
and O [-0.1430007666349411, 0.015726933255791664]
in O [-0.09656428545713425, 0.10035082697868347]
the O [-0.013595168478786945, 0.11601699888706207]
metabolome B-LOC [0.05629028379917145, 0.024100286886096]
of O [-0.12466055154800415, 0.18368400633335114]
mice O [-0.1684795618057251, -0.10214625298976898]
susceptible B-LOC [0.2566826641559601, -0.2204558551311493]
to O [-0.07726321369409561, -0.06281155347824097]
C. B-LOC [-0.12097874283790588, -0.3020422160625458]
difficile B-LOC [0.022756310179829597, -0.14920169115066528]
infection. B-LOC [-0.00932298693805933, -0.12511709332466125]
Levels B-LOC [0.3736579418182373, -0.4088456928730011]
of B-LOC [0.2408449649810791, -0.4752565920352936]
secondary B-LOC [0.0430961437523365, -0.45670512318611145]
bile B-LOC [0.07144671678543091, -0.3489479124546051]
acids, B-LOC [0.3999727964401245, -0.38098371028900146]
glucose, B-LOC [0.28625771403312683, -0.38492512702941895]
free B-LOC [0.27724146842956543, -0.3216049075126648]
fatty B-LOC [0.5338390469551086, -0.4882044792175293]
acids B-LOC [0.4326322078704834, -0.3482811152935028]
and B-LOC [0.31995275616645813, -0.3007275462150574]
dipeptides B-LOC [0.1568332314491272, -0.5152425765991211]
decrease, B-LOC [0.3359415531158447, -0.5115324258804321]
whereas B-LOC [0.27074500918388367, -0.44367504119873047]
those B-LOC [0.673051655292511, -0.5967915654182434]
of B-LOC [0.42844322323799133, -0.5566871762275696]
primary B-LOC [0.2371160387992859, -0.7098200917243958]
bile B-LOC [0.261772483587265, -0.48262158036231995]
acids B-LOC [0.5395697951316833, -0.3857988715171814]
and B-LOC [0.43640971183776855, -0.4929009974002838]
sugar B-LOC [0.40512511134147644, -0.6135197877883911]
alcohols B-LOC [0.44995012879371643, -0.7584995627403259]
increase, B-LOC [0.2918187081813812, -0.6379076242446899]
reflecting B-LOC [0.45996159315109253, -0.5487219095230103]
the B-LOC [0.5001044273376465, -0.47948458790779114]
modified B-LOC [0.29598531126976013, -0.7570397257804871]
metabolic B-LOC [0.47174790501594543, -0.6219371557235718]
activity B-LOC [0.6199195981025696, -0.5950919985771179]
of B-LOC [0.6699214577674866, -0.7904866933822632]
the B-LOC [0.4629819989204407, -0.5691997408866882]
altered B-LOC [0.21815899014472961, -0.8149636387825012]
gut B-LOC [0.08666582405567169, -0.6071259379386902]
microbiome. B-LOC [0.3702945411205292, -0.6753678917884827]
In B-LOC [0.029270479455590248, -0.26558682322502136]
vitro B-LOC [0.13126160204410553, -0.2021215558052063]

and O [-0.5722705721855164, 0.36175665259361267]
ex O [-0.34892886877059937, 0.07670217752456665]
vivo O [-0.26941439509391785, 0.13782629370689392]
analyses O [-0.09771854430437088, 0.31238487362861633]
demonstrate O [-0.28774139285087585, 0.36791756749153137]
that O [-0.8224008083343506, 0.45479080080986023]
C. O [-0.4588056206703186, 0.21855109930038452]
difficile O [-0.3215005695819855, 0.14967355132102966]
can O [-0.5990087389945984, 0.4902070462703705]
exploit O [-0.36164090037345886, 0.442050963640213]
specific O [-0.4199906885623932, 0.4038449227809906]
metabolites O [-0.31437715888023376, 0.5258051753044128]
that O [-0.5291543006896973, 0.4246891438961029]
become O [-0.4923776090145111, 0.49080196022987366]
more O [-0.6864696145057678, 0.7064104676246643]
abundant O [-0.42553627490997314, 0.5190877318382263]
in O [-0.620444118976593, 0.7397168278694153]
the O [-0.7613869905471802, 0.8434846997261047]
mouse O [-0.7251351475715637, 0.5247560143470764]
gut O [-0.43491852283477783, 0.4407915771007538]
after O [-0.7236243486404419, 0.5806316137313843]
antibiotics, O [-0.7075104117393494, 0.6744694113731384]
including O [-0.35475245118141174, 0.5920457243919373]
the O [-0.5938125848770142, 0.695311963558197]
primary O [-0.6509353518486023, 0.5326406359672546]
bile O [-0.5642639398574829, 0.6080098152160645]
acid O [-0.5517939925193787, 0.4739367961883545]
taurocholate O [-0.441175252199173, 0.6080140471458435]
for O [-0.7080023884773254, 0.4160017967224121]
germination, O [-0.757809579372406, 0.8154274821281433]
and O [-0.5830036997795105, 0.7659388184547424]
carbon O [-0.649204432964325, 0.6923306584358215]
sources O [-0.6494434475898743, 0.6770055890083313]
such O [-0.3620467483997345, 0.4754130244255066]
as O [-0.36342474818229675, 0.49779120087623596]
mannitol, O [-0.38320299983024597, 0.4270959198474884]
fructose, O [-0.3394380509853363, 0.5406880974769592]
sorbitol, O [-0.21768352389335632, 0.5809375643730164]
raffinose O [-0.3097511827945709, 0.30261996388435364]
and O [-0.2792240381240845, 0.4728145897388458]
stachyose O [-0.363618940114975, 0.3237583339214325]
for O [-0.5514018535614014, 0.36374610662460327]
growth. O [-0.5217919945716858, 0.8847500681877136]
Our B-LOC [-0.0695933997631073, -0.26078030467033386]
results B-LOC [0.25304701924324036, -0.22514694929122925]
indicate B-LOC [0.08943932503461838, -0.06386925280094147]
that O [-0.18669721484184265, -0.1380661427974701]
antibiotic-mediated B-LOC [0.2107226401567459, -0.2009110003709793]
alteration B-LOC [0.2864309847354889, -0.5590934753417969]
of B-LOC [0.2338036596775055, -0.2963313162326813]
the B-LOC [0.21977442502975464, -0.2915809750556946]
gut B-LOC [0.010703745298087597, -0.4169215261936188]
microbiome B-LOC [0.04772384837269783, -0.3123370110988617]
converts B-LOC [0.04974916949868202, -0.26941370964050293]
the B-LOC [0.14682888984680176, -0.2785128653049469]
global B-LOC [0.09170234203338623, -0.6135972142219543]
metabolic B-LOC [0.14377626776695251, -0.4196438789367676]
profile B-LOC [0.11055435985326767, -0.5297492146492004]
to B-LOC [0.028848061338067055, -0.24300149083137512]
one B-LOC [0.06761081516742706, -0.3536583185195923]
that B-LOC [-0.08767163753509521, -0.5703778266906738]
favours B-LOC [0.07405602931976318, -0.4067680537700653]
C. B-LOC [-0.06733816862106323, -0.34613314270973206]
difficile B-LOC [0.08338204026222229, -0.2675801217556]
germination B-LOC [0.0026984387077391148, -0.46803757548332214]
and B-LOC [-0.022823331877589226, -0.33336305618286133]
growth. B-LOC [0.00036750975414179265, -0.4649008512496948]

The B-LOC [1.399078130722046, -2.0117135047912598]
canonical B-LOC [1.7146409749984741, -2.2346529960632324]
role B-LOC [1.8450384140014648, -2.1697285175323486]
of B-LOC [1.4663879871368408, -2.136536121368408]
messenger B-LOC [1.4996668100357056, -2.105929136276245]
RNA B-LOC [1.5288114547729492, -2.2227847576141357]
(mRNA) B-LOC [1.6398282051086426, -1.9644192457199097]
is B-LOC [2.113964557647705, -2.086627244949341]
to B-LOC [1.9145761728286743, -2.1345102787017822]
deliver B-LOC [1.6064200401306152, -1.9585278034210205]
protein-coding B-LOC [1.7394227981567383, -2.0965325832366943]
information B-LOC [1.4751936197280884, -2.045715093612671]
to B-LOC [1.7046749591827393, -2.3476979732513428]
sites B-LOC [1.8818308115005493, -2.327375650405884]
of B-LOC [2.0661520957946777, -2.818384885787964]
protein B-LOC [1.8416776657104492, -2.1837375164031982]
synthesis. B-LOC [1.7370306253433228, -2.08834171295166]
However, B-LOC [1.667968511581421, -1.4879963397979736]
given B-LOC [1.3373024463653564, -1.1680686473846436]
that B-LOC [1.2444524765014648, -1.1136212348937988]
microRNAs B-LOC [1.3722150325775146, -1.1318413019180298]
bind B-LOC [1.2306596040725708, -1.0643796920776367]
to B-LOC [1.0438511371612549, -1.1295595169067383]
RNAs, B-LOC [1.319230079650879, -1.331131100654602]
we B-LOC [1.2708840370178223, -1.4039466381072998]
hypothesized B-LOC [2.0470261573791504, -1.6727511882781982]
that B-LOC [1.1657724380493164, -1.3312559127807617]
RNAs B-LOC [1.1083409786224365, -1.3396387100219727]
could B-LOC [1.1867502927780151, -1.3714599609375]
possess B-LOC [0.973543107509613, -1.3124593496322632]
a B-LOC [0.9840325713157654, -1.1361802816390991]
regulatory B-LOC [0.9947872757911682, -1.2591955661773682]
role B-LOC [0.6974285244941711, -1.0883713960647583]
that B-LOC [0.8160122632980347, -1.4186204671859741]
relies B-LOC [0.8845493197441101, -1.213243007659912]
on B-LOC [0.8125472664833069, -1.0780612230300903]
their B-LOC [1.1240031719207764, -1.3413562774658203]
ability B-LOC [0.8192867636680603, -1.0851339101791382]
to B-LOC [0.8175012469291687, -1.188563346862793]
compete B-LOC [0.6733892560005188, -1.1175512075424194]
for B-LOC [0.8043219447135925, -1.2230961322784424]
microRNA B-LOC [0.8409915566444397, -1.1036360263824463]
binding, B-LOC [0.8350548148155212, -0.911418616771698]
independently B-LOC [0.6814204454421997, -1.0319421291351318]
of B-LOC [0.8091039061546326, -1.1938376426696777]
their B-LOC [1.168826937675476, -1.581155776977539]
protein-coding B-LOC [1.2177746295928955, -1.6615476608276367]
function. B-LOC [0.7158008217811584, -1.1618293523788452]
As B-LOC [1.7191790342330933, -1.7272886037826538]
a B-LOC [1.9253242015838623, -1.985256552696228]
model B-LOC [1.8849761486053467, -2.112172842025757]
for B-LOC [2.0858776569366455, -2.031165599822998]
the B-LOC [2.1448709964752197, -2.2404990196228027]
protein-coding-independent B-LOC [1.8448892831802368, -2.1792140007019043]
role B-LOC [1.9356880187988281, -2.3033978939056396]
of B-LOC [1.7774286270141602, -2.033208131790161]
RNAs, B-LOC [1.935718059539795, -2.3039679527282715]
we B-LOC [1.572401762008667, -1.4177699089050293]
describe B-LOC [1.827607274055481, -1.8176153898239136]
the B-LOC [2.0240349769592285, -2.119267225265503]
functional B-LOC [2.0544748306274414, -2.0888946056365967]
relationship B-LOC [1.7714076042175293, -2.139695405960083]
between B-LOC [1.90096116065979, -2.2962632179260254]
the B-LOC [1.7900031805038452, -1.700914978981018]
mRNAs B-LOC [1.374119758605957, -1.7699981927871704]
produced B-LOC [1.6805833578109741, -1.8933074474334717]
by B-LOC [1.4727001190185547, -1.6510475873947144]
the B-LOC [1.7142001390457153, -1.8381688594818115]
PTEN B-LOC [1.4594783782958984, -1.6981489658355713]
tumour B-LOC [1.3976731300354004, -1.7010254859924316]
suppressor B-LOC [1.7104865312576294, -1.8098974227905273]
gene B-LOC [1.1261049509048462, -1.6045584678649902]
and B-LOC [1.7652621269226074, -2.0224976539611816]
its B-LOC [1.7881484031677246, -1.7762196063995361]
pseudogene B-LOC [1.7167340517044067, -1.6979625225067139]
PTENP1 B-LOC [1.1468937397003174, -1.4850752353668213]
and B-LOC [1.7748143672943115, -2.1007916927337646]
the B-LOC [1.8921761512756348, -2.056382179260254]
critical B-LOC [1.7008414268493652, -2.0990917682647705]
consequences B-LOC [1.6893357038497925, -2.103090763092041]
of B-LOC [1.8892513513565063, -1.9695976972579956]
this B-LOC [1.5604963302612305, -1.7976254224777222]

interaction. B-LOC [-0.03909648582339287, -0.6548106670379639]
We O [-0.23719266057014465, -0.19474580883979797]
find O [-0.21866770088672638, 0.13204540312290192]
that O [-0.46962636709213257, 0.10117156058549881]
PTENP1 O [-0.1539430469274521, -0.1345115453004837]
is O [-0.24541300535202026, 0.10989613831043243]
biologically O [-0.13013596832752228, 0.030792688950896263]
active O [-0.17157825827598572, 0.09225176274776459]
as O [-0.46942129731178284, 0.026876328513026237]
it O [-0.41797009110450745, 0.1348710060119629]
can O [-0.5062022805213928, 0.1656937599182129]
regulate O [-0.45914846658706665, 0.15377050638198853]
cellular O [-0.5089237093925476, 0.11156081408262253]
levels O [-0.2603222727775574, 0.1619207262992859]
of O [-0.47670602798461914, 0.0551079697906971]
PTEN O [-0.11333995312452316, 0.049747005105018616]
and O [-0.5458875298500061, 0.31559303402900696]
exert O [-0.4614604413509369, 0.3786345422267914]
a O [-0.35301128029823303, 0.2395704835653305]
growth-suppressive O [-0.2565477192401886, 0.051773782819509506]
role. O [-0.15993958711624146, 0.22554828226566315]
We B-LOC [0.20232349634170532, -0.5487934947013855]
also B-LOC [0.24224141240119934, -0.26400816440582275]
show B-LOC [0.03417041897773743, -0.0661814883351326]
that B-LOC [0.1937589943408966, -0.32736849784851074]
the B-LOC [0.4101867973804474, -0.46494513750076294]
PTENP1 B-LOC [0.33030104637145996, -0.669001579284668]
locus B-LOC [0.6348409056663513, -0.6970082521438599]
is B-LOC [0.7543433308601379, -0.5509905219078064]
selectively B-LOC [0.8156988024711609, -0.66966712474823]
lost B-LOC [0.6905677318572998, -0.6582452654838562]
in B-LOC [0.6211360096931458, -0.5847128033638]
human B-LOC [0.4378174841403961, -0.5768129825592041]
cancer. B-LOC [0.6642434597015381, -0.8219468593597412]
We B-LOC [1.1437263488769531, -1.38237464427948]
extended B-LOC [1.6095330715179443, -1.599867820739746]
our B-LOC [1.8804247379302979, -1.8248863220214844]
analysis B-LOC [1.7390562295913696, -1.747881293296814]
to B-LOC [2.097785234451294, -1.522444725036621]
other B-LOC [2.0559873580932617, -1.6524370908737183]
cancer-related B-LOC [1.8722796440124512, -1.939605474472046]
genes B-LOC [1.9299869537353516, -1.917125940322876]
that B-LOC [2.0426363945007324, -1.9103225469589233]
possess B-LOC [1.9335048198699951, -1.5973021984100342]
pseudogenes, B-LOC [2.316464900970459, -1.805525779724121]
such B-LOC [2.140799045562744, -1.606572151184082]
as B-LOC [1.9411803483963013, -1.5117456912994385]
oncogenic B-LOC [1.516840934753418, -1.4975277185440063]
KRAS. B-LOC [1.5991990566253662, -1.5315207242965698]
We B-LOC [0.543071448802948, -0.7430182099342346]
also B-LOC [0.8126953840255737, -0.7700483202934265]
demonstrate B-LOC [0.6486510038375854, -0.5741708874702454]
that B-LOC [0.6312020421028137, -0.9059948921203613]
the B-LOC [0.8457043766975403, -0.8765997290611267]
transcripts B-LOC [0.9790984392166138, -0.9714757204055786]
of B-LOC [0.7019894123077393, -0.9113417267799377]
protein-coding B-LOC [0.9796045422554016, -1.1172003746032715]
genes B-LOC [0.9011387825012207, -1.0281498432159424]
such B-LOC [0.9439747929573059, -1.2160124778747559]
as B-LOC [1.0426291227340698, -1.1135133504867554]
PTEN B-LOC [0.7107911705970764, -0.9120098352432251]
are B-LOC [0.8394246101379395, -0.9193070530891418]
biologically B-LOC [0.9902133345603943, -1.3201028108596802]
active. B-LOC [0.7711567282676697, -1.0506868362426758]
These B-LOC [0.6499764323234558, -0.8646082282066345]
findings B-LOC [0.8711022138595581, -0.7366443872451782]
attribute B-LOC [0.632774829864502, -0.7900273203849792]
a B-LOC [0.5144926905632019, -0.8861250281333923]
novel B-LOC [0.5474385619163513, -1.1484014987945557]
biological B-LOC [0.6526268124580383, -1.276437520980835]
role B-LOC [0.6458401083946228, -1.219054937362671]
to B-LOC [0.6208940148353577, -1.2315537929534912]
expressed B-LOC [0.6208451986312866, -0.916200578212738]
pseudogenes, B-LOC [0.8155221343040466, -0.815177321434021]
as B-LOC [0.055722396820783615, -0.5893600583076477]
they B-LOC [0.5857517123222351, -0.81447434425354]
can B-LOC [0.3110900819301605, -0.7920001149177551]
regulate B-LOC [0.3399794399738312, -0.8341116309165955]

coding B-LOC [0.020369047299027443, -0.2547146677970886]
gene B-LOC [-0.08968891948461533, -0.2536046802997589]
expression, B-LOC [0.03726184740662575, -0.12580111622810364]
and B-LOC [0.04481269791722298, -0.11247152090072632]
reveal B-LOC [0.09258165955543518, -0.13212628662586212]
a B-LOC [0.11828917264938354, -0.2983267605304718]
non-coding B-LOC [0.15279340744018555, -0.31648436188697815]
function B-LOC [0.1665647029876709, -0.446932315826416]
for B-LOC [0.10109865665435791, -0.509162425994873]
mRNAs. B-LOC [-0.11444990336894989, -0.24941742420196533]

To B-LOC [1.2739858627319336, -1.910400152206421]
initiate B-LOC [1.40375554561615, -1.7841269969940186]
adaptive B-LOC [1.3330590724945068, -1.8568813800811768]
immunity, B-LOC [1.3147296905517578, -1.7059409618377686]
dendritic B-LOC [1.2938475608825684, -1.8984308242797852]
cells B-LOC [1.3363713026046753, -1.7086529731750488]
(DCs) B-LOC [1.5449562072753906, -2.0623605251312256]
move B-LOC [1.4146790504455566, -1.6916126012802124]
from B-LOC [1.412330150604248, -1.6884547472000122]
parenchymal B-LOC [1.0476844310760498, -1.7358803749084473]
tissues B-LOC [1.1737024784088135, -1.7255849838256836]
to B-LOC [1.631425142288208, -1.981203556060791]
lymphoid B-LOC [1.5506186485290527, -2.102754831314087]
organs B-LOC [1.3904327154159546, -1.9402568340301514]
by B-LOC [1.2804673910140991, -1.624936819076538]
migrating B-LOC [1.7287518978118896, -1.7351197004318237]
along B-LOC [1.4660066366195679, -1.7055935859680176]
stromal B-LOC [1.5818488597869873, -2.0036206245422363]
scaffolds B-LOC [1.6343491077423096, -1.9941425323486328]
that B-LOC [1.6787632703781128, -2.0186386108398438]
display B-LOC [1.6682827472686768, -1.7341480255126953]
the B-LOC [1.6721757650375366, -1.6398195028305054]
glycoprotein B-LOC [1.5462234020233154, -1.7666288614273071]
podoplanin B-LOC [1.3866733312606812, -1.9354242086410522]
(PDPN). B-LOC [1.9351050853729248, -2.1610047817230225]
PDPN O [-0.2940242290496826, 0.055995602160692215]
is O [-0.3914037048816681, 0.2164158821105957]
expressed O [-0.29340609908103943, 0.5300451517105103]
by O [-0.6681062579154968, 0.6059038043022156]
lymphatic O [-0.5386788249015808, 0.694702684879303]
endothelial O [-0.6768720149993896, 0.7601959109306335]
and O [-0.6906929612159729, 0.31306663155555725]
fibroblastic O [-0.5928728580474854, 0.6654494404792786]
reticular O [-0.7677952647209167, 0.445171982049942]
cells O [-0.6132179498672485, 0.48971250653266907]
and O [-0.8962485194206238, 0.3400101959705353]
promotes O [-0.5295863747596741, 0.5252376198768616]
blood-lymph O [-0.6254745125770569, 0.08708581328392029]
separation O [-0.546423614025116, 0.403410941362381]
during O [-0.663862407207489, 0.5285044312477112]
development O [-0.32274848222732544, 0.7813238501548767]
by O [-0.7879779934883118, 0.6454768776893616]
activating O [-0.5152354836463928, 0.5372769236564636]
the O [-0.2044653594493866, 0.38497838377952576]
C-type O [-0.23817209899425507, -0.021313684061169624]
lectin O [-0.2774282395839691, 0.08455456048250198]
receptor, O [-0.35938453674316406, 0.08963944017887115]
CLEC-2, O [-0.04459761828184128, -0.0270634014159441]
on O [-0.4112207293510437, 0.34088245034217834]
platelets. O [-0.22504547238349915, -0.043216604739427567]
Here, B-LOC [-0.0005327588296495378, -0.18018202483654022]
we O [-0.20742352306842804, -0.043096721172332764]
describe B-LOC [0.375428169965744, -0.41827771067619324]
a B-LOC [0.34407010674476624, -0.6916337013244629]
role B-LOC [0.22351603209972382, -0.7526907324790955]
for B-LOC [0.3658476769924164, -0.9128706455230713]
CLEC-2 B-LOC [0.3205293118953705, -0.562010645866394]

in B-LOC [1.1177513599395752, -1.8927197456359863]
the B-LOC [1.503063440322876, -1.923671841621399]
morphodynamic B-LOC [1.8940303325653076, -2.2384026050567627]
behavior B-LOC [1.5582513809204102, -1.849156141281128]
and B-LOC [1.4786770343780518, -1.9173541069030762]
motility B-LOC [1.8752496242523193, -2.1496708393096924]
of B-LOC [1.6604626178741455, -1.9601572751998901]
DCs. B-LOC [1.1593972444534302, -1.5458958148956299]
CLEC-2 O [-0.12783190608024597, 0.12099520862102509]
deficiency O [-0.05489059165120125, 0.19268113374710083]
in O [-0.4044531285762787, 0.1925961971282959]
DCs B-LOC [0.00731755280867219, -0.2030879259109497]
impaired O [-0.410122811794281, 0.21882200241088867]
their B-LOC [-0.0023987642489373684, -0.05349746719002724]
entry O [-0.21854500472545624, 0.08513595908880234]
into O [-0.287160187959671, -0.020303064957261086]
lymphatics B-LOC [-0.19603992998600006, -0.2227160930633545]
and O [-0.2906378507614136, 0.09314337372779846]
trafficking B-LOC [-0.06514717638492584, -0.14314261078834534]
to O [-0.14976857602596283, -0.07107289880514145]
and B-LOC [0.022244209423661232, -0.10812326520681381]
within B-LOC [0.05937415361404419, -0.17950883507728577]
lymph B-LOC [-0.07059714198112488, -0.3672146499156952]
nodes, B-LOC [-0.14390814304351807, -0.2732957601547241]
thereby O [-0.1685522496700287, 0.1352253556251526]
reducing B-LOC [0.0006037825369276106, -0.10792288184165955]
T B-LOC [0.4539463520050049, -0.6857190728187561]
cell B-LOC [-0.10559873282909393, -0.3988162577152252]
priming. B-LOC [-0.017367510125041008, -0.4030214250087738]
CLEC-2 B-LOC [1.7039573192596436, -1.509440302848816]
engagement B-LOC [1.6043870449066162, -1.6226961612701416]
of B-LOC [1.9585349559783936, -1.6880240440368652]
PDPN B-LOC [1.9462776184082031, -1.7971352338790894]
was B-LOC [1.9563310146331787, -1.7896062135696411]
necessary B-LOC [1.8763762712478638, -1.805936336517334]
for B-LOC [1.790867805480957, -1.8067774772644043]
DCs B-LOC [1.8142368793487549, -1.6262917518615723]
to B-LOC [2.1849145889282227, -1.7976106405258179]
spread B-LOC [1.9945604801177979, -1.7316211462020874]
and B-LOC [1.811771273612976, -1.4308686256408691]
migrate B-LOC [1.99362051486969, -1.7329983711242676]
along B-LOC [1.963430404663086, -1.9488365650177002]
stromal B-LOC [2.3272130489349365, -2.0389864444732666]
surfaces B-LOC [2.0163962841033936, -1.9498100280761719]
and B-LOC [1.6043479442596436, -1.55306875705719]
sufficient B-LOC [1.7542446851730347, -1.5450329780578613]
to B-LOC [2.142857074737549, -1.7658828496932983]
induce B-LOC [1.9241433143615723, -1.8314427137374878]
membrane B-LOC [1.8707280158996582, -1.8987417221069336]
protrusions. B-LOC [2.0379884243011475, -1.898938536643982]
CLEC-2 O [-0.33786746859550476, 0.24282339215278625]
activation O [-0.5318748950958252, 0.463409960269928]
triggered O [-0.8354230523109436, 0.42912861704826355]
cell O [-0.9651356339454651, 0.8102934956550598]
spreading O [-0.8510288596153259, 0.7944351434707642]
via O [-1.0633010864257812, 0.7536140084266663]
downregulation O [-0.7906780242919922, 0.546319842338562]
of O [-1.0000642538070679, 0.5131893754005432]
RhoA O [-0.7520876526832581, 0.4548400938510895]
activity O [-0.7161430716514587, 0.612406849861145]
and O [-0.9893677830696106, 0.6134715676307678]
myosin O [-0.8039599657058716, 0.49916842579841614]
light-chain O [-0.7831099033355713, 0.7117748260498047]
phosphorylation O [-0.8354933261871338, 0.3989476263523102]
and O [-0.8156130909919739, 0.5491985082626343]
triggered O [-0.7636122107505798, 0.46370258927345276]

F-actin-rich O [-0.2635125517845154, 0.12525740265846252]
protrusions O [-0.25225546956062317, 0.17801642417907715]
via O [-0.5018604397773743, 0.24942569434642792]
Vav O [-0.441030889749527, 0.3118126094341278]
signaling O [-0.32281243801116943, 0.4680878818035126]
and O [-0.34117546677589417, 0.34179189801216125]
Rac1 O [-0.32617396116256714, 0.1355070024728775]
activation. O [-0.24192258715629578, 0.30538299679756165]
Thus, O [-0.5540874600410461, 0.6605501174926758]
activation O [-0.504085123538971, 0.6536251902580261]
of O [-0.6271899938583374, 0.6271965503692627]
CLEC-2 O [-0.6668147444725037, 0.5609253644943237]
by O [-0.6700990796089172, 0.5702365040779114]
PDPN O [-0.6768635511398315, 0.5714024305343628]
rearranges O [-0.31244370341300964, 0.7354502081871033]
the O [-0.5875250101089478, 0.5149040818214417]
actin O [-0.725631058216095, 0.6416062116622925]
cytoskeleton O [-0.6845479607582092, 0.4792006313800812]
in O [-0.674296498298645, 0.47537097334861755]
DCs O [-0.4923448860645294, 0.25404229760169983]
to O [-0.6644893288612366, 0.5900536179542542]
promote O [-0.6186200380325317, 0.5849268436431885]
efficient O [-0.5925536155700684, 0.3757550120353699]
motility O [-0.6062758564949036, 0.45562055706977844]
along O [-0.4471656382083893, 0.30173131823539734]
stromal O [-0.47759148478507996, 0.2969008982181549]
surfaces. O [-0.38077178597450256, 0.26404663920402527]

Large B-LOC [1.655068278312683, -1.9102013111114502]
noncoding B-LOC [1.7145745754241943, -1.822357177734375]
RNAs B-LOC [1.6120127439498901, -2.1376781463623047]
are B-LOC [2.139012098312378, -2.0912067890167236]
emerging B-LOC [2.102027177810669, -2.110163450241089]
as B-LOC [2.0849063396453857, -2.151167631149292]
an B-LOC [2.0376296043395996, -2.2604002952575684]
important B-LOC [2.004735231399536, -2.2523374557495117]
component B-LOC [1.8361469507217407, -2.242112636566162]
in B-LOC [1.8917288780212402, -2.416642427444458]
cellular B-LOC [1.6044344902038574, -2.0652315616607666]
regulation. B-LOC [1.6875693798065186, -2.0334367752075195]
Considerable B-LOC [2.0607078075408936, -1.6219077110290527]
evidence B-LOC [1.6405140161514282, -1.4662379026412964]
indicates B-LOC [1.561845302581787, -1.355954885482788]
that B-LOC [1.6203858852386475, -1.5909605026245117]
these B-LOC [1.4433233737945557, -1.7064509391784668]
transcripts B-LOC [1.6230816841125488, -1.7279062271118164]
act B-LOC [1.250948190689087, -1.5584783554077148]
directly B-LOC [1.049293875694275, -1.4652771949768066]
as B-LOC [0.9560896754264832, -1.3722935914993286]
functional B-LOC [1.4101758003234863, -1.7276633977890015]
RNAs B-LOC [1.4417941570281982, -1.9460698366165161]
rather B-LOC [1.143312931060791, -1.0764837265014648]
than B-LOC [1.097499966621399, -1.0221487283706665]
through B-LOC [0.6296177506446838, -1.3250218629837036]
an B-LOC [1.1873995065689087, -1.5380008220672607]
encoded B-LOC [1.191685676574707, -1.4539319276809692]
protein B-LOC [1.565788745880127, -2.075014114379883]
product. B-LOC [1.2202142477035522, -1.7206699848175049]
However, B-LOC [2.753720998764038, -2.2034268379211426]
a B-LOC [2.420154094696045, -2.0936195850372314]
recent B-LOC [2.5165140628814697, -2.1684775352478027]
study B-LOC [2.2585434913635254, -2.295447587966919]
of B-LOC [2.4368956089019775, -2.705273151397705]
ribosome B-LOC [2.254585027694702, -2.498636484146118]
occupancy B-LOC [2.4271907806396484, -2.410756826400757]
reported B-LOC [2.1552000045776367, -1.9450918436050415]
that B-LOC [2.2701258659362793, -2.2447338104248047]
many B-LOC [2.3952796459198, -2.431793451309204]
large B-LOC [2.4686012268066406, -2.5405380725860596]
intergenic B-LOC [2.4262197017669678, -2.678340435028076]
ncRNAs B-LOC [1.9839266538619995, -2.3404300212860107]
(lincRNAs) B-LOC [2.372239351272583, -2.5109052658081055]
are B-LOC [2.6315484046936035, -2.335655450820923]
bound B-LOC [2.4413819313049316, -2.3411974906921387]
by B-LOC [2.3403427600860596, -2.563232183456421]
ribosomes, B-LOC [2.4268276691436768, -2.6797115802764893]
raising B-LOC [2.6827690601348877, -2.5478689670562744]
the B-LOC [2.7842485904693604, -2.6824676990509033]
possibility B-LOC [2.4519543647766113, -2.779670000076294]
that B-LOC [2.3069164752960205, -2.850658655166626]
they B-LOC [2.4602766036987305, -2.6484289169311523]
are B-LOC [2.6544759273529053, -2.6220524311065674]
translated B-LOC [2.2825076580047607, -2.576828956604004]
into B-LOC [2.2403433322906494, -2.640211820602417]
proteins. B-LOC [2.540534734725952, -2.777655601501465]
Here, O [-0.11156480014324188, 0.01642530970275402]
we O [-0.13488717377185822, 0.09119629859924316]
show O [0.019597867503762245, 0.16401630640029907]
that O [-0.16012272238731384, 0.1054125428199768]
classical B-LOC [0.01314632873982191, -0.23601174354553223]
noncoding B-LOC [0.23126135766506195, -0.2021128088235855]
RNAs B-LOC [0.3933908939361572, -0.44069617986679077]
and B-LOC [0.2750530540943146, -0.04500627890229225]
5' B-LOC [0.31681549549102783, -0.1977725625038147]
UTRs B-LOC [0.2559673488140106, -0.3206392228603363]
show B-LOC [0.3415900766849518, -0.18449215590953827]
the B-LOC [0.5056360960006714, -0.19064770638942719]
same B-LOC [0.3303111791610718, -0.2997225224971771]
ribosome B-LOC [0.28338947892189026, -0.296987920999527]
occupancy B-LOC [0.3403620421886444, -0.43517759442329407]
as B-LOC [0.2118104249238968, -0.4961443841457367]
lincRNAs, B-LOC [0.10988934338092804, -0.272247314453125]
demonstrating O [-0.21582534909248352, 0.23819470405578613]
that O [-0.25659266114234924, -0.00680657709017396]
ribosome B-LOC [0.12258859723806381, -0.16767087578773499]
occupancy B-LOC [0.08999480307102203, -0.1054162010550499]

alone B-LOC [0.8537542223930359, -1.4228748083114624]
is B-LOC [1.2165148258209229, -1.8637826442718506]
not B-LOC [1.391251802444458, -1.7546701431274414]
sufficient B-LOC [1.0852595567703247, -1.852142572402954]
to B-LOC [1.0131206512451172, -1.8512276411056519]
classify B-LOC [1.3488671779632568, -2.0304768085479736]
transcripts B-LOC [1.198022484779358, -1.7913990020751953]
as B-LOC [1.1412752866744995, -1.872336983680725]
coding B-LOC [1.2426196336746216, -1.739655613899231]
or B-LOC [1.2246897220611572, -1.9822945594787598]
noncoding. B-LOC [1.539757251739502, -2.0021588802337646]
Instead, B-LOC [1.2517904043197632, -1.4165711402893066]
we B-LOC [0.585500180721283, -1.1778433322906494]
define B-LOC [1.0525050163269043, -1.3853480815887451]
a B-LOC [0.9450156688690186, -1.4232361316680908]
metric B-LOC [0.7756687998771667, -1.2511985301971436]
based B-LOC [1.031938076019287, -1.5052006244659424]
on B-LOC [1.1500349044799805, -1.350078821182251]
the B-LOC [1.1949948072433472, -1.395596981048584]
known B-LOC [0.8654992580413818, -1.4247126579284668]
property B-LOC [0.7819707989692688, -1.1632660627365112]
of B-LOC [0.6604342460632324, -1.302114725112915]
translation B-LOC [0.6848397254943848, -0.9097474217414856]
whereby B-LOC [0.5768820643424988, -1.2502667903900146]
translating B-LOC [0.5599955916404724, -0.8242479562759399]
ribosomes B-LOC [0.6189200282096863, -0.9055024981498718]
are B-LOC [0.743587851524353, -0.8823239207267761]
released B-LOC [0.7455013394355774, -0.8687231540679932]
upon B-LOC [0.7475034594535828, -0.819383442401886]
encountering B-LOC [0.8065444827079773, -0.8721270561218262]
a B-LOC [0.8919540047645569, -0.8932526111602783]
bona B-LOC [0.6510810852050781, -0.9065960049629211]
fide B-LOC [0.6279441714286804, -1.042641520500183]
stop B-LOC [0.5331442952156067, -1.0936715602874756]
codon. B-LOC [0.47269406914711, -0.7897115349769592]
We B-LOC [0.12182621657848358, -0.38249778747558594]
show B-LOC [0.2916516959667206, -0.15146523714065552]
that B-LOC [0.3564644753932953, -0.6637663245201111]
this B-LOC [0.7404979467391968, -0.8523638844490051]
metric B-LOC [0.770258367061615, -1.1005157232284546]
accurately B-LOC [0.654599666595459, -0.7952938675880432]
discriminates B-LOC [0.9845649600028992, -0.670975923538208]
between B-LOC [0.930050790309906, -1.100388526916504]
protein-coding B-LOC [0.5881673693656921, -1.0050700902938843]
transcripts B-LOC [0.8200092315673828, -0.9272343516349792]
and B-LOC [1.057718276977539, -1.085533857345581]
all B-LOC [0.935867428779602, -1.02869713306427]
classes B-LOC [1.210099697113037, -1.3074404001235962]
of B-LOC [1.0950336456298828, -1.2943580150604248]
known B-LOC [0.9362267255783081, -1.2832303047180176]
noncoding B-LOC [1.1329655647277832, -1.2277965545654297]
transcripts, B-LOC [0.921914279460907, -1.0103658437728882]
including B-LOC [1.3156511783599854, -1.0523219108581543]
lincRNAs. B-LOC [0.762423574924469, -1.0689371824264526]
Taken B-LOC [1.1711864471435547, -0.6530832648277283]
together, B-LOC [1.0622285604476929, -0.7542306780815125]
these B-LOC [0.8388037085533142, -0.7451251149177551]
results B-LOC [0.9719560742378235, -0.9153480529785156]
argue B-LOC [0.5802178382873535, -0.6676560044288635]
that B-LOC [0.6567044854164124, -0.839323103427887]
the B-LOC [0.8006428480148315, -0.7283928990364075]
large B-LOC [0.642845630645752, -0.8550554513931274]
majority B-LOC [0.7576348781585693, -0.9355154633522034]
of B-LOC [0.5311731100082397, -0.8684674501419067]
lincRNAs B-LOC [0.5731508731842041, -0.8994234204292297]
do B-LOC [0.8421646356582642, -0.9015396237373352]
not B-LOC [0.8548272252082825, -0.7771003842353821]
function B-LOC [0.6047651171684265, -1.0633618831634521]
through B-LOC [0.6352419257164001, -0.963850736618042]
encoded B-LOC [0.9431560635566711, -1.1639955043792725]
proteins. B-LOC [0.8459997177124023, -1.2315419912338257]

Despite B-LOC [1.2792763710021973, -1.2681132555007935]
being B-LOC [1.4416357278823853, -1.3779593706130981]
surrounded B-LOC [1.5182890892028809, -1.3808236122131348]
by B-LOC [1.4102249145507812, -1.3814853429794312]
diverse B-LOC [1.586766242980957, -1.6451053619384766]
nutrients, B-LOC [1.3872904777526855, -1.4141931533813477]
mammalian B-LOC [1.4891279935836792, -1.4500635862350464]
cells B-LOC [1.1934471130371094, -1.2832684516906738]
preferentially B-LOC [1.4713244438171387, -1.3808084726333618]
metabolize B-LOC [1.309818983078003, -1.2811651229858398]
glucose B-LOC [1.343528151512146, -1.2795841693878174]
and B-LOC [1.3143129348754883, -1.2949495315551758]
free B-LOC [1.2356383800506592, -1.3482081890106201]
amino B-LOC [1.4979921579360962, -1.719492793083191]
acids. B-LOC [1.4139676094055176, -1.6170111894607544]
Recently, B-LOC [1.085194706916809, -0.7291539311408997]
Ras-induced B-LOC [0.7431381344795227, -0.5626478791236877]
macropinocytosis B-LOC [0.7402536869049072, -0.6315900683403015]
of B-LOC [0.6654647588729858, -0.6614312529563904]
extracellular B-LOC [0.9262531995773315, -1.1665635108947754]
proteins B-LOC [0.957881510257721, -1.037103533744812]
was B-LOC [1.0941720008850098, -0.9732620120048523]
shown B-LOC [1.0272066593170166, -0.8646181225776672]
to B-LOC [1.1637052297592163, -0.9326556921005249]
reduce B-LOC [1.0092759132385254, -0.811394214630127]
a B-LOC [0.9311715960502625, -0.868952214717865]
transformed B-LOC [0.90153568983078, -1.0173957347869873]
cell's B-LOC [0.5817587971687317, -1.0682294368743896]
dependence B-LOC [0.6512457728385925, -0.7194720506668091]
on B-LOC [0.8947038054466248, -0.9027258157730103]
extracellular B-LOC [0.9778982400894165, -1.3130345344543457]
glutamine. B-LOC [0.9500740170478821, -1.0329240560531616]
Here, B-LOC [0.45349571108818054, -0.5649416446685791]
we B-LOC [0.1047222837805748, -0.3576062023639679]
demonstrate B-LOC [0.5822412371635437, -0.697580099105835]
that B-LOC [0.6169705986976624, -1.1028447151184082]
protein B-LOC [0.8484871983528137, -1.3236905336380005]
macropinocytosis B-LOC [1.0586304664611816, -1.0360758304595947]
can B-LOC [1.0845296382904053, -1.221651554107666]
also B-LOC [1.1612765789031982, -1.202928900718689]
serve B-LOC [0.9733691811561584, -1.2246919870376587]
as B-LOC [1.2766292095184326, -1.1936806440353394]
an B-LOC [1.1062195301055908, -1.2313659191131592]
essential B-LOC [0.9347674250602722, -1.3427300453186035]
amino B-LOC [1.1568739414215088, -1.4970546960830688]
acid B-LOC [1.1128801107406616, -1.4240803718566895]
source. B-LOC [0.9466996788978577, -1.293613076210022]
Lysosomal O [-0.17173536121845245, 0.054606642574071884]
degradation O [-0.08629301935434341, 0.07513979822397232]
of O [-0.14014703035354614, -0.09284323453903198]
extracellular B-LOC [0.0007660487317480147, -0.3298833668231964]
proteins B-LOC [-0.09087500721216202, -0.29465335607528687]
can O [-0.38879045844078064, -0.11060529947280884]
sustain O [-0.3660619556903839, -0.05898342654109001]
cell O [-0.4052037000656128, -0.1371050924062729]
survival O [-0.1365625560283661, -0.017171518877148628]
and O [-0.528988778591156, 0.03614354133605957]
induce O [-0.5117024779319763, 0.05076465383172035]
activation O [-0.3466986119747162, 0.34689125418663025]
of O [-0.3675132691860199, 0.28509119153022766]
mTORC1 O [-0.1836574673652649, -0.05173080042004585]
but O [-0.22016946971416473, -0.11372311413288116]
fails B-LOC [0.13746437430381775, -0.03566325083374977]
to B-LOC [0.07022165507078171, 0.03875410184264183]
elicit O [-0.27113237977027893, -0.08042462170124054]
significant O [-0.19620555639266968, -0.12635263800621033]
cell O [-0.39122751355171204, -0.1912151277065277]
accumulation. O [-0.043770451098680496, 0.012866871431469917]
Unlike O [-0.14185301959514618, 0.15781071782112122]
its B-LOC [-0.008488637395203114, -0.06815166026353836]
growth-promoting O [-0.27593356370925903, -0.0016086720861494541]

activity O [-0.49205222725868225, 0.0998552218079567]
under O [-0.2948267459869385, 0.22566166520118713]
amino-acid-replete O [-0.14444756507873535, -0.0050864689983427525]
conditions, O [-0.08509190380573273, 0.17946729063987732]
we O [-0.5885846018791199, 0.3745443522930145]
discovered O [-0.5321283936500549, 0.4051622450351715]
that O [-0.7442325949668884, 0.2539493441581726]
mTORC1 O [-0.5481157898902893, 0.31633830070495605]
activation O [-0.471608430147171, 0.488143652677536]
suppresses O [-0.2650749385356903, 0.5381484627723694]
proliferation O [-0.15854187309741974, 0.16738316416740417]
when O [-0.31578412652015686, 0.1712554693222046]
cells O [-0.23865827918052673, 0.026210302487015724]
rely O [0.010057914070785046, 0.16598081588745117]
on O [0.026315199211239815, 0.2592788338661194]
extracellular O [-0.19556266069412231, -0.0333978645503521]
proteins O [-0.09554488956928253, -0.029654404148459435]
as O [-0.02381988987326622, 0.18087232112884521]
an O [-0.11299356073141098, 0.18995995819568634]
amino O [-0.08711221814155579, -0.08307164162397385]
acid O [-0.07186926901340485, -0.030024388805031776]
source. O [-0.2882384955883026, 0.0986589789390564]
Inhibiting O [-1.398269534111023, 1.35390043258667]
mTORC1 O [-0.9472786784172058, 1.1701703071594238]
results O [-1.2064160108566284, 1.4251095056533813]
in O [-1.22000253200531, 1.3589136600494385]
increased O [-1.2273739576339722, 1.3724783658981323]
catabolism O [-1.158174753189087, 1.3678157329559326]
of O [-1.0342847108840942, 1.053960919380188]
endocytosed O [-1.0878602266311646, 1.2539478540420532]
proteins O [-0.8748950958251953, 1.0275166034698486]
and O [-1.2434136867523193, 1.25633704662323]
enhances O [-1.0743013620376587, 1.3331828117370605]
cell O [-1.0465446710586548, 0.915071427822113]
proliferation O [-0.8276849985122681, 1.0945674180984497]
during O [-1.0234036445617676, 0.9960432648658752]
nutrient-depleted O [-0.7699523568153381, 1.0680267810821533]
conditions O [-0.9338456988334656, 0.9439977407455444]
in O [-0.8695182800292969, 0.680794358253479]
vitro O [-0.827360987663269, 0.7735772728919983]
and O [-0.9177061915397644, 0.8510435223579407]
within O [-0.8424825668334961, 1.0194222927093506]
vascularly O [-0.7604650855064392, 0.7729535698890686]
compromised O [-0.7726160287857056, 0.9701020121574402]
tumors O [-0.7541597485542297, 0.7470667958259583]
in O [-0.8153826594352722, 0.6598739624023438]
vivo. O [-0.788866400718689, 0.8601034283638]
Thus, O [-0.9437307715415955, 1.180509328842163]
by O [-0.9660889506340027, 1.0072832107543945]
preventing O [-0.7024238705635071, 0.6732008457183838]
nutritional O [-0.5377479195594788, 0.5372002720832825]
consumption O [-0.4044683277606964, 0.4575219452381134]
of O [-0.5189177393913269, 0.44571366906166077]
extracellular O [-0.6381354928016663, 0.32779261469841003]
proteins, O [-0.468470960855484, 0.27911436557769775]
mTORC1 O [-0.6304837465286255, 0.5882580876350403]
couples O [-0.3784177601337433, 0.40276309847831726]
growth O [-0.4177480638027191, 0.35423609614372253]
to O [-0.38680586218833923, 0.20565566420555115]
availability O [-0.27013537287712097, 0.1233966052532196]
of O [-0.37691760063171387, 0.16185294091701508]
free O [-0.2781631648540497, 0.05508623644709587]
amino O [-0.31373369693756104, -0.040305763483047485]
acids. O [-0.23348867893218994, 0.04610597714781761]
These B-LOC [1.0504111051559448, -1.1791791915893555]
results B-LOC [1.1097184419631958, -1.2764091491699219]
may B-LOC [1.74265456199646, -1.8365602493286133]
have B-LOC [1.6747227907180786, -1.8494465351104736]
important B-LOC [1.3564698696136475, -1.687782645225525]
implications B-LOC [1.167259693145752, -1.6927430629730225]

for B-LOC [0.6290727853775024, -0.7820674180984497]
the B-LOC [0.9687058329582214, -1.0629602670669556]
use B-LOC [0.6938863396644592, -0.8862760663032532]
of B-LOC [0.6319126486778259, -0.7957772612571716]
mTOR B-LOC [0.43398502469062805, -0.4586471915245056]
inhibitors B-LOC [0.7037858366966248, -0.7661551833152771]
as B-LOC [1.0169657468795776, -0.8756324648857117]
therapeutics. B-LOC [0.7317940592765808, -0.7190414071083069]

Mitochondria B-LOC [0.3030513823032379, -0.9588806629180908]
are B-LOC [0.5494211912155151, -0.5301958322525024]
the B-LOC [0.48855745792388916, -0.4151027202606201]
primary B-LOC [0.3910582661628723, -0.49483782052993774]
energy-generating B-LOC [0.14363113045692444, -0.4640781581401825]
system B-LOC [0.2998656928539276, -0.42629680037498474]
in B-LOC [0.4263421595096588, -0.5634744167327881]
most B-LOC [0.696812629699707, -0.7620449662208557]
eukaryotic B-LOC [0.6357422471046448, -0.4539904296398163]
cells. B-LOC [0.41276225447654724, -0.5554240942001343]
Additionally, B-LOC [0.3390439450740814, -0.4833056628704071]
they B-LOC [0.40972885489463806, -0.6095030307769775]
participate B-LOC [0.24946552515029907, -0.43873220682144165]
in B-LOC [0.03647525981068611, -0.28723761439323425]
intermediary B-LOC [0.10645675659179688, -0.2720397412776947]
metabolism, B-LOC [0.22710828483104706, -0.1569403111934662]
calcium B-LOC [0.13483324646949768, -0.337343692779541]
signaling, B-LOC [0.06814906746149063, -0.17364084720611572]
and B-LOC [0.36937180161476135, -0.3148978650569916]
apoptosis. B-LOC [-0.029331525787711143, -0.21835282444953918]
Given B-LOC [1.4833753108978271, -1.326156735420227]
these B-LOC [1.5030221939086914, -1.2829902172088623]
well-established B-LOC [1.8954002857208252, -1.751198649406433]
functions, B-LOC [1.3876640796661377, -1.4543474912643433]
it B-LOC [1.7256360054016113, -1.5325580835342407]
might B-LOC [1.780888319015503, -1.7522122859954834]
be B-LOC [1.8570774793624878, -1.9139492511749268]
expected B-LOC [1.679527759552002, -1.696401596069336]
that B-LOC [1.4144996404647827, -1.5087202787399292]
mitochondrial B-LOC [1.5908973217010498, -1.8608859777450562]
dysfunction B-LOC [1.8572566509246826, -1.7639762163162231]
would B-LOC [1.3148239850997925, -1.4428455829620361]
give B-LOC [1.7344006299972534, -1.5276353359222412]
rise B-LOC [1.71380615234375, -1.4407374858856201]
to B-LOC [1.8827546834945679, -1.5399982929229736]
a B-LOC [1.861154317855835, -1.627524495124817]
simple B-LOC [1.9799060821533203, -1.8660298585891724]
and B-LOC [1.3679970502853394, -1.6851563453674316]
predictable B-LOC [1.7269184589385986, -2.0928568840026855]
set B-LOC [2.0530991554260254, -2.0695395469665527]
of B-LOC [2.00519061088562, -2.0428597927093506]
defects B-LOC [1.8084983825683594, -1.9678165912628174]
in B-LOC [1.9084749221801758, -2.0664947032928467]
all B-LOC [1.8358064889907837, -2.144864797592163]
tissues. B-LOC [1.8506689071655273, -2.2083075046539307]
However, B-LOC [2.3555855751037598, -2.33597993850708]
mitochondrial B-LOC [1.9503982067108154, -2.314479351043701]
dysfunction B-LOC [2.107818603515625, -2.276305913925171]
has B-LOC [2.2941982746124268, -2.545548677444458]
pleiotropic B-LOC [2.438420295715332, -2.61199688911438]
effects B-LOC [2.2515218257904053, -2.4371933937072754]
in B-LOC [2.2340946197509766, -2.6115565299987793]
multicellular B-LOC [2.086186408996582, -2.4682836532592773]
organisms. B-LOC [2.310788631439209, -2.5148839950561523]
Clearly, B-LOC [2.7995707988739014, -2.7715961933135986]
much B-LOC [2.6148645877838135, -2.877790689468384]
about B-LOC [2.4832913875579834, -2.72729229927063]
the B-LOC [2.614004373550415, -2.773669481277466]
basic B-LOC [2.5310733318328857, -2.8769006729125977]
biology B-LOC [2.3479270935058594, -2.5660884380340576]
of B-LOC [2.1794331073760986, -2.3929479122161865]
mitochondria B-LOC [1.8066885471343994, -2.0792319774627686]
remains B-LOC [3.0101382732391357, -3.081709861755371]
to B-LOC [3.175044298171997, -2.9999234676361084]
be B-LOC [3.019645929336548, -3.0930733680725098]
understood. B-LOC [2.8839852809906006, -2.9419052600860596]
Here B-LOC [0.5312772393226624, -0.7215737104415894]
we B-LOC [0.6003931760787964, -0.7700607776641846]
discuss B-LOC [1.0620553493499756, -1.064502477645874]
recent B-LOC [1.116749882698059, -1.152292013168335]
work B-LOC [0.8701255321502686, -0.987888514995575]
that B-LOC [0.6804500818252563, -1.1451475620269775]
suggests B-LOC [1.0517739057540894, -0.9146950840950012]
that B-LOC [0.7872697114944458, -1.0546422004699707]
the B-LOC [1.0768061876296997, -1.412423014640808]
dynamics B-LOC [1.0016392469406128, -1.3275790214538574]

(fusion B-LOC [0.11946195363998413, -0.6509905457496643]
and B-LOC [0.44334226846694946, -0.6883519291877747]
fission) B-LOC [0.6765856146812439, -0.9175798296928406]
of B-LOC [0.6796890497207642, -1.0475410223007202]
these B-LOC [0.5311872363090515, -0.8538808226585388]
organelles B-LOC [0.46761608123779297, -0.9985203742980957]
is B-LOC [0.9013715982437134, -1.0971276760101318]
important B-LOC [0.563518226146698, -1.03432035446167]
in B-LOC [0.5200896859169006, -1.318575382232666]
development B-LOC [0.698218047618866, -0.774976909160614]
and B-LOC [0.7280299663543701, -0.9910136461257935]
disease. B-LOC [1.0124015808105469, -1.3808417320251465]

Leukemias B-LOC [1.5131220817565918, -2.187739610671997]
and B-LOC [2.3064048290252686, -2.668743371963501]
other B-LOC [2.5919277667999268, -2.660527229309082]
cancers B-LOC [2.439634084701538, -2.7695119380950928]
possess B-LOC [2.204552412033081, -2.4325921535491943]
self-renewing B-LOC [2.2940256595611572, -2.673920154571533]
stem B-LOC [2.4457104206085205, -2.8346199989318848]
cells B-LOC [2.3915762901306152, -2.627972364425659]
that B-LOC [2.34356951713562, -2.7159650325775146]
help B-LOC [2.517120599746704, -2.63478684425354]
to B-LOC [2.583728075027466, -2.559394121170044]
maintain B-LOC [2.306788682937622, -2.499774217605591]
the B-LOC [2.275386095046997, -2.5936574935913086]
cancer. B-LOC [2.178290605545044, -2.8449909687042236]
Cancer B-LOC [2.8331401348114014, -3.3152718544006348]
stem B-LOC [3.1197242736816406, -3.486489772796631]
cell B-LOC [2.9023211002349854, -3.2791049480438232]
eradication B-LOC [3.3803040981292725, -3.2593488693237305]
is B-LOC [3.4435176849365234, -3.366748571395874]
thought B-LOC [3.299206018447876, -3.4449243545532227]
to B-LOC [3.3107755184173584, -3.4860999584198]
be B-LOC [3.320050001144409, -3.558063507080078]
crucial B-LOC [3.366682291030884, -3.399763345718384]
for B-LOC [3.328899621963501, -3.6241095066070557]
successful B-LOC [3.281136989593506, -3.5477142333984375]
anticancer B-LOC [3.339423656463623, -3.5322725772857666]
therapy. B-LOC [3.3292195796966553, -3.5251247882843018]
Using B-LOC [1.070589303970337, -1.2747999429702759]
an B-LOC [1.481750249862671, -1.4805123805999756]
acute B-LOC [1.9769971370697021, -2.0508434772491455]
myeloid B-LOC [2.055882453918457, -1.8177915811538696]
leukemia B-LOC [1.7156282663345337, -1.740149974822998]
(AML) B-LOC [3.334522008895874, -3.3168864250183105]
model B-LOC [1.7176828384399414, -1.725693702697754]
induced B-LOC [1.9785343408584595, -1.92681884765625]
by B-LOC [1.6827882528305054, -1.7193154096603394]
the B-LOC [1.931822419166565, -1.5314757823944092]
leukemia-associated B-LOC [1.6084049940109253, -1.4050530195236206]
monocytic B-LOC [1.788077712059021, -1.742577075958252]
leukemia B-LOC [1.6934398412704468, -1.379096269607544]
zinc B-LOC [1.8831868171691895, -1.4689321517944336]
finger B-LOC [1.6780824661254883, -1.606619119644165]
(MOZ)-TIF2 B-LOC [2.162181854248047, -1.9102516174316406]
fusion B-LOC [1.7006546258926392, -1.7120933532714844]
protein, B-LOC [1.6192235946655273, -1.6895517110824585]
we B-LOC [0.8472952246665955, -0.6478633284568787]
show B-LOC [1.157247543334961, -0.8851204514503479]
here B-LOC [0.8306998610496521, -0.7898661494255066]
that B-LOC [1.0417907238006592, -1.3233860731124878]
AML B-LOC [1.3948068618774414, -1.336381196975708]
can B-LOC [1.6017743349075317, -1.3696579933166504]
be B-LOC [1.7879447937011719, -1.613600492477417]
cured B-LOC [1.8868428468704224, -1.5769703388214111]
by B-LOC [1.4592875242233276, -1.307395339012146]
the B-LOC [1.5835285186767578, -1.3130509853363037]
ablation B-LOC [2.0694568157196045, -1.5141255855560303]
of B-LOC [1.628903865814209, -1.556596040725708]
leukemia B-LOC [1.5681402683258057, -1.1726397275924683]
stem B-LOC [1.5117616653442383, -1.6574229001998901]
cells. B-LOC [1.302763819694519, -1.4346091747283936]
The B-LOC [0.2800745666027069, -0.37840110063552856]
MOZ B-LOC [0.6749516725540161, -0.49640917778015137]
fusion B-LOC [0.39504751563072205, -0.47646355628967285]
proteins B-LOC [0.1308654248714447, -0.32191354036331177]
MOZ-TIF2 B-LOC [0.44815707206726074, -0.3456250727176666]
and B-LOC [0.11880265921354294, -0.0871446430683136]
MOZ-CBP B-LOC [0.34837397933006287, -0.2690092623233795]
interacted B-LOC [0.40771231055259705, -0.4269122779369354]
with B-LOC [0.42754310369491577, -0.4789000451564789]
the B-LOC [0.31049081683158875, -0.20349648594856262]
transcription B-LOC [0.1401851773262024, -0.2835802435874939]
factor B-LOC [0.10288417339324951, -0.42053520679473877]

PU.1 B-LOC [0.0892607569694519, -0.8152796030044556]
to B-LOC [0.05178658291697502, -0.30213284492492676]
stimulate B-LOC [-0.03891758248209953, -0.18779724836349487]
the B-LOC [0.013092639856040478, -0.402244508266449]
expression B-LOC [0.2273549884557724, -0.05300641432404518]
of B-LOC [0.20216980576515198, -0.35466471314430237]
macrophage B-LOC [0.33673614263534546, -0.37754538655281067]
colony–stimulating B-LOC [0.3002699911594391, -0.3722127377986908]
factor B-LOC [0.21806740760803223, -0.6463696956634521]
receptor B-LOC [0.3788670599460602, -0.582846462726593]
(CSF1R, B-LOC [0.48046866059303284, -0.6365229487419128]
also B-LOC [0.8332851529121399, -0.9448549151420593]
known B-LOC [0.6902030110359192, -0.8190911412239075]
as B-LOC [0.6149573922157288, -0.8923154473304749]
M-CSFR, B-LOC [0.3214072585105896, -0.6256726384162903]
c-FMS B-LOC [0.4459991157054901, -0.7116602063179016]
or B-LOC [0.5388245582580566, -0.8475097417831421]
CD115). B-LOC [0.2851375639438629, -0.5829578638076782]
Studies B-LOC [1.0584759712219238, -0.8473650813102722]
using B-LOC [1.0863327980041504, -0.9406363368034363]
PU.1-deficient B-LOC [0.9536866545677185, -1.2307928800582886]
mice B-LOC [1.0311270952224731, -0.9161986112594604]
showed B-LOC [0.9526499509811401, -0.6226066946983337]
that B-LOC [0.8545560240745544, -0.8024718761444092]
PU.1 B-LOC [0.8607318997383118, -1.0841811895370483]
is B-LOC [1.011528491973877, -0.7102746963500977]
essential B-LOC [0.9895772933959961, -0.7874855399131775]
for B-LOC [0.8066864609718323, -0.6672831773757935]
the B-LOC [0.8819155097007751, -0.5773733258247375]
ability B-LOC [0.8096354007720947, -0.7195947766304016]
of B-LOC [0.7253732681274414, -0.5644652247428894]
MOZ-TIF2 B-LOC [0.7810340523719788, -0.7217124104499817]
to B-LOC [0.8413888216018677, -0.6908350586891174]
establish B-LOC [0.9927062392234802, -0.7032756209373474]
and B-LOC [0.7622813582420349, -0.662690281867981]
maintain B-LOC [1.0093350410461426, -0.7098272442817688]
AML B-LOC [0.7641162276268005, -0.9765885472297668]
stem B-LOC [0.8555567264556885, -1.0678181648254395]
cells. B-LOC [0.6910209059715271, -0.9245463013648987]
Cells B-LOC [0.08578775078058243, -0.26132506132125854]
expressing B-LOC [0.0738021656870842, -0.3117029368877411]
high B-LOC [0.18289774656295776, -0.382301926612854]
amounts B-LOC [0.1802268922328949, -0.31272563338279724]
of B-LOC [0.06123140826821327, -0.27705857157707214]
CSF1R B-LOC [-0.011614863760769367, -0.4312712550163269]
(CSF1Rhigh B-LOC [0.19564604759216309, -0.29072636365890503]
cells), B-LOC [0.06658244878053665, -0.31293073296546936]
but B-LOC [0.10633890330791473, -0.28451213240623474]
not B-LOC [0.1988896131515503, -0.11669613420963287]
those B-LOC [0.11169995367527008, -0.1390550136566162]
expressing B-LOC [0.04000239074230194, -0.28577086329460144]
low B-LOC [0.13596460223197937, -0.35985949635505676]
amounts B-LOC [0.12356097251176834, -0.27852195501327515]
of B-LOC [0.04418790712952614, -0.28755733370780945]
CSF1R B-LOC [-0.14977127313613892, -0.3661419749259949]
(CSF1Rlow B-LOC [0.11167989671230316, -0.2641775906085968]

cells), B-LOC [0.1492355316877365, -0.6222320795059204]
showed B-LOC [0.19137662649154663, -0.5574348568916321]
potent B-LOC [0.45483461022377014, -0.7483543753623962]
leukemia-initiating B-LOC [0.47336918115615845, -0.6177098155021667]
activity. B-LOC [0.6281586289405823, -0.7895178198814392]
Using O [-0.42989426851272583, 0.16671821475028992]
transgenic O [-0.15542690455913544, 0.1168515533208847]
mice O [-0.19220341742038727, 0.16639865934848785]
expressing O [-0.05088649317622185, 0.045006606727838516]
a O [-0.1462220400571823, 0.014834484085440636]
drug-inducible B-LOC [-0.10172249376773834, -0.13134509325027466]
suicide O [-0.12007099390029907, 0.0563669390976429]
gene B-LOC [-0.0853513777256012, -0.132354736328125]
controlled O [-0.0607990138232708, -0.010252559557557106]
by B-LOC [-0.08318361639976501, -0.12951919436454773]
the O [-0.13802744448184967, -0.0332433246076107]
CSF1R O [-0.325741708278656, -0.02013731561601162]
promoter, O [-0.2632535696029663, -0.046847034245729446]
we O [-0.4549226462841034, 0.08572942018508911]
cured O [-0.3241855800151825, 0.2759687304496765]
AML O [-0.26528987288475037, 0.061067525297403336]
by O [-0.5892793536186218, 0.4152248203754425]
ablation O [-0.4233682155609131, 0.38496771454811096]
of O [-0.48433077335357666, 0.32093095779418945]
CSF1Rhigh O [-0.34243208169937134, -0.010596634820103645]
cells. O [-0.402936190366745, 0.2378571480512619]
Moreover, O [-0.7526724338531494, 0.8448174595832825]
induction O [-0.9144591689109802, 0.8885969519615173]
of O [-0.939699113368988, 0.9070377349853516]
AML O [-0.7555698156356812, 0.704973042011261]
was O [-0.8094046711921692, 0.7800907492637634]
suppressed O [-0.804475724697113, 0.941366970539093]
in O [-0.8783115744590759, 0.9127233624458313]
CSF1R-deficient O [-0.9552077651023865, 0.7588732838630676]
mice O [-0.9366514682769775, 0.9204884171485901]
and O [-0.9723610281944275, 0.8818355798721313]
CSF1R O [-0.9691711068153381, 0.8403061032295227]
inhibitors O [-0.7815554738044739, 0.9718620181083679]
slowed O [-0.8903899788856506, 0.838584303855896]
the O [-0.8201850056648254, 0.7335208058357239]
progression O [-0.7589505910873413, 0.9304378628730774]
of O [-0.7840337753295898, 0.7566304206848145]
MOZ-TIF2–induced O [-0.6232312321662903, 0.5833770632743835]
leukemia. O [-0.675083577632904, 0.9002048373222351]
Thus, B-LOC [0.5462270379066467, -0.41395246982574463]
in B-LOC [0.6655117869377136, -0.6994401216506958]
this B-LOC [0.7185807228088379, -0.7122949361801147]
subtype B-LOC [0.8699467182159424, -0.9779594540596008]
of B-LOC [0.6019209623336792, -0.916483998298645]
AML, B-LOC [0.5103037357330322, -0.7787157297134399]
leukemia B-LOC [0.670354425907135, -0.5840647220611572]
stem B-LOC [0.5935025811195374, -0.9228361248970032]
cells B-LOC [0.6524614691734314, -0.7934669256210327]
are B-LOC [0.8780462741851807, -0.8054569959640503]
contained B-LOC [0.8996410965919495, -0.891320526599884]
within B-LOC [0.9333390593528748, -0.8258927464485168]
the B-LOC [0.4953859746456146, -0.6509841680526733]

CSF1Rhigh B-LOC [-0.1739400327205658, -0.31304407119750977]
cell B-LOC [0.013482834212481976, -0.09928902983665466]
population, B-LOC [0.24524590373039246, -0.15696664154529572]
and B-LOC [0.27919161319732666, -0.28691840171813965]
we O [-0.2005167007446289, -0.027638806030154228]
suggest B-LOC [0.46923330426216125, -0.30745071172714233]
that B-LOC [0.5225224494934082, -0.6591129899024963]
targeting B-LOC [0.3154159486293793, -0.2448587864637375]
of B-LOC [0.06570332497358322, -0.10668602585792542]
PU.1-mediated O [-0.12033887952566147, -0.08932505548000336]
upregulation B-LOC [-0.024164563044905663, -0.3083551526069641]
of B-LOC [-0.07842164486646652, -0.22356441617012024]
CSF1R O [-0.321368545293808, -0.07077651470899582]
expression B-LOC [0.011294486932456493, -0.0056802877224981785]
might B-LOC [0.9379162788391113, -0.9877747297286987]
be B-LOC [0.7796208262443542, -1.0230436325073242]
a B-LOC [0.9141126275062561, -1.0276317596435547]
useful B-LOC [0.7244567275047302, -1.1010135412216187]
therapeutic B-LOC [0.6074066162109375, -0.8974307775497437]
approach. B-LOC [0.5203844904899597, -1.075486660003662]

OBJECTIVE B-LOC [2.848144054412842, -3.626569986343384]
Although B-LOC [2.9151525497436523, -3.2814509868621826]
the B-LOC [3.168564558029175, -3.410771608352661]
Polypill B-LOC [3.060953140258789, -3.6044366359710693]
concept B-LOC [3.1508982181549072, -3.545933485031128]
(proposed B-LOC [3.422121286392212, -3.4636332988739014]
in B-LOC [3.3357534408569336, -3.457604169845581]
2003) B-LOC [3.3623111248016357, -3.501199245452881]
is B-LOC [3.234633207321167, -3.4485466480255127]
promising B-LOC [3.1509320735931396, -3.6003048419952393]
in B-LOC [3.126481771469116, -3.4130733013153076]
terms B-LOC [3.137528896331787, -3.340449333190918]
of B-LOC [3.1289751529693604, -3.647543430328369]
benefits B-LOC [3.4180877208709717, -3.741978883743286]
for B-LOC [3.233696222305298, -3.736112356185913]
cardiovascular B-LOC [3.247988700866699, -3.636056661605835]
risk B-LOC [3.6167542934417725, -3.867673873901367]
management, B-LOC [3.504951238632202, -3.719017505645752]
the B-LOC [3.3101630210876465, -3.502636194229126]
potential B-LOC [3.41413950920105, -3.6079788208007812]
costs B-LOC [3.649710178375244, -3.6431310176849365]
and B-LOC [3.4493348598480225, -3.613508939743042]
adverse B-LOC [3.648378610610962, -3.8967816829681396]
effects B-LOC [3.7045724391937256, -3.80177903175354]
are B-LOC [3.4819884300231934, -3.529317617416382]
its B-LOC [3.367307424545288, -3.704395055770874]
main B-LOC [3.437319040298462, -3.6921331882476807]
pitfalls. B-LOC [3.544240713119507, -3.6623451709747314]
The B-LOC [3.4353134632110596, -3.685582160949707]
objective B-LOC [3.398803234100342, -3.7668142318725586]
of B-LOC [3.33240008354187, -3.5633339881896973]
this B-LOC [3.355302095413208, -3.7829792499542236]
study B-LOC [3.3769843578338623, -3.9198124408721924]
was B-LOC [3.261202096939087, -3.6187143325805664]
to B-LOC [3.474695920944214, -3.713801145553589]
identify B-LOC [3.5372538566589355, -3.7603564262390137]
a B-LOC [3.420381784439087, -3.7734220027923584]
tastier B-LOC [3.3944437503814697, -3.7797958850860596]
and B-LOC [2.9085209369659424, -3.535274028778076]
safer B-LOC [3.2805111408233643, -3.7095930576324463]
alternative B-LOC [3.2374019622802734, -3.734335422515869]
to B-LOC [3.390052080154419, -3.615748405456543]
the B-LOC [3.5288407802581787, -3.6120057106018066]
Polypill: B-LOC [3.1793320178985596, -3.8797638416290283]
the B-LOC [3.4165689945220947, -3.5980336666107178]
Polymeal. B-LOC [3.058305501937866, -3.8700597286224365]
METHODS B-LOC [2.228116273880005, -2.8431396484375]
Data B-LOC [3.1192359924316406, -3.1749117374420166]
on B-LOC [3.154700994491577, -3.2323575019836426]
the B-LOC [3.2525274753570557, -3.2315757274627686]
ingredients B-LOC [3.2219269275665283, -3.180546998977661]
of B-LOC [3.0989487171173096, -2.9552440643310547]
the B-LOC [3.004791259765625, -2.7355988025665283]
Polymeal B-LOC [2.6260766983032227, -3.2211625576019287]
were B-LOC [3.0060055255889893, -2.988248586654663]
taken B-LOC [3.415269613265991, -3.2135581970214844]
from B-LOC [3.312291145324707, -3.058185338973999]
the B-LOC [3.278214693069458, -2.8771615028381348]
literature. B-LOC [3.0289247035980225, -3.105750560760498]
The B-LOC [2.910080671310425, -3.149885892868042]
evidence B-LOC [2.896434783935547, -3.1347920894622803]
based B-LOC [2.9796366691589355, -3.399963140487671]
recipe B-LOC [2.9235079288482666, -3.0778701305389404]
included B-LOC [2.8456649780273438, -2.993931531906128]
wine, B-LOC [2.985328435897827, -3.5322494506835938]
fish, B-LOC [3.1742208003997803, -3.5520212650299072]
dark B-LOC [3.186357259750366, -3.401642084121704]
chocolate, B-LOC [3.076422929763794, -3.4043972492218018]
fruits, B-LOC [3.3071365356445312, -3.4878432750701904]
vegetables, B-LOC [3.5749988555908203, -3.4227867126464844]
garlic, B-LOC [3.2660632133483887, -3.4433090686798096]
and B-LOC [3.0250611305236816, -3.3105854988098145]
almonds. B-LOC [3.3493857383728027, -3.3457133769989014]
Data B-LOC [2.0104944705963135, -2.050964593887329]
from B-LOC [2.1500251293182373, -2.1500096321105957]
the B-LOC [2.168712854385376, -1.9969713687896729]
Framingham B-LOC [2.2272145748138428, -2.0259242057800293]

heart B-LOC [2.527711868286133, -3.109952449798584]
study B-LOC [2.6718873977661133, -3.043705701828003]
and B-LOC [2.847482442855835, -3.0555717945098877]
the B-LOC [3.0154659748077393, -3.0984344482421875]
Framingham B-LOC [2.6470696926116943, -3.114602565765381]
offspring B-LOC [2.7659568786621094, -3.2333710193634033]
study B-LOC [2.849464178085327, -3.18701171875]
were B-LOC [2.8614118099212646, -3.3253133296966553]
used B-LOC [3.010782241821289, -3.5253989696502686]
to B-LOC [3.165668487548828, -3.5304903984069824]
build B-LOC [3.3555965423583984, -3.5458624362945557]
life B-LOC [3.0134148597717285, -3.6040284633636475]
tables B-LOC [3.3535969257354736, -3.6790850162506104]
to B-LOC [3.346491575241089, -3.6296417713165283]
model B-LOC [3.265254020690918, -3.6440885066986084]
the B-LOC [3.3295209407806396, -3.6806838512420654]
benefits B-LOC [3.113138437271118, -3.6609995365142822]
of B-LOC [3.046598196029663, -3.28350567817688]
the B-LOC [2.9020063877105713, -3.073807716369629]
Polymeal B-LOC [2.8031556606292725, -3.511542797088623]
in B-LOC [3.2231664657592773, -3.398507833480835]
the B-LOC [3.235743284225464, -3.3350603580474854]
general B-LOC [3.343195915222168, -3.6838667392730713]
population B-LOC [3.228590250015259, -3.5641658306121826]
from B-LOC [3.25911545753479, -3.533231019973755]
age B-LOC [3.347433090209961, -3.5207931995391846]
50, B-LOC [3.401411294937134, -3.566148042678833]
assuming B-LOC [3.338413953781128, -3.5574262142181396]
multiplicative B-LOC [3.4073710441589355, -3.5818374156951904]
correlations. B-LOC [3.4062283039093018, -3.752790927886963]
RESULTS B-LOC [2.222649097442627, -2.4111621379852295]
Combining B-LOC [2.6553852558135986, -2.464179515838623]
the B-LOC [2.753753900527954, -2.7551748752593994]
ingredients B-LOC [2.7422192096710205, -2.7608745098114014]
of B-LOC [2.6375179290771484, -2.488262414932251]
the B-LOC [2.4375531673431396, -2.3642048835754395]
Polymeal B-LOC [2.431401014328003, -2.807042360305786]
would B-LOC [2.3740885257720947, -2.3965275287628174]
reduce B-LOC [2.478739023208618, -2.662534713745117]
cardiovascular B-LOC [2.433927297592163, -2.70251202583313]
disease B-LOC [2.6331255435943604, -2.9805572032928467]
events B-LOC [2.4434263706207275, -2.626232624053955]
by B-LOC [1.6684222221374512, -1.928864598274231]
76%. B-LOC [2.618487596511841, -2.3017563819885254]
For O [-0.8927936553955078, 0.8147084712982178]
men, O [-0.7117593884468079, 0.8688642382621765]
taking O [-0.6540569067001343, 0.7576501965522766]
the O [-0.44380930066108704, 0.5803577899932861]
Polymeal O [-0.5801643133163452, 0.3056400716304779]
daily O [-0.7937875390052795, 0.8384392261505127]
represented O [-1.0872901678085327, 0.8221569657325745]
an O [-1.0559806823730469, 0.8011059165000916]
increase O [-0.863936722278595, 0.6416075229644775]
in O [-1.111831784248352, 0.7481434941291809]
total O [-0.9819425940513611, 1.1297311782836914]
life O [-0.7832413911819458, 1.029972791671753]
expectancy O [-0.6973201036453247, 1.0795388221740723]
of O [-1.1008667945861816, 0.7661466002464294]
6.6 O [-0.7835731506347656, 0.9728145003318787]
years, O [-0.8213735222816467, 0.8042134642601013]
an O [-1.0572292804718018, 0.7335551977157593]
increase O [-0.8422955870628357, 0.7077776789665222]
in O [-1.0267142057418823, 0.7594228386878967]
life O [-0.7451940774917603, 0.9949689507484436]
expectancy O [-0.6141420602798462, 1.002712368965149]
free O [-0.7234042286872864, 0.8685778975486755]
from O [-0.9669273495674133, 0.8794181942939758]
cardiovascular O [-0.7771461009979248, 0.8788366913795471]
disease O [-0.8422122597694397, 0.7788160443305969]
of O [-0.9419355988502502, 0.7039110064506531]
9.0 O [-0.6301615834236145, 0.7621768116950989]
years, O [-0.7430364489555359, 0.7565801739692688]
and O [-0.9382387399673462, 0.7241133451461792]
a O [-0.8321863412857056, 0.7525150179862976]
decrease O [-0.6376594305038452, 0.6246538758277893]
in O [-0.8261006474494934, 0.5951807498931885]
life O [-0.7231743931770325, 0.8178120255470276]
expectancy O [-0.5803430676460266, 0.8194665908813477]

with B-LOC [0.26562291383743286, -0.6937440037727356]
cardiovascular B-LOC [0.5480314493179321, -1.0546602010726929]
disease B-LOC [0.5697762370109558, -1.020090103149414]
of B-LOC [0.31343480944633484, -0.8826317191123962]
2.4 B-LOC [0.49593156576156616, -0.8009024858474731]
years. B-LOC [0.8318567872047424, -1.1671292781829834]
The B-LOC [1.5959564447402954, -2.217989444732666]
corresponding B-LOC [1.7449827194213867, -2.30625319480896]
differences B-LOC [1.563878059387207, -2.496279001235962]
for B-LOC [1.502278447151184, -2.1199467182159424]
women B-LOC [1.5585370063781738, -2.01725697517395]
were B-LOC [1.5208749771118164, -2.1191699504852295]
4.8, B-LOC [1.4465065002441406, -1.6757845878601074]
8.1, B-LOC [1.5170235633850098, -1.9151759147644043]
and B-LOC [1.2760417461395264, -2.209078550338745]
3.3 B-LOC [1.2201650142669678, -1.6602494716644287]
years. B-LOC [1.7285468578338623, -2.3712799549102783]
CONCLUSION O [-1.155634880065918, 1.0904546976089478]
The O [-0.5849814414978027, 0.9212842583656311]
Polymeal O [-0.6562969088554382, 0.7771398425102234]
promises O [-0.8099188804626465, 1.1315174102783203]
to O [-0.9236299395561218, 1.406717300415039]
be O [-1.0202692747116089, 1.4023754596710205]
an O [-1.0897411108016968, 1.3750423192977905]
effective, O [-0.9071177840232849, 1.2826924324035645]
non-pharmacological, O [-0.8635749220848083, 1.242942214012146]
safe, O [-0.5791899561882019, 1.0118650197982788]
cheap, O [-0.6487089991569519, 0.9692431092262268]
and O [-1.0435726642608643, 1.3406281471252441]
tasty O [-0.7922490835189819, 1.3948235511779785]
alternative O [-1.0025614500045776, 1.2765227556228638]
to O [-1.2265024185180664, 1.3380916118621826]
reduce O [-0.954867422580719, 1.1744778156280518]
cardiovascular O [-0.933871865272522, 1.0803368091583252]
morbidity O [-1.075142502784729, 0.9562777876853943]
and O [-1.2951714992523193, 1.3585944175720215]
increase O [-1.1231544017791748, 1.1583812236785889]
life O [-0.8892344236373901, 0.9666619896888733]
expectancy O [-0.9893677234649658, 1.1669909954071045]
in O [-0.9252373576164246, 0.9142070412635803]
the O [-0.9981348514556885, 1.0233441591262817]
general O [-0.9111424684524536, 0.8430750966072083]
population. O [-0.821807324886322, 0.7724598050117493]

Recent B-LOC [0.7766329646110535, -0.8645305633544922]
studies B-LOC [0.8713123202323914, -0.6843339800834656]
have B-LOC [1.04254949092865, -0.8347042202949524]
investigated B-LOC [1.1232717037200928, -0.942598283290863]
the B-LOC [1.1770583391189575, -1.1414228677749634]
dendritic B-LOC [0.7317919135093689, -0.8495477437973022]
actin B-LOC [0.6502876877784729, -0.8985998034477234]
cytoskeleton B-LOC [0.9553707838058472, -1.148385763168335]
of B-LOC [0.9427893161773682, -1.0205912590026855]
the B-LOC [1.015444040298462, -1.0348597764968872]
cell B-LOC [0.609645664691925, -1.0848853588104248]
edge's B-LOC [0.5949444770812988, -1.0890758037567139]
lamellipodial B-LOC [0.8057628273963928, -0.8220362663269043]
(LP) B-LOC [1.0612709522247314, -1.143418312072754]
region B-LOC [0.7094513773918152, -0.9684900045394897]
by B-LOC [0.7581457495689392, -0.8486008048057556]
experimentally B-LOC [0.7010200619697571, -0.6808860898017883]
decreasing B-LOC [0.7729029059410095, -0.8044430613517761]
the B-LOC [0.8157323002815247, -1.1276708841323853]
activity B-LOC [0.611892580986023, -0.6336185336112976]
of B-LOC [0.6230943202972412, -0.8534669876098633]
the B-LOC [0.6012203693389893, -0.796711266040802]
actin B-LOC [0.2709791660308838, -0.606989324092865]
filament B-LOC [0.24393491446971893, -0.5330280065536499]
nucleator B-LOC [0.3097390830516815, -0.5615227818489075]
and B-LOC [0.3606193959712982, -0.45484659075737]
branch B-LOC [0.6107725501060486, -1.0219142436981201]
former, B-LOC [0.3014669716358185, -0.47951075434684753]
the B-LOC [0.9916803240776062, -1.0891603231430054]
Arp2/3 B-LOC [0.15988479554653168, -0.7144718170166016]
complex. B-LOC [0.42682889103889465, -0.9289782643318176]
Here B-LOC [0.6505985856056213, -0.6503838896751404]
we B-LOC [0.7169187664985657, -0.7839216589927673]
extend B-LOC [0.9793596863746643, -1.0232114791870117]
these B-LOC [1.0965920686721802, -0.9962623715400696]
studies B-LOC [0.9116693139076233, -1.0226094722747803]
via B-LOC [0.8735349774360657, -0.9409738183021545]
pharmacological B-LOC [1.0976879596710205, -1.0258374214172363]
inhibition B-LOC [1.0102988481521606, -0.9918907284736633]
of B-LOC [1.0105221271514893, -0.9519249796867371]
the B-LOC [1.1076560020446777, -0.8393340110778809]
Arp2/3 B-LOC [0.6311890482902527, -0.8403447866439819]
complex B-LOC [0.7798039317131042, -1.1593133211135864]
in B-LOC [0.8461876511573792, -0.8824799060821533]
sea B-LOC [1.1279184818267822, -0.9345179200172424]
urchin B-LOC [1.0349102020263672, -0.9656516909599304]
coelomocytes, B-LOC [0.8697157502174377, -0.8989852070808411]
cells B-LOC [0.7350390553474426, -0.88946932554245]
that B-LOC [0.7931185364723206, -0.9050729870796204]
possess B-LOC [0.7128549814224243, -0.7089962363243103]
an B-LOC [0.8009335994720459, -0.7645357251167297]
unusually B-LOC [0.772313117980957, -0.9417481422424316]
broad B-LOC [0.7101946473121643, -1.0137040615081787]
LP B-LOC [0.9093368053436279, -0.8385161757469177]
region B-LOC [0.5414184927940369, -0.7801262736320496]
and B-LOC [0.48094382882118225, -0.5171341300010681]
display B-LOC [0.9403358697891235, -0.7759549617767334]
correspondingly B-LOC [0.9565284252166748, -0.7971286177635193]
exaggerated B-LOC [0.9322453141212463, -0.8345181345939636]
centripetal B-LOC [1.1275265216827393, -1.0328527688980103]
flow. B-LOC [0.8699493408203125, -0.9414780735969543]
Using B-LOC [0.14383068680763245, -0.5499199032783508]
light B-LOC [0.8117887377738953, -0.5392704606056213]
and B-LOC [0.8404824137687683, -0.6975128054618835]
electron B-LOC [0.8856630325317383, -1.1694523096084595]
microscopy, B-LOC [1.0561583042144775, -0.5126539468765259]
we B-LOC [0.07025718688964844, -0.3193889558315277]
demonstrate B-LOC [0.4019440710544586, -0.14259231090545654]
that B-LOC [0.08097317069768906, -0.3545137941837311]

Arp2/3 O [-0.710420548915863, 0.5223581790924072]
complex O [-0.7621127367019653, 0.5857398509979248]
inhibition O [-0.7823889255523682, 0.7953885197639465]
via O [-0.6060954928398132, 0.43315842747688293]
the O [-0.5323543548583984, 0.5274919867515564]
drug O [-0.5293184518814087, 0.4147998094558716]
CK666 O [-0.7124890685081482, 0.6610867381095886]
dramatically O [-0.8682861924171448, 0.8380991816520691]
altered O [-0.9285793304443359, 0.8222936987876892]
LP O [-0.5519856810569763, 0.6842426061630249]
actin O [-0.9361656308174133, 0.7706338763237]
architecture, O [-0.5703883171081543, 0.7499464154243469]
slowed O [-0.9711665511131287, 0.9196605086326599]
centripetal O [-0.7219268083572388, 0.7475946545600891]
flow, O [-0.5837896466255188, 0.6567829251289368]
drove O [-0.9423759579658508, 0.861920177936554]
a O [-0.93093341588974, 0.8567291498184204]
lamellipodial-to-filopodial O [-0.5954141020774841, 0.6794723868370056]
shape O [-0.4922903776168823, 0.6799659132957458]
change O [-0.8400179147720337, 0.37290313839912415]
in O [-0.902026355266571, 0.6605009436607361]
suspended O [-0.5517875552177429, 0.5519484281539917]
cells, O [-0.6362850666046143, 0.5201088786125183]
and O [-0.7714871168136597, 0.9160670638084412]
induced O [-0.8389157056808472, 0.7555202841758728]
a O [-0.7521933913230896, 0.7042237520217896]
novel O [-0.7094002366065979, 0.5817144513130188]
actin O [-0.6470628976821899, 0.5633447766304016]
structural O [-0.38886502385139465, 0.32707837224006653]
organization O [-0.5927028059959412, 0.44985005259513855]
during O [-0.750577986240387, 0.6396205425262451]
cell O [-0.5562638640403748, 0.26858970522880554]
spreading. O [-0.24602948129177094, 0.29234835505485535]
A B-LOC [0.7273814082145691, -0.9055691361427307]
general B-LOC [0.9055213332176208, -1.1146049499511719]
feature B-LOC [0.8429122567176819, -1.03941810131073]
of B-LOC [0.7014597654342651, -0.8348572850227356]
the B-LOC [0.8989167809486389, -0.8701674342155457]
CK666 B-LOC [0.5116473436355591, -0.7465844750404358]
phenotype B-LOC [0.7599344849586487, -1.1329200267791748]
in B-LOC [0.7151830792427063, -0.9120619893074036]
coelomocytes B-LOC [0.6675641536712646, -1.0224909782409668]
was B-LOC [0.6059359312057495, -0.7894696593284607]
transverse B-LOC [0.6526092886924744, -0.9526465535163879]
actin B-LOC [0.4301600158214569, -0.7636491656303406]
arcs, B-LOC [0.6055358648300171, -0.9936867356300354]
and B-LOC [0.5948126316070557, -0.8038815259933472]
arc B-LOC [0.5494379997253418, -0.8667863607406616]
generation B-LOC [0.43244364857673645, -0.7296810150146484]
was B-LOC [0.6343584656715393, -0.7842441201210022]
arrested B-LOC [0.619967520236969, -0.8257843852043152]
by B-LOC [0.4963567554950714, -0.6920748949050903]
a B-LOC [0.6140974164009094, -0.7088953852653503]
formin B-LOC [0.5763364434242249, -0.9644741415977478]
inhibitor. B-LOC [0.5230059623718262, -0.806459367275238]
We B-LOC [-0.10561256110668182, -0.1700279712677002]
also B-LOC [0.12002934515476227, -0.24619132280349731]
demonstrate B-LOC [-0.005648413207381964, -0.04046683385968208]
that B-LOC [-0.10448173433542252, -0.36205923557281494]
CK666 B-LOC [0.17691825330257416, -0.2631647288799286]
treatment B-LOC [0.022777052596211433, -0.42783287167549133]
produces B-LOC [0.2868823707103729, -0.30807358026504517]
actin B-LOC [-0.09981055557727814, -0.20011240243911743]
arcs B-LOC [0.24668961763381958, -0.3317504823207855]
in B-LOC [0.200790673494339, -0.3352886140346527]
other B-LOC [0.24697110056877136, -0.4506557583808899]
cells B-LOC [0.3083803951740265, -0.6185797452926636]
with B-LOC [0.33011630177497864, -0.5684558749198914]
broad B-LOC [0.43950745463371277, -0.7193968892097473]
LP B-LOC [0.5153837203979492, -0.7782923579216003]
regions, B-LOC [0.40205857157707214, -0.5912994146347046]
namely B-LOC [0.3880394995212555, -0.4825747311115265]
fish B-LOC [0.253540962934494, -0.6449059844017029]
keratocytes B-LOC [0.29764702916145325, -0.4417855441570282]
and B-LOC [0.15599992871284485, -0.3681018650531769]
Drosophila B-LOC [0.21356101334095, -0.6845927834510803]

S2 B-LOC [0.07627344131469727, -0.5230732560157776]
cells. B-LOC [0.07077992707490921, -0.49521404504776]
We O [-0.18804053962230682, -0.14275871217250824]
hypothesize B-LOC [0.4925821125507355, -0.13467392325401306]
that O [-0.06038741022348404, -0.056138474494218826]
the O [-0.05457041785120964, -0.006685199681669474]
actin O [-0.3004518747329712, 0.1686159074306488]
arcs B-LOC [-0.058773864060640335, -0.09965407848358154]
made O [-0.0722000002861023, -0.062280405312776566]
visible O [-0.11372318863868713, 0.13650394976139069]
by O [-0.4418579638004303, 0.04939443990588188]
Arp2/3 O [-0.32427704334259033, 0.13304458558559418]
complex O [-0.39157119393348694, -0.10803379118442535]
inhibition O [-0.24630576372146606, 0.12261418998241425]
in O [-0.1981096714735031, 0.026644496247172356]
coelomocytes O [-0.38123705983161926, 0.08717906475067139]
may B-LOC [0.12710906565189362, -0.134153351187706]
represent B-LOC [0.0052865915931761265, -0.08985890448093414]
an B-LOC [0.0045143538154661655, -0.16222582757472992]
exaggerated B-LOC [-0.005872321780771017, -0.07087592035531998]
manifestation O [-0.12950706481933594, -0.0030847215093672276]
of O [-0.13153257966041565, -0.10137739777565002]
the O [-0.12243097275495529, 0.068747878074646]
elongate O [-0.14251552522182465, 0.022038137540221214]
mother O [-0.22556176781654358, 0.006026295479387045]
filaments O [-0.29799884557724, -0.040261778980493546]
that B-LOC [-0.16616728901863098, -0.2636434733867645]
could B-LOC [0.028138229623436928, -0.289204865694046]
possibly B-LOC [-0.006289330776780844, -0.28566640615463257]
serve O [-0.17629143595695496, -0.12009488791227341]
as O [-0.14830929040908813, -0.06416113674640656]
the O [-0.1707386076450348, 0.06159632280468941]
scaffold O [-0.18845553696155548, -0.016760127618908882]
for O [-0.20767731964588165, -0.13482362031936646]
the O [-0.27873387932777405, -0.09539803862571716]
production O [-0.20353317260742188, -0.0025984817184507847]
of O [-0.13193193078041077, -0.11004552990198135]
the O [-0.08878190815448761, -0.026628689840435982]
dendritic O [-0.20405562222003937, -0.14929261803627014]
actin O [-0.35810205340385437, -0.008388476446270943]
network. O [-0.3716675341129303, -0.13427811861038208]

Although B-LOC [2.5276172161102295, -3.426656484603882]
susceptibility B-LOC [2.7098586559295654, -3.7573082447052]
of B-LOC [2.529623031616211, -3.6459357738494873]
neurons B-LOC [2.298572301864624, -3.3979976177215576]
in B-LOC [2.736212968826294, -3.478433847427368]
the B-LOC [2.774857521057129, -3.5257999897003174]
brain B-LOC [2.5233895778656006, -3.502462387084961]
to B-LOC [2.863081216812134, -3.435398817062378]
microbial B-LOC [3.0951571464538574, -3.514389991760254]
infection B-LOC [2.8272061347961426, -3.46651291847229]
is B-LOC [3.1695172786712646, -3.6607089042663574]
a B-LOC [3.1588780879974365, -3.6295602321624756]
major B-LOC [3.1408369541168213, -3.6584084033966064]
determinant B-LOC [3.11445689201355, -3.6832690238952637]
of B-LOC [2.789290428161621, -3.8787734508514404]
clinical B-LOC [3.1400017738342285, -3.7688655853271484]
outcome, B-LOC [2.949481725692749, -3.832632303237915]
little B-LOC [3.1929819583892822, -3.5409045219421387]
is B-LOC [3.2356648445129395, -3.6301674842834473]
known B-LOC [3.206777811050415, -3.622819185256958]
about B-LOC [3.2077293395996094, -3.757526159286499]
the B-LOC [3.2988789081573486, -3.664196729660034]
molecular B-LOC [3.350433588027954, -3.7239112854003906]
factors B-LOC [3.2192223072052, -3.7200417518615723]
governing B-LOC [3.2026185989379883, -3.542900800704956]
this B-LOC [3.0364387035369873, -3.5455288887023926]
vulnerability. B-LOC [2.7867443561553955, -3.7173962593078613]
Here B-LOC [0.7893038392066956, -0.6515424847602844]
we B-LOC [0.4064212739467621, -0.3166280686855316]
show B-LOC [0.7233633995056152, -0.441301167011261]
that B-LOC [0.7126160264015198, -1.055033802986145]
two B-LOC [1.5408512353897095, -1.5348459482192993]
types B-LOC [1.792798638343811, -1.6735641956329346]
of B-LOC [1.4541957378387451, -1.649242877960205]
neurons B-LOC [1.2920851707458496, -1.4034745693206787]
from B-LOC [1.5300636291503906, -1.5796525478363037]
distinct B-LOC [1.680111289024353, -2.0588419437408447]
brain B-LOC [1.621607780456543, -1.6538105010986328]
regions B-LOC [1.8153198957443237, -1.7716290950775146]
showed B-LOC [0.9961087107658386, -1.148114800453186]
differential B-LOC [1.2722629308700562, -1.6318566799163818]
permissivity B-LOC [1.7125025987625122, -1.6260946989059448]
to B-LOC [1.4149903059005737, -1.4747228622436523]
replication B-LOC [1.966838002204895, -1.6023895740509033]
of B-LOC [1.7683504819869995, -1.8412437438964844]
several B-LOC [1.7482514381408691, -1.8273489475250244]
positive-stranded B-LOC [1.7665690183639526, -2.0224111080169678]
RNA B-LOC [1.9199137687683105, -1.8999981880187988]
viruses. B-LOC [1.6580313444137573, -1.7114145755767822]
Granule B-LOC [1.0250842571258545, -1.1873843669891357]
cell B-LOC [0.6676540374755859, -1.1203104257583618]
neurons B-LOC [0.7780845165252686, -1.1201001405715942]
of B-LOC [0.874757707118988, -1.0215946435928345]
the B-LOC [1.0228971242904663, -0.9990664720535278]
cerebellum B-LOC [1.168202519416809, -1.3331108093261719]
and B-LOC [0.983136773109436, -1.1008803844451904]
cortical B-LOC [1.2208361625671387, -1.3474156856536865]
neurons B-LOC [0.860173761844635, -1.2466537952423096]
from B-LOC [1.0735622644424438, -1.3317270278930664]
the B-LOC [1.100556492805481, -1.1969432830810547]
cerebral B-LOC [0.7783030867576599, -1.214443564414978]
cortex B-LOC [0.9559862017631531, -1.4671417474746704]
have B-LOC [0.9744806885719299, -1.136330008506775]
unique B-LOC [1.1820237636566162, -1.4435412883758545]
innate B-LOC [1.2621420621871948, -1.25958251953125]
immune B-LOC [1.2213746309280396, -1.3846557140350342]
programs B-LOC [0.8311532139778137, -1.159653663635254]
that B-LOC [0.9520213007926941, -1.3857685327529907]
confer B-LOC [1.0462678670883179, -1.178210973739624]
differential B-LOC [0.8672440648078918, -1.5146355628967285]
susceptibility B-LOC [1.1391377449035645, -1.4694403409957886]
to B-LOC [1.0574010610580444, -1.5348436832427979]
viral B-LOC [1.0124510526657104, -1.5573385953903198]
infection B-LOC [1.2638680934906006, -1.5777097940444946]
ex B-LOC [0.6782229542732239, -1.0819437503814697]
vivo B-LOC [1.0036582946777344, -1.4841365814208984]
and B-LOC [1.085889458656311, -1.1348633766174316]
in B-LOC [0.7423282861709595, -1.2823480367660522]
vivo. B-LOC [0.7805250287055969, -1.2697668075561523]
By B-LOC [-0.06568817794322968, -0.20744210481643677]
transducing B-LOC [0.16038155555725098, -0.2522294223308563]
cortical B-LOC [0.05686475336551666, -0.19737198948860168]
neurons B-LOC [0.0029295184649527073, -0.29756084084510803]
with B-LOC [0.2682984173297882, -0.4246990382671356]
genes B-LOC [0.18959549069404602, -0.4762011468410492]
that B-LOC [0.1599399745464325, -0.5636207461357117]
were B-LOC [0.35150015354156494, -0.59254390001297]
expressed B-LOC [0.3432859480381012, -0.4221990406513214]
more B-LOC [-0.013895035721361637, -0.4752613306045532]

highly O [-0.3694189488887787, -0.10163871943950653]
in O [-0.2922649681568146, 0.07363495230674744]
granule B-LOC [-0.012192619033157825, -0.14531362056732178]
cell O [-0.2255817949771881, -0.059925589710474014]
neurons, O [-0.07185043394565582, 0.03794768080115318]
we O [-0.2829889953136444, -0.04765404015779495]
identified O [-0.1016409620642662, 0.09691576659679413]
three B-LOC [0.2787146270275116, -0.16930538415908813]
interferon-stimulated B-LOC [-0.052024710923433304, -0.27646133303642273]
genes B-LOC [0.22726207971572876, -0.1405271291732788]
(ISGs; B-LOC [0.22563742101192474, -0.37893712520599365]
Ifi27, B-LOC [0.1284652203321457, -0.16242915391921997]
Irg1 B-LOC [0.08597629517316818, -0.2449806183576584]
and B-LOC [0.18483050167560577, -0.005732240621000528]
Rsad2 B-LOC [0.0217107106000185, -0.4004112482070923]
(also B-LOC [0.32329317927360535, -0.45165619254112244]
known B-LOC [0.6132193207740784, -0.4591129720211029]
as B-LOC [0.3743547201156616, -0.4670415222644806]
Viperin)) B-LOC [0.12872660160064697, -0.3172459006309509]
that B-LOC [-0.10111406445503235, -0.22015979886054993]
mediated O [-0.20681524276733398, 0.05020644888281822]
the O [-0.1387307345867157, -0.016856195405125618]
antiviral B-LOC [0.02030344493687153, -0.08469623327255249]
effects B-LOC [0.0625368133187294, 0.0015489882789552212]
against B-LOC [0.11065813153982162, -0.01566361077129841]
different B-LOC [0.005153349135071039, -0.40560299158096313]
neurotropic B-LOC [-0.03336209058761597, -0.16636142134666443]
viruses. B-LOC [0.16624078154563904, -0.24484087526798248]
Moreover, O [-0.2080003321170807, 0.30277714133262634]
we O [-0.2759650945663452, 0.10876651108264923]
found O [-0.24736112356185913, 0.4022429883480072]
that O [-0.2991035580635071, 0.18180665373802185]
the B-LOC [0.22628667950630188, -0.040216829627752304]
epigenetic B-LOC [0.26431804895401, -0.27529391646385193]
state B-LOC [0.3166150152683258, -0.26735571026802063]
and B-LOC [0.0984620526432991, -0.188558429479599]
microRNA B-LOC [0.2902320325374603, -0.3623906672000885]
(miRNA)-mediated B-LOC [0.5225512385368347, -0.5797017812728882]
regulation B-LOC [0.23424237966537476, -0.25350847840309143]
of B-LOC [0.24328644573688507, -0.34337738156318665]
ISGs B-LOC [0.30107736587524414, -0.2813867926597595]
correlates B-LOC [0.1774306446313858, 0.06118704378604889]
with B-LOC [0.10262973606586456, -0.1666622757911682]
enhanced B-LOC [-0.010746962390840054, -0.04845605418086052]
antiviral B-LOC [0.27462247014045715, -0.4748908579349518]
response B-LOC [0.2439889907836914, -0.38612160086631775]
in B-LOC [0.1988520324230194, -0.2181982845067978]
granule B-LOC [0.23111876845359802, -0.027459653094410896]
cell B-LOC [-0.08778269588947296, -0.22386711835861206]
neurons. B-LOC [0.06120747700333595, -0.1961365044116974]
Thus, B-LOC [0.5599633455276489, -0.4170815944671631]
neurons B-LOC [0.4756539762020111, -0.9181379079818726]
from B-LOC [0.9915215373039246, -1.0879240036010742]
evolutionarily B-LOC [0.7704431414604187, -1.1413297653198242]
distinct B-LOC [1.021517276763916, -1.6421151161193848]
brain B-LOC [0.598303496837616, -1.0696030855178833]
regions B-LOC [0.9104435443878174, -1.2209700345993042]
have B-LOC [0.9298946261405945, -1.080261468887329]
unique B-LOC [0.9257619976997375, -1.3462754487991333]
innate B-LOC [0.7239084243774414, -1.090337872505188]
immune B-LOC [0.8016912341117859, -1.1120301485061646]
signatures, B-LOC [0.722560465335846, -0.9420906901359558]
which B-LOC [0.661813497543335, -0.9294230937957764]
probably B-LOC [0.9290825724601746, -1.0530831813812256]
contribute B-LOC [0.9418430924415588, -0.9172843098640442]
to B-LOC [0.7267170548439026, -0.9163224101066589]
their B-LOC [1.1507747173309326, -1.3703919649124146]
relative B-LOC [0.4773561358451843, -1.0936174392700195]

permissiveness O [-0.09884537756443024, -0.04620140790939331]
to B-LOC [0.18604230880737305, -0.45293599367141724]
infection. B-LOC [-0.043327655643224716, -0.24873438477516174]

Leucine-rich B-LOC [1.72171151638031, -1.9111980199813843]
repeat B-LOC [1.8922313451766968, -2.0814924240112305]
kinase B-LOC [1.8618789911270142, -2.310420513153076]
2 B-LOC [2.015995740890503, -1.6820721626281738]
(LRRK2) B-LOC [1.9660687446594238, -1.9679834842681885]
mutations B-LOC [2.5255753993988037, -2.2000975608825684]
are B-LOC [2.651827096939087, -2.515498161315918]
the B-LOC [2.67071270942688, -2.4110939502716064]
most B-LOC [2.8268890380859375, -2.7273318767547607]
common B-LOC [2.7196037769317627, -2.642407178878784]
genetic B-LOC [2.691812753677368, -2.5306167602539062]
cause B-LOC [2.5458710193634033, -2.4845569133758545]
of B-LOC [2.332779884338379, -2.4412190914154053]
Parkinson's B-LOC [2.2824761867523193, -2.2634854316711426]
disease. B-LOC [2.513742446899414, -2.501802444458008]
LRRK2 B-LOC [1.6889948844909668, -1.8058009147644043]
is B-LOC [2.147109031677246, -2.179934024810791]
a B-LOC [1.891916036605835, -1.8358017206192017]
multifunctional B-LOC [2.0323264598846436, -2.1958096027374268]
protein B-LOC [1.5444700717926025, -2.0991902351379395]
affecting B-LOC [1.8726310729980469, -2.144078493118286]
many B-LOC [2.118379831314087, -2.336284875869751]
cellular B-LOC [2.0460989475250244, -2.4399971961975098]
processes B-LOC [2.0438578128814697, -2.3501861095428467]
and B-LOC [1.6908413171768188, -2.277470827102661]
has B-LOC [2.584184408187866, -2.5215938091278076]
been B-LOC [2.6618711948394775, -2.7214999198913574]
described B-LOC [2.3037540912628174, -2.4754271507263184]
to B-LOC [2.503068447113037, -2.5025126934051514]
bind B-LOC [1.9448347091674805, -2.0190939903259277]
microtubules. B-LOC [2.063392400741577, -2.3190250396728516]
Defective B-LOC [2.7656524181365967, -3.3115394115448]
microtubule-based B-LOC [2.6533138751983643, -3.2104151248931885]
axonal B-LOC [2.7861077785491943, -3.283454179763794]
transport B-LOC [2.3228719234466553, -2.8958373069763184]
is B-LOC [3.116736888885498, -3.307701826095581]
hypothesized B-LOC [3.250419855117798, -3.5027732849121094]
to B-LOC [3.1564249992370605, -3.488750457763672]
contribute B-LOC [2.884272336959839, -3.4139182567596436]
to B-LOC [2.916116952896118, -3.4163780212402344]
Parkinson's B-LOC [2.859179735183716, -3.532724380493164]
disease, B-LOC [2.909601926803589, -3.483506441116333]
but B-LOC [3.032883405685425, -3.3232948780059814]
whether B-LOC [2.8564865589141846, -3.3793373107910156]
LRRK2 B-LOC [2.689631700515747, -3.096693277359009]
mutations B-LOC [2.981956720352173, -3.12648344039917]
affect B-LOC [2.991044282913208, -3.3833751678466797]
this B-LOC [3.1278645992279053, -3.3776121139526367]
process B-LOC [2.696380376815796, -3.5037660598754883]
to B-LOC [3.2284231185913086, -3.3098909854888916]
mediate B-LOC [2.766874074935913, -3.4955737590789795]
pathogenesis B-LOC [2.967012643814087, -3.401538372039795]
is B-LOC [3.341404914855957, -3.175443172454834]
not B-LOC [3.2653658390045166, -3.269105911254883]
known. B-LOC [3.0344886779785156, -3.29473876953125]
Here O [-0.20797660946846008, 0.005511460360139608]
we O [-0.2601208984851837, 0.06267324835062027]
find O [-0.10598619282245636, 0.08632509410381317]
that O [-0.2493135780096054, 0.10996174812316895]
LRRK2 B-LOC [0.0036544636823236942, -0.13391080498695374]
containing O [-0.015968644991517067, -0.010002413764595985]
pathogenic O [-0.04326244071125984, -0.03315683826804161]
Roc-COR O [-0.16462799906730652, 0.06461749225854874]
domain B-LOC [-0.0895632728934288, -0.1232500821352005]
mutations B-LOC [0.009398325346410275, -0.19212794303894043]
(R1441C, O [-0.012885977514088154, 0.03675084188580513]

Y1699C) B-LOC [-0.06433868408203125, -0.24460923671722412]
preferentially B-LOC [0.1275431364774704, 0.037317559123039246]
associates B-LOC [0.15972568094730377, -0.010847659781575203]
with B-LOC [0.22349411249160767, -0.0779319703578949]
deacetylated O [0.024108828976750374, 0.06128871068358421]
microtubules, B-LOC [0.09152129292488098, -0.1654965877532959]
and O [-0.08424452692270279, 0.045256175100803375]
inhibits O [-0.00846074242144823, 0.034090060740709305]
axonal B-LOC [0.09219881892204285, -0.30674949288368225]
transport B-LOC [0.11841107904911041, -0.10739368945360184]
in B-LOC [0.11380412429571152, -0.22950159013271332]
primary B-LOC [0.2589167058467865, -0.3833948075771332]
neurons B-LOC [0.08593596518039703, -0.21113337576389313]
and B-LOC [0.20267049968242645, -0.206019788980484]
in B-LOC [0.22550076246261597, -0.15582695603370667]
Drosophila, B-LOC [0.34404268860816956, -0.44941607117652893]
causing B-LOC [0.013646009378135204, -0.051070164889097214]
locomotor B-LOC [0.2403624951839447, -0.21223902702331543]
deficits B-LOC [0.0861770287156105, -0.03803662583231926]
in B-LOC [0.20762842893600464, -0.27892160415649414]
vivo. B-LOC [0.24113908410072327, -0.4326167702674866]
In O [-0.8625310659408569, 0.595593273639679]
vitro, O [-0.6244131922721863, 0.8950768113136292]
increasing O [-0.9258278012275696, 0.8380256295204163]
microtubule O [-0.8624712228775024, 0.9701463580131531]
acetylation O [-0.7746201157569885, 0.5884189009666443]
using O [-0.783021867275238, 0.7113420963287354]
deacetylase O [-0.7104009985923767, 0.8729199767112732]
inhibitors O [-0.6867086291313171, 0.8978309035301208]
or O [-0.8938155770301819, 0.7897656559944153]
the O [-0.8203539252281189, 0.8391652703285217]
tubulin O [-0.7107049226760864, 0.6843025088310242]
acetylase O [-0.8583279848098755, 0.7360262274742126]
αTAT1 O [-0.8391217589378357, 0.972460925579071]
prevents O [-0.7212255597114563, 0.9278696775436401]
association O [-0.6545700430870056, 0.8991726040840149]
of O [-0.715548038482666, 0.8902629017829895]
mutant O [-0.8010464906692505, 0.7041999697685242]
LRRK2 O [-0.6519426703453064, 0.5757488012313843]
with O [-0.6722173094749451, 0.5449067950248718]
microtubules, O [-0.7453263401985168, 0.7645367383956909]
and O [-0.7614948153495789, 0.5484175682067871]
the O [-0.528101921081543, 0.5132738947868347]
deacetylase O [-0.5690849423408508, 0.5489138960838318]
inhibitor O [-0.455873042345047, 0.3497453033924103]
trichostatin O [-0.28365465998649597, 0.1321733146905899]
A O [-0.3353198766708374, 0.37898674607276917]
(TSA) O [-0.4587126672267914, 0.3158627152442932]
restores O [-0.6212778091430664, 0.4251674711704254]
axonal O [-0.6102755665779114, 0.382586270570755]
transport. O [-0.48067936301231384, 0.567933201789856]
In B-LOC [0.19726970791816711, -0.4277365505695343]
vivo B-LOC [0.2861140966415405, -0.392543226480484]
knockdown B-LOC [0.8667486310005188, -0.900445282459259]
of B-LOC [0.8483187556266785, -0.8576549887657166]
the B-LOC [0.8461853861808777, -0.8685001730918884]
deacetylases B-LOC [0.5747472643852234, -0.7582349181175232]

HDAC6 O [-0.37329378724098206, 0.1661124974489212]
and O [-0.4656807780265808, 0.46723419427871704]
Sirt2, O [-0.42954811453819275, 0.15473702549934387]
or O [-0.3682405650615692, 0.4319728910923004]
administration O [-0.41419464349746704, 0.33276721835136414]
of O [-0.5288137197494507, 0.4089190661907196]
TSA O [-0.38942456245422363, 0.39011842012405396]
rescues O [-0.49782946705818176, 0.4218103885650635]
both O [-0.5543032288551331, 0.5581881403923035]
axonal O [-0.6769026517868042, 0.5703287720680237]
transport O [-0.4336417615413666, 0.4400593340396881]
and O [-0.6295399069786072, 0.5826346278190613]
locomotor O [-0.3946591317653656, 0.5152471661567688]
behavior. O [-0.5546084046363831, 0.5340206027030945]
Thus, B-LOC [1.2860205173492432, -0.9354415535926819]
this B-LOC [1.3391571044921875, -1.5757479667663574]
study B-LOC [1.0940371751785278, -1.5547678470611572]
reveals B-LOC [1.5236845016479492, -1.4530012607574463]
a B-LOC [1.6647697687149048, -1.9630277156829834]
pathogenic B-LOC [1.868601679801941, -2.13924241065979]
mechanism B-LOC [1.383001446723938, -1.8817591667175293]
and B-LOC [1.683203935623169, -1.8837131261825562]
a B-LOC [1.809903860092163, -2.1577327251434326]
potential B-LOC [1.987206220626831, -2.3446829319000244]
intervention B-LOC [1.4635820388793945, -2.2688541412353516]
for B-LOC [1.6254210472106934, -2.0466840267181396]
Parkinson's B-LOC [1.4685438871383667, -1.7859349250793457]
disease. B-LOC [1.6760870218276978, -2.095069408416748]

To B-LOC [3.101367473602295, -3.7032742500305176]
identify B-LOC [3.5098578929901123, -3.748228073120117]
new B-LOC [3.4717600345611572, -3.9054195880889893]
genetic B-LOC [3.3547112941741943, -3.7889914512634277]
factors B-LOC [3.28147292137146, -3.873720169067383]
for B-LOC [3.2859299182891846, -3.676759719848633]
colorectal B-LOC [3.20312237739563, -3.6743104457855225]
cancer B-LOC [3.0527007579803467, -3.679459810256958]
(CRC), B-LOC [3.4234230518341064, -3.653872489929199]
we B-LOC [2.9635541439056396, -3.1737518310546875]
conducted B-LOC [3.3366072177886963, -3.420072078704834]
a B-LOC [3.2606112957000732, -3.482614278793335]
genome-wide B-LOC [3.537344217300415, -3.8266847133636475]
association B-LOC [3.1244494915008545, -3.63029408454895]
study B-LOC [3.2257018089294434, -3.6598668098449707]
in B-LOC [3.215609550476074, -3.5317578315734863]
east B-LOC [3.24627685546875, -3.440460443496704]
Asians. B-LOC [3.081341028213501, -3.676100015640259]
By B-LOC [2.660029888153076, -3.173967123031616]
analyzing B-LOC [2.993037700653076, -3.2317280769348145]
genome-wide B-LOC [3.3347108364105225, -3.5623867511749268]
data B-LOC [3.1297600269317627, -3.3936641216278076]
in B-LOC [3.0772879123687744, -3.3092639446258545]
2,098 B-LOC [3.474350690841675, -3.2185776233673096]
cases B-LOC [3.1434242725372314, -3.3705410957336426]
and B-LOC [2.998185634613037, -3.2730705738067627]
5,749 B-LOC [3.5671494007110596, -3.256287097930908]
controls, B-LOC [3.2338144779205322, -3.600419282913208]
we B-LOC [2.7611019611358643, -3.1387178897857666]
selected B-LOC [3.1041011810302734, -3.2156403064727783]
64 B-LOC [3.3348565101623535, -3.388666868209839]
promising B-LOC [3.123331069946289, -3.511812686920166]
SNPs B-LOC [3.2407333850860596, -3.411653518676758]
for B-LOC [3.1673600673675537, -3.384645700454712]
replication B-LOC [3.2165000438690186, -3.443726062774658]
in B-LOC [3.1904804706573486, -3.3293817043304443]
an B-LOC [3.2367501258850098, -3.171351194381714]
independent B-LOC [3.1993491649627686, -3.6269290447235107]
set B-LOC [3.411123037338257, -3.4070980548858643]
of B-LOC [3.2024104595184326, -3.392050266265869]
samples, B-LOC [3.1328492164611816, -3.5393097400665283]
including B-LOC [3.2121357917785645, -3.3418562412261963]
up B-LOC [3.195223569869995, -3.534904956817627]
to B-LOC [3.2991597652435303, -3.283642292022705]
5,358 B-LOC [3.5603463649749756, -3.4835922718048096]
cases B-LOC [3.2350332736968994, -3.6714229583740234]
and B-LOC [3.0739479064941406, -3.5703186988830566]
5,922 B-LOC [3.6362411975860596, -3.5339157581329346]
controls. B-LOC [3.3052315711975098, -3.6606030464172363]
We B-LOC [1.3138110637664795, -1.347496747970581]
identified B-LOC [1.505211591720581, -1.2777034044265747]
four B-LOC [1.650704264640808, -1.3671447038650513]
SNPs B-LOC [1.5060653686523438, -1.6544454097747803]
with B-LOC [1.6281259059906006, -1.7562474012374878]
association B-LOC [1.6195640563964844, -1.7301461696624756]
P B-LOC [1.3737412691116333, -1.643614411354065]
values B-LOC [1.3348445892333984, -1.3818786144256592]
of B-LOC [1.2893140316009521, -1.477631688117981]
8.58 B-LOC [1.6998791694641113, -1.2019597291946411]
× B-LOC [1.1003894805908203, -1.275895118713379]
10(-7) B-LOC [1.3690241575241089, -1.3654783964157104]
to B-LOC [1.1470553874969482, -1.24605131149292]
3.77 B-LOC [1.4032782316207886, -0.9491497874259949]
× B-LOC [1.2344496250152588, -1.2563785314559937]
10(-10) B-LOC [1.4327746629714966, -1.5359565019607544]
in B-LOC [1.4216573238372803, -1.570631980895996]
the B-LOC [1.5652241706848145, -1.4424793720245361]
combined B-LOC [1.4998730421066284, -1.536737322807312]
analysis B-LOC [1.4255902767181396, -1.5087177753448486]
of B-LOC [1.7400838136672974, -1.640763759613037]
all B-LOC [1.6113955974578857, -1.5955601930618286]
east B-LOC [1.9487831592559814, -1.8759684562683105]
Asian B-LOC [1.6568220853805542, -1.79172945022583]
samples. B-LOC [1.5168371200561523, -1.6152467727661133]
Three B-LOC [1.7061655521392822, -1.4890120029449463]
of B-LOC [1.7761939764022827, -1.4734909534454346]
the B-LOC [1.78634512424469, -1.338188648223877]
four B-LOC [1.8796520233154297, -1.3127237558364868]
were B-LOC [1.9497580528259277, -1.56829035282135]
replicated B-LOC [1.9458591938018799, -1.74668550491333]
in B-LOC [1.6752488613128662, -1.5781307220458984]
a B-LOC [1.6193690299987793, -1.4691400527954102]
study B-LOC [1.4755868911743164, -1.713536024093628]
conducted B-LOC [1.5282158851623535, -1.7500931024551392]

in B-LOC [0.20474925637245178, -0.37081727385520935]
26,060 B-LOC [1.034480094909668, -0.6569632887840271]
individuals B-LOC [0.39885666966438293, -0.5943215489387512]
of B-LOC [0.8597233891487122, -0.7718609571456909]
European B-LOC [0.4559749662876129, -0.5705496072769165]
descent, B-LOC [0.699647068977356, -0.6196841597557068]
with B-LOC [0.5926783084869385, -0.5533139109611511]
combined B-LOC [0.4703681766986847, -0.4424358904361725]
P B-LOC [0.33894285559654236, -0.5621216297149658]
values B-LOC [0.4436185359954834, -0.4400210678577423]
of B-LOC [0.3908354640007019, -0.45514509081840515]
1.22 B-LOC [0.5227892994880676, -0.35146448016166687]
× B-LOC [0.26918846368789673, -0.4431808888912201]
10(-10) B-LOC [0.5258627533912659, -0.6346481442451477]
for B-LOC [0.3391808867454529, -0.5544410347938538]
rs647161 B-LOC [0.296472430229187, -0.5337929129600525]
(5q31.1), B-LOC [0.26879382133483887, -0.551345944404602]
6.64 B-LOC [0.36550527811050415, 0.03270823881030083]
× B-LOC [0.08691946417093277, -0.1738368719816208]
10(-9) B-LOC [0.40344491600990295, -0.35306939482688904]
for B-LOC [0.3348122239112854, -0.4230201840400696]
rs2423279 B-LOC [0.26252228021621704, -0.499571830034256]
(20p12.3) B-LOC [0.2864719331264496, -0.44379469752311707]
and B-LOC [0.4175545573234558, -0.2504199147224426]
3.06 B-LOC [0.4363166391849518, -0.20742309093475342]
× B-LOC [0.09913375973701477, -0.3288196325302124]
10(-8) B-LOC [0.5021665692329407, -0.6929838061332703]
for B-LOC [0.42386594414711, -0.4654900133609772]
rs10774214 B-LOC [0.30762991309165955, -0.6764129400253296]
(12p13.32 B-LOC [0.45208367705345154, -0.6960033774375916]
near B-LOC [0.5269755721092224, -0.35387179255485535]
the B-LOC [0.6215609908103943, -0.6241700053215027]
CCND2 B-LOC [0.4414001405239105, -0.5651577711105347]
gene), B-LOC [0.23326526582241058, -0.6241823434829712]
derived B-LOC [0.719997763633728, -0.7441818714141846]
from B-LOC [0.6926887631416321, -0.7893667817115784]
meta-analysis B-LOC [1.1129176616668701, -0.9264311194419861]
of B-LOC [0.7461974024772644, -0.8429555892944336]
data B-LOC [0.7340204119682312, -0.8271298408508301]
from B-LOC [0.9094679951667786, -1.0630853176116943]
both B-LOC [0.9048665165901184, -1.0870379209518433]
east B-LOC [1.1490485668182373, -1.1535024642944336]
Asian B-LOC [0.7623246908187866, -0.9701682329177856]
and B-LOC [0.9711740612983704, -1.1170620918273926]
European-ancestry B-LOC [0.9543554186820984, -1.0850746631622314]
populations. B-LOC [0.9458385109901428, -0.8737351298332214]
This B-LOC [0.7121240496635437, -1.0774112939834595]
study B-LOC [0.7964256405830383, -1.1765248775482178]
identified B-LOC [1.1249945163726807, -1.0615675449371338]
three B-LOC [1.1936907768249512, -0.9750544428825378]
new B-LOC [1.2249104976654053, -1.2107146978378296]
CRC B-LOC [0.8536004424095154, -0.9445139169692993]
susceptibility B-LOC [1.2653419971466064, -1.4301464557647705]
loci B-LOC [1.4946763515472412, -1.4178242683410645]
and B-LOC [0.4897864758968353, -1.0316131114959717]
provides B-LOC [1.2107433080673218, -1.4261066913604736]
additional B-LOC [0.9513120055198669, -1.4269508123397827]
insight B-LOC [1.0936505794525146, -1.4957623481750488]
into B-LOC [1.3173165321350098, -1.3591785430908203]
the B-LOC [1.0460481643676758, -1.1437549591064453]

genetics B-LOC [0.43730947375297546, -0.6959503889083862]
and B-LOC [0.6384002566337585, -0.8029226064682007]
biology B-LOC [0.6067891716957092, -0.8647900223731995]
of B-LOC [0.5445670485496521, -0.6853386163711548]
CRC. B-LOC [0.2203250527381897, -0.6553471684455872]

OBJECTIVE B-LOC [3.122748851776123, -3.2595789432525635]
To B-LOC [3.3714191913604736, -3.3152546882629395]
investigate B-LOC [3.6385066509246826, -3.156615972518921]
the B-LOC [3.7121474742889404, -3.075263023376465]
long B-LOC [3.5538337230682373, -3.1324846744537354]
term B-LOC [3.570467710494995, -3.128591537475586]
effect B-LOC [3.6709914207458496, -3.2237184047698975]
of B-LOC [3.4639980792999268, -3.03999662399292]
radioactive B-LOC [3.505601167678833, -3.1329123973846436]
iodine B-LOC [3.2811737060546875, -2.894587755203247]
on B-LOC [3.3491623401641846, -3.410376787185669]
thyroid B-LOC [3.4205546379089355, -3.0234100818634033]
function B-LOC [3.6606767177581787, -3.0325448513031006]
and B-LOC [3.3884496688842773, -3.0676894187927246]
size B-LOC [3.5450098514556885, -3.2941513061523438]
in B-LOC [3.5002176761627197, -3.0943288803100586]
patients B-LOC [3.641970634460449, -3.100616693496704]
with B-LOC [3.4872055053710938, -3.109158754348755]
non-toxic B-LOC [3.238405227661133, -3.093578577041626]
multinodular B-LOC [3.2836108207702637, -3.218615770339966]
goitre. B-LOC [3.25675892829895, -2.969733476638794]
DESIGN B-LOC [3.5404818058013916, -3.0044963359832764]
Consecutive B-LOC [3.271951913833618, -3.04815411567688]
patients B-LOC [3.4067673683166504, -2.8178951740264893]
with B-LOC [3.462836265563965, -2.824289560317993]
multinodular B-LOC [3.292726993560791, -2.876094341278076]
non-toxic B-LOC [3.308192014694214, -2.7326815128326416]
goitre B-LOC [3.1362082958221436, -2.581763982772827]
selected B-LOC [3.509939432144165, -2.9052374362945557]
for B-LOC [3.268954277038574, -2.6896674633026123]
radioactive B-LOC [3.354280710220337, -2.8540074825286865]
iodine B-LOC [3.086385488510132, -2.3749589920043945]
treatment B-LOC [3.4258196353912354, -2.870410680770874]
and B-LOC [3.033806562423706, -2.6571872234344482]
followed B-LOC [3.2060773372650146, -2.901904821395874]
for B-LOC [3.2335879802703857, -2.6131927967071533]
a B-LOC [3.0819945335388184, -2.6441116333007812]
minimum B-LOC [3.3318800926208496, -2.759716272354126]
of B-LOC [3.0387258529663086, -2.482875108718872]
12 B-LOC [3.3230020999908447, -2.583982229232788]
months B-LOC [3.521906614303589, -2.566145181655884]
(median B-LOC [3.5558278560638428, -2.7444534301757812]
48 B-LOC [3.189114809036255, -2.749567747116089]
months) B-LOC [3.5298280715942383, -2.625859022140503]
after B-LOC [3.26025128364563, -2.8729465007781982]
an B-LOC [3.0999908447265625, -2.749769449234009]
intended B-LOC [3.2405900955200195, -2.779914617538452]
dose B-LOC [3.467264413833618, -3.0687544345855713]
of B-LOC [3.067060708999634, -2.688612937927246]
3.7 B-LOC [2.963135242462158, -2.384953498840332]
MBq/g B-LOC [3.084731340408325, -3.0544826984405518]
thyroid B-LOC [3.313555955886841, -2.5112483501434326]
tissue B-LOC [3.116846799850464, -2.7068030834198]
corrected B-LOC [3.273430585861206, -2.920539379119873]
to B-LOC [3.217780351638794, -2.732065439224243]
a B-LOC [3.232698678970337, -2.83900785446167]
100% B-LOC [3.083221673965454, -2.826002836227417]
uptake B-LOC [3.0815603733062744, -2.802820920944214]
of B-LOC [3.247378349304199, -2.761953115463257]
iodine-131 B-LOC [3.168975353240967, -2.6782243251800537]
in B-LOC [2.956615686416626, -2.813800096511841]
24 B-LOC [3.1316335201263428, -2.7426607608795166]
hours. B-LOC [3.502004384994507, -2.920830488204956]
PATIENTS B-LOC [2.002748727798462, -2.4498047828674316]
69 B-LOC [2.2975690364837646, -2.2435028553009033]
patients B-LOC [1.8756701946258545, -2.3071401119232178]
with B-LOC [1.779998540878296, -2.215376615524292]
a B-LOC [1.9551434516906738, -2.2476134300231934]
growing B-LOC [1.8808671236038208, -2.3248159885406494]
multinodular B-LOC [1.9679449796676636, -2.4357173442840576]

non-toxic B-LOC [1.5140070915222168, -2.1587748527526855]
goitre B-LOC [2.23632550239563, -2.8272931575775146]
causing B-LOC [2.3655550479888916, -2.9182217121124268]
local B-LOC [2.3354668617248535, -3.1128194332122803]
compression B-LOC [2.4172017574310303, -3.0503995418548584]
symptoms B-LOC [2.5638763904571533, -2.7770497798919678]
or B-LOC [2.4670543670654297, -3.0339255332946777]
cosmetic B-LOC [2.5572164058685303, -3.0711987018585205]
inconveniences. B-LOC [2.423222303390503, -2.987807035446167]
The B-LOC [3.175959587097168, -3.0473878383636475]
treatment B-LOC [3.244840383529663, -3.322256565093994]
was B-LOC [3.3490688800811768, -3.087430238723755]
chosen B-LOC [3.569620370864868, -3.2155513763427734]
because B-LOC [3.168461561203003, -2.9406580924987793]
of B-LOC [3.0480263233184814, -2.9113171100616455]
a B-LOC [3.0400612354278564, -2.971482038497925]
high B-LOC [3.199209451675415, -3.160644292831421]
operative B-LOC [3.160236120223999, -3.1707546710968018]
risk, B-LOC [3.3245513439178467, -3.243478536605835]
previous B-LOC [3.0430495738983154, -3.422755479812622]
thyroidectomy, B-LOC [3.436000347137451, -3.1605961322784424]
or B-LOC [3.1402647495269775, -3.249011516571045]
refusal B-LOC [3.3052756786346436, -3.12925386428833]
to B-LOC [3.192819118499756, -2.8886613845825195]
be B-LOC [3.0178182125091553, -2.9983913898468018]
operated B-LOC [3.415865182876587, -3.246062994003296]
on. B-LOC [3.145676374435425, -3.0314228534698486]
MAIN B-LOC [3.2775063514709473, -3.122328758239746]
OUTCOME B-LOC [3.345384120941162, -3.1556103229522705]
MEASUREMENTS B-LOC [3.199324131011963, -3.0855507850646973]
Standard B-LOC [3.3519091606140137, -3.4593467712402344]
thyroid B-LOC [3.4500694274902344, -3.1048827171325684]
function B-LOC [3.5784478187561035, -3.388605833053589]
variables B-LOC [3.5288455486297607, -3.2820522785186768]
and B-LOC [3.0343024730682373, -3.032594919204712]
ultrasonically B-LOC [3.294466257095337, -3.2572224140167236]
determined B-LOC [3.387805700302124, -3.2170732021331787]
thyroid B-LOC [3.5079822540283203, -3.1184499263763428]
volume B-LOC [3.438563346862793, -3.3137645721435547]
before B-LOC [3.279787540435791, -3.069045305252075]
treatment B-LOC [3.5509629249572754, -3.192640781402588]
as B-LOC [3.443009853363037, -2.8020787239074707]
well B-LOC [3.3720362186431885, -3.031743288040161]
as B-LOC [3.306509256362915, -2.9728407859802246]
1, B-LOC [3.412956953048706, -2.5577585697174072]
2, B-LOC [3.1245994567871094, -2.5062031745910645]
3, B-LOC [3.023099184036255, -2.409940481185913]
6, B-LOC [3.3098952770233154, -2.8125669956207275]
and B-LOC [3.173293113708496, -3.0779902935028076]
12 B-LOC [3.5798163414001465, -3.000821828842163]
months B-LOC [3.7473678588867188, -3.009310007095337]
after B-LOC [3.566734552383423, -3.180907964706421]
treatment B-LOC [3.598543643951416, -3.206810235977173]
and B-LOC [3.207382917404175, -3.133185386657715]
then B-LOC [3.213899850845337, -3.049039363861084]
once B-LOC [3.3744704723358154, -3.1622931957244873]
a B-LOC [3.2719526290893555, -2.9286160469055176]
year. B-LOC [3.591691732406616, -3.036044120788574]
RESULTS B-LOC [1.9853515625, -2.2861580848693848]
56 B-LOC [2.7485992908477783, -2.780726671218872]
patients B-LOC [2.763355016708374, -2.7961575984954834]
were B-LOC [3.061661958694458, -2.6610546112060547]
treated B-LOC [2.7893500328063965, -2.618133306503296]
with B-LOC [2.7495532035827637, -2.511260986328125]
a B-LOC [2.9405133724212646, -2.398200750350952]
single B-LOC [3.128408908843994, -2.5963478088378906]
dose B-LOC [2.7140469551086426, -2.616142988204956]
of B-LOC [2.0070159435272217, -2.2034828662872314]
131I, B-LOC [2.5208990573883057, -2.8113553524017334]
12 B-LOC [2.8846046924591064, -2.545264482498169]
with B-LOC [2.9753682613372803, -2.607306718826294]
two B-LOC [2.766263723373413, -2.5203511714935303]
doses, B-LOC [2.976773977279663, -2.506110906600952]
and B-LOC [2.735595464706421, -2.703322172164917]
one B-LOC [2.83327317237854, -2.4898693561553955]
with B-LOC [2.7211809158325195, -2.4537386894226074]
four B-LOC [2.6651389598846436, -2.326575994491577]
doses. B-LOC [2.879230260848999, -2.436903238296509]

In O [-0.4821455180644989, 0.18187902867794037]
45 O [0.0038669579662382603, 0.2972795069217682]
patients O [-0.40936657786369324, 0.13665205240249634]
treated O [-0.13460880517959595, 0.04485497251152992]
with O [-0.2273334562778473, 0.009335340932011604]
one O [-0.28634142875671387, 0.23411361873149872]
dose O [-0.19429901242256165, 0.1316283643245697]
and O [-0.30270618200302124, 0.17636650800704956]
remaining O [-0.26935267448425293, 0.19163142144680023]
euthyroid O [-0.21382221579551697, 0.10521800071001053]
the O [-0.3976403772830963, 0.20332568883895874]
median O [-0.5112035870552063, 0.08513985574245453]
thyroid O [-0.35301944613456726, 0.1114514097571373]
volume O [-0.4083695411682129, 0.2624046206474304]
was O [-0.4331481456756592, 0.06708922982215881]
reduced O [-0.2855882942676544, 0.1348533183336258]
from O [-0.4891814887523651, 0.17080046236515045]
73 O [-0.21693289279937744, 0.34079357981681824]
(interquartile O [-0.2564176619052887, 0.12152024358510971]
range O [-0.35782167315483093, 0.010313635692000389]
50-106) O [-0.2576110064983368, 0.1898682415485382]
ml O [-0.6651944518089294, 0.03864408656954765]
to O [-0.5080112218856812, 0.2575509250164032]
29 O [-0.21620380878448486, 0.39034929871559143]
(23-48) O [-0.25661706924438477, -0.010999368503689766]
ml O [-0.5985408425331116, 0.07481200993061066]
at O [-0.35251715779304504, 0.21591271460056305]
24 O [-0.2175813764333725, 0.21083438396453857]
months O [-0.36100590229034424, 0.3147817850112915]
in O [-0.27168339490890503, 0.24867990612983704]
the O [-0.1471007764339447, 0.23597140610218048]
39 O [0.06251781433820724, 0.23027974367141724]
patients O [-0.4066985547542572, 0.2150307595729828]
in B-LOC [0.022128643468022346, -0.12419184297323227]
whom O [-0.31695055961608887, 0.10539378225803375]
this O [-0.3064342141151428, 0.06477394700050354]
was B-LOC [-0.009003465063869953, -0.3041984736919403]
measured B-LOC [0.01053850632160902, -0.16489848494529724]
during B-LOC [-0.047607097774744034, -0.11881066858768463]
follow O [-0.1696949303150177, -0.09803146123886108]
up. B-LOC [-0.15187174081802368, -0.24016742408275604]
The B-LOC [0.505713164806366, -0.5586450695991516]
median B-LOC [0.6070351004600525, -0.7487881779670715]
reduction B-LOC [0.2909575402736664, -0.6637922525405884]
was B-LOC [0.4283577799797058, -0.6757987141609192]
40 B-LOC [0.9769888520240784, -0.6249426007270813]
(22-48) B-LOC [0.6363691091537476, -0.8502916097640991]
ml B-LOC [0.0779690071940422, -0.7683053612709045]
(60% B-LOC [0.6920511722564697, -0.7258675694465637]
reduction, B-LOC [0.057580236345529556, -0.39084485173225403]
p B-LOC [0.24368394911289215, -0.7835374474525452]
< B-LOC [0.3292147219181061, -0.5191384553909302]
0.0001), B-LOC [0.7137160897254944, -0.9577887654304504]
half B-LOC [0.5671091079711914, -0.6172229051589966]
of B-LOC [0.5576702952384949, -0.5137045383453369]
which B-LOC [0.6978093981742859, -0.5851942300796509]
occurred B-LOC [0.35882067680358887, -0.6447281837463379]
within B-LOC [0.5087155103683472, -0.9113628268241882]
three B-LOC [0.5728321671485901, -0.717043399810791]
months. B-LOC [0.8932887315750122, -0.821917712688446]
Patients B-LOC [0.7158100605010986, -1.1545361280441284]
treated B-LOC [0.7792750597000122, -0.9724684357643127]
with B-LOC [0.6010527610778809, -0.8455391526222229]
two B-LOC [0.8013491630554199, -1.1440860033035278]
doses B-LOC [0.7201446890830994, -0.8804762959480286]
as B-LOC [0.8629855513572693, -0.9101101756095886]
well B-LOC [0.8136572241783142, -0.9971151351928711]
as B-LOC [1.2289073467254639, -0.9643295407295227]
those B-LOC [0.7933269143104553, -0.9751375913619995]
developing B-LOC [0.5183534026145935, -0.916754424571991]
hypothyroidism B-LOC [0.6154395937919617, -1.056058645248413]
and B-LOC [0.6894425749778748, -1.0283677577972412]
hyperthyroidism B-LOC [0.5916046500205994, -1.1064006090164185]
had B-LOC [0.2415628731250763, -0.6761612892150879]
a B-LOC [0.44661834836006165, -0.6754355430603027]
significant B-LOC [0.393420547246933, -0.9171329140663147]
reduction B-LOC [0.48601171374320984, -1.0254708528518677]
in B-LOC [0.32179126143455505, -0.9857916831970215]
thyroid B-LOC [0.4423784911632538, -0.866024374961853]
volume. B-LOC [0.21095852553844452, -0.7356427311897278]
Eleven B-LOC [0.833149254322052, -0.8551275134086609]
patients B-LOC [0.29383721947669983, -0.7178319096565247]

developed O [-0.4985944926738739, 0.15532106161117554]
hypothyroidism O [-0.3186352849006653, 0.17075291275978088]
(cumulative O [-0.3901960849761963, 0.17308051884174347]
five O [-0.46298736333847046, 0.10767309367656708]
year O [-0.40415915846824646, 0.12663182616233826]
risk O [-0.5794318318367004, 0.06831376999616623]
22%, O [-0.3449400067329407, 0.2038661539554596]
95% O [-0.5819258689880371, 0.20847150683403015]
confidence O [-0.5629546046257019, 0.11550471186637878]
interval O [-0.5494081974029541, 0.009715666994452477]
4.8% O [-0.5043870806694031, 0.23332634568214417]
to O [-0.5441522598266602, -0.07645335793495178]
38.4%). O [-0.2561571002006531, 0.20766320824623108]
Side B-LOC [1.8764108419418335, -2.243777275085449]
effects B-LOC [1.6447744369506836, -1.968821406364441]
were B-LOC [1.5015921592712402, -1.7655127048492432]
few: B-LOC [1.9676443338394165, -2.0063726902008057]
three B-LOC [1.22588312625885, -1.26578688621521]
cases B-LOC [1.520364761352539, -1.6387089490890503]
of B-LOC [0.9480826258659363, -1.2907984256744385]
hyperthyroidism B-LOC [1.450524926185608, -1.5915613174438477]
and B-LOC [0.9702038168907166, -1.114368200302124]
two B-LOC [0.9864912629127502, -1.125484824180603]
cases B-LOC [1.3885223865509033, -1.5473860502243042]
of B-LOC [0.9662484526634216, -1.273632526397705]
radiation B-LOC [0.9775580763816833, -1.585554838180542]
thyroiditis. B-LOC [1.241203784942627, -1.4220073223114014]
Only B-LOC [2.184382915496826, -2.2504794597625732]
one B-LOC [2.426433801651001, -2.568547010421753]
patient B-LOC [2.232023000717163, -2.6481425762176514]
was B-LOC [2.076017379760742, -2.3657991886138916]
dissatisfied B-LOC [2.3826236724853516, -2.254833459854126]
with B-LOC [2.0360846519470215, -2.180316686630249]
the B-LOC [1.952230453491211, -2.286060094833374]
result; B-LOC [1.5826826095581055, -2.196993112564087]
she B-LOC [2.1273350715637207, -2.486130952835083]
was B-LOC [2.2042081356048584, -2.474703550338745]
referred B-LOC [2.4190733432769775, -2.6062586307525635]
for B-LOC [2.457951545715332, -2.2245447635650635]
operation B-LOC [2.1957528591156006, -2.618466854095459]
six B-LOC [2.4414093494415283, -2.3781614303588867]
months B-LOC [2.6812407970428467, -2.508333206176758]
after B-LOC [2.375521421432495, -2.557265043258667]
treatment. B-LOC [2.376399278640747, -2.5839130878448486]
CONCLUSIONS O [-0.8475196361541748, 0.5200137495994568]
A O [-0.7637525200843811, 0.651902973651886]
substantial O [-0.6654050946235657, 0.7192263603210449]
reduction O [-0.698775589466095, 0.7040928602218628]
in O [-0.8908913135528564, 0.8860285878181458]
thyroid O [-0.698082685470581, 0.7669488787651062]
volume O [-0.7523905634880066, 1.020843505859375]
accompanied O [-0.8209137320518494, 0.8336253762245178]
by O [-0.7721978425979614, 0.8801857829093933]
a O [-0.8772197961807251, 0.844617486000061]
low O [-0.6504741311073303, 0.8437709212303162]
incidence O [-0.7199398875236511, 0.8072452545166016]
of O [-0.9812617897987366, 0.9671218991279602]
hypothyroidism O [-0.8090384602546692, 0.7578954100608826]
and O [-0.7215309739112854, 0.8831154704093933]
few O [-0.36723726987838745, 0.7037004828453064]
side O [-0.6777930855751038, 0.6486764550209045]
effects O [-0.4765164256095886, 0.7001087069511414]
makes O [-0.3534584939479828, 0.5198001265525818]
the O [-0.5087893009185791, 0.4591977596282959]
use O [-0.333183616399765, 0.41899994015693665]
of O [-0.4077088236808777, 0.4965873062610626]
radioactive O [-0.29875174164772034, 0.510197103023529]
iodine O [-0.31074759364128113, 0.2644483745098114]
an O [-0.29613733291625977, 0.3327128291130066]
attractive O [-0.13927537202835083, 0.1212964653968811]
alternative O [-0.39276793599128723, 0.3574313223361969]
to O [-0.3928563594818115, 0.2943662703037262]
surgery O [-0.3903326392173767, 0.13574276864528656]
in O [-0.2585783302783966, 0.1872210055589676]
selected O [-0.11598651111125946, 0.10526306927204132]
cases O [-0.22976717352867126, 0.24730844795703888]
of O [-0.3174578547477722, 0.12391611188650131]

non-toxic B-LOC [0.041190195828676224, -0.11258570849895477]
multinodular B-LOC [0.06642134487628937, -0.26283541321754456]
goitre. B-LOC [0.08626812696456909, -0.1476418673992157]

BACKGROUND B-LOC [1.130190134048462, -1.578338623046875]
Human B-LOC [1.3312630653381348, -1.9888819456100464]
papillomavirus B-LOC [1.3021955490112305, -1.6819255352020264]
(HPV) B-LOC [1.8159756660461426, -1.776261568069458]
testing B-LOC [1.2485657930374146, -1.466622233390808]
is B-LOC [1.3106579780578613, -1.494577169418335]
more B-LOC [0.7111028432846069, -0.5978254675865173]
sensitive B-LOC [1.1158117055892944, -1.0488593578338623]
for B-LOC [1.010847568511963, -1.2200901508331299]
the B-LOC [1.2767510414123535, -1.5279045104980469]
detection B-LOC [1.2412960529327393, -1.2681074142456055]
of B-LOC [0.9779265522956848, -1.102189302444458]
high-grade B-LOC [0.9395144581794739, -1.1707998514175415]
cervical B-LOC [1.1282398700714111, -1.5326663255691528]
lesions B-LOC [1.235621690750122, -1.3157483339309692]
than B-LOC [0.8914947509765625, -0.8317511081695557]
is B-LOC [2.175274133682251, -2.331740140914917]
cytology, B-LOC [2.5759682655334473, -2.6124422550201416]
but B-LOC [2.320164442062378, -2.4128615856170654]
detection B-LOC [2.7373812198638916, -3.345102548599243]
of B-LOC [2.5751402378082275, -3.1108529567718506]
HPV B-LOC [2.1979544162750244, -2.437756061553955]
by B-LOC [2.3576877117156982, -3.0139381885528564]
DNA B-LOC [2.745356798171997, -3.3245272636413574]
screening B-LOC [2.640104293823242, -3.1954493522644043]
in B-LOC [2.854856252670288, -3.135725259780884]
two B-LOC [2.5654988288879395, -2.9744985103607178]
screening B-LOC [2.79005765914917, -3.5687203407287598]
rounds B-LOC [3.132866621017456, -3.2280232906341553]
5 B-LOC [2.852102518081665, -2.9445700645446777]
years B-LOC [3.1220462322235107, -3.3105666637420654]
apart B-LOC [2.524982213973999, -3.222569227218628]
has B-LOC [3.332808017730713, -3.3807790279388428]
not B-LOC [3.2768514156341553, -3.1058990955352783]
been B-LOC [3.097470998764038, -3.5781290531158447]
assessed. B-LOC [3.041429281234741, -3.5339128971099854]
The B-LOC [3.4522547721862793, -3.4797346591949463]
aim B-LOC [3.3766303062438965, -3.552795648574829]
of B-LOC [3.2653207778930664, -3.3217556476593018]
this B-LOC [3.3164865970611572, -3.626378297805786]
study B-LOC [3.346379280090332, -3.5816400051116943]
was B-LOC [3.175093173980713, -3.3563129901885986]
to B-LOC [3.511681318283081, -3.48587965965271]
assess B-LOC [3.578089475631714, -3.6351680755615234]
whether B-LOC [3.378138780593872, -3.608384847640991]
HPV B-LOC [3.0549275875091553, -3.2983152866363525]
DNA B-LOC [2.6350760459899902, -3.282761812210083]
testing B-LOC [2.5883898735046387, -3.311727523803711]
in B-LOC [2.8651843070983887, -3.3685007095336914]
the B-LOC [3.354180335998535, -3.42765212059021]
first B-LOC [2.818359136581421, -3.690991163253784]
screen B-LOC [3.0343682765960693, -3.5137712955474854]
decreases B-LOC [2.6552774906158447, -3.379847288131714]
detection B-LOC [2.9411208629608154, -3.3687968254089355]
of B-LOC [2.9567744731903076, -3.391390800476074]
cervical B-LOC [2.7228028774261475, -3.1215412616729736]
intraepithelial B-LOC [2.703672170639038, -3.0613343715667725]
neoplasia B-LOC [2.8036344051361084, -3.2417876720428467]
(CIN) B-LOC [3.5121076107025146, -3.6354258060455322]
grade B-LOC [3.1814205646514893, -3.4102165699005127]
3 B-LOC [2.837529182434082, -3.2270820140838623]
or B-LOC [3.4647772312164307, -3.44437575340271]
worse, B-LOC [2.8207530975341797, -3.1558570861816406]
CIN B-LOC [2.9327104091644287, -3.269289016723633]
grade B-LOC [3.0131990909576416, -3.205504894256592]
2 B-LOC [2.6369645595550537, -2.7369961738586426]
or B-LOC [3.421483039855957, -3.422297716140747]
worse, B-LOC [2.802046060562134, -3.077097177505493]
and B-LOC [2.6730620861053467, -2.954388380050659]
cervical B-LOC [2.3774688243865967, -2.9414429664611816]
cancer B-LOC [2.3536226749420166, -3.1675050258636475]
in B-LOC [2.7310562133789062, -3.218834638595581]
the B-LOC [3.104793071746826, -3.4416754245758057]
second B-LOC [2.6516764163970947, -3.381408929824829]
screening. B-LOC [2.8435206413269043, -3.580092668533325]
METHODS B-LOC [1.0507898330688477, -1.6541659832000732]
In B-LOC [0.6645368933677673, -1.2482714653015137]
this B-LOC [0.6512728333473206, -1.1129844188690186]

randomised B-LOC [3.5533580780029297, -3.341834306716919]
trial, B-LOC [3.6249966621398926, -3.4053237438201904]
women B-LOC [3.5477964878082275, -3.4161980152130127]
aged B-LOC [3.7672698497772217, -3.185908555984497]
29-56 B-LOC [3.80737042427063, -3.028271198272705]
years B-LOC [3.753619909286499, -3.1373960971832275]
participating B-LOC [3.6842315196990967, -3.3694353103637695]
in B-LOC [3.5246012210845947, -3.305058717727661]
the B-LOC [3.592996597290039, -3.286231279373169]
cervical B-LOC [3.431325674057007, -3.5562679767608643]
screening B-LOC [3.432460069656372, -3.6297249794006348]
programme B-LOC [3.6079628467559814, -3.1766748428344727]
in B-LOC [3.6898348331451416, -3.0541765689849854]
the B-LOC [3.5893614292144775, -2.7955336570739746]
Netherlands B-LOC [3.421231746673584, -3.20906662940979]
were B-LOC [3.557476758956909, -3.226619005203247]
randomly B-LOC [3.6074941158294678, -3.1791841983795166]
assigned B-LOC [3.6716268062591553, -3.370208978652954]
to B-LOC [3.5352885723114014, -3.2391984462738037]
receive B-LOC [3.491142988204956, -3.649587392807007]
HPV B-LOC [3.4322190284729004, -3.384293794631958]
DNA B-LOC [3.347864866256714, -3.910501718521118]
(GP5+/6+-PCR B-LOC [3.7437164783477783, -3.435009241104126]
method) B-LOC [3.600407123565674, -3.5972540378570557]
and B-LOC [3.2649543285369873, -3.3566062450408936]
cytology B-LOC [3.3940441608428955, -3.576597213745117]
co-testing B-LOC [3.5332348346710205, -3.468935966491699]
or B-LOC [3.657186269760132, -3.3209850788116455]
cytology B-LOC [3.478886842727661, -3.5916805267333984]
testing B-LOC [3.5638511180877686, -3.7420623302459717]
alone, B-LOC [3.6726839542388916, -3.562032461166382]
from B-LOC [3.6386425495147705, -3.1457056999206543]
January, B-LOC [3.7142674922943115, -3.136082887649536]
1999, B-LOC [3.5917556285858154, -3.4602322578430176]
to B-LOC [3.663764476776123, -3.19215726852417]
September, B-LOC [3.554715394973755, -3.226247787475586]
2002. B-LOC [3.5733273029327393, -3.4037139415740967]
Randomisation B-LOC [3.5238068103790283, -3.32450795173645]
(in B-LOC [3.5790205001831055, -3.1739838123321533]
a B-LOC [3.306879758834839, -3.049302339553833]
1:1 B-LOC [3.305284023284912, -3.1454343795776367]
ratio) B-LOC [3.2479002475738525, -3.5799031257629395]
was B-LOC [3.401022434234619, -3.053270101547241]
done B-LOC [3.6221261024475098, -3.178731918334961]
with B-LOC [3.541747570037842, -3.289778470993042]
computer-generated B-LOC [3.481048822402954, -3.430147647857666]
random B-LOC [3.6382369995117188, -3.2881128787994385]
numbers B-LOC [3.570406436920166, -3.5825750827789307]
after B-LOC [3.2712268829345703, -3.4082705974578857]
the B-LOC [3.4032340049743652, -3.40874981880188]
cervical B-LOC [3.500469446182251, -3.3450303077697754]
specimen B-LOC [3.4619011878967285, -3.666459798812866]
had B-LOC [3.348557472229004, -3.2045633792877197]
been B-LOC [3.396768569946289, -3.329042911529541]
taken. B-LOC [3.5891215801239014, -3.421278715133667]
At B-LOC [1.482232928276062, -2.0404155254364014]
the B-LOC [2.1648812294006348, -2.1233482360839844]
second B-LOC [1.6380388736724854, -2.1517345905303955]
screening B-LOC [2.1870017051696777, -2.711527109146118]
5 B-LOC [2.0200741291046143, -2.235137701034546]
years B-LOC [2.2720866203308105, -2.2739908695220947]
later, B-LOC [1.9682542085647583, -2.4315669536590576]
HPV B-LOC [2.107450246810913, -2.684382677078247]
DNA B-LOC [2.2413275241851807, -2.7939915657043457]
and B-LOC [2.377821207046509, -2.4834935665130615]
cytology B-LOC [2.473581552505493, -2.6812326908111572]
co-testing B-LOC [2.694988965988159, -2.570955753326416]
was B-LOC [1.6801434755325317, -1.618717908859253]
done B-LOC [1.8919963836669922, -1.833019495010376]
in B-LOC [1.7540364265441895, -1.7879825830459595]
both B-LOC [1.5829198360443115, -1.7435303926467896]
groups; B-LOC [2.019503116607666, -1.92390775680542]
researchers B-LOC [1.8627140522003174, -2.164124011993408]
were B-LOC [1.8703607320785522, -1.8504624366760254]
masked B-LOC [1.762189269065857, -1.3811668157577515]
to B-LOC [1.4145996570587158, -1.4832664728164673]
the B-LOC [2.2073519229888916, -2.2958762645721436]
patient's B-LOC [2.09916615486145, -2.546673536300659]

assignment. B-LOC [3.0666825771331787, -3.558641195297241]
The B-LOC [3.4552643299102783, -3.7136921882629395]
primary B-LOC [3.5562238693237305, -3.952904462814331]
endpoint B-LOC [3.6292624473571777, -3.7191736698150635]
was B-LOC [3.4556987285614014, -3.71386456489563]
the B-LOC [3.6870334148406982, -3.7359745502471924]
number B-LOC [3.6463284492492676, -3.976231813430786]
of B-LOC [3.545180082321167, -3.982992649078369]
CIN B-LOC [3.5778303146362305, -3.7288568019866943]
grade B-LOC [3.7092976570129395, -3.6079607009887695]
3 B-LOC [3.5309321880340576, -3.668499708175659]
or B-LOC [3.4606404304504395, -3.531439781188965]
worse B-LOC [3.490858793258667, -3.5979526042938232]
detected. B-LOC [3.7964322566986084, -3.6768946647644043]
Analysis B-LOC [3.4915733337402344, -3.738309860229492]
was B-LOC [3.2359278202056885, -3.239344358444214]
done B-LOC [3.710395574569702, -3.3898417949676514]
by B-LOC [3.3145158290863037, -3.133531093597412]
intention B-LOC [3.6001908779144287, -3.5782291889190674]
to B-LOC [3.488583564758301, -3.281667709350586]
screen. B-LOC [3.6557657718658447, -3.5661535263061523]
The B-LOC [3.364830493927002, -3.133809804916382]
trial B-LOC [3.4551846981048584, -3.538311719894409]
is B-LOC [3.5651166439056396, -2.9635603427886963]
now B-LOC [3.6202304363250732, -3.1486546993255615]
finished B-LOC [3.74214768409729, -3.1002094745635986]
and B-LOC [3.0494418144226074, -2.951509475708008]
is B-LOC [3.542193651199341, -3.0866200923919678]
registered, B-LOC [3.729255437850952, -3.201350212097168]
number B-LOC [3.5923991203308105, -3.29968523979187]
ISRCTN20781131. B-LOC [3.6510274410247803, -3.3117611408233643]
FINDINGS B-LOC [3.007035970687866, -3.1775848865509033]
22,420 B-LOC [3.6856577396392822, -3.146218776702881]
women B-LOC [3.4797258377075195, -3.5402252674102783]
were B-LOC [3.390929937362671, -3.302112579345703]
randomly B-LOC [3.6231138706207275, -3.379950523376465]
assigned B-LOC [3.6431195735931396, -3.583078145980835]
to B-LOC [3.4492039680480957, -3.495651960372925]
the B-LOC [3.5069851875305176, -3.3481035232543945]
intervention B-LOC [3.3319003582000732, -3.823908567428589]
group B-LOC [3.544447183609009, -3.410814046859741]
and B-LOC [3.3569748401641846, -3.193463087081909]
22 B-LOC [3.7766308784484863, -3.491837501525879]
518 B-LOC [3.7536144256591797, -3.4213242530822754]
to B-LOC [3.56080961227417, -3.6293206214904785]
the B-LOC [3.582266092300415, -3.4043004512786865]
control B-LOC [3.5797152519226074, -3.6662464141845703]
group; B-LOC [3.6057512760162354, -3.3969078063964844]
19 B-LOC [3.6865622997283936, -3.438159227371216]
999 B-LOC [3.6319892406463623, -3.474031925201416]
in B-LOC [3.6578009128570557, -3.662022590637207]
the B-LOC [3.5895116329193115, -3.395495653152466]
intervention B-LOC [3.567753314971924, -3.832366704940796]
group B-LOC [3.669504404067993, -3.365438938140869]
and B-LOC [3.29742693901062, -3.375622272491455]
20,106 B-LOC [3.713399648666382, -3.469076633453369]
in B-LOC [3.7363245487213135, -3.7328693866729736]
the B-LOC [3.747591733932495, -3.450909376144409]
control B-LOC [3.684943437576294, -3.6486623287200928]
group B-LOC [3.758227586746216, -3.3267982006073]
were B-LOC [3.5687386989593506, -3.398533582687378]
eligible B-LOC [3.541752576828003, -3.4622747898101807]
for B-LOC [3.2331321239471436, -3.3480536937713623]
analysis B-LOC [3.5264360904693604, -3.69865083694458]
at B-LOC [3.2931385040283203, -3.477526903152466]
the B-LOC [3.2900502681732178, -3.2397899627685547]
first B-LOC [3.126638650894165, -3.674687385559082]
screen. B-LOC [3.4542019367218018, -3.719071626663208]
At B-LOC [1.9840519428253174, -2.6174118518829346]
the B-LOC [2.4770967960357666, -2.6412429809570312]
second B-LOC [2.2405588626861572, -3.0331239700317383]
screen, B-LOC [2.738908529281616, -3.1729514598846436]
19 B-LOC [2.7886879444122314, -2.7029433250427246]
579 B-LOC [2.869295835494995, -2.892385482788086]
women B-LOC [2.450861930847168, -2.7079858779907227]
in B-LOC [2.336965799331665, -2.63577938079834]
the B-LOC [2.7075040340423584, -2.766597270965576]
intervention B-LOC [2.440005302429199, -3.2563984394073486]
group B-LOC [2.861631155014038, -2.7070436477661133]
and B-LOC [2.3220419883728027, -2.5685653686523438]
19,731 B-LOC [2.8123018741607666, -2.5072710514068604]
in B-LOC [2.408088445663452, -2.546518087387085]
the B-LOC [2.8522837162017822, -2.7909319400787354]
control B-LOC [2.9008214473724365, -3.193213701248169]
group B-LOC [2.9379971027374268, -2.6374855041503906]
were B-LOC [2.601032018661499, -2.6835885047912598]
eligible, B-LOC [2.7932322025299072, -3.1441235542297363]
of B-LOC [2.6245779991149902, -2.4016878604888916]
whom B-LOC [2.3840816020965576, -2.1956512928009033]
16,750 B-LOC [2.3384807109832764, -1.9800209999084473]
and B-LOC [1.4418823719024658, -1.91255521774292]

16,743, B-LOC [2.0709235668182373, -2.1022284030914307]
respectively, B-LOC [2.0788135528564453, -2.51412296295166]
attended B-LOC [2.3092780113220215, -2.5944840908050537]
the B-LOC [2.49092698097229, -2.5960724353790283]
second B-LOC [2.4397709369659424, -2.7050468921661377]
screen. B-LOC [2.27887225151062, -2.673173666000366]
In B-LOC [0.9092365503311157, -1.2832931280136108]
the B-LOC [1.3575701713562012, -1.3209238052368164]
second B-LOC [1.3659757375717163, -1.4695374965667725]
round, B-LOC [1.5907641649246216, -1.6487175226211548]
CIN B-LOC [1.2637300491333008, -1.2880277633666992]
grade B-LOC [1.2157416343688965, -1.158679723739624]
3 B-LOC [1.000420093536377, -0.9984400868415833]
or B-LOC [0.9892606139183044, -1.4235762357711792]
worse B-LOC [1.315352439880371, -1.4560977220535278]
was B-LOC [1.104964256286621, -1.4731183052062988]
less B-LOC [1.2922122478485107, -1.0580596923828125]
common B-LOC [1.2941300868988037, -1.3117692470550537]
in B-LOC [1.2021448612213135, -1.1137642860412598]
the B-LOC [1.5102272033691406, -1.169365644454956]
intervention B-LOC [1.4716975688934326, -1.643326759338379]
group B-LOC [1.7614113092422485, -1.5665186643600464]
than B-LOC [0.9383189082145691, -0.81731116771698]
in B-LOC [1.209445834159851, -1.0433236360549927]
the B-LOC [1.5561840534210205, -1.1656343936920166]
control B-LOC [2.0516536235809326, -1.7699880599975586]
group B-LOC [1.7963827848434448, -1.5566022396087646]
(88 B-LOC [0.9332599639892578, -0.924618124961853]
of B-LOC [1.3498680591583252, -1.02042818069458]
19 B-LOC [1.7390305995941162, -1.2673722505569458]
579 B-LOC [1.613476276397705, -1.077521800994873]
in B-LOC [1.2138080596923828, -1.1569902896881104]
the B-LOC [1.5611432790756226, -0.9870995879173279]
intervention B-LOC [1.4159204959869385, -1.5151972770690918]
group B-LOC [1.7109284400939941, -1.3708288669586182]
vs B-LOC [0.969169557094574, -1.0724551677703857]
122 B-LOC [1.5653607845306396, -1.0706933736801147]
of B-LOC [1.426580786705017, -1.0502756834030151]
19,731 B-LOC [1.7379177808761597, -1.2670198678970337]
in B-LOC [1.258603572845459, -1.2255284786224365]
the B-LOC [1.7146966457366943, -1.216341257095337]
control B-LOC [1.9453623294830322, -1.6407291889190674]
group; B-LOC [1.6038707494735718, -1.4440053701400757]
relative B-LOC [1.381758213043213, -1.282046914100647]
risk B-LOC [0.9837632179260254, -1.1799860000610352]
0·73, B-LOC [1.4410319328308105, -1.6287966966629028]
95% B-LOC [0.7591701149940491, -0.811259388923645]
CI B-LOC [0.872075617313385, -1.0110993385314941]
0·55-0·96; B-LOC [1.3093793392181396, -1.4342162609100342]
p=0·023). B-LOC [0.6774037480354309, -1.0940723419189453]
Cervical B-LOC [0.5314350724220276, -0.5571941137313843]
cancer B-LOC [0.7852827906608582, -0.9157362580299377]
was B-LOC [0.7672346830368042, -1.1245300769805908]
also B-LOC [0.9058260321617126, -0.8932973146438599]
less B-LOC [0.887087345123291, -0.7857515215873718]
common B-LOC [0.8215258717536926, -0.9233645796775818]
in B-LOC [1.0038655996322632, -0.9617293477058411]
the B-LOC [1.0503078699111938, -0.8183209896087646]
intervention B-LOC [0.987847089767456, -1.2976758480072021]
group B-LOC [1.3398652076721191, -1.01374351978302]
than B-LOC [0.7332788705825806, -0.7191103100776672]
in B-LOC [1.0435106754302979, -0.8699362874031067]
the B-LOC [1.0655397176742554, -0.849163830280304]
control B-LOC [1.4264683723449707, -1.2881736755371094]
group B-LOC [1.36353600025177, -1.0698904991149902]
(four B-LOC [0.7467120289802551, -0.7968904972076416]
of B-LOC [1.170457124710083, -0.7646093368530273]
19 B-LOC [1.4927787780761719, -1.1579718589782715]
579 B-LOC [1.3129909038543701, -1.0399842262268066]
in B-LOC [1.1441185474395752, -1.0862939357757568]
the B-LOC [1.1376986503601074, -0.7756059169769287]
intervention B-LOC [1.0517418384552002, -1.3505699634552002]
group B-LOC [1.420227289199829, -1.0940845012664795]
vs B-LOC [0.8393304347991943, -0.949342668056488]
14 B-LOC [1.4248090982437134, -1.0763745307922363]
of B-LOC [1.3741490840911865, -0.9247467517852783]
19,731; B-LOC [1.5285887718200684, -1.386343240737915]
0·29, B-LOC [1.2870137691497803, -1.2328054904937744]
0·10-0·87; B-LOC [1.2960116863250732, -1.286043405532837]

p=0·031). B-LOC [0.5055882334709167, -1.0992629528045654]
In B-LOC [0.5506330728530884, -0.9827268123626709]
the B-LOC [0.9296965599060059, -1.0906212329864502]
baseline B-LOC [1.2769813537597656, -1.5897921323776245]
round, B-LOC [1.0554602146148682, -1.1032172441482544]
detection B-LOC [0.881773054599762, -1.3185229301452637]
of B-LOC [1.0428133010864258, -1.5111374855041504]
CIN B-LOC [1.1425769329071045, -1.428056240081787]
grade B-LOC [1.1448254585266113, -1.3416368961334229]
3 B-LOC [1.1134397983551025, -1.2025322914123535]
or B-LOC [1.1690964698791504, -1.5618442296981812]
worse B-LOC [1.2574130296707153, -1.4483393430709839]
did B-LOC [0.4040926396846771, -0.8782878518104553]
not B-LOC [0.548405110836029, -0.7000377774238586]
differ B-LOC [0.6663025617599487, -1.3889539241790771]
significantly B-LOC [0.6933624148368835, -1.0837790966033936]
between B-LOC [0.8667172193527222, -1.5135271549224854]
groups B-LOC [1.4196833372116089, -1.2547413110733032]
(171 B-LOC [0.8350269198417664, -1.0945658683776855]
of B-LOC [0.8220567107200623, -1.153464436531067]
19 B-LOC [1.4711809158325195, -1.5404928922653198]
999 B-LOC [1.3245677947998047, -1.4516468048095703]
vs B-LOC [0.8419753909111023, -1.2619491815567017]
150 B-LOC [1.4413669109344482, -1.315608024597168]
of B-LOC [0.989055335521698, -1.229753851890564]
20,106; B-LOC [1.6808356046676636, -1.6022412776947021]
1·15, B-LOC [1.1330230236053467, -1.4172402620315552]
0·92-1·43; B-LOC [1.1124765872955322, -1.4213930368423462]
p=0·239) B-LOC [0.7607220411300659, -1.2342276573181152]
but B-LOC [0.4653458893299103, -0.6840751767158508]
was B-LOC [0.5848450660705566, -0.9399657249450684]
significantly B-LOC [0.5853938460350037, -0.817095935344696]
more B-LOC [0.5657396912574768, -0.8114016056060791]
common B-LOC [0.7882081866264343, -1.063100814819336]
in B-LOC [0.6164228320121765, -1.112358570098877]
women B-LOC [0.8393530249595642, -1.0334649085998535]
with B-LOC [0.8568940162658691, -1.1132372617721558]
normal B-LOC [0.5671274065971375, -1.0767874717712402]
cytology B-LOC [1.1731497049331665, -1.3370503187179565]
(34 B-LOC [0.8333461880683899, -1.1107336282730103]
of B-LOC [1.0679548978805542, -1.1093553304672241]
19,286 B-LOC [1.5771629810333252, -1.4176757335662842]
vs B-LOC [0.9071068167686462, -1.3721656799316406]
12 B-LOC [1.52151358127594, -1.599622130393982]
of B-LOC [1.222628116607666, -1.126391887664795]
19,373; B-LOC [1.7908247709274292, -1.5824973583221436]
2·85, B-LOC [1.0333775281906128, -1.089739441871643]
1·47-5·49; B-LOC [0.8477038145065308, -1.0237689018249512]
p=0·001). B-LOC [0.6685988306999207, -1.1671333312988281]
Furthermore, B-LOC [0.1024852842092514, -0.1267634928226471]
significantly B-LOC [0.025838108733296394, -0.10879521071910858]
more B-LOC [-0.012346656061708927, -0.17192459106445312]
cases B-LOC [0.2431803047657013, -0.4940451979637146]
of B-LOC [-0.028314372524619102, -0.31470420956611633]
CIN B-LOC [0.35030514001846313, -0.5918552279472351]
grade B-LOC [0.4172672927379608, -0.5901651382446289]
2 B-LOC [0.25930121541023254, -0.28727981448173523]
or B-LOC [0.29688572883605957, -0.5083189010620117]
worse B-LOC [0.31940826773643494, -0.5669581294059753]
were B-LOC [0.1105865016579628, -0.46663951873779297]
detected B-LOC [0.3313576877117157, -0.5455888509750366]
in B-LOC [0.2689642012119293, -0.3386038839817047]
the B-LOC [0.39228036999702454, -0.43622392416000366]
intervention B-LOC [0.3644516170024872, -0.7847439646720886]
group B-LOC [0.5492546558380127, -0.6225643157958984]
than O [0.04034794494509697, 0.1660253405570984]
in B-LOC [0.3290582001209259, -0.42904987931251526]
the B-LOC [0.43773937225341797, -0.4769711196422577]
control B-LOC [0.512976348400116, -0.7963799238204956]
group B-LOC [0.16464975476264954, -0.43345996737480164]

(267 B-LOC [0.5306382775306702, -0.9448001980781555]
of B-LOC [0.5610312819480896, -0.7753682136535645]
19 B-LOC [1.1983529329299927, -1.0529768466949463]
999 B-LOC [0.9760296940803528, -0.9608142971992493]
vs B-LOC [0.6257798671722412, -1.0089972019195557]
215 B-LOC [0.9352497458457947, -1.0010569095611572]
of B-LOC [0.6205927133560181, -0.8690962195396423]
20,106; B-LOC [1.158712387084961, -1.0779643058776855]
1·25, B-LOC [0.5966796278953552, -1.1080117225646973]
1·05-1·50; B-LOC [0.5456146597862244, -1.0765864849090576]
p=0·015). B-LOC [0.5760974287986755, -1.069090723991394]
In B-LOC [0.381979763507843, -0.4912676513195038]
the B-LOC [0.7258324027061462, -0.6932790875434875]
second B-LOC [0.46886807680130005, -0.5854441523551941]
screen, B-LOC [0.8531402945518494, -0.9602716565132141]
fewer B-LOC [0.3956124186515808, -0.325131356716156]
HPV16-positive B-LOC [0.6835837960243225, -0.8365675210952759]
CIN B-LOC [0.965406060218811, -0.8026027679443359]
grade B-LOC [0.9214707016944885, -0.6879069209098816]
3 B-LOC [0.6515626311302185, -0.30222102999687195]
or B-LOC [0.5287649035453796, -0.46955886483192444]
worse B-LOC [0.6128188967704773, -0.6008111834526062]
were B-LOC [0.4788537919521332, -0.6330878734588623]
detected B-LOC [0.6798463463783264, -0.7524245381355286]
in B-LOC [0.6105964779853821, -0.5827383399009705]
the B-LOC [0.8777332305908203, -0.6539851427078247]
intervention B-LOC [0.9313338398933411, -1.114376187324524]
group B-LOC [1.0703080892562866, -0.8302305340766907]
than B-LOC [0.25743746757507324, -0.00673270458355546]
in B-LOC [0.5915049910545349, -0.5846067070960999]
the B-LOC [0.9038492441177368, -0.6727725267410278]
control B-LOC [1.3698530197143555, -1.1636104583740234]
group B-LOC [1.1176891326904297, -0.9373049736022949]
(17 B-LOC [0.5915660262107849, -0.6337504386901855]
of B-LOC [0.738502562046051, -0.686887264251709]
9481 B-LOC [0.8073484897613525, -0.7937222719192505]
vs B-LOC [0.6786326169967651, -1.0037968158721924]
35 B-LOC [1.027418851852417, -0.8718120455741882]
of B-LOC [0.7893560528755188, -0.6504597663879395]
9354; B-LOC [0.8978673815727234, -0.8142849206924438]
0·48, B-LOC [1.221256971359253, -1.3631792068481445]
0·27-0·85; B-LOC [1.1635322570800781, -1.442723274230957]
p=0·012); B-LOC [0.8212544322013855, -1.078474998474121]
detection B-LOC [1.146294355392456, -1.2851825952529907]
of B-LOC [1.1622624397277832, -1.3038368225097656]
non-HPV16-positive B-LOC [1.0609700679779053, -1.0988175868988037]
CIN B-LOC [1.3627933263778687, -1.334035873413086]
grade B-LOC [1.2335317134857178, -1.2400922775268555]
3 B-LOC [1.3567214012145996, -1.3108465671539307]
or B-LOC [1.4599891901016235, -1.5459359884262085]
worse B-LOC [1.2407450675964355, -1.0342493057250977]
did B-LOC [0.7340598106384277, -0.987945556640625]
not B-LOC [0.7942849397659302, -0.7985914945602417]
differ B-LOC [0.8409084677696228, -1.4595791101455688]
between B-LOC [1.1507833003997803, -1.7112505435943604]
groups B-LOC [1.5230140686035156, -1.2174667119979858]
(25 B-LOC [0.7810260057449341, -0.9174769520759583]
of B-LOC [0.9540619254112244, -1.022926926612854]
9481 B-LOC [0.8085820078849792, -0.8955132961273193]
vs B-LOC [1.0539813041687012, -1.1970967054367065]
25 B-LOC [1.4516561031341553, -1.2884331941604614]
of B-LOC [0.9873489141464233, -0.9597465991973877]
9354; B-LOC [0.902001142501831, -0.9248245358467102]
0·99, B-LOC [1.244828701019287, -1.5172512531280518]

0·57-1·72; B-LOC [0.710690975189209, -1.1964865922927856]
p=1·00). B-LOC [0.8158771991729736, -1.3064805269241333]
The B-LOC [1.8389809131622314, -2.387525796890259]
cumulative B-LOC [2.048391342163086, -2.3926517963409424]
detection B-LOC [1.9247002601623535, -2.4188458919525146]
of B-LOC [2.1984453201293945, -2.5351521968841553]
CIN B-LOC [2.1468722820281982, -2.341892957687378]
grade B-LOC [2.348703384399414, -2.538123846054077]
3 B-LOC [2.0375263690948486, -2.18603253364563]
or B-LOC [2.190049648284912, -2.7653634548187256]
worse B-LOC [2.1936147212982178, -2.5172035694122314]
and B-LOC [1.7321174144744873, -2.255669355392456]
CIN B-LOC [2.0404462814331055, -2.427536964416504]
grade B-LOC [2.3905117511749268, -2.575554609298706]
2 B-LOC [2.154453992843628, -2.2723758220672607]
or B-LOC [2.325636625289917, -2.930229425430298]
worse B-LOC [2.382763385772705, -2.5637125968933105]
did B-LOC [1.4367254972457886, -1.704221248626709]
not B-LOC [1.4958078861236572, -1.60069739818573]
differ B-LOC [1.678213119506836, -2.316122055053711]
significantly B-LOC [1.6852673292160034, -1.937548041343689]
between B-LOC [1.728822946548462, -2.456590175628662]
study B-LOC [2.2745893001556396, -2.560682535171509]
arms, B-LOC [2.5009610652923584, -2.4894373416900635]
neither B-LOC [1.1795676946640015, -1.8781874179840088]
for B-LOC [1.5568151473999023, -2.1936399936676025]
the B-LOC [2.0530459880828857, -2.2563488483428955]
whole B-LOC [2.0837790966033936, -2.2255117893218994]
study B-LOC [2.2748546600341797, -2.310192823410034]
group B-LOC [2.6779897212982178, -2.4675183296203613]
(CIN B-LOC [1.5910063982009888, -1.9321848154067993]
grade B-LOC [2.241957664489746, -2.258896589279175]
3 B-LOC [2.11710524559021, -2.0502569675445557]
or B-LOC [1.8530986309051514, -2.5320611000061035]
worse: B-LOC [2.1981682777404785, -2.3886561393737793]
259 B-LOC [2.387659788131714, -2.1999523639678955]
of B-LOC [1.9617247581481934, -2.1496384143829346]
19 B-LOC [2.471064805984497, -2.511537790298462]
999 B-LOC [2.3328425884246826, -2.3439650535583496]
vs B-LOC [1.6080741882324219, -2.1514170169830322]
272 B-LOC [2.422975540161133, -2.448035478591919]
of B-LOC [1.9768410921096802, -2.1479849815368652]
20,106; B-LOC [2.558037757873535, -2.471510648727417]
0·96, B-LOC [2.3122971057891846, -2.3324382305145264]
0·81-1·14, B-LOC [2.175687313079834, -2.2881791591644287]
p=0·631; B-LOC [1.326149821281433, -1.5996500253677368]
CIN B-LOC [1.778738021850586, -1.8846410512924194]
grade B-LOC [2.2551515102386475, -2.200188636779785]
2 B-LOC [2.059262275695801, -2.0486905574798584]
or B-LOC [1.9748033285140991, -2.430894136428833]
worse: B-LOC [2.064786434173584, -2.288698434829712]
427 B-LOC [2.16729998588562, -1.8556159734725952]
of B-LOC [1.6416997909545898, -2.0705275535583496]
19 B-LOC [1.9818180799484253, -2.22668194770813]
999 B-LOC [1.98955500125885, -1.8698129653930664]
vs B-LOC [1.5134849548339844, -1.9407861232757568]
399 B-LOC [2.0582215785980225, -1.7723716497421265]
of B-LOC [1.6464120149612427, -2.01061749458313]
20,106; B-LOC [2.123967170715332, -1.9280946254730225]
1·08, B-LOC [1.6632919311523438, -1.7943227291107178]
0·94-1·24; B-LOC [1.7936749458312988, -1.997698187828064]
p=0·292), B-LOC [1.2314836978912354, -1.580990195274353]
nor B-LOC [1.5528231859207153, -1.7589797973632812]
for B-LOC [1.2855623960494995, -1.7443081140518188]

subgroups B-LOC [2.0663206577301025, -2.415271282196045]
of B-LOC [2.219829559326172, -2.5735201835632324]
women B-LOC [2.041689157485962, -2.481239080429077]
invited B-LOC [2.037912130355835, -2.5254881381988525]
for B-LOC [1.9186958074569702, -2.2459628582000732]
the B-LOC [2.097667932510376, -2.4576261043548584]
first B-LOC [1.9173357486724854, -2.3463563919067383]
time B-LOC [2.043003559112549, -2.6454288959503174]
(CIN B-LOC [2.051708698272705, -2.381392002105713]
grade B-LOC [2.6357436180114746, -2.6517961025238037]
3 B-LOC [2.36677622795105, -2.6004793643951416]
or B-LOC [2.482015371322632, -2.970879077911377]
worse B-LOC [2.462804079055786, -2.780067205429077]
in B-LOC [1.9180084466934204, -2.5177366733551025]
women B-LOC [2.2891781330108643, -2.5161936283111572]
aged B-LOC [2.7897660732269287, -2.5587055683135986]
29-33 B-LOC [3.160630702972412, -2.705183267593384]
years: B-LOC [2.909771203994751, -2.918757200241089]
102 B-LOC [2.3934741020202637, -2.469829797744751]
of B-LOC [2.044104814529419, -2.147461414337158]
3139 B-LOC [2.483015537261963, -2.35678768157959]
vs B-LOC [1.9406440258026123, -2.4607255458831787]
105 B-LOC [2.464921712875366, -2.390880823135376]
of B-LOC [2.1017842292785645, -2.050982713699341]
3128; B-LOC [2.431246519088745, -2.423261880874634]
0·97, B-LOC [2.322596788406372, -2.5088164806365967]
0·74-1·27; B-LOC [2.3254055976867676, -2.4684579372406006]
CIN B-LOC [2.1277081966400146, -2.231193780899048]
grade B-LOC [2.574338912963867, -2.4592156410217285]
2 B-LOC [2.1666886806488037, -2.3439223766326904]
or B-LOC [2.3799350261688232, -2.637611150741577]
worse B-LOC [2.227200984954834, -2.5572969913482666]
in B-LOC [1.9172073602676392, -2.3242714405059814]
women B-LOC [2.1777422428131104, -2.3840198516845703]
aged B-LOC [2.8432486057281494, -2.3698320388793945]
29-33 B-LOC [3.021713972091675, -2.6338720321655273]
years: B-LOC [2.681644916534424, -2.714595079421997]
153 B-LOC [2.2518680095672607, -2.4251620769500732]
of B-LOC [2.0559158325195312, -2.270657777786255]
3139 B-LOC [2.420748472213745, -2.2745487689971924]
vs B-LOC [1.9387614727020264, -2.448469877243042]
151 B-LOC [2.3037095069885254, -2.5451717376708984]
of B-LOC [2.139151096343994, -2.190438747406006]
3128; B-LOC [2.357377767562866, -2.4128527641296387]
1·01, B-LOC [2.226489305496216, -2.561370611190796]
0·81-1·26; B-LOC [2.3041484355926514, -2.5913279056549072]
CIN B-LOC [2.0855135917663574, -2.3079357147216797]
grade B-LOC [2.4993937015533447, -2.552494764328003]
3 B-LOC [2.3070008754730225, -2.4915943145751953]
or B-LOC [2.465437650680542, -2.75522518157959]
worse B-LOC [2.2468483448028564, -2.5601284503936768]
in B-LOC [2.030919075012207, -2.4107747077941895]
women B-LOC [2.148707866668701, -2.5291855335235596]
aged B-LOC [2.7056334018707275, -2.5003862380981445]
34-56 B-LOC [2.8473904132843018, -2.8317458629608154]
years: B-LOC [2.6260621547698975, -2.730717658996582]
157 B-LOC [2.3599679470062256, -2.462235450744629]
of B-LOC [2.1704928874969482, -2.4412267208099365]
16,860 B-LOC [2.5226948261260986, -2.5675275325775146]
vs B-LOC [2.0121381282806396, -2.6748087406158447]
167 B-LOC [2.277247190475464, -2.3627891540527344]
of B-LOC [2.268002986907959, -2.4639546871185303]
16 B-LOC [2.293680429458618, -2.3291618824005127]
978; B-LOC [2.190509080886841, -2.6049373149871826]
0·95, B-LOC [2.317918300628662, -2.569688081741333]
0·76-1·18; B-LOC [2.316850423812866, -2.5337414741516113]
CIN B-LOC [2.1530368328094482, -2.486229658126831]
grade B-LOC [2.5308268070220947, -2.5398404598236084]
2 B-LOC [2.1126246452331543, -2.406039237976074]
or B-LOC [2.490880250930786, -2.86708402633667]
worse B-LOC [2.051569938659668, -2.5705995559692383]

in B-LOC [1.7248215675354004, -2.6675662994384766]
women B-LOC [2.2946932315826416, -2.972407102584839]
aged B-LOC [2.4951908588409424, -3.0445611476898193]
34-56 B-LOC [2.6372973918914795, -3.187969207763672]
years: B-LOC [2.4330031871795654, -3.1196348667144775]
274 B-LOC [2.6617095470428467, -3.0259602069854736]
of B-LOC [2.0411646366119385, -2.941009044647217]
16,860 B-LOC [2.7049381732940674, -3.0690460205078125]
vs B-LOC [2.194777011871338, -2.9540939331054688]
248 B-LOC [2.4112446308135986, -3.1366212368011475]
of B-LOC [2.143967866897583, -2.961787462234497]
16 B-LOC [2.4803760051727295, -3.0916993618011475]
978; B-LOC [2.3032491207122803, -3.1061246395111084]
1·11, B-LOC [2.120769739151001, -3.0210888385772705]
0·94-1·32). B-LOC [2.2302615642547607, -3.098797559738159]
INTERPRETATION O [-0.7687562108039856, 0.558796226978302]
Implementation O [-0.7948120832443237, 0.6804942488670349]
of O [-0.9027258157730103, 0.8439118266105652]
HPV O [-0.9781115055084229, 0.9774073362350464]
DNA O [-0.8644341230392456, 0.895376980304718]
testing O [-0.8865341544151306, 0.9034740328788757]
in O [-1.2229796648025513, 1.0700838565826416]
cervical O [-1.0588232278823853, 0.8171018958091736]
screening O [-0.7745518088340759, 1.0225749015808105]
leads O [-1.048667311668396, 0.9652377367019653]
to O [-1.1660624742507935, 1.0588574409484863]
earlier O [-1.315285563468933, 1.1365796327590942]
detection O [-1.0457515716552734, 1.0936506986618042]
of O [-1.2374873161315918, 1.119203805923462]
clinically O [-1.0414873361587524, 1.0653502941131592]
relevant O [-1.2941746711730957, 1.076857566833496]
CIN O [-1.1993448734283447, 0.8931655287742615]
grade O [-0.9560953974723816, 1.0484354496002197]
2 O [-1.1076467037200928, 1.1879631280899048]
or O [-1.0916945934295654, 0.8815119862556458]
worse, O [-0.925085186958313, 0.8553655743598938]
which O [-1.319474697113037, 1.0095982551574707]
when O [-1.3257126808166504, 1.085243582725525]
adequately O [-1.0164259672164917, 0.9556048512458801]
treated, O [-1.0559433698654175, 1.0359441041946411]
improves O [-1.2808294296264648, 1.085841417312622]
protection O [-0.9233918786048889, 1.0481550693511963]
against O [-0.8297297954559326, 1.006675362586975]
CIN O [-0.9991462826728821, 0.6804298758506775]
grade O [-0.8436682224273682, 1.0305730104446411]
3 O [-1.0047301054000854, 1.108403205871582]
or O [-0.9511190056800842, 0.8271506428718567]
worse O [-0.915614128112793, 0.8603768348693848]
and O [-1.0664660930633545, 0.9630122780799866]
cervical O [-1.2161002159118652, 1.0422555208206177]
cancer. O [-0.7578325867652893, 0.7667080760002136]
Early B-LOC [0.0517527274787426, -0.28729164600372314]
detection B-LOC [0.33346614241600037, -0.4289804995059967]
of B-LOC [0.33733341097831726, -0.2625405192375183]
high-grade B-LOC [0.16218487918376923, -0.3957027196884155]
cervical O [-0.17726191878318787, -0.14677515625953674]
legions O [-0.14002902805805206, -0.09748749434947968]
caused B-LOC [0.32663676142692566, -0.5720207095146179]
by B-LOC [0.20689904689788818, -0.23156806826591492]
HPV16 B-LOC [0.35595691204071045, -0.5127224922180176]
was B-LOC [0.08793212473392487, -0.38866427540779114]
a B-LOC [0.258207768201828, -0.5257419943809509]
major B-LOC [0.43986696004867554, -0.6513833403587341]
component B-LOC [0.2836669385433197, -0.5846335291862488]
of B-LOC [0.18471524119377136, -0.38787177205085754]
this B-LOC [0.25161075592041016, -0.35927942395210266]
benefit. B-LOC [0.15136708319187164, -0.7303856611251831]
Our B-LOC [0.6547872424125671, -1.0775612592697144]
results B-LOC [0.8298851847648621, -1.1010034084320068]
lend B-LOC [1.0122785568237305, -1.0216535329818726]
support B-LOC [1.040918231010437, -1.2336797714233398]
to B-LOC [1.0277608633041382, -1.2348326444625854]
the B-LOC [1.139225721359253, -1.473179578781128]
use B-LOC [1.105313777923584, -1.3574740886688232]
of B-LOC [1.1955702304840088, -1.4626034498214722]
HPV B-LOC [1.204607605934143, -1.4832065105438232]

DNA B-LOC [2.3632688522338867, -2.8376071453094482]
testing B-LOC [2.8010270595550537, -2.8742570877075195]
for B-LOC [2.955507516860962, -2.6952598094940186]
all B-LOC [2.69915509223938, -2.643080472946167]
women B-LOC [2.4672820568084717, -2.4281222820281982]
aged B-LOC [3.111752510070801, -2.6063244342803955]
29 B-LOC [3.126790761947632, -2.6591293811798096]
years B-LOC [3.2732765674591064, -2.59755539894104]
and B-LOC [2.758446455001831, -2.423290252685547]
older. B-LOC [3.193455457687378, -2.385126829147339]
FUNDING B-LOC [1.9956880807876587, -2.085106134414673]
Zorg B-LOC [1.8803231716156006, -2.099956750869751]
Onderzoek B-LOC [1.7174532413482666, -2.2845914363861084]
Nederland B-LOC [1.9107133150100708, -1.9273087978363037]
(Netherlands B-LOC [2.1906471252441406, -2.269263982772827]
Organisation B-LOC [2.27935528755188, -2.869797945022583]
for B-LOC [2.270824909210205, -2.638263463973999]
Health B-LOC [2.3169610500335693, -2.716560125350952]
Research B-LOC [2.356438636779785, -2.8737294673919678]
and B-LOC [2.3903939723968506, -2.316088914871216]
Development). B-LOC [2.682615280151367, -2.4950568675994873]

Combining B-LOC [2.1400256156921387, -2.1252572536468506]
DNA-demethylating B-LOC [1.9188508987426758, -2.1990649700164795]
agents B-LOC [2.4975035190582275, -2.4697272777557373]
(DNA B-LOC [2.6213080883026123, -2.519514560699463]
methyltransferase B-LOC [2.3776285648345947, -2.3138046264648438]
inhibitors B-LOC [2.4937331676483154, -2.4680991172790527]
[DNMTis]) B-LOC [2.3425710201263428, -2.543057680130005]
with B-LOC [2.752673864364624, -2.5815248489379883]
histone B-LOC [2.632566213607788, -2.714289903640747]
deacetylase B-LOC [2.4519503116607666, -2.5619592666625977]
inhibitors B-LOC [3.04132342338562, -2.748911142349243]
(HDACis) B-LOC [3.089538335800171, -2.6750752925872803]
holds B-LOC [2.7350664138793945, -2.56584095954895]
promise B-LOC [2.847264528274536, -2.709589958190918]
for B-LOC [2.639827013015747, -2.608213186264038]
enhancing B-LOC [2.6838505268096924, -2.6303670406341553]
cancer B-LOC [2.7946832180023193, -2.7921807765960693]
immune B-LOC [2.752084493637085, -2.738121271133423]
therapy. B-LOC [2.892561435699463, -2.836155652999878]
Herein, B-LOC [2.2733700275421143, -2.283674478530884]
pharmacologic B-LOC [3.0164954662323, -3.169527769088745]
and B-LOC [2.3690054416656494, -2.670079231262207]
isoform B-LOC [3.1954171657562256, -3.2224366664886475]
specificity B-LOC [3.0810322761535645, -3.020782709121704]
of B-LOC [2.6729073524475098, -2.741816759109497]
HDACis B-LOC [2.7226626873016357, -2.7243661880493164]
are B-LOC [3.1013171672821045, -2.469848394393921]
investigated B-LOC [3.207453727722168, -2.9894025325775146]
to B-LOC [3.1047775745391846, -2.842411518096924]
guide B-LOC [2.921330690383911, -3.108764410018921]
their B-LOC [2.811234474182129, -2.4956703186035156]
addition B-LOC [2.764658212661743, -2.8505189418792725]
to B-LOC [3.0911238193511963, -2.6842398643493652]
a B-LOC [2.978450298309326, -2.9030263423919678]
DNMTi, B-LOC [2.5818746089935303, -2.570952892303467]
thus B-LOC [2.9643490314483643, -2.7109415531158447]
devising B-LOC [3.399409055709839, -2.907339096069336]
a B-LOC [2.8355085849761963, -2.8161728382110596]
new, B-LOC [3.019157648086548, -2.962566614151001]
low-dose, B-LOC [3.0184848308563232, -3.099562883377075]
sequential B-LOC [3.0564818382263184, -2.855159044265747]
regimen B-LOC [2.452838659286499, -2.7129390239715576]
that B-LOC [2.3235857486724854, -2.747379779815674]
imparts B-LOC [2.7761645317077637, -2.7147161960601807]
a B-LOC [2.535297155380249, -2.69112491607666]
robust B-LOC [2.5714797973632812, -2.820600748062134]
anti-tumor B-LOC [2.775496244430542, -2.790440082550049]
effect B-LOC [2.0975234508514404, -2.5614354610443115]
for B-LOC [2.3146698474884033, -2.509491205215454]
non-small-cell B-LOC [2.512634754180908, -2.551386594772339]
lung B-LOC [2.1730453968048096, -2.569810628890991]
cancer B-LOC [2.5299570560455322, -2.787353277206421]
(NSCLC). B-LOC [2.8443081378936768, -2.954179048538208]
Using B-LOC [1.8676995038986206, -2.250976085662842]

in-vitro-treated B-LOC [-0.004266008269041777, -0.4772264063358307]
NSCLC B-LOC [0.3120478391647339, -0.6294832825660706]
cell B-LOC [-0.05354153737425804, -0.24454432725906372]
lines, B-LOC [0.19869574904441833, -0.2541327178478241]
we B-LOC [0.0029995166696608067, -0.2303670197725296]
elucidate B-LOC [0.37155401706695557, -0.14636223018169403]
an B-LOC [0.12021322548389435, -0.40414589643478394]
interferon B-LOC [0.276541143655777, -0.4249066412448883]
α/β-based B-LOC [0.35549458861351013, -0.4711780846118927]
transcriptional B-LOC [0.31686100363731384, -0.3481285572052002]
program B-LOC [0.07210735976696014, -0.3461116552352905]
with B-LOC [0.13294288516044617, -0.4228581488132477]
accompanying B-LOC [0.01846952922642231, -0.27524736523628235]
upregulation B-LOC [0.06798894703388214, -0.23467350006103516]
of B-LOC [-0.015746502205729485, -0.382539838552475]
antigen B-LOC [0.41969171166419983, -0.523902177810669]
presentation B-LOC [0.23821713030338287, -0.36601969599723816]
machinery, B-LOC [0.058194953948259354, -0.4513583481311798]
mediated B-LOC [0.13218016922473907, -0.3355467617511749]
in B-LOC [-0.009370935149490833, -0.13340555131435394]
part B-LOC [0.20013971626758575, -0.0999351292848587]
through B-LOC [-0.11091823130846024, -0.2865813970565796]
double-stranded B-LOC [0.8747586011886597, -0.449868381023407]
RNA B-LOC [0.4990893304347992, -0.6556940078735352]
(dsRNA) B-LOC [0.3828628957271576, -0.7847777009010315]
induction. B-LOC [0.16762560606002808, -0.30169951915740967]
This B-LOC [0.05801809951663017, -0.21807058155536652]
is B-LOC [0.3408859372138977, -0.28226473927497864]
accompanied B-LOC [0.0744696706533432, -0.09266430139541626]
by B-LOC [0.049988213926553726, -0.06808647513389587]
suppression B-LOC [0.1971016675233841, 0.015333613380789757]
of B-LOC [-0.027320129796862602, -0.0724046602845192]
MYC B-LOC [0.060119498521089554, -0.21471348404884338]
signaling O [-0.03457973524928093, 0.10956316441297531]
and O [-0.051578398793935776, 0.22007785737514496]
an B-LOC [0.022196831181645393, -0.023467274382710457]
increase B-LOC [0.10340680181980133, -0.1124112606048584]
in B-LOC [0.07557018101215363, -0.17983710765838623]
the B-LOC [0.31085485219955444, -0.18817368149757385]
T B-LOC [0.2524571120738983, -0.29419732093811035]
cell B-LOC [-0.11509840935468674, -0.16224199533462524]
chemoattractant B-LOC [0.2127712219953537, -0.16382116079330444]
CCL5. B-LOC [0.2120284140110016, -0.31420207023620605]
Use B-LOC [2.204233169555664, -2.166430711746216]
of B-LOC [2.484889268875122, -1.8556764125823975]
this B-LOC [2.166269540786743, -1.9772179126739502]
combination B-LOC [2.4804608821868896, -2.3575546741485596]
treatment B-LOC [2.400482654571533, -2.3732450008392334]
schema B-LOC [2.9700100421905518, -2.3963541984558105]
in B-LOC [2.7147085666656494, -2.2262465953826904]
mouse B-LOC [2.7558724880218506, -2.29508638381958]
models B-LOC [3.1415984630584717, -2.498203992843628]
of B-LOC [2.536424160003662, -2.2048933506011963]
NSCLC B-LOC [2.0730159282684326, -1.8199414014816284]
reverses B-LOC [2.1790850162506104, -2.0000803470611572]
tumor B-LOC [2.535320281982422, -2.190619707107544]
immune B-LOC [2.399813413619995, -2.296722173690796]
evasion B-LOC [1.963152527809143, -1.6929500102996826]
and B-LOC [1.3654881715774536, -1.3605780601501465]
modulates B-LOC [2.6743152141571045, -2.1363446712493896]
T B-LOC [1.9994409084320068, -2.027686357498169]
cell B-LOC [1.3711175918579102, -1.5327626466751099]
exhaustion B-LOC [1.6239781379699707, -1.6524118185043335]
state B-LOC [1.7572903633117676, -1.5668003559112549]
towards B-LOC [1.86940598487854, -1.9759351015090942]
memory B-LOC [2.351381540298462, -2.1124346256256104]
and B-LOC [1.9293060302734375, -1.7518444061279297]
effector B-LOC [2.2614927291870117, -2.025980234146118]
T B-LOC [2.0680031776428223, -2.1426334381103516]
cell B-LOC [1.5510790348052979, -2.0334630012512207]
phenotypes. B-LOC [2.3697779178619385, -2.3644282817840576]
Key B-LOC [1.8009145259857178, -1.959930181503296]
correlative B-LOC [1.799748182296753, -1.6125352382659912]
science B-LOC [1.2225391864776611, -1.494455099105835]

metrics B-LOC [2.0519168376922607, -2.3100006580352783]
emerge B-LOC [1.905677080154419, -1.9572222232818604]
for B-LOC [2.323599100112915, -2.482698440551758]
an B-LOC [2.279486894607544, -2.6778934001922607]
upcoming B-LOC [2.29097580909729, -2.4305033683776855]
clinical B-LOC [2.4866089820861816, -2.446254014968872]
trial, B-LOC [2.363765001296997, -2.593994379043579]
testing B-LOC [2.1864264011383057, -2.5515389442443848]
enhancement B-LOC [2.3426461219787598, -2.2693159580230713]
of B-LOC [2.214628219604492, -2.3890974521636963]
immune B-LOC [2.004859447479248, -2.1221001148223877]
checkpoint B-LOC [2.2370498180389404, -2.3319785594940186]
therapy B-LOC [2.1622533798217773, -2.14778208732605]
for B-LOC [2.142923593521118, -2.027867078781128]
NSCLC. B-LOC [1.8576215505599976, -1.9093565940856934]

BACKGROUND B-LOC [1.4961724281311035, -2.0641286373138428]
Taxing B-LOC [2.415109157562256, -2.426260471343994]
sugar-sweetened B-LOC [2.4105472564697266, -2.3978488445281982]
beverages B-LOC [2.4750888347625732, -2.3359479904174805]
(SSBs) B-LOC [2.671300172805786, -2.768709897994995]
has B-LOC [2.5708224773406982, -2.3476297855377197]
been B-LOC [2.6260478496551514, -2.54068922996521]
proposed B-LOC [2.5175740718841553, -2.271129846572876]
in B-LOC [2.4669082164764404, -2.3217008113861084]
high-income B-LOC [2.5955333709716797, -2.7274272441864014]
countries B-LOC [2.6850597858428955, -2.5248897075653076]
to B-LOC [2.630460023880005, -2.2670886516571045]
reduce B-LOC [2.344952344894409, -2.3047993183135986]
obesity B-LOC [2.107919454574585, -2.3003337383270264]
and B-LOC [2.062145471572876, -1.9283101558685303]
type B-LOC [2.4027225971221924, -2.233090877532959]
2 B-LOC [2.1151254177093506, -2.214890241622925]
diabetes. B-LOC [2.3462088108062744, -2.2199654579162598]
We B-LOC [3.016197443008423, -3.1477508544921875]
sought B-LOC [3.2151618003845215, -3.23394513130188]
to B-LOC [3.4385008811950684, -3.3578433990478516]
estimate B-LOC [3.191699743270874, -3.584233522415161]
the B-LOC [3.3942973613739014, -3.475762128829956]
potential B-LOC [3.2195866107940674, -3.5947163105010986]
health B-LOC [3.1246352195739746, -3.480891704559326]
effects B-LOC [3.305694580078125, -3.5765445232391357]
of B-LOC [3.12288761138916, -3.287116765975952]
such B-LOC [3.1187195777893066, -3.3274309635162354]
a B-LOC [3.045642375946045, -3.345980167388916]
fiscal B-LOC [3.0605154037475586, -3.4983880519866943]
strategy B-LOC [3.06193470954895, -3.4405195713043213]
in B-LOC [3.2859432697296143, -3.235985279083252]
the B-LOC [3.277822732925415, -3.223008394241333]
middle-income B-LOC [3.0312042236328125, -3.441763162612915]
country B-LOC [3.0979435443878174, -3.4841787815093994]
of B-LOC [2.9315154552459717, -3.199340581893921]
India, B-LOC [2.6532747745513916, -3.5997154712677]
where B-LOC [2.7113611698150635, -3.4288341999053955]
there B-LOC [3.024446725845337, -3.3297946453094482]
is B-LOC [2.9950690269470215, -3.355104446411133]
heterogeneity B-LOC [2.8760344982147217, -3.4968302249908447]
in B-LOC [2.770968198776245, -3.3677051067352295]
SSB B-LOC [2.78437876701355, -2.897416830062866]
consumption, B-LOC [3.2291367053985596, -3.037461042404175]
patterns B-LOC [3.138414144515991, -3.3969814777374268]
of B-LOC [2.9037702083587646, -3.3143298625946045]
substitution B-LOC [2.9315030574798584, -3.2317326068878174]
between B-LOC [2.880859851837158, -3.4314091205596924]
SSBs B-LOC [2.721773147583008, -2.840003728866577]
and B-LOC [3.0285804271698, -3.391515016555786]
other B-LOC [3.1998813152313232, -3.423953056335449]
beverages B-LOC [3.048652172088623, -3.3546228408813477]
after B-LOC [2.862179756164551, -3.19632887840271]
tax B-LOC [2.8404715061187744, -3.04276442527771]
increases, B-LOC [2.6669414043426514, -3.1171011924743652]
and B-LOC [2.926097869873047, -3.2197272777557373]
vast B-LOC [3.196169137954712, -3.5282809734344482]
differences B-LOC [3.011620044708252, -3.4387917518615723]
in B-LOC [2.8588430881500244, -3.3924410343170166]
chronic B-LOC [3.0863382816314697, -3.4597179889678955]
disease B-LOC [3.327683687210083, -3.4591729640960693]
risk B-LOC [3.1507551670074463, -3.4266514778137207]
within B-LOC [3.205970525741577, -3.1914918422698975]
the B-LOC [2.925682544708252, -3.097478151321411]
population. B-LOC [3.116504430770874, -3.5246479511260986]
METHODS B-LOC [1.2883944511413574, -2.11149001121521]
AND B-LOC [1.858254313468933, -2.5481417179107666]
FINDINGS B-LOC [1.4208166599273682, -1.7628488540649414]
Using B-LOC [1.584972620010376, -2.4074952602386475]
consumption B-LOC [2.062483549118042, -2.2404425144195557]
and B-LOC [2.3425543308258057, -2.7522451877593994]
price B-LOC [2.25146222114563, -2.601571798324585]
variations B-LOC [2.0553770065307617, -2.768569231033325]
data B-LOC [2.1485612392425537, -2.384056806564331]
from B-LOC [2.2569587230682373, -2.518775224685669]
a B-LOC [2.32356858253479, -2.2754509449005127]
nationally B-LOC [2.4539318084716797, -2.7383785247802734]
representative B-LOC [2.3340811729431152, -2.6793363094329834]
survey B-LOC [2.210040807723999, -2.4154369831085205]
of B-LOC [2.328972578048706, -2.373169183731079]
100,855 B-LOC [2.6789517402648926, -2.5024847984313965]

Indian B-LOC [1.2622541189193726, -2.149947166442871]
households, B-LOC [1.7172585725784302, -1.9857505559921265]
we B-LOC [1.4824457168579102, -1.8192071914672852]
first B-LOC [1.3391021490097046, -1.699165940284729]
calculated B-LOC [1.8969659805297852, -2.3568997383117676]
how B-LOC [1.5875071287155151, -2.187892198562622]
changes B-LOC [1.6672338247299194, -2.2366139888763428]
in B-LOC [1.4578393697738647, -2.1869828701019287]
SSB B-LOC [1.4138474464416504, -1.5487489700317383]
price B-LOC [1.6685543060302734, -1.876939058303833]
alter B-LOC [1.5116982460021973, -2.2259035110473633]
per B-LOC [1.5232954025268555, -2.1444451808929443]
capita B-LOC [1.6731635332107544, -2.0855743885040283]
consumption B-LOC [1.5817855596542358, -1.784362554550171]
of B-LOC [1.5175215005874634, -1.972254753112793]
SSBs B-LOC [1.3909950256347656, -1.5921545028686523]
and B-LOC [1.9157915115356445, -2.2775185108184814]
substitution B-LOC [1.6159467697143555, -1.8736259937286377]
with B-LOC [1.3731038570404053, -2.2220540046691895]
other B-LOC [1.6113178730010986, -2.01591157913208]
beverages. B-LOC [1.5188500881195068, -1.890432357788086]
We B-LOC [1.5675768852233887, -1.9390536546707153]
then B-LOC [1.7407114505767822, -1.7948381900787354]
incorporated B-LOC [1.8216736316680908, -2.2474844455718994]
SSB B-LOC [1.645462155342102, -1.7646517753601074]
sales B-LOC [1.511199712753296, -1.892886757850647]
trends, B-LOC [1.7347863912582397, -2.0231029987335205]
body B-LOC [1.418341040611267, -1.831555724143982]
mass B-LOC [1.3993949890136719, -1.8107495307922363]
index B-LOC [1.7446424961090088, -2.192464828491211]
(BMI), B-LOC [2.255537986755371, -2.3934824466705322]
and B-LOC [1.8914333581924438, -2.441138982772827]
diabetes B-LOC [1.5482797622680664, -1.991406798362732]
incidence B-LOC [1.6289960145950317, -2.0030252933502197]
data B-LOC [1.8354521989822388, -2.265859365463257]
stratified B-LOC [2.2495431900024414, -2.471994161605835]
by B-LOC [1.6951440572738647, -2.1969358921051025]
age, B-LOC [1.9458589553833008, -2.081448793411255]
sex, B-LOC [1.8267908096313477, -2.093334436416626]
income, B-LOC [1.561452865600586, -1.9248597621917725]
and B-LOC [1.9308278560638428, -2.4489362239837646]
urban/rural B-LOC [1.5638562440872192, -2.032076120376587]
residence B-LOC [1.4391260147094727, -1.8834556341171265]
into B-LOC [1.9479652643203735, -2.207634449005127]
a B-LOC [1.8910362720489502, -2.193765878677368]
validated B-LOC [1.991440773010254, -2.484226703643799]
microsimulation B-LOC [2.0711143016815186, -2.3227436542510986]
of B-LOC [1.8951534032821655, -2.385637044906616]
caloric B-LOC [1.8671964406967163, -2.2210681438446045]
consumption, B-LOC [1.314441204071045, -1.4032946825027466]
glycemic B-LOC [1.8179705142974854, -1.9847122430801392]
load, B-LOC [1.3676307201385498, -1.771033763885498]
overweight/obesity B-LOC [1.6852586269378662, -2.1032683849334717]
prevalence, B-LOC [1.631722092628479, -1.8725416660308838]
and B-LOC [1.8240805864334106, -2.2555670738220215]
type B-LOC [1.71943998336792, -2.0412943363189697]
2 B-LOC [1.7564318180084229, -2.1707043647766113]
diabetes B-LOC [1.4127110242843628, -1.9204552173614502]
incidence B-LOC [1.6624654531478882, -2.0154881477355957]
among B-LOC [1.8487586975097656, -2.2548329830169678]
Indian B-LOC [1.445968747138977, -2.277879238128662]
subpopulations B-LOC [2.079475164413452, -2.318114995956421]
facing B-LOC [1.8103923797607422, -2.128817558288574]
a B-LOC [1.8093475103378296, -2.1749517917633057]
20% B-LOC [1.892345666885376, -2.0746283531188965]
SSB B-LOC [1.3534588813781738, -1.5454516410827637]
excise B-LOC [1.9935988187789917, -2.070253372192383]
tax. B-LOC [1.523078441619873, -1.9553041458129883]
The B-LOC [0.7515223622322083, -0.8239201903343201]
20% B-LOC [0.7857699990272522, -0.7476909756660461]
SSB B-LOC [0.6737992167472839, -0.871982991695404]
tax B-LOC [0.5289320349693298, -0.7112576365470886]
was B-LOC [0.574779748916626, -0.7153481841087341]
anticipated B-LOC [0.864171028137207, -0.8811687231063843]
to B-LOC [0.36792922019958496, -0.6606733798980713]

reduce O [-1.0679340362548828, 0.962239682674408]
overweight O [-1.0321440696716309, 1.021505355834961]
and O [-1.1336429119110107, 0.7915827631950378]
obesity O [-0.996130645275116, 0.9898385405540466]
prevalence O [-1.026833176612854, 0.9779285788536072]
by O [-1.1563462018966675, 0.9547975659370422]
3.0% O [-1.1015069484710693, 1.199257254600525]
(95% O [-1.1219921112060547, 0.7655916213989258]
CI O [-1.093003511428833, 0.8644992709159851]
1.6%-5.9%) O [-1.0715088844299316, 0.9849002957344055]
and O [-1.254378080368042, 0.9709195494651794]
type O [-1.1503407955169678, 1.2039132118225098]
2 O [-1.1603262424468994, 1.1086485385894775]
diabetes O [-0.8982433676719666, 1.0421974658966064]
incidence O [-1.0516035556793213, 0.9979239702224731]
by O [-1.166449785232544, 1.021415114402771]
1.6% O [-1.0255110263824463, 1.0065522193908691]
(95% O [-1.0589604377746582, 0.7032219171524048]
CI O [-1.185096025466919, 0.9805545210838318]
1.2%-1.9%) O [-1.0886869430541992, 0.9884434938430786]
among O [-1.052129864692688, 1.0199754238128662]
various O [-1.049780249595642, 0.8248683214187622]
Indian O [-0.8233408331871033, 0.6414597034454346]
subpopulations O [-0.8342370390892029, 0.9891480207443237]
over O [-0.8136737942695618, 0.7080926895141602]
the O [-0.8507428765296936, 0.7017528414726257]
period O [-0.8094100952148438, 0.34137946367263794]
2014-2023, O [-0.7870097756385803, 0.7852132320404053]
if O [-0.8289254307746887, 0.719243586063385]
SSB O [-0.842663586139679, 0.7781087756156921]
consumption O [-0.6230932474136353, 0.8578110933303833]
continued O [-0.6698787808418274, 0.6961010098457336]
to O [-0.5483402013778687, 0.7330003976821899]
increase O [-0.788885772228241, 0.7950478196144104]
linearly O [-0.7202215790748596, 0.6479213833808899]
in O [-0.715316116809845, 0.5665979981422424]
accordance O [-0.6596089601516724, 0.7472377419471741]
with O [-0.4792654812335968, 0.4350009858608246]
secular O [-0.5784994959831238, 0.3319235146045685]
trends. O [-0.5940872430801392, 0.46739885210990906]
However, O [-0.688080370426178, 0.6164938807487488]
acceleration O [-0.5724377036094666, 0.32275187969207764]
in O [-0.5785762667655945, 0.3173847496509552]
SSB O [-0.4346151351928711, 0.473111093044281]
consumption O [-0.3767687678337097, 0.6925647854804993]
trends O [-0.5790023803710938, 0.624495804309845]
consistent O [-0.5423958897590637, 0.535728394985199]
with O [-0.4640125036239624, 0.32011130452156067]
industry O [-0.41561460494995117, 0.3757355809211731]
marketing O [-0.3387949466705322, 0.5121615529060364]
models O [-0.427946537733078, 0.4537568986415863]
would O [-0.48378419876098633, 0.3553498685359955]
be O [-0.4942586421966553, 0.21077540516853333]
expected O [-0.4298635721206665, 0.3353866934776306]
to O [-0.5199886560440063, 0.4431335926055908]
increase O [-0.6033279299736023, 0.42687687277793884]
the O [-0.6769307255744934, 0.4739495515823364]
impact O [-0.6573619246482849, 0.4581265151500702]
efficacy O [-0.8149218559265137, 0.5607727766036987]
of O [-0.7560542821884155, 0.48374858498573303]
taxation, O [-0.5895374417304993, 0.6386062502861023]
averting O [-0.6777016520500183, 0.7459858655929565]
4.2% O [-0.5575497150421143, 0.6508051753044128]
of O [-0.714913010597229, 0.49675634503364563]
prevalent O [-0.7533757090568542, 0.435439795255661]

overweight/obesity O [-0.1931810826063156, 0.09032726287841797]
(95% O [-0.3383141756057739, 0.12031835317611694]
CI O [-0.5018368363380432, 0.27479463815689087]
2.5-10.0%) O [-0.3958064913749695, 0.43070653080940247]
and O [-0.30384621024131775, 0.19525021314620972]
2.5% O [-0.27455225586891174, 0.35889020562171936]
(95% O [-0.27786827087402344, -0.06845219433307648]
CI O [-0.423291951417923, 0.22355380654335022]
1.0-2.8%) O [-0.3167421519756317, 0.28305599093437195]
of O [-0.24783261120319366, 0.23986150324344635]
incident O [-0.3080255687236786, 0.1250809282064438]
type O [-0.14921675622463226, 0.28393757343292236]
2 O [-0.07842633128166199, 0.057350460439920425]
diabetes O [-0.21993669867515564, 0.2392948567867279]
from O [-0.17167603969573975, 0.011927200481295586]
2014-2023. O [-0.14377833902835846, 0.08964177221059799]
Given B-LOC [1.0286742448806763, -0.8369857668876648]
current B-LOC [1.0506694316864014, -1.0365698337554932]
consumption B-LOC [0.8472673296928406, -0.6607715487480164]
and B-LOC [1.009230375289917, -1.064273476600647]
BMI B-LOC [1.0241999626159668, -0.9590044617652893]
distributions, B-LOC [0.9836252331733704, -0.8052614331245422]
our B-LOC [0.7500981688499451, -0.7820802330970764]
results B-LOC [0.996359646320343, -0.8380454778671265]
suggest B-LOC [1.0975714921951294, -0.7705104947090149]
the B-LOC [1.307760238647461, -0.9650372862815857]
largest B-LOC [1.2648552656173706, -1.136625051498413]
relative B-LOC [1.2710540294647217, -1.3002254962921143]
effect B-LOC [0.9907544851303101, -1.1896817684173584]
would B-LOC [1.050075888633728, -1.0938239097595215]
be B-LOC [1.327251672744751, -1.3252854347229004]
expected B-LOC [1.098694086074829, -1.2684839963912964]
among B-LOC [1.0420687198638916, -1.1159182786941528]
young B-LOC [1.1766623258590698, -0.9528660178184509]
rural B-LOC [1.031955361366272, -1.1161954402923584]
men, B-LOC [0.9962231516838074, -1.0020818710327148]
refuting B-LOC [1.1470887660980225, -0.8124163746833801]
our B-LOC [0.7753421664237976, -0.6824400424957275]
a B-LOC [0.961439847946167, -0.7255851626396179]
priori B-LOC [1.2219057083129883, -0.9040729403495789]
hypothesis B-LOC [0.825308084487915, -0.8104627728462219]
that B-LOC [0.8220295310020447, -0.9890653491020203]
urban B-LOC [0.9679054021835327, -1.0379856824874878]
populations B-LOC [1.0772590637207031, -0.9528955817222595]
would B-LOC [0.922366201877594, -0.9911124110221863]
be B-LOC [0.7937747240066528, -1.0215785503387451]
isolated B-LOC [1.1130988597869873, -1.2236214876174927]
beneficiaries B-LOC [1.2328424453735352, -1.05243980884552]
of B-LOC [1.0022656917572021, -1.0823330879211426]
SSB B-LOC [0.9156846404075623, -0.8975969552993774]
taxation. B-LOC [0.9149994254112244, -0.9511924386024475]
Key B-LOC [0.888841450214386, -0.9631435871124268]
limitations B-LOC [1.049018144607544, -1.133643627166748]
of B-LOC [1.0634148120880127, -1.1581315994262695]
this B-LOC [0.8856438994407654, -1.0939362049102783]
estimation B-LOC [1.0701110363006592, -1.0531423091888428]
approach B-LOC [0.8478527069091797, -1.1676920652389526]
include B-LOC [0.9201135635375977, -0.7416621446609497]
the B-LOC [0.7306444048881531, -0.7191044688224792]
assumption B-LOC [0.5475709438323975, -0.6517852544784546]
that B-LOC [0.38719066977500916, -0.6705760359764099]
consumer B-LOC [0.45074185729026794, -0.6287752985954285]
expenditure B-LOC [0.47429946064949036, -0.6188066005706787]
behavior B-LOC [0.4685572683811188, -0.7013633847236633]
from B-LOC [0.5930304527282715, -0.748304009437561]
prior B-LOC [0.40620216727256775, -0.8316078782081604]
years, B-LOC [0.6375241279602051, -0.7688716053962708]
captured B-LOC [0.53312748670578, -0.7906634211540222]
in B-LOC [0.4949248135089874, -0.7649030685424805]
price B-LOC [0.5897528529167175, -0.6478402614593506]
elasticities, B-LOC [0.8071172833442688, -0.8547491431236267]

will B-LOC [1.7879414558410645, -2.51967453956604]
reflect B-LOC [1.9942553043365479, -2.5115020275115967]
future B-LOC [2.312530994415283, -2.7985503673553467]
behavior B-LOC [2.2530620098114014, -2.93735671043396]
among B-LOC [2.241786241531372, -2.946812868118286]
consumers, B-LOC [2.4012885093688965, -2.91571307182312]
and B-LOC [2.139812469482422, -2.6525936126708984]
potential B-LOC [2.430104970932007, -2.82593035697937]
underreporting B-LOC [2.611631155014038, -2.7850520610809326]
of B-LOC [2.232459306716919, -2.8684675693511963]
consumption B-LOC [2.269108533859253, -2.70827317237854]
in B-LOC [2.2497973442077637, -2.7233307361602783]
dietary B-LOC [2.339447498321533, -2.843895196914673]
recall B-LOC [2.0799598693847656, -2.6846282482147217]
data B-LOC [2.336444616317749, -2.8764708042144775]
used B-LOC [2.618957281112671, -2.9536826610565186]
to B-LOC [2.76265811920166, -2.857088088989258]
inform B-LOC [2.5227456092834473, -2.864000082015991]
our B-LOC [1.9794639348983765, -2.622309923171997]
calculations. B-LOC [2.4040238857269287, -3.0647788047790527]
CONCLUSION O [-1.1266741752624512, 1.1121835708618164]
Sustained O [-0.9979978799819946, 1.002565622329712]
SSB O [-0.8300991654396057, 1.035309076309204]
taxation O [-0.8901888728141785, 0.9552372694015503]
at O [-1.1022777557373047, 1.151487946510315]
a O [-1.1220266819000244, 1.0463576316833496]
high O [-0.9680010080337524, 0.9300703406333923]
tax O [-0.8944515585899353, 0.8914134502410889]
rate O [-1.0129436254501343, 0.854213297367096]
could O [-0.9564234614372253, 0.7834764122962952]
mitigate O [-0.8828973174095154, 1.1763356924057007]
rising O [-1.0163233280181885, 0.7425161004066467]
obesity O [-1.0537703037261963, 1.0282058715820312]
and O [-1.0494920015335083, 0.9887377619743347]
type O [-1.0878219604492188, 1.1105122566223145]
2 O [-1.0605584383010864, 0.9944037199020386]
diabetes O [-0.8234506249427795, 0.7534335255622864]
in O [-0.9448238015174866, 0.7928418517112732]
India O [-0.7338904738426208, 0.46531617641448975]
among O [-0.9470985531806946, 0.8725895881652832]
both O [-0.879330039024353, 0.8046011328697205]
urban O [-0.7879831790924072, 0.5863298773765564]
and O [-0.6908666491508484, 0.543120801448822]
rural O [-0.51804518699646, 0.32219842076301575]
subpopulations. O [-0.6552106142044067, 0.5445813536643982]

Maintaining B-LOC [2.1016623973846436, -2.387153148651123]
hematopoietic B-LOC [2.3525092601776123, -2.7680978775024414]
stem B-LOC [2.2168776988983154, -2.5579593181610107]
cell B-LOC [1.9916250705718994, -2.4681036472320557]
(HSC) B-LOC [2.5632402896881104, -2.725491762161255]
quiescence B-LOC [2.5706169605255127, -2.383533239364624]
is B-LOC [2.490473508834839, -2.331425189971924]
a B-LOC [2.421534776687622, -2.4237558841705322]
critical B-LOC [2.3182268142700195, -2.377805471420288]
property B-LOC [2.023226022720337, -2.323621988296509]
for B-LOC [2.187500238418579, -2.3950798511505127]
the B-LOC [2.0949952602386475, -2.264216899871826]
life-long B-LOC [2.5307528972625732, -2.6644680500030518]
generation B-LOC [2.2913997173309326, -2.4549081325531006]
of B-LOC [2.1662118434906006, -2.4895925521850586]
blood B-LOC [1.7085627317428589, -2.4299581050872803]
cells. B-LOC [2.2174148559570312, -2.4313628673553467]
Approximately B-LOC [1.8918201923370361, -1.6887848377227783]
75% B-LOC [2.225710153579712, -1.6590102910995483]
of B-LOC [1.9299726486206055, -1.875126838684082]
cells B-LOC [1.9378533363342285, -1.8769001960754395]
in B-LOC [1.8666248321533203, -1.479865550994873]
a B-LOC [1.969264030456543, -1.7758803367614746]
highly B-LOC [2.107541799545288, -1.970151662826538]
enriched B-LOC [2.0544192790985107, -1.9134430885314941]
long-term B-LOC [2.234928846359253, -2.0354130268096924]
repopulating B-LOC [2.1497581005096436, -1.9814350605010986]
HSC B-LOC [2.023555040359497, -2.2689807415008545]
(LT-HSC) B-LOC [2.037369966506958, -1.9005115032196045]
pool B-LOC [1.9289382696151733, -1.8009815216064453]
(Lin(-)Sca1(+)c-Kit(hi)CD150(+)CD48(-)) B-LOC [2.036513090133667, -1.7618980407714844]
are B-LOC [2.214604139328003, -1.7723573446273804]
quiescent, B-LOC [2.729046583175659, -2.1195902824401855]
with B-LOC [1.8588117361068726, -1.6546998023986816]
only B-LOC [1.9679126739501953, -1.5825278759002686]
a B-LOC [2.0009140968322754, -1.7611768245697021]
small B-LOC [1.8167786598205566, -1.47317373752594]
percentage B-LOC [2.006464958190918, -1.8442041873931885]
of B-LOC [1.5774644613265991, -1.8192601203918457]
the B-LOC [1.7868176698684692, -1.714871883392334]
LT-HSCs B-LOC [1.4926196336746216, -1.6907988786697388]
in B-LOC [1.7426738739013672, -1.6626904010772705]
cycle. B-LOC [1.6586534976959229, -1.7222108840942383]
Transcription B-LOC [0.5171432495117188, -1.102484941482544]
factor B-LOC [0.48102617263793945, -1.0286284685134888]
GATA-3 B-LOC [0.22435106337070465, -0.8530338406562805]
is B-LOC [1.1784015893936157, -1.0935044288635254]
known B-LOC [1.1280081272125244, -1.266674280166626]
to B-LOC [1.3403067588806152, -1.2809633016586304]
be B-LOC [0.863206684589386, -1.1533015966415405]
vital B-LOC [0.5907933115959167, -1.0217851400375366]
for B-LOC [0.7453805208206177, -0.97725510597229]
the B-LOC [0.5877920985221863, -0.8231566548347473]

development B-LOC [0.5725584030151367, -1.174156665802002]
of B-LOC [0.7445109486579895, -1.314515471458435]
T B-LOC [0.8764881491661072, -1.4594781398773193]
cells B-LOC [0.6411417126655579, -1.260481357574463]
at B-LOC [0.8516133427619934, -1.2383861541748047]
multiple B-LOC [1.0415555238723755, -1.6532459259033203]
stages B-LOC [1.008062481880188, -1.6702125072479248]
in B-LOC [0.9324427843093872, -1.391500473022461]
the B-LOC [0.9396576285362244, -1.1717859506607056]
thymus B-LOC [1.0565218925476074, -1.538627028465271]
and B-LOC [1.045832872390747, -1.5694406032562256]
for B-LOC [0.7250996828079224, -1.6765046119689941]
Th2 B-LOC [0.725498616695404, -1.3000901937484741]
differentiation B-LOC [0.7437556982040405, -1.3645459413528442]
in B-LOC [0.989040195941925, -1.5414479970932007]
the B-LOC [1.0279606580734253, -1.3195425271987915]
peripheral B-LOC [1.2694653272628784, -1.8217025995254517]
organs. B-LOC [0.860637366771698, -1.5093448162078857]
Although B-LOC [2.2964413166046143, -2.689896821975708]
it B-LOC [2.088467836380005, -2.5073907375335693]
is B-LOC [2.393019437789917, -2.6405277252197266]
well B-LOC [2.5014231204986572, -2.739664316177368]
documented B-LOC [2.217351198196411, -2.5068483352661133]
that B-LOC [1.9543944597244263, -2.6923768520355225]
GATA-3 B-LOC [0.9950557351112366, -1.9318293333053589]
is B-LOC [2.123873472213745, -2.561262369155884]
expressed B-LOC [1.737794041633606, -2.2469112873077393]
in B-LOC [1.5780092477798462, -2.354520797729492]
HSCs, B-LOC [1.7019643783569336, -2.586191415786743]
a B-LOC [2.296308755874634, -3.128995656967163]
role B-LOC [1.7671406269073486, -2.813075304031372]
for B-LOC [2.041088342666626, -2.9231793880462646]
GATA-3 B-LOC [1.0506558418273926, -2.034670114517212]
in B-LOC [1.73501455783844, -2.645789861679077]
any B-LOC [2.132230758666992, -2.7259390354156494]
prethymic B-LOC [1.7601115703582764, -2.583527088165283]
progenitor B-LOC [1.6687331199645996, -2.4766457080841064]
cell B-LOC [1.3778879642486572, -2.299365997314453]
has B-LOC [2.878981828689575, -3.052337408065796]
not B-LOC [2.8585031032562256, -3.033669948577881]
been B-LOC [2.6905643939971924, -3.290796995162964]
established. B-LOC [2.507606267929077, -3.2235584259033203]
In O [-0.3266713321208954, 0.39838913083076477]
the O [-0.15232013165950775, 0.5235400795936584]
present O [-0.08012127876281738, 0.4784131348133087]
study, O [-0.2064083218574524, 0.3704111874103546]
we O [-0.4746668338775635, 0.3687644898891449]
show O [-0.4596734642982483, 0.5866307020187378]
that O [-0.6317369341850281, 0.5557324886322021]
Gata3-null O [-0.45055514574050903, 0.3745400011539459]
mutant O [-0.5266938805580139, 0.47052663564682007]
mice O [-0.6200398802757263, 0.47845619916915894]
generate O [-0.39642027020454407, 0.5675823092460632]
fewer O [-0.37942010164260864, 0.6643827557563782]
LT-HSCs O [-0.5052489638328552, 0.5561882257461548]
and O [-0.5813099145889282, 0.9206464886665344]
that O [-0.5703830718994141, 0.6908016204833984]
fewer O [-0.36724770069122314, 0.6523528695106506]
Gata3-null O [-0.4162340462207794, 0.4647330343723297]
LT-HSCs O [-0.4426744282245636, 0.49622321128845215]
are O [-0.38582074642181396, 0.6136954426765442]
in O [-0.40110114216804504, 0.34030696749687195]
cycle. O [-0.41933390498161316, 0.5144563317298889]
Furthermore, O [-0.569644033908844, 0.5611080527305603]
Gata3 O [-0.32811883091926575, 0.3093644082546234]
mutant O [-0.5603604316711426, 0.3524889647960663]
hematopoietic O [-0.4938034117221832, 0.2874438464641571]
progenitor O [-0.3943301737308502, 0.16177725791931152]
cells O [-0.43104150891304016, 0.34382203221321106]
fail O [-0.2248145043849945, 0.2950722873210907]
to O [-0.1405813992023468, 0.3826342821121216]
be O [-0.34332039952278137, 0.2304742932319641]

recruited O [-0.2844231426715851, 0.26165300607681274]
into O [-0.6651120781898499, 0.3626239001750946]
an O [-0.6874855160713196, 0.3238176703453064]
increased O [-0.5254499912261963, 0.416258305311203]
cycling O [-0.453157901763916, 0.278584748506546]
state O [-0.5481705069541931, 0.38371917605400085]
after O [-0.47233447432518005, 0.33971038460731506]
5-fluorouracil-induced O [-0.28263339400291443, 0.2707192301750183]
myelosuppression. O [-0.6552512049674988, 0.5326341986656189]
Therefore, O [-0.25730812549591064, 0.5802841782569885]
GATA-3 O [-0.4001801908016205, 0.0005907691665925086]
is O [-0.14308251440525055, 0.19332255423069]
required O [-0.28442656993865967, 0.2230963408946991]
for O [-0.38783684372901917, 0.18661774694919586]
the O [-0.2928358018398285, 0.2920168936252594]
maintenance O [-0.16359549760818481, 0.3284183442592621]
of O [-0.25911763310432434, 0.2545298635959625]
a O [-0.23910173773765564, 0.14776116609573364]
normal O [-0.23722749948501587, 0.08242841809988022]
number O [-0.10285309702157974, 0.07441726326942444]
of O [-0.16430522501468658, 0.018233252689242363]
LT-HSCs O [-0.27783897519111633, -0.018643097952008247]
and O [-0.3336086571216583, 0.10294437408447266]
for O [-0.33294081687927246, -0.03753418102860451]
their O [-0.07216037064790726, 0.053149864077568054]
entry O [-0.20990069210529327, 0.06743055582046509]
into O [-0.2620624601840973, 0.09313369542360306]
the O [-0.20559708774089813, 0.21566936373710632]
cell O [-0.42410171031951904, 0.01732592098414898]
cycle. O [-0.3866264522075653, -0.008384911343455315]

CONTEXT B-LOC [1.3884061574935913, -1.7510037422180176]
Antibody-based B-LOC [2.510768175125122, -2.350642442703247]
induction B-LOC [1.8511329889297485, -2.217421054840088]
therapy B-LOC [2.0503311157226562, -2.138636827468872]
plus B-LOC [2.1735527515411377, -1.9731340408325195]
calcineurin B-LOC [2.1290109157562256, -1.9852259159088135]
inhibitors B-LOC [2.3799922466278076, -2.1768860816955566]
(CNIs) B-LOC [2.297377824783325, -2.3596508502960205]
reduce B-LOC [1.9563300609588623, -2.0362961292266846]
acute B-LOC [2.0724809169769287, -2.2950384616851807]
rejection B-LOC [2.0890984535217285, -2.4299159049987793]
rates B-LOC [2.319082498550415, -2.359975814819336]
in B-LOC [2.029920816421509, -2.3547840118408203]
kidney B-LOC [2.1617276668548584, -2.6081340312957764]
recipients; B-LOC [1.955926775932312, -2.088840961456299]
however, B-LOC [2.6007893085479736, -2.306175947189331]
opportunistic B-LOC [3.0548696517944336, -2.638817548751831]
infections B-LOC [3.330845355987549, -2.6379761695861816]
and B-LOC [2.822167158126831, -2.3848769664764404]
toxic B-LOC [3.057884931564331, -2.8574378490448]
CNI B-LOC [2.331676721572876, -2.267535448074341]
effects B-LOC [3.0343306064605713, -2.6380250453948975]
remain B-LOC [3.0991098880767822, -2.5176942348480225]
challenging. B-LOC [3.105668306350708, -2.9553487300872803]
Reportedly, B-LOC [3.262308359146118, -3.0299391746520996]
mesenchymal B-LOC [3.197136640548706, -3.0872528553009033]
stem B-LOC [3.0701940059661865, -3.2711074352264404]
cells B-LOC [3.1178853511810303, -3.27116322517395]
(MSCs) B-LOC [3.2015812397003174, -2.893876791000366]
have B-LOC [3.0936315059661865, -2.7777140140533447]
successfully B-LOC [3.173692464828491, -3.0737273693084717]
treated B-LOC [3.3639779090881348, -3.1083786487579346]
graft-vs-host B-LOC [3.4508273601531982, -3.0145623683929443]
disease. B-LOC [3.264816999435425, -3.1977756023406982]
OBJECTIVE B-LOC [3.278778076171875, -2.991131544113159]
To B-LOC [3.336747169494629, -3.019411325454712]
assess B-LOC [3.526571750640869, -3.042109727859497]
autologous B-LOC [3.3867251873016357, -3.1628386974334717]
MSCs B-LOC [3.5057060718536377, -3.034353494644165]
as B-LOC [3.3756043910980225, -3.0502922534942627]
replacement B-LOC [3.484682321548462, -3.3892903327941895]
of B-LOC [3.1120951175689697, -2.8426194190979004]
antibody B-LOC [3.4780759811401367, -3.1033387184143066]
induction B-LOC [3.4566214084625244, -3.15032696723938]
for B-LOC [3.3697073459625244, -2.7366397380828857]
patients B-LOC [3.5338025093078613, -2.867368698120117]
with B-LOC [3.3136515617370605, -2.83501935005188]
end-stage B-LOC [3.5522847175598145, -3.289842367172241]
renal B-LOC [3.293941020965576, -2.9341061115264893]
disease B-LOC [3.5004868507385254, -2.869455575942993]
who B-LOC [3.2238106727600098, -2.8490474224090576]
undergo B-LOC [3.3620364665985107, -2.828411340713501]
ABO-compatible, B-LOC [3.4418246746063232, -2.999924898147583]
cross-match-negative B-LOC [3.3013012409210205, -3.030825614929199]

kidney B-LOC [2.791741132736206, -3.0967609882354736]
transplants B-LOC [3.3836300373077393, -3.2733957767486572]
from B-LOC [3.2236530780792236, -2.9534497261047363]
a B-LOC [3.021989107131958, -2.825164794921875]
living-related B-LOC [3.1365301609039307, -3.147077798843384]
donor. B-LOC [2.9180190563201904, -2.9901649951934814]
DESIGN, B-LOC [3.2786364555358887, -3.1313891410827637]
SETTING, B-LOC [2.73046612739563, -3.082258462905884]
AND B-LOC [3.1387393474578857, -3.270005464553833]
PATIENTS B-LOC [3.1326494216918945, -3.1774964332580566]
One B-LOC [3.2074134349823, -2.91719651222229]
hundred B-LOC [3.2867591381073, -2.8808820247650146]
fifty-nine B-LOC [3.3541183471679688, -2.8317782878875732]
patients B-LOC [3.5413315296173096, -3.0024917125701904]
were B-LOC [3.3289639949798584, -2.727001667022705]
enrolled B-LOC [3.3993990421295166, -2.863342046737671]
in B-LOC [3.160010814666748, -2.588087797164917]
this B-LOC [3.118318557739258, -2.6988346576690674]
single-site, B-LOC [3.1432318687438965, -2.5639350414276123]
prospective, B-LOC [3.1084823608398438, -2.9098222255706787]
open-label, B-LOC [3.308936357498169, -2.493955135345459]
randomized B-LOC [3.3361411094665527, -2.9370431900024414]
study B-LOC [3.3382067680358887, -3.1335856914520264]
from B-LOC [3.4379422664642334, -2.7748076915740967]
February B-LOC [3.3343355655670166, -2.6441619396209717]
2008-May B-LOC [3.181363582611084, -2.7644307613372803]
2009, B-LOC [3.131183385848999, -2.9906864166259766]
when B-LOC [3.125354290008545, -2.7989864349365234]
recruitment B-LOC [3.3962326049804688, -3.037050485610962]
was B-LOC [3.2517120838165283, -2.505312919616699]
completed. B-LOC [3.4917666912078857, -2.7691750526428223]
INTERVENTION B-LOC [2.748074769973755, -2.728241205215454]
Patients B-LOC [3.528947353363037, -2.9588546752929688]
were B-LOC [3.184401512145996, -2.6754777431488037]
inoculated B-LOC [3.4120328426361084, -2.8912582397460938]
with B-LOC [3.331695795059204, -2.749389886856079]
marrow-derived B-LOC [3.224884033203125, -2.623995542526245]
autologous B-LOC [2.9424612522125244, -3.1073546409606934]
MSC B-LOC [3.2948038578033447, -2.6649630069732666]
(1-2 B-LOC [3.4044666290283203, -2.7910702228546143]
x B-LOC [3.109553813934326, -2.9100005626678467]
10(6)/kg) B-LOC [3.072338342666626, -2.939422845840454]
at B-LOC [3.1689178943634033, -2.6084980964660645]
kidney B-LOC [3.2791941165924072, -3.0424230098724365]
reperfusion B-LOC [3.184688091278076, -2.5900776386260986]
and B-LOC [2.980219602584839, -2.8944785594940186]
two B-LOC [3.2202303409576416, -2.9642937183380127]
weeks B-LOC [3.393475294113159, -2.7468655109405518]
later. B-LOC [2.948270559310913, -2.9269864559173584]
Fifty-three B-LOC [3.1408565044403076, -2.8120949268341064]
patients B-LOC [2.9142932891845703, -2.8947272300720215]
received B-LOC [2.739391565322876, -2.890134572982788]
standard-dose B-LOC [3.034090042114258, -3.044025182723999]
and B-LOC [2.364659309387207, -2.9341375827789307]
52 B-LOC [2.941467523574829, -2.9428088665008545]
patients B-LOC [2.71464467048645, -2.965131998062134]

received B-LOC [2.95742130279541, -3.1905746459960938]
low-dose B-LOC [3.2238640785217285, -3.16640567779541]
CNIs B-LOC [3.0130507946014404, -3.3160367012023926]
(80% B-LOC [3.3580636978149414, -2.9961018562316895]
of B-LOC [2.9190096855163574, -3.1764044761657715]
standard); B-LOC [3.1878859996795654, -3.205825090408325]
51 B-LOC [3.4264075756073, -3.2773804664611816]
patients B-LOC [3.4893147945404053, -3.1113836765289307]
in B-LOC [3.489121437072754, -3.116258382797241]
the B-LOC [3.4734959602355957, -3.0352942943573]
control B-LOC [3.3972909450531006, -3.255551815032959]
group B-LOC [3.329212188720703, -3.235804796218872]
received B-LOC [3.3301990032196045, -3.1929824352264404]
anti-IL-2 B-LOC [3.283329486846924, -3.0590741634368896]
receptor B-LOC [3.279984712600708, -3.1849968433380127]
antibody B-LOC [3.1821682453155518, -3.0547902584075928]
plus B-LOC [3.408463478088379, -3.256338596343994]
standard-dose B-LOC [3.3105204105377197, -3.3911378383636475]
CNIs. B-LOC [3.236902952194214, -3.3781473636627197]
MAIN B-LOC [3.014481782913208, -3.2791311740875244]
OUTCOME B-LOC [3.131981611251831, -3.1115291118621826]
MEASURES B-LOC [3.107468366622925, -3.1937644481658936]
The B-LOC [3.1594226360321045, -3.184619426727295]
primary B-LOC [3.1963846683502197, -3.290503740310669]
measure B-LOC [3.2972724437713623, -3.514448642730713]
was B-LOC [3.241591691970825, -3.222917079925537]
1-year B-LOC [3.2382378578186035, -3.0809078216552734]
incidence B-LOC [3.42244553565979, -3.6898694038391113]
of B-LOC [3.3420987129211426, -3.3368234634399414]
acute B-LOC [3.496068239212036, -3.452486276626587]
rejection B-LOC [3.4976656436920166, -3.6132395267486572]
and B-LOC [3.038527727127075, -3.2908968925476074]
renal B-LOC [3.3988187313079834, -3.4084365367889404]
function B-LOC [3.3982174396514893, -3.5178637504577637]
(estimated B-LOC [3.69998836517334, -3.237715244293213]
glomerular B-LOC [3.4496309757232666, -3.3367414474487305]
filtration B-LOC [3.2405989170074463, -3.294074058532715]
rate B-LOC [3.4572300910949707, -3.797938585281372]
[eGFR]); B-LOC [3.1160295009613037, -3.1887364387512207]
the B-LOC [3.3738818168640137, -2.962083101272583]
secondary B-LOC [3.3897786140441895, -3.3564507961273193]
measure B-LOC [3.4429080486297607, -3.4308395385742188]
was B-LOC [3.391629934310913, -3.2828304767608643]
patient B-LOC [3.549009323120117, -3.770428419113159]
and B-LOC [3.090608835220337, -3.319788694381714]
graft B-LOC [3.533961057662964, -3.469876289367676]
survival B-LOC [3.528766393661499, -3.6812949180603027]
and B-LOC [3.3669753074645996, -3.573004961013794]
incidence B-LOC [3.703824520111084, -3.7882096767425537]
of B-LOC [3.629063844680786, -3.6815834045410156]
adverse B-LOC [3.6331722736358643, -3.7649943828582764]
events. B-LOC [3.6533737182617188, -3.714833974838257]
RESULTS B-LOC [1.6825296878814697, -2.321676731109619]
Patient B-LOC [2.1363613605499268, -2.2802977561950684]
and B-LOC [1.9477369785308838, -2.5515356063842773]
graft B-LOC [2.2130608558654785, -2.5485002994537354]
survival B-LOC [2.0604021549224854, -2.606994867324829]
at B-LOC [1.9535553455352783, -2.503222942352295]
13 B-LOC [2.525562047958374, -2.579599618911743]
to B-LOC [1.9848394393920898, -2.4504082202911377]
30 B-LOC [2.3910276889801025, -2.477346181869507]
months B-LOC [2.577484369277954, -2.7529795169830322]
was B-LOC [1.9057698249816895, -2.339611053466797]
similar B-LOC [1.8696796894073486, -2.4960086345672607]
in B-LOC [1.8735613822937012, -2.41015887260437]
all B-LOC [1.8947973251342773, -2.298677444458008]
groups. B-LOC [2.407672882080078, -2.3663110733032227]
After B-LOC [0.978153645992279, -1.4155735969543457]
6 B-LOC [1.2901259660720825, -1.4265098571777344]
months, B-LOC [1.6540637016296387, -1.4634895324707031]

4 O [-0.34865954518318176, 0.4493779242038727]
of O [-0.39497581124305725, 0.6066041588783264]
53 O [-0.2584860026836395, 0.625527560710907]
patients O [-0.6452325582504272, 0.5254440903663635]
(7.5%) O [-0.3550177216529846, 0.3540175259113312]
in O [-0.5513585209846497, 0.7158023118972778]
the O [-0.5400473475456238, 0.6083945631980896]
autologous O [-0.645456850528717, 0.6893897652626038]
MSC O [-0.5543644428253174, 0.6117839217185974]
plus O [-0.6663382649421692, 0.6794919371604919]
standard-dose O [-0.6693592071533203, 0.5719773769378662]
CNI O [-0.7151307463645935, 0.605983316898346]
group O [-0.7469949722290039, 0.9322641491889954]
(95% O [-0.6345317363739014, 0.6482853293418884]
CI, O [-0.723861038684845, 0.6549609303474426]
0.4%-14.7%; O [-0.6596060991287231, 0.7732903957366943]
P O [-0.8354453444480896, 0.7326874732971191]
= O [-0.7450088262557983, 0.7425236701965332]
.04) O [-0.7477919459342957, 0.7401451468467712]
and O [-0.5906371474266052, 0.584204375743866]
4 O [-0.4154585301876068, 0.8700416088104248]
of O [-0.5475792288780212, 0.6748573780059814]
52 O [-0.4135693907737732, 0.807336151599884]
patients O [-0.7451246380805969, 0.6852182745933533]
(7.7%) O [-0.5480109453201294, 0.4866395592689514]
in O [-0.5867464542388916, 0.7494053244590759]
the O [-0.5432262420654297, 0.6338502764701843]
low-dose O [-0.582431972026825, 0.5474883913993835]
group O [-0.6209655404090881, 0.7406589388847351]
(95% O [-0.5540620684623718, 0.4103327691555023]
CI, O [-0.7127469182014465, 0.5437029004096985]
0.5%-14.9%; O [-0.5222432017326355, 0.5559821724891663]
P O [-0.6640350222587585, 0.4934680759906769]
= O [-0.6335180401802063, 0.5700550675392151]
.046) O [-0.6142995953559875, 0.5554434061050415]
compared O [-0.8279092311859131, 0.6670566201210022]
with O [-0.4755191504955292, 0.49081549048423767]
11 O [-0.21507754921913147, 0.6227852702140808]
of O [-0.4113253057003021, 0.37552085518836975]
51 O [-0.3076043426990509, 0.4686044752597809]
controls O [-0.6746522188186646, 0.3744169771671295]
(21.6%; O [-0.5214369297027588, 0.24205678701400757]
95% O [-0.6560849547386169, 0.6076712012290955]
CI, O [-0.6019091010093689, 0.4638119041919708]
10.5%-32.6%) O [-0.46307647228240967, 0.5310975313186646]
had O [-0.4377221167087555, 0.50264972448349]
biopsy-confirmed O [-0.31228700280189514, 0.3396950364112854]
acute O [-0.40393078327178955, 0.32476863265037537]
rejection. O [-0.35067906975746155, 0.4216114580631256]
None B-LOC [0.4339221715927124, -0.40562179684638977]
of B-LOC [0.4434467852115631, -0.18103595077991486]
the B-LOC [0.3401243984699249, -0.37850791215896606]
patients B-LOC [0.11097908020019531, -0.3474402129650116]
in B-LOC [0.207060307264328, -0.20289896428585052]

either O [-0.3656356632709503, 0.12884753942489624]
autologous O [-0.45969927310943604, 0.3504740297794342]
MSC O [-0.3140767514705658, 0.29555606842041016]
group O [-0.3586300015449524, 0.47769761085510254]
had O [-0.4608366787433624, 0.34851324558258057]
glucorticoid-resistant O [-0.38940003514289856, 0.42437687516212463]
rejection, O [-0.23065094649791718, 0.4952854514122009]
whereas O [-0.20688137412071228, 0.30471956729888916]
4 O [-0.3261437714099884, 0.38318654894828796]
patients O [-0.48039117455482483, 0.29515790939331055]
(7.8%) O [-0.27199655771255493, 0.1251467615365982]
in O [-0.31360796093940735, 0.20587879419326782]
the O [-0.40194010734558105, 0.37520602345466614]
control O [-0.35968759655952454, 0.1264568269252777]
group O [-0.5573377013206482, 0.4485071003437042]
did O [-0.3698737621307373, 0.2760177254676819]
(95% O [-0.4031601846218109, 0.2647574543952942]
CI, O [-0.601310670375824, 0.2556946277618408]
0.6%-15.1%; O [-0.5006005167961121, 0.2309585064649582]
overall O [-0.6525603532791138, 0.27253487706184387]
P O [-0.5348803400993347, 0.2695842683315277]
= O [-0.5224875807762146, 0.10177792608737946]
.02). O [-0.4564276933670044, 0.12540027499198914]
Renal B-LOC [0.10175155848264694, -0.1829550862312317]
function B-LOC [0.025861652567982674, -0.1726939082145691]
recovered B-LOC [0.19132167100906372, -0.3221544027328491]
faster B-LOC [0.24458928406238556, -0.3013960123062134]
among B-LOC [0.23810634016990662, -0.04699010029435158]
both B-LOC [0.08680204302072525, -0.2487538903951645]
MSC B-LOC [0.34105584025382996, -0.23373953998088837]
groups B-LOC [0.0991206020116806, 0.012059779837727547]
showing B-LOC [0.0761280208826065, -0.09081554412841797]
increased B-LOC [0.23870912194252014, -0.30518046021461487]
eGFR B-LOC [0.09105119109153748, -0.1205846518278122]
levels B-LOC [0.27448341250419617, -0.18618321418762207]
during B-LOC [0.18557024002075195, -0.24445831775665283]
the B-LOC [0.3496665060520172, -0.26942354440689087]
first B-LOC [0.4616924226284027, -0.37147659063339233]
month B-LOC [0.5544379353523254, -0.46475717425346375]
after B-LOC [0.7015634775161743, -0.4935273230075836]
surgery B-LOC [0.22798892855644226, -0.5194613933563232]
than B-LOC [0.315500408411026, -0.20562273263931274]
the B-LOC [0.3717995584011078, -0.4678157866001129]
control B-LOC [0.412702351808548, -0.5985516905784607]
group. B-LOC [0.17532357573509216, -0.21722514927387238]
Patients B-LOC [-0.04630199819803238, -0.22240017354488373]
receiving B-LOC [-0.059015434235334396, -0.23511332273483276]
standard-dose B-LOC [-0.15620243549346924, -0.2499939203262329]
CNI B-LOC [-0.13388150930404663, -0.21570149064064026]
had B-LOC [0.046067725867033005, -0.06215353310108185]
a B-LOC [-0.0412646047770977, -0.07816939055919647]
mean O [-0.30166560411453247, -0.0672132819890976]
difference O [-0.3085605800151825, -0.18436330556869507]
of O [-0.17938551306724548, -0.14412303268909454]
6.2 O [-0.0018417885294184089, 0.1449788510799408]
mL/min B-LOC [-0.1473696082830429, -0.31762638688087463]
per B-LOC [-0.304678738117218, -0.5019538998603821]
1.73 B-LOC [0.1770714968442917, -0.028092237189412117]
m(2) B-LOC [-0.23625503480434418, -0.380144327878952]
(95% B-LOC [-0.14319124817848206, -0.17574411630630493]
CI, O [-0.28676939010620117, -0.16135847568511963]

0.4-11.9; O [-0.1973687708377838, -0.04970214143395424]
P=.04) O [-0.4921618103981018, 0.15573202073574066]
and O [-0.32626304030418396, 0.34616535902023315]
those O [-0.22586430609226227, 0.33568868041038513]
in O [-0.23501098155975342, 0.32490667700767517]
the O [-0.3214879631996155, 0.305103063583374]
low-dose O [-0.2979367673397064, 0.2071768194437027]
CNI O [-0.43433186411857605, 0.0196425449103117]
of O [-0.40518853068351746, 0.2107217013835907]
10.0 O [-0.19915710389614105, 0.35129281878471375]
mL/min O [-0.39240121841430664, -0.13772282004356384]
per O [-0.35609474778175354, -0.030829422175884247]
1.73 O [-0.04931296035647392, 0.07146233320236206]
m(2) O [-0.40951594710350037, -0.08131717145442963]
(95% O [-0.2939433455467224, 0.006382261868566275]
CI, O [-0.4697076976299286, 0.020519385114312172]
3.8-16.2; O [-0.3044372797012329, 0.5517540574073792]
P=.002). O [-0.44064903259277344, 0.026291565969586372]
Also, O [-1.053910493850708, 1.0404539108276367]
during O [-1.154028058052063, 0.8122915625572205]
the O [-0.9226552844047546, 0.8001232743263245]
1-year O [-0.7460244297981262, 0.7949215769767761]
follow-up, O [-0.6346979737281799, 0.4897030293941498]
combined O [-0.9490625262260437, 0.9921218752861023]
analysis O [-0.7630458474159241, 0.9958622455596924]
of O [-0.74729323387146, 0.8755683898925781]
MSC-treated O [-0.48404660820961, 0.6669175624847412]
groups O [-0.6770642995834351, 0.9128527641296387]
revealed O [-0.8750485777854919, 0.8984822630882263]
significantly O [-1.0482591390609741, 0.888211727142334]
decreased O [-0.9554661512374878, 0.9019404649734497]
risk O [-0.9410980343818665, 0.9400481581687927]
of O [-1.0632476806640625, 1.0056636333465576]
opportunistic O [-0.96950364112854, 1.112459659576416]
infections O [-0.5567378997802734, 0.777351975440979]
than O [-0.9254177212715149, 1.0710440874099731]
the O [-0.80289226770401, 0.6933841109275818]
control O [-0.5961111187934875, 0.5441136360168457]
group O [-0.5864294171333313, 0.9564521312713623]
(hazard O [-0.7596775889396667, 0.7647526860237122]
ratio, O [-0.6967015862464905, 0.635105311870575]
0.42; O [-0.5385207533836365, 0.7160513997077942]
95% O [-1.0587143898010254, 0.9593826532363892]
CI, O [-0.752045750617981, 0.47363942861557007]
0.20-0.85, O [-0.36691033840179443, 0.5423750877380371]
P=.02) O [-0.7376469969749451, 0.5558141469955444]
CONCLUSION O [-1.1226266622543335, 0.9496563076972961]
Among O [-0.7361757159233093, 0.9521312713623047]
patients O [-0.670581579208374, 0.6390244364738464]

undergoing O [-1.1566674709320068, 1.3425248861312866]
renal O [-1.148454189300537, 1.4792661666870117]
transplant, O [-0.7972730398178101, 1.2460455894470215]
the O [-1.1658852100372314, 1.263501763343811]
use O [-0.9276010990142822, 1.292806625366211]
of O [-0.9591092467308044, 1.3276681900024414]
autologous O [-0.9182237386703491, 1.4694559574127197]
MSCs O [-0.7916292548179626, 1.3087929487228394]
compared O [-1.0596867799758911, 1.677689790725708]
with O [-0.8428254723548889, 1.4519996643066406]
anti-IL-2 O [-1.0789908170700073, 1.5265440940856934]
receptor O [-0.9431151747703552, 1.3535544872283936]
antibody O [-0.9943870306015015, 1.5812729597091675]
induction O [-1.1430011987686157, 1.6034055948257446]
therapy O [-0.8599016070365906, 1.4899529218673706]
resulted O [-1.3455898761749268, 1.308027744293213]
in O [-1.3520097732543945, 1.3475186824798584]
lower O [-1.324379563331604, 1.406128168106079]
incidence O [-1.353893518447876, 1.430415391921997]
of O [-1.4415887594223022, 1.4167143106460571]
acute O [-1.4182764291763306, 1.4563658237457275]
rejection, O [-0.999120831489563, 1.4507102966308594]
decreased O [-1.2747845649719238, 1.288154125213623]
risk O [-1.3396713733673096, 1.399804711341858]
of O [-1.4280915260314941, 1.406501054763794]
opportunistic O [-1.2751336097717285, 1.4475104808807373]
infection, O [-0.972529947757721, 1.4090080261230469]
and O [-1.2517590522766113, 1.3412766456604004]
better O [-1.2144181728363037, 1.2366981506347656]
estimated O [-1.1183781623840332, 1.1028176546096802]
renal O [-1.1934797763824463, 1.2209643125534058]
function O [-1.0045310258865356, 1.13252592086792]
at O [-1.1819205284118652, 1.1363192796707153]
1 O [-0.9694825410842896, 1.1112537384033203]
year. O [-1.2536368370056152, 1.1423718929290771]
TRIAL B-LOC [2.273399591445923, -2.3445870876312256]
REGISTRATION B-LOC [2.1130104064941406, -2.239853620529175]
clinicaltrials.gov B-LOC [2.5773606300354004, -2.524641275405884]
Identifier: B-LOC [2.2845280170440674, -2.252289295196533]
NCT00658073. B-LOC [2.567168951034546, -2.663863182067871]

Viral B-LOC [1.1991660594940186, -2.0101993083953857]
replication B-LOC [1.5957410335540771, -1.7131938934326172]
and B-LOC [1.3423409461975098, -1.8035657405853271]
microbial B-LOC [1.6771997213363647, -2.0293095111846924]
translocation B-LOC [1.5240955352783203, -2.016719102859497]
from B-LOC [1.4338569641113281, -1.9086275100708008]
the B-LOC [1.5843195915222168, -1.9627761840820312]
gut B-LOC [1.5292072296142578, -2.161771297454834]
to B-LOC [1.601764440536499, -2.0838465690612793]
the B-LOC [1.7187552452087402, -2.0411527156829834]
blood B-LOC [1.4705064296722412, -2.371628761291504]
during B-LOC [1.4447758197784424, -1.8502386808395386]
HIV B-LOC [1.851477861404419, -2.1574604511260986]
infection B-LOC [1.8182132244110107, -2.2462806701660156]
lead B-LOC [1.5145400762557983, -1.770622968673706]
to B-LOC [1.3635878562927246, -1.747266411781311]
hyperimmune B-LOC [1.5162967443466187, -1.8365517854690552]
activation, B-LOC [1.4543452262878418, -1.8568189144134521]
which B-LOC [1.3795034885406494, -1.7755568027496338]
contributes B-LOC [1.7140367031097412, -1.8853976726531982]
to B-LOC [1.675619125366211, -1.8245766162872314]
the B-LOC [1.6707909107208252, -1.8317234516143799]
decline B-LOC [1.7644109725952148, -2.1030516624450684]
in B-LOC [1.598710060119629, -2.1523311138153076]
CD4+ B-LOC [1.6515288352966309, -1.784913182258606]
T B-LOC [1.517471432685852, -2.285336494445801]
cell B-LOC [1.600708246231079, -2.15993595123291]
numbers B-LOC [1.7434334754943848, -2.14225435256958]
during B-LOC [1.8672956228256226, -2.070115804672241]
HIV B-LOC [2.0587403774261475, -2.3806660175323486]
infection. B-LOC [2.073496103286743, -2.4288928508758545]
Programmed B-LOC [2.785862684249878, -3.0081675052642822]
death-1 B-LOC [2.505066156387329, -2.725432872772217]
(PD-1) B-LOC [2.563948392868042, -2.738935708999634]
and B-LOC [2.69413423538208, -2.4335455894470215]
interleukin-10 B-LOC [2.6654958724975586, -3.2229816913604736]
(IL-10) B-LOC [2.7360572814941406, -2.745579957962036]
are B-LOC [2.906787633895874, -2.6637043952941895]
both B-LOC [2.892068386077881, -2.903048276901245]
upregulated B-LOC [2.975748062133789, -3.0195322036743164]
during B-LOC [2.707855463027954, -2.7486774921417236]
HIV B-LOC [2.7968990802764893, -2.911834955215454]
infection. B-LOC [2.8910248279571533, -2.872131109237671]
Blocking B-LOC [0.608457624912262, -0.4850556254386902]
interactions B-LOC [0.6030756831169128, -0.3884929120540619]
between B-LOC [0.7280421853065491, -0.9266529083251953]
PD-1 B-LOC [0.43419238924980164, -0.5249625444412231]
and B-LOC [0.6830623149871826, -0.7752897143363953]
programmed B-LOC [0.63437420129776, -0.7602530121803284]
death B-LOC [0.5478644371032715, -0.6375822424888611]
ligand-1 B-LOC [0.9521389603614807, -0.7482362389564514]
(PD-L1) B-LOC [0.8823390603065491, -0.8724012970924377]
and B-LOC [0.8172563910484314, -0.7335830330848694]
between B-LOC [0.8569231629371643, -0.9346181750297546]
IL-10 B-LOC [0.31485867500305176, -0.6829789280891418]
and B-LOC [0.7184574007987976, -0.7027466893196106]
IL-10 B-LOC [0.4016985297203064, -0.7840314507484436]
receptor B-LOC [0.5579031705856323, -0.9238986968994141]
(IL-10R) B-LOC [1.0840167999267578, -1.007648229598999]
results B-LOC [0.31808236241340637, -0.6572883725166321]
in B-LOC [0.2554628551006317, -0.3421366512775421]
viral B-LOC [0.5779159665107727, -0.8276618719100952]
clearance B-LOC [0.6219070553779602, -0.7347041964530945]
and B-LOC [0.13522645831108093, -0.3805564343929291]
improves B-LOC [0.4444235861301422, -0.7006645202636719]
T B-LOC [0.7559425234794617, -1.0429916381835938]
cell B-LOC [0.5350757837295532, -0.7749642133712769]
function B-LOC [0.8234677910804749, -0.7703711986541748]
in B-LOC [1.0748610496520996, -0.9348836541175842]
animal B-LOC [1.156973123550415, -1.4920728206634521]
models B-LOC [1.0620979070663452, -0.9504589438438416]
of B-LOC [0.7600451111793518, -1.0349483489990234]

chronic B-LOC [0.29199185967445374, -0.8896821141242981]
viral B-LOC [0.3482743501663208, -0.922625720500946]
infections. B-LOC [0.511443555355072, -0.7862557172775269]
Here O [-0.25052568316459656, -0.1649576872587204]
we O [-0.2920948266983032, -0.10966533422470093]
show O [-0.28960829973220825, 0.11293861269950867]
that O [-0.40622273087501526, 0.02397649548947811]
high B-LOC [-0.004888889845460653, -0.21507784724235535]
amounts B-LOC [0.17615967988967896, -0.21530432999134064]
of B-LOC [0.0429430715739727, -0.2374492883682251]
microbial B-LOC [0.13563203811645508, -0.05485815182328224]
products B-LOC [0.10327817499637604, -0.16343647241592407]
and B-LOC [-0.023907853290438652, -0.03995797410607338]
inflammatory B-LOC [0.03823000565171242, 0.0010911202989518642]
cytokines O [-0.017819447442889214, 0.022067828103899956]
in B-LOC [0.040053579956293106, -0.11403363943099976]
the B-LOC [0.08011825382709503, -0.03232318535447121]
plasma B-LOC [0.14087383449077606, 0.07103253155946732]
of B-LOC [0.13685160875320435, -0.18946732580661774]
HIV-infected B-LOC [0.27836179733276367, -0.307143896818161]
subjects B-LOC [0.02588527835905552, -0.023448510095477104]
lead B-LOC [0.04596764221787453, -0.08315746486186981]
to O [-0.034012045711278915, 0.009811250492930412]
upregulation B-LOC [0.14366325736045837, -0.14891374111175537]
of B-LOC [-0.022343523800373077, -0.18454322218894958]
PD-1 B-LOC [0.007426659110933542, -0.148638054728508]
expression B-LOC [0.12705452740192413, -0.0005039371899329126]
on B-LOC [-0.03783523291349411, -0.10357607901096344]
monocytes B-LOC [-0.013008729554712772, -0.1666828691959381]
that B-LOC [-0.125422403216362, -0.3055170178413391]
correlates B-LOC [0.17314180731773376, -0.05858233943581581]
with B-LOC [0.22781339287757874, -0.2982821464538574]
high B-LOC [0.30458247661590576, -0.45421406626701355]
plasma B-LOC [0.2648843824863434, -0.43582651019096375]
concentrations B-LOC [0.32667961716651917, -0.36334919929504395]
of B-LOC [0.32724037766456604, -0.5725852847099304]
IL-10. B-LOC [0.045625239610672, -0.37940168380737305]
Triggering O [-0.16841313242912292, 0.28090009093284607]
of O [-0.2091914415359497, 0.22024358808994293]
PD-1 O [-0.2915235459804535, 0.05218314751982689]
expressed O [-0.10581967234611511, 0.22083845734596252]
on O [-0.24126197397708893, 0.22310855984687805]
monocytes O [-0.1470561921596527, -0.14466819167137146]
by O [-0.169707790017128, 0.10837777704000473]
PD-L1 O [-0.22019314765930176, 0.022692320868372917]
expressed O [-0.2561333477497101, 0.13779936730861664]
on O [-0.32016125321388245, 0.06354188174009323]
various B-LOC [-0.019756397232413292, -0.35042986273765564]
cell O [-0.25010761618614197, 0.007076126988977194]
types O [-0.07312960177659988, -0.043082620948553085]
induced O [-0.33800986409187317, -0.00086707848822698]
IL-10 O [-0.18250322341918945, -0.08537607640028]
production O [-0.16587699949741364, 0.1144682765007019]
and O [-0.3666815459728241, -0.013945819810032845]
led O [-0.2606936991214752, 0.03082839958369732]
to O [-0.19120827317237854, 0.05902883782982826]
reversible O [-0.19532379508018494, 0.1835136115550995]
CD4+ O [-0.06562301516532898, 0.19616594910621643]
T B-LOC [-0.09372413158416748, -0.2641504406929016]
cell O [-0.36232614517211914, -0.025842981413006783]
dysfunction. B-LOC [0.0895400196313858, -0.13934475183486938]
We O [-0.13825923204421997, -0.12945953011512756]
describe B-LOC [0.18733878433704376, -0.3012508451938629]
a B-LOC [0.07499845325946808, -0.260252982378006]
new B-LOC [0.07815630733966827, -0.26574674248695374]
function B-LOC [-0.17518825829029083, -0.2241302728652954]
for B-LOC [0.13881559669971466, -0.556682825088501]
PD-1 B-LOC [-0.021757973358035088, -0.297798216342926]
whereby O [-0.269052118062973, -0.22169606387615204]
microbial B-LOC [-0.01939964108169079, -0.05217898264527321]
products O [-0.15208391845226288, 0.07879413664340973]
inhibit O [-0.46527600288391113, -0.03343271091580391]
T O [-0.3016302287578583, -0.03673042729496956]
cell O [-0.653156578540802, 0.07944681495428085]
expansion O [-0.3369349241256714, 0.1341308206319809]
and O [-0.43800124526023865, 0.036260467022657394]

function O [-0.6546576619148254, 0.32590267062187195]
by O [-0.8576152324676514, 0.542900800704956]
upregulating O [-0.8106904029846191, 0.6074873805046082]
PD-1 O [-0.7017552852630615, 0.4738899767398834]
levels O [-0.6624051928520203, 0.7088059186935425]
and O [-0.8466765284538269, 0.6515428423881531]
IL-10 O [-0.8019320368766785, 0.404021292924881]
production O [-0.6479191184043884, 0.6585476994514465]
by O [-0.7980467677116394, 0.560096800327301]
monocytes O [-0.7523350119590759, 0.5989843010902405]
after O [-0.6438500881195068, 0.48124873638153076]
binding O [-0.44977623224258423, 0.3360591232776642]
of O [-0.566828727722168, 0.5015972256660461]
PD-1 O [-0.6813281774520874, 0.4805150330066681]
by O [-0.6170545220375061, 0.327139288187027]
PD-L1. O [-0.6268381476402283, 0.35995328426361084]

BACKGROUND B-LOC [2.3210644721984863, -2.9853267669677734]
The B-LOC [3.2369346618652344, -3.418595314025879]
purpose B-LOC [3.4483892917633057, -3.715344190597534]
of B-LOC [3.3185083866119385, -3.4962918758392334]
this B-LOC [3.2521278858184814, -3.633755683898926]
study B-LOC [2.9878039360046387, -3.55411696434021]
was B-LOC [3.354274034500122, -3.5081417560577393]
to B-LOC [3.5054469108581543, -3.6275105476379395]
test B-LOC [3.4866843223571777, -3.713451385498047]
the B-LOC [3.6466197967529297, -3.5502288341522217]
hypothesis B-LOC [3.4290499687194824, -3.4960336685180664]
that B-LOC [2.889977216720581, -3.415776491165161]
vasodilator B-LOC [2.821106195449829, -3.3618392944335938]
responses B-LOC [2.7485344409942627, -3.0943357944488525]
of B-LOC [2.94161319732666, -3.246948003768921]
porcine B-LOC [3.015238046646118, -3.5457890033721924]
coronary B-LOC [3.0924267768859863, -3.3100016117095947]
resistance B-LOC [2.9736216068267822, -3.6323111057281494]
arteries B-LOC [3.1708335876464844, -3.576611042022705]
are B-LOC [3.0320353507995605, -3.3583767414093018]
increased B-LOC [2.766418933868408, -3.4404678344726562]
by B-LOC [2.726940631866455, -3.2903356552124023]
exercise B-LOC [2.9883620738983154, -3.6881015300750732]
training. B-LOC [3.110643148422241, -3.659045934677124]
METHODS B-LOC [2.269937753677368, -2.9520366191864014]
AND B-LOC [2.9827334880828857, -3.394782066345215]
RESULTS B-LOC [2.647832155227661, -3.098612070083618]
Yucatan B-LOC [2.9343035221099854, -3.077589273452759]
miniature B-LOC [3.031886577606201, -3.4896938800811768]
swine B-LOC [3.223200559616089, -3.451166868209839]
were B-LOC [3.276137590408325, -3.4082560539245605]
randomly B-LOC [3.789876937866211, -3.6738059520721436]
divided B-LOC [3.695897102355957, -3.5484204292297363]
into B-LOC [3.590900421142578, -3.577784299850464]
groups B-LOC [3.8558382987976074, -3.428385019302368]
of B-LOC [3.444502353668213, -3.584124803543091]
exercise-trained B-LOC [3.5313189029693604, -3.797991991043091]
(ET) B-LOC [3.5375735759735107, -3.5176405906677246]
and B-LOC [3.5910840034484863, -3.363959550857544]
sedentary B-LOC [3.547553777694702, -3.584620237350464]
(SED) B-LOC [3.672375202178955, -3.6605935096740723]
control B-LOC [3.3069369792938232, -3.758207321166992]
pigs. B-LOC [3.422356128692627, -3.8349368572235107]
ET B-LOC [3.384472131729126, -3.592336654663086]
pigs B-LOC [3.453798294067383, -3.451124906539917]
were B-LOC [3.5750598907470703, -3.2817771434783936]
placed B-LOC [3.7005083560943604, -3.3008406162261963]
on B-LOC [3.44492769241333, -3.166907548904419]
a B-LOC [3.5236785411834717, -3.201528310775757]
progressive B-LOC [3.553929567337036, -3.6434171199798584]
treadmill B-LOC [3.6964478492736816, -3.1581497192382812]
training B-LOC [3.3967723846435547, -3.5349743366241455]
program B-LOC [3.451641798019409, -3.3953263759613037]
lasting B-LOC [3.2647063732147217, -3.3948264122009277]
16 B-LOC [3.552372694015503, -3.1721103191375732]
to B-LOC [3.350471258163452, -3.2463228702545166]
20 B-LOC [3.571044683456421, -3.342480421066284]
weeks, B-LOC [3.5598111152648926, -3.3125085830688477]
and B-LOC [3.0548207759857178, -3.2090446949005127]
SED B-LOC [3.5816080570220947, -3.157212734222412]
pigs B-LOC [3.317902088165283, -3.3599791526794434]
remained B-LOC [3.524648427963257, -3.291717529296875]
inactive B-LOC [3.5603818893432617, -3.1468982696533203]
during B-LOC [3.510239362716675, -3.3470704555511475]
the B-LOC [3.4869296550750732, -3.113431692123413]
same B-LOC [3.1916298866271973, -3.5414421558380127]
time B-LOC [3.3151347637176514, -3.4224908351898193]
period. B-LOC [3.170517921447754, -3.2512476444244385]
Coronary B-LOC [0.7974125742912292, -1.221017599105835]
resistance B-LOC [0.9172260165214539, -1.3932127952575684]
arteries B-LOC [1.2975270748138428, -1.6009047031402588]
64 B-LOC [0.9042015671730042, -0.7913015484809875]
to B-LOC [0.3493393361568451, -0.7764458060264587]
157 B-LOC [1.1468501091003418, -0.8859549760818481]
microns B-LOC [0.6306160092353821, -1.0398142337799072]
in B-LOC [1.2114415168762207, -1.031973123550415]
diameter B-LOC [1.3017498254776, -1.2016414403915405]
were B-LOC [1.5829579830169678, -1.4706214666366577]
isolated B-LOC [1.7517272233963013, -1.3943755626678467]
for B-LOC [1.1324937343597412, -1.0313971042633057]
in B-LOC [1.06995689868927, -0.8340428471565247]

vitro B-LOC [1.4146225452423096, -1.3828520774841309]
evaluation B-LOC [1.638840675354004, -2.040142297744751]
of B-LOC [1.9189331531524658, -2.2118210792541504]
relaxation B-LOC [1.5549761056900024, -1.6788058280944824]
responses B-LOC [1.8112269639968872, -1.9129447937011719]
to B-LOC [1.8564488887786865, -1.9446961879730225]
the B-LOC [1.8027621507644653, -1.730705976486206]
endothelium-independent B-LOC [1.6549935340881348, -1.62803316116333]
dilators B-LOC [1.9354724884033203, -1.8860478401184082]
sodium B-LOC [1.4437556266784668, -1.6777985095977783]
nitroprusside B-LOC [1.1677398681640625, -1.6385705471038818]
(1 B-LOC [1.338910460472107, -1.2422993183135986]
x B-LOC [0.6572055220603943, -1.1187857389450073]
10(-10) B-LOC [1.0231173038482666, -0.9696233868598938]
to B-LOC [1.0063660144805908, -1.1774171590805054]
1 B-LOC [0.8001917004585266, -0.7116047739982605]
x B-LOC [0.33182844519615173, -0.9277894496917725]
10(-4) B-LOC [0.8197829723358154, -0.7659216523170471]
mol/L) B-LOC [0.40991368889808655, -1.0857200622558594]
and B-LOC [0.9635187983512878, -1.0866973400115967]
adenosine B-LOC [0.9573758840560913, -0.9430776834487915]
(1 B-LOC [1.1395230293273926, -1.04759681224823]
x B-LOC [0.32285431027412415, -0.8449789881706238]
10(-10) B-LOC [0.8775258660316467, -0.8779625296592712]
to B-LOC [1.2388989925384521, -1.3087753057479858]
1 B-LOC [1.118751049041748, -1.0747283697128296]
x B-LOC [0.5819471478462219, -1.182304859161377]
10(-5) B-LOC [0.9931356310844421, -0.9784495234489441]
mol/L) B-LOC [0.329997181892395, -1.0053291320800781]
and B-LOC [1.79457688331604, -1.7241846323013306]
to B-LOC [1.4911019802093506, -1.496316909790039]
bradykinin B-LOC [1.3738303184509277, -1.4261592626571655]
(1 B-LOC [1.6172294616699219, -1.511608362197876]
x B-LOC [0.7449984550476074, -1.202252984046936]
10(-13) B-LOC [1.0786635875701904, -1.1075226068496704]
to B-LOC [1.459920048713684, -1.678505539894104]
3 B-LOC [0.6998915076255798, -0.7215877175331116]
x B-LOC [0.9037745594978333, -1.4347455501556396]
10(-7) B-LOC [1.1161094903945923, -1.2616052627563477]
mol/L), B-LOC [0.6406249403953552, -1.327416181564331]
an B-LOC [1.7001523971557617, -1.7200535535812378]
endothelium-dependent B-LOC [1.22853422164917, -1.285834789276123]
agent. B-LOC [1.067569375038147, -1.6868185997009277]
Relaxation B-LOC [1.1053141355514526, -1.5410969257354736]
responses B-LOC [1.316544532775879, -1.601313591003418]
to B-LOC [1.1191924810409546, -1.427365779876709]
adenosine B-LOC [1.2072423696517944, -1.4229099750518799]
and B-LOC [1.1579606533050537, -1.5004184246063232]
sodium B-LOC [1.1647677421569824, -1.5834064483642578]
nitroprusside B-LOC [0.8677211999893188, -1.599470615386963]
were B-LOC [1.5045827627182007, -1.7136679887771606]
not B-LOC [1.356335997581482, -1.492553949356079]
altered B-LOC [1.2777986526489258, -1.9950432777404785]
by B-LOC [1.0483927726745605, -1.7342708110809326]
exercise B-LOC [1.0428566932678223, -1.5185126066207886]
training. B-LOC [1.0779707431793213, -1.4848260879516602]

Endothelium-dependent B-LOC [-0.05153508111834526, -0.32362261414527893]
relaxation B-LOC [0.050848525017499924, -0.10291379690170288]
to B-LOC [0.017896534875035286, -0.23971863090991974]
bradykinin B-LOC [0.04353029653429985, -0.4702496826648712]
was B-LOC [-0.08532427996397018, -0.23290368914604187]
enhanced B-LOC [0.01710638590157032, -0.13765645027160645]
in B-LOC [-0.0689435824751854, -0.19780349731445312]
coronary B-LOC [0.11623800545930862, -0.24708572030067444]
resistance B-LOC [0.05678956210613251, -0.5145632028579712]
arteries B-LOC [0.15060320496559143, -0.5432682037353516]
from B-LOC [0.058141693472862244, -0.1973791867494583]
ET B-LOC [0.411739706993103, -0.45506590604782104]
pigs B-LOC [-0.013479259796440601, -0.32533273100852966]
(IC50: B-LOC [0.24184203147888184, -0.32499662041664124]
ET, B-LOC [0.3463038504123688, -0.3059774935245514]
0.07 B-LOC [0.4195235073566437, -0.6143468022346497]
+/- B-LOC [-0.23496674001216888, -1.1483876705169678]
0.02 B-LOC [0.3161523938179016, -0.8430275321006775]
nmol/L; B-LOC [0.24531897902488708, -0.724302351474762]
SED, B-LOC [0.37520384788513184, -0.3110823631286621]
1.59 B-LOC [0.3248755633831024, -0.29699504375457764]
+/- B-LOC [-0.22627690434455872, -1.0732803344726562]
0.09 B-LOC [0.378517746925354, -0.884652316570282]
nmol/L). B-LOC [0.23717841506004333, -0.6602740287780762]
To B-LOC [1.986397624015808, -2.675992250442505]
determine B-LOC [2.2898080348968506, -2.8711884021759033]
whether B-LOC [2.1268248558044434, -2.5465168952941895]
prostanoids B-LOC [1.187382698059082, -1.6510794162750244]
and/or B-LOC [1.8402082920074463, -2.1983559131622314]
the B-LOC [1.7853693962097168, -2.12519907951355]
nitric B-LOC [1.316282033920288, -2.0208089351654053]
oxide B-LOC [1.3291478157043457, -1.7891359329223633]
synthase B-LOC [1.632583737373352, -1.8979482650756836]
pathway B-LOC [1.1604321002960205, -1.659796953201294]
were B-LOC [1.9217147827148438, -2.286882162094116]
involved B-LOC [1.4234837293624878, -1.883019208908081]
in B-LOC [1.4131349325180054, -1.8562413454055786]
the B-LOC [1.7892802953720093, -2.0150461196899414]
ET-induced B-LOC [1.4834396839141846, -1.6050488948822021]
changes B-LOC [1.2560136318206787, -1.872964859008789]
in B-LOC [1.3032344579696655, -1.8056501150131226]
bradykinin-induced B-LOC [0.9518455862998962, -1.6420152187347412]
vasodilation, B-LOC [1.227919340133667, -1.8205952644348145]
responses B-LOC [1.6523315906524658, -2.169778347015381]
to B-LOC [1.3729147911071777, -1.87557053565979]
bradykinin B-LOC [1.3006188869476318, -1.7825469970703125]
were B-LOC [2.0422539710998535, -2.3244738578796387]
examined B-LOC [2.0577914714813232, -2.380873441696167]
in B-LOC [1.5015039443969727, -2.0918006896972656]
coronary B-LOC [1.4749224185943604, -1.7966371774673462]
resistance B-LOC [1.3263909816741943, -2.2270190715789795]
arteries B-LOC [1.7282248735427856, -2.069401979446411]
from B-LOC [1.377366304397583, -1.8364734649658203]
both B-LOC [1.2276170253753662, -1.757631540298462]
ET B-LOC [1.5526635646820068, -1.7711503505706787]
and B-LOC [1.3576784133911133, -1.6770808696746826]
SED B-LOC [1.6994253396987915, -1.4302420616149902]
pigs B-LOC [1.140860915184021, -1.8013410568237305]
in B-LOC [1.664896011352539, -2.0527031421661377]
the B-LOC [1.98682701587677, -2.2691614627838135]
presence B-LOC [1.8801769018173218, -2.035130500793457]
of B-LOC [1.3784801959991455, -1.7715957164764404]

indomethacin B-LOC [0.33736202120780945, -0.6604599952697754]
and B-LOC [0.4118988811969757, -0.54286128282547]
in B-LOC [0.3394234776496887, -0.5733634829521179]
the B-LOC [0.46638888120651245, -0.7507515549659729]
presence B-LOC [0.5707412958145142, -0.7339191436767578]
of B-LOC [0.5218808650970459, -0.7908466458320618]
nitro-monomethyl B-LOC [0.4414905905723572, -0.9405690431594849]
L-arginine B-LOC [0.4017353057861328, -0.8149566054344177]
(L-NMMA). B-LOC [0.6300670504570007, -0.7916012406349182]
Both O [-0.12993094325065613, 0.09984420984983444]
indomethacin O [-0.03841044753789902, 0.02959141694009304]
and O [-0.047638166695833206, 0.2555422782897949]
L-NMMA B-LOC [0.017845217138528824, -0.05638200789690018]
produced O [-0.32970255613327026, 0.10080872476100922]
significant O [-0.3184516429901123, 0.2110942155122757]
inhibition O [-0.3637247681617737, 0.3038564622402191]
of O [-0.3821469247341156, 0.3111843764781952]
the O [-0.3520621955394745, 0.2550448477268219]
bradykinin-induced O [-0.18004737794399261, -0.15157891809940338]
relaxation O [-0.1259108930826187, 0.2501124143600464]
in O [-0.23232749104499817, 0.0643778145313263]
vessels O [-0.17582231760025024, -0.0770331546664238]
from O [-0.1711311638355255, 0.10423877090215683]
both B-LOC [0.16526611149311066, -0.32652029395103455]
groups. B-LOC [0.15607044100761414, -0.2896476089954376]
Despite B-LOC [0.7911550402641296, -0.5994725227355957]
decreased B-LOC [0.6739534139633179, -0.5592671036720276]
bradykinin-induced B-LOC [0.6005564332008362, -0.7690480351448059]
relaxation B-LOC [0.4808882176876068, -0.34851565957069397]
after B-LOC [0.7819157838821411, -0.5672897100448608]
indomethacin, B-LOC [0.8543288707733154, -0.5463448166847229]
bradykinin-induced B-LOC [0.7804076075553894, -0.9506967067718506]
vasodilation B-LOC [0.42917296290397644, -0.7787026762962341]
was B-LOC [0.6097821593284607, -0.8036279082298279]
still B-LOC [0.8658305406570435, -0.8236803412437439]
enhanced B-LOC [0.6151517033576965, -0.698409914970398]
in B-LOC [0.7154984474182129, -0.9044284224510193]
vessels B-LOC [0.6506174206733704, -0.9574103355407715]
from B-LOC [0.7569552063941956, -0.6987680792808533]
the B-LOC [0.8163522481918335, -0.7847850918769836]
ET B-LOC [0.8930659294128418, -1.003216028213501]
group. B-LOC [0.45062580704689026, -0.7951207756996155]
L-NMMA O [-0.48652300238609314, 0.5022600293159485]
caused O [-0.9290952086448669, 0.5874540209770203]
greater O [-0.7981497049331665, 0.853594958782196]
inhibition O [-1.0400387048721313, 0.764597475528717]
of O [-0.872675359249115, 0.76072758436203]
the O [-0.9329164028167725, 0.7835169434547424]
bradykinin-induced O [-0.7465312480926514, 0.5490767955780029]
relaxation O [-0.6743858456611633, 0.7840484976768494]
in O [-0.8382983803749084, 0.8101735711097717]
coronary O [-0.8334648609161377, 0.9769516587257385]
resistance O [-0.8493315577507019, 0.6485145092010498]
arteries O [-0.9016773104667664, 0.7655931115150452]
from O [-0.8164587616920471, 0.8240494132041931]
ET O [-0.45850029587745667, 0.4547477066516876]
pigs O [-0.8437901139259338, 0.6843225359916687]
relative O [-0.7865106463432312, 0.6734165549278259]
to O [-0.6771441102027893, 0.5885798931121826]

arteries O [-0.4566553235054016, 0.1661996841430664]
from O [-0.5951727032661438, 0.37647077441215515]
SED O [-0.3103048801422119, 0.11311987042427063]
pigs O [-0.49302372336387634, 0.26024356484413147]
and O [-0.730182409286499, 0.43887099623680115]
eliminated O [-0.43561092019081116, 0.4339865446090698]
the O [-0.7264208197593689, 0.5669453740119934]
training-induced O [-0.5003097653388977, 0.2879999577999115]
enhancement O [-0.597149133682251, 0.44069966673851013]
of O [-0.6330326199531555, 0.5219417214393616]
the O [-0.5981014370918274, 0.38121679425239563]
bradykinin O [-0.5012219548225403, 0.13903062045574188]
responses. O [-0.5632345080375671, 0.23157724738121033]
CONCLUSIONS O [-0.8953168392181396, 0.5947474837303162]
These O [-0.5611369013786316, 0.7574601173400879]
results O [-0.7390398979187012, 0.8832135796546936]
suggest O [-0.800150990486145, 0.8640022873878479]
that O [-1.1721642017364502, 0.9621540307998657]
exercise O [-1.063019871711731, 1.0456291437149048]
training O [-1.1116594076156616, 1.1341112852096558]
enhances O [-1.1424520015716553, 1.2367945909500122]
bradykinin-induced O [-1.1962981224060059, 1.098105549812317]
vasodilation O [-1.2070629596710205, 1.1052258014678955]
through O [-1.414996862411499, 1.1365721225738525]
increased O [-1.2679831981658936, 1.230830192565918]
endothelium-derived O [-1.2374943494796753, 1.2303800582885742]
relaxing O [-0.8060974478721619, 1.0549520254135132]
factor/nitric O [-1.0990279912948608, 0.9573177695274353]
oxide O [-0.7429154515266418, 0.734085738658905]
production O [-0.9071819186210632, 1.0807392597198486]
by O [-1.1075183153152466, 0.9503658413887024]
the O [-0.9594925045967102, 1.0636404752731323]
L-arginine/nitric O [-0.8063434362411499, 0.720807671546936]
oxide O [-0.5745508074760437, 0.5648054480552673]
synthase O [-1.008333683013916, 0.9997584819793701]
pathway. O [-1.1166894435882568, 0.9102022647857666]

CONTEXT B-LOC [1.4659423828125, -2.4434125423431396]
More B-LOC [2.7756359577178955, -2.838588237762451]
than B-LOC [2.9492928981781006, -2.874768018722534]
1.5 B-LOC [3.161776304244995, -2.944941520690918]
million B-LOC [3.0702478885650635, -3.0944199562072754]
US B-LOC [3.1774890422821045, -3.131091356277466]
adults B-LOC [3.2827634811401367, -2.952263116836548]
use B-LOC [3.241619825363159, -3.0741841793060303]
stimulants B-LOC [3.4004099369049072, -2.9316630363464355]
and B-LOC [3.1998400688171387, -3.188979387283325]
other B-LOC [3.6087610721588135, -3.0247957706451416]
medications B-LOC [3.093841314315796, -3.1914665699005127]
labeled B-LOC [3.582430362701416, -3.0584309101104736]
for B-LOC [3.44073486328125, -3.1659390926361084]
treatment B-LOC [3.322228193283081, -3.243708848953247]
of B-LOC [3.2353222370147705, -3.0331008434295654]
attention-deficit/hyperactivity B-LOC [2.8496644496917725, -3.102595567703247]
disorder B-LOC [3.0561721324920654, -3.0758109092712402]
(ADHD). B-LOC [3.232928991317749, -3.2975645065307617]
These B-LOC [3.0201621055603027, -2.805487871170044]
agents B-LOC [2.876882791519165, -2.951085329055786]
can B-LOC [2.716830015182495, -2.96498703956604]
increase B-LOC [2.469130754470825, -3.060375928878784]
heart B-LOC [2.6729166507720947, -3.2909493446350098]
rate B-LOC [2.651735544204712, -3.280235767364502]
and B-LOC [2.367835283279419, -2.852098226547241]
blood B-LOC [2.7771642208099365, -3.3690924644470215]
pressure, B-LOC [2.747009038925171, -3.2842447757720947]
raising B-LOC [2.905965566635132, -3.22050142288208]
concerns B-LOC [3.0284714698791504, -3.2809274196624756]
about B-LOC [2.864257574081421, -3.3520896434783936]
their B-LOC [3.122710943222046, -3.2321431636810303]
cardiovascular B-LOC [3.070582151412964, -3.289130449295044]
safety. B-LOC [3.2421908378601074, -3.4877781867980957]
OBJECTIVE B-LOC [3.180798292160034, -3.141279458999634]
To B-LOC [3.336620807647705, -3.2549781799316406]
examine B-LOC [3.4994795322418213, -3.1467912197113037]
whether B-LOC [3.4892807006835938, -3.192319393157959]
current B-LOC [3.372382402420044, -3.149813175201416]
use B-LOC [3.1776535511016846, -3.2055490016937256]
of B-LOC [3.2546536922454834, -2.7976253032684326]
medications B-LOC [3.431485414505005, -3.130279064178467]
prescribed B-LOC [3.580578088760376, -2.8212368488311768]
primarily B-LOC [3.2904865741729736, -2.788058280944824]
to B-LOC [3.235646963119507, -2.9189045429229736]
treat B-LOC [3.6859946250915527, -3.160330057144165]
ADHD B-LOC [3.660524368286133, -3.2698285579681396]
is B-LOC [3.5382847785949707, -3.2789995670318604]
associated B-LOC [3.5008153915405273, -3.367851495742798]
with B-LOC [3.4292638301849365, -3.1985509395599365]
increased B-LOC [3.3551599979400635, -3.5051188468933105]
risk B-LOC [3.640387535095215, -3.3679044246673584]
of B-LOC [3.2345926761627197, -3.0014164447784424]
serious B-LOC [3.525977849960327, -3.2041876316070557]
cardiovascular B-LOC [3.573350191116333, -3.2522318363189697]
events B-LOC [3.552286148071289, -3.267435312271118]
in B-LOC [3.3477251529693604, -3.189366579055786]
young B-LOC [3.6251935958862305, -2.905651330947876]
and B-LOC [3.2395408153533936, -3.051285982131958]
middle-aged B-LOC [3.404075860977173, -3.1513829231262207]
adults. B-LOC [3.6630892753601074, -3.0073158740997314]
DESIGN, B-LOC [2.6667213439941406, -2.745396614074707]
SETTING, B-LOC [1.7285258769989014, -2.3363022804260254]
AND B-LOC [2.5533602237701416, -2.790433168411255]
PARTICIPANTS B-LOC [2.1088359355926514, -2.61565899848938]

Retrospective, B-LOC [2.900023937225342, -3.719517946243286]
population-based B-LOC [3.5834250450134277, -4.038708686828613]
cohort B-LOC [3.4453351497650146, -3.659193277359009]
study B-LOC [3.3604419231414795, -3.845949172973633]
using B-LOC [3.2531967163085938, -3.850116491317749]
electronic B-LOC [3.341242551803589, -3.830937147140503]
health B-LOC [3.4509432315826416, -3.966893434524536]
care B-LOC [3.394822597503662, -3.8632261753082275]
records B-LOC [3.50641131401062, -3.8985183238983154]
from B-LOC [3.4142532348632812, -3.664799451828003]
4 B-LOC [3.469987630844116, -3.7590410709381104]
study B-LOC [3.403777837753296, -3.9824330806732178]
sites B-LOC [3.5338947772979736, -3.7043559551239014]
(OptumInsight B-LOC [3.404822587966919, -3.4999818801879883]
Epidemiology, B-LOC [3.3805758953094482, -3.707716226577759]
Tennessee B-LOC [3.398714303970337, -4.1842241287231445]
Medicaid, B-LOC [3.5171735286712646, -3.7077865600585938]
Kaiser B-LOC [3.400399923324585, -3.7291619777679443]
Permanente B-LOC [3.2454795837402344, -3.326136350631714]
California, B-LOC [3.4435524940490723, -3.75919771194458]
and B-LOC [3.4300358295440674, -3.483785629272461]
the B-LOC [3.49362850189209, -3.4058167934417725]
HMO B-LOC [3.2652266025543213, -3.589578866958618]
Research B-LOC [3.258558988571167, -3.7484002113342285]
Network), B-LOC [3.2649857997894287, -3.538719415664673]
starting B-LOC [3.433789014816284, -3.6355865001678467]
in B-LOC [3.310805082321167, -3.5054404735565186]
1986 B-LOC [3.4190561771392822, -3.753692388534546]
at B-LOC [3.28840708732605, -3.5777220726013184]
1 B-LOC [3.3359363079071045, -3.7550790309906006]
site B-LOC [3.3233697414398193, -3.819345712661743]
and B-LOC [3.3222129344940186, -3.3433213233947754]
ending B-LOC [3.6995227336883545, -3.4884188175201416]
in B-LOC [3.252904176712036, -3.5685150623321533]
2005 B-LOC [3.4347474575042725, -3.6011321544647217]
at B-LOC [3.209151268005371, -3.7477777004241943]
all B-LOC [3.36362624168396, -3.836010456085205]
sites, B-LOC [3.388408899307251, -3.7865657806396484]
with B-LOC [3.431676149368286, -3.685894250869751]
additional B-LOC [3.2805511951446533, -3.7994213104248047]
covariate B-LOC [3.480504274368286, -3.688183307647705]
assessment B-LOC [3.451831102371216, -3.8707878589630127]
using B-LOC [3.350698471069336, -3.749849557876587]
2007 B-LOC [3.501279592514038, -3.7860629558563232]
survey B-LOC [3.4910385608673096, -3.8810038566589355]
data. B-LOC [3.5142273902893066, -3.758152723312378]
Participants B-LOC [2.8516993522644043, -3.37442946434021]
were B-LOC [3.1076159477233887, -3.3972036838531494]
adults B-LOC [3.511955976486206, -3.069679021835327]
aged B-LOC [3.503872871398926, -3.143728494644165]
25 B-LOC [3.5642101764678955, -3.1687171459198]
through B-LOC [3.294339179992676, -3.230620861053467]
64 B-LOC [3.2850804328918457, -3.086308479309082]
years B-LOC [3.5443198680877686, -3.3070175647735596]
with B-LOC [3.3338327407836914, -3.217574119567871]
dispensed B-LOC [3.448862314224243, -3.3882925510406494]
prescriptions B-LOC [3.5700674057006836, -3.460118055343628]
for B-LOC [3.285238742828369, -3.2477850914001465]
methylphenidate, B-LOC [3.393115758895874, -3.297933578491211]
amphetamine, B-LOC [3.1631128787994385, -3.4188196659088135]
or B-LOC [3.392998218536377, -3.6710259914398193]
atomoxetine B-LOC [3.1489269733428955, -3.368084669113159]
at B-LOC [3.4720969200134277, -3.5298075675964355]
baseline. B-LOC [3.5348405838012695, -3.7260937690734863]
Each B-LOC [2.467806816101074, -2.6694459915161133]
medication B-LOC [2.6294150352478027, -2.7822320461273193]
user B-LOC [2.550823926925659, -2.466980218887329]
(n B-LOC [2.567748546600342, -2.1683108806610107]
= B-LOC [1.9593183994293213, -2.263537645339966]
150,359) B-LOC [2.448514223098755, -2.354734182357788]
was B-LOC [2.538790464401245, -2.3443398475646973]

matched B-LOC [3.3683974742889404, -3.4812865257263184]
to B-LOC [3.4874515533447266, -3.3938465118408203]
2 B-LOC [3.363908529281616, -3.4598488807678223]
nonusers B-LOC [3.4142446517944336, -3.497755289077759]
on B-LOC [3.443972587585449, -3.610203266143799]
study B-LOC [3.560525417327881, -3.558177947998047]
site, B-LOC [3.4850261211395264, -3.3442835807800293]
birth B-LOC [3.575659990310669, -3.3627102375030518]
year, B-LOC [3.4639079570770264, -3.1818888187408447]
sex, B-LOC [3.637657642364502, -3.49748158454895]
and B-LOC [3.4465267658233643, -3.4452850818634033]
calendar B-LOC [3.6584770679473877, -3.4211766719818115]
year B-LOC [3.52118182182312, -3.311208724975586]
(443,198 B-LOC [3.7292215824127197, -3.483029365539551]
total B-LOC [3.78175950050354, -3.6941421031951904]
users B-LOC [3.528388023376465, -3.3715035915374756]
and B-LOC [3.2278218269348145, -3.482997179031372]
nonusers). B-LOC [3.635742425918579, -3.4617464542388916]
MAIN B-LOC [3.2785274982452393, -3.0959813594818115]
OUTCOME B-LOC [3.1929409503936768, -2.8313236236572266]
MEASURES B-LOC [3.3261897563934326, -3.0640265941619873]
Serious B-LOC [3.4072153568267822, -2.9017364978790283]
cardiovascular B-LOC [3.3599321842193604, -3.2219226360321045]
events, B-LOC [3.5450565814971924, -3.0966784954071045]
including B-LOC [3.521760940551758, -3.0800564289093018]
myocardial B-LOC [3.2683727741241455, -2.8204591274261475]
infarction B-LOC [3.4374840259552, -3.028277635574341]
(MI), B-LOC [3.253692865371704, -2.8425850868225098]
sudden B-LOC [3.4257431030273438, -3.2909767627716064]
cardiac B-LOC [3.3155250549316406, -3.3439807891845703]
death B-LOC [3.3721563816070557, -3.1445162296295166]
(SCD), B-LOC [3.44684100151062, -3.1086347103118896]
or B-LOC [3.249610185623169, -3.273533821105957]
stroke, B-LOC [3.378011703491211, -3.1245956420898438]
with B-LOC [3.2428603172302246, -2.9392240047454834]
comparison B-LOC [3.400953531265259, -3.1288607120513916]
between B-LOC [3.357017755508423, -3.170290231704712]
current B-LOC [3.4753429889678955, -2.978520393371582]
or B-LOC [3.3055078983306885, -3.120361804962158]
new B-LOC [3.355534076690674, -3.0290579795837402]
users B-LOC [3.4449267387390137, -3.1240992546081543]
and B-LOC [3.370668888092041, -3.0796937942504883]
remote B-LOC [3.3211238384246826, -3.2126176357269287]
users B-LOC [3.446195125579834, -3.1833393573760986]
to B-LOC [3.2612364292144775, -2.8221864700317383]
account B-LOC [3.4594616889953613, -3.1818602085113525]
for B-LOC [3.4805428981781006, -3.0268616676330566]
potential B-LOC [3.3888049125671387, -3.165916681289673]
healthy-user B-LOC [3.3032472133636475, -3.3683578968048096]
bias. B-LOC [3.3135621547698975, -3.3556578159332275]
RESULTS B-LOC [1.1059391498565674, -1.9059631824493408]
During B-LOC [1.390952706336975, -1.8029861450195312]
806,182 B-LOC [2.1758482456207275, -2.0655908584594727]
person-years B-LOC [1.6481518745422363, -2.2710883617401123]
of B-LOC [1.9027012586593628, -2.0140557289123535]
follow-up B-LOC [1.857456922531128, -2.1566519737243652]
(median, B-LOC [2.1432416439056396, -2.140238046646118]
1.3 B-LOC [2.2724807262420654, -1.9556052684783936]
years B-LOC [2.1965816020965576, -2.2835330963134766]
per B-LOC [2.0455386638641357, -2.4979734420776367]
person), B-LOC [2.097546339035034, -2.485377550125122]
1357 B-LOC [2.294311761856079, -2.0362141132354736]
cases B-LOC [1.8201372623443604, -1.9795273542404175]
of B-LOC [1.3902661800384521, -1.9499086141586304]
MI, B-LOC [1.5833483934402466, -1.7905774116516113]
296 B-LOC [2.4853289127349854, -2.1127192974090576]
cases B-LOC [1.7331315279006958, -1.8834433555603027]
of B-LOC [1.2606797218322754, -1.8066165447235107]

SCD, B-LOC [0.8444992303848267, -1.064755916595459]
and B-LOC [1.5156303644180298, -1.5504364967346191]
575 B-LOC [2.5171589851379395, -1.8750972747802734]
cases B-LOC [1.9376215934753418, -1.9589118957519531]
of B-LOC [2.0055456161499023, -1.8020328283309937]
stroke B-LOC [2.0916411876678467, -2.059802770614624]
occurred. B-LOC [1.9797515869140625, -1.8933310508728027]
There B-LOC [1.6602895259857178, -1.4780986309051514]
were B-LOC [2.143878221511841, -1.7458419799804688]
107,322 B-LOC [2.3900504112243652, -2.0264244079589844]
person-years B-LOC [1.4047526121139526, -1.713139533996582]
of B-LOC [2.060903310775757, -2.010512590408325]
current B-LOC [2.147681474685669, -1.648032784461975]
use B-LOC [1.4951045513153076, -1.3525446653366089]
(median, B-LOC [1.9287927150726318, -1.475730299949646]
0.33 B-LOC [2.438013792037964, -1.539578914642334]
years), B-LOC [2.509667158126831, -1.762221097946167]
with B-LOC [1.0387372970581055, -0.6905001997947693]
a B-LOC [0.6562959551811218, -0.6156140565872192]
crude B-LOC [0.379631906747818, -0.48301613330841064]
incidence B-LOC [0.4088194668292999, -0.6155303716659546]
per B-LOC [0.3808703124523163, -0.8085584044456482]
1000 B-LOC [0.7711057066917419, -0.7595419883728027]
person-years B-LOC [0.43024203181266785, -0.7932144403457642]
of B-LOC [0.3911004960536957, -0.758993923664093]
1.34 B-LOC [0.6943780779838562, -0.46774646639823914]
(95% B-LOC [0.42355871200561523, -0.7372058033943176]
CI, B-LOC [-0.07829038053750992, -0.4014001190662384]
1.14-1.57) B-LOC [0.41522663831710815, -0.2727901041507721]
for B-LOC [0.2370399832725525, -0.5162009596824646]
MI, B-LOC [0.024278433993458748, -0.2447294294834137]
0.30 B-LOC [0.41217857599258423, -0.5228491425514221]
(95% B-LOC [0.132526233792305, -0.528863251209259]
CI, O [-0.2633678615093231, -0.12875954806804657]
0.20-0.42) B-LOC [0.29799768328666687, -0.40238627791404724]
for B-LOC [0.2311268001794815, -0.47429022192955017]
SCD, B-LOC [0.2686130702495575, -0.13419464230537415]
and B-LOC [0.19786831736564636, -0.3024391233921051]
0.56 B-LOC [0.4557313323020935, -0.4824927747249603]
(95% B-LOC [0.22767868638038635, -0.6240353584289551]
CI, B-LOC [-0.17685531079769135, -0.20957988500595093]
0.43-0.72) B-LOC [0.40796157717704773, -0.4255644381046295]
for B-LOC [0.21853980422019958, -0.5009040236473083]
stroke. B-LOC [0.48103979229927063, -0.48215970396995544]
The B-LOC [0.6435596346855164, -0.7353465557098389]
multivariable-adjusted B-LOC [0.620270848274231, -0.7608150839805603]
rate B-LOC [0.534237265586853, -0.866759717464447]
ratio B-LOC [0.6113814115524292, -0.8006362318992615]
(RR) B-LOC [1.006941556930542, -1.0319665670394897]
of B-LOC [0.6338731646537781, -0.8501212000846863]
serious B-LOC [0.4472227692604065, -0.7129535675048828]
cardiovascular B-LOC [0.49150294065475464, -0.7027372121810913]
events B-LOC [0.497361958026886, -0.6866387724876404]
for B-LOC [0.6694338321685791, -0.7377604842185974]
current B-LOC [0.5827863812446594, -0.6102334856987]

use B-LOC [-0.03286005184054375, -0.4120481312274933]
vs B-LOC [0.19348199665546417, -0.46042314171791077]
nonuse B-LOC [0.1742163598537445, -0.4108509421348572]
of B-LOC [0.06501385569572449, -0.4680861532688141]
ADHD B-LOC [0.09620297700166702, -0.3398183584213257]
medications B-LOC [-0.05272914841771126, -0.4360414445400238]
was B-LOC [0.13643980026245117, -0.5363696217536926]
0.83 B-LOC [0.28615739941596985, -0.4635387361049652]
(95% B-LOC [0.12918198108673096, -0.5223777890205383]
CI, B-LOC [-0.1697808802127838, -0.3027074635028839]
0.72-0.96). B-LOC [0.2093430906534195, -0.33204856514930725]
Among B-LOC [0.3374878168106079, -0.5017741322517395]
new B-LOC [0.5912646651268005, -0.5620587468147278]
users B-LOC [0.6232215762138367, -0.49238958954811096]
of B-LOC [0.4596974551677704, -0.48714396357536316]
ADHD B-LOC [0.3211650550365448, -0.3849727511405945]
medications, B-LOC [0.1953466683626175, -0.5722620487213135]
the B-LOC [0.5883139967918396, -0.6861365437507629]
adjusted B-LOC [0.21026307344436646, -0.6536325812339783]
RR B-LOC [0.24456924200057983, -0.6352563500404358]
was B-LOC [0.3183456361293793, -0.4831271767616272]
0.77 B-LOC [0.43295741081237793, -0.44173550605773926]
(95% B-LOC [0.24122509360313416, -0.5119447708129883]
CI, B-LOC [-0.02742922119796276, -0.40950146317481995]
0.63-0.94). B-LOC [0.4042356312274933, -0.42685458064079285]
The B-LOC [0.125483900308609, -0.26173651218414307]
adjusted B-LOC [0.022997992113232613, -0.12807545065879822]
RR B-LOC [-0.03401102498173714, -0.17910829186439514]
for B-LOC [0.15073582530021667, -0.22299185395240784]
current B-LOC [0.21395443379878998, -0.13394534587860107]
use B-LOC [0.21419554948806763, -0.2035401463508606]
vs B-LOC [-0.013470721431076527, -0.12340918928384781]
remote B-LOC [0.1650938242673874, -0.1542646288871765]
use B-LOC [0.1295095980167389, -0.18636184930801392]
was B-LOC [0.07216529548168182, -0.03884749487042427]
1.03 B-LOC [0.17219212651252747, -0.12606298923492432]
(95% B-LOC [0.057936687022447586, -0.22440560162067413]
CI, O [-0.2165333330631256, -0.054994139820337296]
0.86-1.24); B-LOC [0.25132450461387634, -0.09241169691085815]
for B-LOC [-0.06250971555709839, -0.06367292255163193]
new B-LOC [0.10919930040836334, -0.0348607562482357]
use B-LOC [0.3332974314689636, -0.17328377068042755]
vs B-LOC [-0.007114102598279715, -0.08268663287162781]
remote B-LOC [0.11269481480121613, -0.062154371291399]
use, B-LOC [0.2446841299533844, -0.2513234317302704]
the B-LOC [0.08870862424373627, -0.22445045411586761]
adjusted B-LOC [-0.10307425260543823, -0.20258928835391998]
RR B-LOC [-0.1440032422542572, -0.16947585344314575]
was B-LOC [-0.007123125251382589, -0.0888957753777504]
1.02 B-LOC [0.1250520944595337, -0.09295772016048431]
(95% B-LOC [0.038159240037202835, -0.26730087399482727]
CI, O [-0.2578577697277069, -0.05118236318230629]
0.82-1.28); B-LOC [0.20482125878334045, -0.10349175333976746]
the B-LOC [0.06228821352124214, -0.12342365831136703]
upper B-LOC [0.06800863146781921, -0.17328496277332306]
limit B-LOC [0.12978136539459229, -0.24576205015182495]
of B-LOC [0.09172821789979935, -0.17291846871376038]
1.28 B-LOC [0.16273407638072968, -0.11970289051532745]

corresponds B-LOC [0.4196036458015442, -0.9952493906021118]
to B-LOC [0.701724112033844, -1.0340226888656616]
an B-LOC [0.7404124140739441, -1.0522757768630981]
additional B-LOC [0.7022761106491089, -1.262784481048584]
0.19 B-LOC [0.9066822528839111, -1.370596170425415]
events B-LOC [0.6388234496116638, -1.2768443822860718]
per B-LOC [0.6757277846336365, -1.5268828868865967]
1000 B-LOC [0.9714105725288391, -1.470520257949829]
person-years B-LOC [0.650778591632843, -1.7126221656799316]
at B-LOC [0.5565987229347229, -1.412956953048706]
ages B-LOC [1.1154818534851074, -1.4307935237884521]
25-44 B-LOC [1.5278971195220947, -1.5866601467132568]
years B-LOC [1.1654117107391357, -1.6244655847549438]
and B-LOC [0.6431381106376648, -1.0276522636413574]
0.77 B-LOC [0.9525021910667419, -1.323828101158142]
events B-LOC [0.723269522190094, -1.3964526653289795]
per B-LOC [0.8849509954452515, -1.595766544342041]
1000 B-LOC [1.104212760925293, -1.5582847595214844]
person-years B-LOC [0.7700942754745483, -1.813126564025879]
at B-LOC [0.7990561127662659, -1.522011399269104]
ages B-LOC [1.3840527534484863, -1.6277580261230469]
45-64 B-LOC [1.5519510507583618, -1.4988067150115967]
years. B-LOC [1.2739965915679932, -1.8488714694976807]
CONCLUSIONS O [-1.3753807544708252, 1.269700527191162]
Among O [-1.1092559099197388, 1.0373433828353882]
young O [-0.8199194073677063, 1.1819922924041748]
and O [-0.9639955163002014, 0.7451486587524414]
middle-aged O [-0.779702365398407, 0.8266743421554565]
adults, O [-0.8664225339889526, 0.988021969795227]
current O [-1.2006640434265137, 1.2981741428375244]
or O [-1.0847444534301758, 0.8787246346473694]
new O [-1.2867918014526367, 1.2482292652130127]
use O [-1.0717612504959106, 1.1600978374481201]
of O [-1.2488030195236206, 1.2167874574661255]
ADHD O [-1.0754663944244385, 1.189619541168213]
medications, O [-0.937221109867096, 1.0128289461135864]
compared O [-1.4489476680755615, 1.4195547103881836]
with O [-1.3745607137680054, 1.2120800018310547]
nonuse O [-1.2456680536270142, 1.3450121879577637]
or O [-1.32058584690094, 0.9934837222099304]
remote O [-1.1915175914764404, 1.0899591445922852]
use, O [-0.9923715591430664, 1.1052649021148682]
was O [-1.4393366575241089, 1.1230754852294922]
not O [-1.30392324924469, 1.326979398727417]
associated O [-1.4505223035812378, 1.2856478691101074]
with O [-1.41390860080719, 1.1817747354507446]
an O [-1.4239275455474854, 1.0446512699127197]
increased O [-1.3362852334976196, 1.0352058410644531]
risk O [-1.3151789903640747, 1.1011096239089966]
of O [-1.414330005645752, 1.1047263145446777]
serious O [-1.3163578510284424, 0.8433936834335327]
cardiovascular O [-1.0383105278015137, 0.9453592896461487]
events. O [-1.1319831609725952, 0.9535455703735352]
Apparent B-LOC [1.4740960597991943, -1.5205662250518799]
protective B-LOC [1.3411645889282227, -1.6642045974731445]
associations B-LOC [1.2673532962799072, -1.5053894519805908]
likely B-LOC [1.6563295125961304, -1.5988208055496216]
represent B-LOC [1.4375090599060059, -1.547836422920227]
healthy-user B-LOC [1.228771686553955, -1.7102155685424805]
bias. B-LOC [1.3028005361557007, -1.7917903661727905]

Molecular B-LOC [1.5379071235656738, -1.9144413471221924]
motors B-LOC [1.4000389575958252, -1.6094609498977661]
play B-LOC [1.7892636060714722, -1.8418922424316406]
critical B-LOC [1.643930196762085, -1.8826431035995483]
roles B-LOC [1.6734404563903809, -1.8525618314743042]
in B-LOC [1.471940040588379, -1.8737781047821045]
the B-LOC [1.5079736709594727, -1.7416075468063354]
formation B-LOC [1.5898315906524658, -1.600019931793213]
of B-LOC [1.4294452667236328, -1.7221786975860596]
mitotic B-LOC [1.6340137720108032, -1.7684814929962158]
spindles, B-LOC [1.9400413036346436, -1.7499035596847534]
either B-LOC [1.8074231147766113, -2.1438162326812744]
through B-LOC [1.329849123954773, -1.8514766693115234]
controlling B-LOC [1.470242977142334, -1.7653660774230957]
the B-LOC [1.6281952857971191, -1.8124382495880127]
stability B-LOC [1.5644011497497559, -1.4535579681396484]
of B-LOC [1.559047818183899, -1.75724458694458]
individual B-LOC [1.5119613409042358, -1.9070614576339722]
microtubules, B-LOC [1.6057755947113037, -1.683912754058838]
or B-LOC [1.8511271476745605, -1.8799227476119995]
by B-LOC [1.353482961654663, -1.779900312423706]
crosslinking B-LOC [1.6021840572357178, -1.6433649063110352]
and B-LOC [1.3838698863983154, -1.5522511005401611]
sliding B-LOC [1.7348929643630981, -1.8624111413955688]
microtubule B-LOC [1.776443600654602, -1.7671211957931519]
arrays. B-LOC [1.7342513799667358, -1.6472984552383423]
Kinesin-8 B-LOC [1.4413838386535645, -1.502974271774292]
motors B-LOC [1.5629467964172363, -1.4661366939544678]
are B-LOC [2.2577250003814697, -1.7028292417526245]
best B-LOC [2.559389114379883, -2.0472559928894043]
known B-LOC [2.2829525470733643, -1.8150972127914429]
for B-LOC [2.231766939163208, -1.9874904155731201]
their B-LOC [2.053574800491333, -1.7786865234375]
regulatory B-LOC [2.327127695083618, -1.9856185913085938]
roles B-LOC [2.141141653060913, -1.8202028274536133]
in B-LOC [2.049938678741455, -1.8340985774993896]
controlling B-LOC [2.4021875858306885, -2.1634275913238525]
microtubule B-LOC [2.2181193828582764, -1.7662514448165894]
dynamics. B-LOC [2.2397191524505615, -1.9994702339172363]
They B-LOC [1.8999933004379272, -1.4048917293548584]
contain B-LOC [1.9824328422546387, -1.6822915077209473]
microtubule-destabilizing B-LOC [1.9560470581054688, -1.755203366279602]
activities, B-LOC [2.120478868484497, -1.7741997241973877]
and B-LOC [1.7102842330932617, -1.3857276439666748]
restrict B-LOC [1.6725802421569824, -1.7040376663208008]
spindle B-LOC [1.9417864084243774, -1.7322248220443726]
length B-LOC [1.652101755142212, -1.8183374404907227]
in B-LOC [1.8836896419525146, -2.0317280292510986]
a B-LOC [2.3145740032196045, -1.7735306024551392]
wide B-LOC [2.293541669845581, -2.0577614307403564]
variety B-LOC [2.2372262477874756, -2.1295998096466064]
of B-LOC [2.1718645095825195, -2.0809004306793213]
cell B-LOC [1.7225290536880493, -1.8483152389526367]
types B-LOC [2.337808847427368, -2.098775625228882]
and B-LOC [2.1518967151641846, -2.1450419425964355]
organisms. B-LOC [2.189138412475586, -2.020522117614746]
Here, B-LOC [0.39037856459617615, -0.4806348383426666]
we B-LOC [0.3245036005973816, -0.30014219880104065]
report B-LOC [0.48960980772972107, -0.512007474899292]
an B-LOC [0.42287418246269226, -0.6273296475410461]
antiparallel B-LOC [0.7064131498336792, -0.7295841574668884]
microtubule-sliding B-LOC [0.6548007130622864, -0.81332927942276]
activity B-LOC [0.5569974780082703, -0.735773503780365]
of B-LOC [0.5673442482948303, -0.7841284275054932]
the B-LOC [0.7529991865158081, -0.6447127461433411]
budding B-LOC [0.6016121506690979, -0.6767676472663879]
yeast B-LOC [0.591942310333252, -0.7960242033004761]
kinesin-8, B-LOC [0.5497310161590576, -0.792455792427063]
Kip3. B-LOC [0.5054164528846741, -0.6922154426574707]
The B-LOC [0.7231910824775696, -0.9031431078910828]
in B-LOC [0.4713593125343323, -0.821448028087616]
vivo B-LOC [0.25163331627845764, -0.6925554871559143]
importance B-LOC [0.7604814767837524, -1.1100867986679077]
of B-LOC [0.989342987537384, -1.0147086381912231]
this B-LOC [0.8311772346496582, -0.8856046199798584]

sliding B-LOC [1.4066689014434814, -1.6691824197769165]
activity B-LOC [1.6248650550842285, -1.587294101715088]
was B-LOC [1.6350252628326416, -1.5505321025848389]
established B-LOC [1.8742055892944336, -1.6768467426300049]
through B-LOC [1.7051591873168945, -1.736776351928711]
the B-LOC [1.9185681343078613, -1.7134512662887573]
identification B-LOC [1.9450781345367432, -1.6650806665420532]
of B-LOC [1.9964544773101807, -1.899459958076477]
complementary B-LOC [1.9385443925857544, -1.9917163848876953]
Kip3 B-LOC [1.5423132181167603, -1.5687096118927002]
mutants B-LOC [1.6414923667907715, -1.6736335754394531]
that B-LOC [2.054964542388916, -1.9305176734924316]
separate B-LOC [1.9318779706954956, -1.7762590646743774]
the B-LOC [1.752180814743042, -1.7248239517211914]
sliding B-LOC [1.724121332168579, -1.759247899055481]
activity B-LOC [1.5047991275787354, -1.6586143970489502]
and B-LOC [1.9018523693084717, -1.9185445308685303]
microtubule-destabilizing B-LOC [1.5651156902313232, -1.704591989517212]
activity. B-LOC [1.559948444366455, -1.6567797660827637]
In B-LOC [0.4361813962459564, -0.4264253079891205]
conjunction B-LOC [0.6585387587547302, -0.37950170040130615]
with B-LOC [0.6534984707832336, -0.6292546391487122]
Cin8, B-LOC [0.5308195948600769, -0.5948358178138733]
a B-LOC [0.6412946581840515, -0.6853781342506409]
kinesin-5 B-LOC [0.8382460474967957, -0.806664228439331]
family B-LOC [0.8816384077072144, -0.7572941780090332]
member, B-LOC [0.990034818649292, -0.9960908889770508]
the B-LOC [0.6948389410972595, -0.6981316208839417]
sliding B-LOC [1.0097625255584717, -0.87068772315979]
activity B-LOC [0.7558179497718811, -0.7353940010070801]
of B-LOC [0.7122089266777039, -0.7181535363197327]
Kip3 B-LOC [0.8241981863975525, -0.7187467217445374]
promotes B-LOC [0.8297103047370911, -0.7711806297302246]
bipolar B-LOC [0.8182113170623779, -0.7976803779602051]
spindle B-LOC [0.9515627026557922, -0.7949140667915344]
assembly B-LOC [0.7676190733909607, -0.7533138394355774]
and B-LOC [0.8046850562095642, -0.7712056040763855]
the B-LOC [0.741557240486145, -0.9672831296920776]
maintenance B-LOC [1.0101220607757568, -0.9610067009925842]
of B-LOC [0.8858018517494202, -1.106022596359253]
genome B-LOC [0.8681747913360596, -1.1353652477264404]
stability. B-LOC [0.9812025427818298, -1.0175234079360962]
We B-LOC [0.8834095001220703, -0.7401461005210876]
propose B-LOC [1.6115705966949463, -1.054539680480957]
a B-LOC [1.459769368171692, -1.3464534282684326]
slide-disassemble B-LOC [1.3036537170410156, -1.759822130203247]
model B-LOC [1.5369302034378052, -1.6934854984283447]
where B-LOC [1.3504384756088257, -1.740532398223877]
the B-LOC [1.60086989402771, -1.540092945098877]
sliding B-LOC [1.229368805885315, -1.4131429195404053]
and B-LOC [1.189856767654419, -1.4627777338027954]
destabilizing B-LOC [1.3416134119033813, -1.5675036907196045]
activity B-LOC [1.3165433406829834, -1.3994407653808594]
of B-LOC [1.3510537147521973, -1.4452894926071167]
Kip3 B-LOC [1.2512508630752563, -1.3785300254821777]
balance B-LOC [1.0568032264709473, -1.4140936136245728]
during B-LOC [1.2646082639694214, -1.4759507179260254]
pre-anaphase. B-LOC [1.1244922876358032, -1.3333637714385986]
This B-LOC [1.320170283317566, -1.445704460144043]
facilitates B-LOC [1.268649697303772, -1.5348918437957764]
normal B-LOC [1.0270445346832275, -1.4667491912841797]
spindle B-LOC [1.4171689748764038, -1.5452922582626343]
assembly. B-LOC [1.25786292552948, -1.3373045921325684]
However, B-LOC [0.4896995425224304, -0.6403839588165283]
the B-LOC [0.40689703822135925, -0.5315458178520203]
destabilizing B-LOC [0.49624618887901306, -0.5794191956520081]
activity B-LOC [0.3776634633541107, -0.49857059121131897]
of B-LOC [0.3773815631866455, -0.549044668674469]
Kip3 B-LOC [0.3375052511692047, -0.4810848534107208]
dominates B-LOC [0.38152143359184265, -0.653025209903717]
in B-LOC [0.32524362206459045, -0.4942304790019989]
late B-LOC [0.3529631793498993, -0.49045440554618835]
anaphase, B-LOC [0.14192956686019897, -0.6235248446464539]

inhibiting O [-0.689363956451416, 0.5581587553024292]
spindle O [-0.22206512093544006, 0.23977527022361755]
elongation O [-0.5086588263511658, 0.3282034695148468]
and O [-0.5389379858970642, 0.4744151532649994]
ultimately O [-0.5506694912910461, 0.47668495774269104]
promoting O [-0.6847277283668518, 0.661257266998291]
spindle O [-0.15410299599170685, 0.22340746223926544]
disassembly. O [-0.30539843440055847, 0.2415173500776291]

Synaptic B-LOC [1.4720178842544556, -2.1051738262176514]
long-term B-LOC [1.5935863256454468, -2.017000913619995]
potentiation B-LOC [1.4720678329467773, -2.0338470935821533]
(LTP) B-LOC [1.9666541814804077, -2.448840618133545]
at B-LOC [1.4231942892074585, -1.932163953781128]
spinal B-LOC [1.738226056098938, -2.463602304458618]
neurons B-LOC [1.6621549129486084, -2.228978157043457]
directly B-LOC [1.5897085666656494, -2.0986716747283936]
communicating B-LOC [1.4137251377105713, -2.069516897201538]
pain-specific B-LOC [1.3541173934936523, -1.9519867897033691]
inputs B-LOC [1.2795705795288086, -2.1316635608673096]
from B-LOC [1.7962572574615479, -2.1081905364990234]
the B-LOC [2.2057878971099854, -2.375582218170166]
periphery B-LOC [1.6979867219924927, -2.308950901031494]
to B-LOC [1.8352516889572144, -2.3195736408233643]
the B-LOC [2.2242801189422607, -2.5589632987976074]
brain B-LOC [1.7480663061141968, -2.5711734294891357]
has B-LOC [2.8177268505096436, -2.451616048812866]
been B-LOC [2.754227876663208, -2.660094976425171]
proposed B-LOC [2.5776784420013428, -2.5853631496429443]
to B-LOC [2.7004432678222656, -2.7099215984344482]
serve B-LOC [2.3412115573883057, -2.691141366958618]
as B-LOC [2.541984796524048, -2.8357253074645996]
a B-LOC [2.4912188053131104, -2.731727123260498]
trigger B-LOC [2.461073398590088, -2.832902193069458]
for B-LOC [2.389763593673706, -2.7417426109313965]
pain B-LOC [1.9833059310913086, -2.581359386444092]
hypersensitivity B-LOC [2.3269083499908447, -2.57985520362854]
in B-LOC [2.4271481037139893, -2.767563581466675]
pathological B-LOC [2.61836838722229, -2.8947792053222656]
states. B-LOC [2.2280399799346924, -2.76025652885437]
Previous B-LOC [2.4777464866638184, -2.509289026260376]
studies B-LOC [2.436095952987671, -2.3509461879730225]
have B-LOC [2.69565749168396, -2.284177541732788]
functionally B-LOC [2.9117095470428467, -2.779513120651245]
implicated B-LOC [2.6070330142974854, -2.5363118648529053]
the B-LOC [2.466024398803711, -2.521840810775757]
NMDA B-LOC [2.117983102798462, -2.477307081222534]
receptor-NO B-LOC [2.0737979412078857, -2.659137010574341]
pathway B-LOC [1.9327620267868042, -2.546564817428589]
and B-LOC [2.410285234451294, -2.511895179748535]
the B-LOC [2.44759202003479, -2.2890069484710693]
downstream B-LOC [2.3911237716674805, -2.6578524112701416]
second B-LOC [2.1786372661590576, -2.4856762886047363]
messenger, B-LOC [1.9155501127243042, -2.566126585006714]
cGMP, B-LOC [1.8739848136901855, -2.453970432281494]
in B-LOC [2.4243884086608887, -2.898101568222046]
these B-LOC [2.510014533996582, -2.6610004901885986]
processes. B-LOC [2.187497615814209, -2.494239330291748]
Because B-LOC [0.5557264685630798, -0.6111846566200256]
cGMP B-LOC [0.6013069152832031, -0.8768711686134338]
can B-LOC [1.0759718418121338, -1.1058505773544312]
broadly B-LOC [1.0820854902267456, -1.164575219154358]
influence B-LOC [0.8106135129928589, -1.1843032836914062]
diverse B-LOC [0.9729358553886414, -1.3431320190429688]
ion-channels, B-LOC [0.7405772805213928, -1.2030625343322754]
kinases, B-LOC [0.944304347038269, -1.1308343410491943]
and B-LOC [1.062394142150879, -1.1818866729736328]
phosphodiesterases, B-LOC [0.8038778901100159, -1.1674935817718506]
pre- B-LOC [0.5077094435691833, -0.986178457736969]
as B-LOC [0.84261155128479, -1.0785748958587646]
well B-LOC [0.891126811504364, -1.111128330230713]
as B-LOC [1.0313622951507568, -1.2331901788711548]
post-synaptically, B-LOC [0.5404824614524841, -0.9505126476287842]
the B-LOC [0.8199321627616882, -0.8521581292152405]

precise B-LOC [2.409740686416626, -2.7652783393859863]
identity B-LOC [2.8380191326141357, -2.619767427444458]
of B-LOC [2.386589765548706, -2.710029363632202]
cGMP B-LOC [2.2375712394714355, -2.4955356121063232]
targets B-LOC [2.6995344161987305, -2.510711908340454]
mediating B-LOC [2.4819483757019043, -2.6232707500457764]
spinal B-LOC [1.889283299446106, -2.460602045059204]
LTP, B-LOC [1.9431068897247314, -2.2743442058563232]
their B-LOC [2.4513378143310547, -2.7815849781036377]
mechanisms B-LOC [2.877423048019409, -2.7554543018341064]
of B-LOC [2.688854217529297, -2.835578680038452]
action, B-LOC [2.5994627475738525, -2.7191970348358154]
and B-LOC [2.827111005783081, -2.7496721744537354]
their B-LOC [2.726900339126587, -2.800229787826538]
locus B-LOC [2.9063775539398193, -2.762786626815796]
in B-LOC [2.6425607204437256, -2.7563929557800293]
the B-LOC [2.7753498554229736, -2.627717971801758]
spinal B-LOC [2.2486793994903564, -2.7571613788604736]
circuitry B-LOC [2.7984025478363037, -2.7375447750091553]
are B-LOC [2.993901491165161, -2.7685368061065674]
still B-LOC [3.0027918815612793, -2.6924431324005127]
unclear. B-LOC [2.9799492359161377, -2.637272596359253]
Here, O [-0.3695990741252899, 0.3629129230976105]
we O [-0.648249089717865, 0.3496275842189789]
found O [-0.6768489480018616, 0.5449233651161194]
that O [-0.8353443145751953, 0.5868938565254211]
Protein O [-0.6103081107139587, 0.32079529762268066]
Kinase O [-0.49121883511543274, 0.33499637246131897]
G1 O [-0.4184025824069977, 0.40480855107307434]
(PKG-I) O [-0.6249248385429382, 0.5361855626106262]
localized O [-0.6334142088890076, 0.5485401749610901]
presynaptically O [-0.7685638666152954, 0.6227344870567322]
in O [-0.659600555896759, 0.6022540330886841]
nociceptor O [-0.5944725871086121, 0.5530514121055603]
terminals O [-0.7113161683082581, 0.4809170663356781]
plays O [-0.6920496225357056, 0.6321973204612732]
an O [-0.6738786697387695, 0.6560278534889221]
essential O [-0.7192118763923645, 0.691977322101593]
role O [-0.7513068318367004, 0.5824077725410461]
in O [-0.6814307570457458, 0.49695855379104614]
the O [-0.6153674125671387, 0.5116581320762634]
expression O [-0.4860800504684448, 0.7673671841621399]
of O [-0.4900643527507782, 0.3673763573169708]
spinal O [-0.5559249520301819, 0.19148845970630646]
LTP. O [-0.3743133246898651, 0.13143384456634521]
Using B-LOC [0.2321292757987976, -0.5935801267623901]
the B-LOC [0.6716771721839905, -0.5827675461769104]
Cre-lox B-LOC [0.5400821566581726, -0.6580755710601807]
P B-LOC [0.2699833810329437, -0.8157656788825989]
system, B-LOC [0.5744432806968689, -0.8705063462257385]
we B-LOC [0.2918826937675476, -0.6027006506919861]
generated B-LOC [0.44564276933670044, -0.42661815881729126]
nociceptor-specific B-LOC [0.16735121607780457, -0.3809601664543152]
knockout B-LOC [0.230600968003273, -0.5412811040878296]
mice B-LOC [0.008966523222625256, -0.5222311019897461]
lacking B-LOC [-0.05097656324505806, -0.2919907867908478]
PKG-I B-LOC [0.13022764027118683, -0.3922572135925293]
specifically B-LOC [-0.12632791697978973, -0.2141142189502716]
in O [-0.0576559416949749, 0.07690343260765076]
presynaptic O [-0.252705842256546, 0.18250501155853271]
terminals O [-0.14259381592273712, 0.08932549506425858]
of O [-0.1864386349916458, 0.11518530547618866]
nociceptors O [-0.24031788110733032, 0.04847941920161247]
in O [-0.08796872198581696, 0.07202886790037155]
the O [-0.04646903648972511, 0.10536395758390427]
spinal B-LOC [-0.11774654686450958, -0.17761960625648499]
cord, O [-0.2548612654209137, -0.22022421658039093]
but B-LOC [0.0775938555598259, -0.13745176792144775]
not B-LOC [0.05051418021321297, 0.03243403509259224]
in B-LOC [0.0082523999735713, -0.03225063905119896]
post-synaptic O [-0.31622204184532166, 0.07206644117832184]

neurons B-LOC [0.11190230399370193, -0.6252292990684509]
or B-LOC [0.6290563941001892, -1.1802499294281006]
elsewhere B-LOC [0.5371820330619812, -0.8713591694831848]
(SNS-PKG-I(-/-) B-LOC [0.6628023982048035, -0.8537383675575256]
mice). B-LOC [0.17597472667694092, -0.5891624093055725]
Patch O [-0.3016338050365448, 0.3597855865955353]
clamp O [-0.3809579312801361, 0.39857831597328186]
recordings O [-0.49037325382232666, 0.42982006072998047]
showed O [-0.6963534951210022, 0.5419728755950928]
that O [-1.1194590330123901, 0.874620795249939]
activity-induced O [-0.7421940565109253, 0.8446718454360962]
LTP O [-0.9382650256156921, 0.9042933583259583]
at O [-0.7993072867393494, 0.8314099311828613]
identified O [-0.8483238816261292, 0.9813977479934692]
synapses O [-0.9015026092529297, 0.7752041220664978]
between O [-0.8317047953605652, 0.7741783261299133]
nociceptors O [-1.0636893510818481, 0.8893458843231201]
and O [-0.9247587323188782, 0.8312996029853821]
spinal O [-0.992060661315918, 0.7411295175552368]
neurons O [-0.7990966439247131, 0.7935395836830139]
projecting O [-0.7808837294578552, 0.7452903985977173]
to O [-0.7763287425041199, 0.8419495820999146]
the O [-0.7826012372970581, 0.9227848052978516]
periaqueductal O [-1.0814416408538818, 0.674531877040863]
grey O [-0.7443367838859558, 0.7952319383621216]
(PAG) O [-0.8333777785301208, 0.6232473254203796]
was O [-0.8727361559867859, 0.8584732413291931]
completely O [-0.6891219019889832, 0.7739913463592529]
abolished O [-0.7188689112663269, 0.8123218417167664]
in O [-0.82121741771698, 0.7471016049385071]
SNS-PKG-I(-/-) O [-0.6889638304710388, 0.4318486154079437]
mice, O [-0.863644540309906, 0.8405691981315613]
although O [-0.7693630456924438, 0.620527982711792]
basal O [-0.6897252202033997, 0.39974430203437805]
synaptic O [-0.7920977473258972, 0.4518325924873352]
transmission O [-0.69504314661026, 0.5614845156669617]
was O [-0.6193857789039612, 0.31220781803131104]
not O [-0.3307570815086365, 0.46729332208633423]
affected. O [-0.6580162644386292, 0.41843757033348083]
Analyses B-LOC [1.0866402387619019, -1.0352277755737305]
of B-LOC [1.0234708786010742, -1.2746739387512207]
synaptic B-LOC [0.904736340045929, -1.2643886804580688]
failure B-LOC [0.8662897944450378, -1.1498836278915405]
rates B-LOC [0.8939741253852844, -1.1732767820358276]
and B-LOC [1.0510292053222656, -1.3593918085098267]
paired-pulse B-LOC [0.8224114775657654, -1.117814302444458]
ratios B-LOC [0.9357605576515198, -1.1552716493606567]
indicated B-LOC [0.6210699081420898, -1.0306131839752197]
a B-LOC [0.6127123236656189, -1.1547192335128784]
role B-LOC [0.48814401030540466, -1.1726152896881104]
for B-LOC [0.6312967538833618, -1.055192470550537]
presynaptic B-LOC [0.4963006377220154, -0.7822728753089905]
PKG-I B-LOC [0.31747111678123474, -0.7932197451591492]
in B-LOC [0.5014190077781677, -1.0703423023223877]
regulating B-LOC [0.7240400910377502, -1.2369086742401123]
the B-LOC [0.8588686585426331, -1.2512294054031372]
probability B-LOC [0.6986396908760071, -1.040522813796997]
of B-LOC [0.6365693211555481, -1.1947307586669922]

neurotransmitter B-LOC [0.09661057591438293, -0.5806699395179749]
release. B-LOC [0.2566574215888977, -0.4859137237071991]
Inositol B-LOC [0.21628843247890472, -0.5543668866157532]
1,4,5-triphosphate B-LOC [0.3403705358505249, -0.27465519309043884]
receptor B-LOC [0.07288651168346405, -0.5798412561416626]
1 B-LOC [0.29068344831466675, -0.07053997367620468]
and B-LOC [0.21409182250499725, -0.21311818063259125]
myosin B-LOC [0.013076170347630978, -0.28544434905052185]
light B-LOC [0.059804584830999374, -0.20195747911930084]
chain B-LOC [0.031150037422776222, -0.4219503700733185]
kinase B-LOC [0.3328211307525635, -0.25045886635780334]
were B-LOC [0.09305694699287415, -0.32260391116142273]
recruited B-LOC [0.31306564807891846, -0.1543085128068924]
as B-LOC [0.10051628947257996, -0.22939367592334747]
key B-LOC [0.07809378206729889, -0.2999500632286072]
phosphorylation B-LOC [-0.013090682215988636, -0.16473621129989624]
targets B-LOC [0.3248359262943268, -0.11096212267875671]
of O [-0.10786355286836624, -0.06422543525695801]
presynaptic O [-0.16152963042259216, 0.07474344968795776]
PKG-I B-LOC [0.01829005964100361, -0.15933392941951752]
in B-LOC [-0.0833587497472763, -0.1429126262664795]
nociceptive B-LOC [0.04301099851727486, -0.22491678595542908]
neurons. B-LOC [0.005382230971008539, -0.10741564631462097]
Finally, B-LOC [0.5211406350135803, -0.48683619499206543]
behavioural B-LOC [0.7117525339126587, -0.8768385648727417]
analyses B-LOC [0.7301253080368042, -0.6254942417144775]
in B-LOC [0.52821284532547, -0.4190341532230377]
vivo B-LOC [0.40504494309425354, -0.6163910031318665]
showed B-LOC [0.5160955786705017, -0.6738548874855042]
marked B-LOC [0.7522187829017639, -0.9871677160263062]
defects B-LOC [0.8264790177345276, -1.0165826082229614]
in B-LOC [0.7626933455467224, -0.9093906879425049]
SNS-PKG-I(-/-) B-LOC [0.5511991381645203, -0.7384140491485596]
mice B-LOC [0.394875168800354, -0.7288655638694763]
in B-LOC [0.883987545967102, -0.9654747247695923]
several B-LOC [0.8623557090759277, -1.0736428499221802]
models B-LOC [1.1165746450424194, -0.9241241812705994]
of B-LOC [1.1230499744415283, -1.3778266906738281]
activity-induced B-LOC [0.8555285334587097, -0.8811092972755432]
nociceptive B-LOC [0.5465875267982483, -0.7995499968528748]
hypersensitivity, B-LOC [0.9824783802032471, -1.0205401182174683]
and B-LOC [0.7819962501525879, -0.9875486493110657]
pharmacological B-LOC [1.0923089981079102, -1.148939847946167]
studies B-LOC [1.1329014301300049, -1.0398857593536377]
identified B-LOC [1.1091415882110596, -0.9662764072418213]
a B-LOC [1.0615736246109009, -1.0913300514221191]
clear B-LOC [1.2040759325027466, -1.3809616565704346]
contribution B-LOC [0.7098262906074524, -0.9992354512214661]
of B-LOC [0.7258010506629944, -0.810470461845398]
PKG-I B-LOC [0.38519883155822754, -0.6693069338798523]
expressed B-LOC [0.7226602435112, -0.46136078238487244]
in B-LOC [0.6225983500480652, -0.6635119318962097]
spinal B-LOC [0.5404484272003174, -0.8206814527511597]
terminals B-LOC [0.46066057682037354, -0.700689435005188]
of B-LOC [0.5274000763893127, -0.7645553946495056]
nociceptors. B-LOC [0.4881317913532257, -0.7166652083396912]
Our B-LOC [0.30532026290893555, -0.6580477356910706]
results B-LOC [0.6605936288833618, -0.8031362891197205]
thus B-LOC [0.5050681233406067, -0.5663395524024963]
indicate B-LOC [0.48495230078697205, -0.520110547542572]

that O [-0.81789231300354, 0.5573104023933411]
presynaptic O [-1.1210386753082275, 1.1641408205032349]
mechanisms O [-0.9661339521408081, 0.9648028612136841]
involving O [-1.070184350013733, 0.8754745125770569]
an O [-1.0202959775924683, 0.7452815175056458]
increase O [-1.0503007173538208, 0.8176041841506958]
in O [-1.0788332223892212, 0.7238386273384094]
release O [-0.9181656241416931, 0.8851323127746582]
probability O [-0.9184617400169373, 0.7437777519226074]
from O [-1.0104224681854248, 0.7941401600837708]
nociceptors O [-0.9682441353797913, 0.8836503028869629]
are O [-0.9593563079833984, 0.8656144738197327]
operational O [-0.9785274267196655, 0.8137536644935608]
in O [-1.1758003234863281, 1.0060654878616333]
the O [-1.212841272354126, 0.9452803134918213]
expression O [-1.0617756843566895, 1.1704530715942383]
of O [-1.2217044830322266, 1.075413465499878]
synaptic O [-1.2230939865112305, 1.1565220355987549]
LTP O [-1.1117830276489258, 1.1124167442321777]
on O [-1.0862107276916504, 1.1472433805465698]
spinal-PAG O [-1.133646845817566, 0.9465548992156982]
projection O [-1.0897748470306396, 1.1185939311981201]
neurons O [-1.0248488187789917, 1.2585039138793945]
and O [-1.0023692846298218, 0.932580828666687]
that O [-1.0587079524993896, 0.809683620929718]
PKG-I O [-0.8656227588653564, 0.8416581749916077]
localized O [-0.7607901692390442, 0.7462694048881531]
in O [-0.6341529488563538, 0.7883651256561279]
presynaptic O [-0.9007717967033386, 0.928776204586029]
nociceptor O [-0.9149928689002991, 1.0125796794891357]
terminals O [-0.8868150115013123, 0.8795377016067505]
plays O [-0.8658363223075867, 0.8350634574890137]
an O [-0.831939697265625, 0.8657394647598267]
essential O [-0.8089364767074585, 0.7887890934944153]
role O [-0.9756837487220764, 0.7719209790229797]
in O [-1.095149278640747, 0.8297646641731262]
this O [-0.9244570136070251, 0.774516761302948]
process O [-0.8934360146522522, 0.865570604801178]
to O [-0.8489469289779663, 0.5645025968551636]
regulate O [-0.822869062423706, 0.8088904023170471]
pain O [-0.5914921760559082, 0.598031222820282]
sensitivity. O [-0.7345372438430786, 0.7568432688713074]

Acute B-LOC [1.7354087829589844, -2.4582254886627197]
Myelogenous B-LOC [2.183976173400879, -2.6770994663238525]
Leukemia B-LOC [1.6435961723327637, -2.1995816230773926]
(AML) B-LOC [2.4258272647857666, -2.8949477672576904]
is B-LOC [2.1398024559020996, -2.5236873626708984]
an B-LOC [1.7002613544464111, -2.1645538806915283]
aggressive B-LOC [1.5259275436401367, -2.2131669521331787]
cancer B-LOC [1.9961351156234741, -2.6247031688690186]
that B-LOC [1.333925485610962, -2.3212215900421143]
strikes B-LOC [1.5285049676895142, -2.1004772186279297]
both B-LOC [1.3359225988388062, -1.927370309829712]
adults B-LOC [2.0213890075683594, -2.200225591659546]
and B-LOC [2.0530221462249756, -2.3952455520629883]
children B-LOC [2.4683735370635986, -2.606989860534668]
and B-LOC [1.394301414489746, -2.1628262996673584]
is B-LOC [2.250173807144165, -2.6889779567718506]
frequently B-LOC [1.9664329290390015, -2.53781795501709]
resistant B-LOC [2.4906601905822754, -2.7157585620880127]
to B-LOC [2.0024425983428955, -2.5268805027008057]
therapy. B-LOC [2.4018681049346924, -2.8851382732391357]
Thus, B-LOC [3.0309295654296875, -3.1666994094848633]
identifying B-LOC [3.145181655883789, -3.6463024616241455]
signals B-LOC [2.9576518535614014, -3.6923677921295166]
needed B-LOC [3.104996919631958, -3.682500123977661]
for B-LOC [2.8433244228363037, -3.5245516300201416]
AML B-LOC [2.6375677585601807, -3.217740297317505]
propagation B-LOC [2.887120008468628, -3.297809362411499]
is B-LOC [3.1009254455566406, -3.597506523132324]
a B-LOC [3.069722890853882, -3.704045534133911]
critical B-LOC [3.0968854427337646, -3.688185453414917]
step B-LOC [3.0261263847351074, -3.8343212604522705]
toward B-LOC [3.1027493476867676, -3.7052628993988037]
developing B-LOC [3.1480491161346436, -3.5619451999664307]
new B-LOC [3.1460225582122803, -3.691014528274536]
approaches B-LOC [3.2249343395233154, -3.7139804363250732]
for B-LOC [3.0850584506988525, -3.4862897396087646]
treating B-LOC [3.2482798099517822, -3.6760683059692383]
this B-LOC [3.034259557723999, -3.5797276496887207]
disease. B-LOC [3.0598649978637695, -3.681152582168579]
Here, B-LOC [0.8146609663963318, -1.015305757522583]
we B-LOC [0.3457067310810089, -0.38418033719062805]
show B-LOC [0.8299608826637268, -0.7651720643043518]
that B-LOC [0.9608666896820068, -1.2703452110290527]
Tetraspanin B-LOC [1.148745059967041, -1.5091060400009155]
3 B-LOC [1.1702648401260376, -1.1577507257461548]
is B-LOC [1.549473524093628, -1.588997721672058]
a B-LOC [1.5029276609420776, -1.4658277034759521]
target B-LOC [1.6151244640350342, -1.866387963294983]
of B-LOC [1.329514503479004, -1.4028452634811401]
the B-LOC [1.6580239534378052, -1.5047926902770996]
RNA B-LOC [1.8116639852523804, -1.7902600765228271]
binding B-LOC [1.5955395698547363, -1.7079582214355469]
protein B-LOC [1.213390827178955, -1.5877859592437744]
Musashi B-LOC [1.055283546447754, -1.3951219320297241]
2, B-LOC [1.4120832681655884, -1.3963521718978882]
which B-LOC [1.3240041732788086, -1.762670874595642]
plays B-LOC [1.822094440460205, -1.7857246398925781]
a B-LOC [1.724315881729126, -1.6440945863723755]
key B-LOC [1.3670331239700317, -1.6039178371429443]
role B-LOC [1.1376583576202393, -1.7000888586044312]
in B-LOC [1.371016025543213, -1.588362455368042]
AML. B-LOC [1.6019549369812012, -2.0012943744659424]
We B-LOC [0.47215837240219116, -0.7005388140678406]
generated B-LOC [0.7279722690582275, -0.5278938412666321]
Tspan3 B-LOC [0.4705335199832916, -0.740868091583252]
knockout B-LOC [0.7136644721031189, -0.8859160542488098]
mice B-LOC [0.4838768541812897, -0.7401478886604309]
that B-LOC [0.804976761341095, -0.945425808429718]
were B-LOC [0.675053596496582, -0.617315948009491]
born B-LOC [0.7970817685127258, -0.5155925750732422]
without B-LOC [0.7013410925865173, -0.8761904239654541]
overt B-LOC [0.5897716879844666, -0.9124701023101807]
defects. B-LOC [0.7529791593551636, -1.0969749689102173]
However, B-LOC [0.3741892874240875, -0.49284908175468445]
Tspan3 B-LOC [0.04521644487977028, -0.08789937198162079]
deletion B-LOC [0.5170616507530212, -0.019159870222210884]
impaired O [-0.16496913135051727, -0.05192017927765846]
leukemia B-LOC [0.08384017646312714, 0.05240925773978233]
stem O [-0.15689469873905182, -0.10144193470478058]
cell O [-0.5391423106193542, -0.10744768381118774]

self-renewal O [-0.2680099904537201, -0.031780991703271866]
and O [-0.22480155527591705, 0.0886731892824173]
disease B-LOC [0.06953747570514679, -0.20061767101287842]
propagation B-LOC [0.16942769289016724, -0.27645742893218994]
and O [-0.3761928677558899, 0.3134422302246094]
markedly O [0.02316051907837391, 0.06964831799268723]
improved O [-0.08404166251420975, -0.007549109403043985]
survival B-LOC [0.28922390937805176, -0.1978689581155777]
in B-LOC [0.09179826825857162, -0.2324933409690857]
mouse B-LOC [0.04975437745451927, -0.009899044409394264]
models B-LOC [0.12201262265443802, -0.10978192836046219]
of B-LOC [0.0957641452550888, -0.3264741599559784]
AML. B-LOC [0.2564983665943146, -0.3920465409755707]
Additionally, O [-0.06726758182048798, 0.13738450407981873]
Tspan3 B-LOC [0.009906898252665997, -0.011907385662198067]
inhibition B-LOC [0.11740095913410187, -0.22882261872291565]
blocked B-LOC [0.04531751200556755, -0.09075281023979187]
growth B-LOC [0.33307501673698425, -0.31169429421424866]
of B-LOC [0.4101676344871521, -0.5001837611198425]
AML B-LOC [0.49240943789482117, -0.6311340928077698]
patient B-LOC [0.2749049961566925, -0.484475702047348]
samples, B-LOC [0.3535001277923584, -0.45326530933380127]
suggesting B-LOC [0.575492799282074, -0.4336540102958679]
that B-LOC [0.48855945467948914, -0.6709140539169312]
Tspan3 B-LOC [0.3047178387641907, -0.42456939816474915]
is B-LOC [0.8415526747703552, -0.9095231294631958]
also B-LOC [0.7545014023780823, -0.6734485030174255]
important B-LOC [0.6304832100868225, -0.751326858997345]
in B-LOC [0.8434452414512634, -1.1548594236373901]
human B-LOC [0.8742936849594116, -1.0255439281463623]
disease. B-LOC [0.839830756187439, -1.0353031158447266]
As O [-0.45934465527534485, 0.2191578894853592]
part O [-0.32409682869911194, 0.3679957687854767]
of O [-0.39148208498954773, 0.24421368539333344]
the O [-0.381708562374115, 0.2843809425830841]
mechanism, O [-0.3568494915962219, 0.2081679403781891]
we O [-0.48752227425575256, 0.20298190414905548]
show O [-0.5124104619026184, 0.3639824092388153]
that O [-0.6303094029426575, 0.31326624751091003]
Tspan3 O [-0.4463285207748413, 0.3107961118221283]
deficiency O [-0.3605491816997528, 0.41665711998939514]
disabled O [-0.5753423571586609, 0.37912556529045105]
responses O [-0.37406259775161743, 0.3774015009403229]
to O [-0.41048070788383484, 0.33556923270225525]
CXCL12/SDF-1 O [-0.5851901769638062, 0.28124451637268066]
and O [-0.501641571521759, 0.46496817469596863]
led O [-0.5120332837104797, 0.41384807229042053]
to O [-0.37995707988739014, 0.3450545072555542]
defects O [-0.33453086018562317, 0.1752171814441681]
in O [-0.45517709851264954, 0.1780572384595871]
AML O [-0.3490951359272003, -0.007399531546980143]
localization O [-0.4306202232837677, 0.3144060969352722]
within O [-0.11918749660253525, 0.08190600574016571]
the O [-0.2269509732723236, 0.16408532857894897]
niche. O [-0.3958500027656555, 0.0636940598487854]
These B-LOC [0.13594785332679749, -0.0925169587135315]
identify B-LOC [0.10044790059328079, -0.11975730955600739]
Tspan3 B-LOC [-0.048738639801740646, -0.1615993231534958]
as O [-0.07498114556074142, 0.04237642511725426]
an O [-0.17760494351387024, 0.027193797752261162]
important O [-0.11654571443796158, -0.027456851676106453]
regulator O [-0.14140596985816956, -0.058357980102300644]
of O [-0.19890502095222473, 0.026198355481028557]
aggressive O [-0.10087235271930695, -0.0013827555812895298]
leukemias O [-0.03028041683137417, 0.09765377640724182]
and B-LOC [0.005476845894008875, -0.12924695014953613]
highlight B-LOC [0.2880622148513794, -0.2577173709869385]
a B-LOC [0.15644031763076782, -0.5262951254844666]
role B-LOC [0.020127059891819954, -0.46731290221214294]
for B-LOC [0.09233570098876953, -0.517061173915863]
Tspan3 B-LOC [-0.061892565339803696, -0.27883172035217285]
in B-LOC [-0.025735141709446907, -0.48187255859375]

oncogenesis. B-LOC [-0.04631580039858818, -0.3599509000778198]

Two-component B-LOC [2.177536725997925, -2.5358686447143555]
signal B-LOC [2.396191358566284, -2.6626226902008057]
transduction B-LOC [2.8895742893218994, -2.830089807510376]
pathways B-LOC [2.4946117401123047, -2.3754804134368896]
comprising B-LOC [2.3505101203918457, -2.3275861740112305]
histidine B-LOC [1.99521803855896, -2.622185468673706]
protein B-LOC [1.9472960233688354, -2.2330739498138428]
kinases B-LOC [2.1972296237945557, -2.346803903579712]
(HPKs) B-LOC [2.531914234161377, -2.624221086502075]
and B-LOC [2.8075969219207764, -2.9877164363861084]
their B-LOC [2.632042646408081, -2.6154067516326904]
response B-LOC [2.6016647815704346, -2.749885320663452]
regulators B-LOC [2.545781373977661, -2.856569290161133]
(RRs) B-LOC [2.8975555896759033, -2.9578359127044678]
are B-LOC [3.0695765018463135, -2.970471143722534]
widely B-LOC [3.0238678455352783, -2.8962149620056152]
used B-LOC [2.963498830795288, -3.006458044052124]
to B-LOC [3.0439369678497314, -3.1448190212249756]
control B-LOC [2.923661947250366, -3.0670080184936523]
bacterial B-LOC [2.5293684005737305, -2.8633639812469482]
responses B-LOC [3.2243411540985107, -3.1872737407684326]
to B-LOC [3.166156768798828, -3.225192070007324]
environmental B-LOC [3.117901563644409, -3.242856979370117]
challenges. B-LOC [3.0151405334472656, -3.1642038822174072]
Some B-LOC [2.500215768814087, -3.021906614303589]
bacteria B-LOC [2.4179673194885254, -2.942594528198242]
have B-LOC [2.461777687072754, -2.8747541904449463]
over B-LOC [2.9484705924987793, -3.0121891498565674]
150 B-LOC [3.0851151943206787, -3.1178853511810303]
different B-LOC [2.69328236579895, -3.2633445262908936]
two-component B-LOC [2.7450332641601562, -3.0411489009857178]
pathways, B-LOC [2.5181148052215576, -2.8288681507110596]
and B-LOC [2.6157073974609375, -3.2077138423919678]
the B-LOC [2.931472063064575, -3.3927927017211914]
specificity B-LOC [3.159419059753418, -3.5372161865234375]
of B-LOC [2.8823161125183105, -3.422373056411743]
the B-LOC [2.8694913387298584, -3.3306329250335693]
phosphotransfer B-LOC [2.7854673862457275, -3.3678767681121826]
reactions B-LOC [2.5706098079681396, -2.892648458480835]
within B-LOC [3.0550363063812256, -3.3095955848693848]
these B-LOC [2.878417730331421, -3.289552927017212]
systems B-LOC [2.930213212966919, -3.3301448822021484]
is B-LOC [3.201833963394165, -3.2487332820892334]
tightly B-LOC [3.1855762004852295, -3.511206865310669]
controlled B-LOC [3.1024656295776367, -3.4783334732055664]
to B-LOC [3.2550384998321533, -3.5115087032318115]
prevent B-LOC [3.1917152404785156, -3.5597691535949707]
unwanted B-LOC [2.8547067642211914, -3.325045347213745]
crosstalk. B-LOC [2.996354818344116, -3.5174477100372314]
One B-LOC [2.7273566722869873, -2.8879129886627197]
of B-LOC [2.9267213344573975, -2.9545865058898926]
the B-LOC [2.977365732192993, -2.7228493690490723]
best B-LOC [3.06142258644104, -2.8695881366729736]
understood B-LOC [2.9960100650787354, -2.755972146987915]
two-component B-LOC [2.881929636001587, -2.870941400527954]
signalling B-LOC [2.4400084018707275, -2.6352012157440186]
pathways B-LOC [2.680384635925293, -2.6145012378692627]
is B-LOC [3.141270875930786, -2.7314040660858154]
the B-LOC [2.86507248878479, -2.685577154159546]
chemotaxis B-LOC [2.536029100418091, -2.6867616176605225]
pathway. B-LOC [2.5036544799804688, -2.8475663661956787]
Here, B-LOC [0.5054462552070618, -0.410145103931427]
we B-LOC [0.32192376255989075, -0.2870984375476837]
present B-LOC [0.8808109164237976, -0.5610237121582031]
the B-LOC [0.8370962142944336, -0.7269718647003174]
1.40 B-LOC [0.8405346274375916, -0.6210853457450867]
A B-LOC [0.7724081873893738, -0.95465487241745]
crystal B-LOC [0.9105501770973206, -0.980413556098938]
structure B-LOC [0.6946597695350647, -0.9962030053138733]
of B-LOC [0.7295953035354614, -0.9907644391059875]
the B-LOC [0.8493455052375793, -0.8550981283187866]
histidine-containing B-LOC [0.3004687428474426, -1.004805088043213]
phosphotransfer B-LOC [0.2949707806110382, -0.9244928956031799]

domain B-LOC [0.9929830431938171, -1.286523699760437]
of B-LOC [1.421130895614624, -1.2608100175857544]
the B-LOC [1.5230106115341187, -1.2337791919708252]
chemotaxis B-LOC [1.5131549835205078, -1.4978671073913574]
HPK, B-LOC [1.1534130573272705, -1.389977216720581]
CheA(3), B-LOC [1.1200376749038696, -1.2991297245025635]
in B-LOC [1.5049494504928589, -1.1454540491104126]
complex B-LOC [1.6665345430374146, -1.0286369323730469]
with B-LOC [1.5442066192626953, -1.4024326801300049]
its B-LOC [1.4915876388549805, -1.3008265495300293]
cognate B-LOC [1.7167341709136963, -1.4966633319854736]
RR, B-LOC [1.1136460304260254, -1.3419233560562134]
CheY(6). B-LOC [1.1331861019134521, -1.2662463188171387]
A B-LOC [1.2303340435028076, -1.1593456268310547]
methionine B-LOC [0.9915127158164978, -1.0292812585830688]
finger B-LOC [0.8933026194572449, -1.000548243522644]
on B-LOC [0.9467877745628357, -0.9226055145263672]
CheY(6) B-LOC [1.1360349655151367, -1.1357316970825195]
that B-LOC [1.0348414182662964, -1.2233853340148926]
nestles B-LOC [1.0723704099655151, -1.1158976554870605]
in B-LOC [1.2200219631195068, -0.9327021241188049]
a B-LOC [1.2028758525848389, -0.9651097655296326]
hydrophobic B-LOC [1.2435652017593384, -1.2430503368377686]
pocket B-LOC [0.739570677280426, -0.7997571229934692]
in B-LOC [0.9536018967628479, -0.9391738772392273]
CheA(3) B-LOC [1.3109841346740723, -1.2430392503738403]
was B-LOC [1.7870908975601196, -1.8027634620666504]
shown B-LOC [1.7097768783569336, -1.5540282726287842]
to B-LOC [2.0216214656829834, -1.5722185373306274]
be B-LOC [1.5703173875808716, -1.5421361923217773]
important B-LOC [1.3651273250579834, -1.3715615272521973]
for B-LOC [1.5375982522964478, -1.7719624042510986]
the B-LOC [1.5409594774246216, -1.4828652143478394]
interaction B-LOC [1.0973541736602783, -1.3555415868759155]
and B-LOC [1.5630906820297241, -1.6689791679382324]
was B-LOC [2.0217690467834473, -1.9163329601287842]
found B-LOC [2.1309895515441895, -1.8362464904785156]
to B-LOC [2.3669588565826416, -1.9883108139038086]
only B-LOC [1.914851188659668, -1.7237012386322021]
occur B-LOC [1.4100416898727417, -1.4173176288604736]
in B-LOC [1.7969675064086914, -1.8327665328979492]
the B-LOC [1.952710747718811, -1.6561298370361328]
cognate B-LOC [2.1377017498016357, -1.8557510375976562]
RRs B-LOC [1.4802885055541992, -1.628661036491394]
of B-LOC [1.8243963718414307, -1.5939953327178955]
CheA(3), B-LOC [1.349740982055664, -1.3804115056991577]
CheY(6), B-LOC [1.15409517288208, -1.2697598934173584]
and B-LOC [1.727555274963379, -1.627117395401001]
CheB(2). B-LOC [1.0589449405670166, -1.2218610048294067]
Site-directed B-LOC [0.8495358824729919, -1.0982462167739868]
mutagenesis B-LOC [1.0284862518310547, -1.2596235275268555]
of B-LOC [0.9905621409416199, -1.0300079584121704]
this B-LOC [0.9634199738502502, -1.0620026588439941]
methionine B-LOC [0.7337640523910522, -1.1468992233276367]
in B-LOC [0.9413233399391174, -1.086192011833191]
combination B-LOC [0.9234232306480408, -0.9173904061317444]
with B-LOC [1.0430378913879395, -1.031217098236084]
two B-LOC [0.976376473903656, -1.0133247375488281]
adjacent B-LOC [0.9218319058418274, -1.179025411605835]
residues B-LOC [0.8495561480522156, -0.941328227519989]
abolished B-LOC [0.5842610001564026, -0.9795769453048706]
binding, B-LOC [0.9248341917991638, -1.052831768989563]
as B-LOC [1.4226174354553223, -1.39752197265625]
shown B-LOC [1.29278564453125, -1.4827094078063965]
by B-LOC [0.9456565976142883, -1.1046777963638306]
surface B-LOC [0.9986220598220825, -1.0989010334014893]

plasmon B-LOC [0.2507266402244568, -0.6420497894287109]
resonance B-LOC [0.6000593900680542, -0.5918136835098267]
studies, B-LOC [0.32110294699668884, -0.5214800238609314]
and B-LOC [0.18952034413814545, -0.3313385844230652]
phosphotransfer B-LOC [0.24096527695655823, -0.5951440334320068]
from B-LOC [0.26567381620407104, -0.4119388163089752]
CheA(3)-P B-LOC [0.4896586835384369, -0.5826340317726135]
to B-LOC [0.25638553500175476, -0.4977794289588928]
CheY(6). B-LOC [0.4783405363559723, -0.6382404565811157]
Introduction O [-0.36428749561309814, 0.489815890789032]
of O [-0.29894736409187317, 0.5695399641990662]
this O [-0.21101921796798706, 0.45835497975349426]
methionine O [-0.3778163492679596, 0.26394858956336975]
and O [-0.30889254808425903, 0.4721212089061737]
an O [-0.3178190290927887, 0.4366469383239746]
adjacent O [-0.2570611536502838, 0.30984678864479065]
alanine O [-0.17514647543430328, 0.25139907002449036]
residue O [-0.19168154895305634, 0.34430399537086487]
into O [-0.39028775691986084, 0.5717064142227173]
a O [-0.44821470975875854, 0.5604141354560852]
range O [-0.23807242512702942, 0.3576190173625946]
of O [-0.2903806269168854, 0.36602795124053955]
noncognate O [-0.36072108149528503, 0.36660563945770264]
CheYs, O [-0.061780210584402084, 0.10052229464054108]
dramatically O [-0.631990909576416, 0.4879361689090729]
changed O [-0.6179875135421753, 0.2816452383995056]
their O [-0.19450771808624268, 0.1916930079460144]
specificity, O [-0.2503020465373993, 0.3558011054992676]
allowing O [-0.7437945008277893, 0.5044738054275513]
protein O [-0.3617009222507477, 0.10823961347341537]
interaction O [-0.3331959545612335, 0.23107293248176575]
and O [-0.749173641204834, 0.5550662279129028]
rapid O [-0.7380529642105103, 0.30154499411582947]
phosphotransfer O [-0.4008595645427704, 0.047694187611341476]
from O [-0.22196805477142334, 0.2611076235771179]
CheA(3)-P. B-LOC [-0.04245345667004585, -0.05820532143115997]
The B-LOC [0.08873584121465683, -0.19985035061836243]
structure B-LOC [0.40380868315696716, -0.4522731304168701]
presented B-LOC [0.5476898550987244, -0.7436981201171875]
here B-LOC [0.375731498003006, -0.30997133255004883]
has B-LOC [0.028977619484066963, -0.28653407096862793]
allowed O [-0.17550499737262726, -0.12735286355018616]
us B-LOC [0.02798626758158207, -0.3472932279109955]
to B-LOC [0.04293021187186241, -0.070514015853405]
identify B-LOC [0.2310611754655838, -0.2807128131389618]
specificity B-LOC [0.2442505657672882, -0.3695996403694153]
determinants B-LOC [0.013216922990977764, -0.09328629076480865]
for B-LOC [-0.09268714487552643, -0.10952560603618622]
the B-LOC [0.033485908061265945, -0.2443634569644928]
CheA-CheY B-LOC [0.3319503962993622, -0.3278462588787079]
interaction B-LOC [0.00023433807655237615, -0.1900913417339325]
and O [-0.20658472180366516, 0.011670758947730064]
subsequently O [-0.08542515337467194, 0.05888067185878754]
to O [-0.08668997883796692, 0.008793270215392113]
successfully O [-0.3250141441822052, 0.004755006637424231]
reengineer O [-0.30252912640571594, 0.1431400179862976]
phosphotransfer B-LOC [-0.03841204568743706, -0.3638606369495392]
signalling. B-LOC [0.13753309845924377, -0.13876399397850037]
In B-LOC [0.5577276349067688, -0.7167844772338867]
summary, B-LOC [0.7304989695549011, -0.649784505367279]
our B-LOC [0.2628640830516815, -0.7643762230873108]
results B-LOC [0.6973537802696228, -0.8659846186637878]
provide B-LOC [0.35486334562301636, -0.9007816910743713]

valuable B-LOC [0.7147398591041565, -0.9078266024589539]
insight B-LOC [1.0584137439727783, -1.1734728813171387]
into B-LOC [1.354601263999939, -1.173781394958496]
how B-LOC [1.1536232233047485, -1.2158931493759155]
cells B-LOC [0.8422386050224304, -0.9722784161567688]
mediate B-LOC [0.8819442391395569, -1.054248571395874]
specificity B-LOC [1.0943998098373413, -1.295350432395935]
in B-LOC [0.9750332236289978, -1.0420048236846924]
one B-LOC [0.9582589268684387, -1.1175390481948853]
of B-LOC [1.0832993984222412, -0.9948248267173767]
the B-LOC [1.117357611656189, -0.9839833378791809]
most B-LOC [1.209291696548462, -1.266582727432251]
abundant B-LOC [0.9769958853721619, -1.1329755783081055]
signalling B-LOC [0.7466587424278259, -0.9884616732597351]
pathways B-LOC [0.8898295760154724, -1.0526782274246216]
in B-LOC [1.2073085308074951, -1.234459638595581]
biology, B-LOC [1.1313443183898926, -1.229653000831604]
two-component B-LOC [1.1231049299240112, -1.110168218612671]
signal B-LOC [0.6538465619087219, -1.0672717094421387]
transduction. B-LOC [0.995556652545929, -1.0177807807922363]

IMPORTANCE B-LOC [2.962111711502075, -3.5429086685180664]
Combining B-LOC [3.1189534664154053, -3.449308156967163]
pharmacotherapies B-LOC [3.5849437713623047, -3.4732329845428467]
for B-LOC [3.6933648586273193, -3.542616367340088]
tobacco-dependence B-LOC [3.1563446521759033, -3.5122976303100586]
treatment B-LOC [3.5181267261505127, -3.6257054805755615]
may B-LOC [3.3521924018859863, -3.5512049198150635]
increase B-LOC [3.1248114109039307, -3.7467496395111084]
smoking B-LOC [3.154747724533081, -3.4910104274749756]
abstinence. B-LOC [3.400977373123169, -3.185420274734497]
OBJECTIVE B-LOC [3.3264901638031006, -3.5614683628082275]
To B-LOC [3.539728879928589, -3.4474713802337646]
determine B-LOC [3.5294458866119385, -3.4296212196350098]
efficacy B-LOC [3.593301773071289, -3.3611812591552734]
and B-LOC [3.31125807762146, -3.15790057182312]
safety B-LOC [3.7929351329803467, -3.290792465209961]
of B-LOC [3.6246695518493652, -3.1565840244293213]
varenicline B-LOC [3.3233206272125244, -3.4680986404418945]
and B-LOC [3.4721267223358154, -3.2281503677368164]
bupropion B-LOC [3.4442989826202393, -3.3080363273620605]
sustained-release B-LOC [3.5869686603546143, -3.12562894821167]
(SR; B-LOC [3.5246217250823975, -3.552313804626465]
combination B-LOC [3.497363567352295, -3.4170315265655518]
therapy) B-LOC [3.586979389190674, -3.4303829669952393]
compared B-LOC [3.5378825664520264, -3.2217159271240234]
with B-LOC [3.612251043319702, -3.364351511001587]
varenicline B-LOC [3.4869539737701416, -3.3606412410736084]
(monotherapy) B-LOC [3.7208986282348633, -3.246821641921997]
in B-LOC [3.6470515727996826, -3.2441787719726562]
cigarette B-LOC [3.658025026321411, -3.382692813873291]
smokers. B-LOC [3.700374126434326, -3.002835512161255]
DESIGN, B-LOC [3.328145980834961, -2.9091131687164307]
SETTING, B-LOC [2.952068567276001, -2.89670991897583]
AND B-LOC [3.3479955196380615, -3.1658594608306885]
PARTICIPANTS B-LOC [2.9207558631896973, -2.809115409851074]
Randomized, B-LOC [3.4996135234832764, -2.8316049575805664]
blinded, B-LOC [3.5125930309295654, -2.863588571548462]
placebo-controlled B-LOC [3.464923858642578, -2.7816169261932373]
multicenter B-LOC [3.2812931537628174, -2.8049182891845703]
clinical B-LOC [3.5395922660827637, -2.8884389400482178]
trial B-LOC [3.4113335609436035, -2.951017141342163]
with B-LOC [3.39490008354187, -2.604947805404663]
a B-LOC [3.1805732250213623, -2.473670721054077]
12-week B-LOC [3.4378011226654053, -2.507782220840454]
treatment B-LOC [3.4854063987731934, -2.7715489864349365]
period B-LOC [3.3758461475372314, -2.741767644882202]
and B-LOC [3.267336130142212, -2.7097694873809814]
follow-up B-LOC [3.2447566986083984, -2.5282065868377686]
through B-LOC [3.415691614151001, -2.578629493713379]
week B-LOC [3.298771619796753, -2.542426347732544]
52 B-LOC [3.2584598064422607, -2.723398208618164]
conducted B-LOC [3.488063335418701, -2.7235758304595947]
between B-LOC [3.3202786445617676, -2.5412981510162354]
October B-LOC [3.390272617340088, -2.460498094558716]
2009 B-LOC [3.1479222774505615, -3.032571315765381]
and B-LOC [3.3446266651153564, -2.6025986671447754]
April B-LOC [3.100794553756714, -2.8200013637542725]

2013 B-LOC [3.4410722255706787, -3.888880968093872]
at B-LOC [3.29071307182312, -3.835827112197876]
3 B-LOC [3.553269147872925, -3.90897536277771]
midwestern B-LOC [3.6030006408691406, -3.7986233234405518]
clinical B-LOC [3.7371652126312256, -3.891735792160034]
research B-LOC [3.5349204540252686, -3.9613795280456543]
sites. B-LOC [3.6585917472839355, -3.962386131286621]
Five B-LOC [3.551284074783325, -3.923586130142212]
hundred B-LOC [3.632391929626465, -3.9363059997558594]
six B-LOC [3.532456636428833, -3.9879841804504395]
adult B-LOC [3.638920307159424, -3.9443466663360596]
(≥18 B-LOC [3.643064260482788, -3.7363064289093018]
years) B-LOC [3.6255152225494385, -3.8341686725616455]
cigarette B-LOC [3.5436289310455322, -3.9877636432647705]
smokers B-LOC [3.7572848796844482, -3.8365559577941895]
were B-LOC [3.6469404697418213, -3.846193313598633]
randomly B-LOC [3.7677371501922607, -3.818272590637207]
assigned B-LOC [3.7408459186553955, -3.8092875480651855]
and B-LOC [3.2625205516815186, -3.7221474647521973]
315 B-LOC [3.590906858444214, -3.8904764652252197]
(62%) B-LOC [3.56026291847229, -3.9097981452941895]
completed B-LOC [3.745918035507202, -3.9483940601348877]
the B-LOC [3.474169969558716, -3.7254011631011963]
study. B-LOC [3.6358835697174072, -4.0240397453308105]
INTERVENTIONS B-LOC [3.1980345249176025, -3.6051526069641113]
Twelve B-LOC [3.4773995876312256, -3.766662359237671]
weeks B-LOC [3.290168523788452, -3.606976270675659]
of B-LOC [3.301008462905884, -3.6705551147460938]
varenicline B-LOC [3.2144904136657715, -3.9282002449035645]
and B-LOC [3.1468889713287354, -3.724597930908203]
bupropion B-LOC [3.330334424972534, -3.821985960006714]
SR B-LOC [3.3919687271118164, -3.6945302486419678]
or B-LOC [3.6176085472106934, -3.9551985263824463]
varenicline B-LOC [3.2673428058624268, -3.82849383354187]
and B-LOC [3.416454792022705, -3.7999155521392822]
placebo. B-LOC [3.3729846477508545, -3.819143772125244]
MAIN B-LOC [2.510234832763672, -2.7630269527435303]
OUTCOMES B-LOC [2.6196084022521973, -2.433544158935547]
AND B-LOC [2.67435622215271, -2.962789535522461]
MEASURES B-LOC [2.8183701038360596, -2.980403184890747]
Primary B-LOC [2.517133951187134, -2.568422555923462]
outcome B-LOC [2.8262009620666504, -2.6105504035949707]
was B-LOC [2.378031015396118, -2.286475419998169]
abstinence B-LOC [2.4658820629119873, -2.1445422172546387]
rates B-LOC [2.653531074523926, -2.42267107963562]
at B-LOC [2.6208901405334473, -2.502722978591919]
week B-LOC [2.7452807426452637, -2.1202642917633057]
12, B-LOC [2.837390422821045, -2.3287301063537598]
defined B-LOC [2.896144151687622, -2.531890630722046]
as B-LOC [2.6630423069000244, -2.2721006870269775]
prolonged B-LOC [1.993402123451233, -1.7996950149536133]
(no B-LOC [2.4580304622650146, -2.129038095474243]
smoking B-LOC [2.0343244075775146, -1.5121617317199707]
from B-LOC [2.3582942485809326, -2.1294119358062744]
2 B-LOC [2.1722185611724854, -2.0780093669891357]
weeks B-LOC [2.8271725177764893, -1.92147696018219]
after B-LOC [2.1255943775177, -1.8829379081726074]
the B-LOC [2.476260185241699, -2.3779382705688477]
target B-LOC [2.602605104446411, -2.6796329021453857]
quit B-LOC [2.3999955654144287, -1.9248809814453125]
date) B-LOC [2.4654533863067627, -2.2521767616271973]
abstinence B-LOC [2.548583984375, -1.786368727684021]
and B-LOC [2.312703847885132, -2.234403133392334]
7-day B-LOC [2.3363959789276123, -1.5719871520996094]
point-prevalence B-LOC [2.3815128803253174, -2.1669318675994873]
(no B-LOC [2.5206806659698486, -2.114701271057129]
smoking B-LOC [1.938397765159607, -1.4062635898590088]
past B-LOC [1.8636598587036133, -1.7523887157440186]
7 B-LOC [1.8187437057495117, -1.421468734741211]
days) B-LOC [2.219696283340454, -1.6327412128448486]

abstinence. B-LOC [1.4235517978668213, -1.8204257488250732]
Secondary B-LOC [2.461137294769287, -2.9084153175354004]
outcomes B-LOC [2.1405441761016846, -2.741725444793701]
were B-LOC [1.9862499237060547, -2.5057060718536377]
prolonged B-LOC [2.0493390560150146, -2.5275089740753174]
and B-LOC [1.910040259361267, -2.5035321712493896]
point-prevalence B-LOC [2.2283201217651367, -3.018235921859741]
smoking B-LOC [1.9441055059432983, -2.466500997543335]
abstinence B-LOC [2.4546587467193604, -2.5629336833953857]
rates B-LOC [2.3549907207489014, -2.889343023300171]
at B-LOC [2.250072717666626, -2.6783924102783203]
weeks B-LOC [2.283535957336426, -2.8480279445648193]
26 B-LOC [2.569139242172241, -2.7293081283569336]
and B-LOC [2.1926746368408203, -2.5935611724853516]
52. B-LOC [2.6515209674835205, -2.9801392555236816]
Outcomes B-LOC [2.5259857177734375, -2.8234658241271973]
were B-LOC [2.6451194286346436, -2.942551851272583]
biochemically B-LOC [2.5480763912200928, -3.1208956241607666]
confirmed. B-LOC [2.7017297744750977, -3.14888596534729]
RESULTS O [-1.1476702690124512, 0.9252715706825256]
At O [-1.2209097146987915, 1.1802020072937012]
12 O [-1.117496132850647, 1.2070400714874268]
weeks, O [-1.1917935609817505, 1.112982988357544]
53.0% O [-1.1400024890899658, 1.3069243431091309]
of O [-1.3599934577941895, 1.2094311714172363]
the O [-1.3173108100891113, 1.171377182006836]
combination O [-1.2289406061172485, 1.144804835319519]
therapy O [-1.1881022453308105, 1.208022117614746]
group O [-1.2361289262771606, 1.4264862537384033]
achieved O [-1.2600990533828735, 1.128739833831787]
prolonged O [-1.2117582559585571, 1.3121671676635742]
smoking O [-0.8818200826644897, 1.151244878768921]
abstinence O [-1.1624375581741333, 1.3000893592834473]
and O [-1.337947130203247, 1.0511068105697632]
56.2% O [-1.2011141777038574, 1.2905197143554688]
achieved O [-1.2013932466506958, 1.1139596700668335]
7-day O [-1.0278308391571045, 1.2818901538848877]
point-prevalence O [-1.300662636756897, 1.064563274383545]
smoking O [-1.0380780696868896, 1.1747187376022339]
abstinence O [-1.1631149053573608, 1.2739455699920654]
compared O [-1.3807697296142578, 1.0884063243865967]
with O [-1.182584285736084, 0.9977284073829651]
43.2% O [-1.0798460245132446, 1.3099241256713867]
and O [-1.3044490814208984, 0.8042764663696289]
48.6% O [-1.2278962135314941, 1.3387694358825684]
in O [-1.2291865348815918, 1.158066749572754]
varenicline O [-0.6658636927604675, 0.7961635589599609]
monotherapy O [-1.0490522384643555, 0.9826890826225281]
(odds O [-1.1895798444747925, 1.0113520622253418]
ratio O [-1.0823054313659668, 0.9186577796936035]
[OR], O [-1.1105600595474243, 0.9481836557388306]
1.49; O [-0.9032973647117615, 1.137207269668579]
95% O [-1.2799065113067627, 1.0833160877227783]
CI, O [-1.0633182525634766, 0.9200018048286438]
1.05-2.12; O [-0.8488196134567261, 1.0238063335418701]
P O [-1.0514891147613525, 0.9571713805198669]
= O [-0.9885110259056091, 0.7759692072868347]

.03 O [-0.27474159002304077, -0.045436423271894455]
and O [-0.11685264110565186, 0.03933713212609291]
OR, O [-0.43264901638031006, 0.15064267814159393]
1.36; O [-0.17491945624351501, 0.11877566576004028]
95% O [-0.27309319376945496, 0.2495352327823639]
CI, O [-0.4735962152481079, 0.05349681153893471]
0.95-1.93; O [-0.18991893529891968, 0.3109685778617859]
P O [-0.5173467993736267, 0.18926268815994263]
= O [-0.44613900780677795, 0.24735380709171295]
.09, O [-0.3467164933681488, 0.09458844363689423]
respectively). B-LOC [0.016807595267891884, -0.08140700310468674]
At O [-1.1870861053466797, 0.8861110210418701]
26 O [-0.8863980174064636, 1.0848333835601807]
weeks, O [-1.0687079429626465, 0.9298587441444397]
36.6% O [-1.0037277936935425, 1.1499652862548828]
of O [-1.2835590839385986, 1.0866310596466064]
the O [-1.218164324760437, 1.0531104803085327]
combination O [-1.1123135089874268, 0.9754272699356079]
therapy O [-1.0917644500732422, 0.9696348905563354]
group O [-1.142127275466919, 1.257797360420227]
achieved O [-1.1206117868423462, 1.0602754354476929]
prolonged O [-1.08820378780365, 1.1721751689910889]
and O [-1.1248325109481812, 0.8095089793205261]
38.2% O [-0.9861685037612915, 1.1219722032546997]
achieved O [-1.0944827795028687, 1.0245916843414307]
7-day O [-0.9006045460700989, 1.0971804857254028]
point-prevalence O [-1.1231855154037476, 0.9074252843856812]
smoking O [-0.8467442989349365, 1.0271165370941162]
abstinence O [-0.9709737300872803, 1.238929271697998]
compared O [-1.267132043838501, 0.8672267198562622]
with O [-1.014952301979065, 0.7959451079368591]
27.6% O [-0.9040967226028442, 1.2979265451431274]
and O [-1.1724814176559448, 0.6631636023521423]
31.9% O [-0.9411412477493286, 1.1313555240631104]
in O [-1.1370561122894287, 1.0746347904205322]
varenicline O [-0.6313467621803284, 0.6825980544090271]
monotherapy O [-0.9175592064857483, 0.8189381957054138]
(OR, O [-0.9862040877342224, 0.7950446605682373]
1.52; O [-0.901457667350769, 0.9317833185195923]
95% O [-1.154824137687683, 1.0174994468688965]
CI, O [-0.9126682281494141, 0.6941819787025452]
1.04-2.22; O [-0.7944396138191223, 0.8628610968589783]
P O [-0.9366273283958435, 0.7710413336753845]
= O [-0.9314669966697693, 0.8096585869789124]
.03 O [-0.8022797703742981, 0.6749432682991028]
and O [-0.8893651962280273, 0.5589959025382996]
OR, O [-0.9273188710212708, 0.7658487558364868]
1.32; O [-0.7202988266944885, 0.7700424194335938]
95% O [-1.0190179347991943, 0.8413712382316589]
CI, O [-0.8577994108200073, 0.5729038119316101]

0.91-1.91; B-LOC [-0.15308083593845367, -0.20062540471553802]
P O [-0.4743064343929291, 0.07562285661697388]
= O [-0.3522721827030182, 0.14471739530563354]
.14, O [-0.3842245042324066, 0.05830549821257591]
respectively). O [-0.30101874470710754, -0.14524176716804504]
At O [-0.7187776565551758, 0.2887369692325592]
52 O [-0.3099648058414459, 0.3507624864578247]
weeks, O [-0.46585559844970703, 0.29150471091270447]
30.9% O [-0.3254709541797638, 0.6936195492744446]
of O [-0.8023495078086853, 0.6486074328422546]
the O [-0.7023414373397827, 0.5296985507011414]
combination O [-0.6912976503372192, 0.44237205386161804]
therapy O [-0.6772618889808655, 0.4956071674823761]
group O [-0.6821940541267395, 0.7542234659194946]
achieved O [-0.686058521270752, 0.6708772778511047]
prolonged O [-0.7150988578796387, 0.789717972278595]
and O [-0.7825283408164978, 0.387444406747818]
36.6% O [-0.5627526640892029, 0.7485440373420715]
achieved O [-0.641532838344574, 0.6203229427337646]
7-day O [-0.4997718930244446, 0.6798760890960693]
point-prevalence O [-0.7528910636901855, 0.5218160152435303]
smoking O [-0.40849414467811584, 0.6279130578041077]
abstinence O [-0.4372064769268036, 0.8099773526191711]
compared O [-0.8099733591079712, 0.4027361571788788]
with O [-0.5572739839553833, 0.3193901479244232]
24.5% O [-0.5691901445388794, 0.6110138297080994]
and O [-0.6825222373008728, 0.23577293753623962]
29.2% O [-0.4720838665962219, 0.7250328063964844]
in O [-0.6613818407058716, 0.5117371678352356]
varenicline O [-0.26500582695007324, 0.24540820717811584]
monotherapy O [-0.4484923779964447, 0.2943524420261383]
(OR, O [-0.46844401955604553, 0.38547125458717346]
1.39; O [-0.45829591155052185, 0.5133328437805176]
95% O [-0.7055968642234802, 0.5569643378257751]
CI, O [-0.5898321866989136, 0.2560087740421295]
0.93-2.07; O [-0.3223755955696106, 0.3035643994808197]
P O [-0.5960896611213684, 0.29198548197746277]
= O [-0.4773140847682953, 0.27742865681648254]
.11 O [-0.41928648948669434, 0.19078955054283142]
and O [-0.3473972976207733, 0.1645975410938263]
OR, O [-0.5248357653617859, 0.32755061984062195]
1.40; O [-0.18959766626358032, 0.250043660402298]
95% O [-0.4852825403213501, 0.29313674569129944]
CI, O [-0.4443194270133972, 0.13297304511070251]
0.96-2.05; O [-0.08798208832740784, 0.06624186038970947]
P O [-0.4458603858947754, 0.11918142437934875]
= O [-0.3108162581920624, 0.14695830643177032]
.08, O [-0.3679053485393524, 0.07106469571590424]
respectively). O [-0.41127318143844604, 0.06479664146900177]
Participants B-LOC [-0.014608305878937244, -0.2770173251628876]

receiving O [-0.6011097431182861, 0.45071545243263245]
combination O [-0.4032488763332367, 0.24003346264362335]
therapy O [-0.5015734434127808, 0.46033504605293274]
reported O [-0.5472790598869324, 0.4813864827156067]
more O [-0.5391942858695984, 0.6877384781837463]
anxiety O [-0.24170677363872528, 0.5559329986572266]
(7.2% O [-0.5777948498725891, 0.45508283376693726]
vs O [-0.72678142786026, 0.16201263666152954]
3.1%; O [-0.5222418308258057, 0.6914159655570984]
P O [-0.6783758997917175, 0.47352004051208496]
= O [-0.7056167125701904, 0.49125558137893677]
.04) O [-0.5072168707847595, 0.47702959179878235]
and O [-0.514756441116333, 0.607905387878418]
depressive O [-0.4649032652378082, 0.5835102200508118]
symptoms O [-0.32194003462791443, 0.43500879406929016]
(3.6% O [-0.5164723992347717, 0.48246124386787415]
vs O [-0.6354153156280518, 0.31306442618370056]
0.8%; O [-0.31302741169929504, 0.45536383986473083]
P O [-0.6813433766365051, 0.39982759952545166]
= O [-0.5659129023551941, 0.44748207926750183]
.03). O [-0.5483968257904053, 0.4384472370147705]
CONCLUSIONS O [-0.9240003228187561, 0.555921196937561]
AND O [-0.6230389475822449, 0.4018591344356537]
RELEVANCE O [-0.77195805311203, 0.4193257987499237]
Among O [-0.5794596076011658, 0.7397485375404358]
cigarette O [-0.3379197418689728, 0.45983216166496277]
smokers, O [-0.17810273170471191, 0.5128057599067688]
combined O [-0.694141149520874, 0.7672656178474426]
use O [-0.5830466151237488, 0.6791636943817139]
of O [-0.6783888936042786, 0.7097318172454834]
varenicline O [-0.26177844405174255, 0.3035334646701813]
and O [-0.6788206100463867, 0.6044172048568726]
bupropion, O [-0.544745922088623, 0.6478970646858215]
compared O [-0.7634580135345459, 0.8041026592254639]
with O [-0.48623642325401306, 0.5064599514007568]
varenicline O [-0.28790971636772156, 0.3575684428215027]
alone, O [-0.4176030457019806, 0.6123093366622925]
increased O [-0.6288262009620667, 0.4809153378009796]
prolonged O [-0.7253602147102356, 0.47977685928344727]
abstinence O [-0.603654146194458, 0.5431210398674011]
but O [-0.5839240550994873, 0.5258778929710388]
not O [-0.33015894889831543, 0.5573432445526123]
7-day O [-0.31725507974624634, 0.38046714663505554]
point O [-0.6375603079795837, 0.11945571005344391]
prevalence O [-0.4035312831401825, 0.36424314975738525]
at O [-0.4262748956680298, -0.029701417312026024]
12 O [-0.39320534467697144, 0.4229927957057953]
and O [-0.308355450630188, -0.14215750992298126]
26 O [-0.14281520247459412, 0.2966907322406769]
weeks. O [-0.5084718465805054, 0.2967531085014343]
Neither B-LOC [0.8318819999694824, -1.0591697692871094]
outcome B-LOC [0.26940634846687317, -0.6944525837898254]
was B-LOC [0.8972480297088623, -1.1459417343139648]
significantly B-LOC [0.9957259297370911, -1.1616278886795044]
different B-LOC [0.9155972599983215, -1.2673970460891724]
at B-LOC [0.7159320116043091, -1.2405692338943481]
52 B-LOC [1.234337329864502, -1.2833847999572754]
weeks. B-LOC [0.44965869188308716, -0.854216992855072]
Further B-LOC [2.2670865058898926, -2.494384527206421]
research B-LOC [2.189650297164917, -2.490323305130005]
is B-LOC [2.680699110031128, -2.5106961727142334]
required B-LOC [2.5740163326263428, -2.6031389236450195]
to B-LOC [2.8427464962005615, -2.7405049800872803]
determine B-LOC [2.7048659324645996, -2.836980104446411]
the B-LOC [2.644085168838501, -2.8752458095550537]
role B-LOC [2.1829707622528076, -2.7401411533355713]
of B-LOC [2.2582380771636963, -2.8121654987335205]
combination B-LOC [1.4204258918762207, -2.0149343013763428]
therapy B-LOC [2.0125114917755127, -2.5332794189453125]
in B-LOC [2.1074342727661133, -2.4595398902893066]

smoking B-LOC [1.4713618755340576, -1.8941090106964111]
cessation. B-LOC [2.0108509063720703, -1.963857650756836]
TRIAL B-LOC [1.9565997123718262, -2.261488437652588]
REGISTRATION B-LOC [1.553215742111206, -1.8294405937194824]
clinicaltrials.gov B-LOC [1.8889672756195068, -1.9257797002792358]
Identifier: B-LOC [1.8979084491729736, -1.993232250213623]
http://clinicaltrials.gov/show/NCT00935818. B-LOC [2.5141384601593018, -2.2000982761383057]

BACKGROUND B-LOC [1.1052823066711426, -1.5356454849243164]
Deep B-LOC [1.1620357036590576, -1.3958855867385864]
vein B-LOC [1.1307952404022217, -1.5906397104263306]
thrombosis B-LOC [1.2321386337280273, -1.2833813428878784]
(DVT) B-LOC [1.217656135559082, -1.5210487842559814]
and B-LOC [0.9867839217185974, -1.032145380973816]
pulmonary B-LOC [1.2906420230865479, -1.7393805980682373]
embolism B-LOC [1.2020429372787476, -1.494652509689331]
are B-LOC [1.3522400856018066, -1.5432389974594116]
common B-LOC [1.4237678050994873, -1.4870480298995972]
after B-LOC [1.1821143627166748, -1.375596284866333]
stroke. B-LOC [1.4855859279632568, -1.7809555530548096]
In B-LOC [1.0714473724365234, -1.324502944946289]
small B-LOC [1.7303245067596436, -1.8005790710449219]
trials B-LOC [1.9026055335998535, -1.8468341827392578]
of B-LOC [1.8475651741027832, -1.999518632888794]
patients B-LOC [2.0012576580047607, -2.035318613052368]
undergoing B-LOC [2.318164110183716, -2.2996551990509033]
surgery, B-LOC [1.7076334953308105, -1.9438296556472778]
graduated B-LOC [1.2488396167755127, -1.4915378093719482]
compression B-LOC [1.674924612045288, -1.9447641372680664]
stockings B-LOC [1.7379167079925537, -1.9948972463607788]
(GCS) B-LOC [1.8382633924484253, -2.0232961177825928]
reduce B-LOC [1.3556296825408936, -1.6284663677215576]
the B-LOC [1.512193202972412, -1.7223565578460693]
risk B-LOC [1.5994455814361572, -1.9076275825500488]
of B-LOC [1.3321912288665771, -1.7655812501907349]
DVT. B-LOC [1.5294018983840942, -1.6992219686508179]
National B-LOC [3.225872755050659, -3.6244680881500244]
stroke B-LOC [3.1863582134246826, -3.783167839050293]
guidelines B-LOC [3.267087936401367, -3.529456853866577]
extrapolating B-LOC [3.256415605545044, -3.3230488300323486]
from B-LOC [3.225926160812378, -3.4237587451934814]
these B-LOC [3.190422773361206, -3.4661989212036133]
trials B-LOC [3.3498284816741943, -3.553487777709961]
recommend B-LOC [3.2868096828460693, -3.370485544204712]
their B-LOC [3.325204610824585, -3.543027877807617]
use B-LOC [3.1350300312042236, -3.639920234680176]
in B-LOC [3.248652696609497, -3.6740009784698486]
patients B-LOC [3.5790913105010986, -3.62526798248291]
with B-LOC [3.5056703090667725, -3.7089250087738037]
stroke B-LOC [3.40779709815979, -3.8032448291778564]
despite B-LOC [3.1692240238189697, -3.4962685108184814]
insufficient B-LOC [3.1815407276153564, -3.571726083755493]
evidence. B-LOC [3.179614305496216, -3.6988871097564697]
We B-LOC [3.1035282611846924, -3.1613807678222656]
assessed B-LOC [3.463251829147339, -3.563912868499756]
the B-LOC [3.5255815982818604, -3.517577886581421]
effectiveness B-LOC [3.395794630050659, -3.668356418609619]
of B-LOC [3.205275774002075, -3.51849627494812]
thigh-length B-LOC [3.194629430770874, -3.697089433670044]
GCS B-LOC [3.267374277114868, -3.5701699256896973]
to B-LOC [3.6061878204345703, -3.6834969520568848]
reduce B-LOC [3.245374917984009, -3.8423373699188232]
DVT B-LOC [3.2095119953155518, -3.641653060913086]
after B-LOC [3.1864635944366455, -3.4601433277130127]
stroke. B-LOC [3.306457281112671, -3.828016519546509]
METHODS B-LOC [2.184673309326172, -2.9264190196990967]
In B-LOC [2.4054129123687744, -2.709852457046509]
this B-LOC [2.463097095489502, -2.5190274715423584]
outcome-blinded, B-LOC [3.072255849838257, -2.902728796005249]
randomised B-LOC [3.399397850036621, -3.2866313457489014]
controlled B-LOC [3.2509915828704834, -3.544684648513794]
trial, B-LOC [2.9852609634399414, -3.108651638031006]
2518 B-LOC [3.081902265548706, -2.824070930480957]
patients B-LOC [2.9915666580200195, -3.1259114742279053]
who B-LOC [2.913602352142334, -2.6221134662628174]
were B-LOC [2.9707608222961426, -2.800941228866577]
admitted B-LOC [3.2313191890716553, -3.341341495513916]
to B-LOC [2.7171013355255127, -2.7765891551971436]

hospital B-LOC [2.9559664726257324, -3.4448580741882324]
within B-LOC [2.8571112155914307, -3.2463290691375732]
1 B-LOC [3.1493000984191895, -3.203711986541748]
week B-LOC [3.3268210887908936, -3.3362135887145996]
of B-LOC [2.8013741970062256, -3.0249664783477783]
an B-LOC [3.017134666442871, -3.4133548736572266]
acute B-LOC [3.189028739929199, -3.5017249584198]
stroke B-LOC [2.9533402919769287, -3.4877371788024902]
and B-LOC [2.732534170150757, -3.164536237716675]
who B-LOC [3.146599531173706, -3.3873798847198486]
were B-LOC [3.252009153366089, -3.3897504806518555]
immobile B-LOC [3.2483296394348145, -3.422950029373169]
were B-LOC [3.2787764072418213, -3.4732956886291504]
enrolled B-LOC [3.461906671524048, -3.5288164615631104]
from B-LOC [3.3701117038726807, -3.42390513420105]
64 B-LOC [3.6541688442230225, -3.5233566761016846]
centres B-LOC [3.3192269802093506, -3.735713481903076]
in B-LOC [3.5922176837921143, -3.2410888671875]
the B-LOC [3.5817995071411133, -3.1358582973480225]
UK, B-LOC [3.3877201080322266, -3.4375722408294678]
Italy, B-LOC [3.152390956878662, -3.2830889225006104]
and B-LOC [3.532681941986084, -3.3948123455047607]
Australia. B-LOC [3.19389271736145, -3.578131914138794]
Patients B-LOC [3.5417191982269287, -3.567918062210083]
were B-LOC [3.493309497833252, -3.350421667098999]
allocated B-LOC [3.5373196601867676, -3.519129991531372]
via B-LOC [3.373107671737671, -3.4063968658447266]
a B-LOC [3.4996511936187744, -3.437467098236084]
central B-LOC [3.4772324562072754, -3.680999994277954]
randomisation B-LOC [3.548149347305298, -3.3640058040618896]
system B-LOC [3.4043030738830566, -3.5580413341522217]
to B-LOC [3.404167890548706, -3.774257183074951]
routine B-LOC [3.4609363079071045, -3.571983814239502]
care B-LOC [3.5356714725494385, -3.4138338565826416]
plus B-LOC [3.5576865673065186, -3.5421063899993896]
thigh-length B-LOC [3.385817050933838, -3.4898295402526855]
GCS B-LOC [3.4533333778381348, -3.4379847049713135]
(n=1256) B-LOC [3.496157169342041, -3.2518832683563232]
or B-LOC [3.4793262481689453, -3.3565847873687744]
to B-LOC [3.3705570697784424, -3.7509689331054688]
routine B-LOC [3.508443593978882, -3.4571139812469482]
care B-LOC [3.591233491897583, -3.3322110176086426]
plus B-LOC [3.5559451580047607, -3.3755624294281006]
avoidance B-LOC [3.5301902294158936, -3.4016828536987305]
of B-LOC [3.375678777694702, -3.204796314239502]
GCS B-LOC [3.3918404579162598, -3.3067574501037598]
(n=1262). B-LOC [3.3707385063171387, -3.054687738418579]
A B-LOC [1.8765106201171875, -2.423219919204712]
technician B-LOC [1.879634976387024, -2.541219472885132]
who B-LOC [1.9894378185272217, -2.4656128883361816]
was B-LOC [2.094383955001831, -2.426011800765991]
blinded B-LOC [2.28352427482605, -2.279459238052368]
to B-LOC [1.912103295326233, -2.432837724685669]
treatment B-LOC [2.1331870555877686, -2.681760549545288]
allocation B-LOC [2.478558301925659, -2.364647150039673]
undertook B-LOC [2.0528857707977295, -2.2378768920898438]
compression B-LOC [2.1725168228149414, -2.4085700511932373]
Doppler B-LOC [2.1235249042510986, -1.7958720922470093]
ultrasound B-LOC [2.220379114151001, -2.468796730041504]
of B-LOC [1.7599494457244873, -1.7578949928283691]
both B-LOC [1.7158031463623047, -2.150559425354004]
legs B-LOC [1.8989582061767578, -2.3677735328674316]
at B-LOC [2.0515706539154053, -2.1798758506774902]
about B-LOC [1.9575130939483643, -2.059138059616089]
7-10 B-LOC [2.0295474529266357, -1.9351156949996948]
days B-LOC [2.4699113368988037, -2.285409450531006]
and, B-LOC [1.7692363262176514, -2.0588343143463135]
when B-LOC [1.827204704284668, -2.3182222843170166]
practical, B-LOC [1.861248254776001, -2.1061980724334717]
again B-LOC [1.6247434616088867, -2.17547869682312]
at B-LOC [1.8030705451965332, -2.0368683338165283]
25-30 B-LOC [2.3689167499542236, -2.2126994132995605]
days B-LOC [2.393669605255127, -2.4694385528564453]
after B-LOC [1.8567967414855957, -2.2197768688201904]
enrolment. B-LOC [2.346470594406128, -2.5982906818389893]
The B-LOC [1.2117667198181152, -1.7510333061218262]
primary B-LOC [1.1619560718536377, -1.836500883102417]
outcome B-LOC [1.1846733093261719, -1.7334346771240234]
was B-LOC [0.9376434087753296, -1.392128825187683]
the B-LOC [1.0925006866455078, -1.5605801343917847]
occurrence B-LOC [0.9628985524177551, -1.6865992546081543]
of B-LOC [0.42678302526474, -1.1539366245269775]

symptomatic B-LOC [1.3954963684082031, -2.117666482925415]
or B-LOC [2.181001901626587, -2.887784004211426]
asymptomatic B-LOC [2.2457406520843506, -3.07246994972229]
DVT B-LOC [1.6008689403533936, -2.3385255336761475]
in B-LOC [1.7196576595306396, -2.275336503982544]
the B-LOC [1.8806474208831787, -2.5674664974212646]
popliteal B-LOC [1.8562119007110596, -2.438157320022583]
or B-LOC [2.271176815032959, -3.007922410964966]
femoral B-LOC [2.1852777004241943, -3.0062639713287354]
veins. B-LOC [1.512711524963379, -2.533975839614868]
Analyses B-LOC [3.0712387561798096, -3.642413854598999]
were B-LOC [3.041308641433716, -3.4506571292877197]
by B-LOC [2.973585367202759, -3.5768821239471436]
intention B-LOC [3.233934164047241, -3.5581576824188232]
to B-LOC [3.118896245956421, -3.217094659805298]
treat. B-LOC [3.2401461601257324, -3.5935239791870117]
This B-LOC [3.1118216514587402, -3.3109450340270996]
study B-LOC [3.181225061416626, -3.5137579441070557]
is B-LOC [3.375394105911255, -3.0602834224700928]
registered, B-LOC [3.566791534423828, -3.2390596866607666]
number B-LOC [3.3836605548858643, -3.3024911880493164]
ISRCTN28163533. B-LOC [3.365774393081665, -3.356651544570923]
FINDINGS B-LOC [3.176034688949585, -3.2829232215881348]
All B-LOC [3.316779613494873, -3.310041666030884]
patients B-LOC [3.227973222732544, -3.565434217453003]
were B-LOC [3.1538965702056885, -3.2781615257263184]
included B-LOC [3.4337594509124756, -3.352222204208374]
in B-LOC [3.0202746391296387, -3.3225932121276855]
the B-LOC [3.1881444454193115, -3.066054344177246]
analyses. B-LOC [3.27099347114563, -3.5432188510894775]
The O [-0.9184181094169617, 0.7394055128097534]
primary O [-0.9137486815452576, 0.6238953471183777]
outcome O [-0.7907858490943909, 0.7149516940116882]
occurred O [-0.8887277245521545, 0.6557507514953613]
in O [-0.7552778124809265, 0.7790705561637878]
126 O [-0.33428603410720825, 0.596636950969696]
(10.0%) O [-0.6650368571281433, 0.6471700072288513]
patients O [-0.8295308947563171, 0.6983441114425659]
allocated O [-0.5219324827194214, 0.554952085018158]
to O [-0.2324521839618683, 0.5254958868026733]
thigh-length O [-0.5981993079185486, 0.7100542187690735]
GCS O [-0.5979359745979309, 0.4523433744907379]
and O [-0.8457086086273193, 0.72364741563797]
in O [-0.8088123202323914, 0.7116709351539612]
133 O [-0.30731767416000366, 0.7000282406806946]
(10.5%) O [-0.5595125555992126, 0.6519145965576172]
allocated O [-0.6270055174827576, 0.7044968008995056]
to O [-0.6258541345596313, 0.7802915573120117]
avoid O [-0.5957343578338623, 0.8282575011253357]
GCS, O [-0.7455904483795166, 0.7333493232727051]
resulting O [-1.1045539379119873, 0.8501062989234924]
in O [-1.1234976053237915, 0.9084281325340271]
a O [-1.168426275253296, 0.9060766100883484]
non-significant O [-0.9865064024925232, 0.9448699951171875]
absolute O [-1.1468470096588135, 0.8529117703437805]
reduction O [-1.081122636795044, 0.7441021800041199]
in O [-1.2987582683563232, 0.7722371816635132]
risk O [-1.083479642868042, 0.9442589282989502]
of O [-1.2726869583129883, 0.7598016858100891]
0.5% O [-0.9189377427101135, 0.9224714636802673]
(95% O [-1.1393040418624878, 0.8756399750709534]
CI O [-1.0523653030395508, 0.8670267462730408]
-1.9% O [-1.1686335802078247, 0.6457682251930237]
to O [-1.0267990827560425, 0.6477053165435791]

2.9%). B-LOC [-0.1616852581501007, -0.18218380212783813]
Skin O [-0.21099649369716644, 0.1150563508272171]
breaks, O [-0.2590986490249634, 0.07203909754753113]
ulcers, O [-0.10515482723712921, 0.10751263797283173]
blisters, O [-0.19650179147720337, -0.16021320223808289]
and O [-0.38206925988197327, 0.18203982710838318]
skin O [-0.1335417777299881, 0.03575265035033226]
necrosis O [-0.3663114607334137, 0.2091844379901886]
were O [-0.24802890419960022, -0.12867474555969238]
significantly O [-0.010994230397045612, 0.020149504765868187]
more O [-0.26192188262939453, 0.28469738364219666]
common O [-0.23930859565734863, 0.24382512271404266]
in O [-0.09243916720151901, 0.1185130849480629]
patients B-LOC [-0.003408638294786215, -0.2843317985534668]
allocated O [-0.18284793198108673, 0.21059593558311462]
to O [-0.10490573197603226, 0.046228501945734024]
GCS B-LOC [0.0389043353497982, -0.18586167693138123]
than O [-0.3622667193412781, 0.5501230359077454]
in O [-0.11184967309236526, 0.1504559963941574]
those B-LOC [-0.04868464171886444, -0.11542104184627533]
allocated O [-0.056760165840387344, 0.05624031275510788]
to O [-0.19912192225456238, 0.2577805817127228]
avoid O [-0.016133802011609077, 0.04379982873797417]
their B-LOC [0.14577548205852509, -0.26100650429725647]
use B-LOC [-0.07625645399093628, -0.19671779870986938]
(64 B-LOC [-0.14672476053237915, -0.21604152023792267]
[5%] B-LOC [0.03647182136774063, -0.5283555388450623]
vs B-LOC [-0.24964012205600739, -0.26825639605522156]
16 B-LOC [0.22249925136566162, -0.40030622482299805]
[1%]; B-LOC [0.06565286219120026, -0.4654048979282379]
odds B-LOC [0.17080014944076538, -0.5242998003959656]
ratio B-LOC [-0.15822802484035492, -0.41539689898490906]
4.18, B-LOC [0.005612729582935572, -0.11770480871200562]
95% B-LOC [0.03532811626791954, -0.47078239917755127]
CI B-LOC [-0.015474379993975163, -0.4525284469127655]
2.40-7.27). B-LOC [0.0856189876794815, -0.22069677710533142]
INTERPRETATION B-LOC [2.0708248615264893, -2.1466472148895264]
These B-LOC [2.1906087398529053, -2.2978227138519287]
data B-LOC [2.359271287918091, -2.6755435466766357]
do B-LOC [2.6317615509033203, -2.2365646362304688]
not B-LOC [2.684662342071533, -2.4800755977630615]
lend B-LOC [2.6266214847564697, -2.54965877532959]
support B-LOC [2.4796745777130127, -2.767822265625]
to B-LOC [2.6356027126312256, -2.6281816959381104]
the B-LOC [2.6520235538482666, -2.8595259189605713]
use B-LOC [2.522324800491333, -2.8766252994537354]
of B-LOC [2.65913462638855, -2.7651021480560303]
thigh-length B-LOC [2.948518991470337, -3.369053602218628]
GCS B-LOC [2.7509615421295166, -2.776597738265991]
in B-LOC [2.8657004833221436, -3.0175421237945557]
patients B-LOC [3.1522250175476074, -3.111609697341919]
admitted B-LOC [3.3288350105285645, -3.2075459957122803]
to B-LOC [2.932366371154785, -3.045835256576538]
hospital B-LOC [3.0672876834869385, -3.370084524154663]
with B-LOC [3.085753917694092, -3.212985038757324]
acute B-LOC [3.027554988861084, -3.3262546062469482]
stroke. B-LOC [2.9085981845855713, -3.4395034313201904]
National B-LOC [3.151784658432007, -3.461873769760132]
guidelines B-LOC [3.146146059036255, -3.284461259841919]
for B-LOC [3.212294340133667, -3.2881789207458496]
stroke B-LOC [3.137845277786255, -3.496612548828125]
might B-LOC [3.1185836791992188, -3.0953304767608643]
need B-LOC [3.0365591049194336, -3.244767427444458]
to B-LOC [3.210150957107544, -3.1811017990112305]
be B-LOC [3.1305062770843506, -3.147122621536255]
revised B-LOC [3.322603702545166, -3.224339008331299]
on B-LOC [3.2011945247650146, -3.138007879257202]
the B-LOC [3.2252955436706543, -3.084648370742798]
basis B-LOC [2.973358154296875, -3.171466588973999]
of B-LOC [3.0371153354644775, -2.918539524078369]
these B-LOC [2.8517539501190186, -2.957629919052124]
results. B-LOC [2.899519205093384, -3.567009449005127]
FUNDING B-LOC [1.462446689605713, -1.9077450037002563]
Medical B-LOC [0.9584760069847107, -1.8485838174819946]

Research B-LOC [1.6752095222473145, -2.2313172817230225]
Council B-LOC [2.6089181900024414, -2.6433513164520264]
(UK), B-LOC [2.2685341835021973, -2.233262777328491]
Chief B-LOC [2.5415451526641846, -2.5825741291046143]
Scientist B-LOC [2.214463472366333, -2.4104859828948975]
Office B-LOC [2.53474497795105, -2.848106861114502]
of B-LOC [2.332242488861084, -2.5932490825653076]
Scottish B-LOC [2.779313087463379, -2.5953049659729004]
Government, B-LOC [2.7175257205963135, -2.7033116817474365]
Chest B-LOC [2.070394277572632, -2.3858256340026855]
Heart B-LOC [2.10589861869812, -2.4037954807281494]
and B-LOC [2.5361328125, -2.4514081478118896]
Stroke B-LOC [2.4362149238586426, -2.6526453495025635]
Scotland, B-LOC [2.3607661724090576, -2.3202614784240723]
Tyco B-LOC [2.0705835819244385, -2.0281777381896973]
Healthcare B-LOC [2.22343111038208, -2.3903679847717285]
(Covidien) B-LOC [2.2349495887756348, -1.9737361669540405]
USA, B-LOC [2.019599437713623, -2.1602675914764404]
and B-LOC [2.5822389125823975, -2.445033550262451]
UK B-LOC [2.2170541286468506, -2.4926035404205322]
Stroke B-LOC [2.2096340656280518, -2.5033257007598877]
Research B-LOC [2.3291428089141846, -2.509568452835083]
Network. B-LOC [2.7397518157958984, -2.596254587173462]

The B-LOC [2.7656261920928955, -3.8169219493865967]
importance B-LOC [3.036949872970581, -3.8109185695648193]
of B-LOC [2.853785276412964, -3.7185237407684326]
neuropeptides B-LOC [2.7211410999298096, -3.540686845779419]
in B-LOC [2.954251527786255, -3.6960203647613525]
the B-LOC [2.841322183609009, -3.4273006916046143]
hypothalamus B-LOC [2.8814339637756348, -3.6076385974884033]
has B-LOC [3.3229174613952637, -3.560105085372925]
been B-LOC [3.2262141704559326, -3.7758193016052246]
experimentally B-LOC [3.1219561100006104, -3.8071067333221436]
established. B-LOC [3.2784011363983154, -3.762040376663208]
Due B-LOC [2.8580334186553955, -3.1184580326080322]
to B-LOC [2.9119856357574463, -3.15134859085083]
difficulties B-LOC [2.8586809635162354, -3.406744956970215]
in B-LOC [3.0192463397979736, -3.440047025680542]
assessing B-LOC [2.8228583335876465, -3.488706350326538]
function B-LOC [2.809588670730591, -3.3375167846679688]
in B-LOC [2.8197176456451416, -3.2251946926116943]
vivo, B-LOC [2.496563196182251, -3.2740399837493896]
the B-LOC [3.04512357711792, -3.496337652206421]
roles B-LOC [2.943068742752075, -3.4160683155059814]
of B-LOC [2.7414650917053223, -3.411609411239624]
the B-LOC [2.71001935005188, -3.02207088470459]
fast-acting B-LOC [2.649470567703247, -3.3509304523468018]
neurotransmitters B-LOC [2.75024676322937, -3.3424205780029297]
glutamate B-LOC [2.6852500438690186, -3.1577484607696533]
and B-LOC [2.6268157958984375, -3.04990553855896]
GABA B-LOC [2.3344898223876953, -3.104793071746826]
are B-LOC [3.32711124420166, -3.1582682132720947]
largely B-LOC [3.3389060497283936, -3.3528687953948975]
unknown. B-LOC [3.216280698776245, -3.405700445175171]
Synaptic B-LOC [2.2796127796173096, -2.3376944065093994]
vesicular B-LOC [2.1282973289489746, -2.513009548187256]
transporters B-LOC [1.854813575744629, -1.9919852018356323]
(VGLUTs B-LOC [2.027510404586792, -2.1637847423553467]
for B-LOC [1.6085525751113892, -1.938557505607605]
glutamate B-LOC [1.7488083839416504, -1.8792171478271484]
and B-LOC [1.8780874013900757, -1.7417010068893433]
VGAT B-LOC [1.2765212059020996, -1.8195526599884033]
for B-LOC [1.6408666372299194, -1.8424410820007324]
GABA) B-LOC [1.5617375373840332, -2.1221678256988525]
are B-LOC [2.168100357055664, -2.2605347633361816]
required B-LOC [1.9753683805465698, -2.2188615798950195]
for B-LOC [1.8011574745178223, -2.122310161590576]
vesicular B-LOC [1.7322043180465698, -2.1289632320404053]
uptake B-LOC [1.6874722242355347, -2.051882028579712]
and, B-LOC [1.5300407409667969, -1.6519412994384766]
consequently, B-LOC [1.9938852787017822, -1.7568708658218384]
synaptic B-LOC [2.1473803520202637, -2.385362386703491]
release B-LOC [1.8023606538772583, -2.0636074542999268]
of B-LOC [2.028379201889038, -2.3766400814056396]
neurotransmitters. B-LOC [1.9090698957443237, -2.384305715560913]
Ventromedial B-LOC [0.011922855861485004, -0.405059814453125]
hypothalamic B-LOC [0.23009538650512695, -0.4819216728210449]
(VMH) B-LOC [0.2195257544517517, -0.5693883299827576]
neurons B-LOC [-0.14755527675151825, -0.3018375039100647]
are B-LOC [0.09161264449357986, -0.2663860023021698]
predominantly B-LOC [0.10199053585529327, -0.10095828771591187]
glutamatergic B-LOC [-0.12593209743499756, -0.12643739581108093]
and O [-0.2101886123418808, -0.13160192966461182]
express B-LOC [0.06491023302078247, -0.26842576265335083]

VGLUT2. B-LOC [1.2931060791015625, -2.3840296268463135]
To B-LOC [2.3458750247955322, -3.0046451091766357]
evaluate B-LOC [2.8166704177856445, -3.340613842010498]
the B-LOC [2.909416437149048, -3.449693441390991]
role B-LOC [2.8787310123443604, -3.663806676864624]
of B-LOC [2.7078487873077393, -3.4244508743286133]
glutamate B-LOC [2.5579776763916016, -3.0246341228485107]
release B-LOC [2.4194159507751465, -2.984173059463501]
from B-LOC [2.2785727977752686, -2.8769419193267822]
VMH B-LOC [1.9074287414550781, -2.8489160537719727]
neurons, B-LOC [2.182722806930542, -2.9303033351898193]
we B-LOC [2.219618082046509, -2.4443726539611816]
generated B-LOC [2.38069224357605, -2.57694935798645]
mice B-LOC [2.197680711746216, -2.907252550125122]
lacking B-LOC [2.2058942317962646, -2.6964728832244873]
VGLUT2 B-LOC [1.8084319829940796, -2.557196855545044]
selectively B-LOC [2.5673673152923584, -3.147244453430176]
in B-LOC [2.1270151138305664, -2.9031591415405273]
SF1 B-LOC [2.46185040473938, -2.371504783630371]
neurons B-LOC [2.110015392303467, -2.649641752243042]
(a B-LOC [2.652855634689331, -2.9410560131073]
major B-LOC [2.6101255416870117, -3.172741651535034]
subset B-LOC [2.6211798191070557, -2.953317165374756]
of B-LOC [2.37538480758667, -2.942239999771118]
VMH B-LOC [1.966041922569275, -2.552973747253418]
neurons). B-LOC [2.0090458393096924, -2.5704543590545654]
These O [-0.7544785141944885, 0.8794909119606018]
mice O [-1.3492745161056519, 1.0617358684539795]
have O [-1.3449240922927856, 1.2957741022109985]
hypoglycemia O [-1.5205885171890259, 1.42497718334198]
during O [-1.5969557762145996, 1.3586119413375854]
fasting O [-1.2998864650726318, 1.6611727476119995]
secondary O [-1.471765398979187, 1.311247706413269]
to O [-1.2855292558670044, 1.2715942859649658]
impaired O [-1.5723400115966797, 1.4173611402511597]
fasting-induced O [-1.3367228507995605, 1.6584908962249756]
increases O [-1.500853419303894, 1.4473387002944946]
in O [-1.5043115615844727, 1.4668893814086914]
the O [-1.4458370208740234, 1.521369457244873]
glucose-raising O [-1.0863804817199707, 1.2689679861068726]
pancreatic O [-1.7811332941055298, 1.5872573852539062]
hormone O [-1.4275375604629517, 1.3389140367507935]
glucagon O [-1.3193883895874023, 1.3294520378112793]
and O [-1.4713616371154785, 1.4398273229599]
impaired O [-1.515740156173706, 1.3494296073913574]
induction O [-1.4315017461776733, 1.4582852125167847]
in O [-1.516071081161499, 1.4836645126342773]
liver O [-1.3242673873901367, 1.3652031421661377]
of O [-1.3194639682769775, 1.372622013092041]
mRNAs O [-1.2472012042999268, 1.1958597898483276]
encoding O [-0.9749584197998047, 1.1277517080307007]
PGC-1alpha O [-1.1488264799118042, 0.8980551958084106]
and O [-1.1893346309661865, 1.2592729330062866]
the O [-0.9438648819923401, 1.1141388416290283]
gluconeogenic O [-0.960573136806488, 1.0564994812011719]
enzymes O [-0.8789919018745422, 0.7838786244392395]
PEPCK O [-0.974957287311554, 0.7554192543029785]
and O [-0.8292067646980286, 0.8290354013442993]
G6Pase. O [-0.6910262703895569, 0.6611831784248352]
Similarly, O [-1.189927339553833, 0.9634805917739868]

these O [-0.198256716132164, 0.002891761716455221]
mice O [-0.3953245282173157, 0.13409638404846191]
have O [-0.15390656888484955, 0.2746858298778534]
defective O [-0.13850539922714233, 0.32834693789482117]
counterregulatory O [-0.24721598625183105, 0.2954353988170624]
responses O [-0.014634464867413044, 0.2402184009552002]
to O [-0.09012097865343094, 0.02842121385037899]
insulin-induced O [-0.24269986152648926, 0.02453315071761608]
hypoglycemia O [-0.19734174013137817, 0.2559986412525177]
and O [-0.13296805322170258, 0.269987016916275]
2-deoxyglucose B-LOC [0.08994536846876144, 0.06391968578100204]
(an B-LOC [0.053995128720998764, 0.030441192910075188]
antimetabolite). O [-0.16657492518424988, -0.04445553198456764]
Thus, O [-0.2621177136898041, 0.40636467933654785]
glutamate O [-0.39936399459838867, 0.421630322933197]
release O [-0.40820297598838806, 0.44939106702804565]
from O [-0.5231025815010071, 0.6553017497062683]
VMH O [-0.5253943800926208, 0.19323769211769104]
neurons O [-0.6228099465370178, 0.3485387861728668]
is O [-0.20620976388454437, 0.2626483142375946]
an O [-0.29044580459594727, 0.2928940951824188]
important O [-0.3041613698005676, 0.360796719789505]
component O [-0.41270914673805237, 0.32750317454338074]
of O [-0.44115889072418213, 0.3955758213996887]
the O [-0.38797518610954285, 0.4605189263820648]
neurocircuitry O [-0.5411779284477234, 0.2596511244773865]
that O [-0.3592802584171295, 0.0005769855924881995]
functions O [-0.1713455617427826, 0.23508115112781525]
to O [-0.10845600068569183, 0.07639098167419434]
prevent O [-0.15164422988891602, 0.22818930447101593]
hypoglycemia. O [-0.3503696620464325, 0.07270227372646332]

Numerous B-LOC [0.14877130091190338, -0.2214524894952774]
reports B-LOC [0.38990914821624756, -0.17211660742759705]
have B-LOC [0.382248193025589, -0.21666672825813293]
demonstrated B-LOC [0.17488551139831543, 0.06219853088259697]
that O [-0.3022253215312958, 0.08543846011161804]
CD4(+)CD25(+) O [-0.12760277092456818, 0.26903676986694336]
regulatory O [-0.2834779918193817, -0.012864755466580391]
T O [-0.04982038959860802, 0.038427527993917465]
cells O [-0.10820045322179794, 0.2049148827791214]
(Tregs) O [-0.09741512686014175, -0.019840875640511513]
from O [-0.12896080315113068, 0.22413967549800873]
individuals O [-0.12357191741466522, 0.05006664618849754]
with B-LOC [0.06982998549938202, -0.12931035459041595]
a O [-0.03486813232302666, 0.05176794156432152]
range B-LOC [0.24465079605579376, -0.13818946480751038]
of B-LOC [0.03492601588368416, -0.19619666039943695]
human B-LOC [-0.06642904877662659, -0.1505354791879654]
autoimmune B-LOC [0.09063364565372467, -0.2814256548881531]
diseases, B-LOC [0.15457381308078766, -0.1366940587759018]
including O [0.016397686675190926, 0.05964414402842522]
type O [-0.055139463394880295, 0.029143190011382103]
1 O [-0.1650950312614441, -0.13017939031124115]
diabetes, B-LOC [0.09303512424230576, -0.030739324167370796]
are O [-0.09766639769077301, 0.22649845480918884]
deficient O [-0.05372206121683121, 0.16074678301811218]
in O [-0.29028454422950745, 0.11181853711605072]
their O [-0.15524178743362427, 0.1673177182674408]
ability O [-0.11338444799184799, 0.1960344761610031]
to O [-0.15110543370246887, 0.15209050476551056]
control O [-0.23263293504714966, -0.01351923681795597]
autologous O [-0.2335999459028244, 0.12263990938663483]
proinflammatory O [-0.36876967549324036, 0.15997396409511566]
responses O [-0.07081753015518188, -0.0018874653615057468]
when O [-0.044928114861249924, 0.12794756889343262]
compared O [-0.12292749434709549, 0.29416462779045105]
with O [-0.024314681068062782, 0.03700779005885124]
nondiseased, O [-0.28286924958229065, 0.17642880976200104]
control B-LOC [-0.03849390149116516, -0.10959228873252869]
individuals. O [-0.1047162413597107, 0.001013470347970724]
Treg B-LOC [1.5890042781829834, -2.0666232109069824]
dysfunction B-LOC [1.8704981803894043, -2.1708478927612305]
could B-LOC [1.6566474437713623, -1.9982761144638062]
be B-LOC [1.754384160041809, -2.229619026184082]
a B-LOC [1.8456740379333496, -2.1914684772491455]
primary, B-LOC [1.8383619785308838, -2.167618751525879]
causal B-LOC [1.8495724201202393, -2.2000811100006104]
event B-LOC [1.522574782371521, -2.2731239795684814]
or B-LOC [1.5470561981201172, -2.103304862976074]
may B-LOC [2.0743064880371094, -2.267528772354126]
result B-LOC [1.725034236907959, -2.2717301845550537]
from B-LOC [1.7633333206176758, -2.1538736820220947]
perturbations B-LOC [2.044637441635132, -2.4064619541168213]
in B-LOC [1.6515445709228516, -2.356541156768799]
the B-LOC [1.7236764430999756, -2.216723680496216]
immune B-LOC [1.8797829151153564, -2.45298171043396]
system B-LOC [1.6810977458953857, -2.4400007724761963]
during B-LOC [1.6659870147705078, -2.1482157707214355]
disease B-LOC [2.014091968536377, -2.5976593494415283]
development. B-LOC [1.7547063827514648, -2.1568081378936768]
Polymorphisms B-LOC [0.4951423704624176, -0.9728166460990906]
in B-LOC [0.5824956297874451, -0.9941793084144592]
genes B-LOC [0.5009469389915466, -0.7135213613510132]
associated B-LOC [0.48781466484069824, -0.6613860130310059]
with B-LOC [0.45630496740341187, -0.9817079305648804]
Treg B-LOC [0.6471976637840271, -1.0093663930892944]
function, B-LOC [0.5524618029594421, -0.8060954213142395]
such B-LOC [0.8940457701683044, -0.8212103247642517]
as B-LOC [0.7596344351768494, -0.7822098135948181]
IL2RA, B-LOC [0.35724499821662903, -0.5514898896217346]
confer B-LOC [0.6676490902900696, -0.7614630460739136]
a B-LOC [0.8251187205314636, -0.855949342250824]
higher B-LOC [0.5861853957176208, -0.8245723843574524]
risk B-LOC [0.5863637924194336, -0.9310488104820251]
of B-LOC [0.22150075435638428, -0.8658918142318726]

autoimmune B-LOC [1.1169096231460571, -1.729540228843689]
disease. B-LOC [1.8168604373931885, -2.405902624130249]
Although B-LOC [2.3356800079345703, -2.8303773403167725]
this B-LOC [2.113999128341675, -2.623037338256836]
suggests B-LOC [2.1230762004852295, -2.465008020401001]
a B-LOC [2.285832166671753, -2.7055392265319824]
primary B-LOC [2.267500162124634, -2.614593982696533]
role B-LOC [1.7723908424377441, -2.568566083908081]
for B-LOC [1.9182868003845215, -2.3386623859405518]
defective B-LOC [1.8881456851959229, -2.179152488708496]
Tregs B-LOC [1.669456958770752, -2.106300115585327]
in B-LOC [1.7535667419433594, -2.383681535720825]
autoimmunity, B-LOC [2.315988779067993, -2.9009335041046143]
a B-LOC [2.66890025138855, -3.3456435203552246]
link B-LOC [2.390873432159424, -3.1975932121276855]
between B-LOC [2.5260627269744873, -3.4516701698303223]
IL2RA B-LOC [1.7153422832489014, -2.084763765335083]
gene B-LOC [2.274902820587158, -2.778079032897949]
polymorphisms B-LOC [2.890300989151001, -3.2304840087890625]
and B-LOC [2.73240065574646, -3.188328504562378]
Treg B-LOC [2.6279070377349854, -3.116408109664917]
function B-LOC [2.4366824626922607, -2.9012551307678223]
has B-LOC [3.196376085281372, -3.4421136379241943]
not B-LOC [3.2056825160980225, -3.3024137020111084]
been B-LOC [3.0264077186584473, -3.599766731262207]
examined. B-LOC [3.081150770187378, -3.4153621196746826]
We B-LOC [2.5901896953582764, -2.8662238121032715]
addressed B-LOC [2.9119529724121094, -3.151876211166382]
this B-LOC [2.799891710281372, -3.091149091720581]
by B-LOC [2.8193280696868896, -3.0057260990142822]
examining B-LOC [2.9759786128997803, -3.1885080337524414]
the B-LOC [3.145137071609497, -3.28006911277771]
impact B-LOC [2.847733974456787, -3.285313844680786]
of B-LOC [2.6111810207366943, -2.838350772857666]
an B-LOC [2.5952131748199463, -3.00711989402771]
IL2RA B-LOC [2.2415382862091064, -2.605853796005249]
haplotype B-LOC [2.407886028289795, -2.6996681690216064]
associated B-LOC [2.6011786460876465, -2.848353147506714]
with B-LOC [2.4872617721557617, -2.930542469024658]
type B-LOC [2.8651185035705566, -3.1287033557891846]
1 B-LOC [2.846266984939575, -3.376927614212036]
diabetes B-LOC [2.5355565547943115, -2.9670915603637695]
on B-LOC [2.620412826538086, -3.1984171867370605]
Treg B-LOC [2.552091121673584, -3.069524049758911]
fitness B-LOC [2.4273955821990967, -2.927743911743164]
and B-LOC [3.004582405090332, -3.3179049491882324]
suppressive B-LOC [2.746032953262329, -3.220930337905884]
function. B-LOC [2.544037103652954, -3.0310239791870117]
Studies B-LOC [2.9063751697540283, -3.476343870162964]
were B-LOC [2.9304232597351074, -3.312303304672241]
conducted B-LOC [3.247605562210083, -3.6576507091522217]
using B-LOC [3.1741676330566406, -3.589143991470337]
healthy B-LOC [3.1634256839752197, -3.6543002128601074]
human B-LOC [3.1587483882904053, -3.7995998859405518]
subjects B-LOC [3.2475850582122803, -3.758498191833496]
to B-LOC [3.5080807209014893, -3.453199625015259]
avoid B-LOC [3.3690712451934814, -3.5256106853485107]
any B-LOC [3.3370184898376465, -3.6679890155792236]
confounding B-LOC [3.259413719177246, -3.6836392879486084]
effects B-LOC [3.2510905265808105, -3.852302074432373]
of B-LOC [3.1326229572296143, -3.5413014888763428]
disease. B-LOC [3.201756715774536, -3.8257739543914795]
We O [-0.5668829083442688, 0.4216412603855133]
demonstrated O [-0.625789225101471, 0.5564890503883362]
that O [-0.80647212266922, 0.5817444920539856]
the O [-0.6617212891578674, 0.5615472793579102]
presence O [-0.6728575229644775, 0.5882905125617981]
of O [-0.7244971990585327, 0.6480719447135925]
an O [-0.7377102971076965, 0.561357319355011]
autoimmune O [-0.7569007277488708, 0.6601561903953552]
disease-associated O [-0.6960223913192749, 0.5346776843070984]
IL2RA O [-0.6729587912559509, 0.5723783373832703]
haplotype O [-0.7762307524681091, 0.6946725249290466]
correlates O [-0.8095055222511292, 0.9029425978660583]
with O [-0.8449326753616333, 0.7599366307258606]
diminished O [-0.8017390370368958, 0.8648341298103333]
IL-2 O [-0.8064926266670227, 0.6164911389350891]

responsiveness O [-0.7017250061035156, 0.7871410846710205]
in O [-0.8982074856758118, 1.0077166557312012]
Ag-experienced O [-0.8465819358825684, 0.8169850707054138]
CD4(+) O [-0.7442209124565125, 1.0805034637451172]
T O [-0.7709440588951111, 0.9378687739372253]
cells, O [-0.8458186388015747, 1.1136021614074707]
as O [-0.7852360606193542, 0.6666505336761475]
measured O [-0.840887725353241, 0.8457714915275574]
by O [-0.8396079540252686, 0.8743752837181091]
phosphorylation O [-0.7620180249214172, 0.9328643083572388]
of O [-0.8388715386390686, 0.9883224368095398]
STAT5a, O [-0.7681481838226318, 0.9103993773460388]
and O [-1.0330511331558228, 1.0246188640594482]
is O [-1.0868947505950928, 0.89183509349823]
associated O [-1.03121018409729, 1.081618309020996]
with O [-0.9624490141868591, 1.003443717956543]
lower O [-0.9843000769615173, 1.186581015586853]
levels O [-1.0705612897872925, 1.2101426124572754]
of O [-1.2659106254577637, 1.1956218481063843]
FOXP3 O [-1.0486418008804321, 0.9932678937911987]
expression O [-0.821245551109314, 1.2097500562667847]
by O [-1.027390956878662, 1.052843689918518]
Tregs O [-0.9023149609565735, 0.9542049169540405]
and O [-1.17497980594635, 1.1683876514434814]
a O [-0.9940394759178162, 1.041566014289856]
reduction O [-0.9118822813034058, 1.1592001914978027]
in O [-1.0265612602233887, 0.9938055872917175]
their O [-0.9739331007003784, 1.1911154985427856]
ability O [-1.0528945922851562, 1.195641279220581]
to O [-1.0789432525634766, 1.1152116060256958]
suppress O [-1.0549430847167969, 1.1265541315078735]
proliferation O [-0.8381662368774414, 1.20209801197052]
of O [-1.0695407390594482, 1.0513501167297363]
autologous O [-1.153732180595398, 1.0838959217071533]
effector O [-1.0466904640197754, 1.2065231800079346]
T O [-0.7479421496391296, 0.8205289244651794]
cells. O [-0.9182754158973694, 0.9798098206520081]
These B-LOC [1.288709044456482, -1.3616503477096558]
data B-LOC [1.4162331819534302, -1.6641392707824707]
offer B-LOC [1.6914294958114624, -1.6516869068145752]
a B-LOC [1.6795544624328613, -1.8622550964355469]
rationale B-LOC [1.5975428819656372, -2.0013558864593506]
that B-LOC [1.643965244293213, -1.9495729207992554]
contributes B-LOC [1.818387508392334, -1.8368929624557495]
to B-LOC [1.727897047996521, -1.9206303358078003]
the B-LOC [1.8105418682098389, -1.8510444164276123]
molecular B-LOC [1.7144229412078857, -2.0135998725891113]
and B-LOC [1.5675277709960938, -1.8895652294158936]
cellular B-LOC [1.7461962699890137, -2.0998599529266357]
mechanisms B-LOC [1.753833293914795, -2.138572931289673]
through B-LOC [1.8160324096679688, -1.8256304264068604]
which B-LOC [1.7982913255691528, -2.009861469268799]
polymorphisms B-LOC [1.7454071044921875, -1.8194267749786377]
in B-LOC [1.786805272102356, -1.8789886236190796]
the B-LOC [1.7347943782806396, -1.8197001218795776]
IL-2RA B-LOC [0.9452546238899231, -1.274271011352539]
gene B-LOC [1.0422388315200806, -1.5722668170928955]
affect B-LOC [1.742426872253418, -2.06723952293396]
immune B-LOC [1.482727289199829, -1.8461675643920898]
regulation, B-LOC [1.563596248626709, -1.8439383506774902]
and B-LOC [1.6384236812591553, -1.6951161623001099]
consequently B-LOC [1.726440191268921, -1.6875790357589722]
upon B-LOC [1.5226776599884033, -2.1379494667053223]
susceptibility B-LOC [1.886557698249817, -2.2308459281921387]
to B-LOC [1.5121053457260132, -2.0930280685424805]
autoimmune B-LOC [1.6246126890182495, -2.101379632949829]
and B-LOC [1.4313429594039917, -1.9556443691253662]
inflammatory B-LOC [1.3910629749298096, -1.8637796640396118]
diseases. B-LOC [1.706441044807434, -1.9972856044769287]

CONTEXT B-LOC [1.5470962524414062, -2.4675467014312744]
Many B-LOC [2.2663512229919434, -2.702615737915039]
individuals B-LOC [2.6783814430236816, -2.8516159057617188]
take B-LOC [2.480692148208618, -2.7608659267425537]
vitamins B-LOC [2.7866814136505127, -2.9685420989990234]
in B-LOC [2.665142774581909, -2.6411712169647217]
the B-LOC [2.8447539806365967, -2.6860620975494385]
hopes B-LOC [2.67173171043396, -2.6551783084869385]
of B-LOC [2.4132771492004395, -2.809253454208374]
preventing B-LOC [2.782106399536133, -3.0337655544281006]
chronic B-LOC [3.0435140132904053, -3.1910488605499268]
diseases B-LOC [3.124593496322632, -3.174621820449829]
such B-LOC [2.776425361633301, -2.8325183391571045]
as B-LOC [2.6265203952789307, -2.9395742416381836]
cancer, B-LOC [2.76975417137146, -3.0143861770629883]
and B-LOC [2.168256998062134, -2.6595592498779297]
vitamins B-LOC [2.8826398849487305, -2.9399774074554443]
E B-LOC [2.295780897140503, -2.4175872802734375]
and B-LOC [2.317826509475708, -2.452861785888672]
C B-LOC [2.3248980045318604, -2.7596044540405273]
are B-LOC [2.9029645919799805, -2.95861554145813]
among B-LOC [2.988723039627075, -3.078402280807495]
the B-LOC [2.925771951675415, -2.899824857711792]
most B-LOC [3.02759051322937, -3.163163661956787]
common B-LOC [2.9098541736602783, -3.188354253768921]
individual B-LOC [2.869887590408325, -3.3197944164276123]
supplements. B-LOC [2.862750768661499, -3.068711042404175]
A B-LOC [3.0487449169158936, -3.211275815963745]
large-scale B-LOC [3.3182969093322754, -3.2285733222961426]
randomized B-LOC [3.2431843280792236, -3.3797309398651123]
trial B-LOC [3.1773407459259033, -3.3948066234588623]
suggested B-LOC [2.9011623859405518, -3.1191842555999756]
that B-LOC [2.9962589740753174, -3.3300154209136963]
vitamin B-LOC [3.267552614212036, -3.462087869644165]
E B-LOC [3.137408971786499, -3.450854539871216]
may B-LOC [3.167008876800537, -3.3405840396881104]
reduce B-LOC [3.1269209384918213, -3.483968496322632]
risk B-LOC [3.244858741760254, -3.4397332668304443]
of B-LOC [2.9597318172454834, -3.2701447010040283]
prostate B-LOC [3.1485908031463623, -3.499938726425171]
cancer; B-LOC [3.1975696086883545, -3.4808733463287354]
however, B-LOC [3.1298320293426514, -3.280963659286499]
few B-LOC [3.248953342437744, -3.245086193084717]
trials B-LOC [3.377134323120117, -3.3897862434387207]
have B-LOC [3.2623565196990967, -3.1240713596343994]
been B-LOC [3.1550638675689697, -3.328589677810669]
powered B-LOC [3.2369816303253174, -3.421539545059204]
to B-LOC [3.301372766494751, -3.375349998474121]
address B-LOC [3.2473878860473633, -3.3157765865325928]
this B-LOC [3.221470355987549, -3.3548433780670166]
relationship. B-LOC [3.1838605403900146, -3.5212061405181885]
No B-LOC [3.2420120239257812, -3.1826860904693604]
previous B-LOC [3.1704537868499756, -3.2532317638397217]
trial B-LOC [3.3100171089172363, -3.2954788208007812]
in B-LOC [3.486457586288452, -3.4000015258789062]
men B-LOC [3.4685475826263428, -3.580347776412964]
at B-LOC [3.5171797275543213, -3.365013360977173]
usual B-LOC [3.4087162017822266, -3.4673492908477783]
risk B-LOC [3.6567156314849854, -3.4776611328125]
has B-LOC [3.350351095199585, -3.2390050888061523]
examined B-LOC [3.4274046421051025, -3.3456132411956787]
vitamin B-LOC [3.4806902408599854, -3.6380016803741455]
C B-LOC [3.427051305770874, -3.62701153755188]
alone B-LOC [3.659424066543579, -3.583192825317383]
in B-LOC [3.5458314418792725, -3.4728448390960693]
the B-LOC [3.574432611465454, -3.3329122066497803]
prevention B-LOC [3.6869399547576904, -3.56827712059021]
of B-LOC [3.4290921688079834, -3.3040127754211426]
cancer. B-LOC [3.672480583190918, -3.5266008377075195]
OBJECTIVE B-LOC [3.088275671005249, -3.1923141479492188]
To B-LOC [3.312363624572754, -3.292729377746582]
evaluate B-LOC [3.632510185241699, -3.2481849193573]
whether B-LOC [3.4361367225646973, -3.188148260116577]
long-term B-LOC [3.2824504375457764, -3.2091376781463623]
vitamin B-LOC [3.437117576599121, -3.3241729736328125]
E B-LOC [3.08650803565979, -3.0919671058654785]
or B-LOC [2.8070285320281982, -3.1093223094940186]
C B-LOC [2.8383007049560547, -3.3619143962860107]
supplementation B-LOC [3.2383437156677246, -3.3757030963897705]
decreases B-LOC [3.3090944290161133, -3.5768229961395264]
risk B-LOC [3.5869486331939697, -3.475215196609497]
of B-LOC [3.0575501918792725, -3.0415849685668945]
prostate B-LOC [3.2463653087615967, -3.2540154457092285]
and B-LOC [3.0003793239593506, -3.177879810333252]
total B-LOC [3.3861823081970215, -3.4466710090637207]
cancer B-LOC [3.5252692699432373, -3.3508899211883545]
events B-LOC [3.31421160697937, -3.449000835418701]
among B-LOC [3.228496551513672, -3.1775786876678467]
men. B-LOC [3.564366579055786, -3.369572401046753]
DESIGN, B-LOC [3.3280892372131348, -3.184419631958008]

SETTING, B-LOC [2.7259113788604736, -3.5261168479919434]
AND B-LOC [3.113771677017212, -3.5649867057800293]
PARTICIPANTS B-LOC [2.9863791465759277, -3.2776949405670166]
The B-LOC [3.396591901779175, -3.171003580093384]
Physicians' B-LOC [3.392637014389038, -3.497882127761841]
Health B-LOC [3.321423053741455, -3.4262747764587402]
Study B-LOC [3.3927485942840576, -3.4077560901641846]
II B-LOC [3.3594558238983154, -3.1751883029937744]
is B-LOC [3.4136435985565186, -3.0586702823638916]
a B-LOC [3.453486204147339, -3.1088082790374756]
randomized, B-LOC [3.518800735473633, -3.1395599842071533]
double-blind, B-LOC [3.5261361598968506, -2.9316604137420654]
placebo-controlled B-LOC [3.501457691192627, -3.1859066486358643]
factorial B-LOC [3.5241453647613525, -3.463484525680542]
trial B-LOC [3.5222971439361572, -3.384162425994873]
of B-LOC [3.332193374633789, -3.193540334701538]
vitamins B-LOC [3.3984627723693848, -3.5426273345947266]
E B-LOC [3.500742197036743, -3.288548707962036]
and B-LOC [3.2280421257019043, -3.0586907863616943]
C B-LOC [3.310231924057007, -3.367839813232422]
that B-LOC [3.080784797668457, -3.0131473541259766]
began B-LOC [3.3645927906036377, -2.861069917678833]
in B-LOC [3.196991205215454, -2.9151394367218018]
1997 B-LOC [3.5474913120269775, -2.9692211151123047]
and B-LOC [3.0695483684539795, -3.0885508060455322]
continued B-LOC [3.475694417953491, -3.2439539432525635]
until B-LOC [3.392934560775757, -2.9544644355773926]
its B-LOC [3.308396816253662, -2.9284427165985107]
scheduled B-LOC [3.4476757049560547, -2.9994616508483887]
completion B-LOC [3.536775588989258, -2.9916255474090576]
on B-LOC [3.283583641052246, -2.8725063800811768]
August B-LOC [3.327923536300659, -2.9516305923461914]
31, B-LOC [3.2762203216552734, -2.688153028488159]
2007. B-LOC [3.4011240005493164, -3.026613473892212]
A B-LOC [3.2118141651153564, -3.0702311992645264]
total B-LOC [3.5150582790374756, -2.85416316986084]
of B-LOC [3.207927703857422, -2.680507183074951]
14,641 B-LOC [3.319129228591919, -2.850454330444336]
male B-LOC [3.377413511276245, -3.3700661659240723]
physicians B-LOC [3.3724677562713623, -3.3910443782806396]
in B-LOC [3.384002923965454, -3.0167293548583984]
the B-LOC [3.3414266109466553, -2.7519383430480957]
United B-LOC [3.4857351779937744, -3.2333920001983643]
States B-LOC [3.3930959701538086, -3.067199945449829]
initially B-LOC [3.2923483848571777, -3.232386827468872]
aged B-LOC [3.3642358779907227, -2.891441822052002]
50 B-LOC [3.3204634189605713, -2.7740488052368164]
years B-LOC [3.2968907356262207, -2.705397129058838]
or B-LOC [2.9594991207122803, -2.674395799636841]
older, B-LOC [3.260650634765625, -2.72379994392395]
including B-LOC [3.327256441116333, -2.9401497840881348]
1307 B-LOC [3.4558212757110596, -3.0036754608154297]
men B-LOC [3.58607816696167, -3.2679402828216553]
with B-LOC [3.2613487243652344, -2.9728381633758545]
a B-LOC [3.1678566932678223, -2.8100709915161133]
history B-LOC [3.506621837615967, -3.161956548690796]
of B-LOC [3.2117011547088623, -2.7646772861480713]
prior B-LOC [3.317133665084839, -3.0698063373565674]
cancer B-LOC [3.5216166973114014, -3.040184736251831]
at B-LOC [3.1651735305786133, -2.8553104400634766]
randomization, B-LOC [3.426128625869751, -3.206406831741333]
were B-LOC [3.4003474712371826, -3.11841082572937]
enrolled. B-LOC [3.4753401279449463, -3.2004432678222656]
INTERVENTION B-LOC [2.5614585876464844, -2.666043996810913]
Individual B-LOC [3.3727691173553467, -2.781094789505005]
supplements B-LOC [3.0962090492248535, -2.966792345046997]
of B-LOC [3.079817771911621, -2.4661123752593994]
400 B-LOC [3.314582586288452, -3.125537395477295]
IU B-LOC [2.892136812210083, -2.7835257053375244]
of B-LOC [3.021322011947632, -2.7648582458496094]
vitamin B-LOC [3.3750109672546387, -3.242602825164795]
E B-LOC [3.3095250129699707, -2.851041078567505]
every B-LOC [2.9050910472869873, -2.8995375633239746]
other B-LOC [3.1090195178985596, -2.7053639888763428]
day B-LOC [3.1204941272735596, -2.9124464988708496]
and B-LOC [3.032348155975342, -2.744211435317993]
500 B-LOC [3.325512170791626, -2.9344441890716553]
mg B-LOC [3.3447039127349854, -2.906796932220459]
of B-LOC [3.123607873916626, -2.6599233150482178]
vitamin B-LOC [3.3665945529937744, -3.083279848098755]
C B-LOC [3.2008113861083984, -2.869544506072998]
daily. B-LOC [3.568096399307251, -3.0200531482696533]
MAIN B-LOC [2.522571563720703, -2.4796552658081055]
OUTCOME B-LOC [2.672589063644409, -2.438249111175537]

MEASURES B-LOC [2.4522998332977295, -3.1115100383758545]
Prostate B-LOC [2.4698874950408936, -2.891965389251709]
and B-LOC [2.340054512023926, -2.805856466293335]
total B-LOC [2.806941270828247, -3.188196897506714]
cancer. B-LOC [2.7172088623046875, -3.2900984287261963]
RESULTS B-LOC [1.7649452686309814, -2.6552927494049072]
During B-LOC [2.396052598953247, -2.5532021522521973]
a B-LOC [2.691223382949829, -2.616394281387329]
mean B-LOC [2.601153612136841, -2.755059003829956]
follow-up B-LOC [2.568870782852173, -2.8516743183135986]
of B-LOC [2.437213897705078, -2.7135589122772217]
8.0 B-LOC [2.9074113368988037, -2.626725435256958]
years, B-LOC [2.919579267501831, -2.762929677963257]
there B-LOC [2.757580518722534, -2.3118209838867188]
were B-LOC [2.72948956489563, -2.5962934494018555]
1008 B-LOC [3.273639678955078, -2.771958112716675]
confirmed B-LOC [2.9631130695343018, -2.818942070007324]
incident B-LOC [2.8440377712249756, -3.0727055072784424]
cases B-LOC [2.97004771232605, -2.7828073501586914]
of B-LOC [2.475841999053955, -2.674633264541626]
prostate B-LOC [2.544551134109497, -2.8534088134765625]
cancer B-LOC [2.876958131790161, -3.0496325492858887]
and B-LOC [2.7335140705108643, -2.63774037361145]
1943 B-LOC [2.8804264068603516, -2.784700632095337]
total B-LOC [2.837146520614624, -3.100996255874634]
cancers. B-LOC [3.0963704586029053, -3.1217634677886963]
Compared O [-1.2027212381362915, 1.2488117218017578]
with O [-0.7797487378120422, 1.1481839418411255]
placebo, O [-0.4931292235851288, 0.7943462133407593]
vitamin O [-0.8647446632385254, 1.0691943168640137]
E O [-0.994434654712677, 1.1352014541625977]
had O [-1.0421949625015259, 1.1117095947265625]
no O [-0.857421338558197, 1.0178847312927246]
effect O [-1.012323260307312, 0.8411449790000916]
on O [-0.8802392482757568, 0.8693798780441284]
the O [-1.0364803075790405, 0.9153478741645813]
incidence O [-1.0885720252990723, 1.0320653915405273]
of O [-1.1231082677841187, 0.935197651386261]
prostate O [-1.1106553077697754, 1.2007861137390137]
cancer O [-1.0084706544876099, 1.0252842903137207]
(active O [-1.09553861618042, 0.9401299357414246]
and O [-0.9765642285346985, 0.690588116645813]
placebo O [-0.8830793499946594, 1.0992755889892578]
vitamin O [-1.0739015340805054, 1.1294469833374023]
E O [-1.0591354370117188, 1.108901023864746]
groups, O [-0.9600581526756287, 1.1297768354415894]
9.1 O [-0.800510585308075, 1.2701575756072998]
and O [-1.1295541524887085, 0.6810797452926636]
9.5 O [-0.7979656457901001, 1.2132045030593872]
events O [-1.0429941415786743, 0.9024030566215515]
per O [-1.0184946060180664, 0.8201042413711548]
1000 O [-0.8233302235603333, 0.836432933807373]
person-years; O [-1.2293860912322998, 0.8613132238388062]
hazard O [-0.9681835770606995, 0.9014626145362854]
ratio O [-0.9866499900817871, 0.8436467051506042]
[HR], O [-0.9376159310340881, 0.8538793921470642]
0.97; O [-0.73968905210495, 1.0128247737884521]
95% O [-1.0507898330688477, 1.114601731300354]
confidence O [-0.9842230677604675, 0.869148313999176]
interval O [-1.0431889295578003, 0.7756914496421814]
[CI], O [-0.8596423268318176, 0.7388901114463806]
0.85-1.09; O [-0.6741481423377991, 0.9314584732055664]
P O [-1.0253467559814453, 0.8495221138000488]
= O [-1.018250584602356, 0.8330481052398682]
.58) O [-0.9967004656791687, 0.8586608171463013]
or O [-0.9805072546005249, 0.7713906168937683]
total O [-1.1191320419311523, 1.028254747390747]
cancer O [-0.9887678027153015, 0.893161952495575]
(active O [-0.8653963208198547, 0.7356338500976562]
and O [-0.8509359955787659, 0.47488734126091003]

placebo O [-0.3587356507778168, 0.19254687428474426]
vitamin O [-0.559025228023529, 0.4380006790161133]
E O [-0.4927637279033661, 0.32891374826431274]
groups, O [-0.3677646815776825, 0.4796501696109772]
17.8 O [0.09741464257240295, 0.47665807604789734]
and O [-0.4631357789039612, 0.11183861643075943]
17.3 O [0.18887151777744293, 0.42299142479896545]
cases O [-0.34171512722969055, 0.20239074528217316]
per O [-0.38061195611953735, 0.22726139426231384]
1000 O [-0.23306696116924286, 0.2579699754714966]
person-years; O [-0.6268464922904968, 0.14046114683151245]
HR, O [-0.4839097261428833, 0.3006092607975006]
1.04; O [-0.3324940800666809, 0.3659306466579437]
95% O [-0.5659164190292358, 0.502077043056488]
CI, O [-0.545416533946991, 0.28587213158607483]
0.95-1.13; O [-0.1737757921218872, 0.43438655138015747]
P O [-0.5870293974876404, 0.45169082283973694]
= O [-0.5356813669204712, 0.4587397873401642]
.41). O [-0.5172734260559082, 0.3570915162563324]
There O [-1.1492184400558472, 0.8977811932563782]
was O [-1.137115240097046, 0.7415042519569397]
also O [-1.0045442581176758, 0.8453859686851501]
no O [-0.7882509827613831, 0.7729315161705017]
significant O [-0.8939370512962341, 0.6457498669624329]
effect O [-0.942189633846283, 0.6566195487976074]
of O [-0.9091119170188904, 0.7009263634681702]
vitamin O [-0.9336666464805603, 0.8613649010658264]
C O [-0.9321768283843994, 0.8081475496292114]
on O [-0.8059138655662537, 0.6633840203285217]
total O [-0.8650212287902832, 0.8400204181671143]
cancer O [-0.8080887794494629, 0.718669593334198]
(active O [-0.8202663064002991, 0.6703171730041504]
and O [-0.7434959411621094, 0.3180810809135437]
placebo O [-0.5943952202796936, 0.4975970983505249]
vitamin O [-0.8829079866409302, 0.7487532496452332]
C O [-0.8711020946502686, 0.7418246865272522]
groups, O [-0.7549771666526794, 0.7566578388214111]
17.6 O [-0.48326799273490906, 0.819901168346405]
and O [-0.8385522961616516, 0.34352198243141174]
17.5 O [-0.3962993025779724, 0.7142869830131531]
events O [-0.8233415484428406, 0.40825024247169495]
per O [-0.6501520276069641, 0.40571874380111694]
1000 O [-0.5178777575492859, 0.3679380714893341]
person-years; O [-0.9768734574317932, 0.426956444978714]
HR, O [-0.9082524180412292, 0.6544669270515442]
1.01; O [-0.600894033908844, 0.6023511290550232]
95% O [-0.9488176703453064, 0.6480280160903931]
CI, O [-0.809930145740509, 0.42836201190948486]
0.92-1.10; O [-0.43828901648521423, 0.44896188378334045]
P O [-0.8532612919807434, 0.5860994458198547]
= O [-0.7851004004478455, 0.6835640072822571]
.86) O [-0.7083277106285095, 0.4973626434803009]
or O [-0.847897469997406, 0.6729430556297302]
prostate O [-1.0792893171310425, 0.9714089632034302]
cancer O [-0.9366865754127502, 0.7769331932067871]
(active O [-0.70787113904953, 0.6106405854225159]
and O [-0.7696256041526794, 0.36778923869132996]
placebo O [-0.6410684585571289, 0.44761693477630615]
vitamin O [-0.9474721550941467, 0.7959908843040466]
C O [-0.8382547497749329, 0.6712431311607361]
groups, O [-0.7859442830085754, 0.854557454586029]
9.4 O [-0.4534578025341034, 0.6762052178382874]
and O [-0.7565210461616516, 0.37750938534736633]
9.2 O [-0.39666858315467834, 0.5568158030509949]
cases O [-0.7461344003677368, 0.4976407289505005]
per O [-0.6380026936531067, 0.4997081160545349]

1000 O [-0.2554139494895935, -0.21145713329315186]
person-years; O [-0.5958570837974548, -0.09503957629203796]
HR, O [-0.39488300681114197, -0.10918724536895752]
1.02; O [-0.2573806345462799, 0.031118107959628105]
95% O [-0.34562405943870544, 0.044955041259527206]
CI, O [-0.44886907935142517, 0.02147073857486248]
0.90-1.15; O [-0.2001844197511673, 0.14341193437576294]
P O [-0.25807127356529236, -0.06652352958917618]
= O [-0.42715391516685486, 0.1600022315979004]
.80). O [-0.32512167096138, -0.11757353693246841]
Neither B-LOC [0.3420085608959198, -0.6448448300361633]
vitamin B-LOC [0.8372291922569275, -1.2964167594909668]
E B-LOC [0.4298747479915619, -0.9839816689491272]
nor B-LOC [0.4282297194004059, -0.7420709729194641]
vitamin B-LOC [1.0609955787658691, -1.458555817604065]
C B-LOC [0.5630049705505371, -1.2207400798797607]
had B-LOC [0.1876835972070694, -0.6998329162597656]
a B-LOC [0.3352252244949341, -0.8011385798454285]
significant B-LOC [0.42938074469566345, -1.0226359367370605]
effect B-LOC [0.37306123971939087, -1.0209563970565796]
on B-LOC [0.34536513686180115, -0.9161334037780762]
colorectal, B-LOC [0.463384747505188, -0.9257829785346985]
lung, B-LOC [0.3879266083240509, -0.8642212152481079]
or B-LOC [0.4646952152252197, -1.127519130706787]
other B-LOC [0.7432697415351868, -1.1404169797897339]
site-specific B-LOC [0.6382118463516235, -1.3458545207977295]
cancers. B-LOC [0.6938907504081726, -1.2399598360061646]
Adjustment B-LOC [2.501281499862671, -3.2796261310577393]
for B-LOC [2.7323427200317383, -2.802473306655884]
adherence B-LOC [2.6585869789123535, -2.961294174194336]
and B-LOC [2.496413469314575, -3.06178617477417]
exclusion B-LOC [2.666522264480591, -3.1316134929656982]
of B-LOC [2.6290032863616943, -2.8260676860809326]
the B-LOC [2.515557050704956, -2.871427297592163]
first B-LOC [2.4723691940307617, -3.14794659614563]
4 B-LOC [2.5994913578033447, -2.869342088699341]
or B-LOC [2.641390323638916, -3.116102457046509]
6 B-LOC [2.55161452293396, -2.981449604034424]
years B-LOC [2.6828882694244385, -3.057755470275879]
of B-LOC [2.635902166366577, -3.0211360454559326]
follow-up B-LOC [2.4445488452911377, -3.273968458175659]
did B-LOC [2.647761821746826, -3.029268503189087]
not B-LOC [2.8522017002105713, -2.966548204421997]
alter B-LOC [2.6244218349456787, -3.1694083213806152]
the B-LOC [2.590259552001953, -3.1284539699554443]
results. B-LOC [2.536444902420044, -3.4791722297668457]
Stratification B-LOC [2.2004921436309814, -2.5564610958099365]
by B-LOC [2.392434597015381, -2.560091257095337]
various B-LOC [2.277855157852173, -2.6850926876068115]
cancer B-LOC [2.4170234203338623, -2.878478765487671]
risk B-LOC [2.8154215812683105, -3.0901026725769043]
factors B-LOC [2.547788619995117, -2.8075788021087646]
demonstrated B-LOC [1.9704620838165283, -2.3465166091918945]
no B-LOC [2.1141934394836426, -2.341118097305298]
significant B-LOC [2.1891963481903076, -2.651547908782959]
modification B-LOC [2.169968843460083, -2.717514991760254]
of B-LOC [2.2382681369781494, -2.657395124435425]
the B-LOC [2.323532819747925, -2.6383934020996094]
effect B-LOC [1.912394404411316, -2.5958940982818604]
of B-LOC [1.9442355632781982, -2.283090829849243]
vitamin B-LOC [1.7851066589355469, -2.4312422275543213]
E B-LOC [1.6157236099243164, -2.1963984966278076]
on B-LOC [1.8423984050750732, -2.5970585346221924]
prostate B-LOC [1.7981176376342773, -2.480895757675171]
cancer B-LOC [1.9963223934173584, -2.6276025772094727]
risk B-LOC [2.0283563137054443, -2.4340126514434814]
or B-LOC [1.9713325500488281, -2.5148279666900635]
either B-LOC [1.9511771202087402, -2.833744764328003]
agent B-LOC [1.8349778652191162, -2.633594274520874]
on B-LOC [1.8411014080047607, -2.620391607284546]
total B-LOC [1.9081223011016846, -2.5441677570343018]
cancer B-LOC [2.0343501567840576, -2.61641526222229]
risk. B-LOC [1.938039779663086, -2.505448341369629]
CONCLUSIONS O [-0.6037126779556274, 0.1386760026216507]
In B-LOC [0.21382637321949005, -0.49395155906677246]
this B-LOC [0.4232616722583771, -0.4022587239742279]
large, B-LOC [0.2855960428714752, -0.36642903089523315]

long-term O [-0.6773160099983215, 0.7981951832771301]
trial O [-0.5615368485450745, 0.8398021459579468]
of O [-0.4701453745365143, 0.6934648752212524]
male O [-0.6403157711029053, 0.7360741496086121]
physicians, O [-0.5648483633995056, 0.6750792264938354]
neither O [-0.5493097901344299, 0.7870662212371826]
vitamin O [-0.3862459361553192, 0.5383508205413818]
E O [-0.4851764440536499, 0.6601728796958923]
nor O [-0.4285590350627899, 0.6446211934089661]
C O [-0.5446808934211731, 0.5376797914505005]
supplementation O [-0.37880995869636536, 0.7564199566841125]
reduced O [-0.731826663017273, 0.671316921710968]
the O [-0.7521034479141235, 0.5188776254653931]
risk O [-0.7377551198005676, 0.5650880932807922]
of O [-0.8221411108970642, 0.6252191662788391]
prostate O [-0.8476265668869019, 0.7542656064033508]
or O [-0.6384149193763733, 0.4943541884422302]
total O [-0.7583180069923401, 0.6683300137519836]
cancer. O [-0.5741463303565979, 0.5330575108528137]
These B-LOC [2.1606194972991943, -1.947782039642334]
data B-LOC [2.0011088848114014, -2.0741987228393555]
provide B-LOC [2.202915906906128, -1.9728825092315674]
no B-LOC [2.1406004428863525, -2.2336509227752686]
support B-LOC [2.190568447113037, -2.3456203937530518]
for B-LOC [2.299920082092285, -2.456108331680298]
the B-LOC [2.2417078018188477, -2.5332534313201904]
use B-LOC [2.067835569381714, -2.4389965534210205]
of B-LOC [2.336258888244629, -2.42260479927063]
these B-LOC [2.050837993621826, -2.11434006690979]
supplements B-LOC [1.957199215888977, -2.337237596511841]
for B-LOC [2.2434473037719727, -2.5532824993133545]
the B-LOC [2.3290205001831055, -2.7024595737457275]
prevention B-LOC [2.4177401065826416, -2.6985251903533936]
of B-LOC [2.352504014968872, -2.674062728881836]
cancer B-LOC [2.361358880996704, -2.5929152965545654]
in B-LOC [2.3892745971679688, -2.5177419185638428]
middle-aged B-LOC [2.50846004486084, -2.5601744651794434]
and B-LOC [2.288161277770996, -2.3526461124420166]
older B-LOC [2.668368339538574, -2.5757954120635986]
men. B-LOC [2.3481643199920654, -2.4800145626068115]
TRIAL B-LOC [2.365675210952759, -2.591707944869995]
REGISTRATION B-LOC [2.1321351528167725, -2.3337275981903076]
clinicaltrials.gov B-LOC [2.58925461769104, -2.6685855388641357]
Identifier: B-LOC [2.315209150314331, -2.43011736869812]
NCT00270647. B-LOC [2.612736940383911, -2.776686668395996]

Historically, B-LOC [2.147559404373169, -2.4857101440429688]
the B-LOC [2.0223000049591064, -2.5112338066101074]
ribosome B-LOC [2.0564773082733154, -2.5869717597961426]
has B-LOC [2.8133208751678467, -2.7268335819244385]
been B-LOC [2.621046304702759, -2.823568344116211]
viewed B-LOC [2.583479166030884, -2.6820476055145264]
as B-LOC [2.2715721130371094, -2.589940071105957]
a B-LOC [2.2207131385803223, -2.6199452877044678]
complex B-LOC [2.295928478240967, -2.7660131454467773]
ribozyme B-LOC [2.1640353202819824, -2.673259735107422]
with B-LOC [1.9956731796264648, -2.492300271987915]
constitutive B-LOC [2.3941471576690674, -2.940624952316284]
rather B-LOC [2.09291410446167, -2.408531904220581]
than B-LOC [2.0775680541992188, -2.3187901973724365]
regulatory B-LOC [2.2123939990997314, -2.8045661449432373]
capacity B-LOC [1.9424242973327637, -2.6608264446258545]
in B-LOC [1.8407702445983887, -2.798321008682251]
mRNA B-LOC [1.942183494567871, -2.5374577045440674]
translation. B-LOC [1.9931000471115112, -2.4654905796051025]
Here B-LOC [0.5521027445793152, -0.5274220108985901]
we B-LOC [0.505008339881897, -0.4707324206829071]
identify B-LOC [0.7650870084762573, -0.6101797819137573]
mutations B-LOC [1.0404689311981201, -0.8306869268417358]
of B-LOC [0.9071674942970276, -1.0690401792526245]
the B-LOC [1.0674835443496704, -1.149576187133789]
Ribosomal B-LOC [0.6828296780586243, -1.0686185359954834]
Protein B-LOC [0.7452585697174072, -1.3718256950378418]
L38 B-LOC [0.9100993275642395, -0.9818171262741089]
(Rpl38) B-LOC [0.8464567065238953, -1.0032765865325928]
gene B-LOC [0.5026853680610657, -0.9705072045326233]
in B-LOC [0.6770804524421692, -0.9309089779853821]
mice B-LOC [0.6819331645965576, -0.8562976717948914]
exhibiting B-LOC [0.7848469614982605, -1.0081195831298828]
surprising B-LOC [0.8224848508834839, -1.0366175174713135]
tissue-specific B-LOC [0.9748139977455139, -1.1305006742477417]
patterning B-LOC [1.1358888149261475, -1.0630460977554321]
defects, B-LOC [1.0728724002838135, -0.9320945739746094]
including B-LOC [0.5736797451972961, -0.5274805426597595]
pronounced B-LOC [0.6470348238945007, -0.7276692986488342]
homeotic B-LOC [0.6570156812667847, -0.6950458288192749]
transformations B-LOC [0.7998218536376953, -0.8140990138053894]
of B-LOC [0.6059672236442566, -0.8923828601837158]
the B-LOC [1.0530897378921509, -1.1569594144821167]
axial B-LOC [0.8330589532852173, -0.9304818511009216]
skeleton. B-LOC [0.8782344460487366, -1.110289454460144]
In B-LOC [0.4421400725841522, -0.6465275287628174]
Rpl38 B-LOC [0.5718962550163269, -0.7666805386543274]
mutant B-LOC [0.3787197768688202, -0.7004656195640564]
embryos, B-LOC [0.551483690738678, -0.5508896112442017]
global B-LOC [0.5936750769615173, -0.9725092053413391]
protein B-LOC [0.5664955973625183, -1.0481581687927246]
synthesis B-LOC [0.5023036599159241, -0.787077784538269]
is B-LOC [0.6932662725448608, -0.7868401408195496]
unchanged; B-LOC [0.6357606649398804, -0.8824051022529602]
however B-LOC [0.7084757685661316, -0.8958824872970581]
the B-LOC [0.5381976962089539, -0.7544650435447693]
translation B-LOC [0.40262070298194885, -0.7408553957939148]
of B-LOC [0.5540341734886169, -0.8198638558387756]
a B-LOC [0.7739387154579163, -0.7026721835136414]
select B-LOC [0.6899804472923279, -0.8503480553627014]
subset B-LOC [0.6739229559898376, -0.8970949649810791]
of B-LOC [0.46223410964012146, -0.7104126214981079]
Homeobox B-LOC [0.45770320296287537, -0.6293148994445801]
mRNAs B-LOC [0.41251978278160095, -0.7281241416931152]
is B-LOC [0.7422250509262085, -0.7870481610298157]
perturbed. B-LOC [0.7351593375205994, -1.0665650367736816]
Our B-LOC [0.07993200421333313, -0.07387201488018036]
data B-LOC [0.22328174114227295, -0.18439586460590363]
reveal B-LOC [-0.04524960741400719, -0.12172241508960724]
that O [-0.3061547577381134, -0.07811387628316879]
RPL38 O [-0.1655089557170868, -0.02789655514061451]
facilitates O [-0.17035551369190216, 0.038721419870853424]

80S B-LOC [0.8290972113609314, -1.1220024824142456]
complex B-LOC [0.9685336947441101, -1.1705700159072876]
formation B-LOC [1.0129996538162231, -1.027287244796753]
on B-LOC [0.8540303707122803, -1.0660054683685303]
these B-LOC [0.8147004246711731, -0.997575581073761]
mRNAs B-LOC [0.7792225480079651, -1.0874950885772705]
as B-LOC [0.8265417814254761, -1.1401784420013428]
a B-LOC [0.9246554374694824, -1.0698599815368652]
regulatory B-LOC [1.0918523073196411, -1.1850242614746094]
component B-LOC [0.876606822013855, -1.1290254592895508]
of B-LOC [0.7851971387863159, -1.0110464096069336]
the B-LOC [0.9406198859214783, -1.0709542036056519]
ribosome B-LOC [0.8081847429275513, -1.1932628154754639]
to B-LOC [0.8929904103279114, -1.0917078256607056]
confer B-LOC [0.9933260083198547, -1.145485758781433]
transcript-specific B-LOC [1.1128056049346924, -1.3807687759399414]
translational B-LOC [0.938923180103302, -1.206743597984314]
control. B-LOC [0.966732919216156, -1.207678198814392]
We O [-0.22326135635375977, -0.1612754911184311]
further B-LOC [0.17488926649093628, -0.06991592049598694]
show O [-0.10628350079059601, -0.022041404619812965]
that B-LOC [-0.17592227458953857, -0.22486263513565063]
Rpl38 B-LOC [0.10303886979818344, -0.5138174891471863]
expression B-LOC [0.24291063845157623, -0.32333245873451233]
is B-LOC [0.2914469540119171, -0.35641562938690186]
markedly B-LOC [0.457485556602478, -0.4632936418056488]
enriched B-LOC [0.4823751747608185, -0.44989463686943054]
in B-LOC [0.39703258872032166, -0.4553416669368744]
regions B-LOC [0.47572603821754456, -0.5309760570526123]
of B-LOC [0.3719409108161926, -0.624622642993927]
the B-LOC [0.11811450123786926, -0.20133328437805176]
embryo B-LOC [0.07409974932670593, -0.3661620020866394]
where B-LOC [0.33067721128463745, -0.8308848738670349]
loss-of-function B-LOC [0.7508835792541504, -0.8796467781066895]
phenotypes B-LOC [0.48264679312705994, -0.5461097359657288]
occur. B-LOC [0.6406052708625793, -0.7735793590545654]
Unexpectedly, B-LOC [0.9308061599731445, -0.9665631651878357]
a B-LOC [0.7367960810661316, -0.9312911629676819]
ribosomal B-LOC [0.9412864446640015, -1.0442218780517578]
protein B-LOC [0.8346684575080872, -1.2496168613433838]
(RP) B-LOC [1.0476598739624023, -1.3796571493148804]
expression B-LOC [0.7490588426589966, -0.8526778817176819]
screen B-LOC [0.7278615832328796, -1.0818073749542236]
reveals B-LOC [0.8475397229194641, -1.020432472229004]
dynamic B-LOC [0.7438941597938538, -1.068603515625]
regulation B-LOC [0.7036451697349548, -1.037013053894043]
of B-LOC [0.8170561790466309, -1.263630747795105]
individual B-LOC [0.8445985913276672, -1.2378225326538086]
RPs B-LOC [0.6092429757118225, -0.8792524933815002]
within B-LOC [0.8165872693061829, -1.0389869213104248]
the B-LOC [0.822402834892273, -0.9411386251449585]
vertebrate B-LOC [0.6413132548332214, -1.0477313995361328]
embryo. B-LOC [0.6323469281196594, -1.0229214429855347]
Collectively, B-LOC [0.2926771938800812, -0.2871728539466858]
these B-LOC [0.30813315510749817, -0.5319709181785583]
findings B-LOC [0.6528227925300598, -0.541134774684906]
suggest B-LOC [0.20841240882873535, -0.26816901564598083]
that B-LOC [-0.004034485202282667, -0.3728681206703186]
RP B-LOC [0.10527662187814713, -0.36707597970962524]
activity B-LOC [0.2326280176639557, -0.3207836151123047]
may B-LOC [0.27405980229377747, -0.504252552986145]
be B-LOC [0.19392898678779602, -0.46563202142715454]
highly B-LOC [0.1927408128976822, -0.5017519593238831]
regulated B-LOC [0.17840337753295898, -0.5028485059738159]
to B-LOC [0.018528195098042488, -0.3759305775165558]
impart B-LOC [0.23993876576423645, -0.3528992831707001]
a B-LOC [0.20923706889152527, -0.3215527832508087]
new B-LOC [0.21461039781570435, -0.5094269514083862]
layer B-LOC [0.3068394958972931, -0.536705732345581]
of B-LOC [0.10255780071020126, -0.5885603427886963]
specificity B-LOC [0.22031044960021973, -0.6992754936218262]
in B-LOC [0.005587200168520212, -0.598098874092102]
the B-LOC [0.2102130949497223, -0.5358715057373047]
control B-LOC [0.1513790786266327, -0.5797494649887085]
of B-LOC [0.1119055524468422, -0.674717903137207]
gene B-LOC [0.07816433161497116, -0.6656084060668945]
expression B-LOC [0.2556806206703186, -0.3185366690158844]
and B-LOC [0.26596468687057495, -0.5220181345939636]
mammalian B-LOC [0.4142489731311798, -0.6297939419746399]
development. B-LOC [0.20580680668354034, -0.39122462272644043]

Expression B-LOC [1.7043509483337402, -1.9833016395568848]
of B-LOC [1.8299211263656616, -1.9524192810058594]
the B-LOC [1.832990050315857, -1.838640809059143]
intermediate B-LOC [1.8106145858764648, -2.0744004249572754]
filament B-LOC [1.7645227909088135, -2.01220440864563]
protein B-LOC [1.6345806121826172, -2.0140230655670166]
keratin B-LOC [1.879276990890503, -2.027717351913452]
17 B-LOC [1.7280464172363281, -1.688798189163208]
(K17) B-LOC [1.950784683227539, -1.9359244108200073]
is B-LOC [2.336209774017334, -2.2327427864074707]
robustly B-LOC [2.21791934967041, -2.2316768169403076]
upregulated B-LOC [2.331254720687866, -2.341167449951172]
in B-LOC [1.9990570545196533, -2.0964150428771973]
inflammatory B-LOC [2.2252273559570312, -2.3336434364318848]
skin B-LOC [2.2385001182556152, -2.136213779449463]
diseases B-LOC [2.179145574569702, -2.0904645919799805]
and B-LOC [1.9311683177947998, -1.9596587419509888]
in B-LOC [1.9097460508346558, -2.0595195293426514]
many B-LOC [2.05448842048645, -2.050518274307251]
tumors B-LOC [2.1729540824890137, -2.1084296703338623]
originating B-LOC [2.0253183841705322, -2.0894763469696045]
in B-LOC [2.0256826877593994, -2.0535061359405518]
stratified B-LOC [2.1879982948303223, -2.2333292961120605]
and B-LOC [2.1230263710021973, -2.148679733276367]
pseudostratified B-LOC [2.4363553524017334, -2.3750476837158203]
epithelia. B-LOC [2.0190722942352295, -1.9030487537384033]
We O [-0.7789940237998962, 0.388176828622818]
report O [-0.8300272822380066, 0.6121436357498169]
that O [-1.0625845193862915, 0.7268708348274231]
autoimmune O [-0.8774014115333557, 0.6642022132873535]
regulator O [-0.6903867125511169, 0.4449715316295624]
(Aire), O [-0.7257530689239502, 0.6437049508094788]
a O [-0.9137185215950012, 0.8468719124794006]
transcriptional O [-0.9503806829452515, 1.071669340133667]
regulator, O [-0.7390172481536865, 0.5665507912635803]
is O [-0.7520676851272583, 0.8041813373565674]
inducibly O [-0.8458914160728455, 0.9909089207649231]
expressed O [-0.658577024936676, 0.8495405912399292]
in O [-0.8225784301757812, 0.8301194906234741]
human O [-0.9050688147544861, 0.8562225699424744]
and O [-0.9385689496994019, 0.8116295337677002]
mouse O [-1.0177947282791138, 0.9305470585823059]
tumor O [-0.8378103375434875, 0.8205417990684509]
keratinocytes O [-0.9498251676559448, 0.9713860154151917]
in O [-0.9935747385025024, 0.9110271334648132]
a O [-0.9688103795051575, 0.9247504472732544]
K17-dependent O [-0.5314270853996277, 0.6043559312820435]
manner O [-0.9931835532188416, 0.9870012402534485]
and O [-0.981866717338562, 0.8198581337928772]
is O [-0.8296810984611511, 0.8290033340454102]
required O [-0.9159638285636902, 0.7684496641159058]
for O [-0.980607271194458, 0.7568265199661255]
timely O [-0.8550344705581665, 0.8647380471229553]
onset O [-0.721130907535553, 0.6606885194778442]
of O [-0.8079912066459656, 0.694869875907898]
Gli2-induced O [-0.5757683515548706, 0.6537837386131287]
skin O [-0.7543495297431946, 0.8000561594963074]
tumorigenesis O [-0.4863854944705963, 0.7360204458236694]
in O [-0.6898072361946106, 0.753295361995697]
mice. O [-0.7896789908409119, 0.750701367855072]
The O [-0.39220163226127625, 0.13254879415035248]
induction O [-0.38865742087364197, 0.0018894127570092678]
of O [-0.13087788224220276, -0.127271831035614]
Aire O [-0.23973314464092255, -0.11412793397903442]
mRNA O [-0.34192535281181335, -0.027702340856194496]
in O [-0.06420136243104935, -0.04658184573054314]
keratinocytes B-LOC [0.003413031343370676, -0.03988375887274742]
depends B-LOC [-0.13915085792541504, -0.4090025722980499]

on B-LOC [0.2305457442998886, -0.3756445348262787]
a B-LOC [0.33498501777648926, -0.27681371569633484]
functional B-LOC [0.47313785552978516, -0.4904143214225769]
interaction B-LOC [0.2991897761821747, -0.5705787539482117]
between B-LOC [0.535467267036438, -0.7119176387786865]
K17 B-LOC [0.15615901350975037, -0.42057904601097107]
and B-LOC [0.515032947063446, -0.5973369479179382]
the B-LOC [0.43201929330825806, -0.47475919127464294]
heterogeneous B-LOC [0.47640714049339294, -0.76351398229599]
nuclear B-LOC [0.37033316493034363, -0.6050737500190735]
ribonucleoprotein B-LOC [0.3434251546859741, -0.7326411604881287]
hnRNP B-LOC [0.36185792088508606, -0.6549693942070007]
K. B-LOC [0.31246328353881836, -0.41958943009376526]
Further, O [-0.12996239960193634, 0.17169639468193054]
K17 O [-0.11325745284557343, -0.01596987433731556]
colocalizes O [-0.25735580921173096, 0.3707965314388275]
with O [-0.10033892095088959, 0.06148794665932655]
Aire O [-0.2357243001461029, 0.05163167789578438]
protein O [-0.29122433066368103, 0.15521647036075592]
in O [-0.2819073796272278, 0.2837184965610504]
the O [-0.26199182868003845, 0.412927508354187]
nucleus O [-0.23696693778038025, 0.2739787995815277]
of O [-0.34040555357933044, 0.20395474135875702]
tumor-prone O [-0.1728484332561493, 0.1798427700996399]
keratinocytes, O [-0.37642791867256165, 0.23777762055397034]
and O [-0.46796515583992004, 0.23811843991279602]
each O [-0.1270826756954193, 0.12736079096794128]
factor O [-0.44603046774864197, -0.10438799858093262]
is O [-0.14335638284683228, 0.2046731561422348]
bound O [-0.07532913982868195, 0.3385797441005707]
to O [-0.09885787963867188, 0.2556215226650238]
a O [0.013538925908505917, 0.26491037011146545]
specific O [-0.0894942656159401, -0.035267386585474014]
promoter O [-0.14875976741313934, 0.2102726399898529]
region O [-0.2829250693321228, 0.12554246187210083]
featuring O [-0.14579150080680847, 0.14052754640579224]
an O [-0.06814625859260559, 0.1618228703737259]
NF-κB O [-0.2858226001262665, 0.11635924130678177]
consensus O [-0.0938931331038475, 0.10898159444332123]
sequence O [-0.19779303669929504, -0.045403555035591125]
in O [-0.20613741874694824, 0.0612795390188694]
a O [0.04908968135714531, 0.1796802580356598]
relevant O [-0.1296878457069397, 0.06052939221262932]
subset O [0.037388090044260025, 0.04500671848654747]
of O [-0.08964554965496063, 0.0627869963645935]
K17- O [-0.16254228353500366, 0.009879490360617638]
and B-LOC [-0.12568730115890503, -0.14437687397003174]
Aire-dependent O [-0.2884543240070343, -0.054436516016721725]
proinflammatory O [-0.21051836013793945, 0.06655431538820267]
genes. O [-0.1806940883398056, 0.08690463751554489]
These B-LOC [0.8411401510238647, -0.9842210412025452]
findings B-LOC [1.0503336191177368, -0.98360675573349]
provide B-LOC [1.3148404359817505, -1.1580089330673218]
radically B-LOC [1.2130045890808105, -1.4505504369735718]
new B-LOC [1.2982903718948364, -1.539874792098999]
insight B-LOC [1.180490493774414, -1.4045737981796265]
into B-LOC [1.1729114055633545, -1.4392728805541992]
keratin B-LOC [1.2840598821640015, -1.3599002361297607]
intermediate B-LOC [0.9295161366462708, -1.2795004844665527]
filament B-LOC [1.197129726409912, -1.255491018295288]
and B-LOC [1.276676058769226, -1.4738800525665283]
Aire B-LOC [0.9591897130012512, -1.2890303134918213]
function, B-LOC [1.2095372676849365, -1.2841455936431885]
along B-LOC [1.0866963863372803, -1.1265437602996826]
with B-LOC [1.1731640100479126, -1.150702953338623]
a B-LOC [1.1093779802322388, -1.5056383609771729]
molecular B-LOC [1.2439364194869995, -1.518918752670288]
basis B-LOC [0.9538063406944275, -1.5483890771865845]
for B-LOC [1.2912551164627075, -1.4469342231750488]
the B-LOC [1.2721936702728271, -1.4039109945297241]
K17-dependent B-LOC [0.9249240756034851, -1.1008294820785522]
amplification B-LOC [1.204324722290039, -1.7934954166412354]
of B-LOC [0.8431064486503601, -1.1071943044662476]

inflammatory B-LOC [0.09463758021593094, -0.5579185485839844]
and B-LOC [0.14259478449821472, -0.6872276067733765]
immune B-LOC [0.11146426200866699, -0.625122606754303]
responses B-LOC [0.1473151594400406, -0.6618907451629639]
in B-LOC [0.22443556785583496, -0.48146671056747437]
diseased B-LOC [0.31339937448501587, -0.530857503414154]
epithelia. B-LOC [0.12930434942245483, -0.29040783643722534]

Limited B-LOC [0.21274951100349426, -0.4705970883369446]
neural B-LOC [0.0914241373538971, -0.3438957631587982]
input B-LOC [-0.07762683928012848, -0.2652008831501007]
results B-LOC [0.22504524886608124, -0.3794635832309723]
in B-LOC [-0.0009686252451501787, -0.19790099561214447]
muscle B-LOC [0.08893880248069763, -0.23161211609840393]
weakness B-LOC [0.22452802956104279, -0.14857952296733856]
in B-LOC [0.05683759227395058, -0.29758086800575256]
neuromuscular B-LOC [0.25858232378959656, -0.45804476737976074]
disease B-LOC [0.22449979186058044, -0.31571152806282043]
because B-LOC [0.16537946462631226, -0.22916632890701294]
of B-LOC [0.31090155243873596, -0.2949928939342499]
a B-LOC [0.05857505276799202, -0.1678132563829422]
reduction B-LOC [0.14313122630119324, -0.3250189423561096]
in B-LOC [0.12276603281497955, -0.5274637341499329]
the B-LOC [0.1649613380432129, -0.4126149117946625]
density B-LOC [0.2228311002254486, -0.16342578828334808]
of B-LOC [0.1780085265636444, -0.5100318193435669]
muscle B-LOC [0.11741603165864944, -0.28807100653648376]
innervation, B-LOC [0.30833885073661804, -0.1350294053554535]
the B-LOC [0.30913183093070984, -0.3697843849658966]
rate B-LOC [0.15592892467975616, -0.5324904322624207]
of B-LOC [0.1699775755405426, -0.5806614756584167]
neuromuscular B-LOC [0.17655107378959656, -0.4086662828922272]
junction B-LOC [0.07351377606391907, -0.5058851838111877]
activation B-LOC [0.4003220498561859, -0.39503079652786255]
or B-LOC [0.7123074531555176, -0.5550358891487122]
the B-LOC [0.4096739888191223, -0.46843427419662476]
efficiency B-LOC [0.4279053509235382, -0.44244104623794556]
of B-LOC [0.2949426472187042, -0.621475100517273]
synaptic B-LOC [0.2576603889465332, -0.6095318794250488]
transmission. B-LOC [0.2612411081790924, -0.42008069157600403]
We O [-0.16094109416007996, -0.034973498433828354]
developed O [0.0458056777715683, 0.20209144055843353]
a O [0.010692681185901165, 0.03865540400147438]
small-molecule B-LOC [0.21755266189575195, 0.16433651745319366]
fast-skeletal-troponin O [-0.2611590623855591, 0.06317023187875748]
activator, O [-0.39702698588371277, 0.22653290629386902]
CK-2017357, O [-0.19828996062278748, 0.15207156538963318]
as O [-0.4824278652667999, 0.2139388620853424]
a O [-0.5431491732597351, 0.3850787281990051]
means O [-0.5372341871261597, 0.2567048966884613]
to O [-0.553861141204834, 0.24102693796157837]
increase O [-0.7325510382652283, 0.5099164843559265]
muscle O [-0.43301254510879517, 0.33792245388031006]
strength O [-0.6126207709312439, 0.4497776925563812]
by O [-0.8466433882713318, 0.7676108479499817]
amplifying O [-0.7902961373329163, 0.5527755618095398]
the O [-0.624293327331543, 0.554945170879364]
response O [-0.439899742603302, 0.4051083028316498]
of O [-0.5177032351493835, 0.5342630743980408]
muscle O [-0.29250821471214294, 0.34691503643989563]
when O [-0.425919771194458, 0.35117107629776]
neural O [-0.500362753868103, 0.2978111207485199]
input O [-0.6888917088508606, 0.43859773874282837]
is O [-0.09173301607370377, 0.3337453305721283]
otherwise O [-0.20754361152648926, 0.27053752541542053]
diminished O [-0.39417901635169983, 0.44549623131752014]
secondary O [-0.5705507397651672, 0.6276388764381409]
to O [-0.602328896522522, 0.6477603316307068]
neuromuscular O [-0.6047449111938477, 0.5281758904457092]
disease. O [-0.46678873896598816, 0.36994901299476624]
Binding O [0.03501575067639351, 0.5335228443145752]
selectively O [-0.23723916709423065, 0.48875144124031067]
to O [-0.120526023209095, 0.20251905918121338]
the O [-0.11431226134300232, 0.3310692310333252]
fast-skeletal-troponin O [-0.23385396599769592, 0.13528214395046234]
complex, O [-0.23544979095458984, 0.28355899453163147]
CK-2017357 O [-0.30604174733161926, 0.31432658433914185]
slows O [-0.23571047186851501, 0.31182196736335754]
the O [-0.3958490192890167, 0.07228139042854309]
rate O [-0.4556943476200104, 0.033470723778009415]

of B-LOC [-0.20874908566474915, -0.309720903635025]
calcium B-LOC [0.11912263184785843, -0.3978962004184723]
release B-LOC [-0.048683661967515945, -0.15925899147987366]
from O [-0.04107657074928284, 0.027432097122073174]
troponin B-LOC [0.05364397540688515, -0.3677993416786194]
C O [-0.0958607941865921, 0.07053225487470627]
and O [-0.30813130736351013, -0.005242990795522928]
sensitizes B-LOC [0.09843869507312775, -0.07117974758148193]
muscle B-LOC [0.05807771161198616, -0.2615959346294403]
to B-LOC [0.022440025582909584, -0.30258724093437195]
calcium. B-LOC [0.3068791627883911, -0.2844608426094055]
As B-LOC [0.4994409382343292, -0.6090666651725769]
a B-LOC [0.8483516573905945, -0.5952587127685547]
consequence, B-LOC [0.8375673890113831, -0.46520355343818665]
the B-LOC [0.639121413230896, -0.7322258949279785]
force-calcium B-LOC [0.39150914549827576, -0.7480461001396179]
relationship B-LOC [0.4928654730319977, -0.7354709506034851]
of B-LOC [0.5801953673362732, -0.9468281269073486]
muscle B-LOC [0.48172441124916077, -0.6902039647102356]
fibers B-LOC [0.4528133273124695, -0.7994274497032166]
shifts B-LOC [0.7573871612548828, -0.8348687887191772]
leftwards, B-LOC [0.7002673745155334, -0.747215747833252]
as B-LOC [0.3555670380592346, -0.6045790910720825]
does B-LOC [0.7755857706069946, -0.8682146668434143]
the B-LOC [0.7493167519569397, -0.9556105732917786]
force-frequency B-LOC [0.41955265402793884, -0.8126271367073059]
relationship B-LOC [0.6276277303695679, -0.9899778962135315]
of B-LOC [0.629629909992218, -0.9932841658592224]
a B-LOC [0.5936180353164673, -0.9097794890403748]
nerve-muscle B-LOC [0.45521408319473267, -1.0151314735412598]
pair, B-LOC [0.45850586891174316, -0.9774693846702576]
so B-LOC [0.5121814608573914, -0.33406245708465576]
that B-LOC [0.3388633131980896, -0.4738920331001282]
CK-2017357 B-LOC [0.1467965543270111, -0.40307536721229553]
increases B-LOC [0.47584089636802673, -0.7374534010887146]
the B-LOC [0.4994136095046997, -0.7724647521972656]
production B-LOC [0.38016417622566223, -0.6914494633674622]
of B-LOC [0.5461558699607849, -0.7708475589752197]
muscle B-LOC [0.45935893058776855, -0.763350784778595]
force B-LOC [0.14904208481311798, -0.5825614333152771]
in B-LOC [0.529904305934906, -0.7222017049789429]
situ B-LOC [0.9055548310279846, -0.7434830665588379]
at B-LOC [0.4859682321548462, -0.7849924564361572]
sub-maximal B-LOC [0.45871248841285706, -0.7167506814002991]
nerve B-LOC [0.4110844135284424, -0.9804991483688354]
stimulation B-LOC [0.40492019057273865, -0.9007043242454529]
rates. B-LOC [0.3804580271244049, -0.8452931046485901]
Notably, O [-0.12526142597198486, 0.29535815119743347]
we O [-0.4036216139793396, 0.1408986747264862]
show O [-0.37135639786720276, 0.4293530583381653]
that O [-0.6641860604286194, 0.3446706533432007]
sensitization O [-0.4584900438785553, 0.682202160358429]
of O [-0.35918527841567993, 0.5384175777435303]
the O [-0.1762576401233673, 0.3932524025440216]
fast-skeletal-troponin O [-0.38756057620048523, 0.1855507493019104]
complex O [-0.2064451277256012, 0.21441704034805298]
to O [-0.20883803069591522, 0.11159485578536987]
calcium O [-0.11952737718820572, 0.13717524707317352]
improves O [-0.5238491296768188, 0.3684134781360626]
muscle O [-0.27146854996681213, 0.2592514753341675]
force O [-0.4813288748264313, 0.43379345536231995]
and O [-0.6346361637115479, 0.426173597574234]
grip O [-0.2824614346027374, 0.32352402806282043]
strength O [-0.4008210599422455, 0.45536544919013977]
immediately O [-0.3767927587032318, 0.1963263303041458]
after O [-0.3804408609867096, 0.32108500599861145]
administration O [-0.0457337386906147, 0.1254376471042633]
of O [-0.06924638897180557, 0.1760040819644928]
single O [-0.08922668546438217, 0.17781633138656616]
doses O [-0.0528947077691555, 0.16860294342041016]
of O [-0.1623816341161728, 0.12363594770431519]
CK-2017357 O [-0.2437809407711029, 0.06600327789783478]
in O [-0.2717360854148865, 0.20856718719005585]
a O [-0.1724637895822525, 0.16590279340744019]
model O [-0.2284943163394928, -0.01744096912443638]
of B-LOC [-0.011621599085628986, -0.23994167149066925]
the B-LOC [0.05815967917442322, -0.09815210849046707]
neuromuscular O [-0.09176729619503021, -0.007187350187450647]
disease B-LOC [-0.23706990480422974, -0.2700808346271515]

myasthenia B-LOC [0.09815408289432526, -0.3657735288143158]
gravis. B-LOC [-0.05281446501612663, -0.3840486705303192]
Troponin B-LOC [0.5357803702354431, -0.541390597820282]
activation B-LOC [0.5478586554527283, -0.4495624899864197]
may B-LOC [1.0165016651153564, -0.9816983938217163]
provide B-LOC [0.8534706830978394, -0.9702482223510742]
a B-LOC [0.769522488117218, -0.8545887470245361]
new B-LOC [1.098799705505371, -1.099488377571106]
therapeutic B-LOC [1.0246013402938843, -1.1373575925827026]
approach B-LOC [0.8680076599121094, -1.0020322799682617]
to B-LOC [0.8847289681434631, -0.9792443513870239]
improve B-LOC [0.7530436515808105, -1.0104095935821533]
physical B-LOC [0.6341045498847961, -0.9088867902755737]
activity B-LOC [0.6472710371017456, -0.874415397644043]
in B-LOC [0.7782583236694336, -0.9318959712982178]
diseases B-LOC [1.0604932308197021, -1.1211713552474976]
where B-LOC [0.5667272210121155, -1.1030985116958618]
neuromuscular B-LOC [0.5199593901634216, -0.9212252497673035]
function B-LOC [0.4911874234676361, -0.7883887887001038]
is B-LOC [0.9285747408866882, -0.7387728095054626]
compromised. B-LOC [0.8226408362388611, -0.7431449294090271]

In B-LOC [-0.03526671230792999, -0.49372708797454834]
systemic B-LOC [0.37054020166397095, -1.1275928020477295]
lupus B-LOC [0.44995182752609253, -1.0557860136032104]
erythematosus B-LOC [0.33807167410850525, -0.9633752703666687]
(SLE), B-LOC [0.5005213022232056, -0.887319028377533]
self-reactive B-LOC [0.20564091205596924, -0.593942403793335]
antibodies B-LOC [0.22893770039081573, -0.4722137451171875]
can B-LOC [0.17759738862514496, -0.6152267456054688]
target B-LOC [0.23358575999736786, -0.5377780199050903]
the B-LOC [0.26512959599494934, -0.5762870907783508]
kidney B-LOC [0.21931929886341095, -0.8559765815734863]
(lupus B-LOC [0.34762483835220337, -0.7399799227714539]
nephritis), B-LOC [0.11845478415489197, -0.8431289792060852]
leading B-LOC [0.2609929144382477, -0.48942530155181885]
to B-LOC [0.16304345428943634, -0.5985872149467468]
functional B-LOC [0.24582721292972565, -0.5950712561607361]
failure B-LOC [0.4051305651664734, -0.674866795539856]
and B-LOC [0.4235231578350067, -0.7071521282196045]
possible B-LOC [0.3731427788734436, -0.8173119425773621]
mortality. B-LOC [0.5079299807548523, -0.9221647381782532]
We O [-1.0514203310012817, 0.726098358631134]
report O [-1.1019688844680786, 0.7375314235687256]
that O [-1.3429707288742065, 0.8968111276626587]
activation O [-1.072690725326538, 1.1137079000473022]
of O [-1.1794459819793701, 1.2506816387176514]
basophils O [-1.2584306001663208, 1.2661499977111816]
by O [-1.2288358211517334, 1.2280466556549072]
autoreactive O [-1.2032688856124878, 1.211794137954712]
IgE O [-1.1743714809417725, 1.2389352321624756]
causes O [-1.2350234985351562, 1.186255931854248]
their O [-1.194441556930542, 1.2943401336669922]
homing O [-1.318190097808838, 1.5287508964538574]
to O [-1.1967519521713257, 1.1938272714614868]
lymph O [-1.38434636592865, 1.4578986167907715]
nodes, O [-1.189328908920288, 1.07175612449646]
promoting O [-1.3502814769744873, 1.2732009887695312]
T O [-1.1031241416931152, 1.1758739948272705]
helper O [-1.0283011198043823, 1.44105064868927]
type O [-1.2513495683670044, 1.5692400932312012]
2 O [-0.9998399615287781, 1.2761210203170776]
(T(H)2) O [-0.9830666184425354, 1.0171306133270264]
cell O [-1.3528231382369995, 1.332769513130188]
differentiation O [-1.1205413341522217, 1.31276273727417]
and O [-1.4137458801269531, 1.2780086994171143]
enhancing O [-1.360195517539978, 1.3199613094329834]
the O [-1.2597590684890747, 1.1682943105697632]
production O [-1.217246174812317, 1.3815116882324219]
of O [-1.2281913757324219, 1.275065302848816]
self-reactive O [-1.2338733673095703, 1.2131519317626953]
antibodies O [-1.1440576314926147, 1.0582330226898193]
that O [-1.0074726343154907, 0.8543729186058044]
cause O [-1.0303452014923096, 1.0667140483856201]
lupus-like O [-0.887572705745697, 0.7078897356987]
nephritis O [-1.019161343574524, 1.067655086517334]
in O [-1.051391363143921, 0.9493196606636047]
mice O [-1.1293833255767822, 0.790145993232727]
lacking O [-0.8578031659126282, 0.7504839301109314]
the O [-0.661499559879303, 0.6876484155654907]
Src O [-0.5424779653549194, 0.33582308888435364]
family O [-0.4385453760623932, 0.5302714109420776]
protein O [-0.9521903991699219, 0.6854142546653748]
tyrosine O [-0.7765106558799744, 0.5921696424484253]
kinase O [-0.7239126563072205, 0.4695819914340973]
Lyn O [-0.5999769568443298, 0.6661033034324646]

(Lyn(-/-) B-LOC [0.2648654878139496, -0.880988359451294]
mice). B-LOC [-0.05824228376150131, -0.597740113735199]
Individuals O [-0.633673906326294, 0.5049744248390198]
with O [-0.5172451138496399, 0.23860521614551544]
SLE O [-0.23107695579528809, 0.156914621591568]
also O [-0.7649949193000793, 0.4738762676715851]
have O [-0.652353048324585, 0.6972022652626038]
elevated O [-0.8741839528083801, 0.8385596871376038]
serum O [-0.8258197903633118, 0.7681218981742859]
IgE, O [-0.7091429233551025, 0.375370591878891]
self-reactive O [-1.0201869010925293, 0.7747437357902527]
IgEs O [-0.6526247262954712, 0.3060411512851715]
and O [-0.9127350449562073, 0.7994527816772461]
activated O [-0.8792160153388977, 0.887990415096283]
basophils O [-0.8458951115608215, 0.7205005884170532]
that O [-0.917410671710968, 0.7131031155586243]
express O [-0.6767525672912598, 0.8873863816261292]
CD62 O [-0.6898670196533203, 0.7617550492286682]
ligand O [-0.7367470860481262, 0.68312668800354]
(CD62L) O [-0.5615355372428894, 0.3802018463611603]
and O [-0.7375648021697998, 0.8993207216262817]
the O [-0.6424495577812195, 0.8954492211341858]
major O [-0.6492608785629272, 0.6086754202842712]
histocompatibility O [-0.4205491542816162, 0.028559936210513115]
complex O [-0.6105446219444275, 0.6412741541862488]
(MHC) O [-0.2555423974990845, 0.3832724988460541]
class O [-0.6095519065856934, 0.6898134350776672]
II O [-0.7117906212806702, 0.592053234577179]
molecule O [-0.689348578453064, 0.65305495262146]
human O [-0.8831745982170105, 0.5844435095787048]
leukocyte O [-0.42124566435813904, 0.6015908122062683]
antigen-DR O [-0.5195499658584595, 0.5935901403427124]
(HLA-DR), O [-0.3568304181098938, 0.32260844111442566]
parameters O [-0.8616928458213806, 0.6851159930229187]
that O [-0.7204213738441467, 0.46278637647628784]
are O [-0.516577422618866, 0.34775522351264954]
associated O [-0.711929976940155, 0.6543070077896118]
with O [-0.7470943331718445, 0.438714861869812]
increased O [-0.8733890056610107, 0.6661001443862915]
disease O [-0.5141972899436951, 0.30374354124069214]
activity O [-0.5134119987487793, 0.5845149755477905]
and O [-0.7973321080207825, 0.5293935537338257]
active O [-0.8025159239768982, 0.6824343800544739]
lupus O [-0.5160517692565918, 0.40526124835014343]
nephritis. O [-0.5172111988067627, 0.4713604152202606]
Basophils B-LOC [0.33069688081741333, -0.5564571619033813]
were B-LOC [0.15750455856323242, -0.5531469583511353]
also B-LOC [0.3389323353767395, -0.48266440629959106]
present B-LOC [0.2647119462490082, -0.48449328541755676]
in B-LOC [0.11431291699409485, -0.24893346428871155]
the B-LOC [0.10270510613918304, -0.14072966575622559]
lymph B-LOC [0.15106576681137085, -0.34558364748954773]
nodes B-LOC [0.10301291197538376, -0.5058872699737549]
and B-LOC [0.15247614681720734, -0.22262702882289886]
spleen B-LOC [-0.015721505507826805, -0.4875270128250122]
of B-LOC [0.014799057506024837, -0.37585586309432983]
subjects B-LOC [0.15206043422222137, -0.6972388029098511]
with B-LOC [0.1935674399137497, -0.6684547066688538]
SLE. B-LOC [0.43538469076156616, -0.49797382950782776]
Thus, B-LOC [0.23854131996631622, -0.30440643429756165]

in O [-0.717232346534729, 0.4902108311653137]
Lyn(-/-) O [-0.4945642054080963, 0.36875632405281067]
mice, O [-0.8498821258544922, 0.5952655673027039]
basophils O [-0.7500215768814087, 0.6241196990013123]
and O [-0.9242746233940125, 0.8073375821113586]
IgE O [-0.6469177007675171, 0.5862985849380493]
autoantibodies O [-0.7513067722320557, 0.8793779015541077]
amplify O [-1.1075809001922607, 1.0743603706359863]
autoantibody O [-1.0695760250091553, 1.0877673625946045]
production O [-0.9470399618148804, 1.1879074573516846]
that O [-1.1104238033294678, 0.8901386857032776]
leads O [-0.9813147187232971, 1.0152333974838257]
to O [-0.9957973957061768, 1.0078725814819336]
lupus O [-1.0750954151153564, 1.245402455329895]
nephritis, O [-1.0273324251174927, 1.2003042697906494]
and O [-0.9809187054634094, 0.6723138689994812]
in O [-0.7403778433799744, 0.5594295859336853]
individuals O [-0.753311812877655, 0.5120852589607239]
with O [-0.5182819962501526, 0.41516950726509094]
SLE O [-0.5166987776756287, 0.6004547476768494]
IgE O [-0.7379209399223328, 0.6449845433235168]
autoantibodies O [-0.4341544806957245, 0.7444493174552917]
and O [-0.5846862196922302, 0.6060997843742371]
activated O [-0.674140989780426, 0.6514644622802734]
basophils O [-0.7505616545677185, 0.5661571621894836]
are O [-0.5412572622299194, 0.3170987665653229]
factors O [-0.7332072257995605, 0.3933763802051544]
associated O [-0.5498595833778381, 0.39630112051963806]
with O [-0.5825963616371155, 0.2952639162540436]
disease O [-0.5600773692131042, 0.2703090012073517]
activity O [-0.5228852033615112, 0.4673408269882202]
and O [-0.4235781133174896, 0.11908607184886932]
nephritis. O [-0.5465494990348816, 0.37991848587989807]

The B-LOC [1.1107836961746216, -1.4657379388809204]
number B-LOC [1.3023319244384766, -1.7742314338684082]
of B-LOC [1.4939932823181152, -1.609331727027893]
women B-LOC [1.4652682542800903, -1.7230942249298096]
dying B-LOC [1.8367780447006226, -1.9158730506896973]
from B-LOC [1.7591487169265747, -1.7971271276474]
cervical B-LOC [1.1349985599517822, -1.8269438743591309]
cancer B-LOC [1.4735689163208008, -1.8980484008789062]
in B-LOC [1.4122798442840576, -1.5342960357666016]
1997 B-LOC [1.4482320547103882, -1.698614478111267]
was B-LOC [1.0701857805252075, -1.46533203125]
7% B-LOC [1.2998756170272827, -1.0771138668060303]
lower B-LOC [1.2206096649169922, -1.47649347782135]
than B-LOC [1.0446758270263672, -1.3659846782684326]
in B-LOC [1.0579192638397217, -1.3706398010253906]
1996 B-LOC [1.3907197713851929, -1.6926900148391724]
and B-LOC [0.7279907464981079, -1.2122290134429932]
has B-LOC [1.2880470752716064, -1.5597155094146729]
fallen B-LOC [1.4463114738464355, -1.5351896286010742]
by B-LOC [0.8932492136955261, -1.1574938297271729]
over B-LOC [1.0188182592391968, -1.3761452436447144]
25% B-LOC [1.6878715753555298, -1.291368842124939]
since B-LOC [1.3596787452697754, -1.619459629058838]
1992.1 B-LOC [1.3930847644805908, -1.5592480897903442]
Such B-LOC [0.6280173659324646, -0.7415784597396851]
rapid B-LOC [0.6789328455924988, -1.0537644624710083]
change B-LOC [0.5677106976509094, -1.2151587009429932]
must B-LOC [0.6151015162467957, -0.9407956600189209]
be B-LOC [0.5745543241500854, -0.8346267342567444]
at B-LOC [0.631929337978363, -0.6983197927474976]
least B-LOC [0.43935826420783997, -0.6901158690452576]
partly B-LOC [0.7304773926734924, -0.511401355266571]
due B-LOC [0.5370534062385559, -0.8561710119247437]
to B-LOC [0.5608047842979431, -0.8531362414360046]
cervical B-LOC [0.538031280040741, -1.107111930847168]
screening, B-LOC [0.5477545857429504, -0.9726065397262573]
although B-LOC [0.46583160758018494, -0.7153592109680176]
strong B-LOC [0.5941923260688782, -0.787423312664032]
cohort B-LOC [0.60462486743927, -0.7112794518470764]
effects B-LOC [0.6895043253898621, -0.9978102445602417]
have B-LOC [0.8590399622917175, -0.9801025986671448]
caused B-LOC [0.7520691752433777, -0.9695674180984497]
large B-LOC [0.7541741728782654, -0.8648395538330078]
fluctuations B-LOC [0.8890990614891052, -1.210805892944336]
in B-LOC [0.8264655470848083, -1.4038474559783936]
cervical B-LOC [0.6572510600090027, -1.2551226615905762]
mortality B-LOC [0.8939267992973328, -1.0807645320892334]
in B-LOC [1.1587773561477661, -1.1920490264892578]
the B-LOC [1.2715051174163818, -1.1563605070114136]
past.2 B-LOC [0.6643720269203186, -1.0537701845169067]
We B-LOC [2.3163962364196777, -2.6433207988739014]
modelled B-LOC [2.790362596511841, -3.1802308559417725]
mortality B-LOC [2.723921775817871, -3.316018581390381]
data, B-LOC [2.7956433296203613, -3.228048086166382]
taking B-LOC [2.9424092769622803, -3.383324384689331]
into B-LOC [3.271428346633911, -3.0221545696258545]
account B-LOC [2.97251296043396, -3.3062825202941895]
the B-LOC [2.886247158050537, -3.099553346633911]
effects B-LOC [2.974311590194702, -3.482058525085449]
of B-LOC [2.431384801864624, -3.1351447105407715]
age B-LOC [3.0614230632781982, -3.3545613288879395]
and B-LOC [2.6640877723693848, -3.0671274662017822]
year B-LOC [2.9581825733184814, -3.446042537689209]
of B-LOC [2.717724084854126, -3.2456963062286377]
birth B-LOC [2.8167383670806885, -3.365353584289551]
and B-LOC [2.8112175464630127, -3.1491103172302246]
looking B-LOC [3.1028735637664795, -3.146418333053589]
for B-LOC [3.260964870452881, -3.2737553119659424]
trends B-LOC [2.7943971157073975, -3.3261454105377197]
in B-LOC [2.868093252182007, -3.4967944622039795]
time B-LOC [2.7489254474639893, -3.4254393577575684]
within B-LOC [3.0312588214874268, -3.2764549255371094]
four B-LOC [3.0220277309417725, -3.0449187755584717]
age B-LOC [2.939323663711548, -3.242619276046753]
groups B-LOC [3.096964120864868, -3.151071071624756]
to B-LOC [3.1809022426605225, -3.251661777496338]
estimate B-LOC [3.0321266651153564, -3.227940559387207]
the B-LOC [2.989921808242798, -3.1430764198303223]
beneficial B-LOC [2.929486036300659, -3.397935628890991]
effects B-LOC [2.902883529663086, -3.4401285648345947]
of B-LOC [2.3776259422302246, -3.018390417098999]
cervical B-LOC [2.400799036026001, -3.129241704940796]
screening. B-LOC [2.50483775138855, -3.1674671173095703]
We B-LOC [1.227353811264038, -1.8923211097717285]
obtained B-LOC [1.577362060546875, -1.9869600534439087]
mortality B-LOC [1.3520216941833496, -1.6927762031555176]
data, B-LOC [1.5916855335235596, -2.172772169113159]
in B-LOC [1.6606194972991943, -2.031107187271118]
5 B-LOC [1.7961268424987793, -1.97548508644104]
year B-LOC [1.7927219867706299, -2.179441213607788]
age B-LOC [1.7864351272583008, -2.061565637588501]
bands, B-LOC [2.0663888454437256, -2.2126266956329346]
from B-LOC [1.7923715114593506, -2.3916945457458496]
death B-LOC [1.5292481184005737, -1.9284310340881348]
registrations B-LOC [1.861156940460205, -2.144972085952759]
in B-LOC [1.4603489637374878, -1.8897534608840942]

England B-LOC [2.099576234817505, -2.6471946239471436]
and B-LOC [2.4716100692749023, -2.931889295578003]
Wales B-LOC [2.5020759105682373, -2.8868420124053955]
and B-LOC [2.034459352493286, -2.8366591930389404]
calculated B-LOC [2.3618569374084473, -2.9684369564056396]
rates B-LOC [2.7175121307373047, -3.415360689163208]
using B-LOC [2.4391136169433594, -3.2931227684020996]
mid-year B-LOC [2.472970724105835, -3.390861988067627]
population B-LOC [2.6158032417297363, -3.07108998298645]
estimates. B-LOC [2.6583712100982666, -3.269899606704712]
Mortality B-LOC [2.2721002101898193, -2.752938985824585]
since B-LOC [1.989422082901001, -2.4431893825531006]
1993 B-LOC [2.259805917739868, -2.5446624755859375]
was B-LOC [2.1162354946136475, -2.4667346477508545]
adjusted B-LOC [1.9710911512374878, -2.6022117137908936]
upwards B-LOC [1.8633323907852173, -2.1947124004364014]
by B-LOC [1.5701367855072021, -2.059433698654175]
4% B-LOC [2.050518751144409, -2.3032760620117188]
because B-LOC [2.0568363666534424, -2.4132513999938965]
of B-LOC [2.0757291316986084, -2.4703171253204346]
changes B-LOC [2.2773687839508057, -2.7409136295318604]
in B-LOC [2.149791955947876, -2.6903412342071533]
classification B-LOC [2.5576083660125732, -2.8036201000213623]
of B-LOC [2.4237968921661377, -2.9422502517700195]
cause B-LOC [2.672734498977661, -3.0541512966156006]
of B-LOC [2.606801748275757, -2.8799197673797607]
death.3 B-LOC [2.708098888397217, -3.0260884761810303]
We B-LOC [0.10737457871437073, -0.4257294833660126]
modelled B-LOC [0.5517331957817078, -0.45556890964508057]
the B-LOC [0.7871927618980408, -0.8478729724884033]
data B-LOC [0.546733021736145, -1.0092339515686035]
assuming B-LOC [0.5324316620826721, -0.36284175515174866]
that B-LOC [0.21105872094631195, -0.4119051992893219]
the B-LOC [0.4155326783657074, -0.761477530002594]
age B-LOC [0.6447564959526062, -0.9356103539466858]
specific B-LOC [0.3166429400444031, -1.0862170457839966]
mortality B-LOC [0.5062293410301208, -0.8943918347358704]
is B-LOC [0.49167537689208984, -0.5786418914794922]
the B-LOC [0.5252500176429749, -0.680722713470459]
product B-LOC [0.4541836082935333, -0.4956912100315094]
of B-LOC [0.38002702593803406, -0.5850294232368469]
a B-LOC [0.40616631507873535, -0.5099820494651794]
smoothly B-LOC [0.28531572222709656, -0.5938234925270081]
varying B-LOC [0.31223100423812866, -1.0354572534561157]
age B-LOC [0.44213977456092834, -0.9391485452651978]
effect, B-LOC [0.16856230795383453, -0.7573683857917786]
birth B-LOC [0.3806726932525635, -0.7593417167663574]
cohort B-LOC [0.4322873651981354, -0.7919567823410034]
effect, B-LOC [0.2598717212677002, -0.7109829783439636]
and B-LOC [0.6487782597541809, -0.6469345092773438]
age B-LOC [0.721099853515625, -0.9818111062049866]
dependent B-LOC [0.33041027188301086, -0.6358829736709595]
… B-LOC [0.18890047073364258, -0.6774314045906067]

Gene B-LOC [0.5836032032966614, -1.6364814043045044]
expression B-LOC [0.7060727477073669, -1.3013910055160522]
is B-LOC [1.2588227987289429, -1.6638073921203613]
a B-LOC [1.249507188796997, -1.6521497964859009]
fundamentally B-LOC [1.2869651317596436, -1.7476645708084106]
stochastic B-LOC [1.2331262826919556, -1.8992791175842285]
process, B-LOC [0.786625325679779, -1.7372342348098755]
with B-LOC [1.0185918807983398, -1.4861910343170166]
randomness B-LOC [1.1334831714630127, -1.6826868057250977]
in B-LOC [0.735970675945282, -1.7580050230026245]
transcription B-LOC [0.8331145644187927, -1.1936193704605103]
and B-LOC [1.0121445655822754, -1.4428644180297852]
translation B-LOC [0.8837718367576599, -1.2751333713531494]
leading B-LOC [0.9924368262290955, -1.3770592212677002]
to B-LOC [0.8237388730049133, -1.441791296005249]
cell-to-cell B-LOC [0.6799043416976929, -1.603140115737915]
variations B-LOC [1.178926944732666, -1.840998649597168]
in B-LOC [0.8096064925193787, -1.9126437902450562]
mRNA B-LOC [0.7376609444618225, -1.2925705909729004]
and B-LOC [1.169596552848816, -1.6465578079223633]
protein B-LOC [1.123892068862915, -1.6263773441314697]
levels. B-LOC [1.0644896030426025, -1.6774934530258179]
This B-LOC [2.276486396789551, -2.656458616256714]
variation B-LOC [2.452388286590576, -2.855717658996582]
appears B-LOC [2.300100803375244, -2.5820772647857666]
in B-LOC [2.171778917312622, -2.6860148906707764]
organisms B-LOC [2.3279998302459717, -2.617759943008423]
ranging B-LOC [2.373762369155884, -2.6353166103363037]
from B-LOC [2.369605302810669, -2.3627383708953857]
microbes B-LOC [2.3791134357452393, -2.457152843475342]
to B-LOC [2.1186749935150146, -2.442037343978882]
metazoans, B-LOC [2.1667826175689697, -2.3531785011291504]
and B-LOC [2.1213271617889404, -2.5894505977630615]
its B-LOC [2.352829933166504, -2.695751905441284]
characteristics B-LOC [2.5262598991394043, -2.825671434402466]
depend B-LOC [2.3817508220672607, -2.6823041439056396]
both B-LOC [2.2327332496643066, -2.650275707244873]
on B-LOC [2.3320655822753906, -2.7943379878997803]
the B-LOC [2.379180669784546, -2.5961406230926514]
biophysical B-LOC [2.3756539821624756, -2.9168684482574463]
parameters B-LOC [2.3283448219299316, -2.7917768955230713]
governing B-LOC [2.1061246395111084, -2.560844659805298]
gene B-LOC [2.331333875656128, -2.8899295330047607]
expression B-LOC [2.2609105110168457, -2.529620885848999]
and B-LOC [2.1955296993255615, -2.239095449447632]
on B-LOC [2.173351764678955, -2.766714334487915]
gene B-LOC [2.131664514541626, -2.7105071544647217]
network B-LOC [1.9261424541473389, -2.4456541538238525]
structure. B-LOC [2.3200950622558594, -2.5125231742858887]
Stochastic B-LOC [1.2194595336914062, -1.8224611282348633]
gene B-LOC [0.8758042454719543, -1.5878422260284424]
expression B-LOC [1.0166971683502197, -1.580885410308838]
has B-LOC [1.467334508895874, -1.7733056545257568]
important B-LOC [1.271324872970581, -1.7387043237686157]
consequences B-LOC [1.402136206626892, -1.943211317062378]
for B-LOC [1.327519416809082, -2.0447213649749756]
cellular B-LOC [1.0316447019577026, -1.7848501205444336]
function, B-LOC [1.2455438375473022, -1.8969753980636597]
being B-LOC [1.3677116632461548, -1.8709548711776733]
beneficial B-LOC [1.1394437551498413, -1.8839545249938965]
in B-LOC [1.3481099605560303, -1.8604645729064941]
some B-LOC [1.1605243682861328, -1.801337480545044]
contexts B-LOC [1.345033884048462, -1.6219711303710938]
and B-LOC [1.307443618774414, -1.4673516750335693]
harmful B-LOC [1.2890338897705078, -1.8725152015686035]
in B-LOC [1.222937822341919, -1.612475872039795]
others. B-LOC [1.4502326250076294, -1.5766675472259521]
These B-LOC [1.5482168197631836, -1.7054250240325928]
situations B-LOC [1.3001410961151123, -1.7018929719924927]
include B-LOC [1.398749828338623, -1.6669507026672363]
the B-LOC [1.104912281036377, -1.6766469478607178]
stress B-LOC [1.1224802732467651, -1.5398168563842773]
response, B-LOC [0.9559845924377441, -1.564833164215088]
metabolism, B-LOC [0.7813583016395569, -1.4810676574707031]
development, B-LOC [0.8757731318473816, -1.2226721048355103]
the B-LOC [1.1226158142089844, -1.5888092517852783]
cell B-LOC [0.7207751274108887, -1.4674477577209473]
cycle, B-LOC [0.7260361909866333, -1.4538922309875488]
circadian B-LOC [1.0447434186935425, -1.3827890157699585]
rhythms, B-LOC [1.0053778886795044, -1.5366263389587402]
and B-LOC [1.3411526679992676, -1.704596996307373]
aging. B-LOC [0.9111781120300293, -1.4251703023910522]

Despite B-LOC [1.4168602228164673, -1.2892595529556274]
accumulating B-LOC [1.9303529262542725, -1.5167253017425537]
evidence B-LOC [1.6036536693572998, -1.1302553415298462]
suggesting B-LOC [1.4410996437072754, -1.2715017795562744]
local B-LOC [1.4099236726760864, -1.629201889038086]
self-maintenance B-LOC [1.5836055278778076, -1.7023625373840332]
of B-LOC [1.366491436958313, -1.6585962772369385]
tissue B-LOC [1.2125637531280518, -1.4817253351211548]
macrophages B-LOC [1.5214943885803223, -1.379830241203308]
in B-LOC [1.7469425201416016, -1.6810111999511719]
the B-LOC [1.7466431856155396, -1.6527905464172363]
steady B-LOC [1.6398996114730835, -2.0006067752838135]
state, B-LOC [1.6432751417160034, -1.7686021327972412]
the B-LOC [1.9391086101531982, -1.3522601127624512]
dogma B-LOC [2.026594400405884, -1.585087537765503]
remains B-LOC [1.8440217971801758, -1.5085994005203247]
that B-LOC [1.6598211526870728, -1.5278120040893555]
tissue B-LOC [1.420109510421753, -1.7407984733581543]
macrophages B-LOC [1.6769721508026123, -1.5110554695129395]
derive B-LOC [1.523205280303955, -1.5893261432647705]
from B-LOC [1.488461971282959, -1.5915520191192627]
monocytes. B-LOC [1.6331931352615356, -1.7853541374206543]
Using B-LOC [1.7472046613693237, -1.8612502813339233]
parabiosis B-LOC [2.1196658611297607, -2.2374160289764404]
and B-LOC [1.9953324794769287, -1.9664517641067505]
fate-mapping B-LOC [1.90366530418396, -2.204188585281372]
approaches, B-LOC [2.1135919094085693, -1.949371576309204]
we B-LOC [1.265220046043396, -1.3016126155853271]
confirmed B-LOC [1.5491900444030762, -1.2243828773498535]
that B-LOC [1.590872883796692, -1.5187675952911377]
monocytes B-LOC [1.519688367843628, -1.6666258573532104]
do B-LOC [1.8412268161773682, -1.552539348602295]
not B-LOC [1.9484663009643555, -1.6031854152679443]
show B-LOC [1.6880336999893188, -1.7217421531677246]
significant B-LOC [1.91817045211792, -2.158966302871704]
contribution B-LOC [1.6260151863098145, -2.0997519493103027]
to B-LOC [1.5003490447998047, -1.9078878164291382]
tissue B-LOC [1.523890733718872, -1.8767750263214111]
macrophages B-LOC [1.8634430170059204, -1.6508746147155762]
in B-LOC [1.880381464958191, -1.9051597118377686]
the B-LOC [1.9866752624511719, -1.888891577720642]
steady B-LOC [1.8704451322555542, -2.098473072052002]
state. B-LOC [1.7325263023376465, -2.0625174045562744]
Similarly, O [-0.23098590970039368, 0.03996998444199562]
we O [-0.46243709325790405, 0.12564437091350555]
found O [-0.43531808257102966, 0.4106237590312958]
that O [-0.6212487816810608, 0.38761571049690247]
after O [-0.32066991925239563, 0.2099473476409912]
depletion B-LOC [0.12368612736463547, 0.08139437437057495]
of O [-0.029768548905849457, -0.0036528133787214756]
lung O [-0.2515496611595154, 0.00038692873204126954]
macrophages, O [-0.06259940564632416, 0.09033482521772385]
the O [-0.24258273839950562, 0.1257075071334839]
majority O [-0.2839904725551605, 0.11590784788131714]
of O [-0.3400067687034607, 0.1365470588207245]
repopulation O [-0.15167666971683502, 0.16069330275058746]
occurred O [-0.28158995509147644, 0.07118599861860275]
by O [-0.3782259523868561, 0.11147046089172363]
stochastic O [-0.1590421199798584, -0.013115288689732552]
cellular O [-0.33174481987953186, -0.007794963661581278]
proliferation O [-0.054591577500104904, 0.05938413366675377]
in B-LOC [0.13943102955818176, -0.20460529625415802]
situ O [0.09940137714147568, 0.39912936091423035]
in O [0.010079744271934032, 0.044361721724271774]
a O [-0.11681798845529556, 0.1748049408197403]
macrophage O [0.006400214973837137, 0.054408468306064606]
colony-stimulating O [-0.1978432834148407, 0.0907895416021347]
factor O [-0.30796435475349426, -0.03899272158741951]

(M-Csf)- B-LOC [-0.162546306848526, -0.16795234382152557]
and O [-0.06414434313774109, 0.2326962649822235]
granulocyte O [-0.11544111371040344, 0.12273754924535751]
macrophage O [-0.06507381796836853, 0.1155039370059967]
(GM)-CSF-dependent O [-0.020181553438305855, 0.10586714744567871]
manner O [-0.16162146627902985, 0.2910570800304413]
but O [-0.05131072551012039, 0.2797200083732605]
independently O [-0.07845406979322433, 0.1515204757452011]
of O [-0.11906848847866058, 0.02011568658053875]
interleukin-4. B-LOC [-0.040927350521087646, -0.11827762424945831]
We O [-0.6388353109359741, 0.2942897379398346]
also O [-0.5035182237625122, 0.41411444544792175]
found O [-0.6893801689147949, 0.6459270119667053]
that O [-0.8621672987937927, 0.725284993648529]
after O [-0.6535207629203796, 0.6033293008804321]
bone O [-0.3592035472393036, 0.34788820147514343]
marrow O [-0.46475642919540405, 0.554118275642395]
transplantation, O [-0.2737998366355896, 0.3973751366138458]
host O [-0.5141217708587646, 0.5185206532478333]
macrophages O [-0.4051797091960907, 0.546995997428894]
retained O [-0.4693670868873596, 0.6525000929832458]
the O [-0.5330584645271301, 0.7130932211875916]
capacity O [-0.3959343433380127, 0.6613637804985046]
to O [-0.6061937808990479, 0.6285692453384399]
expand O [-0.32380375266075134, 0.6226215958595276]
when O [-0.39509111642837524, 0.5510456562042236]
the O [-0.46874532103538513, 0.5292169451713562]
development O [-0.4341617524623871, 0.5774180293083191]
of O [-0.5533620715141296, 0.4240531325340271]
donor O [-0.4789276421070099, 0.37746360898017883]
macrophages O [-0.36921799182891846, 0.5267866849899292]
was O [-0.3480404317378998, 0.5841521620750427]
compromised. O [-0.2142726480960846, 0.4707774817943573]
Expansion O [-0.061721839010715485, 0.043778907507658005]
of B-LOC [0.019929854199290276, -0.10146313905715942]
host O [-0.14123065769672394, -0.02746785618364811]
macrophages B-LOC [-0.006501947995275259, -0.02847762033343315]
was O [-0.287788063287735, 0.07393445074558258]
functional O [0.019297676160931587, 0.10082512348890305]
and O [-0.22022444009780884, 0.3681807219982147]
prevented O [-0.16725189983844757, 0.0844191312789917]
the O [-0.17843666672706604, -0.09140490740537643]
development O [-0.09776721894741058, -0.04196405038237572]
of O [-0.20052069425582886, -0.051188576966524124]
alveolar O [-0.14693310856819153, -0.0009509496740065515]
proteinosis O [-0.23542045056819916, -0.08695085346698761]
in O [-0.1470828652381897, -0.07203669846057892]
mice O [-0.22468969225883484, -0.12477463483810425]
transplanted B-LOC [0.08437968045473099, -0.18057501316070557]
with B-LOC [0.04819202423095703, -0.31242841482162476]
GM-Csf-receptor-deficient B-LOC [-0.062004201114177704, -0.0786878764629364]
progenitors. B-LOC [0.053394198417663574, -0.1854177862405777]
Collectively, B-LOC [0.6699498891830444, -0.5552093982696533]
these B-LOC [0.6046332716941833, -0.6109022498130798]
results B-LOC [0.5767213106155396, -0.6408070921897888]
indicate B-LOC [0.4578154981136322, -0.4485040009021759]
that B-LOC [0.3810521364212036, -0.5868065357208252]
tissue-resident B-LOC [0.08208929002285004, -0.6184601187705994]
macrophages B-LOC [0.26398321986198425, -0.31753209233283997]
and B-LOC [0.2512288987636566, -0.49302938580513]

circulating B-LOC [0.24219270050525665, -1.0206135511398315]
monocytes B-LOC [0.3543955683708191, -0.982964277267456]
should B-LOC [1.1400020122528076, -1.0376315116882324]
be B-LOC [1.5015718936920166, -1.297287106513977]
classified B-LOC [1.2992775440216064, -1.2064937353134155]
as B-LOC [0.7787749171257019, -1.1107709407806396]
mononuclear B-LOC [0.7227780818939209, -0.969094455242157]
phagocyte B-LOC [0.38506025075912476, -0.8936245441436768]
lineages B-LOC [0.6170366406440735, -0.8483467698097229]
that B-LOC [0.6315763592720032, -1.2406985759735107]
are B-LOC [0.9187034368515015, -1.14283287525177]
independently B-LOC [0.8108194470405579, -1.1977779865264893]
maintained B-LOC [0.8533389568328857, -1.0480409860610962]
in B-LOC [0.810936689376831, -0.9730616211891174]
the B-LOC [0.7375792264938354, -1.0049991607666016]
steady B-LOC [0.6342361569404602, -1.1885240077972412]
state. B-LOC [0.6124979853630066, -0.9937857389450073]

West B-LOC [2.313075065612793, -2.897085428237915]
Nile B-LOC [2.3650052547454834, -2.9171509742736816]
virus B-LOC [2.1592419147491455, -2.759531259536743]
(WNV) B-LOC [2.463491678237915, -2.7015886306762695]
is B-LOC [2.8645529747009277, -2.7702863216400146]
the B-LOC [2.8077690601348877, -2.6909947395324707]
most B-LOC [3.019474983215332, -3.0237324237823486]
common B-LOC [2.7784457206726074, -2.814715623855591]
arthropod-borne B-LOC [2.410875082015991, -2.649102210998535]
flavivirus B-LOC [2.3232169151306152, -2.510953664779663]
in B-LOC [2.7988667488098145, -2.5878612995147705]
the B-LOC [2.9513657093048096, -2.6291730403900146]
United B-LOC [2.8232321739196777, -2.9299676418304443]
States; B-LOC [2.6953680515289307, -2.7777116298675537]
however, B-LOC [3.033808946609497, -3.161764621734619]
the B-LOC [3.1156532764434814, -3.127995252609253]
vector B-LOC [3.041109800338745, -3.2217297554016113]
ligand(s) B-LOC [3.0902931690216064, -3.212661027908325]
that B-LOC [3.2542638778686523, -3.2080137729644775]
participate B-LOC [3.072007417678833, -3.105069398880005]
in B-LOC [3.0743257999420166, -3.1611385345458984]
infection B-LOC [3.0037877559661865, -3.190779447555542]
are B-LOC [3.346837043762207, -3.153477907180786]
not B-LOC [3.3865201473236084, -3.306641101837158]
known. B-LOC [3.1220498085021973, -3.1917943954467773]
We O [-0.2196025252342224, 0.17479047179222107]
now B-LOC [0.20986610651016235, 0.19214048981666565]
show O [-0.3981991112232208, 0.5048957467079163]
that O [-0.7619856595993042, 0.30458229780197144]
an O [-0.35609158873558044, 0.2602662742137909]
Aedes O [-0.4614218771457672, -0.105096235871315]
aegypti O [-0.4988763630390167, -0.008882241323590279]
C-type O [-0.32546284794807434, 0.07556789368391037]
lectin, O [-0.5434795618057251, 0.19538141787052155]
mosGCTL-1, O [-0.4908328056335449, 0.11110712587833405]
is O [-0.49297401309013367, 0.5534788966178894]
induced O [-0.3985779285430908, 0.610921323299408]
by O [-0.6508098244667053, 0.6632056832313538]
WNV, O [-0.1530439555644989, -0.07561835646629333]
interacts O [-0.40312662720680237, 0.5979053974151611]
with O [-0.327873557806015, 0.42367926239967346]
WNV O [-0.24286121129989624, 0.039475131779909134]
in O [-0.7445230484008789, 0.6419199705123901]
a O [-0.6963527202606201, 0.6720024347305298]
calcium-dependent O [-0.40777677297592163, 0.3825545310974121]
manner, O [-0.6694707274436951, 0.5993704199790955]
and O [-0.7239507436752319, 0.5517681241035461]
facilitates O [-0.5762618780136108, 0.49300476908683777]
infection O [-0.18079715967178345, 0.1724267154932022]
in O [-0.3820907771587372, 0.16235381364822388]
vivo O [-0.4720241129398346, 0.2792966365814209]
and O [-0.036622438579797745, 0.08451075106859207]
in O [-0.2466345727443695, 0.04396533593535423]
vitro. O [-0.192173033952713, 0.1145472452044487]
A B-LOC [0.3329083323478699, -0.577033519744873]
mosquito B-LOC [0.41187331080436707, -0.5879501104354858]
homolog B-LOC [0.46192285418510437, -0.8481126427650452]
of B-LOC [0.32568615674972534, -0.5138207077980042]
human B-LOC [0.29014191031455994, -0.7209460139274597]
CD45 B-LOC [0.29510989785194397, -0.30035603046417236]
in B-LOC [0.29828977584838867, -0.507451057434082]
A. B-LOC [0.08895491808652878, -0.5982211232185364]
aegypti, B-LOC [0.06561340391635895, -0.6569857597351074]
designated B-LOC [0.7197074890136719, -0.6368335485458374]
mosPTP-1, B-LOC [0.27481773495674133, -0.6578336954116821]
recruits B-LOC [0.20594096183776855, -0.5762104392051697]

mosGCTL-1 B-LOC [0.12762200832366943, -0.5810984969139099]
to B-LOC [0.23724989593029022, -0.3905572295188904]
enable B-LOC [0.05646893382072449, -0.3561074733734131]
viral B-LOC [0.23013880848884583, -0.5472171902656555]
attachment B-LOC [0.30453649163246155, -0.4639270007610321]
to B-LOC [0.24718192219734192, -0.6160304546356201]
cells B-LOC [0.21533805131912231, -0.5725775957107544]
and B-LOC [0.1533154547214508, -0.2905639708042145]
to B-LOC [0.16475683450698853, -0.3160206079483032]
enhance B-LOC [0.13700729608535767, -0.326885461807251]
viral B-LOC [0.30444279313087463, -0.5282385349273682]
entry. B-LOC [0.23964981734752655, -0.6379758715629578]
In B-LOC [0.29386329650878906, -0.5051557421684265]
vivo B-LOC [0.3314823806285858, -0.415571004152298]
experiments B-LOC [0.40079715847969055, -0.4523087441921234]
show B-LOC [0.4396887421607971, -0.33286190032958984]
that B-LOC [0.21755364537239075, -0.4691918194293976]
mosGCTL-1 B-LOC [0.2590027153491974, -0.421648234128952]
and B-LOC [0.3641992509365082, -0.4818500578403473]
mosPTP-1 B-LOC [0.21911868453025818, -0.4165734350681305]
function B-LOC [0.4282391667366028, -0.35741424560546875]
as B-LOC [0.3709058463573456, -0.2864178717136383]
part B-LOC [0.5099437832832336, -0.31171080470085144]
of B-LOC [0.4973759949207306, -0.3871431052684784]
the B-LOC [0.47621020674705505, -0.3968231678009033]
same B-LOC [0.528802216053009, -0.5579490065574646]
pathway B-LOC [0.12266288697719574, -0.42189326882362366]
and B-LOC [0.016442570835351944, -0.18025310337543488]
are B-LOC [0.43146607279777527, -0.45156997442245483]
critical B-LOC [0.12479998916387558, -0.23232501745224]
for B-LOC [0.05373125895857811, -0.34166601300239563]
WNV B-LOC [0.04298929497599602, -0.27368903160095215]
infection B-LOC [0.31012287735939026, -0.23651248216629028]
of B-LOC [0.26225075125694275, -0.2719718813896179]
mosquitoes. B-LOC [0.26492077112197876, -0.4074231684207916]
A B-LOC [0.735961377620697, -0.8961911797523499]
similar B-LOC [0.8113932013511658, -0.8602781891822815]
phenomenon B-LOC [0.6213487982749939, -0.9437940716743469]
was B-LOC [0.7581505179405212, -0.9297241568565369]
also B-LOC [0.8695365786552429, -0.8995240926742554]
observed B-LOC [0.7462565302848816, -0.7394819259643555]
in B-LOC [0.7062518000602722, -0.7485660314559937]
Culex B-LOC [0.5596244931221008, -0.7022331357002258]
quinquefasciatus, B-LOC [0.734184205532074, -0.6483336091041565]
a B-LOC [0.6171591877937317, -0.8454182744026184]
natural B-LOC [0.8705734014511108, -1.1498256921768188]
vector B-LOC [0.8208600878715515, -0.9596458077430725]
of B-LOC [0.6132419109344482, -0.76729416847229]
WNV, B-LOC [0.7269197702407837, -0.8328742980957031]
further B-LOC [0.7988658547401428, -0.6773361563682556]
demonstrating B-LOC [0.8856221437454224, -0.8351219296455383]
that B-LOC [0.8925341963768005, -0.9104960560798645]
these B-LOC [0.8933914303779602, -0.9438098073005676]
genes B-LOC [0.7940734624862671, -0.8331654667854309]
participate B-LOC [0.9248713254928589, -0.9986600279808044]
in B-LOC [0.8603115081787109, -1.0210554599761963]
WNV B-LOC [0.8059425950050354, -0.880192756652832]
infection. B-LOC [0.8608207106590271, -0.9558398127555847]
During B-LOC [0.430071085691452, -0.6415295004844666]
the B-LOC [0.6004215478897095, -0.6869779229164124]
mosquito B-LOC [0.6146919131278992, -0.8941383957862854]
blood-feeding B-LOC [0.39639410376548767, -0.9467933773994446]
process, B-LOC [0.5723045468330383, -0.8702555298805237]
WNV B-LOC [0.4507705271244049, -0.6995297074317932]
infection B-LOC [0.3710874021053314, -0.6180006265640259]
was B-LOC [0.5802000164985657, -0.6154889464378357]
blocked B-LOC [0.49641153216362, -0.5975713133811951]
in B-LOC [0.40647026896476746, -0.5470414161682129]
vivo B-LOC [0.3711869418621063, -0.5232582688331604]
with B-LOC [0.5092846751213074, -0.7187079787254333]
mosGCTL-1 B-LOC [0.6082269549369812, -0.6942583918571472]
antibodies. B-LOC [0.5990324020385742, -0.8291453719139099]
A B-LOC [1.1332614421844482, -1.3438599109649658]
molecular B-LOC [1.6139603853225708, -1.6690964698791504]
understanding B-LOC [1.3740044832229614, -1.4641485214233398]
of B-LOC [1.3365095853805542, -1.4510831832885742]

flaviviral-arthropod B-LOC [0.25256890058517456, -0.6067731380462646]
interactions B-LOC [0.4628978669643402, -0.573027491569519]
may B-LOC [0.7582473158836365, -1.056059718132019]
lead B-LOC [0.6289938688278198, -0.976456344127655]
to B-LOC [0.6400389075279236, -0.9765318036079407]
strategies B-LOC [0.7029287219047546, -0.8786863088607788]
to B-LOC [0.8989621996879578, -1.098873496055603]
control B-LOC [0.5818785429000854, -1.0715556144714355]
viral B-LOC [0.515414297580719, -0.8811464309692383]
dissemination B-LOC [0.6818094849586487, -0.7338526248931885]
in B-LOC [0.9039259552955627, -1.0725600719451904]
nature. B-LOC [0.8536441922187805, -1.253997564315796]

OBJECTIVE B-LOC [3.117170572280884, -3.4776837825775146]
To B-LOC [3.4106192588806152, -3.523667097091675]
determine B-LOC [3.5712664127349854, -3.44814395904541]
the B-LOC [3.7255918979644775, -3.405885696411133]
effects B-LOC [3.7117514610290527, -3.34427547454834]
of B-LOC [3.4855284690856934, -3.3089048862457275]
smoking, B-LOC [3.724030017852783, -3.3076770305633545]
plasma B-LOC [3.5894148349761963, -3.666879415512085]
lipids, B-LOC [3.5653860569000244, -3.471830368041992]
lipoproteins, B-LOC [3.5400640964508057, -3.340413808822632]
apolipoproteins, B-LOC [3.6203601360321045, -3.499722719192505]
and B-LOC [3.5489232540130615, -3.443831205368042]
fibrinogen B-LOC [3.454435110092163, -3.1943535804748535]
on B-LOC [3.458319902420044, -3.434260845184326]
the B-LOC [3.6733322143554688, -3.2400927543640137]
patency B-LOC [3.6355605125427246, -3.411247968673706]
of B-LOC [3.431180715560913, -3.1010379791259766]
saphenous B-LOC [3.6316487789154053, -3.3322062492370605]
vein B-LOC [3.531858205795288, -3.3014023303985596]
femoropopliteal B-LOC [3.611039400100708, -3.36963152885437]
bypass B-LOC [3.612738847732544, -3.482400417327881]
grafts B-LOC [3.7565791606903076, -3.2775609493255615]
at B-LOC [3.5466151237487793, -3.3984222412109375]
one B-LOC [3.3168089389801025, -3.3152668476104736]
year. B-LOC [3.3128817081451416, -3.2444212436676025]
DESIGN B-LOC [3.6837825775146484, -3.52561354637146]
Prospective B-LOC [3.822122812271118, -3.635714292526245]
study B-LOC [3.534658670425415, -3.4684560298919678]
of B-LOC [3.750338077545166, -3.505105495452881]
patients B-LOC [4.055136680603027, -3.45871639251709]
with B-LOC [3.930572271347046, -3.4609835147857666]
saphenous B-LOC [3.868044376373291, -3.38307523727417]
vein B-LOC [3.6516165733337402, -3.378359079360962]
femoropopliteal B-LOC [3.6877923011779785, -3.4010846614837646]
bypass B-LOC [3.7245051860809326, -3.619595527648926]
grafts B-LOC [3.847456932067871, -3.3742892742156982]
entered B-LOC [3.7477211952209473, -3.3363454341888428]
into B-LOC [3.579108476638794, -3.12528133392334]
a B-LOC [3.5466549396514893, -3.1336591243743896]
multicentre B-LOC [3.6089980602264404, -3.496018171310425]
trial. B-LOC [3.7597880363464355, -3.497887134552002]
SETTING B-LOC [2.7068183422088623, -3.129777193069458]
Surgical B-LOC [3.048583984375, -2.831310987472534]
wards, B-LOC [3.4765336513519287, -3.0639820098876953]
outpatient B-LOC [3.417015314102173, -3.1384847164154053]
clinics, B-LOC [3.242219924926758, -3.0853421688079834]
and B-LOC [3.280566930770874, -3.160121440887451]
home B-LOC [3.0741665363311768, -3.0695879459381104]
visits B-LOC [3.4412665367126465, -3.0597774982452393]
coordinated B-LOC [3.5025784969329834, -3.055129289627075]
by B-LOC [3.182378053665161, -2.8648507595062256]
two B-LOC [3.0593955516815186, -2.9945404529571533]
tertiary B-LOC [3.4793708324432373, -3.472032308578491]
referral B-LOC [3.579904317855835, -3.2676351070404053]
centres B-LOC [3.4177651405334473, -2.998157262802124]
in B-LOC [3.532536029815674, -2.714452028274536]
London B-LOC [3.4175591468811035, -2.9832189083099365]
and B-LOC [3.2538530826568604, -2.8174402713775635]
Birmingham. B-LOC [3.0847959518432617, -3.198065757751465]

PATIENTS B-LOC [2.690721273422241, -3.3252217769622803]
157 B-LOC [3.489356279373169, -3.3404788970947266]
Patients B-LOC [3.42303204536438, -3.461793899536133]
(mean B-LOC [3.5105996131896973, -3.265343427658081]
age B-LOC [3.5308175086975098, -3.2278943061828613]
66.6 B-LOC [3.3373661041259766, -2.886129140853882]
(SD B-LOC [3.472433090209961, -3.377363443374634]
8.2) B-LOC [3.3640687465667725, -3.056365966796875]
years), B-LOC [3.6437926292419434, -3.1674036979675293]
113 B-LOC [3.651463508605957, -3.416912794113159]
with B-LOC [3.4597280025482178, -3.29341721534729]
patent B-LOC [3.5640430450439453, -3.6485869884490967]
grafts B-LOC [3.5930585861206055, -3.0778820514678955]
and B-LOC [3.3201687335968018, -3.2441346645355225]
44 B-LOC [3.692608118057251, -3.067110300064087]
with B-LOC [3.53723406791687, -3.280893325805664]
occluded B-LOC [3.4747121334075928, -3.195214033126831]
grafts B-LOC [3.7020561695098877, -3.0539968013763428]
one B-LOC [3.5368897914886475, -3.0689117908477783]
year B-LOC [3.5140702724456787, -2.7818682193756104]
after B-LOC [3.577486276626587, -3.409571647644043]
bypass. B-LOC [3.6099517345428467, -3.430037260055542]
MAIN B-LOC [3.410707950592041, -2.9753055572509766]
OUTCOME B-LOC [3.261693239212036, -2.9373161792755127]
MEASURE B-LOC [3.1534066200256348, -3.022507429122925]
Cumulative B-LOC [3.231600284576416, -2.5852348804473877]
percentage B-LOC [3.408984661102295, -3.093942403793335]
patency B-LOC [3.413825273513794, -3.0612833499908447]
at B-LOC [3.026031494140625, -2.7532308101654053]
one B-LOC [3.201277494430542, -2.891432762145996]
year. B-LOC [3.1492130756378174, -2.607624053955078]
RESULTS B-LOC [0.8909749388694763, -1.4174035787582397]
Markers B-LOC [1.6754194498062134, -1.61277437210083]
for B-LOC [1.4873313903808594, -1.3633582592010498]
smoking B-LOC [1.1463686227798462, -1.14469575881958]
(blood B-LOC [1.3988107442855835, -1.3375232219696045]
carboxyhaemoglobin B-LOC [0.9848341345787048, -1.2982909679412842]
concentration B-LOC [1.3114991188049316, -1.28971266746521]
(p B-LOC [1.3755980730056763, -1.2868542671203613]
less B-LOC [1.238879680633545, -1.5809028148651123]
than B-LOC [0.9383148550987244, -1.4265605211257935]
0.05) B-LOC [1.4417742490768433, -1.6918079853057861]
and B-LOC [1.5109212398529053, -1.7540643215179443]
plasma B-LOC [1.1052669286727905, -1.3937320709228516]
thiocyanate B-LOC [1.164764642715454, -1.2817959785461426]
concentration B-LOC [1.392993450164795, -1.2344146966934204]
(p B-LOC [1.3610197305679321, -1.2229223251342773]
less B-LOC [1.2238423824310303, -1.4172172546386719]
than B-LOC [0.8959293961524963, -1.3493397235870361]
0.01) B-LOC [1.3134379386901855, -1.5695114135742188]
and B-LOC [1.646581768989563, -1.755466103553772]
plasma B-LOC [1.3368570804595947, -1.481020212173462]
concentrations B-LOC [1.4765485525131226, -1.5180755853652954]
of B-LOC [1.1714152097702026, -1.350238561630249]
fibrinogen B-LOC [1.1012144088745117, -1.2256698608398438]
(p B-LOC [1.4403579235076904, -1.2927038669586182]
less B-LOC [1.3101692199707031, -1.4472317695617676]
than B-LOC [1.0259740352630615, -1.3909711837768555]
0.001) B-LOC [1.425919532775879, -1.5988434553146362]
and B-LOC [1.6175894737243652, -1.8444945812225342]

apolipoproteins O [-0.3360340893268585, 0.28798708319664]
AI O [-0.1545037031173706, 0.22329659759998322]
(p B-LOC [-0.009708900935947895, -0.057849813252687454]
less B-LOC [0.19716466963291168, -0.1448739618062973]
than B-LOC [0.0706767812371254, -0.28612032532691956]
0.04) B-LOC [0.2190335988998413, -0.47081488370895386]
and O [-0.06096524000167847, 0.1378534734249115]
(a) B-LOC [0.16530737280845642, -0.029208356514573097]
(p B-LOC [0.08389543741941452, -0.17420276999473572]
less B-LOC [0.13331224024295807, -0.10015572607517242]
than B-LOC [0.05776778236031532, -0.27444830536842346]
0.05) B-LOC [0.18230289220809937, -0.4054463803768158]
were O [-0.21611739695072174, -0.08812036365270615]
significantly O [-0.10832760483026505, 0.02366374246776104]
higher O [-0.01756843365728855, 0.12655213475227356]
in O [-0.13969729840755463, -0.040972139686346054]
patients O [-0.17764812707901, 0.021163636818528175]
with B-LOC [-0.08441896736621857, -0.13113665580749512]
occluded O [-0.09431865811347961, 0.06281707435846329]
grafts. O [-0.058058831840753555, 0.08680306375026703]
Serum B-LOC [0.5321239233016968, -0.5226539373397827]
cholesterol B-LOC [0.27288004755973816, -0.5233694911003113]
concentrations B-LOC [0.3832131326198578, -0.423746794462204]
were B-LOC [0.19421587884426117, -0.5850252509117126]
significantly B-LOC [0.4137243926525116, -0.5311338901519775]
higher B-LOC [0.4877810478210449, -0.4589489996433258]
in B-LOC [0.413679838180542, -0.45785006880760193]
patients B-LOC [0.2618822157382965, -0.40801820158958435]
with B-LOC [0.5426667332649231, -0.6658324599266052]
grafts B-LOC [0.5355117321014404, -0.600154459476471]
that B-LOC [0.35337215662002563, -0.5837914347648621]
remained B-LOC [0.44781067967414856, -0.5781787037849426]
patent B-LOC [0.6938396692276001, -0.6554229259490967]
one B-LOC [0.8082777857780457, -0.5499563813209534]
year B-LOC [0.7526419758796692, -0.6970802545547485]
after B-LOC [0.6303069591522217, -0.6683102250099182]
bypass B-LOC [0.36933669447898865, -0.4102003276348114]
(p B-LOC [0.7092434763908386, -0.698038637638092]
less B-LOC [0.5925303101539612, -0.6996814012527466]
than B-LOC [0.608549177646637, -0.6997575759887695]
0.005). B-LOC [0.7836947441101074, -0.9190712571144104]
Analysis B-LOC [2.166348934173584, -1.886379361152649]
of B-LOC [2.4305620193481445, -2.0872442722320557]
the B-LOC [1.991032600402832, -1.809322714805603]
smoking B-LOC [1.8558440208435059, -2.0178205966949463]
markers B-LOC [2.124746084213257, -2.1562154293060303]
indicated B-LOC [1.9222661256790161, -1.7672699689865112]
that B-LOC [2.061314105987549, -1.9272912740707397]
a B-LOC [2.2591552734375, -1.9712821245193481]
quarter B-LOC [2.217181444168091, -2.1797640323638916]
of B-LOC [2.188387632369995, -2.033916711807251]
patients B-LOC [2.146724224090576, -2.1957645416259766]
(40) B-LOC [2.2898120880126953, -1.6698417663574219]
were B-LOC [2.062112331390381, -1.8479095697402954]
untruthful B-LOC [2.1211001873016357, -1.9800878763198853]
in B-LOC [1.3884224891662598, -1.7231258153915405]
their B-LOC [2.2046284675598145, -1.974393606185913]
claims B-LOC [1.853137493133545, -1.8903639316558838]
to B-LOC [2.523540735244751, -1.8543269634246826]
have B-LOC [2.3294589519500732, -1.8926024436950684]
stopped B-LOC [2.0908563137054443, -1.9342055320739746]
smoking. B-LOC [1.9283232688903809, -1.8010354042053223]
Based B-LOC [0.6092448830604553, -0.42960700392723083]
on B-LOC [0.651111364364624, -0.3284199833869934]
smoking B-LOC [0.5457186102867126, -0.7683760523796082]
markers, B-LOC [0.6147290468215942, -0.7846417427062988]
patency B-LOC [0.643365740776062, -0.7074687480926514]
of B-LOC [0.4759600758552551, -0.7443130016326904]
grafts B-LOC [0.36400532722473145, -0.651519238948822]
in B-LOC [0.436129093170166, -0.7758148312568665]
smokers B-LOC [0.7515843510627747, -0.8089300990104675]
was B-LOC [0.55959153175354, -0.7730153203010559]
significantly B-LOC [0.5629505515098572, -0.7542786598205566]
lower B-LOC [0.5932166576385498, -0.74211186170578]
at B-LOC [0.3732909858226776, -0.8074796795845032]
one B-LOC [0.6791667938232422, -0.5510995388031006]
year B-LOC [0.6916684508323669, -0.80283522605896]
by B-LOC [0.20834577083587646, -0.5463749766349792]
life B-LOC [0.4843573272228241, -0.7098453640937805]
table B-LOC [0.19726520776748657, -0.580566942691803]

analysis B-LOC [-0.11352499574422836, -0.1889200210571289]
than B-LOC [-0.012694333679974079, -0.014657881110906601]
in B-LOC [-0.005967145320028067, -0.1021592915058136]
non-smokers B-LOC [0.09660141170024872, -0.12809330224990845]
(63% B-LOC [-0.0649142935872078, -0.13021697103977203]
v O [-0.40665292739868164, -0.15904298424720764]
84%, O [-0.18208777904510498, 0.1892150640487671]
p B-LOC [-0.1342347264289856, -0.16150349378585815]
less B-LOC [0.011516458354890347, -0.037772152572870255]
than B-LOC [-0.059395138174295425, -0.22107739746570587]
0.02). B-LOC [0.08749423921108246, -0.25931254029273987]
Patency B-LOC [0.5287578701972961, -0.7321473956108093]
was B-LOC [0.3834812641143799, -0.6781954169273376]
significantly B-LOC [0.41002336144447327, -0.46908047795295715]
higher B-LOC [0.5654895901679993, -0.5207025408744812]
by B-LOC [0.36539483070373535, -0.4214616119861603]
life B-LOC [0.4372458755970001, -0.38336876034736633]
table B-LOC [0.3179560899734497, -0.6543605923652649]
analysis B-LOC [0.49450090527534485, -0.3801412880420685]
in B-LOC [0.292379230260849, -0.32038724422454834]
patients B-LOC [0.10413916409015656, -0.23494499921798706]
with B-LOC [0.19709715247154236, -0.39773795008659363]
a B-LOC [0.32311174273490906, -0.34863999485969543]
plasma B-LOC [0.08586347103118896, -0.30083179473876953]
fibrinogen B-LOC [0.3092181980609894, -0.21752728521823883]
concentration B-LOC [0.36399564146995544, -0.258279025554657]
below B-LOC [0.34670358896255493, -0.07891473174095154]
the B-LOC [0.32784926891326904, -0.2497090995311737]
median B-LOC [0.15312489867210388, -0.3347986936569214]
than B-LOC [0.16980840265750885, -0.07599817216396332]
in B-LOC [0.2518053650856018, -0.21344013512134552]
those B-LOC [0.18886500597000122, -0.20819778740406036]
with B-LOC [0.09295317530632019, -0.3521576225757599]
a B-LOC [0.29211172461509705, -0.27277010679244995]
concentration B-LOC [0.24622347950935364, -0.32590869069099426]
above B-LOC [0.18964692950248718, -0.24584846198558807]
(90% B-LOC [0.19899247586727142, -0.18603569269180298]
v B-LOC [-0.2901264727115631, -0.32252344489097595]
57%, B-LOC [0.18203014135360718, 0.0053674629889428616]
p B-LOC [-0.0009429505444131792, -0.3617629110813141]
less B-LOC [0.14088957011699677, -0.1184430867433548]
than B-LOC [0.09491642564535141, -0.2017280012369156]
0.0002). B-LOC [0.3164125382900238, -0.18196427822113037]
Surprisingly, O [-0.6049042344093323, 0.6441667675971985]
increased O [-1.0509613752365112, 1.0123659372329712]
plasma O [-0.9646688103675842, 0.9847492575645447]
low O [-0.7996674180030823, 1.0829036235809326]
density O [-0.9001044034957886, 1.039682388305664]
lipoprotein O [-0.7996641993522644, 0.8861322999000549]
cholesterol O [-0.8817647695541382, 1.106335163116455]
concentration O [-0.7004924416542053, 1.1062870025634766]
was O [-1.0553678274154663, 0.8954697847366333]
significantly O [-0.9709344506263733, 0.9368688464164734]
associated O [-1.12881600856781, 1.0737481117248535]
with O [-1.1260795593261719, 0.9836713075637817]
improved O [-1.0566368103027344, 0.9444811940193176]
patency O [-0.578550398349762, 0.952575147151947]
at O [-0.8078195452690125, 0.7980610728263855]
one O [-0.8118208646774292, 0.9584226012229919]
year O [-0.7714047431945801, 1.1255552768707275]
(85%) O [-0.771915853023529, 0.7395218014717102]
at O [-0.7974819540977478, 0.742438018321991]
values O [-0.7950291037559509, 0.7757946848869324]
above O [-0.5731005072593689, 0.8586739897727966]
the O [-0.8151668906211853, 0.7877876162528992]
median O [-1.0583417415618896, 0.8765645623207092]
compared O [-0.9307625889778137, 0.9595300555229187]
with O [-0.8044077754020691, 0.8650304079055786]
patency O [-0.5988994240760803, 0.7610588073730469]
(only O [-0.7454959750175476, 0.6530655026435852]
68%) O [-0.5145222544670105, 0.9062706828117371]
at O [-0.7110154032707214, 0.616308867931366]
values O [-0.7285202145576477, 0.6121543049812317]
in O [-0.6965894103050232, 0.48590072989463806]
the O [-0.7787457704544067, 0.7216691970825195]
lower O [-0.5802940726280212, 0.595179557800293]
half O [-0.34150680899620056, 0.6267762780189514]
of O [-0.6561642289161682, 0.5508052110671997]
the O [-0.8019840121269226, 0.7072662711143494]
range O [-0.7848017811775208, 0.6617938876152039]
(p O [-0.7502028346061707, 0.6004456877708435]
less O [-0.3952484428882599, 0.616213321685791]
than O [-0.6910057663917542, 0.5220848321914673]

0.02). B-LOC [0.054696667939424515, -0.6380801200866699]
CONCLUSIONS O [-0.6344887018203735, 0.21420013904571533]
Plasma B-LOC [0.11970655620098114, -0.29061001539230347]
fibrinogen B-LOC [0.2179991602897644, -0.06542569398880005]
concentration B-LOC [0.4136784076690674, -0.30226433277130127]
was B-LOC [0.17898470163345337, -0.48123350739479065]
the B-LOC [0.48646482825279236, -0.4955006539821625]
most B-LOC [0.5662320256233215, -0.5480698347091675]
important B-LOC [0.38525933027267456, -0.4899607002735138]
variable B-LOC [0.41732844710350037, -0.7104330062866211]
predicting B-LOC [0.46730998158454895, -0.5928453207015991]
graft B-LOC [0.29891738295555115, -0.10147154331207275]
occlusion, B-LOC [0.5356064438819885, -0.33687862753868103]
followed B-LOC [0.5989713072776794, -0.5953260064125061]
by B-LOC [0.49914219975471497, -0.7235721349716187]
smoking B-LOC [0.24197283387184143, -0.3672436773777008]
markers. B-LOC [0.29548877477645874, -0.6581077575683594]
A B-LOC [1.3082085847854614, -1.224090337753296]
more B-LOC [1.234440565109253, -1.4711048603057861]
forceful B-LOC [1.1115832328796387, -1.2367463111877441]
approach B-LOC [1.2794508934020996, -1.3441162109375]
is B-LOC [1.6014008522033691, -1.3640406131744385]
needed B-LOC [1.708809733390808, -1.5482094287872314]
to B-LOC [1.498077392578125, -1.235593557357788]
stop B-LOC [1.2630338668823242, -1.3030284643173218]
patients B-LOC [0.9796412587165833, -1.1399993896484375]
smoking; B-LOC [0.9083965420722961, -0.8768178820610046]
therapeutic B-LOC [0.7695172429084778, -0.6681973338127136]
measures B-LOC [0.9326927065849304, -0.6722866892814636]
to B-LOC [1.1261341571807861, -0.7825925350189209]
improve B-LOC [0.4329036772251129, -0.55339515209198]
patency B-LOC [0.7752755284309387, -0.3188744783401489]
of B-LOC [0.6266694664955139, -0.4017488360404968]
vein B-LOC [0.2845938503742218, -0.5888580679893494]
grafts B-LOC [0.6094430685043335, -0.3994632661342621]
should B-LOC [1.065901756286621, -0.6979885697364807]
focus B-LOC [0.6846608519554138, -0.58230060338974]
on B-LOC [0.49037083983421326, -0.2798853814601898]
decreasing B-LOC [0.37261635065078735, -0.29624196887016296]
plasma B-LOC [0.010733860544860363, -0.40376588702201843]
fibrinogen B-LOC [0.25298771262168884, -0.19891181588172913]
concentration B-LOC [0.28483089804649353, 0.09539578855037689]
rather B-LOC [0.4114108979701996, 0.11733081936836243]
than B-LOC [0.4240489602088928, 0.07405763864517212]
serum B-LOC [0.007478027138859034, -0.5512973666191101]
cholesterol B-LOC [-0.06860469281673431, -0.17103496193885803]
concentration. B-LOC [0.2360028326511383, 0.0285626407712698]

CONTEXT B-LOC [1.41725492477417, -2.0583603382110596]
Population B-LOC [2.028794050216675, -2.3779382705688477]
surveys B-LOC [2.0860440731048584, -2.160569906234741]
indicate B-LOC [2.349358320236206, -2.284259796142578]
that B-LOC [2.047808885574341, -2.5971639156341553]
physical B-LOC [2.2384188175201416, -2.6434485912323]
activity B-LOC [2.1340339183807373, -2.6725287437438965]
levels B-LOC [2.3074827194213867, -2.693476915359497]
are B-LOC [2.424433946609497, -2.4439218044281006]
low B-LOC [2.442171812057495, -2.633650302886963]
in B-LOC [2.45369815826416, -2.542691946029663]
the B-LOC [2.7719309329986572, -2.679722547531128]
United B-LOC [2.509511709213257, -2.768702983856201]
States. B-LOC [2.5138909816741943, -2.7234227657318115]
One B-LOC [1.0875766277313232, -0.8897263407707214]
consequence B-LOC [0.7260155081748962, -0.7472776174545288]
of B-LOC [0.38117536902427673, -0.45617055892944336]
inactivity, B-LOC [0.5155260562896729, -0.6705169081687927]
low B-LOC [0.19285762310028076, -0.31619688868522644]
cardiorespiratory B-LOC [0.3558262884616852, -0.8929424285888672]
fitness, B-LOC [0.5716882348060608, -0.7072672247886658]
is B-LOC [1.2666689157485962, -1.1206423044204712]
an B-LOC [1.1263198852539062, -1.162109375]
established B-LOC [1.4416210651397705, -1.4087345600128174]
risk B-LOC [1.580286979675293, -1.6606289148330688]
factor B-LOC [1.2688685655593872, -1.4041671752929688]
for B-LOC [1.149065375328064, -1.394716501235962]
cardiovascular B-LOC [1.6986372470855713, -1.916609764099121]
disease B-LOC [1.8979517221450806, -1.8558681011199951]
(CVD) B-LOC [1.7644171714782715, -1.6524354219436646]
morbidity B-LOC [1.642821192741394, -1.5025442838668823]
and B-LOC [1.7168159484863281, -1.676889419555664]
mortality, B-LOC [1.750715970993042, -1.6489793062210083]
but B-LOC [2.005960464477539, -2.0530288219451904]
the B-LOC [2.6203720569610596, -2.7307026386260986]
prevalence B-LOC [2.5868895053863525, -2.8159053325653076]
of B-LOC [2.5416030883789062, -2.933309555053711]
cardiorespiratory B-LOC [2.350491762161255, -2.766990900039673]
fitness B-LOC [2.3138515949249268, -2.9459216594696045]
has B-LOC [3.078903913497925, -3.0601840019226074]
not B-LOC [3.0985538959503174, -3.0346696376800537]
been B-LOC [2.9268248081207275, -3.254324197769165]
quantified B-LOC [2.9953677654266357, -3.280822515487671]
in B-LOC [2.971261739730835, -3.234992265701294]
representative B-LOC [2.8567075729370117, -3.214134454727173]
US B-LOC [2.620684862136841, -2.9912025928497314]
population B-LOC [2.9180009365081787, -3.2593283653259277]
samples. B-LOC [2.8338208198547363, -3.223935842514038]
OBJECTIVES B-LOC [2.9423089027404785, -3.2454452514648438]
To B-LOC [2.7674968242645264, -3.0016891956329346]
describe B-LOC [2.961785316467285, -3.077322244644165]
the B-LOC [3.1312663555145264, -3.2007739543914795]
prevalence B-LOC [2.8928792476654053, -3.0608246326446533]
of B-LOC [2.7810919284820557, -2.927934408187866]
low B-LOC [2.8326003551483154, -3.051748037338257]
fitness B-LOC [2.783151388168335, -2.849630832672119]
in B-LOC [2.889244318008423, -2.839076280593872]
the B-LOC [3.068983316421509, -2.891221284866333]
US B-LOC [2.9340736865997314, -3.1044280529022217]
population B-LOC [2.9731359481811523, -2.981226682662964]
aged B-LOC [3.1797373294830322, -3.0349175930023193]
12 B-LOC [3.1583471298217773, -2.835533380508423]
through B-LOC [2.7776143550872803, -2.7235829830169678]
49 B-LOC [2.9672229290008545, -2.8762896060943604]
years B-LOC [3.3604962825775146, -3.2280328273773193]
and B-LOC [3.1036033630371094, -3.1126105785369873]
to B-LOC [3.289885997772217, -3.07391095161438]
relate B-LOC [3.00736403465271, -3.432163715362549]
low B-LOC [2.910407304763794, -3.184993028640747]
fitness B-LOC [2.8638858795166016, -3.0135390758514404]
to B-LOC [2.704972267150879, -3.1313042640686035]
CVD B-LOC [2.9939000606536865, -2.9086201190948486]
risk B-LOC [3.14754056930542, -3.438018560409546]
factors B-LOC [3.0819947719573975, -3.3063645362854004]
in B-LOC [2.9953291416168213, -2.9954850673675537]
this B-LOC [3.1712329387664795, -2.9404685497283936]
population. B-LOC [2.9634644985198975, -3.090148448944092]
DESIGN, B-LOC [3.191737174987793, -3.208611011505127]

SETTING, B-LOC [2.8799378871917725, -3.5942254066467285]
AND B-LOC [3.3227880001068115, -3.770432710647583]
PARTICIPANTS B-LOC [3.1647603511810303, -3.305274724960327]
Inception B-LOC [3.219370126724243, -3.4993555545806885]
cohort B-LOC [3.5059735774993896, -3.5229897499084473]
study B-LOC [3.146376848220825, -3.5280239582061768]
using B-LOC [3.1276113986968994, -3.7612550258636475]
data B-LOC [3.667343854904175, -3.6036322116851807]
from B-LOC [3.549098491668701, -3.5144731998443604]
the B-LOC [3.528634786605835, -3.3203847408294678]
cross-sectional B-LOC [3.7844293117523193, -3.5124399662017822]
nationally B-LOC [3.699317216873169, -3.6241753101348877]
representative B-LOC [3.437551259994507, -3.6915078163146973]
National B-LOC [3.5664443969726562, -3.6884562969207764]
Health B-LOC [3.4360413551330566, -3.565058708190918]
and B-LOC [3.342113971710205, -3.2542569637298584]
Nutrition B-LOC [3.4461889266967773, -3.5300862789154053]
Examination B-LOC [3.576042890548706, -3.795807361602783]
Survey B-LOC [3.5445315837860107, -3.5036284923553467]
1999-2002. B-LOC [3.5345065593719482, -3.4389660358428955]
Participants B-LOC [2.743612051010132, -2.9397778511047363]
were B-LOC [2.544818162918091, -2.7004780769348145]
adolescents B-LOC [2.9286110401153564, -2.541722297668457]
(aged B-LOC [2.727506399154663, -2.581453800201416]
12-19 B-LOC [3.109635829925537, -2.748741865158081]
years; B-LOC [3.2721612453460693, -2.935939073562622]
n B-LOC [2.909482955932617, -3.08567214012146]
= B-LOC [2.1725568771362305, -2.694905996322632]
3110) B-LOC [2.9715723991394043, -2.990139961242676]
and B-LOC [2.60981822013855, -2.9360475540161133]
adults B-LOC [2.756312608718872, -2.62825608253479]
(aged B-LOC [2.840986490249634, -2.4748694896698]
20-49 B-LOC [3.02970027923584, -2.6579020023345947]
years; B-LOC [3.2052083015441895, -2.746007204055786]
n B-LOC [2.88948130607605, -2.7630374431610107]
= B-LOC [2.175852060317993, -2.5568764209747314]
2205) B-LOC [2.766745090484619, -2.6540274620056152]
free B-LOC [2.3677377700805664, -2.3884518146514893]
from B-LOC [1.865526795387268, -1.9563946723937988]
previously B-LOC [2.3412482738494873, -2.2236692905426025]
diagnosed B-LOC [2.4474761486053467, -2.374706268310547]
CVD B-LOC [2.277331590652466, -2.088468313217163]
who B-LOC [2.624145746231079, -2.660871744155884]
underwent B-LOC [2.635188579559326, -2.650278329849243]
submaximal B-LOC [2.22731614112854, -2.041994333267212]
graded B-LOC [2.3657138347625732, -2.2683050632476807]
exercise B-LOC [2.3573858737945557, -2.3303372859954834]
treadmill B-LOC [2.6505632400512695, -2.3179092407226562]
testing B-LOC [2.269818067550659, -2.3640782833099365]
to B-LOC [2.079213857650757, -2.1843535900115967]
achieve B-LOC [1.7646253108978271, -2.072404623031616]
at B-LOC [2.1562488079071045, -2.293616533279419]
least B-LOC [2.127338171005249, -2.3171703815460205]
75% B-LOC [1.374876618385315, -1.613229513168335]
to B-LOC [1.6438363790512085, -1.9115424156188965]
90% B-LOC [1.3912289142608643, -1.865329623222351]
of B-LOC [1.4391744136810303, -1.897491216659546]
their B-LOC [2.5159876346588135, -2.4236464500427246]
age-predicted B-LOC [2.1710407733917236, -1.9607192277908325]
maximum B-LOC [2.1902549266815186, -2.5484204292297363]
heart B-LOC [2.06953763961792, -2.3937623500823975]
rate. B-LOC [2.0260069370269775, -2.467398166656494]
Maximal B-LOC [1.4312543869018555, -1.8093289136886597]
oxygen B-LOC [1.2886158227920532, -1.7727715969085693]
consumption B-LOC [1.4998691082000732, -1.6276370286941528]
(VO2max) B-LOC [1.7195111513137817, -1.814616322517395]
was B-LOC [1.8021554946899414, -1.8281912803649902]
estimated B-LOC [1.9653644561767578, -2.026869535446167]
by B-LOC [1.6557040214538574, -1.7533090114593506]
measuring B-LOC [1.757307529449463, -1.7182064056396484]

the B-LOC [3.313044786453247, -3.287888765335083]
heart B-LOC [3.477151870727539, -3.9202425479888916]
rate B-LOC [3.329968214035034, -3.8735005855560303]
response B-LOC [3.4422390460968018, -3.5886521339416504]
to B-LOC [3.350545883178711, -3.400625705718994]
reference B-LOC [3.4487435817718506, -3.5713298320770264]
levels B-LOC [3.550220012664795, -3.5150749683380127]
of B-LOC [3.346027135848999, -3.320423126220703]
submaximal B-LOC [3.5255727767944336, -3.4405436515808105]
work. B-LOC [3.215039014816284, -3.6291868686676025]
MAIN B-LOC [3.16980242729187, -3.2841548919677734]
OUTCOME B-LOC [3.255992889404297, -3.3143370151519775]
MEASURES B-LOC [3.4638006687164307, -3.446227788925171]
Low B-LOC [3.343865156173706, -3.5129387378692627]
fitness B-LOC [3.363309144973755, -3.532071113586426]
defined B-LOC [3.5072641372680664, -3.4804039001464844]
using B-LOC [3.2487456798553467, -3.4968104362487793]
percentile B-LOC [3.4432170391082764, -3.563814401626587]
cut B-LOC [3.320251703262329, -3.5159900188446045]
points B-LOC [3.3600728511810303, -3.5477077960968018]
of B-LOC [3.2926993370056152, -3.3377883434295654]
estimated B-LOC [3.4860472679138184, -3.5400424003601074]
VO2max B-LOC [3.3402833938598633, -3.49682354927063]
from B-LOC [3.2034311294555664, -3.4260427951812744]
existing B-LOC [3.496446132659912, -3.5617194175720215]
external B-LOC [3.5328166484832764, -3.7355687618255615]
referent B-LOC [3.4148805141448975, -3.6264991760253906]
populations; B-LOC [3.5534889698028564, -3.6403627395629883]
anthropometric B-LOC [3.695443630218506, -3.533924102783203]
and B-LOC [3.210374593734741, -3.4673240184783936]
other B-LOC [3.657788038253784, -3.4434454441070557]
CVD B-LOC [3.53737473487854, -3.4339535236358643]
risk B-LOC [3.62211537361145, -3.767728328704834]
factors B-LOC [3.5434112548828125, -3.7228009700775146]
measured B-LOC [3.5992941856384277, -3.579223871231079]
according B-LOC [3.5391299724578857, -3.460920572280884]
to B-LOC [3.5287110805511475, -3.437643527984619]
standard B-LOC [3.506620168685913, -3.6198794841766357]
methods. B-LOC [3.655024290084839, -3.708099126815796]
RESULTS B-LOC [-0.032161373645067215, -0.4054275155067444]
Low B-LOC [0.4411216378211975, -0.4351802170276642]
fitness B-LOC [0.17922601103782654, -0.3616017997264862]
was B-LOC [0.19757041335105896, -0.5110716223716736]
identified B-LOC [0.35058119893074036, -0.44136759638786316]
in B-LOC [0.2601233720779419, -0.4024745225906372]
33.6% B-LOC [0.5228223204612732, -0.1135188490152359]
of B-LOC [0.23870344460010529, -0.2719084322452545]
adolescents B-LOC [0.25358471274375916, -0.39449039101600647]
(approximately B-LOC [0.33777403831481934, -0.3979257643222809]
7.5 B-LOC [0.6062044501304626, 0.06414303183555603]
million B-LOC [0.45475777983665466, -0.746889054775238]
US B-LOC [0.2813345491886139, -0.6100834012031555]
adolescents) B-LOC [0.30003437399864197, -0.42656949162483215]
and B-LOC [0.2216983288526535, -0.2563418745994568]
13.9% B-LOC [0.47538402676582336, -0.03169401362538338]
of B-LOC [0.2535983622074127, -0.3553972542285919]
adults B-LOC [0.2981013357639313, -0.46708348393440247]
(approximately B-LOC [0.3770875632762909, -0.5172995924949646]
8.5 B-LOC [0.4118455946445465, 0.13258884847164154]
million B-LOC [0.38900479674339294, -0.7748039364814758]
US B-LOC [0.27110257744789124, -0.6002474427223206]
adults); B-LOC [0.3289591372013092, -0.51436847448349]
the B-LOC [0.10770512372255325, -0.44172272086143494]
prevalence B-LOC [0.14819109439849854, -0.5707573294639587]
was B-LOC [0.18506035208702087, -0.5519344806671143]
similar B-LOC [0.14596763253211975, -0.4482983946800232]
in B-LOC [0.04249018058180809, -0.4017614722251892]
adolescent B-LOC [0.10208041220903397, -0.312326043844223]
females B-LOC [0.10811525583267212, -0.2801075875759125]
(34.4%) B-LOC [0.04478119686245918, -0.47845208644866943]
and B-LOC [0.023607222363352776, -0.3390888273715973]
males B-LOC [-0.03451337292790413, -0.427079439163208]

(32.9%) B-LOC [-0.08557285368442535, -0.4337550103664398]
(P B-LOC [-0.09575633704662323, -0.150551900267601]
= O [-0.27926966547966003, 0.009080817922949791]
.40) O [-0.28754761815071106, -0.10488474369049072]
but O [-0.3520931899547577, -0.01300525851547718]
was O [-0.33553412556648254, -0.11370722204446793]
higher O [-0.15410488843917847, 0.06735552847385406]
in O [-0.30254077911376953, -0.14418905973434448]
adult B-LOC [-0.15059566497802734, -0.1671501249074936]
females B-LOC [0.07547935843467712, -0.17896953225135803]
(16.2%) B-LOC [-0.042046744376420975, -0.31658151745796204]
than O [-0.2806924879550934, -0.009982997551560402]
in B-LOC [-0.1390167772769928, -0.20157670974731445]
males B-LOC [0.0952901542186737, -0.25847604870796204]
(11.8%) B-LOC [0.05211935564875603, -0.4367431104183197]
(P B-LOC [0.0900636538863182, -0.35492345690727234]
= B-LOC [-0.08440444618463516, -0.13442638516426086]
.03). B-LOC [-0.004470547195523977, -0.279967725276947]
Non-Hispanic B-LOC [0.38869792222976685, -0.6686607599258423]
blacks B-LOC [0.49691489338874817, -0.7389726638793945]
and B-LOC [0.28603148460388184, -0.5724602937698364]
Mexican B-LOC [0.4626227915287018, -0.8355875611305237]
Americans B-LOC [0.3148127794265747, -0.7678776383399963]
were B-LOC [0.4148561954498291, -0.7335932850837708]
less B-LOC [0.4944211542606354, -0.56362384557724]
fit B-LOC [0.3252180516719818, -0.6725689172744751]
than B-LOC [0.2874195873737335, -0.7430545687675476]
non-Hispanic B-LOC [0.429222971200943, -0.7349455952644348]
whites. B-LOC [0.634013831615448, -0.9283556342124939]
In B-LOC [0.4310630261898041, -0.7658631205558777]
all B-LOC [0.7057222127914429, -0.8371551036834717]
age-sex B-LOC [0.8025352358818054, -0.8062217831611633]
groups, B-LOC [0.8028348684310913, -0.7937373518943787]
body B-LOC [0.39394062757492065, -0.49328240752220154]
mass B-LOC [0.38880911469459534, -0.44418829679489136]
index B-LOC [0.4730719029903412, -0.7658198475837708]
and B-LOC [0.8240473866462708, -1.0443557500839233]
waist B-LOC [0.5458826422691345, -0.7757493853569031]
circumference B-LOC [0.765507161617279, -0.8400209546089172]
were B-LOC [0.8036445379257202, -1.0112450122833252]
inversely B-LOC [0.9981499910354614, -1.2213184833526611]
associated B-LOC [0.8111904263496399, -1.003693699836731]
with B-LOC [0.6599813103675842, -1.2024328708648682]
fitness; B-LOC [0.3345182538032532, -0.635493814945221]
age- B-LOC [0.6849420070648193, -0.7024529576301575]
and B-LOC [0.6481732130050659, -1.0606207847595215]
race-adjusted B-LOC [0.5703243017196655, -0.9774572253227234]
odds B-LOC [0.40560397505760193, -0.706123411655426]
ratios B-LOC [0.5984050035476685, -0.7412601113319397]
of B-LOC [0.46986913681030273, -0.7444657683372498]
overweight B-LOC [0.4492330253124237, -0.48226189613342285]
or B-LOC [0.5466359257698059, -1.0054895877838135]
obesity B-LOC [0.33304086327552795, -0.668093204498291]
(body B-LOC [0.6337838172912598, -0.890117347240448]
mass B-LOC [0.2646926939487457, -0.3371324837207794]
index B-LOC [0.36643633246421814, -0.5690003037452698]
> B-LOC [0.35572606325149536, -0.7243126630783081]
or B-LOC [0.6555471420288086, -0.9729065895080566]
=25) B-LOC [0.409925639629364, -1.0692534446716309]
ranged B-LOC [0.6328386664390564, -0.903825581073761]
from B-LOC [0.7653577327728271, -0.8864269852638245]
2.1 B-LOC [0.40666094422340393, -0.4327678084373474]
to B-LOC [0.5149526000022888, -0.8951688408851624]
3.7 B-LOC [0.4751471281051636, -0.4316885471343994]
(P<.01 B-LOC [0.37340548634529114, -0.6765119433403015]
for B-LOC [0.1792343556880951, -0.7583714723587036]

all), B-LOC [0.16502757370471954, -0.4258423149585724]
comparing B-LOC [0.22869873046875, -0.25169500708580017]
persons B-LOC [0.26840290427207947, -0.4552297294139862]
with B-LOC [0.34838998317718506, -0.5494874119758606]
low B-LOC [0.5134183764457703, -0.4906207025051117]
fitness B-LOC [0.323320209980011, -0.45197606086730957]
with B-LOC [0.6302152276039124, -0.5370502471923828]
those B-LOC [0.41361376643180847, -0.428726464509964]
with B-LOC [0.3430202901363373, -0.6239438056945801]
moderate B-LOC [0.2902100384235382, -0.4781908094882965]
or B-LOC [0.34800785779953003, -0.7776697278022766]
high B-LOC [0.49374303221702576, -0.6973270773887634]
fitness. B-LOC [0.37415871024131775, -0.537331223487854]
Total O [-0.37223488092422485, 0.23266875743865967]
cholesterol O [-0.45533037185668945, 0.27643492817878723]
levels O [-0.25996577739715576, 0.31998321413993835]
and O [-0.37054744362831116, 0.08608733117580414]
systolic O [-0.24760687351226807, 0.2491266131401062]
blood O [-0.5272811055183411, 0.45918595790863037]
pressure O [-0.2758079767227173, 0.3861522972583771]
were O [-0.15941309928894043, -0.053140584379434586]
higher O [-0.13064289093017578, 0.2937774360179901]
and O [-0.2593545615673065, 0.16862653195858002]
levels O [-0.16223368048667908, 0.09663060307502747]
of O [-0.2915249466896057, 0.10052025318145752]
high-density O [-0.24895133078098297, 0.1749924123287201]
lipoprotein O [-0.31207704544067383, 0.2624184787273407]
cholesterol O [-0.26584872603416443, 0.1619553565979004]
were O [-0.11028683930635452, -0.0921911969780922]
lower O [-0.07625582814216614, 0.22329887747764587]
among O [-0.18315881490707397, 0.10058175027370453]
participants O [-0.3213457465171814, 0.03376148268580437]
with O [-0.1827029138803482, -0.005764153320342302]
low O [-0.08774082362651825, 0.1988869458436966]
vs O [-0.35476458072662354, -0.014141978695988655]
high O [-0.11549839377403259, -0.013853700831532478]
fitness. O [-0.24120771884918213, 0.09504326432943344]
CONCLUSION O [-0.6528420448303223, 0.3852532207965851]
Low B-LOC [-0.03523724153637886, -0.10688599199056625]
fitness B-LOC [-0.08578025549650192, -0.1720142364501953]
in O [-0.24354931712150574, -0.12263455241918564]
adolescents B-LOC [0.12974536418914795, -0.0957350954413414]
and O [-0.09306961297988892, -0.06335114687681198]
adults B-LOC [0.10488469898700714, -0.20504793524742126]
is B-LOC [-0.048174332827329636, -0.3119138777256012]
common B-LOC [0.06268282234668732, -0.16232538223266602]
in B-LOC [0.006511243525892496, -0.3081696927547455]
the B-LOC [-0.01090462226420641, -0.02941502444446087]
US B-LOC [-0.01222845260053873, -0.382474809885025]
population B-LOC [-0.019455036148428917, -0.274352103471756]
and O [-0.32034870982170105, 0.047306668013334274]
is B-LOC [-0.08085795491933823, -0.20171689987182617]
associated O [-0.20454734563827515, 0.19480833411216736]
with O [-0.30425435304641724, -0.0402824841439724]
an O [-0.34564009308815, 0.011496556922793388]
increased O [-0.2679883539676666, -0.04847245290875435]
prevalence B-LOC [0.03976139426231384, -0.07192649692296982]
of O [-0.28509053587913513, -0.09869902580976486]
CVD O [-0.32970666885375977, 0.02959202043712139]
risk B-LOC [-0.13119351863861084, -0.1360265016555786]
factors. O [-0.23588153719902039, -0.08827447146177292]

CONTEXT B-LOC [1.1405266523361206, -2.109584331512451]
Although B-LOC [1.8618603944778442, -2.23779559135437]
acute B-LOC [1.5896110534667969, -2.127533197402954]
hypoglycemia B-LOC [1.457705020904541, -1.8257695436477661]
may B-LOC [2.0816612243652344, -2.312683343887329]
be B-LOC [1.8758472204208374, -2.3602147102355957]
associated B-LOC [1.5863754749298096, -2.1554675102233887]
with B-LOC [1.5071053504943848, -2.1107780933380127]
cognitive B-LOC [1.9605965614318848, -2.4291558265686035]
impairment B-LOC [1.9034814834594727, -2.3530213832855225]
in B-LOC [1.4421336650848389, -2.070260763168335]
children B-LOC [2.1041266918182373, -2.4312076568603516]
with B-LOC [2.3095858097076416, -2.8648741245269775]
type B-LOC [2.191699266433716, -2.7573254108428955]
1 B-LOC [2.1252682209014893, -2.793184518814087]
diabetes, B-LOC [2.1107375621795654, -2.529646396636963]
no B-LOC [3.1128971576690674, -3.15000581741333]
studies B-LOC [3.235966444015503, -3.373370409011841]
to B-LOC [3.4116458892822266, -3.1317641735076904]
date B-LOC [3.390183448791504, -3.3198273181915283]
have B-LOC [3.254972457885742, -3.3388068675994873]
evaluated B-LOC [3.3427743911743164, -3.4830968379974365]
whether B-LOC [3.090017080307007, -3.5748116970062256]
hypoglycemia B-LOC [2.671184778213501, -3.050058603286743]
is B-LOC [3.24965500831604, -3.481847047805786]
a B-LOC [3.334153413772583, -3.602935314178467]
risk B-LOC [3.36492657661438, -3.5688085556030273]
factor B-LOC [3.2972137928009033, -3.741147518157959]
for B-LOC [3.1136972904205322, -3.452949285507202]
dementia B-LOC [3.1849114894866943, -3.446972608566284]
in B-LOC [3.1680967807769775, -3.480355978012085]
older B-LOC [3.3273818492889404, -3.370070219039917]
patients B-LOC [3.3409690856933594, -3.344907522201538]
with B-LOC [3.1521685123443604, -3.4223856925964355]
type B-LOC [3.1763181686401367, -3.3369834423065186]
2 B-LOC [2.901019334793091, -3.221355676651001]
diabetes. B-LOC [3.0833370685577393, -3.2998239994049072]
OBJECTIVE B-LOC [2.9793994426727295, -3.072462320327759]
To B-LOC [3.521585702896118, -3.385657548904419]
determine B-LOC [3.569683790206909, -3.428051710128784]
if B-LOC [3.4114906787872314, -3.4543087482452393]
hypoglycemic B-LOC [3.4030959606170654, -3.2516777515411377]
episodes B-LOC [3.3491714000701904, -3.1990420818328857]
severe B-LOC [3.3087966442108154, -3.1910274028778076]
enough B-LOC [2.831110954284668, -3.015305280685425]
to B-LOC [3.2079360485076904, -2.92648983001709]
require B-LOC [3.234480142593384, -3.390260934829712]
hospitalization B-LOC [3.4661080837249756, -3.452812671661377]
are B-LOC [3.3516488075256348, -3.3593995571136475]
associated B-LOC [3.2825372219085693, -3.6046135425567627]
with B-LOC [3.270676851272583, -3.32940411567688]
an B-LOC [3.381547689437866, -3.4613983631134033]
increased B-LOC [3.087068796157837, -3.6184051036834717]
risk B-LOC [3.572376251220703, -3.585967540740967]
of B-LOC [3.1920857429504395, -3.1660921573638916]
dementia B-LOC [3.464578866958618, -3.0610711574554443]
in B-LOC [3.412550687789917, -3.2680320739746094]
a B-LOC [3.3518426418304443, -3.291332960128784]
population B-LOC [3.3484296798706055, -3.4110021591186523]
of B-LOC [3.295933485031128, -3.2545173168182373]
older B-LOC [3.6267879009246826, -3.378174304962158]
patients B-LOC [3.7138140201568604, -3.2639787197113037]
with B-LOC [3.510775327682495, -3.365184783935547]
type B-LOC [3.5018680095672607, -3.2804625034332275]
2 B-LOC [3.1351499557495117, -3.1291677951812744]
diabetes B-LOC [3.5926642417907715, -3.1790201663970947]
followed B-LOC [3.3599276542663574, -3.40680193901062]
up B-LOC [3.19140362739563, -3.3037374019622803]
for B-LOC [3.2975146770477295, -3.285125732421875]
27 B-LOC [3.4408044815063477, -3.414630651473999]
years. B-LOC [3.45607590675354, -3.2730109691619873]
DESIGN, B-LOC [2.769939661026001, -3.1302661895751953]
SETTING, B-LOC [2.0362226963043213, -2.711879014968872]
AND B-LOC [2.7107250690460205, -3.0853869915008545]
PATIENTS B-LOC [2.46124529838562, -3.193305253982544]
A B-LOC [2.197465181350708, -2.9129045009613037]
longitudinal B-LOC [2.6170976161956787, -3.278939962387085]
cohort B-LOC [2.788344383239746, -2.855151414871216]
study B-LOC [2.3585071563720703, -2.881561279296875]
from B-LOC [2.592745780944824, -3.0422568321228027]

1980-2007 B-LOC [3.1903076171875, -3.130070924758911]
of B-LOC [3.411133050918579, -3.4183101654052734]
16,667 B-LOC [3.6503121852874756, -3.3452515602111816]
patients B-LOC [3.7607884407043457, -3.4253833293914795]
with B-LOC [3.7238609790802, -3.265263319015503]
a B-LOC [3.6254732608795166, -3.260070562362671]
mean B-LOC [3.458979368209839, -3.625614643096924]
age B-LOC [3.7516238689422607, -3.2256572246551514]
of B-LOC [3.4032516479492188, -3.2775321006774902]
65 B-LOC [3.6509785652160645, -3.0542726516723633]
years B-LOC [3.6799564361572266, -3.1330344676971436]
and B-LOC [3.3285813331604004, -3.5303943157196045]
type B-LOC [3.6788151264190674, -3.3368241786956787]
2 B-LOC [3.4108283519744873, -3.2652974128723145]
diabetes B-LOC [3.7459981441497803, -3.5716769695281982]
who B-LOC [3.6040685176849365, -3.283064603805542]
are B-LOC [3.5296480655670166, -3.2456321716308594]
members B-LOC [3.694939374923706, -3.5036776065826416]
of B-LOC [3.5363686084747314, -3.261416435241699]
an B-LOC [3.626049280166626, -3.3834869861602783]
integrated B-LOC [3.6961300373077393, -3.633755922317505]
health B-LOC [3.607328176498413, -3.7165849208831787]
care B-LOC [3.4908409118652344, -3.535458564758301]
delivery B-LOC [3.6341021060943604, -3.62727427482605]
system B-LOC [3.6790153980255127, -3.4995739459991455]
in B-LOC [3.8811357021331787, -3.2147860527038574]
northern B-LOC [3.717750310897827, -3.363314390182495]
California. B-LOC [3.6262803077697754, -3.453575849533081]
MAIN B-LOC [3.5733211040496826, -3.255171298980713]
OUTCOME B-LOC [3.4025282859802246, -3.2066009044647217]
MEASURE B-LOC [3.461463689804077, -3.2466752529144287]
Hypoglycemic B-LOC [3.4648616313934326, -3.3243303298950195]
events B-LOC [3.5653114318847656, -3.411038875579834]
from B-LOC [3.345041513442993, -3.165471076965332]
1980-2002 B-LOC [3.5940442085266113, -3.1789939403533936]
were B-LOC [3.5674092769622803, -3.2581098079681396]
collected B-LOC [3.8749048709869385, -3.486314058303833]
and B-LOC [3.102621078491211, -3.0998919010162354]
reviewed B-LOC [3.823681592941284, -3.3428757190704346]
using B-LOC [3.339397430419922, -3.3863637447357178]
hospital B-LOC [3.641876220703125, -3.6529829502105713]
discharge B-LOC [3.748762845993042, -3.565882921218872]
and B-LOC [3.384788751602173, -3.3228819370269775]
emergency B-LOC [3.6177098751068115, -3.5050954818725586]
department B-LOC [3.414926052093506, -3.470454692840576]
diagnoses. B-LOC [3.8042402267456055, -3.3156206607818604]
Cohort B-LOC [3.059983015060425, -3.259423017501831]
members B-LOC [3.2912609577178955, -3.3233327865600586]
with B-LOC [3.117595911026001, -3.0473973751068115]
no B-LOC [3.18015718460083, -3.226907730102539]
prior B-LOC [3.1993601322174072, -3.564833879470825]
diagnoses B-LOC [3.4457976818084717, -3.3040945529937744]
of B-LOC [3.1132867336273193, -3.0764758586883545]
dementia, B-LOC [3.388983964920044, -3.1471142768859863]
mild B-LOC [3.3931374549865723, -3.3953754901885986]
cognitive B-LOC [3.377340316772461, -3.5798614025115967]
impairment, B-LOC [3.4020321369171143, -3.3155481815338135]
or B-LOC [3.1383211612701416, -3.355337619781494]
general B-LOC [3.4164838790893555, -3.60162091255188]
memory B-LOC [3.4298551082611084, -3.665839910507202]
complaints B-LOC [3.5255558490753174, -3.3256757259368896]
as B-LOC [3.402071714401245, -3.158824920654297]
of B-LOC [3.1845192909240723, -3.1024725437164307]
January B-LOC [3.414827585220337, -3.484344720840454]
1, B-LOC [3.2218997478485107, -3.045043468475342]
2003, B-LOC [3.347271680831909, -3.327087879180908]
were B-LOC [3.13039231300354, -3.1718618869781494]
followed B-LOC [3.4975874423980713, -3.548952341079712]
up B-LOC [3.2046797275543213, -3.1341021060943604]
for B-LOC [3.2895703315734863, -3.17256498336792]
a B-LOC [3.2953083515167236, -3.490461587905884]
dementia B-LOC [3.2846741676330566, -3.1499221324920654]
diagnosis B-LOC [3.4298739433288574, -3.554276466369629]
through B-LOC [3.350423574447632, -3.280529737472534]
January B-LOC [3.3482000827789307, -3.3642404079437256]
15, B-LOC [3.3713314533233643, -3.041780710220337]
2007. B-LOC [3.1286303997039795, -3.2854349613189697]
Dementia B-LOC [1.795026183128357, -2.357789993286133]
risk B-LOC [2.410221815109253, -2.9662928581237793]
was B-LOC [2.7922894954681396, -2.8532848358154297]
examined B-LOC [3.0371463298797607, -3.1243889331817627]
using B-LOC [3.003633499145508, -3.0674936771392822]
Cox B-LOC [2.747925281524658, -2.560560464859009]
proportional B-LOC [2.5941436290740967, -2.779700994491577]
hazard B-LOC [2.095627546310425, -2.6608080863952637]

regression B-LOC [2.351410150527954, -2.9134256839752197]
models, B-LOC [2.5494563579559326, -2.974902391433716]
adjusted B-LOC [2.6664774417877197, -3.1901967525482178]
for B-LOC [2.5395777225494385, -3.037475347518921]
age, B-LOC [3.197049856185913, -3.264352321624756]
sex, B-LOC [2.8423969745635986, -3.1022140979766846]
race/ethnicity, B-LOC [2.7371222972869873, -3.125030517578125]
education, B-LOC [2.4505083560943604, -2.9386065006256104]
body B-LOC [2.299480676651001, -2.830090045928955]
mass B-LOC [2.4233803749084473, -2.802783250808716]
index, B-LOC [2.3884124755859375, -2.916682481765747]
duration B-LOC [2.73152494430542, -3.0676755905151367]
of B-LOC [2.3460609912872314, -2.9785940647125244]
diabetes, B-LOC [2.4938700199127197, -2.9701526165008545]
7-year B-LOC [2.2415084838867188, -2.4633944034576416]
mean B-LOC [2.3656325340270996, -3.2127394676208496]
glycated B-LOC [2.7871456146240234, -3.1298465728759766]
hemoglobin, B-LOC [2.040208578109741, -2.8611648082733154]
diabetes B-LOC [1.9531928300857544, -2.6698715686798096]
treatment, B-LOC [2.5403904914855957, -2.8705055713653564]
duration B-LOC [2.5546727180480957, -2.8544116020202637]
of B-LOC [2.1212432384490967, -2.7005512714385986]
insulin B-LOC [2.170598268508911, -3.0894782543182373]
use, B-LOC [2.1962456703186035, -2.4691436290740967]
hyperlipidemia, B-LOC [2.4367473125457764, -3.0151803493499756]
hypertension, B-LOC [2.2985188961029053, -2.853672742843628]
cardiovascular B-LOC [2.4211137294769287, -2.876413106918335]
disease, B-LOC [2.566654682159424, -3.0903563499450684]
stroke, B-LOC [2.7346277236938477, -3.2517480850219727]
transient B-LOC [2.4927029609680176, -3.152808666229248]
cerebral B-LOC [2.016443967819214, -2.838151216506958]
ischemia, B-LOC [1.808839201927185, -2.3971986770629883]
and B-LOC [2.599841594696045, -3.0033323764801025]
end-stage B-LOC [2.7147133350372314, -3.1133229732513428]
renal B-LOC [2.639251470565796, -3.012481927871704]
disease. B-LOC [2.6892592906951904, -3.126753091812134]
RESULTS B-LOC [-0.0926833301782608, -0.5882120132446289]
At B-LOC [-0.08914247155189514, -0.43198132514953613]
least B-LOC [0.2548084259033203, -0.5510812401771545]
1 B-LOC [0.10739487409591675, -0.30779463052749634]
episode B-LOC [-0.01132881361991167, -0.4215564727783203]
of B-LOC [0.1096034049987793, -0.34285658597946167]
hypoglycemia B-LOC [0.257951021194458, -0.506028413772583]
was B-LOC [0.24317069351673126, -0.5185399651527405]
diagnosed B-LOC [0.1619841605424881, -0.2747507393360138]
in B-LOC [0.405828595161438, -0.5049668550491333]
1465 B-LOC [0.6448398232460022, -0.46707165241241455]
patients B-LOC [0.17524540424346924, -0.4255885183811188]
(8.8%) B-LOC [0.15098366141319275, -0.4621565043926239]
and B-LOC [-0.0022248527966439724, -0.3589901328086853]
dementia B-LOC [0.4750911295413971, -0.6113582849502563]
was B-LOC [0.3390248715877533, -0.6309931874275208]
diagnosed B-LOC [0.258402556180954, -0.34136760234832764]
in B-LOC [0.4519446790218353, -0.6928828358650208]
1822 B-LOC [0.40157750248908997, -0.5621436238288879]
patients B-LOC [0.22466059029102325, -0.6001563668251038]
(11%) B-LOC [0.3768593966960907, -0.6251652240753174]
during B-LOC [0.30230382084846497, -0.6321487426757812]
follow-up; B-LOC [0.40406984090805054, -0.70707768201828]
250 B-LOC [0.8583422899246216, -0.8059591054916382]
patients B-LOC [0.30958864092826843, -0.6476372480392456]
had B-LOC [0.6346635222434998, -0.7152612805366516]
both B-LOC [0.2510446310043335, -0.4814864695072174]

dementia B-LOC [-0.08167821913957596, -0.25339141488075256]
and B-LOC [-0.05377155542373657, -0.1402353048324585]
at B-LOC [0.06530477851629257, -0.3477306067943573]
least B-LOC [0.1420297622680664, -0.3802807629108429]
1 B-LOC [0.3381615877151489, -0.3112388551235199]
episode B-LOC [0.07961405813694, -0.3702758848667145]
of B-LOC [0.05703575536608696, -0.1805483102798462]
hypoglycemia B-LOC [0.15455922484397888, -0.37296491861343384]
(16.95%). B-LOC [0.08891816437244415, -0.4072472155094147]
Compared O [-0.7540584206581116, 0.8589671850204468]
with O [-0.416935533285141, 0.5376226902008057]
patients O [-0.7817474007606506, 0.5666183829307556]
with O [-0.7058451771736145, 0.3315010368824005]
no O [-0.5653010606765747, 0.7179982662200928]
hypoglycemia, O [-0.6268185973167419, 0.3253786861896515]
patients O [-0.8942280411720276, 0.7571732401847839]
with O [-0.6538591980934143, 0.4559338390827179]
single O [-0.39941033720970154, 0.3925856649875641]
or O [-0.4395816922187805, 0.08986994624137878]
multiple O [-0.3714471459388733, 0.21084943413734436]
episodes O [-0.5826374292373657, 0.4320736229419708]
had O [-0.7702027559280396, 0.577943742275238]
a O [-0.7947138547897339, 0.6377450823783875]
graded O [-0.6616353988647461, 0.5018081665039062]
increase O [-0.785782516002655, 0.6282171607017517]
in O [-0.9982125163078308, 0.6563162803649902]
risk O [-0.8079319000244141, 0.8833196759223938]
with O [-0.8492682576179504, 0.6445191502571106]
fully O [-0.6682463884353638, 0.48279765248298645]
adjusted O [-0.7744566202163696, 0.3826655447483063]
hazard O [-0.6391274333000183, 0.5345439314842224]
ratios O [-0.6973839998245239, 0.5780884623527527]
(HRs): O [-0.34956374764442444, 0.353758305311203]
for O [-1.0641767978668213, 0.7246357798576355]
1 O [-0.755476176738739, 0.7929560542106628]
episode O [-0.6998565196990967, 0.8257907629013062]
(HR, O [-0.7399144172668457, 0.4943605959415436]
1.26; O [-0.7058627009391785, 0.8790540099143982]
95% O [-0.9843772053718567, 0.9441431164741516]
confidence O [-0.898780107498169, 0.7604170441627502]
interval O [-1.0092297792434692, 0.7795370221138]
[CI], O [-0.841497004032135, 0.6428883075714111]
1.10-1.49); O [-0.7447322607040405, 0.9012331366539001]
2 O [-0.5822941660881042, 0.7690665125846863]
episodes O [-0.7087715268135071, 0.6623243093490601]
(HR, O [-0.6876623034477234, 0.5035582780838013]
1.80; O [-0.6473150253295898, 0.828663170337677]
95% O [-0.9742061495780945, 0.84506756067276]
CI, O [-0.8414798378944397, 0.5123136639595032]
1.37-2.36); O [-0.7314398884773254, 0.7219005823135376]
and O [-0.6881780624389648, 0.5095734000205994]
3 O [-0.5397525429725647, 0.6640568375587463]
or O [-0.7701123356819153, 0.28383466601371765]
more O [-0.44888558983802795, 0.5534486770629883]
episodes O [-0.6509609818458557, 0.5288039445877075]
(HR, O [-0.6071404814720154, 0.4830559492111206]
1.94; O [-0.5965821743011475, 0.6599662899971008]
95% O [-0.8984915614128113, 0.6897960305213928]

CI, B-LOC [-0.13336718082427979, -0.49941951036453247]
1.42-2.64). B-LOC [0.08773425221443176, -0.2758963406085968]
The B-LOC [0.6376788020133972, -1.0545692443847656]
attributable B-LOC [0.7347195744514465, -1.231888771057129]
risk B-LOC [0.4418794512748718, -1.0149331092834473]
of B-LOC [0.4095979928970337, -0.9486071467399597]
dementia B-LOC [0.734730064868927, -1.3716778755187988]
between B-LOC [0.17346630990505219, -0.7240786552429199]
individuals B-LOC [0.45099911093711853, -0.9501731395721436]
with B-LOC [0.3843649625778198, -0.5858623385429382]
and B-LOC [0.5255511403083801, -0.6168814301490784]
without B-LOC [0.6160546541213989, -0.5830796957015991]
a B-LOC [0.41919735074043274, -0.848438024520874]
history B-LOC [0.20422235131263733, -0.7362962365150452]
of B-LOC [0.24654540419578552, -0.8288814425468445]
hypoglycemia B-LOC [0.5630444884300232, -1.0032057762145996]
was B-LOC [0.3012652099132538, -1.0421710014343262]
2.39% B-LOC [0.15150603652000427, -0.57124924659729]
per B-LOC [0.2751694321632385, -0.9878630042076111]
year B-LOC [0.5145410895347595, -1.2132508754730225]
(95% B-LOC [0.44536134600639343, -0.9605379700660706]
CI, B-LOC [-0.033032480627298355, -0.6512474417686462]
1.72%-3.01%). B-LOC [0.09502461552619934, -0.4468306005001068]
Results B-LOC [2.2623450756073, -2.9466469287872314]
were B-LOC [2.3524625301361084, -2.8072903156280518]
not B-LOC [2.4209482669830322, -2.716594934463501]
attenuated B-LOC [2.373450517654419, -3.147157907485962]
when B-LOC [2.3118598461151123, -2.967799425125122]
medical B-LOC [2.404958963394165, -3.253170967102051]
utilization B-LOC [2.645482301712036, -3.1370608806610107]
rates, B-LOC [2.4288864135742188, -3.0038435459136963]
length B-LOC [2.7512733936309814, -3.1564228534698486]
of B-LOC [2.437311887741089, -3.0636889934539795]
health B-LOC [2.4861233234405518, -3.2241017818450928]
plan B-LOC [2.531040906906128, -3.310847043991089]
membership, B-LOC [2.598078489303589, -3.1386518478393555]
or B-LOC [2.4720771312713623, -2.968258857727051]
time B-LOC [2.627619981765747, -3.2682206630706787]
since B-LOC [2.5118815898895264, -2.9179675579071045]
initial B-LOC [2.2413060665130615, -2.9377858638763428]
diabetes B-LOC [2.3294517993927, -2.9521617889404297]
diagnosis B-LOC [2.482105016708374, -2.9221057891845703]
were B-LOC [2.5192441940307617, -2.8472888469696045]
added B-LOC [2.664170980453491, -3.1954967975616455]
to B-LOC [2.4730920791625977, -2.9145355224609375]
the B-LOC [2.680675983428955, -2.9674131870269775]
model. B-LOC [2.283818483352661, -3.12043833732605]
When B-LOC [0.9946988224983215, -1.0746634006500244]
examining B-LOC [1.563623070716858, -1.6123387813568115]
emergency B-LOC [1.3531663417816162, -1.6824674606323242]
department B-LOC [1.5662673711776733, -1.8949878215789795]
admissions B-LOC [1.4428268671035767, -1.7054579257965088]
for B-LOC [1.5624502897262573, -1.7027684450149536]
hypoglycemia B-LOC [1.3374897241592407, -1.6027984619140625]
for B-LOC [1.5569084882736206, -1.7797861099243164]
association B-LOC [1.3864552974700928, -1.5153859853744507]
with B-LOC [1.253108263015747, -1.6052206754684448]
risk B-LOC [1.3061550855636597, -1.5478391647338867]
of B-LOC [1.101212501525879, -1.4416186809539795]
dementia B-LOC [1.6411917209625244, -1.634233832359314]
(535 B-LOC [1.1683286428451538, -1.5031383037567139]
episodes), B-LOC [0.8430442214012146, -1.4976983070373535]
results B-LOC [1.0548105239868164, -1.2865122556686401]
were B-LOC [0.9729081392288208, -1.1889363527297974]
similar B-LOC [0.9670767784118652, -1.1267216205596924]
(compared B-LOC [0.8816054463386536, -1.0506856441497803]
with B-LOC [0.8551914095878601, -1.012132167816162]
patients B-LOC [0.9152069091796875, -1.277380108833313]
with B-LOC [0.7998509407043457, -1.1566686630249023]
0 B-LOC [1.1608521938323975, -1.0426408052444458]
episodes) B-LOC [0.8836454153060913, -1.2141600847244263]
with B-LOC [0.7576630711555481, -0.941349983215332]

fully B-LOC [0.509334146976471, -0.8833707571029663]
adjusted B-LOC [0.5658196806907654, -1.075901985168457]
HRs: B-LOC [0.6384694576263428, -1.2855727672576904]
for B-LOC [0.3865130841732025, -0.902400016784668]
1 B-LOC [0.6666819453239441, -0.9703928828239441]
episode B-LOC [0.45595136284828186, -0.8163618445396423]
(HR, B-LOC [0.4481985867023468, -0.8379167914390564]
1.42; B-LOC [0.15971067547798157, -0.430087149143219]
95% B-LOC [0.06021368131041527, -0.5328413844108582]
CI, B-LOC [-0.08355166018009186, -0.5425480604171753]
1.12-1.78) B-LOC [0.06236919388175011, -0.32558494806289673]
and B-LOC [0.5356286764144897, -0.8569541573524475]
for B-LOC [0.3627782464027405, -0.746769905090332]
2 B-LOC [0.24313825368881226, -0.4794212877750397]
or B-LOC [0.34250763058662415, -1.0879449844360352]
more B-LOC [0.4678767919540405, -0.8368627429008484]
episodes B-LOC [0.43262267112731934, -0.8888881206512451]
(HR, B-LOC [0.597141444683075, -0.9379795789718628]
2.36; B-LOC [0.009286864660680294, -0.2094419002532959]
95% B-LOC [-0.138918936252594, -0.2424716055393219]
CI, B-LOC [-0.026367833837866783, -0.5856807231903076]
1.57-3.55). O [-0.1756390631198883, 0.1827213168144226]
CONCLUSIONS O [-0.8804100751876831, 0.46079951524734497]
Among O [-0.6096318364143372, 0.6798797249794006]
older O [-0.30213913321495056, 0.5095113515853882]
patients O [-0.4720449149608612, 0.21761459112167358]
with O [-0.39391028881073, 0.2562398612499237]
type O [-0.6082437634468079, 0.49182063341140747]
2 O [-0.4607047140598297, 0.4483886659145355]
diabetes, O [-0.26559174060821533, 0.13282784819602966]
a O [-0.5634508728981018, 0.42738059163093567]
history O [-0.5009645819664001, 0.17880816757678986]
of O [-0.7227013111114502, 0.4784943759441376]
severe O [-0.6115684509277344, 0.3164174258708954]
hypoglycemic O [-0.5371387004852295, 0.3552677035331726]
episodes O [-0.5525056719779968, 0.36031532287597656]
was O [-0.501859724521637, 0.12380753457546234]
associated O [-0.6064104437828064, 0.45567306876182556]
with O [-0.6339566111564636, 0.3646308481693268]
a O [-0.48176127672195435, 0.2807835042476654]
greater O [-0.5801699757575989, 0.4235459268093109]
risk O [-0.5680038928985596, 0.3383984863758087]
of O [-0.6736788153648376, 0.3851475119590759]
dementia. O [-0.307490736246109, 0.1467548906803131]
Whether B-LOC [1.356015682220459, -1.953444004058838]
minor B-LOC [1.0021209716796875, -1.251145601272583]
hypoglycemic B-LOC [0.5615047812461853, -0.8362013101577759]
episodes B-LOC [0.5694544911384583, -0.8750079274177551]
increase B-LOC [0.9800994992256165, -1.4700149297714233]
risk B-LOC [0.9452672600746155, -1.4365500211715698]
of B-LOC [0.5299286246299744, -1.1844879388809204]
dementia B-LOC [1.0679049491882324, -1.3813691139221191]
is B-LOC [2.298269033432007, -2.1027557849884033]
unknown. B-LOC [1.9957268238067627, -1.9568467140197754]

Background B-LOC [0.9391152262687683, -1.2683558464050293]
Checkpoint B-LOC [1.0592753887176514, -1.2870795726776123]
kinase B-LOC [0.7952180504798889, -1.0448276996612549]
2 B-LOC [0.9095061421394348, -0.8114814162254333]
(CHEK2) B-LOC [0.7726858854293823, -1.0313273668289185]
averts B-LOC [0.6032336354255676, -0.5899890661239624]
cancer B-LOC [0.6801927089691162, -0.947521448135376]
development B-LOC [0.3433370292186737, -0.5620909333229065]
by B-LOC [-0.1073739230632782, -0.16084961593151093]
promoting B-LOC [0.16041845083236694, -0.3171815574169159]
cell B-LOC [0.10108353942632675, -0.5320488214492798]
cycle B-LOC [0.22718006372451782, -0.6769421696662903]
arrest B-LOC [0.10280943661928177, -0.29432201385498047]
and B-LOC [0.028032781556248665, -0.05066027119755745]
activating B-LOC [0.24833667278289795, -0.22718943655490875]
DNA B-LOC [0.46326491236686707, -0.7161468267440796]
repair B-LOC [0.36843615770339966, -0.5167371034622192]
in B-LOC [0.33304131031036377, -0.508938729763031]
genetically B-LOC [0.5726491808891296, -0.7761856913566589]
damaged B-LOC [0.7329607605934143, -0.9363235831260681]
cells. B-LOC [0.4336673319339752, -0.8213528990745544]
Previous B-LOC [2.2910516262054443, -2.721503973007202]
investigation B-LOC [2.469285726547241, -2.689201593399048]
has B-LOC [2.794243812561035, -2.590996026992798]
established B-LOC [2.6430587768554688, -2.6736629009246826]
a B-LOC [2.6829230785369873, -2.901546001434326]
role B-LOC [2.6026198863983154, -2.915487051010132]
for B-LOC [2.720261335372925, -2.864581823348999]
the B-LOC [2.4271597862243652, -2.537529945373535]
CHEK2 B-LOC [1.9637154340744019, -2.183659076690674]
gene B-LOC [2.111675500869751, -2.7826879024505615]
in B-LOC [2.5365231037139893, -3.1138978004455566]
breast B-LOC [2.309044599533081, -2.66552472114563]
cancer B-LOC [2.502643585205078, -2.91330623626709]
aetiology, B-LOC [2.7611935138702393, -3.0308592319488525]
but B-LOC [2.735023021697998, -3.1078710556030273]
studies B-LOC [2.6320242881774902, -2.9541432857513428]
have B-LOC [3.051118850708008, -2.832397222518921]
largely B-LOC [3.078442335128784, -3.1239376068115234]
been B-LOC [2.831127643585205, -2.9947569370269775]
limited B-LOC [3.1910579204559326, -3.0094263553619385]
to B-LOC [2.9370949268341064, -2.8735549449920654]
the B-LOC [2.7177093029022217, -2.764559507369995]
rare B-LOC [2.6415865421295166, -2.7982242107391357]
1100delC B-LOC [1.4327491521835327, -1.4813520908355713]
mutation. B-LOC [2.0305192470550537, -2.766866445541382]
Whether B-LOC [2.6389074325561523, -2.9996442794799805]
common B-LOC [2.7222204208374023, -2.982943296432495]
polymorphisms B-LOC [2.6913297176361084, -3.042494535446167]
in B-LOC [2.5589442253112793, -2.6206488609313965]
this B-LOC [2.3168764114379883, -2.5886242389678955]
gene B-LOC [2.0550215244293213, -2.6773812770843506]
influence B-LOC [2.560541868209839, -2.8681557178497314]
breast B-LOC [2.0277321338653564, -2.711426258087158]
cancer B-LOC [2.3994438648223877, -3.0272586345672607]
risk B-LOC [2.510626792907715, -2.9391372203826904]
remains B-LOC [3.176363706588745, -2.7730979919433594]
unknown. B-LOC [3.1285207271575928, -2.813544511795044]
In B-LOC [2.1027395725250244, -2.3447697162628174]
this B-LOC [1.9840800762176514, -2.3617048263549805]
study, B-LOC [2.070924997329712, -2.7596004009246826]
we B-LOC [1.895850419998169, -2.324751138687134]
aimed B-LOC [2.283531904220581, -2.610541343688965]
to B-LOC [2.5880157947540283, -2.776437759399414]
assess B-LOC [2.4421191215515137, -3.0043632984161377]
the B-LOC [2.6985924243927, -3.140533685684204]
importance B-LOC [2.4970507621765137, -3.215606451034546]
of B-LOC [2.294708251953125, -2.7868974208831787]
common B-LOC [2.0446455478668213, -2.625279188156128]
CHEK2 B-LOC [1.5748863220214844, -1.9622693061828613]
variants B-LOC [1.8962008953094482, -2.1920533180236816]
on B-LOC [2.11545991897583, -2.8327789306640625]
population B-LOC [2.03786039352417, -2.5494186878204346]
risk B-LOC [2.155325174331665, -2.7122576236724854]
for B-LOC [2.110369920730591, -2.5673954486846924]
breast B-LOC [1.6278573274612427, -2.0104939937591553]
cancer B-LOC [1.84415602684021, -2.5273876190185547]
by B-LOC [1.9116296768188477, -2.2797553539276123]
capturing B-LOC [2.1390140056610107, -2.4805705547332764]
the B-LOC [2.0671632289886475, -2.3335607051849365]
majority B-LOC [2.0061872005462646, -2.437497138977051]
of B-LOC [1.8779664039611816, -2.439148187637329]
diversity B-LOC [1.8861260414123535, -2.3941385746002197]
in B-LOC [2.0294528007507324, -2.259369134902954]
the B-LOC [2.008890390396118, -2.2963993549346924]
gene B-LOC [1.764329433441162, -2.512253522872925]
using B-LOC [1.968231439590454, -2.2901771068573]
haplotype B-LOC [1.9699043035507202, -2.0574018955230713]

tagging B-LOC [2.1064600944519043, -2.8671762943267822]
single B-LOC [2.6191318035125732, -2.871668815612793]
nucleotide B-LOC [2.4825799465179443, -2.8394272327423096]
polymorphisms B-LOC [2.5126140117645264, -2.8650996685028076]
(tagSNPs). B-LOC [2.7901437282562256, -3.074354410171509]
Methods B-LOC [2.1486120223999023, -2.699531078338623]
and B-LOC [2.4926164150238037, -3.057898759841919]
Findings B-LOC [2.6030662059783936, -2.664984941482544]
We B-LOC [1.6626911163330078, -2.03155779838562]
analyzed B-LOC [2.032846450805664, -2.2344813346862793]
14 B-LOC [2.305215358734131, -2.3782052993774414]
common B-LOC [2.0078585147857666, -2.495659589767456]
SNPs B-LOC [1.8861110210418701, -2.2702043056488037]
spanning B-LOC [1.9525535106658936, -2.171952486038208]
52 B-LOC [2.2871429920196533, -2.0344130992889404]
kilobases B-LOC [2.1636784076690674, -2.653014898300171]
(kb) B-LOC [2.0527632236480713, -2.2906196117401123]
of B-LOC [1.5665407180786133, -1.8340991735458374]
the B-LOC [1.7990323305130005, -2.0460715293884277]
CHEK2 B-LOC [1.6758060455322266, -2.056816339492798]
gene B-LOC [1.3228031396865845, -1.7731759548187256]
in B-LOC [1.9685182571411133, -2.3561880588531494]
92 B-LOC [2.4869766235351562, -2.884342908859253]
Swedish B-LOC [1.7058355808258057, -2.495755910873413]
women. B-LOC [2.017382860183716, -2.358008861541748]
Coverage B-LOC [2.1560819149017334, -2.507566213607788]
evaluation B-LOC [2.007864236831665, -2.51887583732605]
indicated B-LOC [1.7939435243606567, -2.146599531173706]
that B-LOC [1.8164312839508057, -2.228853225708008]
these B-LOC [1.8685235977172852, -2.347198247909546]
typed B-LOC [1.9175738096237183, -2.546661376953125]
SNPs B-LOC [2.008563756942749, -2.569464921951294]
would B-LOC [1.7307000160217285, -2.073413372039795]
efficiently B-LOC [1.7786200046539307, -2.282409191131592]
convey B-LOC [1.835231065750122, -2.340181589126587]
association B-LOC [1.7781734466552734, -2.417747974395752]
signal B-LOC [1.6670864820480347, -2.380471706390381]
also B-LOC [1.6752551794052124, -2.187513828277588]
from B-LOC [1.8319885730743408, -2.5005762577056885]
untyped B-LOC [2.2710745334625244, -2.785749673843384]
SNPs B-LOC [2.116882085800171, -2.771108865737915]
in B-LOC [2.361149311065674, -2.6976473331451416]
the B-LOC [2.566136598587036, -2.7938225269317627]
same B-LOC [2.2194316387176514, -2.8002512454986572]
region. B-LOC [2.2010581493377686, -2.85111927986145]
Six B-LOC [2.4884140491485596, -2.3926804065704346]
of B-LOC [2.43037748336792, -2.214656352996826]
the B-LOC [2.5113155841827393, -2.1976239681243896]
14 B-LOC [2.717655897140503, -2.3647210597991943]
SNPs B-LOC [2.2730424404144287, -2.415729284286499]
predicted B-LOC [2.198167562484741, -2.3183677196502686]
well B-LOC [2.4332051277160645, -2.370265483856201]
both B-LOC [2.1191439628601074, -2.290454864501953]
the B-LOC [2.3552401065826416, -2.2225024700164795]
haplotypic B-LOC [2.460169553756714, -2.3444364070892334]
and B-LOC [2.269603967666626, -2.1233861446380615]
single B-LOC [2.776543140411377, -2.582141637802124]
SNP B-LOC [2.357793092727661, -2.5163357257843018]
variations B-LOC [2.3681228160858154, -2.389037609100342]
within B-LOC [2.539140462875366, -2.4012691974639893]
CHEK2. B-LOC [2.0317800045013428, -2.30637526512146]
We B-LOC [0.5452066659927368, -1.1009844541549683]
genotyped B-LOC [0.8018873333930969, -0.8706275820732117]
these B-LOC [0.8757343292236328, -0.8374280333518982]
six B-LOC [0.8090453743934631, -1.0056332349777222]
tagSNPs B-LOC [0.6534391641616821, -1.0563255548477173]
in B-LOC [0.55440354347229, -0.7449169158935547]
1,577 B-LOC [0.6830049157142639, -0.6725295186042786]
postmenopausal B-LOC [0.484916627407074, -0.5688799023628235]
breast B-LOC [0.45226529240608215, -0.8035451173782349]
cancer B-LOC [0.46902790665626526, -0.7327234148979187]
cases B-LOC [0.539808452129364, -0.5011436343193054]
and B-LOC [0.5399133563041687, -0.9920729994773865]

1,513 B-LOC [0.9917733073234558, -0.9781050086021423]
population B-LOC [1.1957265138626099, -1.489819049835205]
controls, B-LOC [1.243505835533142, -1.4864044189453125]
but B-LOC [0.9542850852012634, -1.2997175455093384]
found B-LOC [0.9150726795196533, -1.004103660583496]
no B-LOC [1.1991074085235596, -1.2420563697814941]
convincing B-LOC [1.3671166896820068, -1.4972248077392578]
association B-LOC [1.0474034547805786, -1.391601800918579]
between B-LOC [1.3646466732025146, -1.7852734327316284]
any B-LOC [1.164462924003601, -1.4012079238891602]
common B-LOC [1.2747701406478882, -1.5290284156799316]
CHEK2 B-LOC [1.018670916557312, -1.2948923110961914]
haplotype B-LOC [1.1689670085906982, -1.2012102603912354]
and B-LOC [1.576541781425476, -1.788701057434082]
breast B-LOC [0.9872493147850037, -1.232226848602295]
cancer B-LOC [1.2198325395584106, -1.5444908142089844]
risk. B-LOC [1.3163496255874634, -1.561828851699829]
The O [-0.6421899199485779, 0.5032459497451782]
1100delC O [-0.023764224722981453, 0.18831457197666168]
mutation O [-0.60945063829422, 0.33340591192245483]
was O [-0.5672290325164795, 0.2392486035823822]
rare O [-0.2786262333393097, 0.5644211173057556]
in O [-0.4459647834300995, 0.568062424659729]
our O [-0.4411158859729767, 0.31948503851890564]
Swedish O [-0.48100578784942627, 0.037354204803705215]
population—0.7% O [-0.5818719267845154, 0.43299198150634766]
in O [-0.5652638673782349, 0.25514087080955505]
cases O [-0.609188973903656, 0.6063326001167297]
and O [-0.6666672229766846, 0.4348387122154236]
0.4% O [-0.35920342803001404, 0.4872402846813202]
in O [-0.6093558669090271, 0.4368777871131897]
controls— O [-0.5565740466117859, 0.5148487687110901]
with O [-0.40034714341163635, 0.3689727187156677]
a O [-0.35195139050483704, 0.3217071294784546]
corresponding O [-0.34349945187568665, 0.1787523627281189]
odds O [-0.4347195029258728, 0.29753413796424866]
ratio O [-0.3905748128890991, 0.17029032111167908]
for O [-0.341095894575119, 0.2293764352798462]
carriers O [-0.3412230610847473, 0.3827064335346222]
versus O [-0.2808118164539337, 0.3083488643169403]
noncarriers O [-0.39215001463890076, 0.4256468117237091]
of O [-0.39728283882141113, 0.1361331045627594]
2.26 O [-0.27436837553977966, 0.4985308349132538]
(95% O [-0.19173574447631836, 0.027149951085448265]
confidence O [-0.43981751799583435, 0.09084202349185944]
interval, O [-0.5020462870597839, 0.1509101837873459]
0.99–5.15). O [-0.023722251877188683, 0.051670875400304794]
Estimates B-LOC [0.9503418207168579, -0.9593233466148376]
of B-LOC [0.8857928514480591, -1.0763453245162964]
the B-LOC [0.9171382784843445, -1.2292587757110596]
population B-LOC [0.7630786299705505, -1.0001375675201416]
frequency B-LOC [0.7232311964035034, -1.2621395587921143]
and B-LOC [1.0378742218017578, -1.1220064163208008]
the B-LOC [1.2663570642471313, -1.4058529138565063]
odds B-LOC [0.8964515328407288, -1.341241478919983]
ratio B-LOC [0.9145069122314453, -1.289718747138977]
of B-LOC [0.9097860455513, -1.2044048309326172]
1100delC B-LOC [0.6096203923225403, -0.66572505235672]
indicate B-LOC [0.9916432499885559, -0.8314869403839111]
that B-LOC [0.7876960039138794, -1.1172200441360474]
our B-LOC [0.49689653515815735, -0.7680492997169495]
sample B-LOC [0.480608195066452, -0.9817995429039001]
is B-LOC [1.0096964836120605, -0.9531554579734802]
representative B-LOC [0.9335669279098511, -1.011301040649414]
of B-LOC [0.7514745593070984, -0.9804412722587585]
a B-LOC [0.7762001156806946, -1.013037085533142]
Northern B-LOC [1.0435705184936523, -1.2296624183654785]
European B-LOC [0.7614837884902954, -1.0243895053863525]
population. B-LOC [0.580566942691803, -1.0136948823928833]

Nuclear B-LOC [2.203423261642456, -2.9894020557403564]
receptors B-LOC [2.0420753955841064, -2.5600152015686035]
undergo B-LOC [1.9784812927246094, -2.4036142826080322]
ligand-dependent B-LOC [2.091541051864624, -2.655082941055298]
conformational B-LOC [2.5630953311920166, -2.9513370990753174]
changes B-LOC [2.040930986404419, -2.538118600845337]
that B-LOC [1.7531652450561523, -2.5160434246063232]
are B-LOC [2.0461556911468506, -2.4175193309783936]
required B-LOC [1.9419182538986206, -2.565023183822632]
for B-LOC [1.790836215019226, -2.495338201522827]
corepressor-coactivator B-LOC [1.6373131275177002, -2.2317378520965576]
exchange, B-LOC [1.8664010763168335, -2.360245943069458]
but B-LOC [2.7977511882781982, -3.065544366836548]
whether B-LOC [2.9067397117614746, -3.5685269832611084]
there B-LOC [3.1047043800354004, -3.2827093601226807]
is B-LOC [3.128702402114868, -3.3429391384124756]
an B-LOC [3.0078036785125732, -3.5849297046661377]
actual B-LOC [2.9786975383758545, -3.460848808288574]
requirement B-LOC [2.7330009937286377, -3.341418743133545]
for B-LOC [2.7557790279388428, -3.441770076751709]
specific B-LOC [2.899407148361206, -3.5906097888946533]
epigenetic B-LOC [2.997298240661621, -3.475252389907837]
landmarks B-LOC [2.7334587574005127, -3.5408384799957275]
to B-LOC [3.0352396965026855, -3.237929105758667]
impose B-LOC [2.5999867916107178, -3.326669216156006]
ligand B-LOC [2.8887922763824463, -3.5444798469543457]
dependency B-LOC [3.0268452167510986, -3.4028749465942383]
for B-LOC [2.5549232959747314, -3.2698819637298584]
gene B-LOC [2.605989456176758, -3.3341243267059326]
activation B-LOC [2.6150338649749756, -3.307413339614868]
remains B-LOC [3.4685115814208984, -3.21803879737854]
unknown. B-LOC [3.298001527786255, -3.2119195461273193]
Here B-LOC [-0.12615607678890228, -0.24858079850673676]
we O [-0.23305997252464294, -0.08135206997394562]
report B-LOC [0.08827108889818192, -0.4187410771846771]
an B-LOC [0.11119253188371658, -0.6955545544624329]
unexpected B-LOC [0.3130638301372528, -0.8034716844558716]
and B-LOC [0.393951416015625, -0.717110276222229]
general B-LOC [0.4227457046508789, -0.9284995198249817]
strategy B-LOC [0.40237128734588623, -0.5780135989189148]
that B-LOC [0.10410664230585098, -0.8106289505958557]
is B-LOC [0.3922393023967743, -0.5797554850578308]
based B-LOC [0.28768834471702576, -0.5665693879127502]
on B-LOC [0.5324422717094421, -0.49149128794670105]
the B-LOC [0.4229918122291565, -0.44759905338287354]
requirement B-LOC [0.431747704744339, -0.5312578082084656]
for B-LOC [0.5019669532775879, -0.5441411733627319]
specific B-LOC [0.5151144862174988, -0.6799501776695251]
cohorts B-LOC [0.334506630897522, -0.46930575370788574]
of B-LOC [0.44342008233070374, -0.6044718623161316]
inhibitory B-LOC [0.47813984751701355, -0.5239526033401489]
histone B-LOC [0.234878808259964, -0.5897179841995239]
methyltransferases B-LOC [0.4414377808570862, -0.5054155588150024]
(HMTs) B-LOC [0.5893017649650574, -0.61323481798172]
to B-LOC [0.5377790331840515, -0.4091944396495819]
impose B-LOC [0.18061542510986328, -0.3256394565105438]
gene-specific B-LOC [0.1894194483757019, -0.35338857769966125]
gatekeeper B-LOC [0.037186551839113235, -0.23883312940597534]
functions B-LOC [0.18013232946395874, -0.09428241848945618]
that B-LOC [0.19111847877502441, -0.30364611744880676]
prevent B-LOC [0.16937194764614105, -0.2227090448141098]
unliganded B-LOC [0.2784122824668884, -0.17801180481910706]
nuclear B-LOC [0.20208340883255005, -0.4144497215747833]
receptors B-LOC [0.17944160103797913, -0.4582380950450897]
and B-LOC [0.02257763035595417, -0.16235753893852234]
other B-LOC [0.34493428468704224, -0.2579347789287567]
classes B-LOC [0.6245003938674927, -0.32022687792778015]
of B-LOC [0.1481781303882599, -0.35822662711143494]
regulated B-LOC [0.12022366374731064, -0.3366377353668213]
transcription B-LOC [-0.0915473997592926, -0.23306921124458313]
factors B-LOC [-0.10123785585165024, -0.2137802541255951]
from B-LOC [0.11205685138702393, 0.05593753978610039]
binding B-LOC [-0.0727638527750969, -0.15247245132923126]
to B-LOC [-0.1285562962293625, -0.1395321488380432]
their B-LOC [0.4458620250225067, -0.5146704316139221]
target B-LOC [0.1838388890028, -0.5087645649909973]
gene B-LOC [-0.2088114470243454, -0.31314560770988464]
promoters B-LOC [-0.12895402312278748, -0.14201045036315918]
and O [-0.03670421615242958, 0.1378038376569748]
causing B-LOC [0.013875982724130154, -0.25165489315986633]
constitutive B-LOC [0.12537139654159546, -0.20668813586235046]
gene B-LOC [0.04563802853226662, -0.23952358961105347]

activation B-LOC [-0.15103915333747864, -0.3262299597263336]
in B-LOC [0.1338130533695221, -0.1628580540418625]
the B-LOC [0.13443028926849365, -0.1709672212600708]
absence B-LOC [0.22026309370994568, -0.14134451746940613]
of B-LOC [-0.0760769322514534, -0.1995393931865692]
stimulating B-LOC [-0.013037354685366154, -0.23314541578292847]
signals. B-LOC [-0.05184977129101753, -0.24572861194610596]
This B-LOC [0.12898284196853638, -0.23676033318042755]
strategy, B-LOC [0.17277102172374725, -0.22316975891590118]
based B-LOC [0.05257490649819374, -0.1454986035823822]
at O [0.09204736351966858, 0.1591539978981018]
least B-LOC [-0.04805431514978409, -0.07275493443012238]
in O [0.06266237795352936, 0.3646530210971832]
part O [0.08197583258152008, 0.18474410474300385]
on B-LOC [0.2999092638492584, -0.3721519410610199]
an B-LOC [0.1651286482810974, -0.3108975291252136]
HMT-dependent B-LOC [0.07128272950649261, -0.08883176743984222]
inhibitory B-LOC [0.1782429963350296, -0.37897926568984985]
histone B-LOC [-0.07979662716388702, -0.3719548285007477]
code, B-LOC [0.016812073066830635, -0.18748360872268677]
imposes B-LOC [0.14109955728054047, 0.09046588838100433]
a O [0.09372693300247192, 0.1418781578540802]
requirement B-LOC [0.16242091357707977, -0.03673573210835457]
for B-LOC [0.09256836771965027, -0.1553124040365219]
specific B-LOC [0.15252086520195007, -0.26974067091941833]
histone B-LOC [0.02228650636970997, -0.12116357684135437]
demethylases, B-LOC [0.1046067401766777, -0.06990385055541992]
including B-LOC [0.24806970357894897, -0.07096508890390396]
LSD1, B-LOC [0.011845915578305721, -0.03456439450383186]
to B-LOC [0.17370030283927917, -0.135149285197258]
permit O [-0.1587851345539093, -0.002354095224291086]
ligand- B-LOC [-0.01807723380625248, -0.03873569145798683]
and O [-0.1742231845855713, -0.06386668980121613]
signal-dependent B-LOC [-0.012718976475298405, -0.06134345382452011]
activation O [-0.008496562950313091, 0.10166934132575989]
of O [-0.08786068856716156, -0.0656118094921112]
regulated O [-0.13399437069892883, -0.06599180400371552]
gene O [-0.19011549651622772, -0.18079441785812378]
expression. O [-0.019239431247115135, 0.10702112317085266]
These B-LOC [0.9355904459953308, -1.067702293395996]
events B-LOC [0.8670711517333984, -1.1983346939086914]
link B-LOC [1.1491868495941162, -1.0592124462127686]
an B-LOC [0.9487555623054504, -1.2134771347045898]
inhibitory B-LOC [1.2881900072097778, -1.5120490789413452]
methylation B-LOC [1.5029062032699585, -1.5073795318603516]
component B-LOC [0.9701619744300842, -1.1626441478729248]
of B-LOC [0.9941872954368591, -1.2993648052215576]
the B-LOC [1.162142276763916, -1.1544456481933594]
histone B-LOC [0.9780369997024536, -1.5124319791793823]
code B-LOC [0.889073371887207, -1.3104705810546875]
to B-LOC [1.1381423473358154, -1.3685802221298218]
a B-LOC [1.0789769887924194, -1.2241342067718506]
broadly B-LOC [1.5304043292999268, -1.574410080909729]
used B-LOC [1.2591025829315186, -1.4181374311447144]
strategy B-LOC [1.01771080493927, -1.4055343866348267]
that B-LOC [0.799936056137085, -1.3292014598846436]
circumvents B-LOC [1.2841334342956543, -1.087836742401123]
pathological B-LOC [1.3304779529571533, -1.4876327514648438]
constitutive B-LOC [1.3672685623168945, -1.3623778820037842]
gene B-LOC [0.7139044404029846, -1.3311679363250732]
induction B-LOC [0.8478086590766907, -1.2419408559799194]
by B-LOC [0.8946444988250732, -1.3376035690307617]
physiologically B-LOC [1.1095530986785889, -1.4404749870300293]
regulated B-LOC [0.9813671112060547, -1.3772238492965698]
transcription B-LOC [0.8228315114974976, -1.5168571472167969]
factors. B-LOC [0.9974860548973083, -1.491849422454834]

OBJECTIVES B-LOC [2.989441156387329, -3.6503007411956787]
To B-LOC [3.2220146656036377, -3.8430213928222656]
carry B-LOC [3.1986494064331055, -3.53745436668396]
out B-LOC [3.222036123275757, -3.7490053176879883]
a B-LOC [3.2410361766815186, -3.649506092071533]
further B-LOC [3.2032363414764404, -3.8253729343414307]
survey B-LOC [3.357511520385742, -3.647352933883667]
of B-LOC [3.2282297611236572, -3.573146104812622]
archived B-LOC [3.2647383213043213, -3.767972469329834]
appendix B-LOC [3.380768299102783, -3.866834878921509]
samples B-LOC [3.358361005783081, -3.774982213973999]
to B-LOC [3.3043935298919678, -3.770245313644409]
understand B-LOC [3.3210623264312744, -3.7240874767303467]
better B-LOC [3.1224234104156494, -3.7142012119293213]
the B-LOC [3.422370195388794, -3.799201250076294]
differences B-LOC [3.2160775661468506, -3.759381055831909]
between B-LOC [3.0859196186065674, -3.8547770977020264]
existing B-LOC [3.2133519649505615, -3.7066092491149902]
estimates B-LOC [3.2609059810638428, -3.631331205368042]
of B-LOC [3.1174628734588623, -3.723088026046753]
the B-LOC [3.3289310932159424, -3.71484637260437]
prevalence B-LOC [3.3647100925445557, -3.569370985031128]
of B-LOC [2.99615740776062, -3.5199320316314697]
subclinical B-LOC [3.1890437602996826, -3.580338478088379]
infection B-LOC [3.312163829803467, -3.4324164390563965]
with B-LOC [3.0792195796966553, -3.557948589324951]
prions B-LOC [3.1898064613342285, -3.4594056606292725]
after B-LOC [3.002912759780884, -3.6011226177215576]
the B-LOC [3.0836939811706543, -3.3648970127105713]
bovine B-LOC [2.883518934249878, -3.2726311683654785]
spongiform B-LOC [2.9285600185394287, -3.3348731994628906]
encephalopathy B-LOC [2.325467348098755, -3.0733187198638916]
epizootic B-LOC [3.222460985183716, -3.5020711421966553]
and B-LOC [3.004749298095703, -3.4575235843658447]
to B-LOC [3.3487050533294678, -3.712610960006714]
see B-LOC [3.4785993099212646, -3.7142632007598877]
whether B-LOC [3.3142311573028564, -3.8877081871032715]
a B-LOC [3.3977110385894775, -3.704408884048462]
broader B-LOC [3.312758684158325, -3.89689564704895]
birth B-LOC [3.154489755630493, -3.703521490097046]
cohort B-LOC [3.2432143688201904, -3.6788036823272705]
was B-LOC [3.0885355472564697, -3.6629385948181152]
affected, B-LOC [3.1788980960845947, -3.7160515785217285]
and B-LOC [3.1248130798339844, -3.402454137802124]
to B-LOC [3.440925121307373, -3.717306137084961]
understand B-LOC [3.5203938484191895, -3.6535918712615967]
better B-LOC [3.3260295391082764, -3.7048723697662354]
the B-LOC [3.571850061416626, -3.7543418407440186]
implications B-LOC [3.491914987564087, -3.7730672359466553]
for B-LOC [3.4897408485412598, -3.640962600708008]
the B-LOC [3.482666492462158, -3.670158624649048]
management B-LOC [3.6740634441375732, -3.7765605449676514]
of B-LOC [3.4261910915374756, -3.7207279205322266]
blood B-LOC [3.3750100135803223, -4.078019618988037]
and B-LOC [3.261060953140259, -3.5229156017303467]
blood B-LOC [3.2906527519226074, -4.065322399139404]
products B-LOC [3.6630759239196777, -3.974736452102661]
and B-LOC [3.379345178604126, -3.514251947402954]
for B-LOC [3.395354986190796, -3.7987592220306396]
the B-LOC [3.405137777328491, -3.6859474182128906]
handling B-LOC [3.521679162979126, -3.823591709136963]
of B-LOC [3.375492811203003, -3.7897050380706787]
surgical B-LOC [3.4198172092437744, -4.029001235961914]
instruments. B-LOC [3.47090744972229, -4.084992408752441]
DESIGN B-LOC [3.352091073989868, -3.6023294925689697]
Irreversibly B-LOC [3.2365548610687256, -3.11973237991333]
unlinked B-LOC [3.3997175693511963, -3.0829110145568848]
and B-LOC [3.1476972103118896, -3.1337778568267822]
anonymised B-LOC [3.244391918182373, -3.065181016921997]
large B-LOC [3.4045298099517822, -2.9911792278289795]
scale B-LOC [3.2443997859954834, -3.276899576187134]
survey B-LOC [3.07942271232605, -3.1813127994537354]
of B-LOC [3.378466844558716, -3.247485637664795]
archived B-LOC [3.318057060241699, -3.4435880184173584]
appendix B-LOC [3.366199493408203, -3.601473569869995]
samples. B-LOC [3.4646263122558594, -3.566561698913574]
SETTING B-LOC [2.513580083847046, -3.0572633743286133]
Archived B-LOC [2.5537707805633545, -2.998347759246826]
appendix B-LOC [2.8604650497436523, -3.039411783218384]

samples B-LOC [3.190687894821167, -3.889570713043213]
from B-LOC [3.4285995960235596, -3.8417270183563232]
the B-LOC [3.5696494579315186, -3.57869553565979]
pathology B-LOC [3.5637147426605225, -3.9713149070739746]
departments B-LOC [3.6238114833831787, -3.8517203330993652]
of B-LOC [3.5057756900787354, -3.729983329772949]
41 B-LOC [3.712144136428833, -3.833097219467163]
UK B-LOC [3.6351165771484375, -3.759366035461426]
hospitals B-LOC [3.542963981628418, -3.930502414703369]
participating B-LOC [3.5903100967407227, -3.947296142578125]
in B-LOC [3.3860690593719482, -3.7011561393737793]
the B-LOC [3.4682085514068604, -3.6834654808044434]
earlier B-LOC [3.480332136154175, -4.097893714904785]
survey, B-LOC [3.4887421131134033, -3.849616765975952]
and B-LOC [3.2557361125946045, -3.6237316131591797]
additional B-LOC [3.4078338146209717, -3.923121690750122]
hospitals B-LOC [3.5872628688812256, -3.916414976119995]
in B-LOC [3.5972654819488525, -3.7217495441436768]
regions B-LOC [3.7552428245544434, -3.9149749279022217]
with B-LOC [3.4704887866973877, -3.7013251781463623]
lower B-LOC [3.4279305934906006, -3.940765857696533]
levels B-LOC [3.5716147422790527, -3.8069095611572266]
of B-LOC [3.4639363288879395, -3.751603841781616]
participation B-LOC [3.5675160884857178, -3.962052822113037]
in B-LOC [3.4531850814819336, -3.711390733718872]
that B-LOC [3.3738503456115723, -3.775376319885254]
survey. B-LOC [3.506193161010742, -3.9071481227874756]
SAMPLE B-LOC [2.89127779006958, -2.933917760848999]
32,441 B-LOC [3.5761098861694336, -3.569462776184082]
archived B-LOC [3.4532296657562256, -3.4420714378356934]
appendix B-LOC [3.356900930404663, -3.402937173843384]
samples B-LOC [3.475438356399536, -3.312377452850342]
fixed B-LOC [3.491107940673828, -3.255298614501953]
in B-LOC [3.309925079345703, -2.960860013961792]
formalin B-LOC [3.2319393157958984, -3.4188036918640137]
and B-LOC [2.9113762378692627, -2.8374812602996826]
embedded B-LOC [3.387202262878418, -3.3932108879089355]
in B-LOC [3.4340078830718994, -3.154710054397583]
paraffin B-LOC [3.4081544876098633, -3.252417802810669]
and B-LOC [3.0923757553100586, -3.0750620365142822]
tested B-LOC [3.6535441875457764, -3.7231080532073975]
for B-LOC [3.56610369682312, -3.583739757537842]
the B-LOC [3.675121307373047, -3.4457767009735107]
presence B-LOC [3.4080088138580322, -3.763911008834839]
of B-LOC [3.36203932762146, -3.430410385131836]
abnormal B-LOC [3.3765664100646973, -3.602088212966919]
prion B-LOC [3.2518229484558105, -3.5070302486419678]
protein B-LOC [3.207397699356079, -3.5776584148406982]
(PrP). B-LOC [3.4769277572631836, -3.613806962966919]
RESULTS B-LOC [0.5983099937438965, -1.1435986757278442]
Of B-LOC [0.7254834771156311, -0.5166178345680237]
the B-LOC [1.0398151874542236, -0.6981582045555115]
32,441 B-LOC [1.5994279384613037, -1.2631702423095703]
appendix B-LOC [0.9933086037635803, -1.1285276412963867]
samples B-LOC [0.7163234353065491, -0.9221783876419067]
16 B-LOC [1.0710830688476562, -0.8484594821929932]
were B-LOC [0.6821131110191345, -0.740886926651001]
positive B-LOC [0.6763126254081726, -0.8689653873443604]
for B-LOC [0.6236606240272522, -0.6797854900360107]
abnormal B-LOC [0.7985811233520508, -1.1029657125473022]
PrP, B-LOC [0.6138759255409241, -1.029608964920044]
indicating B-LOC [0.39977410435676575, -0.7290826439857483]
an B-LOC [0.37941667437553406, -0.859494149684906]
overall B-LOC [0.5440619587898254, -0.8468354940414429]
prevalence B-LOC [0.5212580561637878, -0.983156144618988]
of B-LOC [0.2544737756252289, -0.7661808133125305]
493 B-LOC [0.9199439883232117, -0.8329966068267822]
per B-LOC [0.47366097569465637, -0.6547101140022278]
million B-LOC [0.5344200730323792, -1.227738857269287]
population B-LOC [0.5257161259651184, -0.9647177457809448]
(95% B-LOC [0.2826380431652069, -0.7283521890640259]
confidence B-LOC [0.25949254631996155, -0.7192806005477905]
interval B-LOC [0.03301050886511803, -0.7564652562141418]
282 B-LOC [0.5546953678131104, -0.47107794880867004]
to B-LOC [0.1258295178413391, -0.7477770447731018]
801 B-LOC [0.605312168598175, -0.7574390769004822]
per B-LOC [0.19214823842048645, -0.5296615362167358]
million). B-LOC [0.5626216530799866, -1.0366506576538086]
The B-LOC [0.5180550813674927, -0.7438907623291016]
prevalence B-LOC [0.3552815616130829, -0.8021985292434692]
in B-LOC [0.4229632019996643, -0.6246199011802673]
those B-LOC [0.31697824597358704, -0.39150622487068176]
born B-LOC [0.45409783720970154, -0.6501990556716919]
in B-LOC [0.563208818435669, -0.86475670337677]
1941-60 B-LOC [0.5037034749984741, -0.6620306372642517]
(733 B-LOC [0.24159277975559235, -0.5362324118614197]
per B-LOC [0.18787898123264313, -0.44625434279441833]
million, B-LOC [0.3651377260684967, -0.7504824995994568]
269 B-LOC [0.8960810899734497, -0.8065595030784607]

to B-LOC [0.9094339609146118, -1.4634051322937012]
1596 B-LOC [1.6864814758300781, -1.632439136505127]
per B-LOC [1.0156086683273315, -1.5284618139266968]
million) B-LOC [1.395860195159912, -1.740140676498413]
did B-LOC [1.2473664283752441, -1.5340795516967773]
not B-LOC [1.4675064086914062, -1.587857961654663]
differ B-LOC [1.6252638101577759, -1.9147670269012451]
significantly B-LOC [1.5149153470993042, -1.8503246307373047]
from B-LOC [1.5867798328399658, -1.8263163566589355]
those B-LOC [1.3910014629364014, -1.663090467453003]
born B-LOC [1.6470401287078857, -1.9476341009140015]
between B-LOC [1.8843265771865845, -1.9649507999420166]
1961 B-LOC [1.6064130067825317, -1.701048493385315]
and B-LOC [1.89967942237854, -1.99849534034729]
1985 B-LOC [1.825011968612671, -2.0939252376556396]
(412 B-LOC [1.4159824848175049, -1.7583928108215332]
per B-LOC [1.358912467956543, -1.6286649703979492]
million, B-LOC [1.6691124439239502, -1.923861026763916]
198 B-LOC [1.8627228736877441, -1.975601077079773]
to B-LOC [1.350008249282837, -1.9222211837768555]
758 B-LOC [2.0060536861419678, -1.8994885683059692]
per B-LOC [1.5327107906341553, -1.7959452867507935]
million) B-LOC [1.825071096420288, -2.0839576721191406]
and B-LOC [1.1840786933898926, -1.7255759239196777]
was B-LOC [1.545426607131958, -1.9065155982971191]
similar B-LOC [1.8311094045639038, -2.1200308799743652]
in B-LOC [1.4877591133117676, -1.8983099460601807]
both B-LOC [1.599882960319519, -2.0971851348876953]
sexes B-LOC [2.084933042526245, -2.112872362136841]
and B-LOC [1.636446475982666, -2.0454771518707275]
across B-LOC [1.80872642993927, -2.1879146099090576]
the B-LOC [2.125619888305664, -2.1235344409942627]
three B-LOC [2.023881673812866, -2.2491419315338135]
broad B-LOC [2.2015979290008545, -2.325056314468384]
geographical B-LOC [2.402937173843384, -2.443185567855835]
areas B-LOC [2.408682107925415, -2.3921382427215576]
sampled. B-LOC [2.1287152767181396, -2.248286485671997]
Genetic B-LOC [1.780759334564209, -1.6405997276306152]
testing B-LOC [1.2265838384628296, -1.2772654294967651]
of B-LOC [1.4084055423736572, -1.2446088790893555]
the B-LOC [1.5387721061706543, -1.29909348487854]
positive B-LOC [1.4277937412261963, -1.4842967987060547]
specimens B-LOC [1.6686923503875732, -1.4984686374664307]
for B-LOC [1.4162224531173706, -1.4381587505340576]
the B-LOC [1.6035655736923218, -1.3954570293426514]
genotype B-LOC [1.9189987182617188, -1.7672818899154663]
at B-LOC [1.6716203689575195, -1.4920032024383545]
PRNP B-LOC [1.2386094331741333, -1.2290326356887817]
codon B-LOC [1.8272217512130737, -1.500335454940796]
129 B-LOC [1.6405255794525146, -1.4680224657058716]
revealed B-LOC [1.1883571147918701, -0.9280573129653931]
a B-LOC [1.4769923686981201, -1.3901108503341675]
high B-LOC [1.341554880142212, -1.3882389068603516]
proportion B-LOC [1.7601869106292725, -1.5701220035552979]
that B-LOC [1.4712250232696533, -1.5680625438690186]
were B-LOC [1.588209867477417, -1.415771484375]
valine B-LOC [1.5162032842636108, -1.6377983093261719]
homozygous B-LOC [1.439672589302063, -1.4983007907867432]
compared B-LOC [1.1956089735031128, -1.3115726709365845]
with B-LOC [1.5456174612045288, -1.5578454732894897]
the B-LOC [1.5306825637817383, -1.5426865816116333]
frequency B-LOC [1.7405238151550293, -1.7497258186340332]
in B-LOC [1.3972580432891846, -1.4357142448425293]
the B-LOC [1.6652653217315674, -1.4874180555343628]
normal B-LOC [1.2594926357269287, -1.484281063079834]
population, B-LOC [1.5332791805267334, -1.6416881084442139]
and B-LOC [1.0479803085327148, -0.8460851311683655]
in B-LOC [1.2589222192764282, -0.911386251449585]
stark B-LOC [1.2500782012939453, -0.987572193145752]
contrast B-LOC [1.410507321357727, -1.1046627759933472]
with B-LOC [1.5276384353637695, -1.385744571685791]
confirmed B-LOC [1.3083198070526123, -1.4549086093902588]
clinical B-LOC [1.426703929901123, -1.543489694595337]
cases B-LOC [1.452834129333496, -1.325937032699585]
of B-LOC [1.3283058404922485, -1.3360955715179443]
vCJD, B-LOC [1.3093900680541992, -1.3240923881530762]
all B-LOC [1.3148446083068848, -1.2066000699996948]
of B-LOC [1.5916608572006226, -1.1114290952682495]
which B-LOC [1.3403561115264893, -1.1305979490280151]
were B-LOC [1.3465826511383057, -1.1353152990341187]
methionine B-LOC [1.0937776565551758, -1.2687420845031738]
homozygous B-LOC [1.0473496913909912, -1.1175363063812256]
at B-LOC [1.417184829711914, -1.3231524229049683]
PRNP B-LOC [0.9369451403617859, -1.0307204723358154]
codon B-LOC [1.4480137825012207, -1.1930065155029297]
129. B-LOC [1.2964155673980713, -1.3444374799728394]
CONCLUSIONS O [-0.5397710800170898, 0.20435146987438202]
This B-LOC [0.9300845265388489, -0.7962079644203186]
study B-LOC [0.7593498826026917, -1.2254979610443115]
corroborates B-LOC [1.2874233722686768, -0.7889932990074158]

previous O [-0.15728409588336945, 0.032543864101171494]
studies O [-0.08558467030525208, 0.1807439774274826]
and O [-0.06671017408370972, 0.140096053481102]
suggests B-LOC [0.11294704675674438, 0.03885815292596817]
a B-LOC [0.0625070333480835, 0.008076159283518791]
high B-LOC [0.14882948994636536, -0.13451744616031647]
prevalence B-LOC [0.23167870938777924, -0.12160443514585495]
of B-LOC [0.07804668694734573, -0.07941028475761414]
infection B-LOC [0.09486882388591766, -0.027752535417675972]
with O [0.05325360223650932, 0.06300189346075058]
abnormal B-LOC [0.07787232846021652, -0.08173532038927078]
PrP, O [-0.16434744000434875, -0.07780835032463074]
indicating B-LOC [0.176182821393013, -0.07109424471855164]
vCJD B-LOC [0.05293287709355354, -0.20417283475399017]
carrier B-LOC [0.10231064260005951, -0.047244567424058914]
status B-LOC [0.2217857986688614, -0.2694041132926941]
in B-LOC [0.3977638781070709, -0.6483768820762634]
the B-LOC [0.6386036276817322, -0.5916098356246948]
population B-LOC [0.36855489015579224, -0.5542758107185364]
compared B-LOC [0.19232073426246643, -0.35599544644355774]
with B-LOC [0.48325613141059875, -0.46589359641075134]
the B-LOC [0.6356589794158936, -0.599252462387085]
177 B-LOC [0.7386996746063232, -0.5959848761558533]
vCJD B-LOC [0.17933166027069092, -0.3915230333805084]
cases B-LOC [0.3806760013103485, -0.4753548502922058]
to B-LOC [1.4529935121536255, -1.1382391452789307]
date. B-LOC [1.150098443031311, -1.024031639099121]
These B-LOC [1.793344259262085, -2.1727311611175537]
findings B-LOC [1.9091410636901855, -2.2732198238372803]
have B-LOC [2.223139524459839, -2.23280930519104]
important B-LOC [1.9331567287445068, -2.178211212158203]
implications B-LOC [2.034348249435425, -2.3362362384796143]
for B-LOC [1.901831865310669, -2.2922420501708984]
the B-LOC [2.0352234840393066, -2.4617080688476562]
management B-LOC [2.1153066158294678, -2.530851125717163]
of B-LOC [1.973548412322998, -2.493776559829712]
blood B-LOC [1.9611716270446777, -2.9158127307891846]
and B-LOC [2.101207733154297, -2.6513805389404297]
blood B-LOC [1.968876600265503, -2.997148275375366]
products B-LOC [2.145289897918701, -2.660433530807495]
and B-LOC [1.916372299194336, -2.1917874813079834]
for B-LOC [1.9720308780670166, -2.507244348526001]
the B-LOC [2.050185441970825, -2.518343687057495]
handling B-LOC [2.0905778408050537, -2.6289474964141846]
of B-LOC [2.0641961097717285, -2.6435482501983643]
surgical B-LOC [1.9531093835830688, -2.5344200134277344]
instruments. B-LOC [1.981359839439392, -2.5425827503204346]

BACKGROUND B-LOC [1.1463795900344849, -1.7534737586975098]
The B-LOC [2.410993814468384, -2.806367874145508]
prognosis B-LOC [2.868558168411255, -3.031597137451172]
and B-LOC [2.4597480297088623, -2.8932015895843506]
treatment B-LOC [2.650672674179077, -2.9236068725585938]
of B-LOC [2.6014859676361084, -2.7018439769744873]
the B-LOC [2.6437718868255615, -2.6388614177703857]
2 B-LOC [2.2572989463806152, -2.322209596633911]
main B-LOC [2.5353198051452637, -2.811735153198242]
types B-LOC [2.7962067127227783, -2.860492467880249]
of B-LOC [2.316505193710327, -2.8011281490325928]
cardiac B-LOC [2.1496284008026123, -2.882826566696167]
amyloidosis, B-LOC [2.0745999813079834, -2.9554989337921143]
immunoglobulin B-LOC [2.4952383041381836, -2.8795578479766846]
light B-LOC [2.467101812362671, -2.2957851886749268]
chain B-LOC [2.005676507949829, -2.3595569133758545]
(AL) B-LOC [2.551210641860962, -2.5667531490325928]
and B-LOC [2.42573618888855, -2.3111393451690674]
transthyretin B-LOC [2.1256234645843506, -2.4813694953918457]
(ATTR) B-LOC [2.582031011581421, -2.7257068157196045]
amyloidosis, B-LOC [1.982755184173584, -2.6140406131744385]
are B-LOC [2.5598106384277344, -2.828997850418091]
substantially B-LOC [2.6170613765716553, -2.7413365840911865]
influenced B-LOC [2.5107548236846924, -2.9035096168518066]
by B-LOC [2.425537109375, -2.9807145595550537]
cardiac B-LOC [2.377316474914551, -3.0573813915252686]
involvement. B-LOC [2.353048086166382, -2.789616823196411]
Cardiovascular B-LOC [3.0839569568634033, -3.408143997192383]
magnetic B-LOC [3.1067111492156982, -3.4513444900512695]
resonance B-LOC [3.1589019298553467, -3.244860887527466]
with B-LOC [3.276578187942505, -3.2096798419952393]
late B-LOC [3.3285186290740967, -3.522148847579956]
gadolinium B-LOC [3.199925661087036, -3.2174410820007324]
enhancement B-LOC [3.1533825397491455, -3.3700530529022217]
(LGE) B-LOC [3.3253724575042725, -3.267364501953125]
is B-LOC [3.3143279552459717, -3.0692026615142822]
a B-LOC [3.393277168273926, -3.369191884994507]
reference B-LOC [3.3063480854034424, -3.5377211570739746]
standard B-LOC [3.222757577896118, -3.524221181869507]
for B-LOC [3.3118367195129395, -3.4147820472717285]
the B-LOC [3.367316961288452, -3.3461368083953857]
diagnosis B-LOC [3.3501064777374268, -3.444988250732422]
of B-LOC [3.2882750034332275, -3.393460512161255]
cardiac B-LOC [3.168973207473755, -3.6297757625579834]
amyloidosis, B-LOC [3.1753194332122803, -3.4153554439544678]
but B-LOC [3.2800300121307373, -3.29701566696167]
its B-LOC [3.2582762241363525, -3.3481438159942627]
potential B-LOC [3.228407144546509, -3.5217361450195312]
for B-LOC [3.2452328205108643, -3.5735275745391846]
stratifying B-LOC [3.2897212505340576, -3.4357340335845947]
risk B-LOC [3.5384538173675537, -3.5054728984832764]
is B-LOC [3.522038698196411, -3.1460607051849365]
unknown. B-LOC [3.425184488296509, -3.340982675552368]
METHODS B-LOC [0.9477271437644958, -1.7575100660324097]
AND B-LOC [1.763144612312317, -2.298771381378174]
RESULTS B-LOC [0.9048947095870972, -1.6453981399536133]
Two B-LOC [1.6725189685821533, -2.3739259243011475]
hundred B-LOC [2.2572686672210693, -2.463822841644287]
fifty B-LOC [2.200319766998291, -2.4274673461914062]
prospectively B-LOC [2.162533760070801, -2.483947992324829]
recruited B-LOC [2.1783335208892822, -2.6099817752838135]
subjects, B-LOC [2.0249531269073486, -2.3883426189422607]
122 B-LOC [2.013160467147827, -2.4206488132476807]

patients B-LOC [2.0223639011383057, -2.5379011631011963]
with B-LOC [1.9571924209594727, -2.0779218673706055]
ATTR B-LOC [1.449782133102417, -1.8990874290466309]
amyloid, B-LOC [1.8126106262207031, -2.0865988731384277]
9 B-LOC [1.802367091178894, -2.121407985687256]
asymptomatic B-LOC [1.9201741218566895, -2.2861249446868896]
mutation B-LOC [1.8189553022384644, -2.1545138359069824]
carriers, B-LOC [2.018380880355835, -2.133652448654175]
and B-LOC [2.1885979175567627, -2.3740363121032715]
119 B-LOC [2.38242506980896, -2.543921709060669]
patients B-LOC [2.2901484966278076, -2.563856601715088]
with B-LOC [2.3191072940826416, -2.3564326763153076]
AL B-LOC [1.8762147426605225, -2.306466817855835]
amyloidosis, B-LOC [2.3482019901275635, -2.8919689655303955]
underwent B-LOC [2.627328395843506, -2.9040610790252686]
LGE B-LOC [2.846755266189575, -2.922286033630371]
cardiovascular B-LOC [2.9730632305145264, -3.268254280090332]
magnetic B-LOC [2.9911296367645264, -3.40114426612854]
resonance. B-LOC [2.7902138233184814, -2.9712297916412354]
Subjects B-LOC [3.3057219982147217, -3.7189295291900635]
were B-LOC [3.0525524616241455, -3.5159170627593994]
followed B-LOC [3.042736291885376, -3.6999266147613525]
up B-LOC [3.1352360248565674, -3.6039750576019287]
for B-LOC [3.3340227603912354, -3.4306960105895996]
a B-LOC [3.1983542442321777, -3.446925163269043]
mean B-LOC [3.1067192554473877, -3.518831491470337]
of B-LOC [2.9586029052734375, -3.4435713291168213]
24±13 B-LOC [3.2519562244415283, -3.4951796531677246]
months. B-LOC [3.2293314933776855, -3.463862180709839]
LGE B-LOC [2.653628349304199, -2.8327229022979736]
was B-LOC [2.9537785053253174, -3.026721715927124]
performed B-LOC [2.9475486278533936, -3.212536334991455]
with B-LOC [2.8797314167022705, -3.1677005290985107]
phase-sensitive B-LOC [3.2544848918914795, -3.5902302265167236]
inversion B-LOC [3.2117302417755127, -3.3794825077056885]
recovery B-LOC [2.8999147415161133, -3.194065570831299]
(PSIR) B-LOC [3.294614791870117, -3.5230753421783447]
and B-LOC [3.0546953678131104, -3.0538952350616455]
without B-LOC [3.008018970489502, -3.1779630184173584]
(magnitude B-LOC [3.2230465412139893, -3.104579210281372]
only). B-LOC [3.0517897605895996, -3.3061985969543457]
These B-LOC [2.9286625385284424, -3.229036569595337]
were B-LOC [3.1385886669158936, -3.1280744075775146]
compared B-LOC [3.0259242057800293, -3.2075705528259277]
with B-LOC [2.8188862800598145, -3.2113773822784424]
extracellular B-LOC [3.22546124458313, -3.4592397212982178]
volume B-LOC [2.938037157058716, -3.201664447784424]
measured B-LOC [3.3422179222106934, -3.4076085090637207]
with B-LOC [2.9398586750030518, -3.47038197517395]
T1 B-LOC [3.0448687076568604, -3.4187610149383545]
mapping. B-LOC [3.0159757137298584, -3.4710514545440674]
PSIR B-LOC [0.794131338596344, -0.932111918926239]
was B-LOC [0.34676602482795715, -0.22993478178977966]
superior B-LOC [0.2760178744792938, -0.1494385153055191]
to B-LOC [0.2065945565700531, -0.30787891149520874]
magnitude-only B-LOC [0.7623181343078613, -0.6058779954910278]
inversion B-LOC [0.6848334670066833, -0.6069654822349548]
recovery B-LOC [0.7625459432601929, -0.8469215035438538]
LGE B-LOC [0.5346163511276245, -0.22071540355682373]
because O [-0.06380815804004669, 0.26904788613319397]
PSIR B-LOC [0.30434805154800415, -0.18870782852172852]
always O [-0.07511919736862183, 0.17023155093193054]
nulled B-LOC [0.23500561714172363, 0.047825854271650314]
the B-LOC [0.1343400478363037, 0.023345036432147026]
tissue O [-0.10147511959075928, -0.09913468360900879]
(blood B-LOC [0.19778800010681152, -0.1937982738018036]
or B-LOC [0.26777681708335876, -0.3193969130516052]
myocardium) O [-0.22849765419960022, -0.1265929490327835]
with B-LOC [0.3327554166316986, -0.28777775168418884]
the B-LOC [0.20354628562927246, 0.019222168251872063]
longest B-LOC [0.188929945230484, -0.02999180741608143]
T1 B-LOC [0.27207693457603455, -0.29598018527030945]
(least B-LOC [0.17753681540489197, 0.07848543673753738]

gadolinium). B-LOC [0.07809210568666458, -0.5031291842460632]
LGE B-LOC [0.16618087887763977, -0.5190971493721008]
was B-LOC [0.32721802592277527, -0.6381841897964478]
classified B-LOC [0.5876675844192505, -0.6358969807624817]
into B-LOC [0.5875518918037415, -0.6655946373939514]
3 B-LOC [0.4687671363353729, -0.5444400906562805]
patterns: B-LOC [0.5844004154205322, -0.5810931324958801]
none, B-LOC [0.6624976992607117, -0.7705321907997131]
subendocardial, B-LOC [0.3736056685447693, -0.7247952818870544]
and B-LOC [0.630106508731842, -0.7682451009750366]
transmural, B-LOC [0.2643452286720276, -0.6484707593917847]
which B-LOC [0.1547524333000183, -0.7392773628234863]
were B-LOC [0.20817901194095612, -0.6368159055709839]
associated B-LOC [0.19428303837776184, -0.178383469581604]
with B-LOC [0.012447777204215527, -0.32545655965805054]
increasing B-LOC [-0.04856054112315178, -0.2033131718635559]
amyloid B-LOC [-0.07827022671699524, -0.29821404814720154]
burden B-LOC [0.3181791305541992, -0.17928306758403778]
as B-LOC [0.19684891402721405, -0.46805113554000854]
defined B-LOC [0.4441407322883606, -0.533259391784668]
by B-LOC [0.2952480912208557, -0.29838621616363525]
extracellular B-LOC [-0.10277874767780304, -0.3222385346889496]
volume B-LOC [0.1748408079147339, -0.3704235553741455]
(P<0.0001), B-LOC [0.2835804522037506, -0.2910875082015991]
with B-LOC [0.08064079284667969, -0.23426604270935059]
transitions B-LOC [0.042319346219301224, -0.2330716997385025]
from B-LOC [0.09807074069976807, -0.31210556626319885]
none B-LOC [0.19407571852207184, -0.1760847270488739]
to B-LOC [0.02913975529372692, -0.47743210196495056]
subendocardial B-LOC [-0.021577706560492516, -0.19245517253875732]
LGE B-LOC [0.04209945723414421, -0.06474246084690094]
at B-LOC [0.061138901859521866, -0.22255593538284302]
an B-LOC [-0.002197468187659979, -0.09498156607151031]
extracellular O [-0.23139041662216187, -0.1377117931842804]
volume B-LOC [-0.06359630078077316, -0.3410729169845581]
of B-LOC [-0.19235432147979736, -0.3076024055480957]
0.40 B-LOC [0.15802344679832458, -0.40117743611335754]
to B-LOC [-0.18600788712501526, -0.45672091841697693]
0.43 B-LOC [0.139064222574234, -0.414794921875]
(AL) B-LOC [0.12148624658584595, -0.5208186507225037]
and B-LOC [-0.23799259960651398, -0.3656297028064728]
0.39 B-LOC [0.14993266761302948, -0.44238030910491943]
to B-LOC [-0.19226904213428497, -0.5273450613021851]
0.40 B-LOC [0.15912297368049622, -0.5064575672149658]
(ATTR) B-LOC [0.2239047884941101, -0.5922673344612122]
and B-LOC [0.04007880762219429, -0.3710657060146332]
to B-LOC [0.2054167538881302, -0.3810708522796631]
transmural B-LOC [0.2268405258655548, -0.3662723898887634]
at B-LOC [0.11630256474018097, -0.4474131464958191]
0.48 B-LOC [0.4415517747402191, -0.5737482905387878]
to B-LOC [0.03167804703116417, -0.6721640229225159]
0.55 B-LOC [0.46087270975112915, -0.6803076267242432]
(AL) B-LOC [0.3156614601612091, -0.7671499848365784]
and B-LOC [-0.0028030104003846645, -0.5742208361625671]
0.47 B-LOC [0.4497685432434082, -0.6832216382026672]
to B-LOC [0.10117043554782867, -0.7549243569374084]
0.59 B-LOC [0.4743536412715912, -0.7538774013519287]
(ATTR). B-LOC [0.3831581473350525, -0.7812129855155945]

Sixty-seven B-LOC [1.055060625076294, -1.2442281246185303]
patients B-LOC [1.206085443496704, -1.5272011756896973]
(27%) B-LOC [1.1845682859420776, -1.3196653127670288]
died. B-LOC [1.5552706718444824, -1.5847015380859375]
Transmural B-LOC [0.49584075808525085, -0.6700106263160706]
LGE B-LOC [0.5440587401390076, -0.5238603353500366]
predicted B-LOC [0.2984597384929657, -0.3159673810005188]
death B-LOC [0.5363292098045349, -0.4759790003299713]
(hazard B-LOC [0.2167145311832428, -0.17206133902072906]
ratio, O [-0.22740808129310608, 0.12779591977596283]
5.4; O [-0.12297984212636948, 0.267019659280777]
95% O [-0.10692371428012848, 0.060951199382543564]
confidence O [-0.2740180492401123, 0.22129228711128235]
interval, O [-0.42204388976097107, 0.11705073714256287]
2.1-13.7; O [-0.19427265226840973, 0.4190727770328522]
P<0.0001) O [-0.2611987888813019, 0.12456409633159637]
and B-LOC [0.6103458404541016, -0.5271673798561096]
remained B-LOC [0.898970365524292, -0.9017179608345032]
independent B-LOC [0.9191204905509949, -0.982769250869751]
after B-LOC [0.8026816248893738, -0.9003348350524902]
adjustment B-LOC [0.860568106174469, -1.0624010562896729]
for B-LOC [0.6472175717353821, -0.7761188745498657]
N-terminal B-LOC [0.30325421690940857, -0.5392946600914001]
pro-brain B-LOC [0.09113867580890656, -0.36097580194473267]
natriuretic B-LOC [0.30924203991889954, -0.5128951668739319]
peptide, B-LOC [0.4700760245323181, -0.7072805166244507]
ejection B-LOC [0.4769831895828247, -0.61648029088974]
fraction, B-LOC [0.27697059512138367, -0.2642141878604889]
stroke B-LOC [0.27289071679115295, -0.5706031918525696]
volume B-LOC [0.14599964022636414, -0.3029899001121521]
index, B-LOC [0.22891902923583984, -0.40888139605522156]
E/E', B-LOC [0.024034546688199043, -0.28957775235176086]
and B-LOC [0.7057963609695435, -0.6863427758216858]
left B-LOC [0.22957484424114227, -0.3142011761665344]
ventricular B-LOC [-0.10366459935903549, -0.22946321964263916]
mass B-LOC [0.13048595190048218, -0.1906110942363739]
index B-LOC [0.21191763877868652, -0.4301927387714386]
(hazard B-LOC [0.5640100836753845, -0.4954855144023895]
ratio, B-LOC [0.05553852394223213, -0.32617902755737305]
4.1; B-LOC [0.24221622943878174, -0.17424920201301575]
95% B-LOC [0.18721497058868408, -0.291175901889801]
confidence B-LOC [0.052045028656721115, -0.4008633494377136]
interval, B-LOC [0.05589913949370384, -0.41103875637054443]
1.3-13.1; O [-0.006992486771196127, 0.02318236045539379]
P<0.05). B-LOC [-0.12568746507167816, -0.22641393542289734]
CONCLUSIONS O [-0.8483219742774963, 0.37003085017204285]
There B-LOC [0.21799540519714355, -0.3437592089176178]
is B-LOC [0.28515005111694336, -0.3534333407878876]
a B-LOC [0.34009337425231934, -0.36744028329849243]

continuum B-LOC [0.7041680216789246, -1.1731548309326172]
of B-LOC [1.0218677520751953, -1.464972734451294]
cardiac B-LOC [0.6238560676574707, -1.3476790189743042]
involvement B-LOC [0.7640689611434937, -1.2435529232025146]
in B-LOC [0.8197662234306335, -1.2112337350845337]
systemic B-LOC [0.7182546854019165, -1.5121334791183472]
AL B-LOC [0.6563081741333008, -1.0539395809173584]
and B-LOC [0.821951687335968, -1.3411948680877686]
ATTR B-LOC [0.5421871542930603, -1.235497236251831]
amyloidosis. B-LOC [0.7213433384895325, -1.5013699531555176]
Transmural B-LOC [0.7878478169441223, -0.9677626490592957]
LGE B-LOC [0.670238196849823, -0.9127626419067383]
is B-LOC [0.7309057712554932, -1.0776386260986328]
determined B-LOC [0.7439839243888855, -1.1755205392837524]
reliably B-LOC [0.75174480676651, -0.8623618483543396]
by B-LOC [0.5379633903503418, -0.9797924160957336]
PSIR B-LOC [0.8448988795280457, -1.1422350406646729]
and B-LOC [0.3653853237628937, -0.856004536151886]
represents B-LOC [0.7565189003944397, -1.0340514183044434]
advanced B-LOC [0.5559861063957214, -0.9019433856010437]
cardiac B-LOC [0.4505173861980438, -1.0903382301330566]
amyloidosis. B-LOC [0.47773656249046326, -1.2226800918579102]
The B-LOC [1.0119118690490723, -1.4551451206207275]
PSIR B-LOC [1.089557409286499, -1.6563143730163574]
technique B-LOC [0.8087499141693115, -1.5244594812393188]
provides B-LOC [0.9404670596122742, -1.4151179790496826]
incremental B-LOC [0.9332881569862366, -1.573620080947876]
information B-LOC [1.0267727375030518, -1.6883535385131836]
on B-LOC [1.3009294271469116, -1.898313045501709]
outcome B-LOC [0.9966688752174377, -1.699796199798584]
even B-LOC [1.2600767612457275, -1.7459118366241455]
after B-LOC [1.0078130960464478, -1.369280457496643]
adjustment B-LOC [1.0291039943695068, -1.628791332244873]
for B-LOC [1.2466970682144165, -1.845951795578003]
known B-LOC [1.0561267137527466, -1.876463532447815]
prognostic B-LOC [1.072028636932373, -1.8589030504226685]
factors. B-LOC [0.898727536201477, -1.6455928087234497]

BACKGROUND B-LOC [1.338980793952942, -2.0535619258880615]
The B-LOC [2.759124994277954, -3.242891311645508]
Global B-LOC [2.972529888153076, -3.529578685760498]
Burden B-LOC [2.8234119415283203, -3.468165397644043]
of B-LOC [2.895632028579712, -3.5065877437591553]
Diseases, B-LOC [3.2293288707733154, -3.5403964519500732]
Injuries, B-LOC [2.9287514686584473, -3.416273355484009]
and B-LOC [3.151069402694702, -3.417212963104248]
Risk B-LOC [3.327378034591675, -3.487118721008301]
Factors B-LOC [3.043339729309082, -3.5437722206115723]
Study B-LOC [2.796426773071289, -3.1966655254364014]
2015 B-LOC [2.662307024002075, -3.327120065689087]
provides B-LOC [2.5415894985198975, -3.2386667728424072]
an B-LOC [2.6859042644500732, -3.2290403842926025]
up-to-date B-LOC [3.104734182357788, -3.7391185760498047]
synthesis B-LOC [2.8060476779937744, -3.365379571914673]
of B-LOC [2.8520593643188477, -3.5451419353485107]
the B-LOC [3.0568742752075195, -3.421647787094116]
evidence B-LOC [2.9890496730804443, -3.4478752613067627]
for B-LOC [3.1229710578918457, -3.5159261226654053]
risk B-LOC [3.4755289554595947, -3.620668649673462]
factor B-LOC [3.1292364597320557, -3.7144083976745605]
exposure B-LOC [3.529571771621704, -3.5520660877227783]
and B-LOC [3.114741325378418, -3.371790647506714]
the B-LOC [3.337918519973755, -3.6024773120880127]
attributable B-LOC [3.304955244064331, -3.7875027656555176]
burden B-LOC [3.34633469581604, -3.746354579925537]
of B-LOC [3.1617257595062256, -3.5957069396972656]
disease. B-LOC [3.431462526321411, -3.6151843070983887]
By B-LOC [2.520019769668579, -2.9999024868011475]
providing B-LOC [2.9611594676971436, -3.4481828212738037]
national B-LOC [3.277341604232788, -3.6282150745391846]
and B-LOC [3.126296281814575, -3.3959133625030518]
subnational B-LOC [3.3202733993530273, -3.3248541355133057]
assessments B-LOC [3.3337514400482178, -3.6065542697906494]
spanning B-LOC [3.252380132675171, -3.514782190322876]
the B-LOC [3.2512338161468506, -3.2809135913848877]
past B-LOC [3.259739637374878, -3.540786027908325]
25 B-LOC [3.2279515266418457, -3.3392951488494873]
years, B-LOC [3.3394038677215576, -3.5330569744110107]
this B-LOC [2.953118085861206, -3.4763500690460205]
study B-LOC [3.152930974960327, -3.5416390895843506]
can B-LOC [3.0688860416412354, -3.5070273876190186]
inform B-LOC [3.2166812419891357, -3.460068941116333]
debates B-LOC [3.3823320865631104, -3.5507962703704834]
on B-LOC [3.491931200027466, -3.7140562534332275]
the B-LOC [3.544846773147583, -3.633577585220337]
importance B-LOC [3.419874429702759, -3.6454973220825195]
of B-LOC [3.3492934703826904, -3.551279306411743]
addressing B-LOC [3.456969738006592, -3.670214891433716]
risks B-LOC [3.5462844371795654, -3.7920377254486084]
in B-LOC [3.373600482940674, -3.6287014484405518]
context. B-LOC [3.293832540512085, -3.6036288738250732]
METHODS B-LOC [1.5593469142913818, -2.6350486278533936]
We B-LOC [1.559631586074829, -2.3442165851593018]
used B-LOC [1.8917988538742065, -2.5519254207611084]
the B-LOC [2.2918288707733154, -2.1984665393829346]
comparative B-LOC [2.310453176498413, -2.9978344440460205]
risk B-LOC [2.7093381881713867, -3.1267292499542236]
assessment B-LOC [2.6240603923797607, -3.1430675983428955]
framework B-LOC [2.3388724327087402, -2.6170098781585693]
developed B-LOC [2.4189655780792236, -2.5210623741149902]
for B-LOC [2.20762038230896, -2.4294583797454834]
previous B-LOC [2.082134962081909, -2.6154046058654785]
iterations B-LOC [2.532106637954712, -2.432835340499878]
of B-LOC [2.4096453189849854, -2.7810986042022705]
the B-LOC [2.563621759414673, -2.7577695846557617]
Global B-LOC [2.4699771404266357, -3.181328058242798]
Burden B-LOC [2.529207468032837, -3.0352349281311035]
of B-LOC [2.4779417514801025, -2.988459825515747]
Disease B-LOC [2.6617062091827393, -3.1297543048858643]
Study B-LOC [2.4618303775787354, -2.9141037464141846]
to B-LOC [2.321747064590454, -2.905776262283325]
estimate B-LOC [2.476905584335327, -3.213667154312134]
attributable B-LOC [2.7269625663757324, -3.2523891925811768]
deaths, B-LOC [2.5073537826538086, -2.723485231399536]
disability-adjusted B-LOC [2.406381368637085, -2.903608560562134]
life-years B-LOC [2.591998338699341, -2.8511688709259033]

(DALYs), B-LOC [2.5827643871307373, -3.283818483352661]
and B-LOC [2.871452569961548, -3.2271745204925537]
trends B-LOC [3.444877862930298, -3.526681661605835]
in B-LOC [3.1516971588134766, -3.4796204566955566]
exposure B-LOC [3.333566427230835, -3.4972376823425293]
by B-LOC [2.9141411781311035, -3.207547664642334]
age B-LOC [3.6514499187469482, -3.546851396560669]
group, B-LOC [3.7273411750793457, -3.4482340812683105]
sex, B-LOC [3.377009630203247, -3.445852518081665]
year, B-LOC [3.7329018115997314, -3.633225202560425]
and B-LOC [3.2375900745391846, -3.479433059692383]
geography B-LOC [3.6018571853637695, -3.492384672164917]
for B-LOC [3.138479471206665, -3.207775592803955]
79 B-LOC [3.35591197013855, -3.4368836879730225]
behavioural, B-LOC [3.663264751434326, -3.754254102706909]
environmental B-LOC [3.697352647781372, -3.7358925342559814]
and B-LOC [3.0240910053253174, -3.334338426589966]
occupational, B-LOC [3.601529836654663, -3.5817556381225586]
and B-LOC [3.136948347091675, -3.455265998840332]
metabolic B-LOC [3.5009493827819824, -3.899729013442993]
risks B-LOC [3.5461106300354004, -3.530855655670166]
or B-LOC [3.4764323234558105, -3.52018666267395]
clusters B-LOC [3.6959521770477295, -3.5306918621063232]
of B-LOC [3.281813144683838, -3.511647939682007]
risks B-LOC [3.57861328125, -3.5983083248138428]
from B-LOC [3.3424324989318848, -3.3125927448272705]
1990 B-LOC [3.216015338897705, -3.504404306411743]
to B-LOC [3.5692851543426514, -3.3260796070098877]
2015. B-LOC [3.3592920303344727, -3.567128896713257]
This B-LOC [3.162346601486206, -3.4438908100128174]
study B-LOC [3.1047065258026123, -3.482679605484009]
included B-LOC [3.3844187259674072, -3.2003307342529297]
388 B-LOC [3.5876529216766357, -3.3612022399902344]
risk-outcome B-LOC [3.415649175643921, -3.7065417766571045]
pairs B-LOC [3.4045565128326416, -3.614058494567871]
that B-LOC [3.246137857437134, -3.329122543334961]
met B-LOC [3.494110107421875, -3.5831491947174072]
World B-LOC [3.0813701152801514, -3.5528786182403564]
Cancer B-LOC [3.3285577297210693, -3.5386416912078857]
Research B-LOC [3.130629062652588, -3.500441551208496]
Fund-defined B-LOC [3.3134288787841797, -3.459447145462036]
criteria B-LOC [3.4347846508026123, -3.5631372928619385]
for B-LOC [3.3338375091552734, -3.415807008743286]
convincing B-LOC [3.288027286529541, -3.6301677227020264]
or B-LOC [3.3054277896881104, -3.663607358932495]
probable B-LOC [3.2985501289367676, -3.639613389968872]
evidence. B-LOC [3.3495876789093018, -3.838493585586548]
We B-LOC [2.0043537616729736, -2.3893558979034424]
extracted B-LOC [2.8789846897125244, -3.047727584838867]
relative B-LOC [3.1745707988739014, -3.4293713569641113]
risk B-LOC [3.2146809101104736, -3.328291177749634]
and B-LOC [2.955195188522339, -3.1625964641571045]
exposure B-LOC [3.0524022579193115, -3.3095343112945557]
estimates B-LOC [3.133089303970337, -3.2818074226379395]
from B-LOC [3.1399428844451904, -3.2540557384490967]
randomised B-LOC [3.3567681312561035, -3.337258815765381]
controlled B-LOC [3.274693250656128, -3.517590045928955]
trials, B-LOC [3.2664754390716553, -3.2885801792144775]
cohorts, B-LOC [3.4661099910736084, -3.2490344047546387]
pooled B-LOC [3.518012762069702, -3.4321038722991943]
cohorts, B-LOC [3.369770050048828, -3.1999170780181885]
household B-LOC [3.085177183151245, -3.272801399230957]
surveys, B-LOC [3.3545427322387695, -3.3077571392059326]
census B-LOC [3.4547533988952637, -3.3870983123779297]
data, B-LOC [3.4838993549346924, -3.3958332538604736]
satellite B-LOC [3.464954137802124, -3.419661521911621]
data, B-LOC [3.481966495513916, -3.3837392330169678]
and B-LOC [3.3031976222991943, -3.4450650215148926]
other B-LOC [3.446525812149048, -3.396315813064575]
sources. B-LOC [3.2953641414642334, -3.330594778060913]
We B-LOC [2.0510756969451904, -2.5790393352508545]
used B-LOC [2.5250601768493652, -2.8367929458618164]
statistical B-LOC [2.678528070449829, -2.99509334564209]
models B-LOC [2.856137752532959, -3.0030081272125244]
to B-LOC [2.651339530944824, -2.964129686355591]
pool B-LOC [2.658762216567993, -2.9535419940948486]
data, B-LOC [2.85056734085083, -3.0698249340057373]
adjust B-LOC [2.5047593116760254, -2.9312801361083984]
for B-LOC [2.602276086807251, -2.7225403785705566]
bias, B-LOC [2.737180233001709, -3.0580151081085205]
and B-LOC [2.5782649517059326, -2.6178805828094482]
incorporate B-LOC [2.421018600463867, -2.606273889541626]

covariates. B-LOC [1.852974772453308, -2.7589681148529053]
We B-LOC [2.1758272647857666, -2.9946460723876953]
developed B-LOC [2.7753636837005615, -2.879241704940796]
a B-LOC [2.948150396347046, -3.0961337089538574]
metric B-LOC [2.7817330360412598, -3.388526678085327]
that B-LOC [2.8446671962738037, -3.2946689128875732]
allows B-LOC [2.826880931854248, -3.3557441234588623]
comparisons B-LOC [2.9874608516693115, -3.5364830493927]
of B-LOC [3.132392168045044, -3.564537763595581]
exposure B-LOC [2.91416597366333, -3.3529467582702637]
across B-LOC [2.9524691104888916, -3.5651769638061523]
risk B-LOC [3.181976795196533, -3.550931215286255]
factors-the B-LOC [3.158399820327759, -3.680816173553467]
summary B-LOC [2.7626259326934814, -3.5109517574310303]
exposure B-LOC [2.760380268096924, -3.359463930130005]
value. B-LOC [2.868089437484741, -3.5638539791107178]
Using B-LOC [2.7293875217437744, -3.3218679428100586]
the B-LOC [3.033857583999634, -3.1546077728271484]
counterfactual B-LOC [2.8425068855285645, -3.403064489364624]
scenario B-LOC [2.904562473297119, -3.2663819789886475]
of B-LOC [2.85817551612854, -3.384157419204712]
theoretical B-LOC [3.0028913021087646, -3.4005930423736572]
minimum B-LOC [2.9664957523345947, -3.4837381839752197]
risk B-LOC [3.028909921646118, -3.387657880783081]
level, B-LOC [2.843785524368286, -3.4769160747528076]
we B-LOC [2.250361680984497, -3.026240825653076]
estimated B-LOC [2.710082769393921, -3.3082735538482666]
the B-LOC [3.0298495292663574, -3.341233253479004]
portion B-LOC [2.9274632930755615, -3.328326463699341]
of B-LOC [2.7391488552093506, -3.216521739959717]
deaths B-LOC [2.8790252208709717, -3.1031394004821777]
and B-LOC [2.7008039951324463, -3.259645700454712]
DALYs B-LOC [2.8587453365325928, -3.4738450050354004]
that B-LOC [2.8817756175994873, -3.399306058883667]
could B-LOC [2.981760025024414, -3.4036545753479004]
be B-LOC [2.980539560317993, -3.4599883556365967]
attributed B-LOC [3.0091114044189453, -3.428438425064087]
to B-LOC [2.7212839126586914, -3.3786444664001465]
a B-LOC [2.964067220687866, -3.29126238822937]
given B-LOC [2.861320734024048, -3.5581982135772705]
risk. B-LOC [2.7976386547088623, -3.364042282104492]
We B-LOC [2.3475894927978516, -3.1809351444244385]
decomposed B-LOC [2.9305601119995117, -3.350318431854248]
trends B-LOC [2.8409929275512695, -3.4454362392425537]
in B-LOC [2.6950275897979736, -3.3711636066436768]
attributable B-LOC [3.1199452877044678, -3.3704094886779785]
burden B-LOC [2.7887184619903564, -3.515432834625244]
into B-LOC [2.9580819606781006, -3.1554293632507324]
contributions B-LOC [2.6962006092071533, -3.333901882171631]
from B-LOC [2.6654231548309326, -3.256605625152588]
population B-LOC [2.914653778076172, -3.5158982276916504]
growth, B-LOC [2.8296241760253906, -3.543011426925659]
population B-LOC [2.9401261806488037, -3.5414466857910156]
age B-LOC [3.2838728427886963, -3.682116746902466]
structure, B-LOC [3.0792062282562256, -3.5649917125701904]
risk B-LOC [2.9211108684539795, -3.756953477859497]
exposure, B-LOC [3.04008412361145, -3.587583303451538]
and B-LOC [2.884878635406494, -3.5134198665618896]
risk-deleted B-LOC [2.972377300262451, -3.631873846054077]
cause-specific B-LOC [2.98382568359375, -3.5797979831695557]
DALY B-LOC [3.062178373336792, -3.5930287837982178]
rates. B-LOC [2.9622528553009033, -3.6037213802337646]
We B-LOC [2.5460562705993652, -3.099841833114624]
characterised B-LOC [2.919875144958496, -3.341247320175171]
risk B-LOC [3.0571510791778564, -3.547593593597412]
exposure B-LOC [2.9262821674346924, -3.251020908355713]
in B-LOC [3.2246809005737305, -3.1158647537231445]
relation B-LOC [3.275343418121338, -3.3398325443267822]
to B-LOC [3.177826404571533, -3.2401304244995117]
a B-LOC [3.202134609222412, -3.5482218265533447]
Socio-demographic B-LOC [3.180393695831299, -3.538708448410034]
Index B-LOC [2.987276077270508, -3.678212881088257]
(SDI). B-LOC [3.194295883178711, -3.4664289951324463]
FINDINGS B-LOC [1.3813776969909668, -1.858670711517334]
Between B-LOC [1.349999189376831, -1.6980180740356445]
1990 B-LOC [1.43120276927948, -1.7560453414916992]
and B-LOC [1.7851618528366089, -1.9827972650527954]
2015, B-LOC [1.809061884880066, -2.255965232849121]
global B-LOC [1.22751784324646, -1.6631711721420288]
exposure B-LOC [0.8317687511444092, -1.384248971939087]

to B-LOC [0.10051279515028, -0.271325945854187]
unsafe B-LOC [0.36975353956222534, -0.6100986003875732]
sanitation, B-LOC [0.6141999363899231, -0.6928358674049377]
household B-LOC [0.26375868916511536, -0.40193840861320496]
air B-LOC [0.5988931059837341, -0.9329075217247009]
pollution, B-LOC [0.5653013586997986, -0.583106279373169]
childhood B-LOC [0.28906679153442383, -0.37499406933784485]
underweight, B-LOC [0.35457125306129456, -0.3237934708595276]
childhood B-LOC [0.26013168692588806, -0.34586119651794434]
stunting, B-LOC [0.21393108367919922, -0.4599517285823822]
and B-LOC [0.24170005321502686, -0.5889869928359985]
smoking B-LOC [0.6214694380760193, -0.5715017318725586]
each B-LOC [0.3265799582004547, -0.6040056347846985]
decreased B-LOC [0.42148375511169434, -0.6422977447509766]
by B-LOC [0.10728633403778076, -0.4896913766860962]
more B-LOC [0.39246806502342224, -0.4484533965587616]
than B-LOC [0.38179388642311096, -0.6110855937004089]
25%. B-LOC [0.5301366448402405, -0.600473940372467]
Global B-LOC [2.090641498565674, -2.1072704792022705]
exposure B-LOC [1.973562240600586, -2.0412211418151855]
for B-LOC [1.9199327230453491, -2.002437114715576]
several B-LOC [2.108290195465088, -2.191235065460205]
occupational B-LOC [2.2525622844696045, -2.2004683017730713]
risks, B-LOC [2.3542046546936035, -2.3415462970733643]
high B-LOC [2.047569990158081, -2.4449195861816406]
body-mass B-LOC [2.1398541927337646, -2.3430051803588867]
index B-LOC [2.0439560413360596, -2.2163572311401367]
(BMI), B-LOC [2.4763388633728027, -2.5717477798461914]
and B-LOC [1.5208193063735962, -1.872463583946228]
drug B-LOC [2.3045265674591064, -2.4556753635406494]
use B-LOC [2.0585572719573975, -2.097529172897339]
increased B-LOC [1.7989572286605835, -2.012542963027954]
by B-LOC [1.582039475440979, -1.964073657989502]
more B-LOC [1.9805564880371094, -2.030097723007202]
than B-LOC [2.0237414836883545, -2.1394240856170654]
25% B-LOC [2.4306440353393555, -1.9693822860717773]
over B-LOC [1.577467441558838, -1.9929078817367554]
the B-LOC [1.8603341579437256, -2.036532163619995]
same B-LOC [1.9726672172546387, -2.1913092136383057]
period. B-LOC [2.049896478652954, -2.422414541244507]
All B-LOC [2.179046869277954, -2.048236131668091]
risks B-LOC [2.556758165359497, -2.111070156097412]
jointly B-LOC [2.1820929050445557, -1.6241997480392456]
evaluated B-LOC [2.5162250995635986, -1.956739068031311]
in B-LOC [2.3233370780944824, -1.8818473815917969]
2015 B-LOC [2.524869680404663, -2.0876121520996094]
accounted B-LOC [2.1908822059631348, -1.8805358409881592]
for B-LOC [2.288738965988159, -2.0074026584625244]
57·8% B-LOC [2.4910295009613037, -2.095848798751831]
(95% B-LOC [2.1401031017303467, -2.1104612350463867]
CI B-LOC [1.9463025331497192, -1.8966424465179443]
56·6-58·8) B-LOC [2.0945699214935303, -1.846175193786621]
of B-LOC [2.0573155879974365, -2.169480800628662]
global B-LOC [2.229973554611206, -2.0297434329986572]
deaths B-LOC [2.452258825302124, -2.2338454723358154]
and B-LOC [2.036011219024658, -1.9571747779846191]
41·2% B-LOC [2.124476671218872, -1.7112144231796265]
(39·8-42·8) B-LOC [1.856968879699707, -1.9877146482467651]
of B-LOC [2.148766279220581, -2.189073324203491]
DALYs. B-LOC [2.3151867389678955, -2.3622772693634033]
In B-LOC [0.4976896643638611, -0.60499507188797]
2015, B-LOC [0.730780839920044, -0.7554306387901306]
the B-LOC [0.6542487740516663, -0.42576250433921814]
ten B-LOC [0.8750233054161072, -0.4417899549007416]
largest B-LOC [0.6332464814186096, -0.5248751044273376]
contributors B-LOC [0.5377363562583923, -0.5587815642356873]
to B-LOC [0.35826006531715393, -0.6615808010101318]
global B-LOC [0.590809166431427, -0.7630221843719482]

DALYs O [-0.34509021043777466, 0.03419686481356621]
among O [-0.023230595514178276, 0.16464519500732422]
Level O [-0.1487111896276474, 0.2967331111431122]
3 B-LOC [0.1757388561964035, 0.17027202248573303]
risks O [-0.44612735509872437, 0.46774739027023315]
were O [-0.5486801266670227, 0.40418240427970886]
high O [-0.6309598684310913, 0.5492814183235168]
systolic O [-0.4825933575630188, 0.4092106819152832]
blood O [-0.553297758102417, 0.4245462119579315]
pressure O [-0.4519737660884857, 0.5578988194465637]
(211·8 O [-0.6288305521011353, 0.46343061327934265]
million O [-0.8369963765144348, 0.5702560544013977]
[192·7 O [-0.4109354019165039, 0.09713688492774963]
million O [-0.5337514281272888, 0.13020187616348267]
to O [-0.5292061567306519, -0.12086863070726395]
231·1 B-LOC [0.04239560663700104, -0.1775178611278534]
million] O [-0.5409273505210876, 0.030063925310969353]
global O [-0.6410072445869446, 0.15799611806869507]
DALYs), O [-0.40881291031837463, 0.1354197859764099]
smoking O [-0.447687029838562, 0.7395060658454895]
(148·6 O [-0.8777198195457458, 0.7790401577949524]
million O [-0.9758776426315308, 0.6463128924369812]
[134·2 O [-0.734287679195404, 0.36689308285713196]
million O [-0.9279413819313049, 0.4076620638370514]
to O [-0.8465332388877869, 0.18253901600837708]
163·1 O [-0.22490830719470978, 0.08782581239938736]
million]), O [-0.8851464986801147, 0.20604276657104492]
high O [-0.748749852180481, 0.7892623543739319]
fasting O [-0.6947855353355408, 1.1217310428619385]
plasma O [-0.7644770741462708, 0.7265013456344604]
glucose O [-0.5787076354026794, 0.7642015218734741]
(143·1 O [-0.8507619500160217, 0.6750034689903259]
million O [-1.100588321685791, 0.673376739025116]
[125·1 O [-0.7496182918548584, 0.39037057757377625]
million O [-1.022274136543274, 0.6376295685768127]
to O [-0.9033998847007751, 0.33840450644493103]
163·5 O [-0.3206595480442047, 0.34320759773254395]
million]), O [-1.0050475597381592, 0.39020946621894836]
high O [-0.7373751401901245, 0.7688382267951965]
BMI O [-0.5460625886917114, 0.7200130820274353]
(120·1 O [-0.8508476614952087, 0.6965246200561523]
million O [-0.9463551640510559, 0.7172005772590637]
[83·8 O [-0.6907256841659546, 0.3558066487312317]
million O [-0.8454141020774841, 0.526472806930542]
to O [-0.840020477771759, 0.2782060205936432]
158·4 O [-0.13896656036376953, 0.18442311882972717]
million]), O [-0.886023998260498, 0.313711017370224]
childhood O [-0.5978326797485352, 0.7530547976493835]
undernutrition O [-0.5784908533096313, 0.7767699360847473]
(113·3 O [-0.8264450430870056, 0.5932462811470032]
million O [-0.872602641582489, 0.5450361371040344]
[103·9 O [-0.6648346781730652, 0.2574951946735382]
million O [-0.880338728427887, 0.4996018707752228]
to O [-0.7868180871009827, 0.25773629546165466]
123·4 O [-0.2830996811389923, 0.07515943050384521]
million]), O [-0.8586689829826355, 0.38836780190467834]

ambient O [-0.4903990924358368, 0.1157645508646965]
particulate O [-0.2739759087562561, -0.0043663629330694675]
matter O [-0.3425392806529999, 0.14943969249725342]
(103·1 O [-0.42045819759368896, 0.09896250814199448]
million O [-0.6210466027259827, 0.08797793090343475]
[90·8 O [-0.45520323514938354, -0.01884743757545948]
million O [-0.6531586050987244, -0.0018649869598448277]
to O [-0.5309608578681946, -0.10193470120429993]
115·1 O [-0.1329481601715088, -0.037686869502067566]
million]), O [-0.708999514579773, -0.05715915933251381]
high O [-0.5270544290542603, 0.26841476559638977]
total O [-0.5403922200202942, 0.20897148549556732]
cholesterol O [-0.5091356635093689, 0.2708173096179962]
(88·7 O [-0.5476365685462952, 0.23056991398334503]
million O [-0.7492774128913879, 0.3062531054019928]
[74·6 O [-0.5364902019500732, 0.09227149188518524]
million O [-0.7871147394180298, 0.18693697452545166]
to O [-0.5940439701080322, -0.013382070697844028]
105·7 O [-0.26213183999061584, -0.08033143728971481]
million]), O [-0.7980565428733826, 0.06750151515007019]
household O [-0.4133690893650055, 0.2674349546432495]
air O [-0.3306046426296234, -0.0051522464491426945]
pollution O [-0.3849821090698242, 0.2854866087436676]
(85·6 O [-0.5384151339530945, 0.2123071849346161]
million O [-0.8014046549797058, 0.30454328656196594]
[66·7 O [-0.5529829859733582, 0.05058377608656883]
million O [-0.812427282333374, 0.1869920790195465]
to O [-0.6453163623809814, 0.02626539207994938]
106·1 O [-0.3255595862865448, 0.027720848098397255]
million]), O [-0.8728640675544739, 0.12068895995616913]
alcohol O [-0.22743934392929077, 0.01315557025372982]
use O [-0.4325498044490814, 0.26567667722702026]
(85·0 O [-0.4177822172641754, 0.14203323423862457]
million O [-0.5995765328407288, 0.04768596217036247]
[77·2 O [-0.37901973724365234, -0.05929875746369362]
million O [-0.6756706833839417, 0.08552706986665726]
to O [-0.515052855014801, -0.029334841296076775]
93·0 O [-0.2932194471359253, 0.1153462678194046]
million]), O [-0.6921364665031433, 0.033212970942258835]
and O [-0.21761570870876312, 0.18616315722465515]
diets B-LOC [0.06418368220329285, -0.023741597309708595]
high O [-0.22853222489356995, -0.08395424485206604]
in O [-0.2175287902355194, -0.05596842244267464]
sodium B-LOC [0.1620812714099884, -0.46191757917404175]
(83·0 B-LOC [0.11445501446723938, -0.38479524850845337]
million B-LOC [0.24899810552597046, -0.5765246748924255]
[49·3 B-LOC [-0.03293309733271599, -0.3517468273639679]
million B-LOC [0.017191017046570778, -0.31349045038223267]
to B-LOC [-0.03418103605508804, -0.23385900259017944]
127·5 B-LOC [0.3641991913318634, -0.3748971223831177]
million]). B-LOC [0.07755327224731445, -0.5416094064712524]
From B-LOC [1.1351919174194336, -0.8134440183639526]
1990 B-LOC [1.305631399154663, -1.1828738451004028]
to B-LOC [1.7963836193084717, -1.1970462799072266]
2015, B-LOC [1.47128164768219, -1.4522883892059326]
attributable B-LOC [1.6818797588348389, -1.5634652376174927]
DALYs B-LOC [1.147626280784607, -1.0658462047576904]
declined B-LOC [1.2025803327560425, -1.1342320442199707]

for B-LOC [-0.09169615805149078, -0.19929084181785583]
micronutrient B-LOC [0.4244867265224457, -0.3627217710018158]
deficiencies, B-LOC [0.6439259648323059, -0.429710328578949]
childhood B-LOC [0.2592240571975708, -0.2839517295360565]
undernutrition, B-LOC [0.571232259273529, -0.4999466836452484]
unsafe B-LOC [0.3047269284725189, -0.4965014159679413]
sanitation B-LOC [0.8900684118270874, -0.795005738735199]
and B-LOC [0.5043781399726868, -0.7471884489059448]
water, B-LOC [0.8292659521102905, -0.8843552470207214]
and B-LOC [0.4292382299900055, -0.31941869854927063]
household B-LOC [0.3483264744281769, -0.47753921151161194]
air B-LOC [0.6676446795463562, -1.004387617111206]
pollution; B-LOC [0.7461494207382202, -0.6734434962272644]
reductions B-LOC [0.18374890089035034, -0.17759500443935394]
in B-LOC [0.03978535905480385, -0.462546169757843]
risk-deleted B-LOC [0.23788976669311523, -0.528051495552063]
DALY B-LOC [0.187563955783844, -0.4976235032081604]
rates B-LOC [0.22774961590766907, -0.45655831694602966]
rather B-LOC [0.10019498318433762, -0.2143232375383377]
than B-LOC [0.21293169260025024, -0.09308840334415436]
reductions B-LOC [0.44557985663414, -0.6473140120506287]
in B-LOC [0.2243727147579193, -0.8679003715515137]
exposure B-LOC [0.49010828137397766, -0.6733320355415344]
drove B-LOC [0.4918455481529236, -0.6582790017127991]
these B-LOC [0.41831132769584656, -0.6948893666267395]
declines. B-LOC [0.7792767882347107, -0.9615594148635864]
Rising B-LOC [1.3963537216186523, -1.5569965839385986]
exposure B-LOC [1.5791150331497192, -1.424769639968872]
contributed B-LOC [1.18563973903656, -1.1451921463012695]
to B-LOC [1.0726463794708252, -1.0087072849273682]
notable B-LOC [1.2650415897369385, -1.2451506853103638]
increases B-LOC [1.290785551071167, -1.500903606414795]
in B-LOC [1.2221194505691528, -1.5514323711395264]
attributable B-LOC [1.6956827640533447, -1.7630257606506348]
DALYs B-LOC [1.3543295860290527, -1.6436901092529297]
from B-LOC [1.0854750871658325, -1.162277340888977]
high B-LOC [1.0941145420074463, -1.4444160461425781]
BMI, B-LOC [1.4777355194091797, -1.8366740942001343]
high B-LOC [0.9653112292289734, -1.2645201683044434]
fasting B-LOC [1.4550585746765137, -1.5515141487121582]
plasma B-LOC [1.2128186225891113, -1.703059434890747]
glucose, B-LOC [1.4875144958496094, -1.5519030094146729]
occupational B-LOC [1.2678537368774414, -1.5770267248153687]
carcinogens, B-LOC [1.79774808883667, -1.8443074226379395]
and B-LOC [1.0919842720031738, -1.1597063541412354]
drug B-LOC [1.7291805744171143, -1.8994910717010498]
use. B-LOC [1.4082791805267334, -1.550723910331726]
Environmental B-LOC [1.0575547218322754, -1.2067453861236572]
risks B-LOC [1.042799472808838, -1.2397840023040771]
and B-LOC [0.824606716632843, -1.0064061880111694]
childhood B-LOC [0.9979069232940674, -1.1513792276382446]
undernutrition B-LOC [1.1133276224136353, -1.339034080505371]
declined B-LOC [1.0456291437149048, -1.253733515739441]
steadily B-LOC [0.8727526664733887, -1.248213291168213]
with B-LOC [0.5879149436950684, -0.9575478434562683]
SDI; B-LOC [1.180462121963501, -1.2168322801589966]
low B-LOC [0.3904910981655121, -0.6571125388145447]
physical B-LOC [0.3803481161594391, -0.47825872898101807]
activity, B-LOC [0.3677182197570801, -0.5072824358940125]
high B-LOC [0.19229987263679504, -0.5657487511634827]
BMI, B-LOC [0.7389105558395386, -1.0793451070785522]
and B-LOC [0.048382360488176346, -0.3725234568119049]
high B-LOC [0.14920669794082642, -0.5797858834266663]
fasting B-LOC [0.6386511921882629, -0.767998993396759]
plasma B-LOC [0.4679310619831085, -1.0816378593444824]
glucose B-LOC [0.6669931411743164, -0.9165846705436707]
increased B-LOC [0.39505425095558167, -0.8259003758430481]
with B-LOC [0.23337410390377045, -0.6620171666145325]
SDI. B-LOC [0.9779898524284363, -0.9829866290092468]
In B-LOC [0.16437223553657532, -0.6303570866584778]
119 B-LOC [0.460680216550827, -0.609348475933075]

countries, B-LOC [1.8180903196334839, -1.8351504802703857]
metabolic B-LOC [2.135370969772339, -2.344172239303589]
risks, B-LOC [2.1568610668182373, -2.078437566757202]
such B-LOC [1.7137327194213867, -1.6321481466293335]
as B-LOC [1.6829044818878174, -1.787198781967163]
high B-LOC [1.6593694686889648, -2.012010097503662]
BMI B-LOC [2.0376908779144287, -2.236633062362671]
and B-LOC [1.4265366792678833, -1.5160553455352783]
fasting B-LOC [2.4109342098236084, -2.2663466930389404]
plasma B-LOC [2.0768377780914307, -2.5599632263183594]
glucose, B-LOC [2.1104609966278076, -2.343585252761841]
contributed B-LOC [2.1667792797088623, -2.4561493396759033]
the B-LOC [2.3802504539489746, -2.3943288326263428]
most B-LOC [2.42439866065979, -2.508840322494507]
attributable B-LOC [2.806245803833008, -2.8647077083587646]
DALYs B-LOC [2.0939412117004395, -2.4716084003448486]
in B-LOC [2.5094566345214844, -2.395231008529663]
2015. B-LOC [2.6906416416168213, -2.5453174114227295]
Regionally, B-LOC [2.8857412338256836, -2.8426973819732666]
smoking B-LOC [2.873783826828003, -2.6279304027557373]
still B-LOC [3.052314519882202, -2.868213653564453]
ranked B-LOC [3.0003511905670166, -2.751589059829712]
among B-LOC [3.1158344745635986, -2.6875178813934326]
the B-LOC [3.087236166000366, -2.6413421630859375]
leading B-LOC [3.025768280029297, -3.007622480392456]
five B-LOC [3.073725461959839, -2.874678134918213]
risk B-LOC [3.1619086265563965, -3.133690118789673]
factors B-LOC [3.1887967586517334, -3.1154630184173584]
for B-LOC [2.8370723724365234, -2.928942918777466]
attributable B-LOC [3.0248022079467773, -2.9224843978881836]
DALYs B-LOC [3.030484914779663, -3.012446165084839]
in B-LOC [2.9334981441497803, -2.737231492996216]
109 B-LOC [3.0013110637664795, -2.9900691509246826]
countries; B-LOC [3.1694209575653076, -3.0714871883392334]
childhood B-LOC [2.9008123874664307, -2.8418080806732178]
underweight B-LOC [3.190183401107788, -2.727489948272705]
and B-LOC [2.716766119003296, -2.5715861320495605]
unsafe B-LOC [2.966998338699341, -2.887576103210449]
sex B-LOC [2.987955331802368, -2.9666430950164795]
remained B-LOC [2.793962240219116, -2.8921241760253906]
primary B-LOC [2.9822440147399902, -2.947721004486084]
drivers B-LOC [3.1814773082733154, -3.015758991241455]
of B-LOC [3.036087989807129, -2.9430510997772217]
early B-LOC [2.849214792251587, -2.86682391166687]
death B-LOC [3.155057907104492, -3.0071940422058105]
and B-LOC [2.855041265487671, -2.635115385055542]
disability B-LOC [3.143184185028076, -2.896719217300415]
in B-LOC [3.1048219203948975, -2.875948429107666]
much B-LOC [3.1353213787078857, -2.851257562637329]
of B-LOC [3.177905797958374, -2.7897849082946777]
sub-Saharan B-LOC [3.283531427383423, -3.0686473846435547]
Africa. B-LOC [3.066563844680786, -3.119171142578125]
INTERPRETATION B-LOC [2.2223212718963623, -2.35428786277771]
Declines B-LOC [2.6718380451202393, -2.7157444953918457]
in B-LOC [2.563586711883545, -2.944420576095581]
some B-LOC [2.69541335105896, -3.0051262378692627]
key B-LOC [2.7865254878997803, -2.793543815612793]
environmental B-LOC [2.921241521835327, -3.102731227874756]
risks B-LOC [3.0532495975494385, -3.1434390544891357]
have B-LOC [2.8777613639831543, -2.8783493041992188]
contributed B-LOC [2.764054298400879, -3.0202443599700928]
to B-LOC [2.537562847137451, -2.8171370029449463]
declines B-LOC [2.9235498905181885, -3.10172963142395]
in B-LOC [2.7647080421447754, -3.236802339553833]
critical B-LOC [2.884852647781372, -3.320404291152954]
infectious B-LOC [3.0963385105133057, -3.4168102741241455]
diseases. B-LOC [3.1634645462036133, -3.3038175106048584]
Some B-LOC [2.4828779697418213, -3.0463998317718506]
risks B-LOC [2.9786205291748047, -3.0863335132598877]
appear B-LOC [3.0063092708587646, -2.815451145172119]
to B-LOC [3.075817346572876, -2.950831890106201]
be B-LOC [2.959756851196289, -2.961869955062866]
invariant B-LOC [2.978299856185913, -3.1209850311279297]
to B-LOC [2.700087308883667, -3.1706645488739014]
SDI. B-LOC [2.964712619781494, -3.156494140625]
Increasing B-LOC [0.5612813830375671, -0.9962022304534912]
risks, B-LOC [1.1631115674972534, -1.3975229263305664]

including O [-0.2071378082036972, -0.009000660851597786]
high O [-0.2309032380580902, -0.03996523097157478]
BMI, B-LOC [0.29842448234558105, -0.2318565845489502]
high O [-0.2427096962928772, 0.010597093030810356]
fasting O [0.0738203376531601, 0.25098103284835815]
plasma B-LOC [-0.06529688090085983, -0.08904207497835159]
glucose, B-LOC [0.2515081763267517, -0.04983699694275856]
drug B-LOC [0.4783485531806946, -0.4854637682437897]
use, B-LOC [0.290721595287323, -0.18052054941654205]
and O [-0.09556708484888077, 0.07246236503124237]
some B-LOC [0.16412439942359924, -0.32226428389549255]
occupational B-LOC [0.4167211353778839, -0.3462735116481781]
exposures, B-LOC [0.5360058546066284, -0.4518045485019684]
contribute B-LOC [0.2904004156589508, -0.30324479937553406]
to B-LOC [0.2075963020324707, -0.26452717185020447]
rising B-LOC [0.6909475326538086, -0.8199834227561951]
burden B-LOC [0.7937459349632263, -0.6971432566642761]
from B-LOC [0.49400463700294495, -0.6674083471298218]
some B-LOC [0.41228625178337097, -0.7942026257514954]
conditions, B-LOC [0.7446655631065369, -0.7760714888572693]
but B-LOC [0.3797084391117096, -0.44258609414100647]
also B-LOC [0.5143545269966125, -0.680436372756958]
provide B-LOC [0.6637430787086487, -0.7083719968795776]
opportunities B-LOC [1.0885214805603027, -1.1616911888122559]
for B-LOC [0.9682148694992065, -1.3469722270965576]
intervention. B-LOC [0.8505190014839172, -1.0179613828659058]
Some B-LOC [2.3582913875579834, -2.324436902999878]
highly B-LOC [2.722992420196533, -2.590951681137085]
preventable B-LOC [2.686650514602661, -2.4272310733795166]
risks, B-LOC [2.662262439727783, -2.418238878250122]
such B-LOC [2.653284788131714, -2.1661226749420166]
as B-LOC [2.4914731979370117, -2.1879918575286865]
smoking, B-LOC [2.2818868160247803, -2.1488592624664307]
remain B-LOC [2.405639410018921, -2.1970741748809814]
major B-LOC [2.5582973957061768, -2.3160712718963623]
causes B-LOC [2.763261556625366, -2.506007432937622]
of B-LOC [2.474504232406616, -2.4475252628326416]
attributable B-LOC [2.8791489601135254, -2.634666681289673]
DALYs, B-LOC [2.6131856441497803, -2.438028335571289]
even B-LOC [2.9333064556121826, -2.613636016845703]
as B-LOC [2.655118227005005, -2.319340229034424]
exposure B-LOC [2.6257638931274414, -2.406395673751831]
is B-LOC [2.9198782444000244, -2.334496259689331]
declining. B-LOC [2.707427978515625, -2.5366532802581787]
Public B-LOC [2.8732593059539795, -3.1567769050598145]
policy B-LOC [2.920743227005005, -3.1162941455841064]
makers B-LOC [3.0933263301849365, -3.1544816493988037]
need B-LOC [3.1236183643341064, -3.0572218894958496]
to B-LOC [3.347376585006714, -3.240283966064453]
pay B-LOC [3.3146519660949707, -3.3382062911987305]
attention B-LOC [3.3874030113220215, -3.084310531616211]
to B-LOC [3.2567832469940186, -3.2635810375213623]
the B-LOC [3.153085470199585, -3.1695961952209473]
risks B-LOC [3.0962445735931396, -3.398216485977173]
that B-LOC [3.056785821914673, -3.178541421890259]
are B-LOC [3.051603317260742, -3.004425287246704]
increasingly B-LOC [3.010927677154541, -3.112023115158081]
major B-LOC [3.056403875350952, -3.2019922733306885]
contributors B-LOC [3.076939582824707, -3.164278268814087]
to B-LOC [2.826639175415039, -3.1523075103759766]
global B-LOC [2.954390287399292, -3.1182820796966553]
burden. B-LOC [2.738286018371582, -3.184843063354492]
FUNDING B-LOC [1.809051513671875, -1.8476529121398926]
Bill B-LOC [2.0513756275177, -1.8358039855957031]
& B-LOC [1.955228328704834, -1.8492640256881714]
Melinda B-LOC [2.635542154312134, -2.4609673023223877]
Gates B-LOC [2.1443216800689697, -2.152916193008423]
Foundation. B-LOC [1.7033181190490723, -1.7162933349609375]

OBJECTIVE B-LOC [3.2828590869903564, -3.5389320850372314]
To B-LOC [3.468233823776245, -3.642740249633789]
evaluate B-LOC [3.7059967517852783, -3.5366976261138916]
the B-LOC [3.692716121673584, -3.374513864517212]
cost B-LOC [3.626573324203491, -3.5170600414276123]
effectiveness B-LOC [3.5607171058654785, -3.493210554122925]
of B-LOC [3.4658918380737305, -3.3023078441619873]
standard B-LOC [3.47581148147583, -3.5122785568237305]
treatment B-LOC [3.861388921737671, -3.538706064224243]
with B-LOC [3.8597331047058105, -3.3538477420806885]
and B-LOC [3.1450560092926025, -2.763192892074585]
without B-LOC [3.3981235027313232, -3.2835893630981445]
the B-LOC [3.426698684692383, -3.189260959625244]
addition B-LOC [3.5215179920196533, -3.360135793685913]
of B-LOC [3.3588578701019287, -3.1684396266937256]
ward B-LOC [3.464973211288452, -3.152583360671997]
based B-LOC [3.428400754928589, -3.310457468032837]
non-invasive B-LOC [3.6166913509368896, -3.2872049808502197]
ventilation B-LOC [3.4499919414520264, -3.349269151687622]
in B-LOC [3.618163824081421, -3.256441831588745]
patients B-LOC [3.7636139392852783, -3.21142315864563]
admitted B-LOC [3.7273108959198, -3.320523500442505]
to B-LOC [3.423478364944458, -3.2927417755126953]
hospital B-LOC [3.5333452224731445, -3.328425884246826]
with B-LOC [3.6414248943328857, -3.2995238304138184]
an B-LOC [3.4622929096221924, -3.255030393600464]
acute B-LOC [3.578101873397827, -3.303579092025757]
exacerbation B-LOC [3.5770838260650635, -3.3372275829315186]
of B-LOC [3.532097339630127, -3.311622381210327]
chronic B-LOC [3.482081174850464, -3.3324193954467773]
obstructive B-LOC [3.585685968399048, -3.2295894622802734]
pulmonary B-LOC [3.485153913497925, -3.2527847290039062]
disease. B-LOC [3.7042076587677, -3.112990379333496]
DESIGN B-LOC [3.669642686843872, -3.5443923473358154]
Incremental B-LOC [3.6620404720306396, -3.554133176803589]
cost B-LOC [3.6505959033966064, -3.246623992919922]
effectiveness B-LOC [3.434676170349121, -3.408841371536255]
analysis B-LOC [3.634634256362915, -3.5117437839508057]
of B-LOC [3.467195510864258, -3.272247791290283]
a B-LOC [3.574556589126587, -3.244882822036743]
randomised B-LOC [3.579303026199341, -3.36910343170166]
controlled B-LOC [3.725194215774536, -3.4758737087249756]
trial. B-LOC [3.704054832458496, -3.5444653034210205]
SETTING B-LOC [2.6978256702423096, -2.9809749126434326]
Medical B-LOC [3.4429476261138916, -3.3966586589813232]
wards B-LOC [3.8353524208068848, -3.196218252182007]
in B-LOC [3.6687896251678467, -3.1793830394744873]
14 B-LOC [3.9661130905151367, -3.3274104595184326]
hospitals B-LOC [3.7777082920074463, -3.2385003566741943]
in B-LOC [3.9301693439483643, -3.139493703842163]
the B-LOC [3.824259042739868, -3.0399444103240967]
United B-LOC [3.8278298377990723, -3.4218080043792725]
Kingdom. B-LOC [3.696943521499634, -3.194340467453003]
PARTICIPANTS B-LOC [2.1149656772613525, -2.7127575874328613]
The B-LOC [2.2333643436431885, -2.568800926208496]
trial B-LOC [2.716000556945801, -2.793231725692749]
comprised B-LOC [2.427220344543457, -2.351121187210083]
236 B-LOC [2.57238507270813, -2.6797494888305664]
patients B-LOC [2.6370296478271484, -2.650848150253296]
admitted B-LOC [2.8906710147857666, -2.7721574306488037]
to B-LOC [2.7090091705322266, -2.415189027786255]
hospital B-LOC [2.9044253826141357, -2.8065969944000244]
with B-LOC [2.3252999782562256, -2.3411355018615723]
an B-LOC [2.3910534381866455, -2.3343505859375]
acute B-LOC [2.5973823070526123, -2.512239456176758]
exacerbation B-LOC [2.2598888874053955, -2.522318124771118]
of B-LOC [2.0659945011138916, -2.224893808364868]
chronic B-LOC [2.325554847717285, -2.503481388092041]
obstructive B-LOC [1.8337252140045166, -2.1044771671295166]
pulmonary B-LOC [2.3239965438842773, -2.8746399879455566]
disease B-LOC [2.174874782562256, -2.2975265979766846]
and B-LOC [1.7291922569274902, -2.3054699897766113]
mild B-LOC [1.7955303192138672, -1.9633629322052002]
to B-LOC [1.910569667816162, -2.4385392665863037]
moderate B-LOC [1.7091498374938965, -1.9575268030166626]
acidosis B-LOC [1.7549357414245605, -2.3527426719665527]

(pH B-LOC [2.4922940731048584, -2.701799154281616]
7.25-7.35) B-LOC [2.4355967044830322, -2.679799795150757]
secondary B-LOC [3.067660331726074, -2.810084581375122]
to B-LOC [2.8299872875213623, -2.8646373748779297]
respiratory B-LOC [3.1227314472198486, -3.31781005859375]
failure. B-LOC [2.891263723373413, -3.1256840229034424]
The B-LOC [3.463191032409668, -3.2029666900634766]
economic B-LOC [3.654655694961548, -3.519972085952759]
analysis B-LOC [3.464041233062744, -3.3951046466827393]
compared B-LOC [3.5871033668518066, -3.5355947017669678]
the B-LOC [3.557690382003784, -3.2955591678619385]
costs B-LOC [3.707641363143921, -3.517983913421631]
of B-LOC [3.4750020503997803, -3.2399163246154785]
treatment B-LOC [3.626410961151123, -3.522684335708618]
that B-LOC [3.586047887802124, -3.2752702236175537]
these B-LOC [3.4525644779205322, -3.3974955081939697]
patients B-LOC [3.5819404125213623, -3.426469564437866]
received B-LOC [3.6961991786956787, -3.4150705337524414]
after B-LOC [3.5629842281341553, -3.341827869415283]
randomisation. B-LOC [3.588118314743042, -3.496349811553955]
MAIN B-LOC [3.302640676498413, -3.1778743267059326]
OUTCOME B-LOC [3.3223230838775635, -3.031555652618408]
MEASURE B-LOC [3.232138156890869, -3.0055384635925293]
Incremental B-LOC [3.316721200942993, -3.0815117359161377]
cost B-LOC [3.221923351287842, -2.934769868850708]
per B-LOC [3.1543281078338623, -2.8879334926605225]
in-hospital B-LOC [3.270998239517212, -2.9365079402923584]
death. B-LOC [3.3489198684692383, -3.075543165206909]
RESULTS B-LOC [1.4869270324707031, -1.77622652053833]
24/118 B-LOC [2.4305975437164307, -2.1949870586395264]
died B-LOC [2.363701343536377, -1.646956205368042]
in B-LOC [2.052391767501831, -1.6301994323730469]
the B-LOC [2.4466400146484375, -1.7411808967590332]
group B-LOC [2.300320863723755, -1.7339035272598267]
receiving B-LOC [2.591111660003662, -2.3022091388702393]
standard B-LOC [2.323354959487915, -2.0078628063201904]
treatment B-LOC [2.2525041103363037, -1.9174941778182983]
and B-LOC [1.9473702907562256, -1.436098337173462]
12/118 B-LOC [2.41581392288208, -2.236132860183716]
in B-LOC [2.13517689704895, -1.4152412414550781]
the B-LOC [2.472398042678833, -1.634819507598877]
group B-LOC [2.343867540359497, -1.5542327165603638]
receiving B-LOC [2.444359302520752, -2.1727497577667236]
non-invasive B-LOC [2.139423370361328, -1.6108574867248535]
ventilation B-LOC [2.0158185958862305, -2.0141890048980713]
(P=0.05). B-LOC [2.1357219219207764, -1.6810574531555176]
Allocation B-LOC [0.36125388741493225, 0.08751611411571503]
to B-LOC [0.5418168902397156, -0.08850860595703125]
the B-LOC [0.7661534547805786, -0.2747604548931122]
group B-LOC [0.7972994446754456, -0.32757022976875305]
receiving B-LOC [0.5709131956100464, -0.5782006978988647]
non-invasive B-LOC [0.30006733536720276, -0.1391308456659317]
ventilation B-LOC [0.36437931656837463, -0.35628750920295715]
was B-LOC [0.03914906457066536, -0.0076168910600245]
associated O [-0.09458130598068237, 0.20968537032604218]
with O [-0.0735512226819992, 0.16150328516960144]
a O [-0.2895848751068115, 0.19472843408584595]
reduction O [-0.18546096980571747, -0.052142489701509476]
in O [-0.38929590582847595, -0.07901743054389954]
costs O [-0.07432441413402557, 0.089968740940094]
of O [-0.3213672935962677, 0.22335609793663025]
49362 B-LOC [0.12824365496635437, 0.010794805362820625]
pounds B-LOC [0.17745593190193176, -0.021345393732190132]
sterling B-LOC [0.42929747700691223, -0.13899023830890656]
(78741 O [-0.0966917872428894, 0.1775360405445099]
dollars; B-LOC [0.21590986847877502, -0.095855213701725]
73109 B-LOC [0.23519755899906158, -0.05355078727006912]

euros), B-LOC [0.1470598727464676, -0.32129842042922974]
mainly O [-0.0560612715780735, 0.29769638180732727]
through O [-0.3733689486980438, 0.2965940833091736]
reduced O [-0.11854029446840286, 0.2888231873512268]
use B-LOC [0.20844198763370514, 0.005379644688218832]
of B-LOC [0.13504675030708313, -0.0484616756439209]
intensive B-LOC [0.585172176361084, -0.2568613588809967]
care B-LOC [0.6473197340965271, -0.305192232131958]
units. B-LOC [0.3399820923805237, -0.22499674558639526]
The B-LOC [-0.02132115326821804, -0.12543879449367523]
incremental B-LOC [-0.08442524075508118, -0.10804487764835358]
cost B-LOC [0.16143111884593964, -0.11877793073654175]
effectiveness B-LOC [-0.036426957696676254, -0.20636151731014252]
ratio B-LOC [-0.10439249873161316, -0.18209382891654968]
was O [-0.21510672569274902, -0.03521299734711647]
-645 O [-0.32202908396720886, 0.053311679512262344]
pounds B-LOC [0.08148770779371262, -0.07236457616090775]
sterling B-LOC [0.1112271249294281, -0.29365530610084534]
per O [-0.17602936923503876, 0.12423309683799744]
death B-LOC [0.03495953604578972, -0.02596225030720234]
avoided O [-0.13383731245994568, 0.10823602974414825]
(95% O [-0.2243892401456833, 0.06976806372404099]
confidence O [-0.28068798780441284, 0.08181191980838776]
interval O [-0.3298753798007965, -0.002758693415671587]
-2310 O [-0.37973904609680176, -0.06205931678414345]
pounds O [-0.037680719047784805, -0.0059517198242247105]
sterling B-LOC [-0.07860850542783737, -0.20928694307804108]
to O [-0.36329540610313416, -0.02989376150071621]
386 O [-0.0342337004840374, 0.26601698994636536]
pounds B-LOC [0.04708058387041092, -0.10541120171546936]
sterling), B-LOC [0.11831477284431458, -0.27500119805336]
indicating O [-0.04488735273480415, 0.056753791868686676]
a B-LOC [-0.010774445720016956, -0.1293867528438568]
dominant B-LOC [0.12302394956350327, -0.15541428327560425]
(more B-LOC [-0.012714591808617115, -0.04495304077863693]
effective B-LOC [0.0025291540659964085, -0.1529361605644226]
and O [-0.16644269227981567, 0.12510448694229126]
less O [-0.05513140186667442, 0.2728462517261505]
costly) B-LOC [0.19362938404083252, -0.0769696906208992]
strategy. B-LOC [0.08486945927143097, -0.27989479899406433]
Modelling B-LOC [1.9122061729431152, -1.4323288202285767]
of B-LOC [1.868377685546875, -1.3760738372802734]
these B-LOC [1.5496010780334473, -1.2756552696228027]
data B-LOC [1.6479778289794922, -1.49233078956604]
indicates B-LOC [1.2564936876296997, -1.0572583675384521]
that B-LOC [1.1609123945236206, -1.1797515153884888]
a B-LOC [1.302396535873413, -1.182612657546997]
typical B-LOC [1.2522599697113037, -1.2303322553634644]
UK B-LOC [1.473595380783081, -1.341592788696289]
hospital B-LOC [1.2782871723175049, -1.5933716297149658]
providing B-LOC [1.5323646068572998, -1.2581915855407715]
a B-LOC [1.402275562286377, -1.1817485094070435]
non-invasive B-LOC [1.5387146472930908, -1.2853021621704102]
ventilation B-LOC [1.3522148132324219, -1.675382375717163]
service B-LOC [1.2428492307662964, -1.4807257652282715]
will B-LOC [1.14467453956604, -1.1457501649856567]
avoid B-LOC [1.5249989032745361, -1.351088523864746]
six B-LOC [1.7814033031463623, -1.5662271976470947]
deaths B-LOC [1.940549373626709, -1.6665189266204834]
and B-LOC [1.524730920791626, -1.3598334789276123]
three B-LOC [1.2983677387237549, -1.0704317092895508]
to B-LOC [1.2179303169250488, -1.3760876655578613]
nine B-LOC [2.066317081451416, -1.7055714130401611]
admissions B-LOC [1.7987730503082275, -1.716389536857605]
to B-LOC [1.7426131963729858, -1.7294797897338867]
intensive B-LOC [2.292771816253662, -1.8628350496292114]
care B-LOC [2.2288777828216553, -1.7985754013061523]
units B-LOC [1.967280387878418, -1.761951208114624]
per B-LOC [1.4074451923370361, -1.4775917530059814]
year, B-LOC [1.6940408945083618, -1.8541545867919922]
with B-LOC [0.8822806477546692, -0.8077665567398071]
an B-LOC [0.8708400726318359, -1.0512306690216064]
associated B-LOC [0.9297533631324768, -0.9668050408363342]
cost B-LOC [1.357772946357727, -1.2758457660675049]
reduction B-LOC [0.9924637675285339, -1.33523690700531]
of B-LOC [0.5376845002174377, -0.9750270247459412]
12000-53000 B-LOC [0.7460142970085144, -0.9738596081733704]
pounds B-LOC [1.5317785739898682, -1.6328449249267578]
sterling B-LOC [1.6606392860412598, -1.6103793382644653]
per B-LOC [1.0638465881347656, -1.3662229776382446]
year. B-LOC [1.4265451431274414, -1.744734287261963]
CONCLUSIONS O [-0.6686433553695679, 0.18591256439685822]

Non-invasive O [-0.4573373794555664, 0.6362223029136658]
ventilation O [-0.3654096722602844, 0.38210225105285645]
is O [-0.7521299123764038, 0.8451469540596008]
a O [-0.8679553866386414, 1.011948585510254]
highly O [-0.5554078221321106, 0.6916993260383606]
cost O [-0.21055394411087036, 0.49051961302757263]
effective O [-0.6885231733322144, 0.9543716311454773]
treatment O [-0.569229006767273, 0.6777984499931335]
that O [-1.14583420753479, 0.8490082621574402]
both O [-1.0491814613342285, 1.0320197343826294]
reduced O [-0.7088071703910828, 0.8327897191047668]
total O [-0.6659467816352844, 0.6360318064689636]
costs O [-0.2919350564479828, 0.509711503982544]
and O [-0.9713959693908691, 0.9702646136283875]
improved O [-0.9664905667304993, 0.7725462317466736]
mortality O [-0.26323843002319336, 0.20496919751167297]
in O [-0.49182403087615967, 0.3582405745983124]
hospital. O [-0.5175157189369202, 0.2000352442264557]

BACKGROUND B-LOC [1.2214571237564087, -1.9810569286346436]
Self-harm B-LOC [2.0802836418151855, -2.6428463459014893]
and B-LOC [2.3303160667419434, -2.908576488494873]
suicide B-LOC [2.591204881668091, -3.031090021133423]
are B-LOC [2.6600072383880615, -3.0332605838775635]
common B-LOC [2.506791114807129, -2.9320662021636963]
in B-LOC [2.1282613277435303, -2.8178951740264893]
prisoners, B-LOC [2.2366442680358887, -2.6886560916900635]
yet B-LOC [2.4617931842803955, -3.1610519886016846]
robust B-LOC [2.7173895835876465, -3.344372510910034]
information B-LOC [2.565999984741211, -3.355699300765991]
on B-LOC [2.8871684074401855, -3.5459647178649902]
the B-LOC [3.204962968826294, -3.6661159992218018]
full B-LOC [3.0160179138183594, -3.5830600261688232]
extent B-LOC [2.987772226333618, -3.679875612258911]
and B-LOC [2.958937168121338, -3.609909772872925]
characteristics B-LOC [3.1135880947113037, -3.7322165966033936]
of B-LOC [2.817763566970825, -3.5339536666870117]
people B-LOC [3.1061127185821533, -3.4890310764312744]
at B-LOC [3.0237529277801514, -3.4054276943206787]
risk B-LOC [3.1977696418762207, -3.4523630142211914]
of B-LOC [2.7391932010650635, -3.561129093170166]
self-harm B-LOC [2.7569401264190674, -3.539557695388794]
is B-LOC [3.0573155879974365, -3.2695071697235107]
scant. B-LOC [3.2453839778900146, -3.372903823852539]
Furthermore, B-LOC [3.206601858139038, -3.455333948135376]
understanding B-LOC [3.0783145427703857, -3.7982566356658936]
how B-LOC [3.0179460048675537, -3.733851194381714]
frequently B-LOC [2.693294048309326, -3.551769971847534]
self-harm B-LOC [2.9224469661712646, -3.7765581607818604]
is B-LOC [3.2977404594421387, -3.608161687850952]
followed B-LOC [2.6732242107391357, -3.3623363971710205]
by B-LOC [2.58858323097229, -3.231595754623413]
suicide, B-LOC [2.9408457279205322, -3.4181666374206543]
and B-LOC [3.0993032455444336, -3.5031869411468506]
in B-LOC [2.870544672012329, -3.624938726425171]
which B-LOC [3.0198991298675537, -3.607003688812256]
prisoners B-LOC [3.015302896499634, -3.5435330867767334]
this B-LOC [3.0549371242523193, -3.638068675994873]
progression B-LOC [2.6355550289154053, -3.680581569671631]
is B-LOC [3.383608341217041, -3.676271915435791]
most B-LOC [3.169119358062744, -3.709635019302368]
likely B-LOC [3.29378342628479, -3.751781940460205]
to B-LOC [3.223240375518799, -3.6312789916992188]
happen, B-LOC [2.6440818309783936, -3.577242612838745]
is B-LOC [3.2087409496307373, -3.5076096057891846]
important. B-LOC [3.22338604927063, -3.6388306617736816]
We B-LOC [3.01418399810791, -3.018807888031006]
did B-LOC [3.300532102584839, -3.0595781803131104]
a B-LOC [3.373258113861084, -3.196091413497925]
case-control B-LOC [3.4837231636047363, -3.5204086303710938]
study B-LOC [3.169100761413574, -3.2701056003570557]
of B-LOC [3.286334276199341, -3.1481056213378906]
all B-LOC [3.4326541423797607, -3.3740854263305664]
prisoners B-LOC [3.269571542739868, -3.4553492069244385]
in B-LOC [3.587146520614624, -3.2732667922973633]
England B-LOC [3.4473326206207275, -3.2162840366363525]
and B-LOC [3.2622745037078857, -2.9954705238342285]
Wales B-LOC [3.313676118850708, -3.280322790145874]
to B-LOC [3.4798085689544678, -3.2104604244232178]
ascertain B-LOC [3.35984206199646, -3.186779737472534]
the B-LOC [3.464512825012207, -3.2649800777435303]
prevalence B-LOC [3.5479209423065186, -3.3202388286590576]
of B-LOC [3.301941156387329, -3.239732027053833]
self-harm B-LOC [3.4478976726531982, -3.6114323139190674]
in B-LOC [3.496647834777832, -3.2809503078460693]
this B-LOC [3.288989782333374, -3.2352731227874756]
population, B-LOC [3.4569287300109863, -3.4599931240081787]
associated B-LOC [3.425346612930298, -3.6073825359344482]
risk B-LOC [3.6251161098480225, -3.5018818378448486]
factors, B-LOC [3.4649691581726074, -3.431567430496216]
clustering B-LOC [3.450768232345581, -3.4049222469329834]
effects, B-LOC [3.568889856338501, -3.546018600463867]
and B-LOC [3.3025286197662354, -3.349161386489868]
risk B-LOC [3.535590648651123, -3.5162904262542725]
of B-LOC [3.3167564868927, -3.218682050704956]
subsequent B-LOC [3.1571033000946045, -3.543884038925171]
suicide B-LOC [3.4658713340759277, -3.492875814437866]
after B-LOC [3.146857976913452, -3.243558883666992]
self-harm. B-LOC [3.256995677947998, -3.452537775039673]
METHODS B-LOC [1.2047218084335327, -2.055847644805908]
Records B-LOC [1.2720448970794678, -1.5573147535324097]
of B-LOC [1.440686583518982, -1.8987298011779785]
self-harm B-LOC [1.6345216035842896, -1.931736707687378]
incidents B-LOC [1.4065842628479004, -1.6471117734909058]
in B-LOC [1.7584482431411743, -1.712458610534668]
all B-LOC [1.5484063625335693, -1.4629721641540527]

prisons B-LOC [3.3556244373321533, -3.833592176437378]
in B-LOC [3.621816873550415, -3.6097843647003174]
England B-LOC [3.635119915008545, -3.566450595855713]
and B-LOC [3.5771830081939697, -3.4676642417907715]
Wales B-LOC [3.5856547355651855, -3.6594793796539307]
were B-LOC [3.4819438457489014, -3.7887957096099854]
gathered B-LOC [3.6224377155303955, -3.8702776432037354]
routinely B-LOC [3.5859482288360596, -3.8058364391326904]
between B-LOC [3.6501309871673584, -3.935260534286499]
January, B-LOC [3.7743465900421143, -3.9555985927581787]
2004, B-LOC [3.815786123275757, -3.9721858501434326]
and B-LOC [3.70033860206604, -3.84464693069458]
December, B-LOC [3.843238115310669, -4.099433898925781]
2009. B-LOC [3.529820203781128, -4.041977405548096]
We B-LOC [3.1463510990142822, -3.514244794845581]
did B-LOC [3.171907663345337, -3.5854570865631104]
a B-LOC [3.3011295795440674, -3.723749876022339]
case-control B-LOC [3.591642141342163, -3.977757453918457]
comparison B-LOC [3.2911036014556885, -3.8644046783447266]
of B-LOC [3.2467567920684814, -3.8934097290039062]
prisoners B-LOC [3.0714681148529053, -3.7866947650909424]
who B-LOC [3.1636412143707275, -3.7633512020111084]
self-harmed B-LOC [3.1234018802642822, -3.903501272201538]
and B-LOC [3.4376771450042725, -3.825361490249634]
those B-LOC [3.2622954845428467, -3.7844629287719727]
who B-LOC [3.213794469833374, -3.6397626399993896]
did B-LOC [3.092548370361328, -3.596306085586548]
not B-LOC [3.331732988357544, -3.6017115116119385]
between B-LOC [3.4143409729003906, -4.054830551147461]
January, B-LOC [3.6118128299713135, -3.9671595096588135]
2006, B-LOC [3.5205090045928955, -3.8410532474517822]
and B-LOC [3.531052827835083, -3.909707546234131]
December, B-LOC [3.7936086654663086, -4.053032398223877]
2009. B-LOC [3.435041666030884, -4.055267333984375]
We B-LOC [3.144838333129883, -3.468958616256714]
also B-LOC [3.306709051132202, -3.5594594478607178]
used B-LOC [3.1525967121124268, -3.497863292694092]
a B-LOC [3.228396415710449, -3.3714141845703125]
Bayesian B-LOC [3.122403383255005, -3.5881593227386475]
approach B-LOC [3.214561700820923, -3.5782411098480225]
to B-LOC [3.333179473876953, -3.621736764907837]
look B-LOC [3.4173061847686768, -3.747300148010254]
at B-LOC [3.449744462966919, -3.6980843544006348]
clustering B-LOC [3.428068161010742, -3.760711193084717]
of B-LOC [3.4013988971710205, -3.7590765953063965]
people B-LOC [3.416815996170044, -3.8077595233917236]
who B-LOC [3.3470468521118164, -3.791001558303833]
self-harmed. B-LOC [3.350796937942505, -3.9560370445251465]
Prisoners B-LOC [2.9599592685699463, -3.4421885013580322]
who B-LOC [2.6539251804351807, -3.2279679775238037]
self-harmed B-LOC [2.884096145629883, -3.4052093029022217]
and B-LOC [2.4087185859680176, -2.747756242752075]
subsequently B-LOC [2.838228225708008, -2.93987774848938]
died B-LOC [3.079058885574341, -3.371692419052124]
by B-LOC [2.9293296337127686, -2.9687440395355225]
suicide B-LOC [3.2359111309051514, -3.6559274196624756]
in B-LOC [3.2612216472625732, -3.1916685104370117]
prison B-LOC [3.2099549770355225, -3.633881092071533]
were B-LOC [3.133615732192993, -3.5892817974090576]
compared B-LOC [3.2066614627838135, -3.8148586750030518]
with B-LOC [3.080454111099243, -3.7865731716156006]
other B-LOC [2.9832427501678467, -3.6570467948913574]
inmates B-LOC [3.2605791091918945, -3.7430522441864014]
who B-LOC [2.849961757659912, -3.3148677349090576]
self-harmed. B-LOC [3.0083258152008057, -3.4967026710510254]
FINDINGS B-LOC [0.6613118052482605, -0.8869693279266357]
139,195 B-LOC [0.8550750017166138, -0.8106246590614319]
self-harm B-LOC [0.6804201602935791, -0.8722624182701111]
incidents B-LOC [0.4577987492084503, -0.6051981449127197]
were B-LOC [0.6712570786476135, -0.7943053841590881]
recorded B-LOC [0.6614139676094055, -0.6259728074073792]
in B-LOC [0.6491064429283142, -0.6816028356552124]
26,510 B-LOC [1.2321770191192627, -0.7504065632820129]
individual B-LOC [0.37858155369758606, -0.7582659125328064]
prisoners B-LOC [0.6311556696891785, -0.7678491473197937]
between B-LOC [0.8571721315383911, -0.8427704572677612]
2004 B-LOC [0.9734991788864136, -0.7473048567771912]
and B-LOC [0.9116691946983337, -0.8624507784843445]
2009; B-LOC [1.008211612701416, -1.1275449991226196]
5-6% B-LOC [0.1150527149438858, -0.24421387910842896]
of B-LOC [0.06286647915840149, -0.2868545353412628]

male B-LOC [0.2549535036087036, -0.6455113291740417]
prisoners B-LOC [0.38262635469436646, -0.6309491395950317]
and B-LOC [0.32958561182022095, -0.6123309135437012]
20-24% B-LOC [0.7233147621154785, -0.6062378883361816]
of B-LOC [0.34104374051094055, -0.5975956916809082]
female B-LOC [0.5842008590698242, -0.6857922077178955]
inmates B-LOC [0.4838762581348419, -0.8117859959602356]
self-harmed B-LOC [0.4583663046360016, -0.7328396439552307]
every B-LOC [0.38603582978248596, -0.6394097208976746]
year. B-LOC [0.5068086981773376, -0.7583706378936768]
Self-harm B-LOC [0.5972988605499268, -1.0266858339309692]
rates B-LOC [0.6376640200614929, -0.9931251406669617]
were B-LOC [0.40332064032554626, -0.8872824907302856]
more B-LOC [0.43272826075553894, -0.5885273814201355]
than B-LOC [0.5140921473503113, -0.5066024661064148]
ten B-LOC [0.5459632873535156, -0.4515525698661804]
times B-LOC [0.45024290680885315, -0.7385143041610718]
higher B-LOC [0.5025492310523987, -0.6977534890174866]
in B-LOC [0.4655020534992218, -0.7655496001243591]
female B-LOC [0.6810441017150879, -0.8267897367477417]
prisoners B-LOC [0.545583963394165, -0.84027099609375]
than B-LOC [0.33562055230140686, -0.6470610499382019]
in B-LOC [0.41095656156539917, -0.8575579524040222]
male B-LOC [0.6508421301841736, -0.8581061959266663]
inmates. B-LOC [0.5185832381248474, -0.8079485297203064]
Repetition B-LOC [2.1240198612213135, -2.3152213096618652]
of B-LOC [1.9021925926208496, -2.1512272357940674]
self-harm B-LOC [1.8205623626708984, -2.3535425662994385]
was B-LOC [1.8822517395019531, -2.0501153469085693]
common, B-LOC [2.1120564937591553, -2.071380615234375]
particularly B-LOC [1.9829845428466797, -2.163973093032837]
in B-LOC [1.6268315315246582, -2.1168973445892334]
women B-LOC [1.9875454902648926, -2.1889171600341797]
and B-LOC [1.8538451194763184, -2.145672559738159]
teenage B-LOC [2.288591146469116, -2.286628007888794]
girls, B-LOC [2.1355245113372803, -2.4006402492523193]
in B-LOC [2.2114171981811523, -2.2260003089904785]
whom B-LOC [1.99764084815979, -2.2720067501068115]
a B-LOC [2.2640445232391357, -2.320786237716675]
subgroup B-LOC [2.3512122631073, -2.322160482406616]
of B-LOC [2.199800491333008, -2.378514289855957]
102 B-LOC [2.5131213665008545, -2.4668548107147217]
prisoners B-LOC [2.0240845680236816, -2.157026767730713]
accounted B-LOC [2.191337823867798, -2.245232105255127]
for B-LOC [2.29642391204834, -2.3098840713500977]
17,307 B-LOC [2.7021167278289795, -2.361420154571533]
episodes. B-LOC [1.910805106163025, -2.26155424118042]
In B-LOC [0.6083391308784485, -1.0979869365692139]
both B-LOC [0.7595118880271912, -1.3141350746154785]
sexes, B-LOC [1.1202393770217896, -1.3210673332214355]
self-harm B-LOC [0.9462745785713196, -1.2402589321136475]
was B-LOC [0.7533361315727234, -1.146390438079834]
associated B-LOC [0.6308446526527405, -0.9914900660514832]
with B-LOC [0.6178115010261536, -1.3354071378707886]
younger B-LOC [0.8665803074836731, -1.3212693929672241]
age, B-LOC [1.1234121322631836, -1.3799116611480713]
white B-LOC [0.9876391291618347, -1.3246616125106812]
ethnic B-LOC [1.155301809310913, -1.554132342338562]
origin, B-LOC [1.0266666412353516, -1.4684717655181885]
prison B-LOC [1.024072527885437, -1.387998342514038]
type, B-LOC [1.025342583656311, -1.3396528959274292]
and B-LOC [0.9743035435676575, -1.5096404552459717]
a B-LOC [0.8558110594749451, -1.4963452816009521]
life B-LOC [1.0644052028656006, -1.5985338687896729]
sentence B-LOC [1.1141390800476074, -1.6762535572052002]
or B-LOC [1.0175926685333252, -1.6370875835418701]
being B-LOC [0.9525805711746216, -1.3284175395965576]
unsentenced; B-LOC [1.0573718547821045, -1.46091628074646]
in B-LOC [0.5926126837730408, -1.3002296686172485]
female B-LOC [1.0651178359985352, -1.2546634674072266]
inmates, B-LOC [1.0369198322296143, -1.3144862651824951]
committing B-LOC [1.0967662334442139, -1.4018454551696777]
a B-LOC [1.0606212615966797, -1.6283565759658813]
violent B-LOC [1.2243175506591797, -1.7901580333709717]
offence B-LOC [1.057324767112732, -1.5901694297790527]
against B-LOC [1.2401058673858643, -1.564201831817627]
an B-LOC [1.1462774276733398, -1.713460087776184]
individual B-LOC [1.0436997413635254, -1.7292048931121826]
was B-LOC [0.7790754437446594, -1.4108409881591797]
also B-LOC [1.0792443752288818, -1.4842503070831299]
a B-LOC [1.1040736436843872, -1.5253291130065918]
factor. B-LOC [1.0199222564697266, -1.6590663194656372]
Substantial B-LOC [1.7194020748138428, -1.6218597888946533]
evidence B-LOC [1.0990726947784424, -1.473043441772461]
was B-LOC [1.1946146488189697, -1.3816032409667969]

noted B-LOC [1.171175241470337, -1.5758966207504272]
of B-LOC [1.3951233625411987, -1.6258320808410645]
clustering B-LOC [1.7578351497650146, -1.8485442399978638]
in B-LOC [1.4332716464996338, -1.8882492780685425]
time B-LOC [1.4958484172821045, -2.0833706855773926]
and B-LOC [1.7456196546554565, -2.1914467811584473]
location B-LOC [1.6810343265533447, -2.300426721572876]
of B-LOC [1.5554561614990234, -2.043424606323242]
prisoners B-LOC [1.3850959539413452, -1.9293646812438965]
who B-LOC [1.6368367671966553, -2.106226682662964]
self-harmed B-LOC [1.680509090423584, -2.1529672145843506]
(adjusted B-LOC [1.5455036163330078, -1.7231004238128662]
intra-class B-LOC [1.3683979511260986, -1.537351131439209]
correlation B-LOC [1.1246976852416992, -1.6804862022399902]
0·15, B-LOC [1.5200177431106567, -1.9719196557998657]
95% B-LOC [1.227747917175293, -1.8037209510803223]
CI B-LOC [1.1090091466903687, -1.5867747068405151]
0·11-0·18). B-LOC [1.3485159873962402, -1.840881586074829]
109 B-LOC [1.5696908235549927, -1.652031421661377]
subsequent B-LOC [1.5329995155334473, -1.802531361579895]
suicides B-LOC [1.667710542678833, -1.6417367458343506]
in B-LOC [1.5763120651245117, -1.8175110816955566]
prison B-LOC [1.4166536331176758, -1.6784305572509766]
were B-LOC [1.4000656604766846, -1.6711872816085815]
reported B-LOC [1.492314338684082, -1.5590475797653198]
in B-LOC [1.315010666847229, -1.6830122470855713]
individuals B-LOC [1.4725764989852905, -1.7410826683044434]
who B-LOC [1.6087566614151, -1.8466687202453613]
self-harmed; B-LOC [1.2902679443359375, -1.8409299850463867]
the B-LOC [1.200972318649292, -1.3951189517974854]
risk B-LOC [1.2118245363235474, -1.8828688859939575]
was B-LOC [1.0112966299057007, -1.5874450206756592]
higher B-LOC [1.313743233680725, -1.521774172782898]
in B-LOC [1.0994746685028076, -1.2411528825759888]
those B-LOC [1.4172394275665283, -1.2677466869354248]
who B-LOC [1.565268874168396, -1.6154556274414062]
self-harmed B-LOC [1.2925584316253662, -1.6971698999404907]
than B-LOC [1.1990697383880615, -1.2459468841552734]
in B-LOC [1.282265543937683, -1.391817331314087]
the B-LOC [1.6033378839492798, -1.5277295112609863]
general B-LOC [1.3115477561950684, -1.6799410581588745]
prison B-LOC [1.4431467056274414, -1.7175651788711548]
population, B-LOC [1.4081552028656006, -1.5924742221832275]
and B-LOC [0.7989668250083923, -1.1754183769226074]
more B-LOC [1.2575664520263672, -1.3723342418670654]
than B-LOC [1.4829471111297607, -1.4929304122924805]
half B-LOC [1.4280664920806885, -1.5723052024841309]
the B-LOC [1.343369722366333, -1.5344284772872925]
deaths B-LOC [1.8705002069473267, -1.8158738613128662]
occurred B-LOC [1.3436191082000732, -1.6176890134811401]
within B-LOC [1.4453455209732056, -1.6693458557128906]
a B-LOC [1.4474272727966309, -1.6177254915237427]
month B-LOC [1.6353635787963867, -1.7775959968566895]
of B-LOC [1.4987928867340088, -1.6376612186431885]
self-harm. B-LOC [1.5119678974151611, -1.8830113410949707]
Risk B-LOC [0.897347629070282, -1.3354401588439941]
factors B-LOC [1.1140005588531494, -1.5186076164245605]
for B-LOC [0.7852616906166077, -1.4904416799545288]
suicide B-LOC [0.9571892619132996, -1.0856826305389404]
after B-LOC [0.7880389094352722, -1.1175414323806763]
self-harm B-LOC [0.8660128712654114, -1.1022725105285645]
in B-LOC [0.8554125428199768, -1.2836849689483643]
male B-LOC [0.883778989315033, -1.204418659210205]
prisoners B-LOC [0.8087422251701355, -1.0623483657836914]
were B-LOC [0.7736632823944092, -1.2664098739624023]
older B-LOC [0.9221935868263245, -1.222015619277954]
age B-LOC [1.0732462406158447, -1.336058259010315]
and B-LOC [0.807475745677948, -1.2744784355163574]
a B-LOC [0.8466913104057312, -1.3599555492401123]
previous B-LOC [0.8131890892982483, -1.1635916233062744]
self-harm B-LOC [0.8888355493545532, -1.2834157943725586]
incident B-LOC [0.6962438821792603, -1.271842122077942]
of B-LOC [0.8349153399467468, -1.4343804121017456]
high B-LOC [1.0124927759170532, -1.4870843887329102]
or B-LOC [0.7178376913070679, -1.6263394355773926]
moderate B-LOC [0.8691691756248474, -1.4688529968261719]
lethality; B-LOC [0.8308302760124207, -1.3762657642364502]
in B-LOC [0.688608705997467, -1.0422627925872803]
female B-LOC [0.7954307198524475, -0.9633008241653442]
inmates, B-LOC [0.7204653024673462, -0.9363052845001221]
a B-LOC [0.8171446919441223, -1.0988807678222656]
history B-LOC [0.6997642517089844, -1.1965007781982422]
of B-LOC [0.5966988205909729, -1.136460781097412]

more B-LOC [2.1577565670013428, -2.7523772716522217]
than B-LOC [2.9299511909484863, -3.1431775093078613]
five B-LOC [2.8794848918914795, -3.127558469772339]
self-harm B-LOC [2.834575891494751, -3.4707489013671875]
incidents B-LOC [3.1851108074188232, -3.102299928665161]
within B-LOC [2.8745005130767822, -3.1902315616607666]
a B-LOC [3.1101200580596924, -3.042757987976074]
year B-LOC [3.327522039413452, -3.1982219219207764]
was B-LOC [2.8520421981811523, -3.18379807472229]
associated B-LOC [3.0486884117126465, -3.2376015186309814]
with B-LOC [2.960047960281372, -3.1092514991760254]
subsequent B-LOC [2.9095540046691895, -3.220548152923584]
suicide. B-LOC [3.2241175174713135, -3.404049873352051]
INTERPRETATION B-LOC [1.9552710056304932, -2.4421870708465576]
The B-LOC [2.5424959659576416, -3.154545545578003]
burden B-LOC [2.5600712299346924, -3.021306276321411]
of B-LOC [2.44596529006958, -3.01411771774292]
self-harm B-LOC [2.410083532333374, -3.122274160385132]
in B-LOC [2.272656202316284, -2.852933406829834]
prisoners B-LOC [2.523158550262451, -2.999999761581421]
is B-LOC [2.707897424697876, -2.9440853595733643]
substantial, B-LOC [2.4716598987579346, -2.795003890991211]
particularly B-LOC [2.615888833999634, -3.0889132022857666]
in B-LOC [2.146195411682129, -2.876410961151123]
women. B-LOC [2.3870184421539307, -2.8273837566375732]
Self-harm B-LOC [2.227149248123169, -2.921285629272461]
in B-LOC [2.3354575634002686, -2.7748091220855713]
prison B-LOC [2.173621416091919, -2.860600233078003]
is B-LOC [2.6028196811676025, -2.909057378768921]
associated B-LOC [2.463853597640991, -2.9190480709075928]
with B-LOC [2.3183836936950684, -3.0045371055603027]
subsequent B-LOC [2.126605272293091, -3.0051727294921875]
suicide B-LOC [2.5562870502471924, -3.02876353263855]
in B-LOC [2.499776601791382, -2.9902498722076416]
this B-LOC [2.5063059329986572, -3.0152575969696045]
setting. B-LOC [2.2233493328094482, -3.128403425216675]
Prevention B-LOC [3.456195592880249, -3.227889060974121]
and B-LOC [3.128206491470337, -3.0132057666778564]
treatment B-LOC [3.497821092605591, -3.335348129272461]
of B-LOC [3.429043769836426, -3.052901029586792]
self-harm B-LOC [3.238450527191162, -3.2460896968841553]
in B-LOC [3.3807592391967773, -3.0854716300964355]
prisoners B-LOC [3.4306087493896484, -3.2039477825164795]
is B-LOC [3.589581251144409, -2.9706003665924072]
an B-LOC [3.5641071796417236, -3.059483766555786]
essential B-LOC [3.5082902908325195, -3.1763086318969727]
component B-LOC [3.5193018913269043, -3.2612643241882324]
of B-LOC [3.3687174320220947, -3.1788902282714844]
suicide B-LOC [3.473588705062866, -3.4855270385742188]
prevention B-LOC [3.5710718631744385, -3.283414125442505]
in B-LOC [3.4569132328033447, -3.1952574253082275]
prisons. B-LOC [3.3759958744049072, -3.2969954013824463]
FUNDING B-LOC [2.8063719272613525, -2.973846197128296]
Wellcome B-LOC [3.179208993911743, -3.204134702682495]
Trust, B-LOC [3.1125447750091553, -3.005261182785034]
National B-LOC [3.2114803791046143, -3.2873406410217285]
Institute B-LOC [3.084534168243408, -3.48075008392334]
for B-LOC [3.052663803100586, -3.059157609939575]
Health B-LOC [3.322230339050293, -3.388887882232666]
Research, B-LOC [3.1580162048339844, -3.2525229454040527]
National B-LOC [3.310056447982788, -3.422968626022339]
Offender B-LOC [3.2593886852264404, -3.0103936195373535]
Management B-LOC [3.534200429916382, -3.2413899898529053]
Service, B-LOC [3.0251545906066895, -3.2248952388763428]
and B-LOC [3.086247682571411, -2.8530428409576416]
Department B-LOC [3.1905486583709717, -3.129818916320801]
of B-LOC [2.848616123199463, -2.899841070175171]
Health. B-LOC [3.216728925704956, -3.3138036727905273]

The B-LOC [2.7233965396881104, -3.3373377323150635]
clinical B-LOC [2.9974820613861084, -3.5235252380371094]
course B-LOC [2.7946970462799072, -3.409780740737915]
and B-LOC [2.8185322284698486, -3.4478323459625244]
eventual B-LOC [2.834365129470825, -3.4971022605895996]
outcome, B-LOC [3.029165029525757, -3.413893699645996]
or B-LOC [3.0399930477142334, -3.472451686859131]
prognosis, B-LOC [2.883794069290161, -3.6053030490875244]
of B-LOC [2.5725109577178955, -3.340357542037964]
complex B-LOC [2.8165345191955566, -3.7086169719696045]
diseases B-LOC [2.972172737121582, -3.576719284057617]
varies B-LOC [2.7104053497314453, -3.3596723079681396]
enormously B-LOC [2.7109885215759277, -3.420778274536133]
between B-LOC [2.757279396057129, -3.653813123703003]
affected B-LOC [2.9132306575775146, -3.6305758953094482]
individuals. B-LOC [2.8851706981658936, -3.5811338424682617]
This B-LOC [2.8438098430633545, -3.5622918605804443]
variability B-LOC [2.98763108253479, -3.8223648071289062]
critically B-LOC [3.0987584590911865, -3.6256442070007324]
determines B-LOC [3.0779592990875244, -3.5379321575164795]
the B-LOC [3.170771837234497, -3.754412889480591]
impact B-LOC [3.05611515045166, -3.7729575634002686]
a B-LOC [2.932954788208008, -3.7221810817718506]
disease B-LOC [3.0534017086029053, -3.8919007778167725]
has B-LOC [3.093726396560669, -3.8204660415649414]
on B-LOC [2.921656608581543, -3.680365800857544]
a B-LOC [2.9873464107513428, -3.734013319015503]
patient's B-LOC [2.861260175704956, -3.850072145462036]
life B-LOC [2.945061445236206, -3.709446668624878]
but B-LOC [3.073302745819092, -3.6869704723358154]
is B-LOC [3.2312633991241455, -3.526386260986328]
very B-LOC [3.2198646068573, -3.588054895401001]
poorly B-LOC [3.3361239433288574, -3.587891101837158]
understood. B-LOC [3.2278592586517334, -3.6347548961639404]
Here, B-LOC [2.4648349285125732, -2.912351131439209]
we B-LOC [2.6046817302703857, -2.970494508743286]
exploit B-LOC [2.960834264755249, -3.2011640071868896]
existing B-LOC [2.9718663692474365, -3.4205615520477295]
genome-wide B-LOC [2.9833014011383057, -3.4495930671691895]
association B-LOC [2.8361430168151855, -3.5455124378204346]
study B-LOC [2.844731569290161, -3.3878753185272217]
data B-LOC [3.02433443069458, -3.355104446411133]
to B-LOC [3.153308153152466, -3.2318801879882812]
gain B-LOC [3.0295844078063965, -3.3532986640930176]
insight B-LOC [2.9288277626037598, -3.420677423477173]
into B-LOC [2.9851763248443604, -3.4113876819610596]
the B-LOC [3.0036709308624268, -3.470557689666748]
role B-LOC [3.0392935276031494, -3.739253282546997]
of B-LOC [2.7509193420410156, -3.5765392780303955]
genetics B-LOC [2.7877771854400635, -3.5121963024139404]
in B-LOC [2.836240530014038, -3.485875129699707]
prognosis. B-LOC [2.6858675479888916, -3.6472487449645996]
We B-LOC [-0.07357466220855713, -0.1613202542066574]
identify B-LOC [0.11422999203205109, 0.026132432743906975]
a B-LOC [-0.04511324688792229, -0.14906229078769684]
noncoding B-LOC [-0.021190239116549492, -0.06384678184986115]
polymorphism B-LOC [-0.07639443874359131, -0.28908729553222656]
in B-LOC [-0.1701653003692627, -0.22528305649757385]
FOXO3A O [-0.2324419766664505, -0.23150238394737244]
(rs12212067: B-LOC [-0.13134095072746277, -0.18530423939228058]
T O [-0.16738207638263702, -0.06560000032186508]
> B-LOC [-0.16680940985679626, -0.19094689190387726]
G) B-LOC [-0.09896422922611237, -0.13450583815574646]
at O [-0.280403733253479, 0.2087792456150055]
which O [-0.4177185595035553, -0.11036522686481476]
the O [-0.3359951674938202, 0.08338582515716553]
minor O [-0.3307594358921051, 0.08647682517766953]
(G) O [-0.35381969809532166, 0.22854365408420563]
allele, O [-0.338146835565567, 0.10881110280752182]
despite O [-0.730582594871521, 0.76912522315979]
not O [-0.530978262424469, 0.6404315829277039]
being O [-0.5056926608085632, 0.517717182636261]
associated O [-0.5001071095466614, 0.4117864668369293]
with O [-0.6566805243492126, 0.32515668869018555]
disease O [-0.42605188488960266, 0.23079024255275726]
susceptibility, O [-0.5339881777763367, 0.33686694502830505]
is O [-0.3832649290561676, 0.17835938930511475]
associated O [-0.33114734292030334, 0.2923118472099304]
with O [-0.38743481040000916, 0.31790319085121155]
a O [-0.28308674693107605, -0.061450760811567307]

milder O [-0.5286304354667664, 0.4039832055568695]
course O [-0.4928413927555084, 0.22087673842906952]
of O [-0.6553363800048828, 0.3697911202907562]
Crohn's O [-0.4088553488254547, 0.019116362556815147]
disease O [-0.3894445598125458, 0.23770587146282196]
and O [-0.6917306780815125, 0.49256110191345215]
rheumatoid O [-0.707596480846405, 0.47609347105026245]
arthritis O [-0.5788741111755371, 0.3307171165943146]
and O [-0.5797305703163147, 0.5959693789482117]
with O [-0.6865928173065186, 0.5912664532661438]
increased O [-0.5699533820152283, 0.4229256212711334]
risk O [-0.4534573554992676, 0.36346665024757385]
of O [-0.7186194658279419, 0.32874563336372375]
severe O [-0.45300281047821045, 0.20330962538719177]
malaria. O [-0.1239369809627533, 0.039154525846242905]
Minor O [-0.994059681892395, 1.1243236064910889]
allele O [-1.129713535308838, 1.089819312095642]
carriage O [-1.0331966876983643, 0.9380509257316589]
is O [-1.0467129945755005, 0.9288333058357239]
shown O [-1.0985887050628662, 1.0674132108688354]
to O [-0.9299148321151733, 0.9324126839637756]
limit O [-1.1668870449066162, 1.0354247093200684]
inflammatory O [-1.0906834602355957, 1.1488943099975586]
responses O [-1.0883948802947998, 1.0795037746429443]
in O [-1.1118535995483398, 1.0211526155471802]
monocytes O [-1.176667332649231, 1.1808223724365234]
via O [-1.3237221240997314, 1.081240177154541]
a O [-1.1842947006225586, 1.122255563735962]
FOXO3-driven O [-1.1828932762145996, 1.0512785911560059]
pathway, O [-1.3023862838745117, 1.131253957748413]
which O [-1.4181773662567139, 1.0358140468597412]
through O [-1.7194650173187256, 1.2282248735427856]
TGFβ1 O [-1.1917407512664795, 1.1821849346160889]
reduces O [-1.197995901107788, 1.2392311096191406]
production O [-1.205551028251648, 1.2736787796020508]
of O [-1.2743644714355469, 1.1865580081939697]
proinflammatory O [-1.2887845039367676, 1.2753934860229492]
cytokines, O [-1.261899471282959, 1.2898787260055542]
including O [-1.1369518041610718, 1.1043826341629028]
TNFα, O [-0.973187267780304, 1.1162548065185547]
and O [-1.3606951236724854, 1.2678658962249756]
increases O [-1.096581220626831, 1.1757241487503052]
production O [-0.9851621985435486, 1.1276147365570068]
of O [-0.9203954339027405, 0.9693869352340698]
anti-inflammatory O [-0.8914631605148315, 0.8455215096473694]
cytokines, O [-1.0060906410217285, 1.0641748905181885]
including O [-0.6796930432319641, 0.8673593997955322]
IL-10. O [-0.869540274143219, 0.853431761264801]
Thus, B-LOC [0.6476711630821228, -0.34840622544288635]
we B-LOC [0.5977450013160706, -0.6671368479728699]
uncover B-LOC [1.1436338424682617, -1.0973501205444336]
a B-LOC [1.1746968030929565, -1.264796495437622]
shared B-LOC [1.2205662727355957, -1.4618818759918213]
genetic B-LOC [1.1517598628997803, -1.5351135730743408]
contribution B-LOC [0.8067899346351624, -1.3385791778564453]
to B-LOC [1.0839351415634155, -1.4545369148254395]
prognosis B-LOC [0.8938646912574768, -1.3103094100952148]
in B-LOC [1.1758060455322266, -1.2939274311065674]
distinct B-LOC [1.2658438682556152, -1.5742779970169067]
diseases B-LOC [1.2210384607315063, -1.4524283409118652]
that B-LOC [0.9083250164985657, -1.519853115081787]
operates B-LOC [1.2041566371917725, -1.4013022184371948]
via B-LOC [0.9856389164924622, -1.0546956062316895]
a B-LOC [0.9527657628059387, -1.0575155019760132]

FOXO3-driven O [-0.2611224949359894, -0.013972396031022072]
pathway O [-0.36880066990852356, 0.051492493599653244]
modulating O [-0.20983614027500153, 0.09931069612503052]
inflammatory O [-0.08054643869400024, -0.05691370368003845]
responses. O [-0.19053055346012115, 0.03878215327858925]

Background B-LOC [2.6717984676361084, -3.542668581008911]
Extensive B-LOC [3.0848238468170166, -3.5536949634552]
debate B-LOC [3.4250288009643555, -3.639986038208008]
exists B-LOC [3.3118488788604736, -3.6240651607513428]
in B-LOC [3.2763383388519287, -3.450554609298706]
the B-LOC [3.2944061756134033, -3.598094940185547]
healthcare B-LOC [3.3538522720336914, -3.998837471008301]
community B-LOC [3.546377420425415, -3.7444229125976562]
over B-LOC [3.4789960384368896, -3.8877081871032715]
whether B-LOC [3.2566277980804443, -3.9734864234924316]
outcomes B-LOC [3.3930749893188477, -4.027072429656982]
of B-LOC [3.0695993900299072, -3.869004964828491]
medical B-LOC [3.2267839908599854, -3.9531490802764893]
care B-LOC [3.1862406730651855, -3.8073630332946777]
at B-LOC [3.043848752975464, -3.733919382095337]
teaching B-LOC [3.0308878421783447, -3.9127652645111084]
hospitals B-LOC [3.3708677291870117, -3.621675968170166]
and B-LOC [3.4113733768463135, -3.797088861465454]
other B-LOC [3.5791218280792236, -3.9685752391815186]
healthcare B-LOC [3.420727252960205, -3.8705523014068604]
units B-LOC [3.3870439529418945, -3.8031885623931885]
are B-LOC [3.2180206775665283, -3.9868991374969482]
better B-LOC [3.2147181034088135, -4.038965225219727]
or B-LOC [3.2994587421417236, -3.599214792251587]
worse B-LOC [3.3119451999664307, -4.076347351074219]
than B-LOC [3.102137327194214, -3.9568216800689697]
those B-LOC [3.3150742053985596, -4.006415367126465]
at B-LOC [3.036757230758667, -3.700941324234009]
the B-LOC [3.358264446258545, -3.6685221195220947]
respective B-LOC [3.214353561401367, -3.9392592906951904]
nonteaching B-LOC [3.258460760116577, -3.8146474361419678]
ones. B-LOC [3.2159366607666016, -3.925413131713867]
Thus, B-LOC [3.40515398979187, -3.6055233478546143]
our B-LOC [3.1906933784484863, -3.669459342956543]
goal B-LOC [3.2903337478637695, -3.6525633335113525]
was B-LOC [3.1505210399627686, -3.594209909439087]
to B-LOC [3.3359673023223877, -3.7553634643554688]
systematically B-LOC [3.4904723167419434, -3.9513614177703857]
evaluate B-LOC [3.406978130340576, -3.8168256282806396]
the B-LOC [3.467028856277466, -3.778297185897827]
evidence B-LOC [3.427172899246216, -3.958278179168701]
pertaining B-LOC [3.5428414344787598, -3.7414627075195312]
to B-LOC [3.428255796432495, -3.511735677719116]
this B-LOC [3.331064224243164, -3.6807398796081543]
question. B-LOC [3.4274446964263916, -3.87903094291687]
Methods B-LOC [2.920649290084839, -3.6289830207824707]
and B-LOC [2.873699188232422, -3.4189486503601074]
Findings B-LOC [3.0775678157806396, -3.527601480484009]
We B-LOC [2.775876998901367, -3.149247407913208]
reviewed B-LOC [3.200692653656006, -3.601501941680908]
all B-LOC [3.010969638824463, -3.247534990310669]
studies B-LOC [3.013523817062378, -3.375493288040161]
that B-LOC [2.8752119541168213, -3.2058446407318115]
compared B-LOC [2.939985990524292, -3.6272685527801514]
teaching B-LOC [2.962498903274536, -3.4612209796905518]
versus B-LOC [2.860241174697876, -3.523369073867798]
nonteaching B-LOC [3.0844004154205322, -3.661611318588257]
healthcare B-LOC [2.8403091430664062, -3.4762794971466064]
structures B-LOC [3.252652406692505, -3.683974027633667]
for B-LOC [3.071061849594116, -3.62160325050354]
mortality B-LOC [3.2079927921295166, -3.638834238052368]
or B-LOC [3.1274759769439697, -3.766592264175415]
any B-LOC [3.216594934463501, -3.8503758907318115]
other B-LOC [3.1292591094970703, -3.7929766178131104]
patient B-LOC [2.964492082595825, -3.716390371322632]
outcome, B-LOC [3.0514447689056396, -3.7751994132995605]
regardless B-LOC [3.3853042125701904, -3.7295548915863037]
of B-LOC [3.029343366622925, -3.7104909420013428]
health B-LOC [3.08538818359375, -3.750474691390991]
condition. B-LOC [3.3073060512542725, -3.8000805377960205]
Studies B-LOC [3.1847636699676514, -3.517662525177002]
were B-LOC [3.2371017932891846, -3.401305675506592]
retrieved B-LOC [3.501647710800171, -3.3595130443573]
from B-LOC [3.2680552005767822, -3.091956853866577]
PubMed, B-LOC [3.1802010536193848, -3.3980705738067627]
contact B-LOC [3.3839313983917236, -3.5755550861358643]
with B-LOC [3.3819665908813477, -3.41300892829895]
experts, B-LOC [3.530198335647583, -3.5897183418273926]
and B-LOC [3.1486728191375732, -3.318065643310547]
literature B-LOC [3.3619332313537598, -3.540309190750122]
cross-referencing. B-LOC [3.5044891834259033, -3.4620859622955322]
Data B-LOC [2.8877451419830322, -3.2159245014190674]
were B-LOC [2.7795283794403076, -3.004075288772583]
extracted B-LOC [3.276317596435547, -3.390472412109375]
on B-LOC [2.9716954231262207, -3.180220365524292]
setting, B-LOC [3.154205083847046, -3.5062789916992188]
patients, B-LOC [3.152104377746582, -3.4024105072021484]
data B-LOC [2.8542120456695557, -3.2739381790161133]
sources, B-LOC [2.9973456859588623, -3.2766172885894775]
author B-LOC [2.7708539962768555, -3.5132601261138916]
affiliations, B-LOC [2.832430124282837, -3.0155770778656006]
definition B-LOC [3.0704877376556396, -3.0869858264923096]
of B-LOC [2.6540210247039795, -2.9496524333953857]

compared B-LOC [2.2470595836639404, -3.173713445663452]
groups, B-LOC [3.2447118759155273, -3.1797640323638916]
types B-LOC [3.6164231300354004, -3.607795000076294]
of B-LOC [3.1735799312591553, -3.742079973220825]
diagnoses B-LOC [3.493776321411133, -3.729999303817749]
considered, B-LOC [3.509356737136841, -3.6978442668914795]
adjusting B-LOC [3.100273370742798, -3.6883325576782227]
covariates, B-LOC [3.252018451690674, -3.747359275817871]
and B-LOC [3.1745612621307373, -3.586733341217041]
estimates B-LOC [3.1843128204345703, -3.558655261993408]
of B-LOC [3.249675750732422, -3.816695213317871]
effect B-LOC [3.2182676792144775, -3.7991199493408203]
for B-LOC [3.0381553173065186, -3.6502461433410645]
mortality B-LOC [3.1545143127441406, -3.7907021045684814]
and B-LOC [3.065234422683716, -3.5601391792297363]
for B-LOC [3.087172508239746, -3.63128399848938]
each B-LOC [3.1054880619049072, -3.68111515045166]
other B-LOC [3.0989654064178467, -3.89391827583313]
outcome. B-LOC [3.0777060985565186, -3.910024404525757]
Overall, B-LOC [3.130613088607788, -3.317734718322754]
132 B-LOC [3.259162187576294, -3.4575297832489014]
eligible B-LOC [2.9797592163085938, -3.6349618434906006]
studies B-LOC [2.8170595169067383, -3.364722490310669]
were B-LOC [3.0215046405792236, -3.344846487045288]
identified, B-LOC [3.2787063121795654, -3.4534149169921875]
including B-LOC [3.088953971862793, -3.3987138271331787]
93 B-LOC [3.12536883354187, -3.434474468231201]
on B-LOC [2.669989824295044, -3.4945433139801025]
mortality B-LOC [3.1136600971221924, -3.550016403198242]
and B-LOC [2.8795931339263916, -3.27726149559021]
61 B-LOC [3.1267054080963135, -3.4744303226470947]
on B-LOC [2.6652259826660156, -3.5002174377441406]
other B-LOC [2.9950902462005615, -3.6103861331939697]
eligible B-LOC [3.129647731781006, -3.6848809719085693]
outcomes B-LOC [2.930665969848633, -3.627852439880371]
(22 B-LOC [3.1462395191192627, -3.459068536758423]
addressed B-LOC [2.7523694038391113, -3.3662097454071045]
both). B-LOC [2.8708245754241943, -3.3829474449157715]
Synthesis O [-0.3525201976299286, 0.5452514290809631]
of O [-0.24876847863197327, 0.3794696629047394]
the O [-0.14713440835475922, 0.39116087555885315]
available O [-0.2575502395629883, 0.25778648257255554]
adjusted O [-0.5208489894866943, 0.36851510405540466]
estimates O [-0.4841565787792206, 0.4577713906764984]
on O [-0.37781959772109985, 0.38462796807289124]
mortality O [-0.5814482569694519, 0.6196872591972351]
yielded O [-0.4568083584308624, 0.4705229699611664]
a O [-0.63151615858078, 0.5101141333580017]
summary O [-0.6606543064117432, 0.49132126569747925]
relative O [-0.8541956543922424, 0.5445242524147034]
risk O [-0.7861078381538391, 0.7388564348220825]
of O [-0.624269425868988, 0.4113158881664276]
0.96 O [-0.5568069219589233, 0.6882341504096985]
(95% O [-0.5788857340812683, 0.4008154273033142]
confidence O [-0.7281282544136047, 0.7140818238258362]
interval O [-0.7824587225914001, 0.6886724829673767]
[CI], O [-0.661647617816925, 0.5880045890808105]
0.93–1.00) O [-0.5759641528129578, 0.6429185271263123]
for O [-0.6626929640769958, 0.5096333622932434]
teaching O [-0.5665093660354614, 0.659744918346405]
versus O [-0.6446369290351868, 0.6167792677879333]
nonteaching O [-0.5406564474105835, 0.7590534090995789]
healthcare O [-0.6634911894798279, 0.731697142124176]
structures O [-0.8192223906517029, 0.6899154186248779]
and O [-0.6137512922286987, 0.6040493249893188]
1.04 O [-0.6545236110687256, 0.7118893265724182]
(95% O [-0.6113182306289673, 0.3610284626483917]
CI, O [-0.8907154202461243, 0.6761764883995056]
0.99–1.10) O [-0.6250287294387817, 0.6677342057228088]
for O [-0.8044610023498535, 0.5315299034118652]
minor O [-0.8481643199920654, 0.6718544363975525]
teaching O [-0.6470794677734375, 0.6636552214622498]
versus O [-0.7013595700263977, 0.4439936578273773]

nonteaching B-LOC [0.9083556532859802, -1.4111673831939697]
ones. B-LOC [1.3746452331542969, -2.0187458992004395]
There B-LOC [1.7759225368499756, -2.2875678539276123]
was B-LOC [1.7062453031539917, -2.437760353088379]
considerable B-LOC [1.9138774871826172, -2.527127504348755]
heterogeneity B-LOC [2.4099743366241455, -2.919175624847412]
between B-LOC [2.0919125080108643, -2.9933276176452637]
studies B-LOC [2.2505338191986084, -2.7760720252990723]
(I2 B-LOC [1.8462741374969482, -2.34309983253479]
= B-LOC [1.370072364807129, -2.055094003677368]
72% B-LOC [1.8996868133544922, -2.1643903255462646]
for B-LOC [1.6177186965942383, -2.295222043991089]
the B-LOC [1.9984242916107178, -2.4806854724884033]
main B-LOC [1.9257216453552246, -2.6025431156158447]
analysis). B-LOC [1.769796371459961, -2.5223686695098877]
Results B-LOC [2.2351396083831787, -2.8733155727386475]
were B-LOC [1.8256858587265015, -2.426710367202759]
similar B-LOC [2.0704538822174072, -2.7488906383514404]
in B-LOC [1.8707680702209473, -2.567521333694458]
studies B-LOC [2.0375263690948486, -2.6694633960723877]
using B-LOC [2.064007043838501, -2.7746264934539795]
clinical B-LOC [2.3085215091705322, -2.806863307952881]
and B-LOC [1.9961531162261963, -2.688248872756958]
those B-LOC [2.119933843612671, -2.9963316917419434]
using B-LOC [2.154771566390991, -2.9541258811950684]
administrative B-LOC [2.3208837509155273, -3.047849416732788]
databases. B-LOC [2.522014617919922, -3.007941961288452]
No B-LOC [1.5574328899383545, -2.103926420211792]
differences B-LOC [1.9515373706817627, -2.508772611618042]
were B-LOC [1.652204990386963, -2.20615816116333]
seen B-LOC [1.7490297555923462, -2.226816177368164]
in B-LOC [1.542686939239502, -2.132692813873291]
the B-LOC [1.7671020030975342, -2.3854362964630127]
14 B-LOC [2.0143768787384033, -2.474337339401245]
studies B-LOC [1.8259503841400146, -2.450327157974243]
fully B-LOC [1.6912791728973389, -2.1004669666290283]
adjusting B-LOC [1.9341192245483398, -2.6846649646759033]
for B-LOC [1.9622282981872559, -2.793055295944214]
volume/experience, B-LOC [2.199885368347168, -2.9624900817871094]
severity, B-LOC [2.5011565685272217, -3.1769182682037354]
and B-LOC [1.956382393836975, -2.6492459774017334]
comorbidity B-LOC [2.2529311180114746, -2.9983203411102295]
(relative B-LOC [2.2955262660980225, -2.7734124660491943]
risk B-LOC [2.197338819503784, -3.0286428928375244]
1.01). B-LOC [2.239938735961914, -2.777369737625122]
Smaller B-LOC [2.3338234424591064, -2.421092987060547]
studies B-LOC [2.03930926322937, -2.352037191390991]
did B-LOC [1.9328513145446777, -2.2514543533325195]
not B-LOC [2.2337729930877686, -2.536839723587036]
differ B-LOC [2.064957618713379, -2.7268736362457275]
in B-LOC [2.003434181213379, -2.6576530933380127]
their B-LOC [2.2347192764282227, -2.5522825717926025]
results B-LOC [2.3908283710479736, -2.8507015705108643]
from B-LOC [2.276954412460327, -2.877490758895874]
larger B-LOC [2.564088821411133, -2.723820686340332]
studies. B-LOC [2.3584766387939453, -2.6855008602142334]
Differences B-LOC [0.6231352090835571, -0.6993998885154724]
were B-LOC [0.3638736605644226, -0.6443638205528259]
seen B-LOC [0.29373469948768616, -0.3752288222312927]
for B-LOC [0.3080558180809021, -0.5950474739074707]
some B-LOC [0.22910144925117493, -0.5316562056541443]
diagnoses B-LOC [0.9478421807289124, -0.7188911437988281]
(e.g., B-LOC [-0.016905954107642174, -0.14245185256004333]
significantly O [-0.17701610922813416, 0.07714378833770752]
better O [-0.13319718837738037, 0.16771019995212555]
survival B-LOC [0.1258140653371811, -0.06029258295893669]
for O [-0.017712734639644623, 0.02293076552450657]
breast O [0.028867872431874275, 0.10189279913902283]
cancer B-LOC [0.12290707975625992, 0.0043090893886983395]
and B-LOC [-0.03412557765841484, -0.058351125568151474]
cerebrovascular O [-0.07395423948764801, 0.12151815742254257]
accidents B-LOC [0.06508181244134903, 0.0080034751445055]
in O [-0.06498054414987564, 0.1754443347454071]
teaching O [-0.10834187269210815, -0.05182942748069763]
hospitals B-LOC [0.12647384405136108, -0.10361646115779877]
and O [-0.19800490140914917, 0.2251431941986084]
significantly O [-0.2501489818096161, 0.24785402417182922]
better O [-0.1567964255809784, 0.30673667788505554]
survival O [0.04059464856982231, 0.08942200988531113]
from O [-0.26103585958480835, 0.3086602985858917]
cholecystectomy O [-0.21746161580085754, 0.24688288569450378]

in B-LOC [0.030550437048077583, -0.5434906482696533]
nonteaching B-LOC [0.6178733110427856, -0.7851007580757141]
hospitals), B-LOC [0.46551331877708435, -0.7947648167610168]
but B-LOC [0.6154136657714844, -1.01484215259552]
these B-LOC [0.7254311442375183, -1.0013868808746338]
were B-LOC [0.5689063668251038, -0.9799571633338928]
small B-LOC [0.9137871265411377, -0.9831737279891968]
in B-LOC [0.4925892651081085, -0.996123194694519]
magnitude. B-LOC [0.7712979316711426, -1.0884113311767578]
Other B-LOC [0.7832927703857422, -1.0677920579910278]
outcomes B-LOC [0.8273511528968811, -1.264084815979004]
were B-LOC [0.5129866003990173, -1.1596530675888062]
diverse, B-LOC [1.0031205415725708, -1.3800272941589355]
but B-LOC [0.5087305903434753, -1.0803300142288208]
typically B-LOC [0.6506808400154114, -0.8547295331954956]
teaching B-LOC [0.5354440212249756, -0.803033709526062]
healthcare B-LOC [0.5569521188735962, -1.1504212617874146]
structures B-LOC [0.6030530333518982, -1.131269931793213]
did B-LOC [0.3899180293083191, -0.7225616574287415]
not B-LOC [0.6746237277984619, -0.5836944580078125]
do B-LOC [0.5061697959899902, -0.9494511485099792]
better B-LOC [0.6350135207176208, -0.8813219666481018]
than B-LOC [0.3002097010612488, -0.8869525790214539]
nonteaching B-LOC [0.6358509659767151, -1.020897388458252]
ones. B-LOC [0.6206337809562683, -1.1962332725524902]
Conclusions O [-0.3640024960041046, 0.33075350522994995]
The O [-0.1804521232843399, 0.42606422305107117]
available O [-0.054685015231370926, 0.09670025110244751]
data O [-0.3798869550228119, 0.3497298061847687]
are O [-0.24150317907333374, 0.28361746668815613]
limited O [-0.28921565413475037, 0.3861876130104065]
by O [-0.4907757341861725, 0.6308383345603943]
their O [-0.23712414503097534, 0.5229012370109558]
nonrandomized O [-0.43315213918685913, 0.4868423640727997]
design, O [-0.2414606362581253, 0.35242825746536255]
but O [-0.6738919019699097, 0.7195996046066284]
overall O [-0.8449578881263733, 0.8020814657211304]
they O [-0.4390207827091217, 0.5932480096817017]
do O [-0.5563727021217346, 0.7614077925682068]
not O [-0.4408811926841736, 0.8520467877388]
suggest O [-0.7174171805381775, 0.7244829535484314]
that O [-0.818102240562439, 0.5976415276527405]
a O [-0.7096070647239685, 0.41682368516921997]
healthcare O [-0.7101449370384216, 0.3878921568393707]
facility's O [-0.514409601688385, 0.13698340952396393]
teaching O [-0.5447167754173279, 0.5372021794319153]
status O [-0.57573002576828, 0.5110035538673401]
on O [-0.6759243011474609, 0.68793123960495]
its O [-0.6203087568283081, 0.5657240748405457]
own O [-0.6161768436431885, 0.65365070104599]
markedly O [-0.8959820866584778, 0.7312659621238708]
improves O [-0.7022519707679749, 0.5410937666893005]
or O [-0.6670215129852295, 0.44087401032447815]
worsens O [-0.42970389127731323, 0.4081227481365204]
patient O [-0.4477789103984833, -0.03978543356060982]
outcomes. O [-0.3552798330783844, 0.2070208638906479]
Differences B-LOC [1.6513794660568237, -2.0443594455718994]
for B-LOC [1.6266000270843506, -2.150357484817505]
specific B-LOC [1.8372128009796143, -2.3836941719055176]
diseases B-LOC [1.6242547035217285, -2.1875293254852295]
cannot B-LOC [1.796081304550171, -1.8581132888793945]
be B-LOC [1.7872793674468994, -2.241834878921509]
excluded, B-LOC [1.9255685806274414, -2.0470592975616455]
but B-LOC [1.7322096824645996, -2.1187593936920166]
are B-LOC [1.7945926189422607, -2.1899755001068115]
likely B-LOC [1.965074896812439, -2.3892204761505127]
to B-LOC [1.9323182106018066, -2.298560857772827]
be B-LOC [1.8438167572021484, -2.447122812271118]
small. B-LOC [2.0809006690979004, -2.178039312362671]

Autoimmune B-LOC [2.005023717880249, -2.897472381591797]
diseases B-LOC [2.3156042098999023, -2.695739269256592]
are B-LOC [2.375781774520874, -2.6846470832824707]
thought B-LOC [2.620896577835083, -2.851243257522583]
to B-LOC [2.5262300968170166, -2.93943452835083]
result B-LOC [2.252901792526245, -2.7645070552825928]
from B-LOC [1.9148447513580322, -2.395554780960083]
imbalances B-LOC [2.380204439163208, -2.751173496246338]
in B-LOC [1.746454119682312, -2.9481375217437744]
normal B-LOC [2.0811896324157715, -2.904090166091919]
immune B-LOC [2.0380990505218506, -2.6428678035736084]
physiology B-LOC [2.094031572341919, -2.5594208240509033]
and B-LOC [2.1821773052215576, -2.6719682216644287]
regulation. B-LOC [2.2779603004455566, -2.740802049636841]
Here, B-LOC [0.24622753262519836, -0.22018519043922424]
we O [-0.1396379917860031, -0.060098882764577866]
show O [0.015470231883227825, 0.04395852982997894]
that O [-0.09645892679691315, -0.06403876096010208]
autoimmune B-LOC [0.4131491482257843, -0.4728371202945709]
disease B-LOC [0.2494821846485138, -0.37515386939048767]
susceptibility B-LOC [0.4377276599407196, -0.18344604969024658]
and B-LOC [0.3693270981311798, -0.3461049497127533]
resistance B-LOC [0.5148019194602966, -0.43665382266044617]
alleles B-LOC [0.5554617047309875, -0.37356600165367126]
on B-LOC [0.39658302068710327, -0.31684747338294983]
mouse B-LOC [0.31067439913749695, -0.40224942564964294]
chromosome B-LOC [0.3382960259914398, -0.49148544669151306]
3 B-LOC [0.6822388768196106, -0.5350613594055176]
(Idd3) B-LOC [0.5180854201316833, -0.39960187673568726]
correlate B-LOC [0.44603225588798523, -0.189985454082489]
with B-LOC [0.4670083820819855, -0.444941908121109]
differential B-LOC [0.4604269862174988, -0.706964910030365]
expression B-LOC [0.6175445914268494, -0.42791563272476196]
of B-LOC [0.7371925115585327, -0.883887767791748]
the B-LOC [0.6945286393165588, -0.7165290713310242]
key B-LOC [0.29976192116737366, -0.681648313999176]
immunoregulatory B-LOC [0.467708021402359, -0.7671825289726257]
cytokine B-LOC [0.5312893390655518, -0.731359601020813]
interleukin-2 B-LOC [0.472425252199173, -0.794008195400238]
(IL-2). B-LOC [0.7427453398704529, -0.8371346592903137]
In O [-0.36204275488853455, 0.3124261200428009]
order O [-0.22861894965171814, 0.2906359136104584]
to B-LOC [0.19590717554092407, 0.051065053790807724]
test B-LOC [0.19327552616596222, -0.042582206428050995]
directly B-LOC [0.016142601147294044, 0.0002942174323834479]
that B-LOC [0.21221360564231873, 0.08241419494152069]
an O [-0.25761136412620544, 0.16303224861621857]
approximately O [-0.13315102458000183, 0.06672520935535431]
twofold O [0.14482943713665009, 0.29555243253707886]
reduction O [-0.2422182857990265, -0.04035194590687752]
in O [-0.38803187012672424, 0.0546916238963604]
IL-2 O [-0.3239545524120331, -0.0028154649771749973]
underpins B-LOC [0.17023859918117523, 0.16865494847297668]
the O [-0.10241337865591049, 0.21231943368911743]
Idd3-linked O [-0.11423024535179138, 0.12025672942399979]
destabilization O [-0.16006135940551758, -0.02684991993010044]
of O [-0.2028142809867859, 0.21715091168880463]
immune O [-0.453706294298172, -0.019954176619648933]
homeostasis, O [-0.43940025568008423, 0.3415917456150055]
we O [-0.31261083483695984, 0.2334221601486206]
show O [-0.14486128091812134, 0.2328447550535202]
that O [-0.5825914740562439, 0.4601687490940094]
engineered O [-0.7601639032363892, 0.5876842141151428]
haplodeficiency O [-0.4556160867214203, 0.4653337895870209]
of O [-0.6775447130203247, 0.5459560751914978]
Il2 O [-0.31338292360305786, 0.04443523660302162]
gene O [-0.582139790058136, 0.3297185003757477]
expression O [-0.5882652401924133, 0.5486356019973755]
not O [-0.7940661311149597, 1.095484733581543]
only O [-0.9004285931587219, 0.9156298637390137]
reduces O [-0.8315305113792419, 0.36195483803749084]

T B-LOC [0.03239423409104347, -0.46331655979156494]
cell O [-0.3449486494064331, -0.2792457044124603]
IL-2 B-LOC [-0.046272505074739456, -0.27702346444129944]
production B-LOC [0.20278795063495636, -0.2848544716835022]
by O [-0.33092522621154785, 0.05235765501856804]
twofold B-LOC [0.2444925755262375, -0.024670975282788277]
but O [-0.07050547003746033, 0.0691584050655365]
also O [0.0027143885381519794, 0.10621058195829391]
mimics B-LOC [0.2544242739677429, -0.022412287071347237]
the B-LOC [0.2196563482284546, -0.16575075685977936]
autoimmune B-LOC [0.24080201983451843, -0.43806180357933044]
dysregulatory B-LOC [0.1966402232646942, -0.06498296558856964]
effects B-LOC [0.31728145480155945, -0.33814120292663574]
of B-LOC [0.3166571855545044, -0.45671650767326355]
the B-LOC [0.2704388499259949, -0.40872615575790405]
naturally B-LOC [0.2512238621711731, -0.5846003890037537]
occurring B-LOC [0.17784950137138367, -0.5525729656219482]
susceptibility B-LOC [0.19642886519432068, -0.4318327009677887]
alleles B-LOC [0.2963086664676666, -0.4105481803417206]
of B-LOC [0.07869439572095871, -0.3796863257884979]
Il2. B-LOC [0.2770635485649109, -0.5119467377662659]
Reduced O [-0.33539143204689026, 0.5006242394447327]
IL-2 O [-0.48764434456825256, 0.31515195965766907]
production O [-0.3891230523586273, 0.5232728123664856]
achieved O [-0.46336477994918823, 0.4293660521507263]
by O [-0.43853551149368286, 0.5127440690994263]
either O [-0.16329362988471985, 0.3692806363105774]
genetic O [-0.2653338313102722, 0.3942057490348816]
mechanism O [-0.41107627749443054, 0.49575990438461304]
correlates O [-0.2605823278427124, 0.7316519021987915]
with O [-0.25922489166259766, 0.4308989346027374]
reduced O [-0.3436630368232727, 0.5282028913497925]
function O [-0.28317031264305115, 0.5406053066253662]
of O [-0.3246244490146637, 0.343823105096817]
CD4+ O [-0.46820706129074097, 0.5704634785652161]
CD25+ O [-0.4527463912963867, 0.47634080052375793]
regulatory O [-0.2599655091762543, 0.04700722172856331]
T O [-0.32625189423561096, 0.2342928797006607]
cells, O [-0.3602951765060425, 0.4391419291496277]
which O [-0.223051980137825, 0.21892812848091125]
are O [-0.21103408932685852, 0.2604978680610657]
critical O [-0.2793509364128113, 0.27876201272010803]
for O [-0.3286348581314087, 0.2236473709344864]
maintaining O [-0.22429285943508148, 0.25326067209243774]
immune O [-0.454274445772171, 0.01880190335214138]
homeostasis. O [-0.4671923816204071, 0.3461028039455414]

Genome-wide B-LOC [2.3715012073516846, -3.2233493328094482]
association B-LOC [2.9880173206329346, -3.5252623558044434]
studies B-LOC [2.7497947216033936, -3.278107166290283]
are B-LOC [2.836611270904541, -2.93672776222229]
now B-LOC [2.9464938640594482, -3.0988051891326904]
identifying B-LOC [2.927278757095337, -3.481820583343506]
disease-associated B-LOC [3.2321853637695312, -3.6816537380218506]
chromosome B-LOC [2.957690954208374, -3.6565849781036377]
regions. B-LOC [3.0994985103607178, -3.5579144954681396]
However, B-LOC [2.770261287689209, -3.024092435836792]
even B-LOC [2.6695547103881836, -2.9083149433135986]
after B-LOC [2.4975392818450928, -2.8342483043670654]
convincing B-LOC [2.5533719062805176, -3.0633227825164795]
replication, B-LOC [2.8285725116729736, -3.1859347820281982]
the B-LOC [2.8340976238250732, -3.0484209060668945]
localization B-LOC [3.054485559463501, -3.463228225708008]
of B-LOC [2.94415545463562, -3.303030252456665]
the B-LOC [2.997600793838501, -3.1756350994110107]
causal B-LOC [2.9553985595703125, -3.376012086868286]
variant(s) B-LOC [2.9112837314605713, -3.4558351039886475]
requires B-LOC [2.8377604484558105, -2.948106527328491]
comprehensive B-LOC [2.8177242279052734, -3.1237852573394775]
resequencing, B-LOC [3.069127321243286, -3.318089246749878]
extensive B-LOC [2.676159620285034, -3.020665407180786]
genotyping B-LOC [3.1744556427001953, -3.335390090942383]
and B-LOC [2.7348010540008545, -3.01011323928833]
statistical B-LOC [3.0913145542144775, -3.4421024322509766]
analyses B-LOC [3.086135149002075, -3.2789204120635986]
in B-LOC [3.1263701915740967, -3.2322332859039307]
large B-LOC [3.021512269973755, -3.2351725101470947]
sample B-LOC [3.2407305240631104, -3.4244487285614014]
sets B-LOC [3.2522265911102295, -3.4407761096954346]
leading B-LOC [2.9113125801086426, -3.082392454147339]
to B-LOC [2.8028206825256348, -2.9617795944213867]
targeted B-LOC [3.0708556175231934, -3.5548646450042725]
functional B-LOC [3.287379503250122, -3.5557148456573486]
studies. B-LOC [3.090071439743042, -3.348750591278076]
Here, B-LOC [0.05121762305498123, -0.4332273304462433]
we B-LOC [0.02762763388454914, -0.4049754738807678]
have B-LOC [0.4395808279514313, -0.37675923109054565]
localized B-LOC [0.3388395607471466, -0.5209629535675049]
the B-LOC [0.2616724967956543, -0.6553660035133362]
type B-LOC [0.20612218976020813, -0.5883491039276123]
1 B-LOC [0.11257226765155792, -0.5542445778846741]
diabetes B-LOC [0.2594883143901825, -0.7513311505317688]
(T1D) B-LOC [0.14923200011253357, -0.4950627088546753]
association B-LOC [0.01185609307140112, -0.5948813557624817]
in B-LOC [0.015172216109931469, -0.34446266293525696]
the B-LOC [0.13722433149814606, -0.45685115456581116]
interleukin B-LOC [0.11983314156532288, -0.509380042552948]
2 B-LOC [0.4710817039012909, -0.3982894718647003]
receptor B-LOC [-0.03691938892006874, -0.5932796001434326]
alpha B-LOC [0.16721467673778534, -0.4385896921157837]
(IL2RA) B-LOC [0.23083826899528503, -0.5098568201065063]
gene B-LOC [-0.044460512697696686, -0.5561032295227051]
region B-LOC [-0.009621408767998219, -0.4639701247215271]
to B-LOC [0.10548484325408936, -0.46185266971588135]
two B-LOC [0.16315172612667084, -0.5815850496292114]
independent B-LOC [0.19705039262771606, -0.69781494140625]
groups B-LOC [0.32638317346572876, -0.45482736825942993]
of B-LOC [0.21744906902313232, -0.6622509360313416]
SNPs, B-LOC [0.08661356568336487, -0.6119269728660583]
spanning B-LOC [0.3577403128147125, -0.7930819392204285]
overlapping B-LOC [0.5361136198043823, -0.8080317378044128]
regions B-LOC [0.41593143343925476, -0.582804799079895]
of B-LOC [0.22637051343917847, -0.6429998278617859]
14 B-LOC [0.3401419222354889, -0.45059487223625183]
and B-LOC [0.0769057646393776, -0.7066099643707275]
40 B-LOC [0.6298491954803467, -0.5415422320365906]
kb, B-LOC [0.34309276938438416, -0.5556244850158691]
encompassing B-LOC [0.42230650782585144, -0.626237690448761]
IL2RA B-LOC [0.031025676056742668, -0.3718703091144562]
intron B-LOC [0.16520515084266663, -0.23029862344264984]
1 B-LOC [0.14756229519844055, -0.2724290192127228]
and B-LOC [0.4699946343898773, -0.4917120337486267]
the B-LOC [0.46296390891075134, -0.5462429523468018]
5′ B-LOC [0.24845516681671143, -0.38418343663215637]
regions B-LOC [0.25311610102653503, -0.6057364344596863]
of B-LOC [0.22525106370449066, -0.6792431473731995]

IL2RA O [-0.22164931893348694, 0.04358888417482376]
and O [-0.07650596648454666, 0.09625018388032913]
RBM17 O [-0.1775512993335724, 0.29237574338912964]
(odds O [-0.22317130863666534, 0.28929153084754944]
ratio O [-0.33992740511894226, 0.25034698843955994]
= O [-0.26522234082221985, 0.28319472074508667]
2.04, O [-0.45721790194511414, 0.6393337845802307]
95% O [-0.5644940137863159, 0.57728511095047]
confidence O [-0.45788660645484924, 0.3648216128349304]
interval O [-0.5007863640785217, 0.26165714859962463]
= O [-0.3866390287876129, 0.208024799823761]
1.70–2.45; O [-0.3054908812046051, 0.49351879954338074]
P O [-0.5252173542976379, 0.2368369996547699]
= O [-0.4681122899055481, 0.33720141649246216]
1.92 O [-0.2889375388622284, 0.4503951370716095]
× O [-0.48439034819602966, 0.15884026885032654]
10−28; O [-0.3365381062030792, 0.25960150361061096]
control O [-0.28526923060417175, 0.10771768540143967]
frequency O [-0.36238154768943787, 0.17077773809432983]
= O [-0.30710873007774353, 0.06745382398366928]
0.635). O [-0.21278369426727295, 0.2958357036113739]
Furthermore, O [-0.7804577946662903, 0.8250955939292908]
we O [-0.6966968178749084, 0.46940022706985474]
have O [-0.4038864076137543, 0.5346383452415466]
associated O [-0.5585027933120728, 0.7190344333648682]
IL2RA O [-0.7019479870796204, 0.5672466158866882]
T1D O [-0.809465229511261, 0.7908125519752502]
susceptibility O [-0.6559890508651733, 0.6931885480880737]
genotypes O [-0.48908188939094543, 0.7394443154335022]
with O [-0.5810796022415161, 0.6216845512390137]
lower O [-0.6007082462310791, 0.6494988799095154]
circulating O [-0.6634009480476379, 0.5801846385002136]
levels O [-0.5943896174430847, 0.7083367705345154]
of O [-0.6400039792060852, 0.7789524793624878]
the O [-0.5817784070968628, 0.6240333914756775]
biomarker, O [-0.6386456489562988, 0.6340538859367371]
soluble O [-0.59303879737854, 0.44079890847206116]
IL-2RA O [-0.7372272610664368, 0.5023064017295837]
(P O [-0.4774133265018463, 0.37802430987358093]
= O [-0.6316180229187012, 0.34309878945350647]
6.28 O [-0.544702410697937, 0.5937932729721069]
× O [-0.6199266314506531, 0.1194683164358139]
10−28), O [-0.5345047116279602, 0.3739466965198517]
suggesting O [-0.5484935641288757, 0.5693960785865784]
that O [-0.6913529634475708, 0.4481358826160431]
an O [-0.7413358092308044, 0.5014930367469788]
inherited O [-0.7517426609992981, 0.6269920468330383]
lower O [-0.6892707943916321, 0.577463686466217]
immune O [-0.7595746517181396, 0.3458121120929718]
responsiveness O [-0.6925651431083679, 0.8479198813438416]
predisposes O [-0.5608838796615601, 0.5132603645324707]
to O [-0.5732516646385193, 0.4303525984287262]
T1D. O [-0.62977534532547, 0.33655110001564026]

OBJECTIVE B-LOC [3.3970706462860107, -3.92313814163208]
To B-LOC [3.5283782482147217, -3.91917085647583]
determine B-LOC [3.589906930923462, -3.672645092010498]
whether B-LOC [3.5510432720184326, -3.7845475673675537]
perceived B-LOC [3.6168220043182373, -4.015998840332031]
age B-LOC [3.734586000442505, -3.9200313091278076]
correlates B-LOC [3.515824317932129, -3.860830307006836]
with B-LOC [3.4663920402526855, -4.129530906677246]
survival B-LOC [3.786242961883545, -4.052474498748779]
and B-LOC [3.5379436016082764, -3.856217861175537]
important B-LOC [3.7166061401367188, -4.049121856689453]
age B-LOC [3.7128331661224365, -3.9788858890533447]
related B-LOC [3.5298476219177246, -4.161266326904297]
phenotypes. B-LOC [3.6877822875976562, -3.9367730617523193]
DESIGN B-LOC [3.6645357608795166, -3.8468806743621826]
Follow-up B-LOC [3.5130879878997803, -3.6279780864715576]
study, B-LOC [3.4623138904571533, -3.814162492752075]
with B-LOC [3.6302871704101562, -3.5173532962799072]
survival B-LOC [3.7438881397247314, -3.7209312915802]
of B-LOC [3.5384998321533203, -3.591214895248413]
twins B-LOC [3.6124985218048096, -3.737358331680298]
determined B-LOC [3.573338747024536, -3.6282808780670166]
up B-LOC [3.6415960788726807, -3.5361030101776123]
to B-LOC [3.659628391265869, -3.3836891651153564]
January B-LOC [3.5706822872161865, -3.470824718475342]
2008, B-LOC [3.5278265476226807, -3.543555974960327]
by B-LOC [3.387890100479126, -3.376372814178467]
which B-LOC [3.371025323867798, -3.491976737976074]
time B-LOC [3.4723525047302246, -3.641392946243286]
675 B-LOC [3.253657579421997, -3.2428979873657227]
(37%) B-LOC [3.4978740215301514, -3.642627477645874]
had B-LOC [3.621837854385376, -3.4792072772979736]
died. B-LOC [3.612027645111084, -3.7522995471954346]
SETTING B-LOC [3.0328755378723145, -3.527303695678711]
Population B-LOC [3.251434087753296, -3.386115550994873]
based B-LOC [2.7199769020080566, -3.311174154281616]
twin B-LOC [3.0960428714752197, -3.4559481143951416]
cohort B-LOC [3.471470832824707, -3.431800127029419]
in B-LOC [3.2075397968292236, -3.2635343074798584]
Denmark. B-LOC [3.4016973972320557, -3.716615915298462]
PARTICIPANTS B-LOC [2.8926827907562256, -3.1710245609283447]
20 B-LOC [3.570666551589966, -3.516824245452881]
nurses, B-LOC [3.5486929416656494, -3.493744134902954]
10 B-LOC [3.4405765533447266, -3.326535224914551]
young B-LOC [3.284064531326294, -3.0970025062561035]
men, B-LOC [3.4170308113098145, -3.3337996006011963]
and B-LOC [3.247011423110962, -3.4666757583618164]
11 B-LOC [3.494908571243286, -3.2859318256378174]
older B-LOC [3.4035415649414062, -3.262420892715454]
women B-LOC [3.5183117389678955, -3.169790744781494]
(assessors); B-LOC [3.5982611179351807, -3.2628679275512695]
1826 B-LOC [3.4754326343536377, -3.4686083793640137]
twins B-LOC [3.501342535018921, -3.4492552280426025]
aged B-LOC [3.5260798931121826, -3.246941328048706]
>or=70. B-LOC [2.8267788887023926, -2.9485137462615967]
MAIN B-LOC [3.1670875549316406, -3.1722469329833984]
OUTCOME B-LOC [3.0152924060821533, -3.0769002437591553]
MEASURES B-LOC [2.9092209339141846, -2.955077886581421]
Assessors: B-LOC [3.2510337829589844, -3.354633092880249]
perceived B-LOC [3.297882318496704, -3.3282642364501953]
age B-LOC [3.4031851291656494, -3.2710702419281006]
of B-LOC [3.271960973739624, -3.161653518676758]
twins B-LOC [3.501655340194702, -3.27945876121521]
from B-LOC [2.916168451309204, -3.0832831859588623]
photographs. B-LOC [3.3591768741607666, -3.231961488723755]
Twins: B-LOC [2.50807785987854, -2.6749918460845947]
physical B-LOC [2.1526544094085693, -2.6028831005096436]

and B-LOC [1.3324551582336426, -1.968736171722412]
cognitive B-LOC [1.5687731504440308, -2.285097122192383]
tests B-LOC [1.48885178565979, -2.278015375137329]
and B-LOC [1.4811537265777588, -2.1481688022613525]
molecular B-LOC [1.8268487453460693, -2.369579553604126]
biomarker B-LOC [1.637547492980957, -2.4132649898529053]
of B-LOC [1.4911104440689087, -2.272923707962036]
ageing B-LOC [1.9723467826843262, -2.4873950481414795]
(leucocyte B-LOC [1.7164051532745361, -2.215343713760376]
telomere B-LOC [1.6289424896240234, -2.230848550796509]
length). B-LOC [1.5792181491851807, -2.285325050354004]
RESULTS B-LOC [0.7847411036491394, -1.5393791198730469]
For B-LOC [0.9597658514976501, -1.515026330947876]
all B-LOC [1.2288081645965576, -1.5742056369781494]
three B-LOC [1.3061596155166626, -1.6203504800796509]
groups B-LOC [1.507859230041504, -1.9030400514602661]
of B-LOC [1.3867754936218262, -2.2089247703552246]
assessors, B-LOC [1.4922161102294922, -1.9761021137237549]
perceived B-LOC [1.2602368593215942, -1.718644618988037]
age B-LOC [1.3843369483947754, -1.8539586067199707]
was B-LOC [0.9794337153434753, -1.6645045280456543]
significantly B-LOC [1.039975643157959, -1.6183545589447021]
associated B-LOC [1.0430138111114502, -1.6473857164382935]
with B-LOC [0.9099851250648499, -1.8710861206054688]
survival, B-LOC [1.2495557069778442, -1.7724589109420776]
even B-LOC [1.185707688331604, -1.6693872213363647]
after B-LOC [0.9779033064842224, -1.6329492330551147]
adjustment B-LOC [1.1232680082321167, -1.8303226232528687]
for B-LOC [1.3540563583374023, -2.1183676719665527]
chronological B-LOC [1.4276992082595825, -2.039450168609619]
age, B-LOC [1.595557451248169, -2.094343900680542]
sex, B-LOC [1.3249309062957764, -1.793393611907959]
and B-LOC [1.2797610759735107, -1.7589325904846191]
rearing B-LOC [1.1670001745224, -1.4902068376541138]
environment. B-LOC [1.3484543561935425, -1.7676653861999512]
Perceived B-LOC [1.4704949855804443, -1.8502154350280762]
age B-LOC [1.6358879804611206, -1.8872636556625366]
was B-LOC [1.0883151292800903, -1.6545510292053223]
still B-LOC [1.376480221748352, -1.728362798690796]
significantly B-LOC [1.2757744789123535, -1.6739978790283203]
associated B-LOC [1.2148447036743164, -1.6440017223358154]
with B-LOC [1.032036304473877, -1.7432219982147217]
survival B-LOC [1.4208002090454102, -1.8291504383087158]
after B-LOC [1.2667770385742188, -1.746468186378479]
further B-LOC [1.2359400987625122, -1.8394198417663574]
adjustment B-LOC [1.2883727550506592, -1.786989688873291]
for B-LOC [1.2735811471939087, -2.0761709213256836]
physical B-LOC [1.2854101657867432, -1.8454649448394775]
and B-LOC [1.1457575559616089, -1.800363540649414]
cognitive B-LOC [1.415414571762085, -1.8565325736999512]
functioning. B-LOC [1.2753489017486572, -1.9144105911254883]
The B-LOC [0.09846269339323044, -0.3062644302845001]
likelihood B-LOC [0.10242097824811935, -0.17526262998580933]
that B-LOC [-0.05754281207919121, -0.3140556514263153]
the B-LOC [0.12501761317253113, -0.23675628006458282]
older B-LOC [0.1429382711648941, -0.24266694486141205]
looking B-LOC [0.12842710316181183, -0.25140565633773804]
twin B-LOC [0.1545034497976303, -0.4094337224960327]
of B-LOC [0.19428817927837372, -0.39906179904937744]
the B-LOC [0.22116999328136444, -0.33423948287963867]
pair B-LOC [0.11577523499727249, -0.4863743484020233]
died B-LOC [0.1578860580921173, -0.3472333550453186]
first B-LOC [0.011332246474921703, -0.24819043278694153]
increased B-LOC [-0.07838036119937897, -0.45468753576278687]
with B-LOC [-0.07741817086935043, -0.4238301217556]
increasing B-LOC [-0.05121184512972832, -0.3286646604537964]
discordance B-LOC [0.41483211517333984, -0.25219500064849854]
in B-LOC [0.04170050844550133, -0.6567955017089844]
perceived B-LOC [0.17473405599594116, -0.36191892623901367]
age B-LOC [0.35851234197616577, -0.3249227702617645]
within B-LOC [0.2890773117542267, -0.42984020709991455]
the B-LOC [0.18235187232494354, -0.2874852120876312]
twin B-LOC [0.09193069487810135, -0.596631646156311]
pair-that B-LOC [0.12215238064527512, -0.4047869145870209]
is, O [-0.015472632832825184, 0.06980191171169281]
the B-LOC [0.03489971533417702, -0.09869030117988586]
bigger O [0.07263806462287903, 0.1721954345703125]
the B-LOC [0.20456162095069885, -0.20090222358703613]
difference B-LOC [-0.02534499578177929, -0.4667229950428009]
in B-LOC [0.1486005038022995, -0.4890494644641876]
perceived B-LOC [0.18179050087928772, -0.24751070141792297]
age B-LOC [0.28498923778533936, -0.23948456346988678]
within B-LOC [0.38827478885650635, -0.4047427475452423]
the B-LOC [0.24446599185466766, -0.30869367718696594]
pair, B-LOC [0.14898794889450073, -0.45610296726226807]
the B-LOC [0.5343645215034485, -0.07817608118057251]
more O [-0.04777931794524193, -0.04307885840535164]
likely B-LOC [-0.20924364030361176, -0.24592101573944092]

that B-LOC [0.5821704864501953, -0.9932135939598083]
the B-LOC [0.7586315870285034, -0.9838576912879944]
older B-LOC [0.781046450138092, -1.1269804239273071]
looking B-LOC [0.8431361317634583, -1.1660022735595703]
twin B-LOC [0.7757676243782043, -1.248608112335205]
died B-LOC [0.8276278972625732, -1.1129579544067383]
first. B-LOC [0.6874731779098511, -0.8725886940956116]
Twin B-LOC [2.2460975646972656, -2.591153860092163]
analyses B-LOC [2.1071956157684326, -2.3155267238616943]
suggested B-LOC [2.0492987632751465, -2.188525438308716]
that B-LOC [1.9059922695159912, -2.2545294761657715]
common B-LOC [2.151405096054077, -2.4810075759887695]
genetic B-LOC [2.338010549545288, -2.6969821453094482]
factors B-LOC [2.407794952392578, -2.761744260787964]
influence B-LOC [2.1167783737182617, -2.4929988384246826]
both B-LOC [2.2204856872558594, -2.5659525394439697]
perceived B-LOC [2.043187379837036, -2.4465560913085938]
age B-LOC [2.4134762287139893, -2.6861681938171387]
and B-LOC [2.329273223876953, -2.5019404888153076]
survival. B-LOC [2.0773298740386963, -2.580725908279419]
Perceived B-LOC [1.824012041091919, -2.4621732234954834]
age, B-LOC [2.0305838584899902, -2.435560464859009]
controlled B-LOC [1.9801592826843262, -2.330127239227295]
for B-LOC [1.8051481246948242, -2.4676144123077393]
chronological B-LOC [2.1435577869415283, -2.623002052307129]
age B-LOC [2.09580397605896, -2.5944502353668213]
and B-LOC [1.7141646146774292, -2.3193087577819824]
sex, B-LOC [1.9024064540863037, -2.4909777641296387]
also B-LOC [1.7196247577667236, -2.120049238204956]
correlated B-LOC [1.5466747283935547, -2.156989812850952]
significantly B-LOC [1.6400401592254639, -2.19004225730896]
with B-LOC [1.5406761169433594, -2.3215508460998535]
physical B-LOC [1.388617753982544, -2.0658953189849854]
and B-LOC [1.0852112770080566, -2.0550999641418457]
cognitive B-LOC [1.4477788209915161, -1.9024808406829834]
functioning B-LOC [1.4331600666046143, -2.00107741355896]
as B-LOC [1.3749747276306152, -1.6623822450637817]
well B-LOC [1.5978341102600098, -1.735622525215149]
as B-LOC [1.58844792842865, -1.6700845956802368]
with B-LOC [1.5139209032058716, -2.2930965423583984]
leucocyte B-LOC [1.6751807928085327, -1.9027019739151]
telomere B-LOC [1.5935311317443848, -2.0842559337615967]
length. B-LOC [1.4735565185546875, -2.0800082683563232]
CONCLUSION O [-0.3998909592628479, 0.16362154483795166]
Perceived B-LOC [0.21520709991455078, -0.40296605229377747]
age-which B-LOC [0.5376884341239929, -0.6317804455757141]
is B-LOC [0.7404899001121521, -0.7467635273933411]
widely B-LOC [0.8700588941574097, -0.9374706149101257]
used B-LOC [0.8424131274223328, -0.9438746571540833]
by B-LOC [0.8116522431373596, -1.0030949115753174]
clinicians B-LOC [0.8145338892936707, -0.8974952697753906]
as B-LOC [0.546603262424469, -0.75417560338974]
a B-LOC [0.6605560183525085, -0.8084434270858765]
general B-LOC [0.5171746611595154, -0.7905067205429077]
indication B-LOC [0.602776050567627, -0.8747270107269287]
of B-LOC [0.6919329166412354, -1.1409802436828613]
a B-LOC [0.6789247393608093, -1.1274213790893555]
patient's B-LOC [0.5485081076622009, -1.1132842302322388]
health-is B-LOC [0.4649782180786133, -0.974526047706604]
a B-LOC [0.09758508205413818, -0.26477935910224915]
robust B-LOC [0.24680018424987793, -0.3292783796787262]
biomarker B-LOC [0.18470904231071472, -0.48144057393074036]
of B-LOC [0.09820947051048279, -0.4692372679710388]
ageing B-LOC [0.5008036494255066, -0.6201996803283691]
that B-LOC [-0.08335267752408981, -0.5081706643104553]
predicts B-LOC [0.15015575289726257, -0.39873942732810974]
survival B-LOC [0.3212739825248718, -0.6084913611412048]
among B-LOC [0.28990501165390015, -0.550876259803772]
those B-LOC [0.401535302400589, -0.5375609993934631]
aged B-LOC [0.5907909274101257, -0.9531208872795105]
>or=70 B-LOC [0.46544504165649414, -0.7902609705924988]
and B-LOC [-0.05211818590760231, -0.3350473940372467]
correlates B-LOC [0.26483073830604553, -0.22057542204856873]
with B-LOC [0.38493403792381287, -0.604198157787323]
important B-LOC [0.24486669898033142, -0.7862569093704224]
functional B-LOC [0.31027692556381226, -0.7902181148529053]
and B-LOC [0.25270554423332214, -0.7046399116516113]
molecular B-LOC [0.28447064757347107, -0.6249986290931702]
ageing B-LOC [0.6900680065155029, -0.7591825127601624]
phenotypes. B-LOC [0.3343876600265503, -0.7367815375328064]

Phosphatidylinositol-3-kinase B-LOC [0.4993125796318054, -1.366304636001587]
(PI3K) B-LOC [1.174849033355713, -1.5289758443832397]
pathway B-LOC [0.6816222071647644, -1.2230440378189087]
deregulation B-LOC [1.3715667724609375, -1.2841286659240723]
is B-LOC [1.0721290111541748, -1.3143962621688843]
a B-LOC [1.0509841442108154, -1.2078964710235596]
common B-LOC [1.0300586223602295, -1.142488956451416]
event B-LOC [0.8281022310256958, -1.2920255661010742]
in B-LOC [1.070458173751831, -1.321799397468567]
human B-LOC [0.8949247002601624, -1.1402279138565063]
cancer, B-LOC [1.104821801185608, -1.3188581466674805]
either B-LOC [0.6277529001235962, -1.2852530479431152]
through B-LOC [0.6325899958610535, -1.0411438941955566]
inactivation B-LOC [0.6925496459007263, -0.8945109844207764]
of B-LOC [0.6579940319061279, -0.9053924679756165]
the B-LOC [0.600969672203064, -0.6249808669090271]
tumor B-LOC [0.647970974445343, -0.8422123193740845]
suppressor B-LOC [0.5799763798713684, -0.8192506432533264]
phosphatase B-LOC [0.5081959366798401, -0.9884669184684753]
and B-LOC [0.35310086607933044, -0.6165501475334167]
tensin B-LOC [0.3377063572406769, -0.7778310775756836]
homologue B-LOC [0.4555351436138153, -0.8250249624252319]
deleted B-LOC [0.7417203783988953, -0.6560075879096985]
from B-LOC [0.4592759907245636, -0.8008216023445129]
chromosome B-LOC [0.6877095103263855, -1.1515233516693115]
10 B-LOC [0.9187272191047668, -0.9819360375404358]
or B-LOC [0.5128452777862549, -0.9442530274391174]
activating B-LOC [0.449248343706131, -0.7313027381896973]
mutations B-LOC [0.6743562817573547, -0.8779007196426392]
of B-LOC [0.34208106994628906, -0.8754483461380005]
p110-alpha. B-LOC [0.5064161419868469, -1.249934434890747]
These B-LOC [1.0955489873886108, -1.2218976020812988]
hotspot B-LOC [1.4102036952972412, -1.3832052946090698]
mutations B-LOC [1.5639045238494873, -1.3682862520217896]
result B-LOC [1.306925892829895, -1.1450810432434082]
in B-LOC [0.752106249332428, -0.8764644861221313]
oncogenic B-LOC [0.9811878204345703, -1.2195005416870117]
activity B-LOC [1.3744149208068848, -1.2257366180419922]
of B-LOC [0.9139867424964905, -1.0974210500717163]
the B-LOC [1.1018999814987183, -1.4933137893676758]
enzyme B-LOC [1.1635477542877197, -1.7925500869750977]
and B-LOC [0.7942572236061096, -0.9764451384544373]
contribute B-LOC [1.64681077003479, -1.2726447582244873]
to B-LOC [1.2864084243774414, -1.1337502002716064]
therapeutic B-LOC [1.9404584169387817, -1.8714160919189453]
resistance B-LOC [1.8668971061706543, -1.7163922786712646]
to B-LOC [1.4090096950531006, -1.3951854705810547]
the B-LOC [1.6538976430892944, -1.4535361528396606]
anti-HER2 B-LOC [1.7626100778579712, -1.819653034210205]
antibody B-LOC [1.7264496088027954, -1.8427231311798096]
trastuzumab. B-LOC [1.2923917770385742, -1.576326608657837]
The B-LOC [1.7896591424942017, -1.9173288345336914]
PI3K B-LOC [1.0666077136993408, -1.8110978603363037]
pathway B-LOC [1.2885501384735107, -2.1224241256713867]
is, B-LOC [2.3440778255462646, -2.1052346229553223]
therefore, B-LOC [2.4172580242156982, -1.9164268970489502]
an B-LOC [2.2410333156585693, -2.1954262256622314]
attractive B-LOC [2.2156496047973633, -2.3409464359283447]
target B-LOC [2.2184090614318848, -2.4837722778320312]
for B-LOC [2.2478554248809814, -2.3746607303619385]
cancer B-LOC [2.257354259490967, -2.6653831005096436]
therapy. B-LOC [2.197179079055786, -2.5321600437164307]
We B-LOC [0.8077982068061829, -1.0854603052139282]
have B-LOC [1.4185659885406494, -1.2133517265319824]
studied B-LOC [1.339815616607666, -1.3656396865844727]

NVP-BEZ235, B-LOC [0.5385136604309082, -1.2536402940750122]
a B-LOC [0.9776776432991028, -0.9179436564445496]
dual B-LOC [1.4045319557189941, -1.3304507732391357]
inhibitor B-LOC [1.0541472434997559, -1.1608083248138428]
of B-LOC [1.1211081743240356, -1.039802074432373]
the B-LOC [1.1554515361785889, -1.069790005683899]
PI3K B-LOC [1.0301462411880493, -1.4027976989746094]
and B-LOC [1.2241878509521484, -1.1499894857406616]
the B-LOC [1.1816461086273193, -1.0509661436080933]
downstream B-LOC [1.497323989868164, -1.6027257442474365]
mammalian B-LOC [1.6723687648773193, -1.8074231147766113]
target B-LOC [1.3205077648162842, -1.455723762512207]
of B-LOC [1.4130969047546387, -1.5591803789138794]
rapamycin B-LOC [1.143405556678772, -1.481331467628479]
(mTOR). B-LOC [1.6571506261825562, -1.424124836921692]
NVP-BEZ235 B-LOC [-0.027976570650935173, -0.10394062101840973]
inhibited O [-0.19164913892745972, 0.15726186335086823]
the O [0.006719904486089945, 0.06545700877904892]
activation O [0.01715182699263096, 0.37145039439201355]
of O [0.04294967278838158, 0.27469709515571594]
the B-LOC [0.23429502546787262, 0.07175236195325851]
downstream B-LOC [0.08687359094619751, -0.04832577332854271]
effectors O [-0.1376478672027588, 0.2260635942220688]
Akt, O [-0.28648507595062256, 0.10927072167396545]
S6 O [-0.058402154594659805, 0.025981472805142403]
ribosomal O [-0.2311733514070511, 0.02857067994773388]
protein, O [-0.0611589215695858, 0.07451100647449493]
and O [-0.01792527548968792, 0.15869738161563873]
4EBP1 O [-0.10926470160484314, -0.00029286969220265746]
in O [-0.16248896718025208, 0.18376243114471436]
breast B-LOC [0.07359574735164642, -0.032475005835294724]
cancer B-LOC [0.008020716719329357, -0.05871893838047981]
cells. O [-0.3253627121448517, 0.24595913290977478]
The B-LOC [1.0901532173156738, -1.0490024089813232]
antiproliferative B-LOC [1.271470546722412, -1.0182161331176758]
activity B-LOC [1.0679017305374146, -0.9392772912979126]
of B-LOC [1.0890555381774902, -0.8800530433654785]
NVP-BEZ235 B-LOC [0.5638728737831116, -0.7770020365715027]
was B-LOC [1.0371215343475342, -1.1556912660598755]
superior B-LOC [1.01060950756073, -1.1352413892745972]
to B-LOC [1.1016356945037842, -1.132683277130127]
the B-LOC [1.223623275756836, -1.056115746498108]
allosteric B-LOC [1.3130338191986084, -0.9094915390014648]
selective B-LOC [0.9047949910163879, -1.1167142391204834]
mTOR B-LOC [0.8548176884651184, -1.0298311710357666]
complex B-LOC [0.9151095747947693, -0.9442412257194519]
inhibitor B-LOC [0.8435870409011841, -0.9022712111473083]
everolimus B-LOC [0.7319952249526978, -0.7687203884124756]
in B-LOC [1.22663152217865, -0.8985219597816467]
a B-LOC [1.3039261102676392, -0.8913463950157166]
panel B-LOC [1.1950359344482422, -0.8067912459373474]
of B-LOC [1.192301630973816, -1.097235918045044]
21 B-LOC [1.4208896160125732, -1.29583740234375]
cancer B-LOC [1.2772319316864014, -1.455224633216858]
cell B-LOC [1.1145436763763428, -1.1749529838562012]
lines B-LOC [1.2119622230529785, -1.2036383152008057]
of B-LOC [1.248631238937378, -1.4420208930969238]
different B-LOC [1.2883493900299072, -1.8599352836608887]
origin B-LOC [1.5024588108062744, -1.58998441696167]
and B-LOC [1.4175183773040771, -1.6401846408843994]
mutation B-LOC [1.2995295524597168, -1.4701005220413208]

status. B-LOC [0.4348549246788025, -1.185438632965088]
The B-LOC [0.8253387808799744, -1.320805311203003]
described B-LOC [0.9084228873252869, -1.302912712097168]
Akt B-LOC [0.7162676453590393, -1.309399962425232]
activation B-LOC [0.5692219734191895, -1.208832025527954]
due B-LOC [0.8413559794425964, -1.153686285018921]
to B-LOC [0.9443585872650146, -1.2875654697418213]
mTOR B-LOC [0.9061971306800842, -1.6020622253417969]
inhibition B-LOC [1.099816083908081, -1.5474046468734741]
was B-LOC [0.8986676335334778, -1.1756491661071777]
prevented B-LOC [1.1013336181640625, -1.2855899333953857]
by B-LOC [0.9331095218658447, -1.2257814407348633]
higher B-LOC [0.9766543507575989, -1.6301065683364868]
doses B-LOC [1.0647344589233398, -1.2184534072875977]
of B-LOC [0.8317186832427979, -1.287595510482788]
NVP-BEZ235. B-LOC [0.7328144907951355, -1.3298333883285522]
NVP-BEZ235 O [-1.0609471797943115, 1.1253982782363892]
reversed O [-1.3460559844970703, 1.0268571376800537]
the O [-1.2304279804229736, 1.0411999225616455]
hyperactivation O [-1.3398780822753906, 1.0279695987701416]
of O [-1.1933730840682983, 1.0112515687942505]
the O [-1.218017816543579, 1.0023442506790161]
PI3K/mTOR O [-1.2383112907409668, 0.8438318371772766]
pathway O [-1.2940826416015625, 0.9375442862510681]
caused O [-1.222593069076538, 1.0027117729187012]
by O [-1.12473464012146, 0.9506447911262512]
the O [-1.0321074724197388, 0.940122663974762]
oncogenic O [-1.1569287776947021, 1.004591941833496]
mutations O [-0.9839658737182617, 0.8943368792533875]
of O [-0.9971963763237, 0.927865743637085]
p110-alpha, O [-1.0473432540893555, 0.4854494631290436]
E545K, O [-0.9520180225372314, 0.5964875817298889]
and O [-1.0929361581802368, 0.9633151888847351]
H1047R, O [-0.8771018981933594, 0.40762850642204285]
and O [-1.2393627166748047, 1.0035722255706787]
inhibited O [-1.3917078971862793, 1.182936668395996]
the O [-1.0948823690414429, 1.0185836553573608]
proliferation O [-0.7952703833580017, 1.0046935081481934]
of O [-0.8839654326438904, 0.8817964196205139]
HER2-amplified O [-0.7995288372039795, 0.5734545588493347]
BT474 O [-0.4218040108680725, 0.34276172518730164]
cells O [-0.8139925003051758, 0.7438402771949768]
exogenously O [-0.7097530961036682, 0.6284841895103455]
expressing O [-0.6768220663070679, 0.7564508318901062]
these O [-0.549310564994812, 0.4873715341091156]
mutations O [-0.5456207394599915, 0.46152421832084656]
that O [-0.5161334872245789, 0.5343043804168701]
render O [-0.40621188282966614, 0.6180245876312256]
them O [-0.5018987059593201, 0.6061061024665833]
resistant O [-0.3600471317768097, 0.42953282594680786]
to O [-0.512940526008606, 0.44046804308891296]
trastuzumab. O [-0.2984769940376282, 0.24876482784748077]
In O [-0.7188624739646912, 0.21777664124965668]

trastuzumab-resistant O [-0.2586960196495056, 0.2084600031375885]
BT474 O [-0.009891116060316563, 0.006883738096803427]
H1047R O [-0.25014811754226685, 0.04427827522158623]
breast O [-0.3408331871032715, 0.42434754967689514]
cancer O [-0.2758537828922272, 0.34964868426322937]
xenografts, O [-0.13932615518569946, 0.4510640501976013]
NVP-BEZ235 O [-0.27908793091773987, 0.18538546562194824]
inhibited O [-0.37564507126808167, 0.2967657148838043]
PI3K O [-0.2026674449443817, -0.003951145801693201]
signaling O [-0.21748054027557373, 0.36595967411994934]
and O [-0.32326358556747437, 0.2511747181415558]
had O [-0.2233077585697174, 0.018423816189169884]
potent O [-0.06027933582663536, -0.02720198966562748]
antitumor O [-0.2307143360376358, 0.14986714720726013]
activity. B-LOC [0.1854543536901474, 0.01635671965777874]
In B-LOC [1.4892911911010742, -1.3549927473068237]
treated B-LOC [1.6895233392715454, -1.659934401512146]
animals, B-LOC [1.6814990043640137, -1.8602356910705566]
there B-LOC [1.609973669052124, -1.484459400177002]
was B-LOC [1.4256972074508667, -1.3205868005752563]
complete B-LOC [1.3599605560302734, -1.0724165439605713]
inhibition B-LOC [1.5058096647262573, -1.339563250541687]
of B-LOC [1.3111265897750854, -1.407057762145996]
PI3K B-LOC [0.9925193786621094, -1.2843804359436035]
signaling B-LOC [0.9571927189826965, -1.0626252889633179]
in B-LOC [1.42130708694458, -1.3044779300689697]
the B-LOC [1.438856840133667, -1.2013413906097412]
skin B-LOC [1.4203708171844482, -1.6768653392791748]
at B-LOC [2.0300562381744385, -2.361445188522339]
pharmacologically B-LOC [2.3957831859588623, -2.6044530868530273]
active B-LOC [2.00470232963562, -2.335029363632202]
doses, B-LOC [1.8909986019134521, -1.7950525283813477]
suggesting B-LOC [2.0517492294311523, -2.0494682788848877]
that B-LOC [2.047384262084961, -2.3676750659942627]
skin B-LOC [1.8377110958099365, -2.2419064044952393]
may B-LOC [2.419182777404785, -2.4219987392425537]
serve B-LOC [2.273691415786743, -2.535187005996704]
as B-LOC [2.270263195037842, -2.490673303604126]
surrogate B-LOC [2.4370930194854736, -2.5491621494293213]
tissue B-LOC [1.8641129732131958, -2.4309442043304443]
for B-LOC [2.3366284370422363, -2.5873353481292725]
pharmacodynamic B-LOC [2.414856195449829, -2.7667744159698486]
studies. B-LOC [2.1240270137786865, -2.632004737854004]
In B-LOC [0.20704038441181183, -0.03611112758517265]
summary, O [0.24810799956321716, 0.27079740166664124]
NVP-BEZ235 O [-0.11757791042327881, 0.10796993970870972]
inhibits O [-0.30191099643707275, 0.31301751732826233]
the O [-0.18123629689216614, 0.3324519991874695]
PI3K/mTOR O [-0.2672111392021179, -0.12260075658559799]
axis O [-0.4340265691280365, 0.19234825670719147]
and O [-0.553331196308136, 0.41344425082206726]
results O [-0.24389061331748962, 0.3981064260005951]
in O [-0.25634023547172546, 0.5233848690986633]
antiproliferative O [-0.20840150117874146, 0.4797062575817108]

and O [-0.32557812333106995, 0.20044660568237305]
antitumoral O [-0.3477298319339752, 0.255679190158844]
activity O [-0.16643419861793518, 0.12996330857276917]
in O [-0.3632478415966034, 0.3043307363986969]
cancer O [-0.11801110208034515, -0.010270493105053902]
cells O [-0.40438053011894226, 0.13655439019203186]
with O [-0.255685031414032, 0.17215558886528015]
both O [-0.1631445586681366, 0.0652017742395401]
wild-type O [-0.22027772665023804, -0.0384160615503788]
and O [-0.16983294486999512, 0.08891265094280243]
mutated O [-0.0874294638633728, 0.157430037856102]
p110-alpha. O [-0.36860138177871704, -0.1007818952202797]

The B-LOC [1.5116076469421387, -1.5793967247009277]
non-enveloped B-LOC [1.6396255493164062, -1.6808435916900635]
bacilliform B-LOC [1.2591391801834106, -1.5334805250167847]
viruses B-LOC [1.4444494247436523, -1.704734444618225]
are B-LOC [1.827998161315918, -1.7005784511566162]
the B-LOC [1.8760424852371216, -1.394296646118164]
second B-LOC [1.7980408668518066, -1.4068324565887451]
group B-LOC [1.9365657567977905, -1.7991468906402588]
of B-LOC [1.6325533390045166, -1.7235796451568604]
plant B-LOC [1.5204925537109375, -1.7065258026123047]
viruses B-LOC [1.4954018592834473, -1.7549980878829956]
known B-LOC [2.1731863021850586, -1.80062735080719]
to B-LOC [2.0953643321990967, -1.774423360824585]
possess B-LOC [1.8595129251480103, -1.7356185913085938]
a B-LOC [1.8006476163864136, -1.5226809978485107]
genome B-LOC [1.636812686920166, -1.8106729984283447]
consisting B-LOC [1.658961296081543, -1.5316119194030762]
of B-LOC [1.507441759109497, -1.3993406295776367]
circular B-LOC [1.616407871246338, -1.6387052536010742]
double-stranded B-LOC [1.8057076930999756, -1.564903974533081]
DNA. B-LOC [1.5129315853118896, -1.7513952255249023]
We B-LOC [1.8880082368850708, -2.1823737621307373]
have B-LOC [2.3461334705352783, -2.3272993564605713]
characterized B-LOC [2.463768482208252, -2.5169427394866943]
the B-LOC [2.450887441635132, -2.425679922103882]
viral B-LOC [2.205919027328491, -2.4782087802886963]
transcript B-LOC [2.5250227451324463, -2.6951210498809814]
and B-LOC [2.1969287395477295, -2.459989070892334]
determined B-LOC [2.70772385597229, -2.7178714275360107]
the B-LOC [2.6670076847076416, -2.569640874862671]
complete B-LOC [2.8184196949005127, -2.9595534801483154]
sequence B-LOC [2.6065101623535156, -2.974379777908325]
of B-LOC [2.708664655685425, -2.7321712970733643]
the B-LOC [2.706608295440674, -2.5342562198638916]
genome B-LOC [2.6576931476593018, -3.0793097019195557]
of B-LOC [2.598625421524048, -2.7421634197235107]
Commelina B-LOC [2.0809895992279053, -2.506357431411743]
mellow B-LOC [2.298734664916992, -2.4614455699920654]
mottle B-LOC [2.5188820362091064, -2.310533285140991]
virus B-LOC [1.9577432870864868, -2.612947463989258]
(CoYMV), B-LOC [2.6325185298919678, -2.706813097000122]
a B-LOC [2.7676281929016113, -2.7391550540924072]
member B-LOC [2.729509115219116, -2.8397133350372314]
of B-LOC [2.581327199935913, -2.5814661979675293]
this B-LOC [2.607734441757202, -2.543431043624878]
group. B-LOC [2.5507307052612305, -2.439784288406372]
Analysis B-LOC [1.726811408996582, -1.379338026046753]
of B-LOC [1.9818682670593262, -1.5849313735961914]
the B-LOC [1.9007433652877808, -1.6354804039001465]
viral B-LOC [1.3558562994003296, -1.5436160564422607]
transcript B-LOC [2.018845796585083, -1.7969231605529785]
indicates B-LOC [1.6026581525802612, -1.2937710285186768]
that B-LOC [1.5960311889648438, -1.4751169681549072]
the B-LOC [1.7519919872283936, -1.6353468894958496]
virus B-LOC [1.1522847414016724, -1.5863456726074219]
encodes B-LOC [1.907953143119812, -1.4450104236602783]
a B-LOC [1.7039909362792969, -1.3540997505187988]
single B-LOC [2.0179336071014404, -1.9414286613464355]
terminally-redundant B-LOC [1.9076648950576782, -1.9457948207855225]
genome-length B-LOC [1.5761770009994507, -1.9116871356964111]
plus B-LOC [1.407902717590332, -1.4582644701004028]
120 B-LOC [1.546689510345459, -1.6923341751098633]
nucleotide B-LOC [1.7469756603240967, -1.8034439086914062]
transcript. B-LOC [1.5071783065795898, -1.7893034219741821]
A B-LOC [1.2247257232666016, -1.1905910968780518]
fraction B-LOC [1.039949655532837, -1.2531185150146484]
of B-LOC [0.8176407814025879, -1.2259166240692139]
the B-LOC [1.0839413404464722, -1.2566554546356201]
transcripts B-LOC [1.0087008476257324, -1.256949543952942]
is B-LOC [1.359689712524414, -1.2410142421722412]
polyadenylated, B-LOC [0.8778729438781738, -1.0610277652740479]
although B-LOC [0.7787448763847351, -1.0216572284698486]
the B-LOC [0.7777687907218933, -0.9489725828170776]
majority B-LOC [0.659516453742981, -1.1334247589111328]
of B-LOC [0.43644195795059204, -1.0972975492477417]
the B-LOC [0.647217333316803, -1.145302176475525]
transcript B-LOC [0.8099917769432068, -1.148590087890625]
is B-LOC [0.7187807559967041, -1.1039581298828125]

not B-LOC [0.32663694024086, -0.4235988259315491]
polyadenylated. B-LOC [0.33543622493743896, -0.5601531267166138]
Analysis B-LOC [0.5957813858985901, -0.31100988388061523]
of B-LOC [0.6192265152931213, -0.4795311689376831]
the B-LOC [0.6859691143035889, -0.4789438545703888]
genome B-LOC [0.5760220885276794, -0.6855757832527161]
sequence B-LOC [0.6505222916603088, -0.6165546774864197]
indicates B-LOC [0.4139302968978882, -0.33359506726264954]
that B-LOC [0.13284249603748322, -0.30706965923309326]
the B-LOC [0.4836251735687256, -0.3770293891429901]
genome B-LOC [0.42884957790374756, -0.5172165036201477]
is B-LOC [0.35467255115509033, -0.2829945683479309]
7489 B-LOC [0.49349913001060486, -0.07047788053750992]
bp B-LOC [0.11312481760978699, -0.5514745116233826]
in B-LOC [0.15505468845367432, -0.269948273897171]
size B-LOC [0.4611590504646301, -0.3980374038219452]
and O [-0.028527090325951576, 0.10668741166591644]
that B-LOC [0.0831044390797615, -0.11598163098096848]
the B-LOC [0.3956198990345001, -0.14054541289806366]
transcribed B-LOC [0.3316933214664459, -0.28174182772636414]
strand B-LOC [0.3130270540714264, -0.21238160133361816]
contains B-LOC [0.3529655635356903, -0.0664299726486206]
three B-LOC [0.26507920026779175, 0.019701926037669182]
open B-LOC [0.2553768754005432, -0.24444271624088287]
reading B-LOC [0.49471503496170044, -0.2773495614528656]
frames B-LOC [0.35002705454826355, -0.034102972596883774]
capable B-LOC [0.1708955317735672, -0.16319797933101654]
of B-LOC [0.05892418697476387, 0.04278479889035225]
encoding B-LOC [0.2832442820072174, -0.10264965891838074]
proteins B-LOC [0.32329925894737244, -0.24236029386520386]
of B-LOC [0.014321680180728436, -0.1694296896457672]
23, O [0.19099943339824677, 0.20529213547706604]
15 B-LOC [0.17304684221744537, -0.0997699499130249]
and B-LOC [0.12507864832878113, -0.2062959223985672]
216 B-LOC [0.4515579640865326, -0.2651364207267761]
kd. B-LOC [0.10430389642715454, -0.5047710537910461]
The B-LOC [2.1843888759613037, -2.472909688949585]
function B-LOC [2.140719175338745, -2.45462703704834]
of B-LOC [2.092951536178589, -2.3024659156799316]
the B-LOC [1.5588741302490234, -1.3741328716278076]
25 B-LOC [1.7090147733688354, -1.6187570095062256]
and B-LOC [1.788464903831482, -2.0918428897857666]
15 B-LOC [1.7098560333251953, -1.9149388074874878]
kd B-LOC [1.2892773151397705, -1.7579631805419922]
proteins B-LOC [1.5027107000350952, -1.741568922996521]
is B-LOC [2.6818339824676514, -2.2435081005096436]
unknown. B-LOC [2.5148355960845947, -2.2391738891601562]
Similarities B-LOC [0.9264817237854004, -0.9807074069976807]
between B-LOC [1.1817988157272339, -1.299638271331787]
the B-LOC [1.0663143396377563, -0.9508638381958008]
216 B-LOC [0.9481659531593323, -0.8006749749183655]
kd B-LOC [0.6737949252128601, -0.9421901106834412]
polypeptide B-LOC [1.001790165901184, -1.6522808074951172]
and B-LOC [1.021394968032837, -1.0455758571624756]
the B-LOC [1.056154489517212, -0.9742094278335571]
cauliflower B-LOC [0.5449557900428772, -0.7948735356330872]
mosaic B-LOC [0.6893496513366699, -0.906960666179657]
virus B-LOC [0.4965823292732239, -0.954190731048584]
coat B-LOC [0.6420304179191589, -0.8751429915428162]
protein B-LOC [0.5931763648986816, -0.9453946948051453]
and B-LOC [0.9547186493873596, -0.9678022265434265]
protease/reverse B-LOC [0.590488612651825, -1.0251973867416382]
transcriptase B-LOC [0.6751197576522827, -0.8949323296546936]
polyprotein B-LOC [0.7775416970252991, -1.0198354721069336]
suggest B-LOC [0.6278458833694458, -0.6469908356666565]
that B-LOC [0.5662615895271301, -0.8984835147857666]
the B-LOC [0.8138095140457153, -0.9472873210906982]
216 B-LOC [0.9206296801567078, -0.7787292003631592]
kd B-LOC [0.5072298645973206, -0.7372592687606812]
polypeptide B-LOC [0.41855287551879883, -1.0445982217788696]
is B-LOC [0.7709447741508484, -0.9275892972946167]
a B-LOC [0.6424044370651245, -0.9373824000358582]
polyprotein B-LOC [0.3979901969432831, -0.8667213320732117]
that B-LOC [0.32793232798576355, -1.0514557361602783]
is B-LOC [0.8693721890449524, -0.8530262112617493]
proteolytically B-LOC [0.37410768866539, -0.7447946071624756]
processed B-LOC [0.7426177859306335, -0.9223276972770691]
to B-LOC [0.7429203391075134, -0.9332892298698425]
yield B-LOC [0.7292149662971497, -0.6665003299713135]
the B-LOC [0.44688114523887634, -0.9294877052307129]

virion B-LOC [0.48934927582740784, -1.218578577041626]
coat B-LOC [0.7826836705207825, -1.2843561172485352]
protein, B-LOC [0.7991198301315308, -1.5299582481384277]
a B-LOC [0.8525245785713196, -1.464768409729004]
protease, B-LOC [0.6540452837944031, -1.418603777885437]
and B-LOC [0.9859896302223206, -1.5700141191482544]
replicase B-LOC [0.8420911431312561, -1.5132434368133545]
(reverse B-LOC [1.0832072496414185, -1.5717833042144775]
transcriptase B-LOC [0.8412864804267883, -1.5098406076431274]
and B-LOC [0.881293535232544, -1.5455822944641113]
ribonuclease B-LOC [0.8210605978965759, -1.5194463729858398]
H). B-LOC [1.0290004014968872, -1.563098669052124]
Each B-LOC [1.167917013168335, -2.0057015419006348]
strand B-LOC [1.3703023195266724, -1.9910459518432617]
of B-LOC [1.3768846988677979, -1.9957351684570312]
the B-LOC [1.4241230487823486, -1.7663732767105103]
CoYMV B-LOC [0.8536027073860168, -1.2291089296340942]
genome B-LOC [1.2288594245910645, -2.1097257137298584]
is B-LOC [1.6509581804275513, -1.8742001056671143]
interrupted B-LOC [1.6826603412628174, -2.04439640045166]
by B-LOC [1.1908299922943115, -1.6732087135314941]
site-specific B-LOC [1.8842558860778809, -2.3529157638549805]
discontinuities. B-LOC [1.756957769393921, -2.2480580806732178]
The B-LOC [2.101148843765259, -1.988229751586914]
locations B-LOC [2.360189199447632, -2.276934862136841]
of B-LOC [2.155722141265869, -2.265176773071289]
the B-LOC [2.151506185531616, -2.044492244720459]
5'-ends B-LOC [1.6663415431976318, -1.796097993850708]
of B-LOC [1.9297764301300049, -2.1357600688934326]
these B-LOC [1.7287087440490723, -1.833878517150879]
discontinuities, B-LOC [2.037536382675171, -2.2876124382019043]
and B-LOC [2.0210232734680176, -2.0234014987945557]
the B-LOC [2.31245493888855, -2.2361319065093994]
presence B-LOC [2.09161639213562, -2.353088140487671]
and B-LOC [2.1580166816711426, -1.9366021156311035]
location B-LOC [2.3307688236236572, -2.385988235473633]
of B-LOC [2.3616206645965576, -2.222402811050415]
a B-LOC [2.275237560272217, -2.229219913482666]
region B-LOC [1.5707367658615112, -2.091273546218872]
on B-LOC [1.7681798934936523, -1.9729576110839844]
the B-LOC [2.1559696197509766, -1.8786596059799194]
CoYMV B-LOC [1.1508269309997559, -1.478237509727478]
transcript B-LOC [1.9966107606887817, -2.0295114517211914]
capable B-LOC [1.5362834930419922, -1.9533839225769043]
of B-LOC [1.7765405178070068, -1.6540162563323975]
annealing B-LOC [2.0671184062957764, -1.9053089618682861]
with B-LOC [1.5239094495773315, -1.775136947631836]
the B-LOC [1.8525705337524414, -1.691333293914795]
3'-end B-LOC [1.4066661596298218, -1.621655821800232]
of B-LOC [1.519226312637329, -1.7178845405578613]
cytosolic B-LOC [1.4005436897277832, -1.8291044235229492]
initiator B-LOC [0.9266053438186646, -1.4280219078063965]
methionine B-LOC [1.3285932540893555, -1.7753056287765503]
tRNA B-LOC [1.4685043096542358, -1.8796828985214233]
are B-LOC [2.4249660968780518, -1.666258692741394]
consistent B-LOC [2.2641210556030273, -2.091520071029663]
with B-LOC [1.9106698036193848, -2.0237200260162354]
replication B-LOC [2.340456008911133, -2.0175554752349854]
by B-LOC [1.7799310684204102, -2.137700319290161]
reverse B-LOC [2.4212541580200195, -2.449589729309082]
transcription. B-LOC [2.0956051349639893, -2.2448973655700684]
We B-LOC [0.17871281504631042, -0.23208516836166382]
have B-LOC [0.3670447766780853, -0.07463324815034866]
demonstrated B-LOC [0.35155147314071655, -0.12680403888225555]
that B-LOC [0.29935726523399353, -0.26015788316726685]
a B-LOC [0.3995141386985779, -0.3959810137748718]
construct B-LOC [0.4441324770450592, -0.5711080431938171]
containing B-LOC [0.5203683972358704, -0.49556249380111694]
1.3 B-LOC [0.6032346487045288, -0.3937370181083679]
CoYMV B-LOC [0.35840368270874023, -0.557243824005127]

genomes B-LOC [-0.05473262816667557, -0.5985656976699829]
is B-LOC [0.0501185767352581, -0.32205888628959656]
infective B-LOC [0.21268008649349213, -0.3512078821659088]
when B-LOC [-0.07888422906398773, -0.29045701026916504]
introduced B-LOC [0.11899551749229431, -0.3070434629917145]
into B-LOC [0.040765561163425446, -0.14619877934455872]
Commelina B-LOC [-0.008135427720844746, -0.3157298266887665]
diffusa, B-LOC [0.15446737408638, -0.26687368750572205]
the B-LOC [-0.1253850907087326, -0.1611613631248474]
host B-LOC [0.16163332760334015, -0.5104204416275024]
for B-LOC [0.03004385717213154, -0.3763766288757324]
CoYMV, B-LOC [0.002546465490013361, -0.33054497838020325]
using B-LOC [-0.2055377960205078, -0.2089536339044571]
Agrobacterium-mediated B-LOC [0.2556762099266052, -0.2660786211490631]
infection. B-LOC [0.05780323967337608, -0.32776254415512085]

UNLABELLED B-LOC [0.5285680294036865, -0.7358799576759338]
Congruent B-LOC [0.18840011954307556, -0.35929492115974426]
audiovisual B-LOC [0.24165183305740356, -0.7472755312919617]
speech B-LOC [0.27398934960365295, -0.2716635763645172]
enhances B-LOC [0.05464069917798042, -0.15214604139328003]
our B-LOC [0.13083775341510773, -0.5253642201423645]
ability B-LOC [0.18739229440689087, -0.61869877576828]
to B-LOC [0.2966691553592682, -0.5469087958335876]
comprehend B-LOC [0.2734406888484955, -0.5257788300514221]
a B-LOC [0.21775315701961517, -0.6542698740959167]
speaker, B-LOC [0.22191964089870453, -0.7210946679115295]
even B-LOC [0.42340418696403503, -0.48379623889923096]
in B-LOC [0.33701327443122864, -0.6103648543357849]
noise-free B-LOC [0.35759568214416504, -0.7519270181655884]
conditions. B-LOC [0.43737849593162537, -0.6872798800468445]
When O [-0.1519809514284134, -0.015118034556508064]
incongruent B-LOC [0.18944932520389557, -0.23586755990982056]
auditory O [-0.143510639667511, -0.13530376553535461]
and O [-0.2849316895008087, -0.2776554524898529]
visual B-LOC [-0.07291001081466675, -0.3475167453289032]
information B-LOC [-0.13519926369190216, -0.3588941991329193]
is B-LOC [-0.04124583303928375, -0.08732891082763672]
presented B-LOC [0.19924679398536682, -0.1781681329011917]
concurrently, B-LOC [0.043049849569797516, -0.2247522473335266]
it O [-0.3527716100215912, 0.09569388628005981]
can O [-0.37505578994750977, 0.026450959965586662]
hinder O [-0.017224928364157677, 0.0577155165374279]
a B-LOC [-0.14070652425289154, -0.4214721620082855]
listener's B-LOC [-0.10496459156274796, -0.423603355884552]
perception B-LOC [-0.010184121318161488, -0.3389207124710083]
and O [-0.44991549849510193, 0.17466577887535095]
even O [-0.30213597416877747, 0.163974791765213]
cause O [-0.2984602153301239, -0.1303994357585907]
him B-LOC [-0.14301298558712006, -0.4333261549472809]
or B-LOC [-0.03218533471226692, -0.497437983751297]
her B-LOC [0.09782715141773224, -0.31098082661628723]
to B-LOC [-0.057620804756879807, -0.2926810085773468]
perceive B-LOC [0.026555577293038368, -0.27531108260154724]
information B-LOC [0.08696798235177994, -0.551420271396637]
that B-LOC [0.01975894160568714, -0.6801559925079346]
was B-LOC [-0.09242460131645203, -0.3167400062084198]
not B-LOC [0.04727713391184807, -0.3264721632003784]
presented B-LOC [0.2294011116027832, -0.45870429277420044]
in B-LOC [0.13946035504341125, -0.769504189491272]
either B-LOC [0.1722414344549179, -0.5839673280715942]
modality. B-LOC [0.3351694643497467, -0.6052907109260559]
Efforts B-LOC [1.9687100648880005, -2.187858819961548]
to B-LOC [2.5175435543060303, -2.5888965129852295]
investigate B-LOC [2.378650426864624, -2.4103996753692627]
the B-LOC [2.6867516040802, -2.763563394546509]
neural B-LOC [2.362004280090332, -2.842773199081421]
basis B-LOC [2.407874345779419, -2.7133889198303223]
of B-LOC [2.420257329940796, -2.590956449508667]
these B-LOC [2.1988003253936768, -2.2776613235473633]
effects B-LOC [2.1082680225372314, -2.548046112060547]
have B-LOC [2.4040093421936035, -2.1189606189727783]
often B-LOC [2.4117088317871094, -2.1910665035247803]
focused B-LOC [2.047490119934082, -2.07718563079834]
on B-LOC [2.4337069988250732, -2.123389959335327]
the B-LOC [2.491615056991577, -2.067241668701172]
special B-LOC [2.279583692550659, -2.253493070602417]
case B-LOC [2.3498950004577637, -2.1911580562591553]
of B-LOC [1.76564621925354, -2.0820987224578857]
discrete B-LOC [1.9636034965515137, -2.2115278244018555]
audiovisual B-LOC [1.4857478141784668, -2.221428155899048]
syllables B-LOC [1.5959439277648926, -1.9700912237167358]
that B-LOC [1.7530184984207153, -2.183413028717041]
are B-LOC [2.050135612487793, -2.275101900100708]
spatially B-LOC [2.0086843967437744, -2.367737054824829]
and B-LOC [1.8336422443389893, -2.176185131072998]
temporally B-LOC [2.2211551666259766, -2.3449881076812744]
congruent, B-LOC [1.7383503913879395, -2.20784592628479]
with B-LOC [1.8519552946090698, -1.7837958335876465]
less B-LOC [1.7654650211334229, -2.088759183883667]
work B-LOC [1.901414394378662, -2.3178608417510986]
done B-LOC [2.0149619579315186, -2.214912176132202]
on B-LOC [2.001577854156494, -2.28536319732666]
the B-LOC [2.0567386150360107, -2.1520726680755615]
case B-LOC [1.8414701223373413, -2.184159755706787]

of B-LOC [0.890703022480011, -1.6848392486572266]
natural, B-LOC [1.1903623342514038, -1.9684548377990723]
continuous B-LOC [1.4335709810256958, -2.1396279335021973]
speech. B-LOC [1.275869369506836, -1.6055667400360107]
Recent B-LOC [1.851768136024475, -1.9843088388442993]
electrophysiological B-LOC [1.759548544883728, -2.4031014442443848]
studies B-LOC [2.0370852947235107, -2.0721704959869385]
have B-LOC [2.1388187408447266, -2.083076238632202]
demonstrated B-LOC [1.8776650428771973, -1.9610347747802734]
that B-LOC [1.60947847366333, -2.2620527744293213]
cortical B-LOC [1.6128294467926025, -2.2225701808929443]
response B-LOC [1.577688455581665, -2.2658636569976807]
measures B-LOC [1.8840081691741943, -2.1372103691101074]
to B-LOC [1.6929266452789307, -2.5164380073547363]
continuous B-LOC [1.6568572521209717, -2.368079423904419]
auditory B-LOC [1.6585299968719482, -2.3763511180877686]
speech B-LOC [1.5442917346954346, -1.8200682401657104]
can B-LOC [2.033668041229248, -2.3827476501464844]
be B-LOC [2.066354513168335, -2.5465779304504395]
easily B-LOC [2.140144109725952, -2.627807378768921]
obtained B-LOC [2.0054855346679688, -2.6036159992218018]
using B-LOC [2.059805154800415, -2.458876371383667]
multivariate B-LOC [1.8198968172073364, -2.43476939201355]
analysis B-LOC [2.0126330852508545, -2.509793281555176]
methods. B-LOC [2.3050997257232666, -2.384398937225342]
Here, B-LOC [1.5357625484466553, -1.605839729309082]
we B-LOC [1.597896695137024, -1.7987465858459473]
apply B-LOC [2.2046101093292236, -2.301853656768799]
such B-LOC [2.1461336612701416, -1.9056813716888428]
methods B-LOC [2.169487237930298, -2.401613473892212]
to B-LOC [2.2489302158355713, -2.5453009605407715]
the B-LOC [2.3112215995788574, -2.3965766429901123]
case B-LOC [2.265901565551758, -2.491370439529419]
of B-LOC [1.9008549451828003, -2.500225305557251]
audiovisual B-LOC [1.7679965496063232, -2.503997564315796]
speech B-LOC [1.7284092903137207, -2.050429582595825]
and, B-LOC [1.4864075183868408, -2.078197717666626]
importantly, B-LOC [2.124403476715088, -2.040454626083374]
present B-LOC [2.030834197998047, -2.3540871143341064]
a B-LOC [2.1782987117767334, -2.5056424140930176]
novel B-LOC [2.230306625366211, -2.6061832904815674]
framework B-LOC [2.248652696609497, -2.4734127521514893]
for B-LOC [2.08194899559021, -2.2613189220428467]
indexing B-LOC [2.237722635269165, -2.613898992538452]
multisensory B-LOC [2.06380295753479, -2.568044900894165]
integration B-LOC [1.845839262008667, -2.386213779449463]
in B-LOC [2.315140962600708, -2.502882242202759]
the B-LOC [2.500547170639038, -2.5003156661987305]
context B-LOC [2.4625794887542725, -2.568129777908325]
of B-LOC [2.027594566345215, -2.5678329467773438]
continuous B-LOC [2.0693891048431396, -2.5676472187042236]
speech. B-LOC [1.8528155088424683, -2.31217885017395]
Specifically, B-LOC [2.2698357105255127, -1.8900516033172607]
we B-LOC [1.697295904159546, -1.659364938735962]
examine B-LOC [2.155709743499756, -2.0619776248931885]
how B-LOC [2.2590701580047607, -2.3255984783172607]
the B-LOC [2.347935199737549, -2.3318235874176025]
temporal B-LOC [2.1028289794921875, -2.2441844940185547]
and B-LOC [2.0903971195220947, -2.314685106277466]
contextual B-LOC [2.374856472015381, -2.299590826034546]
congruency B-LOC [1.9417269229888916, -2.3109490871429443]
of B-LOC [1.8459506034851074, -2.219468593597412]
ongoing B-LOC [1.7706595659255981, -2.2597877979278564]
audiovisual B-LOC [1.6276295185089111, -2.0547640323638916]
speech B-LOC [1.439523458480835, -1.701289415359497]
affects B-LOC [2.1017837524414062, -2.4743216037750244]
the B-LOC [2.1426820755004883, -2.2674663066864014]
cortical B-LOC [1.6714587211608887, -1.873888611793518]
encoding B-LOC [1.4922895431518555, -1.7351984977722168]
of B-LOC [1.8873658180236816, -2.0060322284698486]
the B-LOC [1.9354498386383057, -2.000492811203003]
speech B-LOC [1.2651495933532715, -1.6242326498031616]
envelope B-LOC [1.4637610912322998, -1.8555827140808105]
in B-LOC [1.728743314743042, -2.126983880996704]
humans B-LOC [1.6775239706039429, -1.9942020177841187]
using B-LOC [1.944104790687561, -2.238602876663208]
electroencephalography. B-LOC [1.8708510398864746, -2.413022518157959]
We B-LOC [0.039964500814676285, -0.1736014485359192]
demonstrate B-LOC [0.4451548457145691, -0.2680778205394745]
that B-LOC [0.09052728861570358, -0.3477282226085663]
the B-LOC [0.33758655190467834, -0.49879971146583557]
cortical B-LOC [0.3282088339328766, -0.611729621887207]
representation B-LOC [-0.010684755630791187, -0.5648710131645203]

of O [-0.2663836181163788, 0.11777906119823456]
the O [-0.10111543536186218, -0.01905512996017933]
speech B-LOC [-0.048599764704704285, -0.17270657420158386]
envelope O [-0.12087196856737137, -0.09869636595249176]
is O [-0.05562402680516243, -0.05490276589989662]
enhanced O [-0.01597602106630802, 0.11682969331741333]
by O [-0.225815087556839, 0.10093079507350922]
the O [-0.10363923013210297, 0.10263405740261078]
presentation O [0.036671411246061325, 0.11409373581409454]
of B-LOC [-0.048895832151174545, -0.08404527604579926]
congruent B-LOC [-0.027056438848376274, -0.10626727342605591]
audiovisual B-LOC [-0.13527244329452515, -0.17763793468475342]
speech O [0.030465470626950264, 0.13955381512641907]
in B-LOC [0.06009021773934364, -0.13820073008537292]
noise-free B-LOC [0.05994883552193642, -0.17398282885551453]
conditions. B-LOC [0.024251000955700874, -0.12125688791275024]
Furthermore, O [-0.17750853300094604, 0.2742733657360077]
we O [-0.6483176350593567, 0.31635311245918274]
show O [-0.4970468282699585, 0.44366663694381714]
that O [-0.6375452876091003, 0.31286945939064026]
this O [-0.28020957112312317, 0.31746193766593933]
is O [-0.09929458796977997, 0.09387620538473129]
likely O [-0.07701289653778076, 0.20132847130298615]
attributable O [0.02890116162598133, 0.19430972635746002]
to O [-0.31878697872161865, 0.29753005504608154]
the O [-0.3775404393672943, 0.4496312439441681]
contribution O [-0.40301594138145447, 0.41107720136642456]
of O [-0.2798595130443573, 0.46634772419929504]
neural O [-0.47500255703926086, 0.41183415055274963]
generators O [-0.39210131764411926, 0.4111746847629547]
that O [-0.46488043665885925, 0.46739381551742554]
are O [-0.2744377851486206, 0.4917851388454437]
not O [-0.27480563521385193, 0.6652807593345642]
particularly O [-0.2678723931312561, 0.3698575794696808]
active O [-0.31124821305274963, 0.6392759084701538]
during O [-0.3897985816001892, 0.46439895033836365]
unimodal O [-0.40610113739967346, 0.5096710324287415]
stimulation O [-0.3836756646633148, 0.5455539226531982]
and O [-0.5036582350730896, 0.6037091612815857]
that O [-0.6062135100364685, 0.2610466182231903]
it O [-0.5594320893287659, 0.322456955909729]
is O [-0.3213442265987396, 0.25795477628707886]
most O [-0.1921212524175644, 0.26909032464027405]
prominent O [-0.21689361333847046, 0.3680402338504791]
at O [-0.16651341319084167, 0.1749393343925476]
the O [-0.14770551025867462, 0.2852051556110382]
temporal O [-0.4737882912158966, 0.279021292924881]
scale O [-0.36917999386787415, -0.008882546797394753]
corresponding O [-0.14601334929466248, 0.030828041955828667]
to O [-0.10670279711484909, 0.06659575551748276]
syllabic O [-0.26374807953834534, 0.04043857380747795]
rate O [-0.3193223178386688, 0.09882190823554993]
(2-6 O [-0.11392157524824142, -0.08641767501831055]
Hz). O [-0.3757137358188629, -0.0588313452899456]
Finally, O [0.07050562649965286, 0.18930038809776306]
our O [-0.11445868760347366, -0.06389740109443665]
data B-LOC [0.08497162163257599, -0.22639986872673035]
suggest O [-0.015060019679367542, 0.010964488610625267]
that B-LOC [-0.12790119647979736, -0.26190653443336487]
neural B-LOC [-0.07248356193304062, -0.4437727928161621]
entrainment B-LOC [0.08277733623981476, -0.2760525941848755]
to B-LOC [0.10608508437871933, -0.36187997460365295]
the B-LOC [0.03335653990507126, -0.275816410779953]
speech B-LOC [0.02620519883930683, -0.4702623188495636]
envelope B-LOC [-0.17224931716918945, -0.36894452571868896]
is B-LOC [0.08288790285587311, -0.30678367614746094]
inhibited B-LOC [0.2107728123664856, -0.27395108342170715]
when B-LOC [0.04735886678099632, -0.298658549785614]
the B-LOC [0.04145031049847603, -0.435742050409317]
auditory B-LOC [-0.06275847554206848, -0.4788522720336914]
and B-LOC [-0.046410251408815384, -0.4850383698940277]
visual B-LOC [-0.15563879907131195, -0.4396648108959198]
streams B-LOC [-0.05829458311200142, -0.39861318469047546]
are B-LOC [0.2532035708427429, -0.5126631259918213]
incongruent B-LOC [0.4666458070278168, -0.37315595149993896]
both B-LOC [0.031782593578100204, -0.3210321366786957]
temporally B-LOC [0.18700772523880005, -0.5755388140678406]
and B-LOC [0.2037673145532608, -0.3419209122657776]
contextually. B-LOC [0.26261934638023376, -0.5324350595474243]

SIGNIFICANCE B-LOC [0.999616801738739, -1.9619872570037842]
STATEMENT B-LOC [1.3984737396240234, -1.7096084356307983]
Seeing B-LOC [1.0136504173278809, -1.2187168598175049]
a B-LOC [1.3456141948699951, -1.7633262872695923]
speaker's B-LOC [1.591404914855957, -1.9538874626159668]
face B-LOC [1.3096134662628174, -1.560563087463379]
as B-LOC [1.208556890487671, -1.2543659210205078]
he B-LOC [1.383680820465088, -1.9075995683670044]
or B-LOC [1.3167246580123901, -1.9217708110809326]
she B-LOC [1.3956272602081299, -1.7153871059417725]
talks B-LOC [1.6108955144882202, -1.5930583477020264]
can B-LOC [0.9166529178619385, -1.4147063493728638]
greatly B-LOC [1.008812665939331, -1.236012578010559]
help B-LOC [1.2493830919265747, -1.549538016319275]
in B-LOC [1.2467622756958008, -1.6778820753097534]
understanding B-LOC [1.3407342433929443, -1.599204421043396]
what B-LOC [1.522848129272461, -1.628910779953003]
the B-LOC [1.5028204917907715, -1.8201638460159302]
speaker B-LOC [1.463270902633667, -1.8879904747009277]
is B-LOC [1.4324901103973389, -1.6295864582061768]
saying. B-LOC [1.5161280632019043, -1.5507181882858276]
This B-LOC [0.4285051226615906, -0.63776695728302]
is B-LOC [0.47617945075035095, -0.5297902226448059]
because B-LOC [0.1315421313047409, -0.41528254747390747]
the B-LOC [0.33927121758461, -0.7324919104576111]
speaker's B-LOC [0.5467233061790466, -1.1028029918670654]
facial B-LOC [0.527055561542511, -0.8252158761024475]
movements B-LOC [0.492263525724411, -0.6775152087211609]
relay B-LOC [0.5163660645484924, -0.653993546962738]
information B-LOC [0.5841148495674133, -1.0519399642944336]
about B-LOC [0.5784820318222046, -0.9275795221328735]
what B-LOC [0.6491818428039551, -0.9898380041122437]
the B-LOC [0.6189170479774475, -1.1973761320114136]
speaker B-LOC [0.8459562659263611, -1.3878425359725952]
is B-LOC [0.750960111618042, -0.9310204982757568]
saying, B-LOC [0.9329103827476501, -1.0654280185699463]
but B-LOC [0.3335258662700653, -0.40566372871398926]
also, B-LOC [0.41190847754478455, -0.46939584612846375]
importantly, B-LOC [0.49161651730537415, -0.7028207182884216]
when B-LOC [0.31162765622138977, -1.0946736335754395]
the B-LOC [0.5949415564537048, -1.3160172700881958]
speaker B-LOC [0.8821259140968323, -1.5075328350067139]
is B-LOC [0.916333019733429, -1.0739827156066895]
saying B-LOC [0.87575763463974, -0.9928881525993347]
it. B-LOC [0.7353053092956543, -1.2365078926086426]
Studying B-LOC [2.993201971054077, -3.149700403213501]
how B-LOC [3.1923601627349854, -3.358273506164551]
the B-LOC [2.9529950618743896, -3.097898006439209]
brain B-LOC [2.345179557800293, -3.2103054523468018]
uses B-LOC [3.1499223709106445, -3.2210912704467773]
this B-LOC [2.886122941970825, -2.99965500831604]
timing B-LOC [2.8392751216888428, -3.575561285018921]
relationship B-LOC [2.740065813064575, -3.2471578121185303]
to B-LOC [3.160405397415161, -3.131110429763794]
combine B-LOC [2.7579028606414795, -3.328706979751587]
information B-LOC [2.83564829826355, -3.290895938873291]
from B-LOC [2.761715888977051, -3.3554179668426514]
continuous B-LOC [2.764319658279419, -3.342007637023926]
auditory B-LOC [2.4603965282440186, -3.374948263168335]
and B-LOC [2.7141425609588623, -3.092646837234497]
visual B-LOC [2.4514403343200684, -3.1969377994537354]
speech B-LOC [2.488577127456665, -3.1064059734344482]
has B-LOC [3.3944451808929443, -3.000836133956909]
traditionally B-LOC [3.3809902667999268, -3.3390586376190186]
been B-LOC [3.205913543701172, -3.3017427921295166]
methodologically B-LOC [3.2521674633026123, -3.404214859008789]
difficult. B-LOC [3.2111756801605225, -3.31477427482605]
Here B-LOC [0.3616824746131897, -0.5999676585197449]
we B-LOC [0.5249115824699402, -0.6359153389930725]
introduce B-LOC [0.9254553914070129, -1.0464541912078857]
a B-LOC [1.053741216659546, -1.1347525119781494]
new B-LOC [1.2159624099731445, -1.2854483127593994]
approach B-LOC [1.1142570972442627, -1.3726792335510254]
for B-LOC [0.8232317566871643, -0.9959920644760132]
doing B-LOC [1.1828981637954712, -1.3543236255645752]
this B-LOC [1.1631977558135986, -1.1542643308639526]
using B-LOC [0.9680829644203186, -1.3484702110290527]
relatively B-LOC [1.3779584169387817, -1.279485821723938]
inexpensive B-LOC [1.3221298456192017, -1.339569330215454]
and B-LOC [0.9357153177261353, -0.9033610224723816]
noninvasive B-LOC [1.3188652992248535, -1.2136561870574951]
scalp B-LOC [0.9850332736968994, -1.5634512901306152]
recordings. B-LOC [1.1728874444961548, -1.41908860206604]
Specifically, B-LOC [0.7421140670776367, -0.7684088945388794]

we O [-0.3896910846233368, 0.1500195860862732]
show O [-0.5031823515892029, 0.5534946918487549]
that O [-0.7940204739570618, 0.39848294854164124]
the O [-0.4550311863422394, 0.3893817961215973]
brain's O [-0.6164472699165344, 0.081871896982193]
representation O [-0.4071468114852905, 0.26442500948905945]
of O [-0.3828139007091522, 0.19385120272636414]
auditory O [-0.41033637523651123, 0.15582668781280518]
speech O [-0.22344636917114258, 0.24996206164360046]
is O [-0.24094483256340027, 0.33711478114128113]
enhanced O [-0.1238202303647995, 0.23322796821594238]
when O [-0.3759624660015106, 0.3198079764842987]
the O [-0.08414949476718903, -0.0015404471196234226]
accompanying O [-0.21040764451026917, -0.023389073088765144]
visual O [-0.47762343287467957, 0.11752131581306458]
speech O [-0.3485856354236603, 0.1999237835407257]
signal O [-0.4454978406429291, 0.09528373926877975]
shares B-LOC [0.038103263825178146, 0.03229619935154915]
the O [0.02134368009865284, 0.09201653301715851]
same O [-0.08232778310775757, -0.018687130883336067]
timing. O [-0.08973132818937302, -0.02134029008448124]
Furthermore, O [-0.2871967852115631, 0.3521653711795807]
we O [-0.5061465501785278, 0.3325441777706146]
show O [-0.35226938128471375, 0.36970001459121704]
that O [-0.5502082705497742, 0.11726830899715424]
this O [-0.16532400250434875, 0.08503758162260056]
enhancement O [-0.3758111894130707, 0.11755452305078506]
is O [-0.2245866060256958, 0.00392183056101203]
most O [-0.10554303228855133, -0.011855080723762512]
pronounced O [-0.12312908470630646, 0.12149881571531296]
at O [-0.11188764870166779, -0.008263163268566132]
a O [-0.040378767997026443, -0.007520443294197321]
time O [-0.10433263331651688, -0.002595847938209772]
scale B-LOC [-0.24409767985343933, -0.2713354229927063]
that B-LOC [-0.16754509508609772, -0.39327991008758545]
corresponds B-LOC [0.12156924605369568, -0.13121919333934784]
to B-LOC [0.08917422592639923, -0.20718300342559814]
mean O [-0.20085826516151428, 0.023276114836335182]
syllable B-LOC [-0.1265677958726883, -0.1735289841890335]
length. B-LOC [-0.09300895780324936, -0.2893442213535309]

Histone B-LOC [0.8927013278007507, -1.611708164215088]
levels B-LOC [1.2720109224319458, -1.4526362419128418]
are B-LOC [1.3881840705871582, -1.478967547416687]
tightly B-LOC [1.320528507232666, -1.43161141872406]
regulated B-LOC [1.2600281238555908, -1.4774744510650635]
to B-LOC [1.288313627243042, -1.4333384037017822]
prevent B-LOC [1.1872999668121338, -1.3800443410873413]
harmful B-LOC [1.3743882179260254, -1.6796867847442627]
effects B-LOC [1.128411889076233, -1.5584707260131836]
such B-LOC [1.0008745193481445, -1.2979906797409058]
as B-LOC [0.9931452870368958, -1.340147852897644]
genomic B-LOC [1.0376577377319336, -1.372603178024292]
instability B-LOC [0.910158097743988, -1.3393614292144775]
and B-LOC [0.9529356360435486, -1.2052923440933228]
hypersensitivity B-LOC [1.1459267139434814, -1.3951467275619507]
to B-LOC [0.9280100464820862, -1.3320316076278687]
DNA-damaging B-LOC [1.0362815856933594, -1.5668556690216064]
agents B-LOC [1.1349742412567139, -1.4741191864013672]
due B-LOC [1.0851340293884277, -1.2832741737365723]
to B-LOC [0.978276789188385, -1.0905976295471191]
the B-LOC [0.9514604210853577, -1.123238444328308]
accumulation B-LOC [1.2599592208862305, -1.1761761903762817]
of B-LOC [1.0780785083770752, -1.2027215957641602]
these B-LOC [0.9190588593482971, -1.218184471130371]
highly B-LOC [0.979579746723175, -1.313957929611206]
basic B-LOC [1.0587049722671509, -1.4128391742706299]
proteins B-LOC [1.156052589416504, -1.2779958248138428]
when B-LOC [0.881895124912262, -1.2971580028533936]
DNA B-LOC [0.9922663569450378, -1.442082405090332]
replication B-LOC [1.0161455869674683, -1.2257434129714966]
slows B-LOC [0.9764611124992371, -1.1770856380462646]
down B-LOC [1.0719081163406372, -1.3256893157958984]
or B-LOC [0.9408424496650696, -1.4303219318389893]
stops. B-LOC [1.046044945716858, -1.3309674263000488]
Although B-LOC [1.2956130504608154, -1.1243712902069092]
chromosomal B-LOC [1.5702879428863525, -1.4657725095748901]
histones B-LOC [1.0894262790679932, -1.4255774021148682]
are B-LOC [1.6737529039382935, -1.2359930276870728]
stable, B-LOC [1.741240382194519, -1.3314485549926758]
excess B-LOC [1.4453455209732056, -1.3677570819854736]
(non-chromatin B-LOC [1.3889257907867432, -1.236484169960022]
bound) B-LOC [1.2023892402648926, -1.2133498191833496]
histones B-LOC [1.1680247783660889, -1.4199825525283813]
are B-LOC [1.8000835180282593, -1.3255265951156616]
rapidly B-LOC [1.4746334552764893, -1.3963603973388672]
degraded B-LOC [1.8141752481460571, -1.4865859746932983]
in B-LOC [1.1233317852020264, -1.1948161125183105]
a B-LOC [1.1041648387908936, -1.0853118896484375]
Rad53 B-LOC [1.4570515155792236, -1.350677251815796]
(radiation B-LOC [1.5573534965515137, -1.4385340213775635]
sensitive B-LOC [1.141198992729187, -1.4115016460418701]
53) B-LOC [1.6773625612258911, -1.3140658140182495]
kinase-dependent B-LOC [1.4052517414093018, -1.5520051717758179]
manner B-LOC [1.0712462663650513, -1.3379991054534912]
in B-LOC [1.3334283828735352, -1.3050024509429932]
Saccharomyces B-LOC [1.573133945465088, -1.32603120803833]
cerevisiae. B-LOC [1.3631269931793213, -1.3938724994659424]
Here O [-0.3320294916629791, -0.018249208107590675]
we O [-0.5500784516334534, 0.23223377764225006]
demonstrate O [-0.31076472997665405, 0.09946174919605255]
that O [-0.6626960635185242, 0.1949489712715149]
excess O [-0.14321273565292358, 0.06810539215803146]
histones O [-0.3063493072986603, -0.15963923931121826]
associate O [-0.10236994177103043, 0.10437259078025818]
with O [-0.08893010765314102, 0.06883218884468079]
Rad53 O [-0.19901823997497559, 0.05589376762509346]
in O [-0.386636883020401, 0.21037298440933228]
vivo O [-0.5399988293647766, 0.21802470088005066]
and O [-0.38594573736190796, 0.06023398041725159]
seem O [-0.28447943925857544, -0.030045123770833015]
to O [-0.12276244163513184, 0.05011391267180443]
undergo O [-0.2877819240093231, -0.09655380249023438]
modifications O [-0.08918105065822601, 0.02551964484155178]
such O [-0.18066194653511047, 0.055495649576187134]
as O [-0.21026794612407684, 0.07458001375198364]
tyrosine O [-0.28331732749938965, 0.16165108978748322]

phosphorylation B-LOC [0.16000139713287354, -0.798596978187561]
and B-LOC [0.5076243281364441, -0.692453920841217]
polyubiquitylation, B-LOC [0.345599502325058, -0.8070626258850098]
before B-LOC [0.6112611293792725, -0.6877428889274597]
their B-LOC [0.6586580276489258, -0.8664031624794006]
proteolysis B-LOC [0.5188335180282593, -0.7580677270889282]
by B-LOC [0.41384610533714294, -0.8640097975730896]
the B-LOC [0.7082697153091431, -0.7762964367866516]
proteasome. B-LOC [0.5877876877784729, -0.8211768269538879]
We B-LOC [0.2994155287742615, -0.46476462483406067]
have B-LOC [0.600562572479248, -0.31059491634368896]
identified B-LOC [0.5710989832878113, -0.3662605285644531]
the B-LOC [0.4283857047557831, -0.3756318986415863]
Tyr B-LOC [0.48172953724861145, -0.47118908166885376]
99 B-LOC [0.4354890286922455, -0.3188645839691162]
residue B-LOC [0.4460046589374542, -0.462132066488266]
of B-LOC [0.20903608202934265, -0.4988841116428375]
histone B-LOC [0.4164346754550934, -0.734582781791687]
H3 B-LOC [0.4063953459262848, -0.6510950922966003]
as B-LOC [0.23358917236328125, -0.3164815604686737]
being B-LOC [0.22975923120975494, -0.40814274549484253]
critical B-LOC [0.04040118679404259, -0.2662484645843506]
for B-LOC [0.043476227670907974, -0.4293910264968872]
the B-LOC [0.09933409094810486, -0.3055056631565094]
efficient B-LOC [0.06942516565322876, -0.3831455409526825]
ubiquitylation B-LOC [0.21589042246341705, -0.35540398955345154]
and B-LOC [0.1234436184167862, -0.2835840582847595]
degradation B-LOC [0.4680371880531311, -0.33515772223472595]
of B-LOC [0.352400541305542, -0.45652657747268677]
this B-LOC [0.40434056520462036, -0.7040461897850037]
histone. B-LOC [0.35743167996406555, -0.8207522034645081]
We B-LOC [0.6337813138961792, -0.8772637248039246]
have B-LOC [0.9352572560310364, -0.7190809845924377]
also B-LOC [0.9775503873825073, -0.8602342009544373]
identified B-LOC [1.0119919776916504, -0.925092339515686]
the B-LOC [0.9766344428062439, -0.9069463610649109]
ubiquitin B-LOC [0.5353885889053345, -0.7496236562728882]
conjugating B-LOC [0.7450961470603943, -0.9867453575134277]
enzymes B-LOC [0.7702165246009827, -1.0391391515731812]
(E2) B-LOC [0.8543817400932312, -0.8812142610549927]
Ubc4 B-LOC [0.6122521162033081, -0.787678599357605]
and B-LOC [0.5914235711097717, -0.6393181085586548]
Ubc5, B-LOC [0.7830806374549866, -0.7757914662361145]
as B-LOC [1.1979022026062012, -0.7811934351921082]
well B-LOC [1.0607414245605469, -0.8350642323493958]
as B-LOC [1.1987264156341553, -0.8964493274688721]
the B-LOC [1.094303011894226, -0.9838175773620605]
ubiquitin B-LOC [0.6580861210823059, -0.9832950234413147]
ligase B-LOC [0.8412965536117554, -0.8710867762565613]
(E3) B-LOC [0.9854908585548401, -1.1034290790557861]
Tom1 B-LOC [0.49968308210372925, -0.6681775450706482]
(temperature B-LOC [0.8246901631355286, -1.1663048267364502]
dependent B-LOC [0.776400625705719, -1.1666901111602783]
organization B-LOC [0.7633467316627502, -1.0007827281951904]
in B-LOC [0.8833715915679932, -0.9010151028633118]
mitotic B-LOC [0.7298247218132019, -0.8815509080886841]
nucleus B-LOC [0.8441027402877808, -0.9650428891181946]
1), B-LOC [0.8590673804283142, -0.9718769788742065]
as B-LOC [0.7897719740867615, -1.025941252708435]
enzymes B-LOC [0.8046956658363342, -0.9492847919464111]
involved B-LOC [0.7484226822853088, -1.0691332817077637]
in B-LOC [0.7020747661590576, -0.9822039604187012]
the B-LOC [0.7902109026908875, -0.9769976735115051]
ubiquitylation B-LOC [0.6170307993888855, -0.8377858996391296]
of B-LOC [0.7942172884941101, -0.8190213441848755]
excess B-LOC [0.7650207877159119, -0.9983344674110413]
histones. B-LOC [0.5442520976066589, -1.0042508840560913]
Regulated B-LOC [0.7971622943878174, -0.769294798374176]
histone B-LOC [0.7017664909362793, -0.9261566996574402]

proteolysis B-LOC [0.33119288086891174, -0.8338714838027954]
has B-LOC [1.1747788190841675, -1.2210124731063843]
major B-LOC [0.9815762639045715, -1.1147438287734985]
implications B-LOC [1.060115933418274, -1.3827311992645264]
for B-LOC [0.8973817229270935, -1.29037344455719]
the B-LOC [0.9045185446739197, -1.1937191486358643]
maintenance B-LOC [0.924470841884613, -1.1243587732315063]
of B-LOC [0.6905362010002136, -1.1674693822860718]
epigenetic B-LOC [0.9984415769577026, -1.1326093673706055]
marks B-LOC [0.7032360434532166, -1.2230658531188965]
on B-LOC [0.5364810824394226, -1.1295639276504517]
chromatin, B-LOC [0.7347007989883423, -0.9693920016288757]
genomic B-LOC [0.9138081669807434, -1.0090280771255493]
stability B-LOC [0.6763498187065125, -0.9645010828971863]
and B-LOC [0.9762834310531616, -1.072893738746643]
the B-LOC [0.8406746983528137, -1.131831169128418]
packaging B-LOC [0.8574553728103638, -1.0571650266647339]
of B-LOC [0.6258952617645264, -1.0779485702514648]
sperm B-LOC [0.713403046131134, -1.236948013305664]
DNA. B-LOC [0.5134417414665222, -1.09623122215271]

Genome-wide B-LOC [2.413935899734497, -3.201850652694702]
association B-LOC [2.9731879234313965, -3.3735415935516357]
studies B-LOC [2.872577428817749, -2.949909210205078]
(GWAS) B-LOC [3.168287992477417, -3.5137388706207275]
have B-LOC [3.1379354000091553, -2.865990400314331]
now B-LOC [3.14609694480896, -2.9330456256866455]
identified B-LOC [3.0261614322662354, -3.0498154163360596]
at B-LOC [3.1783432960510254, -2.954680919647217]
least B-LOC [3.1851110458374023, -3.1056249141693115]
2,000 B-LOC [3.3517282009124756, -2.9802258014678955]
common B-LOC [2.959855794906616, -3.3490471839904785]
variants B-LOC [3.0445001125335693, -3.2411630153656006]
that B-LOC [2.8962485790252686, -3.206512451171875]
appear B-LOC [3.1326076984405518, -3.1684138774871826]
associated B-LOC [3.105285406112671, -3.1789960861206055]
with B-LOC [3.0637624263763428, -3.323112964630127]
common B-LOC [3.000601291656494, -3.5246245861053467]
diseases B-LOC [3.240971326828003, -3.398963212966919]
or B-LOC [3.274256706237793, -3.545006036758423]
related B-LOC [3.3119614124298096, -3.5524349212646484]
traits B-LOC [3.0040273666381836, -3.318756341934204]
(http://www.genome.gov/gwastudies), B-LOC [3.0468504428863525, -3.269629955291748]
hundreds B-LOC [3.330336809158325, -3.4013848304748535]
of B-LOC [3.1131203174591064, -3.493992805480957]
which B-LOC [3.215395212173462, -3.2754039764404297]
have B-LOC [3.2528235912323, -3.110377550125122]
been B-LOC [3.1551411151885986, -3.415135145187378]
convincingly B-LOC [3.099985122680664, -3.4190750122070312]
replicated. B-LOC [3.2327640056610107, -3.519449472427368]
It B-LOC [1.0735268592834473, -0.7713439464569092]
is B-LOC [1.6179320812225342, -1.0657256841659546]
generally B-LOC [1.4280650615692139, -1.0988283157348633]
thought B-LOC [1.093506097793579, -0.8054858446121216]
that B-LOC [0.6163102984428406, -0.7257320284843445]
the B-LOC [0.771727979183197, -0.6918759942054749]
associated B-LOC [0.6114133596420288, -0.9808241128921509]
markers B-LOC [0.5883187055587769, -0.8587369918823242]
reflect B-LOC [0.5996333360671997, -0.6880475878715515]
the B-LOC [0.6001920104026794, -0.758642852306366]
effect B-LOC [0.4902019202709198, -0.9101169109344482]
of B-LOC [0.6138612627983093, -0.8059518933296204]
a B-LOC [0.6856791377067566, -0.7811434268951416]
nearby B-LOC [0.6465510725975037, -1.0094029903411865]
common B-LOC [0.5579171776771545, -0.9115869402885437]
(minor B-LOC [0.5158168077468872, -0.7075601816177368]
allele B-LOC [0.4571581780910492, -0.9552257061004639]
frequency B-LOC [0.5517390370368958, -1.0013784170150757]
>0.05) B-LOC [0.3895851671695709, -0.8608241677284241]
causal B-LOC [0.4214511513710022, -1.0248210430145264]
site, B-LOC [0.47023048996925354, -1.0798883438110352]
which B-LOC [0.5581246614456177, -0.8908870220184326]
is B-LOC [0.9657653570175171, -0.9819545149803162]
associated B-LOC [0.7016121745109558, -0.9023589491844177]
with B-LOC [0.5823885798454285, -0.8633847832679749]
the B-LOC [0.7123865485191345, -0.9131082892417908]
marker, B-LOC [0.41640612483024597, -1.128553867340088]
leading B-LOC [0.6646941304206848, -0.9716199040412903]
to B-LOC [0.7291065454483032, -0.7848851084709167]
extensive B-LOC [0.987738847732544, -1.1586613655090332]
resequencing B-LOC [1.41497802734375, -1.5739495754241943]
efforts B-LOC [1.2687259912490845, -1.29905366897583]
to B-LOC [1.6759352684020996, -1.5983303785324097]
find B-LOC [1.637683629989624, -1.6367504596710205]
causal B-LOC [1.4135079383850098, -1.469393253326416]
sites. B-LOC [1.289689540863037, -1.5577845573425293]
We B-LOC [0.48605772852897644, -0.6243716478347778]
propose B-LOC [1.286125898361206, -0.5196812748908997]
as B-LOC [1.1459944248199463, -0.8038803935050964]
an B-LOC [1.169238567352295, -0.9859522581100464]
alternative B-LOC [1.2313166856765747, -1.1892797946929932]
explanation B-LOC [0.8159416317939758, -0.9135228991508484]
that B-LOC [0.8793486952781677, -0.7106124758720398]
variants B-LOC [0.9143638610839844, -0.960483968257904]
much B-LOC [0.9947829246520996, -0.9104827046394348]
less B-LOC [0.8199086785316467, -0.8782517910003662]
common B-LOC [0.9121772646903992, -1.048341989517212]
than B-LOC [0.70565265417099, -0.5658215284347534]
the B-LOC [0.9643621444702148, -0.8760067820549011]
associated B-LOC [0.8269245624542236, -1.1554358005523682]
one B-LOC [0.5836736559867859, -0.9338070750236511]
may B-LOC [0.8027784824371338, -0.8946407437324524]
create B-LOC [0.42219650745391846, -0.774654746055603]

"synthetic B-LOC [0.8487218618392944, -1.3028407096862793]
associations" B-LOC [0.8458182215690613, -1.079549789428711]
by B-LOC [0.7154068350791931, -1.0832250118255615]
occurring, B-LOC [0.9874981045722961, -1.2553043365478516]
stochastically, B-LOC [1.1246533393859863, -1.3334347009658813]
more B-LOC [0.6372813582420349, -0.8570596575737]
often B-LOC [1.0254024267196655, -1.0750107765197754]
in B-LOC [0.7305392026901245, -0.8909642100334167]
association B-LOC [1.100852370262146, -1.1235499382019043]
with B-LOC [0.9623481631278992, -1.2849228382110596]
one B-LOC [0.7655813097953796, -1.3354029655456543]
of B-LOC [1.0741924047470093, -1.2146551609039307]
the B-LOC [1.1557517051696777, -1.2350218296051025]
alleles B-LOC [1.202622413635254, -1.6946747303009033]
at B-LOC [0.8692843914031982, -1.022397518157959]
the B-LOC [1.2053983211517334, -1.3604964017868042]
common B-LOC [0.8713237643241882, -1.4681873321533203]
site B-LOC [0.708286702632904, -1.274420976638794]
versus B-LOC [0.8368947505950928, -0.8462246656417847]
the B-LOC [1.335106372833252, -1.5626084804534912]
other B-LOC [0.8742722868919373, -1.2815916538238525]
allele. B-LOC [1.758167028427124, -2.268275022506714]
Although B-LOC [2.865455150604248, -3.078702449798584]
synthetic B-LOC [3.0324952602386475, -3.406597375869751]
associations B-LOC [3.074005365371704, -3.316126823425293]
are B-LOC [3.1423070430755615, -3.132249593734741]
an B-LOC [3.1531870365142822, -3.288749933242798]
obvious B-LOC [3.1274983882904053, -3.4332377910614014]
theoretical B-LOC [3.1919381618499756, -3.3928797245025635]
possibility, B-LOC [3.1016108989715576, -3.5352652072906494]
they B-LOC [3.0378682613372803, -3.377366065979004]
have B-LOC [3.2484874725341797, -3.12300181388855]
never B-LOC [3.1753830909729004, -3.259139060974121]
been B-LOC [3.1948800086975098, -3.391078233718872]
systematically B-LOC [3.290477991104126, -3.320314645767212]
explored B-LOC [3.3025381565093994, -3.28974986076355]
as B-LOC [3.172868013381958, -3.3683247566223145]
a B-LOC [3.117540121078491, -3.3632967472076416]
possible B-LOC [3.2395317554473877, -3.4567439556121826]
explanation B-LOC [3.0665013790130615, -3.395540237426758]
for B-LOC [3.1845951080322266, -3.3061575889587402]
GWAS B-LOC [2.846442937850952, -2.992767810821533]
findings. B-LOC [3.1023178100585938, -3.2398455142974854]
Here, B-LOC [0.9482669234275818, -1.0847575664520264]
we B-LOC [1.1898982524871826, -1.5166950225830078]
use B-LOC [1.9948086738586426, -2.35530161857605]
simple B-LOC [1.7502074241638184, -2.1238744258880615]
computer B-LOC [1.9907176494598389, -2.5775833129882812]
simulations B-LOC [1.9072734117507935, -2.2136244773864746]
to B-LOC [2.2710208892822266, -2.3986334800720215]
show B-LOC [2.0754234790802, -2.23781681060791]
the B-LOC [2.191843271255493, -2.262115716934204]
conditions B-LOC [2.207944869995117, -2.1975860595703125]
under B-LOC [2.3712289333343506, -2.568819522857666]
which B-LOC [2.1235201358795166, -2.4605183601379395]
such B-LOC [2.0506722927093506, -2.093637228012085]
synthetic B-LOC [1.5423598289489746, -1.936171531677246]
associations B-LOC [1.556374192237854, -1.8111109733581543]
will B-LOC [2.4239094257354736, -2.509129285812378]
arise B-LOC [2.1695966720581055, -2.4187114238739014]
and B-LOC [2.389758586883545, -2.443916082382202]
how B-LOC [2.410273790359497, -2.6952836513519287]
they B-LOC [2.0942490100860596, -2.545759677886963]
may B-LOC [2.654925584793091, -2.6389880180358887]
be B-LOC [2.765514850616455, -3.103673219680786]
recognized. B-LOC [2.4054911136627197, -2.6811201572418213]
We B-LOC [0.1799408197402954, -0.6317022442817688]
show B-LOC [0.21003295481204987, -0.4703073501586914]
that B-LOC [-0.052214931696653366, -0.43597978353500366]
they B-LOC [0.7976397275924683, -1.1465733051300049]
are B-LOC [0.5750780701637268, -0.6896786093711853]
not B-LOC [0.3445931673049927, -0.1806223839521408]
only B-LOC [0.46100401878356934, -0.6040382981300354]
possible, B-LOC [0.8390413522720337, -1.259889006614685]
but B-LOC [0.9769765138626099, -0.949459969997406]
inevitable, B-LOC [0.848012387752533, -1.244039535522461]
and B-LOC [-0.05187118798494339, -0.22032655775547028]
that B-LOC [-0.06828650832176208, -0.3311810791492462]
under B-LOC [0.33057108521461487, -0.6890186667442322]
simple B-LOC [0.5145710706710815, -0.6146159768104553]
but B-LOC [0.26512378454208374, -0.48990052938461304]
reasonable B-LOC [0.33917686343193054, -0.6833080053329468]
genetic B-LOC [0.682691752910614, -0.7893105149269104]
models, B-LOC [0.5235634446144104, -0.5985762476921082]
they B-LOC [0.5893146395683289, -0.7254724502563477]
are B-LOC [0.38542839884757996, -0.5496699810028076]
likely B-LOC [0.42301782965660095, -0.6923179030418396]
to B-LOC [0.4545555114746094, -0.5985208749771118]
account B-LOC [0.38877856731414795, -0.4941819906234741]
for B-LOC [0.5646823048591614, -0.443026065826416]
or B-LOC [0.3539870083332062, -0.6223315000534058]
contribute B-LOC [0.30863550305366516, -0.6165308356285095]
to B-LOC [0.42111560702323914, -0.65506911277771]
many B-LOC [0.4830789268016815, -0.7651931643486023]
of B-LOC [0.6182858943939209, -0.6354367136955261]
the B-LOC [0.6401720643043518, -0.800491988658905]
recently B-LOC [0.5947635769844055, -0.9076914191246033]
identified B-LOC [0.5030633807182312, -0.8229718208312988]

signals B-LOC [1.0162529945373535, -1.6201543807983398]
reported B-LOC [1.593576192855835, -1.7686679363250732]
in B-LOC [1.3303344249725342, -1.648024082183838]
genome-wide B-LOC [1.827992558479309, -2.004610061645508]
association B-LOC [1.5198380947113037, -1.817507028579712]
studies. B-LOC [1.5145268440246582, -1.6029471158981323]
We B-LOC [0.017514776438474655, -0.284681499004364]
also B-LOC [0.30667001008987427, -0.42102524638175964]
illustrate B-LOC [0.4097827672958374, -0.5759051442146301]
the B-LOC [0.5273199677467346, -0.7094472050666809]
behavior B-LOC [0.5338523983955383, -0.9020938277244568]
of B-LOC [0.46253326535224915, -0.7138624787330627]
synthetic B-LOC [0.6028680205345154, -0.7423369884490967]
associations B-LOC [0.6493831276893616, -0.7998172640800476]
in B-LOC [0.46343961358070374, -0.8746364712715149]
real B-LOC [0.4609639644622803, -0.9625802636146545]
datasets B-LOC [0.524511456489563, -0.7738381624221802]
by B-LOC [0.046773068606853485, -0.23240704834461212]
showing O [-0.08523692190647125, -0.06287232041358948]
that O [-0.5798406600952148, -0.0034254887141287327]
rare O [-0.14845022559165955, 0.1899605095386505]
causal O [-0.4916682541370392, 0.2693094313144684]
mutations O [-0.05196217820048332, 0.14992056787014008]
responsible O [-0.6018579602241516, 0.5145922303199768]
for O [-0.623690128326416, 0.45985859632492065]
both O [-0.814079225063324, 0.7173708081245422]
hearing O [-0.1327027678489685, 0.2263748049736023]
loss O [-0.33128947019577026, 0.4147484600543976]
and O [-0.6559565663337708, 0.6148162484169006]
sickle O [-0.11516691744327545, 0.15772880613803864]
cell O [-0.5610015392303467, 0.322011798620224]
anemia O [-0.5824667811393738, 0.3639499843120575]
create O [-0.2978898584842682, 0.23646889626979828]
genome-wide B-LOC [0.0703900158405304, -0.06637996435165405]
significant O [-0.21682119369506836, 0.013169361278414726]
synthetic O [-0.04153263196349144, 0.01019960455596447]
associations, B-LOC [0.06319579482078552, 0.00275709992274642]
in O [-0.34567925333976746, 0.16081872582435608]
the O [-0.18439920246601105, 0.29434219002723694]
latter O [-0.1466641128063202, 0.4422624707221985]
case O [-0.2349008023738861, 0.37151557207107544]
extending B-LOC [-0.0019248550524935126, -0.2566734850406647]
over B-LOC [0.08312717080116272, -0.11785715818405151]
a O [-0.04348614439368248, 0.1229473203420639]
2.5-Mb B-LOC [0.26978960633277893, 0.05302877351641655]
interval O [-0.2018798440694809, -0.16907736659049988]
encompassing B-LOC [0.16715145111083984, -0.20862771570682526]
scores B-LOC [0.19076505303382874, -0.11599227786064148]
of B-LOC [0.25181761384010315, -0.3485318422317505]
"blocks" B-LOC [0.12420833855867386, -0.26129844784736633]
of B-LOC [0.3341086804866791, -0.48188942670822144]
associated B-LOC [0.34194669127464294, -0.4990310072898865]
variants. B-LOC [0.48618724942207336, -0.5013081431388855]
In B-LOC [1.2590062618255615, -1.4678401947021484]
conclusion, B-LOC [1.5191543102264404, -1.1636760234832764]
uncommon B-LOC [1.547147512435913, -1.5735645294189453]
or B-LOC [1.7662723064422607, -1.7087504863739014]
rare B-LOC [1.6120702028274536, -1.600082278251648]
genetic B-LOC [1.701505184173584, -1.8090121746063232]
variants B-LOC [1.527730941772461, -1.4075233936309814]
can B-LOC [1.3351545333862305, -1.3664016723632812]
easily B-LOC [1.402597188949585, -1.5672502517700195]
create B-LOC [1.1130545139312744, -1.243928074836731]
synthetic B-LOC [1.4894652366638184, -1.845633864402771]
associations B-LOC [1.3677401542663574, -1.4561691284179688]
that B-LOC [1.4706530570983887, -1.7237049341201782]
are B-LOC [1.9226105213165283, -1.805974006652832]
credited B-LOC [1.7344515323638916, -1.8357281684875488]
to B-LOC [1.5211780071258545, -1.9437907934188843]
common B-LOC [1.7231271266937256, -2.0236892700195312]
variants, B-LOC [1.893474817276001, -2.0468389987945557]
and B-LOC [1.757794976234436, -1.7967500686645508]
this B-LOC [2.0316898822784424, -2.200827121734619]
possibility B-LOC [2.1522488594055176, -2.624990940093994]
requires B-LOC [2.0496909618377686, -2.4315123558044434]
careful B-LOC [2.1556174755096436, -2.526319980621338]
consideration B-LOC [2.2179620265960693, -2.4634687900543213]
in B-LOC [1.9052231311798096, -2.504674196243286]
the B-LOC [2.075207471847534, -2.5485105514526367]
interpretation B-LOC [1.9903743267059326, -2.5139923095703125]
and B-LOC [2.0250635147094727, -2.574826240539551]
follow B-LOC [2.1304209232330322, -2.69197154045105]
up B-LOC [2.2087159156799316, -2.626427412033081]
of B-LOC [2.054413080215454, -2.6791536808013916]
GWAS B-LOC [1.868437647819519, -2.09942364692688]
signals. B-LOC [1.9035546779632568, -2.496171236038208]

Intestinal B-LOC [0.150308758020401, -0.8900855779647827]
microbiota B-LOC [0.2783398926258087, -0.6761539578437805]
metabolism B-LOC [0.3742019236087799, -0.4701702296733856]
of B-LOC [0.3065810799598694, -0.5792289972305298]
choline B-LOC [0.24447274208068848, -0.8914679288864136]
and B-LOC [0.3364875614643097, -0.6283426880836487]
phosphatidylcholine B-LOC [0.337818443775177, -0.9194206595420837]
produces B-LOC [0.6762713193893433, -0.7591076493263245]
trimethylamine B-LOC [0.6254741549491882, -0.9976642727851868]
(TMA), B-LOC [0.8365402817726135, -1.2556226253509521]
which B-LOC [0.4829694330692291, -1.1115238666534424]
is B-LOC [0.9399495124816895, -1.1916072368621826]
further B-LOC [0.7264764904975891, -0.9890231490135193]
metabolized B-LOC [1.024172067642212, -1.1502559185028076]
to B-LOC [0.7878361344337463, -0.9722936749458313]
a B-LOC [0.8839578032493591, -1.0710967779159546]
proatherogenic B-LOC [0.6494771838188171, -1.2115839719772339]
species, B-LOC [0.6609087586402893, -1.1295584440231323]
trimethylamine-N-oxide B-LOC [0.7755191922187805, -1.1460262537002563]
(TMAO). B-LOC [0.9869397878646851, -1.5012421607971191]
We O [-0.5243865251541138, 0.16448327898979187]
demonstrate O [-0.36472657322883606, 0.3215084373950958]
here O [-0.33527815341949463, 0.28207406401634216]
that O [-0.7662221789360046, 0.4225556254386902]
metabolism O [-0.38694366812705994, 0.5246711373329163]
by O [-0.7215328216552734, 0.5911150574684143]
intestinal O [-0.8177562355995178, 0.7455151677131653]
microbiota O [-0.7186757922172546, 0.7017579078674316]
of O [-0.6193055510520935, 0.662185788154602]
dietary O [-0.5860421061515808, 0.8250182271003723]
L-carnitine, O [-0.4574125111103058, 0.28369417786598206]
a O [-0.6140395998954773, 0.5775290131568909]
trimethylamine O [-0.36946284770965576, 0.6362820267677307]
abundant O [-0.7025483846664429, 0.554766833782196]
in O [-0.5565906167030334, 0.7040185332298279]
red O [-0.500367283821106, 0.4391038417816162]
meat, O [-0.526505708694458, 0.35682064294815063]
also O [-0.800687313079834, 0.6213552355766296]
produces O [-0.6199249625205994, 0.7920891642570496]
TMAO O [-0.4758536219596863, 0.3258174657821655]
and O [-0.9826781749725342, 0.7886989712715149]
accelerates O [-0.7268491387367249, 0.7207610011100769]
atherosclerosis O [-0.881621778011322, 0.8380958437919617]
in O [-0.5871561765670776, 0.593660295009613]
mice. O [-0.4542405903339386, 0.2846629023551941]
Omnivorous B-LOC [0.04305510222911835, -0.08286470174789429]
human B-LOC [0.0695449560880661, -0.3843010365962982]
subjects B-LOC [0.006561363581568003, -0.2496623694896698]
produced B-LOC [0.012457872740924358, -0.21372628211975098]
more B-LOC [0.013398225419223309, -0.16755175590515137]
TMAO B-LOC [0.11055924743413925, -0.329130619764328]
than B-LOC [-0.1085948795080185, -0.1250647008419037]
did B-LOC [0.1800437867641449, -0.13286049664020538]
vegans B-LOC [0.09565086662769318, -0.5036376118659973]

or B-LOC [0.4263976514339447, -1.040701985359192]
vegetarians B-LOC [0.48694413900375366, -1.1095162630081177]
following B-LOC [0.4838935434818268, -0.9817370176315308]
ingestion B-LOC [0.6995968222618103, -1.0782867670059204]
of B-LOC [0.45720311999320984, -0.8950412273406982]
L-carnitine B-LOC [0.6435139179229736, -1.0495002269744873]
through B-LOC [0.4177892208099365, -0.9734150767326355]
a B-LOC [0.694882333278656, -1.0203529596328735]
microbiota-dependent B-LOC [0.5621218681335449, -1.0250003337860107]
mechanism. B-LOC [0.5308383703231812, -1.1920009851455688]
The B-LOC [1.3747482299804688, -1.7657153606414795]
presence B-LOC [1.353675365447998, -1.8185819387435913]
of B-LOC [1.4820294380187988, -1.9831833839416504]
specific B-LOC [1.598868489265442, -2.15506911277771]
bacterial B-LOC [1.454068899154663, -2.0221316814422607]
taxa B-LOC [1.578491449356079, -2.1832010746002197]
in B-LOC [1.391851782798767, -1.936682939529419]
human B-LOC [1.3509631156921387, -2.004220724105835]
feces B-LOC [1.322326898574829, -1.8991403579711914]
was B-LOC [1.1782150268554688, -1.8040997982025146]
associated B-LOC [1.3178622722625732, -1.803105354309082]
with B-LOC [1.250392198562622, -2.10256290435791]
both B-LOC [1.2409212589263916, -1.8661460876464844]
plasma B-LOC [1.2967259883880615, -2.1241838932037354]
TMAO B-LOC [1.339392900466919, -1.6954247951507568]
concentration B-LOC [1.4439663887023926, -1.8736441135406494]
and B-LOC [1.3144078254699707, -1.743802547454834]
dietary B-LOC [1.4798415899276733, -2.0959959030151367]
status. B-LOC [1.333259105682373, -2.0562398433685303]
Plasma B-LOC [2.6219117641448975, -2.5917327404022217]
L-carnitine B-LOC [2.4729745388031006, -2.385326623916626]
levels B-LOC [3.0215978622436523, -2.591395139694214]
in B-LOC [2.3019819259643555, -2.4856536388397217]
subjects B-LOC [2.9850308895111084, -2.8735902309417725]
undergoing B-LOC [2.965179204940796, -2.8027024269104004]
cardiac B-LOC [2.757429361343384, -3.107346296310425]
evaluation B-LOC [3.08209228515625, -2.846128225326538]
(n B-LOC [2.952623128890991, -2.3946893215179443]
= B-LOC [2.5966575145721436, -2.8850362300872803]
2,595) B-LOC [2.964590311050415, -2.6054530143737793]
predicted B-LOC [2.5550637245178223, -2.6360690593719482]
increased B-LOC [2.507136583328247, -2.849487781524658]
risks B-LOC [3.1130197048187256, -2.9251019954681396]
for B-LOC [2.5738813877105713, -2.7650959491729736]
both B-LOC [2.2112386226654053, -2.4195761680603027]
prevalent B-LOC [2.570216178894043, -2.560518503189087]
cardiovascular B-LOC [2.897254705429077, -2.8688557147979736]
disease B-LOC [3.195497751235962, -2.905233144760132]
(CVD) B-LOC [3.0294628143310547, -2.765934705734253]
and B-LOC [2.610259771347046, -2.5267574787139893]
incident B-LOC [2.776089906692505, -3.0502536296844482]
major B-LOC [2.8453316688537598, -2.83817982673645]
adverse B-LOC [3.073620080947876, -3.057523012161255]
cardiac B-LOC [2.9308974742889404, -3.1516053676605225]
events B-LOC [3.1732535362243652, -2.8461406230926514]
(myocardial B-LOC [2.7196872234344482, -2.5500547885894775]
infarction, B-LOC [2.7468018531799316, -2.5837342739105225]
stroke B-LOC [3.005077600479126, -2.9094367027282715]
or B-LOC [2.7461347579956055, -2.6735761165618896]
death), B-LOC [3.0634162425994873, -2.7445273399353027]
but B-LOC [2.148909330368042, -2.3376352787017822]
only B-LOC [2.118298292160034, -2.316298246383667]
among B-LOC [2.1178088188171387, -2.3479483127593994]
subjects B-LOC [2.5208232402801514, -2.6358482837677]
with B-LOC [2.0501468181610107, -2.2782821655273438]
concurrently B-LOC [1.9569380283355713, -2.161916732788086]
high B-LOC [2.4263899326324463, -2.8079826831817627]
TMAO B-LOC [1.901860237121582, -1.9740103483200073]
levels. B-LOC [2.8190877437591553, -2.4375293254852295]
Chronic B-LOC [0.9632425904273987, -1.1533839702606201]
dietary B-LOC [1.1222904920578003, -1.3202416896820068]

L-carnitine O [-0.45519569516181946, 0.6153053045272827]
supplementation O [-0.823253870010376, 1.1290507316589355]
in O [-0.8892779350280762, 0.8285996317863464]
mice O [-0.9623459577560425, 1.0136299133300781]
altered O [-1.111092448234558, 0.9610925316810608]
cecal O [-0.9596722722053528, 1.1317567825317383]
microbial O [-0.808652937412262, 1.135728120803833]
composition, O [-0.5797039270401001, 0.9676044583320618]
markedly O [-1.0554920434951782, 1.1366627216339111]
enhanced O [-1.1729285717010498, 1.1523628234863281]
synthesis O [-0.7181960940361023, 1.0179749727249146]
of O [-0.9403452277183533, 0.9032039046287537]
TMA O [-0.7521376609802246, 0.8884166479110718]
and O [-1.063491702079773, 0.8926588296890259]
TMAO, O [-0.737074077129364, 0.8373009562492371]
and O [-1.0953809022903442, 1.0041184425354004]
increased O [-1.0912439823150635, 0.9852966666221619]
atherosclerosis, O [-1.035134196281433, 0.8581345677375793]
but O [-0.8872124552726746, 0.620975911617279]
this O [-0.87908536195755, 0.5732880234718323]
did O [-0.7461382746696472, 0.48283103108406067]
not O [-0.5139623880386353, 0.6186530590057373]
occur O [-0.8017588257789612, 0.3785528838634491]
if O [-0.5807210206985474, 0.12123274058103561]
intestinal O [-0.8963819742202759, 0.5630790591239929]
microbiota O [-0.8210271000862122, 0.7693690657615662]
was O [-0.5389556288719177, 0.35447853803634644]
concurrently O [-0.5946984887123108, 0.4035252332687378]
suppressed. O [-0.5103570818901062, 0.4729052484035492]
In O [0.02795262075960636, 0.05839892476797104]
mice B-LOC [0.07223072648048401, -0.03530775383114815]
with B-LOC [0.16438141465187073, -0.18683284521102905]
an B-LOC [0.2710617184638977, -0.085391104221344]
intact B-LOC [0.13007338345050812, -0.044648800045251846]
intestinal O [-0.1315246969461441, 0.01795257441699505]
microbiota, O [-0.1430007517337799, 0.011697990819811821]
dietary O [0.09287060797214508, 0.16889947652816772]
supplementation B-LOC [0.022193150594830513, -0.08282069861888885]
with B-LOC [0.02921082265675068, -0.03820301219820976]
TMAO B-LOC [0.14980708062648773, -0.08655941486358643]
or B-LOC [0.055423248559236526, -0.046465713530778885]
either B-LOC [0.14064940810203552, -0.11109579354524612]
carnitine B-LOC [-0.001766656874679029, -0.3055402338504791]
or B-LOC [0.20914486050605774, -0.08752208948135376]
choline B-LOC [-0.05789656564593315, -0.22181487083435059]
reduced B-LOC [0.07535025477409363, -0.00021928777277935296]
in O [-0.08841218799352646, 0.0017407811246812344]
vivo B-LOC [-0.08245548605918884, -0.11487899720668793]
reverse B-LOC [-0.06638717651367188, -0.08831354975700378]
cholesterol O [-0.16191917657852173, -0.13785777986049652]
transport. O [-0.025554699823260307, -0.018529167398810387]
Intestinal B-LOC [0.8758826851844788, -1.3685383796691895]
microbiota B-LOC [1.2701752185821533, -1.5147887468338013]
may B-LOC [1.4160758256912231, -1.5699440240859985]
thus B-LOC [1.3263561725616455, -1.2648422718048096]
contribute B-LOC [1.3832571506500244, -1.5570847988128662]
to B-LOC [1.4275834560394287, -1.424722671508789]
the B-LOC [1.4402977228164673, -1.3352692127227783]
well-established B-LOC [1.6327996253967285, -1.6071140766143799]
link B-LOC [1.1248788833618164, -1.6350427865982056]
between B-LOC [1.3874653577804565, -1.8043776750564575]
high B-LOC [1.2650657892227173, -1.839191198348999]
levels B-LOC [1.4242167472839355, -1.8824703693389893]
of B-LOC [1.3233699798583984, -1.93416428565979]
red B-LOC [0.9792011380195618, -1.526404857635498]
meat B-LOC [0.7229194045066833, -1.5656688213348389]
consumption B-LOC [1.114544153213501, -1.43351411819458]
and B-LOC [1.4895062446594238, -1.8191345930099487]
CVD B-LOC [1.0012357234954834, -1.429682970046997]
risk. B-LOC [1.2701398134231567, -1.6689538955688477]

Deinococcus B-LOC [2.31561541557312, -2.211994171142578]
spp. B-LOC [2.6329171657562256, -2.267193555831909]
are B-LOC [2.616109848022461, -2.167642593383789]
renowned B-LOC [2.5151662826538086, -2.214261770248413]
for B-LOC [2.5278899669647217, -2.219160795211792]
their B-LOC [2.589069128036499, -2.2672643661499023]
amazing B-LOC [2.4523537158966064, -2.4838902950286865]
ability B-LOC [2.3103673458099365, -2.368597984313965]
to B-LOC [2.4633371829986572, -2.246089220046997]
recover B-LOC [2.629422903060913, -2.2955780029296875]
rapidly B-LOC [2.706446886062622, -2.5359561443328857]
from B-LOC [2.9462432861328125, -2.441588878631592]
severe B-LOC [2.830890417098999, -2.680382013320923]
genomic B-LOC [2.950866937637329, -2.681464910507202]
fragmentation B-LOC [3.112548589706421, -2.622469186782837]
as B-LOC [2.7810661792755127, -2.431918144226074]
a B-LOC [2.9654810428619385, -2.580266237258911]
result B-LOC [2.9660632610321045, -2.6868021488189697]
of B-LOC [2.783777952194214, -2.6461563110351562]
exposure B-LOC [3.2213213443756104, -2.784013271331787]
to B-LOC [3.007084369659424, -2.6282055377960205]
extreme B-LOC [3.101909637451172, -3.010985851287842]
levels B-LOC [3.140347719192505, -2.8626272678375244]
of B-LOC [3.059710741043091, -2.788393020629883]
ionizing B-LOC [3.116981029510498, -2.927752733230591]
radiation B-LOC [3.047711133956909, -2.8176662921905518]
or B-LOC [2.9103100299835205, -2.6050875186920166]
desiccation. B-LOC [3.2402968406677246, -2.6969594955444336]
Despite B-LOC [2.7985775470733643, -2.9713122844696045]
having B-LOC [3.0363261699676514, -2.902162790298462]
been B-LOC [2.98822283744812, -3.093492269515991]
originally B-LOC [2.884760618209839, -3.237501621246338]
characterized B-LOC [3.0675904750823975, -3.248441457748413]
over B-LOC [3.210137128829956, -3.290752649307251]
50 B-LOC [3.17215895652771, -3.1599626541137695]
years B-LOC [3.025113344192505, -3.1050941944122314]
ago, B-LOC [2.91660475730896, -3.2603352069854736]
the B-LOC [3.0316531658172607, -3.1342217922210693]
mechanism B-LOC [2.9283387660980225, -3.2618391513824463]
underlying B-LOC [3.0820679664611816, -3.2804887294769287]
this B-LOC [3.02846360206604, -3.1018426418304443]
remarkable B-LOC [3.094568967819214, -3.2877118587493896]
repair B-LOC [2.9767510890960693, -3.1343183517456055]
process B-LOC [2.967172384262085, -3.240706443786621]
is B-LOC [3.258814573287964, -3.0743069648742676]
still B-LOC [3.3608763217926025, -3.06430983543396]
poorly B-LOC [3.3330507278442383, -3.0705959796905518]
understood. B-LOC [3.1150095462799072, -3.1435282230377197]
Here, B-LOC [0.6045381426811218, -0.6328555345535278]
we B-LOC [0.687955915927887, -0.44525596499443054]
report B-LOC [0.8825560212135315, -0.7818982005119324]
the B-LOC [1.0405596494674683, -0.9489673972129822]
2.8 B-LOC [1.3980801105499268, -0.7961550354957581]
A B-LOC [1.0646477937698364, -1.1272666454315186]
structure B-LOC [1.126967191696167, -1.2994613647460938]
of B-LOC [1.129384994506836, -1.3167333602905273]
DdrB, B-LOC [0.9094242453575134, -1.101938247680664]
a B-LOC [1.1090798377990723, -1.217333436012268]
single-stranded B-LOC [1.5251938104629517, -1.561530351638794]
DNA B-LOC [1.0597140789031982, -1.480480432510376]
(ssDNA) B-LOC [1.2539050579071045, -1.3923060894012451]
binding B-LOC [1.354149341583252, -1.4282190799713135]
protein B-LOC [0.7746279835700989, -1.2296830415725708]
unique B-LOC [1.3388738632202148, -1.296687364578247]
to B-LOC [1.2795287370681763, -1.2270618677139282]
Deinococcus B-LOC [1.2011957168579102, -1.2090823650360107]
spp. B-LOC [1.1629663705825806, -1.2944307327270508]
that B-LOC [1.104987382888794, -1.5026253461837769]
is B-LOC [1.650059461593628, -1.568744421005249]
crucial B-LOC [1.1736609935760498, -1.4297430515289307]
for B-LOC [1.2436091899871826, -1.506788969039917]
recovery B-LOC [1.5556000471115112, -1.3371918201446533]
following B-LOC [1.6201252937316895, -1.5485602617263794]
DNA B-LOC [1.2179582118988037, -1.472954273223877]
damage. B-LOC [1.5118576288223267, -1.5493099689483643]
DdrB B-LOC [0.2614378333091736, -0.3622485101222992]
forms B-LOC [0.13847512006759644, 0.041138868778944016]
a O [-0.03810309246182442, 0.1366111934185028]
pentameric O [-0.1333909034729004, 0.008839083835482597]
ring O [-0.0075867450796067715, 0.02070574276149273]
capable O [-0.36414870619773865, -0.022227639332413673]
of O [-0.579859733581543, 0.2816944420337677]
binding O [-0.10413600504398346, 0.07066220045089722]
single-stranded B-LOC [0.03406297788023949, 0.012279955670237541]
but O [-0.2336963415145874, 0.09914796054363251]
not O [-0.23944680392742157, 0.18347859382629395]

double-stranded B-LOC [1.2124803066253662, -1.3443834781646729]
DNA. B-LOC [1.2360469102859497, -1.5634338855743408]
Unexpectedly, B-LOC [1.4777493476867676, -1.535746693611145]
the B-LOC [1.459425449371338, -1.463686227798462]
crystal B-LOC [1.8249270915985107, -1.6003628969192505]
structure B-LOC [1.722495198249817, -1.7058916091918945]
reveals B-LOC [1.2536613941192627, -1.1654258966445923]
that B-LOC [1.1731709241867065, -1.3786866664886475]
DdrB B-LOC [0.9225863218307495, -1.1133167743682861]
comprises B-LOC [1.659741759300232, -1.4120814800262451]
a B-LOC [1.5128220319747925, -1.4351621866226196]
novel B-LOC [1.5950086116790771, -1.744563102722168]
fold B-LOC [1.5834403038024902, -1.7799592018127441]
that B-LOC [1.5798922777175903, -2.09186053276062]
is B-LOC [2.066635847091675, -2.0619871616363525]
structurally B-LOC [2.21802020072937, -1.9482591152191162]
and B-LOC [1.9547778367996216, -2.073181629180908]
topologically B-LOC [2.2501888275146484, -2.314674139022827]
distinct B-LOC [2.0640063285827637, -2.2296879291534424]
from B-LOC [1.9904687404632568, -1.8940563201904297]
all B-LOC [2.1466758251190186, -2.171858787536621]
other B-LOC [2.227456569671631, -2.0059726238250732]
single-stranded B-LOC [1.869422435760498, -1.9085910320281982]
binding B-LOC [1.6217706203460693, -1.8327380418777466]
(SSB) B-LOC [1.9520235061645508, -2.2376644611358643]
proteins B-LOC [1.5744847059249878, -1.6555697917938232]
characterized B-LOC [2.5545194149017334, -2.098634958267212]
to B-LOC [2.966242551803589, -2.5888783931732178]
date. B-LOC [2.566720485687256, -2.364168405532837]
The B-LOC [1.6212193965911865, -1.5079237222671509]
need B-LOC [1.4800069332122803, -1.726312279701233]
for B-LOC [1.7796202898025513, -1.7080883979797363]
a B-LOC [1.6680086851119995, -1.6920682191848755]
unique B-LOC [1.6664267778396606, -2.0319647789001465]
ssDNA B-LOC [1.1963369846343994, -1.6092345714569092]
binding B-LOC [1.1880383491516113, -1.3985023498535156]
function B-LOC [1.1765838861465454, -1.4636590480804443]
in B-LOC [1.4409503936767578, -1.7486755847930908]
response B-LOC [1.7805309295654297, -1.5638856887817383]
to B-LOC [1.7817639112472534, -1.6795786619186401]
severe B-LOC [1.7039289474487305, -1.800979733467102]
damage, B-LOC [1.4568519592285156, -1.523327350616455]
suggests B-LOC [1.3514671325683594, -1.4683388471603394]
a B-LOC [1.7402132749557495, -1.8173109292984009]
distinct B-LOC [1.7976176738739014, -2.003695011138916]
role B-LOC [1.2987490892410278, -1.7514116764068604]
for B-LOC [1.4727182388305664, -1.636981725692749]
DdrB B-LOC [0.9225314259529114, -1.166353702545166]
which B-LOC [1.3947370052337646, -1.8035378456115723]
may B-LOC [1.5024312734603882, -1.8594603538513184]
encompass B-LOC [1.7264808416366577, -1.857998013496399]
not B-LOC [0.8800083994865417, -1.2310380935668945]
only B-LOC [1.108127474784851, -1.4568109512329102]
standard B-LOC [1.1017366647720337, -1.814652442932129]
SSB B-LOC [1.2240902185440063, -1.3595317602157593]
protein B-LOC [1.0385619401931763, -1.4381964206695557]
function B-LOC [1.1035500764846802, -1.5003631114959717]
in B-LOC [1.17555570602417, -1.7066757678985596]
protection B-LOC [1.3508501052856445, -1.5378977060317993]
of B-LOC [1.1347365379333496, -1.579856276512146]
ssDNA, B-LOC [1.0943236351013184, -1.5565786361694336]
but B-LOC [1.2244330644607544, -1.2112808227539062]
also B-LOC [1.389696717262268, -1.6225354671478271]
more B-LOC [1.1755123138427734, -1.9130462408065796]
specialized B-LOC [1.4182939529418945, -2.004786968231201]
roles B-LOC [1.3644236326217651, -1.8622816801071167]
in B-LOC [1.2243901491165161, -1.8701937198638916]
protein B-LOC [1.1275269985198975, -1.6636401414871216]
recruitment B-LOC [0.983571469783783, -1.3849577903747559]
or B-LOC [1.4660061597824097, -1.7801597118377686]
DNA B-LOC [1.0365859270095825, -1.6161446571350098]
architecture B-LOC [1.149342656135559, -1.5211734771728516]
maintenance. B-LOC [1.4344621896743774, -1.7432568073272705]
Possible B-LOC [1.767882227897644, -2.0749382972717285]
mechanisms B-LOC [1.724706768989563, -2.1079657077789307]
of B-LOC [1.4664220809936523, -2.0082666873931885]
DdrB B-LOC [0.7157836556434631, -1.028030514717102]
action B-LOC [1.2026982307434082, -1.685802936553955]
in B-LOC [1.3559532165527344, -1.819507360458374]
damage B-LOC [1.3581454753875732, -1.5225307941436768]
recovery B-LOC [1.3890981674194336, -1.5128507614135742]
are B-LOC [2.2369844913482666, -2.066725730895996]
discussed. B-LOC [2.250678062438965, -1.9402906894683838]

Background B-LOC [1.4883724451065063, -1.7442907094955444]
The B-LOC [1.7079070806503296, -1.7957648038864136]
catalytically B-LOC [1.620482087135315, -2.1089205741882324]
active B-LOC [1.4952776432037354, -1.845293641090393]
66-kDa B-LOC [1.4618408679962158, -1.4203007221221924]
subunit B-LOC [1.4849939346313477, -1.8435044288635254]
of B-LOC [1.6243798732757568, -1.669060468673706]
the B-LOC [1.783334493637085, -1.6452442407608032]
human B-LOC [1.33065664768219, -1.8143117427825928]
immunodeficiency B-LOC [1.7216283082962036, -2.0309135913848877]
virus B-LOC [1.4462412595748901, -1.960653305053711]
type B-LOC [1.904260516166687, -1.817819595336914]
1 B-LOC [1.6055498123168945, -1.9065301418304443]
(HIV-1) B-LOC [1.4504504203796387, -1.7946929931640625]
reverse B-LOC [1.7203054428100586, -2.1328155994415283]
transcriptase B-LOC [1.337640643119812, -1.7105727195739746]
(RT) B-LOC [1.6098254919052124, -1.5127146244049072]
consists B-LOC [1.8145778179168701, -1.635218620300293]
of B-LOC [1.3457651138305664, -1.4265367984771729]
DNA B-LOC [1.4148560762405396, -1.9783705472946167]
polymerase, B-LOC [1.5821537971496582, -1.9489941596984863]
connection, B-LOC [1.8947410583496094, -2.0252251625061035]
and B-LOC [1.8512496948242188, -1.7589404582977295]
ribonuclease B-LOC [1.7076297998428345, -1.767033576965332]
H B-LOC [1.6968958377838135, -1.9498084783554077]
(RNase B-LOC [1.7522090673446655, -1.8049192428588867]
H) B-LOC [1.419097661972046, -1.7582244873046875]
domains. B-LOC [1.6855747699737549, -1.8435397148132324]
Almost B-LOC [3.0187509059906006, -2.670550584793091]
all B-LOC [2.7854578495025635, -2.6519763469696045]
known B-LOC [2.9903037548065186, -2.5242552757263184]
RT B-LOC [2.280693531036377, -2.468339681625366]
inhibitor B-LOC [2.7557342052459717, -2.7893033027648926]
resistance B-LOC [2.9088172912597656, -2.738926410675049]
mutations B-LOC [3.0919687747955322, -2.668290615081787]
identified B-LOC [3.272660255432129, -2.5386478900909424]
to B-LOC [3.3054230213165283, -2.513957977294922]
date B-LOC [3.2004594802856445, -2.8057971000671387]
map B-LOC [2.9497363567352295, -2.4757254123687744]
to B-LOC [3.0637495517730713, -2.920758008956909]
the B-LOC [3.066343069076538, -2.74064564704895]
polymerase B-LOC [2.5520424842834473, -2.831799268722534]
domain B-LOC [2.861133337020874, -2.8863327503204346]
of B-LOC [2.8777196407318115, -2.708134412765503]
the B-LOC [2.823317289352417, -2.7344601154327393]
enzyme. B-LOC [2.5387918949127197, -2.9725501537323]
However, B-LOC [2.988999128341675, -2.779348373413086]
the B-LOC [3.0330758094787598, -2.6957919597625732]
connection B-LOC [2.913015127182007, -2.9139230251312256]
and B-LOC [2.8358399868011475, -2.7863173484802246]
RNase B-LOC [2.6873667240142822, -2.6870462894439697]
H B-LOC [2.8653404712677, -2.8486053943634033]
domains B-LOC [3.014615297317505, -2.8200461864471436]
are B-LOC [3.296241521835327, -2.691936731338501]
not B-LOC [3.3468587398529053, -2.860891819000244]
routinely B-LOC [3.173326253890991, -3.0437653064727783]
analysed B-LOC [3.266814947128296, -2.8906986713409424]
in B-LOC [3.090763807296753, -3.0176734924316406]
clinical B-LOC [3.185236692428589, -3.1629793643951416]
samples B-LOC [3.2044694423675537, -3.04660964012146]
and B-LOC [2.6059505939483643, -2.4163906574249268]
none B-LOC [3.2186827659606934, -2.7630367279052734]
of B-LOC [3.041076421737671, -2.6752865314483643]
the B-LOC [3.1330106258392334, -2.5309479236602783]
genotyping B-LOC [3.2315146923065186, -2.836249589920044]
assays B-LOC [3.129812479019165, -2.8610446453094482]
available B-LOC [3.346916437149048, -2.847360849380493]
for B-LOC [3.184373378753662, -2.999537944793701]
patient B-LOC [3.1350114345550537, -3.1384904384613037]
management B-LOC [3.2738687992095947, -3.0297882556915283]
sequence B-LOC [2.9794704914093018, -2.8432507514953613]
the B-LOC [3.0177111625671387, -2.83378267288208]
entire B-LOC [3.0942330360412598, -2.9378011226654053]
RT B-LOC [2.777010202407837, -2.835845470428467]
coding B-LOC [2.971694231033325, -2.980623483657837]
region. B-LOC [2.9621949195861816, -3.1271283626556396]
The B-LOC [1.028612494468689, -1.3468667268753052]
British B-LOC [1.3349895477294922, -1.9619760513305664]
Columbia B-LOC [0.7497206330299377, -1.5338001251220703]

Centre B-LOC [2.457947254180908, -3.4374916553497314]
for B-LOC [3.0840671062469482, -3.3351376056671143]
Excellence B-LOC [2.943934202194214, -3.2199206352233887]
in B-LOC [2.924227714538574, -3.2128093242645264]
HIV/AIDS B-LOC [2.8041584491729736, -3.222973108291626]
(the B-LOC [3.001404285430908, -3.0532777309417725]
Centre) B-LOC [2.7378036975860596, -3.4811408519744873]
genotypes B-LOC [2.566236734390259, -2.725945234298706]
clinical B-LOC [2.6302878856658936, -3.025906801223755]
isolates B-LOC [2.9370219707489014, -3.0408527851104736]
up B-LOC [2.717038869857788, -3.0706443786621094]
to B-LOC [2.7826569080352783, -2.8453433513641357]
codon B-LOC [2.346109390258789, -2.7639944553375244]
400 B-LOC [2.3021910190582275, -2.537628173828125]
in B-LOC [2.1505532264709473, -2.6010544300079346]
RT, B-LOC [2.579437255859375, -2.9899888038635254]
and B-LOC [2.444481134414673, -3.0594122409820557]
our B-LOC [2.4455087184906006, -2.8596584796905518]
retrospective B-LOC [2.899055004119873, -3.369744300842285]
statistical B-LOC [3.080566883087158, -3.3110291957855225]
analyses B-LOC [2.95378041267395, -3.1477420330047607]
of B-LOC [2.8986988067626953, -3.082195520401001]
the B-LOC [3.0369017124176025, -3.180938482284546]
Centre’s B-LOC [2.7483718395233154, -3.555419921875]
database B-LOC [3.0831642150878906, -3.430631399154663]
have B-LOC [2.51750111579895, -2.8226797580718994]
identified B-LOC [2.468953847885132, -2.857037305831909]
an B-LOC [2.408879041671753, -2.699130058288574]
N348I B-LOC [2.1320629119873047, -2.52170991897583]
mutation B-LOC [2.184584140777588, -2.8264873027801514]
in B-LOC [2.5280368328094482, -2.6727726459503174]
the B-LOC [2.835714101791382, -2.988332986831665]
RT B-LOC [2.695145606994629, -3.1410646438598633]
connection B-LOC [2.3679306507110596, -3.071425676345825]
domain B-LOC [2.6512579917907715, -3.1089766025543213]
in B-LOC [2.0937392711639404, -2.8533031940460205]
treatment-experienced B-LOC [2.8398966789245605, -3.3215060234069824]
individuals. B-LOC [3.0178463459014893, -3.347999334335327]
The B-LOC [3.347111940383911, -3.557739496231079]
objective B-LOC [3.286393642425537, -3.56050181388855]
of B-LOC [3.1719748973846436, -3.240096092224121]
this B-LOC [3.1529550552368164, -3.6282901763916016]
multidisciplinary B-LOC [3.0986952781677246, -3.6501760482788086]
study B-LOC [3.2878823280334473, -3.7660696506500244]
was B-LOC [3.1678788661956787, -3.427412986755371]
to B-LOC [3.3243746757507324, -3.568709135055542]
establish B-LOC [3.3513379096984863, -3.703090190887451]
the B-LOC [3.5377955436706543, -3.710007905960083]
in B-LOC [2.972055673599243, -3.2842562198638916]
vivo B-LOC [2.88146710395813, -2.939410448074341]
relevance B-LOC [3.3769209384918213, -3.6478614807128906]
of B-LOC [3.55710506439209, -3.5986013412475586]
this B-LOC [3.2158782482147217, -3.662151575088501]
mutation B-LOC [2.971109628677368, -3.8110899925231934]
and B-LOC [3.3490498065948486, -3.55916166305542]
its B-LOC [3.259613513946533, -3.472620964050293]
role B-LOC [3.3072445392608643, -3.599247694015503]
in B-LOC [3.3276984691619873, -3.6956052780151367]
drug B-LOC [3.2713544368743896, -3.937702178955078]
resistance. B-LOC [3.4124772548675537, -3.8782098293304443]
Methods B-LOC [2.7616822719573975, -3.1698215007781982]
and B-LOC [2.701326847076416, -3.14974308013916]
Findings B-LOC [2.7481448650360107, -2.925535202026367]
The B-LOC [2.310098648071289, -2.5898561477661133]
prevalence B-LOC [2.15580415725708, -2.511289119720459]
of B-LOC [2.245091676712036, -2.675584077835083]
N348I B-LOC [1.8948248624801636, -2.242159843444824]
in B-LOC [1.884205937385559, -2.595975875854492]
clinical B-LOC [2.4431557655334473, -2.8104469776153564]
isolates, B-LOC [2.795743703842163, -2.8140957355499268]
the B-LOC [2.5971105098724365, -2.723289728164673]
time B-LOC [2.1067516803741455, -2.621422529220581]
taken B-LOC [2.525794744491577, -2.9675450325012207]
for B-LOC [2.2863271236419678, -2.388340950012207]
it B-LOC [2.159501314163208, -2.705950975418091]
to B-LOC [2.28788423538208, -2.508300542831421]
emerge B-LOC [2.1189420223236084, -2.507512331008911]
under B-LOC [2.271477222442627, -2.5916621685028076]
selective B-LOC [2.3141181468963623, -2.9082095623016357]
drug B-LOC [2.3914716243743896, -2.988677740097046]
pressure, B-LOC [2.4585635662078857, -2.6901164054870605]
and B-LOC [2.5999014377593994, -2.7661354541778564]
its B-LOC [2.1676676273345947, -2.785572052001953]
association B-LOC [2.137288808822632, -2.461920976638794]
with B-LOC [1.9061036109924316, -2.7245702743530273]
changes B-LOC [2.1798582077026367, -2.8454291820526123]
in B-LOC [1.6957842111587524, -2.6427414417266846]
viral B-LOC [1.9854018688201904, -2.5913431644439697]
load, B-LOC [2.1862633228302, -2.4599320888519287]
specific B-LOC [2.3951783180236816, -3.0164899826049805]
drug B-LOC [1.929600715637207, -2.427316904067993]

treatment, B-LOC [2.5782923698425293, -3.4172616004943848]
and B-LOC [3.170506238937378, -3.8304944038391113]
known B-LOC [3.3123934268951416, -3.918595552444458]
drug B-LOC [3.233079195022583, -3.8158061504364014]
resistance B-LOC [3.303738594055176, -3.8446035385131836]
mutations B-LOC [3.487081289291382, -3.813389539718628]
was B-LOC [3.191387891769409, -3.795628309249878]
analysed B-LOC [3.665541648864746, -3.8540565967559814]
from B-LOC [3.4568030834198, -3.9146029949188232]
genotypes, B-LOC [3.6497654914855957, -3.7966220378875732]
viral B-LOC [3.4163310527801514, -3.807560443878174]
loads, B-LOC [3.4487640857696533, -3.8291006088256836]
and B-LOC [3.413038969039917, -3.911297559738159]
treatment B-LOC [3.201601505279541, -3.744035243988037]
histories B-LOC [3.444321870803833, -3.775390386581421]
from B-LOC [3.444690704345703, -3.8680999279022217]
the B-LOC [3.2473127841949463, -3.5298845767974854]
Centre’s B-LOC [2.5173346996307373, -3.608952045440674]
database. B-LOC [3.4459354877471924, -3.8377225399017334]
N348I B-LOC [1.9936338663101196, -2.6836283206939697]
increased B-LOC [1.9004966020584106, -2.520563840866089]
in B-LOC [1.8271303176879883, -2.435309886932373]
prevalence B-LOC [2.1190195083618164, -2.571575403213501]
from B-LOC [1.805211067199707, -2.3332319259643555]
below B-LOC [2.0441410541534424, -2.32785964012146]
1% B-LOC [2.152228593826294, -2.4724514484405518]
in B-LOC [1.7982467412948608, -2.473828077316284]
368 B-LOC [2.4741809368133545, -2.6333587169647217]
treatmentnao B-LOC [1.9042863845825195, -2.2585721015930176]
¨ve B-LOC [1.690927505493164, -2.2021634578704834]
individuals B-LOC [2.2068698406219482, -2.7303574085235596]
to B-LOC [1.7897772789001465, -2.1275675296783447]
12.1% B-LOC [2.128047466278076, -2.5307986736297607]
in B-LOC [1.9230397939682007, -2.6955642700195312]
1,009 B-LOC [2.6265668869018555, -2.7130982875823975]
treatment-experienced B-LOC [2.3068487644195557, -2.9270503520965576]
patients B-LOC [2.2428970336914062, -2.6765363216400146]
(p B-LOC [2.1790120601654053, -2.5023796558380127]
¼ B-LOC [1.9603828191757202, -2.6244451999664307]
7.7 B-LOC [2.2515881061553955, -2.653916120529175]
3 B-LOC [1.977035641670227, -2.58056378364563]
10 B-LOC [1.5012927055358887, -2.0938713550567627]
12 B-LOC [1.9636677503585815, -2.933863878250122]
). B-LOC [2.360731363296509, -2.7641441822052]
N348I B-LOC [0.4240425229072571, -0.5937598347663879]
appeared B-LOC [0.4261507987976074, -0.7220326066017151]
early B-LOC [0.20188890397548676, -0.7166840434074402]
in B-LOC [0.24500739574432373, -0.8273844718933105]
therapy B-LOC [0.5408863425254822, -0.6301966309547424]
and B-LOC [0.03597981855273247, -0.4460509717464447]
was B-LOC [0.2957400679588318, -0.5141575932502747]
highly B-LOC [0.37763336300849915, -0.7019747495651245]
associated B-LOC [0.26510971784591675, -0.6402842998504639]
with B-LOC [0.3905632793903351, -0.5977638959884644]
thymidine B-LOC [0.5738753080368042, -0.9575458765029907]
analogue B-LOC [0.5340994596481323, -0.860677182674408]
mutations B-LOC [0.5578436851501465, -0.6778988242149353]
(TAMs) B-LOC [0.7915753722190857, -0.8812680840492249]
M41L B-LOC [0.40134549140930176, -0.632560670375824]
and B-LOC [0.43222299218177795, -0.3941483199596405]
T215Y/F B-LOC [0.42220601439476013, -0.5325483083724976]
(p B-LOC [0.5963841080665588, -0.6659497618675232]
, B-LOC [0.4706939160823822, -0.722178041934967]
0.001), B-LOC [0.9437058568000793, -0.9700703620910645]
the B-LOC [0.5662529468536377, -0.623502254486084]
lamivudine B-LOC [0.4771917760372162, -0.5048484206199646]
resistance B-LOC [0.3694172203540802, -0.6498532295227051]
mutations B-LOC [0.26490163803100586, -0.6562564969062805]

M184V/I B-LOC [0.5207855105400085, -0.8361021876335144]
(p B-LOC [0.6906746029853821, -0.8149616718292236]
, B-LOC [0.5812616348266602, -0.7662584185600281]
0.001), B-LOC [0.9183283448219299, -1.1353142261505127]
and B-LOC [0.9126914143562317, -0.8041122555732727]
non-nucleoside B-LOC [1.3652973175048828, -1.343803882598877]
RTI B-LOC [0.9206836819648743, -1.470106840133667]
(NNRTI) B-LOC [1.1528820991516113, -1.3746352195739746]
resistance B-LOC [0.8940584063529968, -1.2366595268249512]
mutations B-LOC [0.8224624991416931, -1.1900190114974976]
K103N B-LOC [0.5733160376548767, -0.8288622498512268]
and B-LOC [0.7956409454345703, -0.8383886218070984]
Y181C/I B-LOC [0.5736547112464905, -0.969307005405426]
(p B-LOC [0.8350059390068054, -0.993212878704071]
, B-LOC [0.6546586751937866, -0.8905854821205139]
0.001). B-LOC [0.9866369366645813, -1.1762652397155762]
The B-LOC [2.1635615825653076, -2.2775557041168213]
association B-LOC [1.9483270645141602, -2.107269525527954]
with B-LOC [2.172156572341919, -2.1923773288726807]
TAMs B-LOC [2.079908609390259, -2.2835609912872314]
and B-LOC [2.0538196563720703, -2.225579261779785]
NNRTI B-LOC [1.7760833501815796, -2.0691142082214355]
resistance B-LOC [2.2021853923797607, -2.2994167804718018]
mutations B-LOC [2.386091947555542, -2.180997610092163]
was B-LOC [2.092668056488037, -2.1755454540252686]
consistent B-LOC [2.270329475402832, -2.1743853092193604]
with B-LOC [2.2724077701568604, -2.314687967300415]
the B-LOC [2.269000768661499, -2.2962687015533447]
selection B-LOC [2.0291872024536133, -2.182922840118408]
of B-LOC [2.1667609214782715, -2.21529221534729]
N348I B-LOC [1.7665460109710693, -1.9806227684020996]
in B-LOC [2.0590755939483643, -2.210963726043701]
patients B-LOC [2.000251531600952, -2.0923755168914795]
treated B-LOC [2.120649576187134, -2.1862692832946777]
with B-LOC [2.159386396408081, -2.2329399585723877]
regimens B-LOC [1.9344837665557861, -2.036972999572754]
that B-LOC [1.8780053853988647, -2.145540475845337]
included B-LOC [2.1391923427581787, -2.0511958599090576]
both B-LOC [1.7686669826507568, -1.9571572542190552]
zidovudine B-LOC [1.4799753427505493, -1.6670281887054443]
and B-LOC [1.9443496465682983, -1.7253515720367432]
nevirapine B-LOC [1.573988914489746, -1.8711960315704346]
(odds B-LOC [1.4347096681594849, -1.6290010213851929]
ratio B-LOC [0.9243413805961609, -1.334041714668274]
2.62, B-LOC [1.0812134742736816, -0.9315863847732544]
95% B-LOC [0.6473627090454102, -1.0686964988708496]
confidence B-LOC [0.5099051594734192, -1.2314592599868774]
interval B-LOC [0.512101948261261, -1.1338341236114502]
1.43–4.81). B-LOC [0.6653830409049988, -0.7083315849304199]
The O [-0.23819538950920105, -0.027958659455180168]
appearance O [-0.19989429414272308, -0.15663358569145203]
of B-LOC [-0.14195698499679565, -0.213682621717453]
N348I B-LOC [-0.16905134916305542, -0.1903597116470337]
was O [-0.39702731370925903, -0.10539790242910385]
associated O [-0.2912442982196808, -0.05187626928091049]
with O [-0.41386881470680237, -0.1821146458387375]
a O [-0.4022888243198395, -0.09262117743492126]
significant O [-0.31204313039779663, -0.1542772501707077]
increase B-LOC [-0.25554272532463074, -0.3382880389690399]
in O [-0.4174747169017792, -0.252867192029953]
viral B-LOC [-0.15126971900463104, -0.1791587620973587]
load O [-0.19418485462665558, -0.08290515094995499]
(p O [-0.1759822815656662, -0.142859548330307]
, B-LOC [-0.2902645170688629, -0.42737892270088196]

0.001), B-LOC [0.3396954834461212, -0.9678477048873901]
which B-LOC [0.454653799533844, -1.1055995225906372]
was B-LOC [0.432498961687088, -0.909773051738739]
as B-LOC [0.7099674940109253, -0.9386692047119141]
large B-LOC [0.7905526757240295, -0.9827374219894409]
as B-LOC [0.5475751757621765, -1.0720152854919434]
the B-LOC [0.7368072271347046, -1.0478971004486084]
viral B-LOC [0.6589009761810303, -1.1823723316192627]
load B-LOC [0.6571491360664368, -1.072904109954834]
increases B-LOC [0.754906177520752, -1.1401257514953613]
observed B-LOC [0.8222203850746155, -1.1353379487991333]
for B-LOC [0.7933327555656433, -1.2040784358978271]
any B-LOC [1.020747423171997, -1.4345965385437012]
of B-LOC [0.9783957004547119, -1.2324060201644897]
the B-LOC [0.9413492679595947, -1.060431957244873]
TAMs. B-LOC [0.8382651209831238, -1.110722541809082]
However, B-LOC [1.9054069519042969, -2.367117404937744]
this B-LOC [2.0394411087036133, -2.5231807231903076]
analysis B-LOC [2.090404748916626, -2.7830193042755127]
did B-LOC [2.1918036937713623, -2.619860887527466]
not B-LOC [2.4071390628814697, -2.5692460536956787]
account B-LOC [2.1580679416656494, -2.8684420585632324]
for B-LOC [2.3212664127349854, -2.8339130878448486]
the B-LOC [2.3605687618255615, -2.7731375694274902]
simultaneous B-LOC [2.1861324310302734, -2.994727373123169]
selection B-LOC [2.324019432067871, -2.9182538986206055]
of B-LOC [2.2899653911590576, -2.91471266746521]
other B-LOC [2.4548280239105225, -2.891993761062622]
RT B-LOC [1.9352049827575684, -2.656959056854248]
or B-LOC [2.27555251121521, -2.7692387104034424]
protease B-LOC [1.9334003925323486, -2.6078734397888184]
inhibitor B-LOC [2.0060153007507324, -2.6672306060791016]
resistance B-LOC [2.1622486114501953, -2.847050428390503]
mutations B-LOC [2.327604055404663, -2.878856658935547]
on B-LOC [2.1845130920410156, -3.023411512374878]
viral B-LOC [2.4245376586914062, -2.891023874282837]
load. B-LOC [2.246429920196533, -2.7939608097076416]
To B-LOC [2.172395944595337, -2.2920734882354736]
delineate B-LOC [2.72102952003479, -2.709977388381958]
the B-LOC [2.638462781906128, -2.567429780960083]
role B-LOC [2.542267322540283, -2.7093963623046875]
of B-LOC [2.5754106044769287, -2.501002311706543]
this B-LOC [2.244180202484131, -2.4403579235076904]
mutation B-LOC [2.1422643661499023, -2.5740063190460205]
in B-LOC [2.4341626167297363, -2.7475578784942627]
RT B-LOC [2.503767251968384, -2.6236236095428467]
inhibitor B-LOC [2.4595110416412354, -2.6196813583374023]
resistance, B-LOC [2.4982454776763916, -2.4517767429351807]
N348I B-LOC [2.0698680877685547, -1.9673476219177246]
was B-LOC [2.2548582553863525, -1.8805104494094849]
introduced B-LOC [2.259939432144165, -2.0088448524475098]
into B-LOC [2.1053593158721924, -2.0630722045898438]
HIV-1 B-LOC [2.0263988971710205, -2.2338335514068604]
molecular B-LOC [2.3738348484039307, -2.2067534923553467]
clones B-LOC [2.474815607070923, -1.9603626728057861]
containing B-LOC [2.5054547786712646, -2.0873606204986572]
different B-LOC [2.1942625045776367, -2.3227269649505615]
genetic B-LOC [2.247577667236328, -2.0424106121063232]
backbones. B-LOC [2.2395448684692383, -2.035762071609497]
N348I B-LOC [0.48267027735710144, -0.5150112509727478]
decreased B-LOC [0.5193192958831787, -0.7019850611686707]
zidovudine B-LOC [0.47574758529663086, -0.42355504631996155]
susceptibility B-LOC [0.48746630549430847, -0.5237576961517334]
2- O [-0.019537365064024925, -0.009193075820803642]
to B-LOC [-0.14062784612178802, -0.4073408246040344]
4-fold B-LOC [0.1087372750043869, -0.05115572735667229]
in B-LOC [0.4226706922054291, -0.5560846924781799]
the B-LOC [0.7360841035842896, -0.540826141834259]
context B-LOC [0.6633764505386353, -0.42744579911231995]
of B-LOC [0.63076251745224, -0.610696017742157]
wildtype B-LOC [0.5010591745376587, -0.6083235144615173]
HIV-1 B-LOC [0.6007358431816101, -0.8268807530403137]
or B-LOC [0.7826089262962341, -0.7259292602539062]
when B-LOC [0.5560715198516846, -0.5460989475250244]
combined B-LOC [0.7090076804161072, -0.532241702079773]
with B-LOC [0.7177640199661255, -0.6959653496742249]
TAMs. B-LOC [0.76368248462677, -0.7479376196861267]

N348I O [-0.5994703769683838, 0.40268662571907043]
also O [-1.0047613382339478, 0.9442612528800964]
decreased O [-0.9262577891349792, 0.9391511082649231]
susceptibility O [-0.9008451104164124, 0.9379767775535583]
to O [-0.7794337272644043, 0.6116707921028137]
nevirapine O [-0.808454692363739, 0.9721722602844238]
(7.4fold) O [-0.7507124543190002, 0.6169527173042297]
and O [-1.125586986541748, 0.9882546663284302]
efavirenz O [-1.001884937286377, 1.0277011394500732]
(2.5-fold) O [-0.7332327961921692, 0.6649096012115479]
and O [-1.0092641115188599, 0.9989010691642761]
significantly O [-0.9480895400047302, 1.0006929636001587]
potentiated O [-0.8428795337677002, 0.9877367615699768]
resistance O [-0.5689160823822021, 0.7723278999328613]
to O [-0.5139341354370117, 0.47346416115760803]
these O [-0.5398569107055664, 0.39943191409111023]
drugs O [-0.46686428785324097, 0.36480554938316345]
when O [-0.6202641129493713, 0.6270713806152344]
combined O [-0.35408923029899597, 0.7495164275169373]
with O [-0.42058542370796204, 0.7528035044670105]
K103N. O [-0.3579435348510742, 0.4250330924987793]
Biochemical B-LOC [1.9665679931640625, -1.9428691864013672]
analyses B-LOC [2.1287920475006104, -1.9589025974273682]
of B-LOC [2.1370694637298584, -1.8991093635559082]
recombinant B-LOC [2.184142589569092, -1.8162615299224854]
RT B-LOC [2.00512433052063, -2.023635149002075]
containing B-LOC [2.1786763668060303, -1.8740711212158203]
N348I B-LOC [1.7367709875106812, -1.8047139644622803]
provide B-LOC [2.379554510116577, -1.9861129522323608]
supporting B-LOC [2.2565009593963623, -2.199280023574829]
evidence B-LOC [2.183654546737671, -2.1663894653320312]
for B-LOC [2.1332051753997803, -2.0945513248443604]
the B-LOC [2.1323678493499756, -2.164935350418091]
role B-LOC [2.113774299621582, -2.359926462173462]
of B-LOC [2.0022356510162354, -2.0939860343933105]
this B-LOC [1.6785944700241089, -1.9501781463623047]
mutation B-LOC [1.7669036388397217, -2.1514976024627686]
in B-LOC [1.8889954090118408, -2.2403953075408936]
zidovudine B-LOC [1.8752963542938232, -2.013948678970337]
and B-LOC [2.057452440261841, -2.07344388961792]
NNRTI B-LOC [1.6492540836334229, -1.8443386554718018]
resistance B-LOC [2.0855321884155273, -2.10825514793396]
and B-LOC [1.9891842603683472, -1.9924430847167969]
give B-LOC [2.532284736633301, -2.2314915657043457]
some B-LOC [2.301741600036621, -2.2829511165618896]
insight B-LOC [2.2716476917266846, -2.416750192642212]
into B-LOC [2.3911237716674805, -2.281566858291626]
the B-LOC [2.3063559532165527, -2.406698226928711]
molecular B-LOC [2.3392553329467773, -2.419368028640747]
mechanism B-LOC [2.208618402481079, -2.5721726417541504]
of B-LOC [2.0670058727264404, -2.425931215286255]
resistance. B-LOC [2.2446539402008057, -2.3736042976379395]
Conclusions B-LOC [1.3504847288131714, -1.5246071815490723]

BACKGROUND B-LOC [2.362816572189331, -3.109032154083252]
Elderly B-LOC [3.4923698902130127, -3.6064372062683105]
and B-LOC [3.142482042312622, -3.4948747158050537]
frail B-LOC [3.4720160961151123, -3.6348674297332764]
patients B-LOC [3.5909578800201416, -3.725106954574585]
with B-LOC [3.502681016921997, -3.736701488494873]
cancer, B-LOC [3.638856887817383, -3.752793312072754]
although B-LOC [3.1497743129730225, -3.5091681480407715]
often B-LOC [3.295231342315674, -3.654512643814087]
treated B-LOC [3.6675667762756348, -3.796525716781616]
with B-LOC [3.325428009033203, -3.760941982269287]
chemotherapy, B-LOC [3.400967597961426, -3.858271837234497]
are B-LOC [3.22149920463562, -3.5880239009857178]
under-represented B-LOC [3.4525952339172363, -3.842331647872925]
in B-LOC [3.232656240463257, -3.83790922164917]
clinical B-LOC [3.7478482723236084, -3.940703868865967]
trials. B-LOC [3.608114004135132, -3.9636499881744385]
We B-LOC [3.2339742183685303, -3.6141912937164307]
designed B-LOC [3.4671218395233154, -3.483600616455078]
FOCUS2 B-LOC [3.3190762996673584, -3.643007278442383]
to B-LOC [3.4505114555358887, -3.5829107761383057]
investigate B-LOC [3.544685125350952, -3.735943078994751]
reduced-dose B-LOC [3.4258782863616943, -3.8604202270507812]
chemotherapy B-LOC [3.5177626609802246, -3.7909185886383057]
options B-LOC [3.7217607498168945, -3.7926077842712402]
and B-LOC [3.4437878131866455, -3.7551779747009277]
to B-LOC [3.5468180179595947, -3.7525794506073]
seek B-LOC [3.568608045578003, -3.8314871788024902]
objective B-LOC [3.5475521087646484, -3.9927186965942383]
predictors B-LOC [3.613075017929077, -3.983851432800293]
of B-LOC [3.5277276039123535, -3.872065305709839]
outcome B-LOC [3.598135232925415, -3.9462063312530518]
in B-LOC [3.5334560871124268, -3.8419880867004395]
frail B-LOC [3.550525426864624, -3.7555267810821533]
patients B-LOC [3.7053632736206055, -3.789013624191284]
with B-LOC [3.606783390045166, -3.878063678741455]
advanced B-LOC [3.4714953899383545, -4.045082092285156]
colorectal B-LOC [3.4189484119415283, -3.900740385055542]
cancer. B-LOC [3.5952439308166504, -3.6928820610046387]
METHODS B-LOC [2.506683111190796, -3.082585573196411]
We B-LOC [2.74684739112854, -3.031599760055542]
undertook B-LOC [3.2349188327789307, -3.0309927463531494]
an B-LOC [3.1075632572174072, -3.1439175605773926]
open, B-LOC [3.4747495651245117, -3.2446815967559814]
2 B-LOC [3.389096736907959, -3.234779119491577]
× B-LOC [3.1233468055725098, -3.259680986404419]
2 B-LOC [3.4254820346832275, -3.334956645965576]
factorial B-LOC [3.1589300632476807, -3.599940776824951]
trial B-LOC [3.280118703842163, -3.494579315185547]
in B-LOC [3.4039173126220703, -3.336888074874878]
61 B-LOC [3.54854679107666, -3.424389123916626]
UK B-LOC [3.4276082515716553, -3.245922803878784]
centres B-LOC [3.4297103881835938, -3.525228261947632]
for B-LOC [3.4859108924865723, -3.4280707836151123]
patients B-LOC [3.526353597640991, -3.4117794036865234]
with B-LOC [3.443046808242798, -3.3387279510498047]
previously B-LOC [3.3408052921295166, -3.524808168411255]
untreated B-LOC [3.4518301486968994, -3.5751137733459473]
advanced B-LOC [3.393656015396118, -3.6400980949401855]
colorectal B-LOC [3.2754058837890625, -3.49668025970459]
cancer B-LOC [3.444711923599243, -3.412379741668701]
who B-LOC [3.3797004222869873, -3.394207239151001]
were B-LOC [3.426537275314331, -3.4020707607269287]
considered B-LOC [3.620715856552124, -3.336944103240967]
unfit B-LOC [3.584001064300537, -3.475735664367676]
for B-LOC [3.1527392864227295, -3.406909227371216]
full-dose B-LOC [3.386996030807495, -3.6771159172058105]
chemotherapy. B-LOC [3.4348223209381104, -3.5679574012756348]
After B-LOC [2.600721597671509, -3.1227571964263916]
comprehensive B-LOC [3.1295511722564697, -3.041217803955078]
health B-LOC [2.972283124923706, -3.252519369125366]
assessment B-LOC [3.0144824981689453, -3.2481181621551514]
(CHA), B-LOC [2.7618701457977295, -3.2209455966949463]
patients B-LOC [3.0028626918792725, -3.255268096923828]
were B-LOC [2.782855749130249, -3.022167444229126]

randomly B-LOC [2.4647109508514404, -2.805981159210205]
assigned B-LOC [2.826657295227051, -2.9467155933380127]
by B-LOC [2.8640058040618896, -2.6863296031951904]
minimisation B-LOC [2.8020267486572266, -2.598252058029175]
to: B-LOC [2.827427625656128, -2.9994056224823]
48-h B-LOC [1.7917429208755493, -2.0293028354644775]
intravenous B-LOC [2.1726114749908447, -2.3842074871063232]
fluorouracil B-LOC [1.5826375484466553, -2.3736040592193604]
with B-LOC [1.8667701482772827, -2.1722023487091064]
levofolinate B-LOC [1.830479383468628, -1.9094752073287964]
(group B-LOC [2.4674184322357178, -2.640061855316162]
A); B-LOC [1.9290640354156494, -2.17972731590271]
oxaliplatin B-LOC [1.681828498840332, -2.048253297805786]
and B-LOC [1.8148064613342285, -2.0688374042510986]
fluorouracil B-LOC [1.2946559190750122, -2.132586717605591]
(group B-LOC [2.3392677307128906, -2.467420816421509]
B); B-LOC [1.9709231853485107, -2.01684308052063]
capecitabine B-LOC [1.4969823360443115, -1.9292652606964111]
(group B-LOC [2.275556802749634, -2.4619202613830566]
C); B-LOC [1.888394832611084, -2.040715456008911]
or B-LOC [2.7572243213653564, -3.040865182876587]
oxaliplatin B-LOC [2.478163719177246, -3.0633938312530518]
and B-LOC [2.314481735229492, -2.812960386276245]
capecitabine B-LOC [1.417754888534546, -1.8982306718826294]
(group B-LOC [2.553330659866333, -2.984072208404541]
D). B-LOC [2.420156240463257, -2.5038535594940186]
Treatment B-LOC [2.759044885635376, -3.2897627353668213]
allocation B-LOC [2.746856927871704, -3.4066367149353027]
was B-LOC [2.499675750732422, -2.8646609783172607]
not B-LOC [2.6903574466705322, -2.8959219455718994]
masked. B-LOC [2.888174295425415, -3.2237184047698975]
Starting B-LOC [2.689915180206299, -3.20746111869812]
doses B-LOC [2.9763944149017334, -2.970839738845825]
were B-LOC [2.943126678466797, -3.1231038570404053]
80% B-LOC [2.941152811050415, -3.1428840160369873]
of B-LOC [2.819719076156616, -3.4043986797332764]
standard B-LOC [3.0058019161224365, -3.503882884979248]
doses, B-LOC [3.052637815475464, -3.0899319648742676]
with B-LOC [3.125068426132202, -2.9927268028259277]
discretionary B-LOC [3.112229108810425, -3.350175142288208]
escalation B-LOC [2.946129083633423, -3.028414249420166]
to B-LOC [2.9347987174987793, -3.339711904525757]
full B-LOC [2.986577272415161, -3.2947568893432617]
dose B-LOC [3.089198112487793, -3.213641881942749]
after B-LOC [2.755753755569458, -3.2835776805877686]
6 B-LOC [2.9131476879119873, -3.0164759159088135]
weeks. B-LOC [3.147533416748047, -3.1367013454437256]
The B-LOC [2.032719612121582, -2.1329338550567627]
two B-LOC [1.615708589553833, -1.4994163513183594]
primary B-LOC [1.7915161848068237, -1.9765183925628662]
outcome B-LOC [1.2188966274261475, -1.5768367052078247]
measures B-LOC [1.6148521900177002, -1.705221176147461]
were: B-LOC [1.3443174362182617, -1.566798210144043]
addition B-LOC [0.8060545921325684, -1.01419997215271]
of B-LOC [0.7532733082771301, -1.1189602613449097]
oxaliplatin B-LOC [0.857068657875061, -1.0129237174987793]
([A B-LOC [0.7419347167015076, -0.8299267292022705]
vs B-LOC [0.5651330351829529, -0.9418923854827881]
B] B-LOC [0.5471442341804504, -0.8838306665420532]
+ B-LOC [0.6449803113937378, -1.2786624431610107]

[C B-LOC [1.0651559829711914, -2.0019116401672363]
vs B-LOC [1.548592209815979, -2.2472870349884033]
D]), B-LOC [1.8693286180496216, -2.1723954677581787]
assessed B-LOC [2.1011159420013428, -2.664104700088501]
with B-LOC [2.126763105392456, -2.4692351818084717]
progression-free B-LOC [2.0763394832611084, -2.5193443298339844]
survival B-LOC [2.1709401607513428, -2.531362533569336]
(PFS); B-LOC [2.2154672145843506, -2.7925660610198975]
and B-LOC [2.017420530319214, -2.4885284900665283]
substitution B-LOC [1.9728996753692627, -2.7104885578155518]
of B-LOC [1.9923408031463623, -2.7022273540496826]
fluorouracil B-LOC [2.0513381958007812, -2.806643009185791]
with B-LOC [2.0153558254241943, -2.6669061183929443]
capecitabine B-LOC [1.6810288429260254, -2.4912426471710205]
([A B-LOC [2.1160805225372314, -2.510915994644165]
vs B-LOC [1.3744248151779175, -2.0121991634368896]
C] B-LOC [1.4640626907348633, -2.146608591079712]
+ B-LOC [1.5815322399139404, -2.525045394897461]
[B B-LOC [1.7544344663619995, -2.4649834632873535]
vs B-LOC [1.4633616209030151, -2.116631269454956]
D]), B-LOC [1.677661418914795, -2.2181313037872314]
assessed B-LOC [2.422344923019409, -2.9885377883911133]
by B-LOC [2.605740785598755, -3.047990083694458]
change B-LOC [2.3092586994171143, -3.350046396255493]
from B-LOC [2.5788097381591797, -3.2562878131866455]
baseline B-LOC [2.7615764141082764, -3.40769362449646]
to B-LOC [2.483466625213623, -3.2952468395233154]
12 B-LOC [2.7594168186187744, -3.1390292644500732]
weeks B-LOC [2.7370340824127197, -3.219890594482422]
in B-LOC [2.412658452987671, -3.214357614517212]
global B-LOC [2.527553081512451, -3.3880507946014404]
quality B-LOC [2.88122296333313, -3.5713984966278076]
of B-LOC [2.8246347904205322, -3.133235216140747]
life B-LOC [2.6323325634002686, -3.169257879257202]
(QoL). B-LOC [2.7635695934295654, -3.417273998260498]
Analysis B-LOC [3.2498419284820557, -3.6133689880371094]
was B-LOC [3.0959649085998535, -3.2871005535125732]
by B-LOC [3.0373153686523438, -3.4313292503356934]
intention B-LOC [3.5001535415649414, -3.588606119155884]
to B-LOC [3.2500646114349365, -3.400134325027466]
treat. B-LOC [3.3762238025665283, -3.7737925052642822]
Baseline B-LOC [3.3835480213165283, -3.5443506240844727]
clinical B-LOC [3.408989191055298, -3.6771340370178223]
and B-LOC [3.101208448410034, -3.280621290206909]
CHA B-LOC [3.1389529705047607, -3.82513165473938]
data B-LOC [3.368757486343384, -3.5344057083129883]
were B-LOC [3.328718423843384, -3.153473377227783]
modelled B-LOC [3.577207326889038, -3.458981990814209]
against B-LOC [3.4946041107177734, -3.4166276454925537]
outcomes B-LOC [3.5053887367248535, -3.6693856716156006]
with B-LOC [3.5324203968048096, -3.1932737827301025]
a B-LOC [3.6027543544769287, -3.1071994304656982]
novel B-LOC [3.4454963207244873, -3.5192296504974365]
composite B-LOC [3.4417757987976074, -3.4622764587402344]
measure, B-LOC [3.517080545425415, -3.4821019172668457]
overall B-LOC [3.564145565032959, -3.544274091720581]
treatment B-LOC [3.426992177963257, -3.7159316539764404]
utility B-LOC [3.4946095943450928, -3.6555979251861572]
(OTU). B-LOC [3.452305555343628, -3.262423038482666]
This B-LOC [3.0534040927886963, -3.303952932357788]
study B-LOC [3.0860209465026855, -3.4134039878845215]
is B-LOC [3.389158248901367, -2.938642740249634]
registered, B-LOC [3.683518648147583, -3.231778383255005]
number B-LOC [3.4799411296844482, -3.3409011363983154]
ISRCTN21221452. B-LOC [3.421706199645996, -3.2735953330993652]
FINDINGS B-LOC [2.1077277660369873, -2.1440939903259277]
459 B-LOC [2.8575239181518555, -1.8707890510559082]

patients B-LOC [2.109973669052124, -2.8316726684570312]
were B-LOC [2.612285852432251, -3.036620855331421]
randomly B-LOC [2.9382386207580566, -3.302711248397827]
assigned B-LOC [2.916139602661133, -3.2592294216156006]
(115 B-LOC [2.558363676071167, -2.8108856678009033]
to B-LOC [2.5717852115631104, -3.147806406021118]
each B-LOC [2.9148380756378174, -3.1504786014556885]
of B-LOC [3.0700275897979736, -3.051377058029175]
groups B-LOC [2.721205472946167, -2.9823384284973145]
A-C, B-LOC [2.310359001159668, -2.6705784797668457]
114 B-LOC [2.5067100524902344, -2.7957513332366943]
to B-LOC [2.5590386390686035, -3.2872202396392822]
group B-LOC [2.901365041732788, -2.9651641845703125]
D). B-LOC [2.4700703620910645, -2.9811179637908936]
Factorial B-LOC [1.7599364519119263, -2.0816943645477295]
comparison B-LOC [1.6824696063995361, -1.7950090169906616]
of B-LOC [1.749511957168579, -1.979871392250061]
addition B-LOC [1.443009614944458, -1.6569403409957886]
of B-LOC [1.5008156299591064, -1.7609972953796387]
oxaliplatin B-LOC [1.3022544384002686, -1.4487762451171875]
versus B-LOC [1.5973320007324219, -1.7385997772216797]
no B-LOC [1.4644290208816528, -1.4673670530319214]
addition B-LOC [1.4895901679992676, -1.749659538269043]
suggested B-LOC [1.4049451351165771, -1.697679042816162]
some B-LOC [1.4214086532592773, -1.8320205211639404]
improvement B-LOC [1.4284837245941162, -2.110839605331421]
in B-LOC [1.4551935195922852, -1.8878380060195923]
PFS, B-LOC [1.4616444110870361, -1.9163105487823486]
but B-LOC [1.8372868299484253, -1.8828715085983276]
the B-LOC [2.01274037361145, -2.097787857055664]
finding B-LOC [1.7066049575805664, -2.0751006603240967]
was B-LOC [1.8697115182876587, -2.1437742710113525]
not B-LOC [2.1531646251678467, -1.9757575988769531]
significant B-LOC [2.000803232192993, -2.413661241531372]
(median B-LOC [1.059597373008728, -1.4777112007141113]
5·8 B-LOC [1.2840135097503662, -1.7972503900527954]
months B-LOC [1.345445156097412, -1.8319759368896484]
[IQR B-LOC [0.7921714186668396, -1.2755157947540283]
3·3-7·5] B-LOC [0.5896095037460327, -0.813300371170044]
vs B-LOC [1.1313693523406982, -1.5288100242614746]
4·5 B-LOC [0.6695331335067749, -0.9366758465766907]
months B-LOC [1.1453555822372437, -1.4702669382095337]
[2·8-6·4]; B-LOC [0.5990704894065857, -1.0502655506134033]
hazard B-LOC [1.0837247371673584, -1.5020580291748047]
ratio B-LOC [0.6461744904518127, -0.9833657145500183]
0·84, B-LOC [0.7648743987083435, -0.9879663586616516]
95% B-LOC [0.2676643133163452, -0.6538588404655457]
CI B-LOC [0.37314677238464355, -0.6708471179008484]
0·69-1·01, B-LOC [0.6227824687957764, -0.8038492202758789]
p=0·07). B-LOC [0.41072118282318115, -0.686421811580658]
Replacement B-LOC [0.913297712802887, -0.9748820066452026]
of B-LOC [0.8319048881530762, -0.7663403749465942]
fluorouracil B-LOC [0.5850505828857422, -1.1930491924285889]
with B-LOC [0.7978940010070801, -0.8511921167373657]
capecitabine B-LOC [0.640895426273346, -0.7897407412528992]
did B-LOC [0.4398840367794037, -0.9569156765937805]
not B-LOC [0.6164451241493225, -0.7426251769065857]
improve B-LOC [0.31587836146354675, -1.0857294797897339]
global B-LOC [0.39439597725868225, -0.6467203497886658]

QoL: B-LOC [0.8228465914726257, -0.984739363193512]
69 B-LOC [1.3176867961883545, -0.6544272899627686]
of B-LOC [0.9897945523262024, -0.568351686000824]
124 B-LOC [1.3812756538391113, -0.893436074256897]
(56%) B-LOC [1.0352048873901367, -0.8236352205276489]
patients B-LOC [0.7087063193321228, -0.6211615204811096]
receiving B-LOC [0.8267108798027039, -0.6567208170890808]
fluorouracil B-LOC [0.6228261590003967, -1.034535527229309]
reported B-LOC [0.6266130805015564, -0.40594151616096497]
improvement B-LOC [0.7428945899009705, -0.6343558430671692]
in B-LOC [0.6131817698478699, -0.4713238775730133]
global B-LOC [0.7376808524131775, -0.7157127261161804]
QoL B-LOC [0.9382529258728027, -0.8401098847389221]
compared B-LOC [0.44419410824775696, -0.4375156760215759]
with B-LOC [0.7731828093528748, -0.6741729974746704]
69 B-LOC [1.2857874631881714, -0.7357502579689026]
of B-LOC [0.9557726979255676, -0.7107873558998108]
123 B-LOC [1.3324540853500366, -0.9383820295333862]
(56%) B-LOC [0.9167008996009827, -0.994101345539093]
receiving B-LOC [0.735859215259552, -0.6468698978424072]
capecitabine. B-LOC [0.7907149195671082, -0.9583439230918884]
The B-LOC [0.038832176476716995, -0.25772079825401306]
risk B-LOC [-0.12212690711021423, -0.1586327701807022]
of O [-0.11846043169498444, -0.11440233141183853]
having B-LOC [-0.02157696895301342, -0.2237127125263214]
any O [-0.0744192823767662, -0.06990431249141693]
grade B-LOC [0.11816099286079407, -0.2577070891857147]
3 B-LOC [-0.0006943619227968156, -0.039587873965501785]
or B-LOC [-0.024749843403697014, -0.3275977075099945]
worse B-LOC [0.03185184672474861, -0.27933552861213684]
toxic B-LOC [0.14034292101860046, -0.399636834859848]
effect O [-0.15992861986160278, -0.07835861295461655]
was B-LOC [-0.17595767974853516, -0.2200453132390976]
not O [-0.10765021294355392, 0.11242617666721344]
significantly B-LOC [-0.14102257788181305, -0.14120016992092133]
increased B-LOC [0.01553343515843153, -0.17172566056251526]
with B-LOC [-0.08767092972993851, -0.1263808310031891]
oxaliplatin B-LOC [-0.06628762185573578, -0.14427025616168976]
(83/219 B-LOC [-0.03693419322371483, -0.11779134720563889]
[38%] B-LOC [-0.04296667501330376, -0.3003329932689667]
vs B-LOC [-0.25678229331970215, -0.3602348566055298]
70/221 B-LOC [0.08847427368164062, -0.08304081857204437]
[32%]; B-LOC [-0.02735733799636364, -0.3236641585826874]
p=0·17), B-LOC [-0.21615703403949738, -0.28324756026268005]
but O [-0.4206232726573944, 0.14755745232105255]
was O [-0.33209678530693054, -0.09371739625930786]
higher O [-0.16526073217391968, 0.1421051025390625]
with O [-0.10743284225463867, -0.05031619593501091]
capecitabine B-LOC [0.0003210851864423603, -0.3022170960903168]
than O [-0.3349952697753906, 0.10830888152122498]
with B-LOC [-0.08477751910686493, -0.13471642136573792]
fluorouracil B-LOC [-0.08119041472673416, -0.4623399078845978]
(88/222 B-LOC [-0.07840308547019958, -0.18555983901023865]
[40%] B-LOC [-0.09369229525327682, -0.19843347370624542]
vs B-LOC [-0.21886378526687622, -0.2595905661582947]
65/218 B-LOC [0.1391012966632843, -0.12833379209041595]
[30%]; B-LOC [-0.07864753901958466, -0.229420006275177]
p=0·03). B-LOC [-0.1296311914920807, -0.352662593126297]
In O [-0.30054327845573425, -0.16193684935569763]

multivariable B-LOC [0.3301074802875519, -0.6706397533416748]
analysis, B-LOC [1.0025880336761475, -1.1180155277252197]
fewer B-LOC [0.5909243226051331, -0.6795528531074524]
baseline B-LOC [1.019081711769104, -1.3892488479614258]
symptoms B-LOC [1.0441036224365234, -1.0970228910446167]
(odds B-LOC [0.7602418661117554, -0.9223929643630981]
ratio B-LOC [0.3785669803619385, -0.9187787771224976]
1·32, B-LOC [0.42283329367637634, -0.6966723799705505]
95% B-LOC [0.2551766335964203, -0.3866773247718811]
CI B-LOC [0.29450199007987976, -0.7403902411460876]
1·14-1·52), B-LOC [0.29509299993515015, -0.5812293887138367]
less B-LOC [0.6193771958351135, -0.6627452373504639]
widespread B-LOC [0.9913246035575867, -1.1859394311904907]
disease B-LOC [1.1367595195770264, -1.2911016941070557]
(1·51, B-LOC [1.1103920936584473, -1.2898097038269043]
1·05-2·19), B-LOC [0.8025925159454346, -1.2394094467163086]
and B-LOC [0.9428533911705017, -1.0553840398788452]
use B-LOC [1.3555729389190674, -1.492354154586792]
of B-LOC [1.3541327714920044, -1.4968864917755127]
oxaliplatin B-LOC [1.1864415407180786, -1.3269107341766357]
(0·57, B-LOC [1.5610918998718262, -1.6926192045211792]
0·39-0·82) B-LOC [1.765562653541565, -2.174297571182251]
were B-LOC [1.5073506832122803, -1.6242886781692505]
predictive B-LOC [1.9651669263839722, -2.1517012119293213]
of B-LOC [1.8323596715927124, -2.1785805225372314]
better B-LOC [1.8066060543060303, -2.161621570587158]
OTU. B-LOC [1.8469926118850708, -2.2485153675079346]
INTERPRETATION B-LOC [2.407536268234253, -2.4911067485809326]
FOCUS2 B-LOC [2.492988348007202, -2.5495121479034424]
shows B-LOC [2.5093233585357666, -2.5176491737365723]
that B-LOC [2.3885085582733154, -2.2621009349823]
with B-LOC [2.1840624809265137, -2.2591707706451416]
an B-LOC [2.585357666015625, -2.414414644241333]
appropriate B-LOC [2.551844835281372, -2.848588705062866]
design, B-LOC [2.9179627895355225, -2.7126686573028564]
including B-LOC [2.491074323654175, -2.409881591796875]
reduced B-LOC [2.251993417739868, -2.2982943058013916]
starting B-LOC [2.7344839572906494, -2.9567668437957764]
doses B-LOC [3.1073477268218994, -2.5039002895355225]
of B-LOC [2.810565710067749, -2.442286491394043]
chemotherapy, B-LOC [3.0799779891967773, -2.7376739978790283]
frail B-LOC [2.8895394802093506, -2.3329691886901855]
and B-LOC [2.424415349960327, -2.652850866317749]
elderly B-LOC [3.1162469387054443, -2.7235424518585205]
patients B-LOC [3.116701364517212, -2.842667818069458]
can B-LOC [3.0827977657318115, -2.5916106700897217]
participate B-LOC [3.0672054290771484, -3.005821943283081]
in B-LOC [3.0531294345855713, -2.749865770339966]
a B-LOC [2.9881350994110107, -2.6974236965179443]
randomised B-LOC [3.162653684616089, -3.0121042728424072]
controlled B-LOC [3.1077520847320557, -3.189202308654785]
trial. B-LOC [2.9671790599823, -3.089179754257202]
On B-LOC [2.3708713054656982, -2.3183982372283936]
balance, B-LOC [2.5668885707855225, -2.408898115158081]
a B-LOC [2.552276849746704, -2.5618841648101807]
combination B-LOC [2.333113431930542, -2.491356611251831]
including B-LOC [2.044759511947632, -2.001753807067871]

oxaliplatin O [-0.18775655329227448, 0.2650831937789917]
was O [-0.27099350094795227, 0.14014467597007751]
preferable O [-0.07453329116106033, 0.2544894814491272]
to O [-0.05502304062247276, 0.17110124230384827]
single-agent B-LOC [0.003737280610948801, -0.0030458965338766575]
fluoropyrimidines, B-LOC [-0.08346590399742126, -0.4571012556552887]
although O [-0.17982567846775055, -0.14843271672725677]
the B-LOC [-0.0006419545388780534, -0.16565869748592377]
primary B-LOC [-0.06366852670907974, -0.2052621841430664]
endpoint B-LOC [-0.049185384064912796, -0.21465124189853668]
of O [-0.2505854666233063, -0.19935093820095062]
PFS B-LOC [-0.10854403674602509, -0.13384389877319336]
was B-LOC [-0.18166162073612213, -0.20653823018074036]
not B-LOC [0.034047845751047134, -0.02820020169019699]
met. B-LOC [-0.05418519675731659, -0.21481648087501526]
Capecitabine B-LOC [0.10108452290296555, -0.10977952927350998]
did B-LOC [0.02320658601820469, -0.07853757590055466]
not B-LOC [0.21082207560539246, 0.029797064140439034]
improve B-LOC [0.03129616007208824, -0.347476989030838]
QoL B-LOC [0.1694456934928894, -0.23947924375534058]
compared O [-0.08434775471687317, 0.21688541769981384]
with B-LOC [0.266037255525589, -0.22330912947654724]
fluorouracil. B-LOC [0.0792359933257103, -0.5473269820213318]
Comprehensive B-LOC [3.234999895095825, -3.2033097743988037]
baseline B-LOC [3.309135913848877, -3.6137802600860596]
assessment B-LOC [3.149209499359131, -3.395286798477173]
holds B-LOC [3.3080074787139893, -2.9769718647003174]
promise B-LOC [3.316711902618408, -3.2494914531707764]
as B-LOC [3.2581942081451416, -3.2109203338623047]
an B-LOC [3.35357666015625, -3.3283820152282715]
objective B-LOC [3.401162624359131, -3.609220027923584]
predictor B-LOC [3.4335031509399414, -3.6377079486846924]
of B-LOC [3.192106008529663, -3.2467567920684814]
treatment B-LOC [3.4128620624542236, -3.5597736835479736]
benefit. B-LOC [3.4449384212493896, -3.6679954528808594]
FUNDING B-LOC [2.5860707759857178, -2.5872020721435547]
Cancer B-LOC [2.8555164337158203, -3.0635483264923096]
Research B-LOC [2.721155881881714, -2.7348110675811768]
UK B-LOC [2.7772486209869385, -2.5205564498901367]
and B-LOC [2.847210645675659, -2.738717794418335]
the B-LOC [2.845155954360962, -2.852238893508911]
Medical B-LOC [3.043128728866577, -3.1519534587860107]
Research B-LOC [2.877338409423828, -2.9987571239471436]
Council. B-LOC [3.020883798599243, -2.8805954456329346]

OBJECTIVE B-LOC [3.1834428310394287, -3.629301071166992]
To B-LOC [3.2540032863616943, -3.69492506980896]
determine B-LOC [3.4301388263702393, -3.5251808166503906]
whether B-LOC [3.1985082626342773, -3.51488995552063]
ultrasound B-LOC [3.1589882373809814, -3.327955961227417]
imaging B-LOC [2.380035161972046, -2.6954195499420166]
can B-LOC [2.5755162239074707, -3.076965808868408]
reduce B-LOC [2.4655330181121826, -3.134510040283203]
the B-LOC [3.1844842433929443, -3.4554436206817627]
risk B-LOC [2.890432834625244, -3.2526919841766357]
of B-LOC [2.608330249786377, -3.0036027431488037]
failed B-LOC [2.5015742778778076, -2.9607224464416504]
lumbar B-LOC [3.215756416320801, -3.3302652835845947]
punctures B-LOC [2.8088223934173584, -3.030640125274658]
or B-LOC [2.415269374847412, -3.0103163719177246]
epidural B-LOC [2.9235780239105225, -3.3338000774383545]
catheterisations, B-LOC [2.9567043781280518, -3.4400393962860107]
when B-LOC [2.7708334922790527, -3.407879114151001]
compared B-LOC [2.4834365844726562, -3.186218738555908]
with B-LOC [2.204711675643921, -3.0821635723114014]
standard B-LOC [2.685499429702759, -3.2161927223205566]
palpation B-LOC [2.9624674320220947, -3.498363971710205]
methods, B-LOC [2.8531980514526367, -3.1085517406463623]
and B-LOC [3.037194013595581, -3.221184253692627]
whether B-LOC [3.085446357727051, -3.6016294956207275]
ultrasound B-LOC [3.10795259475708, -3.371013879776001]
imaging B-LOC [2.625995397567749, -2.922922372817993]
can B-LOC [2.8541147708892822, -3.3101966381073]
reduce B-LOC [2.715822458267212, -3.3105366230010986]
traumatic B-LOC [3.1990082263946533, -3.509350299835205]
procedures, B-LOC [3.2874157428741455, -3.3977792263031006]
insertion B-LOC [3.105275869369507, -3.5240044593811035]
attempts, B-LOC [3.1036131381988525, -3.30619740486145]
and B-LOC [2.9660305976867676, -3.349452018737793]
needle B-LOC [3.2412514686584473, -3.831822395324707]
redirections. B-LOC [3.145805835723877, -3.6485140323638916]
DESIGN B-LOC [3.7353649139404297, -3.3109452724456787]
Systematic B-LOC [3.457432270050049, -2.7598764896392822]
review B-LOC [3.625281572341919, -2.993304491043091]
and B-LOC [3.5278964042663574, -2.8977577686309814]
meta-analysis B-LOC [3.6702771186828613, -3.0722780227661133]
of B-LOC [3.7544867992401123, -3.225693702697754]
randomised B-LOC [3.891855478286743, -3.2460169792175293]
controlled B-LOC [3.9109442234039307, -3.455810308456421]
trials. B-LOC [3.9695653915405273, -3.2563624382019043]
DATA B-LOC [3.7016701698303223, -3.2633068561553955]
SOURCES B-LOC [3.266188621520996, -2.9613542556762695]
Ovid B-LOC [3.134760856628418, -2.723398447036743]
Medline, B-LOC [3.1062405109405518, -2.5711724758148193]
Embase, B-LOC [3.2793238162994385, -2.9091951847076416]
and B-LOC [3.113947629928589, -2.6424686908721924]
Cochrane B-LOC [3.3980367183685303, -3.2643649578094482]
Central B-LOC [3.346979856491089, -3.253469228744507]
Register B-LOC [3.2818641662597656, -2.98716139793396]
of B-LOC [3.1831557750701904, -2.8391430377960205]
Controlled B-LOC [3.586500406265259, -3.159095048904419]
Trials B-LOC [3.550304889678955, -2.8773467540740967]
up B-LOC [3.4401121139526367, -2.8176400661468506]
to B-LOC [3.408550500869751, -2.6069047451019287]
May B-LOC [3.623884439468384, -2.7701468467712402]
2012, B-LOC [3.412208080291748, -2.899975061416626]
without B-LOC [3.2694740295410156, -2.99534273147583]
restriction B-LOC [3.1623525619506836, -2.98299503326416]
by B-LOC [2.929900646209717, -2.899362564086914]
language B-LOC [3.272033929824829, -2.990901231765747]
or B-LOC [3.068382978439331, -2.9902737140655518]
publication B-LOC [3.2324774265289307, -3.2275609970092773]
status. B-LOC [3.425713539123535, -3.0342023372650146]
REVIEW B-LOC [1.583683967590332, -2.315502166748047]
METHODS B-LOC [1.0414750576019287, -1.6908724308013916]

Randomised B-LOC [3.514028310775757, -4.049013137817383]
trials B-LOC [3.6266589164733887, -3.977226972579956]
that B-LOC [3.5305330753326416, -3.9233925342559814]
compared B-LOC [3.5533676147460938, -4.059719085693359]
ultrasound B-LOC [3.573018789291382, -4.0479841232299805]
imaging B-LOC [3.2333714962005615, -4.058858871459961]
with B-LOC [3.537907361984253, -4.032328128814697]
standard B-LOC [3.4217240810394287, -4.205643653869629]
methods B-LOC [3.501772403717041, -4.145233631134033]
(no B-LOC [3.6482975482940674, -3.8650896549224854]
imaging) B-LOC [3.1906025409698486, -4.147122859954834]
in B-LOC [3.4547221660614014, -4.086987018585205]
the B-LOC [3.5408742427825928, -3.9440200328826904]
performance B-LOC [3.5531883239746094, -4.1666412353515625]
of B-LOC [3.4136033058166504, -3.978753089904785]
a B-LOC [3.4907116889953613, -4.118460655212402]
lumbar B-LOC [3.3357620239257812, -3.999130964279175]
puncture B-LOC [3.2553346157073975, -3.9959893226623535]
or B-LOC [3.4592111110687256, -4.069820880889893]
epidural B-LOC [3.4522552490234375, -4.184976100921631]
catheterisation B-LOC [3.292152166366577, -4.270817756652832]
were B-LOC [3.6759049892425537, -3.819324493408203]
identified. B-LOC [3.730638265609741, -3.9157845973968506]
RESULTS B-LOC [3.1617257595062256, -3.6427407264709473]
14 B-LOC [3.460615396499634, -3.6350157260894775]
studies B-LOC [3.1903398036956787, -3.825632095336914]
with B-LOC [3.2949297428131104, -3.610579252243042]
a B-LOC [3.318830966949463, -3.468851089477539]
total B-LOC [3.5630784034729004, -3.517855167388916]
of B-LOC [3.2835991382598877, -3.480271339416504]
1334 B-LOC [3.5385751724243164, -3.6168160438537598]
patients B-LOC [3.4142868518829346, -3.9451775550842285]
were B-LOC [3.1450002193450928, -3.555856466293335]
included B-LOC [3.3977978229522705, -3.927013874053955]
(674 B-LOC [3.287964105606079, -3.670053243637085]
patients B-LOC [3.4404067993164062, -3.9285154342651367]
assigned B-LOC [3.4381675720214844, -3.7908804416656494]
to B-LOC [3.332685708999634, -3.6507601737976074]
the B-LOC [3.353268623352051, -3.5022337436676025]
ultrasound B-LOC [3.4351072311401367, -3.937783718109131]
group, B-LOC [3.4933342933654785, -3.7654590606689453]
660 B-LOC [3.3009321689605713, -3.7657477855682373]
to B-LOC [3.2091312408447266, -3.8508310317993164]
the B-LOC [3.3386387825012207, -3.6458587646484375]
control B-LOC [3.4321272373199463, -3.9261369705200195]
group). B-LOC [3.371643304824829, -3.774306058883667]
Five B-LOC [3.452751398086548, -3.6498420238494873]
studies B-LOC [3.509056806564331, -3.4584336280822754]
evaluated B-LOC [3.5714869499206543, -3.656782865524292]
lumbar B-LOC [3.5339133739471436, -3.8205771446228027]
punctures B-LOC [3.4977684020996094, -3.7929630279541016]
and B-LOC [3.4992592334747314, -3.560620069503784]
nine B-LOC [3.6566109657287598, -3.717785358428955]
evaluated B-LOC [3.6371772289276123, -3.900526523590088]
epidural B-LOC [3.6579692363739014, -3.9715611934661865]
catheterisations. B-LOC [3.5247833728790283, -4.081330299377441]
Six B-LOC [3.3112637996673584, -3.5650851726531982]
of B-LOC [3.122875928878784, -3.2762608528137207]
624 B-LOC [3.606238603591919, -3.323223352432251]
procedures B-LOC [3.1870198249816895, -3.6745312213897705]
conducted B-LOC [3.421550750732422, -3.6734001636505127]
in B-LOC [3.161834478378296, -3.457064390182495]
the B-LOC [3.258054733276367, -3.31020450592041]
ultrasound B-LOC [3.477107524871826, -3.7124288082122803]
group B-LOC [3.5328304767608643, -3.485917806625366]
failed; B-LOC [3.378328323364258, -3.7356483936309814]
44 B-LOC [3.2721571922302246, -3.0959322452545166]
of B-LOC [2.7886476516723633, -3.042762517929077]
610 B-LOC [3.2887485027313232, -3.034700870513916]
procedures B-LOC [3.00140118598938, -3.3630034923553467]
in B-LOC [3.1909382343292236, -3.2559821605682373]
the B-LOC [3.305635690689087, -3.2189300060272217]
control B-LOC [3.487475633621216, -3.721886396408081]
group B-LOC [3.3717215061187744, -3.3487555980682373]
failed. B-LOC [3.312305450439453, -3.523076057434082]
Ultrasound B-LOC [0.047653887420892715, -0.1335228532552719]
imaging O [0.005153635982424021, 0.028575634583830833]
reduced O [-0.1217305138707161, 0.0472838319838047]
the B-LOC [-0.13624316453933716, -0.1592169851064682]
risk B-LOC [-0.06459175795316696, -0.23441825807094574]
of B-LOC [-0.0629529356956482, -0.3855654299259186]
failed B-LOC [0.5300773978233337, -0.88424152135849]
procedures B-LOC [0.35862037539482117, -0.8651769757270813]
(risk B-LOC [0.16544391214847565, -0.4068913161754608]
ratio B-LOC [0.19742271304130554, -0.7749606966972351]

0.21 B-LOC [0.07166042923927307, -0.4396381676197052]
(95% B-LOC [0.06451480835676193, -0.45439276099205017]
confidence B-LOC [-0.07373625785112381, -0.17245449125766754]
interval B-LOC [-0.15264561772346497, -0.2769533693790436]
0.10 B-LOC [-0.08567154407501221, -0.29458844661712646]
to B-LOC [-0.044607799500226974, -0.4550606608390808]
0.43), B-LOC [0.15644825994968414, -0.5160189270973206]
P<0.001). B-LOC [-0.005915386136621237, -0.3103034496307373]
Risk B-LOC [0.6367101073265076, -0.9056476354598999]
reduction B-LOC [0.7368060350418091, -0.9831126928329468]
was B-LOC [0.6704680323600769, -0.9840984344482422]
similar B-LOC [0.6635101437568665, -0.8381333351135254]
when B-LOC [0.6211711168289185, -0.829909086227417]
subgroup B-LOC [0.6980059742927551, -0.6530928015708923]
analysis B-LOC [0.6823469400405884, -0.7798183560371399]
was B-LOC [0.700954258441925, -0.9607935547828674]
performed B-LOC [0.67924964427948, -0.8962045907974243]
for B-LOC [0.6748220324516296, -0.9103110432624817]
lumbar B-LOC [0.618243396282196, -0.6786084771156311]
punctures B-LOC [0.43338873982429504, -0.6452980637550354]
(risk B-LOC [0.48338988423347473, -0.5864372849464417]
ratio B-LOC [0.3641109764575958, -0.796797513961792]
0.19 B-LOC [0.5087752938270569, -0.8818591237068176]
(0.07 B-LOC [0.3775177001953125, -0.804089367389679]
to B-LOC [0.24890382587909698, -0.8552073836326599]
0.56), B-LOC [0.6122719645500183, -0.9020254015922546]
P=0.002) B-LOC [0.15248340368270874, -0.6118031144142151]
or B-LOC [0.6461186408996582, -0.8574256300926208]
epidural B-LOC [0.3850523829460144, -0.5979866981506348]
catheterisations B-LOC [0.4947102963924408, -0.7163853049278259]
(0.23 B-LOC [0.4702414572238922, -0.6349328756332397]
(0.09 B-LOC [0.35786598920822144, -0.8281907439231873]
to B-LOC [0.1496802419424057, -0.7101538181304932]
0.60), B-LOC [0.398958683013916, -0.7987269759178162]
P=0.003). B-LOC [0.14656980335712433, -0.5774022340774536]
Ultrasound O [-0.33608564734458923, 0.2832612693309784]
imaging O [-0.3489771783351898, 0.432709276676178]
also O [-0.5488312840461731, 0.4252043664455414]
significantly O [-0.48575708270072937, 0.487114280462265]
reduced O [-0.40051189064979553, 0.4155939221382141]
the O [-0.549021303653717, 0.33831512928009033]
risk O [-0.5420687198638916, 0.315314382314682]
of O [-0.5754642486572266, 0.3566780388355255]
traumatic O [-0.35100606083869934, 0.27498555183410645]
procedures O [-0.5589190721511841, 0.28332987427711487]
(risk O [-0.5845860838890076, 0.2392846792936325]
ratio O [-0.487058162689209, 0.0356084443628788]
0.27 O [-0.34120145440101624, -0.01887737400829792]
(0.11 O [-0.37613192200660706, -0.14960551261901855]
to O [-0.3802860379219055, -0.2722812294960022]
0.67), B-LOC [0.029569854959845543, -0.2798989713191986]
P=0.005), O [-0.4428921043872833, 0.0936553031206131]

the O [-0.3827967047691345, 0.24870523810386658]
number O [-0.2340136617422104, 0.11640626192092896]
of O [-0.24835646152496338, -0.012638973072171211]
insertion O [-0.15006837248802185, 0.0371009036898613]
attempts O [-0.18700455129146576, 0.13675838708877563]
(mean O [-0.35603997111320496, 0.112188920378685]
difference O [-0.46206697821617126, -0.003314065281301737]
-0.44 O [-0.497409850358963, -0.04718548431992531]
(-0.64 O [-0.2871258556842804, -0.10342659056186676]
to O [-0.354934960603714, -0.2359936535358429]
-0.24), O [-0.480160117149353, -0.024896161630749702]
P<0.001), O [-0.4546438157558441, 0.10848624259233475]
and O [-0.2621491551399231, 0.1756901741027832]
the O [-0.2880890965461731, 0.1598566621541977]
number O [-0.22191917896270752, 0.17423167824745178]
of O [-0.2568623125553131, 0.02614457719027996]
needle O [-0.2664116621017456, 0.07776154577732086]
redirections O [-0.2519983649253845, -0.08331965655088425]
(mean O [-0.36576786637306213, 0.08889126032590866]
difference O [-0.4326423704624176, 0.009697167202830315]
-1.00 O [-0.5070531964302063, -0.026470329612493515]
(-1.24 O [-0.30999496579170227, -0.09677323698997498]
to O [-0.3902674913406372, -0.17096027731895447]
-0.75), O [-0.5053636431694031, -0.015973011031746864]
P<0.001). O [-0.4271942675113678, 0.13067853450775146]
CONCLUSIONS O [-0.816521942615509, 0.5472370982170105]
Ultrasound O [-0.33317431807518005, 0.4160686433315277]
imaging O [-0.32469600439071655, 0.321154922246933]
can O [-0.6076028943061829, 0.4212855398654938]
reduce O [-0.5250374674797058, 0.5149980783462524]
the O [-0.643765389919281, 0.4191644787788391]
risk O [-0.45907020568847656, 0.3792562782764435]
of O [-0.6388260722160339, 0.3758305013179779]
failed O [-0.6491245627403259, 0.45132961869239807]
or O [-0.6803954243659973, 0.08075997233390808]
traumatic O [-0.7133013606071472, 0.2242189347743988]
lumbar O [-0.46018311381340027, 0.1268589347600937]
punctures O [-0.5218587517738342, 0.27259930968284607]
and O [-0.667556881904602, 0.3578834533691406]
epidural O [-0.6888391971588135, 0.31461283564567566]
catheterisations, O [-0.5137790441513062, 0.25233912467956543]
as O [-0.23995882272720337, 0.2440665066242218]
well O [-0.3848133087158203, 0.29087454080581665]
as O [-0.30606675148010254, 0.3516542911529541]
the O [-0.38997480273246765, 0.012766538187861443]
number O [-0.3425762951374054, 0.04505659267306328]
of O [-0.37824636697769165, -0.03319266811013222]
needle O [-0.3213483989238739, -0.22566480934619904]
insertions O [-0.1158270537853241, -0.09823652356863022]
and B-LOC [-0.11685911566019058, -0.2182064652442932]
redirections. O [-0.35013899207115173, -0.14585894346237183]
Ultrasound B-LOC [0.7172143459320068, -1.0570967197418213]
may B-LOC [1.0751010179519653, -1.3277335166931152]
be B-LOC [1.0334339141845703, -1.4204833507537842]
a B-LOC [1.0134292840957642, -1.2375341653823853]
useful B-LOC [0.8485546708106995, -1.2783952951431274]
adjunct B-LOC [0.9090301990509033, -1.0362658500671387]
for B-LOC [0.6925720572471619, -1.0492361783981323]

these B-LOC [0.15895360708236694, -0.6041548252105713]
procedures. B-LOC [0.24048928916454315, -0.699009120464325]

Successful B-LOC [1.8837519884109497, -2.5187652111053467]
pregnancy B-LOC [1.7715214490890503, -2.27158784866333]
requires B-LOC [1.9770894050598145, -2.6837317943573]
coordination B-LOC [2.291043996810913, -2.6235134601593018]
of B-LOC [2.3880081176757812, -2.9123589992523193]
an B-LOC [2.265641450881958, -2.6038389205932617]
array B-LOC [2.4904696941375732, -2.7262535095214844]
of B-LOC [2.468472957611084, -2.7053823471069336]
signals B-LOC [2.2658538818359375, -2.8858537673950195]
and B-LOC [2.5786802768707275, -2.8917529582977295]
factors B-LOC [2.6408610343933105, -3.082562208175659]
from B-LOC [2.4427316188812256, -2.8371598720550537]
multiple B-LOC [2.2613563537597656, -2.9195735454559326]
tissues. B-LOC [2.6229798793792725, -2.9220621585845947]
One B-LOC [2.248176336288452, -2.5578057765960693]
such B-LOC [2.3786697387695312, -2.373167037963867]
element, B-LOC [2.0971262454986572, -2.487802743911743]
liver B-LOC [1.6011898517608643, -2.2581355571746826]
receptor B-LOC [1.8446741104125977, -2.6274375915527344]
homolog-1 B-LOC [2.0667479038238525, -2.598863363265991]
(Lrh-1), B-LOC [2.4665420055389404, -2.539501428604126]
is B-LOC [2.5379812717437744, -2.513410806655884]
an B-LOC [2.5685222148895264, -2.653907537460327]
orphan B-LOC [2.6773178577423096, -2.7350382804870605]
nuclear B-LOC [2.1764862537384033, -2.826094388961792]
receptor B-LOC [2.2257111072540283, -2.810912847518921]
that B-LOC [2.163921356201172, -2.5935986042022705]
regulates B-LOC [2.50593638420105, -2.5718472003936768]
metabolism B-LOC [2.3142056465148926, -2.4883031845092773]
and B-LOC [2.3707916736602783, -2.4821951389312744]
hormone B-LOC [2.084815502166748, -2.8116066455841064]
synthesis. B-LOC [2.378824234008789, -2.4628875255584717]
It B-LOC [2.1484334468841553, -2.412083148956299]
is B-LOC [2.30338716506958, -2.2696094512939453]
strongly B-LOC [2.1232376098632812, -2.154496908187866]
expressed B-LOC [1.960521936416626, -1.872668743133545]
in B-LOC [1.693273901939392, -1.8414902687072754]
granulosa B-LOC [1.793639063835144, -1.6532669067382812]
cells B-LOC [1.4648551940917969, -1.6486222743988037]
of B-LOC [1.4467467069625854, -1.5245766639709473]
ovarian B-LOC [1.9070082902908325, -2.2290964126586914]
follicles B-LOC [1.6040432453155518, -1.721814513206482]
and B-LOC [1.2204136848449707, -1.374044418334961]
in B-LOC [1.2978906631469727, -1.5155099630355835]
the B-LOC [1.5088021755218506, -1.3232121467590332]
corpus B-LOC [1.6270158290863037, -1.8316105604171753]
luteum B-LOC [1.6097599267959595, -1.6810669898986816]
of B-LOC [1.3410570621490479, -1.7472715377807617]
rodents B-LOC [1.631288766860962, -2.535552740097046]
and B-LOC [1.501704216003418, -2.092161178588867]
humans. B-LOC [1.8342475891113281, -2.375328779220581]
Germline B-LOC [0.1296565979719162, -0.27611830830574036]
ablation B-LOC [0.2549770176410675, -0.23584622144699097]
of B-LOC [0.10021284222602844, -0.040497053414583206]
Nr5a2 B-LOC [0.051217351108789444, -0.38592997193336487]
(also B-LOC [0.20254607498645782, -0.2895626425743103]
called B-LOC [0.42327338457107544, -0.585286557674408]
Lrh-1), B-LOC [0.19670037925243378, -0.42814114689826965]
the B-LOC [0.18880248069763184, -0.4184536933898926]
gene B-LOC [0.062183115631341934, -0.5188972353935242]
coding B-LOC [0.019434267655014992, -0.34100401401519775]
for B-LOC [0.20536547899246216, -0.47757458686828613]
Lrh-1, B-LOC [0.2581143081188202, -0.396508127450943]
in B-LOC [0.12423497438430786, -0.2457001507282257]
mice B-LOC [0.005467234645038843, -0.43526771664619446]
is B-LOC [0.4191400110721588, -0.6896260380744934]
embryonically B-LOC [0.01257824432104826, -0.43577682971954346]
lethal B-LOC [0.2693125009536743, -0.7075467109680176]
at B-LOC [0.16877968609333038, -0.6470609307289124]

gastrulation. B-LOC [0.03509354218840599, -0.8152438998222351]
Depletion B-LOC [0.7087656855583191, -0.5188936591148376]
of B-LOC [0.5721628069877625, -0.5046057105064392]
Lrh-1 B-LOC [0.40570351481437683, -0.6145457625389099]
in B-LOC [0.5232923626899719, -0.5456801056861877]
the B-LOC [0.49123576283454895, -0.498367041349411]
ovarian B-LOC [0.4054836332798004, -0.7144930958747864]
follicle B-LOC [0.3713034689426422, -0.6745747327804565]
shows B-LOC [0.4160713255405426, -0.41277238726615906]
that B-LOC [0.3808220624923706, -0.6509241461753845]
it B-LOC [0.4416900873184204, -0.707808256149292]
regulates B-LOC [0.6240053772926331, -0.5870025157928467]
genes B-LOC [0.4437805116176605, -0.5432621836662292]
required B-LOC [0.35548338294029236, -0.6526332497596741]
for B-LOC [0.2534775733947754, -0.6813812851905823]
both B-LOC [0.42763516306877136, -0.4679480791091919]
steroid B-LOC [0.314454585313797, -0.8041288256645203]
synthesis B-LOC [0.45316794514656067, -0.33180728554725647]
and B-LOC [0.6197399497032166, -0.5108550786972046]
ovulation. B-LOC [0.38267919421195984, -0.7212617993354797]
To B-LOC [1.8028316497802734, -1.8687750101089478]
study B-LOC [2.0228114128112793, -2.0965142250061035]
the B-LOC [2.4385390281677246, -2.460545778274536]
effects B-LOC [2.0271451473236084, -2.2659084796905518]
of B-LOC [1.5929418802261353, -1.6853591203689575]
Lrh-1 B-LOC [1.2536299228668213, -1.4424185752868652]
on B-LOC [1.8065438270568848, -2.194122791290283]
mouse B-LOC [1.509293556213379, -1.980570912361145]
gestation, B-LOC [1.9567725658416748, -2.1434407234191895]
we B-LOC [1.789635181427002, -1.7521675825119019]
genetically B-LOC [1.9609979391098022, -1.9018807411193848]
disrupted B-LOC [1.3941270112991333, -1.6846835613250732]
its B-LOC [1.3713825941085815, -1.6905828714370728]
expression B-LOC [1.4073699712753296, -1.6066195964813232]
in B-LOC [1.4996001720428467, -1.6705844402313232]
the B-LOC [1.4081395864486694, -1.6435093879699707]
corpus B-LOC [1.4025609493255615, -1.7185992002487183]
luteum, B-LOC [1.4641786813735962, -1.680356740951538]
resulting B-LOC [1.2401103973388672, -1.3674468994140625]
in B-LOC [1.4111628532409668, -1.688154697418213]
luteal B-LOC [1.5539610385894775, -1.7282308340072632]
insufficiency. B-LOC [1.5871542692184448, -1.6627734899520874]
Hormone O [-0.7490609288215637, 0.8143134117126465]
replacement O [-0.7303180694580078, 0.9357731342315674]
permitted O [-1.016469120979309, 0.8700420260429382]
embryo O [-0.7865971922874451, 0.9151695370674133]
implantation O [-0.7684788107872009, 0.8257654309272766]
but O [-0.7913329005241394, 0.6751410365104675]
was O [-0.8350318074226379, 0.8419886231422424]
followed O [-0.9297923445701599, 0.8984360098838806]
by O [-0.8936801552772522, 0.789554238319397]
gestational O [-0.8437073826789856, 0.9581506848335266]
failure O [-0.740595817565918, 0.9574713706970215]
with O [-1.02801513671875, 0.883046567440033]
impaired O [-1.011616826057434, 0.8008366227149963]
endometrial O [-0.954703152179718, 1.0889536142349243]
decidualization, O [-0.9186928868293762, 1.0487669706344604]
compromised O [-1.0916321277618408, 0.7425428032875061]
placental O [-0.68483966588974, 0.9421889185905457]
formation, O [-0.7588085532188416, 1.062720775604248]
fetal O [-1.0186502933502197, 0.915634274482727]
growth O [-0.7698126435279846, 1.0503885746002197]
retardation O [-0.9745399951934814, 1.1224961280822754]
and O [-0.784529983997345, 0.8965429067611694]
fetal O [-0.9498834013938904, 0.9070047736167908]
death. O [-0.744102954864502, 0.8385105729103088]

Lrh-1 O [-0.6054214835166931, 0.15381397306919098]
is O [-0.8532745242118835, 0.7409024834632874]
also O [-0.9065435528755188, 0.7582859396934509]
expressed O [-0.7308714985847473, 0.7699041366577148]
in O [-0.9374305009841919, 0.8459336757659912]
the O [-0.9187487363815308, 0.9839156270027161]
mouse O [-0.8699241280555725, 0.8356316685676575]
and O [-0.9865870475769043, 0.6743319630622864]
human O [-0.8392665982246399, 0.6426516175270081]
endometrium, O [-0.9267899394035339, 0.7869976758956909]
and O [-1.0326402187347412, 0.7935211062431335]
in O [-1.1115777492523193, 0.8310713171958923]
a O [-1.0321941375732422, 0.7942196726799011]
primary O [-0.9993137717247009, 0.9570598602294922]
culture O [-0.7739074230194092, 0.8372941613197327]
of O [-1.1175823211669922, 0.7989824414253235]
human O [-0.9126966595649719, 0.8259238004684448]
endometrial O [-1.0066639184951782, 0.8084830045700073]
stromal O [-0.9894402623176575, 0.7789660096168518]
cells, O [-0.8377044796943665, 0.8751447200775146]
reduction O [-0.9200208783149719, 0.881827175617218]
of O [-1.082094430923462, 0.8034692406654358]
NR5A2 O [-0.823634922504425, 0.7167644500732422]
transcript O [-0.9843873977661133, 0.97291499376297]
abundance O [-0.8163028955459595, 1.072869062423706]
by O [-0.9947017431259155, 0.9564960598945618]
RNA O [-0.5738329291343689, 0.6733877062797546]
interference O [-0.6537141799926758, 0.9505728483200073]
abrogated O [-0.9527305960655212, 1.007420301437378]
decidualization. O [-0.836783766746521, 0.9818208813667297]
These B-LOC [0.061710868030786514, -0.11894866824150085]
findings B-LOC [0.07355132699012756, -0.054396796971559525]
show O [-0.1420748233795166, 0.14062891900539398]
that O [-0.42471328377723694, 0.005665970500558615]
Lrh-1 O [-0.06709972769021988, -0.05883133038878441]
is O [-0.2119847685098648, 0.13320408761501312]
necessary O [-0.2639888823032379, 0.1514776051044464]
for O [-0.5404213070869446, 0.1823890209197998]
maintenance O [-0.2594018578529358, 0.27098798751831055]
of O [-0.44330957531929016, 0.4247073829174042]
the O [-0.3785940408706665, 0.4036998152732849]
corpus O [-0.31200724840164185, -0.0714714378118515]
luteum, O [-0.2579633891582489, 0.08261089026927948]
for O [-0.5645374655723572, 0.09225247800350189]
promotion O [-0.45788857340812683, 0.38917049765586853]
of O [-0.5152270197868347, 0.1997675746679306]
decidualization O [-0.40135279297828674, 0.296127051115036]
and O [-0.44897642731666565, 0.32298287749290466]
for O [-0.5721229314804077, 0.10264197736978531]
formation O [-0.24730345606803894, 0.3156721293926239]
of O [-0.36263567209243774, 0.2837755084037781]
the O [-0.3710940480232239, 0.3501753509044647]
placenta. O [-0.2876984477043152, -0.1659681499004364]
It B-LOC [0.08383364230394363, -0.4467311203479767]
therefore B-LOC [0.11701122671365738, -0.3190498650074005]
has B-LOC [0.5233184695243835, -0.6748618483543396]
multiple, B-LOC [0.5794058442115784, -1.0368103981018066]
indispensible B-LOC [0.5869969725608826, -1.0121344327926636]
roles B-LOC [0.43144041299819946, -0.7886987328529358]
in B-LOC [0.38210591673851013, -0.9291848540306091]
establishing B-LOC [0.4780444800853729, -0.8780907988548279]
and B-LOC [0.6143986582756042, -0.8088293075561523]
sustaining B-LOC [0.34377679228782654, -0.7889764904975891]
pregnancy. B-LOC [0.3125530779361725, -0.7275102734565735]

Panic B-LOC [0.9350383281707764, -1.7599403858184814]
disorder B-LOC [1.170466423034668, -1.738102674484253]
is B-LOC [1.1266626119613647, -1.5478122234344482]
a B-LOC [1.18135666847229, -1.5500407218933105]
severe B-LOC [1.2785735130310059, -1.6859151124954224]
anxiety B-LOC [1.4227041006088257, -1.648796796798706]
disorder B-LOC [1.2100329399108887, -1.6675578355789185]
with B-LOC [1.2036007642745972, -1.691667914390564]
recurrent, B-LOC [1.1342799663543701, -1.5638236999511719]
debilitating B-LOC [1.2790303230285645, -1.6585747003555298]
panic B-LOC [1.504502296447754, -1.8012259006500244]
attacks. B-LOC [1.345022201538086, -1.6497350931167603]
In O [-0.2610795795917511, -0.03699660673737526]
individuals B-LOC [0.011178876273334026, -0.3288309872150421]
with B-LOC [0.15045224130153656, -0.40955808758735657]
panic B-LOC [0.20720632374286652, -0.11854250729084015]
disorder B-LOC [0.273556649684906, -0.2701243460178375]
there O [-0.34716951847076416, 0.14918842911720276]
is B-LOC [-0.019761262461543083, -0.153245747089386]
evidence O [-0.20987538993358612, 0.0655229240655899]
of O [-0.2736549377441406, -0.035889673978090286]
decreased O [-0.2588043212890625, -0.04116922244429588]
central O [-0.30757060647010803, -0.10044846683740616]
gamma-aminobutyric B-LOC [0.036179784685373306, -0.20920807123184204]
acid B-LOC [0.002403507474809885, -0.2118401825428009]
(GABA) B-LOC [-0.009753857739269733, -0.2921275794506073]
activity O [-0.1975063979625702, 0.06475008279085159]
as O [-0.25001367926597595, 0.0815848559141159]
well O [-0.21689769625663757, 0.1744338870048523]
as O [-0.15690425038337708, 0.1506921499967575]
marked O [-0.22178831696510315, -0.004113177303224802]
increases O [-0.36042582988739014, -0.05415823683142662]
in O [-0.5104385018348694, -0.08093555271625519]
autonomic O [-0.5820151567459106, 0.3588375151157379]
and O [-0.47479087114334106, 0.050465699285268784]
respiratory O [-0.23525646328926086, -0.10290341824293137]
responses O [-0.3316707909107208, 0.06345523148775101]
after O [-0.32748231291770935, 0.08115677535533905]
intravenous O [-0.5130892395973206, 0.1835014820098877]
infusions O [-0.46200788021087646, 0.055027734488248825]
of O [-0.17386597394943237, 0.04304403439164162]
hypertonic O [-0.16627758741378784, -0.1600712239742279]
sodium B-LOC [0.2226046621799469, -0.5150943398475647]
lactate. B-LOC [-0.12196656316518784, -0.1886816918849945]
In B-LOC [0.26356634497642517, -0.19678016006946564]
a B-LOC [0.40104544162750244, -0.268492728471756]
rat B-LOC [0.2616792619228363, -0.6444055438041687]
model B-LOC [0.41422250866889954, -0.43512171506881714]
of B-LOC [0.5607703328132629, -0.6872007846832275]
panic B-LOC [0.38267287611961365, -0.5781388878822327]
disorder, B-LOC [0.5061610341072083, -0.5864137411117554]
chronic O [-0.23829320073127747, -0.17580291628837585]
inhibition O [-0.21420952677726746, -0.1523582637310028]
of B-LOC [-0.12700559198856354, -0.24257473647594452]
GABA B-LOC [-0.03840072453022003, -0.379663348197937]
synthesis B-LOC [-0.0626278966665268, -0.12321043014526367]
in B-LOC [0.08872854709625244, -0.13218143582344055]
the B-LOC [0.20730993151664734, 0.056602124124765396]
dorsomedial-perifornical B-LOC [-0.0460088774561882, -0.26010003685951233]
hypothalamus B-LOC [0.03840848430991173, -0.30213725566864014]
of B-LOC [0.04577826336026192, -0.07773761451244354]
rats B-LOC [0.1706634908914566, -0.5676476955413818]
produces B-LOC [0.1919826865196228, -0.3866150677204132]
anxiety-like B-LOC [0.1276194006204605, -0.3423484265804291]
states B-LOC [-0.08844104409217834, -0.19766877591609955]
and B-LOC [0.3285417854785919, -0.5359923243522644]
a B-LOC [0.35154131054878235, -0.35898613929748535]
similar B-LOC [0.3678474426269531, -0.5526882410049438]
vulnerability B-LOC [0.2713657021522522, -0.7002323269844055]
to B-LOC [0.08423776179552078, -0.43560633063316345]
sodium B-LOC [0.2469147890806198, -0.594089686870575]

lactate-induced B-LOC [-0.0026647872291505337, -0.5368350148200989]
cardioexcitatory B-LOC [0.10868462920188904, -0.777599036693573]
responses. B-LOC [0.23911744356155396, -0.7203407883644104]
The B-LOC [0.9103860259056091, -1.225193977355957]
dorsomedial-perifornical B-LOC [0.4614523947238922, -0.8543123602867126]
hypothalamus B-LOC [0.8418757319450378, -1.4451539516448975]
is B-LOC [1.0115220546722412, -1.295874834060669]
enriched B-LOC [1.178291916847229, -1.3981674909591675]
in B-LOC [0.9954937100410461, -1.1977646350860596]
neurons B-LOC [0.8930616974830627, -1.2202341556549072]
containing B-LOC [1.1401301622390747, -1.281915545463562]
orexin B-LOC [0.7685627937316895, -1.3052762746810913]
(ORX, B-LOC [0.9922710061073303, -1.1524735689163208]
also B-LOC [1.1366910934448242, -1.2634227275848389]
known B-LOC [1.116926908493042, -1.0562242269515991]
as B-LOC [0.9780515432357788, -1.0610285997390747]
hypocretin), B-LOC [0.8236069679260254, -1.3896706104278564]
which B-LOC [0.8774740695953369, -1.2935264110565186]
have B-LOC [1.2517695426940918, -1.4022822380065918]
a B-LOC [1.1762940883636475, -1.2276588678359985]
crucial B-LOC [0.9613756537437439, -1.1518025398254395]
role B-LOC [0.8719114661216736, -1.1775193214416504]
in B-LOC [0.8926119208335876, -1.4059582948684692]
arousal, B-LOC [0.9700390100479126, -1.1812785863876343]
vigilance B-LOC [0.9291042685508728, -1.3072681427001953]
and B-LOC [1.2233840227127075, -1.2147458791732788]
central B-LOC [0.7163075804710388, -1.317065954208374]
autonomic B-LOC [1.0706080198287964, -1.5570247173309326]
mobilization, B-LOC [1.0451668500900269, -1.2660443782806396]
all B-LOC [1.3852295875549316, -1.497408151626587]
of B-LOC [1.6359443664550781, -1.4034523963928223]
which B-LOC [1.2920811176300049, -1.3491756916046143]
are B-LOC [1.3482108116149902, -1.4513827562332153]
key B-LOC [1.0933802127838135, -1.492005705833435]
components B-LOC [1.1134662628173828, -1.4257967472076416]
of B-LOC [0.9786906838417053, -1.5099456310272217]
panic. B-LOC [1.0498042106628418, -1.558638334274292]
Here O [-0.7443970441818237, 0.37706583738327026]
we O [-0.8101819753646851, 0.3722021281719208]
show O [-0.7303013801574707, 0.44013485312461853]
that O [-1.0943210124969482, 0.5612877607345581]
activation O [-0.7062527537345886, 0.6560430526733398]
of O [-0.6864896416664124, 0.6810744404792786]
ORX-synthesizing O [-0.5174475312232971, 0.33316323161125183]
neurons O [-0.6645563244819641, 0.535318911075592]
is O [-0.7116891741752625, 0.6291844248771667]
necessary O [-0.8223613500595093, 0.6400306820869446]
for O [-0.9008994102478027, 0.6208618879318237]
developing O [-0.5780298113822937, 0.6903701424598694]
a O [-0.6989580392837524, 0.6528030037879944]
panic-prone O [-0.4609892666339874, 0.33234789967536926]
state O [-0.6948937773704529, 0.5026151537895203]
in O [-0.7511832118034363, 0.5275632739067078]
the O [-0.6626265048980713, 0.6728419661521912]
rat O [-0.8248348832130432, 0.4204000234603882]
panic O [-0.4720633625984192, 0.26121988892555237]
model, O [-0.720556914806366, 0.4757106900215149]
and O [-0.7530131936073303, 0.7243376970291138]
either O [-0.7658461928367615, 0.47497737407684326]
silencing O [-0.669414222240448, 0.5408538579940796]
of O [-0.5762943625450134, 0.6057536005973816]
the O [-0.6262578964233398, 0.5475388765335083]
hypothalamic O [-0.6477908492088318, 0.40613386034965515]
gene O [-0.6172414422035217, 0.30744338035583496]
encoding O [-0.6222766637802124, 0.3814484477043152]
ORX O [-0.5282349586486816, 0.22864088416099548]

(Hcrt) O [-0.25941652059555054, -0.0222857017070055]
with O [-0.30988308787345886, 0.3098060190677643]
RNAi O [-0.28179991245269775, 0.16158746182918549]
or O [-0.21297277510166168, 0.22357499599456787]
systemic O [-0.4642045199871063, 0.302491694688797]
ORX-1 O [-0.3217913806438446, -0.012073559686541557]
receptor O [-0.3054409325122833, 0.35695210099220276]
antagonists O [-0.07077936828136444, 0.5226214528083801]
blocks O [-0.2146068811416626, 0.43480727076530457]
the O [-0.3899327218532562, 0.36474987864494324]
panic O [-0.26382890343666077, 0.08091405779123306]
responses. O [-0.41484346985816956, 0.18208470940589905]
Moreover, O [-0.9827778339385986, 0.8634342551231384]
we O [-0.9096836447715759, 0.5950153470039368]
show O [-0.9904666543006897, 0.8912697434425354]
that O [-1.201073408126831, 0.7637723684310913]
human O [-0.8915023803710938, 0.8782323002815247]
subjects O [-0.9312593340873718, 0.917867124080658]
with O [-0.9376491904258728, 0.8638240694999695]
panic O [-0.6367617249488831, 0.6720378994941711]
anxiety O [-0.6572691798210144, 0.8198469281196594]
have O [-1.0213125944137573, 0.9661901593208313]
elevated O [-0.89900803565979, 0.8202731013298035]
levels O [-0.9159024357795715, 0.930120050907135]
of O [-1.0987868309020996, 0.9092280864715576]
ORX O [-0.9911905527114868, 0.915848970413208]
in O [-1.0423924922943115, 0.9238634705543518]
the O [-1.0543075799942017, 1.0845725536346436]
cerebrospinal O [-0.9822357296943665, 0.9997043609619141]
fluid O [-1.0220669507980347, 0.9155716896057129]
compared O [-0.9343380928039551, 1.0052329301834106]
to O [-0.7258017659187317, 0.867383599281311]
subjects O [-0.832379937171936, 0.7383570075035095]
without O [-0.6663846373558044, 0.686238169670105]
panic O [-0.4889218211174011, 0.34775587916374207]
anxiety. O [-0.6067669987678528, 0.6267575621604919]
Taken B-LOC [1.0563554763793945, -0.8923841714859009]
together, B-LOC [0.9869443774223328, -1.014766812324524]
our B-LOC [0.6103119850158691, -0.9248695373535156]
results B-LOC [1.018760323524475, -1.006369709968567]
suggest B-LOC [0.7425851225852966, -0.8430564999580383]
that B-LOC [0.8279761075973511, -1.23533034324646]
the B-LOC [1.0543186664581299, -1.2334951162338257]
ORX B-LOC [0.7467601299285889, -1.1081016063690186]
system B-LOC [0.5957393050193787, -1.413679838180542]
may B-LOC [1.0629103183746338, -1.2720195055007935]
be B-LOC [0.9533993601799011, -1.4261633157730103]
involved B-LOC [0.9120775461196899, -1.4929108619689941]
in B-LOC [0.9685025811195374, -1.3700721263885498]
the B-LOC [1.0770659446716309, -1.3555879592895508]
pathophysiology B-LOC [1.2264268398284912, -1.4906035661697388]
of B-LOC [1.1937968730926514, -1.5067503452301025]
panic B-LOC [1.0598573684692383, -1.545048475265503]
anxiety B-LOC [1.0539922714233398, -1.264968991279602]
and B-LOC [0.7202137112617493, -0.9059296250343323]
that B-LOC [0.7120891809463501, -1.16798734664917]
ORX B-LOC [0.7812803387641907, -1.1497832536697388]
antagonists B-LOC [1.0961074829101562, -1.2275950908660889]
constitute B-LOC [1.068421721458435, -1.2888450622558594]
a B-LOC [1.1097972393035889, -1.4145636558532715]
potential B-LOC [1.304664969444275, -1.6229941844940186]
new B-LOC [1.2371783256530762, -1.6662654876708984]
treatment B-LOC [1.2603676319122314, -1.4792723655700684]
strategy B-LOC [1.4007792472839355, -1.5928434133529663]
for B-LOC [1.1665198802947998, -1.5858155488967896]
panic B-LOC [1.2441809177398682, -1.6667060852050781]
disorder. B-LOC [1.236065149307251, -1.5838710069656372]

Podosomes B-LOC [0.9206249713897705, -1.8540005683898926]
(also B-LOC [1.6513270139694214, -1.7858737707138062]
termed B-LOC [1.4803988933563232, -1.7631386518478394]
invadopodia B-LOC [1.0023815631866455, -1.4804439544677734]
in B-LOC [1.2032222747802734, -1.630279541015625]
cancer B-LOC [1.340550184249878, -1.9520658254623413]
cells) B-LOC [1.292902946472168, -1.8921544551849365]
are B-LOC [1.6865637302398682, -1.9394108057022095]
actin-rich B-LOC [1.3630222082138062, -1.6821845769882202]
adhesion B-LOC [1.2545710802078247, -1.3994672298431396]
structures B-LOC [1.5969278812408447, -1.6325647830963135]
with B-LOC [1.740362524986267, -2.016141653060913]
matrix B-LOC [1.3410996198654175, -1.620787262916565]
degradation B-LOC [1.8706973791122437, -1.8978214263916016]
activity B-LOC [1.7632379531860352, -1.804945945739746]
that B-LOC [1.5717055797576904, -2.0280048847198486]
develop B-LOC [1.807864785194397, -2.0687901973724365]
in B-LOC [1.6934688091278076, -2.1068780422210693]
various B-LOC [2.081671953201294, -2.6314384937286377]
cell B-LOC [2.4530463218688965, -2.8715426921844482]
types. B-LOC [2.3500378131866455, -2.629304885864258]
Despite B-LOC [2.683375835418701, -2.7529549598693848]
their B-LOC [2.817042589187622, -2.948873519897461]
significant B-LOC [2.914565324783325, -3.0699005126953125]
physiological B-LOC [2.892237424850464, -3.207270622253418]
importance, B-LOC [2.784248113632202, -2.787705183029175]
the B-LOC [2.9208147525787354, -3.0946438312530518]
molecular B-LOC [2.970423460006714, -3.2182512283325195]
mechanism B-LOC [2.6472623348236084, -3.1585190296173096]
of B-LOC [2.505239725112915, -3.0837533473968506]
podosome B-LOC [2.1188032627105713, -2.8881473541259766]
formation B-LOC [2.5113513469696045, -2.8723089694976807]
is B-LOC [3.130542755126953, -2.850698709487915]
largely B-LOC [3.159454822540283, -2.915363073348999]
unknown. B-LOC [3.109110116958618, -2.9796273708343506]
In B-LOC [2.618772506713867, -3.0376484394073486]
this B-LOC [2.7991843223571777, -2.8552749156951904]
study, B-LOC [2.583282470703125, -2.9493415355682373]
we B-LOC [2.524955987930298, -2.6641881465911865]
investigated B-LOC [2.682448148727417, -2.9009251594543457]
the B-LOC [2.861220121383667, -3.0002667903900146]
molecular B-LOC [2.836369752883911, -3.10583233833313]
mechanisms B-LOC [2.6915671825408936, -3.0772883892059326]
of B-LOC [2.48874831199646, -2.9692413806915283]
podosome B-LOC [2.267892599105835, -2.980309247970581]
formation. B-LOC [2.491410255432129, -2.8345258235931396]
The B-LOC [0.362393856048584, -0.4885522425174713]
expression B-LOC [0.4075281322002411, -0.1478426158428192]
of B-LOC [0.550690233707428, -0.4010763168334961]
various B-LOC [0.3819373548030853, -0.39766940474510193]
phosphoinositide-binding B-LOC [0.3084762692451477, -0.5449991226196289]
domains B-LOC [0.434165894985199, -0.29981720447540283]
revealed B-LOC [0.1338607370853424, -0.027142854407429695]
that B-LOC [-0.06623833626508713, -0.08341291546821594]
the B-LOC [0.30739814043045044, -0.2761746346950531]
podosomes B-LOC [0.08451524376869202, -0.2843039333820343]
in B-LOC [0.2651357054710388, -0.14201220870018005]
Src-transformed B-LOC [0.2853235602378845, -0.42699429392814636]
NIH3T3 B-LOC [0.16880232095718384, -0.3222968876361847]
(NIH-src) B-LOC [0.3122311532497406, -0.2914232909679413]
cells B-LOC [-0.005546045955270529, -0.16796478629112244]
are B-LOC [0.4626348912715912, -0.16660812497138977]
enriched B-LOC [0.418424516916275, -0.1750308871269226]
with B-LOC [0.29496675729751587, -0.23222345113754272]
PtdIns(3,4)P2, B-LOC [0.18024525046348572, -0.25899049639701843]
suggesting B-LOC [-0.06214868649840355, -0.23630757629871368]

an B-LOC [0.2769242823123932, -0.7166891098022461]
important B-LOC [0.5145063996315002, -0.6887030601501465]
role B-LOC [0.5273416638374329, -0.7698861360549927]
of B-LOC [0.715194582939148, -0.6845715045928955]
this B-LOC [0.6091718673706055, -0.7409457564353943]
phosphoinositide B-LOC [0.5534180402755737, -0.7904458045959473]
in B-LOC [0.5313567519187927, -0.8679829835891724]
podosome B-LOC [0.549335777759552, -0.757338285446167]
formation. B-LOC [0.654561460018158, -0.5772270560264587]
Live-cell B-LOC [0.5058791041374207, -0.462491899728775]
imaging B-LOC [0.3591599464416504, -0.2045365273952484]
analysis B-LOC [0.318570613861084, -0.11295536160469055]
revealed B-LOC [0.13151800632476807, 0.09934613853693008]
that O [-0.1047249585390091, 0.05045095458626747]
Src-expression B-LOC [0.21240025758743286, -0.2504422962665558]
stimulated O [-0.099553182721138, 0.05432554706931114]
podosome B-LOC [-0.04408321902155876, -0.06925179064273834]
formation O [-0.025009552016854286, 0.16473394632339478]
at O [-0.04190720245242119, -0.00032269436633214355]
focal O [-0.06022040918469429, 0.010811833664774895]
adhesions O [-0.0915798544883728, 0.0030617988668382168]
of O [-0.06130305305123329, 0.054084476083517075]
NIH3T3 B-LOC [-0.00039760899380780756, -0.08899517357349396]
cells O [-0.0936356708407402, 0.007337076123803854]
after O [-0.06596972048282623, 0.0029621399007737637]
PtdIns(3,4)P2 B-LOC [-0.06762810051441193, -0.12830960750579834]
accumulation. B-LOC [0.11159245669841766, -0.010404529049992561]
The B-LOC [0.18747232854366302, -0.0416412390768528]
adaptor B-LOC [-0.05288306996226311, -0.09935292601585388]
protein B-LOC [0.04196152463555336, -0.23949265480041504]
Tks5/FISH, B-LOC [-0.09333615005016327, -0.1846415102481842]
which O [-0.18188965320587158, -0.13683553040027618]
is B-LOC [0.19903333485126495, -0.200797438621521]
essential B-LOC [-0.013172213919460773, -0.18335986137390137]
for B-LOC [-0.18150046467781067, -0.24241697788238525]
podosome B-LOC [-0.06853128224611282, -0.24573209881782532]
formation, B-LOC [0.19807404279708862, -0.08905528485774994]
was B-LOC [0.24248546361923218, -0.16168120503425598]
found B-LOC [0.13079425692558289, -0.0779309868812561]
to B-LOC [0.2953844666481018, -0.10867049545049667]
form B-LOC [0.14952848851680756, -0.087342269718647]
a B-LOC [0.12527549266815186, -0.044353608042001724]
complex B-LOC [0.1451067328453064, -0.18608613312244415]
with B-LOC [0.1804964691400528, -0.2910461723804474]
Grb2 B-LOC [0.12981677055358887, -0.24472388625144958]
at B-LOC [0.029097700491547585, -0.24965399503707886]
adhesion B-LOC [0.17316949367523193, -0.20341941714286804]
sites B-LOC [0.0917605310678482, -0.2002013623714447]
in B-LOC [-0.051780376583337784, -0.08783721923828125]
an B-LOC [-0.03927035257220268, -0.05566055700182915]
Src-dependent B-LOC [0.09740284085273743, -0.09950776398181915]
manner. B-LOC [-0.051424115896224976, -0.12640446424484253]
Further, O [-0.19867339730262756, 0.21651515364646912]
it O [-0.24469882249832153, 0.10723088681697845]
was O [-0.11257271468639374, 0.030119774863123894]
found O [-0.13708674907684326, 0.22294166684150696]
that O [-0.1885492205619812, 0.19392597675323486]
N-WASP O [-0.13752883672714233, 0.07910378277301788]
bound O [0.07753902673721313, 0.17268997430801392]
all O [0.01059133093804121, 0.11041894555091858]
SH3 O [-0.22534407675266266, 0.1303195059299469]
domains O [-0.05154940113425255, 0.027370216324925423]
of O [-0.13517844676971436, -0.06351876258850098]

Tks5/FISH, B-LOC [-0.1042376160621643, -0.16764533519744873]
which B-LOC [0.008458486758172512, -0.03756082430481911]
facilitated O [-0.18265491724014282, 0.05205845832824707]
circular B-LOC [-0.023225681856274605, -0.06173595413565636]
podosome B-LOC [-0.050043925642967224, -0.12837040424346924]
formation. B-LOC [0.09150221198797226, -0.029598305001854897]
These O [0.038574252277612686, 0.07706309854984283]
results B-LOC [0.06745047867298126, 0.06289486587047577]
indicate O [-0.03132734075188637, 0.20381973683834076]
that O [-0.32233190536499023, 0.19442887604236603]
augmentation O [-0.20867149531841278, 0.2780497372150421]
of O [-0.24646927416324615, 0.2775600850582123]
the O [-0.2624914348125458, 0.2266533076763153]
N-WASP-Arp2/3 O [-0.30128130316734314, 0.08352148532867432]
signal O [-0.35904213786125183, 0.14228862524032593]
was O [-0.32498958706855774, 0.34290704131126404]
accomplished O [-0.37331247329711914, 0.3785775899887085]
on O [-0.21302101016044617, 0.2626807391643524]
the O [-0.1908160150051117, 0.27325502038002014]
platform O [-0.20259934663772583, 0.18377867341041565]
of O [-0.26260146498680115, 0.2496507167816162]
Tks5/FISH-Grb2 O [-0.31145182251930237, 0.004558173473924398]
complex O [-0.3060786724090576, -0.023371191695332527]
at O [-0.1279997080564499, 0.06483457237482071]
focal O [-0.14378996193408966, -0.008295955136418343]
adhesions, O [-0.24567630887031555, 0.09943577647209167]
which O [-0.0814300924539566, -0.039616260677576065]
is B-LOC [0.12039671093225479, -0.12271609902381897]
stabilized B-LOC [0.06785635650157928, -0.016763189807534218]
by O [-0.004386333283036947, 0.04212092235684395]
PtdIns(3,4)P2. B-LOC [0.10167286545038223, -0.11011168360710144]

Human B-LOC [1.7823774814605713, -2.4934372901916504]
astrocytes B-LOC [1.80613374710083, -2.2915732860565186]
are B-LOC [2.402298927307129, -2.349726915359497]
larger B-LOC [2.4169323444366455, -2.449434757232666]
and B-LOC [2.3695857524871826, -2.5232975482940674]
more B-LOC [2.3633618354797363, -2.7472903728485107]
complex B-LOC [2.4290075302124023, -2.681701421737671]
than B-LOC [2.065351724624634, -2.3550634384155273]
those B-LOC [2.1830508708953857, -2.4428091049194336]
of B-LOC [1.926448941230774, -2.425516128540039]
infraprimate B-LOC [2.308544158935547, -2.364215850830078]
mammals, B-LOC [2.115588426589966, -2.5442488193511963]
suggesting B-LOC [2.2599809169769287, -2.318314790725708]
that B-LOC [2.2499983310699463, -2.6170809268951416]
their B-LOC [2.4354124069213867, -2.7285468578338623]
role B-LOC [2.4763309955596924, -2.9169070720672607]
in B-LOC [2.3600761890411377, -3.081437826156616]
neural B-LOC [2.3840878009796143, -2.9896254539489746]
processing B-LOC [2.216914653778076, -2.7300331592559814]
has B-LOC [2.831326484680176, -2.912329912185669]
expanded B-LOC [2.6939780712127686, -2.9990131855010986]
with B-LOC [2.2086756229400635, -2.6789932250976562]
evolution. B-LOC [2.681652784347534, -2.9172770977020264]
To B-LOC [2.8318161964416504, -3.2238352298736572]
assess B-LOC [3.0189859867095947, -3.416404962539673]
the B-LOC [3.1633362770080566, -3.46783447265625]
cell-autonomous B-LOC [2.831590414047241, -3.49355149269104]
and B-LOC [2.9006412029266357, -3.3529255390167236]
species-selective B-LOC [3.1696155071258545, -3.533649206161499]
properties B-LOC [3.196293592453003, -3.4637014865875244]
of B-LOC [2.8885467052459717, -3.2828030586242676]
human B-LOC [2.824314832687378, -3.354175329208374]
glia, B-LOC [2.895730972290039, -3.1856629848480225]
we B-LOC [2.7585151195526123, -2.947143316268921]
engrafted B-LOC [2.834243059158325, -3.1839778423309326]
human B-LOC [2.807429552078247, -3.433351516723633]
glial B-LOC [3.0404741764068604, -3.272324323654175]
progenitor B-LOC [2.8971848487854004, -3.3431966304779053]
cells B-LOC [2.773068428039551, -3.19980788230896]
(GPCs) B-LOC [2.877229690551758, -3.1983745098114014]
into B-LOC [2.689497947692871, -3.251054048538208]
neonatal B-LOC [2.6239230632781982, -3.3016560077667236]
immunodeficient B-LOC [3.0420565605163574, -3.4583847522735596]
mice. B-LOC [2.6855876445770264, -3.454401731491089]
Upon B-LOC [0.1630706936120987, -0.6273038387298584]
maturation, B-LOC [0.7929419279098511, -0.5529550313949585]
the B-LOC [0.5567148923873901, -0.5726422071456909]
recipient B-LOC [0.5480961799621582, -0.860975980758667]
brains B-LOC [0.41429638862609863, -0.6065462231636047]
exhibited B-LOC [0.3551955819129944, -0.564255952835083]
large B-LOC [0.4862372577190399, -0.73750901222229]
numbers B-LOC [0.5828326940536499, -0.632771909236908]
and B-LOC [0.43348634243011475, -0.6094171404838562]
high B-LOC [0.4758947491645813, -0.902344286441803]
proportions B-LOC [0.5664504170417786, -0.7410261034965515]
of B-LOC [0.2609419524669647, -0.6883596777915955]
both B-LOC [0.2510684132575989, -0.7389618754386902]
human B-LOC [0.4291365444660187, -0.8489428162574768]
glial B-LOC [0.5726670622825623, -0.7374341487884521]
progenitors B-LOC [0.41530391573905945, -0.6614922285079956]
and B-LOC [0.4324043393135071, -0.5627472400665283]
astrocytes. B-LOC [0.3512626588344574, -0.7754648923873901]
The B-LOC [0.4038972556591034, -0.445548951625824]
engrafted B-LOC [0.4244338572025299, -0.5485240817070007]
human B-LOC [0.19312714040279388, -0.5823988318443298]
glia B-LOC [0.15045876801013947, -0.6598096489906311]
were B-LOC [0.43295562267303467, -0.4247329831123352]
gap-junction-coupled B-LOC [0.3877245783805847, -0.5814192891120911]
to B-LOC [0.40056970715522766, -0.6343584656715393]
host B-LOC [0.19301003217697144, -0.47455325722694397]
astroglia, B-LOC [0.07451755553483963, -0.5720771551132202]

yet B-LOC [0.21881510317325592, -0.08028341829776764]
retained B-LOC [0.21603606641292572, -0.15660782158374786]
the B-LOC [0.12659527361392975, -0.039519716054201126]
size B-LOC [0.2752963900566101, -0.1547233760356903]
and B-LOC [0.06716923415660858, -0.4265671372413635]
pleomorphism B-LOC [0.31274083256721497, -0.5019792914390564]
of B-LOC [0.207059845328331, -0.35120484232902527]
hominid B-LOC [0.47283700108528137, -0.5194748044013977]
astroglia, B-LOC [0.05539349839091301, -0.34340304136276245]
and O [-0.02341310866177082, 0.021798713132739067]
propagated B-LOC [0.32501110434532166, -0.24092158675193787]
Ca2+ B-LOC [0.1389428973197937, -0.4449620246887207]
signals B-LOC [0.21606293320655823, -0.45300060510635376]
3-fold B-LOC [0.1393284648656845, -0.16880029439926147]
faster B-LOC [0.382453054189682, -0.42612937092781067]
than B-LOC [0.32257992029190063, -0.4015820026397705]
their B-LOC [0.44759705662727356, -0.5533060431480408]
hosts. B-LOC [0.5126783847808838, -0.6055949330329895]
Long-term B-LOC [2.4337308406829834, -2.3791096210479736]
potentiation B-LOC [2.0074446201324463, -2.398634672164917]
(LTP) B-LOC [2.2468903064727783, -2.4914052486419678]
was B-LOC [1.972040057182312, -2.0576236248016357]
sharply B-LOC [1.8914127349853516, -2.1330957412719727]
enhanced B-LOC [1.8501851558685303, -2.094224214553833]
in B-LOC [1.624704122543335, -1.8162320852279663]
the B-LOC [1.9532747268676758, -1.866969108581543]
human B-LOC [2.087580442428589, -2.3276607990264893]
glial B-LOC [2.4151782989501953, -2.6246323585510254]
chimeric B-LOC [1.7947261333465576, -2.235222578048706]
mice, B-LOC [1.9288291931152344, -2.3210031986236572]
as B-LOC [1.795076847076416, -1.9155747890472412]
was B-LOC [1.9690725803375244, -2.0642077922821045]
their B-LOC [2.077042818069458, -2.2582221031188965]
learning, B-LOC [2.0421383380889893, -2.3108017444610596]
as B-LOC [2.3704144954681396, -2.4241890907287598]
assessed B-LOC [2.3107595443725586, -2.599404811859131]
by B-LOC [2.3000471591949463, -2.6724836826324463]
Barnes B-LOC [2.3448867797851562, -2.56792950630188]
maze B-LOC [2.2808942794799805, -2.7514231204986572]
navigation, B-LOC [2.333669424057007, -2.552976131439209]
object-location B-LOC [2.539790391921997, -2.9678475856781006]
memory, B-LOC [2.456429958343506, -2.6587302684783936]
and B-LOC [2.1194334030151367, -2.3378803730010986]
both B-LOC [2.0727362632751465, -2.5666472911834717]
contextual B-LOC [2.7531697750091553, -2.9927523136138916]
and B-LOC [2.325373888015747, -2.5533127784729004]
tone B-LOC [2.2687697410583496, -2.9301440715789795]
fear B-LOC [2.2553980350494385, -2.6378912925720215]
conditioning. B-LOC [2.314631462097168, -2.6730852127075195]
Mice B-LOC [1.1740655899047852, -0.9407723546028137]
allografted B-LOC [1.3542581796646118, -0.7247928380966187]
with B-LOC [0.9450104236602783, -0.8077185750007629]
murine B-LOC [1.0957942008972168, -0.8935976028442383]
GPCs B-LOC [0.9240853190422058, -0.783178985118866]
showed B-LOC [0.6804280877113342, -0.553701639175415]
no B-LOC [0.8279877305030823, -0.675579309463501]
enhancement B-LOC [0.6084986329078674, -0.8807659149169922]
of B-LOC [0.4240158498287201, -0.5999259948730469]
either B-LOC [0.7615833878517151, -1.1252985000610352]
LTP B-LOC [0.8136387467384338, -0.7126174569129944]
or B-LOC [0.7192104458808899, -0.6762071847915649]
learning. B-LOC [0.5361682772636414, -0.7483838796615601]
These B-LOC [0.43353819847106934, -0.3427946865558624]
findings B-LOC [0.52128666639328, -0.20305386185646057]
indicate B-LOC [0.381363183259964, -0.18493160605430603]
that B-LOC [0.21433024108409882, -0.40835028886795044]
human B-LOC [-0.03265926614403725, -0.3596751391887665]
glia B-LOC [0.04053618386387825, -0.4187176525592804]
differentially B-LOC [0.25670626759529114, -0.3920608460903168]
enhance B-LOC [0.23640227317810059, -0.33443236351013184]
both B-LOC [-0.0135499881580472, -0.36636480689048767]

activity-dependent O [-0.2532148063182831, -0.05699877813458443]
plasticity B-LOC [0.03190246969461441, -0.04291928559541702]
and B-LOC [0.13300147652626038, -0.28165173530578613]
learning O [-0.07438094168901443, 0.026288693770766258]
in O [-0.03174488618969917, 0.07257596403360367]
mice. O [-0.17809462547302246, 0.05974910035729408]

BACKGROUND B-LOC [1.268966555595398, -2.1037962436676025]
Birth B-LOC [1.9747079610824585, -2.7765588760375977]
size, B-LOC [2.039297580718994, -2.6731302738189697]
perhaps B-LOC [1.6917903423309326, -2.438673257827759]
a B-LOC [1.5209534168243408, -2.2803728580474854]
proxy B-LOC [1.6007988452911377, -2.412017345428467]
for B-LOC [1.5784941911697388, -2.4009134769439697]
prenatal B-LOC [1.6006711721420288, -2.189993143081665]
environment, B-LOC [1.6168874502182007, -2.4125256538391113]
might B-LOC [1.9535930156707764, -2.680502414703369]
be B-LOC [1.9293676614761353, -2.7681772708892822]
a B-LOC [2.1786155700683594, -2.6967344284057617]
correlate B-LOC [2.385010242462158, -2.983147144317627]
of B-LOC [2.0627424716949463, -3.0409939289093018]
subsequent B-LOC [2.1028263568878174, -2.9523725509643555]
breast B-LOC [2.4428420066833496, -3.095876932144165]
cancer B-LOC [3.0073530673980713, -3.5941622257232666]
risk, B-LOC [2.7046167850494385, -3.1043808460235596]
but B-LOC [2.6902496814727783, -3.1448628902435303]
findings B-LOC [3.070185422897339, -3.2605903148651123]
from B-LOC [3.0587804317474365, -3.4871888160705566]
epidemiological B-LOC [3.2234010696411133, -3.53841233253479]
studies B-LOC [3.0310847759246826, -3.2594616413116455]
have B-LOC [3.1410863399505615, -3.2041633129119873]
been B-LOC [2.841059446334839, -3.3188636302948]
inconsistent. B-LOC [3.13737416267395, -3.4348397254943848]
We B-LOC [3.0071487426757812, -3.309901714324951]
re-analysed B-LOC [3.3910374641418457, -3.6306772232055664]
individual B-LOC [3.292825937271118, -3.6462318897247314]
participant B-LOC [3.348802089691162, -3.9258127212524414]
data B-LOC [3.3194162845611572, -3.700248956680298]
from B-LOC [3.230222225189209, -3.6877551078796387]
published B-LOC [3.293034791946411, -3.543736219406128]
and B-LOC [3.1000401973724365, -3.4373552799224854]
unpublished B-LOC [3.384842872619629, -3.603929042816162]
studies B-LOC [3.3788466453552246, -3.5122768878936768]
to B-LOC [3.475522994995117, -3.494067907333374]
obtain B-LOC [3.391859769821167, -3.5771987438201904]
more B-LOC [3.1963441371917725, -3.645437240600586]
precise B-LOC [3.3876302242279053, -3.705096483230591]
estimates B-LOC [3.3914172649383545, -3.636444091796875]
of B-LOC [3.422055244445801, -3.6910502910614014]
the B-LOC [3.493975877761841, -3.6849820613861084]
magnitude B-LOC [3.5787627696990967, -3.9162116050720215]
and B-LOC [3.2756268978118896, -3.5083916187286377]
shape B-LOC [3.7579185962677, -3.755723237991333]
of B-LOC [3.510209083557129, -3.608736991882324]
the B-LOC [3.389940023422241, -3.596930503845215]
birth B-LOC [3.2024953365325928, -3.715017557144165]
size-breast B-LOC [3.314340353012085, -3.795654058456421]
cancer B-LOC [3.387814521789551, -3.9234228134155273]
association. B-LOC [3.3137896060943604, -3.751504421234131]
METHODS B-LOC [1.9449577331542969, -2.7838690280914307]
AND B-LOC [2.5585832595825195, -3.010150194168091]
FINDINGS B-LOC [2.1112661361694336, -2.594449758529663]
Studies B-LOC [2.67680025100708, -3.0045700073242188]
were B-LOC [2.49888014793396, -2.8370039463043213]
identified B-LOC [3.3876893520355225, -3.453624963760376]
through B-LOC [2.6566779613494873, -3.471270799636841]
computer-assisted B-LOC [3.059791326522827, -3.801025629043579]
and B-LOC [2.965914249420166, -3.555104970932007]
manual B-LOC [2.8298418521881104, -3.617405652999878]
searches, B-LOC [3.253751516342163, -3.541661024093628]
and B-LOC [2.978332281112671, -3.4763717651367188]
personal B-LOC [3.0913736820220947, -3.617478609085083]
communication B-LOC [3.030479669570923, -3.2802088260650635]
with B-LOC [2.939040422439575, -3.461751699447632]
investigators. B-LOC [3.0061728954315186, -3.418821096420288]
Individual B-LOC [1.9592430591583252, -2.519923448562622]
participant B-LOC [2.122102737426758, -2.770549774169922]
data B-LOC [2.0850424766540527, -2.4551308155059814]
from B-LOC [1.941615104675293, -2.5194575786590576]
32 B-LOC [2.4106967449188232, -2.6354503631591797]
studies, B-LOC [1.711872935295105, -2.0629336833953857]
comprising B-LOC [2.235924482345581, -2.2637200355529785]
22,058 B-LOC [2.6057889461517334, -2.2269999980926514]
breast B-LOC [1.7890913486480713, -2.3464534282684326]
cancer B-LOC [1.9893319606781006, -2.7241642475128174]
cases, B-LOC [2.1793437004089355, -2.446040391921997]
were B-LOC [2.2318928241729736, -2.850053548812866]

obtained. B-LOC [2.6412322521209717, -3.0841314792633057]
Random B-LOC [3.3089382648468018, -3.751668930053711]
effect B-LOC [2.945366144180298, -3.5677900314331055]
models B-LOC [3.1661293506622314, -3.4467527866363525]
were B-LOC [3.0733230113983154, -3.338535785675049]
used, B-LOC [3.4121382236480713, -3.584587335586548]
if B-LOC [3.3828375339508057, -3.6891605854034424]
appropriate, B-LOC [3.3160064220428467, -3.554994583129883]
to B-LOC [3.5512380599975586, -3.5965068340301514]
combine B-LOC [3.3342838287353516, -3.663100481033325]
study-specific B-LOC [3.2181060314178467, -3.6486856937408447]
estimates B-LOC [3.121892213821411, -3.4255127906799316]
of B-LOC [3.0722649097442627, -3.444166421890259]
effect. B-LOC [3.2138326168060303, -3.648639440536499]
Birth O [-0.985368013381958, 0.9435331225395203]
weight O [-0.8363317251205444, 1.1125370264053345]
was O [-1.1528284549713135, 0.7574140429496765]
positively O [-1.1383485794067383, 1.005554437637329]
associated O [-1.1521910429000854, 0.9580415487289429]
with O [-1.063751220703125, 0.9246715307235718]
breast O [-1.180047869682312, 1.236526608467102]
cancer O [-1.0643430948257446, 1.151387333869934]
risk O [-1.1316101551055908, 1.161374568939209]
in O [-1.1321364641189575, 0.9185654520988464]
studies O [-1.2451108694076538, 1.1176342964172363]
based O [-1.1772640943527222, 1.0100805759429932]
on O [-1.001405119895935, 1.0193369388580322]
birth O [-1.1507173776626587, 1.2882858514785767]
records O [-1.1913546323776245, 1.0531598329544067]
(pooled O [-1.1688342094421387, 1.0362651348114014]
relative O [-1.2422771453857422, 0.9761200547218323]
risk O [-1.2404906749725342, 1.1790800094604492]
[RR] O [-1.162697196006775, 1.1050035953521729]
per O [-1.197667121887207, 0.9960122108459473]
one O [-0.95818692445755, 1.1237523555755615]
standard O [-1.1148090362548828, 0.9236584305763245]
deviation O [-1.0169646739959717, 1.2098667621612549]
[SD] O [-1.1174994707107544, 1.1140989065170288]
[= O [-1.1444973945617676, 1.0737929344177246]
0.5 O [-1.0214496850967407, 1.109431505203247]
kg] O [-1.2046589851379395, 1.2123706340789795]
increment O [-1.14821195602417, 1.126887559890747]
in O [-1.172729253768921, 0.9783007502555847]
birth O [-1.1767094135284424, 1.262648582458496]
weight: O [-0.9471074938774109, 1.3264744281768799]
1.06; O [-0.9996556043624878, 1.2355000972747803]
95% O [-1.2101945877075195, 1.2898285388946533]
confidence O [-1.1507923603057861, 1.186418056488037]
interval O [-1.1773884296417236, 1.062410831451416]
[CI] O [-1.0667036771774292, 1.1045374870300293]
1.02-1.09) O [-1.125644564628601, 1.1552300453186035]
and O [-1.070612907409668, 1.0391045808792114]
parental O [-1.121010184288025, 1.1962448358535767]
recall O [-1.0127179622650146, 1.1861152648925781]
when O [-1.0074207782745361, 0.955419659614563]
the O [-0.906963050365448, 0.9064481854438782]
participants O [-1.143267273902893, 0.9299471378326416]
were O [-0.6560903787612915, 0.8227832317352295]
children O [-0.7529731392860413, 0.9410593509674072]
(1.02; O [-0.9631130695343018, 0.925469160079956]
95% O [-1.131470799446106, 1.171077013015747]
CI O [-1.095147967338562, 0.8589857220649719]
0.99-1.05), O [-0.8474258780479431, 0.6640599966049194]
but O [-1.0542259216308594, 0.9670934677124023]
not O [-0.8362063765525818, 1.0485143661499023]
in O [-0.8185476660728455, 0.823531448841095]
those O [-0.946262776851654, 0.9563549160957336]
based O [-0.9649398326873779, 0.7538607716560364]
on O [-0.8217032551765442, 0.7785410284996033]
adult O [-1.0965863466262817, 0.8755736947059631]
self-reports, O [-1.065425992012024, 1.0055011510849]
or O [-1.0122486352920532, 0.8906291127204895]

maternal B-LOC [0.13965833187103271, -0.6088464856147766]
recall B-LOC [0.2033916562795639, -0.5440688729286194]
during B-LOC [0.2503941059112549, -0.5186083912849426]
the B-LOC [0.1935146301984787, -0.6091325283050537]
woman's B-LOC [0.0441766120493412, -0.6434985995292664]
adulthood B-LOC [0.25854548811912537, -0.47139111161231995]
(0.98; B-LOC [0.2432243376970291, -0.6114839315414429]
95% B-LOC [0.20254355669021606, -0.4844166338443756]
CI B-LOC [0.074745774269104, -0.45966053009033203]
0.95-1.01) B-LOC [0.3271040618419647, -0.6255853772163391]
(p B-LOC [0.2504822313785553, -0.5917031168937683]
for B-LOC [0.2720809280872345, -0.6164794564247131]
heterogeneity B-LOC [0.8032791018486023, -1.0030028820037842]
between B-LOC [0.692495584487915, -0.9779793620109558]
data B-LOC [0.6512617468833923, -0.8680832982063293]
sources B-LOC [0.575947105884552, -0.8796287775039673]
= B-LOC [0.35655492544174194, -0.7217544317245483]
0.003). B-LOC [0.6250114440917969, -0.8309029936790466]
Relative O [-0.39802637696266174, 0.45375069975852966]
to O [-0.3910025358200073, 0.4775802195072174]
women O [-0.6401309370994568, 0.3803933262825012]
who O [-0.8325361609458923, 0.17712584137916565]
weighed O [-0.43932685256004333, 0.23240308463573456]
3.000-3.499 O [-0.26228010654449463, 0.5906447768211365]
kg, O [-0.49186477065086365, 0.3047909438610077]
the O [-0.5896490812301636, 0.2709260582923889]
risk O [-0.7881737351417542, 0.19074547290802002]
was O [-0.5271658897399902, 0.15694767236709595]
0.96 O [-0.37828579545021057, 0.3236726224422455]
(CI O [-0.4877758324146271, 0.14239034056663513]
0.80-1.16) O [-0.310293972492218, 0.1885233223438263]
in O [-0.719636857509613, 0.302717387676239]
those O [-0.6726750731468201, 0.4265896677970886]
who O [-0.7843853831291199, 0.2912043333053589]
weighed O [-0.513574481010437, 0.28881922364234924]
< O [-0.5033193826675415, 0.3852161467075348]
2.500 O [-0.2999485433101654, 0.6124941110610962]
kg, O [-0.6375668048858643, 0.26620832085609436]
and O [-0.7761741876602173, 0.49133166670799255]
1.12 O [-0.3578829765319824, 0.479923814535141]
(95% O [-0.5397505164146423, 0.09509918838739395]
CI O [-0.5101754069328308, 0.20648208260536194]
1.00-1.25) O [-0.35723355412483215, 0.263889342546463]
in O [-0.6561578512191772, 0.34987545013427734]
those O [-0.5659974217414856, 0.3623711168766022]
who O [-0.6515390276908875, 0.25660255551338196]
weighed O [-0.4562952220439911, 0.21360042691230774]
> O [-0.5162698030471802, 0.42847681045532227]
or O [-0.5835619568824768, 0.12243785709142685]
= O [-0.6231834888458252, -0.03816596046090126]
4.000 O [-0.3760257661342621, 0.38411208987236023]
kg O [-0.6007445454597473, 0.20911820232868195]
(p O [-0.47277843952178955, 0.10812891274690628]
for O [-0.20291268825531006, -0.03327181562781334]
linear O [-0.34430333971977234, 0.036360081285238266]
trend O [-0.39434799551963806, 0.137475848197937]
= O [-0.29983898997306824, -0.1593538224697113]
0.001) O [-0.17064131796360016, 0.0637856274843216]

in B-LOC [0.17047490179538727, -0.8478822708129883]
birth B-LOC [0.4350767433643341, -0.7620051503181458]
record B-LOC [0.3709513247013092, -0.8128933310508728]
data. B-LOC [0.3118581175804138, -0.6500809788703918]
Birth B-LOC [0.33861246705055237, -0.5709379315376282]
length B-LOC [0.36200931668281555, -0.6261735558509827]
and B-LOC [0.5583833456039429, -0.7837263941764832]
head B-LOC [0.33654895424842834, -0.5952475666999817]
circumference B-LOC [0.6478584408760071, -0.7142413854598999]
from B-LOC [0.38291260600090027, -0.8368046283721924]
birth B-LOC [0.40144214034080505, -0.5012423396110535]
records B-LOC [0.2917124629020691, -0.60807204246521]
were B-LOC [0.3121625781059265, -0.7468074560165405]
also B-LOC [0.3674057722091675, -0.6070614457130432]
positively B-LOC [0.30499693751335144, -0.6367048621177673]
associated B-LOC [0.4621058404445648, -0.578235387802124]
with B-LOC [0.35730841755867004, -0.728947103023529]
breast B-LOC [0.11257550120353699, -0.3733108341693878]
cancer B-LOC [0.17108844220638275, -0.5327021479606628]
risk B-LOC [0.23188671469688416, -0.4405471384525299]
(pooled B-LOC [0.31211867928504944, -0.6005994081497192]
RR B-LOC [0.2053566426038742, -0.578899621963501]
per B-LOC [0.24362172186374664, -0.5613715052604675]
one B-LOC [0.40448272228240967, -0.5876802802085876]
SD B-LOC [0.4291161298751831, -0.5548579692840576]
increment: B-LOC [0.3518396317958832, -0.5407493114471436]
1.06 B-LOC [0.21866527199745178, -0.4795227348804474]
[95% B-LOC [0.004301870707422495, -0.590783417224884]
CI B-LOC [-0.14304450154304504, -0.41097143292427063]
1.03-1.10] B-LOC [-0.1309523731470108, -0.3974595367908478]
and B-LOC [0.022183025255799294, -0.5113903880119324]
1.09 B-LOC [0.025996098294854164, -0.45553910732269287]
[95% B-LOC [0.05531306937336922, -0.7511987090110779]
CI B-LOC [-0.15015560388565063, -0.40247151255607605]
1.03-1.15], B-LOC [0.031980086117982864, -0.5496490597724915]
respectively). B-LOC [0.1729099154472351, -0.7506941556930542]
Simultaneous B-LOC [1.5466561317443848, -1.5911155939102173]
adjustment B-LOC [1.5431333780288696, -1.8196769952774048]
for B-LOC [1.808584213256836, -1.6103482246398926]
these B-LOC [1.5429201126098633, -1.472791075706482]
three B-LOC [1.8451321125030518, -1.8447771072387695]
birth B-LOC [1.2675034999847412, -1.566216230392456]
size B-LOC [1.5588024854660034, -1.9519505500793457]
variables B-LOC [1.6791162490844727, -1.9603240489959717]
showed B-LOC [1.2718137502670288, -1.5233159065246582]
that B-LOC [1.2570953369140625, -1.8568084239959717]
length B-LOC [1.6236902475357056, -2.2270145416259766]
was B-LOC [1.649482250213623, -2.0006120204925537]
the B-LOC [1.9935173988342285, -2.0139412879943848]
strongest B-LOC [1.944480538368225, -2.0812246799468994]
independent B-LOC [1.9834492206573486, -2.3137927055358887]
predictor B-LOC [1.848219633102417, -2.3593266010284424]
of B-LOC [1.7769854068756104, -2.3036162853240967]
risk. B-LOC [1.7139043807983398, -2.3365986347198486]
The B-LOC [0.932460367679596, -1.2422360181808472]
birth B-LOC [0.5227939486503601, -0.9814954400062561]
size B-LOC [0.7171425819396973, -0.9960922598838806]
effects B-LOC [0.7492430806159973, -1.2840287685394287]
did B-LOC [0.805381178855896, -1.0356968641281128]
not B-LOC [1.0301387310028076, -1.0931880474090576]
appear B-LOC [1.1600303649902344, -1.2475314140319824]
to B-LOC [1.2808253765106201, -1.2950375080108643]
be B-LOC [1.0889692306518555, -1.2356544733047485]
confounded B-LOC [1.2461531162261963, -1.4152789115905762]
or B-LOC [1.03685462474823, -1.4578742980957031]
mediated B-LOC [0.8364529013633728, -1.2856125831604004]
by B-LOC [0.9536958932876587, -1.2881739139556885]
established B-LOC [0.7716449499130249, -1.1893049478530884]
breast B-LOC [0.6016461253166199, -1.1481623649597168]
cancer B-LOC [0.7836549282073975, -1.5203193426132202]
risk B-LOC [0.8350934386253357, -1.2675226926803589]
factors B-LOC [0.8861646056175232, -1.2626127004623413]
and B-LOC [0.5488818883895874, -1.125182867050171]
were B-LOC [0.9528236985206604, -1.3574879169464111]
not B-LOC [1.045133352279663, -1.2354652881622314]
modified B-LOC [0.6039289832115173, -1.2282190322875977]

by B-LOC [0.5597252249717712, -1.2592228651046753]
age B-LOC [1.58840811252594, -1.6914739608764648]
or B-LOC [1.2302882671356201, -1.751366138458252]
menopausal B-LOC [1.3253923654556274, -1.7408223152160645]
status. B-LOC [0.9805947542190552, -1.557164192199707]
The B-LOC [1.1198949813842773, -1.4880149364471436]
cumulative B-LOC [1.293302059173584, -1.5199017524719238]
incidence B-LOC [0.8293513059616089, -1.4018628597259521]
of B-LOC [1.0480856895446777, -1.326550006866455]
breast B-LOC [0.7628437876701355, -1.2876994609832764]
cancer B-LOC [0.841109573841095, -1.5556491613388062]
per B-LOC [1.079398512840271, -1.190929651260376]
100 B-LOC [1.4128761291503906, -1.534131646156311]
women B-LOC [1.0930497646331787, -1.495142936706543]
by B-LOC [1.0249433517456055, -1.5199729204177856]
age B-LOC [1.7903704643249512, -1.8356527090072632]
80 B-LOC [1.458512783050537, -1.9674773216247559]
y B-LOC [0.8259245753288269, -1.461536169052124]
in B-LOC [1.1366281509399414, -1.2133500576019287]
the B-LOC [1.4125127792358398, -1.3721240758895874]
study B-LOC [1.1933757066726685, -1.6032724380493164]
populations B-LOC [1.03587806224823, -1.4648653268814087]
was B-LOC [0.9485634565353394, -1.4699673652648926]
estimated B-LOC [1.1037051677703857, -1.5501739978790283]
to B-LOC [1.1932497024536133, -1.6531598567962646]
be B-LOC [0.9053231477737427, -1.571506142616272]
10.0, B-LOC [0.9464954137802124, -1.5718374252319336]
10.0, B-LOC [0.9897791743278503, -1.5363445281982422]
10.4, B-LOC [0.9824821352958679, -1.56985604763031]
and B-LOC [0.881373405456543, -1.613410234451294]
11.5 B-LOC [1.1112515926361084, -1.5721087455749512]
in B-LOC [0.7022252678871155, -1.558883547782898]
those B-LOC [1.074961543083191, -1.4257516860961914]
who B-LOC [0.8661745190620422, -1.5154129266738892]
were, B-LOC [0.8771503567695618, -1.5387904644012451]
respectively, B-LOC [0.9543858170509338, -1.8861110210418701]
in B-LOC [0.8356189131736755, -1.449411153793335]
the B-LOC [1.1128406524658203, -1.4664052724838257]
bottom, B-LOC [1.1038358211517334, -1.5094997882843018]
second, B-LOC [0.8656192421913147, -1.4955861568450928]
third, B-LOC [0.9804255962371826, -1.7272627353668213]
and B-LOC [0.8497961163520813, -1.4945955276489258]
top B-LOC [0.9617598652839661, -1.7656821012496948]
fourths B-LOC [1.0822949409484863, -1.571394443511963]
of B-LOC [1.1295125484466553, -1.6532280445098877]
the B-LOC [1.3071566820144653, -1.5766452550888062]
birth B-LOC [1.0304324626922607, -1.5557314157485962]
length B-LOC [1.0550496578216553, -1.6897515058517456]
distribution. B-LOC [1.0150322914123535, -1.5023952722549438]
CONCLUSIONS O [-0.5066917538642883, 0.34403690695762634]
This B-LOC [0.026081183925271034, 0.011828090995550156]
pooled B-LOC [0.4147074222564697, -0.11136317253112793]
analysis B-LOC [0.17103463411331177, -0.25516536831855774]
of B-LOC [0.28147485852241516, -0.25586244463920593]
individual B-LOC [0.11361903697252274, -0.2944558560848236]
participant B-LOC [0.10699555277824402, -0.43235883116722107]
data B-LOC [0.01653398759663105, -0.3292880654335022]
is B-LOC [0.18423904478549957, -0.06962540745735168]
consistent O [0.04285178706049919, 0.07379334419965744]
with O [-0.09834042191505432, 0.028996413573622704]
birth O [-0.02701432816684246, 0.07299292832612991]
size, B-LOC [0.04388761892914772, -0.11900117248296738]
and B-LOC [0.061929527670145035, 0.020467912778258324]
in O [0.0007827380322851241, 0.0769016370177269]
particular B-LOC [0.11689174175262451, 0.017031563445925713]
birth O [-0.05547362193465233, 0.10147695988416672]
length, B-LOC [0.029110180214047432, -0.13868844509124756]
being O [-0.017010090872645378, 0.021747073158621788]
an O [-0.06866121292114258, 0.011190725490450859]
independent B-LOC [0.013497400097548962, -0.02523440308868885]
correlate B-LOC [0.10602082312107086, -0.06388268619775772]
of B-LOC [-0.045418377965688705, -0.32598909735679626]
breast B-LOC [-0.013208047486841679, -0.15999162197113037]
cancer B-LOC [-0.06356002390384674, -0.291868656873703]
risk B-LOC [-0.11935929954051971, -0.2378864586353302]
in B-LOC [-0.14016014337539673, -0.3084579110145569]
adulthood. B-LOC [-0.06449049711227417, -0.15141862630844116]

G-quadruplex B-LOC [1.7956500053405762, -2.0979151725769043]
(G4)-forming B-LOC [1.993272304534912, -2.253032684326172]
genomic B-LOC [2.345700979232788, -2.4338386058807373]
sequences, B-LOC [2.1704049110412598, -2.279585838317871]
including B-LOC [2.190239906311035, -2.1195240020751953]
telomeres, B-LOC [2.08728289604187, -2.412487268447876]
represent B-LOC [2.105295419692993, -2.193228006362915]
natural B-LOC [2.0758779048919678, -2.42242169380188]
replication B-LOC [2.2320783138275146, -2.4388251304626465]
fork B-LOC [2.1003341674804688, -2.7690417766571045]
barriers. B-LOC [2.2045676708221436, -2.436021089553833]
Stalled B-LOC [2.40732741355896, -2.59504771232605]
replication B-LOC [2.3589601516723633, -2.4637763500213623]
forks B-LOC [2.2623817920684814, -2.81750750541687]
can B-LOC [2.266619920730591, -2.4372355937957764]
be B-LOC [2.3392794132232666, -2.6922123432159424]
stabilized B-LOC [2.5843493938446045, -2.7210042476654053]
and B-LOC [2.159555196762085, -2.2807211875915527]
restarted B-LOC [2.226238489151001, -2.6390016078948975]
by B-LOC [2.2485949993133545, -2.4024016857147217]
homologous B-LOC [2.4051594734191895, -2.949291944503784]
recombination B-LOC [2.601168155670166, -2.8185300827026367]
(HR), B-LOC [2.501589059829712, -2.8572542667388916]
which B-LOC [1.8955657482147217, -2.1465165615081787]
also B-LOC [2.2556612491607666, -2.276763439178467]
repairs B-LOC [2.2500619888305664, -2.4546024799346924]
DNA B-LOC [2.1802608966827393, -2.7063353061676025]
double-strand B-LOC [2.908062219619751, -2.735910177230835]
breaks B-LOC [2.6606128215789795, -2.661144971847534]
(DSBs) B-LOC [2.4919822216033936, -2.691667079925537]
arising B-LOC [2.210078716278076, -2.4104456901550293]
at B-LOC [2.3827974796295166, -2.597303628921509]
collapsed B-LOC [2.426011562347412, -2.7075648307800293]
forks. B-LOC [2.4084012508392334, -2.914384126663208]
We B-LOC [1.3925660848617554, -1.4669227600097656]
have B-LOC [2.2117042541503906, -1.6024709939956665]
previously B-LOC [2.0061533451080322, -1.6187885999679565]
shown B-LOC [1.8216469287872314, -1.3408247232437134]
that B-LOC [1.4493184089660645, -1.6783394813537598]
HR B-LOC [1.486350178718567, -1.6026867628097534]
facilitates B-LOC [1.6353453397750854, -1.594734787940979]
telomere B-LOC [2.039194345474243, -2.08878493309021]
replication. B-LOC [1.8859925270080566, -1.7639400959014893]
Here, O [-0.3011256754398346, 0.09099935740232468]
we O [-0.33546948432922363, 0.0722273588180542]
demonstrate O [-0.26385805010795593, 0.23594221472740173]
that O [-0.491210013628006, 0.17623507976531982]
the O [-0.14998328685760498, -0.1030823364853859]
replication B-LOC [0.13165408372879028, 0.0564328096807003]
efficiency B-LOC [-0.07308120280504227, -0.14379969239234924]
of B-LOC [0.08197826892137527, -0.1362840235233307]
guanine-rich O [-0.002167677041143179, 0.11105270683765411]
(G-rich) O [-0.08142143487930298, -0.05940365418791771]
telomeric B-LOC [0.2135305106639862, -0.24703353643417358]
repeats B-LOC [0.09096935391426086, -0.0464727021753788]
is B-LOC [0.07062247395515442, -0.05169566348195076]
decreased B-LOC [0.014790656976401806, -0.044788483530282974]
significantly O [-0.1745707094669342, 0.014115503057837486]
in B-LOC [0.1300463080406189, 0.008229097351431847]
cells B-LOC [-0.021670037880539894, -0.07866378128528595]
lacking O [0.014613685198128223, 0.0233090128749609]
HR. B-LOC [-0.05056660994887352, -0.17178203165531158]
Treatment B-LOC [0.2769176661968231, -0.25042954087257385]
with B-LOC [0.35494470596313477, -0.2859914302825928]
the B-LOC [0.19470509886741638, -0.19118797779083252]

G4-stabilizing O [-0.07403910160064697, 0.0626630038022995]
compound B-LOC [0.04086645692586899, -0.14569750428199768]
pyridostatin B-LOC [0.0043238927610218525, -0.15524615347385406]
(PDS) O [-0.07682964950799942, 0.15751546621322632]
increases O [-0.04654178023338318, 0.14982429146766663]
telomere B-LOC [0.020888609811663628, -0.07054062932729721]
fragility O [-0.01599833555519581, 0.09024491161108017]
in O [-0.17627689242362976, 0.053716134279966354]
BRCA2-deficient O [-0.14874598383903503, -0.013207385316491127]
cells, O [-0.2191532701253891, 0.017206816002726555]
suggesting O [-0.13703672587871552, 0.14419950544834137]
that O [-0.3112165629863739, 0.005424556788057089]
G4 O [-0.12727515399456024, 0.08787480741739273]
formation O [-0.0067515200935304165, 0.08792787790298462]
drives B-LOC [-0.02279248647391796, -0.0854281634092331]
telomere B-LOC [0.07104219496250153, -0.21495762467384338]
instability. B-LOC [0.03146945312619209, -0.11291806399822235]
Remarkably, O [-0.5884303450584412, 0.8873186111450195]
PDS O [-0.5662644505500793, 0.768025815486908]
reduces O [-0.8912561535835266, 1.0645668506622314]
proliferation O [-0.9235664010047913, 1.128484845161438]
of O [-1.126064419746399, 0.9943482875823975]
HR-defective O [-0.6936708092689514, 0.6495486497879028]
cells O [-0.9011740684509277, 0.8403862714767456]
by O [-1.4185386896133423, 1.216468334197998]
inducing O [-1.3049259185791016, 1.2001217603683472]
DSB O [-0.8268188834190369, 0.866986870765686]
accumulation, O [-0.8166781067848206, 1.0971531867980957]
checkpoint O [-1.1161479949951172, 0.9308639168739319]
activation, O [-0.892374575138092, 0.9360218048095703]
and O [-1.312992811203003, 1.1023752689361572]
deregulated O [-1.0427571535110474, 1.0386908054351807]
G2/M O [-0.614181637763977, 0.6751790046691895]
progression O [-0.9798721671104431, 0.9870254397392273]
and O [-0.8781903982162476, 0.9841615557670593]
by O [-1.2154135704040527, 1.137548804283142]
enhancing O [-1.0687588453292847, 1.0430045127868652]
the O [-0.942281186580658, 0.8320322632789612]
replication O [-0.5683807134628296, 0.6426488757133484]
defect O [-0.8358509540557861, 0.9070329070091248]
intrinsic O [-0.6550062298774719, 0.6850161552429199]
to O [-0.4999416172504425, 0.517041802406311]
HR O [-0.55729740858078, 0.38768044114112854]
deficiency. O [-0.6157954335212708, 0.6688255667686462]
PDS B-LOC [0.32201895117759705, -0.590029776096344]
toxicity B-LOC [0.4940764904022217, -0.7385787963867188]
extends B-LOC [0.5957481265068054, -0.7982845306396484]
to B-LOC [0.5927668213844299, -0.5478345155715942]
HR-defective B-LOC [0.25869715213775635, -0.6243265867233276]
cells B-LOC [0.16908347606658936, -0.5590388774871826]
that B-LOC [0.2065543234348297, -0.7437576651573181]
have B-LOC [0.2987968623638153, -0.5952462553977966]
acquired B-LOC [0.07356451451778412, -0.38858720660209656]
olaparib B-LOC [-0.05626634508371353, -0.20019133388996124]
resistance B-LOC [0.012935790233314037, -0.29096680879592896]
through B-LOC [-0.09986202418804169, -0.3961770534515381]
loss B-LOC [0.16178041696548462, -0.2841450273990631]
of B-LOC [-0.13891658186912537, -0.3357018232345581]

53BP1 B-LOC [0.26707515120506287, -0.4641137421131134]
or B-LOC [0.431594580411911, -0.5686770081520081]
REV7. B-LOC [0.1735934615135193, -0.4954227805137634]
Altogether, B-LOC [0.4798332154750824, -0.6682237386703491]
these B-LOC [0.6051543951034546, -0.4540543556213379]
results B-LOC [0.6248199939727783, -0.3817744851112366]
highlight B-LOC [0.8333137631416321, -0.6879938840866089]
the B-LOC [0.9411875605583191, -0.974212110042572]
therapeutic B-LOC [0.7176308035850525, -0.6726252436637878]
potential B-LOC [0.6258636116981506, -0.8154589533805847]
of B-LOC [0.3756333291530609, -0.6962054967880249]
G4-stabilizing B-LOC [0.23690134286880493, -0.2609175145626068]
drugs B-LOC [0.43689945340156555, -0.5357258915901184]
to B-LOC [0.41386544704437256, -0.5958858132362366]
selectively B-LOC [0.4187332093715668, -0.43366122245788574]
eliminate B-LOC [0.4409850537776947, -0.22459112107753754]
HR-compromised B-LOC [0.29337528347969055, -0.3798076808452606]
cells B-LOC [0.08146774768829346, -0.3577852249145508]
and B-LOC [0.4306545555591583, -0.39454442262649536]
tumors, B-LOC [0.3315398395061493, -0.5019926428794861]
including B-LOC [0.5387946367263794, -0.2905561625957489]
those B-LOC [0.3289078176021576, -0.15736988186836243]
resistant B-LOC [0.4311995804309845, -0.36410242319107056]
to B-LOC [0.13377082347869873, -0.44389817118644714]
PARP B-LOC [0.23037120699882507, -0.38861382007598877]
inhibition. B-LOC [0.17140188813209534, -0.3943474590778351]

OBJECTIVES B-LOC [3.2328035831451416, -3.645646095275879]
To B-LOC [3.3604061603546143, -3.585031270980835]
determine B-LOC [3.5690200328826904, -3.495556116104126]
the B-LOC [3.671309471130371, -3.385000467300415]
incidence B-LOC [3.639495849609375, -3.428135395050049]
and B-LOC [3.3279716968536377, -3.2551887035369873]
clinical B-LOC [3.8416762351989746, -3.501722574234009]
importance B-LOC [3.502782106399536, -3.400041341781616]
of B-LOC [3.5786163806915283, -3.521301507949829]
errors B-LOC [3.4697463512420654, -3.298769950866699]
in B-LOC [3.4304826259613037, -3.255847692489624]
the B-LOC [3.5669777393341064, -3.3625879287719727]
preparation B-LOC [3.7534401416778564, -3.6254847049713135]
and B-LOC [3.2917721271514893, -3.145209789276123]
administration B-LOC [3.714811325073242, -3.4575583934783936]
of B-LOC [3.392779588699341, -3.297072649002075]
intravenous B-LOC [3.361043930053711, -3.5503828525543213]
drugs B-LOC [3.62014102935791, -3.599710464477539]
and B-LOC [3.509242296218872, -3.2471072673797607]
the B-LOC [3.68625545501709, -3.2906334400177]
stages B-LOC [3.726931095123291, -3.2400879859924316]
of B-LOC [3.4950554370880127, -3.225429058074951]
the B-LOC [3.6377828121185303, -3.187774658203125]
process B-LOC [3.6874654293060303, -3.2420828342437744]
in B-LOC [3.2283236980438232, -3.1185107231140137]
which B-LOC [3.393765926361084, -3.2344772815704346]
errors B-LOC [3.4444470405578613, -3.1667678356170654]
occur. B-LOC [3.51468825340271, -3.3833744525909424]
DESIGN B-LOC [3.45906925201416, -3.482905864715576]
Prospective B-LOC [3.390972852706909, -3.4873220920562744]
ethnographic B-LOC [3.5469300746917725, -3.4598605632781982]
study B-LOC [3.4227309226989746, -3.498566150665283]
using B-LOC [3.1852614879608154, -3.499953031539917]
disguised B-LOC [3.418330430984497, -3.3845419883728027]
observation. B-LOC [3.6910247802734375, -3.5548627376556396]
PARTICIPANTS B-LOC [3.1692657470703125, -3.3976714611053467]
Nurses B-LOC [3.6073827743530273, -3.5009806156158447]
who B-LOC [3.3231639862060547, -3.479750394821167]
prepared B-LOC [3.6218085289001465, -3.547389030456543]
and B-LOC [3.058026075363159, -3.091049909591675]
administered B-LOC [3.6211769580841064, -3.36893367767334]
intravenous B-LOC [3.4667906761169434, -3.238044023513794]
drugs. B-LOC [3.615438461303711, -3.5134494304656982]
SETTING B-LOC [3.1488964557647705, -3.185152292251587]
10 B-LOC [3.718841075897217, -3.059422254562378]
wards B-LOC [3.8261237144470215, -3.0927014350891113]
in B-LOC [3.494290351867676, -2.736612558364868]
a B-LOC [3.2289206981658936, -2.791417360305786]
teaching B-LOC [3.4400579929351807, -3.1305081844329834]
and B-LOC [3.23382306098938, -2.7847347259521484]
non-teaching B-LOC [3.1047043800354004, -2.7274844646453857]
hospital B-LOC [3.5592594146728516, -3.294729232788086]
in B-LOC [3.707374334335327, -2.87272047996521]
the B-LOC [3.5743112564086914, -2.920801877975464]
United B-LOC [3.432544231414795, -3.346859931945801]
Kingdom. B-LOC [3.413240909576416, -3.1765072345733643]
MAIN B-LOC [3.3337385654449463, -3.1571881771087646]
OUTCOME B-LOC [3.1083571910858154, -2.9179937839508057]
MEASURES B-LOC [3.0325732231140137, -2.9643263816833496]
Number, B-LOC [3.3918607234954834, -3.0865046977996826]
type, B-LOC [3.640346050262451, -3.155327796936035]
and B-LOC [3.1563897132873535, -2.85772705078125]
clinical B-LOC [3.7962770462036133, -3.1372344493865967]
importance B-LOC [3.32049298286438, -3.2100746631622314]
of B-LOC [3.2984111309051514, -3.0417544841766357]
errors. B-LOC [3.391523599624634, -3.051020860671997]
RESULTS B-LOC [2.01228404045105, -2.5926010608673096]
249 B-LOC [3.1493589878082275, -2.8771047592163086]
errors B-LOC [3.1536712646484375, -3.121021270751953]
were B-LOC [3.246880292892456, -3.0969579219818115]
identified. B-LOC [3.612522602081299, -3.0750341415405273]
At B-LOC [2.204331636428833, -2.5659847259521484]
least B-LOC [2.8118999004364014, -2.4674832820892334]
one B-LOC [1.7930846214294434, -2.0230705738067627]

error B-LOC [0.3528389036655426, -0.6973766684532166]
occurred B-LOC [0.46298518776893616, -0.7364686131477356]
in B-LOC [0.5280229449272156, -0.7231821417808533]
212 B-LOC [0.8259530067443848, -0.6464898586273193]
out B-LOC [0.484557569026947, -0.5464321374893188]
of B-LOC [0.5076408982276917, -0.6450028419494629]
430 B-LOC [0.712662935256958, -0.581292450428009]
intravenous B-LOC [0.32200393080711365, -0.7955849766731262]
drug B-LOC [0.29884228110313416, -0.8758611083030701]
doses B-LOC [0.3265600800514221, -0.5457495450973511]
(49%, B-LOC [0.318219929933548, -0.6178408861160278]
95% B-LOC [-0.05386127158999443, -0.3093961775302887]
confidence B-LOC [-0.0538751445710659, -0.2637600600719452]
interval B-LOC [-0.044562581926584244, -0.3777296245098114]
45% O [-0.1226167306303978, -0.08916210383176804]
to B-LOC [-0.12198120355606079, -0.38968390226364136]
54%). B-LOC [0.11845416575670242, -0.38951918482780457]
Three B-LOC [0.3228472173213959, -0.5015068054199219]
doses B-LOC [0.508455753326416, -0.5435810089111328]
(1%) B-LOC [0.4580492675304413, -0.6902950406074524]
had B-LOC [0.4185549318790436, -0.7436209917068481]
potentially B-LOC [0.4323069453239441, -0.8328220248222351]
severe B-LOC [0.2967580258846283, -0.7206704020500183]
errors, B-LOC [0.4724946916103363, -0.7733836770057678]
126 B-LOC [0.6272484660148621, -0.6377430558204651]
(29%) B-LOC [0.37222203612327576, -0.5856341123580933]
potentially B-LOC [0.2884328067302704, -0.7786372900009155]
moderate B-LOC [0.17116281390190125, -0.6077367663383484]
errors, B-LOC [0.3848181664943695, -0.7116659879684448]
and B-LOC [0.5849499106407166, -0.7527273297309875]
83 B-LOC [0.7428032755851746, -0.7459802031517029]
(19%) B-LOC [0.46698909997940063, -0.6646981835365295]
potentially B-LOC [0.4419002830982208, -0.9339307546615601]
minor B-LOC [0.3291424512863159, -0.7384203672409058]
errors. B-LOC [0.49495407938957214, -0.9427303671836853]
Most B-LOC [1.3963865041732788, -1.7091741561889648]
errors B-LOC [1.3263870477676392, -1.796800136566162]
occurred B-LOC [1.1992753744125366, -1.6199506521224976]
when B-LOC [1.0007727146148682, -1.3829176425933838]
giving B-LOC [1.0861811637878418, -1.4262574911117554]
bolus B-LOC [0.9723219871520996, -1.4957265853881836]
doses B-LOC [1.181563138961792, -1.4854130744934082]
or B-LOC [1.2099802494049072, -1.4575506448745728]
making B-LOC [1.384832739830017, -1.555518627166748]
up B-LOC [1.3861565589904785, -1.6562952995300293]
drugs B-LOC [1.0227417945861816, -1.6326675415039062]
that B-LOC [1.0272563695907593, -1.4961602687835693]
required B-LOC [0.8325596451759338, -1.3952610492706299]
multiple B-LOC [1.2585066556930542, -1.778839111328125]
step B-LOC [1.1957093477249146, -1.8049132823944092]
preparation. B-LOC [1.1237231492996216, -1.450927972793579]
CONCLUSIONS O [-0.33640947937965393, -0.2422848790884018]
The B-LOC [1.3205312490463257, -1.897478699684143]
rate B-LOC [1.588545322418213, -2.3687868118286133]
of B-LOC [1.724974513053894, -2.1294968128204346]
intravenous B-LOC [1.4831565618515015, -2.190239191055298]
drug B-LOC [1.5676734447479248, -2.4659252166748047]
errors B-LOC [1.6629602909088135, -2.119943857192993]
was B-LOC [1.2799440622329712, -1.9040348529815674]
high. B-LOC [1.5326156616210938, -2.1808464527130127]
Although B-LOC [1.0595611333847046, -1.440971851348877]
most B-LOC [1.4995627403259277, -1.8575468063354492]
errors B-LOC [1.8883389234542847, -2.141042709350586]
would B-LOC [1.3444072008132935, -1.5912199020385742]
cause B-LOC [1.6007318496704102, -2.12882661819458]
only B-LOC [1.8681247234344482, -1.8471243381500244]
short B-LOC [1.7955974340438843, -1.6176154613494873]
term B-LOC [1.8514655828475952, -1.9997292757034302]
adverse B-LOC [2.001289129257202, -2.408221960067749]
effects, B-LOC [1.9303267002105713, -2.2293612957000732]
a B-LOC [1.6133638620376587, -2.0399253368377686]
few B-LOC [1.6569768190383911, -2.0445492267608643]
could B-LOC [1.3778451681137085, -1.968802571296692]
have B-LOC [1.5578455924987793, -1.8390132188796997]
been B-LOC [1.585840106010437, -2.1429336071014404]
serious. B-LOC [1.8851087093353271, -2.122506618499756]
A B-LOC [0.20843951404094696, -0.5024940371513367]
combination B-LOC [0.1446906179189682, -0.3768383264541626]
of B-LOC [0.13473281264305115, -0.3557989001274109]
reducing B-LOC [0.2086557298898697, -0.35169580578804016]
the B-LOC [0.2841745615005493, -0.43880191445350647]
amount B-LOC [0.22324109077453613, -0.46456149220466614]
of B-LOC [0.1494588851928711, -0.5158883929252625]
preparation B-LOC [0.5206264853477478, -0.6694675087928772]
on B-LOC [0.3789108097553253, -0.5787333846092224]
the B-LOC [0.34431976079940796, -0.45063504576683044]
ward, B-LOC [0.7086557149887085, -1.026330590248108]

training, O [-0.23773318529129028, 0.11792077124118805]
and O [0.011877122335135937, 0.17386549711227417]
technology B-LOC [0.1130729615688324, -0.11961384117603302]
to O [0.15330776572227478, 0.21218132972717285]
administer B-LOC [0.16849276423454285, -0.07704778760671616]
slow O [-0.05949101969599724, 0.07073305547237396]
bolus B-LOC [-0.06340828537940979, -0.23723706603050232]
doses B-LOC [0.03767702355980873, -0.002982946578413248]
would B-LOC [0.06756749749183655, -0.21429523825645447]
probably B-LOC [0.30509376525878906, -0.19935977458953857]
have B-LOC [0.26397794485092163, -0.23227515816688538]
the B-LOC [0.5256673097610474, -0.21235689520835876]
greatest B-LOC [0.3496192991733551, -0.2872937321662903]
effect B-LOC [0.0963468849658966, -0.5503730773925781]
on B-LOC [0.11201749742031097, -0.3595997989177704]
error B-LOC [0.2344716489315033, -0.3184351623058319]
rates. B-LOC [0.11359463632106781, -0.31391963362693787]

CONTEXT B-LOC [1.4279803037643433, -2.219924211502075]
Blood B-LOC [1.8194117546081543, -2.8392372131347656]
type B-LOC [2.314432144165039, -2.6392178535461426]
and B-LOC [2.1867949962615967, -2.642970323562622]
crossmatch B-LOC [2.1073410511016846, -3.0084948539733887]
incompatibility B-LOC [2.1364238262176514, -2.75130033493042]
will B-LOC [1.8892042636871338, -2.4724366664886475]
exclude B-LOC [2.1505587100982666, -2.3328371047973633]
at B-LOC [2.266632318496704, -2.7041280269622803]
least B-LOC [2.223224401473999, -2.9094488620758057]
one B-LOC [2.021329641342163, -2.554462194442749]
third B-LOC [2.193901300430298, -2.6953675746917725]
of B-LOC [2.0822458267211914, -2.808310031890869]
patients B-LOC [2.24635910987854, -2.790299892425537]
in B-LOC [2.74544358253479, -2.944730281829834]
need B-LOC [2.4807181358337402, -2.76151967048645]
from B-LOC [2.2391021251678467, -2.6571695804595947]
receiving B-LOC [2.0865068435668945, -2.656191110610962]
a B-LOC [2.219294548034668, -2.8767731189727783]
live B-LOC [1.9869468212127686, -2.7610960006713867]
donor B-LOC [2.290235757827759, -2.9505345821380615]
kidney B-LOC [1.848299264907837, -2.8268167972564697]
transplant. B-LOC [1.9920270442962646, -2.708404779434204]
Kidney B-LOC [2.1028692722320557, -2.025830030441284]
paired B-LOC [2.0106360912323, -2.2715961933135986]
donation B-LOC [1.794696569442749, -2.153437852859497]
(KPD) B-LOC [1.8509364128112793, -2.0612456798553467]
offers B-LOC [1.6846598386764526, -1.650602102279663]
incompatible B-LOC [1.615644931793213, -1.765714406967163]
donor/recipient B-LOC [2.086899518966675, -2.279320001602173]
pairs B-LOC [1.9547415971755981, -2.2364695072174072]
the B-LOC [1.7782833576202393, -1.9626505374908447]
opportunity B-LOC [1.6589066982269287, -2.1041650772094727]
to B-LOC [1.877171277999878, -2.3613603115081787]
match B-LOC [1.8582415580749512, -2.390702247619629]
for B-LOC [2.090815782546997, -2.4526257514953613]
compatible B-LOC [1.7595105171203613, -2.45353627204895]
transplants. B-LOC [1.8985729217529297, -2.42037296295166]
Despite B-LOC [2.5881805419921875, -2.3477938175201416]
its B-LOC [2.598886728286743, -2.414050817489624]
increasing B-LOC [2.3920252323150635, -2.316692352294922]
popularity, B-LOC [2.5983035564422607, -2.1827099323272705]
very B-LOC [2.8974714279174805, -2.278770685195923]
few B-LOC [2.755850315093994, -2.6361029148101807]
transplants B-LOC [3.203237771987915, -3.0335891246795654]
have B-LOC [2.95656418800354, -2.6044251918792725]
resulted B-LOC [2.951781988143921, -2.748044729232788]
from B-LOC [2.765535593032837, -2.5112216472625732]
KPD. B-LOC [2.2375946044921875, -2.2439124584198]
OBJECTIVE B-LOC [3.1639866828918457, -3.16015362739563]
To B-LOC [3.2658421993255615, -3.0712883472442627]
determine B-LOC [3.449371099472046, -3.097642421722412]
the B-LOC [3.4761993885040283, -2.89695143699646]
potential B-LOC [3.3812716007232666, -3.247525453567505]
impact B-LOC [3.3054518699645996, -3.280454158782959]
of B-LOC [3.1416642665863037, -2.907715082168579]
improved B-LOC [3.0571422576904297, -3.3131330013275146]
matching B-LOC [3.1727445125579834, -3.2471024990081787]
schemes B-LOC [3.4385147094726562, -3.189500093460083]
on B-LOC [3.184283494949341, -2.814288854598999]
the B-LOC [3.4250900745391846, -2.790511131286621]
number B-LOC [3.293902635574341, -3.175952672958374]
and B-LOC [3.110443353652954, -2.796907663345337]
quality B-LOC [3.3701858520507812, -3.414757013320923]
of B-LOC [3.2610015869140625, -2.960552930831909]
transplants B-LOC [3.3876006603240967, -3.1363561153411865]
achievable B-LOC [3.459002733230591, -3.072896957397461]
with B-LOC [3.284759998321533, -3.091092109680176]
KPD. B-LOC [3.170619487762451, -2.9558379650115967]
DESIGN, B-LOC [2.908910036087036, -2.8550922870635986]
SETTING, B-LOC [2.3235158920288086, -2.73799729347229]
AND B-LOC [2.857976198196411, -3.10737943649292]

POPULATION B-LOC [2.62099289894104, -3.347367525100708]
We B-LOC [3.114532470703125, -3.414888858795166]
developed B-LOC [3.366708517074585, -3.26859450340271]
a B-LOC [3.4026854038238525, -3.476907253265381]
model B-LOC [3.417443037033081, -3.7193892002105713]
that B-LOC [3.265413999557495, -3.7823832035064697]
simulates B-LOC [3.5745742321014404, -3.8490407466888428]
pools B-LOC [3.5858778953552246, -3.6171538829803467]
of B-LOC [3.526414632797241, -3.7228260040283203]
incompatible B-LOC [3.517688512802124, -3.6821224689483643]
donor/recipient B-LOC [3.5084540843963623, -3.723372220993042]
pairs. B-LOC [3.4303925037384033, -3.5765633583068848]
We B-LOC [3.276132345199585, -3.572298049926758]
designed B-LOC [3.567967414855957, -3.464085102081299]
a B-LOC [3.559537887573242, -3.680233955383301]
mathematically B-LOC [3.753964424133301, -3.8126885890960693]
verifiable B-LOC [3.648010492324829, -3.718296766281128]
optimized B-LOC [3.5911452770233154, -3.7876789569854736]
matching B-LOC [3.621371269226074, -3.9042227268218994]
algorithm B-LOC [3.5911242961883545, -3.8608810901641846]
and B-LOC [3.4069509506225586, -3.5968077182769775]
compared B-LOC [3.708573341369629, -3.753723621368408]
it B-LOC [3.4753801822662354, -3.795724630355835]
with B-LOC [3.652831554412842, -3.919804334640503]
the B-LOC [3.6198151111602783, -3.7664947509765625]
scheme B-LOC [3.6221702098846436, -3.740410804748535]
currently B-LOC [3.69939923286438, -3.7156097888946533]
used B-LOC [3.6112468242645264, -3.7489404678344727]
in B-LOC [3.5567662715911865, -3.6629772186279297]
some B-LOC [3.4364960193634033, -3.913679361343384]
centers B-LOC [3.7118980884552, -3.9096224308013916]
and B-LOC [3.478532552719116, -3.7392752170562744]
regions. B-LOC [3.8755946159362793, -3.812655448913574]
Simulated B-LOC [3.1591432094573975, -3.4520955085754395]
patients B-LOC [3.6522836685180664, -3.404691457748413]
from B-LOC [3.529747724533081, -3.6363136768341064]
the B-LOC [3.4778430461883545, -3.256249189376831]
general B-LOC [3.5867912769317627, -3.7841951847076416]
community B-LOC [3.617952585220337, -3.540727138519287]
with B-LOC [3.463116407394409, -3.4593167304992676]
characteristics B-LOC [3.581838846206665, -3.6758687496185303]
drawn B-LOC [3.5121805667877197, -3.5308375358581543]
from B-LOC [3.4496686458587646, -3.5734665393829346]
distributions B-LOC [3.7935211658477783, -3.4946346282958984]
describing B-LOC [3.490565538406372, -3.6011016368865967]
end-stage B-LOC [3.729469060897827, -3.57405161857605]
renal B-LOC [3.356506824493408, -3.314230442047119]
disease B-LOC [3.6027281284332275, -3.4790942668914795]
patients B-LOC [3.610081434249878, -3.295276403427124]
eligible B-LOC [3.5952553749084473, -3.3507649898529053]
for B-LOC [3.1336772441864014, -2.8858823776245117]
renal B-LOC [3.3266093730926514, -3.221771478652954]
transplantation B-LOC [3.594501256942749, -3.272568464279175]
and B-LOC [3.646049737930298, -3.5858547687530518]
their B-LOC [3.5620694160461426, -3.4416425228118896]
willing B-LOC [3.5100457668304443, -3.654738664627075]
and B-LOC [3.3320157527923584, -3.4808719158172607]
eligible B-LOC [3.6538660526275635, -3.520505666732788]
live B-LOC [3.4778685569763184, -3.749774217605591]
donors. B-LOC [3.5952136516571045, -3.32405161857605]
MAIN B-LOC [2.9619884490966797, -2.8464090824127197]
OUTCOME B-LOC [2.64550518989563, -2.50844144821167]
MEASURES B-LOC [2.596362352371216, -2.432004928588867]
Number B-LOC [2.908503293991089, -2.4149656295776367]
of B-LOC [2.9329679012298584, -2.5719943046569824]
kidneys B-LOC [3.1111533641815186, -3.064549207687378]
matched, B-LOC [3.1995575428009033, -2.806992769241333]
HLA B-LOC [3.0387136936187744, -2.608586072921753]
mismatch B-LOC [3.103855848312378, -2.6808159351348877]
of B-LOC [3.1183595657348633, -2.438669443130493]
matched B-LOC [3.008206367492676, -2.876671075820923]
kidneys, B-LOC [3.136896848678589, -3.015899419784546]
and B-LOC [2.9827003479003906, -2.7644853591918945]
number B-LOC [3.011759042739868, -2.619642972946167]
of B-LOC [2.9979965686798096, -2.393911123275757]
grafts B-LOC [3.2953569889068604, -2.5804214477539062]
surviving B-LOC [3.4439384937286377, -2.7168073654174805]
5 B-LOC [3.1052637100219727, -2.3876230716705322]
years B-LOC [3.119420051574707, -2.4407026767730713]

after B-LOC [0.18615564703941345, -0.6048088073730469]
transplantation. B-LOC [0.28654351830482483, -0.6267136335372925]
RESULTS O [-0.6930457949638367, 0.2854554355144501]
A O [-0.8075776696205139, 0.8325182795524597]
national O [-0.6871887445449829, 0.7220192551612854]
optimized O [-0.49043238162994385, 0.8827494978904724]
matching O [-0.4583750069141388, 0.6941200494766235]
algorithm O [-0.4509698152542114, 0.7583637833595276]
would O [-0.8692544102668762, 0.9270405173301697]
result O [-0.7934180498123169, 1.0048410892486572]
in O [-0.8866435885429382, 1.1247470378875732]
more O [-0.8027195930480957, 1.1557451486587524]
transplants O [-0.4984630346298218, 1.00052011013031]
(47.7% O [-0.9386391043663025, 1.0338428020477295]
vs O [-0.7732903361320496, 0.474370539188385]
42.0%, O [-0.40478837490081787, 0.9124245047569275]
P<.001), O [-0.6188061833381653, 0.9073880314826965]
better O [-0.8229818940162659, 1.2370797395706177]
HLA O [-0.7346316576004028, 1.0472744703292847]
concordance O [-0.6606734991073608, 0.9824968576431274]
(3.0 O [-0.8373552560806274, 1.1137421131134033]
vs O [-0.6531586050987244, 0.7024291157722473]
4.5 O [-0.633108377456665, 1.213600516319275]
mismatched O [-0.4934532046318054, 0.8396018743515015]
antigens; O [-0.6435197591781616, 1.0675158500671387]
P<.001), O [-0.6754248738288879, 1.0305185317993164]
more O [-0.8136126399040222, 1.261750340461731]
grafts O [-0.6668415665626526, 1.0787553787231445]
surviving O [-0.534152090549469, 1.0524340867996216]
at O [-0.8064335584640503, 1.0869450569152832]
5 O [-0.6526795625686646, 1.1199333667755127]
years O [-0.6315433382987976, 1.057138204574585]
(34.9% O [-0.863376796245575, 0.8742664456367493]
vs O [-0.7978084683418274, 0.4413917362689972]
28.7%; O [-0.44780561327934265, 1.0835086107254028]
P<.001), O [-0.6722176671028137, 0.8075869083404541]
and O [-0.9040426015853882, 1.1510047912597656]
a O [-0.869166374206543, 1.0689765214920044]
reduction O [-0.7094834446907043, 0.8904690146446228]
in O [-0.7668636441230774, 0.7863027453422546]
the O [-0.8461686968803406, 0.902056872844696]
number O [-0.5339220762252808, 0.6981042623519897]
of O [-0.5919831991195679, 0.6655744910240173]
pairs O [-0.4962334632873535, 0.45114609599113464]
required O [-0.4526938498020172, 0.4650662839412689]
to O [-0.42950138449668884, 0.323079913854599]
travel O [-0.5197650790214539, 0.4523569345474243]
(2.9% O [-0.7922462821006775, 0.643215000629425]
vs O [-0.7537513375282288, 0.2513066828250885]
18.4%; O [-0.5224378108978271, 0.7476664185523987]
P<.001) O [-0.6044095754623413, 0.6188854575157166]
when O [-0.736285388469696, 0.8660888671875]
compared O [-0.8030106425285339, 1.052846908569336]
with O [-0.5577811002731323, 0.829617440700531]
an O [-0.5984649062156677, 0.6223122477531433]
extension O [-0.3649626672267914, 0.5882654190063477]
of O [-0.4861646592617035, 0.5566368699073792]
the O [-0.3817993700504303, 0.5414997935295105]
currently O [-0.23800721764564514, 0.3251822590827942]
used O [-0.40434935688972473, 0.39609861373901367]

first-accept B-LOC [-0.08817695826292038, -0.35710373520851135]
scheme B-LOC [0.11954362690448761, -0.3023230731487274]
to B-LOC [0.09911647439002991, -0.3683876097202301]
a B-LOC [0.10659502446651459, -0.22734177112579346]
national B-LOC [0.07769009470939636, -0.3925154209136963]
level. B-LOC [-0.007135485764592886, -0.3941865861415863]
Furthermore, B-LOC [0.04651371389627457, 0.022844223305583]
highly B-LOC [-0.04519465193152428, -0.1905379444360733]
sensitized B-LOC [0.17685389518737793, -0.1593054234981537]
patients B-LOC [-0.030172672122716904, -0.2600875794887543]
would B-LOC [-0.034550223499536514, -0.18063859641551971]
benefit B-LOC [0.0012368509778752923, -0.1818731129169464]
6-fold O [-0.025872526690363884, 0.020138828083872795]
from B-LOC [0.0849742442369461, -0.041299182921648026]
a B-LOC [0.04927597567439079, -0.1591046154499054]
national B-LOC [-0.07782117277383804, -0.36257997155189514]
optimized B-LOC [0.07924550771713257, -0.21992218494415283]
scheme B-LOC [0.016758328303694725, -0.27575576305389404]
(2.3% B-LOC [-0.01854572258889675, -0.15208245813846588]
vs B-LOC [-0.1693764179944992, -0.28295329213142395]
14.1% O [-0.018700597807765007, 0.05795527249574661]
successfully O [-0.09024506062269211, -0.022399647161364555]
matched; B-LOC [0.09043420851230621, -0.27454012632369995]
P<.001). O [-0.1521761268377304, -0.11092963069677353]
Even O [0.04242479428648949, 0.07314173877239227]
if O [-0.30346235632896423, -0.0846191793680191]
only O [-0.034019920974969864, 0.11951937526464462]
7% O [0.13522984087467194, 0.14459145069122314]
of O [-0.30485641956329346, 0.13863514363765717]
patients O [-0.19178423285484314, 0.03625788539648056]
awaiting O [-0.15154001116752625, 0.05176926776766777]
kidney B-LOC [-0.10903021693229675, -0.22759845852851868]
transplantation B-LOC [-0.0403282605111599, -0.05184100940823555]
participated O [-0.28961437940597534, 0.18854066729545593]
in O [-0.22504675388336182, 0.20687270164489746]
an O [-0.27824726700782776, -0.026847364380955696]
optimized O [-0.15652664005756378, 0.08000731468200684]
national B-LOC [-0.1774030327796936, -0.2832694947719574]
KPD B-LOC [0.21209785342216492, -0.431612104177475]
program, O [-0.3263770639896393, -0.057314611971378326]
the B-LOC [-0.030148496851325035, -0.24026957154273987]
health B-LOC [0.2262255847454071, -0.6983151435852051]
care B-LOC [0.13363432884216309, -0.5857445597648621]
system B-LOC [0.047687824815511703, -0.6588415503501892]
could O [-0.17748743295669556, 0.05686340108513832]
save O [-0.1335294246673584, -0.10591025650501251]
as O [-0.1940925121307373, 0.07787378132343292]
much O [-0.20693036913871765, 0.12116706371307373]
as O [-0.2713182270526886, -0.078278087079525]
$750 B-LOC [0.015389415435492992, -0.11512722074985504]
million. B-LOC [-0.12513017654418945, -0.2855689525604248]
CONCLUSIONS O [-0.5324810147285461, 0.18961547315120697]
The B-LOC [0.6662362217903137, -0.49801722168922424]
combination B-LOC [1.0904414653778076, -0.7682780027389526]
of B-LOC [0.9781021475791931, -0.9102924466133118]
a B-LOC [0.9470195770263672, -0.9784983992576599]
national B-LOC [0.9049056768417358, -1.1965105533599854]
KPD B-LOC [0.8288820385932922, -0.9999372363090515]
program B-LOC [0.7821853756904602, -0.9406461715698242]
and B-LOC [1.1503093242645264, -1.115047812461853]
a B-LOC [1.259347915649414, -1.0406030416488647]
mathematically B-LOC [1.30122971534729, -0.9790552258491516]
optimized B-LOC [1.2302383184432983, -1.0487412214279175]
matching B-LOC [1.0815551280975342, -1.177878737449646]
algorithm B-LOC [1.1088969707489014, -1.169320821762085]
yields B-LOC [1.1057838201522827, -0.7403990030288696]
more B-LOC [0.9892303943634033, -0.9693412184715271]
matches B-LOC [1.2753959894180298, -0.9526481032371521]
with B-LOC [1.2148526906967163, -0.909960925579071]
lower B-LOC [1.0493355989456177, -0.9556378126144409]
HLA B-LOC [1.2393383979797363, -1.0205656290054321]
disparity. B-LOC [1.5423426628112793, -1.3382346630096436]
Optimized B-LOC [0.6143988966941833, -0.5391159057617188]

matching B-LOC [0.4586065709590912, -0.23511949181556702]
affords B-LOC [0.13437619805335999, 0.13316331803798676]
patients B-LOC [0.39632493257522583, -0.5964822769165039]
the B-LOC [0.1487417370080948, -0.07009397447109222]
flexibility B-LOC [0.3770478665828705, -0.273681104183197]
of B-LOC [0.25805798172950745, -0.24639250338077545]
customizing B-LOC [0.7059770822525024, -0.7234952449798584]
their B-LOC [0.8261373043060303, -0.82743901014328]
matching B-LOC [0.9013868570327759, -0.9707959890365601]
priorities B-LOC [0.7197415828704834, -0.7004758715629578]
and B-LOC [0.11386403441429138, -0.0037060403265058994]
the B-LOC [0.2027653157711029, -0.1037689745426178]
security B-LOC [0.5695093274116516, -0.39236146211624146]
of B-LOC [0.30152446031570435, -0.209101140499115]
knowing B-LOC [0.7266350388526917, -0.589273989200592]
that B-LOC [0.5426114201545715, -0.6185991168022156]
the B-LOC [0.9978026747703552, -0.8064661622047424]
greatest B-LOC [0.8597237467765808, -0.978894829750061]
number B-LOC [0.8482744693756104, -0.9428024291992188]
of B-LOC [0.7073158025741577, -0.9632508754730225]
high-quality B-LOC [0.5543130040168762, -0.9437192678451538]
matches B-LOC [0.7462756037712097, -0.8001147508621216]
will B-LOC [0.5999013781547546, -0.5935127139091492]
be B-LOC [0.8045968413352966, -0.9369085431098938]
found B-LOC [1.0809860229492188, -0.9638621211051941]
and B-LOC [0.6450246572494507, -0.6914334893226624]
distributed B-LOC [0.9501349329948425, -0.9316660761833191]
equitably. B-LOC [0.7056615948677063, -0.7127664685249329]

Finding B-LOC [2.311277151107788, -2.5634238719940186]
new B-LOC [2.34150767326355, -2.390723943710327]
treatment-shortening B-LOC [2.3057987689971924, -2.6588032245635986]
antibiotics B-LOC [2.613494634628296, -2.6739211082458496]
to B-LOC [2.1354894638061523, -2.3124594688415527]
improve B-LOC [2.0342161655426025, -2.3832271099090576]
cure B-LOC [2.4820926189422607, -2.5702173709869385]
rates B-LOC [2.3918025493621826, -2.551861047744751]
and B-LOC [1.949785590171814, -2.0307726860046387]
curb B-LOC [2.2045857906341553, -2.270002603530884]
the B-LOC [2.442525625228882, -2.2731244564056396]
alarming B-LOC [2.65419864654541, -2.9022748470306396]
emergence B-LOC [2.481459379196167, -2.6777243614196777]
of B-LOC [2.3927323818206787, -2.6597909927368164]
drug B-LOC [2.9407598972320557, -3.127052068710327]
resistance B-LOC [2.770695447921753, -2.9143879413604736]
is B-LOC [2.9579145908355713, -2.8911850452423096]
the B-LOC [3.0524113178253174, -2.885406017303467]
major B-LOC [2.9468581676483154, -3.049635648727417]
objective B-LOC [2.9086859226226807, -3.037976026535034]
of B-LOC [2.835599422454834, -3.1110098361968994]
tuberculosis B-LOC [2.6519827842712402, -3.0726230144500732]
(TB) B-LOC [2.9557485580444336, -3.1268599033355713]
drug B-LOC [3.0752828121185303, -3.115140676498413]
development. B-LOC [3.126312732696533, -2.9781296253204346]
Using B-LOC [0.7234179973602295, -1.0500483512878418]
a B-LOC [1.5425214767456055, -1.2767243385314941]
matrix-assisted B-LOC [1.7128511667251587, -1.5380849838256836]
laser B-LOC [1.8032170534133911, -1.676327109336853]
desorption/ionization B-LOC [2.255075216293335, -2.1265289783477783]
(MALDI) B-LOC [2.4581141471862793, -2.4461257457733154]
mass B-LOC [1.8973724842071533, -1.5719671249389648]
spectrometry B-LOC [2.4026777744293213, -2.091040849685669]
imaging B-LOC [1.5683622360229492, -1.505321979522705]
suite B-LOC [1.7695462703704834, -1.4730637073516846]
in B-LOC [1.5868308544158936, -1.1861145496368408]
a B-LOC [1.4553256034851074, -1.1750653982162476]
biosafety B-LOC [1.3899046182632446, -1.4305685758590698]
containment B-LOC [2.019582509994507, -1.5234808921813965]
facility, B-LOC [1.7515356540679932, -1.6988050937652588]
we B-LOC [0.668634295463562, -0.41877439618110657]
show B-LOC [0.4176466464996338, -0.22274532914161682]
that B-LOC [0.22636285424232483, -0.2398943305015564]
the B-LOC [0.6005474925041199, -0.1749432533979416]
key B-LOC [0.4347116947174072, -0.3811517059803009]
sterilizing B-LOC [0.5444769263267517, -0.314546138048172]
drugs B-LOC [0.5423824191093445, -0.2534871995449066]
rifampicin B-LOC [0.30984142422676086, -0.0705193430185318]
and B-LOC [0.35587313771247864, 0.0895928144454956]
pyrazinamide B-LOC [0.48870453238487244, -0.2253999263048172]
efficiently B-LOC [0.30162423849105835, -0.05792167782783508]
penetrate B-LOC [0.5101853609085083, -0.21264027059078217]
the B-LOC [0.4211583137512207, -0.07046160846948624]
sites B-LOC [0.24813467264175415, -0.21368946135044098]
of B-LOC [0.18650057911872864, -0.28261563181877136]
TB B-LOC [0.521087110042572, -0.3255601227283478]
infection B-LOC [0.3570248782634735, -0.30014151334762573]
in B-LOC [0.3357056975364685, -0.23585271835327148]
lung B-LOC [0.3739018142223358, -0.42109763622283936]
lesions. B-LOC [0.2751163840293884, -0.34719517827033997]
Rifampicin B-LOC [0.16221743822097778, -0.058338601142168045]
even B-LOC [0.0981098860502243, -0.032991502434015274]
accumulates B-LOC [0.0880327820777893, -0.0844036191701889]
in B-LOC [0.1522766798734665, 0.006863085087388754]
necrotic B-LOC [-1.7010992451105267e-05, -0.047921378165483475]
caseum, B-LOC [0.05058763921260834, -0.05076806619763374]
a B-LOC [0.05179227516055107, -0.18913428485393524]
critical B-LOC [0.018488751724362373, -0.3439292907714844]
lesion B-LOC [0.21138246357440948, -0.17691655457019806]
site O [-0.19417011737823486, -0.12821877002716064]
where B-LOC [-0.26454266905784607, -0.33317017555236816]

persisting B-LOC [0.23937055468559265, -0.14858350157737732]
tubercle B-LOC [0.19903141260147095, -0.24813242256641388]
bacilli B-LOC [0.11503429710865021, -0.057885218411684036]
reside. B-LOC [0.35012468695640564, -0.0733368992805481]
In B-LOC [0.1702454686164856, 0.021963326260447502]
contrast, O [0.17650479078292847, 0.19153380393981934]
moxifloxacin, O [0.07835216820240021, 0.09874077141284943]
which O [-0.23468303680419922, 0.1481701284646988]
is O [-0.16398948431015015, 0.1826702058315277]
active O [-0.19792810082435608, 0.4604305326938629]
in O [-0.08495000749826431, 0.10994209349155426]
vitro O [-0.0777825266122818, 0.10519196093082428]
against O [0.031071292236447334, 0.3022538125514984]
a O [-0.09667077660560608, 0.2524990737438202]
subpopulation O [-0.051036398857831955, 0.22152173519134521]
of O [-0.1640392243862152, 0.3586292564868927]
Mycobacterium O [-0.08194036036729813, 0.10061665624380112]
tuberculosis O [-0.08761473745107651, 0.2628346085548401]
that O [-0.2779811918735504, 0.12280294299125671]
persists O [0.03309215232729912, 0.26097163558006287]
in O [0.16080674529075623, 0.20764489471912384]
specific B-LOC [0.08136352896690369, -0.050514500588178635]
niches O [0.11539290845394135, 0.17142117023468018]
under B-LOC [0.19550937414169312, 0.09087756276130676]
drug O [-0.005339158233255148, 0.12348808348178864]
pressure B-LOC [0.1441003978252411, 0.14020439982414246]
and O [-0.18816739320755005, 0.36328837275505066]
has B-LOC [0.10080254077911377, 0.10021623969078064]
achieved O [-0.1608251929283142, 0.22530898451805115]
treatment O [0.048412974923849106, 0.22116123139858246]
shortening O [0.02937488444149494, 0.43322524428367615]
in O [0.13056641817092896, 0.1531703770160675]
mice, O [0.024445848539471626, 0.16192016005516052]
does B-LOC [0.36433887481689453, 0.19467869400978088]
not O [0.37106356024742126, 0.39895400404930115]
diffuse B-LOC [0.8953767418861389, -0.2973514497280121]
well B-LOC [0.2611876130104065, 0.02918524108827114]
in B-LOC [0.6063621044158936, -0.37739717960357666]
caseum, B-LOC [0.4427342414855957, -0.05920076742768288]
concordant B-LOC [0.3312538266181946, 0.13886260986328125]
with B-LOC [0.4291750490665436, -0.08828014135360718]
its B-LOC [0.48708486557006836, -0.10584524273872375]
failure B-LOC [0.6277869939804077, -0.1272507607936859]
to B-LOC [0.7309103012084961, -0.21063460409641266]
shorten B-LOC [0.8930749893188477, -0.4437773525714874]
therapy B-LOC [0.7899251580238342, -0.617885410785675]
in B-LOC [1.163893699645996, -0.8309311866760254]
recent B-LOC [1.1988627910614014, -0.6548110842704773]
clinical B-LOC [0.9745171666145325, -0.8048592805862427]
trials. B-LOC [1.026906967163086, -0.7469514012336731]
We B-LOC [0.022645609453320503, -0.22158649563789368]
suggest B-LOC [0.26042434573173523, -0.30764782428741455]
that B-LOC [0.2200445532798767, -0.6223071217536926]
such B-LOC [0.5747894644737244, -0.4631553888320923]
differential B-LOC [0.614400327205658, -1.134903907775879]
spatial B-LOC [0.7883588671684265, -1.176902174949646]
distribution B-LOC [0.8006823658943176, -1.0299569368362427]
and B-LOC [0.8184332251548767, -1.0581096410751343]
kinetics B-LOC [0.7308980822563171, -0.9337905049324036]
of B-LOC [0.8345551490783691, -1.1977574825286865]
accumulation B-LOC [0.9216614365577698, -0.9473981857299805]
in B-LOC [0.7465100884437561, -1.0706075429916382]
lesions B-LOC [0.6590641140937805, -0.8481477499008179]
may B-LOC [0.5639897584915161, -0.8560126423835754]
create B-LOC [0.561805784702301, -0.8608080744743347]
temporal B-LOC [0.8179579377174377, -1.101709008216858]
and B-LOC [0.559781551361084, -1.160555124282837]
spatial B-LOC [0.759256899356842, -1.1881005764007568]
windows B-LOC [0.7381698489189148, -1.0878658294677734]
of B-LOC [0.6853615641593933, -1.3583354949951172]
monotherapy B-LOC [0.6699591279029846, -1.1360687017440796]
in B-LOC [0.8557014465332031, -1.2389079332351685]
specific B-LOC [0.7815688252449036, -1.4901072978973389]
niches, B-LOC [1.0713989734649658, -1.2033469676971436]
allowing B-LOC [0.39367279410362244, -0.7615915536880493]
the B-LOC [0.6669955849647522, -0.7390790581703186]
gradual B-LOC [0.6526381969451904, -1.0552654266357422]
development B-LOC [0.7810291647911072, -0.9028714895248413]
of B-LOC [0.6820316314697266, -1.050573468208313]
multidrug-resistant B-LOC [0.6068950891494751, -1.0077555179595947]

TB. B-LOC [0.8586031794548035, -1.4515132904052734]
We B-LOC [1.1343543529510498, -1.387362003326416]
propose B-LOC [1.8344202041625977, -1.7982841730117798]
an B-LOC [1.9352728128433228, -2.4125893115997314]
alternative B-LOC [1.9481761455535889, -2.5381295680999756]
working B-LOC [2.117037534713745, -2.5884320735931396]
model B-LOC [1.9208194017410278, -2.4790782928466797]
to B-LOC [2.1347415447235107, -2.6353254318237305]
prioritize B-LOC [1.9450397491455078, -2.2264020442962646]
new B-LOC [2.0040152072906494, -2.4338812828063965]
antibiotic B-LOC [1.9627505540847778, -2.2816643714904785]
regimens B-LOC [2.0067155361175537, -2.3048436641693115]
based B-LOC [1.9215471744537354, -2.6383752822875977]
on B-LOC [1.7480050325393677, -2.436378240585327]
quantitative B-LOC [1.690171718597412, -2.067734956741333]
and B-LOC [1.6951837539672852, -2.2245657444000244]
spatial B-LOC [1.7128678560256958, -2.1489417552948]
distribution B-LOC [1.8330564498901367, -2.246988534927368]
of B-LOC [1.768141508102417, -2.4825236797332764]
TB B-LOC [1.320152759552002, -1.5801787376403809]
drugs B-LOC [1.5443365573883057, -2.0343563556671143]
in B-LOC [1.6566753387451172, -2.1993632316589355]
the B-LOC [1.6928765773773193, -1.918814778327942]
major B-LOC [1.4151611328125, -1.8935351371765137]
lesion B-LOC [1.7718102931976318, -1.9246728420257568]
types B-LOC [1.6222071647644043, -1.4927035570144653]
found B-LOC [1.4838287830352783, -1.6534448862075806]
in B-LOC [1.397292137145996, -1.7293156385421753]
human B-LOC [1.4319838285446167, -2.0338358879089355]
lungs. B-LOC [1.3842713832855225, -1.938535451889038]
The B-LOC [1.6610541343688965, -1.89035165309906]
finding B-LOC [1.4885144233703613, -1.74422025680542]
that B-LOC [1.5652801990509033, -2.1126887798309326]
lesion B-LOC [1.6782944202423096, -1.6537458896636963]
penetration B-LOC [1.3858718872070312, -1.6435449123382568]
may B-LOC [1.7061173915863037, -2.1930830478668213]
contribute B-LOC [1.4466878175735474, -2.1895954608917236]
to B-LOC [1.6281434297561646, -2.3083183765411377]
treatment B-LOC [1.611665964126587, -2.1369683742523193]
outcome B-LOC [1.6458675861358643, -2.070824384689331]
has B-LOC [1.9845830202102661, -2.1933748722076416]
wide B-LOC [1.769014596939087, -2.334136724472046]
implications B-LOC [1.9047062397003174, -2.357527017593384]
for B-LOC [1.7124290466308594, -2.192723035812378]
TB. B-LOC [1.3468410968780518, -1.7258857488632202]

Genetic B-LOC [0.7982025742530823, -1.1899164915084839]
mutations B-LOC [0.970434844493866, -1.047203540802002]
in B-LOC [0.7187657952308655, -1.0657520294189453]
TAR B-LOC [0.4662032127380371, -0.9932213425636292]
DNA-binding B-LOC [0.46137985587120056, -0.9301937818527222]
protein B-LOC [0.6974342465400696, -1.0885765552520752]
43 B-LOC [1.0845872163772583, -0.8258456587791443]
(TARDBP, B-LOC [0.7132733464241028, -0.9588181972503662]
also B-LOC [0.8927765488624573, -1.0427601337432861]
known B-LOC [0.8032031655311584, -0.733524739742279]
as B-LOC [0.6297076344490051, -0.8726159334182739]
TDP-43) B-LOC [0.1280900537967682, -0.6103206276893616]
cause B-LOC [0.30971118807792664, -0.4989412724971771]
amyotrophic B-LOC [-0.036813054233789444, -0.5132675170898438]
lateral B-LOC [0.2587631940841675, -1.089019536972046]
sclerosis B-LOC [0.43143975734710693, -0.7908182740211487]
(ALS), B-LOC [0.619128942489624, -0.7745286226272583]
and B-LOC [0.13203808665275574, -0.2869279682636261]
an B-LOC [0.2808074653148651, -0.5494622588157654]
increase B-LOC [0.2423393279314041, -0.6989611983299255]
in B-LOC [0.21745246648788452, -0.6897231936454773]
the B-LOC [0.536396324634552, -0.6954635381698608]
presence B-LOC [0.4374473989009857, -0.591122031211853]
of B-LOC [0.4216572046279907, -0.48306965827941895]
TDP-43 B-LOC [0.12566982209682465, -0.5380294919013977]
(encoded B-LOC [0.5073438286781311, -0.7563584446907043]
by B-LOC [0.43890324234962463, -0.9863694906234741]
TARDBP) B-LOC [0.4415217339992523, -0.8103711605072021]
in B-LOC [0.18325428664684296, -0.56659996509552]
the B-LOC [0.569848895072937, -0.8689011335372925]
cytoplasm B-LOC [1.0459520816802979, -1.3763982057571411]
is B-LOC [1.0400711297988892, -0.9333972334861755]
a B-LOC [0.8554150462150574, -0.9061856865882874]
prominent B-LOC [0.9464991092681885, -1.0016965866088867]
histopathological B-LOC [1.2770828008651733, -1.5571269989013672]
feature B-LOC [0.8592536449432373, -1.210396409034729]
of B-LOC [0.9610950350761414, -1.0680887699127197]
degenerating B-LOC [1.681870460510254, -1.5463649034500122]
neurons B-LOC [0.9287999272346497, -1.440187692642212]
in B-LOC [1.2423019409179688, -1.319489598274231]
various B-LOC [1.6897436380386353, -1.899570345878601]
neurodegenerative B-LOC [1.4990758895874023, -1.8411457538604736]
diseases. B-LOC [1.6330816745758057, -1.6687326431274414]
However, B-LOC [2.7871005535125732, -2.469909906387329]
the B-LOC [2.9441821575164795, -2.733146905899048]
molecular B-LOC [2.949068784713745, -2.754225015640259]
mechanisms B-LOC [2.761619806289673, -2.718553304672241]
by B-LOC [2.7789578437805176, -2.811466932296753]
which B-LOC [2.73568058013916, -2.732729434967041]
TDP-43 B-LOC [1.436515212059021, -1.804471731185913]
contributes B-LOC [2.6662356853485107, -2.591796636581421]
to B-LOC [2.633932113647461, -2.7120978832244873]
ALS B-LOC [2.3199565410614014, -2.5606513023376465]
pathophysiology B-LOC [2.8384761810302734, -2.7134525775909424]
remain B-LOC [3.1196014881134033, -2.630483388900757]
elusive. B-LOC [3.1831483840942383, -2.8197834491729736]
Here B-LOC [-0.06806965917348862, -0.1877947896718979]
we O [-0.22872011363506317, -0.03247193247079849]
have B-LOC [0.06609132885932922, -0.07905136048793793]
found O [-0.021178817376494408, 0.10571333765983582]
that O [-0.27250638604164124, -0.009399481117725372]
TDP-43 B-LOC [0.07394196838140488, -0.334852397441864]
accumulates B-LOC [0.10627724975347519, -0.13776712119579315]

in B-LOC [0.8905006647109985, -1.2082507610321045]
the B-LOC [1.280888557434082, -1.3752310276031494]
mitochondria B-LOC [1.5440387725830078, -1.6266694068908691]
of B-LOC [1.2527167797088623, -1.4777026176452637]
neurons B-LOC [1.1820869445800781, -1.581115484237671]
in B-LOC [1.1845581531524658, -1.5240898132324219]
subjects B-LOC [1.4316327571868896, -1.6580474376678467]
with B-LOC [1.6655855178833008, -1.7897882461547852]
ALS B-LOC [1.634002447128296, -1.9080737829208374]
or B-LOC [1.7474086284637451, -1.8928523063659668]
frontotemporal B-LOC [1.4129118919372559, -2.1441726684570312]
dementia B-LOC [1.8795599937438965, -2.0940682888031006]
(FTD). B-LOC [1.907383680343628, -2.095618486404419]
Disease-associated B-LOC [2.2518577575683594, -2.1782939434051514]
mutations B-LOC [1.8455910682678223, -1.7150593996047974]
increase B-LOC [1.7002705335617065, -1.8432799577713013]
TDP-43 B-LOC [1.1933612823486328, -1.5304908752441406]
mitochondrial B-LOC [1.6450426578521729, -2.1808922290802]
localization. B-LOC [1.743656039237976, -1.8995816707611084]
In B-LOC [0.10042525082826614, -0.16226863861083984]
mitochondria, B-LOC [0.3104041516780853, -0.2840885818004608]
wild-type B-LOC [0.2632167935371399, -0.5402524471282959]
(WT) B-LOC [0.48709359765052795, -0.8522929549217224]
and B-LOC [0.03605804964900017, -0.2443918138742447]
mutant B-LOC [0.007965612225234509, -0.2636726200580597]
TDP-43 B-LOC [0.04708993807435036, -0.5605440735816956]
preferentially B-LOC [0.06907273828983307, -0.05476941540837288]
bind B-LOC [0.12959209084510803, -0.2333487719297409]
mitochondria-transcribed B-LOC [0.05587157979607582, -0.1535661667585373]
messenger B-LOC [0.0670914500951767, -0.46304962038993835]
RNAs B-LOC [0.3163749873638153, -0.6500684022903442]
(mRNAs) B-LOC [0.46219155192375183, -0.5252915024757385]
encoding B-LOC [0.07966122031211853, -0.15853169560432434]
respiratory B-LOC [0.11861497908830643, -0.5307514071464539]
complex B-LOC [0.24319195747375488, -0.5533441305160522]
I B-LOC [0.16126561164855957, -0.3639829456806183]
subunits B-LOC [0.19282621145248413, -0.46544957160949707]
ND3 B-LOC [0.17885315418243408, -0.48406484723091125]
and B-LOC [0.17673331499099731, -0.20175135135650635]
ND6, B-LOC [0.3290781080722809, -0.4901888072490692]
impair B-LOC [-0.14910608530044556, -0.1803249567747116]
their B-LOC [0.4834133982658386, -0.5284383893013]
expression B-LOC [0.29764899611473083, -0.09278835356235504]
and B-LOC [0.019637851044535637, -0.052191559225320816]
specifically B-LOC [0.2915658950805664, -0.316610723733902]
cause B-LOC [0.16741207242012024, -0.33319640159606934]
complex B-LOC [0.6126402020454407, -0.7958437204360962]
I B-LOC [0.5449452996253967, -0.5479015111923218]
disassembly. B-LOC [0.69295734167099, -0.6136626601219177]
The O [-0.10277855396270752, -0.03650064766407013]
suppression O [-0.16936267912387848, 0.0025706342421472073]
of O [-0.21981844305992126, -0.021447541192173958]
TDP-43 B-LOC [-0.04670698568224907, -0.35123199224472046]
mitochondrial B-LOC [-0.12304604798555374, -0.34679484367370605]
localization B-LOC [-0.1349237859249115, -0.15816284716129303]
abolishes O [-0.032049570232629776, 0.11508974432945251]
WT B-LOC [0.06474617123603821, 0.004679470788687468]

and O [-0.981722891330719, 0.9373865723609924]
mutant O [-1.074016809463501, 1.0456221103668213]
TDP-43-induced O [-0.7118189930915833, 0.6023259162902832]
mitochondrial O [-1.0883008241653442, 1.071521520614624]
dysfunction O [-0.9365108609199524, 1.1558893918991089]
and O [-1.1865206956863403, 1.0834476947784424]
neuronal O [-1.1256932020187378, 1.2331284284591675]
loss, O [-0.7606139183044434, 1.1930944919586182]
and O [-1.1132631301879883, 1.0122883319854736]
improves O [-0.991874098777771, 1.1710535287857056]
phenotypes O [-0.9255441427230835, 1.0604090690612793]
of O [-0.8599476218223572, 0.9928435683250427]
transgenic O [-0.8660535216331482, 0.895740807056427]
mutant O [-0.8268476724624634, 0.8836040496826172]
TDP-43 O [-0.5968914031982422, 0.5602603554725647]
mice. O [-0.8566303849220276, 0.9245588183403015]
Thus, B-LOC [1.2271769046783447, -0.9065397381782532]
our B-LOC [0.9297956824302673, -1.3102271556854248]
studies B-LOC [1.4736216068267822, -1.525710105895996]
link B-LOC [1.4166018962860107, -1.756821632385254]
TDP-43 B-LOC [0.8490824103355408, -0.9917870163917542]
toxicity B-LOC [1.5300202369689941, -1.766052007675171]
directly B-LOC [1.1970735788345337, -1.797623872756958]
to B-LOC [1.2997392416000366, -2.048325300216675]
mitochondrial B-LOC [1.5096207857131958, -2.1354057788848877]
bioenergetics B-LOC [1.583009958267212, -2.289454698562622]
and B-LOC [1.1400909423828125, -1.5228127241134644]
propose B-LOC [1.9098098278045654, -1.924479365348816]
the B-LOC [2.117191791534424, -2.3441903591156006]
targeting B-LOC [1.8661220073699951, -2.315701723098755]
of B-LOC [1.7402162551879883, -2.2205123901367188]
TDP-43 B-LOC [0.8385929465293884, -1.1832352876663208]
mitochondrial B-LOC [1.421561360359192, -2.1525683403015137]
localization B-LOC [1.9565365314483643, -2.1955811977386475]
as B-LOC [1.9997062683105469, -2.1890931129455566]
a B-LOC [2.093794107437134, -2.3950624465942383]
promising B-LOC [2.1072099208831787, -2.585817575454712]
therapeutic B-LOC [1.8677400350570679, -2.4181771278381348]
approach B-LOC [2.0332372188568115, -2.5991737842559814]
for B-LOC [2.1047894954681396, -2.5006837844848633]
neurodegeneration. B-LOC [1.670741319656372, -2.1103107929229736]

OBJECTIVES B-LOC [3.3189640045166016, -3.9691214561462402]
To B-LOC [3.390608549118042, -4.0222697257995605]
explore B-LOC [3.641247272491455, -3.817628860473633]
the B-LOC [3.7675719261169434, -3.8317441940307617]
association B-LOC [3.6812350749969482, -3.9046690464019775]
between B-LOC [3.519477605819702, -4.109922409057617]
a B-LOC [3.529968023300171, -4.063159465789795]
stable B-LOC [3.604567050933838, -4.077579021453857]
partnership B-LOC [3.608886957168579, -3.982379913330078]
and B-LOC [3.4787397384643555, -3.856456995010376]
clinical B-LOC [3.922999858856201, -4.068933486938477]
outcome B-LOC [3.7827510833740234, -4.087573051452637]
in B-LOC [3.6510324478149414, -4.047133922576904]
HIV B-LOC [3.676546573638916, -3.9902188777923584]
infected B-LOC [3.7197983264923096, -3.958597183227539]
patients B-LOC [3.8822407722473145, -3.8731777667999268]
receiving B-LOC [3.7335283756256104, -4.123288154602051]
highly B-LOC [3.6320393085479736, -4.055696964263916]
active B-LOC [3.6035678386688232, -4.072818756103516]
antiretroviral B-LOC [3.7441351413726807, -3.830061674118042]
therapy B-LOC [3.737589120864868, -3.884930372238159]
(HAART). B-LOC [3.6936287879943848, -3.8102152347564697]
DESIGN B-LOC [3.6633613109588623, -3.9056618213653564]
Prospective B-LOC [3.7016382217407227, -3.9661097526550293]
cohort B-LOC [3.660349130630493, -3.874297618865967]
study B-LOC [3.4436025619506836, -3.7527894973754883]
of B-LOC [3.6791129112243652, -3.843681573867798]
adults B-LOC [3.894981622695923, -3.8066561222076416]
with B-LOC [3.8462579250335693, -4.051506996154785]
HIV B-LOC [3.7429392337799072, -4.037668704986572]
(Swiss B-LOC [3.7320048809051514, -3.937495231628418]
HIV B-LOC [3.5913376808166504, -4.062667369842529]
cohort B-LOC [3.6374154090881348, -3.9254486560821533]
study). B-LOC [3.5612614154815674, -3.8386495113372803]
SETTING B-LOC [3.2540431022644043, -3.7037360668182373]
Seven B-LOC [3.7447502613067627, -3.8241355419158936]
outpatient B-LOC [3.709200143814087, -3.7561588287353516]
clinics B-LOC [3.7887215614318848, -3.8305044174194336]
throughout B-LOC [3.702193021774292, -3.6708593368530273]
Switzerland. B-LOC [3.598118543624878, -3.8542211055755615]
PARTICIPANTS B-LOC [2.8721625804901123, -3.3428235054016113]
The B-LOC [3.359691858291626, -3.150041341781616]
3736 B-LOC [3.454911708831787, -3.22552752494812]
patients B-LOC [3.5290119647979736, -3.420180082321167]
in B-LOC [3.478076696395874, -3.35478138923645]
the B-LOC [3.415787696838379, -3.2161004543304443]
cohort B-LOC [3.356295347213745, -3.3489363193511963]
who B-LOC [3.3041880130767822, -3.231822967529297]
started B-LOC [3.3868637084960938, -3.462580919265747]
HAART B-LOC [3.496856927871704, -3.815477132797241]
before B-LOC [3.5395238399505615, -3.167419672012329]
2002 B-LOC [3.5036637783050537, -3.3923499584198]
(median B-LOC [3.4836785793304443, -3.2464725971221924]
age B-LOC [3.2951486110687256, -3.229595422744751]
36 B-LOC [3.153616189956665, -2.97035813331604]
years, B-LOC [3.2604949474334717, -3.4171388149261475]
29% B-LOC [3.207176685333252, -2.5525567531585693]
female, B-LOC [3.236212968826294, -3.235377311706543]
median B-LOC [3.155021905899048, -3.2462010383605957]
follow B-LOC [3.263364553451538, -3.2569406032562256]
up B-LOC [3.0623347759246826, -3.16499662399292]
3.6 B-LOC [2.8031060695648193, -2.36322283744812]
years). B-LOC [3.2494451999664307, -3.1749508380889893]
MAIN B-LOC [2.8134207725524902, -2.9792027473449707]
OUTCOME B-LOC [2.4490959644317627, -2.709223985671997]
MEASURES B-LOC [2.369779586791992, -2.4167399406433105]

Time B-LOC [1.59915292263031, -2.1317994594573975]
to B-LOC [1.7020869255065918, -2.4160473346710205]
AIDS B-LOC [1.8023567199707031, -2.2009408473968506]
or B-LOC [1.6064019203186035, -2.0964205265045166]
death B-LOC [2.1812093257904053, -2.517301321029663]
(primary B-LOC [1.911369800567627, -2.277602434158325]
endpoint), B-LOC [1.8267219066619873, -2.3368098735809326]
death B-LOC [1.9958075284957886, -2.408759593963623]
alone, B-LOC [1.508385419845581, -2.1630632877349854]
increases B-LOC [1.3995165824890137, -2.189183473587036]
in B-LOC [1.2905151844024658, -2.048140048980713]
CD4 B-LOC [1.5422651767730713, -1.9382404088974]
cell B-LOC [1.2944939136505127, -1.8580992221832275]
count B-LOC [1.4513747692108154, -1.9409624338150024]
of B-LOC [1.1892181634902954, -1.8960168361663818]
at B-LOC [1.7194857597351074, -2.145728349685669]
least B-LOC [1.5532705783843994, -2.2704286575317383]
50 B-LOC [1.8487911224365234, -1.9004766941070557]
and B-LOC [1.1458837985992432, -1.8456430435180664]
100 B-LOC [1.8336751461029053, -2.0580039024353027]
above B-LOC [1.6363284587860107, -1.8970625400543213]
baseline, B-LOC [1.8748801946640015, -2.529346466064453]
optimal B-LOC [1.5916136503219604, -2.0827667713165283]
viral B-LOC [1.8122286796569824, -2.2728681564331055]
suppression B-LOC [1.6092054843902588, -2.2768990993499756]
(a B-LOC [1.6654186248779297, -1.9796719551086426]
viral B-LOC [1.7144631147384644, -2.17142653465271]
load B-LOC [1.6099374294281006, -2.0459532737731934]
below B-LOC [1.351870059967041, -1.5550957918167114]
400 B-LOC [1.69471275806427, -1.9625012874603271]
copies/ml), B-LOC [1.5835371017456055, -2.265554666519165]
and B-LOC [1.740619421005249, -2.1454951763153076]
viral B-LOC [1.709979772567749, -2.063466787338257]
rebound. B-LOC [1.8404011726379395, -2.2522315979003906]
RESULTS B-LOC [1.272024393081665, -1.627547264099121]
During B-LOC [1.4625005722045898, -1.370905876159668]
follow B-LOC [1.8848265409469604, -1.8245320320129395]
up B-LOC [1.5781736373901367, -1.9051902294158936]
2985 B-LOC [2.544409990310669, -1.5891138315200806]
(80%) B-LOC [1.7148113250732422, -1.7955416440963745]
participants B-LOC [1.6296813488006592, -1.9223846197128296]
reported B-LOC [1.6587755680084229, -1.5399779081344604]
a B-LOC [1.8739389181137085, -1.8816291093826294]
stable B-LOC [1.9349656105041504, -2.0274319648742676]
partnership B-LOC [1.6048173904418945, -1.8699719905853271]
on B-LOC [1.8417472839355469, -1.755336880683899]
at B-LOC [2.1746551990509033, -1.7412233352661133]
least B-LOC [2.122351884841919, -1.8646936416625977]
one B-LOC [1.7743427753448486, -2.063697576522827]
occasion. B-LOC [1.5930484533309937, -2.0352251529693604]
When B-LOC [1.1141269207000732, -0.9040233492851257]
starting B-LOC [1.3260860443115234, -1.3926947116851807]
HAART, B-LOC [1.661295771598816, -1.6987448930740356]
52% B-LOC [1.4297842979431152, -0.9630006551742554]
(545/1042) B-LOC [1.3167048692703247, -1.3325543403625488]
of B-LOC [1.4107517004013062, -1.2606714963912964]
participants B-LOC [1.3764967918395996, -1.5639376640319824]
reported B-LOC [1.3815480470657349, -0.9932416081428528]
a B-LOC [1.412444829940796, -1.0376602411270142]
stable B-LOC [1.667128324508667, -1.3988595008850098]
partnership; B-LOC [1.4597246646881104, -1.478018045425415]
after B-LOC [1.049417495727539, -1.130418062210083]
five B-LOC [1.1299774646759033, -0.908231794834137]
years B-LOC [1.3206863403320312, -1.1339131593704224]
of B-LOC [1.2271661758422852, -1.0644294023513794]
follow B-LOC [1.5443692207336426, -1.4682973623275757]
up B-LOC [1.3438351154327393, -1.504709243774414]
46% B-LOC [1.1786121129989624, -0.6530113220214844]
(190/412) B-LOC [1.3409419059753418, -1.3947725296020508]
of B-LOC [1.4043211936950684, -1.3207241296768188]
participants B-LOC [1.4511548280715942, -1.5742640495300293]
reported B-LOC [1.4697524309158325, -1.0163296461105347]
a B-LOC [1.4086190462112427, -1.0494868755340576]
stable B-LOC [1.650760293006897, -1.4148638248443604]
partnership. B-LOC [1.404752254486084, -1.4411203861236572]
In B-LOC [0.806776762008667, -0.8508552312850952]
an B-LOC [0.9452905058860779, -0.9533350467681885]
analysis B-LOC [0.9532028436660767, -1.0366032123565674]
stratified B-LOC [1.1211639642715454, -1.2931439876556396]
by B-LOC [0.8181558847427368, -1.233055591583252]
previous B-LOC [1.0523505210876465, -1.061315894126892]
antiretroviral B-LOC [1.5476963520050049, -1.3237959146499634]

therapy O [-0.5222592353820801, 0.4955601394176483]
and O [-0.5206969380378723, 0.48199155926704407]
clinical O [-0.4517172873020172, 0.5354773998260498]
stage O [-0.4545116126537323, 0.45511946082115173]
when O [-0.48859021067619324, 0.400570809841156]
starting O [-0.47629809379577637, 0.3700704872608185]
HAART O [-0.3261873424053192, 0.28225448727607727]
(US O [-0.3821600377559662, 0.22773541510105133]
Centers O [-0.28702932596206665, -0.05729886516928673]
for B-LOC [0.6103801727294922, -0.5396871566772461]
Disease B-LOC [0.3334704041481018, -0.19875429570674896]
Control B-LOC [0.372160404920578, -0.33358439803123474]
and B-LOC [0.3143828511238098, -0.36094173789024353]
Prevention O [-0.00039462503627873957, 0.21316686272621155]
group O [-0.14096739888191223, 0.18455663323402405]
A, O [-0.31020060181617737, 0.31213608384132385]
B, O [-0.3190479576587677, 0.2483476996421814]
or B-LOC [-0.09225808084011078, -0.0968356728553772]
C), O [-0.25133201479911804, 0.1083393469452858]
the O [-0.5155633687973022, 0.497453898191452]
adjusted O [-0.6064123511314392, 0.45910415053367615]
hazard O [-0.4892965853214264, 0.46953147649765015]
ratio O [-0.536954402923584, 0.5758413672447205]
for O [-0.6417574286460876, 0.4957933723926544]
progression O [-0.572458803653717, 0.5249060988426208]
to O [-0.6485460996627808, 0.47718408703804016]
AIDS O [-0.313953161239624, 0.5587137937545776]
or O [-0.5660240054130554, 0.4602493643760681]
death O [-0.32281309366226196, 0.471366286277771]
was O [-0.5402658581733704, 0.4663833677768707]
0.79 O [-0.3615151345729828, 0.5762814283370972]
(95% O [-0.6424991488456726, 0.4404313266277313]
confidence O [-0.6805469989776611, 0.5827835202217102]
interval O [-0.7378749251365662, 0.4983714520931244]
0.63 O [-0.32865628600120544, 0.4984946548938751]
to O [-0.694392740726471, 0.24799631536006927]
0.98) O [-0.3453758656978607, 0.43963417410850525]
for O [-0.5167493224143982, 0.5324538350105286]
participants O [-0.531355619430542, 0.45243677496910095]
with O [-0.46887263655662537, 0.5129730701446533]
a O [-0.5592343807220459, 0.651038646697998]
stable O [-0.5391538739204407, 0.6549057364463806]
partnership O [-0.5339288115501404, 0.5514373183250427]
compared O [-0.6194919943809509, 0.769542932510376]
with O [-0.37197408080101013, 0.4775930345058441]
those O [-0.4458039104938507, 0.44760003685951233]
without. O [-0.36248961091041565, 0.6223092079162598]
Adjusted O [-0.013799239881336689, 0.03730686381459236]
hazards O [-0.0024502850137650967, -0.0001474790769862011]
ratios O [-0.05367974564433098, 0.1040550023317337]
for B-LOC [0.04806854948401451, -0.007677348796278238]
other O [-0.01587473414838314, 0.10646747797727585]
endpoints O [-0.03835013136267662, 0.06968037784099579]
were O [-0.1993202418088913, 0.10578274726867676]
0.59 B-LOC [0.0588025338947773, -0.04930267110466957]
(0.44 B-LOC [-0.018557129427790642, -0.14856234192848206]
to B-LOC [-0.21621392667293549, -0.3160625696182251]
0.79) B-LOC [0.2101534605026245, -0.17421549558639526]
for O [-0.20775772631168365, -0.02427843026816845]
progression O [-0.2617739140987396, 0.15146173536777496]
to B-LOC [-0.08089344203472137, -0.16789290308952332]
death, O [-0.06914497911930084, 0.17281651496887207]
1.15 O [-0.057917144149541855, 0.1638171374797821]
(1.06 B-LOC [-0.10786983370780945, -0.15914283692836761]
to O [-0.33229097723960876, -0.23636868596076965]
1.24) B-LOC [-0.028686651960015297, -0.13819943368434906]
for O [-0.30642467737197876, 0.05005740374326706]
an O [-0.36045950651168823, 0.07010478526353836]
increase O [-0.4191203713417053, 0.09910987317562103]
in O [-0.34366488456726074, -0.03352348878979683]
CD4 O [-0.27829840779304504, 0.3823075592517853]
cells O [-0.43320372700691223, 0.14889921247959137]
of O [-0.38481405377388, 0.18291550874710083]
100 O [-0.17301109433174133, 0.07758073508739471]
counts/microl O [-0.201607346534729, -0.035437505692243576]
or O [-0.283041387796402, -0.2821204364299774]
more, O [-0.12320735305547714, 0.19784364104270935]
and O [-0.2335272580385208, 0.05386611819267273]

1.06 B-LOC [-0.07040035724639893, -0.3257507383823395]
(0.98 B-LOC [0.061801034957170486, -0.4404940903186798]
to B-LOC [-0.04573904350399971, -0.6360886096954346]
1.14) B-LOC [-0.01247118879109621, -0.4718019664287567]
for B-LOC [-0.02098584733903408, -0.35415884852409363]
optimal B-LOC [0.04503505304455757, -0.29412248730659485]
viral B-LOC [-0.05429423972964287, -0.2723049819469452]
suppression. B-LOC [0.19105017185211182, -0.36402633786201477]
CONCLUSIONS O [-1.0739235877990723, 0.9286296963691711]
A O [-0.9882637858390808, 0.8714048266410828]
stable O [-0.8204281330108643, 0.8694918751716614]
partnership O [-0.7460344433784485, 0.816709041595459]
is O [-0.961895227432251, 0.8117116689682007]
associated O [-0.9567880034446716, 0.9987497925758362]
with O [-1.0168499946594238, 0.9246695041656494]
a O [-1.0046470165252686, 0.8885160684585571]
slower O [-0.9766789674758911, 0.9419015049934387]
rate O [-0.9977628588676453, 0.706455409526825]
of O [-1.198996901512146, 0.8438562750816345]
progression O [-0.9499924778938293, 0.6672133207321167]
to O [-1.1583099365234375, 0.7714728713035583]
AIDS O [-0.6245046257972717, 0.6167373061180115]
or O [-1.0531299114227295, 0.8616655468940735]
death O [-0.7986103892326355, 0.5452465415000916]
in O [-0.9434184432029724, 0.7138758301734924]
HIV O [-0.5676991939544678, 0.5362258553504944]
infected O [-0.7502268552780151, 0.7134034633636475]
patients O [-0.8454204201698303, 0.623538613319397]
receiving O [-0.8503519296646118, 0.5968074798583984]
HAART. O [-0.9307631850242615, 0.6628323197364807]

INTRODUCTION B-LOC [2.0970330238342285, -2.9301517009735107]
Various B-LOC [2.3933475017547607, -2.821019411087036]
perinatal B-LOC [2.3913795948028564, -2.9545977115631104]
factors, B-LOC [2.319568395614624, -2.907902717590332]
including B-LOC [2.2659900188446045, -2.676163673400879]
birth B-LOC [1.9386544227600098, -2.322399377822876]
weight, B-LOC [2.4978742599487305, -2.62911057472229]
birth B-LOC [1.8818559646606445, -2.1678876876831055]
order, B-LOC [1.8746047019958496, -2.5901238918304443]
maternal B-LOC [2.1306369304656982, -2.4574520587921143]
age, B-LOC [2.4356534481048584, -2.765124559402466]
gestational B-LOC [2.5743887424468994, -2.632568120956421]
age, B-LOC [2.307926654815674, -2.5812392234802246]
twin B-LOC [1.983728051185608, -2.4784157276153564]
status, B-LOC [1.9425315856933594, -2.3215224742889404]
and B-LOC [2.267881155014038, -2.8149781227111816]
parental B-LOC [1.7874908447265625, -2.1764488220214844]
smoking, B-LOC [2.002903699874878, -2.2068140506744385]
have B-LOC [2.5451276302337646, -2.7196342945098877]
been B-LOC [2.5318057537078857, -2.908898115158081]
postulated B-LOC [2.5271942615509033, -2.6938059329986572]
to B-LOC [2.368919610977173, -2.5488154888153076]
affect B-LOC [2.1193642616271973, -2.80766224861145]
breast B-LOC [2.009101152420044, -2.588815927505493]
cancer B-LOC [2.2295682430267334, -3.0177338123321533]
risk B-LOC [2.2009236812591553, -2.586951732635498]
in B-LOC [1.835768461227417, -2.4834015369415283]
daughters B-LOC [1.977914571762085, -2.492962598800659]
by B-LOC [1.6806939840316772, -2.095046043395996]
altering B-LOC [2.01322340965271, -2.62296986579895]
the B-LOC [2.473532199859619, -2.7178122997283936]
hormonal B-LOC [2.1787853240966797, -2.5408976078033447]
environment B-LOC [1.7016620635986328, -2.177302122116089]
of B-LOC [1.827987790107727, -2.3521535396575928]
the B-LOC [2.0225284099578857, -2.5892770290374756]
developing B-LOC [1.7962080240249634, -2.4941182136535645]
fetal B-LOC [2.098417043685913, -2.5871331691741943]
mammary B-LOC [2.159766435623169, -2.743535280227661]
glands. B-LOC [1.7177529335021973, -2.3988754749298096]
Despite B-LOC [3.0149612426757812, -3.087682008743286]
ample B-LOC [3.1852211952209473, -3.192002058029175]
biologic B-LOC [3.2255122661590576, -3.415956974029541]
plausibility, B-LOC [3.24259352684021, -2.96488881111145]
epidemiologic B-LOC [3.2567226886749268, -3.2235381603240967]
studies B-LOC [3.229712724685669, -3.279480218887329]
to B-LOC [3.574122667312622, -3.137199640274048]
date B-LOC [3.3852932453155518, -3.3670434951782227]
have B-LOC [3.2300548553466797, -2.9608757495880127]
yielded B-LOC [3.2377569675445557, -3.129669427871704]
conflicting B-LOC [3.2285444736480713, -3.169847249984741]
results. B-LOC [3.268712282180786, -3.306748151779175]
We B-LOC [2.9715993404388428, -3.061741352081299]
investigated B-LOC [3.2423884868621826, -3.1768383979797363]
the B-LOC [3.4206323623657227, -3.317244291305542]
associations B-LOC [3.289621114730835, -3.407587766647339]
between B-LOC [3.039649248123169, -3.407968044281006]
perinatal B-LOC [3.0235910415649414, -3.419036865234375]
factors B-LOC [3.146902084350586, -3.496478319168091]
and B-LOC [3.1387388706207275, -3.347043752670288]
subsequent B-LOC [3.2532198429107666, -3.465454339981079]
breast B-LOC [2.7450361251831055, -3.4281797409057617]
cancer B-LOC [3.132754325866699, -3.534156322479248]
risk B-LOC [3.3378958702087402, -3.4761438369750977]
through B-LOC [3.1966395378112793, -3.2735049724578857]
meta-analyses. B-LOC [3.4045612812042236, -3.5262205600738525]
METHODS B-LOC [1.7961359024047852, -2.7545082569122314]
We B-LOC [1.7841861248016357, -2.295163631439209]
reviewed B-LOC [2.5086514949798584, -2.8012449741363525]
breast B-LOC [1.899033546447754, -2.5018670558929443]
cancer B-LOC [2.1631810665130615, -2.871110439300537]
studies B-LOC [2.233881950378418, -2.7713584899902344]
published B-LOC [2.689821720123291, -3.0352437496185303]
from B-LOC [2.6061174869537354, -2.9148476123809814]
January B-LOC [3.0145208835601807, -3.171860933303833]
1966 B-LOC [2.5173609256744385, -3.1065635681152344]
to B-LOC [2.9975898265838623, -2.965914011001587]
February B-LOC [3.060870885848999, -2.866600513458252]
2007 B-LOC [2.887676954269409, -3.2543795108795166]
that B-LOC [2.447495222091675, -2.798741102218628]
included B-LOC [2.720102071762085, -2.9322171211242676]
data B-LOC [2.2821359634399414, -2.9139597415924072]

on B-LOC [2.4593963623046875, -3.3669676780700684]
birth B-LOC [2.0428621768951416, -2.6878044605255127]
weight, B-LOC [2.4203503131866455, -2.8744609355926514]
birth B-LOC [2.1844642162323, -2.8191840648651123]
order, B-LOC [2.468270778656006, -3.2338457107543945]
maternal B-LOC [2.6373026371002197, -3.352215528488159]
age, B-LOC [2.712733507156372, -3.088681697845459]
gestational B-LOC [2.961470365524292, -3.5801749229431152]
age, B-LOC [2.8167808055877686, -3.1346936225891113]
twin B-LOC [2.727557897567749, -3.8028759956359863]
status, B-LOC [2.301642894744873, -2.973071336746216]
and B-LOC [2.9002254009246826, -3.5166618824005127]
maternal B-LOC [2.9042065143585205, -3.4187710285186768]
or B-LOC [3.132380723953247, -3.7608630657196045]
paternal B-LOC [2.553783416748047, -3.3948566913604736]
smoking. B-LOC [2.8429982662200928, -3.656395673751831]
Meta-analyses B-LOC [3.2223546504974365, -3.753953695297241]
using B-LOC [3.214284896850586, -3.8147687911987305]
random B-LOC [3.3866472244262695, -3.947596549987793]
effect B-LOC [3.2400591373443604, -4.037446975708008]
models B-LOC [3.3224668502807617, -3.8676838874816895]
were B-LOC [3.060462713241577, -3.597351312637329]
employed B-LOC [3.35959792137146, -3.773263454437256]
to B-LOC [3.369103193283081, -3.767991304397583]
summarize B-LOC [3.324767589569092, -3.7308526039123535]
the B-LOC [3.140542507171631, -3.683014392852783]
results. B-LOC [2.9899580478668213, -3.743708848953247]
RESULTS O [-1.073500394821167, 0.830632209777832]
We O [-1.2745758295059204, 1.1697920560836792]
found O [-1.3480210304260254, 1.0780940055847168]
that O [-1.534267783164978, 1.2006691694259644]
heavier O [-1.255365014076233, 1.446932315826416]
birth O [-1.27490234375, 1.4284570217132568]
weights O [-1.0510356426239014, 1.4564647674560547]
were O [-1.3587126731872559, 1.3341732025146484]
associated O [-1.4337499141693115, 1.4949504137039185]
with O [-1.4621943235397339, 1.401263952255249]
increased O [-1.43205726146698, 1.3796768188476562]
breast O [-1.2393258810043335, 1.4041857719421387]
cancer O [-1.0646672248840332, 1.2216441631317139]
risk, O [-1.2229204177856445, 1.4585027694702148]
with O [-1.324195146560669, 1.2474730014801025]
studies O [-1.3814377784729004, 1.3115463256835938]
involving O [-1.325487732887268, 1.2265461683273315]
five O [-1.2173666954040527, 1.261068344116211]
categories O [-1.2943830490112305, 1.2461040019989014]
of O [-1.4116194248199463, 1.2758733034133911]
birth O [-1.2821028232574463, 1.42264986038208]
weight O [-1.0961532592773438, 1.4621903896331787]
identifying O [-1.244410514831543, 1.1504521369934082]
odds O [-1.2847604751586914, 1.4034440517425537]
ratios O [-1.1737011671066284, 1.1478291749954224]
(ORs) O [-1.0764058828353882, 1.0101444721221924]
of O [-1.435858964920044, 1.263363003730774]
1.24 O [-1.1424221992492676, 1.382371425628662]
(95% O [-1.1706101894378662, 1.0128505229949951]
confidence O [-1.2558765411376953, 1.180122971534729]
interval O [-1.191652774810791, 1.183357834815979]
[CI] O [-1.00986647605896, 1.0029969215393066]
1.04 O [-1.1140673160552979, 1.2948670387268066]
to O [-1.3398973941802979, 0.735231339931488]
1.48) O [-0.8619346022605896, 1.035675048828125]
for O [-1.2510876655578613, 1.09062659740448]
4,000 O [-0.9370059370994568, 1.352403163909912]
g O [-1.1471304893493652, 0.9876547455787659]
or O [-1.3003029823303223, 0.8338835835456848]
more O [-1.0941909551620483, 1.2607505321502686]
and O [-1.0939204692840576, 0.8824149966239929]
1.15 O [-1.0380371809005737, 1.0519778728485107]
(95% O [-0.9603381752967834, 0.748619556427002]
CI O [-1.1431374549865723, 0.9277788400650024]
1.04 O [-0.9885603785514832, 1.0159249305725098]
to O [-1.2595511674880981, 0.6823853254318237]
1.26) O [-0.8518192172050476, 0.8527479767799377]
for O [-1.1840424537658691, 1.000474214553833]

3,500 B-LOC [-0.12042370438575745, -0.22529570758342743]
g O [-0.2993021607398987, -0.2278374284505844]
to O [-0.36404702067375183, -0.23345184326171875]
3,999 O [-0.16096046566963196, 0.14834457635879517]
g, B-LOC [-0.28973275423049927, -0.3268428444862366]
relative O [-0.10933216661214828, -0.06034180894494057]
to B-LOC [-0.016107046976685524, -0.06363946944475174]
a B-LOC [-0.13181710243225098, -0.2191736400127411]
birth O [-0.2343866527080536, -0.17806781828403473]
weight B-LOC [-0.014077720232307911, -0.11679359525442123]
of O [-0.30961599946022034, -0.2307349145412445]
2,500 O [-0.10536755621433258, -0.04104866459965706]
to O [-0.3543265461921692, -0.2765803039073944]
2,599 B-LOC [-0.0026981118135154247, -0.02396654523909092]
g. B-LOC [-0.23390227556228638, -0.3610527515411377]
These B-LOC [0.4143848121166229, -0.3560616075992584]
studies B-LOC [0.16056540608406067, -0.38322287797927856]
provided B-LOC [0.4794912040233612, -0.49736157059669495]
no B-LOC [0.6174012422561646, -0.49461162090301514]
support B-LOC [0.537825345993042, -0.5153052806854248]
for B-LOC [0.5315784215927124, -0.6164664626121521]
a B-LOC [0.5714883804321289, -0.6512245535850525]
J-shaped B-LOC [0.3728632628917694, -0.7504147887229919]
relationship B-LOC [0.21975383162498474, -0.8339918255805969]
of B-LOC [0.5366082787513733, -0.9494923949241638]
birthweight B-LOC [0.39313894510269165, -0.5895800590515137]
to B-LOC [0.8278159499168396, -1.1443120241165161]
risk. B-LOC [0.5149742364883423, -0.8014199137687683]
Support B-LOC [0.38292577862739563, -0.6245353817939758]
for B-LOC [0.3390604257583618, -0.6320633888244629]
an B-LOC [0.3437897264957428, -0.870491623878479]
association B-LOC [0.4133649468421936, -0.5594635009765625]
with B-LOC [0.1725473552942276, -0.7647094130516052]
birthweight O [-0.04251536354422569, -0.009333396330475807]
was B-LOC [0.29031509160995483, -0.5170087814331055]
also B-LOC [0.34896013140678406, -0.5355545878410339]
derived B-LOC [0.4753854274749756, -0.666694700717926]
from B-LOC [0.3492608964443207, -0.5375171303749084]
studies B-LOC [-0.011113223619759083, -0.1511189192533493]
based B-LOC [0.15685352683067322, -0.452997088432312]
on B-LOC [0.3474351763725281, -0.3049594461917877]
three B-LOC [0.3194419741630554, -0.3514556884765625]
birth O [-0.16688913106918335, 0.1439286768436432]
weight B-LOC [0.06877347826957703, 0.017751654610037804]
categories B-LOC [0.21446867287158966, -0.20927223563194275]
(OR B-LOC [0.1964680701494217, -0.17099493741989136]
1.15 B-LOC [0.25338295102119446, -0.1952255666255951]
[95% B-LOC [-0.14401456713676453, -0.1850680410861969]
CI O [-0.351759135723114, -0.025416722521185875]
1.01 B-LOC [-0.06769613176584244, -0.11740729212760925]
to O [-0.35752949118614197, -0.20660695433616638]
1.31] B-LOC [0.02662723697721958, -0.11154636740684509]
for B-LOC [0.05199681594967842, -0.4172608256340027]
> B-LOC [-0.018405837938189507, -0.21674543619155884]
or B-LOC [0.027122007682919502, -0.409471333026886]
=4,000 B-LOC [-0.2365339696407318, -0.4293694794178009]
g O [-0.21240322291851044, -0.1724206507205963]
relative B-LOC [-0.12367624044418335, -0.14886397123336792]
to B-LOC [0.03894877806305885, -0.12174572050571442]
<3,000 O [-0.127055361866951, -0.11293116956949234]
g) O [-0.26288747787475586, -0.15699926018714905]
and B-LOC [0.2707810401916504, -0.3314283490180969]
two B-LOC [0.25395667552948, -0.338920921087265]
birth O [-0.1418057084083557, 0.0628034770488739]
weight B-LOC [0.03177716210484505, -0.01177026517689228]
categories B-LOC [0.23555435240268707, -0.2453555464744568]
(OR B-LOC [0.16217654943466187, -0.13317649066448212]
1.09 B-LOC [0.20173662900924683, -0.06579810380935669]
[95% O [-0.19952180981636047, -0.19582806527614594]
CI O [-0.3715221881866455, -0.02001497708261013]
1.02 O [-0.14069335162639618, -0.08385675400495529]
to O [-0.29092469811439514, -0.18067705631256104]
1.18] B-LOC [0.009873787872493267, -0.15242277085781097]
for B-LOC [0.15078382194042206, -0.35029780864715576]
> B-LOC [0.11257894337177277, -0.2211989313364029]
or B-LOC [0.23886248469352722, -0.5005950927734375]
=3,000 B-LOC [-0.045468103140592575, -0.5657773613929749]
g B-LOC [-0.09554829448461533, -0.33406510949134827]
relative B-LOC [-0.14714545011520386, -0.4150405824184418]

to B-LOC [0.22569915652275085, -0.7806963324546814]
<3,000 B-LOC [0.7359210252761841, -1.070149540901184]
g). B-LOC [0.6815643310546875, -1.3351430892944336]
Women B-LOC [1.7438726425170898, -2.3601443767547607]
born B-LOC [1.762358546257019, -2.2398295402526855]
to B-LOC [1.3696882724761963, -2.0952155590057373]
older B-LOC [1.8519901037216187, -2.458871603012085]
mothers B-LOC [1.8824084997177124, -2.058664083480835]
and B-LOC [1.9183775186538696, -2.5001962184906006]
twins B-LOC [1.9583739042282104, -2.3128533363342285]
were B-LOC [1.239642858505249, -2.029453754425049]
also B-LOC [1.3052133321762085, -1.7941832542419434]
at B-LOC [1.7580090761184692, -2.2314388751983643]
some B-LOC [1.5951590538024902, -2.1866886615753174]
increased B-LOC [1.7541619539260864, -2.4150912761688232]
risk, B-LOC [2.0597727298736572, -2.6602933406829834]
but B-LOC [2.2620747089385986, -2.648411750793457]
the B-LOC [2.4952967166900635, -2.912858724594116]
results B-LOC [2.6275479793548584, -3.0201632976531982]
were B-LOC [2.637571334838867, -2.8389639854431152]
heterogeneous B-LOC [2.8291714191436768, -3.0922930240631104]
across B-LOC [2.607508420944214, -3.0091800689697266]
studies B-LOC [2.9689223766326904, -2.9133923053741455]
and B-LOC [2.7640278339385986, -2.9927687644958496]
publication B-LOC [2.690209150314331, -3.0684449672698975]
years. B-LOC [2.961831569671631, -3.1423254013061523]
Birth B-LOC [1.2704657316207886, -1.598313570022583]
order, B-LOC [1.1087316274642944, -1.9301282167434692]
prematurity, B-LOC [1.6601593494415283, -1.9811255931854248]
and B-LOC [1.4661099910736084, -2.1469972133636475]
maternal B-LOC [1.5401058197021484, -2.2121453285217285]
smoking B-LOC [1.3075811862945557, -1.8401978015899658]
were B-LOC [1.3476660251617432, -1.7776156663894653]
unrelated B-LOC [1.8609472513198853, -2.1801493167877197]
to B-LOC [1.770246982574463, -2.302440643310547]
breast B-LOC [0.2395077347755432, -0.5593469738960266]
cancer B-LOC [0.9733615517616272, -1.7756006717681885]
risk. B-LOC [1.7088896036148071, -2.4232466220855713]
CONCLUSION O [-0.8288609981536865, 0.508374035358429]
Our O [-0.3439420163631439, 0.06695889681577682]
findings O [-0.23973432183265686, 0.10571806132793427]
provide B-LOC [0.29976886510849, -0.13806116580963135]
some B-LOC [0.03231917694211006, -0.07657697796821594]
support B-LOC [0.2534971237182617, -0.050718534737825394]
for B-LOC [0.3068259060382843, -0.05517241731286049]
the B-LOC [0.13336831331253052, -0.046955544501543045]
hypothesis O [-0.047525402158498764, -0.04281902685761452]
that O [-0.6167842149734497, 0.21136732399463654]
in O [-0.861726701259613, 0.7102457880973816]
utero O [-0.6583821177482605, 0.47923845052719116]
exposures O [-0.422626256942749, 0.4921870231628418]
reflective O [-0.6621700525283813, 0.5734530091285706]
of O [-0.7081829905509949, 0.5262870192527771]
higher O [-0.792998194694519, 0.43398377299308777]
endogenous O [-0.7054615616798401, 0.5040348172187805]
hormone O [-0.5915395617485046, 0.25215962529182434]
levels O [-0.5400018095970154, 0.5000728964805603]
could O [-0.6380696892738342, 0.3037385940551758]
affect O [-0.6714320182800293, 0.38397082686424255]
risk O [-0.7221555709838867, 0.48145750164985657]
for O [-0.823405921459198, 0.3751783072948456]
development O [-0.6008283495903015, 0.4887376129627228]
of O [-0.7593198418617249, 0.4173988997936249]
breast O [-0.5007362961769104, 0.25247254967689514]
cancer O [-0.38962212204933167, 0.04397698864340782]
in O [-0.7407345175743103, 0.276467889547348]
adulthood. O [-0.2952512800693512, 0.24307741224765778]

Dnmt1 B-LOC [0.23510822653770447, -0.8370164632797241]
epigenetically B-LOC [1.1236674785614014, -1.258449912071228]
propagates B-LOC [1.0238368511199951, -1.3333799839019775]
symmetrical B-LOC [0.8863864541053772, -1.0505772829055786]
CG B-LOC [0.5696614384651184, -0.8586204051971436]
methylation B-LOC [0.8530033230781555, -1.2369318008422852]
in B-LOC [0.8416051864624023, -1.209980845451355]
many B-LOC [1.3215242624282837, -1.5320050716400146]
eukaryotes. B-LOC [1.249658465385437, -1.1131179332733154]
Their B-LOC [1.540910243988037, -1.6220979690551758]
genomes B-LOC [1.4887596368789673, -1.7150635719299316]
are B-LOC [1.8845558166503906, -1.9058337211608887]
typically B-LOC [1.9798648357391357, -1.8534057140350342]
depleted B-LOC [1.8378537893295288, -1.7105839252471924]
of B-LOC [1.5694634914398193, -1.755009651184082]
CG B-LOC [1.0181708335876465, -1.3634113073349]
dinucleotides B-LOC [0.9397059679031372, -1.3727667331695557]
because B-LOC [1.6532917022705078, -1.3178224563598633]
of B-LOC [1.681544542312622, -1.484122633934021]
imperfect B-LOC [1.7379837036132812, -1.6562767028808594]
repair B-LOC [1.477243423461914, -1.2847050428390503]
of B-LOC [1.6613136529922485, -1.7201324701309204]
deaminated B-LOC [1.6095213890075684, -1.648971676826477]
methylcytosines. B-LOC [1.453411340713501, -1.8653286695480347]
Here, B-LOC [0.56121426820755, -0.6467670202255249]
we B-LOC [0.5284437537193298, -0.5257941484451294]
extensively B-LOC [0.9417288899421692, -0.945952832698822]
survey B-LOC [0.9676982760429382, -0.9116668701171875]
diverse B-LOC [1.146360158920288, -1.3094780445098877]
species B-LOC [1.1793460845947266, -1.0429980754852295]
lacking B-LOC [1.0080069303512573, -1.128615379333496]
Dnmt1 B-LOC [0.546286940574646, -0.6862322092056274]
and B-LOC [0.8028882145881653, -0.9470900893211365]
show B-LOC [0.7377501130104065, -0.7578441500663757]
that, B-LOC [0.7972933650016785, -0.9388635754585266]
surprisingly, B-LOC [1.006004810333252, -0.8892250061035156]
symmetrical B-LOC [0.9215912818908691, -1.1228331327438354]
CG B-LOC [0.5777396559715271, -0.9492964744567871]
methylation B-LOC [0.9866697192192078, -1.1991592645645142]
is B-LOC [1.3110727071762085, -1.129363775253296]
nonetheless B-LOC [1.1521830558776855, -1.0716384649276733]
frequently B-LOC [1.095665693283081, -1.1348072290420532]
present B-LOC [1.1175973415374756, -1.228184700012207]
and B-LOC [1.116155743598938, -0.9362389445304871]
catalyzed B-LOC [1.2708892822265625, -1.338175654411316]
by B-LOC [1.1424882411956787, -1.2246932983398438]
a B-LOC [1.3198403120040894, -1.1603496074676514]
different B-LOC [1.2785770893096924, -1.5986014604568481]
DNA B-LOC [0.7371185421943665, -1.2136836051940918]
methyltransferase B-LOC [1.119114637374878, -1.2957230806350708]
family, B-LOC [1.2993080615997314, -1.3569179773330688]
Dnmt5. B-LOC [0.45604225993156433, -0.7375408411026001]
Numerous B-LOC [0.8356582522392273, -0.8645461201667786]
Dnmt5-containing B-LOC [0.502627432346344, -0.6029634475708008]
organisms B-LOC [1.0385806560516357, -1.2042927742004395]
that B-LOC [1.1787221431732178, -1.0235779285430908]
diverged B-LOC [1.244523048400879, -1.4259312152862549]
more B-LOC [1.3831883668899536, -1.1378939151763916]
than B-LOC [1.3060073852539062, -0.9000746607780457]
a B-LOC [1.015426516532898, -0.7636538147926331]

billion B-LOC [1.3204495906829834, -1.786961317062378]
years B-LOC [1.5057545900344849, -1.7402254343032837]
ago B-LOC [1.2032034397125244, -1.4895830154418945]
exhibit B-LOC [0.935795247554779, -1.3424787521362305]
clustered B-LOC [1.4363255500793457, -1.6145809888839722]
methylation, B-LOC [1.3496962785720825, -1.6854476928710938]
specifically B-LOC [1.1604199409484863, -1.6118760108947754]
in B-LOC [1.0835925340652466, -1.3570406436920166]
nucleosome B-LOC [1.183354377746582, -1.4211252927780151]
linkers. B-LOC [1.0526819229125977, -1.2975326776504517]
Clustered B-LOC [0.057464849203825, -0.07742093503475189]
methylation B-LOC [0.17220905423164368, -0.3362044394016266]
occurs O [-0.12071748077869415, 0.09670256078243256]
at O [-0.0996505469083786, -0.003449814859777689]
unprecedented O [-0.20736762881278992, -0.08151279389858246]
densities B-LOC [0.09213247895240784, 0.08252093195915222]
and O [-0.5207818746566772, 0.26834556460380554]
directly O [-0.3984571397304535, 0.2062993049621582]
disfavors O [-0.17182482779026031, 0.3001627027988434]
nucleosomes, B-LOC [0.04527090862393379, 0.03101758472621441]
contributing O [-0.20113985240459442, 0.1325504183769226]
to O [-0.1522826850414276, 0.08627525717020035]
nucleosome O [0.03859236091375351, 0.07753422856330872]
positioning B-LOC [0.1651424765586853, -0.05056646093726158]
between B-LOC [0.0928788036108017, -0.38393160700798035]
clusters. B-LOC [0.4250888526439667, -0.2133534997701645]
Dense B-LOC [2.4307119846343994, -2.1282708644866943]
methylation B-LOC [2.4389426708221436, -2.230595588684082]
is B-LOC [2.3944568634033203, -1.957527756690979]
enabled B-LOC [2.118394613265991, -2.057407855987549]
by B-LOC [2.1870181560516357, -1.8905049562454224]
a B-LOC [2.326511859893799, -1.828060507774353]
regime B-LOC [2.2476091384887695, -2.104661226272583]
of B-LOC [2.206692934036255, -2.043431043624878]
genomic B-LOC [2.520184278488159, -2.176226854324341]
sequence B-LOC [2.309155225753784, -2.2742464542388916]
evolution B-LOC [2.2712466716766357, -2.1962878704071045]
that B-LOC [1.7757971286773682, -2.0405313968658447]
enriches B-LOC [2.5219662189483643, -2.025001287460327]
CG B-LOC [1.8385730981826782, -1.9334688186645508]
dinucleotides B-LOC [1.9308664798736572, -2.1050918102264404]
and B-LOC [1.5909886360168457, -1.6575204133987427]
drives B-LOC [2.4184436798095703, -2.0903313159942627]
the B-LOC [2.3052828311920166, -1.8475348949432373]
highest B-LOC [2.1619858741760254, -2.3817765712738037]
CG B-LOC [1.92652428150177, -2.0152275562286377]
frequencies B-LOC [2.1689465045928955, -2.2510106563568115]
known. B-LOC [2.6365206241607666, -2.211395740509033]
Species B-LOC [1.1206289529800415, -1.2803031206130981]
with B-LOC [1.4382266998291016, -1.9604412317276]
linker B-LOC [1.558020830154419, -1.331129550933838]
methylation B-LOC [1.5862663984298706, -1.6998074054718018]
have B-LOC [1.2766767740249634, -1.2556136846542358]
small, B-LOC [1.4694775342941284, -1.3932125568389893]
transcriptionally B-LOC [1.298943281173706, -1.4710381031036377]
active B-LOC [1.1662988662719727, -1.4768736362457275]
nuclei B-LOC [1.4469459056854248, -1.527069091796875]
that B-LOC [1.3818308115005493, -1.760800838470459]
approach B-LOC [1.5887837409973145, -1.7216845750808716]
the B-LOC [1.5635132789611816, -1.7164831161499023]
physical B-LOC [1.6952719688415527, -2.024728775024414]
limits B-LOC [1.601441502571106, -1.9138143062591553]
of B-LOC [1.5662425756454468, -1.9373674392700195]
chromatin B-LOC [1.3176648616790771, -1.7221527099609375]
compaction. B-LOC [1.7086254358291626, -1.6776355504989624]
These B-LOC [1.6757724285125732, -1.7307624816894531]
features B-LOC [1.5009658336639404, -1.9006590843200684]
constitute B-LOC [2.127732753753662, -1.7656816244125366]
a B-LOC [1.8858215808868408, -1.9295132160186768]
previously B-LOC [1.5282069444656372, -2.078791618347168]
unappreciated B-LOC [2.1090309619903564, -1.972675085067749]
genome B-LOC [1.1659138202667236, -1.7929266691207886]

architecture, B-LOC [0.23767413198947906, -0.6048806309700012]
in B-LOC [0.298421710729599, -0.28758880496025085]
which B-LOC [0.33112427592277527, -0.41783735156059265]
dense B-LOC [0.48505353927612305, -0.4307311475276947]
methylation B-LOC [0.5251744389533997, -0.5668051242828369]
influences B-LOC [0.21008403599262238, -0.603638768196106]
nucleosome B-LOC [0.36100366711616516, -0.438098281621933]
positions, B-LOC [0.37454503774642944, -0.4351489841938019]
likely B-LOC [0.6061381697654724, -0.6358823776245117]
facilitating B-LOC [0.44948408007621765, -0.38274165987968445]
nuclear B-LOC [0.3899044692516327, -0.5087939500808716]
processes B-LOC [0.21891334652900696, -0.5590558648109436]
under B-LOC [0.6221781373023987, -0.6193157434463501]
extreme B-LOC [0.5032206177711487, -0.8605113625526428]
spatial B-LOC [0.5628746151924133, -0.7224216461181641]
constraints. B-LOC [0.5685002207756042, -0.730301022529602]

Modification B-LOC [2.5476396083831787, -3.2312893867492676]
of B-LOC [2.8469431400299072, -3.280440330505371]
proteins B-LOC [2.766111135482788, -3.3253014087677]
by B-LOC [2.761796236038208, -3.1910626888275146]
SUMO B-LOC [2.8939507007598877, -3.427722930908203]
is B-LOC [3.089651346206665, -3.1303045749664307]
essential B-LOC [2.9783551692962646, -3.2720136642456055]
for B-LOC [2.908306837081909, -3.190032482147217]
the B-LOC [3.0234179496765137, -3.171894073486328]
maintenance B-LOC [3.0996408462524414, -3.2094125747680664]
of B-LOC [2.799718141555786, -3.3720543384552]
genome B-LOC [2.8441646099090576, -3.4016921520233154]
integrity. B-LOC [2.8927741050720215, -3.281912326812744]
During B-LOC [1.1651809215545654, -1.4856337308883667]
DNA B-LOC [1.5543980598449707, -1.7791441679000854]
replication, B-LOC [1.80559504032135, -1.7259948253631592]
the B-LOC [1.3765761852264404, -1.3748077154159546]
Mms21-branch B-LOC [1.1911847591400146, -1.4656418561935425]
of B-LOC [1.2161259651184082, -1.5191786289215088]
the B-LOC [1.437745451927185, -1.5389225482940674]
SUMO B-LOC [1.2865252494812012, -1.6559090614318848]
pathway B-LOC [1.1076569557189941, -1.5959477424621582]
counteracts B-LOC [1.4333224296569824, -1.4464869499206543]
recombination B-LOC [1.2353441715240479, -1.5177677869796753]
intermediates B-LOC [1.1641526222229004, -1.4945025444030762]
at B-LOC [1.1864910125732422, -1.5590611696243286]
damaged B-LOC [1.2360107898712158, -1.7947596311569214]
replication B-LOC [1.5358922481536865, -1.6327903270721436]
forks, B-LOC [1.3714535236358643, -1.9226182699203491]
thus B-LOC [1.1850401163101196, -1.0592807531356812]
facilitating B-LOC [1.3153339624404907, -1.3087434768676758]
sister B-LOC [1.3948884010314941, -1.6821141242980957]
chromatid B-LOC [1.5255041122436523, -1.5964912176132202]
disjunction. B-LOC [1.6647522449493408, -1.723353385925293]
The B-LOC [1.8643606901168823, -1.6039950847625732]
Mms21 B-LOC [1.227437973022461, -1.3702046871185303]
SUMO B-LOC [1.262026071548462, -1.5688269138336182]
ligase B-LOC [1.832586407661438, -1.637289047241211]
docks B-LOC [1.7513644695281982, -1.2139108180999756]
to B-LOC [1.3065614700317383, -1.2540373802185059]
the B-LOC [1.762922763824463, -1.5219573974609375]
arm B-LOC [1.8359949588775635, -1.822363257408142]
region B-LOC [1.5034301280975342, -1.5928300619125366]
of B-LOC [1.5923373699188232, -1.5138171911239624]
the B-LOC [1.8878488540649414, -1.4622795581817627]
Smc5 B-LOC [1.619665503501892, -1.642663598060608]
protein B-LOC [1.329824447631836, -1.682152509689331]
in B-LOC [1.6991033554077148, -1.407745599746704]
the B-LOC [2.093134641647339, -1.541016936302185]
Smc5/6 B-LOC [1.8100388050079346, -1.7902013063430786]
complex; B-LOC [1.6980289220809937, -1.8572381734848022]
together, B-LOC [2.3433101177215576, -2.0075442790985107]
they B-LOC [2.062592029571533, -1.8779423236846924]
cooperate B-LOC [2.175771951675415, -1.8848116397857666]
during B-LOC [2.109149694442749, -1.8322151899337769]
recombinational B-LOC [2.700373411178589, -2.4556102752685547]
DNA B-LOC [2.2018203735351562, -2.19724178314209]
repair. B-LOC [2.2629854679107666, -2.1841881275177]
Yet B-LOC [3.0678889751434326, -2.6942293643951416]
how B-LOC [2.8164589405059814, -3.050919771194458]
the B-LOC [2.876523733139038, -2.8351054191589355]
activity B-LOC [2.5453357696533203, -2.777984857559204]
of B-LOC [2.7314207553863525, -2.618452310562134]
the B-LOC [2.744691848754883, -2.5512845516204834]
SUMO B-LOC [2.0392706394195557, -2.554086446762085]
ligase B-LOC [2.6041736602783203, -2.433835506439209]
is B-LOC [3.3926830291748047, -2.7953288555145264]
controlled B-LOC [3.0675952434539795, -3.000978708267212]
remains B-LOC [3.3563897609710693, -2.6728546619415283]
unknown. B-LOC [3.2866384983062744, -2.582789897918701]
Here B-LOC [0.21397794783115387, -0.5124486088752747]
we B-LOC [0.1408449411392212, -0.41028115153312683]
show B-LOC [0.24032960832118988, -0.5676904320716858]

that B-LOC [0.3137769103050232, -0.36814025044441223]
the B-LOC [0.9066181778907776, -0.9523472189903259]
SUMO B-LOC [0.5167819857597351, -1.0350953340530396]
ligase B-LOC [0.8751804232597351, -1.0679134130477905]
and B-LOC [1.0111973285675049, -1.0237410068511963]
the B-LOC [1.071470856666565, -0.9435802698135376]
chromosome B-LOC [0.6627084612846375, -0.9308260679244995]
disjunction B-LOC [1.1112035512924194, -1.181894302368164]
functions B-LOC [0.9753614664077759, -1.1601574420928955]
of B-LOC [0.9887761473655701, -1.0875362157821655]
Mms21 B-LOC [0.43281090259552, -0.669434666633606]
depend B-LOC [0.9887495636940002, -0.987739622592926]
on B-LOC [1.2305423021316528, -1.0945279598236084]
its B-LOC [0.9271184206008911, -0.8807258605957031]
docking B-LOC [0.9444484710693359, -0.7875868678092957]
to B-LOC [1.145543098449707, -1.1227234601974487]
an B-LOC [1.0158967971801758, -0.8807584047317505]
intact B-LOC [0.992866575717926, -0.935080349445343]
and B-LOC [0.6847484707832336, -0.7559036612510681]
active B-LOC [0.7011860013008118, -0.8720438480377197]
Smc5/6 B-LOC [0.49257180094718933, -0.7352349162101746]
complex, B-LOC [0.6656654477119446, -1.040615439414978]
indicating B-LOC [0.7704759836196899, -0.3799932897090912]
that B-LOC [0.7537985444068909, -0.6146999597549438]
the B-LOC [0.968250572681427, -0.778682291507721]
Smc5/6-Mms21 B-LOC [0.5634210109710693, -0.6763373613357544]
complex B-LOC [0.7436023354530334, -1.0165842771530151]
operates B-LOC [0.947913408279419, -0.9730613827705383]
as B-LOC [0.8679295778274536, -0.8156574964523315]
a B-LOC [0.822817862033844, -0.8801431059837341]
large B-LOC [0.9377866387367249, -1.0559256076812744]
SUMO B-LOC [0.7834830284118652, -0.8650897145271301]
ligase B-LOC [0.9014940857887268, -0.9734441041946411]
in B-LOC [0.6377505660057068, -0.7563735842704773]
vivo. B-LOC [0.6352041959762573, -0.8994913101196289]
In B-LOC [0.3750089704990387, -0.13801489770412445]
spite B-LOC [0.38487786054611206, -0.06500808894634247]
of B-LOC [0.5926092267036438, -0.28437599539756775]
the B-LOC [0.5475504994392395, -0.33346569538116455]
physical B-LOC [0.5183314085006714, -0.484440416097641]
distance B-LOC [0.5518475770950317, -0.4775991141796112]
separating B-LOC [0.6737073063850403, -0.6833221316337585]
the B-LOC [0.6373019814491272, -0.645134449005127]
E3 B-LOC [0.3832077980041504, -0.6218351721763611]
and B-LOC [0.7846908569335938, -0.68739914894104]
the B-LOC [0.7431555390357971, -0.6818469762802124]
nucleotide-binding B-LOC [0.5275166034698486, -0.6495247483253479]
domains B-LOC [0.5985733866691589, -0.7617524862289429]
in B-LOC [0.6376728415489197, -0.6222105622291565]
Smc5/6, B-LOC [0.44328656792640686, -0.5998192429542542]
Mms21-dependent B-LOC [0.07026271522045135, -0.3839053809642792]
sumoylation B-LOC [0.1896507889032364, -0.49410170316696167]
requires B-LOC [0.29279664158821106, -0.45674949884414673]
binding B-LOC [0.4956286549568176, -0.19342517852783203]
of B-LOC [0.28696921467781067, -0.36127611994743347]
ATP B-LOC [0.4235195219516754, -0.33086177706718445]
to B-LOC [0.3338351547718048, -0.49398690462112427]
Smc5, B-LOC [0.34155943989753723, -0.47215113043785095]
a B-LOC [0.10343915224075317, -0.14665193855762482]
step B-LOC [0.3020438849925995, -0.47991499304771423]
that B-LOC [0.17614468932151794, -0.6334676146507263]
is B-LOC [0.5163408517837524, -0.38243478536605835]
part B-LOC [0.43003955483436584, -0.2991579473018646]
of B-LOC [0.40987223386764526, -0.4589289724826813]
the B-LOC [0.3754912316799164, -0.3810991942882538]
ligase B-LOC [0.4576396644115448, -0.5501477122306824]
mechanism B-LOC [0.15664255619049072, -0.46191805601119995]
that B-LOC [0.328106164932251, -0.5425904989242554]
assists B-LOC [0.532005250453949, -0.5982685685157776]
Ubc9 B-LOC [0.4018045961856842, -0.4001801311969757]
function. B-LOC [0.4237077534198761, -0.6174837350845337]
The B-LOC [0.3938237428665161, -0.707125186920166]
communication B-LOC [0.3675689399242401, -0.5912732481956482]
is B-LOC [0.5679609179496765, -0.6653466820716858]
enabled B-LOC [0.3439580202102661, -0.6922745108604431]
by B-LOC [0.29377493262290955, -0.5018080472946167]
the B-LOC [0.4356422424316406, -0.5441517233848572]
presence B-LOC [0.3699027895927429, -0.5393889546394348]

of B-LOC [0.27639076113700867, -0.4644347131252289]
a B-LOC [0.42292508482933044, -0.51370769739151]
conserved B-LOC [0.5730205774307251, -0.5580449104309082]
disruption B-LOC [0.3652932345867157, -0.5992410778999329]
in B-LOC [0.3860289454460144, -0.6740350127220154]
the B-LOC [0.4554915428161621, -0.4241235852241516]
coiled B-LOC [0.5005587935447693, -0.7195767164230347]
coil B-LOC [0.5786742568016052, -0.4946093261241913]
domain B-LOC [0.36492595076560974, -0.4781641364097595]
of B-LOC [0.3981379568576813, -0.5101023316383362]
Smc5, B-LOC [0.3925332725048065, -0.6113424897193909]
pointing B-LOC [0.4444393217563629, -0.6719133257865906]
to B-LOC [0.5288406014442444, -0.8644173741340637]
potential B-LOC [0.63835209608078, -1.007148027420044]
conformational B-LOC [0.791479229927063, -0.8793123960494995]
changes B-LOC [0.5498371124267578, -1.0239217281341553]
for B-LOC [0.6336148381233215, -1.1114736795425415]
SUMO B-LOC [0.36509594321250916, -0.8250080943107605]
ligase B-LOC [0.627884566783905, -0.9957747459411621]
activation. B-LOC [0.6874100565910339, -0.8103976845741272]
In B-LOC [0.044820357114076614, -0.2016659528017044]
accordance, B-LOC [0.2086561620235443, 0.032286230474710464]
scanning B-LOC [0.5276966094970703, -0.32826128602027893]
force B-LOC [0.4684992730617523, -0.12081828713417053]
microscopy B-LOC [0.5760101675987244, -0.10663560032844543]
of B-LOC [0.35932204127311707, -0.09137983620166779]
the B-LOC [0.4481818675994873, -0.20228789746761322]
Smc5-Mms21 B-LOC [0.3688552677631378, -0.32986119389533997]
heterodimer B-LOC [0.3951030373573303, -0.5122520327568054]
shows B-LOC [0.19217918813228607, 0.07561497390270233]
that B-LOC [0.11010576784610748, -0.11980678141117096]
the B-LOC [0.5460193157196045, -0.5249370336532593]
molecule B-LOC [0.2813713550567627, -0.6612953543663025]
is B-LOC [0.3855421841144562, -0.27364233136177063]
physically B-LOC [0.3873802125453949, -0.20190362632274628]
remodeled B-LOC [0.5012426376342773, -0.2591533362865448]
in B-LOC [0.11502807587385178, -0.16496913135051727]
an B-LOC [0.08661004155874252, -0.1875254511833191]
ATP-dependent B-LOC [0.41280636191368103, -0.26479092240333557]
manner. B-LOC [0.11600695550441742, -0.27249154448509216]
Our O [-0.3836577236652374, 0.008380880579352379]
results B-LOC [-0.021430058404803276, -0.11023388803005219]
demonstrate O [-0.2726639211177826, 0.1322430968284607]
that O [-0.5388388633728027, -0.07724200189113617]
the B-LOC [-0.16469329595565796, -0.24890616536140442]
ATP-binding B-LOC [-0.10499085485935211, -0.19237056374549866]
activity B-LOC [-0.022443799301981926, -0.20483054220676422]
of B-LOC [0.010999533347785473, -0.21142660081386566]
the B-LOC [0.20127561688423157, -0.2878152132034302]
Smc5/6 B-LOC [-0.06676005572080612, -0.29540207982063293]
complex B-LOC [-0.14089059829711914, -0.47580686211586]
is B-LOC [0.009297947399318218, -0.18240657448768616]
coordinated B-LOC [-0.13086985051631927, -0.274052232503891]
with B-LOC [-0.17027460038661957, -0.4662966728210449]
its B-LOC [0.06884124130010605, -0.4368740916252136]
SUMO B-LOC [-0.12773650884628296, -0.3317302465438843]
ligase, B-LOC [-0.07786828279495239, -0.35914990305900574]
through O [-0.2980574667453766, -0.27482396364212036]
the B-LOC [-0.026250725612044334, -0.21373623609542847]
coiled B-LOC [0.10367897152900696, -0.335434228181839]
coil B-LOC [0.1950390487909317, -0.18779626488685608]
domain B-LOC [0.038082197308540344, -0.22248144447803497]
of B-LOC [0.03872670605778694, -0.3398934304714203]
Smc5 B-LOC [-0.010567155666649342, -0.25212356448173523]
and B-LOC [-0.1428573727607727, -0.18477627635002136]
the B-LOC [-0.10942810773849487, -0.1102488562464714]
physical B-LOC [0.029328221455216408, -0.1986876130104065]
remodeling B-LOC [0.18741920590400696, -0.29227933287620544]
of B-LOC [0.18302753567695618, -0.42288509011268616]
the B-LOC [0.1797570437192917, -0.3558637499809265]
molecule, B-LOC [0.04304558411240578, -0.6089365482330322]
to B-LOC [0.0279203150421381, -0.2520858943462372]
promote B-LOC [-0.3107868432998657, -0.3113473355770111]

sumoylation B-LOC [-0.15387482941150665, -0.27883681654930115]
and B-LOC [0.23296833038330078, -0.32261213660240173]
chromosome B-LOC [-0.09086281806230545, -0.3149658739566803]
disjunction B-LOC [0.34633785486221313, -0.43753764033317566]
during B-LOC [0.13393732905387878, -0.32745155692100525]
DNA B-LOC [0.12692153453826904, -0.3678492307662964]
repair. B-LOC [0.07825779169797897, -0.35194605588912964]

Small-vessel B-LOC [1.9463047981262207, -2.263456106185913]
vasculitis B-LOC [1.4060800075531006, -2.330108404159546]
(SVV) B-LOC [1.7150344848632812, -2.216738700866699]
is B-LOC [1.8783921003341675, -2.3909952640533447]
a B-LOC [1.8438453674316406, -2.263838529586792]
chronic B-LOC [1.9390369653701782, -2.39894700050354]
autoinflammatory B-LOC [1.8448363542556763, -2.3569986820220947]
condition B-LOC [1.4871547222137451, -2.1432998180389404]
linked B-LOC [1.9968291521072388, -2.190282106399536]
to B-LOC [1.9319826364517212, -2.2636544704437256]
antineutrophil B-LOC [1.993314504623413, -2.4158477783203125]
cytoplasm B-LOC [2.0071895122528076, -2.2937633991241455]
autoantibodies B-LOC [2.292968273162842, -2.557873249053955]
(ANCAs). B-LOC [2.2841880321502686, -2.22804856300354]
Here O [-0.4153654873371124, 0.05887444689869881]
we O [-0.5529424548149109, 0.19073791801929474]
show O [-0.5031139254570007, 0.25308719277381897]
that O [-0.753928005695343, 0.22323709726333618]
chromatin O [-0.24264295399188995, 0.08500995486974716]
fibers, O [-0.17245440185070038, 0.15275704860687256]
so-called O [-0.21002355217933655, 0.02402280829846859]
neutrophil O [-0.22332563996315002, 0.18580809235572815]
extracellular O [-0.24661844968795776, 0.04651928320527077]
traps O [-0.13395869731903076, 0.07914485037326813]
(NETs), B-LOC [0.0996670126914978, -0.2547188699245453]
are O [-0.207391619682312, 0.1889190524816513]
released O [-0.11633439362049103, 0.06137567386031151]
by O [-0.3454684317111969, 0.25229573249816895]
ANCA-stimulated O [-0.264180451631546, 0.02176648937165737]
neutrophils O [-0.3503626883029938, 0.4628284275531769]
and O [-0.3094088137149811, 0.1706582009792328]
contain O [0.04844478890299797, 0.27882739901542664]
the O [0.011082942597568035, 0.2893562316894531]
targeted O [-0.2773302495479584, 0.25088950991630554]
autoantigens O [-0.2609194815158844, 0.08939963579177856]
proteinase-3 O [-0.24418389797210693, -0.07933101058006287]
(PR3) O [-0.23892830312252045, 0.07057249546051025]
and O [-0.2214447557926178, 0.23766648769378662]
myeloperoxidase O [-0.04362643137574196, 0.1783520132303238]
(MPO). B-LOC [-0.0022485083900392056, -0.1074662134051323]
Deposition O [-0.23217007517814636, -0.006976692471653223]
of O [-0.13839738070964813, -0.08555039018392563]
NETs B-LOC [0.04338676109910011, 0.021508948877453804]
in O [-0.19806712865829468, 0.010054340586066246]
inflamed O [-0.15688462555408478, 0.11411996185779572]
kidneys O [-0.4224819242954254, -0.3157888650894165]
and O [-0.23647567629814148, -0.16356807947158813]
circulating O [-0.2831719219684601, -0.2636971175670624]

MPO-DNA O [-0.21786344051361084, -0.10675850510597229]
complexes O [0.10685325413942337, 0.15427225828170776]
suggest O [-0.2511542737483978, 0.14477011561393738]
that O [-0.6745915412902832, 0.18540796637535095]
NET O [-0.3748021423816681, 0.4777480661869049]
formation O [-0.37270352244377136, 0.5491484999656677]
triggers O [-0.597554087638855, 0.6183485984802246]
vasculitis O [-0.7165204882621765, 0.47643643617630005]
and O [-0.8181995749473572, 0.5270121693611145]
promotes O [-0.5469818711280823, 0.5720838308334351]
the O [-0.629999577999115, 0.5595525503158569]
autoimmune O [-0.6947097778320312, 0.4981360137462616]
response O [-0.6594274640083313, 0.49657124280929565]
against O [-0.419116348028183, 0.5423027873039246]
neutrophil O [-0.5596339106559753, 0.5499691367149353]
components O [-0.6083968281745911, 0.48407647013664246]
in O [-0.4452097713947296, 0.3194163143634796]
individuals O [-0.5045313239097595, 0.24275550246238708]
with O [-0.4150979816913605, 0.036965396255254745]
SVV. O [-0.46722471714019775, 0.1799304485321045]

Tumor B-LOC [1.1324137449264526, -1.630064845085144]
cells B-LOC [1.0126621723175049, -1.2303991317749023]
have B-LOC [1.226055383682251, -1.510462760925293]
high-energetic B-LOC [1.1989227533340454, -1.6466811895370483]
and B-LOC [1.0411170721054077, -1.5202354192733765]
anabolic B-LOC [1.2718777656555176, -1.6673836708068848]
needs B-LOC [1.2502509355545044, -1.2927008867263794]
and B-LOC [0.985088050365448, -1.4415066242218018]
are B-LOC [1.3980329036712646, -1.5605827569961548]
known B-LOC [1.41975998878479, -1.56554114818573]
to B-LOC [1.4139845371246338, -1.5491280555725098]
adapt B-LOC [1.2895047664642334, -1.5180389881134033]
their B-LOC [1.467319130897522, -1.7374709844589233]
metabolism B-LOC [1.275252103805542, -1.3760672807693481]
to B-LOC [1.5803250074386597, -1.547366976737976]
be B-LOC [1.2311499118804932, -1.6807801723480225]
able B-LOC [1.476817011833191, -1.6624267101287842]
to B-LOC [1.4300882816314697, -1.6883577108383179]
survive B-LOC [1.7159998416900635, -1.587205171585083]
and B-LOC [1.273040771484375, -1.4757411479949951]
keep B-LOC [1.3768699169158936, -1.6311836242675781]
proliferating B-LOC [1.546841025352478, -1.6796150207519531]
under B-LOC [1.78073251247406, -1.860746145248413]
conditions B-LOC [1.7567349672317505, -1.7470500469207764]
of B-LOC [1.679863691329956, -2.0753719806671143]
nutrient B-LOC [1.8769068717956543, -1.9207648038864136]
stress. B-LOC [1.7441949844360352, -1.6133967638015747]
We B-LOC [0.45000046491622925, -0.5494645833969116]
show B-LOC [0.5121368169784546, -0.3405475914478302]
that B-LOC [0.5445709824562073, -0.7221105098724365]
PKCζ B-LOC [0.818652331829071, -0.9351201057434082]
deficiency B-LOC [0.9514606595039368, -0.691879391670227]
promotes B-LOC [0.8860514760017395, -0.662787139415741]
the B-LOC [0.8384279608726501, -0.7192737460136414]
plasticity B-LOC [1.2248764038085938, -1.0621111392974854]
necessary B-LOC [0.9361789226531982, -1.0403709411621094]
for B-LOC [0.8609451651573181, -0.970521092414856]
cancer B-LOC [1.1852219104766846, -1.3205405473709106]
cells B-LOC [0.9177238345146179, -1.0945757627487183]
to B-LOC [1.2471752166748047, -1.1432613134384155]
reprogram B-LOC [1.3776754140853882, -1.2190446853637695]
their B-LOC [1.2543836832046509, -1.30732262134552]
metabolism B-LOC [0.9759262204170227, -1.1365211009979248]
to B-LOC [1.3440909385681152, -1.3248745203018188]
utilize B-LOC [1.0928460359573364, -1.2182763814926147]
glutamine B-LOC [1.0849120616912842, -1.0840821266174316]
through B-LOC [1.0854828357696533, -1.3501123189926147]
the B-LOC [1.2832823991775513, -1.1545424461364746]
serine B-LOC [1.2037067413330078, -1.1835545301437378]
biosynthetic B-LOC [1.2028121948242188, -1.384164810180664]
pathway B-LOC [0.9334824681282043, -1.3403452634811401]
in B-LOC [1.0985426902770996, -1.1081407070159912]
the B-LOC [1.1884878873825073, -1.0608839988708496]
absence B-LOC [1.1640779972076416, -0.9703165292739868]
of B-LOC [1.0030901432037354, -1.0518429279327393]
glucose. B-LOC [1.094165563583374, -1.1485856771469116]
PKCζ B-LOC [0.06344140321016312, -0.49864742159843445]
represses B-LOC [0.17835256457328796, -0.1154676079750061]
the B-LOC [0.27856412529945374, -0.24626871943473816]
expression B-LOC [0.2803179919719696, -0.046772103756666183]
of B-LOC [0.2907513380050659, -0.3340013325214386]
two B-LOC [0.4649876654148102, -0.5386618971824646]
key B-LOC [0.32915130257606506, -0.7821411490440369]
enzymes B-LOC [0.19472378492355347, -0.5650029182434082]
of B-LOC [0.579002320766449, -0.6778250932693481]
the B-LOC [0.7320008277893066, -0.8731188178062439]
pathway, B-LOC [0.3936067819595337, -0.9436805248260498]
PHGDH B-LOC [0.1464645266532898, -0.5685523748397827]
and B-LOC [0.1995924711227417, -0.3314172625541687]
PSAT1, B-LOC [0.2889273464679718, -0.5485785603523254]
and B-LOC [-0.09254130721092224, -0.32082292437553406]
phosphorylates B-LOC [0.06144871935248375, -0.3449225425720215]
PHGDH B-LOC [0.1017577201128006, -0.3208436667919159]
at B-LOC [0.29284507036209106, -0.29251009225845337]
key B-LOC [0.44554200768470764, -0.7817447781562805]

residues B-LOC [0.1421382576227188, -0.5142760872840881]
to B-LOC [0.3500574231147766, -0.3884287476539612]
inhibit B-LOC [0.6179878115653992, -0.945351779460907]
its B-LOC [0.5890308022499084, -0.7095678448677063]
enzymatic B-LOC [0.7963937520980835, -1.1552457809448242]
activity. B-LOC [0.6760229468345642, -0.7700809836387634]
Interestingly, O [-0.2871658504009247, 0.2993011772632599]
the O [-0.3701304793357849, 0.4824775457382202]
loss O [-0.15580129623413086, 0.34836405515670776]
of O [-0.4058907926082611, 0.43372949957847595]
PKCζ O [-0.25306618213653564, 0.15225720405578613]
in O [-0.48604145646095276, 0.419911652803421]
mice O [-0.46856358647346497, 0.5606551766395569]
results O [-0.6212836503982544, 0.6114740371704102]
in O [-0.7325834631919861, 0.6920592188835144]
enhanced O [-0.8057235479354858, 0.7576791644096375]
intestinal O [-1.0192465782165527, 0.9304210543632507]
tumorigenesis O [-0.7817778587341309, 0.8246141076087952]
and O [-0.8830981254577637, 0.7496770024299622]
increased O [-0.7125174403190613, 0.7289877533912659]
levels O [-0.6934525966644287, 0.7623854279518127]
of O [-0.8674378991127014, 0.7535558342933655]
these O [-0.5129957795143127, 0.37701353430747986]
two O [-0.5247397422790527, 0.3289456069469452]
metabolic O [-0.5291199088096619, 0.6964613795280457]
enzymes, O [-0.6012729406356812, 0.6284762620925903]
whereas O [-0.6433402895927429, 0.742647111415863]
patients O [-0.5634024143218994, 0.5806743502616882]
with O [-0.4551585018634796, 0.34300222992897034]
low O [-0.3050293028354645, 0.4474020004272461]
levels O [-0.5891587138175964, 0.5981569886207581]
of O [-0.8159216046333313, 0.6055176258087158]
PKCζ O [-0.48717641830444336, 0.3684682846069336]
have O [-0.5765564441680908, 0.5749760866165161]
a O [-0.5764427781105042, 0.6087278723716736]
poor O [-0.37097403407096863, 0.4629628658294678]
prognosis. O [-0.6116281151771545, 0.6378264427185059]
Furthermore, B-LOC [0.3877332806587219, -0.4461625814437866]
PKCζ B-LOC [0.47185418009757996, -0.916161835193634]
and B-LOC [1.1941778659820557, -1.5203840732574463]
caspase-3 B-LOC [0.995272696018219, -1.3440121412277222]
activities B-LOC [1.2217764854431152, -1.31703519821167]
are B-LOC [1.4740360975265503, -1.4527262449264526]
correlated B-LOC [1.2081001996994019, -1.3969796895980835]
with B-LOC [1.0495933294296265, -1.4930615425109863]
PHGDH B-LOC [0.7474202513694763, -1.2046308517456055]
levels B-LOC [1.1836521625518799, -1.381594181060791]
in B-LOC [1.2388067245483398, -1.4408334493637085]
human B-LOC [1.114622712135315, -1.6700867414474487]
intestinal B-LOC [1.030928134918213, -1.2256581783294678]
tumors. B-LOC [1.2437105178833008, -1.5618820190429688]
Taken B-LOC [0.7888389825820923, -0.53968745470047]
together, B-LOC [0.6225058436393738, -0.4015515148639679]
this B-LOC [0.5855997204780579, -0.6311867833137512]
demonstrates B-LOC [0.4240514039993286, -0.4392198622226715]
that B-LOC [0.06334924697875977, -0.4704876244068146]
PKCζ B-LOC [0.0072826542891561985, -0.3605840504169464]
is B-LOC [0.29207441210746765, -0.17643555998802185]
a B-LOC [0.07958011329174042, -0.09240610897541046]
critical B-LOC [-0.0813072994351387, -0.4196428954601288]
metabolic B-LOC [-0.034935735166072845, -0.19343852996826172]
tumor B-LOC [0.1336669623851776, -0.24569706618785858]
suppressor B-LOC [0.17559391260147095, -0.11602603644132614]
in B-LOC [-0.09614571183919907, -0.20788820087909698]
mouse B-LOC [0.37382772564888, -0.6472157835960388]
and B-LOC [0.04935453459620476, -0.28849634528160095]
human B-LOC [0.27684929966926575, -0.7329155802726746]
cancer. B-LOC [0.22781966626644135, -0.5837692618370056]

OBJECTIVE B-LOC [3.293067693710327, -3.6148860454559326]
To B-LOC [3.4382429122924805, -3.6326982975006104]
evaluate B-LOC [3.6919586658477783, -3.471372604370117]
the B-LOC [3.751976251602173, -3.3162550926208496]
association B-LOC [3.5585927963256836, -3.5652029514312744]
of B-LOC [3.5776515007019043, -3.308903455734253]
overall B-LOC [3.853572130203247, -3.572122573852539]
and B-LOC [3.464617967605591, -3.4214842319488525]
specific B-LOC [3.647994041442871, -3.791496515274048]
headaches B-LOC [3.7051360607147217, -3.5863163471221924]
with B-LOC [3.479421377182007, -3.589932918548584]
volume B-LOC [3.669464588165283, -3.6339709758758545]
of B-LOC [3.6092019081115723, -3.436830997467041]
white B-LOC [3.5542051792144775, -3.511449098587036]
matter B-LOC [3.519730806350708, -3.529951333999634]
hyperintensities, B-LOC [3.7772905826568604, -3.547682046890259]
brain B-LOC [3.7634239196777344, -3.651860237121582]
infarcts, B-LOC [3.8379969596862793, -3.359560966491699]
and B-LOC [3.5867202281951904, -3.5024588108062744]
cognition. B-LOC [3.606001377105713, -3.4986789226531982]
DESIGN B-LOC [3.6485021114349365, -3.5371248722076416]
Population B-LOC [3.5785698890686035, -3.4491994380950928]
based, B-LOC [3.3192532062530518, -3.3642373085021973]
cross B-LOC [3.691706895828247, -3.413999557495117]
sectional B-LOC [3.4921600818634033, -3.384181261062622]
study. B-LOC [3.4778006076812744, -3.542292356491089]
SETTING B-LOC [3.2692432403564453, -3.4980156421661377]
Epidemiology B-LOC [3.3119254112243652, -3.197338819503784]
of B-LOC [3.5262062549591064, -3.362478017807007]
Vascular B-LOC [3.3752095699310303, -3.615283966064453]
Ageing B-LOC [3.548687219619751, -3.4668073654174805]
study, B-LOC [3.335498571395874, -3.4070494174957275]
Nantes, B-LOC [3.2512948513031006, -3.390526056289673]
France. B-LOC [3.401524066925049, -3.455271005630493]
PARTICIPANTS B-LOC [3.1549909114837646, -3.280320167541504]
780 B-LOC [3.7313950061798096, -3.2039873600006104]
participants B-LOC [3.3928802013397217, -3.529972553253174]
(mean B-LOC [3.5784385204315186, -3.399113416671753]
age B-LOC [3.5576224327087402, -3.3332149982452393]
69, B-LOC [3.27999210357666, -3.04658842086792]
58.5% B-LOC [3.229179620742798, -3.0009913444519043]
women) B-LOC [3.5265963077545166, -3.355104446411133]
with B-LOC [3.4830119609832764, -3.20078444480896]
detailed B-LOC [3.435772657394409, -3.542249917984009]
headache B-LOC [3.6027657985687256, -3.634561777114868]
assessment. B-LOC [3.6181013584136963, -3.573867082595825]
MAIN B-LOC [3.166926622390747, -3.0636250972747803]
OUTCOME B-LOC [2.983632802963257, -2.842923164367676]
MEASURES B-LOC [2.972487211227417, -2.9249913692474365]
Brain B-LOC [3.4073379039764404, -3.26401424407959]
scans B-LOC [3.472834348678589, -3.302459478378296]
were B-LOC [3.4192795753479004, -2.797334909439087]
evaluated B-LOC [3.693837881088257, -3.058673620223999]
for B-LOC [3.4202888011932373, -3.247563600540161]
volume B-LOC [3.4952681064605713, -3.3654062747955322]
of B-LOC [3.3515751361846924, -3.3611748218536377]
white B-LOC [3.505223512649536, -3.3686063289642334]
matter B-LOC [3.2701022624969482, -3.313115358352661]
hyperintensities B-LOC [3.6037378311157227, -3.1954100131988525]
(by B-LOC [3.5097382068634033, -2.9938361644744873]
fully B-LOC [3.488515853881836, -2.9273996353149414]
automated B-LOC [3.3617329597473145, -3.118983268737793]

imaging B-LOC [2.819046974182129, -3.945594310760498]
processing) B-LOC [3.2198078632354736, -4.178074359893799]
and B-LOC [3.2279915809631348, -3.700342893600464]
for B-LOC [3.2212412357330322, -4.100443363189697]
classification B-LOC [3.5564146041870117, -3.9503684043884277]
of B-LOC [3.5189058780670166, -3.9813950061798096]
infarcts B-LOC [3.6432137489318848, -4.100417137145996]
(by B-LOC [3.521700620651245, -4.07169771194458]
visual B-LOC [3.52892804145813, -4.248875141143799]
reading B-LOC [3.537471055984497, -4.349305629730225]
with B-LOC [3.6432836055755615, -4.139797210693359]
a B-LOC [3.5369513034820557, -4.038880348205566]
standardised B-LOC [3.6292049884796143, -4.19825553894043]
assessment B-LOC [3.427759885787964, -4.232393264770508]
grid). B-LOC [3.5598490238189697, -4.205012798309326]
Cognitive B-LOC [3.33734393119812, -4.025483131408691]
function B-LOC [3.3838374614715576, -4.05488395690918]
was B-LOC [3.3111026287078857, -3.945422410964966]
assessed B-LOC [3.5313913822174072, -4.072213649749756]
by B-LOC [3.424424648284912, -4.058980941772461]
a B-LOC [3.4809682369232178, -3.9810101985931396]
battery B-LOC [3.559282064437866, -4.089216709136963]
of B-LOC [3.4095590114593506, -4.005530834197998]
tests B-LOC [3.459804058074951, -4.122824192047119]
including B-LOC [3.5436978340148926, -3.9043140411376953]
the B-LOC [3.5102970600128174, -3.965313673019409]
mini-mental B-LOC [3.4493117332458496, -4.1781840324401855]
state B-LOC [3.4712464809417725, -4.220996379852295]
examination. B-LOC [3.5157034397125244, -4.1425580978393555]
RESULTS B-LOC [0.47546514868736267, -0.9341430068016052]
163 B-LOC [1.1021232604980469, -0.5862900614738464]
(20.9%) B-LOC [0.9665096998214722, -0.5644546747207642]
participants B-LOC [0.6727867722511292, -0.7081575393676758]
reported B-LOC [0.6457710266113281, -0.3861550986766815]
a B-LOC [0.5738100409507751, -0.3441961407661438]
history B-LOC [0.6188693642616272, -0.4813250005245209]
of B-LOC [0.6214772462844849, -0.4821098744869232]
severe B-LOC [0.6628767848014832, -0.618568480014801]
headache B-LOC [0.8614259958267212, -0.7480579018592834]
and B-LOC [0.39328017830848694, -0.5793768763542175]
116 B-LOC [1.0386319160461426, -0.7048819661140442]
had B-LOC [0.5439116358757019, -0.5085853338241577]
migraine, B-LOC [0.6414392590522766, -0.4751627445220947]
of B-LOC [0.6681572198867798, -0.3200437128543854]
whom B-LOC [0.7255668044090271, -0.40378037095069885]
17 B-LOC [1.3172752857208252, -0.7264267206192017]
(14.7%) B-LOC [0.937586784362793, -0.7101136445999146]
reported B-LOC [0.42508697509765625, -0.5438876748085022]
aura B-LOC [0.706364631652832, -1.0620990991592407]
symptoms. B-LOC [0.6765997409820557, -0.69353848695755]
An B-LOC [1.3803415298461914, -1.7065720558166504]
association B-LOC [1.4877949953079224, -1.6956496238708496]
was B-LOC [1.5029211044311523, -1.7040339708328247]
found B-LOC [1.5051385164260864, -1.620576024055481]
between B-LOC [1.5546038150787354, -1.9717085361480713]
any B-LOC [1.511474370956421, -1.6746058464050293]
history B-LOC [1.3931852579116821, -1.6744370460510254]
of B-LOC [1.2730786800384521, -1.6620101928710938]
severe B-LOC [1.3072255849838257, -1.5212057828903198]
headache B-LOC [1.2891435623168945, -1.2158210277557373]
and B-LOC [1.643479585647583, -1.7205324172973633]
increasing B-LOC [1.277580738067627, -1.5912774801254272]
volume B-LOC [1.3214046955108643, -1.7412712574005127]
of B-LOC [1.3773033618927002, -1.6861366033554077]
white B-LOC [1.5479848384857178, -1.5256041288375854]
matter B-LOC [1.1218754053115845, -1.4826877117156982]
hyperintensities. B-LOC [1.4508816003799438, -1.5714483261108398]
The B-LOC [0.8951525092124939, -0.790248692035675]
adjusted B-LOC [0.6953123807907104, -0.855941116809845]
odds B-LOC [0.6142016053199768, -0.6576594114303589]
ratio B-LOC [0.6802629828453064, -0.8078591823577881]
of B-LOC [0.598427951335907, -0.49818313121795654]
being B-LOC [0.739959180355072, -0.6944472193717957]
in B-LOC [0.6936271786689758, -0.5599209666252136]
the B-LOC [0.8720926642417908, -0.6446555852890015]
highest B-LOC [0.7029746174812317, -0.8210330605506897]
third B-LOC [0.7550594210624695, -0.6610541343688965]
for B-LOC [0.7334254384040833, -0.5780110955238342]
total B-LOC [0.8631868958473206, -0.6787026524543762]
volume B-LOC [0.8482828736305237, -0.9276340007781982]
of B-LOC [0.6272304058074951, -0.8471760153770447]
white B-LOC [1.0655220746994019, -1.1476504802703857]
matter B-LOC [0.530000627040863, -0.6971270442008972]

hyperintensities O [-0.10770203173160553, -0.06480671465396881]
was B-LOC [-0.002496225293725729, -0.25544339418411255]
2.0 O [-0.003900816198438406, 0.1643456220626831]
(95% B-LOC [-0.16624286770820618, -0.1753595620393753]
confidence O [-0.3368070423603058, 0.11504720151424408]
interval O [-0.3628945052623749, -0.0414787121117115]
1.3 O [-0.16925550997257233, 0.163221538066864]
to O [-0.3096418082714081, -0.1990458220243454]
3.1, O [-0.05602389574050903, 0.2116003781557083]
P O [-0.15984836220741272, -0.024976106360554695]
for B-LOC [-0.03931248560547829, -0.2878885567188263]
trend O [-0.10553104430437088, -0.03231685981154442]
0.002) B-LOC [0.13970836997032166, -0.09886011481285095]
for B-LOC [-0.05700298026204109, -0.12449875473976135]
participants O [-0.09862314164638519, -0.008022220805287361]
with B-LOC [0.10841222107410431, -0.2629057466983795]
any B-LOC [0.1484786868095398, -0.1398906409740448]
history B-LOC [0.010448235087096691, -0.08649320900440216]
of B-LOC [0.14773276448249817, -0.35417208075523376]
severe B-LOC [0.3296172320842743, -0.3973473608493805]
headache B-LOC [0.3025660812854767, -0.13963742554187775]
when B-LOC [0.17054863274097443, -0.11766588687896729]
compared O [0.10177754610776901, 0.19967806339263916]
with B-LOC [0.3749445974826813, -0.13606871664524078]
participants B-LOC [0.054804977029561996, -0.16215835511684418]
without B-LOC [0.25981467962265015, -0.23847420513629913]
severe B-LOC [0.15635773539543152, -0.21737220883369446]
headache B-LOC [0.2508075535297394, -0.12041376531124115]
being B-LOC [0.28945234417915344, -0.3180026710033417]
in B-LOC [0.4568435251712799, -0.5178393721580505]
the B-LOC [0.4671618938446045, -0.3516499102115631]
lowest B-LOC [0.40733128786087036, -0.5522311925888062]
third. B-LOC [0.3731043338775635, -0.3575335741043091]
The B-LOC [2.068434476852417, -2.3487958908081055]
association B-LOC [2.232224941253662, -2.511838674545288]
pattern B-LOC [1.9805197715759277, -2.5261974334716797]
was B-LOC [2.084033727645874, -2.2054407596588135]
similar B-LOC [2.2381865978240967, -2.556994676589966]
for B-LOC [2.1018359661102295, -2.376534938812256]
all B-LOC [2.245997428894043, -2.2552671432495117]
headache B-LOC [2.0862653255462646, -2.3843986988067627]
types. B-LOC [2.0836949348449707, -2.233823537826538]
Migraine O [-0.1738130897283554, 0.04313020035624504]
with O [-0.11426523327827454, -0.0860494077205658]
aura O [0.011409292928874493, 0.019387317821383476]
was O [-0.06405657529830933, -0.017809303477406502]
the B-LOC [0.12164699286222458, 0.06489181518554688]
only B-LOC [0.1354007124900818, -0.01122509129345417]
headache O [0.062172889709472656, 0.0626542717218399]
type O [-0.07959739118814468, 0.04330719634890556]
strongly B-LOC [-0.04598179832100868, -0.054672855883836746]
associated O [-0.04619999974966049, 0.041956912726163864]
with O [-0.048018623143434525, -0.012896480038762093]
volume B-LOC [0.022986503317952156, -0.007744448725134134]
of B-LOC [-0.05722067877650261, -0.07395404577255249]
deep B-LOC [-0.007235353346914053, -0.17099174857139587]
white B-LOC [0.09695947170257568, -0.2197025567293167]
matter B-LOC [-0.05867723748087883, -0.21985943615436554]
hyperintensities O [-0.040663983672857285, 0.040940891951322556]
(highest O [-0.015652379021048546, 0.005216462071985006]
third B-LOC [0.23871532082557678, -0.25430533289909363]
odds B-LOC [0.18630367517471313, -0.16087651252746582]
ratio B-LOC [0.10584595799446106, -0.39719903469085693]
12.4, B-LOC [0.23037225008010864, -0.0025289678014814854]
1.6 B-LOC [0.27755722403526306, -0.00538210803642869]
to B-LOC [-0.018034255132079124, -0.4389096200466156]
99.4, B-LOC [0.30091845989227295, -0.2965424358844757]
P B-LOC [0.14236010611057281, -0.2543441653251648]
for B-LOC [0.18393224477767944, -0.3350884020328522]
trend B-LOC [0.15102991461753845, -0.21459394693374634]
0.005) B-LOC [0.4027159512042999, -0.33798640966415405]
and O [-0.08646944910287857, 0.07361201196908951]
with O [-0.04788314178586006, 0.02429020218551159]
brain O [-0.21690210700035095, 0.10707935690879822]
infarcts O [-0.10198789834976196, 0.020079566165804863]
(3.4, B-LOC [0.05308960750699043, 0.015915585681796074]
1.2 B-LOC [0.11031840741634369, -0.08082036674022675]

to B-LOC [0.27768516540527344, -0.9027110934257507]
9.3). B-LOC [0.8041395545005798, -1.1732441186904907]
The B-LOC [1.1487360000610352, -1.5675355195999146]
location B-LOC [1.1527621746063232, -1.664583683013916]
of B-LOC [1.3432509899139404, -1.7558221817016602]
infarcts B-LOC [1.3725321292877197, -1.6404507160186768]
was B-LOC [1.1923985481262207, -1.4682307243347168]
predominantly B-LOC [1.4603463411331177, -1.472700595855713]
outside B-LOC [1.3169820308685303, -1.370573878288269]
the B-LOC [1.2495049238204956, -1.3657629489898682]
cerebellum B-LOC [1.256663203239441, -1.5472779273986816]
and B-LOC [1.132381796836853, -1.4444036483764648]
brain B-LOC [1.1571223735809326, -1.6161301136016846]
stem. B-LOC [1.1163073778152466, -1.6523312330245972]
Evidence B-LOC [0.7509711384773254, -1.027180552482605]
was B-LOC [1.004154920578003, -1.2940278053283691]
lacking B-LOC [1.439789891242981, -1.3781177997589111]
for B-LOC [0.8954299092292786, -1.2904890775680542]
cognitive B-LOC [0.8859588503837585, -1.365774393081665]
impairment B-LOC [1.037858486175537, -1.4530868530273438]
for B-LOC [0.9595310091972351, -1.3266527652740479]
any B-LOC [0.9387394785881042, -1.2371770143508911]
headache B-LOC [0.8604061007499695, -1.185234546661377]
type B-LOC [0.7856125235557556, -1.000622272491455]
with B-LOC [0.5192969441413879, -0.7256031632423401]
or B-LOC [1.1491914987564087, -1.3965394496917725]
without B-LOC [0.8991557955741882, -0.8079091906547546]
brain B-LOC [0.9517517685890198, -1.3799055814743042]
lesions. B-LOC [0.9206840395927429, -1.2045607566833496]
CONCLUSIONS B-LOC [0.03652651235461235, -0.42388755083084106]
In B-LOC [1.2359020709991455, -1.0843453407287598]
this B-LOC [1.365965723991394, -1.2318923473358154]
population B-LOC [1.6043782234191895, -1.5393685102462769]
based B-LOC [1.3794753551483154, -1.6093913316726685]
study, B-LOC [1.2702915668487549, -1.3744173049926758]
any B-LOC [1.1610523462295532, -1.3242589235305786]
history B-LOC [1.250119924545288, -1.3758946657180786]
of B-LOC [1.275567889213562, -1.523010492324829]
severe B-LOC [1.2348854541778564, -1.4740676879882812]
headache B-LOC [1.282963752746582, -1.4590489864349365]
was B-LOC [1.1396764516830444, -1.3373587131500244]
associated B-LOC [1.0437865257263184, -1.1480529308319092]
with B-LOC [1.1115494966506958, -1.3296895027160645]
an B-LOC [1.1616703271865845, -1.3496696949005127]
increased B-LOC [1.0818902254104614, -1.4017541408538818]
volume B-LOC [1.1544781923294067, -1.411267638206482]
of B-LOC [1.2111681699752808, -1.5050742626190186]
white B-LOC [1.8646388053894043, -2.012568473815918]
matter B-LOC [1.1814316511154175, -1.7705459594726562]
hyperintensities. B-LOC [1.2730858325958252, -1.5696120262145996]
Migraine B-LOC [0.7555654644966125, -0.8431194424629211]
with B-LOC [0.6330925822257996, -0.8879155516624451]
aura B-LOC [0.7878709435462952, -0.9183441996574402]
was B-LOC [1.000461220741272, -1.2389386892318726]
the B-LOC [1.3066667318344116, -1.2282999753952026]
only B-LOC [1.3191025257110596, -1.2673333883285522]
headache B-LOC [1.0629310607910156, -1.098995566368103]
type B-LOC [0.9392613768577576, -1.0721452236175537]
associated B-LOC [1.1882498264312744, -1.27858567237854]
with B-LOC [1.140140175819397, -1.3470754623413086]
brain B-LOC [1.1732192039489746, -1.6698317527770996]
infarcts. B-LOC [1.267700433731079, -1.3845983743667603]
Evidence B-LOC [0.7529324889183044, -1.0805585384368896]
that B-LOC [0.6165298819541931, -1.0879629850387573]
headache B-LOC [0.49323153495788574, -0.46809491515159607]
of B-LOC [0.39790502190589905, -0.8176027536392212]
any B-LOC [0.6250672936439514, -0.9578165411949158]
type B-LOC [0.6105757355690002, -0.7986541390419006]
by B-LOC [0.23611263930797577, -0.6453422904014587]
itself B-LOC [0.3919408321380615, -0.762356162071228]
or B-LOC [0.6391233801841736, -0.831466794013977]
in B-LOC [0.397650808095932, -0.6377120018005371]
combination B-LOC [0.39001521468162537, -0.4286210834980011]
with B-LOC [0.2543317675590515, -0.5546340942382812]
brain B-LOC [0.5968096852302551, -0.933763325214386]
lesions B-LOC [0.5212920308113098, -0.6900365948677063]
was B-LOC [0.9327453970909119, -1.2211973667144775]
associated B-LOC [0.7040827870368958, -0.7547551989555359]
with B-LOC [0.5652664303779602, -0.9643267393112183]
cognitive B-LOC [0.6951274275779724, -1.1905877590179443]
impairment B-LOC [0.8254006505012512, -1.3327326774597168]
was B-LOC [1.095846176147461, -1.3352657556533813]
lacking. B-LOC [1.5261478424072266, -1.381232738494873]

Regulatory B-LOC [1.4604356288909912, -2.138507604598999]
T B-LOC [1.3791381120681763, -1.982809066772461]
(Treg) B-LOC [1.6406148672103882, -2.045706033706665]
cells B-LOC [1.5327681303024292, -1.942761778831482]
play B-LOC [1.671381950378418, -1.8311222791671753]
a B-LOC [1.6506917476654053, -1.7220168113708496]
pivotal B-LOC [1.6175153255462646, -1.6531201601028442]
role B-LOC [1.4316226243972778, -1.7503297328948975]
in B-LOC [1.2935686111450195, -1.4991576671600342]
suppressing B-LOC [1.6507573127746582, -1.6878142356872559]
self-harmful B-LOC [1.3640446662902832, -1.9097678661346436]
T B-LOC [1.6699085235595703, -2.124596118927002]
cell B-LOC [1.5332192182540894, -2.430781602859497]
responses, B-LOC [1.382580041885376, -1.6929633617401123]
but B-LOC [2.3438055515289307, -2.5568456649780273]
how B-LOC [2.5292749404907227, -3.1290063858032227]
Treg B-LOC [2.1573355197906494, -2.3602559566497803]
cells B-LOC [2.175536870956421, -2.545212984085083]
mediate B-LOC [2.2690205574035645, -2.61486554145813]
suppression B-LOC [2.270875930786133, -2.754196882247925]
to B-LOC [2.5805752277374268, -2.6643736362457275]
maintain B-LOC [2.1761608123779297, -2.5474767684936523]
immune B-LOC [2.132603406906128, -2.57702374458313]
homeostasis B-LOC [2.2060492038726807, -2.807006597518921]
and B-LOC [2.3689229488372803, -2.4637956619262695]
limit B-LOC [2.576122760772705, -3.0519797801971436]
responses B-LOC [2.3792831897735596, -2.9416046142578125]
during B-LOC [2.0629310607910156, -2.5260097980499268]
inflammation B-LOC [2.338050127029419, -2.6046907901763916]
is B-LOC [3.2977676391601562, -2.985940933227539]
unclear. B-LOC [3.139432430267334, -2.9725773334503174]
Here O [-0.6589843034744263, 0.421261727809906]
we O [-0.7541185021400452, 0.37052029371261597]
show O [-0.7063083052635193, 0.5341266989707947]
that O [-1.0330967903137207, 0.5161445140838623]
effector O [-0.5987562537193298, 0.8036121726036072]
Treg O [-0.35650894045829773, 0.2139008492231369]
cells O [-0.6659315228462219, 0.5554230809211731]
express O [-0.45314714312553406, 0.7054349780082703]
high O [-0.5036243200302124, 0.586567759513855]
amounts O [-0.4266497790813446, 0.7064192891120911]
of O [-0.5037041306495667, 0.7564013004302979]
the O [-0.5423789024353027, 0.7319302558898926]
integrin O [-0.6909046769142151, 0.6373734474182129]
αvβ8, O [-0.4072250425815582, 0.4778859317302704]
which O [-0.5903022885322571, 0.3522147834300995]
enables O [-0.5212206244468689, 0.6538711190223694]
them O [-0.5325876474380493, 0.5167173743247986]
to O [-0.551068902015686, 0.6005691289901733]
activate O [-0.4817919433116913, 0.6502464413642883]
latent O [-0.4572708308696747, 0.601010799407959]
transforming O [-0.2977156937122345, 0.26675477623939514]
growth O [-0.46478331089019775, 0.34502625465393066]
factor-β O [-0.5402029156684875, 0.3897499144077301]
(TGF-β). O [-0.4186127483844757, 0.3913262188434601]
Treg-cell-specific O [-0.34431323409080505, 0.33027884364128113]
deletion O [-0.09825146943330765, 0.21151399612426758]
of O [-0.41388005018234253, 0.29622337222099304]
integrin O [-0.4497065544128418, 0.11996528506278992]
αvβ8 O [-0.24459977447986603, 0.07980667799711227]
did O [-0.4423746168613434, 0.15907499194145203]
not O [-0.2264091819524765, 0.31987449526786804]
result O [-0.3886401355266571, 0.20203633606433868]
in O [-0.42653337121009827, 0.1971040517091751]
a O [-0.2466941624879837, 0.16444335877895355]
spontaneous O [-0.4053352177143097, 0.0687045305967331]

inflammatory B-LOC [0.49579015374183655, -1.0863375663757324]
phenotype, B-LOC [0.5731492042541504, -1.084437608718872]
suggesting B-LOC [0.7164323925971985, -0.6534748673439026]
that B-LOC [0.6329144239425659, -0.9992029666900635]
this B-LOC [0.6307750344276428, -1.102156639099121]
pathway B-LOC [0.2972703278064728, -1.006716251373291]
is B-LOC [0.967326283454895, -1.0961647033691406]
not B-LOC [0.9901363849639893, -0.9952359795570374]
important B-LOC [0.8436132073402405, -1.358473777770996]
in B-LOC [0.753724992275238, -1.3391330242156982]
Treg-cell-mediated B-LOC [0.4810549318790436, -0.8488317728042603]
maintenance B-LOC [0.8785414099693298, -1.1565816402435303]
of B-LOC [0.7599819302558899, -1.3944340944290161]
immune B-LOC [0.6696273684501648, -1.089286208152771]
homeostasis. B-LOC [0.5720993280410767, -0.9554567933082581]
However, B-LOC [-0.06188690662384033, -0.12099707126617432]
Treg O [-0.24656635522842407, 0.2087538242340088]
cells O [-0.4592355489730835, 0.45237815380096436]
lacking O [-0.2807992696762085, 0.42409056425094604]
expression O [-0.3310565948486328, 0.6132161617279053]
of O [-0.5448905825614929, 0.47109100222587585]
integrin O [-0.4878377914428711, 0.3930372893810272]
αvβ8 O [-0.33052995800971985, 0.3386598229408264]
were O [-0.4418533742427826, 0.38585755228996277]
unable O [-0.2707440257072449, 0.36219656467437744]
to O [-0.3257819712162018, 0.31943657994270325]
suppress O [-0.2764361798763275, 0.27340570092201233]
pathogenic O [-0.5546228885650635, 0.44602105021476746]
T O [-0.29795873165130615, 0.2186792492866516]
cell O [-0.5596267580986023, 0.39550599455833435]
responses O [-0.39999526739120483, 0.33140143752098083]
during O [-0.3616614043712616, 0.21651089191436768]
active O [-0.4431847035884857, 0.2984025776386261]
inflammation. O [-0.14363503456115723, 0.2381201535463333]
Thus, O [0.11068302392959595, 0.19911745190620422]
our B-LOC [0.12895441055297852, -0.19059613347053528]
results B-LOC [0.3928532600402832, -0.3242446780204773]
identify B-LOC [0.38195380568504333, -0.2504485249519348]
a B-LOC [0.2789404094219208, -0.4834202229976654]
mechanism B-LOC [0.07053004205226898, -0.3698999285697937]
by O [-0.049214135855436325, -0.031468216329813004]
which B-LOC [-0.013700460083782673, -0.5724280476570129]
Treg B-LOC [0.04483318328857422, -0.22624967992305756]
cells B-LOC [-0.038161057978868484, -0.09215317666530609]
suppress B-LOC [0.08444609493017197, -0.21152862906455994]
exuberant O [-0.13025590777397156, -0.09538695216178894]
immune B-LOC [-0.10099399834871292, -0.22368332743644714]
responses, O [-0.11005957424640656, -0.014030160382390022]
highlighting B-LOC [0.19562605023384094, -0.3048620820045471]
a B-LOC [0.00751506770029664, -0.2770914137363434]
key B-LOC [-0.08057084679603577, -0.2109513133764267]
role B-LOC [-0.09113743156194687, -0.23643790185451508]
for B-LOC [0.012952405028045177, -0.3778383433818817]
effector O [-0.25881531834602356, 0.08416397869586945]
Treg-cell-mediated O [-0.21560171246528625, -0.05210370197892189]
activation O [-0.4091446101665497, 0.3564549386501312]
of O [-0.487953782081604, 0.22053733468055725]
latent O [-0.36960336565971375, 0.4778028428554535]
TGF-β O [-0.4442945122718811, 0.2535945773124695]
in O [-0.5840649604797363, 0.22778235375881195]
suppression O [-0.3201872408390045, 0.3308086693286896]
of O [-0.3964708149433136, 0.3064287602901459]
self-harmful O [-0.3661137521266937, 0.06434939056634903]
T O [-0.25286054611206055, -0.03005283512175083]
cell O [-0.5511048436164856, 0.2075960785150528]
responses O [-0.42284226417541504, 0.3190740942955017]
during O [-0.3728119730949402, 0.16353029012680054]
active O [-0.3403356373310089, -0.05912064388394356]

inflammation. O [-0.4718115031719208, -0.02120061405003071]

BACKGROUND B-LOC [0.48861008882522583, -1.0030841827392578]
The B-LOC [0.771952211856842, -1.0809674263000488]
heritable B-LOC [1.118249535560608, -1.259246587753296]
haemoglobinopathy B-LOC [0.8895057439804077, -1.379156231880188]
alpha(+)-thalassaemia B-LOC [0.6730617880821228, -1.0918450355529785]
is B-LOC [0.7356899380683899, -1.089510440826416]
caused B-LOC [0.7626593708992004, -0.909682035446167]
by B-LOC [0.4583432972431183, -0.7063288688659668]
the B-LOC [0.5879920125007629, -0.5884140729904175]
reduced B-LOC [0.5265643000602722, -0.663773238658905]
synthesis B-LOC [0.5508965849876404, -0.5607229471206665]
of B-LOC [0.47369199991226196, -0.6098099946975708]
alpha-globin B-LOC [0.5330020189285278, -0.9929220080375671]
chains B-LOC [0.49376025795936584, -0.581171989440918]
that B-LOC [0.46448013186454773, -0.9091185331344604]
form B-LOC [0.6908555030822754, -0.8725610375404358]
part B-LOC [0.6214029788970947, -0.6996047496795654]
of B-LOC [0.5552905797958374, -0.8396257162094116]
normal B-LOC [0.5300375819206238, -0.9430177211761475]
adult B-LOC [0.5511308908462524, -1.0192360877990723]
haemoglobin B-LOC [0.6242665648460388, -1.0018665790557861]
(Hb). B-LOC [0.6906946897506714, -1.1259757280349731]
Individuals B-LOC [0.8306074142456055, -0.8520352244377136]
homozygous B-LOC [0.8112699389457703, -1.0143760442733765]
for B-LOC [0.7008767127990723, -0.8546560406684875]
alpha(+)-thalassaemia B-LOC [0.8652552962303162, -1.3068207502365112]
have B-LOC [0.7363545298576355, -0.8772467374801636]
microcytosis B-LOC [0.5939422249794006, -0.8467891216278076]
and B-LOC [0.5050633549690247, -0.6048271059989929]
an B-LOC [0.7048446536064148, -0.8779050707817078]
increased B-LOC [0.7372111678123474, -1.1191426515579224]
erythrocyte B-LOC [0.8116946816444397, -1.1904313564300537]
count. B-LOC [0.6155734062194824, -0.8521592617034912]
Alpha(+)-thalassaemia B-LOC [0.010425704531371593, -0.21139907836914062]
homozygosity O [-0.1304180920124054, -0.021426038816571236]
confers O [-0.09709537029266357, 0.13148942589759827]
considerable O [-0.1329997330904007, -0.037008244544267654]
protection O [-0.053249191492795944, 0.02290085144340992]
against B-LOC [0.0605926476418972, 0.01084713451564312]
severe B-LOC [-0.03890850022435188, -0.10007041692733765]
malaria, B-LOC [0.19203919172286987, -0.22327005863189697]
including O [-0.10768666863441467, 0.22390447556972504]
severe O [-0.12423089891672134, -0.07083471119403839]
malarial B-LOC [0.1191064715385437, -0.2057347595691681]
anaemia B-LOC [-0.07986216992139816, -0.22172869741916656]
(SMA) B-LOC [0.024213092401623726, -0.1757756620645523]
(Hb O [-0.24760696291923523, -0.08534471690654755]
concentration B-LOC [-0.016161983832716942, -0.20819945633411407]
< B-LOC [-0.02281990461051464, -0.24237017333507538]
50 B-LOC [0.09518860280513763, -0.042749639600515366]
g/l), B-LOC [-0.13158708810806274, -0.15387317538261414]
but O [-0.25907638669013977, -0.06114887818694115]
does O [-0.15115267038345337, 0.11507649719715118]

not B-LOC [1.0178444385528564, -1.3156776428222656]
influence B-LOC [1.5853303670883179, -2.2621004581451416]
parasite B-LOC [2.0030689239501953, -2.4398369789123535]
count. B-LOC [2.039264440536499, -2.30092191696167]
We B-LOC [2.3152246475219727, -2.7887890338897705]
tested B-LOC [2.732800245285034, -2.861738920211792]
the B-LOC [3.014894723892212, -2.8976004123687744]
hypothesis B-LOC [2.8802552223205566, -2.9538357257843018]
that B-LOC [2.4015727043151855, -2.6460113525390625]
the B-LOC [2.3466603755950928, -2.5872483253479004]
erythrocyte B-LOC [2.1517186164855957, -2.6389410495758057]
indices B-LOC [2.6738131046295166, -2.7933847904205322]
associated B-LOC [2.506746768951416, -2.5584769248962402]
with B-LOC [2.291760206222534, -2.4620800018310547]
alpha(+)-thalassaemia B-LOC [2.1456456184387207, -2.4074935913085938]
homozygosity B-LOC [2.3340675830841064, -2.6739728450775146]
provide B-LOC [2.3850977420806885, -2.757892370223999]
a B-LOC [2.540694236755371, -2.8517255783081055]
haematological B-LOC [2.5249722003936768, -2.7747421264648438]
benefit B-LOC [2.257826089859009, -2.911057710647583]
during B-LOC [2.4165194034576416, -2.7688188552856445]
acute B-LOC [2.9140512943267822, -3.2395811080932617]
malaria. B-LOC [2.616792917251587, -2.9579057693481445]
METHODS B-LOC [2.04632830619812, -2.916388750076294]
AND B-LOC [2.841548204421997, -3.246225595474243]
FINDINGS B-LOC [2.2441611289978027, -2.5262582302093506]
Data B-LOC [3.09723162651062, -3.3132312297821045]
from B-LOC [3.020458936691284, -3.2667179107666016]
children B-LOC [3.401944637298584, -3.376689910888672]
living B-LOC [3.3939425945281982, -3.2338755130767822]
on B-LOC [3.368633985519409, -3.2333872318267822]
the B-LOC [3.3099617958068848, -3.1048476696014404]
north B-LOC [3.057722806930542, -3.077324151992798]
coast B-LOC [3.261521577835083, -3.150733232498169]
of B-LOC [3.1701204776763916, -2.974938154220581]
Papua B-LOC [2.969083786010742, -3.216377019882202]
New B-LOC [2.9636762142181396, -2.85311222076416]
Guinea B-LOC [3.0270931720733643, -3.225576162338257]
who B-LOC [3.042703628540039, -3.4521484375]
had B-LOC [3.0768206119537354, -3.179685592651367]
participated B-LOC [3.064828872680664, -3.4740383625030518]
in B-LOC [3.02864933013916, -3.090350866317749]
a B-LOC [3.035797357559204, -3.3409016132354736]
case-control B-LOC [3.4738333225250244, -3.58132266998291]
study B-LOC [3.2733476161956787, -3.4422447681427]
of B-LOC [3.1963675022125244, -3.412550210952759]
the B-LOC [3.287987470626831, -3.223836660385132]
protection B-LOC [3.1567842960357666, -3.256380796432495]
afforded B-LOC [3.2045507431030273, -3.083423137664795]
by B-LOC [2.9726972579956055, -2.8042333126068115]
alpha(+)-thalassaemia B-LOC [2.8336341381073, -3.0397331714630127]
against B-LOC [3.1702072620391846, -3.120496988296509]
severe B-LOC [3.307512044906616, -3.4003169536590576]
malaria B-LOC [3.145634412765503, -3.1456291675567627]
were B-LOC [2.961909770965576, -3.1353583335876465]
reanalysed B-LOC [3.2187201976776123, -3.446645975112915]
to B-LOC [3.257690668106079, -3.3292455673217773]
assess B-LOC [3.2956013679504395, -3.590456008911133]
the B-LOC [3.2099673748016357, -3.313244104385376]
genotype-specific B-LOC [3.16447114944458, -3.205199956893921]
reduction B-LOC [2.8620095252990723, -3.4917750358581543]
in B-LOC [2.6263537406921387, -3.124425172805786]
erythrocyte B-LOC [2.7335364818573, -3.0770037174224854]
count B-LOC [2.941371202468872, -3.1746623516082764]
and B-LOC [2.9012868404388428, -3.107701539993286]
Hb B-LOC [2.7487242221832275, -3.3316776752471924]
levels B-LOC [2.933706521987915, -3.1336822509765625]
associated B-LOC [2.9524683952331543, -3.0976853370666504]
with B-LOC [2.837388753890991, -2.8983004093170166]
acute B-LOC [3.1386752128601074, -3.5113096237182617]
malarial B-LOC [3.0423316955566406, -3.1588947772979736]
disease. B-LOC [3.0540478229522705, -3.219716787338257]
We B-LOC [2.4883127212524414, -2.717681884765625]

observed O [-0.24018403887748718, 0.018700314685702324]
a O [-0.21880590915679932, 0.0880572572350502]
reduction B-LOC [-0.1253705620765686, -0.13126350939273834]
in O [-0.24366579949855804, -0.12190838158130646]
median O [-0.1947612762451172, 0.06712426990270615]
erythrocyte O [-0.30709508061408997, -0.018204810097813606]
count O [-0.2105312943458557, 0.11564049124717712]
of O [-0.38787227869033813, 0.03697645291686058]
approximately O [-0.12209576368331909, 0.062140900641679764]
1.5 O [-0.010665585286915302, 0.07047184556722641]
x O [-0.38245758414268494, -0.053430426865816116]
10(12)/l B-LOC [0.19326874613761902, -0.10054446011781693]
in O [-0.2029106318950653, -0.005537225399166346]
all O [0.048020537942647934, 0.061118677258491516]
children B-LOC [0.0708644837141037, -0.007921384647488594]
with B-LOC [0.04906101152300835, -0.12214946746826172]
acute B-LOC [-0.014144551940262318, -0.11799789220094681]
falciparum O [-0.056121546775102615, -0.008995840325951576]
malaria B-LOC [0.07608769088983536, -0.015297086909413338]
relative B-LOC [0.24133655428886414, -0.15737387537956238]
to B-LOC [0.35852596163749695, -0.09135556221008301]
values B-LOC [0.1590830683708191, -0.3430028259754181]
in B-LOC [0.14158977568149567, -0.2976258099079132]
community B-LOC [0.14133572578430176, -0.18719707429409027]
children B-LOC [0.10532574355602264, -0.14365938305854797]
(p B-LOC [0.3578609526157379, -0.20374135673046112]
< B-LOC [0.27852120995521545, -0.31330186128616333]
0.001). B-LOC [0.3615338206291199, -0.4809646010398865]
We B-LOC [0.7350283861160278, -0.869027853012085]
developed B-LOC [1.575646162033081, -1.4064602851867676]
a B-LOC [1.6790921688079834, -1.5278239250183105]
simple B-LOC [1.7450196743011475, -1.6497427225112915]
mathematical B-LOC [1.8184806108474731, -1.8367512226104736]
model B-LOC [1.6459542512893677, -1.8374335765838623]
of B-LOC [1.6882636547088623, -1.8711910247802734]
the B-LOC [1.8733322620391846, -1.9283645153045654]
linear B-LOC [1.7853953838348389, -1.9328351020812988]
relationship B-LOC [1.6617356538772583, -2.041581630706787]
between B-LOC [1.856124997138977, -2.051793336868286]
Hb B-LOC [1.070239782333374, -1.6867098808288574]
concentration B-LOC [1.210163950920105, -1.4844001531600952]
and B-LOC [1.7534255981445312, -1.8943872451782227]
erythrocyte B-LOC [1.3606057167053223, -1.918878436088562]
count. B-LOC [1.3506443500518799, -1.6406874656677246]
This B-LOC [0.024601908400654793, -0.25105658173561096]
model O [-0.23545733094215393, -0.026751257479190826]
predicted O [-0.4204033315181732, 0.3306170105934143]
that O [-0.7335357069969177, 0.5431851744651794]
children O [-0.6356952786445618, 0.6824969053268433]
homozygous O [-0.7078405022621155, 0.8739511966705322]
for O [-0.8810189366340637, 0.6890689730644226]
alpha(+)-thalassaemia O [-0.6461760401725769, 0.5838605165481567]
lose O [-0.8454459309577942, 0.8599222302436829]
less O [-0.7675756216049194, 0.9570091366767883]
Hb O [-0.7270129323005676, 0.4749886691570282]
than O [-0.8646252751350403, 0.8369526267051697]
children O [-0.6652109026908875, 0.7648959755897522]
of O [-0.9079351425170898, 0.7897608876228333]
normal O [-0.9373267889022827, 0.6286906003952026]
genotype O [-0.8356882333755493, 0.7998695969581604]
for O [-1.1077218055725098, 0.8090481162071228]
a O [-0.855580747127533, 0.7587026953697205]
reduction O [-0.9089506268501282, 0.7023492455482483]
in O [-1.0138068199157715, 0.7394770383834839]
erythrocyte O [-1.0998280048370361, 0.846043050289154]
count O [-0.727631151676178, 0.7204864621162415]
of O [-0.9540244340896606, 0.5956874489784241]
>1.1 O [-0.8777300715446472, 0.6159700155258179]
x O [-1.092932939529419, 0.44691506028175354]
10(12)/l O [-0.36760541796684265, 0.36365583539009094]
as O [-0.868365466594696, 0.5108620524406433]
a O [-0.7080373764038086, 0.5145137906074524]
result O [-0.5780858397483826, 0.5528784394264221]
of O [-0.589821994304657, 0.5889459252357483]
the O [-0.8342792391777039, 0.6517645716667175]
reduced O [-0.7339475750923157, 0.5313325524330139]
mean O [-0.85478276014328, 0.6739805936813354]
cell O [-0.9954400658607483, 0.5456597805023193]

Hb B-LOC [0.026071125641465187, -0.5603860020637512]
in B-LOC [0.030044155195355415, -0.191194549202919]
homozygous B-LOC [0.20633289217948914, -0.10285330563783646]
alpha(+)-thalassaemia. B-LOC [0.0932653620839119, -0.2599581778049469]
In O [-0.7029760479927063, 0.54974764585495]
addition, O [-0.8118268847465515, 0.6632630825042725]
children O [-0.542588472366333, 0.6074633002281189]
homozygous O [-0.443217933177948, 0.7788780331611633]
for O [-0.9548289775848389, 0.5644853711128235]
alpha(+)-thalassaemia O [-0.6371465921401978, 0.4739913046360016]
require O [-0.8084370493888855, 0.7836838960647583]
a O [-0.8067811131477356, 0.7511503100395203]
10% O [-0.582927405834198, 0.6209785342216492]
greater O [-0.7926961779594421, 0.9054058194160461]
reduction O [-0.7541367411613464, 0.7273710370063782]
in O [-0.9041685461997986, 0.707029402256012]
erythrocyte O [-1.0341624021530151, 0.7416550517082214]
count O [-0.6995348334312439, 0.8035716414451599]
than O [-0.7884442210197449, 0.9018436074256897]
children O [-0.5604910254478455, 0.5886792540550232]
of O [-0.6820451617240906, 0.5091877579689026]
normal O [-0.8124780058860779, 0.34465357661247253]
genotype O [-0.6398769021034241, 0.5784973502159119]
(p O [-0.7255083918571472, 0.4176640808582306]
= O [-0.5528629422187805, 0.11675596237182617]
0.02) O [-0.467463880777359, 0.27419358491897583]
for O [-0.8340914845466614, 0.43992140889167786]
Hb O [-0.5436270236968994, 0.2621205151081085]
concentration O [-0.5036406517028809, 0.4282413423061371]
to O [-0.45650914311408997, 0.5368388891220093]
fall O [-0.48213887214660645, 0.4904846251010895]
to O [-0.5210838317871094, 0.3015711009502411]
50 O [-0.3351013958454132, 0.36061394214630127]
g/l, O [-0.5564669370651245, 0.2412133663892746]
the O [-0.47952935099601746, 0.3536672592163086]
cutoff O [-0.597025454044342, 0.2646828591823578]
for O [-0.4865642786026001, 0.0844411700963974]
SMA. O [-0.3119548559188843, 0.27195584774017334]
We O [-0.6554170250892639, 0.27490633726119995]
estimated O [-0.6951882243156433, 0.38077816367149353]
that O [-0.8189873695373535, 0.35859787464141846]
the O [-0.5059716105461121, 0.5431852340698242]
haematological O [-0.37264350056648254, 0.3613804280757904]
profile O [-0.5166056752204895, 0.31610986590385437]
in O [-0.5953765511512756, 0.5133752822875977]
children O [-0.4410680830478668, 0.44200482964515686]
homozygous O [-0.3421485722064972, 0.6027891039848328]
for O [-0.5749520659446716, 0.40417301654815674]
alpha(+)-thalassaemia O [-0.3346445858478546, 0.26653721928596497]
reduces O [-0.5537567734718323, 0.5704140663146973]
the O [-0.5565606951713562, 0.47692668437957764]
risk O [-0.6571770906448364, 0.5500414967536926]
of O [-0.8252066969871521, 0.6174440383911133]
SMA O [-0.40492239594459534, 0.5757485032081604]
during O [-0.7573657631874084, 0.5207991003990173]
acute O [-0.7191031575202942, 0.513185441493988]
malaria O [-0.4368620216846466, 0.41413235664367676]
compared O [-0.6799806356430054, 0.6308384537696838]
to O [-0.5117450952529907, 0.5711240768432617]
children O [-0.549172043800354, 0.4955950081348419]
of O [-0.69100421667099, 0.3977178633213043]
normal O [-0.7147875428199768, 0.34755951166152954]
genotype O [-0.5118947625160217, 0.41296306252479553]
(relative O [-0.6254071593284607, 0.34078699350357056]
risk O [-0.508934736251831, 0.4386739730834961]

0.52; B-LOC [-0.13605131208896637, -0.23592594265937805]
95% O [-0.34221991896629333, 0.18040230870246887]
confidence O [-0.29061898589134216, -0.011161824688315392]
interval O [-0.33470824360847473, -0.05973280966281891]
[CI] O [-0.2642265856266022, -0.08291143923997879]
0.24-1.12, O [-0.16685035824775696, -0.12263954430818558]
p O [-0.28978395462036133, -0.21001529693603516]
= O [-0.26661232113838196, -0.1418135166168213]
0.09). B-LOC [-0.1413441002368927, -0.14719995856285095]
CONCLUSIONS O [-0.7654445171356201, 0.37221667170524597]
The O [-0.864132285118103, 0.6924326419830322]
increased O [-0.8055548071861267, 0.625568687915802]
erythrocyte O [-0.9763830304145813, 0.7166160941123962]
count O [-0.6028823256492615, 0.7698106169700623]
and O [-1.1001217365264893, 0.7557308673858643]
microcytosis O [-0.9848392605781555, 0.9431948661804199]
in O [-0.7871719002723694, 0.7802281975746155]
children O [-0.5497017502784729, 0.7723327875137329]
homozygous O [-0.6851574778556824, 0.8411585688591003]
for O [-0.9198992848396301, 0.5858452916145325]
alpha(+)-thalassaemia O [-0.5503566861152649, 0.449391633272171]
may O [-0.5586646199226379, 0.3190484046936035]
contribute O [-0.5273858904838562, 0.4299510419368744]
substantially O [-0.6010801792144775, 0.5271559357643127]
to O [-0.602443516254425, 0.4898000657558441]
their O [-0.5252025127410889, 0.5200029015541077]
protection O [-0.41436654329299927, 0.46346315741539]
against O [-0.5224312543869019, 0.42011338472366333]
SMA. O [-0.44350430369377136, 0.40346023440361023]
A B-LOC [0.048455264419317245, -0.16586759686470032]
lower B-LOC [0.06615351140499115, 0.02376306615769863]
concentration B-LOC [0.08471867442131042, -0.024348998442292213]
of B-LOC [-0.021844027563929558, -0.10556186735630035]
Hb B-LOC [-0.11507122218608856, -0.1353451907634735]
per O [-0.04965786635875702, 0.04832504317164421]
erythrocyte O [-0.4215528666973114, -0.024399394169449806]
and O [0.1004517674446106, 0.14964821934700012]
a B-LOC [0.13868343830108643, -0.10693022608757019]
larger B-LOC [0.25103870034217834, 0.13254766166210175]
population B-LOC [0.21045100688934326, -0.14021822810173035]
of B-LOC [0.05050571635365486, -0.0493943877518177]
erythrocytes O [-0.30764463543891907, -0.00694884592667222]
may B-LOC [0.4810478091239929, -0.4923939108848572]
be B-LOC [0.17171305418014526, -0.521786093711853]
a B-LOC [0.17484772205352783, -0.4305803179740906]
biologically B-LOC [0.3309873044490814, -0.4259544909000397]
advantageous B-LOC [0.19839778542518616, -0.3707403242588043]
strategy B-LOC [0.14130505919456482, -0.37486550211906433]
against B-LOC [0.11113327741622925, -0.22751787304878235]
the B-LOC [0.08521442115306854, -0.14066287875175476]
significant B-LOC [-0.010139442048966885, -0.29813700914382935]
reduction B-LOC [-0.0911802276968956, -0.3760090470314026]
in B-LOC [-0.07171561568975449, -0.40460801124572754]
erythrocyte O [-0.269697904586792, -0.22537575662136078]
count O [-0.07138136774301529, 0.022394945845007896]
that B-LOC [-0.054077379405498505, -0.37100061774253845]
occurs B-LOC [-0.0416928268969059, -0.3760817050933838]
during B-LOC [-0.08308592438697815, -0.1737527698278427]
acute B-LOC [0.11979328095912933, -0.3669823706150055]
infection B-LOC [0.21831142902374268, -0.3067757189273834]
with B-LOC [0.09760475158691406, -0.47243547439575195]
the B-LOC [0.22617533802986145, -0.40093597769737244]
malaria B-LOC [0.20778757333755493, -0.48218291997909546]
parasite B-LOC [0.16351580619812012, -0.533737063407898]
Plasmodium B-LOC [0.12348546087741852, -0.3799952566623688]

falciparum. B-LOC [0.024136560037732124, -0.3771636486053467]
This O [-0.1673591434955597, 0.12667158246040344]
haematological O [-0.11036908626556396, -0.06643958389759064]
profile O [-0.13272562623023987, 0.01265706680715084]
may B-LOC [0.025084363296628, -0.254028856754303]
reduce O [-0.08011510968208313, -0.010739507153630257]
the B-LOC [-0.06940293312072754, -0.20239341259002686]
risk O [-0.07675565034151077, -0.07584910094738007]
of O [-0.30096617341041565, -0.12304171919822693]
anaemia B-LOC [-0.14484956860542297, -0.20694583654403687]
by O [-0.27250751852989197, -0.08923491835594177]
other B-LOC [-0.06292982399463654, -0.1694597601890564]
Plasmodium B-LOC [-0.05454963073134422, -0.3406502604484558]
species, B-LOC [0.13833144307136536, -0.14524860680103302]
as B-LOC [0.12430603802204132, -0.14673419296741486]
well B-LOC [-0.037826742976903915, -0.06915833801031113]
as B-LOC [0.04973146691918373, -0.24808168411254883]
other B-LOC [-0.038998913019895554, -0.38721513748168945]
causes B-LOC [-0.03605266287922859, -0.2628463804721832]
of B-LOC [-0.10583095252513885, -0.32871535420417786]
anaemia. B-LOC [-0.06013688072562218, -0.2521355450153351]
Other B-LOC [0.8319355845451355, -0.9953039288520813]
host B-LOC [0.66987144947052, -1.1315802335739136]
polymorphisms B-LOC [0.9158454537391663, -0.9914918541908264]
that B-LOC [0.6505352258682251, -0.9974283576011658]
induce B-LOC [0.5183834433555603, -0.7691795825958252]
an B-LOC [0.4410341680049896, -0.7824505567550659]
increased B-LOC [0.34750527143478394, -0.9603569507598877]
erythrocyte B-LOC [0.38358768820762634, -0.9325295090675354]
count B-LOC [0.4470374584197998, -0.7241448760032654]
and B-LOC [0.49617087841033936, -0.7903742790222168]
microcytosis B-LOC [0.4288741648197174, -0.8674352169036865]
may B-LOC [1.0595877170562744, -1.2452900409698486]
confer B-LOC [0.9917051792144775, -1.1745555400848389]
a B-LOC [0.9449069499969482, -1.1591994762420654]
similar B-LOC [1.026994228363037, -1.3691297769546509]
advantage. B-LOC [0.7690650224685669, -1.2912487983703613]

BACKGROUND B-LOC [1.3569929599761963, -2.119844436645508]
Information B-LOC [2.4231138229370117, -3.0093750953674316]
is B-LOC [2.7078516483306885, -2.914684534072876]
scarce B-LOC [2.9272420406341553, -3.021449327468872]
about B-LOC [2.5903921127319336, -3.108741044998169]
the B-LOC [2.6887667179107666, -2.986558198928833]
combined B-LOC [2.3779828548431396, -3.0541398525238037]
effects B-LOC [2.624727487564087, -3.217275381088257]
on B-LOC [2.450486421585083, -3.0203497409820557]
breast B-LOC [2.078322410583496, -2.7340123653411865]
cancer B-LOC [2.187288999557495, -2.9997613430023193]
incidence B-LOC [2.3687994480133057, -2.917844295501709]
of B-LOC [2.282573938369751, -2.9175827503204346]
low-penetrance B-LOC [2.303680181503296, -2.9288718700408936]
genetic B-LOC [2.450446367263794, -3.147386312484741]
susceptibility B-LOC [2.4894003868103027, -3.061408519744873]
polymorphisms B-LOC [2.534090042114258, -2.8376500606536865]
and B-LOC [2.4476473331451416, -2.9362423419952393]
environmental B-LOC [2.9166290760040283, -3.383129119873047]
factors B-LOC [2.538323402404785, -3.268604278564453]
(reproductive, B-LOC [2.4933760166168213, -2.8678462505340576]
behavioural, B-LOC [2.751232385635376, -3.176105260848999]
and B-LOC [2.2352497577667236, -2.92960524559021]
anthropometric B-LOC [2.774348020553589, -3.270113468170166]
risk B-LOC [2.803844451904297, -3.3494675159454346]
factors B-LOC [2.6930606365203857, -3.2456297874450684]
for B-LOC [2.478039503097534, -2.909165859222412]
breast B-LOC [2.3518900871276855, -2.9964418411254883]
cancer). B-LOC [2.4455039501190186, -3.2166879177093506]
To B-LOC [3.038602352142334, -3.3846166133880615]
test B-LOC [3.1886861324310303, -3.507014513015747]
for B-LOC [3.289121389389038, -3.4881107807159424]
evidence B-LOC [3.0980591773986816, -3.5867578983306885]
of B-LOC [3.123608112335205, -3.5278985500335693]
gene-environment B-LOC [2.9738032817840576, -3.7788288593292236]
interactions, B-LOC [3.1434876918792725, -3.4883110523223877]
we B-LOC [2.899930238723755, -2.8697850704193115]
compared B-LOC [3.1064839363098145, -3.3458516597747803]
genotypic B-LOC [3.32099986076355, -3.3785994052886963]
relative B-LOC [3.2057347297668457, -3.510495901107788]
risks B-LOC [3.3145172595977783, -3.654160261154175]
for B-LOC [3.131817579269409, -3.41355037689209]
breast B-LOC [2.650474786758423, -3.2154548168182373]
cancer B-LOC [3.0434625148773193, -3.5110361576080322]
across B-LOC [3.1953818798065186, -3.466055154800415]
the B-LOC [3.2831029891967773, -3.412956714630127]
other B-LOC [3.2191569805145264, -3.518097162246704]
risk B-LOC [3.3840718269348145, -3.7101752758026123]
factors B-LOC [3.301772356033325, -3.6981358528137207]
in B-LOC [3.3672049045562744, -3.3387608528137207]
a B-LOC [3.324826955795288, -3.278329610824585]
large B-LOC [3.2887325286865234, -3.5147135257720947]
UK B-LOC [3.191967010498047, -3.4945061206817627]
prospective B-LOC [3.3779351711273193, -3.6884615421295166]
study. B-LOC [3.19476056098938, -3.5466830730438232]
METHODS B-LOC [0.8306702375411987, -1.3076045513153076]
We B-LOC [0.400227814912796, -0.8439146280288696]
tested B-LOC [0.4740913212299347, -0.6179535388946533]
gene-environment B-LOC [0.266875296831131, -0.6158707737922668]
interactions B-LOC [0.17265918850898743, -0.30930835008621216]
in B-LOC [0.18666663765907288, -0.3287460505962372]
7610 B-LOC [0.784617006778717, -0.43215620517730713]
women B-LOC [0.2665596306324005, -0.2795960307121277]
who B-LOC [0.16966916620731354, -0.2655526101589203]
developed O [0.02636622078716755, 0.04978657886385918]
breast B-LOC [0.20223191380500793, -0.12652745842933655]
cancer B-LOC [0.2588019073009491, -0.16499683260917664]
and B-LOC [0.32275986671447754, -0.3138220012187958]
10 B-LOC [0.6332802176475525, -0.21520590782165527]
196 B-LOC [0.041415371000766754, -0.19368621706962585]
controls O [-0.046906571835279465, -0.04587838426232338]
without O [0.03918587043881416, 0.15524925291538239]
the O [0.04408777132630348, 0.11869354546070099]
disease, O [-0.22624555230140686, -0.19935745000839233]
studying B-LOC [0.46455612778663635, -0.5154744386672974]
the B-LOC [0.6383708119392395, -0.42963704466819763]
effects B-LOC [0.25369012355804443, -0.217240110039711]
of B-LOC [0.21052145957946777, -0.2085288017988205]
12 B-LOC [0.506514847278595, -0.2897314131259918]

polymorphisms B-LOC [0.028352418914437294, -0.39807605743408203]
(FGFR2-rs2981582, B-LOC [0.19160346686840057, -0.24214862287044525]
TNRC9-rs3803662, B-LOC [-0.017638830468058586, -0.04794600233435631]
2q35-rs13387042, O [-0.046365026384592056, 0.041639283299446106]
MAP3K1-rs889312, O [-0.2869277894496918, 0.07353031635284424]
8q24-rs13281615, O [-0.12204533070325851, 0.15045487880706787]
2p-rs4666451, O [-0.10894540697336197, 0.11503145098686218]
5p12-rs981782, O [0.043246764689683914, 0.05780480429530144]
CASP8-rs1045485, O [-0.1722039431333542, 0.0674026608467102]
LSP1-rs3817198, O [-0.019016286358237267, 0.06932263821363449]
5q-rs30099, O [-0.028507618233561516, 0.036845989525318146]
TGFB1-rs1982073, B-LOC [-0.007002381142228842, -0.0648585706949234]
and B-LOC [0.23463174700737, -0.11750461161136627]

ATM-rs1800054) O [-0.5848840475082397, 0.4009440839290619]
in O [-0.7846397161483765, 0.6347659826278687]
relation O [-0.6200942397117615, 0.6851029992103577]
to O [-0.5774828195571899, 0.6743645071983337]
prospectively O [-0.6775071024894714, 0.855320930480957]
collected O [-0.6256026029586792, 0.5825405120849609]
information O [-0.5616196393966675, 0.4742206037044525]
about O [-0.5433474779129028, 0.5258662104606628]
ten O [-0.38468286395072937, 0.597050130367279]
established O [-0.7138360738754272, 0.5419082641601562]
environmental O [-0.44173648953437805, 0.3436813950538635]
risk O [-0.4430669844150543, 0.3767476975917816]
factors O [-0.4662661850452423, 0.30673840641975403]
(age O [-0.5790384411811829, 0.2621874511241913]
at O [-0.5921823978424072, 0.2761116027832031]
menarche, O [-0.45897024869918823, 0.4250386655330658]
parity, O [-0.5152421593666077, 0.38017454743385315]
age O [-0.3939068019390106, 0.28017476201057434]
at O [-0.5076012015342712, 0.16196486353874207]
first O [-0.6044405102729797, 0.3253920376300812]
birth, O [-0.4998062551021576, 0.4296470582485199]
breastfeeding, O [-0.38314202427864075, 0.46806269884109497]
menopausal O [-0.32705435156822205, 0.40627148747444153]
status, O [-0.40480396151542664, 0.3634963929653168]
age O [-0.34429341554641724, 0.22751988470554352]
at O [-0.43744611740112305, 0.24051842093467712]
menopause, O [-0.2142169028520584, 0.33873480558395386]
use O [-0.48030003905296326, 0.33106550574302673]
of O [-0.5694651007652283, 0.3267936110496521]
hormone O [-0.47424831986427307, 0.2487519383430481]
replacement O [-0.5335159301757812, 0.4053935706615448]
therapy, O [-0.4584367573261261, 0.21779543161392212]
body-mass O [-0.43552112579345703, 0.32276979088783264]
index, O [-0.3560517728328705, 0.15062569081783295]
height, O [-0.2052014023065567, 0.03290362283587456]
and O [-0.1848539412021637, 0.19517605006694794]
alcohol O [-0.2718559801578522, 0.16187819838523865]
consumption). O [-0.15634316205978394, 0.3592670261859894]
FINDINGS B-LOC [1.0092159509658813, -1.1015329360961914]
After B-LOC [1.3604607582092285, -1.1247289180755615]
allowance B-LOC [1.6607446670532227, -0.9746930599212646]
for B-LOC [1.892388105392456, -0.9688135385513306]
multiple B-LOC [1.7411518096923828, -1.673784852027893]
testing B-LOC [1.8533856868743896, -1.6798553466796875]
none B-LOC [1.8548321723937988, -1.3356459140777588]
of B-LOC [2.0520565509796143, -1.221266508102417]
the B-LOC [1.8536564111709595, -1.131831407546997]
120 B-LOC [1.9351723194122314, -1.5957086086273193]
comparisons B-LOC [1.5669715404510498, -1.6128292083740234]
yielded B-LOC [1.7059097290039062, -1.3940321207046509]
significant B-LOC [1.7677133083343506, -1.7790658473968506]
evidence B-LOC [1.792484164237976, -1.6083797216415405]
of B-LOC [1.7071189880371094, -1.8770605325698853]
a B-LOC [1.6576430797576904, -2.017512083053589]
gene-environment B-LOC [1.355463981628418, -1.8640390634536743]
interaction. B-LOC [1.2725032567977905, -1.8392877578735352]
By B-LOC [0.57746821641922, -0.5359675884246826]
contrast B-LOC [0.779345691204071, -0.6837678551673889]
with B-LOC [0.8973721265792847, -0.8222078680992126]
previous B-LOC [0.6101701259613037, -0.7207940220832825]
suggestions, B-LOC [0.8249511122703552, -0.7658849358558655]
there B-LOC [0.642490565776825, -0.7505372166633606]
was B-LOC [0.6531699299812317, -0.8007048964500427]
little B-LOC [0.8062952160835266, -0.6712318062782288]
evidence B-LOC [0.6743096709251404, -0.683426558971405]
that B-LOC [0.7254523634910583, -1.1007853746414185]
the B-LOC [0.7633047103881836, -1.016059160232544]
genotypic B-LOC [0.896364152431488, -1.10104238986969]
relative B-LOC [0.7084823250770569, -1.144809603691101]
risks B-LOC [0.583630383014679, -0.932228684425354]
were B-LOC [0.8078718781471252, -1.078679084777832]
affected B-LOC [0.8458132147789001, -1.1599719524383545]
by B-LOC [0.578201949596405, -1.039739727973938]
use B-LOC [0.5331547260284424, -0.9135246872901917]
of B-LOC [0.4885956943035126, -0.9901496171951294]
hormone B-LOC [0.38485509157180786, -0.944644570350647]
replacement B-LOC [0.42164066433906555, -0.7645143866539001]
therapy, B-LOC [0.4222636818885803, -0.9286556839942932]
either B-LOC [0.3611077070236206, -1.0795742273330688]

overall B-LOC [0.49271997809410095, -0.8847627639770508]
or B-LOC [0.9102551937103271, -1.1863024234771729]
for B-LOC [0.7616165280342102, -1.3750405311584473]
oestrogen-receptor-positive B-LOC [0.9418769478797913, -1.3539108037948608]
disease. B-LOC [0.739582359790802, -1.1343936920166016]
Only B-LOC [1.1473603248596191, -1.244234323501587]
one B-LOC [1.2455716133117676, -1.3026965856552124]
of B-LOC [1.4559388160705566, -1.1279480457305908]
the B-LOC [1.2166796922683716, -1.1769163608551025]
12 B-LOC [1.3387086391448975, -1.3755227327346802]
polymorphisms B-LOC [1.4271866083145142, -1.603805422782898]
was B-LOC [1.4163854122161865, -1.603265404701233]
correlated B-LOC [1.4295908212661743, -1.632050633430481]
with B-LOC [1.3934226036071777, -1.7040443420410156]
any B-LOC [1.3837274312973022, -1.551290512084961]
of B-LOC [1.7634841203689575, -1.4572393894195557]
the B-LOC [1.6781147718429565, -1.3531503677368164]
ten B-LOC [1.615715503692627, -1.5306977033615112]
other B-LOC [1.6095869541168213, -1.5578720569610596]
risk B-LOC [1.1313608884811401, -1.4251595735549927]
factors: B-LOC [1.3378022909164429, -1.6723086833953857]
carriers B-LOC [0.7857099175453186, -0.8346074223518372]
of B-LOC [0.8216506838798523, -0.8074889779090881]
the B-LOC [1.2292983531951904, -1.0532844066619873]
high-risk B-LOC [0.8683571219444275, -1.098940134048462]
C B-LOC [0.7732107639312744, -1.1168222427368164]
allele B-LOC [0.9334061741828918, -1.0458542108535767]
of B-LOC [0.9074337482452393, -1.1101521253585815]
MAP3K1-rs889312 B-LOC [0.6566309332847595, -1.0211260318756104]
were B-LOC [0.7212101221084595, -0.9994543194770813]
significantly B-LOC [0.8488214612007141, -1.0850785970687866]
shorter B-LOC [0.7518016695976257, -0.8949664235115051]
than B-LOC [0.482114315032959, -0.7051233649253845]
non-carriers B-LOC [0.2913771867752075, -0.7291193008422852]
(mean B-LOC [0.8595784306526184, -0.9289205074310303]
height B-LOC [0.39930030703544617, -1.065216064453125]
162.4 B-LOC [0.7011377215385437, -0.5862494707107544]
cm B-LOC [0.4993613660335541, -1.1262067556381226]
[95% B-LOC [0.32350972294807434, -0.7203641533851624]
CI B-LOC [0.07926520705223083, -0.5643988847732544]
162.1-162.7] B-LOC [0.5023418068885803, -0.447078675031662]
vs B-LOC [0.2724257707595825, -0.8946767449378967]
163.1 B-LOC [0.4976290166378021, -0.279464989900589]
cm B-LOC [0.3824290335178375, -0.9215610027313232]
[162.9-163.2]; B-LOC [0.2921365797519684, -0.9118900895118713]
p=0.01 B-LOC [0.4898647964000702, -0.8862598538398743]
after B-LOC [0.8824036121368408, -1.0591464042663574]
allowance B-LOC [1.031078577041626, -1.022538661956787]
for B-LOC [1.2702432870864868, -1.1339941024780273]
multiple B-LOC [1.113812804222107, -1.391187310218811]
testing). B-LOC [0.9090198278427124, -1.2272592782974243]
INTERPRETATION B-LOC [0.4711456000804901, -1.0574069023132324]
Risks B-LOC [0.537288248538971, -0.6809372901916504]
of B-LOC [0.22053347527980804, -0.6106722950935364]
breast B-LOC [0.5665797591209412, -0.9687656760215759]
cancer B-LOC [0.7348607182502747, -1.0908178091049194]
associated B-LOC [0.5656212568283081, -0.7106198072433472]
with B-LOC [0.1811847686767578, -0.7636349201202393]

low-penetrance O [-0.6567824482917786, 0.7506588101387024]
susceptibility O [-0.4514749348163605, 0.5514540076255798]
polymorphisms O [-0.40268608927726746, 0.6683561205863953]
do O [-0.4484820067882538, 0.5768650770187378]
not O [-0.40962693095207214, 0.8665387034416199]
vary O [-0.37368279695510864, 0.308925598859787]
significantly O [-0.4009700119495392, 0.5191112160682678]
with O [-0.00548379635438323, 0.33803051710128784]
these O [-0.08521043509244919, 0.27028509974479675]
ten O [-0.05474929139018059, 0.16857413947582245]
established B-LOC [-0.06092524901032448, -0.1720786839723587]
environmental B-LOC [-0.019345788285136223, -0.10804234445095062]
risk B-LOC [0.23638999462127686, -0.21336278319358826]
factors. O [-0.04983457550406456, 0.053524237126111984]
FUNDING B-LOC [1.805225133895874, -1.7431020736694336]
Cancer B-LOC [2.1847586631774902, -2.3179752826690674]
Research B-LOC [2.1033883094787598, -2.097034215927124]
UK B-LOC [2.22939395904541, -1.9254249334335327]
and B-LOC [1.9466800689697266, -1.8717247247695923]
the B-LOC [1.8173414468765259, -1.8993643522262573]
UK B-LOC [2.254491090774536, -2.1511452198028564]
Medical B-LOC [2.1168503761291504, -2.2270708084106445]
Research B-LOC [2.129011631011963, -2.271644115447998]
Council. B-LOC [2.3156282901763916, -2.32346248626709]

Fast B-LOC [0.9091805815696716, -1.5546448230743408]
axonal B-LOC [0.823272168636322, -1.5894768238067627]
transport B-LOC [0.9366782307624817, -1.3161298036575317]
(FAT) B-LOC [1.1710636615753174, -1.6210362911224365]
requires B-LOC [1.09769606590271, -1.2500931024551392]
consistent B-LOC [0.9618331789970398, -1.3848260641098022]
energy B-LOC [0.850559651851654, -1.3186700344085693]
over B-LOC [1.1068871021270752, -1.6260064840316772]
long B-LOC [1.2278966903686523, -1.588363766670227]
distances B-LOC [1.2775495052337646, -1.545447587966919]
to B-LOC [0.9843623638153076, -1.2643927335739136]
fuel B-LOC [1.0760037899017334, -1.3508609533309937]
the B-LOC [0.98276287317276, -1.1254392862319946]
molecular B-LOC [1.0347459316253662, -1.4341198205947876]
motors B-LOC [1.0264900922775269, -1.4150996208190918]
that B-LOC [1.102674961090088, -1.420360803604126]
transport B-LOC [1.2931272983551025, -1.3499000072479248]
vesicles. B-LOC [0.9407959580421448, -1.5891622304916382]
We B-LOC [-0.017986508086323738, -0.3039817214012146]
demonstrate B-LOC [0.2521415650844574, -0.23392026126384735]
that B-LOC [0.019052701070904732, -0.5619933009147644]
glycolysis B-LOC [0.38904204964637756, -0.4709482491016388]
provides B-LOC [0.3465123474597931, -0.4190090596675873]
ATP B-LOC [0.48237770795822144, -0.6405228972434998]
for B-LOC [0.33871129155158997, -0.4900842308998108]
the B-LOC [0.36154839396476746, -0.41764435172080994]
FAT B-LOC [0.35748693346977234, -0.6067052483558655]
of B-LOC [0.3045240342617035, -0.5905718803405762]
vesicles. B-LOC [0.32934725284576416, -0.7196101546287537]
Although B-LOC [0.002342099789530039, -0.16649653017520905]
inhibiting B-LOC [0.03876647353172302, -0.1393953114748001]
ATP B-LOC [0.4240027666091919, -0.6046595573425293]
production B-LOC [0.20583727955818176, -0.4091477692127228]
from B-LOC [0.12134804576635361, -0.20588526129722595]
mitochondria B-LOC [0.13708339631557465, -0.1736321896314621]
did B-LOC [0.03283054009079933, -0.20529696345329285]
not B-LOC [0.48543331027030945, -0.21292446553707123]
affect B-LOC [0.2891092896461487, -0.6074759364128113]
vesicles B-LOC [0.47309479117393494, -0.7947679758071899]
motility, B-LOC [0.622715950012207, -0.6393792033195496]
pharmacological B-LOC [0.7485082745552063, -0.9530509114265442]
or B-LOC [0.34646159410476685, -0.5192522406578064]
genetic B-LOC [0.5973631739616394, -0.7355780601501465]
inhibition B-LOC [0.49987757205963135, -0.6812020540237427]
of B-LOC [0.5587149858474731, -0.6841039657592773]
the B-LOC [0.6209264993667603, -0.7176859974861145]
glycolytic B-LOC [0.7943623661994934, -0.9033100605010986]
enzyme B-LOC [0.5727555155754089, -0.9171769618988037]
GAPDH B-LOC [0.26692715287208557, -0.6992877125740051]
reduced B-LOC [0.4096434414386749, -0.7023104429244995]
transport B-LOC [0.6538026332855225, -0.9280574321746826]
in B-LOC [0.4214208126068115, -0.7115049958229065]
cultured B-LOC [0.7007043957710266, -0.9251416921615601]
neurons B-LOC [0.36204293370246887, -0.8326715230941772]
and B-LOC [0.4433862864971161, -0.8567274212837219]
in B-LOC [0.5872184038162231, -0.7537232637405396]
Drosophila B-LOC [0.9690523147583008, -1.3497220277786255]
larvae. B-LOC [0.7301368713378906, -0.9471104741096497]
GAPDH B-LOC [-0.22499024868011475, -0.23409351706504822]
localizes B-LOC [-0.0693286582827568, -0.23780322074890137]
on B-LOC [0.06283204257488251, -0.058716271072626114]
vesicles B-LOC [-0.10757408291101456, -0.18669463694095612]
via O [-0.14510351419448853, -0.12374653667211533]
a B-LOC [0.12002041935920715, -0.0407598502933979]
huntingtin-dependent B-LOC [-0.07124686986207962, -0.11129529774188995]
mechanism B-LOC [-0.20097266137599945, -0.27335479855537415]
and B-LOC [-0.1164747029542923, -0.2817491292953491]
is B-LOC [0.1325708031654358, -0.12961873412132263]
transported B-LOC [0.1727861911058426, -0.26427432894706726]
on B-LOC [-0.023228345438838005, -0.1986796259880066]
fast-moving B-LOC [0.039817292243242264, -0.1904219090938568]
vesicles B-LOC [-0.09503472596406937, -0.27978387475013733]
within B-LOC [0.0407322533428669, -0.34619763493537903]
axons. B-LOC [0.03639275208115578, -0.13239964842796326]

Purified B-LOC [0.1089191660284996, -0.35274389386177063]
motile B-LOC [0.2893241047859192, -0.3596036434173584]
vesicles B-LOC [0.06898397207260132, -0.37060680985450745]
showed B-LOC [0.10861482471227646, -0.2637832760810852]
GAPDH B-LOC [0.13341601192951202, -0.30649760365486145]
enzymatic B-LOC [0.2799936532974243, -0.39560961723327637]
activity B-LOC [0.26773756742477417, -0.3212182819843292]
and B-LOC [0.123417928814888, -0.2572505474090576]
produced B-LOC [0.23629161715507507, -0.32958149909973145]
ATP. B-LOC [0.18217742443084717, -0.282379686832428]
Finally, O [-0.23966729640960693, 0.24435824155807495]
we O [-0.600145161151886, 0.24169594049453735]
show O [-0.5243944525718689, 0.3967120051383972]
that O [-0.6872765421867371, 0.2621045708656311]
vesicular O [-0.6417431235313416, 0.48437365889549255]
GAPDH O [-0.5595690608024597, 0.2884838581085205]
is O [-0.4789842665195465, 0.5690181851387024]
necessary O [-0.41329026222229004, 0.49885159730911255]
and O [-0.5110716223716736, 0.47452783584594727]
sufficient O [-0.45627909898757935, 0.5133181214332581]
to O [-0.5252713561058044, 0.5233216881752014]
provide O [-0.5338656306266785, 0.523501992225647]
on-board O [-0.6593698263168335, 0.5234457850456238]
energy O [-0.41007712483406067, 0.4990210235118866]
for O [-0.6182352304458618, 0.4546224772930145]
fast O [-0.3838024139404297, 0.36750391125679016]
vesicular O [-0.4535406529903412, 0.27021291851997375]
transport. O [-0.18180540204048157, 0.3751858174800873]
Although O [-0.8612977862358093, 0.9141843318939209]
detaching O [-0.5478181838989258, 0.8675088286399841]
GAPDH O [-0.6702088117599487, 0.6657514572143555]
from O [-0.6532037854194641, 0.5462197065353394]
vesicles O [-0.7509179711341858, 0.7004592418670654]
reduced O [-0.7753024101257324, 0.8619149327278137]
transport, O [-0.653224766254425, 0.5956279635429382]
targeting O [-0.6414273977279663, 0.7253560423851013]
GAPDH O [-0.6568776369094849, 0.584843099117279]
to O [-0.5376867651939392, 0.48758837580680847]
vesicles O [-0.8971500992774963, 0.6819021105766296]
was O [-0.8446375727653503, 0.6988071203231812]
sufficient O [-0.7014859914779663, 0.8017199635505676]
to O [-0.7840198278427124, 0.6993722319602966]
promote O [-0.7839286923408508, 0.7399831414222717]
FAT O [-0.6606355309486389, 0.5105414986610413]
in O [-0.6680169105529785, 0.6749964356422424]
GAPDH O [-0.5997319221496582, 0.452962189912796]
deficient O [-0.6458578705787659, 0.6586273312568665]
neurons. O [-0.6985877156257629, 0.4561091363430023]
This B-LOC [0.18452304601669312, -0.15389905869960785]
specifically B-LOC [0.1030072495341301, -0.2273615002632141]
localized B-LOC [0.0655478984117508, -0.2870376408100128]
glycolytic B-LOC [0.07535988837480545, -0.25599804520606995]
machinery B-LOC [-0.04700537398457527, -0.34728753566741943]
may B-LOC [0.3797352910041809, -0.5487497448921204]
supply B-LOC [0.11615536361932755, -0.4405535161495209]
constant B-LOC [0.15562942624092102, -0.666297435760498]
energy, B-LOC [-0.02392270229756832, -0.33986932039260864]
independent B-LOC [0.3241640329360962, -0.5475257039070129]
of B-LOC [0.35736241936683655, -0.5849473476409912]
mitochondria, B-LOC [0.1275227665901184, -0.33816972374916077]
for B-LOC [0.06257162243127823, -0.548168957233429]
the B-LOC [0.08361287415027618, -0.4600796401500702]
processive B-LOC [0.12752708792686462, -0.39001965522766113]
movement B-LOC [0.2733137011528015, -0.5374635457992554]
of B-LOC [0.3353535234928131, -0.6154832243919373]
vesicles B-LOC [0.030959995463490486, -0.6311724781990051]
over B-LOC [0.42713963985443115, -0.8240929841995239]
long B-LOC [0.5381402373313904, -0.8763096928596497]
distances B-LOC [0.33272141218185425, -0.7221778631210327]
in B-LOC [0.20261426270008087, -0.6696270108222961]
axons. B-LOC [0.18675407767295837, -0.4113757014274597]

IMPORTANCE B-LOC [0.5480700135231018, -0.8361372351646423]
Bariatric B-LOC [0.36387160420417786, -0.46277791261672974]
surgery B-LOC [0.10070103406906128, -0.4833260178565979]
is B-LOC [0.18316729366779327, -0.40011152625083923]
associated B-LOC [0.165873184800148, -0.28957870602607727]
with B-LOC [-0.025594113394618034, -0.2858003079891205]
sustained B-LOC [0.0003923499898519367, -0.36598870158195496]
weight B-LOC [0.5728645920753479, -0.4893748462200165]
loss B-LOC [0.2778065502643585, -0.23598819971084595]
and B-LOC [-0.03616827353835106, -0.22141580283641815]
improved B-LOC [0.015524658374488354, -0.376459002494812]
physical B-LOC [0.4254101514816284, -0.5792668461799622]
health B-LOC [0.45013222098350525, -0.801108717918396]
status B-LOC [0.39898934960365295, -0.4135734736919403]
for B-LOC [0.3357861042022705, -0.5189496874809265]
severely B-LOC [0.3412862718105316, -0.5515187978744507]
obese B-LOC [0.49016645550727844, -0.6791258454322815]
individuals. B-LOC [0.39438238739967346, -0.6221703290939331]
Mental B-LOC [2.8117876052856445, -3.402864456176758]
health B-LOC [3.0366151332855225, -3.6225662231445312]
conditions B-LOC [3.130605936050415, -3.5795328617095947]
may B-LOC [2.760242223739624, -3.43765926361084]
be B-LOC [2.50311541557312, -3.434175729751587]
common B-LOC [2.5131590366363525, -3.1442325115203857]
among B-LOC [2.3637421131134033, -3.2494242191314697]
patients B-LOC [3.0483295917510986, -3.4488866329193115]
seeking B-LOC [2.8103456497192383, -3.6884090900421143]
bariatric B-LOC [2.662043333053589, -3.393366575241089]
surgery; B-LOC [2.265265703201294, -3.0225369930267334]
however, B-LOC [3.082219362258911, -3.373112916946411]
the B-LOC [3.1914756298065186, -3.5767462253570557]
prevalence B-LOC [3.170515537261963, -3.478912591934204]
of B-LOC [3.046578884124756, -3.586211919784546]
these B-LOC [2.916529893875122, -3.4549553394317627]
conditions B-LOC [3.0973238945007324, -3.470324993133545]
and B-LOC [3.118647336959839, -3.5120975971221924]
whether B-LOC [2.9367477893829346, -3.6075851917266846]
they B-LOC [3.1569631099700928, -3.6271965503692627]
are B-LOC [3.250359296798706, -3.661285877227783]
associated B-LOC [3.012251853942871, -3.6020047664642334]
with B-LOC [2.823484420776367, -3.7297616004943848]
postoperative B-LOC [2.9220240116119385, -3.5406060218811035]
outcomes B-LOC [2.93410325050354, -3.642000436782837]
remains B-LOC [3.3900461196899414, -3.503580331802368]
unknown. B-LOC [3.31184458732605, -3.5153520107269287]
OBJECTIVE B-LOC [3.2305057048797607, -3.1661415100097656]
To B-LOC [2.9855635166168213, -3.1685216426849365]
determine B-LOC [3.5305016040802, -3.3523433208465576]
the B-LOC [3.544417142868042, -3.206835985183716]
prevalence B-LOC [3.4162542819976807, -3.3344693183898926]
of B-LOC [3.1354422569274902, -3.1659820079803467]
mental B-LOC [3.456907033920288, -3.2594447135925293]
health B-LOC [3.1937308311462402, -3.3090882301330566]
conditions B-LOC [3.3642289638519287, -3.2644147872924805]
among B-LOC [3.2488021850585938, -3.3486979007720947]
bariatric B-LOC [3.319331407546997, -3.4019291400909424]
surgery B-LOC [3.171046733856201, -3.193225860595703]
candidates B-LOC [3.544787883758545, -3.297638416290283]
and B-LOC [3.17859148979187, -3.139808177947998]
recipients, B-LOC [3.424255132675171, -3.352908134460449]
to B-LOC [3.3902664184570312, -3.4206788539886475]
evaluate B-LOC [3.5155115127563477, -3.367074728012085]
the B-LOC [3.584540605545044, -3.219911575317383]
association B-LOC [3.363306760787964, -3.333411931991577]
between B-LOC [3.237663984298706, -3.5158140659332275]
preoperative B-LOC [3.3520448207855225, -3.352695941925049]
mental B-LOC [3.467682123184204, -3.1500096321105957]
health B-LOC [3.196695566177368, -3.36094069480896]
conditions B-LOC [3.454301595687866, -3.250014066696167]
and B-LOC [3.0630595684051514, -3.2403857707977295]
health B-LOC [3.3626747131347656, -3.462904214859009]
outcomes B-LOC [3.5759098529815674, -3.501816987991333]
following B-LOC [3.271104097366333, -3.4712111949920654]
bariatric B-LOC [3.3931164741516113, -3.3745453357696533]
surgery, B-LOC [3.460228204727173, -3.1789097785949707]
and B-LOC [3.4390928745269775, -3.165438413619995]
to B-LOC [3.5690810680389404, -3.518101453781128]
evaluate B-LOC [3.6107492446899414, -3.3975446224212646]
the B-LOC [3.652700424194336, -3.3200953006744385]
association B-LOC [3.3947572708129883, -3.5199897289276123]
between B-LOC [3.227506399154663, -3.5933451652526855]
surgery B-LOC [3.469087839126587, -3.2847256660461426]
and B-LOC [3.3418586254119873, -3.3412506580352783]
the B-LOC [3.5444529056549072, -3.423304796218872]
clinical B-LOC [3.618237257003784, -3.6333634853363037]
course B-LOC [3.295524835586548, -3.5538575649261475]
of B-LOC [3.431464433670044, -3.5269200801849365]
mental B-LOC [3.5184342861175537, -3.3081419467926025]
health B-LOC [3.3085310459136963, -3.4312353134155273]
conditions. B-LOC [3.505420207977295, -3.432758092880249]

DATA B-LOC [3.3864634037017822, -3.8469326496124268]
SOURCES B-LOC [3.2951693534851074, -3.517329216003418]
We B-LOC [3.307948350906372, -3.548517942428589]
searched B-LOC [3.694915533065796, -3.5944831371307373]
PubMed, B-LOC [3.53092360496521, -3.748537063598633]
MEDLINE B-LOC [3.563872814178467, -3.736560583114624]
on B-LOC [3.461993932723999, -3.9061968326568604]
OVID, B-LOC [3.495265245437622, -3.5546092987060547]
and B-LOC [3.625269889831543, -3.6406846046447754]
PsycINFO B-LOC [3.7174646854400635, -3.7888343334198]
for B-LOC [3.612675905227661, -3.804879903793335]
studies B-LOC [3.6499216556549072, -3.9094388484954834]
published B-LOC [3.707444667816162, -3.8242905139923096]
between B-LOC [3.6166062355041504, -3.518583059310913]
January B-LOC [3.7365970611572266, -3.4857068061828613]
1988 B-LOC [3.638258457183838, -3.6702980995178223]
and B-LOC [3.642552614212036, -3.4158289432525635]
November B-LOC [3.7245023250579834, -3.4717819690704346]
2015. B-LOC [3.5412001609802246, -3.7729876041412354]
Study B-LOC [3.309178590774536, -3.8145692348480225]
quality B-LOC [3.285167932510376, -3.7508511543273926]
was B-LOC [3.391918182373047, -3.8937723636627197]
assessed B-LOC [3.4948484897613525, -3.706162452697754]
using B-LOC [3.4235785007476807, -3.79785418510437]
an B-LOC [3.4663655757904053, -3.7480032444000244]
adapted B-LOC [3.527747392654419, -3.8778979778289795]
tool B-LOC [3.4612810611724854, -3.8637778759002686]
for B-LOC [3.4708330631256104, -3.814978837966919]
risk B-LOC [3.512887954711914, -3.8930203914642334]
of B-LOC [3.3165130615234375, -3.583766460418701]
bias; B-LOC [3.3337697982788086, -3.8623366355895996]
quality B-LOC [3.3271026611328125, -3.6570656299591064]
of B-LOC [3.3332207202911377, -3.569321870803833]
evidence B-LOC [3.4408607482910156, -3.8404698371887207]
was B-LOC [3.4476850032806396, -3.7545344829559326]
rated B-LOC [3.4459164142608643, -3.6199629306793213]
based B-LOC [3.233830213546753, -3.5431597232818604]
on B-LOC [3.358057975769043, -3.6652884483337402]
GRADE B-LOC [3.522660255432129, -3.6878502368927]
(Grading B-LOC [3.3872950077056885, -3.633561849594116]
of B-LOC [3.174100399017334, -3.419253349304199]
Recommendations B-LOC [3.266859769821167, -3.6026999950408936]
Assessment, B-LOC [3.37349534034729, -3.4812183380126953]
Development B-LOC [3.3389549255371094, -3.6317760944366455]
and B-LOC [3.120685338973999, -3.1403751373291016]
Evaluation) B-LOC [3.420600652694702, -3.486135959625244]
criteria. B-LOC [3.3929665088653564, -3.536447048187256]
FINDINGS B-LOC [2.036595582962036, -2.402874708175659]
We B-LOC [1.9696009159088135, -2.4025180339813232]
identified B-LOC [2.6328237056732178, -2.8271477222442627]
68 B-LOC [2.846682071685791, -3.0492255687713623]
publications B-LOC [2.6349120140075684, -2.8604660034179688]
meeting B-LOC [2.841296434402466, -3.1852686405181885]
inclusion B-LOC [2.9572455883026123, -3.1729323863983154]
criteria: B-LOC [3.0207290649414062, -3.261691093444824]
59 B-LOC [2.4882686138153076, -2.6647019386291504]
reporting B-LOC [2.4230105876922607, -2.858691692352295]
the B-LOC [2.769117832183838, -2.8592026233673096]
prevalence B-LOC [2.84870982170105, -2.860713481903076]
of B-LOC [2.4644486904144287, -2.732347011566162]
preoperative B-LOC [2.4867124557495117, -2.9044225215911865]
mental B-LOC [2.780413866043091, -2.8003575801849365]
health B-LOC [2.552353858947754, -3.057931661605835]
conditions B-LOC [3.0935940742492676, -2.7165207862854004]
(65,363 B-LOC [2.537416458129883, -2.55222225189209]
patients) B-LOC [2.849818229675293, -2.9562361240386963]
and B-LOC [2.5410916805267334, -2.667041778564453]
27 B-LOC [2.9349310398101807, -2.545114755630493]
reporting B-LOC [2.21380877494812, -2.774656057357788]
associations B-LOC [2.6620118618011475, -2.947252035140991]
between B-LOC [2.583544969558716, -3.2019174098968506]
preoperative B-LOC [2.303879976272583, -2.6695916652679443]
mental B-LOC [2.754955530166626, -2.551729440689087]
health B-LOC [2.4531548023223877, -2.920210123062134]
conditions B-LOC [2.9410030841827393, -2.5530662536621094]
and B-LOC [2.3476357460021973, -2.877485990524292]
postoperative B-LOC [2.3383471965789795, -2.5009543895721436]
outcomes B-LOC [2.383697032928467, -2.835747241973877]

(50,182 B-LOC [0.6255407929420471, -1.0716524124145508]
patients). B-LOC [1.1143684387207031, -1.4811400175094604]
Among B-LOC [1.4229178428649902, -1.3501713275909424]
patients B-LOC [1.3345437049865723, -1.5038601160049438]
seeking B-LOC [1.33316969871521, -1.6413843631744385]
and B-LOC [1.8443772792816162, -1.879122257232666]
undergoing B-LOC [1.9188904762268066, -1.950279712677002]
bariatric B-LOC [1.5497360229492188, -1.926405668258667]
surgery, B-LOC [1.2395005226135254, -1.5999410152435303]
the B-LOC [1.7843098640441895, -1.5789380073547363]
most B-LOC [1.725480079650879, -1.6282799243927002]
common B-LOC [1.573699951171875, -1.3943431377410889]
mental B-LOC [1.3304287195205688, -1.4824087619781494]
health B-LOC [1.3242946863174438, -1.7037214040756226]
conditions, B-LOC [1.3512223958969116, -1.4549614191055298]
based B-LOC [1.4650522470474243, -1.4426391124725342]
on B-LOC [1.52315092086792, -1.4200083017349243]
random-effects B-LOC [1.7609052658081055, -1.6383440494537354]
estimates B-LOC [1.247523307800293, -1.3737223148345947]
of B-LOC [1.5850050449371338, -1.6723947525024414]
prevalence, B-LOC [1.5134179592132568, -1.4016366004943848]
were B-LOC [1.0802958011627197, -1.1546416282653809]
depression B-LOC [1.2045409679412842, -1.0420149564743042]
(19% B-LOC [0.8686308860778809, -1.2087063789367676]
[95% B-LOC [0.41258370876312256, -0.9553083777427673]
CI, B-LOC [0.22025194764137268, -0.5508843064308167]
14%-25%]) B-LOC [0.5312058329582214, -0.6867940425872803]
and B-LOC [1.1508033275604248, -1.1898062229156494]
binge B-LOC [0.8072026371955872, -0.8458914160728455]
eating B-LOC [0.7595638036727905, -1.119659185409546]
disorder B-LOC [0.8016178011894226, -0.8674368262290955]
(17% B-LOC [0.8531091809272766, -1.1301970481872559]
[95% B-LOC [0.9030768275260925, -1.2125718593597412]
CI, B-LOC [0.08711782097816467, -0.3573908507823944]
13%-21%]). B-LOC [0.5920067429542542, -0.7197944521903992]
There B-LOC [2.3090670108795166, -2.1608026027679443]
was B-LOC [2.3192949295043945, -2.371356725692749]
conflicting B-LOC [2.545529365539551, -2.695810079574585]
evidence B-LOC [2.4348905086517334, -2.5185155868530273]
regarding B-LOC [2.4845969676971436, -2.6750874519348145]
the B-LOC [2.5366506576538086, -2.816697835922241]
association B-LOC [2.2736802101135254, -2.6564571857452393]
between B-LOC [2.2607486248016357, -2.8874142169952393]
preoperative B-LOC [2.0074751377105713, -2.6776065826416016]
mental B-LOC [1.9876309633255005, -2.4145309925079346]
health B-LOC [2.213343620300293, -2.694363594055176]
conditions B-LOC [2.205453872680664, -2.5090909004211426]
and B-LOC [2.236172676086426, -2.6454784870147705]
postoperative B-LOC [2.2402286529541016, -2.5638632774353027]
weight B-LOC [2.1637299060821533, -2.6802074909210205]
loss. B-LOC [2.032309055328369, -2.520418167114258]
Neither B-LOC [1.1560741662979126, -1.6075621843338013]
depression B-LOC [1.2676401138305664, -1.3067641258239746]
nor B-LOC [1.3168531656265259, -1.6709163188934326]
binge B-LOC [1.2889820337295532, -1.3764851093292236]
eating B-LOC [1.4137134552001953, -1.8303470611572266]
disorder B-LOC [1.1448060274124146, -1.5197477340698242]
was B-LOC [1.546811580657959, -1.6889195442199707]
consistently B-LOC [1.357627272605896, -1.767392635345459]
associated B-LOC [1.4367353916168213, -1.8510496616363525]
with B-LOC [1.2845813035964966, -1.8629649877548218]
differences B-LOC [1.5776827335357666, -2.3952009677886963]
in B-LOC [1.213534951210022, -2.1876742839813232]
weight B-LOC [1.2123522758483887, -1.6088504791259766]
outcomes. B-LOC [1.282922387123108, -1.8354265689849854]
Bariatric B-LOC [0.08667164295911789, -0.13167336583137512]
surgery B-LOC [0.070840984582901, -0.17624907195568085]
was, B-LOC [0.1212056428194046, -0.40753254294395447]
however, B-LOC [0.28423866629600525, -0.5609608888626099]
consistently B-LOC [0.20891150832176208, -0.36611026525497437]
associated B-LOC [0.015743201598525047, -0.027977759018540382]
with B-LOC [-0.16246217489242554, -0.2564225494861603]

postoperative O [-0.45619645714759827, 0.18507930636405945]
decreases O [-0.31444111466407776, 0.10925082117319107]
in O [-0.37162747979164124, 0.05963079258799553]
the O [-0.3418078124523163, 0.06204383447766304]
prevalence O [-0.2736258804798126, 0.11030437797307968]
of O [-0.41532984375953674, 0.04512769728899002]
depression O [-0.15489698946475983, 0.24605891108512878]
(7 O [-0.39814630150794983, 0.04254183545708656]
studies; O [-0.40159210562705994, 0.2150462567806244]
8%-74% O [-0.4536433517932892, 0.30723342299461365]
decrease) O [-0.29423484206199646, -0.013799527660012245]
and O [-0.3099741041660309, 0.0402861163020134]
the O [-0.26924213767051697, 0.09169887006282806]
severity O [-0.17434628307819366, -0.025946663692593575]
of O [-0.3435065448284149, -0.021590406075119972]
depressive O [-0.291486531496048, 0.08827361464500427]
symptoms O [-0.12936656177043915, -0.040445733815431595]
(6 O [-0.30228593945503235, -0.02158779464662075]
studies; O [-0.3483637869358063, 0.15527714788913727]
40%-70% O [-0.2616780400276184, 0.17254090309143066]
decrease). O [-0.10837946832180023, -0.0886501595377922]
CONCLUSIONS O [-0.3652675449848175, -0.02365012653172016]
AND B-LOC [0.7263471484184265, -1.3094725608825684]
RELEVANCE B-LOC [0.45897746086120605, -1.0197117328643799]
Mental B-LOC [1.388068675994873, -1.506105899810791]
health B-LOC [1.4171313047409058, -1.7529014348983765]
conditions B-LOC [1.511523723602295, -1.5957396030426025]
are B-LOC [1.4754321575164795, -1.6382229328155518]
common B-LOC [1.49017333984375, -1.5127835273742676]
among B-LOC [1.3203630447387695, -1.59541916847229]
bariatric B-LOC [1.4276779890060425, -2.023852586746216]
surgery B-LOC [1.196925163269043, -1.6312999725341797]
patients-in B-LOC [1.5903432369232178, -1.401759147644043]
particular, B-LOC [1.7029308080673218, -1.7517430782318115]
depression B-LOC [1.556769609451294, -1.2895653247833252]
and B-LOC [1.185070514678955, -1.2586973905563354]
binge B-LOC [1.2853057384490967, -1.1896543502807617]
eating B-LOC [1.3511587381362915, -1.6644177436828613]
disorder. B-LOC [1.170284390449524, -1.214319109916687]
There B-LOC [2.2622058391571045, -2.1224138736724854]
is B-LOC [2.6508123874664307, -2.211858034133911]
inconsistent B-LOC [2.5169217586517334, -2.554436445236206]
evidence B-LOC [2.448521852493286, -2.517824172973633]
regarding B-LOC [2.478307008743286, -2.6036524772644043]
the B-LOC [2.4884049892425537, -2.7875945568084717]
association B-LOC [2.2262275218963623, -2.5817582607269287]
between B-LOC [2.112194776535034, -2.7960479259490967]
preoperative B-LOC [2.0711872577667236, -2.534555196762085]
mental B-LOC [1.9720737934112549, -2.161562204360962]
health B-LOC [2.237858772277832, -2.6509673595428467]
conditions B-LOC [2.201244831085205, -2.4011902809143066]
and B-LOC [2.180298089981079, -2.6217782497406006]
postoperative B-LOC [2.2742152214050293, -2.478605031967163]
weight B-LOC [2.201413154602051, -2.483424186706543]
loss. B-LOC [2.0423152446746826, -2.248695135116577]
Moderate-quality B-LOC [0.74508136510849, -0.756033718585968]
evidence B-LOC [0.6149660348892212, -0.6698333621025085]
supports B-LOC [0.8453803658485413, -0.6576685309410095]
an B-LOC [0.7082218527793884, -0.8357331156730652]
association B-LOC [0.6513960361480713, -0.8667929768562317]
between B-LOC [0.5953728556632996, -0.9753453135490417]
bariatric B-LOC [0.5415943264961243, -1.046454668045044]
surgery B-LOC [0.288295716047287, -0.5832390189170837]
and B-LOC [0.8745540976524353, -0.8945112824440002]
lower B-LOC [0.5886597633361816, -0.8111213445663452]
rates B-LOC [0.44623222947120667, -0.8516286015510559]
of B-LOC [0.23706799745559692, -0.7281984686851501]
depression B-LOC [0.7819345593452454, -0.8034916520118713]
postoperatively. B-LOC [0.40648430585861206, -0.5333709120750427]

Inflammation B-LOC [1.7537668943405151, -2.2740108966827393]
induced B-LOC [1.9257968664169312, -2.1485908031463623]
by B-LOC [1.6925559043884277, -2.014143228530884]
recognition B-LOC [1.9462459087371826, -2.122561454772949]
of B-LOC [1.9205904006958008, -2.4134044647216797]
pathogen-associated B-LOC [2.3660120964050293, -2.7533700466156006]
molecular B-LOC [2.151240825653076, -2.6020405292510986]
patterns B-LOC [2.0794899463653564, -2.510404109954834]
markedly B-LOC [2.301098108291626, -2.641819953918457]
affects B-LOC [2.1809167861938477, -2.7172353267669678]
subsequent B-LOC [2.07295298576355, -2.6547610759735107]
adaptive B-LOC [2.2879767417907715, -2.9327995777130127]
responses. B-LOC [2.3753230571746826, -2.8491432666778564]
We B-LOC [1.9215147495269775, -2.2257766723632812]
asked B-LOC [2.671717882156372, -2.74810528755188]
whether B-LOC [2.8589980602264404, -3.1431148052215576]
the B-LOC [2.578552007675171, -3.088505744934082]
adaptive B-LOC [2.2671163082122803, -3.1309964656829834]
immune B-LOC [2.274498701095581, -2.9323246479034424]
system B-LOC [1.8927685022354126, -2.630265951156616]
can B-LOC [2.551910638809204, -3.195729970932007]
also B-LOC [2.707454204559326, -3.100715160369873]
affect B-LOC [2.3367464542388916, -3.1988365650177]
the B-LOC [2.761488199234009, -3.1795437335968018]
character B-LOC [2.7084343433380127, -3.30527925491333]
and B-LOC [2.603191614151001, -3.185499906539917]
magnitude B-LOC [2.7132818698883057, -3.3602330684661865]
of B-LOC [2.3888676166534424, -3.1474289894104004]
innate B-LOC [2.2950470447540283, -3.1878082752227783]
inflammatory B-LOC [2.319814920425415, -2.822556257247925]
responses. B-LOC [2.3586442470550537, -2.8016550540924072]
We O [-0.8394529223442078, 0.5316367745399475]
found O [-1.0974329710006714, 0.786482036113739]
that O [-1.344538688659668, 0.8432915806770325]
the O [-1.0320212841033936, 0.9358411431312561]
response O [-0.9299941062927246, 1.0161387920379639]
of O [-1.0538227558135986, 1.0601283311843872]
memory, O [-0.9246565699577332, 1.0030550956726074]
but O [-1.138331651687622, 1.2558025121688843]
not O [-0.9789713621139526, 1.3197658061981201]
naive, O [-1.0672338008880615, 1.0229480266571045]
CD4+ O [-0.8785920739173889, 1.2915289402008057]
T O [-1.036482334136963, 0.9380688071250916]
cells O [-0.981477677822113, 1.0258229970932007]
enhances O [-1.015344262123108, 1.0443710088729858]
production O [-0.9913369417190552, 1.066043734550476]
of O [-1.1595489978790283, 1.1507320404052734]
multiple O [-0.9504311084747314, 0.9685623049736023]
innate O [-1.108577847480774, 1.208042860031128]
inflammatory O [-0.8220008611679077, 0.8092231154441833]
cytokines O [-0.9687978625297546, 1.0324355363845825]
and O [-1.1534888744354248, 0.910862386226654]
chemokines O [-0.8873484134674072, 0.8628644347190857]
(IICs) O [-0.7662137150764465, 0.6967607140541077]
in O [-1.0870928764343262, 1.0947405099868774]
the O [-1.005258321762085, 1.1885597705841064]
lung O [-0.9535504579544067, 0.7839493155479431]
and O [-1.133523941040039, 0.7687163352966309]
that, O [-1.3313368558883667, 0.7661519646644592]
during O [-1.1061829328536987, 0.709047257900238]
influenza O [-1.0192453861236572, 0.787277340888977]
infection, O [-0.7824112772941589, 0.7349699139595032]
this O [-0.8866403698921204, 0.7795771360397339]
leads O [-0.8048645257949829, 0.7071506381034851]
to O [-0.8432386517524719, 0.7328606247901917]
early O [-0.9120877385139465, 0.7747560143470764]
control O [-0.744390606880188, 0.5376678109169006]
of O [-0.6357408165931702, 0.4617242217063904]
virus. O [-0.47990110516548157, 0.321353942155838]
Memory O [-0.31851693987846375, 0.1863330900669098]
CD4+ O [-0.17768774926662445, 0.21213656663894653]
T O [-0.2272588610649109, -0.07145772874355316]
cell–induced O [-0.31053850054740906, 0.10733141005039215]
IICs O [-0.12343266606330872, -0.08559136837720871]
and B-LOC [-0.10026927292346954, -0.17948785424232483]
viral B-LOC [-0.17078348994255066, -0.2333645522594452]
control O [-0.33461660146713257, -0.03822965547442436]
require B-LOC [-0.25784361362457275, -0.30731162428855896]

cognate B-LOC [-0.0420273132622242, -0.10765653848648071]
antigen B-LOC [0.20423167943954468, 0.08484205603599548]
recognition O [0.08418674767017365, 0.16405242681503296]
and O [-0.08340277522802353, 0.22391346096992493]
are O [-0.0925973504781723, 0.13789169490337372]
optimal O [-0.12286969274282455, 0.1985936462879181]
when O [-0.2499767541885376, 0.12195323407649994]
memory O [-0.18433991074562073, 0.3762229382991791]
cells O [-0.31819918751716614, 0.4036673605442047]
are O [-0.07811077684164047, 0.1988968551158905]
either O [-0.024020066484808922, 0.05413564667105675]
T O [-0.0898003876209259, 0.13848726451396942]
helper O [0.1563456505537033, 0.21307438611984253]
type O [0.11133159697055817, 0.26261964440345764]
1 B-LOC [0.18226748704910278, -0.08056393265724182]
(TH1) B-LOC [0.2916437089443207, -0.17336997389793396]
or O [-0.06473468244075775, -0.05708438530564308]
TH17 O [-0.09359817951917648, 0.040133554488420486]
polarized O [-0.10884638130664825, 0.10860110819339752]
but O [-0.2828463613986969, 0.4329121708869934]
are O [-0.18647050857543945, 0.4816202223300934]
independent O [-0.20049834251403809, 0.4446045756340027]
of O [-0.4077395498752594, 0.10671018809080124]
interferon-γ O [-0.36653009057044983, 0.19413600862026215]
(IFN-γ) O [-0.03786376863718033, 0.022088995203375816]
and O [-0.4781118333339691, 0.3694070279598236]
tumor O [-0.18968656659126282, 0.12557606399059296]
necrosis O [-0.348972886800766, 0.218753844499588]
factor-α O [-0.348677396774292, 0.19995662569999695]
(TNF-α) B-LOC [0.09400342404842377, -0.130663201212883]
production O [-0.2671789824962616, 0.40675702691078186]
and O [-0.5427874326705933, 0.6260188817977905]
do O [-0.16943895816802979, 0.4576529264450073]
not O [-0.08614327758550644, 0.5233830809593201]
require O [-0.29759469628334045, 0.09898953139781952]
activation O [-0.08653692156076431, 0.24625486135482788]
of O [-0.1726902723312378, -0.1423831582069397]
conserved B-LOC [0.01704142428934574, -0.25243380665779114]
pathogen B-LOC [-0.09521973133087158, -0.12421776354312897]
recognition O [0.0525638721883297, 0.07638759911060333]
pathways. O [-0.15702393651008606, 0.07577486336231232]
This B-LOC [0.607236921787262, -0.7682886719703674]
represents B-LOC [0.9170183539390564, -0.8128608465194702]
a B-LOC [0.775985062122345, -0.7801399230957031]
previously B-LOC [1.317260503768921, -1.1674669981002808]
undescribed B-LOC [1.7533811330795288, -1.404837965965271]
mechanism B-LOC [0.3415427505970001, -0.9147993326187134]
by B-LOC [0.36303582787513733, -0.48060038685798645]
which B-LOC [0.6429013609886169, -0.8930867314338684]
memory B-LOC [0.5909073948860168, -0.6101557612419128]
CD4+ B-LOC [0.3464997112751007, -0.255735844373703]
T B-LOC [0.23608428239822388, -0.5391393899917603]
cells B-LOC [0.10569704324007034, -0.38029924035072327]
induce B-LOC [0.21386045217514038, -0.2912537157535553]
an B-LOC [0.40800154209136963, -0.5457426905632019]
early B-LOC [0.33268436789512634, -0.5486429333686829]
innate B-LOC [0.3817937672138214, -0.725045382976532]
response B-LOC [0.06833940744400024, -0.5886595845222473]
that B-LOC [0.22488176822662354, -0.7799464464187622]
enhances B-LOC [0.540592610836029, -0.7460898160934448]
immune B-LOC [0.6273006796836853, -1.0501497983932495]
protection B-LOC [0.6423856616020203, -0.7973018884658813]
against B-LOC [0.4985295236110687, -0.5332415103912354]
pathogens. B-LOC [0.6161412596702576, -0.9597418904304504]

Using B-LOC [1.9501906633377075, -3.1291236877441406]
the B-LOC [3.1472411155700684, -3.3526077270507812]
Princeton B-LOC [2.537897825241089, -3.055529832839966]
School B-LOC [2.9118213653564453, -3.6422977447509766]
District B-LOC [2.9870595932006836, -3.8464243412017822]
Family B-LOC [2.995184898376465, -3.487813949584961]
Study B-LOC [2.9881675243377686, -3.661412239074707]
cohort, B-LOC [3.2458250522613525, -3.621462106704712]
our B-LOC [2.623474359512329, -3.53879714012146]
specific B-LOC [3.1328999996185303, -3.8307955265045166]
aim B-LOC [3.177828073501587, -3.6852402687072754]
was B-LOC [2.800443649291992, -3.4743125438690186]
to B-LOC [3.014791965484619, -3.72505784034729]
estimate B-LOC [2.9204905033111572, -3.764158010482788]
the B-LOC [3.201796293258667, -3.86281418800354]
prevalence B-LOC [3.220209836959839, -3.7498648166656494]
of B-LOC [3.0209367275238037, -3.8102223873138428]
suspected B-LOC [2.979003429412842, -3.817500591278076]
familial B-LOC [3.1246187686920166, -3.8341591358184814]
ponderosity B-LOC [2.813937187194824, -3.420926332473755]
and B-LOC [2.766059160232544, -3.628490447998047]
leanness, B-LOC [2.8818461894989014, -3.528144598007202]
to B-LOC [2.8443801403045654, -3.6215035915374756]
provide B-LOC [2.947110891342163, -3.676225185394287]
empirical B-LOC [2.9076743125915527, -3.792248487472534]
risk B-LOC [3.1026015281677246, -3.6491379737854004]
estimates B-LOC [2.9900386333465576, -3.6498453617095947]
for B-LOC [3.0072991847991943, -3.536747932434082]
the B-LOC [3.1329545974731445, -3.741722345352173]
proportion B-LOC [3.0610618591308594, -3.6555325984954834]
of B-LOC [2.931211233139038, -3.5184133052825928]
probands' B-LOC [2.7207744121551514, -3.4750449657440186]
first-degree B-LOC [2.9390037059783936, -3.5599331855773926]
relatives B-LOC [3.0578091144561768, -3.5913774967193604]
who B-LOC [2.938516855239868, -3.63543701171875]
were B-LOC [2.8554575443267822, -3.5524961948394775]
similarly B-LOC [2.881249189376831, -3.516540288925171]
affected, B-LOC [3.0309295654296875, -3.523461103439331]
and B-LOC [2.8045387268066406, -3.3251898288726807]
to B-LOC [3.029006242752075, -3.667167901992798]
estimate B-LOC [2.952584981918335, -3.7647030353546143]
the B-LOC [3.1385691165924072, -3.8002655506134033]
contributions B-LOC [2.850254535675049, -3.7242090702056885]
of B-LOC [2.885662078857422, -3.6478641033172607]
diseases, B-LOC [3.272742748260498, -3.6266114711761475]
drugs B-LOC [3.059913396835327, -3.7242376804351807]
and B-LOC [2.961207628250122, -3.678461790084839]
caloric B-LOC [3.236638307571411, -3.8928921222686768]
intake B-LOC [2.8860480785369873, -3.4514901638031006]
to B-LOC [2.9046528339385986, -3.6239962577819824]
relative B-LOC [2.9439103603363037, -3.809907913208008]
obesity B-LOC [2.8459668159484863, -3.7436368465423584]
and B-LOC [2.8498423099517822, -3.5954437255859375]
leanness. B-LOC [2.875094175338745, -3.4730870723724365]
We B-LOC [1.7857229709625244, -2.0861258506774902]
studied B-LOC [2.2897818088531494, -2.4969451427459717]
379 B-LOC [2.6370961666107178, -2.8332412242889404]
probands, B-LOC [1.9431285858154297, -2.0881011486053467]
125 B-LOC [2.296704053878784, -2.796236753463745]
whites B-LOC [2.3705217838287354, -2.614886999130249]
and B-LOC [1.9535887241363525, -2.5935893058776855]
52 B-LOC [2.406403064727783, -2.5945427417755127]
blacks B-LOC [2.263471841812134, -2.6222074031829834]
from B-LOC [2.2011942863464355, -2.8749704360961914]
a B-LOC [2.4097092151641846, -2.7332777976989746]
random B-LOC [2.8024823665618896, -3.1066105365753174]
recall B-LOC [2.273329496383667, -2.5706398487091064]
group, B-LOC [2.536303758621216, -2.756328821182251]
147 B-LOC [2.1783251762390137, -2.5589241981506348]
whites B-LOC [2.400851011276245, -2.43107008934021]
and B-LOC [1.909968376159668, -2.5406715869903564]
55 B-LOC [2.1865928173065186, -2.5490691661834717]
blacks B-LOC [2.1790878772735596, -2.577462911605835]
from B-LOC [2.1125073432922363, -2.6472764015197754]
a B-LOC [2.208574056625366, -2.505157709121704]
hyperlipidemic B-LOC [2.4776134490966797, -2.643068313598633]
recall B-LOC [2.1331820487976074, -2.3757705688476562]
group. B-LOC [2.172950506210327, -2.471588373184204]
Suspected B-LOC [2.046705961227417, -2.4521291255950928]
familial B-LOC [1.8136239051818848, -2.0257701873779297]

obesity B-LOC [0.9772471785545349, -1.3821606636047363]
and B-LOC [1.742447018623352, -1.864477515220642]
leanness B-LOC [1.4344837665557861, -1.6430913209915161]
were B-LOC [1.5114781856536865, -1.8908555507659912]
arbitrarily B-LOC [1.99576997756958, -2.0413103103637695]
identified B-LOC [1.6681859493255615, -1.837378978729248]
in B-LOC [1.5384035110473633, -1.9192519187927246]
those B-LOC [1.5328562259674072, -1.8111200332641602]
kindreds B-LOC [1.8908791542053223, -1.9180309772491455]
with B-LOC [1.7633596658706665, -2.043381929397583]
at B-LOC [1.950165867805481, -1.8491297960281372]
least B-LOC [1.8168015480041504, -1.9038567543029785]
two B-LOC [1.7295957803726196, -2.0647659301757812]
first-degree B-LOC [1.6402575969696045, -1.91080904006958]
relatives B-LOC [1.8603055477142334, -2.0139925479888916]
in B-LOC [1.7496418952941895, -1.8772159814834595]
the B-LOC [1.7980225086212158, -1.7895147800445557]
same B-LOC [1.64225435256958, -1.812010407447815]
Quetelet B-LOC [1.257721185684204, -1.5740807056427002]
index B-LOC [1.4637234210968018, -1.8200902938842773]
decile B-LOC [1.7616381645202637, -1.666010856628418]
as B-LOC [1.6287710666656494, -2.0302960872650146]
the B-LOC [1.7894706726074219, -1.9264483451843262]
proband, B-LOC [1.454363226890564, -1.7448880672454834]
top B-LOC [1.6478439569473267, -2.2139647006988525]
or B-LOC [1.7707672119140625, -1.9554100036621094]
bottom B-LOC [1.9849708080291748, -2.1415765285491943]
respectively. B-LOC [1.631159782409668, -2.17946457862854]
Suspected B-LOC [0.5969153046607971, -0.6902787089347839]
familial B-LOC [0.6174355745315552, -0.5849726796150208]
obesity B-LOC [0.6998036503791809, -0.6127817034721375]
was B-LOC [0.609419047832489, -0.6461009383201599]
observed B-LOC [0.5342229604721069, -0.4600757658481598]
in B-LOC [0.4744219481945038, -0.5395700335502625]
2.4 B-LOC [0.7021026015281677, -0.38275957107543945]
percent B-LOC [0.6365395784378052, -0.7242164611816406]
and B-LOC [0.5083703994750977, -0.6281887888908386]
6 B-LOC [0.8313553333282471, -0.7183557152748108]
percent B-LOC [0.6543942093849182, -0.6902283430099487]
respectively B-LOC [0.5119509696960449, -0.9715644717216492]
of B-LOC [0.4479491710662842, -0.5176133513450623]
random B-LOC [0.8042603135108948, -0.7488418817520142]
and B-LOC [0.6968547701835632, -0.7876093983650208]
hyperlipidemic B-LOC [0.8051381707191467, -0.8021894097328186]
recall B-LOC [0.7695630788803101, -0.7330562472343445]
group B-LOC [0.8077402114868164, -0.6345561146736145]
whites. B-LOC [0.7467369437217712, -0.7993333339691162]
Suspected B-LOC [0.1679142862558365, -0.1861826479434967]
familial B-LOC [0.26117244362831116, -0.16666239500045776]
leanness B-LOC [0.22021639347076416, -0.09418506175279617]
was B-LOC [0.24199146032333374, -0.32397031784057617]
identified B-LOC [0.2078131139278412, -0.058935705572366714]
in B-LOC [0.14564085006713867, -0.22782546281814575]
2.4 B-LOC [0.13363878428936005, 0.04885434731841087]
percent B-LOC [0.37132877111434937, -0.45338934659957886]
and B-LOC [-0.06254546344280243, -0.29997754096984863]
1.4 B-LOC [0.2850058376789093, -0.23704925179481506]
percent B-LOC [0.31665846705436707, -0.4695180356502533]
of B-LOC [0.26101237535476685, -0.24839362502098083]
random B-LOC [0.5162039995193481, -0.36073973774909973]
and B-LOC [0.2315235286951065, -0.45870450139045715]
hyperlipidemic B-LOC [0.4242710471153259, -0.2831663489341736]
recall B-LOC [0.5260403156280518, -0.37996944785118103]
whites B-LOC [0.48648878931999207, -0.5010160803794861]
and B-LOC [0.04679922014474869, -0.2560676336288452]
in B-LOC [0.13735438883304596, -0.14733675122261047]
3.8 B-LOC [0.12261220812797546, 0.0519254170358181]
percent B-LOC [0.33794358372688293, -0.508621871471405]
of B-LOC [0.2728980481624603, -0.300918847322464]
randomly B-LOC [0.458601713180542, -0.4115898013114929]
recalled B-LOC [0.43642374873161316, -0.5228602290153503]
blacks. B-LOC [0.3997063934803009, -0.6228882670402527]

Approximately B-LOC [0.6653594374656677, -0.7759373784065247]
twice B-LOC [0.7790187001228333, -0.7528718113899231]
as B-LOC [0.8177094459533691, -0.5981000065803528]
many B-LOC [0.8062164783477783, -0.7814850807189941]
as B-LOC [0.7637522220611572, -0.6812589168548584]
expected B-LOC [0.8334924578666687, -0.7383422255516052]
white B-LOC [0.8276012539863586, -0.82133549451828]
first-degree B-LOC [0.7741517424583435, -0.9244920611381531]
relatives B-LOC [1.0125102996826172, -0.9727457761764526]
of B-LOC [0.8387531638145447, -0.8769534230232239]
top B-LOC [0.7340657114982605, -0.9430564641952515]
Quetelet B-LOC [0.7366883754730225, -0.8727815747261047]
index B-LOC [0.8932972550392151, -0.9289786219596863]
decile B-LOC [0.8768821954727173, -0.8561452031135559]
probands B-LOC [0.9540141224861145, -1.1460195779800415]
themselves B-LOC [0.5941635966300964, -0.9482526779174805]
had B-LOC [0.7724501490592957, -0.8856530785560608]
top B-LOC [0.8613074421882629, -0.9746748208999634]
decile B-LOC [0.7264532446861267, -0.7681114673614502]
Quetelet B-LOC [0.6764568090438843, -0.8498415946960449]
indices; B-LOC [0.9768213629722595, -1.16836678981781]
approximately B-LOC [0.7226750254631042, -0.7297058701515198]
three B-LOC [0.9960888028144836, -0.8120676875114441]
times B-LOC [1.0332868099212646, -0.8180679082870483]
as B-LOC [0.9925107955932617, -0.7060070037841797]
many B-LOC [0.8764333128929138, -0.774533212184906]
as B-LOC [0.8511108756065369, -0.781840443611145]
expected B-LOC [0.8422439098358154, -0.8558034300804138]
first-degree B-LOC [1.0293165445327759, -1.0176959037780762]
relatives B-LOC [1.1437036991119385, -1.008310079574585]
of B-LOC [0.9209004640579224, -0.8079466819763184]
bottom B-LOC [1.078554391860962, -0.9922941327095032]
decile B-LOC [0.9765454530715942, -0.8486074805259705]
Quetelet B-LOC [0.7554752230644226, -0.9856966137886047]
index B-LOC [0.9821860194206238, -0.9875149130821228]
probands B-LOC [1.1710665225982666, -1.1604418754577637]
themselves B-LOC [0.9796389937400818, -0.9533125758171082]
had B-LOC [0.9507235288619995, -0.9059409499168396]
bottom B-LOC [1.1219043731689453, -1.0380947589874268]
decile B-LOC [0.8913285732269287, -0.7906926274299622]
Quetelet B-LOC [0.800153374671936, -0.9916595816612244]
indices. B-LOC [1.118295669555664, -1.1887110471725464]
Nineteen B-LOC [0.2666243016719818, 0.009901285171508789]
percent B-LOC [0.22584268450737, -0.26829949021339417]
and B-LOC [-0.03149633854627609, -0.15290093421936035]
31 B-LOC [0.5922474265098572, -0.1869826316833496]
percent B-LOC [0.29257914423942566, -0.4371558129787445]
of B-LOC [0.30869123339653015, -0.29741227626800537]
top B-LOC [0.29141104221343994, -0.49740299582481384]
decile B-LOC [0.39219537377357483, -0.4064967930316925]
Quetelet B-LOC [0.4977991282939911, -0.6331647634506226]
index B-LOC [0.37348687648773193, -0.3743050694465637]
white B-LOC [0.4283556044101715, -0.48966655135154724]
probands B-LOC [0.3413812220096588, -0.38776224851608276]
from B-LOC [0.37604764103889465, -0.16109336912631989]
random B-LOC [0.4321259558200836, -0.4740021824836731]
and B-LOC [0.25629621744155884, -0.4443031847476959]
hyperlipidemic B-LOC [0.6015962362289429, -0.5328375101089478]
recall B-LOC [0.3545897603034973, -0.46115145087242126]
groups B-LOC [0.32524585723876953, -0.30903980135917664]
came B-LOC [0.40268927812576294, -0.2124449610710144]
from B-LOC [0.3284000754356384, -0.153206005692482]
families B-LOC [0.244866281747818, -0.22877389192581177]
where B-LOC [0.07161621004343033, -0.4234292507171631]
at B-LOC [0.44579923152923584, -0.24362577497959137]
least B-LOC [0.4154207408428192, -0.38702452182769775]
two B-LOC [0.3180815875530243, -0.3494609296321869]
other B-LOC [0.23474319279193878, -0.206364706158638]
first-degree B-LOC [0.268903911113739, -0.33575955033302307]
relatives B-LOC [0.38837772607803345, -0.4795546233654022]
were B-LOC [0.30773505568504333, -0.21868452429771423]
similarly B-LOC [0.24076932668685913, -0.26085084676742554]
obese; B-LOC [0.1806291788816452, -0.05938701704144478]
18 B-LOC [0.21266046166419983, 0.025607621297240257]
percent B-LOC [0.24531637132167816, -0.2672499418258667]
and B-LOC [0.08598316460847855, -0.2979336678981781]
20 B-LOC [0.4431550204753876, -0.14333607256412506]
percent B-LOC [0.2560442388057709, -0.3447651267051697]
of B-LOC [0.15158095955848694, -0.12156632542610168]
white B-LOC [0.43723568320274353, -0.2371189147233963]
random B-LOC [0.12845154106616974, -0.28798654675483704]
and B-LOC [0.018820414319634438, -0.32712677121162415]

hyperlipidemic B-LOC [0.16248242557048798, 0.00028511654818430543]
recall B-LOC [0.32279089093208313, -0.059971604496240616]
group B-LOC [0.3136533796787262, -0.0796794444322586]
probands B-LOC [0.3802812397480011, -0.29043444991111755]
with B-LOC [0.31476739048957825, -0.2249496728181839]
bottom B-LOC [0.36403515934944153, -0.27168095111846924]
decile B-LOC [0.25453293323516846, -0.2536565363407135]
Quetelet B-LOC [0.2555753290653229, -0.42081940174102783]
indices B-LOC [0.4263787865638733, -0.38135167956352234]
had B-LOC [0.19143566489219666, -0.30312302708625793]
suspected B-LOC [0.34135064482688904, -0.14930841326713562]
familial B-LOC [0.3582801818847656, -0.3955075442790985]
leanness. B-LOC [0.43746063113212585, -0.3381839394569397]
Nearly B-LOC [0.8665357232093811, -0.7245901823043823]
all B-LOC [0.8104789853096008, -0.7182746529579163]
subjects B-LOC [0.5941534042358398, -0.8167014718055725]
with B-LOC [0.7904148697853088, -0.8990179896354675]
familial B-LOC [0.7539870142936707, -1.020689606666565]
obesity B-LOC [0.5753909349441528, -0.9578704237937927]
or B-LOC [0.6814196109771729, -0.912839412689209]
leanness B-LOC [0.8208468556404114, -0.858043372631073]
had B-LOC [0.6402040123939514, -0.683722734451294]
no B-LOC [0.7363436818122864, -0.5936540961265564]
overt B-LOC [0.5461171269416809, -0.7376523017883301]
metabolic B-LOC [0.5150375962257385, -0.7292602062225342]
or B-LOC [0.6574321389198303, -1.0798273086547852]
pharmacological B-LOC [0.7307935953140259, -1.0481853485107422]
explanations B-LOC [0.6226217150688171, -0.882878839969635]
for B-LOC [0.7364148497581482, -1.015129804611206]
their B-LOC [0.8768103718757629, -0.8988157510757446]
body B-LOC [0.5601957440376282, -0.8146457672119141]
habitus. B-LOC [0.8621302247047424, -0.9069578051567078]
Within-family B-LOC [1.3797473907470703, -1.5523269176483154]
clustering B-LOC [1.373652696609497, -1.2243402004241943]
of B-LOC [1.229538917541504, -1.0834178924560547]
hypertension B-LOC [1.0193700790405273, -1.0813500881195068]
was B-LOC [1.2106127738952637, -1.3265485763549805]
common B-LOC [1.2571488618850708, -1.1036878824234009]
in B-LOC [1.0670642852783203, -1.159155011177063]
kindreds B-LOC [1.662103533744812, -1.2502050399780273]
with B-LOC [1.277494192123413, -1.2770779132843018]
suspected B-LOC [1.355764389038086, -1.041892409324646]
familial B-LOC [1.3495407104492188, -1.2904129028320312]
obesity B-LOC [1.2163971662521362, -1.2408602237701416]
and B-LOC [0.731941282749176, -1.0514334440231323]
was B-LOC [1.0098801851272583, -1.2275891304016113]
absent B-LOC [1.2637126445770264, -1.0349217653274536]
in B-LOC [1.1727466583251953, -1.1304435729980469]
kindreds B-LOC [1.5988491773605347, -1.1516733169555664]
with B-LOC [1.3488402366638184, -1.4097315073013306]
suspected B-LOC [1.4473154544830322, -1.290015459060669]
familial B-LOC [1.4500939846038818, -1.5594661235809326]
leanness. B-LOC [1.3951170444488525, -1.4041783809661865]
Marked B-LOC [1.8467450141906738, -2.0796477794647217]
within-family B-LOC [1.9181673526763916, -2.083137035369873]
clustering B-LOC [1.6419038772583008, -1.7377138137817383]
of B-LOC [1.5500390529632568, -2.166930913925171]
both B-LOC [1.572129487991333, -1.8743999004364014]
obesity B-LOC [1.2006007432937622, -1.6379190683364868]
and B-LOC [1.8373368978500366, -1.9921042919158936]
leanness B-LOC [1.3652257919311523, -1.470780372619629]
is B-LOC [2.503687858581543, -2.475583791732788]
useful B-LOC [2.3748650550842285, -2.5771708488464355]
diagnostically; B-LOC [2.235260248184204, -2.5494887828826904]
therapeutic B-LOC [2.0451178550720215, -2.18218731880188]
intervention B-LOC [2.0661392211914062, -2.214409589767456]
to B-LOC [2.548640489578247, -2.072763204574585]
reduce B-LOC [1.9652705192565918, -1.8843934535980225]

obesity, O [-0.10618525743484497, -0.018843429163098335]
to B-LOC [0.34849655628204346, -0.2317337691783905]
be B-LOC [0.35266411304473877, -0.40521523356437683]
most B-LOC [0.37728068232536316, -0.2918066680431366]
effective, B-LOC [0.03586729243397713, -0.12957708537578583]
should B-LOC [0.45233583450317383, -0.3357328474521637]
be B-LOC [0.19929620623588562, -0.15684905648231506]
family-wide B-LOC [0.43273624777793884, -0.20180830359458923]
in B-LOC [0.18745936453342438, -0.10544900596141815]
the B-LOC [0.3679615557193756, -0.22130975127220154]
many B-LOC [0.38279059529304504, -0.7598397135734558]
kindreds B-LOC [0.6397246718406677, -0.32555922865867615]
which B-LOC [0.27939313650131226, -0.7204264998435974]
share B-LOC [0.6727970242500305, -0.6843763589859009]
familial B-LOC [0.606910765171051, -0.5604131817817688]
obesity. B-LOC [0.2883017361164093, -0.3946318030357361]

CONTEXT B-LOC [2.2863500118255615, -3.428234338760376]
The B-LOC [3.605134963989258, -3.870878219604492]
epidemic B-LOC [3.5788609981536865, -3.8483221530914307]
of B-LOC [3.340909481048584, -3.699127435684204]
heart B-LOC [3.4042670726776123, -3.8767149448394775]
failure B-LOC [3.4113152027130127, -3.6848323345184326]
has B-LOC [3.7827975749969482, -3.706650495529175]
yet B-LOC [3.561311960220337, -3.799259662628174]
to B-LOC [3.6080000400543213, -3.6430258750915527]
be B-LOC [3.450364112854004, -3.7989413738250732]
fully B-LOC [3.672567129135132, -3.8008267879486084]
investigated, B-LOC [3.8105876445770264, -3.8368499279022217]
and B-LOC [3.3168108463287354, -3.6572425365448]
data B-LOC [3.5981223583221436, -4.00539493560791]
on B-LOC [3.5275697708129883, -3.9929263591766357]
incidence, B-LOC [3.663282871246338, -3.888239860534668]
survival, B-LOC [3.5929408073425293, -3.894620895385742]
and B-LOC [3.48850417137146, -3.8611655235290527]
sex-specific B-LOC [3.511547803878784, -4.031729698181152]
temporal B-LOC [3.6087281703948975, -3.9683549404144287]
trends B-LOC [3.57008695602417, -3.8973278999328613]
in B-LOC [3.590787649154663, -3.7416560649871826]
community-based B-LOC [3.5307834148406982, -3.9015278816223145]
populations B-LOC [3.660505771636963, -3.9126107692718506]
are B-LOC [3.611215353012085, -3.584882974624634]
limited. B-LOC [3.6238512992858887, -3.7104766368865967]
OBJECTIVE B-LOC [3.0589916706085205, -3.5829713344573975]
To B-LOC [3.2198212146759033, -3.5154972076416016]
test B-LOC [3.26678466796875, -3.689990520477295]
the B-LOC [3.4528377056121826, -3.590493679046631]
hypothesis B-LOC [3.4089696407318115, -3.731320381164551]
that B-LOC [2.971336603164673, -3.541069269180298]
the B-LOC [3.0067825317382812, -3.5203025341033936]
incidence B-LOC [3.2493207454681396, -3.591271162033081]
of B-LOC [2.9073326587677, -3.235686779022217]
heart B-LOC [3.1367685794830322, -3.7270760536193848]
failure B-LOC [2.995509386062622, -3.510044574737549]
has B-LOC [3.1205203533172607, -3.3131368160247803]
declined B-LOC [2.7988967895507812, -3.2240309715270996]
and B-LOC [2.5496726036071777, -3.0927364826202393]
survival B-LOC [3.19230580329895, -3.648179531097412]
after B-LOC [2.793668746948242, -3.134392023086548]
heart B-LOC [3.023963451385498, -3.6085152626037598]
failure B-LOC [3.0169613361358643, -3.4074392318725586]
diagnosis B-LOC [2.8973865509033203, -3.3279213905334473]
has B-LOC [2.9954049587249756, -3.0660719871520996]
improved B-LOC [2.563993215560913, -3.2322304248809814]
over B-LOC [2.5485100746154785, -2.75671124458313]
time B-LOC [3.0155365467071533, -3.3994643688201904]
but B-LOC [2.7943642139434814, -3.1478421688079834]
that B-LOC [2.9712092876434326, -3.5013747215270996]
secular B-LOC [2.9332876205444336, -3.6504249572753906]
trends B-LOC [3.128150224685669, -3.576148271560669]
have B-LOC [3.1245288848876953, -3.240173101425171]
diverged B-LOC [3.113105535507202, -3.663477897644043]
by B-LOC [3.0471861362457275, -3.2159264087677]
sex. B-LOC [3.2071645259857178, -3.9142868518829346]
DESIGN, B-LOC [2.803189516067505, -2.817225694656372]
SETTING, B-LOC [2.4226973056793213, -2.65606951713562]
AND B-LOC [2.7225546836853027, -2.8924596309661865]
PARTICIPANTS B-LOC [2.5875751972198486, -2.7458322048187256]
Population-based B-LOC [2.6435492038726807, -2.766033172607422]
cohort B-LOC [2.8716084957122803, -2.726634979248047]
study B-LOC [2.4842844009399414, -2.904895305633545]
using B-LOC [2.351378917694092, -2.882020950317383]
the B-LOC [2.778627395629883, -2.3006598949432373]
resources B-LOC [2.7375147342681885, -2.5928781032562256]
of B-LOC [2.6974563598632812, -2.2703311443328857]
the B-LOC [2.904480218887329, -2.460569143295288]
Rochester B-LOC [2.2389254570007324, -2.8542044162750244]
Epidemiology B-LOC [2.7290141582489014, -2.870959758758545]
Project B-LOC [2.6150028705596924, -2.4739339351654053]
conducted B-LOC [2.7148592472076416, -2.715832471847534]
in B-LOC [2.806483030319214, -2.641841411590576]
Olmsted B-LOC [2.0704452991485596, -2.5871827602386475]
County, B-LOC [2.6575334072113037, -2.611079216003418]

Minnesota. B-LOC [2.89235520362854, -3.2025840282440186]
Patients B-LOC [3.4542877674102783, -3.36972975730896]
were B-LOC [3.435542583465576, -3.001573324203491]
4537 B-LOC [3.6378822326660156, -3.075984239578247]
Olmsted B-LOC [3.451690435409546, -3.103501558303833]
County B-LOC [3.3960459232330322, -3.0520901679992676]
residents B-LOC [3.580690622329712, -2.979029893875122]
(57% B-LOC [3.444934129714966, -3.2132880687713623]
women; B-LOC [3.4901952743530273, -3.1501033306121826]
mean B-LOC [3.463989496231079, -3.240104913711548]
[SD] B-LOC [3.0479602813720703, -3.0290324687957764]
age, B-LOC [3.6680076122283936, -2.8339877128601074]
74 B-LOC [3.4098660945892334, -2.670700788497925]
[14] B-LOC [3.3651015758514404, -3.070507764816284]
years) B-LOC [3.5655643939971924, -2.87475848197937]
with B-LOC [3.5682411193847656, -2.901637554168701]
a B-LOC [3.4888761043548584, -3.034797430038452]
diagnosis B-LOC [3.6632442474365234, -3.14198899269104]
of B-LOC [3.410061836242676, -3.150485038757324]
heart B-LOC [3.3075709342956543, -3.33260178565979]
failure B-LOC [3.4006803035736084, -3.244321584701538]
between B-LOC [3.6211555004119873, -2.9856555461883545]
1979 B-LOC [3.4246153831481934, -3.0619895458221436]
and B-LOC [3.4188148975372314, -2.8626887798309326]
2000. B-LOC [3.433934450149536, -3.0175564289093018]
Framingham B-LOC [3.365006685256958, -2.9367763996124268]
criteria B-LOC [3.602530002593994, -3.135810613632202]
and B-LOC [3.2098705768585205, -2.9841763973236084]
clinical B-LOC [3.729701280593872, -3.1950843334198]
criteria B-LOC [3.626418352127075, -3.1768484115600586]
were B-LOC [3.512629747390747, -3.0164592266082764]
used B-LOC [3.410507917404175, -3.125465154647827]
to B-LOC [3.412839651107788, -2.917384624481201]
validate B-LOC [3.4488723278045654, -3.153925895690918]
the B-LOC [3.4477908611297607, -2.974766492843628]
diagnosis B-LOC [3.562518358230591, -3.3093464374542236]
MAIN B-LOC [3.399376153945923, -2.9668455123901367]
OUTCOME B-LOC [3.4121270179748535, -2.959350824356079]
MEASURES B-LOC [3.4565320014953613, -3.0616424083709717]
Incidence B-LOC [3.4077529907226562, -3.1275079250335693]
of B-LOC [3.47033429145813, -3.036994695663452]
heart B-LOC [3.533482789993286, -3.343187093734741]
failure B-LOC [3.6197917461395264, -3.324679374694824]
and B-LOC [3.2886998653411865, -2.938539743423462]
survival B-LOC [3.6772351264953613, -3.308328866958618]
after B-LOC [3.6611452102661133, -3.185076951980591]
heart B-LOC [3.525991439819336, -3.280266761779785]
failure B-LOC [3.5660464763641357, -3.3232579231262207]
diagnosis. B-LOC [3.6407976150512695, -3.1088807582855225]
RESULTS O [-0.5030264854431152, 0.10702504217624664]
The O [-0.5074406862258911, 0.17313125729560852]
incidence O [-0.5644141435623169, 0.23308929800987244]
of O [-0.6303075551986694, 0.35737547278404236]
heart O [-0.3358234167098999, 0.3294390141963959]
failure O [-0.43052396178245544, 0.40985748171806335]
was O [-0.5250570178031921, -0.019284727051854134]
higher O [-0.4470236003398895, 0.4122723639011383]
among O [-0.4005657732486725, 0.4372793734073639]
men O [-0.5497206449508667, 0.4855973422527313]
(378/100 O [-0.5515766739845276, 0.38013938069343567]
000 O [-0.4816322326660156, 0.2451895773410797]
persons; O [-0.8808541893959045, 0.38397517800331116]
95% O [-0.7530314326286316, 0.6466826796531677]
confidence O [-0.7012879252433777, 0.6925072073936462]
interval O [-0.7023486495018005, 0.49050241708755493]
[CI], O [-0.551810622215271, 0.44650253653526306]
361-395 O [-0.16520914435386658, 0.8410731554031372]
for O [-0.48487725853919983, 0.3688836395740509]
men; O [-0.5358914136886597, 0.5870600342750549]
289/100 O [-0.25257301330566406, 0.7661413550376892]
000 O [-0.47317826747894287, 0.33078715205192566]
persons; O [-0.8563253283500671, 0.42409783601760864]
95% O [-0.8007996082305908, 0.604532778263092]
CI, O [-0.7115611433982849, 0.4295702278614044]

277-300 B-LOC [0.5019277930259705, -0.7082167267799377]
for B-LOC [0.400059312582016, -1.154473066329956]
women) B-LOC [0.8896910548210144, -1.0448017120361328]
and B-LOC [0.12499591708183289, -0.7515480518341064]
did B-LOC [0.42267248034477234, -0.8400905132293701]
not B-LOC [0.6792088747024536, -0.8604488968849182]
change B-LOC [0.47176793217658997, -1.1320878267288208]
over B-LOC [0.6600130200386047, -1.3049507141113281]
time B-LOC [0.7703678011894226, -1.309220314025879]
among B-LOC [0.7024258971214294, -1.362623929977417]
men B-LOC [0.8638193011283875, -0.9995958209037781]
or B-LOC [0.8701708912849426, -1.4154380559921265]
women. B-LOC [1.008958339691162, -1.2064857482910156]
After B-LOC [0.9582186937332153, -1.336941123008728]
a B-LOC [1.0730230808258057, -1.3789596557617188]
mean B-LOC [1.0949513912200928, -1.4110703468322754]
follow-up B-LOC [0.9848030209541321, -1.5935068130493164]
of B-LOC [0.7791149020195007, -1.3339260816574097]
4.2 B-LOC [1.238663911819458, -1.129823088645935]
years B-LOC [1.2003450393676758, -1.4544873237609863]
(range, B-LOC [1.2554303407669067, -1.3313651084899902]
0-23.8 B-LOC [1.3217084407806396, -1.4634913206100464]
years), B-LOC [1.330984354019165, -1.6730735301971436]
3347 B-LOC [2.0786211490631104, -1.7011134624481201]
deaths B-LOC [1.3875172138214111, -1.8189711570739746]
occurred, B-LOC [1.1420650482177734, -1.7242743968963623]
including B-LOC [1.4904967546463013, -1.6353795528411865]
1930 B-LOC [1.5992190837860107, -1.64003324508667]
among B-LOC [1.1429600715637207, -1.6467289924621582]
women B-LOC [1.2954638004302979, -1.546412706375122]
and B-LOC [1.2874572277069092, -1.5019702911376953]
1417 B-LOC [1.8737235069274902, -1.5616278648376465]
among B-LOC [1.1852000951766968, -1.7494863271713257]
men. B-LOC [1.3144288063049316, -1.7280415296554565]
Survival B-LOC [0.4017241895198822, -0.5909712910652161]
after B-LOC [0.02956720069050789, -0.22949489951133728]
heart B-LOC [0.21378937363624573, -0.3923702836036682]
failure B-LOC [0.046331290155649185, -0.19559167325496674]
diagnosis B-LOC [-0.0956190824508667, -0.12467503547668457]
was B-LOC [0.16027018427848816, -0.4695459306240082]
worse B-LOC [0.2516864240169525, -0.2809034287929535]
among B-LOC [0.24201488494873047, -0.3829457461833954]
men B-LOC [0.3491680324077606, -0.2997542917728424]
than B-LOC [-0.06414224207401276, -0.18677394092082977]
women B-LOC [0.4074101746082306, -0.28731733560562134]
(relative B-LOC [0.15471917390823364, -0.15799182653427124]
risk, B-LOC [-0.03978100046515465, -0.0797887071967125]
1.33; B-LOC [0.19951191544532776, -0.0015151374973356724]
95% B-LOC [0.09708818793296814, 0.057098038494586945]
CI, O [-0.20039020478725433, -0.11759167164564133]
1.24-1.43) B-LOC [0.14172577857971191, 0.10234634578227997]
but B-LOC [0.36145687103271484, -0.3775958716869354]
overall B-LOC [0.24714846909046173, -0.35171082615852356]
improved B-LOC [0.4073026180267334, -0.532139003276825]
over B-LOC [0.24345196783542633, -0.5065634250640869]
time B-LOC [0.5810006260871887, -0.7500181198120117]
(5-year B-LOC [0.42940789461135864, -0.5166685581207275]
age-adjusted B-LOC [0.7824109196662903, -0.6480514407157898]
survival, B-LOC [0.4751437306404114, -0.6624141931533813]
43% B-LOC [0.8395470976829529, -0.2146379053592682]
in B-LOC [0.2800000011920929, -0.6877083778381348]
1979-1984 B-LOC [0.3490058481693268, -0.6683067679405212]
vs B-LOC [0.19801999628543854, -0.5121176838874817]
52% B-LOC [0.788206160068512, -0.2410716563463211]
in B-LOC [0.4426629841327667, -0.7724817991256714]
1996-2000, B-LOC [0.7026943564414978, -0.6723905205726624]
P<.001). B-LOC [0.29382216930389404, -0.5256397724151611]
However, B-LOC [0.5480613708496094, -0.5580329298973083]
men B-LOC [0.6023143529891968, -0.6268265843391418]
and B-LOC [0.39212411642074585, -0.7083215117454529]
younger B-LOC [0.933489978313446, -0.7261741757392883]
persons B-LOC [0.3713724911212921, -0.6508220434188843]

experienced B-LOC [0.25385725498199463, -0.596128523349762]
larger B-LOC [0.5701459646224976, -0.5752136707305908]
survival B-LOC [0.7128276824951172, -0.9392253756523132]
gains, B-LOC [0.6830597519874573, -0.6509298086166382]
contrasting B-LOC [0.5331119298934937, -0.3662533164024353]
with B-LOC [0.5684667229652405, -0.5114940404891968]
less B-LOC [0.8158912658691406, -0.5820345282554626]
or B-LOC [0.7295222878456116, -0.9969107508659363]
no B-LOC [0.6496723294258118, -0.7373696565628052]
improvement B-LOC [0.690690815448761, -0.90383380651474]
for B-LOC [0.41248592734336853, -0.923690140247345]
women B-LOC [0.7175139784812927, -0.7950580716133118]
and B-LOC [0.5941343903541565, -0.8575314879417419]
elderly B-LOC [1.0997607707977295, -1.1030263900756836]
persons. B-LOC [0.6426334977149963, -1.0624449253082275]
CONCLUSION O [-0.7610819935798645, 0.5598360896110535]
In O [-0.12928254902362823, 0.2557040750980377]
this O [-0.052686721086502075, 0.1728682518005371]
community-based O [-0.07523554563522339, -0.06960959732532501]
cohort, O [-0.17681851983070374, 0.09946471452713013]
the O [-0.06522522866725922, 0.0669851005077362]
incidence O [-0.21880879998207092, 0.1136004626750946]
of O [-0.3785930573940277, 0.12096055597066879]
heart B-LOC [-0.002955713775008917, -0.15909168124198914]
failure O [-0.1574350893497467, 0.014126662164926529]
has B-LOC [0.1423998475074768, -0.02541033737361431]
not O [0.19758425652980804, 0.2589278519153595]
declined B-LOC [0.012305560521781445, -0.02063988335430622]
during O [-0.09482483565807343, -0.059807535260915756]
2 O [0.12642782926559448, 0.18322381377220154]
decades, B-LOC [0.046375878155231476, 0.03542458638548851]
but O [-0.3045875132083893, 0.13675004243850708]
survival O [-0.011366923339664936, 0.01876876689493656]
after O [-0.0022178865037858486, 0.007908662781119347]
onset B-LOC [-0.1135559231042862, -0.1208772212266922]
of O [-0.12892185151576996, -0.006901758257299662]
heart B-LOC [0.030387459322810173, -0.1504136621952057]
failure O [-0.03496961668133736, -0.023698193952441216]
has B-LOC [0.23566409945487976, -0.12025459855794907]
increased B-LOC [0.08907268941402435, -0.0485101155936718]
overall, O [-0.14190071821212769, 0.14063426852226257]
with B-LOC [0.09054110944271088, -0.07762512564659119]
less O [0.048641983419656754, 0.07114971429109573]
improvement B-LOC [0.029106544330716133, -0.17321990430355072]
among B-LOC [0.11095735430717468, -0.21565675735473633]
women B-LOC [0.1666344702243805, -0.20316825807094574]
and B-LOC [0.16203294694423676, -0.12389081716537476]
elderly B-LOC [0.5585945248603821, -0.4286591708660126]
persons. B-LOC [0.09864954650402069, -0.38687703013420105]

Human B-LOC [1.9023655652999878, -2.698279857635498]
tumors B-LOC [2.3088767528533936, -2.408860683441162]
show B-LOC [2.2409868240356445, -2.447373390197754]
a B-LOC [2.281437397003174, -2.6243345737457275]
high B-LOC [2.3391788005828857, -2.7612156867980957]
level B-LOC [2.409848690032959, -2.881920576095581]
of B-LOC [2.2135705947875977, -2.9877092838287354]
genetic B-LOC [2.661363363265991, -2.962412118911743]
heterogeneity, B-LOC [2.6005477905273438, -2.98873233795166]
but B-LOC [2.4471652507781982, -2.759084463119507]
the B-LOC [2.8587660789489746, -3.1730892658233643]
processes B-LOC [2.7711102962493896, -3.0547196865081787]
that B-LOC [3.027606248855591, -3.1568119525909424]
influence B-LOC [2.8233120441436768, -3.094099283218384]
the B-LOC [2.921872615814209, -3.237828493118286]
timing B-LOC [2.8655812740325928, -3.2545578479766846]
and B-LOC [2.912914752960205, -3.03993821144104]
route B-LOC [2.8560478687286377, -3.4191291332244873]
of B-LOC [2.6457366943359375, -3.1957881450653076]
metastatic B-LOC [2.8774614334106445, -3.011449098587036]
dissemination B-LOC [2.874901294708252, -2.8782131671905518]
of B-LOC [2.739173650741577, -2.990196466445923]
the B-LOC [2.6787538528442383, -2.7979605197906494]
subclones B-LOC [2.544790506362915, -2.6956732273101807]
are B-LOC [3.3075268268585205, -3.057225227355957]
unknown. B-LOC [3.1737492084503174, -3.0270230770111084]
Here B-LOC [1.3438953161239624, -1.144862413406372]
we B-LOC [1.4452917575836182, -1.373124122619629]
have B-LOC [1.794243335723877, -1.3856563568115234]
used B-LOC [1.6894267797470093, -1.8413329124450684]
whole-exome B-LOC [2.0536959171295166, -2.065643072128296]
sequencing B-LOC [2.1989872455596924, -1.8451251983642578]
of B-LOC [1.755746603012085, -1.7869669198989868]
103 B-LOC [2.0905601978302, -1.9588215351104736]
matched B-LOC [1.98994779586792, -2.2511117458343506]
benign, B-LOC [1.982956886291504, -1.9415327310562134]
malignant B-LOC [2.1008236408233643, -2.068006753921509]
and B-LOC [1.8658859729766846, -1.9820905923843384]
metastatic B-LOC [2.1392710208892822, -2.115802049636841]
skin B-LOC [1.7710291147232056, -1.8767515420913696]
tumors B-LOC [1.8529744148254395, -1.8110496997833252]
from B-LOC [1.7943851947784424, -1.9439430236816406]
genetically B-LOC [2.154634952545166, -2.1849310398101807]
heterogeneous B-LOC [1.7688084840774536, -2.010706663131714]
mice B-LOC [1.7228925228118896, -1.8767634630203247]
to B-LOC [1.884846568107605, -1.7314895391464233]
demonstrate B-LOC [1.7199149131774902, -1.62685227394104]
that B-LOC [1.5587735176086426, -1.5923588275909424]
most B-LOC [1.7670814990997314, -1.9000312089920044]
metastases B-LOC [2.0747833251953125, -2.0947868824005127]
disseminate B-LOC [2.2305150032043457, -1.9571948051452637]
synchronously B-LOC [2.2972609996795654, -2.002176284790039]
from B-LOC [1.6688809394836426, -1.8877854347229004]
the B-LOC [1.9957356452941895, -2.1831164360046387]
primary B-LOC [1.6730728149414062, -2.3112330436706543]
tumor, B-LOC [1.798682451248169, -2.0289995670318604]
supporting B-LOC [1.9900957345962524, -1.9271730184555054]
parallel B-LOC [1.8608958721160889, -2.073604106903076]
rather B-LOC [1.55022132396698, -1.5345001220703125]
than B-LOC [1.6916131973266602, -1.4863009452819824]
linear B-LOC [2.0109691619873047, -2.1330978870391846]
evolution B-LOC [1.9677889347076416, -1.9883832931518555]
as B-LOC [2.1323089599609375, -2.144409418106079]
the B-LOC [2.0861449241638184, -2.154836893081665]
predominant B-LOC [2.0150184631347656, -2.2891957759857178]
model B-LOC [2.210502862930298, -2.1972925662994385]
of B-LOC [2.070861577987671, -2.2766923904418945]
metastasis. B-LOC [2.1312291622161865, -2.343613862991333]
Shared B-LOC [1.321065068244934, -1.462353229522705]
mutations B-LOC [1.0530568361282349, -1.294609546661377]
between B-LOC [1.263296365737915, -1.78159761428833]
primary B-LOC [1.0217602252960205, -1.496286153793335]
carcinomas B-LOC [1.0885921716690063, -1.5156784057617188]
and B-LOC [1.4810372591018677, -1.790475606918335]
their B-LOC [1.5054385662078857, -1.56536865234375]
matched B-LOC [1.322601079940796, -1.7911697626113892]
metastases B-LOC [1.2635104656219482, -1.452297329902649]
have B-LOC [1.3002111911773682, -1.2204391956329346]

the B-LOC [0.29691165685653687, -0.3376000225543976]
distinct B-LOC [0.4194415509700775, -0.5723551511764526]
A-to-T B-LOC [0.12431630492210388, -0.5323801040649414]
signature B-LOC [0.3842828869819641, -0.47928479313850403]
of B-LOC [0.4615856111049652, -0.5631375312805176]
the B-LOC [0.5389317870140076, -0.5638937950134277]
initiating B-LOC [0.3278592526912689, -0.5267954468727112]
carcinogen B-LOC [0.38717663288116455, -0.8144441246986389]
dimethylbenzanthracene, B-LOC [0.4774096608161926, -0.5826447010040283]
but B-LOC [0.4474621117115021, -0.5760941505432129]
non-shared B-LOC [0.42569443583488464, -0.4791322946548462]
mutations B-LOC [0.49168315529823303, -0.5846806168556213]
are B-LOC [0.5272906422615051, -0.6325334906578064]
primarily B-LOC [0.42156562209129333, -0.48689690232276917]
G-to-T, B-LOC [0.1372482180595398, -0.4653105139732361]
a B-LOC [0.2727210223674774, -0.5964876413345337]
signature B-LOC [0.2884275019168854, -0.530596911907196]
associated B-LOC [0.29601314663887024, -0.5185589790344238]
with B-LOC [0.2775195837020874, -0.5914697647094727]
oxidative B-LOC [0.23964235186576843, -0.6137327551841736]
stress. B-LOC [0.378456175327301, -0.3972669541835785]
The B-LOC [1.3168871402740479, -1.0430048704147339]
existence B-LOC [1.2578786611557007, -1.2351641654968262]
of B-LOC [1.2844270467758179, -1.173463225364685]
carcinomas B-LOC [1.1746587753295898, -1.4803500175476074]
that B-LOC [1.1692686080932617, -1.3802902698516846]
either B-LOC [1.1772503852844238, -1.517696738243103]
did B-LOC [0.8421128392219543, -1.0488181114196777]
or B-LOC [1.3326807022094727, -1.4912083148956299]
did B-LOC [0.930186927318573, -1.0614266395568848]
not B-LOC [1.0334844589233398, -1.1437381505966187]
metastasize B-LOC [1.1516138315200806, -1.3069642782211304]
in B-LOC [1.090850830078125, -1.1994884014129639]
the B-LOC [1.580610752105713, -1.370985984802246]
same B-LOC [1.1667039394378662, -1.4886194467544556]
host B-LOC [1.5827231407165527, -1.6953094005584717]
animal B-LOC [1.2966285943984985, -1.68620765209198]
suggests B-LOC [1.2646065950393677, -1.1392478942871094]
that B-LOC [1.262840986251831, -1.3856520652770996]
there B-LOC [1.4821341037750244, -1.481131911277771]
are B-LOC [1.4412270784378052, -1.4457149505615234]
tumor-intrinsic B-LOC [1.3515779972076416, -1.549147367477417]
factors B-LOC [1.2266594171524048, -1.5031752586364746]
that B-LOC [1.362056016921997, -1.6823246479034424]
influence B-LOC [1.2573105096817017, -1.652508020401001]
metastatic B-LOC [1.4369839429855347, -1.4910118579864502]
seeding. B-LOC [1.2018611431121826, -1.3272981643676758]
We B-LOC [0.22355127334594727, -0.6020895838737488]
also B-LOC [0.4354383945465088, -0.8871540427207947]
demonstrate B-LOC [0.44683098793029785, -0.8443864583969116]
the B-LOC [0.7126989960670471, -1.1488202810287476]
importance B-LOC [0.6634679436683655, -1.1276495456695557]
of B-LOC [0.5890379548072815, -1.1358627080917358]
germline B-LOC [0.6277953386306763, -0.8845826387405396]
polymorphisms B-LOC [0.721004068851471, -0.8988760113716125]
in B-LOC [0.6573901772499084, -1.2122085094451904]
determining B-LOC [0.6156536936759949, -1.1402702331542969]
allele-specific B-LOC [0.8004185557365417, -1.1089403629302979]
mutations, B-LOC [0.7132527828216553, -0.9784942269325256]
and B-LOC [0.2758779227733612, -0.8316249251365662]
we B-LOC [0.2782036364078522, -0.8486024141311646]
identify B-LOC [0.5449352264404297, -0.7710443139076233]
somatic B-LOC [0.5388267636299133, -0.8174068331718445]
genetic B-LOC [0.634990394115448, -1.0027917623519897]
alterations B-LOC [0.43183788657188416, -0.8486794829368591]
that B-LOC [0.4855789542198181, -1.0732390880584717]
are B-LOC [0.8372178673744202, -1.0075414180755615]
specifically B-LOC [0.6594741940498352, -1.169086217880249]
related B-LOC [0.6596360206604004, -1.0576753616333008]
to B-LOC [0.4917663633823395, -1.1802098751068115]
initiation B-LOC [0.5521165728569031, -1.0403869152069092]
of B-LOC [0.2986036241054535, -0.9137449860572815]

carcinogenesis B-LOC [0.17478980123996735, -0.8399596810340881]
by B-LOC [0.277091920375824, -0.8285136222839355]
Hras B-LOC [0.2882770597934723, -0.7311356067657471]
or B-LOC [0.37604644894599915, -0.8811430335044861]
Kras B-LOC [0.2810705900192261, -0.6571642756462097]
mutations. B-LOC [0.4861077070236206, -0.9457992911338806]
Mouse B-LOC [-0.06487441062927246, -0.15495173633098602]
tumors B-LOC [0.2962397038936615, -0.19477330148220062]
that O [-0.15936443209648132, 0.03131264075636864]
mimic O [-0.10739375650882721, 0.09285743534564972]
the O [-0.10683318227529526, 0.00956772081553936]
genetic O [-0.0009533739066682756, 0.05761554464697838]
heterogeneity B-LOC [-0.061750076711177826, -0.07600941509008408]
of B-LOC [-0.0754089280962944, -0.17605748772621155]
human O [-0.26281046867370605, -0.08777114748954773]
cancers B-LOC [0.09291327744722366, -0.2781677842140198]
can O [-0.4334578812122345, 0.030376536771655083]
aid O [-0.36217963695526123, -0.04646627977490425]
our O [-0.22438040375709534, -0.1631040871143341]
understanding B-LOC [0.03413882106542587, 0.01652604155242443]
of O [-0.12964560091495514, -0.07016714662313461]
the O [-0.15036413073539734, -0.04465816542506218]
clonal O [-0.04195258021354675, 0.049124475568532944]
evolution O [-0.21988186240196228, 0.1337883621454239]
of O [-0.3429243266582489, -0.028134526684880257]
metastasis B-LOC [-0.06856200844049454, -0.1254081130027771]
and O [-0.37771251797676086, 0.24643990397453308]
provide B-LOC [-0.10793550312519073, -0.13299357891082764]
a O [-0.18412117660045624, -0.055018361657857895]
realistic B-LOC [0.044102687388658524, -0.20442737638950348]
model B-LOC [0.12944342195987701, -0.30294790863990784]
for B-LOC [0.06809183210134506, -0.5665068626403809]
the B-LOC [0.14929279685020447, -0.6424276828765869]
testing B-LOC [0.3545694947242737, -0.6522833704948425]
of B-LOC [0.4032995402812958, -0.9212409853935242]
novel B-LOC [0.4557779133319855, -0.9093651175498962]
therapies. B-LOC [0.808174729347229, -0.6862404346466064]

The B-LOC [1.2434858083724976, -1.6013346910476685]
only B-LOC [1.6426364183425903, -1.8260860443115234]
proven B-LOC [1.9043679237365723, -2.1312057971954346]
requirement B-LOC [1.2799317836761475, -1.762277603149414]
for B-LOC [1.3449323177337646, -1.8509979248046875]
ascorbic B-LOC [0.7791462540626526, -1.6483774185180664]
acid B-LOC [0.9982675909996033, -1.5471324920654297]
(vitamin B-LOC [1.672182559967041, -2.033599615097046]
C) B-LOC [0.9038702845573425, -1.5802994966506958]
is B-LOC [1.6788054704666138, -2.0236124992370605]
in B-LOC [1.1047418117523193, -1.5120874643325806]
preventing B-LOC [1.1534755229949951, -1.399806261062622]
scurvy, B-LOC [1.0773309469223022, -1.3466508388519287]
presumably B-LOC [1.4488673210144043, -1.5980565547943115]
because B-LOC [1.192268967628479, -1.322169303894043]
it B-LOC [0.8199241161346436, -1.090014100074768]
is B-LOC [0.9138945937156677, -1.0930466651916504]
a B-LOC [0.6818430423736572, -0.8852407336235046]
cofactor B-LOC [0.7794339060783386, -0.9769669771194458]
for B-LOC [0.9146263003349304, -1.0900754928588867]
hydroxylases B-LOC [0.8674480319023132, -1.0712345838546753]
required B-LOC [0.7571728229522705, -1.0050406455993652]
for B-LOC [0.7429206967353821, -0.990692138671875]
post-translational B-LOC [0.5417702198028564, -0.9578850269317627]
modifications B-LOC [0.7446195483207703, -0.7980862259864807]
that B-LOC [0.7010425925254822, -1.0669746398925781]
stabilize B-LOC [0.9205211997032166, -1.1271661520004272]
collagen. B-LOC [0.880642831325531, -1.1777691841125488]
We B-LOC [1.5887186527252197, -1.5762524604797363]
have B-LOC [2.2062580585479736, -1.793432593345642]
created B-LOC [2.1869375705718994, -1.9696507453918457]
mice B-LOC [1.8041915893554688, -2.30000638961792]
deficient B-LOC [2.4221413135528564, -2.1014668941497803]
in B-LOC [2.521540403366089, -2.155742883682251]
the B-LOC [2.383965492248535, -2.0133354663848877]
mouse B-LOC [1.9083243608474731, -2.423250913619995]
ortholog B-LOC [2.079200267791748, -2.2089359760284424]
(solute B-LOC [2.334777593612671, -1.9710681438446045]
carrier B-LOC [1.872330665588379, -2.017524242401123]
family B-LOC [2.127462148666382, -1.980844259262085]
23 B-LOC [2.2201640605926514, -2.0259602069854736]
member B-LOC [2.2619540691375732, -2.000868558883667]
1 B-LOC [2.2323198318481445, -1.9244723320007324]
or B-LOC [2.0813958644866943, -2.0687577724456787]
Slc23a1) B-LOC [1.950122356414795, -2.2176291942596436]
of B-LOC [2.3566596508026123, -2.2407338619232178]
a B-LOC [2.3917617797851562, -2.463193655014038]
rat B-LOC [1.733296513557434, -2.637781858444214]
ascorbic-acid B-LOC [1.766473412513733, -2.3157827854156494]
transporter, B-LOC [1.9427634477615356, -2.1120717525482178]
Svct2 B-LOC [1.8702229261398315, -2.2252447605133057]
(ref. B-LOC [2.191131114959717, -2.024644374847412]
4). B-LOC [1.8492481708526611, -2.1460118293762207]
Cultured B-LOC [0.3208857476711273, -0.4498583674430847]
embryonic B-LOC [0.14943808317184448, -0.2629825174808502]
fibroblasts B-LOC [0.08504053950309753, -0.19194987416267395]
from B-LOC [0.11226645112037659, -0.11868302524089813]
homozygous B-LOC [0.04491475597023964, -0.2139943540096283]
Slc23a1−/− B-LOC [0.011547635309398174, -0.42150041460990906]
mice B-LOC [-0.04276448115706444, -0.37067943811416626]
had B-LOC [0.1336565911769867, -0.3038812279701233]
less B-LOC [0.3536055386066437, -0.2579752206802368]
than B-LOC [0.10127540677785873, -0.40684178471565247]
5% B-LOC [0.27613362669944763, -0.1562010943889618]

of B-LOC [0.0803840309381485, -0.6082979440689087]
normal B-LOC [-0.002477338071912527, -0.3108650743961334]
ascorbic-acid B-LOC [0.001100833178497851, -0.3775557577610016]
uptake. B-LOC [-0.039931219071149826, -0.2984474003314972]
Ascorbic-acid B-LOC [-0.12776276469230652, -0.26351475715637207]
levels B-LOC [0.23803268373012543, -0.12052866816520691]
were B-LOC [-0.17005638778209686, -0.24954308569431305]
undetectable B-LOC [0.011832921765744686, -0.15026289224624634]
or B-LOC [0.12084798514842987, -0.16926264762878418]
markedly O [-0.05513601377606392, -0.05385327711701393]
reduced B-LOC [0.06118464097380638, -0.1561262160539627]
in B-LOC [0.009932967834174633, -0.07827277481555939]
the B-LOC [0.025286657735705376, 0.016706792637705803]
blood B-LOC [-0.11827334016561508, -0.3467589318752289]
and B-LOC [0.25163522362709045, -0.2785687744617462]
tissues B-LOC [0.12019924819469452, -0.2431889772415161]
of B-LOC [-0.04900927469134331, -0.1191142350435257]
Slc23a1−/− B-LOC [0.1597435474395752, -0.34918013215065]
mice. B-LOC [0.09345487505197525, -0.3157553970813751]
Prenatal B-LOC [1.1035046577453613, -1.13486647605896]
supplementation B-LOC [0.6910489201545715, -1.040513277053833]
of B-LOC [0.9640816450119019, -1.0029845237731934]
pregnant B-LOC [1.152287244796753, -1.2067198753356934]
females B-LOC [1.0295464992523193, -1.180209755897522]
did B-LOC [0.6778039336204529, -0.724388062953949]
not B-LOC [0.9055539965629578, -0.7265285849571228]
elevate B-LOC [0.9901939630508423, -1.308008074760437]
blood B-LOC [0.723685622215271, -1.5449012517929077]
ascorbic B-LOC [0.9110434651374817, -1.3438994884490967]
acid B-LOC [0.8917060494422913, -1.371475100517273]
in B-LOC [1.0216037034988403, -1.321579933166504]
Slc23a1−/− B-LOC [1.0358432531356812, -1.2823286056518555]
fetuses, B-LOC [1.430537462234497, -1.622570276260376]
suggesting B-LOC [1.2485837936401367, -1.1509191989898682]
Slc23a1 B-LOC [1.1921374797821045, -1.3681479692459106]
is B-LOC [1.5699646472930908, -1.612840175628662]
important B-LOC [1.3637245893478394, -1.5434987545013428]
in B-LOC [1.4751293659210205, -1.613568902015686]
placental B-LOC [1.8136639595031738, -1.6997089385986328]
ascorbic-acid B-LOC [1.1833574771881104, -1.6436890363693237]
transport. B-LOC [1.2913129329681396, -1.4709547758102417]
Slc23a1−/− B-LOC [0.2803802192211151, -0.7503143548965454]
mice B-LOC [-0.11623447388410568, -0.5737825036048889]
died B-LOC [0.3910934627056122, -0.5776806473731995]
within B-LOC [0.476348876953125, -0.6065136790275574]
a B-LOC [0.39683952927589417, -0.5220404863357544]
few B-LOC [0.3348560035228729, -0.5600975751876831]
minutes B-LOC [0.34906962513923645, -0.5346735119819641]
of B-LOC [0.027870895341038704, -0.34075477719306946]
birth B-LOC [0.10914910584688187, -0.3553953468799591]
with B-LOC [-0.0902259349822998, -0.27360039949417114]
respiratory B-LOC [0.052097637206315994, -0.6112834811210632]
failure B-LOC [0.08160468935966492, -0.5528496503829956]
and B-LOC [-0.058890726417303085, -0.08056531846523285]
intraparenchymal B-LOC [0.11516716331243515, -0.48846694827079773]
brain B-LOC [-0.14520849287509918, -0.2905409038066864]
hemorrhage. B-LOC [-0.04020347818732262, -0.44136616587638855]
Lungs B-LOC [0.21762746572494507, -0.3686116337776184]

showed B-LOC [-0.10340160131454468, -0.10418589413166046]
no O [-0.04947504773736, 0.07027638703584671]
postnatal O [-0.21646183729171753, 0.029028957709670067]
expansion B-LOC [-0.04103277996182442, -0.13458827137947083]
but B-LOC [0.05615098401904106, -0.015005307272076607]
had B-LOC [0.03336859866976738, -0.07437807321548462]
normal B-LOC [-0.046247448772192, -0.05793565884232521]
surfactant B-LOC [0.06083345785737038, -0.21655040979385376]
protein B-LOC [-0.04286499693989754, -0.11397842317819595]
B O [-0.09489449858665466, -0.05920650437474251]
levels. B-LOC [-0.008149032481014729, -0.04466557875275612]
Brain B-LOC [-0.11373791098594666, -0.137256920337677]
hemorrhage B-LOC [0.1396719217300415, -0.5791902542114258]
was B-LOC [0.17771565914154053, -0.38937222957611084]
unlikely B-LOC [0.5849398970603943, -0.4887917935848236]
to B-LOC [0.6836207509040833, -0.5792598724365234]
be B-LOC [0.3449473977088928, -0.5286478996276855]
simply B-LOC [0.4374030530452728, -0.501987874507904]
a B-LOC [0.35464242100715637, -0.4281235933303833]
form B-LOC [0.12741094827651978, -0.39479538798332214]
of B-LOC [0.1441347748041153, -0.32468798756599426]
scurvy B-LOC [0.0679861456155777, -0.3278507888317108]
since O [0.03930409252643585, 0.2088714838027954]
Slc23a1−/− O [-0.19681861996650696, 0.26825883984565735]
mice O [-0.2547641694545746, 0.350331574678421]
showed O [-0.2724105417728424, 0.4597664177417755]
no O [-0.1444208025932312, 0.5459542870521545]
hemorrhage O [-0.18414291739463806, 0.14473406970500946]
in O [-0.26438018679618835, 0.48363277316093445]
any O [-0.1980399787425995, 0.3767305910587311]
other O [-0.23598837852478027, 0.4525426924228668]
tissues O [-0.25743037462234497, 0.2842661142349243]
and O [-0.2376396656036377, 0.5595524907112122]
their O [-0.027122436091303825, 0.37880465388298035]
skin O [-0.2187916338443756, 0.358395516872406]
had O [-0.16220524907112122, 0.2987067699432373]
normal O [-0.11453671753406525, 0.32514068484306335]
skin O [-0.24518521130084991, 0.3264179527759552]
4-hydroxyproline O [-0.2113620787858963, 0.4110298454761505]
levels O [-0.13027435541152954, 0.3908800184726715]
despite O [-0.20110175013542175, 0.37340134382247925]
low O [-0.02548002265393734, 0.28435584902763367]
ascorbic-acid O [-0.2947898805141449, 0.19351814687252045]
content. O [-0.049651581794023514, 0.3330431878566742]
We B-LOC [0.38735657930374146, -0.5632765889167786]
conclude B-LOC [0.9322671294212341, -0.6888787746429443]
that B-LOC [0.808698832988739, -1.0533616542816162]
Slc23a1 B-LOC [0.6986024379730225, -1.134347915649414]
is B-LOC [0.9040288329124451, -1.032551884651184]
required B-LOC [0.7133204340934753, -1.0819849967956543]
for B-LOC [0.6134592294692993, -1.0464516878128052]
transport B-LOC [0.7977384924888611, -0.8387783169746399]
of B-LOC [0.7140666842460632, -0.8611556887626648]
ascorbic B-LOC [0.6434715986251831, -1.098217248916626]
acid B-LOC [0.6776819229125977, -0.9993245005607605]
into B-LOC [0.7652128338813782, -1.0705029964447021]
many B-LOC [0.853509247303009, -1.3387234210968018]
tissues B-LOC [0.8335104584693909, -1.1323833465576172]
and B-LOC [0.8203851580619812, -1.0538110733032227]
across B-LOC [0.8503345251083374, -1.339898943901062]
the B-LOC [0.9265084862709045, -1.0355359315872192]
placenta. B-LOC [0.7758364081382751, -1.2685163021087646]
Deficiency B-LOC [0.5581005215644836, -0.7845107913017273]
of B-LOC [0.7018994688987732, -0.9636757373809814]
the B-LOC [0.693977952003479, -0.9339528679847717]
transporter B-LOC [0.5875913500785828, -0.8952402472496033]
is B-LOC [0.7082563042640686, -1.0268782377243042]
lethal B-LOC [0.4297926127910614, -1.0191996097564697]
in B-LOC [0.43195000290870667, -0.8401095867156982]
newborn B-LOC [0.4765698313713074, -0.691518247127533]
mice, B-LOC [0.4024191200733185, -0.7908647656440735]
thereby B-LOC [0.5649272799491882, -0.5566829442977905]
revealing B-LOC [0.5122620463371277, -0.8234482407569885]

a B-LOC [0.2792716324329376, -0.4187038838863373]
previously B-LOC [0.5199503898620605, -0.6224599480628967]
unrecognized B-LOC [0.6852597594261169, -0.741935670375824]
requirement B-LOC [0.18880562484264374, -0.5826043486595154]
for B-LOC [0.21726089715957642, -0.5379986763000488]
ascorbic B-LOC [0.20482374727725983, -0.4972671866416931]
acid B-LOC [0.27215737104415894, -0.457792192697525]
in B-LOC [0.34243330359458923, -0.4730358421802521]
the B-LOC [0.35240933299064636, -0.35579821467399597]
perinatal B-LOC [0.14629113674163818, -0.50236976146698]
period. B-LOC [0.11788035929203033, -0.4671976566314697]

DNA B-LOC [1.5715630054473877, -2.0847630500793457]
damage B-LOC [1.986893892288208, -2.1087489128112793]
tolerance B-LOC [1.8650133609771729, -2.11417293548584]
during B-LOC [1.7393767833709717, -1.8517165184020996]
eukaryotic B-LOC [1.9263966083526611, -1.8951244354248047]
replication B-LOC [2.0421979427337646, -2.092198371887207]
is B-LOC [2.0108730792999268, -2.0332846641540527]
orchestrated B-LOC [2.0515964031219482, -2.05641508102417]
by B-LOC [1.720021367073059, -2.0958092212677]
PCNA B-LOC [1.885334849357605, -2.203709125518799]
ubiquitination. B-LOC [2.012655735015869, -2.2597360610961914]
While B-LOC [0.7140300273895264, -0.496236652135849]
monoubiquitination B-LOC [0.8114010691642761, -0.815895140171051]
activates B-LOC [0.8174423575401306, -0.7294126152992249]
mutagenic B-LOC [1.0078647136688232, -0.9411910176277161]
translesion B-LOC [0.9199577569961548, -1.0483717918395996]
synthesis, B-LOC [0.7364235520362854, -0.7397052049636841]
polyubiquitination B-LOC [1.0239808559417725, -1.0505443811416626]
activates B-LOC [0.9828203320503235, -0.8445318341255188]
an B-LOC [0.9624047875404358, -0.9216458201408386]
error-free B-LOC [1.057154893875122, -1.3623592853546143]
pathway, B-LOC [0.6600647568702698, -1.0588628053665161]
elusive B-LOC [1.4305918216705322, -1.283739447593689]
in B-LOC [1.0616557598114014, -1.1316922903060913]
mammals, B-LOC [1.1399729251861572, -1.248085379600525]
enabling B-LOC [0.7986981272697449, -0.9610728621482849]
damage B-LOC [1.011399269104004, -1.058327078819275]
bypass B-LOC [1.0673894882202148, -1.0809634923934937]
by B-LOC [0.810189425945282, -1.107790470123291]
template B-LOC [1.0837907791137695, -1.3384052515029907]
switching. B-LOC [0.8629248738288879, -1.1877695322036743]
Fork B-LOC [0.9851527810096741, -1.2842376232147217]
reversal B-LOC [1.188420295715332, -1.0679885149002075]
is B-LOC [1.4297597408294678, -1.2706115245819092]
driven B-LOC [1.318511724472046, -1.2500001192092896]
in B-LOC [1.207801103591919, -1.4078426361083984]
vitro B-LOC [1.3090777397155762, -1.1790978908538818]
by B-LOC [1.2335561513900757, -1.067350149154663]
multiple B-LOC [1.6261625289916992, -1.4416776895523071]
enzymes, B-LOC [1.8393731117248535, -1.6446868181228638]
including B-LOC [2.0033071041107178, -1.5250294208526611]
the B-LOC [1.5488390922546387, -1.2927923202514648]
DNA B-LOC [1.3987131118774414, -1.560129165649414]
translocase B-LOC [1.5531601905822754, -1.4876182079315186]
ZRANB3, B-LOC [1.2221437692642212, -1.1532560586929321]
shown B-LOC [1.6385891437530518, -1.5902013778686523]
to B-LOC [1.842620611190796, -1.6356921195983887]
bind B-LOC [1.702729344367981, -1.6007541418075562]
polyubiquitinated B-LOC [1.6378666162490845, -1.612053394317627]
PCNA. B-LOC [1.469163179397583, -1.586184024810791]
However, B-LOC [2.476651668548584, -2.401341676712036]
whether B-LOC [2.405172109603882, -2.867058038711548]
this B-LOC [2.2488911151885986, -2.4635393619537354]
interaction B-LOC [1.6199257373809814, -2.1431241035461426]
promotes B-LOC [1.9613001346588135, -2.3721554279327393]
fork B-LOC [1.531799554824829, -2.088029146194458]
remodeling B-LOC [2.0206234455108643, -1.8887829780578613]
and B-LOC [2.1183478832244873, -2.2120683193206787]
template B-LOC [1.9819469451904297, -2.342397451400757]
switching B-LOC [1.7546601295471191, -2.3165111541748047]
in B-LOC [2.0474636554718018, -2.266570806503296]
vivo B-LOC [1.7612833976745605, -2.3505289554595947]
was B-LOC [2.888348340988159, -2.966341018676758]
unknown. B-LOC [2.9210257530212402, -2.673123598098755]
Here B-LOC [0.7584890723228455, -1.15909743309021]

we O [-0.4027489721775055, 0.05374009534716606]
show O [-0.4986327588558197, 0.3095596730709076]
that O [-0.6568719148635864, 0.12876008450984955]
damage-induced O [-0.03264717385172844, 0.044744912534952164]
fork B-LOC [-0.09203130006790161, -0.11724457144737244]
reversal O [-0.0880093052983284, 0.09003464132547379]
in O [-0.20942062139511108, 0.13259828090667725]
mammalian O [-0.030596060678362846, 0.23417919874191284]
cells O [-0.21709585189819336, 0.22084015607833862]
requires O [-0.23122736811637878, 0.2661225497722626]
PCNA O [-0.26213207840919495, 0.23707398772239685]
ubiquitination, O [-0.2191314697265625, 0.36599066853523254]
UBC13, O [-0.2191765308380127, 0.260572224855423]
and O [-0.17756597697734833, 0.41312670707702637]
K63-linked O [-0.060455966740846634, 0.15191848576068878]
polyubiquitin O [-0.3579881489276886, 0.14147095382213593]
chains, O [-0.16421717405319214, 0.3339262008666992]
previously O [-0.24043184518814087, 0.19519047439098358]
involved O [-0.22704975306987762, 0.20420882105827332]
in O [-0.32732143998146057, 0.23486009240150452]
error-free B-LOC [-0.044336576014757156, -0.06034911796450615]
damage B-LOC [0.03115689940750599, -0.005180435720831156]
tolerance. O [-0.04020402580499649, 0.20448088645935059]
Fork B-LOC [-0.03167523816227913, -0.19445520639419556]
reversal O [0.0019023536005988717, 0.02491247095167637]
in O [-0.22179827094078064, 0.15360127389431]
vivo O [-0.24265381693840027, 0.2634802758693695]
also O [-0.12622526288032532, 0.0760144293308258]
requires B-LOC [-0.007643891032785177, -0.04193521663546562]
ZRANB3 O [-0.02444479614496231, -0.006580980960279703]
translocase O [-0.2346871942281723, 0.14340732991695404]
activity O [-0.10660339146852493, 0.15306544303894043]
and O [0.013886372558772564, 0.03733043000102043]
its B-LOC [0.03891604393720627, -0.007058980409055948]
interaction B-LOC [0.1006845235824585, -0.10296538472175598]
with B-LOC [0.1049884632229805, -0.1864718794822693]
polyubiquitinated B-LOC [0.05317283049225807, -0.18746037781238556]
PCNA, O [-0.05715068802237511, -0.0258504506200552]
pinpointing B-LOC [0.5130231380462646, -0.3870079517364502]
ZRANB3 B-LOC [0.3452237546443939, -0.39897069334983826]
as B-LOC [0.4568440914154053, -0.48631811141967773]
a B-LOC [0.26409202814102173, -0.3260657787322998]
key B-LOC [0.1770940124988556, -0.3604193329811096]
effector B-LOC [0.21301372349262238, -0.44515812397003174]
of B-LOC [0.3636470139026642, -0.5936146378517151]
error-free B-LOC [0.33550360798835754, -0.5038018226623535]
DNA B-LOC [0.1260245442390442, -0.31367406249046326]
damage B-LOC [0.2460310459136963, -0.3287205994129181]
tolerance. B-LOC [0.40204378962516785, -0.49005910754203796]
Mutations B-LOC [0.171647846698761, -0.4915022850036621]
affecting B-LOC [-0.0021656802855432034, -0.2969150245189667]
fork B-LOC [0.10637669265270233, -0.49559932947158813]
reversal B-LOC [0.24857088923454285, -0.3625357747077942]
also B-LOC [0.16187816858291626, -0.31404247879981995]
induced B-LOC [-0.05414677783846855, -0.43133875727653503]
unrestrained B-LOC [0.25211548805236816, -0.48761501908302307]
fork B-LOC [0.2188100814819336, -0.6425727009773254]
progression B-LOC [0.029582703486084938, -0.44521746039390564]
and B-LOC [0.10402598977088928, -0.4234163463115692]
chromosomal B-LOC [0.12758868932724, -0.43332114815711975]

breakage, B-LOC [0.30546918511390686, -0.5378956198692322]
suggesting B-LOC [0.4956388771533966, -0.36973291635513306]
fork B-LOC [0.4634959399700165, -0.7467051148414612]
remodeling B-LOC [0.9830816984176636, -0.6613920331001282]
as B-LOC [0.7088442444801331, -0.7487223148345947]
a B-LOC [0.7212689518928528, -0.7257634401321411]
global B-LOC [0.7338467240333557, -0.8373364806175232]
fork B-LOC [0.5137863755226135, -0.8102710843086243]
slowing B-LOC [0.5702146291732788, -0.7001451849937439]
and B-LOC [0.7209145426750183, -0.7866870760917664]
protection B-LOC [0.8527916669845581, -0.8917774558067322]
mechanism. B-LOC [0.7719308733940125, -0.9443932771682739]
Targeting B-LOC [1.6168084144592285, -1.4304522275924683]
these B-LOC [1.2344359159469604, -1.1712480783462524]
fork B-LOC [1.093161940574646, -1.3980642557144165]
protection B-LOC [1.2553484439849854, -1.3028931617736816]
systems B-LOC [1.2293938398361206, -1.309002161026001]
represents B-LOC [1.8230377435684204, -1.6918474435806274]
a B-LOC [1.7153770923614502, -1.7689270973205566]
promising B-LOC [1.8693668842315674, -1.870243787765503]
strategy B-LOC [1.6824193000793457, -1.782341480255127]
to B-LOC [1.7455108165740967, -1.7943397760391235]
potentiate B-LOC [1.747825264930725, -1.7273387908935547]
cancer B-LOC [1.5908448696136475, -1.731923222541809]
chemotherapy. B-LOC [1.623232364654541, -1.549231767654419]

Mice B-LOC [1.1896185874938965, -1.6383750438690186]
lacking B-LOC [1.5309193134307861, -1.6470253467559814]
the B-LOC [1.3808472156524658, -1.4661381244659424]
transcription B-LOC [1.222416639328003, -1.7494550943374634]
factor B-LOC [1.292576551437378, -1.7685246467590332]
T-bet B-LOC [1.1341851949691772, -1.6086755990982056]
in B-LOC [1.3470160961151123, -1.5931742191314697]
the B-LOC [1.4773982763290405, -1.582473635673523]
innate B-LOC [1.3747628927230835, -2.3094563484191895]
immune B-LOC [1.3580737113952637, -1.9451770782470703]
system B-LOC [1.0955252647399902, -1.6493232250213623]
develop B-LOC [1.410921335220337, -1.5068302154541016]
microbiota-dependent B-LOC [1.5419610738754272, -1.941504716873169]
colitis. B-LOC [1.3559155464172363, -1.8884763717651367]
Here, O [-0.38046303391456604, 0.16525280475616455]
we O [-0.522191047668457, 0.12350911647081375]
show O [-0.40139853954315186, 0.27135801315307617]
that O [-0.5345055460929871, 0.29038262367248535]
interleukin-17A O [-0.253086656332016, 0.09041054546833038]
(IL-17A)-producing B-LOC [-0.0029043755494058132, -0.07670369744300842]
IL-7Rα(+) O [-0.11488853394985199, 0.03221249207854271]
innate O [-0.07455717027187347, 0.24549949169158936]
lymphoid O [-0.07728852331638336, 0.004488320555537939]
cells O [-0.34816446900367737, 0.30707576870918274]
(ILCs) B-LOC [-0.05972994491457939, -0.0873338133096695]
were O [-0.26702314615249634, 0.28549447655677795]
potent O [-0.2648267447948456, 0.304417222738266]
promoters O [-0.22669720649719238, 0.38167425990104675]
of O [-0.322616308927536, 0.31020358204841614]
disease O [-0.2399561107158661, 0.040648989379405975]
in O [-0.31033217906951904, 0.3771824836730957]
Tbx21(-/-)Rag2(-/-) O [-0.20312055945396423, 0.09510812163352966]
ulcerative O [-0.09073970466852188, 0.06284218281507492]
colitis B-LOC [-0.13800302147865295, -0.1672082543373108]
(TRUC) O [-0.20972932875156403, -0.015051843598484993]
mice. O [-0.32732483744621277, 0.1854715794324875]
TNF-α O [-0.15381425619125366, 0.023880688473582268]
produced O [-0.0970950499176979, -0.056373562663793564]
by O [-0.09665439277887344, 0.09063930809497833]
CD103(-)CD11b(+) O [-0.25160297751426697, 0.10967659950256348]
dendritic O [-0.2202008217573166, 0.14769574999809265]
cells O [-0.1948729157447815, 0.05690789595246315]
synergized O [-0.16964924335479736, 0.03168179467320442]

with B-LOC [0.7654775977134705, -1.0359375476837158]
IL-23 B-LOC [0.6956583261489868, -0.9247502684593201]
to B-LOC [0.9839147925376892, -1.0001603364944458]
drive B-LOC [0.8586413264274597, -1.1794517040252686]
IL-17A B-LOC [0.6929095387458801, -0.9201386570930481]
production B-LOC [1.0828931331634521, -1.1927719116210938]
by B-LOC [0.9468573927879333, -1.302032470703125]
ILCs, B-LOC [1.1957998275756836, -1.4057254791259766]
demonstrating B-LOC [1.3477517366409302, -1.4242767095565796]
a B-LOC [1.3902161121368408, -1.484823226928711]
previously B-LOC [1.60905122756958, -1.825627326965332]
unrecognized B-LOC [1.9713490009307861, -1.9236994981765747]
layer B-LOC [1.6227272748947144, -1.770216464996338]
of B-LOC [1.610750675201416, -1.8481416702270508]
cellular B-LOC [1.4896371364593506, -1.7782756090164185]
crosstalk B-LOC [1.698319911956787, -1.928408145904541]
between B-LOC [1.702284574508667, -1.9253191947937012]
dendritic B-LOC [1.4745595455169678, -1.6810762882232666]
cells B-LOC [1.405566692352295, -1.6600425243377686]
and B-LOC [1.705288290977478, -1.8545358180999756]
ILCs. B-LOC [1.558337926864624, -1.739487648010254]
We B-LOC [0.7642280459403992, -0.7965080142021179]
have B-LOC [1.0055522918701172, -0.8138241171836853]
identified B-LOC [1.0025370121002197, -0.7192859649658203]
Helicobacter B-LOC [0.6767949461936951, -0.9610710740089417]
typhlonius B-LOC [0.5651355385780334, -0.7051435708999634]
as B-LOC [0.6421051025390625, -0.6770229935646057]
a B-LOC [0.49620676040649414, -0.599217414855957]
key B-LOC [0.5308732390403748, -0.9223923087120056]
disease B-LOC [0.7881268262863159, -0.8945761919021606]
trigger B-LOC [0.27560290694236755, -0.5976407527923584]
driving B-LOC [0.42622634768486023, -0.6791072487831116]
excess B-LOC [0.8187840580940247, -0.8542019724845886]
TNF-α B-LOC [0.49479660391807556, -0.7482901811599731]
production B-LOC [0.48767992854118347, -0.5154134035110474]
and B-LOC [0.23089954257011414, -0.37407442927360535]
promoting B-LOC [0.5287556052207947, -0.6642367243766785]
colitis B-LOC [0.5893091559410095, -1.0769808292388916]
in B-LOC [0.6570645570755005, -0.7303207516670227]
TRUC B-LOC [0.9406396746635437, -1.1231281757354736]
mice. B-LOC [0.7396233677864075, -1.1221179962158203]
Crucially, B-LOC [0.2824329137802124, -0.3066471219062805]
T-bet B-LOC [0.18791966140270233, -0.2972497045993805]
also B-LOC [0.1975105255842209, -0.2803223133087158]
suppressed B-LOC [0.3291170299053192, -0.2372465878725052]
the B-LOC [0.2507549822330475, -0.31567418575286865]
expression B-LOC [0.11281687766313553, 0.05702150985598564]
of B-LOC [0.19552038609981537, -0.2491571456193924]
IL-7R, B-LOC [0.04497051611542702, -0.24176475405693054]
a B-LOC [0.19876441359519958, -0.24739733338356018]
key B-LOC [0.05047808215022087, -0.28600579500198364]
molecule B-LOC [-0.04019168019294739, -0.29549965262413025]
involved B-LOC [-0.025751201435923576, -0.2696417272090912]
in B-LOC [0.01466947328299284, -0.2611634135246277]
controlling B-LOC [0.15143448114395142, -0.282785028219223]
intestinal B-LOC [0.08976537734270096, -0.015219910070300102]
ILC B-LOC [0.09417422115802765, -0.22859525680541992]
homeostasis. B-LOC [0.041885897517204285, 0.024299299344420433]
The B-LOC [0.8583022952079773, -1.1992297172546387]
importance B-LOC [0.6853658556938171, -1.1764225959777832]
of B-LOC [0.663760781288147, -1.2574715614318848]
IL-7R B-LOC [0.38119199872016907, -0.8786395192146301]
signaling B-LOC [0.5901336073875427, -1.1188863515853882]
in B-LOC [0.817409873008728, -1.3329824209213257]
TRUC B-LOC [0.7449671030044556, -1.1973974704742432]
disease B-LOC [0.6496489644050598, -1.1164950132369995]
was B-LOC [0.753790557384491, -1.0750868320465088]

highlighted O [-0.08847451210021973, 0.07078762352466583]
by O [-0.25776562094688416, 0.20183569192886353]
the O [-0.26970788836479187, 0.23517857491970062]
dramatic O [-0.2934339642524719, 0.12670539319515228]
reduction O [-0.2749185860157013, 0.16259364783763885]
in O [-0.49606820940971375, 0.23762674629688263]
intestinal O [-0.7664580345153809, 0.5739530920982361]
ILCs O [-0.3736555874347687, 0.30096814036369324]
and O [-0.31826943159103394, 0.24611133337020874]
attenuated O [-0.5259249210357666, 0.4542265832424164]
colitis O [-0.5674459338188171, 0.4493408799171448]
following O [-0.3493379056453705, 0.1757480949163437]
IL-7R O [-0.39617666602134705, 0.14687605202198029]
blockade. O [-0.13119487464427948, 0.23107221722602844]
Taken B-LOC [1.3192944526672363, -0.9653488993644714]
together, B-LOC [0.8580705523490906, -0.9710391163825989]
these B-LOC [0.8463938236236572, -0.7990886569023132]
data B-LOC [0.8061769008636475, -0.9155654311180115]
demonstrate B-LOC [0.8835468292236328, -0.8042996525764465]
the B-LOC [1.0906554460525513, -1.0446398258209229]
mechanism B-LOC [0.8062460422515869, -1.2112079858779907]
by B-LOC [0.7369102239608765, -0.8031560182571411]
which B-LOC [0.9672251343727112, -1.2149770259857178]
T-bet B-LOC [0.6069839000701904, -0.8735224008560181]
regulates B-LOC [0.7993165254592896, -1.0257993936538696]
the B-LOC [1.0247814655303955, -1.0172691345214844]
complex B-LOC [0.817911684513092, -1.1359024047851562]
interplay B-LOC [0.7705174088478088, -1.0288548469543457]
between B-LOC [0.8297358155250549, -1.3367815017700195]
mucosal B-LOC [0.6865562200546265, -0.9320356845855713]
dendritic B-LOC [0.5227006077766418, -0.939999520778656]
cells, B-LOC [0.5933366417884827, -0.8505520820617676]
ILCs, B-LOC [0.70284503698349, -0.9521743655204773]
and B-LOC [0.960184633731842, -1.2222436666488647]
the B-LOC [0.9571471214294434, -1.1347602605819702]
intestinal B-LOC [0.5126507878303528, -1.026225209236145]
microbiota. B-LOC [0.7157357335090637, -1.0616645812988281]

S-nitrosylation B-LOC [1.1906046867370605, -1.84773588180542]
of B-LOC [1.5832748413085938, -1.7769975662231445]
proteins B-LOC [1.6598615646362305, -1.8221735954284668]
by B-LOC [1.1222623586654663, -1.5104186534881592]
nitric B-LOC [1.4126578569412231, -1.9346075057983398]
oxide B-LOC [1.4843261241912842, -1.741882085800171]
is B-LOC [2.176177501678467, -2.1717116832733154]
a B-LOC [1.9753797054290771, -2.1597907543182373]
major B-LOC [1.8731098175048828, -2.1056408882141113]
mode B-LOC [1.8631867170333862, -2.282701015472412]
of B-LOC [1.7315988540649414, -2.2518489360809326]
signalling B-LOC [1.7118537425994873, -1.9600205421447754]
in B-LOC [1.7277202606201172, -1.997749924659729]
cells. B-LOC [1.701136827468872, -1.9386327266693115]
S-nitrosylation B-LOC [1.2911474704742432, -1.7586236000061035]
can B-LOC [1.773358702659607, -1.9059478044509888]
mediate B-LOC [1.5708309412002563, -1.7211169004440308]
the B-LOC [1.6438405513763428, -1.7406054735183716]
regulation B-LOC [1.5167386531829834, -1.702256679534912]
of B-LOC [1.622143268585205, -1.9286439418792725]
a B-LOC [1.9462722539901733, -2.0470173358917236]
range B-LOC [2.054636240005493, -2.172787666320801]
of B-LOC [1.7944047451019287, -2.1555240154266357]
proteins, B-LOC [1.8347140550613403, -2.127958297729492]
including B-LOC [1.9068893194198608, -2.109529972076416]
prominent B-LOC [1.6595170497894287, -1.9961193799972534]
nuclear B-LOC [1.7430627346038818, -2.1056065559387207]
proteins, B-LOC [1.7528525590896606, -2.0783541202545166]
such B-LOC [1.9859676361083984, -2.2302961349487305]
as B-LOC [1.9014657735824585, -2.063754081726074]
HDAC2 B-LOC [1.4688953161239624, -1.7199580669403076]
(ref. B-LOC [1.5085647106170654, -1.8327205181121826]
2) B-LOC [1.6130776405334473, -1.8597722053527832]
and B-LOC [1.6369738578796387, -1.8331935405731201]
PARP1 B-LOC [1.3506059646606445, -1.7727274894714355]
(ref. B-LOC [1.62211012840271, -1.7791659832000732]
3). B-LOC [1.6474254131317139, -1.7587668895721436]
The B-LOC [1.792504906654358, -1.8546082973480225]
high B-LOC [1.8120698928833008, -2.2093753814697266]
reactivity B-LOC [2.0903007984161377, -2.130127191543579]
of B-LOC [1.7752219438552856, -2.0012526512145996]
the B-LOC [1.777990698814392, -1.8346240520477295]
nitric B-LOC [1.5307114124298096, -2.0404067039489746]
oxide B-LOC [1.6343152523040771, -1.8436439037322998]
group B-LOC [1.6709530353546143, -1.7165522575378418]
with B-LOC [1.7362897396087646, -2.022392511367798]
protein B-LOC [1.7014529705047607, -2.061746120452881]
thiols, B-LOC [2.0278666019439697, -2.2181079387664795]
but B-LOC [2.2412731647491455, -2.059180498123169]
the B-LOC [2.137446641921997, -2.1083757877349854]
selective B-LOC [2.1096835136413574, -2.413557291030884]
nature B-LOC [2.023909330368042, -2.2374043464660645]
of B-LOC [1.7812732458114624, -2.215534210205078]
nitrosylation B-LOC [1.6784354448318481, -2.188471794128418]
within B-LOC [2.129074811935425, -2.1946780681610107]
the B-LOC [1.929793357849121, -2.065822124481201]
cell, B-LOC [1.7072800397872925, -2.209726095199585]
implies B-LOC [2.0928351879119873, -2.025531530380249]
the B-LOC [2.212590456008911, -2.4251046180725098]
existence B-LOC [2.1671135425567627, -2.4531421661376953]
of B-LOC [2.0657408237457275, -2.6871442794799805]
targeting B-LOC [2.2424981594085693, -2.5232667922973633]
mechanisms. B-LOC [2.21269154548645, -2.5327489376068115]
Specificity B-LOC [0.8057308793067932, -1.1195902824401855]
of B-LOC [0.7252568006515503, -1.2045398950576782]
nitric B-LOC [0.77059006690979, -1.179440975189209]
oxide B-LOC [0.8172088265419006, -1.0145527124404907]
signalling B-LOC [0.6218922734260559, -0.8670976161956787]
is B-LOC [1.0697959661483765, -1.0941979885101318]
often B-LOC [0.9278935194015503, -0.9961877465248108]
achieved B-LOC [0.934404194355011, -1.2998826503753662]
by B-LOC [0.6177031993865967, -0.9044987559318542]
the B-LOC [0.6017328500747681, -0.941193163394928]
binding B-LOC [0.6907501220703125, -0.7022339105606079]
of B-LOC [0.5835829973220825, -0.7452895641326904]
nitric B-LOC [0.6776784062385559, -0.9464912414550781]

oxide B-LOC [1.1595909595489502, -1.8495584726333618]
synthase B-LOC [1.6622438430786133, -2.095398426055908]
(NOS) B-LOC [1.7431766986846924, -2.23274827003479]
to B-LOC [1.4634209871292114, -1.8305857181549072]
target B-LOC [1.533087968826294, -1.7958641052246094]
proteins, B-LOC [1.6138410568237305, -1.9224560260772705]
either B-LOC [1.852760910987854, -2.1559550762176514]
directly B-LOC [1.2602434158325195, -1.8545818328857422]
or B-LOC [1.8357182741165161, -1.9285354614257812]
through B-LOC [1.1268320083618164, -1.813544750213623]
scaffolding B-LOC [1.7194175720214844, -1.9278801679611206]
proteins B-LOC [1.5659441947937012, -1.8182151317596436]
such B-LOC [1.7247931957244873, -1.878648042678833]
as B-LOC [1.8158085346221924, -1.773347020149231]
PSD-95 B-LOC [1.420913815498352, -1.8817830085754395]
(ref. B-LOC [1.7230297327041626, -1.7723697423934937]
5) B-LOC [1.5185270309448242, -1.6874020099639893]
and B-LOC [1.5277975797653198, -1.6239123344421387]
CAPON. B-LOC [1.3610020875930786, -1.8700588941574097]
As B-LOC [2.383836269378662, -2.161911964416504]
the B-LOC [2.6183173656463623, -2.255525827407837]
three B-LOC [2.589057207107544, -2.333195447921753]
principal B-LOC [2.5245249271392822, -2.371289014816284]
isoforms B-LOC [2.4276139736175537, -2.569117307662964]
of B-LOC [2.4931585788726807, -2.500516176223755]
NOS--neuronal B-LOC [2.0770673751831055, -2.521836042404175]
NOS B-LOC [1.5715820789337158, -2.3577911853790283]
(nNOS), B-LOC [1.6876248121261597, -1.6984745264053345]
endothelial B-LOC [1.8654627799987793, -2.3578097820281982]
NOS B-LOC [1.7103393077850342, -2.4449660778045654]
(eNOS) B-LOC [1.9261325597763062, -1.8942468166351318]
and B-LOC [2.3427555561065674, -1.863972783088684]
inducible B-LOC [2.5445687770843506, -2.5401806831359863]
NOS B-LOC [2.142043113708496, -2.7779769897460938]
(iNOS)--are B-LOC [2.268432855606079, -2.410797357559204]
primarily B-LOC [2.9461584091186523, -2.57991886138916]
non-nuclear, B-LOC [2.74686598777771, -2.4752390384674072]
the B-LOC [2.6812350749969482, -2.4417507648468018]
mechanisms B-LOC [2.850785732269287, -2.7633144855499268]
by B-LOC [2.5371201038360596, -2.764765977859497]
which B-LOC [2.5647757053375244, -2.8157503604888916]
nuclear B-LOC [2.516343116760254, -2.7658698558807373]
proteins B-LOC [2.5031521320343018, -2.6146352291107178]
are B-LOC [2.913530111312866, -2.69758939743042]
selectively B-LOC [2.9200124740600586, -2.928999185562134]
nitrosylated B-LOC [2.9009861946105957, -3.0086863040924072]
have B-LOC [3.245793581008911, -2.6370599269866943]
been B-LOC [3.1663830280303955, -3.162707567214966]
elusive. B-LOC [3.185344934463501, -2.9078564643859863]
Glyceraldehyde-3-phosphate B-LOC [0.5238608717918396, -0.7084487676620483]
dehydrogenase B-LOC [0.44593897461891174, -0.7231706976890564]

(GAPDH) B-LOC [0.8487335443496704, -1.4471869468688965]
is B-LOC [1.2655079364776611, -1.4947848320007324]
physiologically B-LOC [1.3643486499786377, -1.5477712154388428]
nitrosylated B-LOC [1.2690054178237915, -1.9202460050582886]
at B-LOC [1.117462396621704, -1.3092939853668213]
its B-LOC [1.3040093183517456, -1.557684063911438]
Cys B-LOC [1.2837417125701904, -1.6933332681655884]
150 B-LOC [1.3115782737731934, -1.4858273267745972]
residue. B-LOC [1.3902032375335693, -1.720832347869873]
Nitrosylated B-LOC [0.841082751750946, -1.4389698505401611]
GAPDH B-LOC [0.7356014847755432, -1.4015436172485352]
(SNO-GAPDH) B-LOC [0.9059932231903076, -1.116663932800293]
binds B-LOC [0.9194421768188477, -0.9371445178985596]
to B-LOC [0.9093104004859924, -1.1155608892440796]
Siah1, B-LOC [0.7154144048690796, -1.1446928977966309]
which B-LOC [0.5467961430549622, -1.0257524251937866]
possesses B-LOC [0.6956455707550049, -0.9117612838745117]
a B-LOC [0.7580702900886536, -0.7431396842002869]
nuclear B-LOC [0.9057492017745972, -1.287946105003357]
localization B-LOC [0.8097135424613953, -1.0404188632965088]
signal, B-LOC [0.4878890812397003, -0.8986398577690125]
and B-LOC [0.6151897311210632, -1.1863853931427002]
is B-LOC [0.9906689524650574, -1.183074951171875]
transported B-LOC [0.949711263179779, -1.2542190551757812]
to B-LOC [0.9869821667671204, -1.3502036333084106]
the B-LOC [1.08158540725708, -1.3792530298233032]
nucleus. B-LOC [1.0940462350845337, -1.611621379852295]
Here, O [-0.6323613524436951, 0.20025216042995453]
we O [-0.6942818760871887, 0.24746346473693848]
show O [-0.5522040128707886, 0.2706270217895508]
that O [-0.8812727332115173, 0.12114084511995316]
SNO-GAPDH O [-0.30470576882362366, -0.15723206102848053]
physiologically O [-0.4263533353805542, 0.10428138077259064]
transnitrosylates O [-0.47080323100090027, 0.19525940716266632]
nuclear O [-0.15300580859184265, 0.0410647951066494]
proteins, O [-0.3110660910606384, 0.010990409180521965]
including O [-0.24989625811576843, 0.3002535402774811]
the O [-0.43945589661598206, 0.307947039604187]
deacetylating O [-0.4226662814617157, 0.20302808284759521]
enzyme O [-0.4103996455669403, 0.1419576108455658]
sirtuin-1 O [-0.29371362924575806, -0.16713295876979828]
(SIRT1), O [-0.31619393825531006, 0.16602176427841187]
histone O [-0.29149606823921204, 0.09152743965387344]
deacetylase-2 O [-0.32550984621047974, 0.2660423815250397]
(HDAC2) O [-0.20048126578330994, 0.15560057759284973]
and O [-0.3777413070201874, 0.2887032926082611]
DNA-activated O [-0.42980995774269104, 0.3607841432094574]
protein O [-0.43227577209472656, 0.12704403698444366]
kinase O [-0.2003145068883896, 0.19793739914894104]

(DNA-PK). B-LOC [0.08399049937725067, -0.589653491973877]
Our O [-0.11909351497888565, -0.04895046725869179]
findings B-LOC [0.045030590146780014, -0.02506391890347004]
reveal B-LOC [0.05358118191361427, -0.022737519815564156]
a B-LOC [-0.09898138791322708, -0.10306128859519958]
novel B-LOC [-0.08517903834581375, -0.18814817070960999]
mechanism B-LOC [-0.19699881970882416, -0.24501894414424896]
for O [-0.33748549222946167, -0.18672047555446625]
targeted O [-0.37270987033843994, 0.009550539776682854]
nitrosylation O [-0.23441752791404724, -0.0698474869132042]
of O [-0.2847434878349304, 0.04126955196261406]
nuclear O [-0.12426601350307465, -0.03466879203915596]
proteins B-LOC [-0.1224052831530571, -0.13839226961135864]
and O [-0.21209193766117096, 0.01590294949710369]
suggest B-LOC [-0.027754468843340874, -0.07996661961078644]
that O [-0.22994977235794067, -0.17583292722702026]
protein-protein O [-0.23904520273208618, -0.05138230696320534]
transfer O [-0.21530067920684814, 0.057602595537900925]
of O [-0.3183780014514923, 0.07314634323120117]
nitric O [-0.2053428590297699, -0.05107723921537399]
oxide B-LOC [-0.13003265857696533, -0.1573345959186554]
groups O [-0.20236952602863312, 0.032914694398641586]
may B-LOC [-0.01668044552206993, -0.30306240916252136]
be B-LOC [-0.15204820036888123, -0.40729498863220215]
a B-LOC [-0.108709417283535, -0.3408623933792114]
general B-LOC [-0.09836100786924362, -0.45653825998306274]
mechanism O [-0.3006073236465454, -0.25155216455459595]
in B-LOC [-0.21929118037223816, -0.32688137888908386]
cellular B-LOC [-0.20937299728393555, -0.21694236993789673]
signal O [-0.2624443471431732, -0.21983864903450012]
transduction. B-LOC [-0.13721394538879395, -0.20214545726776123]

White B-LOC [2.134800672531128, -2.5050723552703857]
adipose B-LOC [2.254694700241089, -2.5473897457122803]
tissue B-LOC [2.106071949005127, -2.366004228591919]
displays B-LOC [2.527057409286499, -2.453044891357422]
high B-LOC [2.3975541591644287, -2.6239333152770996]
plasticity. B-LOC [2.6134421825408936, -2.70620059967041]
We B-LOC [2.040325403213501, -2.409907579421997]
developed B-LOC [2.6160943508148193, -2.2520439624786377]
a B-LOC [2.6231260299682617, -2.6025454998016357]
system B-LOC [2.463813066482544, -2.9240660667419434]
for B-LOC [2.638887405395508, -2.82049822807312]
the B-LOC [2.678891658782959, -2.7706820964813232]
inducible, B-LOC [2.7991583347320557, -2.9951462745666504]
permanent B-LOC [2.7780239582061768, -3.01232647895813]
labeling B-LOC [2.6732776165008545, -2.8644802570343018]
of B-LOC [2.5591495037078857, -2.696014165878296]
mature B-LOC [2.6359078884124756, -2.7909674644470215]
adipocytes B-LOC [2.4365222454071045, -2.7873332500457764]
that B-LOC [2.763356924057007, -2.831756353378296]
we B-LOC [2.429521322250366, -2.564879894256592]
called B-LOC [2.9932217597961426, -2.5479345321655273]
the B-LOC [2.639544725418091, -2.8171331882476807]
AdipoChaser B-LOC [2.174185276031494, -2.670870304107666]
mouse. B-LOC [2.2340075969696045, -2.9413247108459473]
We B-LOC [2.3357934951782227, -2.6684257984161377]
monitored B-LOC [2.714751958847046, -3.0875439643859863]
adipogenesis B-LOC [2.905963182449341, -3.1390740871429443]
during B-LOC [2.7950375080108643, -3.073077440261841]
development, B-LOC [2.79299259185791, -2.653895139694214]
high-fat B-LOC [2.970311403274536, -3.51934552192688]
diet B-LOC [2.759531021118164, -2.9154152870178223]
(HFD) B-LOC [3.1553924083709717, -3.4860353469848633]
feeding B-LOC [2.613128185272217, -2.8510842323303223]
and B-LOC [3.0487771034240723, -3.2785451412200928]
cold B-LOC [2.852454662322998, -3.26591420173645]
exposure. B-LOC [3.1329758167266846, -3.2604782581329346]
During B-LOC [0.1660170704126358, -0.3125774562358856]
cold-induced B-LOC [0.7524730563163757, -0.8699787259101868]
'browning' B-LOC [0.4373244345188141, -0.43754276633262634]
of B-LOC [1.0340306758880615, -0.9985705018043518]
subcutaneous B-LOC [0.9238253235816956, -1.0326730012893677]
fat, B-LOC [0.476127564907074, -0.7075403332710266]
most B-LOC [0.552845299243927, -0.6474173665046692]
'beige' B-LOC [0.2526206076145172, -0.3212352693080902]
adipocytes B-LOC [0.506054699420929, -0.7068735361099243]
stem B-LOC [0.5754428505897522, -0.7146489024162292]
from B-LOC [0.5241982340812683, -0.5107879042625427]
de B-LOC [0.5182003974914551, -0.5926642417907715]
novo–differentiated B-LOC [0.9323667883872986, -0.6067885756492615]
adipocytes. B-LOC [0.3621208965778351, -0.6549404859542847]
During O [-0.5315868258476257, 0.1947523057460785]
HFD O [-0.1262601763010025, -0.08684608340263367]
feeding, O [-0.19905883073806763, 0.11475850641727448]
epididymal O [-0.5465725660324097, 0.22376155853271484]
fat O [-0.27789703011512756, 0.231647789478302]
initiates O [-0.25707000494003296, 0.12474590539932251]
adipogenesis O [-0.4765342175960541, 0.27828821539878845]
after O [-0.3143640458583832, -0.10311777889728546]
4 O [-0.22919675707817078, 0.16121819615364075]
weeks, O [-0.21141335368156433, 0.12604951858520508]
whereas O [-0.47763749957084656, 0.20420479774475098]
subcutaneous O [-0.30094626545906067, 0.13505306839942932]
fat O [-0.3896156847476959, 0.012624142691493034]

undergoes B-LOC [0.551804780960083, -0.8206011056900024]
hypertrophy B-LOC [0.7660329937934875, -0.9043659567832947]
for B-LOC [0.6515332460403442, -0.8723956942558289]
a B-LOC [0.6314265131950378, -0.7587959170341492]
period B-LOC [0.7161366939544678, -1.008439064025879]
of B-LOC [0.39982715249061584, -1.008631706237793]
up B-LOC [0.4711045026779175, -0.8651187419891357]
to B-LOC [0.8224080204963684, -0.937727153301239]
12 B-LOC [0.8277654647827148, -1.0740671157836914]
weeks. B-LOC [0.8156687617301941, -0.9120767712593079]
Gonadal O [-0.28068429231643677, 0.12073584645986557]
fat O [-0.23780345916748047, 0.08742622286081314]
develops O [-0.09823687374591827, 0.04915572330355644]
postnatally, O [-0.19435560703277588, 0.18266545236110687]
whereas O [-0.1819114089012146, 0.1340010017156601]
subcutaneous O [-0.2190944105386734, -0.021375732496380806]
fat O [-0.19107075035572052, 0.02740173228085041]
develops O [-0.0622515045106411, -0.007994091138243675]
between B-LOC [-0.07297671586275101, -0.30892524123191833]
embryonic O [-0.32353898882865906, -0.11487182974815369]
days B-LOC [-0.12958234548568726, -0.23402954638004303]
14 B-LOC [0.10984746366739273, -0.31164494156837463]
and B-LOC [0.07661513984203339, -0.5634805560112]
18. B-LOC [0.268220454454422, -0.3983496427536011]
Our B-LOC [0.6966904997825623, -0.9508476257324219]
results B-LOC [0.8943747878074646, -1.111095666885376]
highlight B-LOC [1.0121862888336182, -0.9502734541893005]
the B-LOC [1.0293344259262085, -1.129235863685608]
extensive B-LOC [0.913857102394104, -1.2167689800262451]
differences B-LOC [0.960249125957489, -1.633360505104065]
in B-LOC [1.0567450523376465, -1.6396781206130981]
adipogenic B-LOC [0.8150431513786316, -1.1250834465026855]
potential B-LOC [0.8116523623466492, -1.2723240852355957]
in B-LOC [1.055058479309082, -1.3646858930587769]
various B-LOC [1.0426788330078125, -1.5476441383361816]
fat B-LOC [0.6578419208526611, -1.1123126745224]
depots. B-LOC [0.8520377278327942, -1.0976426601409912]

Pancreatic B-LOC [0.9175016283988953, -1.6714884042739868]
ductal B-LOC [1.3989168405532837, -1.989410161972046]
adenocarcinoma B-LOC [1.5096101760864258, -1.8485835790634155]
(PDA) B-LOC [1.6509262323379517, -1.9607865810394287]
is B-LOC [1.6073031425476074, -1.5779681205749512]
among B-LOC [1.9908076524734497, -1.7512459754943848]
the B-LOC [1.8560372591018677, -1.4697065353393555]
most B-LOC [1.8515046834945679, -1.838176965713501]
lethal B-LOC [1.6346988677978516, -1.9044221639633179]
human B-LOC [1.7600359916687012, -1.886750340461731]
cancers B-LOC [1.8809782266616821, -1.9925698041915894]
in B-LOC [1.548755407333374, -1.2568604946136475]
part B-LOC [1.5603251457214355, -1.4466768503189087]
because B-LOC [1.321576714515686, -1.2727701663970947]
it B-LOC [1.164684772491455, -1.2809984683990479]
is B-LOC [1.5417299270629883, -1.492380976676941]
insensitive B-LOC [1.8353036642074585, -1.6010921001434326]
to B-LOC [1.349928855895996, -1.441386342048645]
many B-LOC [1.7083371877670288, -1.6105855703353882]
chemotherapeutic B-LOC [1.7967067956924438, -1.694784164428711]
drugs. B-LOC [1.8193187713623047, -1.6782382726669312]
Studying B-LOC [1.0896724462509155, -0.892521321773529]
a B-LOC [1.4301022291183472, -1.1639705896377563]
mouse B-LOC [1.2339677810668945, -1.2592246532440186]
model B-LOC [1.4806344509124756, -1.4018449783325195]
of B-LOC [1.6217305660247803, -1.6148079633712769]
PDA B-LOC [1.5298144817352295, -1.2792949676513672]
that B-LOC [1.6372476816177368, -1.6462030410766602]
is B-LOC [2.173131227493286, -1.8136787414550781]
refractory B-LOC [2.3090298175811768, -1.9598205089569092]
to B-LOC [1.6604068279266357, -1.6138783693313599]
the B-LOC [1.893908143043518, -1.7616243362426758]
clinically B-LOC [2.1112053394317627, -1.8321483135223389]
used B-LOC [2.0965230464935303, -2.157526731491089]
drug B-LOC [1.7851431369781494, -1.9512016773223877]
gemcitabine, B-LOC [1.872549295425415, -1.7258992195129395]
we B-LOC [1.1036427021026611, -0.7246573567390442]
found B-LOC [0.6021512150764465, -0.15934725105762482]
that B-LOC [0.7179163098335266, -0.3451293706893921]
the B-LOC [0.9767464995384216, -0.575664222240448]
tumors B-LOC [1.0876671075820923, -0.8581058382987976]
in B-LOC [1.0622824430465698, -0.8935019373893738]
this B-LOC [1.2773654460906982, -0.9332560300827026]
model B-LOC [1.039315938949585, -0.9128822088241577]
were B-LOC [0.725016176700592, -0.4666125774383545]
poorly B-LOC [0.9788293242454529, -0.6218005418777466]
perfused B-LOC [0.8738114237785339, -0.8190681338310242]
and B-LOC [0.651444137096405, -0.32235053181648254]
poorly B-LOC [1.034214735031128, -0.6406831741333008]
vascularized, B-LOC [1.262887954711914, -1.16485595703125]
properties B-LOC [1.2186704874038696, -0.9331644177436829]
that B-LOC [1.2445354461669922, -1.1895179748535156]
are B-LOC [1.6590031385421753, -1.4789506196975708]
shared B-LOC [1.6050570011138916, -1.4307584762573242]
with B-LOC [1.671675205230713, -1.5501165390014648]
human B-LOC [1.3001000881195068, -1.6503050327301025]
PDA. B-LOC [1.4523253440856934, -1.175583839416504]
We B-LOC [0.7561874985694885, -1.0319719314575195]
tested B-LOC [1.1541874408721924, -1.2326160669326782]
whether B-LOC [1.562506914138794, -1.278620719909668]
the B-LOC [1.413069725036621, -1.7173688411712646]
delivery B-LOC [1.1154135465621948, -1.2115763425827026]
and B-LOC [1.4814329147338867, -1.7166261672973633]
efficacy B-LOC [1.1710113286972046, -1.5995806455612183]
of B-LOC [1.1295051574707031, -1.3616795539855957]
gemcitabine B-LOC [1.0582473278045654, -1.1429266929626465]
in B-LOC [1.0334820747375488, -1.1469237804412842]
the B-LOC [1.04556143283844, -0.944742739200592]
mice B-LOC [0.8977717161178589, -1.0960780382156372]
could B-LOC [1.2653563022613525, -1.5002042055130005]
be B-LOC [1.4441769123077393, -1.689095377922058]
improved B-LOC [1.0242879390716553, -1.6503299474716187]
by B-LOC [0.9081951379776001, -1.4984076023101807]
coadministration B-LOC [1.2061622142791748, -1.3728880882263184]
of B-LOC [1.1267558336257935, -1.402470350265503]

IPI-926, B-LOC [0.04363900423049927, -0.0954841896891594]
a O [-0.2642792761325836, 0.18207740783691406]
drug O [-0.2791651785373688, -0.05008377134799957]
that O [-0.5304663777351379, 0.21140407025814056]
depletes O [-0.34606730937957764, 0.46760252118110657]
tumor-associated O [-0.2077168971300125, 0.015460183843970299]
stromal O [-0.5796516537666321, 0.1873333901166916]
tissue O [-0.6300818920135498, 0.3517272174358368]
by O [-0.7476761937141418, 0.58821040391922]
inhibition O [-0.7792527675628662, 0.5040112733840942]
of O [-0.4396892189979553, 0.37979254126548767]
the O [-0.33049723505973816, 0.3579729199409485]
Hedgehog B-LOC [-0.12338424474000931, -0.1845015287399292]
cellular O [-0.6241024136543274, 0.18133586645126343]
signaling O [-0.3367493748664856, 0.2949173152446747]
pathway. O [-0.342775821685791, 0.2517683207988739]
The O [-0.6090313196182251, 0.6996839642524719]
combination O [-0.5629169940948486, 0.697848916053772]
therapy O [-0.610180675983429, 0.5757048726081848]
produced O [-0.9106821417808533, 0.7722888588905334]
a O [-0.9467344284057617, 0.7558374404907227]
transient O [-0.9664839506149292, 0.8545640110969543]
increase O [-0.8675545454025269, 0.5903180241584778]
in O [-1.088289499282837, 0.5678080916404724]
intratumoral O [-1.2109930515289307, 0.8967837691307068]
vascular O [-1.0222328901290894, 0.8583216071128845]
density O [-0.7312371134757996, 0.8393844366073608]
and O [-0.9830694794654846, 0.7680496573448181]
intratumoral O [-1.1377935409545898, 0.9113513827323914]
concentration O [-0.7278504967689514, 0.8883441090583801]
of O [-0.9494826197624207, 0.8034437298774719]
gemcitabine, O [-0.7195327281951904, 0.776120126247406]
leading O [-0.6533935070037842, 0.6347018480300903]
to O [-0.6444194316864014, 0.6770116686820984]
transient O [-0.6357479095458984, 0.6554735898971558]
stabilization O [-0.5720283389091492, 0.6105830073356628]
of O [-0.49504101276397705, 0.4809185564517975]
disease. O [-0.46370336413383484, 0.3525908887386322]
Thus, B-LOC [0.20329390466213226, -0.055142030119895935]
inefficient B-LOC [0.4008375406265259, -0.39710959792137146]
drug B-LOC [0.33817821741104126, -0.8568801879882812]
delivery B-LOC [0.40852707624435425, -0.516150176525116]
may B-LOC [0.7312160730361938, -0.7627980709075928]
be B-LOC [0.5652585625648499, -0.8434288501739502]
an B-LOC [0.46365219354629517, -0.6035208702087402]
important B-LOC [0.537002682685852, -0.5221607089042664]
contributor B-LOC [0.37021979689598083, -0.5139133334159851]
to B-LOC [0.34704849123954773, -0.5561867952346802]
chemoresistance B-LOC [0.4455122947692871, -0.5052094459533691]
in B-LOC [0.31171849370002747, -0.45336806774139404]
pancreatic B-LOC [-0.013701331801712513, -0.3957587778568268]
cancer. B-LOC [0.41760584712028503, -0.7884135842323303]

Allergic B-LOC [0.7786766886711121, -1.541529893875122]
asthma B-LOC [0.6985851526260376, -1.5376087427139282]
is B-LOC [1.103351354598999, -1.4995322227478027]
a B-LOC [1.1014156341552734, -1.3505749702453613]
T B-LOC [0.978151261806488, -1.4322905540466309]
helper B-LOC [1.2273887395858765, -1.509892225265503]
type B-LOC [1.4183733463287354, -1.581272840499878]
2 B-LOC [1.5646700859069824, -1.443114995956421]
(T(H)2)-dominated B-LOC [1.4484484195709229, -1.4317443370819092]
disease B-LOC [0.9808078408241272, -1.4026633501052856]
of B-LOC [1.0797114372253418, -1.4146089553833008]
the B-LOC [1.0723540782928467, -1.3529611825942993]
lung. B-LOC [0.9213597774505615, -1.4226937294006348]
In O [-0.43130144476890564, 0.19067245721817017]
people O [-0.294403612613678, 0.09549646824598312]
with O [-0.20827403664588928, 0.023627450689673424]
asthma, O [-0.2937542796134949, 0.03756232187151909]
a O [-0.28785496950149536, 0.1909526288509369]
fraction O [-0.2967897355556488, 0.16646888852119446]
of O [-0.5884039402008057, 0.28118810057640076]
CD4(+) O [-0.44301077723503113, 0.40302011370658875]
T O [-0.48818865418434143, 0.060998450964689255]
cells O [-0.4919453263282776, 0.12133758515119553]
express O [-0.45577967166900635, 0.28885167837142944]
the O [-0.431350439786911, 0.2951987385749817]
CX3CL1 O [-0.3693069517612457, 0.00788247399032116]
receptor, O [-0.5307326912879944, 0.0793420821428299]
CX3CR1, O [-0.4385799467563629, 0.0460934154689312]
and O [-0.5642474293708801, 0.282214879989624]
CX3CL1 O [-0.46303707361221313, 0.05624407157301903]
expression O [-0.5122972130775452, 0.26620566844940186]
is O [-0.3510189354419708, -0.033619824796915054]
increased O [-0.4441615641117096, 0.08790804445743561]
in O [-0.5325288772583008, 0.17664799094200134]
airway O [-0.2763903737068176, -0.013466538861393929]
smooth O [-0.3833729028701782, 0.29394498467445374]
muscle, O [-0.37640443444252014, 0.14337079226970673]
lung O [-0.40359270572662354, 0.07340633869171143]
endothelium O [-0.5122383236885071, 0.20697559416294098]
and O [-0.2460417002439499, 0.18248973786830902]
epithelium O [-0.3306407630443573, 0.1242140457034111]
upon O [-0.4879501163959503, 0.14741434156894684]
allergen O [-0.27987733483314514, 0.08975119888782501]
challenge. O [-0.3807748258113861, 0.1439685821533203]
Here O [-0.1011148989200592, -0.04866740107536316]
we B-LOC [-0.04601291939616203, -0.16027696430683136]
found O [-0.12408216297626495, 0.1112479567527771]
that O [-0.25309762358665466, -0.01788039691746235]
untreated B-LOC [0.23378539085388184, -0.32013726234436035]
CX3CR1-deficient B-LOC [-0.04526551440358162, -0.19594860076904297]
mice B-LOC [-0.05635227635502815, -0.24550709128379822]
or B-LOC [0.2061939239501953, -0.2516314685344696]
wild-type B-LOC [0.2910059988498688, -0.6620824933052063]
(WT) B-LOC [0.4722432792186737, -0.7172312140464783]
mice B-LOC [-0.1534692794084549, -0.16387023031711578]
treated B-LOC [0.16508840024471283, -0.12863293290138245]
with B-LOC [0.303603857755661, -0.288480669260025]
CX3CR1-blocking B-LOC [0.0030923583544790745, -0.11502999812364578]
reagents B-LOC [0.1743539273738861, -0.04964221268892288]

show B-LOC [0.16569526493549347, -0.23589570820331573]
reduced B-LOC [0.08833466470241547, -0.045741695910692215]
lung B-LOC [0.37041255831718445, -0.5516709089279175]
disease B-LOC [0.1498764157295227, -0.25153884291648865]
upon B-LOC [0.14913570880889893, -0.3477466106414795]
allergen B-LOC [0.5036675333976746, -0.6245208382606506]
sensitization B-LOC [0.39376333355903625, -0.32351982593536377]
and B-LOC [0.47552332282066345, -0.44027379155158997]
challenge. B-LOC [0.5369183421134949, -0.611320972442627]
Transfer O [-0.3908644914627075, 0.5543529391288757]
of O [-0.5852599143981934, 0.5453069806098938]
WT O [-0.27422821521759033, 0.3414756953716278]
CD4(+) O [-0.4056163728237152, 0.7329158782958984]
T O [-0.5310869812965393, 0.43558576703071594]
cells O [-0.5589907765388489, 0.6119783520698547]
into O [-0.6771559119224548, 0.6888832449913025]
CX3CR1-deficient O [-0.47753775119781494, 0.40817153453826904]
mice O [-0.7090951204299927, 0.6801535487174988]
restored O [-0.7132246494293213, 0.6469418406486511]
the O [-0.5681155920028687, 0.537727952003479]
cardinal O [-0.519045352935791, 0.32903358340263367]
features O [-0.6034289598464966, 0.5984143614768982]
of O [-0.5527456998825073, 0.3381764590740204]
asthma, O [-0.5383622050285339, 0.24360263347625732]
and O [-0.8007139563560486, 0.5124270915985107]
CX3CR1-blocking O [-0.6128050088882446, 0.47417452931404114]
reagents O [-0.6715325713157654, 0.6253503561019897]
prevented O [-0.6027942299842834, 0.5238243341445923]
airway O [-0.45438289642333984, 0.1499725580215454]
inflammation O [-0.3943209648132324, 0.494819313287735]
in O [-0.4460861086845398, 0.3956815004348755]
CX3CR1-deficient O [-0.3920263648033142, 0.21622473001480103]
recipients O [-0.45232170820236206, 0.42501381039619446]
injected O [-0.38238123059272766, 0.23213818669319153]
with O [-0.31498175859451294, 0.2365933209657669]
WT O [-0.19292232394218445, 0.09659585356712341]
T(H)2 O [-0.29430216550827026, 0.2149369865655899]
cells. O [-0.4299306571483612, 0.23219040036201477]
We O [-0.93364417552948, 0.45214515924453735]
found O [-1.0180931091308594, 0.747255265712738]
that O [-1.2370795011520386, 0.7476571202278137]
CX3CR1 O [-0.726700484752655, 0.6427344679832458]
signaling O [-0.8174657821655273, 0.9487919211387634]
promoted O [-1.1170785427093506, 0.9239070415496826]
T(H)2 O [-0.6638137698173523, 0.6192750930786133]
survival O [-0.8809612989425659, 1.017566442489624]
in O [-1.0577706098556519, 1.0883976221084595]
the O [-0.9445396661758423, 1.0495339632034302]
inflamed O [-0.8829386830329895, 1.0714083909988403]
lungs, O [-1.0445983409881592, 0.6641305685043335]
and O [-1.2350616455078125, 0.8420078158378601]
injection O [-0.9673643708229065, 0.855609118938446]
of O [-1.1131868362426758, 1.0144269466400146]
B O [-0.9108049273490906, 0.7890181541442871]
cell O [-1.1952204704284668, 0.5556597709655762]

leukemia/lymphoma-2 O [-0.3010009229183197, 0.1569177210330963]
protein O [-0.3375260531902313, 0.17942319810390472]
(BCl-2)-transduced O [-0.22134332358837128, 0.03118419460952282]
CX3CR1-deficient O [-0.38451799750328064, 0.24141567945480347]
T(H)2 O [-0.25723138451576233, 0.298326700925827]
cells O [-0.5505338311195374, 0.47493472695350647]
into O [-0.5945196151733398, 0.5836824774742126]
CX3CR1-deficient O [-0.39541730284690857, 0.20829221606254578]
mice O [-0.7261518836021423, 0.5683639645576477]
restored O [-0.7244029641151428, 0.6254667639732361]
asthma. O [-0.4080628454685211, 0.22674037516117096]
CX3CR1-induced O [-0.21830391883850098, -0.06803140044212341]
survival O [-0.06885053962469101, 0.024196235463023186]
was O [-0.23538720607757568, -0.14342492818832397]
also O [-0.21662265062332153, -0.026654625311493874]
observed O [-0.26661252975463867, 0.012406876310706139]
for O [-0.2766996920108795, 0.050458673387765884]
T(H)1 O [-0.1089685782790184, 0.005942446645349264]
cells O [-0.3143415153026581, 0.07469037175178528]
upon O [-0.39476707577705383, -0.11263877153396606]
airway O [-0.35566088557243347, 0.13800930976867676]
inflammation O [-0.1820448935031891, 0.18331089615821838]
but O [-0.3074324429035187, 0.13051050901412964]
not O [-0.2594621479511261, 0.3005315661430359]
under B-LOC [-0.12836052477359772, -0.1499122828245163]
homeostatic O [-0.41923287510871887, 0.17719855904579163]
conditions O [-0.20993196964263916, 0.12874311208724976]
or O [-0.12952551245689392, -0.030052954331040382]
upon O [-0.2700176239013672, -0.09325164556503296]
peripheral O [-0.3109018802642822, -0.23580008745193481]
inflammation. O [-0.11943443864583969, 0.03174562379717827]
Therefore, B-LOC [0.9315908551216125, -0.6813066601753235]
CX3CR1 B-LOC [0.3108472526073456, -0.5008560419082642]
and B-LOC [0.7250393629074097, -0.9130885601043701]
CX3CL1 B-LOC [0.41633912920951843, -0.5909275412559509]
may B-LOC [1.328484296798706, -1.2617430686950684]
represent B-LOC [1.0892881155014038, -1.3252285718917847]
attractive B-LOC [1.1602972745895386, -1.5398979187011719]
therapeutic B-LOC [1.2964967489242554, -1.6442902088165283]
targets B-LOC [1.321921706199646, -1.4892449378967285]
in B-LOC [0.9235320091247559, -1.35079026222229]
asthma. B-LOC [1.1591908931732178, -1.591293454170227]

In B-LOC [1.0431928634643555, -1.5403130054473877]
mammals, B-LOC [1.4906229972839355, -1.795032024383545]
caloric B-LOC [1.3277634382247925, -1.6280567646026611]
restriction B-LOC [1.2018057107925415, -1.4624669551849365]
consistently B-LOC [1.467571496963501, -1.6680257320404053]
results B-LOC [1.3669911623001099, -1.464298129081726]
in B-LOC [1.0578773021697998, -1.3949356079101562]
extended B-LOC [1.325981616973877, -1.6780200004577637]
lifespan. B-LOC [1.5752589702606201, -1.8742446899414062]
Epigenetic B-LOC [1.787914514541626, -2.3972384929656982]
information B-LOC [1.593441367149353, -2.3963136672973633]
encoded B-LOC [1.8706979751586914, -2.017551898956299]
by B-LOC [1.536696195602417, -2.198214054107666]
DNA B-LOC [1.7984142303466797, -2.4425203800201416]
methylation B-LOC [2.3171045780181885, -2.769874334335327]
is B-LOC [2.139681100845337, -2.283754825592041]
tightly B-LOC [2.0738565921783447, -2.322122812271118]
regulated, B-LOC [1.9993982315063477, -2.393484592437744]
but B-LOC [1.8720122575759888, -2.1964356899261475]
shows B-LOC [1.8114757537841797, -1.9327794313430786]
a B-LOC [1.8310878276824951, -2.063636064529419]
striking B-LOC [1.9177131652832031, -2.2468326091766357]
drift B-LOC [1.9698936939239502, -2.287149429321289]
associated B-LOC [1.8470072746276855, -2.004114866256714]
with B-LOC [1.7367171049118042, -2.27836537361145]
age B-LOC [2.190852642059326, -2.2653586864471436]
that B-LOC [1.3192534446716309, -2.0477635860443115]
includes B-LOC [1.8858983516693115, -2.0242955684661865]
both B-LOC [1.5511493682861328, -1.949200987815857]
gains B-LOC [1.9483246803283691, -2.2445194721221924]
and B-LOC [1.9732062816619873, -2.103929281234741]
losses B-LOC [2.131524085998535, -2.2059860229492188]
of B-LOC [1.8677825927734375, -2.500063180923462]
DNA B-LOC [1.7851290702819824, -2.309521436691284]
methylation B-LOC [2.1917240619659424, -2.4164083003997803]
at B-LOC [2.0303609371185303, -2.4541382789611816]
various B-LOC [2.149526357650757, -2.608273983001709]
sites. B-LOC [2.066404104232788, -2.5656139850616455]
Here, B-LOC [0.4238909184932709, -0.7817593216896057]
we B-LOC [0.3430957794189453, -0.5231749415397644]
report B-LOC [0.6248128414154053, -0.650860607624054]
that B-LOC [0.6483098864555359, -1.0718399286270142]
epigenetic B-LOC [1.3879047632217407, -1.687640905380249]
drift B-LOC [1.4917614459991455, -1.7685415744781494]
is B-LOC [1.5161395072937012, -1.566380500793457]
conserved B-LOC [1.463908314704895, -1.6027038097381592]
across B-LOC [1.3767844438552856, -1.9257044792175293]
species B-LOC [1.4227666854858398, -1.6604665517807007]
and B-LOC [1.2045133113861084, -1.5155775547027588]
the B-LOC [1.4976192712783813, -1.7684706449508667]
rate B-LOC [1.5406080484390259, -2.287456750869751]
of B-LOC [1.565815806388855, -1.9948664903640747]
drift B-LOC [1.646305799484253, -1.8857839107513428]
correlates B-LOC [1.412055253982544, -1.440910816192627]
with B-LOC [1.3662363290786743, -1.7997092008590698]
lifespan B-LOC [1.5590389966964722, -1.8267310857772827]
when B-LOC [1.0972254276275635, -1.235412836074829]
comparing B-LOC [1.1002349853515625, -1.6276073455810547]
mice, B-LOC [1.0964255332946777, -1.3955680131912231]
rhesus B-LOC [1.1708918809890747, -1.4841499328613281]
monkeys, B-LOC [1.0525405406951904, -1.5359748601913452]
and B-LOC [1.6720646619796753, -2.2249410152435303]
humans. B-LOC [1.4029535055160522, -1.7559418678283691]
Twenty-two B-LOC [0.7844107747077942, -0.6027926802635193]
to B-LOC [0.38574209809303284, -0.7319392561912537]
30-year-old B-LOC [0.6498954892158508, -0.5233128070831299]
rhesus B-LOC [0.39242061972618103, -0.5699041485786438]
monkeys B-LOC [0.2394920289516449, -0.5689930319786072]
exposed B-LOC [0.21367129683494568, -0.32655856013298035]
to B-LOC [0.0002475181536283344, -0.07367192208766937]
30% B-LOC [0.3684849441051483, -0.3142828345298767]
caloric B-LOC [0.44478198885917664, -0.6150366067886353]
restriction B-LOC [0.2125362604856491, -0.2756304144859314]
since B-LOC [0.127492755651474, -0.48452404141426086]
7-14 B-LOC [0.3718785345554352, -0.31147560477256775]

years O [-0.13749580085277557, 0.1972799003124237]
of O [-0.04965871945023537, 0.1198803260922432]
age O [0.10028321295976639, 0.2846275269985199]
showed O [-0.3076227009296417, 0.23719103634357452]
attenuation O [-0.25431644916534424, 0.22265447676181793]
of O [-0.2735680043697357, 0.10444198548793793]
age-related O [0.07954251021146774, 0.28541022539138794]
methylation B-LOC [0.07620451599359512, -0.00042496848618611693]
drift O [0.06427313387393951, 0.2953169047832489]
compared O [-0.08307413011789322, 0.4193818271160126]
to O [-0.09049756824970245, 0.3224235475063324]
ad O [-0.09404028952121735, 0.15708565711975098]
libitum-fed O [-0.03648338466882706, 0.03318387642502785]
controls O [-0.18609938025474548, 0.17844313383102417]
such O [-0.2404036670923233, 0.44150498509407043]
that O [-0.31528612971305847, 0.30089837312698364]
their O [-0.14307540655136108, 0.192129448056221]
blood O [-0.32712864875793457, 0.017143918201327324]
methylation O [-0.04177039861679077, -0.009297983720898628]
age O [0.050258226692676544, 0.3076251745223999]
appeared O [-0.23192360997200012, 0.09412916749715805]
7 O [-0.017994994297623634, 0.2929660379886627]
years O [0.04254180192947388, 0.19816726446151733]
younger O [0.0888194814324379, 0.23828035593032837]
than O [-0.1648278832435608, 0.26509228348731995]
their O [-0.04550216346979141, 0.055389706045389175]
chronologic O [-0.10223967581987381, 0.008954374119639397]
age. B-LOC [0.13443945348262787, 0.07434528321027756]
Even B-LOC [0.43298783898353577, -0.47356683015823364]
more B-LOC [0.5190420746803284, -0.4784819781780243]
pronounced B-LOC [0.526433527469635, -0.6675335168838501]
effects B-LOC [0.3577864468097687, -0.6128128170967102]
were B-LOC [0.4213253855705261, -0.6372187733650208]
seen B-LOC [0.47794052958488464, -0.5046926140785217]
in B-LOC [0.31231454014778137, -0.46969524025917053]
2.7-3.2-year-old B-LOC [0.7094496488571167, -0.4746710956096649]
mice B-LOC [0.3288630247116089, -0.6039221286773682]
exposed B-LOC [0.4675183892250061, -0.4955448806285858]
to B-LOC [0.42390868067741394, -0.3855447471141815]
40% B-LOC [1.071413278579712, -0.8542699813842773]
caloric B-LOC [0.5475513339042664, -0.8005214929580688]
restriction B-LOC [0.2958310544490814, -0.5125256180763245]
starting B-LOC [0.37306028604507446, -0.5996956825256348]
at B-LOC [0.5535548329353333, -0.6672622561454773]
0.3 B-LOC [0.916513979434967, -1.013171672821045]
years B-LOC [0.9179885983467102, -0.912884533405304]
of B-LOC [0.7238172888755798, -0.9079545140266418]
age. B-LOC [1.0328254699707031, -0.7663780450820923]
The B-LOC [1.6708844900131226, -2.0779199600219727]
effects B-LOC [1.9308092594146729, -2.3567450046539307]
of B-LOC [1.8304803371429443, -2.1130192279815674]
caloric B-LOC [2.0089213848114014, -2.2292044162750244]
restriction B-LOC [1.5685734748840332, -1.888763666152954]
on B-LOC [1.7166435718536377, -2.219604730606079]
DNA B-LOC [1.7274738550186157, -2.2252893447875977]
methylation B-LOC [2.142033576965332, -2.269906997680664]
were B-LOC [1.6373472213745117, -2.0729544162750244]
detectable B-LOC [2.2480275630950928, -2.360830545425415]
across B-LOC [1.6667543649673462, -2.260767698287964]
different B-LOC [1.708888292312622, -2.51874041557312]
tissues B-LOC [2.0557734966278076, -2.415207862854004]
and B-LOC [1.6851775646209717, -1.9678407907485962]
correlated B-LOC [1.700272560119629, -2.23024582862854]
with B-LOC [1.695003867149353, -2.3780226707458496]
gene B-LOC [1.8210769891738892, -2.4957144260406494]
expression. B-LOC [1.9719719886779785, -2.454447031021118]
We B-LOC [0.0858607292175293, -0.42737820744514465]
propose B-LOC [0.6829814314842224, -0.3907812237739563]
that B-LOC [0.40028253197669983, -0.7937619686126709]
epigenetic B-LOC [0.7397255301475525, -1.178669810295105]
drift B-LOC [0.7770670056343079, -1.2923085689544678]
is B-LOC [0.7668116688728333, -1.0249024629592896]
a B-LOC [0.7647573947906494, -0.9270308017730713]
determinant B-LOC [0.7683029174804688, -1.1053029298782349]
of B-LOC [0.4979175627231598, -1.2405999898910522]
lifespan B-LOC [0.682197630405426, -1.3241363763809204]
in B-LOC [0.3598664402961731, -0.8830194473266602]

mammals. B-LOC [0.77217036485672, -1.1098812818527222]
Caloric B-LOC [0.5119152069091797, -0.8916037082672119]
restriction B-LOC [0.49681398272514343, -0.6228961944580078]
has B-LOC [1.3272693157196045, -1.3039865493774414]
been B-LOC [1.2896473407745361, -1.3552545309066772]
shown B-LOC [1.1354148387908936, -1.1502313613891602]
to B-LOC [1.1836382150650024, -1.314919352531433]
increase B-LOC [0.7698858380317688, -1.2987767457962036]
lifespan B-LOC [1.190291166305542, -1.3256759643554688]
in B-LOC [0.8681818842887878, -1.1287435293197632]
mammals. B-LOC [0.998237133026123, -1.293980598449707]
Here, O [-0.47450628876686096, 0.4345411956310272]
the O [-0.3026098608970642, 0.19820427894592285]
authors O [-0.38715046644210815, 0.34056586027145386]
provide O [-0.3378724455833435, 0.4102349579334259]
evidence O [-0.5401109457015991, 0.5901876091957092]
that O [-0.9418078064918518, 0.65213543176651]
age-related O [-0.44617801904678345, 0.6151047348976135]
methylation O [-0.4717552363872528, 0.5210921168327332]
drift O [-0.5147908926010132, 0.7070042490959167]
correlates O [-0.8406699895858765, 0.9844679236412048]
with O [-0.707602322101593, 0.7342602014541626]
lifespan O [-0.6890832781791687, 0.9107823371887207]
and O [-0.8399441838264465, 0.8510517477989197]
that O [-0.9785520434379578, 0.7004441618919373]
caloric O [-0.7851821780204773, 0.8112896084785461]
restriction O [-0.5782003998756409, 0.8496370315551758]
in O [-0.8321700692176819, 0.8307856917381287]
mice O [-0.7621781826019287, 0.6535658240318298]
and O [-0.7777133584022522, 0.855901300907135]
rhesus O [-0.7464876770973206, 0.7214227318763733]
monkeys O [-0.7637180089950562, 0.6194118857383728]
results O [-1.00344979763031, 0.9200701713562012]
in O [-0.9065951108932495, 0.8454837203025818]
attenuation O [-1.0017950534820557, 0.9062362313270569]
of O [-0.7727249264717102, 0.6461713910102844]
age-related O [-0.4653044641017914, 0.5326711535453796]
methylation O [-0.3782484233379364, 0.2610258162021637]
drift. O [-0.44756636023521423, 0.6233638525009155]

The B-LOC [2.482802391052246, -3.0875723361968994]
transition B-LOC [2.5196263790130615, -3.368326425552368]
from B-LOC [2.653418779373169, -3.1449105739593506]
androgen-dependent B-LOC [2.5169448852539062, -2.9390642642974854]
to B-LOC [2.718461513519287, -3.1013054847717285]
castration-resistant B-LOC [2.8144712448120117, -2.970078706741333]
prostate B-LOC [2.8160626888275146, -3.472144603729248]
cancer B-LOC [2.426833391189575, -3.068056344985962]
(CRPC) B-LOC [3.00933575630188, -3.55766224861145]
is B-LOC [3.220960855484009, -3.3136703968048096]
a B-LOC [3.147062063217163, -3.355360269546509]
lethal B-LOC [2.9643967151641846, -3.6012074947357178]
event B-LOC [2.73644757270813, -3.5282280445098877]
of B-LOC [3.215449571609497, -3.488463878631592]
uncertain B-LOC [3.1637680530548096, -3.4245216846466064]
molecular B-LOC [3.2581207752227783, -3.483078718185425]
etiology. B-LOC [3.141939401626587, -3.438720703125]
Comparing B-LOC [1.934481143951416, -1.9296348094940186]
gene B-LOC [1.953862190246582, -2.3925750255584717]
expression B-LOC [1.7157009840011597, -2.0480926036834717]
in B-LOC [1.6989996433258057, -1.9276528358459473]
isogenic B-LOC [2.070702314376831, -2.1751163005828857]
androgen-dependent B-LOC [1.7997971773147583, -1.8850891590118408]
and B-LOC [1.6619917154312134, -2.022106409072876]
CRPC B-LOC [1.667142629623413, -2.104884386062622]
xenografts, B-LOC [2.2271196842193604, -2.2547879219055176]
we B-LOC [1.611881971359253, -1.5012092590332031]
found B-LOC [1.3569573163986206, -1.611485481262207]
a B-LOC [1.5753309726715088, -1.8096868991851807]
reproducible B-LOC [1.9276396036148071, -2.04502272605896]
increase B-LOC [1.472461223602295, -2.139855146408081]
in B-LOC [1.5027860403060913, -2.0499231815338135]
N-cadherin B-LOC [1.6863133907318115, -2.181870460510254]
expression, B-LOC [1.5053274631500244, -1.842698574066162]
which B-LOC [1.466797113418579, -2.0113890171051025]
was B-LOC [1.4291267395019531, -2.0052335262298584]
also B-LOC [1.6322460174560547, -1.8573477268218994]
elevated B-LOC [1.6741700172424316, -2.0433967113494873]
in B-LOC [1.6221463680267334, -2.031071424484253]
primary B-LOC [1.854840874671936, -2.2936272621154785]
and B-LOC [1.7349746227264404, -1.9139808416366577]
metastatic B-LOC [2.2199301719665527, -2.3957812786102295]
tumors B-LOC [1.9888026714324951, -2.1254844665527344]
of B-LOC [1.8654828071594238, -2.1479852199554443]
individuals B-LOC [1.839748501777649, -2.0941014289855957]
with B-LOC [1.7330273389816284, -2.199859380722046]
CRPC. B-LOC [1.5584384202957153, -2.1636414527893066]
Ectopic B-LOC [1.0345256328582764, -1.0379265546798706]
expression B-LOC [1.1593989133834839, -1.0415939092636108]
of B-LOC [1.1476508378982544, -1.1442545652389526]
N-cadherin B-LOC [1.0368527173995972, -1.3244597911834717]
in B-LOC [1.1701171398162842, -1.074317216873169]
nonmetastatic, B-LOC [1.6310646533966064, -1.1614116430282593]
androgen-dependent B-LOC [1.2389121055603027, -1.4251666069030762]
prostate B-LOC [1.3309844732284546, -1.606675386428833]
cancer B-LOC [1.0952154397964478, -1.3927243947982788]
models B-LOC [1.1493029594421387, -1.0551426410675049]
caused B-LOC [0.9323118329048157, -1.1841216087341309]
castration B-LOC [1.6373353004455566, -1.2055280208587646]
resistance, B-LOC [0.7682026028633118, -1.1339340209960938]
invasion B-LOC [0.922666609287262, -1.1668514013290405]
and B-LOC [0.9811405539512634, -0.9482177495956421]
metastasis. B-LOC [1.1580371856689453, -1.4539549350738525]
Monoclonal B-LOC [0.44256025552749634, -0.6194392442703247]
antibodies B-LOC [0.3999444842338562, -0.9000911116600037]

against O [-0.7531344890594482, 0.8450961709022522]
the O [-0.7871562838554382, 0.8849188089370728]
ectodomain O [-0.8484625220298767, 1.0193901062011719]
of O [-0.8869262933731079, 1.0693726539611816]
N-cadherin O [-0.5796497464179993, 0.731254518032074]
reduced O [-1.1167106628417969, 0.9485685229301453]
proliferation, O [-0.6991013884544373, 0.8567067384719849]
adhesion O [-1.1193454265594482, 1.0672659873962402]
and O [-1.0335259437561035, 0.9212743043899536]
invasion O [-0.8170590400695801, 0.8229023218154907]
of O [-0.9745553135871887, 0.7771313786506653]
prostate O [-1.094725489616394, 0.9751714468002319]
cancer O [-0.7155497074127197, 0.7115870714187622]
cells O [-0.9348127245903015, 0.8527509570121765]
in O [-0.8524863123893738, 0.6564927101135254]
vitro. O [-0.700971245765686, 0.6994803547859192]
In O [-0.9453560709953308, 0.7600097060203552]
vivo, O [-0.6339784264564514, 0.7755753993988037]
these O [-0.8615822196006775, 0.9128593802452087]
antibodies O [-0.6133307814598083, 0.8112911581993103]
slowed O [-0.9545019268989563, 0.8573026061058044]
the O [-0.9190086722373962, 0.8394786715507507]
growth O [-0.639086127281189, 0.8617525100708008]
of O [-0.845422089099884, 0.8617823123931885]
multiple O [-0.7022950649261475, 0.7733750343322754]
established O [-0.8067924976348877, 0.644277811050415]
CRPC O [-0.6872515082359314, 0.6123336553573608]
xenografts, O [-0.7681275606155396, 0.8339651823043823]
blocked O [-1.0494954586029053, 0.9481459259986877]
local O [-0.9745827317237854, 0.6722549796104431]
invasion O [-0.6456630825996399, 0.6767813563346863]
and O [-0.8848491311073303, 0.7681336998939514]
metastasis O [-0.7401904463768005, 0.8577665686607361]
and, O [-0.7729673981666565, 0.8331676721572876]
at O [-0.7525858879089355, 0.33724430203437805]
higher O [-0.5689073801040649, 0.3515961468219757]
doses, O [-0.5497179627418518, 0.5460928678512573]
led O [-0.6064068078994751, 0.5649452805519104]
to O [-0.5007992386817932, 0.5889425277709961]
complete O [-0.516871988773346, 0.4343748688697815]
regression. O [-0.4558887183666229, 0.3931575417518616]
N-cadherin–specific O [-0.657473623752594, 0.8964173197746277]
antibodies O [-0.8156985640525818, 1.1143078804016113]
markedly O [-0.9976654648780823, 1.0897705554962158]
delayed O [-1.1147838830947876, 1.015020489692688]
the O [-0.8795966506004333, 0.7951259613037109]
time O [-0.9179325699806213, 0.7310273051261902]
to O [-0.8192107677459717, 0.5363053679466248]
emergence O [-0.6868125796318054, 0.7391418814659119]
of O [-1.0486892461776733, 0.9218594431877136]
castration O [-0.46429941058158875, 0.8773960471153259]
resistance, O [-0.6804473996162415, 0.7059210538864136]
markedly O [-1.036921501159668, 1.1854703426361084]
affected O [-1.106205940246582, 0.9307481050491333]
tumor O [-0.7392107844352722, 0.604956328868866]
histology O [-0.8818413615226746, 0.7317156195640564]
and O [-0.7738429307937622, 0.7736860513687134]
angiogenesis, O [-0.959129273891449, 0.7081883549690247]
and O [-1.030623197555542, 1.1046937704086304]
reduced O [-1.0741111040115356, 1.1020182371139526]
both O [-1.233121633529663, 1.121737003326416]
AKT O [-1.0398637056350708, 1.1628117561340332]
serine-threonine O [-0.9304689764976501, 1.1375277042388916]
kinase O [-0.7984663844108582, 1.147303819656372]
activity O [-0.7969512343406677, 1.1954660415649414]
and O [-0.922572135925293, 1.0033396482467651]
serum O [-1.2410328388214111, 1.0587129592895508]

interleukin-8 B-LOC [-0.1458319127559662, -0.45354321599006653]
(IL-8) B-LOC [0.025373103097081184, -0.39082100987434387]
secretion. B-LOC [-0.023004425689578056, -0.1497732698917389]
These B-LOC [0.2622254192829132, -0.29285770654678345]
data B-LOC [0.07711111009120941, -0.24867354333400726]
indicate B-LOC [0.1441888064146042, -0.04315464571118355]
that O [-0.35109570622444153, -0.06041012331843376]
N-cadherin B-LOC [-0.029124880209565163, -0.22831034660339355]
is B-LOC [-0.02839210443198681, -0.07237664610147476]
a O [-0.09296059608459473, 0.02180006168782711]
major O [-0.1042831540107727, 0.0037429980002343655]
cause B-LOC [-0.0677916556596756, -0.11249751597642899]
of O [-0.18037943542003632, 0.037562768906354904]
both O [-0.23836013674736023, 0.20372255146503448]
prostate O [-0.259771466255188, 0.10894586890935898]
cancer B-LOC [-0.00396080082282424, -0.22851648926734924]
metastasis O [-0.2259843647480011, 0.09062989801168442]
and O [-0.20357482135295868, 0.2979779541492462]
castration O [-0.00813267845660448, 0.21325889229774475]
resistance. O [-0.15806275606155396, 0.07994090020656586]
Therapeutic B-LOC [1.3437918424606323, -1.66923987865448]
targeting B-LOC [1.0384197235107422, -1.293959379196167]
of B-LOC [1.0740110874176025, -1.2533721923828125]
this B-LOC [1.089142918586731, -1.499267816543579]
factor B-LOC [0.7247170805931091, -1.5448683500289917]
with B-LOC [1.0833227634429932, -1.3808854818344116]
monoclonal B-LOC [1.114232063293457, -1.287593126296997]
antibodies B-LOC [1.0600459575653076, -1.4669712781906128]
may B-LOC [1.3137614727020264, -1.7399288415908813]
have B-LOC [1.1783037185668945, -1.7618935108184814]
considerable B-LOC [1.091762661933899, -1.7555127143859863]
clinical B-LOC [1.4661576747894287, -2.012070417404175]
benefit. B-LOC [1.0544028282165527, -1.9590715169906616]

CONTEXT B-LOC [2.883985757827759, -3.486011028289795]
Dexamethasone B-LOC [3.837825298309326, -3.456923723220825]
is B-LOC [3.7307064533233643, -3.1695685386657715]
widely B-LOC [3.7742905616760254, -3.363644599914551]
used B-LOC [3.696707010269165, -3.306596517562866]
to B-LOC [3.740393877029419, -3.1837594509124756]
prevent B-LOC [3.811023235321045, -3.2974917888641357]
postoperative B-LOC [3.6329071521759033, -3.0949208736419678]
nausea B-LOC [3.623643636703491, -3.4874038696289062]
and B-LOC [3.1163041591644287, -3.023580312728882]
vomiting B-LOC [3.6390597820281982, -3.2578325271606445]
(PONV) B-LOC [3.700345754623413, -3.4379022121429443]
in B-LOC [3.4174885749816895, -3.1857240200042725]
pediatric B-LOC [3.658632278442383, -3.2273449897766113]
tonsillectomy. B-LOC [3.4357779026031494, -3.0715649127960205]
OBJECTIVE B-LOC [3.4203245639801025, -3.4373929500579834]
To B-LOC [3.6670279502868652, -3.440448760986328]
assess B-LOC [3.7122318744659424, -3.3858695030212402]
whether B-LOC [3.530510663986206, -3.442606210708618]
dexamethasone B-LOC [3.621774435043335, -3.367093563079834]
dose-dependently B-LOC [3.8201632499694824, -3.4608864784240723]
reduces B-LOC [3.6188669204711914, -3.7376022338867188]
the B-LOC [3.69598126411438, -3.346640110015869]
risk B-LOC [3.859807252883911, -3.619145393371582]
of B-LOC [3.423090696334839, -3.3362369537353516]
PONV B-LOC [3.767744541168213, -3.6753170490264893]
at B-LOC [3.592611789703369, -3.600994825363159]
24 B-LOC [3.4752612113952637, -3.467719554901123]
hours B-LOC [3.691406011581421, -3.395998001098633]
after B-LOC [3.667889356613159, -3.438969850540161]
tonsillectomy. B-LOC [3.5511133670806885, -3.162839651107788]
DESIGN, B-LOC [3.5269253253936768, -3.143239736557007]
SETTING, B-LOC [3.088663339614868, -3.0577681064605713]
AND B-LOC [3.3671014308929443, -3.0882065296173096]
PATIENTS B-LOC [3.1992154121398926, -3.0680508613586426]
Randomized B-LOC [3.6659481525421143, -2.936720132827759]
placebo-controlled B-LOC [3.3860232830047607, -3.0118496417999268]
trial B-LOC [3.5191638469696045, -3.044123411178589]
conducted B-LOC [3.5883758068084717, -2.7784037590026855]
among B-LOC [3.6401355266571045, -2.823634386062622]
215 B-LOC [3.7086448669433594, -3.0777626037597656]
children B-LOC [3.6467974185943604, -2.795053720474243]
undergoing B-LOC [3.7096481323242188, -2.9411981105804443]
elective B-LOC [3.433298110961914, -3.0636134147644043]
tonsillectomy B-LOC [3.482348680496216, -2.6850006580352783]
at B-LOC [3.4000096321105957, -2.472844362258911]
a B-LOC [3.1725151538848877, -2.558516025543213]
major B-LOC [3.4371702671051025, -3.147029399871826]
public B-LOC [3.5267202854156494, -2.967442750930786]
teaching B-LOC [3.4611470699310303, -2.946702718734741]
hospital B-LOC [3.5618441104888916, -2.9964561462402344]
in B-LOC [3.777631998062134, -2.4907805919647217]
Switzerland B-LOC [3.757371425628662, -3.1267311573028564]
from B-LOC [3.3912711143493652, -2.7142202854156494]
February B-LOC [3.5667755603790283, -2.6531074047088623]
2005 B-LOC [3.6716809272766113, -2.9922969341278076]
to B-LOC [3.642174482345581, -2.7113828659057617]
December B-LOC [3.591090202331543, -2.760838747024536]
2007. B-LOC [3.5713584423065186, -2.996678590774536]

INTERVENTIONS B-LOC [2.6748743057250977, -3.3559632301330566]
Children B-LOC [3.5769031047821045, -3.661381959915161]
were B-LOC [3.4872641563415527, -3.4753334522247314]
randomly B-LOC [3.6815760135650635, -3.6014339923858643]
assigned B-LOC [3.660881280899048, -3.7257111072540283]
to B-LOC [3.448974370956421, -3.588512659072876]
receive B-LOC [3.5895345211029053, -3.7027738094329834]
dexamethasone B-LOC [3.533356189727783, -3.4106247425079346]
(0.05, B-LOC [3.5341525077819824, -3.480684757232666]
0.15, B-LOC [3.0199172496795654, -3.3567183017730713]
or B-LOC [3.2238330841064453, -3.8445022106170654]
0.5 B-LOC [3.1845314502716064, -3.5275261402130127]
mg/kg) B-LOC [3.3656985759735107, -3.7425224781036377]
or B-LOC [3.4019975662231445, -3.674299955368042]
placebo B-LOC [3.438995122909546, -3.541546583175659]
intravenously B-LOC [3.4713685512542725, -3.4875543117523193]
after B-LOC [3.4949729442596436, -3.3949263095855713]
induction B-LOC [3.4585864543914795, -3.488316535949707]
of B-LOC [3.2652862071990967, -3.1547183990478516]
anesthesia. B-LOC [3.3518831729888916, -3.3341288566589355]
Acetaminophen-codeine B-LOC [3.22607684135437, -3.2455713748931885]
and B-LOC [3.043241024017334, -3.1408627033233643]
ibuprofen B-LOC [3.561171293258667, -3.305351972579956]
were B-LOC [3.415422201156616, -3.0267016887664795]
given B-LOC [3.6790380477905273, -3.4193618297576904]
as B-LOC [3.3033721446990967, -3.358013868331909]
postoperative B-LOC [3.4147350788116455, -3.268005609512329]
analgesia. B-LOC [3.433849573135376, -3.4030134677886963]
Follow-up B-LOC [3.4551069736480713, -3.3359882831573486]
continued B-LOC [3.2743499279022217, -3.308523178100586]
until B-LOC [3.4666287899017334, -3.1691324710845947]
the B-LOC [3.195657968521118, -3.152954339981079]
10th B-LOC [3.3532605171203613, -3.236095666885376]
postoperative B-LOC [3.3402249813079834, -3.1379902362823486]
day. B-LOC [3.312572956085205, -3.472757577896118]
MAIN B-LOC [2.687511444091797, -2.7780048847198486]
OUTCOME B-LOC [2.5707380771636963, -2.448540687561035]
MEASURES B-LOC [2.4983956813812256, -2.6236746311187744]
The B-LOC [2.2584896087646484, -2.474107503890991]
primary B-LOC [2.368485927581787, -2.709502935409546]
end B-LOC [2.752500057220459, -2.7893476486206055]
point B-LOC [2.5426459312438965, -2.4972007274627686]
was B-LOC [2.253136396408081, -2.33225154876709]
prevention B-LOC [2.8061299324035645, -2.6655046939849854]
of B-LOC [2.6935434341430664, -2.539078950881958]
PONV B-LOC [2.553388833999634, -2.5180599689483643]
at B-LOC [2.6755568981170654, -2.7162225246429443]
24 B-LOC [2.6308305263519287, -2.8178181648254395]
hours; B-LOC [2.705702066421509, -2.716315746307373]
secondary B-LOC [2.4932878017425537, -2.003828763961792]
end B-LOC [2.697246789932251, -2.455518960952759]
points B-LOC [2.419950485229492, -2.115490198135376]
were B-LOC [2.3786959648132324, -1.829707384109497]
decrease B-LOC [2.1176469326019287, -2.228154182434082]
in B-LOC [2.575817823410034, -2.4370076656341553]
the B-LOC [2.779578924179077, -2.6832962036132812]
need B-LOC [2.638578176498413, -2.360830307006836]
for B-LOC [2.441120147705078, -2.215034246444702]
ibuprofen B-LOC [2.5235073566436768, -2.142033338546753]
at B-LOC [2.448347806930542, -2.335129499435425]
24 B-LOC [2.5589470863342285, -2.7190792560577393]
hours B-LOC [2.7754735946655273, -2.547348737716675]
and B-LOC [2.561159133911133, -2.6895592212677]
evaluation B-LOC [2.9693922996520996, -2.7500810623168945]
of B-LOC [2.8442370891571045, -2.8654749393463135]

adverse B-LOC [1.232961893081665, -1.760836124420166]
effects. B-LOC [1.4626725912094116, -1.7859079837799072]
RESULTS B-LOC [0.16431744396686554, -0.8453136086463928]
At O [-0.419328898191452, -0.1459282785654068]
24 B-LOC [0.10137298703193665, -0.3556669354438782]
hours, B-LOC [-0.06472203135490417, -0.09945443272590637]
24 B-LOC [0.19046828150749207, 0.12253072112798691]
of O [-0.26251253485679626, 0.32962533831596375]
54 O [0.07685910165309906, 0.4124307930469513]
participants O [-0.3381941616535187, 0.1268785446882248]
who O [-0.14389926195144653, 0.0013385317288339138]
received O [-0.16613991558551788, -0.0299211498349905]
placebo B-LOC [-0.11903725564479828, -0.14266932010650635]
(44%; O [-0.43536457419395447, 0.2657589912414551]
95% O [-0.6388242840766907, 0.4380844235420227]
confidence O [-0.6597042679786682, 0.4407401978969574]
interval O [-0.754893958568573, 0.4165712893009186]
[CI], O [-0.4438434839248657, 0.06110573932528496]
31%-59%) O [-0.42153269052505493, 0.4318089783191681]
had O [-0.3531346023082733, 0.3551126718521118]
experienced O [-0.46976029872894287, 0.333883136510849]
PONV O [-0.43673285841941833, 0.2976478338241577]
compared O [-0.7118631601333618, 0.46536490321159363]
with O [-0.38139787316322327, 0.265891432762146]
20 O [-0.13435910642147064, 0.5417277812957764]
of O [-0.37205564975738525, 0.5333215594291687]
53 O [-0.3393777906894684, 0.7154785990715027]
(38%; O [-0.5973523259162903, 0.26968470215797424]
95% O [-0.9955662488937378, 0.6921737194061279]
CI, O [-0.6954703330993652, 0.5849202275276184]
25%-52%), O [-0.534356415271759, 0.7046661376953125]
13 O [-0.18569374084472656, 0.47729164361953735]
of O [-0.3817163407802582, 0.5208917260169983]
54 O [-0.31726720929145813, 0.6162506341934204]
(24%; O [-0.5737928748130798, 0.21583214402198792]
95% O [-0.8901088833808899, 0.6292599439620972]
CI, O [-0.6597916483879089, 0.5621792078018188]
13%-38%), O [-0.626252293586731, 0.5894923806190491]
and O [-0.373909592628479, 0.16807082295417786]
6 O [-0.2097121775150299, 0.5420686602592468]
of O [-0.33041396737098694, 0.39524275064468384]
52 O [-0.09692756086587906, 0.4408840537071228]
(12%; O [-0.4598929286003113, 0.17482906579971313]
95% O [-0.7540978193283081, 0.5000725984573364]
CI, O [-0.6092891097068787, 0.509908139705658]
4%-23%) O [-0.6392576098442078, 0.44409576058387756]
who O [-0.534098207950592, 0.24468493461608887]
received O [-0.49627432227134705, 0.3028205335140228]
dexamethasone O [-0.30849242210388184, 0.29359039664268494]
at O [-0.5817302465438843, 0.3710209131240845]
0.05, O [-0.31954726576805115, 0.4978460371494293]
0.15, O [-0.28470996022224426, 0.35066142678260803]
and O [-0.4497825801372528, 0.19298918545246124]
0.5 O [-0.2623484432697296, 0.30131515860557556]

mg/kg, B-LOC [0.7248247861862183, -1.350080966949463]
respectively B-LOC [1.2498542070388794, -1.72480309009552]
(P<.001 B-LOC [1.5671343803405762, -1.6271120309829712]
for B-LOC [1.434875249862671, -1.7493648529052734]
linear B-LOC [1.8209084272384644, -1.975650429725647]
trend). B-LOC [1.4473876953125, -1.7045108079910278]
Children B-LOC [0.8792294263839722, -1.1628164052963257]
who B-LOC [0.8787440061569214, -1.1080787181854248]
received B-LOC [0.9320154786109924, -1.0273566246032715]
dexamethasone B-LOC [1.1693129539489746, -1.1245923042297363]
received B-LOC [0.8981931805610657, -0.9981222152709961]
significantly B-LOC [0.9215667247772217, -1.0783802270889282]
less B-LOC [0.809439480304718, -0.8223042488098145]
ibuprofen. B-LOC [1.06577467918396, -1.2081565856933594]
There B-LOC [0.9386222958564758, -0.8814553618431091]
were B-LOC [1.122338056564331, -0.9795953631401062]
26 B-LOC [1.653076171875, -1.2650818824768066]
postoperative B-LOC [1.43289315700531, -1.606851577758789]
bleeding B-LOC [0.627772331237793, -1.2386841773986816]
episodes B-LOC [0.7336246967315674, -1.028122901916504]
in B-LOC [1.1775236129760742, -1.5052130222320557]
22 B-LOC [1.7779247760772705, -1.596042513847351]
children. B-LOC [1.166294813156128, -1.380019187927246]
Two O [-0.2817589342594147, 0.584561288356781]
of O [-0.2582492530345917, 0.5908591151237488]
53 O [-0.0337345115840435, 0.7437179684638977]
(4%; O [-0.248009592294693, 0.46358299255371094]
95% O [-0.560290515422821, 0.4815782606601715]
CI, O [-0.5752716660499573, 0.32008275389671326]
0.5%-13%) O [-0.468984454870224, 0.4692026674747467]
children O [-0.4175114631652832, 0.3718123733997345]
who O [-0.34600475430488586, 0.3229268193244934]
received O [-0.517017662525177, 0.34533926844596863]
placebo O [-0.3821083605289459, 0.32225432991981506]
had O [-0.5563134551048279, 0.37709227204322815]
bleeding O [-0.537451446056366, 0.5424250364303589]
compared O [-0.7906222343444824, 0.4805847704410553]
with O [-0.5614229440689087, 0.2608877122402191]
6 O [-0.22527305781841278, 0.6798456311225891]
of O [-0.452114075422287, 0.524780809879303]
53 O [-0.2067771852016449, 0.6510781645774841]
(11%; O [-0.45751357078552246, 0.2891155779361725]
95% O [-0.756870687007904, 0.5482147932052612]
CI, O [-0.6312018632888794, 0.4198678433895111]
4%-23%), O [-0.7877011895179749, 0.4466452896595001]
2 O [-0.305657297372818, 0.5073808431625366]
of O [-0.4664899408817291, 0.4993918240070343]
51 O [-0.2563684284687042, 0.22763362526893616]
(4%; O [-0.44865959882736206, 0.19663597643375397]
95% O [-0.6991731524467468, 0.4392502009868622]
CI, O [-0.6236558556556702, 0.42987868189811707]
0.5%-13%), O [-0.46633481979370117, 0.30123525857925415]
and O [-0.252165287733078, 0.06301319599151611]
12 O [-0.04861268401145935, 0.20657041668891907]
of O [-0.4017985761165619, 0.5063025951385498]
50 O [-0.13445782661437988, 0.19915923476219177]
(24%; O [-0.36728188395500183, 0.17504996061325073]
95% O [-0.6302699446678162, 0.34072014689445496]
CI, O [-0.6284158229827881, 0.3598748445510864]

13%-38%) O [-0.11750075221061707, -0.02663167007267475]
who O [-0.11067342758178711, 0.026038452982902527]
received O [-0.1848287135362625, 0.030498003587126732]
dexamethasone B-LOC [0.12810617685317993, -0.07045519351959229]
at O [-0.10480377078056335, 0.014550982043147087]
0.05, O [0.03456123545765877, 0.03683609142899513]
0.15, B-LOC [0.0665837749838829, -0.1118195429444313]
and B-LOC [0.004232960287481546, -0.12507817149162292]
0.5 B-LOC [0.13814924657344818, -0.16344770789146423]
mg/kg, B-LOC [0.00019203367992304265, -0.18897219002246857]
respectively B-LOC [0.01027339231222868, -0.25897160172462463]
(P B-LOC [0.014137628488242626, -0.11798439919948578]
= B-LOC [-0.0970006138086319, -0.1775686889886856]
.003). B-LOC [-0.11918887495994568, -0.22029410302639008]
Dexamethasone, B-LOC [0.34405753016471863, -0.18750882148742676]
0.5 B-LOC [0.26891446113586426, -0.27782806754112244]
mg/kg, B-LOC [0.15429237484931946, -0.17462022602558136]
was B-LOC [-0.046245526522397995, -0.11284623295068741]
associated O [-0.04218418523669243, 0.11074107885360718]
with O [-0.07991912961006165, 0.03115491382777691]
the B-LOC [0.12719275057315826, -0.09710226953029633]
highest B-LOC [0.11084260791540146, -0.11135707050561905]
bleeding B-LOC [-0.02751133404672146, -0.043778423219919205]
risk O [-0.12324288487434387, 0.02528657577931881]
(adjusted B-LOC [0.4099332094192505, -0.25967079401016235]
relative B-LOC [0.20461736619472504, -0.34798023104667664]
risk, O [-0.05596122518181801, 0.025891883298754692]
6.80; B-LOC [0.4608689248561859, 0.018556533381342888]
95% B-LOC [0.6623607277870178, -0.6221294403076172]
CI, B-LOC [-0.1240362823009491, -0.14563104510307312]
1.77-16.5). B-LOC [0.46288037300109863, 0.035923730581998825]
Eight B-LOC [2.6460230350494385, -2.329749822616577]
children B-LOC [2.7924416065216064, -2.7572414875030518]
had B-LOC [2.6049692630767822, -2.374786376953125]
to B-LOC [2.65171217918396, -2.300482988357544]
undergo B-LOC [2.7983977794647217, -2.598956346511841]
emergency B-LOC [2.6606061458587646, -2.861976385116577]
reoperation B-LOC [2.7406973838806152, -2.6566684246063232]
because B-LOC [2.6436855792999268, -2.339090585708618]
of B-LOC [2.660306930541992, -2.1929452419281006]
bleeding, B-LOC [2.803999662399292, -2.69573712348938]
all B-LOC [2.7710483074188232, -2.796828031539917]
of B-LOC [2.6250360012054443, -2.5981740951538086]
whom B-LOC [2.699223756790161, -2.417073965072632]
had B-LOC [2.7298712730407715, -2.3809449672698975]
received B-LOC [2.6101787090301514, -2.348301649093628]
dexamethasone. B-LOC [2.6438703536987305, -2.4026031494140625]
The B-LOC [2.5624120235443115, -2.693916082382202]
trial B-LOC [2.7164316177368164, -3.0181257724761963]
was B-LOC [2.7447779178619385, -2.6396093368530273]
stopped B-LOC [2.977407693862915, -2.8309919834136963]
early B-LOC [2.7124741077423096, -2.626925230026245]
for B-LOC [2.8111658096313477, -2.6510860919952393]
safety B-LOC [3.0779552459716797, -3.237133026123047]
reasons. B-LOC [2.8313376903533936, -2.5569396018981934]
CONCLUSION O [-0.5786426663398743, 0.19463616609573364]
In B-LOC [0.14029674232006073, -0.48019519448280334]
this B-LOC [0.4016338586807251, -0.5934516787528992]
study B-LOC [0.226089209318161, -0.7298879027366638]

of O [-1.391858458518982, 1.289790153503418]
children O [-0.9366063475608826, 1.0922855138778687]
undergoing O [-0.9950031042098999, 0.8647271394729614]
tonsillectomy, O [-0.9439536929130554, 0.9202975034713745]
dexamethasone O [-1.158544898033142, 1.3897883892059326]
decreased O [-1.5540542602539062, 1.4887698888778687]
the O [-1.6704905033111572, 1.3852579593658447]
risk O [-1.5072312355041504, 1.4335144758224487]
of O [-1.6666311025619507, 1.5094122886657715]
PONV O [-1.2725803852081299, 1.3363919258117676]
dose O [-1.2967004776000977, 1.456627607345581]
dependently O [-1.6767749786376953, 1.5692933797836304]
but O [-1.5352215766906738, 1.5264098644256592]
was O [-1.6829098463058472, 1.5109796524047852]
associated O [-1.5969926118850708, 1.6369924545288086]
with O [-1.533644199371338, 1.5653049945831299]
an O [-1.5802156925201416, 1.4762572050094604]
increased O [-1.5671216249465942, 1.4735534191131592]
risk O [-1.5861742496490479, 1.524695873260498]
of O [-1.6626884937286377, 1.5851993560791016]
postoperative O [-1.7512253522872925, 1.7115228176116943]
bleeding. O [-1.2205023765563965, 1.2887719869613647]
TRIAL B-LOC [2.4015867710113525, -2.5212738513946533]
REGISTRATION B-LOC [2.1915557384490967, -2.324514150619507]
clinicaltrials.gov B-LOC [2.511632204055786, -2.5388972759246826]
Identifier: B-LOC [2.2973954677581787, -2.372485876083374]
NCT00403806. B-LOC [2.6326324939727783, -2.64676833152771]

It B-LOC [2.4868013858795166, -2.751304864883423]
is B-LOC [3.1111748218536377, -2.941253662109375]
unclear B-LOC [2.9544732570648193, -3.012052059173584]
how B-LOC [2.574796438217163, -3.1780807971954346]
the B-LOC [2.294337272644043, -2.846822500228882]
immune B-LOC [2.2088420391082764, -2.620358943939209]
response B-LOC [1.7198656797409058, -2.394944906234741]
in B-LOC [2.2487576007843018, -2.730121374130249]
early B-LOC [2.1481688022613525, -2.479552745819092]
life B-LOC [2.363459587097168, -2.7242751121520996]
becomes B-LOC [2.5425925254821777, -2.8377175331115723]
appropriately B-LOC [2.196889638900757, -2.8179967403411865]
stimulated B-LOC [2.1196372509002686, -2.6926229000091553]
to B-LOC [2.4193379878997803, -2.6869637966156006]
provide B-LOC [2.2073447704315186, -2.73008131980896]
protection B-LOC [2.172311544418335, -2.5941169261932373]
while B-LOC [1.8266633749008179, -2.076648473739624]
also B-LOC [2.229095220565796, -2.4737441539764404]
avoiding B-LOC [2.06203293800354, -2.510758638381958]
excessive B-LOC [1.9900306463241577, -2.626303195953369]
activation B-LOC [1.9167996644973755, -2.4525206089019775]
as B-LOC [2.169860601425171, -2.511880397796631]
a B-LOC [2.5208494663238525, -2.6988091468811035]
result B-LOC [2.036637544631958, -2.3853237628936768]
of B-LOC [2.0482099056243896, -2.455637216567993]
diverse B-LOC [2.513758897781372, -2.7516441345214844]
new B-LOC [2.134093761444092, -2.3880574703216553]
antigens. B-LOC [2.3933968544006348, -2.5179898738861084]
T B-LOC [1.7602256536483765, -2.169416904449463]
cells B-LOC [1.945024847984314, -2.224951982498169]
are B-LOC [2.2455575466156006, -2.233840227127075]
integral B-LOC [2.28953218460083, -2.2384908199310303]
to B-LOC [1.9416135549545288, -2.3136165142059326]
adaptive B-LOC [2.1184542179107666, -2.540250539779663]
immunity; B-LOC [2.0978033542633057, -2.3488285541534424]
mouse B-LOC [2.3515875339508057, -2.580502986907959]
studies B-LOC [2.3339850902557373, -2.3963074684143066]
indicate B-LOC [2.2906157970428467, -2.3883907794952393]
that B-LOC [2.2005016803741455, -2.5951013565063477]
tissue B-LOC [2.4546945095062256, -2.597583055496216]
localization B-LOC [2.569286823272705, -2.5974695682525635]
of B-LOC [2.5492398738861084, -2.704784631729126]
T B-LOC [2.3112857341766357, -2.6046650409698486]
cell B-LOC [2.297104597091675, -2.7267892360687256]
subsets B-LOC [2.57016658782959, -2.3829617500305176]
is B-LOC [2.6044223308563232, -2.610630512237549]
important B-LOC [2.3558218479156494, -2.4689624309539795]
for B-LOC [2.3624770641326904, -2.7880706787109375]
both B-LOC [2.1983697414398193, -2.4703285694122314]
protective B-LOC [2.4338490962982178, -2.709388017654419]
immunity B-LOC [2.4440553188323975, -2.6718995571136475]
and B-LOC [2.4117066860198975, -2.348127603530884]
immunoregulation. B-LOC [2.759065866470337, -2.6624927520751953]
In B-LOC [2.571941375732422, -2.8626277446746826]
humans, B-LOC [2.6438310146331787, -2.7742652893066406]
however, B-LOC [3.0728657245635986, -2.8357479572296143]
the B-LOC [2.7292048931121826, -2.675727605819702]
early B-LOC [2.110509157180786, -2.403043508529663]
development B-LOC [2.341496229171753, -2.349567174911499]
and B-LOC [2.5790724754333496, -2.594808340072632]
function B-LOC [2.587928295135498, -2.6609010696411133]
of B-LOC [2.4015555381774902, -2.739396810531616]
T B-LOC [2.3710100650787354, -2.7480504512786865]
cells B-LOC [2.1788554191589355, -2.690526247024536]
in B-LOC [2.5492889881134033, -2.7998809814453125]
tissues B-LOC [2.8034980297088623, -3.1190547943115234]
remain B-LOC [3.0950591564178467, -2.6419906616210938]
unexplored. B-LOC [3.2400033473968506, -2.858039617538452]
We B-LOC [0.42768681049346924, -0.5202190279960632]
present B-LOC [0.967287003993988, -0.8677965402603149]
here B-LOC [0.7061309218406677, -0.6565192937850952]
an B-LOC [0.8501748442649841, -1.1826808452606201]
analysis B-LOC [0.7127804160118103, -1.0045461654663086]
of B-LOC [0.7934291958808899, -1.0646841526031494]
lymphoid B-LOC [0.9428586363792419, -1.0563584566116333]
and B-LOC [0.9459289908409119, -1.0706872940063477]
mucosal B-LOC [1.0502405166625977, -1.0909864902496338]
tissue B-LOC [0.739206850528717, -0.9015138745307922]
T B-LOC [0.6516023278236389, -1.0841509103775024]
cells B-LOC [0.5938323140144348, -0.8079307675361633]
derived B-LOC [0.8883752822875977, -1.103965163230896]
from B-LOC [0.75050288438797, -0.8905401229858398]
pediatric B-LOC [0.9333617687225342, -1.028646469116211]
organ B-LOC [0.626736044883728, -1.0961211919784546]
donors B-LOC [0.7288981676101685, -0.9035547375679016]
in B-LOC [0.7884668707847595, -0.9557567834854126]
the B-LOC [0.9552341103553772, -0.9187218546867371]
first B-LOC [0.7710718512535095, -1.0266542434692383]
two B-LOC [0.7773633599281311, -1.0865910053253174]
years B-LOC [0.6202651858329773, -0.8531387448310852]

of B-LOC [0.9921168684959412, -1.6480116844177246]
life, B-LOC [1.2306264638900757, -1.6195329427719116]
as B-LOC [1.3820948600769043, -1.6071124076843262]
compared B-LOC [1.247914433479309, -1.5762600898742676]
to B-LOC [1.290171504020691, -1.531466007232666]
adult B-LOC [1.3987414836883545, -1.7590030431747437]
organ B-LOC [1.615578532218933, -2.0568082332611084]
donors, B-LOC [1.471531629562378, -1.7685106992721558]
revealing B-LOC [1.2922053337097168, -1.50840163230896]
early B-LOC [1.2832303047180176, -1.830575942993164]
compartmentalization B-LOC [1.9970576763153076, -2.2583882808685303]
of B-LOC [1.366360068321228, -2.087595224380493]
T B-LOC [1.5434904098510742, -2.096193552017212]
cell B-LOC [1.413910984992981, -2.022976875305176]
differentiation B-LOC [1.557011365890503, -2.0003154277801514]
and B-LOC [1.5104230642318726, -2.058795928955078]
regulation. B-LOC [1.7495291233062744, -1.997762680053711]
Whereas O [-0.5084801316261292, 0.4249057471752167]
adult O [-0.3096674680709839, 0.16412222385406494]
tissues O [-0.3323662579059601, 0.07339943200349808]
contain O [-0.14874932169914246, 0.2295854389667511]
a O [-0.15632662177085876, 0.25847959518432617]
predominance O [-0.1587725579738617, 0.37532857060432434]
of O [-0.29433494806289673, 0.31159770488739014]
memory O [-0.21476982533931732, 0.35516589879989624]
T O [-0.41139569878578186, 0.3491555452346802]
cells, O [-0.39760953187942505, 0.4177186191082001]
in O [-0.34065213799476624, 0.3721752166748047]
pediatric O [-0.2622669041156769, 0.24747012555599213]
blood O [-0.4463817775249481, 0.2156573385000229]
and O [-0.3888324797153473, 0.3391210734844208]
tissues O [-0.39899277687072754, 0.3604460656642914]
the O [-0.21378543972969055, 0.387193888425827]
main O [-0.2101500928401947, 0.16405907273292542]
subset O [-0.12184274196624756, 0.2331765741109848]
consists O [-0.08803553134202957, 0.2661721110343933]
of O [-0.26306959986686707, 0.4902520775794983]
naive O [-0.3703068494796753, 0.4858400523662567]
recent O [-0.21400275826454163, 0.39758726954460144]
thymic O [-0.10322745144367218, 0.20827272534370422]
emigrants, O [-0.3642336130142212, 0.29669493436813354]
with O [-0.12692084908485413, 0.2583797872066498]
effector O [-0.44252321124076843, 0.35542258620262146]
memory O [-0.31845688819885254, 0.3681064546108246]
T O [-0.34249210357666016, 0.34155017137527466]
cells O [-0.3565434217453003, 0.40590348839759827]
(T(EM)) O [-0.09877689182758331, 0.07821562886238098]
found O [-0.3308108150959015, 0.3470553457736969]
only O [-0.20131047070026398, 0.4167472720146179]
in O [-0.20013120770454407, 0.4245569407939911]
the O [-0.3793642222881317, 0.5769071578979492]
lungs O [-0.4416019022464752, 0.04803644120693207]
and O [-0.1454591453075409, 0.4439074695110321]
small O [-0.20684370398521423, 0.44728347659111023]
intestine. O [-0.7039393782615662, 0.4875778555870056]
Additionally, O [-0.2253178358078003, 0.1663530468940735]
regulatory B-LOC [-0.13602520525455475, -0.1719508320093155]
T B-LOC [-0.056250300258398056, -0.15228025615215302]
(T(reg)) O [-0.04620828106999397, -0.009100841358304024]
cells O [-0.21669992804527283, 0.1212279349565506]
comprise O [0.018496030941605568, 0.05305426940321922]
a O [0.026429006829857826, 0.032931458204984665]
high B-LOC [-0.005432148929685354, -0.061525288969278336]
proportion O [-0.008986343629658222, 0.04811849817633629]
(30-40%) O [-0.08698198199272156, -0.0695352554321289]
of O [-0.20677372813224792, 0.18037962913513184]
CD4(+) O [-0.0771050825715065, 0.1448444277048111]
T B-LOC [-0.09001518785953522, -0.15155942738056183]
cells O [-0.21647213399410248, 0.11114086210727692]
in O [-0.059014853090047836, -0.05566786974668503]
pediatric B-LOC [0.009743775241076946, -0.20591241121292114]
tissues O [-0.1401514708995819, -0.07209113240242004]
but B-LOC [-0.06007888540625572, -0.13908235728740692]

are B-LOC [1.2051255702972412, -1.3957594633102417]
present B-LOC [1.4743773937225342, -1.4488250017166138]
at B-LOC [1.4905526638031006, -1.4857540130615234]
much B-LOC [1.489284873008728, -1.5814250707626343]
lower B-LOC [1.5175122022628784, -1.6051504611968994]
frequencies B-LOC [1.3527967929840088, -1.5570802688598633]
(1-10%) B-LOC [1.2815542221069336, -1.3395410776138306]
in B-LOC [1.3685355186462402, -1.401984453201294]
adult B-LOC [1.495805025100708, -1.485753059387207]
tissues. B-LOC [1.228304386138916, -1.5087203979492188]
Pediatric B-LOC [0.4155706763267517, -0.33150234818458557]
tissue B-LOC [0.11903387308120728, -0.18984295427799225]
T(reg) B-LOC [0.04743354395031929, -0.23565766215324402]
cells B-LOC [0.0020941407419741154, -0.04531140252947807]
suppress O [-0.05911531671881676, 0.13080313801765442]
endogenous O [-0.37891873717308044, 0.16693654656410217]
T B-LOC [0.056269314140081406, -0.06195317581295967]
cell O [-0.22834861278533936, 0.00030575465643778443]
activation, O [-0.29488781094551086, 0.36290442943573]
and B-LOC [-0.004624349530786276, -0.06653767824172974]
early B-LOC [0.20794124901294708, -0.3408834636211395]
T B-LOC [0.24523520469665527, -0.35490357875823975]
cell B-LOC [0.18057098984718323, -0.3763950765132904]
functionality B-LOC [0.2535940110683441, -0.25602027773857117]
is B-LOC [0.5457406640052795, -0.5115579962730408]
confined B-LOC [0.6410204172134399, -0.3390514850616455]
to B-LOC [0.559141218662262, -0.18361109495162964]
the B-LOC [0.41912391781806946, -0.23780709505081177]
mucosal B-LOC [0.21321210265159607, -0.2739604711532593]
sites B-LOC [0.26785987615585327, -0.27834558486938477]
that B-LOC [0.4248998761177063, -0.6478158235549927]
have B-LOC [0.7837561368942261, -0.5901576280593872]
the B-LOC [0.806086003780365, -0.5697991847991943]
lowest B-LOC [0.782690167427063, -0.8082298040390015]
T(reg):T(EM) B-LOC [0.41978350281715393, -0.5751292109489441]
cell B-LOC [0.3346795439720154, -0.6107137203216553]
ratios, B-LOC [0.5285232067108154, -0.6541933417320251]
which B-LOC [0.6809383034706116, -0.8768020272254944]
suggests B-LOC [0.9630106687545776, -0.9615962505340576]
control B-LOC [0.9176045060157776, -1.257259488105774]
in B-LOC [1.2448097467422485, -1.2992677688598633]
situ B-LOC [1.537126064300537, -1.1859077215194702]
of B-LOC [0.9494447112083435, -1.3534462451934814]
immune B-LOC [0.8567558526992798, -1.0643980503082275]
responses B-LOC [0.869526743888855, -1.1360772848129272]
in B-LOC [0.9540629386901855, -1.1402194499969482]
early B-LOC [0.759605348110199, -0.8350853323936462]
life. B-LOC [0.9230150580406189, -1.0571829080581665]

BACKGROUND B-LOC [1.2720993757247925, -1.8237738609313965]
Emerging B-LOC [2.359649896621704, -2.609344244003296]
evidence B-LOC [1.9964736700057983, -2.559779405593872]
suggests B-LOC [2.1019012928009033, -2.4573333263397217]
an B-LOC [1.9810043573379517, -2.6167495250701904]
association B-LOC [2.0582997798919678, -2.7337889671325684]
between B-LOC [2.0578579902648926, -2.994412660598755]
female B-LOC [1.8557145595550537, -2.563993215560913]
prenatal B-LOC [1.8556039333343506, -2.316821575164795]
experience B-LOC [1.7153337001800537, -2.3459722995758057]
and B-LOC [2.194895029067993, -2.762148141860962]
her B-LOC [1.8522447347640991, -2.582953691482544]
subsequent B-LOC [1.9474067687988281, -2.7172014713287354]
risk B-LOC [2.1088955402374268, -2.674924850463867]
of B-LOC [1.6429919004440308, -2.3539488315582275]
developing B-LOC [2.0264651775360107, -2.3732616901397705]
breast B-LOC [1.9479485750198364, -2.5030791759490967]
cancer. B-LOC [2.156233072280884, -2.828824281692505]
Potential B-LOC [2.6564218997955322, -3.0731868743896484]
underlying B-LOC [2.820474624633789, -3.1660525798797607]
mechanisms B-LOC [2.6776044368743896, -3.1028690338134766]
include B-LOC [2.674020290374756, -2.807262659072876]
variation B-LOC [2.6255581378936768, -3.2159006595611572]
in B-LOC [2.6305649280548096, -3.353839635848999]
amounts B-LOC [2.7520880699157715, -3.2065365314483643]
of B-LOC [2.5889923572540283, -3.202096700668335]
maternal B-LOC [2.5409834384918213, -3.074847459793091]
endogenous B-LOC [2.414757490158081, -3.0727953910827637]
sex B-LOC [2.6713037490844727, -3.2260618209838867]
hormones B-LOC [2.577227830886841, -3.072338342666626]
and B-LOC [2.4032673835754395, -3.0240023136138916]
growth B-LOC [2.3755626678466797, -2.9642977714538574]
hormones, B-LOC [2.5826873779296875, -3.0844719409942627]
germ-cell B-LOC [2.6375200748443604, -3.1743404865264893]
mutations, B-LOC [2.7108957767486572, -3.1559529304504395]
formation B-LOC [2.6787750720977783, -3.1866872310638428]
of B-LOC [2.7215731143951416, -3.2779908180236816]
cancer B-LOC [2.9098739624023438, -3.5180904865264893]
stem-cells, B-LOC [2.864302635192871, -3.2775256633758545]
and B-LOC [2.8840689659118652, -3.2376999855041504]
other B-LOC [3.068514585494995, -3.4272844791412354]
genetic B-LOC [3.151189088821411, -3.4648334980010986]
or B-LOC [2.872331380844116, -3.3549816608428955]
epigenetic B-LOC [3.0903799533843994, -3.465458631515503]
events. B-LOC [2.8190886974334717, -3.407719373703003]
We B-LOC [2.8944332599639893, -2.8914778232574463]
reviewed B-LOC [3.538088083267212, -3.1917364597320557]
and B-LOC [3.3928146362304688, -3.1491620540618896]
summarised B-LOC [3.4662511348724365, -3.1027755737304688]
quantitatively B-LOC [3.6885385513305664, -3.385322332382202]
the B-LOC [3.6264548301696777, -3.2835755348205566]
available B-LOC [3.473745584487915, -3.3522918224334717]
data B-LOC [3.5059263706207275, -3.3716535568237305]
on B-LOC [3.3845632076263428, -3.2660224437713623]
intrauterine B-LOC [3.279327869415283, -3.169534206390381]
exposures B-LOC [3.52929425239563, -3.5076730251312256]
and B-LOC [3.366466999053955, -3.406160831451416]
risk B-LOC [3.6075005531311035, -3.684391736984253]
of B-LOC [3.254394769668579, -3.24194598197937]
breast B-LOC [2.9367618560791016, -3.3605799674987793]
cancer. B-LOC [3.4418435096740723, -3.5920801162719727]
METHODS B-LOC [1.9099485874176025, -2.8309409618377686]
We B-LOC [2.1020596027374268, -2.50854754447937]
systematically B-LOC [2.8532216548919678, -2.9115021228790283]
searched B-LOC [3.102487325668335, -3.0591065883636475]
for B-LOC [2.97023606300354, -3.1237595081329346]
studies B-LOC [2.5907633304595947, -2.872591257095337]
that B-LOC [2.7303194999694824, -3.199760675430298]
assessed B-LOC [2.610900640487671, -3.0196292400360107]
association B-LOC [2.726294755935669, -3.0783987045288086]
between B-LOC [2.3504459857940674, -3.0736076831817627]
perinatal B-LOC [2.37469744682312, -3.0200464725494385]
factors B-LOC [2.4935758113861084, -3.094597578048706]
and B-LOC [2.5039749145507812, -3.0285162925720215]
risk B-LOC [2.9237396717071533, -3.244795799255371]
of B-LOC [2.3514490127563477, -2.964688539505005]
breast B-LOC [2.0731804370880127, -2.566133737564087]
cancer. B-LOC [2.4498355388641357, -3.004887342453003]
We B-LOC [1.7160741090774536, -2.3899059295654297]
reviewed B-LOC [2.464221715927124, -2.5848259925842285]

separately B-LOC [2.449371099472046, -2.8488800525665283]
each B-LOC [2.699589967727661, -3.073673963546753]
of B-LOC [2.8231890201568604, -3.0421016216278076]
the B-LOC [2.785865545272827, -2.9481794834136963]
perinatal B-LOC [2.895098924636841, -3.259857654571533]
factors, B-LOC [2.5552313327789307, -3.226332902908325]
including B-LOC [2.8603885173797607, -3.105435371398926]
birthweight, B-LOC [2.099714517593384, -2.7507903575897217]
birth B-LOC [1.7868232727050781, -2.5181984901428223]
length, B-LOC [1.8332264423370361, -2.6078553199768066]
parental B-LOC [2.1535871028900146, -2.8199844360351562]
age B-LOC [2.3223230838775635, -2.9528515338897705]
at B-LOC [1.7545889616012573, -2.563741445541382]
delivery, B-LOC [1.8996365070343018, -2.4554178714752197]
gestational B-LOC [2.5441958904266357, -3.093724489212036]
age, B-LOC [2.426471471786499, -2.902669668197632]
intrauterine B-LOC [2.315443277359009, -2.9032998085021973]
exposure B-LOC [2.312065839767456, -3.1462490558624268]
to B-LOC [2.4476287364959717, -2.93009877204895]
diethylstilbestrol, B-LOC [2.7615129947662354, -3.104553461074829]
twin B-LOC [2.7113120555877686, -3.4428274631500244]
membership, B-LOC [2.500185251235962, -3.1925580501556396]
maternal B-LOC [2.6908538341522217, -3.3756041526794434]
pre-eclampsia B-LOC [2.482631206512451, -3.237610340118408]
or B-LOC [2.614039659500122, -3.3068130016326904]
eclampsia, B-LOC [2.5473415851593018, -3.139192819595337]
and B-LOC [3.031022310256958, -3.3327386379241943]
other B-LOC [3.1755411624908447, -3.462883710861206]
factors. B-LOC [2.9446918964385986, -3.6925034523010254]
FINDINGS B-LOC [2.5081286430358887, -2.7607712745666504]
We B-LOC [2.568768262863159, -2.488675355911255]
identified B-LOC [3.0232861042022705, -2.9712345600128174]
57 B-LOC [3.151737689971924, -3.3020098209381104]
studies B-LOC [2.787510871887207, -3.179713249206543]
published B-LOC [2.9821531772613525, -2.9817328453063965]
between B-LOC [3.154411554336548, -3.3805010318756104]
Oct B-LOC [3.231795310974121, -3.254132032394409]
1, B-LOC [3.2050058841705322, -2.9570157527923584]
1980, B-LOC [3.194028377532959, -3.36245059967041]
and B-LOC [3.259894847869873, -3.364243745803833]
June B-LOC [3.3524231910705566, -3.1872572898864746]
21, B-LOC [3.500061511993408, -3.173123359680176]
2007. B-LOC [3.18461537361145, -3.3255205154418945]
Increased O [-1.0104554891586304, 0.7784671187400818]
risk O [-0.9524697065353394, 0.8113664984703064]
of O [-1.2353142499923706, 0.955484926700592]
breast O [-0.8594701290130615, 0.8804149031639099]
cancer O [-0.8356032371520996, 0.7035079598426819]
was O [-1.1059962511062622, 0.7114138007164001]
noted O [-1.1676400899887085, 0.8675197958946228]
with O [-1.1475565433502197, 0.7927796840667725]
increased O [-1.1482906341552734, 0.7042469382286072]
birthweight O [-1.0322434902191162, 1.1198127269744873]
(relative O [-0.9840875267982483, 0.8167519569396973]
risk O [-0.9558280110359192, 0.9051272869110107]
[RR] O [-0.9187085032463074, 0.6497135758399963]
1.15 O [-0.8798906207084656, 0.9965850114822388]
[95% O [-0.9598797559738159, 0.5544063448905945]
CI O [-1.010133981704712, 0.6086820960044861]
1.09-1.21]), O [-0.8808183073997498, 0.6751802563667297]
birth O [-0.9311314821243286, 1.0826166868209839]
length O [-0.8001710176467896, 0.9634028673171997]
(1.28 O [-0.8427661061286926, 0.6643469929695129]

[1.11-1.48]), B-LOC [-0.15108662843704224, -0.5326042771339417]
higher B-LOC [-0.09657975286245346, -0.15909606218338013]
maternal B-LOC [0.05711831897497177, -0.30146822333335876]
age B-LOC [0.11214233934879303, -0.1968027949333191]
(1.13 B-LOC [-0.012305890209972858, -0.2917521297931671]
[1.02-1.25]), B-LOC [-0.16537196934223175, -0.4621972143650055]
and B-LOC [0.19820626080036163, -0.18306922912597656]
paternal B-LOC [0.08001742511987686, -0.28894391655921936]
age B-LOC [0.1698949635028839, -0.24922583997249603]
(1.12 B-LOC [0.031251367181539536, -0.44938167929649353]
[1.05-1.19]). B-LOC [-0.12599501013755798, -0.5481056571006775]
Decreased B-LOC [0.6031492352485657, -0.44072383642196655]
risk B-LOC [0.4808390736579895, -0.724198043346405]
of B-LOC [0.1722283959388733, -0.5113627910614014]
breast B-LOC [0.5674696564674377, -0.6745548844337463]
cancer B-LOC [0.6275380253791809, -0.8683504462242126]
was B-LOC [0.2807374596595764, -0.6329339146614075]
noted B-LOC [0.3721253275871277, -0.5481280088424683]
for B-LOC [0.31224533915519714, -0.640670120716095]
maternal B-LOC [0.44050291180610657, -0.7379183173179626]
pre-eclampsia B-LOC [0.5166899561882019, -0.7159032821655273]
and B-LOC [0.46631088852882385, -0.6457754969596863]
eclampsia B-LOC [0.7055897116661072, -0.6212978363037109]
(0.48 B-LOC [0.39893609285354614, -0.6476219892501831]
[0.30-0.78]) B-LOC [0.4053923487663269, -0.9949010014533997]
and B-LOC [0.35935309529304504, -0.4814496338367462]
twin B-LOC [0.5448638796806335, -0.8753306269645691]
membership B-LOC [0.5255795121192932, -0.7881587743759155]
(0.93 B-LOC [0.47012749314308167, -0.6797678470611572]
[0.87-1.00]). B-LOC [0.327627032995224, -1.1224565505981445]
No B-LOC [0.49868711829185486, -0.6764907836914062]
association B-LOC [0.4955267608165741, -0.881079375743866]
was B-LOC [0.48834267258644104, -0.9187484383583069]
noted B-LOC [0.6388101577758789, -0.8902270197868347]
between B-LOC [0.7603145241737366, -1.0963764190673828]
risk B-LOC [0.33331170678138733, -0.7649885416030884]
of B-LOC [0.2086612582206726, -0.6713206171989441]
breast B-LOC [0.21905621886253357, -0.5739722847938538]
cancer B-LOC [0.32431620359420776, -0.7237616181373596]
and B-LOC [0.7503201365470886, -1.0460257530212402]
gestational B-LOC [0.3203420042991638, -0.6961104869842529]
age B-LOC [0.4453427195549011, -0.7508237957954407]
at B-LOC [0.4047103226184845, -0.7135526537895203]
birth B-LOC [0.2796803116798401, -0.40998703241348267]
(0.95 B-LOC [0.08734230697154999, -0.6578460931777954]

[0.71-1.26]) B-LOC [0.5826195478439331, -1.42490553855896]
or B-LOC [1.4670926332473755, -1.8348745107650757]
maternal B-LOC [1.286250352859497, -1.9228971004486084]
diethylstilbestrol B-LOC [1.343625783920288, -1.8956010341644287]
treatment B-LOC [1.2169649600982666, -1.9550573825836182]
(1.40 B-LOC [1.1929097175598145, -1.6632052659988403]
[0.86-2.28]). B-LOC [0.8589485287666321, -1.8381516933441162]
INTERPRETATION B-LOC [1.0522935390472412, -1.683122158050537]
The B-LOC [1.3385741710662842, -2.07003116607666]
intrauterine B-LOC [1.1943042278289795, -1.73241126537323]
environment B-LOC [1.0960197448730469, -1.7816567420959473]
contributes B-LOC [1.5504119396209717, -2.072711706161499]
to B-LOC [1.4373970031738281, -2.031475067138672]
the B-LOC [1.6155734062194824, -2.1581876277923584]
predisposition B-LOC [1.6177177429199219, -2.23032283782959]
of B-LOC [1.3373808860778809, -2.0511324405670166]
women B-LOC [1.4398053884506226, -1.874324083328247]
to B-LOC [1.2480976581573486, -1.868528127670288]
breast B-LOC [1.3585939407348633, -1.8624440431594849]
cancer B-LOC [1.541597604751587, -2.203305959701538]
in B-LOC [1.346926212310791, -2.080214262008667]
adulthood. B-LOC [1.5698518753051758, -1.8144112825393677]
The B-LOC [2.3272838592529297, -2.4994938373565674]
in-utero B-LOC [2.0165791511535645, -2.587458848953247]
mechanisms B-LOC [2.13191294670105, -2.7476754188537598]
responsible B-LOC [2.3546295166015625, -2.709028720855713]
for B-LOC [2.2352311611175537, -2.610687017440796]
such B-LOC [2.325010061264038, -2.6182045936584473]
predisposition B-LOC [2.1618425846099854, -2.752380132675171]
need B-LOC [2.498228073120117, -2.6321794986724854]
to B-LOC [2.670039415359497, -2.8533737659454346]
be B-LOC [2.692997694015503, -2.882518768310547]
elucidated. B-LOC [2.6773388385772705, -2.720832586288452]

Mutations B-LOC [2.6138172149658203, -3.13374924659729]
in B-LOC [2.705537796020508, -3.090162992477417]
cancer B-LOC [3.0956263542175293, -3.3692824840545654]
reprogram B-LOC [3.0728161334991455, -3.1159040927886963]
amino B-LOC [2.895796298980713, -3.1954028606414795]
acid B-LOC [2.7786457538604736, -3.2366092205047607]
metabolism B-LOC [2.8982651233673096, -3.3151981830596924]
to B-LOC [3.20930552482605, -3.079200267791748]
drive B-LOC [2.9091689586639404, -3.250293016433716]
tumor B-LOC [3.1064720153808594, -3.4596431255340576]
growth, B-LOC [2.970123052597046, -3.396104097366333]
but B-LOC [3.2601094245910645, -3.4598872661590576]
the B-LOC [3.4505879878997803, -3.4829704761505127]
molecular B-LOC [3.437917947769165, -3.507272720336914]
mechanisms B-LOC [3.2247135639190674, -3.4901628494262695]
are B-LOC [3.451826810836792, -3.2414865493774414]
not B-LOC [3.4960358142852783, -3.250518560409546]
well B-LOC [3.4603655338287354, -3.348773241043091]
understood. B-LOC [3.3853189945220947, -3.2417984008789062]
Using B-LOC [1.5612154006958008, -2.048902750015259]
an B-LOC [2.242680311203003, -2.3642160892486572]
unbiased B-LOC [2.8873813152313232, -2.915579080581665]
proteomic B-LOC [2.478339910507202, -2.9051711559295654]
screen, B-LOC [2.142303705215454, -2.664036989212036]
we B-LOC [1.5430564880371094, -1.597437858581543]
identified B-LOC [1.4860763549804688, -1.5045242309570312]
mTORC2 B-LOC [1.3946707248687744, -1.5038807392120361]
as B-LOC [1.0572969913482666, -1.4668984413146973]
a B-LOC [0.8407061696052551, -1.2987548112869263]
critical B-LOC [1.0335814952850342, -1.645843744277954]
regulator B-LOC [1.0134003162384033, -1.5212945938110352]
of B-LOC [0.9268117547035217, -1.6022095680236816]
amino B-LOC [1.3497190475463867, -1.5954399108886719]
acid B-LOC [1.300952434539795, -1.6951446533203125]
metabolism B-LOC [0.9450578093528748, -1.1760114431381226]
in B-LOC [0.9833666682243347, -1.312300682067871]
cancer B-LOC [1.3715258836746216, -1.531245231628418]
via B-LOC [0.6411763429641724, -1.1846336126327515]
phosphorylation B-LOC [1.0967154502868652, -1.579081416130066]
of B-LOC [0.623689591884613, -0.9119588732719421]
the B-LOC [0.8787275552749634, -0.9551343321800232]
cystine-glutamate B-LOC [0.515214204788208, -0.8541657328605652]
antiporter B-LOC [0.8258894681930542, -1.2336256504058838]
xCT. B-LOC [1.202768087387085, -1.5753148794174194]
mTORC2 B-LOC [0.19028714299201965, -0.3810618817806244]
phosphorylates B-LOC [0.1345350444316864, -0.4754761755466461]
serine B-LOC [0.426442950963974, -0.5886280536651611]
26 B-LOC [0.4870890974998474, -0.3955795466899872]
at B-LOC [0.46949076652526855, -0.4736466407775879]
the B-LOC [0.539890468120575, -0.4582853317260742]
cytosolic B-LOC [0.06745607405900955, -0.44322669506073]
N B-LOC [0.3903404176235199, -0.5182876586914062]
terminus B-LOC [0.10766834020614624, -0.49802103638648987]
of B-LOC [0.20472490787506104, -0.48396021127700806]
xCT, B-LOC [0.2539464235305786, -0.5959383249282837]
inhibiting B-LOC [0.34210050106048584, -0.783240020275116]
its B-LOC [0.6796168684959412, -0.9697899222373962]
activity. B-LOC [0.5017132759094238, -0.619927167892456]
Genetic B-LOC [1.1202216148376465, -1.3418176174163818]
inhibition B-LOC [0.9435863494873047, -1.253056287765503]
of B-LOC [0.8321098685264587, -0.7833442091941833]
mTORC2, B-LOC [0.6803146600723267, -0.9071823954582214]
or B-LOC [0.6597882509231567, -1.0806632041931152]
pharmacologic B-LOC [1.0842794179916382, -1.3297260999679565]
inhibition B-LOC [0.8307739496231079, -1.237699270248413]
of B-LOC [0.8077396750450134, -0.9720645546913147]
the B-LOC [0.6536751389503479, -0.9252568483352661]

mammalian O [-0.15413230657577515, -0.11729499697685242]
target O [-0.10997603833675385, 0.3151446580886841]
of O [-0.33921194076538086, 0.07300364971160889]
rapamycin B-LOC [-0.023951156064867973, -0.08535641431808472]
(mTOR) O [-0.028407348319888115, 0.15887658298015594]
kinase, O [-0.05667902156710625, 0.36030763387680054]
promotes O [-0.3466808497905731, 0.2939364016056061]
glutamate O [-0.4007505178451538, 0.43935996294021606]
secretion, O [-0.3607856035232544, 0.7839513421058655]
cystine O [-0.5018848180770874, 0.36877456307411194]
uptake, O [-0.7078274488449097, 0.5415704846382141]
and O [-0.44003531336784363, 0.39624306559562683]
incorporation O [-0.14376139640808105, 0.5178815722465515]
into O [-0.3603018820285797, 0.5084846615791321]
glutathione, O [-0.33054402470588684, 0.40381672978401184]
linking O [-0.5049932599067688, 0.25939029455184937]
growth O [-0.4623982012271881, 0.42702051997184753]
factor O [-0.5122291445732117, 0.2994571328163147]
receptor O [-0.482290118932724, 0.31259188055992126]
signaling O [-0.41014066338539124, 0.5700281858444214]
with O [-0.3193882405757904, -0.08727072179317474]
amino O [-0.17525362968444824, 0.003351104911416769]
acid O [-0.2717389166355133, -0.11940130591392517]
uptake O [-0.33341261744499207, 0.1921703964471817]
and O [-0.17457516491413116, -0.1051991656422615]
utilization. O [-0.2575191855430603, 0.12448333203792572]
These B-LOC [0.40164628624916077, -0.49664393067359924]
results B-LOC [0.6490240693092346, -0.4444735050201416]
identify B-LOC [0.6679834723472595, -0.5809535384178162]
an B-LOC [0.5137655735015869, -0.7659718990325928]
unanticipated B-LOC [0.8351613879203796, -0.897716760635376]
mechanism B-LOC [0.3060850501060486, -0.8127349615097046]
regulating B-LOC [0.3520473837852478, -0.9813515543937683]
amino B-LOC [0.6200708746910095, -0.8711367845535278]
acid B-LOC [0.5486437678337097, -0.8563886284828186]
metabolism B-LOC [0.44684770703315735, -0.7179304957389832]
in B-LOC [0.522622287273407, -0.8546736836433411]
cancer, B-LOC [0.7771541476249695, -0.9316511154174805]
enabling B-LOC [0.31933942437171936, -0.8349933624267578]
tumor B-LOC [0.5591118931770325, -0.8737784624099731]
cells B-LOC [0.40977415442466736, -0.6776277422904968]
to B-LOC [0.6135162711143494, -0.8102720975875854]
adapt B-LOC [0.5899270176887512, -0.8197893500328064]
to B-LOC [0.6213293671607971, -0.9480695128440857]
changing B-LOC [0.7310158610343933, -1.3523645401000977]
environmental B-LOC [0.8774957060813904, -1.1170282363891602]
conditions. B-LOC [0.7707488536834717, -0.9376664757728577]

CONTEXT B-LOC [2.490105390548706, -3.4738898277282715]
A B-LOC [3.344769239425659, -3.662992000579834]
number B-LOC [3.3793447017669678, -3.6609256267547607]
of B-LOC [3.226046323776245, -3.6552939414978027]
countries B-LOC [3.7252838611602783, -3.767801523208618]
have B-LOC [3.4593312740325928, -3.480858325958252]
implemented B-LOC [3.6195244789123535, -3.5663371086120605]
a B-LOC [3.6902143955230713, -3.6297247409820557]
policy B-LOC [3.740576982498169, -3.7799272537231445]
of B-LOC [3.519317150115967, -3.506894111633301]
universal B-LOC [3.706387996673584, -3.8792409896850586]
leukoreduction B-LOC [3.55599045753479, -3.597306966781616]
of B-LOC [3.400954484939575, -3.636277675628662]
their B-LOC [3.510934352874756, -3.6566452980041504]
blood B-LOC [3.4656870365142822, -4.085265159606934]
supply, B-LOC [3.574892520904541, -3.9812843799591064]
but B-LOC [3.4824163913726807, -3.7427480220794678]
the B-LOC [3.5828819274902344, -3.7942826747894287]
potential B-LOC [3.4182968139648438, -3.786276340484619]
role B-LOC [3.486027479171753, -3.794938087463379]
of B-LOC [3.3493592739105225, -3.706740617752075]
leukoreduction B-LOC [3.472841739654541, -3.6237034797668457]
in B-LOC [3.431152820587158, -3.6228489875793457]
decreasing B-LOC [3.581531286239624, -3.9956159591674805]
postoperative B-LOC [3.538400411605835, -3.6950862407684326]
mortality B-LOC [3.703322410583496, -3.8389246463775635]
and B-LOC [3.3425357341766357, -3.706573247909546]
infection B-LOC [3.682713270187378, -3.898158550262451]
is B-LOC [3.718379497528076, -3.6464152336120605]
unclear. B-LOC [3.7400591373443604, -3.7361435890197754]
OBJECTIVE B-LOC [3.2928693294525146, -3.5094516277313232]
To B-LOC [3.445957899093628, -3.538811445236206]
evaluate B-LOC [3.58398699760437, -3.585573434829712]
clinical B-LOC [3.817075490951538, -3.757446527481079]
outcomes B-LOC [3.7804503440856934, -3.737560510635376]
following B-LOC [3.5825116634368896, -3.4342029094696045]
adoption B-LOC [3.750877618789673, -3.5573947429656982]
of B-LOC [3.45231032371521, -3.2469279766082764]
a B-LOC [3.4716997146606445, -3.4625251293182373]
national B-LOC [3.523428201675415, -3.7423386573791504]
universal B-LOC [3.6712241172790527, -3.7321536540985107]
prestorage B-LOC [3.5124828815460205, -3.58119797706604]
leukoreduction B-LOC [3.66455078125, -3.36295485496521]
program B-LOC [3.554875373840332, -3.5656557083129883]
for B-LOC [3.598457098007202, -3.472054958343506]
blood B-LOC [3.5011680126190186, -3.8739850521087646]
transfusions. B-LOC [3.573577642440796, -3.5832388401031494]
DESIGN, B-LOC [3.1923105716705322, -3.229672431945801]
SETTING, B-LOC [2.792001485824585, -3.0376925468444824]
AND B-LOC [3.228416681289673, -3.113476276397705]
POPULATION B-LOC [2.7878267765045166, -3.0456199645996094]
Retrospective B-LOC [2.7257120609283447, -2.943725824356079]
before-and-after B-LOC [2.6085622310638428, -2.8012189865112305]
cohort B-LOC [3.0594754219055176, -3.0280802249908447]
study B-LOC [3.0207817554473877, -3.1438801288604736]
conducted B-LOC [3.1824653148651123, -3.1421878337860107]
from B-LOC [2.8995041847229004, -2.897346019744873]
August B-LOC [3.125312328338623, -3.301255941390991]
1998 B-LOC [3.0612521171569824, -3.3883285522460938]
to B-LOC [3.4432168006896973, -3.1482183933258057]
August B-LOC [3.162153482437134, -3.219838857650757]
2000 B-LOC [3.1990177631378174, -3.4934847354888916]
in B-LOC [3.228597402572632, -3.236180067062378]
23 B-LOC [3.3100826740264893, -3.4127771854400635]
academic B-LOC [3.0721099376678467, -3.4742767810821533]
and B-LOC [3.1610300540924072, -3.1955678462982178]
community B-LOC [3.1774933338165283, -3.3645012378692627]
hospitals B-LOC [3.318877935409546, -3.474311590194702]
throughout B-LOC [3.3305065631866455, -3.134704828262329]
Canada, B-LOC [2.699342727661133, -3.466691017150879]
enrolling B-LOC [3.4985358715057373, -3.3470470905303955]

14 B-LOC [2.9779727458953857, -3.411008596420288]
786 B-LOC [3.3315932750701904, -3.4719736576080322]
patients B-LOC [3.3277242183685303, -3.503166437149048]
who B-LOC [3.1092355251312256, -3.2856357097625732]
received B-LOC [3.0921428203582764, -3.436577081680298]
red B-LOC [3.1214048862457275, -3.416905403137207]
blood B-LOC [2.763390302658081, -3.1688997745513916]
cell B-LOC [2.6768810749053955, -3.3311140537261963]
transfusions B-LOC [2.7485339641571045, -3.2131454944610596]
following B-LOC [3.1413872241973877, -3.2270267009735107]
cardiac B-LOC [3.071591377258301, -3.501370429992676]
surgery B-LOC [3.068913221359253, -3.103917360305786]
or B-LOC [3.0710690021514893, -3.2627103328704834]
repair B-LOC [3.029409170150757, -3.0213425159454346]
of B-LOC [2.934156656265259, -2.959489107131958]
hip B-LOC [3.2255520820617676, -3.2993788719177246]
fracture, B-LOC [3.202073574066162, -3.198573350906372]
or B-LOC [3.168424367904663, -3.383958339691162]
who B-LOC [3.12610125541687, -3.258563756942749]
required B-LOC [2.9419467449188232, -3.3338234424591064]
intensive B-LOC [3.1771085262298584, -3.4163601398468018]
care B-LOC [3.2424986362457275, -3.3506338596343994]
following B-LOC [3.1986515522003174, -3.2118136882781982]
a B-LOC [3.1429970264434814, -3.0246803760528564]
surgical B-LOC [3.0168111324310303, -3.410814046859741]
intervention B-LOC [2.9889185428619385, -3.244428873062134]
or B-LOC [3.250062942504883, -3.3723816871643066]
multiple B-LOC [3.153445243835449, -3.3451087474823]
trauma. B-LOC [3.254318952560425, -3.3455913066864014]
INTERVENTION B-LOC [2.994208574295044, -3.5180366039276123]
Universal B-LOC [3.3208839893341064, -3.503878355026245]
prestorage B-LOC [3.085028648376465, -3.3635599613189697]
leukoreduction B-LOC [3.405566930770874, -3.426934242248535]
program B-LOC [3.359342098236084, -3.5772910118103027]
introduced B-LOC [3.5062551498413086, -3.480572462081909]
by B-LOC [3.29496693611145, -3.3863131999969482]
2 B-LOC [3.46840500831604, -3.32637357711792]
Canadian B-LOC [3.1213953495025635, -3.628628730773926]
blood B-LOC [3.2047603130340576, -3.8893086910247803]
agencies. B-LOC [3.5229763984680176, -3.5852019786834717]
A B-LOC [3.4167444705963135, -3.6092922687530518]
total B-LOC [3.7526276111602783, -3.369168758392334]
of B-LOC [3.426494598388672, -3.2215044498443604]
6982 B-LOC [3.711738348007202, -3.3337831497192383]
patients B-LOC [3.6928226947784424, -3.6158130168914795]
were B-LOC [3.478827714920044, -3.4930779933929443]
enrolled B-LOC [3.6840338706970215, -3.6385183334350586]
during B-LOC [3.404402732849121, -3.531217336654663]
the B-LOC [3.4375107288360596, -3.4488437175750732]
control B-LOC [3.62363600730896, -3.7022311687469482]
period B-LOC [3.4666037559509277, -3.5257036685943604]
and B-LOC [3.2729392051696777, -3.460252523422241]
7804 B-LOC [3.671483278274536, -3.3242318630218506]
patients B-LOC [3.7304201126098633, -3.6367506980895996]
were B-LOC [3.5547189712524414, -3.498958110809326]
enrolled B-LOC [3.7556798458099365, -3.665132761001587]
following B-LOC [3.532973289489746, -3.7253239154815674]
prestorage B-LOC [3.3860113620758057, -3.526904821395874]
leukoreduction. B-LOC [3.610325336456299, -3.393348455429077]
MAIN B-LOC [2.9368412494659424, -3.1145224571228027]
OUTCOME B-LOC [2.818023920059204, -2.8545188903808594]
MEASURES B-LOC [2.773790121078491, -2.7926366329193115]
All-cause B-LOC [2.7961032390594482, -2.6194674968719482]
in-hospital B-LOC [2.8570897579193115, -2.460426092147827]
mortality B-LOC [2.8238632678985596, -2.598935604095459]
and B-LOC [2.396164655685425, -2.5664660930633545]
serious B-LOC [2.7111361026763916, -2.5815179347991943]
nosocomial B-LOC [2.6079318523406982, -2.475597858428955]
infections B-LOC [2.911956787109375, -2.504277467727661]
(pneumonia, B-LOC [2.1539533138275146, -2.1396963596343994]
bacteremia, B-LOC [2.502002477645874, -2.612276554107666]
septic B-LOC [2.697645425796509, -2.453881025314331]
shock, B-LOC [2.3949081897735596, -2.454223871231079]
all B-LOC [2.5808465480804443, -2.5002353191375732]
surgical B-LOC [2.539968490600586, -2.4163167476654053]
site B-LOC [2.5420970916748047, -2.66581654548645]

infections) B-LOC [0.9601866602897644, -1.5296891927719116]
occurring B-LOC [0.9934020042419434, -1.61442232131958]
after B-LOC [1.016366720199585, -1.4661386013031006]
first B-LOC [0.9757387638092041, -1.5016486644744873]
transfusion B-LOC [1.6330057382583618, -2.168342351913452]
and B-LOC [1.0845153331756592, -1.572126865386963]
at B-LOC [1.1026275157928467, -1.7674728631973267]
least B-LOC [1.2962443828582764, -2.085832357406616]
2 B-LOC [1.2139060497283936, -1.609641432762146]
days B-LOC [1.3692905902862549, -1.719754695892334]
after B-LOC [1.2743706703186035, -1.682767391204834]
index B-LOC [1.2151901721954346, -2.001098394393921]
procedure B-LOC [1.2058359384536743, -1.7241296768188477]
or B-LOC [1.365882396697998, -1.8204609155654907]
intensive B-LOC [1.6939117908477783, -2.119279146194458]
care B-LOC [1.7682068347930908, -2.3682754039764404]
unit B-LOC [1.5232899188995361, -2.2614283561706543]
admission. B-LOC [1.3363744020462036, -1.874239206314087]
Secondary B-LOC [2.328348398208618, -2.7305853366851807]
outcomes B-LOC [1.887336254119873, -2.5509700775146484]
included B-LOC [2.005303144454956, -2.5050110816955566]
rates B-LOC [1.9622371196746826, -2.705641508102417]
of B-LOC [1.9273830652236938, -2.501652479171753]
posttransfusion B-LOC [2.1745901107788086, -2.700744390487671]
fever B-LOC [2.2612571716308594, -2.8534061908721924]
and B-LOC [1.9770417213439941, -2.5499861240386963]
antibiotic B-LOC [2.5747697353363037, -3.0161006450653076]
use. B-LOC [2.243764638900757, -2.8573384284973145]
RESULTS O [-0.10472887009382248, -0.09434457868337631]
Unadjusted B-LOC [0.2636112570762634, 0.09262284636497498]
in-hospital B-LOC [0.013652714900672436, -0.03448070213198662]
mortality B-LOC [-0.06008606776595116, -0.11438006162643433]
rates O [-0.05805018171668053, 0.011273818090558052]
were B-LOC [-0.09521051496267319, -0.25888755917549133]
significantly B-LOC [0.027988212183117867, -0.11693194508552551]
lower B-LOC [0.18379539251327515, -0.08713553845882416]
following B-LOC [0.005644234362989664, -0.040767502039670944]
the B-LOC [0.05437976494431496, -0.06654918193817139]
introduction B-LOC [0.11376328021287918, -0.19597220420837402]
of O [-0.0944211408495903, 0.08027098327875137]
leukoreduction O [-0.1143275573849678, 0.09106944501399994]
compared O [-0.2796601951122284, 0.2873574495315552]
with O [-0.04272203519940376, 0.003024411853402853]
the O [-0.04948477819561958, 0.11007891595363617]
control O [-0.31438925862312317, -0.05401253700256348]
period O [-0.3408529460430145, -0.09431996196508408]
(6.19% O [-0.07218196988105774, 0.05276374891400337]
vs O [-0.3867394030094147, -0.1989263892173767]
7.03%, O [-0.08314961194992065, 0.38676896691322327]
respectively; O [-0.38258764147758484, -0.11668320000171661]
P O [-0.4530133605003357, 0.16044139862060547]
=.04). O [-0.49144241213798523, 0.09217498451471329]
Compared O [-0.45883482694625854, 0.6717470288276672]
with O [-0.21646609902381897, 0.45709291100502014]
the O [-0.3198031485080719, 0.36122921109199524]
control O [-0.5150744318962097, 0.22148467600345612]
period, O [-0.5400223731994629, 0.27790963649749756]
the O [-0.3299647867679596, 0.3924040198326111]
adjusted O [-0.5057130455970764, 0.36053773760795593]
odds O [-0.4546985924243927, 0.39389488101005554]
of O [-0.4602773189544678, 0.36136555671691895]
death O [-0.3359600603580475, 0.2845216393470764]
following O [-0.45573893189430237, 0.22964471578598022]
leukoreduction O [-0.3646709620952606, 0.3799996078014374]
were O [-0.2426140308380127, 0.25734639167785645]
reduced O [-0.25143811106681824, 0.3519103527069092]
(odds O [-0.5031547546386719, 0.3661523163318634]
ratio O [-0.4966084659099579, 0.36818572878837585]
[OR], O [-0.42275211215019226, 0.3065125048160553]
0.87; O [-0.3056742250919342, 0.4507288336753845]
95% O [-0.6096522808074951, 0.5520729422569275]
confidence O [-0.6720524430274963, 0.4864625930786133]
interval O [-0.5967637300491333, 0.44014137983322144]

[CI], O [-0.31872767210006714, -0.27019187808036804]
0.75-0.99), B-LOC [0.30776599049568176, -0.22569699585437775]
but O [-0.3406324088573456, 0.01932079903781414]
serious O [-0.3536068797111511, 0.04890261963009834]
nosocomial O [-0.3161957561969757, 0.1411944329738617]
infections O [-0.2213040441274643, 0.07269057631492615]
did O [-0.20944973826408386, -0.0793190598487854]
not O [-0.0812847763299942, 0.1434064507484436]
decrease B-LOC [-0.09121865034103394, -0.12787467241287231]
(adjusted O [-0.1417521983385086, -0.09305497258901596]
OR, O [-0.3744567334651947, 0.11530202627182007]
0.97; B-LOC [-0.058743175119161606, -0.11393848061561584]
95% O [-0.39145129919052124, 0.07992792129516602]
CI, O [-0.4603303372859955, -0.12378756701946259]
0.87-1.09). B-LOC [-0.032774705439805984, -0.07119716703891754]
The B-LOC [0.4720754623413086, -0.4868537485599518]
frequency B-LOC [0.41555896401405334, -0.4393549859523773]
of B-LOC [0.42105305194854736, -0.4713748097419739]
posttransfusion B-LOC [-0.031814027577638626, -0.13479222357273102]
fevers B-LOC [0.24428775906562805, -0.38473591208457947]
decreased B-LOC [0.421481192111969, -0.5273445248603821]
significantly B-LOC [0.3646315634250641, -0.47634467482566833]
following B-LOC [0.34903275966644287, -0.40953975915908813]
leukoreduction B-LOC [0.33494529128074646, -0.17014126479625702]
(adjusted B-LOC [0.45502910017967224, -0.39536580443382263]
OR, B-LOC [0.10504812002182007, -0.1660333275794983]
0.86; B-LOC [0.5111358761787415, -0.33765068650245667]
95% B-LOC [0.19321414828300476, -0.31737396121025085]
CI, B-LOC [-0.12174463272094727, -0.2983703315258026]
0.79-0.94), B-LOC [0.45723235607147217, -0.25521567463874817]
as B-LOC [0.1607171595096588, -0.3263262212276459]
did B-LOC [0.3563048541545868, -0.4778647720813751]
antibiotic B-LOC [0.43628326058387756, -0.5860218405723572]
use B-LOC [0.3007511794567108, -0.46640637516975403]
(adjusted B-LOC [0.43679243326187134, -0.5325731635093689]
OR, B-LOC [0.1091349720954895, -0.17577378451824188]
0.90; B-LOC [0.5603744387626648, -0.43988287448883057]
95% B-LOC [-0.025857554748654366, -0.3483952283859253]
CI, B-LOC [-0.021329743787646294, -0.4324786067008972]
0.82-0.99). B-LOC [0.7882229685783386, -0.6540160179138184]
CONCLUSION O [-0.6599195003509521, 0.2131139039993286]
A B-LOC [0.28658950328826904, -0.6411029696464539]
national B-LOC [0.425169974565506, -0.6724839210510254]
universal B-LOC [0.20788155496120453, -0.7612612843513489]

leukoreduction O [-0.6955380439758301, 0.7614378333091736]
program O [-1.0790518522262573, 1.0493221282958984]
is O [-0.9940325617790222, 0.7943623661994934]
potentially O [-0.7932665348052979, 0.5722048878669739]
associated O [-0.8696236610412598, 0.8531695604324341]
with O [-0.9518745541572571, 0.8094994425773621]
decreased O [-0.9704341888427734, 0.9242303967475891]
mortality O [-0.5913508534431458, 0.841869056224823]
as O [-0.7773625254631042, 0.8505401015281677]
well O [-1.0182507038116455, 0.9004945158958435]
as O [-0.8786473870277405, 0.8717573881149292]
decreased O [-1.0504390001296997, 0.9556507468223572]
fever O [-0.5556266903877258, 0.6701200604438782]
episodes O [-0.798157811164856, 0.9326199293136597]
and O [-1.0424704551696777, 0.8080640435218811]
antibiotic O [-0.8861702680587769, 0.8716925382614136]
use O [-0.7905115485191345, 0.9278684854507446]
after O [-0.9051975011825562, 0.7805261015892029]
red O [-0.7810744643211365, 0.7719990611076355]
blood O [-0.8499588370323181, 0.6831667423248291]
cell O [-0.8807897567749023, 0.8543736338615417]
transfusion O [-0.8366515636444092, 0.9371573328971863]
in O [-0.8426289558410645, 0.7364082932472229]
high-risk O [-0.5100706219673157, 0.5164021253585815]
patients. O [-0.7775226831436157, 0.5971569418907166]

The B-LOC [2.4936726093292236, -2.894411325454712]
signals B-LOC [2.3434674739837646, -2.9461915493011475]
and B-LOC [2.765207529067993, -2.908679723739624]
molecular B-LOC [2.817554235458374, -2.9408628940582275]
mechanisms B-LOC [2.6398379802703857, -2.845214605331421]
that B-LOC [2.79470157623291, -2.84611439704895]
regulate B-LOC [2.3828794956207275, -2.563208818435669]
the B-LOC [2.745573043823242, -2.865133047103882]
replication B-LOC [2.7121803760528564, -2.984846591949463]
of B-LOC [2.255082368850708, -2.6220357418060303]
terminally B-LOC [2.617908239364624, -3.0711400508880615]
differentiated B-LOC [2.345629930496216, -2.9170756340026855]
beta B-LOC [1.9365731477737427, -2.3760204315185547]
cells B-LOC [1.855820655822754, -2.546492576599121]
are B-LOC [3.3312244415283203, -2.900222063064575]
unknown. B-LOC [3.0624337196350098, -2.9562509059906006]
Here, B-LOC [1.2432911396026611, -1.3571715354919434]
we B-LOC [0.9875611662864685, -1.1105165481567383]
report B-LOC [1.220638632774353, -1.3484681844711304]
the B-LOC [1.387028694152832, -1.8386287689208984]
identification B-LOC [1.5756165981292725, -1.631209373474121]
and B-LOC [1.588083028793335, -2.080118417739868]
characterization B-LOC [1.5375709533691406, -1.7328840494155884]
of B-LOC [1.552947759628296, -1.8897714614868164]
transmembrane B-LOC [1.6354985237121582, -1.8267929553985596]
protein B-LOC [1.527376413345337, -1.9770686626434326]
27 B-LOC [1.8550829887390137, -1.6862646341323853]
(Tmem27, B-LOC [1.4474127292633057, -1.762790322303772]
collectrin) B-LOC [1.0315834283828735, -1.1259818077087402]
in B-LOC [1.3992708921432495, -1.6856753826141357]
pancreatic B-LOC [0.9207085967063904, -1.5460463762283325]
beta B-LOC [1.459000825881958, -1.6869064569473267]
cells. B-LOC [1.369657039642334, -1.7924813032150269]
Expression B-LOC [2.225353479385376, -2.2896647453308105]
of B-LOC [2.1448256969451904, -2.1328136920928955]
Tmem27 B-LOC [1.6196675300598145, -2.035277843475342]
is B-LOC [2.632708787918091, -2.0653698444366455]
reduced B-LOC [2.1604373455047607, -2.2246317863464355]
in B-LOC [2.0499539375305176, -2.147813081741333]
Tcf1(-/-) B-LOC [1.6291453838348389, -1.9479296207427979]
mice B-LOC [1.9522461891174316, -2.36574125289917]
and B-LOC [1.8699203729629517, -1.9962403774261475]
is B-LOC [2.6395699977874756, -2.164395332336426]
increased B-LOC [2.1167337894439697, -2.4623703956604004]
in B-LOC [2.13382887840271, -2.2429685592651367]
islets B-LOC [2.695945978164673, -2.3212039470672607]
of B-LOC [2.393541097640991, -2.3212854862213135]
mouse B-LOC [2.2168757915496826, -2.4957821369171143]
models B-LOC [2.3842086791992188, -2.2344181537628174]
with B-LOC [2.4802615642547607, -2.523831844329834]
hypertrophy B-LOC [2.6148717403411865, -2.1503841876983643]
of B-LOC [2.448528289794922, -2.2470269203186035]
the B-LOC [2.3182291984558105, -2.1555356979370117]
endocrine B-LOC [2.0879337787628174, -2.1224892139434814]
pancreas. B-LOC [1.6289536952972412, -2.1431071758270264]
Tmem27 B-LOC [0.351357638835907, -0.671653687953949]
forms B-LOC [0.5645831823348999, -0.6763200163841248]
dimers B-LOC [0.7154543399810791, -0.9006472229957581]
and B-LOC [0.14672277867794037, -0.6917369961738586]
its B-LOC [0.6432195901870728, -0.7047416567802429]
extracellular B-LOC [0.2302798628807068, -0.4564410150051117]
domain B-LOC [0.10944100469350815, -0.42911484837532043]
is B-LOC [0.6150596141815186, -0.6064327955245972]
glycosylated, B-LOC [0.4523213803768158, -0.5295113921165466]
cleaved B-LOC [0.5969789028167725, -0.5658448338508606]
and B-LOC [0.28460922837257385, -0.5084700584411621]
shed B-LOC [0.6894870400428772, -0.5719072222709656]
from B-LOC [0.4036983251571655, -0.28725704550743103]
the B-LOC [0.4048974812030792, -0.5323112607002258]
plasma B-LOC [0.23840990662574768, -0.5856541991233826]
membrane B-LOC [0.05696246400475502, -0.3426955044269562]
of B-LOC [0.10830453038215637, -0.4551078677177429]
beta B-LOC [0.3960758447647095, -0.5685731172561646]
cells. B-LOC [0.0523955263197422, -0.5412055253982544]

This B-LOC [0.4104454815387726, -1.149643063545227]
cleavage B-LOC [0.8136870265007019, -1.436434030532837]
process B-LOC [0.46009960770606995, -1.1466302871704102]
is B-LOC [0.9414857625961304, -1.1954457759857178]
beta B-LOC [1.1489667892456055, -1.348110318183899]
cell B-LOC [0.6007673740386963, -1.3867915868759155]
specific B-LOC [0.7654935121536255, -1.5076099634170532]
and B-LOC [0.4147452414035797, -0.9332793354988098]
does B-LOC [1.0993797779083252, -1.0739670991897583]
not B-LOC [1.170017957687378, -1.149029016494751]
occur B-LOC [0.5897515416145325, -1.2379668951034546]
in B-LOC [1.0044662952423096, -1.3443458080291748]
other B-LOC [1.032869815826416, -1.463901400566101]
cell B-LOC [0.5595136284828186, -1.387331485748291]
types. B-LOC [1.347447156906128, -1.4563119411468506]
Overexpression O [-0.5544682145118713, 0.5307384729385376]
of O [-0.39058271050453186, 0.34426912665367126]
full-length O [-0.4721144139766693, 0.485808402299881]
Tmem27, O [-0.18925391137599945, 0.1739141345024109]
but O [-0.6801000833511353, 0.7225667834281921]
not O [-0.5844769477844238, 0.8473275303840637]
the O [-0.44552308320999146, 0.3705414831638336]
truncated O [-0.4507664144039154, 0.41248324513435364]
or O [-0.3370787501335144, 0.2707584500312805]
soluble O [-0.3820776641368866, 0.20338088274002075]
protein, O [-0.27470630407333374, 0.16301126778125763]
leads O [-0.6538706421852112, 0.7398238778114319]
to O [-0.7048099040985107, 0.7064743638038635]
increased O [-0.7024918794631958, 0.6430363655090332]
thymidine O [-0.2745376229286194, 0.38203102350234985]
incorporation, O [-0.3773115575313568, 0.6078735589981079]
whereas O [-0.7765602469444275, 0.8191583156585693]
silencing O [-0.4940243661403656, 0.4953756630420685]
of O [-0.49412763118743896, 0.44749200344085693]
Tmem27 O [-0.36186355352401733, 0.4472813308238983]
using O [-0.6476736664772034, 0.3766199052333832]
RNAi O [-0.4496668875217438, 0.26067861914634705]
results O [-0.629988968372345, 0.6360257267951965]
in O [-0.6432207226753235, 0.5730311274528503]
a O [-0.6294442415237427, 0.5738845467567444]
reduction O [-0.47771164774894714, 0.49567970633506775]
of O [-0.5677699446678162, 0.32286691665649414]
cell O [-0.6412152647972107, 0.22596341371536255]
replication. O [-0.21521645784378052, 0.3087068796157837]
Furthermore, O [-0.47959405183792114, 0.36137130856513977]
transgenic O [-0.3017558157444, 0.255729079246521]
mice O [-0.38679540157318115, 0.05808066949248314]
with O [-0.39406725764274597, 0.049799032509326935]
increased O [-0.3372364640235901, 0.09081487357616425]
expression O [-0.15959157049655914, 0.17312844097614288]
of O [-0.21358774602413177, 0.11918757855892181]
Tmem27 O [-0.12502944469451904, -0.03326142206788063]
in O [-0.327682226896286, 0.25067007541656494]
pancreatic O [-0.7510059475898743, 0.47140657901763916]
beta O [-0.23156848549842834, 0.08414074033498764]
cells O [-0.3201601207256317, 0.043295230716466904]
exhibit O [-0.3611995279788971, 0.04638154059648514]
increased O [-0.2991103231906891, 0.08655032515525818]
beta O [-0.21255004405975342, 0.06168728694319725]
cell O [-0.35135379433631897, -0.09221935272216797]
mass. O [-0.16888880729675293, 0.206261545419693]
Our B-LOC [0.14245831966400146, -0.4068205952644348]
results B-LOC [0.25892725586891174, -0.37050846219062805]
identify B-LOC [0.31931763887405396, -0.3428548574447632]
a B-LOC [0.16198945045471191, -0.44307684898376465]
pancreatic O [-0.2700028717517853, -0.21591821312904358]
beta B-LOC [0.00968147348612547, -0.17054547369480133]
cell B-LOC [-0.18649202585220337, -0.37987038493156433]
transmembrane B-LOC [0.14674484729766846, -0.35363367199897766]
protein B-LOC [-0.050620097666978836, -0.48472458124160767]
that B-LOC [-0.05652480199933052, -0.5456026196479797]
regulates B-LOC [-0.052062273025512695, -0.2840959131717682]
cell B-LOC [-0.2498951405286789, -0.3151872158050537]
growth B-LOC [-0.117407888174057, -0.20169685781002045]
of B-LOC [-0.012277134694159031, -0.31047898530960083]
pancreatic O [-0.3805029094219208, -0.14710521697998047]
islets. B-LOC [-0.1333567202091217, -0.40956398844718933]

The B-LOC [1.5965030193328857, -2.155580759048462]
PI3K B-LOC [1.30851411819458, -2.113553524017334]
signaling B-LOC [1.587752342224121, -2.153064250946045]
pathway B-LOC [1.5409542322158813, -2.2237305641174316]
regulates B-LOC [1.9544219970703125, -2.2422397136688232]
cell B-LOC [1.5955557823181152, -2.2622618675231934]
growth B-LOC [1.6537504196166992, -2.275625467300415]
and B-LOC [1.8509135246276855, -2.302938938140869]
movement B-LOC [1.997685432434082, -2.6024649143218994]
and B-LOC [1.9845263957977295, -2.3545968532562256]
is B-LOC [2.470238447189331, -2.4953551292419434]
heavily B-LOC [2.388801097869873, -2.635788679122925]
mutated B-LOC [2.540410280227661, -2.708177328109741]
in B-LOC [2.177157163619995, -2.5429203510284424]
cancer. B-LOC [2.104619026184082, -2.5300498008728027]
Class B-LOC [1.5584136247634888, -1.690060019493103]
I B-LOC [1.3777536153793335, -1.6901216506958008]
PI3Ks B-LOC [1.2474215030670166, -1.7511042356491089]
synthesize B-LOC [1.4619340896606445, -1.514917016029358]
the B-LOC [1.2691463232040405, -1.265906810760498]
lipid B-LOC [1.0223699808120728, -1.3273870944976807]
messenger B-LOC [0.6254255175590515, -1.1525239944458008]
PI(3,4,5)P3. B-LOC [0.8791616559028625, -1.3122743368148804]
PI(3,4,5)P3 B-LOC [0.6073694229125977, -1.0973767042160034]
can B-LOC [1.293853998184204, -1.2285438776016235]
be B-LOC [1.3631083965301514, -1.4568363428115845]
dephosphorylated B-LOC [1.3408509492874146, -1.0856586694717407]
by B-LOC [0.7730465531349182, -0.9497724175453186]
3- B-LOC [0.7966904044151306, -0.9118910431861877]
or B-LOC [1.1411195993423462, -1.4294811487197876]
5-phosphatases, B-LOC [0.9176689386367798, -1.1807868480682373]
the B-LOC [1.250523328781128, -1.4937942028045654]
latter B-LOC [1.2607944011688232, -1.227126121520996]
producing B-LOC [1.1600981950759888, -0.9557932019233704]
PI(3,4)P2. B-LOC [0.6589782238006592, -1.0372674465179443]
The B-LOC [1.0274732112884521, -1.0222114324569702]
PTEN B-LOC [0.8503549695014954, -1.219011664390564]
tumor B-LOC [0.7372642159461975, -0.9366628527641296]
suppressor B-LOC [0.782637894153595, -1.0790165662765503]
is B-LOC [1.2063376903533936, -1.0606577396392822]
thought B-LOC [1.264000654220581, -1.053728699684143]
to B-LOC [1.2904819250106812, -1.1594271659851074]
function B-LOC [0.8204297423362732, -0.9065458178520203]
primarily B-LOC [1.0098707675933838, -0.8775975108146667]
as B-LOC [0.9637022018432617, -0.8273784518241882]
a B-LOC [0.7263486981391907, -0.7791151404380798]
PI(3,4,5)P3 B-LOC [0.48256781697273254, -0.9419392943382263]

3-phosphatase, B-LOC [0.7391036152839661, -0.9911531805992126]
limiting B-LOC [0.6535804867744446, -0.9483875632286072]
activation B-LOC [0.8557866215705872, -1.0957409143447876]
of B-LOC [0.9086421132087708, -1.1717565059661865]
this B-LOC [0.8697309494018555, -1.1657428741455078]
pathway. B-LOC [0.5422332882881165, -1.1319475173950195]
Here B-LOC [0.13230547308921814, -0.42838409543037415]
we O [-0.24677857756614685, -0.14745289087295532]
show B-LOC [0.13142526149749756, -0.22641408443450928]
that B-LOC [0.30638206005096436, -0.7454730868339539]
PTEN B-LOC [0.4408629238605499, -0.837460994720459]
also B-LOC [0.6468596458435059, -0.7588889002799988]
functions B-LOC [0.7085011005401611, -0.7286291122436523]
as B-LOC [0.5401028990745544, -0.6954393982887268]
a B-LOC [0.48841217160224915, -0.7604570388793945]
PI(3,4)P2 B-LOC [0.48833176493644714, -0.8137134909629822]
3-phosphatase, B-LOC [0.5238026976585388, -0.6224575638771057]
both B-LOC [0.40134015679359436, -0.7285662293434143]
in B-LOC [0.2176719605922699, -0.5752221941947937]
vitro B-LOC [0.20272384583950043, -0.4911998212337494]
and B-LOC [0.6630929708480835, -0.4692477285861969]
in B-LOC [0.34387433528900146, -0.6340203881263733]
vivo. B-LOC [0.4318754971027374, -0.7015071511268616]
PTEN O [-0.1916067898273468, 0.0024702451191842556]
is O [-0.16106845438480377, 0.25134503841400146]
a O [-0.11854249238967896, 0.32481613755226135]
major O [-0.2284376323223114, 0.18173924088478088]
PI(3,4)P2 O [-0.2835988700389862, -0.03741830959916115]
phosphatase O [-0.4220668077468872, 0.03550371155142784]
in O [-0.28573939204216003, 0.2366776168346405]
Mcf10a O [-0.20896774530410767, 0.18339744210243225]
cytosol, O [-0.309915155172348, 0.05492449179291725]
and O [-0.6107286810874939, 0.3282563388347626]
loss O [-0.2424478530883789, 0.24668195843696594]
of O [-0.33358144760131836, 0.22959452867507935]
PTEN O [-0.3776524066925049, 0.2110588550567627]
and O [-0.4353354275226593, 0.2993895709514618]
INPP4B, O [-0.48976051807403564, 0.11236705631017685]
a O [-0.2032119333744049, 0.1303410828113556]
known O [-0.1908787339925766, -0.1350438892841339]
PI(3,4)P2 O [-0.26782622933387756, -0.16288712620735168]
4-phosphatase, O [-0.29355567693710327, 0.020414186641573906]
leads O [-0.39216360449790955, 0.2831210792064667]
to O [-0.4136894643306732, 0.457328736782074]
synergistic O [-0.45091530680656433, 0.36388954520225525]
accumulation O [-0.1180524230003357, 0.36989933252334595]
of O [-0.24348998069763184, 0.11669032275676727]
PI(3,4)P2, O [-0.41224345564842224, -0.018803533166646957]
which O [-0.33774223923683167, 0.1310116946697235]

correlated B-LOC [-0.10171201825141907, -0.25499987602233887]
with B-LOC [0.024650154635310173, -0.28198832273483276]
increased B-LOC [-0.024854576215147972, -0.1178324818611145]
invadopodia B-LOC [-0.05347352847456932, -0.22599127888679504]
in B-LOC [-0.09036574512720108, -0.15277084708213806]
epidermal B-LOC [0.07119788229465485, -0.43751516938209534]
growth B-LOC [0.09833922982215881, -0.3235783278942108]
factor B-LOC [0.16739873588085175, -0.4411529302597046]
(EGF)-stimulated B-LOC [0.26487255096435547, -0.6512538194656372]
cells. B-LOC [-0.09129156172275543, -0.2789728045463562]
PTEN O [-0.31506985425949097, 0.3377017378807068]
deletion O [-0.1358344554901123, 0.4954547584056854]
increased O [-0.5491533279418945, 0.43260297179222107]
PI(3,4)P2 O [-0.5370040535926819, 0.4066866636276245]
levels O [-0.4496702253818512, 0.5268995761871338]
in O [-0.5116422772407532, 0.36982765793800354]
a O [-0.21554633975028992, 0.31662648916244507]
mouse O [-0.41917508840560913, 0.5180647373199463]
model O [-0.4800572395324707, 0.5591215491294861]
of O [-0.23931002616882324, 0.3425242602825165]
prostate O [-0.4645545184612274, 0.4690972864627838]
cancer, O [-0.3259514272212982, 0.2249612808227539]
and O [-0.4607742726802826, 0.3406236171722412]
it O [-0.5645323395729065, 0.3478623032569885]
inversely O [0.0043167308904230595, 0.2691536843776703]
correlated O [-0.3175758421421051, 0.321870356798172]
with O [-0.31139710545539856, 0.11960490047931671]
PI(3,4)P2 O [-0.45471328496932983, 0.2984578311443329]
levels O [-0.28415435552597046, 0.28062209486961365]
across O [-0.25600582361221313, 0.17021363973617554]
several O [-0.03444908931851387, -0.018102431669831276]
EGF-stimulated O [-0.3517843782901764, 0.12217527627944946]
prostate O [-0.2593376934528351, 0.1385267674922943]
and B-LOC [0.02195771597325802, -0.11821132153272629]
breast B-LOC [0.11733771860599518, -0.27655306458473206]
cancer B-LOC [-0.019029749557375908, -0.24394071102142334]
lines. O [-0.1286512315273285, -0.07293424010276794]
These B-LOC [0.8326497077941895, -1.0398811101913452]
results B-LOC [1.0275180339813232, -0.8930026888847351]
point B-LOC [1.0100982189178467, -1.0091760158538818]
to B-LOC [1.0444610118865967, -1.2515743970870972]
a B-LOC [1.025435447692871, -1.2201581001281738]
role B-LOC [0.7229061722755432, -1.3000227212905884]
for B-LOC [0.9616679549217224, -1.1074450016021729]
PI(3,4)P2 B-LOC [0.42095670104026794, -0.7721045613288879]
in B-LOC [0.7622794508934021, -1.1872261762619019]
the B-LOC [0.8680152893066406, -1.0414552688598633]
phenotype B-LOC [0.8074637651443481, -1.1601498126983643]
caused B-LOC [0.7941915392875671, -1.1490312814712524]
by B-LOC [0.7219139337539673, -0.986971378326416]
loss-of-function B-LOC [0.8615934252738953, -1.2370688915252686]
mutations B-LOC [0.6722108721733093, -1.1188280582427979]
or B-LOC [0.8992369771003723, -0.9981093406677246]
deletions B-LOC [1.1728861331939697, -1.038610816001892]
in B-LOC [0.6417424082756042, -1.1496903896331787]
PTEN. B-LOC [0.5732617378234863, -0.9441396594047546]

BACKGROUND B-LOC [1.3678206205368042, -2.076221466064453]
Interferon-gamma B-LOC [2.1112401485443115, -2.740581512451172]
(IFN-gamma) B-LOC [2.334602117538452, -2.610779047012329]
is B-LOC [2.572159767150879, -2.7579994201660156]
an B-LOC [2.610067844390869, -2.8426525592803955]
essential B-LOC [2.4580748081207275, -2.975242853164673]
cytokine B-LOC [2.3888938426971436, -2.7965545654296875]
in B-LOC [2.6219046115875244, -2.8292934894561768]
the B-LOC [2.8212482929229736, -2.93310284614563]
regulation B-LOC [2.6525275707244873, -2.9141082763671875]
of B-LOC [2.7037646770477295, -3.0537638664245605]
inflammatory B-LOC [2.8804562091827393, -3.0876448154449463]
responses B-LOC [2.743947744369507, -3.1103460788726807]
in B-LOC [2.8040692806243896, -2.9066901206970215]
autoimmune B-LOC [2.782317876815796, -3.1200668811798096]
diseases. B-LOC [3.0091965198516846, -2.999427556991577]
Little B-LOC [2.870417833328247, -2.804791212081909]
is B-LOC [2.8853018283843994, -2.8349716663360596]
known B-LOC [2.8373515605926514, -2.817915916442871]
about B-LOC [2.8985912799835205, -3.0675618648529053]
its B-LOC [2.751150131225586, -3.0307528972625732]
role B-LOC [2.6650094985961914, -2.8333261013031006]
in B-LOC [2.9242422580718994, -2.86478590965271]
inflammatory B-LOC [2.9180002212524414, -3.027431011199951]
heart B-LOC [2.6906371116638184, -3.2932894229888916]
disease. B-LOC [2.966792106628418, -2.8955142498016357]
METHODS B-LOC [0.7177860140800476, -1.1311498880386353]
AND B-LOC [1.0893868207931519, -1.6065585613250732]
RESULTS B-LOC [0.5143621563911438, -1.1761126518249512]
We O [-0.6631004214286804, 0.42605289816856384]
showed O [-0.8990431427955627, 0.7138407230377197]
that O [-1.1736901998519897, 0.672368586063385]
IFN-gamma O [-0.4149065613746643, 0.23496279120445251]
receptor-deficient O [-0.6158111691474915, 0.3149263560771942]
mice O [-0.8043966889381409, 0.4718891680240631]
(IFN-gammaR(-/-)) O [-0.4232313930988312, 0.4246768057346344]
on O [-0.4369078576564789, 0.7177560329437256]
a O [-0.36372649669647217, 0.5643386840820312]
BALB/c O [-0.4041864573955536, 0.33609020709991455]
background O [-0.47835925221443176, 0.29076090455055237]
immunized O [-0.6651735901832581, 0.7978811860084534]
with O [-0.44595012068748474, 0.36115768551826477]
a O [-0.41748300194740295, 0.5970136523246765]
peptide O [-0.7581352591514587, 0.5505784153938293]
derived O [-0.564151406288147, 0.4369089901447296]
from O [-0.4756215810775757, 0.6568693518638611]
cardiac O [-0.6604516506195068, 0.5338979363441467]
alpha-myosin O [-0.530125617980957, 0.48466870188713074]
heavy O [-0.7436522245407104, 0.782812774181366]
chain O [-0.5831089019775391, 0.6019347906112671]
develop O [-0.8510575294494629, 0.8041664361953735]
severe O [-0.9855714440345764, 0.9447643160820007]
myocarditis O [-1.0241000652313232, 0.8386776447296143]
with O [-0.9930360317230225, 0.9176539778709412]
high O [-0.9611678719520569, 1.0286645889282227]

mortality. B-LOC [-0.07166437059640884, -0.3846561908721924]
Although B-LOC [-0.0916348248720169, -0.237024188041687]
myocarditis B-LOC [-0.008864243514835835, -0.19074195623397827]
subsided B-LOC [0.24570021033287048, -0.14258769154548645]
in B-LOC [-0.009471570141613483, -0.2340218871831894]
wild-type B-LOC [0.12549886107444763, -0.38173601031303406]
mice B-LOC [0.029767585918307304, -0.2428905963897705]
after B-LOC [-0.0028551570139825344, -0.4388779401779175]
3 B-LOC [0.04728880152106285, -0.09994286298751831]
weeks, B-LOC [0.13385853171348572, -0.2756156623363495]
IFN-gammaR(-/-) B-LOC [0.0333542674779892, -0.211564838886261]
mice O [-0.11864148080348969, 0.006619160529226065]
showed O [-0.13972777128219604, -0.08966304361820221]
persistent B-LOC [0.12299595773220062, -0.3214455842971802]
disease. B-LOC [0.04990672692656517, -0.18648380041122437]
The O [-0.6118223667144775, 0.587934672832489]
persistent O [-0.6459335088729858, 0.5677387714385986]
inflammation O [-0.5683112144470215, 0.6115055680274963]
was O [-0.7376134395599365, 0.4053671658039093]
accompanied O [-0.806533694267273, 0.544474184513092]
by O [-0.6832284927368164, 0.5458927750587463]
vigorous O [-0.754580557346344, 0.6135556697845459]
in O [-0.7841914296150208, 0.6649067997932434]
vitro O [-0.5351259112358093, 0.6467100977897644]
CD4 O [-0.8065925240516663, 1.062782883644104]
T-cell O [-0.9837208986282349, 0.830548882484436]
responses O [-0.749607503414154, 0.7258512377738953]
and O [-0.8173422813415527, 0.5534818768501282]
impaired O [-0.69231778383255, 0.39572155475616455]
inducible O [-0.9761214852333069, 0.8788488507270813]
nitric O [-0.8679128885269165, 0.7010934948921204]
oxide O [-0.6280596256256104, 0.7426816821098328]
synthase O [-0.9953674674034119, 0.7650344967842102]
expression, O [-0.5461438298225403, 0.8791924118995667]
together O [-0.5363990664482117, 0.5211971402168274]
with O [-0.5491026043891907, 0.38146311044692993]
evidence O [-0.5651305913925171, 0.3149874210357666]
of O [-0.5817219614982605, 0.253574401140213]
impaired O [-0.6063619256019592, 0.2593581974506378]
nitric O [-0.568241536617279, 0.28621533513069153]
oxide O [-0.443399578332901, 0.3652542531490326]
production O [-0.5148926377296448, 0.501226007938385]
in O [-0.5462401509284973, 0.24793756008148193]
IFN-gammaR(-/-) O [-0.22522631287574768, 0.20739327371120453]
hearts. O [-0.5968409180641174, 0.4422778785228729]
Treatment B-LOC [1.18853759765625, -1.4459437131881714]
of B-LOC [1.2530592679977417, -1.243326187133789]
wild-type B-LOC [1.138817310333252, -1.6708495616912842]
mice B-LOC [0.912388265132904, -1.4374713897705078]
with B-LOC [1.5006623268127441, -1.515903115272522]
the B-LOC [1.4130113124847412, -1.366593837738037]
nitric B-LOC [1.2257888317108154, -1.7316703796386719]
oxide B-LOC [1.10028874874115, -1.632260799407959]
synthetase B-LOC [1.2265667915344238, -1.543702483177185]
inhibitor B-LOC [0.9937720894813538, -1.5897024869918823]

N:-nitro-l-arginine-methyl-ester O [-0.38741955161094666, 0.06967811286449432]
enhanced O [-0.7611401677131653, 0.7525403499603271]
in O [-0.6899093985557556, 0.40477097034454346]
vitro O [-0.242567777633667, 0.4119626581668854]
CD4 O [-0.7443689703941345, 0.9256619215011597]
T-cell O [-0.8236574530601501, 0.6198002099990845]
proliferation O [-0.5177502632141113, 0.7303990721702576]
and O [-0.7529696226119995, 0.6152480244636536]
prevented O [-0.6839157938957214, 0.7066581845283508]
healing O [-0.6046778559684753, 0.8343251943588257]
of O [-0.7069493532180786, 0.7899176478385925]
myocarditis. O [-0.685341477394104, 0.450313925743103]
CONCLUSIONS O [-0.8741226196289062, 0.6054015159606934]
Our O [-0.48359623551368713, 0.4659646451473236]
data O [-0.5357179045677185, 0.39329424500465393]
provide O [-0.20686525106430054, 0.24925129115581512]
evidence O [-0.4864914119243622, 0.5180976390838623]
that O [-0.9384327530860901, 0.5521337389945984]
IFN-gamma O [-0.6091009378433228, 0.36670657992362976]
protects O [-0.8609771132469177, 0.7380027770996094]
mice O [-1.000685453414917, 0.6330426335334778]
from O [-0.7826863527297974, 0.8465752005577087]
lethal O [-0.9796242117881775, 0.7494931817054749]
autoimmune O [-1.0492925643920898, 0.7803061604499817]
myocarditis O [-0.9075559973716736, 0.7466210722923279]
by O [-1.3137502670288086, 1.001749038696289]
inducing O [-1.327330231666565, 0.9554997086524963]
the O [-1.090825080871582, 0.9674459099769592]
expression O [-1.0541437864303589, 1.0953779220581055]
of O [-1.1957310438156128, 1.070371150970459]
inducible O [-1.1603469848632812, 0.9936208128929138]
nitric O [-0.9216421842575073, 0.6910749077796936]
oxide O [-0.6437293291091919, 0.6056710481643677]
synthase O [-1.0829695463180542, 0.9212111830711365]
followed O [-1.0905611515045166, 0.8683931231498718]
by O [-1.0363502502441406, 0.8991664052009583]
the O [-1.008893609046936, 0.9419975876808167]
downregulation O [-0.8814277052879333, 0.7788600325584412]
of O [-0.9202819466590881, 0.7922578454017639]
T-cell O [-0.7490618228912354, 0.5039610266685486]
responses. O [-0.9029430747032166, 0.6756051182746887]

CONTEXT B-LOC [0.945119321346283, -1.8947993516921997]
The B-LOC [2.1519646644592285, -2.4850714206695557]
growth B-LOC [1.9748543500900269, -2.2988944053649902]
inhibitory B-LOC [2.8677432537078857, -2.6994693279266357]
effect B-LOC [2.3219261169433594, -2.4510529041290283]
of B-LOC [1.8949434757232666, -2.05403995513916]
tamoxifen, B-LOC [1.4329748153686523, -1.9681849479675293]
which B-LOC [2.04074764251709, -2.519789218902588]
is B-LOC [2.553314447402954, -2.2753260135650635]
used B-LOC [2.421710252761841, -2.317892551422119]
for B-LOC [2.6984798908233643, -2.497767686843872]
the B-LOC [2.7237355709075928, -2.3774588108062744]
treatment B-LOC [2.53700852394104, -2.289329767227173]
of B-LOC [2.2832424640655518, -2.2155368328094482]
hormone B-LOC [2.1003172397613525, -2.517421007156372]
receptor-positive B-LOC [2.373859167098999, -2.4170289039611816]
breast B-LOC [2.1245291233062744, -2.184929132461548]
cancer, B-LOC [2.5468735694885254, -2.444852352142334]
is B-LOC [2.3423807621002197, -2.1565604209899902]
mediated B-LOC [2.242352247238159, -2.39298415184021]
by B-LOC [1.9949439764022827, -2.032802104949951]
its B-LOC [1.911222219467163, -2.128887176513672]
metabolites, B-LOC [2.415060043334961, -2.4845685958862305]
4-hydroxytamoxifen B-LOC [1.8466029167175293, -1.8230633735656738]
and B-LOC [1.794501543045044, -1.7718777656555176]
endoxifen. B-LOC [1.362180471420288, -1.8663939237594604]
The B-LOC [2.2804009914398193, -2.2320680618286133]
formation B-LOC [2.397353410720825, -2.1534104347229004]
of B-LOC [2.1435256004333496, -1.903748631477356]
active B-LOC [2.566467523574829, -2.2119150161743164]
metabolites B-LOC [2.6716339588165283, -2.122802972793579]
is B-LOC [2.4702861309051514, -1.9300917387008667]
catalyzed B-LOC [2.4984827041625977, -2.0265307426452637]
by B-LOC [2.441584825515747, -1.8592984676361084]
the B-LOC [2.5109894275665283, -1.9394193887710571]
polymorphic B-LOC [2.592104196548462, -2.1497268676757812]
cytochrome B-LOC [2.4283671379089355, -2.1411473751068115]
P450 B-LOC [2.346125364303589, -2.2412211894989014]
2D6 B-LOC [2.54362154006958, -2.1504902839660645]
(CYP2D6) B-LOC [2.307462453842163, -2.373098611831665]
enzyme. B-LOC [2.363379716873169, -2.482225179672241]
OBJECTIVE B-LOC [3.154069662094116, -3.168348550796509]
To B-LOC [3.2640058994293213, -3.320073127746582]
determine B-LOC [3.492974042892456, -3.293088436126709]
whether B-LOC [3.5255565643310547, -3.4020004272460938]
CYP2D6 B-LOC [3.300168991088867, -3.1352083683013916]
variation B-LOC [3.2375729084014893, -3.468658924102783]
is B-LOC [3.3996171951293945, -3.2170825004577637]
associated B-LOC [3.3509409427642822, -3.4525420665740967]
with B-LOC [2.9392449855804443, -3.418553352355957]
clinical B-LOC [3.5310757160186768, -3.4712932109832764]
outcomes B-LOC [3.4574532508850098, -3.5325281620025635]
in B-LOC [3.264861583709717, -3.4643301963806152]
women B-LOC [3.6065690517425537, -3.2552096843719482]
receiving B-LOC [3.551731586456299, -3.337796688079834]
adjuvant B-LOC [3.42292857170105, -3.344156265258789]
tamoxifen. B-LOC [3.0126125812530518, -3.138709545135498]
DESIGN, B-LOC [3.329551935195923, -3.215766668319702]

SETTING, B-LOC [2.336467981338501, -3.32403826713562]
AND B-LOC [2.8355801105499268, -3.598156213760376]
PATIENTS B-LOC [2.7585372924804688, -3.478149652481079]
Retrospective B-LOC [2.796128511428833, -3.360199213027954]
analysis B-LOC [2.7819933891296387, -3.293661117553711]
of B-LOC [3.058523178100586, -3.2689273357391357]
German B-LOC [3.0257625579833984, -3.462113857269287]
and B-LOC [3.063910722732544, -3.460766553878784]
US B-LOC [3.1382381916046143, -3.5246987342834473]
cohorts B-LOC [3.46936297416687, -3.5259830951690674]
of B-LOC [3.2420454025268555, -3.3551065921783447]
patients B-LOC [3.3948848247528076, -3.485931634902954]
treated B-LOC [3.5199620723724365, -3.5502121448516846]
with B-LOC [3.3515427112579346, -3.649393320083618]
adjuvant B-LOC [3.532463788986206, -3.5870370864868164]
tamoxifen B-LOC [3.071254014968872, -3.5506198406219482]
for B-LOC [3.3795998096466064, -3.512528657913208]
early B-LOC [2.9580304622650146, -3.5044286251068115]
stage B-LOC [2.9814345836639404, -3.6808924674987793]
breast B-LOC [3.0170772075653076, -3.481506586074829]
cancer. B-LOC [3.196580410003662, -3.442253351211548]
The B-LOC [2.9903461933135986, -3.274508476257324]
1325 B-LOC [3.287886142730713, -3.429448366165161]
patients B-LOC [3.2414796352386475, -3.469022035598755]
had B-LOC [3.1834707260131836, -3.324387311935425]
diagnoses B-LOC [3.5473763942718506, -3.5510897636413574]
between B-LOC [3.2579362392425537, -3.580866813659668]
1986 B-LOC [3.142197370529175, -3.326617956161499]
and B-LOC [3.107754945755005, -3.3035342693328857]
2005 B-LOC [3.211775064468384, -3.5273935794830322]
of B-LOC [2.9781975746154785, -3.201408863067627]
stage B-LOC [2.938084840774536, -3.409480333328247]
I B-LOC [2.9751837253570557, -3.2853517532348633]
through B-LOC [2.9738965034484863, -3.1846659183502197]
III B-LOC [2.6364293098449707, -3.155334234237671]
breast B-LOC [3.0001847743988037, -3.3453073501586914]
cancer B-LOC [2.997929573059082, -3.3902547359466553]
and B-LOC [2.7783663272857666, -3.2651147842407227]
were B-LOC [3.2212843894958496, -3.4006683826446533]
mainly B-LOC [3.1742594242095947, -3.6161892414093018]
postmenopausal B-LOC [3.18949818611145, -3.508859395980835]
(95.4%). B-LOC [3.0777928829193115, -3.5337300300598145]
Last B-LOC [3.1941449642181396, -3.2084388732910156]
follow-up B-LOC [3.086846351623535, -3.4911997318267822]
was B-LOC [3.180974245071411, -3.17046856880188]
in B-LOC [3.287752389907837, -3.033586263656616]
December B-LOC [3.553413152694702, -2.854752779006958]
2008; B-LOC [3.3583009243011475, -3.153362989425659]
inclusion B-LOC [3.3919572830200195, -3.581634521484375]
criteria B-LOC [3.2455761432647705, -3.568387508392334]
were B-LOC [2.9896466732025146, -3.1884706020355225]
hormone B-LOC [3.3772661685943604, -3.82792067527771]
receptor B-LOC [3.3148598670959473, -3.5637459754943848]
positivity, B-LOC [3.333529472351074, -3.311041831970215]
no B-LOC [3.073951482772827, -3.4734184741973877]
metastatic B-LOC [3.3589847087860107, -3.3884854316711426]
disease B-LOC [3.3884692192077637, -3.4037106037139893]
at B-LOC [3.1766583919525146, -3.602351665496826]
diagnosis, B-LOC [3.549076795578003, -3.2056539058685303]
adjuvant B-LOC [3.42214298248291, -3.4168484210968018]
tamoxifen B-LOC [3.4383437633514404, -3.334174871444702]
therapy, B-LOC [3.197697162628174, -3.3425068855285645]
and B-LOC [2.817042589187622, -3.320647716522217]
no B-LOC [3.027998685836792, -3.299037218093872]
chemotherapy. B-LOC [3.2684457302093506, -3.690906286239624]
DNA B-LOC [1.541057825088501, -2.039362668991089]
from B-LOC [1.8509483337402344, -2.2304179668426514]
tumor B-LOC [1.9803271293640137, -2.392831563949585]
tissue B-LOC [1.6287802457809448, -2.0226247310638428]
or B-LOC [1.75434148311615, -2.001601457595825]
blood B-LOC [1.7375251054763794, -2.563310146331787]
was B-LOC [1.9587244987487793, -2.0177576541900635]
genotyped B-LOC [2.192497491836548, -2.077291488647461]
for B-LOC [1.5120902061462402, -1.7327085733413696]
CYP2D6 B-LOC [1.3987886905670166, -1.4756779670715332]

variants B-LOC [1.1541173458099365, -1.409178614616394]
associated B-LOC [2.0700531005859375, -1.7508177757263184]
with B-LOC [1.8829869031906128, -1.641113042831421]
reduced B-LOC [1.6857951879501343, -1.7444210052490234]
(*10, B-LOC [1.5945849418640137, -1.7202179431915283]
*41) B-LOC [1.2455084323883057, -1.673462152481079]
or B-LOC [1.920244812965393, -1.7403379678726196]
absent B-LOC [1.8993680477142334, -1.8183057308197021]
(*3, B-LOC [1.6029298305511475, -1.731424331665039]
*4, B-LOC [1.1753041744232178, -1.550528883934021]
*5) B-LOC [1.2977874279022217, -1.6330583095550537]
enzyme B-LOC [1.845594048500061, -2.0830271244049072]
activity. B-LOC [1.7166463136672974, -1.936660885810852]
Women B-LOC [2.776315450668335, -2.1824491024017334]
were B-LOC [3.123095750808716, -2.3719446659088135]
classified B-LOC [3.2143683433532715, -2.338798999786377]
as B-LOC [2.942768096923828, -2.1064112186431885]
having B-LOC [2.8541648387908936, -2.4127626419067383]
an B-LOC [2.7637155055999756, -2.0114822387695312]
extensive B-LOC [2.796173334121704, -2.2020750045776367]
(n=609), B-LOC [2.5479846000671387, -2.3140499591827393]
heterozygous B-LOC [2.3163721561431885, -2.465125322341919]
extensive/intermediate B-LOC [2.459233522415161, -2.1391818523406982]
(n=637), B-LOC [2.6437740325927734, -2.3350720405578613]
or B-LOC [2.797781229019165, -2.214608907699585]
poor B-LOC [2.863409996032715, -1.9719823598861694]
(n=79) B-LOC [2.8307406902313232, -2.383831739425659]
CYP2D6 B-LOC [2.6914641857147217, -2.4646177291870117]
metabolism. B-LOC [2.6508419513702393, -2.4942338466644287]
MAIN B-LOC [2.7418429851531982, -2.577500343322754]
OUTCOME B-LOC [2.757563352584839, -2.364128351211548]
MEASURES B-LOC [2.7935471534729004, -2.5515592098236084]
Time B-LOC [2.5617289543151855, -2.3782434463500977]
to B-LOC [2.5579428672790527, -2.4150586128234863]
recurrence, B-LOC [2.9059555530548096, -2.676464319229126]
event-free B-LOC [2.8038008213043213, -2.8436310291290283]
survival, B-LOC [2.869323968887329, -2.5925958156585693]
disease-free B-LOC [3.2216525077819824, -2.595940113067627]
survival, B-LOC [2.996931314468384, -2.5461506843566895]
and B-LOC [2.956197500228882, -2.52899432182312]
overall B-LOC [3.258429765701294, -2.672800064086914]
survival. B-LOC [3.0097320079803467, -2.567810297012329]
RESULTS B-LOC [0.9352678060531616, -1.7523822784423828]
Median B-LOC [1.1987040042877197, -1.397233486175537]
follow-up B-LOC [1.431408405303955, -1.630749225616455]
was B-LOC [0.8770508766174316, -1.4493815898895264]
6.3 B-LOC [1.2598387002944946, -1.6091282367706299]
years. B-LOC [1.4402531385421753, -1.709273338317871]
At B-LOC [0.6768316030502319, -1.0831739902496338]
9 B-LOC [0.9622029662132263, -1.258642315864563]
years B-LOC [1.1955761909484863, -1.1508257389068604]
of B-LOC [0.9840251207351685, -0.8868283629417419]
follow-up, B-LOC [1.14436936378479, -1.2953075170516968]
the B-LOC [0.7951903343200684, -0.8311008214950562]
recurrence B-LOC [0.8356369137763977, -1.0689655542373657]

rates O [-0.7900590300559998, 0.3851880431175232]
were O [-0.7486498951911926, 0.3566664755344391]
14.9% O [-0.7269377112388611, 0.7481223344802856]
for O [-0.6820355653762817, 0.3895636796951294]
extensive O [-0.4944814145565033, 0.5415809154510498]
metabolizers, O [-0.46262991428375244, 0.537002682685852]
20.9% O [-0.6943583488464355, 0.8900639414787292]
for O [-0.7026445269584656, 0.4096849262714386]
heterozygous O [-0.5519382357597351, 0.5044286251068115]
extensive/intermediate O [-0.28558412194252014, 0.525109589099884]
metabolizers, O [-0.4048936665058136, 0.606406033039093]
and O [-0.8086269497871399, 0.543510377407074]
29.0% O [-0.5879983901977539, 0.8774464130401611]
for O [-0.7914589047431946, 0.46670231223106384]
poor O [-0.5920812487602234, 0.5846662521362305]
metabolizers, O [-0.446405827999115, 0.47127625346183777]
and O [-0.8940884470939636, 0.3879624903202057]
all-cause O [-0.7642616629600525, 0.4146685302257538]
mortality O [-0.5982536673545837, 0.40645813941955566]
rates O [-0.6625601053237915, 0.4474159777164459]
were O [-0.7043032646179199, 0.22898688912391663]
16.7%, O [-0.5891948342323303, 0.5917659401893616]
18.0%, O [-0.6042520999908447, 0.5801374316215515]
and O [-0.4688112735748291, 0.035644497722387314]
22.8%, O [-0.378120094537735, 0.4356677532196045]
respectively. O [-0.6314881443977356, 0.0785432830452919]
Compared O [-0.9478983283042908, 0.8747391700744629]
with O [-0.6803229451179504, 0.6366286873817444]
extensive O [-0.6708438396453857, 0.6097705960273743]
metabolizers, O [-0.6070312261581421, 0.5655108094215393]
there O [-0.9416691064834595, 0.873531699180603]
was O [-0.9098814129829407, 0.735187828540802]
a O [-0.9071913361549377, 0.794078528881073]
significantly O [-0.8285099864006042, 0.7324641942977905]
increased O [-0.8675540089607239, 0.7246536612510681]
risk O [-0.856899082660675, 0.7514840364456177]
of O [-0.9970218539237976, 0.8520074486732483]
recurrence O [-0.9160064458847046, 0.8223193287849426]
for O [-0.8929601907730103, 0.6537930369377136]
heterozygous O [-0.7052506804466248, 0.44784095883369446]
extensive/intermediate O [-0.45717495679855347, 0.42802828550338745]
metabolizers O [-0.530029833316803, 0.4487383961677551]
(time O [-0.775860607624054, 0.6442140936851501]
to O [-0.6242871284484863, -0.043205659836530685]
recurrence O [-0.6024492979049683, 0.48487141728401184]
adjusted O [-0.7133788466453552, 0.31911730766296387]
hazard O [-0.5039511322975159, 0.366217702627182]
ratio O [-0.6932511925697327, 0.4351353347301483]
[HR], O [-0.49542632699012756, 0.3672221004962921]
1.40; O [-0.6403059959411621, 0.7839459180831909]
95% O [-0.8473971486091614, 0.7280195355415344]
confidence O [-0.7141483426094055, 0.5239676237106323]
interval O [-0.7292465567588806, 0.46414369344711304]

[CI], O [-0.39943283796310425, -0.09881512075662613]
1.04-1.90) O [-0.28578540682792664, 0.3198647201061249]
and O [-0.4013420045375824, 0.4815099239349365]
for O [-0.3783944547176361, 0.3631375730037689]
poor O [-0.15816271305084229, 0.3333585560321808]
metabolizers O [-0.15948650240898132, 0.1394382268190384]
(time O [-0.22732971608638763, 0.27805694937705994]
to B-LOC [-0.2599680423736572, -0.2603386342525482]
recurrence O [-0.20694303512573242, 0.0621354915201664]
HR, O [-0.3756661117076874, 0.1494728922843933]
1.90; O [-0.1289031207561493, 0.391094446182251]
95% O [-0.3643653690814972, 0.510992705821991]
CI, O [-0.41721248626708984, 0.0635467916727066]
1.10-3.28). O [-0.2780199944972992, 0.3974277973175049]
Compared O [-1.0966103076934814, 1.2132811546325684]
with O [-0.8365144729614258, 0.9717110395431519]
extensive O [-0.8641371726989746, 0.9237861037254333]
metabolizers, O [-0.731039822101593, 0.9527243971824646]
those O [-0.6247026920318604, 0.9960971474647522]
with O [-1.049566388130188, 0.8693931102752686]
decreased O [-0.840002715587616, 0.9871956706047058]
CYP2D6 O [-0.8547515273094177, 0.7371301054954529]
activity O [-0.7813683152198792, 1.0383636951446533]
(heterozygous O [-1.0204310417175293, 1.0649336576461792]
extensive/intermediate O [-0.790285050868988, 0.9395290613174438]
and O [-0.9938737750053406, 0.8855333924293518]
poor O [-0.7477759718894958, 1.0156586170196533]
metabolism) O [-0.7878618836402893, 0.8760574460029602]
had O [-1.0165245532989502, 1.0213545560836792]
worse O [-0.9315999746322632, 1.0369067192077637]
event-free O [-0.9956525564193726, 0.8473026752471924]
survival O [-0.8017891645431519, 1.0550205707550049]
(HR, O [-0.9577983617782593, 0.9622945785522461]
1.33; O [-0.7741392850875854, 1.2088229656219482]
95% O [-1.0641875267028809, 1.2657101154327393]
CI, O [-0.9422346949577332, 0.7333974242210388]
1.06-1.68) O [-0.8114245533943176, 1.13478422164917]
and O [-1.1378865242004395, 1.0589507818222046]
disease-free O [-0.9419100880622864, 0.7978261709213257]
survival O [-0.8206020593643188, 1.0498707294464111]
(HR, O [-0.9410943388938904, 0.8758131861686707]
1.29; O [-0.7545990347862244, 1.041975975036621]
95% O [-0.9699276089668274, 1.0954203605651855]
CI, O [-0.9219267964363098, 0.6357936859130859]

1.03-1.61), O [-0.324137806892395, -0.18197274208068848]
but O [-0.39362138509750366, 0.10515037178993225]
there O [-0.24708306789398193, -0.019089022651314735]
was O [-0.32084840536117554, -0.12627707421779633]
no O [-0.17039580643177032, 0.006083106156438589]
significant O [-0.272197961807251, -0.21055009961128235]
difference O [-0.3002011477947235, -0.26731979846954346]
in O [-0.3971751034259796, -0.25736603140830994]
overall O [-0.30671393871307373, -0.13444101810455322]
survival O [-0.15835845470428467, -0.1274924874305725]
(HR, O [-0.14414456486701965, -0.14079511165618896]
1.15; O [-0.2208898663520813, 0.08030425012111664]
95% O [-0.4118906259536743, 0.11938652396202087]
CI, O [-0.45676103234291077, -0.11667545884847641]
0.88-1.51). B-LOC [-0.08385100215673447, -0.16315168142318726]
CONCLUSION O [-0.9533782601356506, 0.6231521964073181]
Among O [-0.6388347744941711, 0.7986552119255066]
women O [-0.5890539884567261, 0.7166123390197754]
with O [-0.579549252986908, 0.4395280182361603]
breast O [-0.5613819360733032, 0.717147946357727]
cancer O [-0.4759807288646698, 0.6303483843803406]
treated O [-0.5024238228797913, 0.6321067214012146]
with O [-0.4558696746826172, 0.48130616545677185]
tamoxifen, O [-0.21541066467761993, 0.45414045453071594]
there O [-0.6755079627037048, 0.627497673034668]
was O [-0.7869047522544861, 0.5525258183479309]
an O [-0.6123095750808716, 0.46933749318122864]
association O [-0.6824237704277039, 0.6106892824172974]
between O [-0.7220897078514099, 0.36426714062690735]
CYP2D6 O [-0.764829695224762, 0.7072303891181946]
variation O [-0.4508739709854126, 0.5082618594169617]
and O [-0.4558030068874359, 0.22787028551101685]
clinical O [-0.588266909122467, 0.647878885269165]
outcomes, O [-0.6200597882270813, 0.7040720582008362]
such O [-0.837593138217926, 0.6684392690658569]
that O [-0.9077833890914917, 0.7423638701438904]
the O [-0.7936457991600037, 0.8276790976524353]
presence O [-0.6831700801849365, 0.8561099767684937]
of O [-0.6382065415382385, 0.7711116671562195]
2 O [-0.5662118792533875, 0.8582152724266052]
functional O [-0.5772281289100647, 0.7706636190414429]
CYP2D6 O [-0.813808262348175, 0.7891989946365356]
alleles O [-0.7340970635414124, 0.7376082539558411]
was O [-0.7778591513633728, 0.7599384188652039]
associated O [-0.8700219988822937, 1.0271251201629639]
with O [-0.8806372284889221, 0.8626248240470886]
better O [-0.780853807926178, 0.9752969741821289]
clinical O [-0.7918218970298767, 0.9313390851020813]
outcomes O [-0.776032030582428, 1.0722782611846924]
and O [-0.6709425449371338, 0.7397688031196594]
the O [-0.7176477313041687, 0.8514959216117859]
presence O [-0.6913184523582458, 0.9139453172683716]
of O [-0.7899060249328613, 0.8071865439414978]
nonfunctional O [-0.6696516275405884, 0.8990532755851746]
or O [-0.5696588754653931, 0.5262354612350464]
reduced-function O [-0.6317625641822815, 0.8292444348335266]
alleles O [-0.6835697293281555, 0.7607693076133728]
with O [-0.7498945593833923, 0.8422900438308716]
worse O [-0.6754992604255676, 0.9246622920036316]
outcomes. O [-0.7880931496620178, 0.9573268294334412]

Nucleosomes B-LOC [1.4665180444717407, -2.2522456645965576]
containing B-LOC [2.166447877883911, -2.416666030883789]
the B-LOC [1.9733459949493408, -2.1240806579589844]
histone B-LOC [2.0303454399108887, -2.556591510772705]
variant B-LOC [1.7904632091522217, -2.103686571121216]
H3.3 B-LOC [1.5606000423431396, -2.3224406242370605]
tend B-LOC [2.1780898571014404, -2.4101343154907227]
to B-LOC [2.3785459995269775, -2.5688745975494385]
be B-LOC [2.092576026916504, -2.6530258655548096]
clustered B-LOC [2.2859086990356445, -2.7183644771575928]
in B-LOC [1.9351708889007568, -2.419113874435425]
vivo B-LOC [1.7168781757354736, -2.4086802005767822]
in B-LOC [2.0499327182769775, -2.6167593002319336]
the B-LOC [2.0263116359710693, -2.6650216579437256]
neighborhood B-LOC [2.094665765762329, -2.474738836288452]
of B-LOC [1.9411379098892212, -2.7891108989715576]
transcriptionally B-LOC [1.9781453609466553, -2.825448513031006]
active B-LOC [1.8636088371276855, -2.6179826259613037]
genes B-LOC [2.060680627822876, -2.649519681930542]
and B-LOC [2.1184494495391846, -2.574038505554199]
over B-LOC [2.156953811645508, -2.8571720123291016]
regulatory B-LOC [2.644404172897339, -3.2569901943206787]
elements. B-LOC [2.568049669265747, -3.221630334854126]
It B-LOC [2.992596387863159, -3.178501844406128]
has B-LOC [3.0984156131744385, -3.276491403579712]
not B-LOC [3.1888458728790283, -3.098400354385376]
been B-LOC [2.8989522457122803, -3.345717668533325]
clear, B-LOC [2.956627368927002, -3.129875659942627]
however, B-LOC [2.916229486465454, -3.071787118911743]
whether B-LOC [2.8558764457702637, -3.390599012374878]
H3.3-containing B-LOC [2.4933412075042725, -3.26747727394104]
nucleosomes B-LOC [2.617149591445923, -3.088740348815918]
possess B-LOC [3.0358293056488037, -3.265343189239502]
unique B-LOC [2.9997141361236572, -3.4209368228912354]
properties B-LOC [2.8605005741119385, -3.28558611869812]
that B-LOC [3.0253217220306396, -3.3644535541534424]
would B-LOC [2.9398114681243896, -3.283399820327759]
affect B-LOC [2.811037302017212, -3.271550178527832]
transcription. B-LOC [2.667715311050415, -3.4148457050323486]
We B-LOC [0.513782799243927, -0.5258625149726868]
report B-LOC [0.7003668546676636, -0.6756274104118347]
here B-LOC [0.4480968117713928, -0.4239465296268463]
that B-LOC [0.9580654501914978, -1.0256342887878418]
H3.3 B-LOC [0.9883533120155334, -1.401892900466919]
nucleosomes B-LOC [1.2704031467437744, -1.2702980041503906]
isolated B-LOC [1.467960238456726, -1.5216023921966553]
from B-LOC [1.509070873260498, -1.2312053442001343]
vertebrates, B-LOC [1.0553913116455078, -1.4471091032028198]
regardless B-LOC [1.6900006532669067, -1.511080026626587]
of B-LOC [1.5650346279144287, -1.492584466934204]
whether B-LOC [1.817926287651062, -1.7200466394424438]
they B-LOC [1.3143861293792725, -1.4637761116027832]
are B-LOC [1.5306156873703003, -1.4322185516357422]
partnered B-LOC [1.3485386371612549, -1.4042046070098877]
with B-LOC [1.2798902988433838, -1.5157766342163086]
H2A B-LOC [1.2231950759887695, -1.5513038635253906]
or B-LOC [1.7796707153320312, -2.119067430496216]
H2A.Z, B-LOC [1.1847976446151733, -1.5995062589645386]
are B-LOC [1.3031021356582642, -1.1976919174194336]
unusually B-LOC [0.9472158551216125, -1.016338586807251]
sensitive B-LOC [1.020249843597412, -1.0801008939743042]
to B-LOC [0.6571587324142456, -0.7562499642372131]
salt-dependent B-LOC [0.9550731778144836, -1.0353965759277344]
disruption, B-LOC [0.8760363459587097, -1.0050996541976929]
losing B-LOC [0.7502540946006775, -1.0687251091003418]
H2A/H2B B-LOC [0.689876139163971, -1.0380580425262451]
or B-LOC [0.8824271559715271, -1.1954303979873657]
H2A.Z/H2B B-LOC [0.660240113735199, -1.0641262531280518]

dimers. B-LOC [0.4670756459236145, -0.7742609977722168]
Immunoprecipitation B-LOC [0.611163318157196, -0.6419637799263]
studies B-LOC [0.3566865921020508, -0.19488851726055145]
of B-LOC [0.7037872672080994, -0.5001174211502075]
nucleosome B-LOC [0.6588755249977112, -0.5640326738357544]
core B-LOC [0.8066465258598328, -0.6439199447631836]
particles B-LOC [0.6837529540061951, -0.5632069706916809]
(NCPs) B-LOC [0.7619121670722961, -0.6319019198417664]
show B-LOC [0.2449990212917328, -0.07361124455928802]
that B-LOC [0.09713546931743622, -0.1670072376728058]
NCPs B-LOC [0.508624255657196, -0.31379663944244385]
that B-LOC [0.2994054853916168, -0.2466190755367279]
contain B-LOC [0.37690919637680054, -0.1318885236978531]
both O [0.08858080208301544, 0.09214870631694794]
H3.3 B-LOC [0.09210789948701859, -0.22434422373771667]
and B-LOC [0.04342782124876976, -0.026564614847302437]
H2A.Z B-LOC [0.04484788700938225, -0.20842407643795013]
are B-LOC [0.3602692782878876, -0.030866572633385658]
even B-LOC [0.3281494677066803, 0.06730325520038605]
less B-LOC [0.36237215995788574, 0.2047901600599289]
stable B-LOC [0.38283464312553406, -0.015581810846924782]
than B-LOC [0.04988524690270424, 0.030093370005488396]
NCPs B-LOC [0.15750622749328613, -0.19388476014137268]
containing B-LOC [0.11924801766872406, -0.18556061387062073]
H3.3 B-LOC [-0.09536164999008179, -0.10100097209215164]
and O [-0.05592111498117447, -0.003058346454054117]
H2A. B-LOC [-0.05707777664065361, -0.1874278038740158]
Intriguingly, B-LOC [0.7216524481773376, -0.4219925105571747]
NCPs B-LOC [0.5650544166564941, -0.6249503493309021]
containing B-LOC [0.6700791120529175, -0.4207656681537628]
H3 B-LOC [0.42358341813087463, -0.48008593916893005]
and B-LOC [0.6010490655899048, -0.7029775381088257]
H2A.Z B-LOC [0.4739002585411072, -0.6280107498168945]
are B-LOC [0.8358080983161926, -0.7185320258140564]
at B-LOC [1.270847201347351, -0.93486487865448]
least B-LOC [1.1767874956130981, -1.0521020889282227]
as B-LOC [1.109902262687683, -0.8999868035316467]
stable B-LOC [1.1259427070617676, -0.8126438856124878]
as B-LOC [1.1335054636001587, -1.1358354091644287]
H3/H2A B-LOC [0.86068195104599, -1.1715149879455566]
NCPs. B-LOC [0.6033214330673218, -0.8601633906364441]
These B-LOC [1.2107430696487427, -1.4237492084503174]
results B-LOC [1.4753518104553223, -1.36713445186615]
establish B-LOC [1.6448777914047241, -1.421694040298462]
an B-LOC [1.616398572921753, -1.742208480834961]
hierarchy B-LOC [1.706085443496704, -1.8415447473526]
of B-LOC [1.7646565437316895, -2.0781173706054688]
stabilities B-LOC [1.8284940719604492, -1.830573558807373]
for B-LOC [1.6841237545013428, -1.747596025466919]
native B-LOC [1.570213794708252, -1.7751166820526123]
nucleosomes B-LOC [1.622231125831604, -1.6409391164779663]
carrying B-LOC [1.7772648334503174, -1.9561707973480225]
different B-LOC [1.680793285369873, -2.1894521713256836]
complements B-LOC [1.8382281064987183, -1.7042464017868042]
of B-LOC [1.8156707286834717, -2.013678789138794]
variants, B-LOC [1.9433863162994385, -1.7978286743164062]
and B-LOC [1.0587208271026611, -1.1894557476043701]
suggest B-LOC [1.4751619100570679, -1.430068016052246]
how B-LOC [1.4844801425933838, -1.7708311080932617]
H2A.Z B-LOC [1.3956327438354492, -1.7210326194763184]
could B-LOC [1.1694128513336182, -1.6414953470230103]
play B-LOC [1.3118343353271484, -1.8420528173446655]
different B-LOC [1.3708062171936035, -2.1128358840942383]
roles B-LOC [1.3568931818008423, -1.6060740947723389]
depending B-LOC [1.4302685260772705, -2.054619073867798]
on B-LOC [1.6421598196029663, -1.9337745904922485]
its B-LOC [1.336940050125122, -1.6038851737976074]
partners B-LOC [1.7004163265228271, -1.6745476722717285]
within B-LOC [1.1126384735107422, -1.450348138809204]

the B-LOC [0.35684385895729065, -0.6397460103034973]
NCP. B-LOC [0.5002158284187317, -0.9737948179244995]
They B-LOC [0.6655154824256897, -0.7690067291259766]
also B-LOC [0.6787046790122986, -0.5168949365615845]
are B-LOC [0.8121032118797302, -0.6582757234573364]
consistent B-LOC [0.7743244767189026, -0.6818347573280334]
with B-LOC [0.8888224363327026, -0.8267237544059753]
the B-LOC [0.7819309830665588, -0.789779543876648]
idea B-LOC [0.7174621820449829, -0.7542387843132019]
that B-LOC [0.4485771059989929, -0.6838688850402832]
H3.3 B-LOC [0.43760785460472107, -0.7670132517814636]
plays B-LOC [0.6462215781211853, -0.5468104481697083]
an B-LOC [0.6191213726997375, -0.574898362159729]
active B-LOC [0.4706803858280182, -0.496800035238266]
role B-LOC [0.334169864654541, -0.6786556839942932]
in B-LOC [0.3366108238697052, -0.5489853620529175]
maintaining B-LOC [0.6082391142845154, -0.6468489170074463]
accessible B-LOC [0.5528143644332886, -0.8880574107170105]
chromatin B-LOC [0.49232789874076843, -0.8160053491592407]
structures B-LOC [0.5771877765655518, -0.6867767572402954]
in B-LOC [0.44159770011901855, -0.8611276745796204]
enhancer B-LOC [0.7049084901809692, -0.772270917892456]
regions B-LOC [0.5133123397827148, -0.721676766872406]
and B-LOC [0.702639639377594, -0.8453176021575928]
transcribed B-LOC [0.6183068156242371, -0.8706676959991455]
regions. B-LOC [0.5141491293907166, -0.8213353753089905]
Consistent B-LOC [0.6501539945602417, -0.4959840476512909]
with B-LOC [0.5620042085647583, -0.7751920819282532]
this B-LOC [0.6543818116188049, -0.6772539615631104]
idea, B-LOC [0.6536315083503723, -0.865105152130127]
promoters B-LOC [0.29200002551078796, -0.5315552949905396]
and B-LOC [0.20213675498962402, -0.459434449672699]
enhancers B-LOC [0.2403292953968048, -0.3949476182460785]
at B-LOC [0.39749881625175476, -0.45124173164367676]
transcriptionally B-LOC [0.32988378405570984, -0.4253735840320587]
active B-LOC [0.16533401608467102, -0.49909499287605286]
genes B-LOC [0.22006374597549438, -0.4921171963214874]
and B-LOC [0.36732932925224304, -0.43742549419403076]
coding B-LOC [0.4432806968688965, -0.6500965356826782]
regions B-LOC [0.3329654335975647, -0.5186770558357239]
at B-LOC [0.34551575779914856, -0.48602569103240967]
highly B-LOC [0.4253602921962738, -0.6920217871665955]
expressed B-LOC [0.4310726821422577, -0.6430248618125916]
genes B-LOC [0.27116623520851135, -0.5703607201576233]
have B-LOC [0.46800604462623596, -0.38581278920173645]
nucleosomes B-LOC [0.5730921626091003, -0.4275757968425751]
that B-LOC [0.4108503460884094, -0.5545634627342224]
simultaneously B-LOC [0.41898849606513977, -0.4666272699832916]
carry B-LOC [0.3447650372982025, -0.544754147529602]
both B-LOC [0.33265820145606995, -0.39961355924606323]
H3.3 B-LOC [0.30782079696655273, -0.70252925157547]
and B-LOC [0.2706497013568878, -0.46974632143974304]
H2A.Z, B-LOC [0.21792301535606384, -0.7323479056358337]
and B-LOC [0.3323433995246887, -0.4757104218006134]
should B-LOC [0.7999224066734314, -0.849439799785614]
therefore B-LOC [0.6784119009971619, -0.4757092297077179]
be B-LOC [0.6641228795051575, -0.8684157729148865]
extremely B-LOC [0.6409578919410706, -0.8386195302009583]
sensitive B-LOC [0.8119902014732361, -0.8050593137741089]
to B-LOC [0.6162570714950562, -0.6541734337806702]
disruption. B-LOC [0.4767058193683624, -0.6998265385627747]

With B-LOC [1.2583848237991333, -1.95208740234375]
respect B-LOC [2.1470694541931152, -2.001067638397217]
to B-LOC [1.9435443878173828, -2.4488871097564697]
cervical B-LOC [1.5015664100646973, -2.333566427230835]
cancer B-LOC [1.729172706604004, -2.480337619781494]
management, B-LOC [1.9408917427062988, -2.2877750396728516]
Finland B-LOC [1.7277297973632812, -2.4072234630584717]
and B-LOC [1.7730625867843628, -2.3488755226135254]
the B-LOC [2.3125133514404297, -2.3706424236297607]
Netherlands B-LOC [1.8801944255828857, -2.2111480236053467]
are B-LOC [2.058361053466797, -2.5453574657440186]
comparable B-LOC [1.9556599855422974, -2.709723711013794]
in B-LOC [1.0680980682373047, -2.0818934440612793]
relevant B-LOC [1.7620879411697388, -2.499976396560669]
characteristics, B-LOC [1.8897173404693604, -2.5879435539245605]
e.g., B-LOC [1.6304495334625244, -2.083282709121704]
fertility B-LOC [1.4847649335861206, -1.875732421875]
rate, B-LOC [1.6470401287078857, -2.3099677562713623]
age-of-mother B-LOC [2.0905182361602783, -2.388566255569458]
at B-LOC [1.4727752208709717, -2.0582082271575928]
first B-LOC [1.2427805662155151, -1.8261606693267822]
birth B-LOC [1.6745288372039795, -1.7548747062683105]
and B-LOC [1.509285807609558, -1.929044246673584]
a B-LOC [1.6450779438018799, -2.3064563274383545]
national B-LOC [1.6361055374145508, -2.2941486835479736]
screening B-LOC [1.5982565879821777, -2.3348469734191895]
programme B-LOC [1.639694094657898, -2.2859365940093994]
for B-LOC [1.5680906772613525, -2.2781741619110107]
several B-LOC [1.7114814519882202, -2.4234421253204346]
years. B-LOC [2.1840548515319824, -2.6072402000427246]
The B-LOC [3.0437774658203125, -3.493424654006958]
aim B-LOC [2.9903652667999268, -3.487363815307617]
of B-LOC [2.8905465602874756, -3.097520112991333]
this B-LOC [2.810645341873169, -3.3285696506500244]
study B-LOC [2.8874166011810303, -3.485764503479004]
is B-LOC [3.1302638053894043, -3.073944568634033]
to B-LOC [3.161878824234009, -3.493253469467163]
compare B-LOC [3.218747854232788, -3.6284570693969727]
trends B-LOC [3.206634759902954, -3.622333288192749]
in B-LOC [3.018033742904663, -3.6600005626678467]
incidence B-LOC [3.219221591949463, -3.51423978805542]
of B-LOC [3.089470148086548, -3.5313260555267334]
and B-LOC [2.9710280895233154, -3.367410182952881]
mortality B-LOC [3.050311803817749, -3.4446403980255127]
from B-LOC [2.7132608890533447, -3.2692031860351562]
cervical B-LOC [2.55171275138855, -3.123861074447632]
cancer B-LOC [2.7438876628875732, -3.1254708766937256]
in B-LOC [3.0361599922180176, -3.319706678390503]
Finland B-LOC [2.8231375217437744, -3.4046010971069336]
and B-LOC [3.0630264282226562, -3.2842729091644287]
the B-LOC [3.499690294265747, -3.395456075668335]
Netherlands B-LOC [3.098789691925049, -3.32022762298584]
in B-LOC [3.198845148086548, -3.321568727493286]
relation B-LOC [3.2837183475494385, -3.511146306991577]
to B-LOC [3.1973350048065186, -3.583372116088867]
the B-LOC [3.307215452194214, -3.5647528171539307]
introduction B-LOC [3.2648093700408936, -4.031224727630615]
and B-LOC [3.1275904178619385, -3.370180368423462]
intensity B-LOC [3.19270396232605, -3.9402596950531006]
of B-LOC [3.088421583175659, -3.605015516281128]
the B-LOC [3.057053327560425, -3.527940034866333]
screening B-LOC [3.0099549293518066, -3.749814748764038]
programmes. B-LOC [3.3463034629821777, -3.641432285308838]
Therefore, B-LOC [3.1843178272247314, -3.4300155639648438]
incidence B-LOC [3.212592840194702, -3.5976126194000244]
and B-LOC [2.7294602394104004, -3.319711446762085]
mortality B-LOC [3.2065155506134033, -3.41998291015625]
rates B-LOC [3.149207830429077, -3.6542904376983643]
were B-LOC [2.953352689743042, -3.129072427749634]
calculated B-LOC [3.2917869091033936, -3.562957525253296]
using B-LOC [3.060899019241333, -3.434553384780884]
the B-LOC [3.2186286449432373, -3.280269145965576]
Cancer B-LOC [2.6751351356506348, -3.4188649654388428]
Registries B-LOC [3.3121025562286377, -3.5093822479248047]
of B-LOC [3.220791816711426, -3.136431932449341]
Finland B-LOC [2.8237075805664062, -3.425299644470215]
and B-LOC [2.93910551071167, -3.1637184619903564]
the B-LOC [3.3632118701934814, -3.1742184162139893]
Netherlands. B-LOC [3.2186152935028076, -3.4609553813934326]
Data B-LOC [2.4496967792510986, -2.832266092300415]
on B-LOC [2.6161272525787354, -3.0766589641571045]
screening B-LOC [2.6556992530822754, -2.9676625728607178]
intensity B-LOC [2.645690679550171, -3.175633430480957]
were B-LOC [2.573094606399536, -2.4503417015075684]
obtained B-LOC [3.0351874828338623, -2.922612190246582]
from B-LOC [2.5886166095733643, -2.677372694015503]
the B-LOC [2.6592633724212646, -2.640824794769287]
Finnish B-LOC [2.1031813621520996, -2.906290292739868]
Cancer B-LOC [2.3399226665496826, -2.8801400661468506]
Registry B-LOC [2.876882553100586, -2.900491952896118]
and B-LOC [2.4489905834198, -2.714711904525757]
the B-LOC [2.8433408737182617, -2.7148666381835938]
Dutch B-LOC [2.4438841342926025, -2.938941478729248]
evaluation B-LOC [2.627342939376831, -3.1969399452209473]
centre B-LOC [2.6905782222747803, -2.9560537338256836]
at B-LOC [2.4112088680267334, -2.5802955627441406]

ErasmusMC-Rotterdam. B-LOC [2.8860912322998047, -3.499129295349121]
Women B-LOC [3.0687601566314697, -3.515709400177002]
aged B-LOC [3.6804511547088623, -3.537767171859741]
30-60 B-LOC [3.6554925441741943, -3.4102771282196045]
have B-LOC [3.330094575881958, -3.380520820617676]
been B-LOC [3.2609496116638184, -3.509308338165283]
screened B-LOC [3.2854163646698, -3.5948994159698486]
every B-LOC [3.206749200820923, -3.7104740142822266]
5 B-LOC [3.291339159011841, -3.550790548324585]
years, B-LOC [3.5389134883880615, -3.5068519115448]
in B-LOC [3.4637696743011475, -3.5034873485565186]
Finland B-LOC [2.8216443061828613, -3.559870481491089]
since B-LOC [3.5401077270507812, -3.662025213241577]
1992 B-LOC [3.332855463027954, -3.454826831817627]
and B-LOC [3.353243589401245, -3.486562967300415]
in B-LOC [3.6202657222747803, -3.544226884841919]
the B-LOC [3.594604015350342, -3.2900023460388184]
Netherlands B-LOC [3.3552043437957764, -3.616495370864868]
since B-LOC [3.703763961791992, -3.7111356258392334]
1996. B-LOC [3.497753620147705, -3.65061616897583]
Screening B-LOC [3.322726011276245, -3.8567662239074707]
protocols B-LOC [3.3245694637298584, -3.76641583442688]
for B-LOC [3.325378894805908, -3.927964925765991]
smear B-LOC [3.5112290382385254, -3.9464128017425537]
taking B-LOC [3.411529302597046, -3.9143452644348145]
and B-LOC [3.2098660469055176, -3.8330013751983643]
referral B-LOC [3.483259677886963, -3.7788960933685303]
to B-LOC [3.368422269821167, -3.901545524597168]
the B-LOC [3.454116106033325, -3.8271172046661377]
gynaecologist B-LOC [3.4861674308776855, -3.9440698623657227]
are B-LOC [3.4764561653137207, -3.660515308380127]
comparable. B-LOC [3.3317339420318604, -4.020244121551514]
Incidence B-LOC [2.5514283180236816, -2.949373245239258]
and B-LOC [2.402583599090576, -2.997095823287964]
mortality B-LOC [2.8024744987487793, -3.1032848358154297]
rates B-LOC [2.7446935176849365, -3.1541426181793213]
have B-LOC [2.91697096824646, -2.928356885910034]
declined B-LOC [2.8772735595703125, -3.185839891433716]
more B-LOC [2.71805739402771, -3.0253355503082275]
in B-LOC [2.6909611225128174, -2.643961191177368]
Finland. B-LOC [2.527514696121216, -3.1335294246673584]
In B-LOC [2.1917946338653564, -2.3040683269500732]
2003, B-LOC [2.6692419052124023, -2.5548553466796875]
age-adjusted B-LOC [2.6984755992889404, -2.762451648712158]
incidence B-LOC [1.9731626510620117, -2.593506097793579]
and B-LOC [1.9713366031646729, -2.4284753799438477]
mortality B-LOC [2.453246593475342, -2.6625919342041016]
in B-LOC [2.3764889240264893, -2.2956511974334717]
Finland B-LOC [1.8368206024169922, -2.6016757488250732]
were B-LOC [1.9065191745758057, -2.2110536098480225]
4.0 B-LOC [2.0424835681915283, -2.074854850769043]
and B-LOC [1.6792476177215576, -2.342435359954834]
0.9 B-LOC [2.1298649311065674, -2.3248419761657715]
and B-LOC [1.813539743423462, -2.3453500270843506]
in B-LOC [2.1789095401763916, -2.269998788833618]
the B-LOC [2.5145156383514404, -2.454395294189453]
Netherlands B-LOC [2.0725314617156982, -2.5408003330230713]
4.9 B-LOC [2.0278971195220947, -2.0885281562805176]
and B-LOC [1.7863754034042358, -2.3198533058166504]
1.4 B-LOC [1.781714677810669, -2.073986053466797]
per B-LOC [1.4742510318756104, -2.151136636734009]
100,000 B-LOC [2.190812349319458, -2.4250576496124268]
woman-years, B-LOC [2.116579294204712, -2.647066831588745]
respectively. B-LOC [2.170759439468384, -2.6351916790008545]
Excess B-LOC [0.693295419216156, -1.0795303583145142]
smear B-LOC [0.8481412529945374, -1.0397367477416992]
use B-LOC [0.6971319317817688, -0.9160996079444885]
in B-LOC [0.9011749625205994, -0.9367076754570007]
the B-LOC [1.0195603370666504, -0.846462070941925]
Netherlands B-LOC [0.867297887802124, -0.8976297378540039]
was B-LOC [0.5484395623207092, -0.9853052496910095]
estimated B-LOC [0.7534207105636597, -0.9442738890647888]
to B-LOC [0.6448778510093689, -0.8227159380912781]
be B-LOC [0.5627502799034119, -0.9203332662582397]
24 B-LOC [0.6946848034858704, -0.7787582278251648]
per B-LOC [0.7060455083847046, -0.7684759497642517]
1,000 B-LOC [1.1841027736663818, -0.8050028681755066]
women B-LOC [0.6770607233047485, -0.852499783039093]
during B-LOC [0.4508269727230072, -0.9298719763755798]

a B-LOC [0.25884079933166504, -0.6750643849372864]
5-year B-LOC [0.4320776164531708, -0.5912253260612488]
interval B-LOC [0.428637832403183, -0.9418869614601135]
compared B-LOC [0.4021572470664978, -0.6567715406417847]
to B-LOC [0.5363594889640808, -0.7643524408340454]
121 B-LOC [0.7619533538818359, -0.7974855899810791]
in B-LOC [0.6022845506668091, -0.829730749130249]
Finland. B-LOC [0.6090346574783325, -0.8914899230003357]
The B-LOC [1.4021073579788208, -1.4918842315673828]
decline B-LOC [1.4008777141571045, -1.5752209424972534]
in B-LOC [1.372293472290039, -1.7644118070602417]
mortality B-LOC [1.237696886062622, -1.4365229606628418]
in B-LOC [1.4733394384384155, -1.3590049743652344]
Finland B-LOC [1.0324089527130127, -1.4324750900268555]
seems B-LOC [1.5832161903381348, -1.2382619380950928]
to B-LOC [1.7050220966339111, -1.3644808530807495]
be B-LOC [1.6631609201431274, -1.3867676258087158]
almost B-LOC [1.5384031534194946, -1.1236846446990967]
completely B-LOC [1.4741237163543701, -1.1863203048706055]
related B-LOC [1.4958394765853882, -1.23318612575531]
to B-LOC [1.3407690525054932, -1.251490592956543]
the B-LOC [1.303113579750061, -1.4800257682800293]
screening B-LOC [0.9915493130683899, -1.2982938289642334]
programme B-LOC [1.2620224952697754, -1.4361464977264404]
whereas B-LOC [0.9919183850288391, -0.9759693741798401]
in B-LOC [0.9055284261703491, -1.1189836263656616]
the B-LOC [1.226255178451538, -1.2627900838851929]
Netherlands B-LOC [1.1630829572677612, -1.1494871377944946]
it B-LOC [0.8460190892219543, -1.3877007961273193]
was B-LOC [1.0768274068832397, -1.2383817434310913]
initially B-LOC [0.9488995671272278, -1.1737197637557983]
considered B-LOC [1.4010534286499023, -1.2024238109588623]
to B-LOC [1.7212302684783936, -1.3490134477615356]
be B-LOC [1.335141658782959, -1.3963600397109985]
a B-LOC [1.1339857578277588, -1.3412995338439941]
natural B-LOC [1.2694761753082275, -1.4621399641036987]
decline. B-LOC [1.3305433988571167, -1.4512691497802734]
Differences B-LOC [0.8002910017967224, -1.0644980669021606]
in B-LOC [0.8397302031517029, -1.4838329553604126]
risk B-LOC [1.0166149139404297, -1.2782037258148193]
factors B-LOC [1.0297515392303467, -1.337612509727478]
might B-LOC [0.7895089387893677, -1.1964012384414673]
also B-LOC [0.778710126876831, -1.0531662702560425]
play B-LOC [0.9345186948776245, -1.2637516260147095]
a B-LOC [0.9324384331703186, -1.245737910270691]
role: B-LOC [0.7352396845817566, -1.3362679481506348]
the B-LOC [0.36398157477378845, -0.45742806792259216]
Netherlands B-LOC [0.41387322545051575, -0.5170864462852478]
has B-LOC [0.40275490283966064, -0.5197300314903259]
higher B-LOC [0.2220362275838852, -0.2130517065525055]
population B-LOC [0.6396309733390808, -0.6846889853477478]
density B-LOC [0.6135637760162354, -0.49611619114875793]
and B-LOC [0.31048041582107544, -0.36765843629837036]
higher B-LOC [0.21537861227989197, -0.19670894742012024]
percentages B-LOC [0.6246365904808044, -0.636175811290741]
of B-LOC [0.43006399273872375, -0.6925871968269348]
immigrants B-LOC [0.47903960943222046, -0.5371593832969666]
and B-LOC [0.48546162247657776, -0.5858291983604431]
(female) B-LOC [0.5083265900611877, -0.48516106605529785]
smokers. B-LOC [0.7052342295646667, -0.701885998249054]
The B-LOC [0.47111067175865173, -0.7398178577423096]
greater B-LOC [0.12553483247756958, -0.45103898644447327]
excess B-LOC [0.24113184213638306, -0.6262224912643433]
smear B-LOC [0.43202656507492065, -0.5700027346611023]
use B-LOC [0.35291311144828796, -0.5799480080604553]
in B-LOC [0.40659329295158386, -0.5848313570022583]
Finland B-LOC [0.31789878010749817, -0.8396331667900085]
might B-LOC [0.6375405192375183, -1.003053903579712]
also B-LOC [0.6793564558029175, -0.8793428540229797]
have B-LOC [0.3867490887641907, -0.8769584894180298]
affected B-LOC [0.5048447847366333, -1.1679861545562744]
incidence. B-LOC [0.4538659155368805, -1.0218803882598877]

OBJECTIVE B-LOC [3.1579856872558594, -3.483383893966675]
To B-LOC [3.434098720550537, -3.559218645095825]
assess B-LOC [3.5779852867126465, -3.3179972171783447]
whether B-LOC [3.4666035175323486, -3.376629590988159]
population B-LOC [3.6289937496185303, -3.3883514404296875]
screening B-LOC [3.566729784011841, -3.471742868423462]
for B-LOC [3.6199288368225098, -3.3983829021453857]
impaired B-LOC [3.7149112224578857, -3.215522527694702]
vision B-LOC [3.719296932220459, -3.205493211746216]
among B-LOC [3.4735910892486572, -3.295548677444458]
older B-LOC [3.62762713432312, -3.3425540924072266]
people B-LOC [3.6319284439086914, -3.323652505874634]
in B-LOC [3.6802637577056885, -3.308946132659912]
the B-LOC [3.679938793182373, -3.2228097915649414]
community B-LOC [3.537942886352539, -3.4333791732788086]
leads B-LOC [3.456737518310547, -3.570436954498291]
to B-LOC [3.390958547592163, -3.5199239253997803]
improvements B-LOC [3.500746011734009, -3.625805139541626]
in B-LOC [3.319234848022461, -3.6286404132843018]
vision. B-LOC [3.7351906299591064, -3.3904082775115967]
DESIGN B-LOC [3.535918712615967, -3.3074638843536377]
Systematic B-LOC [3.3526265621185303, -3.009678602218628]
review B-LOC [3.550762414932251, -3.079782247543335]
of B-LOC [3.4535717964172363, -3.0889267921447754]
randomised B-LOC [3.5276787281036377, -3.0002145767211914]
controlled B-LOC [3.5946366786956787, -3.349003314971924]
trials B-LOC [3.592799186706543, -3.206334352493286]
of B-LOC [3.5025084018707275, -3.0212271213531494]
population B-LOC [3.6536285877227783, -3.2454349994659424]
screening B-LOC [3.5681748390197754, -3.153414487838745]
in B-LOC [3.777621030807495, -2.8756282329559326]
the B-LOC [3.7039692401885986, -2.751821756362915]
community B-LOC [3.5743095874786377, -3.244250535964966]
that B-LOC [3.514112710952759, -2.9185709953308105]
included B-LOC [3.527919054031372, -3.1016228199005127]
any B-LOC [3.433807849884033, -3.1355550289154053]
assessment B-LOC [3.5124266147613525, -3.1765499114990234]
of B-LOC [3.3686466217041016, -3.019197702407837]
vision B-LOC [3.5769617557525635, -3.217463493347168]
or B-LOC [3.219168186187744, -3.2520618438720703]
visual B-LOC [3.4248673915863037, -3.3017771244049072]
function B-LOC [3.4014241695404053, -3.303046941757202]
with B-LOC [3.494248390197754, -2.896651268005371]
at B-LOC [3.204925775527954, -2.800727605819702]
least B-LOC [3.2648677825927734, -2.83744740486145]
6 B-LOC [3.3577520847320557, -2.795057773590088]
months' B-LOC [3.5381579399108887, -2.9407174587249756]
follow B-LOC [3.3421618938446045, -3.1619904041290283]
up. B-LOC [3.337005376815796, -3.006878614425659]
SUBJECTS B-LOC [3.247781276702881, -3.2255990505218506]
Adults B-LOC [3.410780429840088, -3.0089330673217773]
aged B-LOC [3.388848066329956, -3.0359246730804443]
65 B-LOC [3.3865673542022705, -2.7447240352630615]
or B-LOC [3.0720577239990234, -2.925750970840454]
over. B-LOC [3.1695468425750732, -2.7981700897216797]
MAIN B-LOC [3.1973836421966553, -2.9787323474884033]
OUTCOME B-LOC [3.131653308868408, -2.7749342918395996]
MEASURE B-LOC [3.153071880340576, -2.9393551349639893]
Proportions B-LOC [3.126146078109741, -2.665534019470215]
with B-LOC [3.289680242538452, -2.882793664932251]
visual B-LOC [3.3981316089630127, -2.9224016666412354]
impairment B-LOC [3.2402570247650146, -2.9396607875823975]
in B-LOC [3.184586763381958, -2.5455901622772217]
intervention B-LOC [3.228296995162964, -3.033294916152954]
and B-LOC [3.360011577606201, -2.656062364578247]
control B-LOC [3.393334150314331, -2.9216878414154053]
groups B-LOC [3.4325780868530273, -2.7864134311676025]
with B-LOC [3.475259304046631, -2.825608491897583]
any B-LOC [3.3750154972076416, -2.888331651687622]
method B-LOC [3.369018793106079, -2.862661600112915]
of B-LOC [3.0978000164031982, -2.3131158351898193]
assessing B-LOC [3.380796194076538, -2.914400577545166]
visual B-LOC [3.501603603363037, -2.948321580886841]
impairment. B-LOC [3.254488468170166, -2.9287145137786865]
RESULTS B-LOC [1.6061875820159912, -2.3116519451141357]
There B-LOC [1.9710625410079956, -2.131129503250122]
were B-LOC [2.1221745014190674, -2.2107441425323486]
no B-LOC [2.193793535232544, -2.1647980213165283]
trials B-LOC [2.8227503299713135, -2.8521358966827393]
that B-LOC [1.9889600276947021, -2.369927167892456]
primarily B-LOC [2.3651986122131348, -2.4390861988067627]
assessed B-LOC [2.469184637069702, -2.6878716945648193]
visual B-LOC [2.2236859798431396, -2.0086123943328857]

screening. B-LOC [2.282205820083618, -2.989227294921875]
Outcome B-LOC [3.339938163757324, -3.666520595550537]
data B-LOC [3.1799445152282715, -3.449357748031616]
on B-LOC [3.1541430950164795, -3.6219351291656494]
vision B-LOC [2.8504626750946045, -3.368622303009033]
were B-LOC [3.1593663692474365, -3.3492276668548584]
available B-LOC [3.5363821983337402, -3.4558608531951904]
for B-LOC [3.2073071002960205, -3.356044054031372]
3494 B-LOC [3.532747983932495, -3.3713512420654297]
people B-LOC [3.2118537425994873, -3.670252799987793]
in B-LOC [3.2992260456085205, -3.4070916175842285]
five B-LOC [3.5923168659210205, -3.4667136669158936]
trials B-LOC [3.478445053100586, -3.585232734680176]
of B-LOC [3.4300410747528076, -3.675769805908203]
multiphasic B-LOC [3.432483434677124, -3.525146722793579]
assessment. B-LOC [3.430431604385376, -3.7239129543304443]
All B-LOC [2.115760564804077, -2.4050588607788086]
the B-LOC [2.271934747695923, -2.361124277114868]
trials B-LOC [2.1515181064605713, -2.4317586421966553]
used B-LOC [1.8498269319534302, -2.4364240169525146]
self B-LOC [2.030733823776245, -2.2644102573394775]
reported B-LOC [2.144120216369629, -2.4106810092926025]
measures B-LOC [2.1093714237213135, -2.248992443084717]
for B-LOC [2.0196478366851807, -2.5546865463256836]
vision B-LOC [1.9335349798202515, -2.2053840160369873]
impairment, B-LOC [2.0825366973876953, -2.300241470336914]
both B-LOC [1.3745841979980469, -1.8499045372009277]
as B-LOC [1.6225745677947998, -2.3073651790618896]
screening B-LOC [1.999537706375122, -2.4520890712738037]
tools B-LOC [1.9195243120193481, -2.2068159580230713]
and B-LOC [1.5594635009765625, -1.451619267463684]
as B-LOC [1.6085679531097412, -2.352672576904297]
outcome B-LOC [2.0339195728302, -2.5176193714141846]
measures. B-LOC [1.890135407447815, -2.194343328475952]
The O [-0.581649661064148, 0.5937418341636658]
inclusion O [-0.4039854407310486, 0.448862224817276]
of O [-0.5806704163551331, 0.5031327605247498]
a O [-0.3770209848880768, 0.35240039229393005]
visual O [-0.46420881152153015, 0.2718426585197449]
screening O [-0.38804003596305847, 0.3013359606266022]
component O [-0.4924437701702118, 0.23597951233386993]
in O [-0.43351927399635315, 0.2183643877506256]
the O [-0.2798668444156647, 0.17950096726417542]
assessment O [-0.46249186992645264, 0.2140117883682251]
did O [-0.6476640105247498, 0.5243978500366211]
not O [-0.41000139713287354, 0.5643731951713562]
result O [-0.6466032862663269, 0.41287466883659363]
in O [-0.7390742897987366, 0.41820189356803894]
improvements O [-0.6764776110649109, 0.2512682378292084]
in O [-0.669041633605957, 0.266320139169693]
self O [-0.6652219891548157, 0.44371497631073]
reported O [-0.7191980481147766, 0.31166234612464905]
visual O [-0.5370116233825684, 0.19932830333709717]
problems O [-0.5551897883415222, 0.37056559324264526]
(pooled O [-0.3974827826023102, 0.23856747150421143]
odds O [-0.4079084098339081, 0.20881851017475128]
ratio O [-0.5259935259819031, -0.04075562581419945]
1.04:95% O [-0.5155394077301025, 0.3148660957813263]
confidence O [-0.5788107514381409, 0.2886095941066742]
interval O [-0.6617376208305359, 0.21904700994491577]
0.89 O [-0.304095059633255, 0.27701839804649353]
to O [-0.8111506104469299, 0.08542152494192123]
1.22). O [-0.2725221812725067, 0.3191170394420624]
A B-LOC [1.2031197547912598, -1.5744012594223022]
small B-LOC [1.5497239828109741, -1.4941145181655884]
reduction B-LOC [1.0470869541168213, -1.714539647102356]
(11%) B-LOC [1.3943705558776855, -1.535776138305664]
in B-LOC [1.1079747676849365, -1.7240047454833984]
the B-LOC [1.2837342023849487, -1.7485744953155518]
number B-LOC [1.2885491847991943, -1.732042670249939]
of B-LOC [1.3570045232772827, -1.616394281387329]
older B-LOC [1.8370895385742188, -1.6531566381454468]
people B-LOC [1.4442442655563354, -1.6510279178619385]
with B-LOC [1.4443607330322266, -1.7090167999267578]
self B-LOC [1.4941948652267456, -1.8034965991973877]
reported B-LOC [1.4575732946395874, -1.7902343273162842]
visual B-LOC [1.1861892938613892, -1.7582080364227295]
problems B-LOC [1.369640827178955, -1.582397222518921]
cannot B-LOC [1.8470920324325562, -1.5532405376434326]
be B-LOC [1.9157615900039673, -1.922194004058838]
excluded. B-LOC [1.9171092510223389, -1.7377997636795044]
CONCLUSIONS O [-0.5842694044113159, 0.25603994727134705]
Screening B-LOC [0.22059839963912964, -0.3925556242465973]
of B-LOC [0.22152741253376007, -0.1607489138841629]
asymptomatic B-LOC [0.18872743844985962, -0.3261776864528656]
older B-LOC [0.5616149306297302, -0.4384824335575104]
people B-LOC [0.30018025636672974, -0.5561135411262512]

in B-LOC [0.4160724878311157, -0.6669774651527405]
the B-LOC [0.664682149887085, -0.735385537147522]
community B-LOC [0.5136141777038574, -0.9335973858833313]
is B-LOC [0.6358690857887268, -1.0495145320892334]
not B-LOC [0.7558169960975647, -0.8503164649009705]
justified B-LOC [0.7023136019706726, -0.9947789907455444]
on B-LOC [0.6151324510574341, -1.0532593727111816]
present B-LOC [0.8415049910545349, -1.067478895187378]
evidence. B-LOC [0.7909688353538513, -1.1065391302108765]
Visual B-LOC [0.24773938953876495, -0.6075006127357483]
impairment B-LOC [0.42420080304145813, -0.8077327609062195]
in B-LOC [0.21189415454864502, -0.29297056794166565]
this B-LOC [0.24654299020767212, -0.4328813850879669]
age B-LOC [0.5726304650306702, -0.6018204092979431]
group B-LOC [0.18600612878799438, -0.4854506552219391]
can B-LOC [0.3474605977535248, -0.5823671817779541]
usually B-LOC [0.44086533784866333, -0.5166856050491333]
be B-LOC [0.3273317217826843, -0.616658627986908]
reduced B-LOC [0.2580966055393219, -0.4489039480686188]
with B-LOC [0.2816348969936371, -0.3996800482273102]
treatment. B-LOC [0.2202528566122055, -0.35313865542411804]
It B-LOC [2.197370767593384, -2.1799962520599365]
is B-LOC [2.5713608264923096, -2.1448233127593994]
unclear B-LOC [2.7177703380584717, -2.4059948921203613]
why B-LOC [1.9106889963150024, -2.1167843341827393]
no B-LOC [1.7919617891311646, -2.069903612136841]
benefit B-LOC [1.3901965618133545, -2.279970645904541]
was B-LOC [1.3483870029449463, -1.8381991386413574]
seen. B-LOC [1.518227458000183, -1.758346438407898]
Further B-LOC [2.730807065963745, -2.8500020503997803]
work B-LOC [2.705414295196533, -2.862683057785034]
is B-LOC [3.104966878890991, -2.9166979789733887]
needed B-LOC [3.019808530807495, -2.9682672023773193]
to B-LOC [3.22092342376709, -3.026563882827759]
clarify B-LOC [3.076873540878296, -2.846982479095459]
what B-LOC [2.952838659286499, -3.169555425643921]
interventions B-LOC [2.84501051902771, -3.0981462001800537]
are B-LOC [3.1983802318573, -3.0995562076568604]
appropriate B-LOC [3.162564516067505, -3.33225417137146]
for B-LOC [3.004934549331665, -2.8952348232269287]
older B-LOC [3.1429522037506104, -3.0424492359161377]
people B-LOC [2.740619421005249, -2.8984365463256836]
with B-LOC [2.625869035720825, -2.6560795307159424]
unreported B-LOC [2.9901957511901855, -3.2907516956329346]
impairment B-LOC [2.567784070968628, -3.0276644229888916]
of B-LOC [2.460399866104126, -3.178149700164795]
vision. B-LOC [2.5566489696502686, -2.999093770980835]

We B-LOC [1.4222700595855713, -1.7222691774368286]
generated B-LOC [2.1487460136413574, -1.7164857387542725]
a B-LOC [2.1461610794067383, -2.080134153366089]
series B-LOC [2.1999661922454834, -2.0278894901275635]
of B-LOC [1.9799151420593262, -1.8748637437820435]
knockin B-LOC [2.0110909938812256, -2.2686069011688232]
mouse B-LOC [1.8470386266708374, -2.142549514770508]
lines, B-LOC [2.144723653793335, -2.2305915355682373]
in B-LOC [1.663529634475708, -1.937927484512329]
which B-LOC [2.0869481563568115, -2.0811376571655273]
the B-LOC [1.5503277778625488, -1.7912135124206543]
cytokine B-LOC [1.3810780048370361, -1.678497314453125]
receptor B-LOC [1.5165376663208008, -1.9106711149215698]
gp130-dependent B-LOC [1.366321086883545, -1.6979979276657104]
STAT3 B-LOC [1.6911934614181519, -1.872510552406311]
and/or B-LOC [1.2576382160186768, -1.547876238822937]
SHP2 B-LOC [1.0574889183044434, -1.6371145248413086]
signals B-LOC [1.1596503257751465, -1.6137337684631348]
were B-LOC [2.0558598041534424, -1.8676772117614746]
disrupted, B-LOC [1.9292322397232056, -1.9677057266235352]
by B-LOC [1.4288676977157593, -1.4014711380004883]
replacing B-LOC [1.6955647468566895, -1.6550724506378174]
the B-LOC [1.7247527837753296, -1.8812209367752075]
mouse B-LOC [1.4949688911437988, -1.9977678060531616]
gp130 B-LOC [1.4898622035980225, -1.9116735458374023]
gene B-LOC [1.3040213584899902, -1.8732450008392334]
with B-LOC [1.7528040409088135, -1.7833032608032227]
human B-LOC [1.459352731704712, -1.9818575382232666]
gp130 B-LOC [1.6186033487319946, -1.979203224182129]
mutant B-LOC [1.360756516456604, -1.9308717250823975]
cDNAs. B-LOC [1.2061333656311035, -1.8338978290557861]
The O [-0.11637312173843384, 0.15460437536239624]
SHP2 B-LOC [-0.18541203439235687, -0.23096510767936707]
signal-deficient O [-0.5397750735282898, 0.011623835191130638]
mice O [-0.43802326917648315, 0.0741611123085022]
(gp130F759/F759 O [-0.29073408246040344, 0.42728808522224426]
were O [-0.26742780208587646, 0.23199833929538727]
born O [-0.3173969089984894, 0.5896026492118835]
normal O [-0.3943130075931549, 0.21315670013427734]
but O [-0.5105642676353455, 0.26304319500923157]
displayed O [-0.6737255454063416, 0.5106810927391052]
splenomegaly O [-0.6640859842300415, 0.6325128674507141]
and O [-0.9437761306762695, 0.625298261642456]
lymphadenopathy O [-0.6985526084899902, 0.7465665340423584]
and O [-0.9007044434547424, 0.5946093201637268]
an O [-0.7453846335411072, 0.5915064215660095]
enhanced O [-0.624578058719635, 0.5330429673194885]
acute O [-0.7034441828727722, 0.648341715335846]
phase O [-0.691016435623169, 0.4258740544319153]
reaction. O [-0.6800267696380615, 0.32740622758865356]
In O [-0.2014879584312439, -0.0590771846473217]
contrast, O [-0.12099558860063553, 0.13064244389533997]
the O [-0.09042078256607056, 0.10988057404756546]
STAT3 B-LOC [0.12158381938934326, -0.19221976399421692]
signal-deficient O [-0.3984394371509552, -0.11630985885858536]
mice O [-0.28379762172698975, -0.1182459145784378]

(gp130FXQ/FXXQ) B-LOC [0.6525352597236633, -1.097764492034912]
died B-LOC [1.1525859832763672, -1.1790913343429565]
perinatally, B-LOC [1.5327165126800537, -1.5210933685302734]
like B-LOC [1.3653068542480469, -1.2627463340759277]
the B-LOC [1.0373047590255737, -1.1569066047668457]
gp130-deficient B-LOC [1.1816091537475586, -1.421687364578247]
mice B-LOC [1.0113389492034912, -1.4291337728500366]
(gp130D/D). B-LOC [1.2788053750991821, -1.4269108772277832]
The B-LOC [1.7348098754882812, -1.3327772617340088]
gp130F759/F759 B-LOC [1.8233728408813477, -1.547971248626709]
mice B-LOC [1.3502941131591797, -1.5093965530395508]
showed B-LOC [1.7716838121414185, -1.470381259918213]
prolonged B-LOC [1.779677391052246, -1.5607179403305054]
gp130-induced B-LOC [1.7986031770706177, -1.7425343990325928]
STAT3 B-LOC [1.605453610420227, -1.6279388666152954]
activation, B-LOC [1.4778766632080078, -1.5404800176620483]
indicating B-LOC [1.5577406883239746, -1.4825284481048584]
a B-LOC [1.8313623666763306, -1.696854829788208]
negative B-LOC [2.015169858932495, -1.9444139003753662]
regulatory B-LOC [1.6188464164733887, -1.8929420709609985]
role B-LOC [1.468942642211914, -1.8726016283035278]
for B-LOC [1.6541717052459717, -1.8274884223937988]
SHP2. B-LOC [1.2027667760849, -1.611926794052124]
Th1-type B-LOC [-0.15256142616271973, -0.20452570915222168]
cytokine B-LOC [-0.06287025660276413, -0.23803067207336426]
production B-LOC [-0.017337827011942863, -0.2646312415599823]
and B-LOC [-0.20384424924850464, -0.3953833281993866]
IgG2a O [-0.2239951193332672, -0.06655425578355789]
and O [-0.23345604538917542, -0.1787881851196289]
IgG2b O [-0.21502739191055298, -0.042436037212610245]
production B-LOC [0.03623398765921593, -0.25761744379997253]
were B-LOC [0.10662058740854263, -0.5086709856987]
increased B-LOC [0.03024008311331272, -0.49398139119148254]
in B-LOC [0.019771041348576546, -0.3324548304080963]
the B-LOC [0.08288241922855377, -0.15808884799480438]
gp130F759/F759 B-LOC [0.05152418464422226, -0.274179071187973]
mice, B-LOC [-0.1683221459388733, -0.307588666677475]
while B-LOC [-0.039214376360177994, -0.16339778900146484]
they B-LOC [0.1867273449897766, -0.4967992603778839]
were B-LOC [0.21160051226615906, -0.5074794888496399]
decreased B-LOC [0.20090733468532562, -0.3654695451259613]
in B-LOC [0.053739283233881, -0.3763349950313568]
the B-LOC [-0.004465324338525534, -0.30213257670402527]

gp130FXXQ/FXXQ B-LOC [-0.06952343881130219, -0.2638491690158844]
immune B-LOC [-0.09207826107740402, -0.31381848454475403]
system. B-LOC [-0.09935636073350906, -0.19368548691272736]
These B-LOC [0.18609635531902313, -0.28668609261512756]
results B-LOC [0.24296057224273682, -0.1611948311328888]
indicate B-LOC [0.2237045019865036, -0.2355331927537918]
that B-LOC [-0.02036767266690731, -0.4515915513038635]
the B-LOC [0.08725043386220932, -0.254893034696579]
balance B-LOC [0.03414728119969368, -0.4159873425960541]
of B-LOC [0.0262060035020113, -0.29891109466552734]
positive B-LOC [-0.1474718153476715, -0.275333046913147]
and B-LOC [0.2130332887172699, -0.3992396891117096]
negative B-LOC [0.21965496242046356, -0.46860232949256897]
signals B-LOC [-0.0414750874042511, -0.2658897042274475]
generated B-LOC [0.02440233714878559, -0.4371384382247925]
through B-LOC [-0.1583787351846695, -0.18489497900009155]
gp130 B-LOC [-0.04192527011036873, -0.2567778527736664]
regulates B-LOC [0.15921513736248016, -0.4708248972892761]
the B-LOC [0.01860652305185795, -0.538976788520813]
immune B-LOC [0.08667729049921036, -0.42655515670776367]
responses. B-LOC [0.03858064487576485, -0.4182887375354767]

Breast B-LOC [1.43534517288208, -2.5667929649353027]
cancer B-LOC [2.031229019165039, -2.931739091873169]
may B-LOC [1.9030375480651855, -2.693002223968506]
originate B-LOC [1.2793546915054321, -2.2063381671905518]
in B-LOC [1.2098064422607422, -2.05238676071167]
utero. B-LOC [1.6403470039367676, -2.62459397315979]
We B-LOC [2.689697265625, -3.3301424980163574]
reviewed B-LOC [3.2339041233062744, -3.556077003479004]
the B-LOC [3.4291017055511475, -3.5479190349578857]
available B-LOC [3.3457067012786865, -3.650463819503784]
evidence B-LOC [3.079103708267212, -3.673131227493286]
on B-LOC [3.2232015132904053, -3.789255380630493]
the B-LOC [3.278705358505249, -3.6673717498779297]
association B-LOC [3.0618269443511963, -3.6807267665863037]
between B-LOC [2.8711283206939697, -3.7335119247436523]
birthweight B-LOC [2.4162135124206543, -3.344792604446411]
and B-LOC [3.0229804515838623, -3.749361991882324]
the B-LOC [3.1991207599639893, -3.8332507610321045]
risk B-LOC [3.1061720848083496, -3.90415358543396]
of B-LOC [2.7616541385650635, -3.6661195755004883]
breast B-LOC [2.7806050777435303, -3.5094709396362305]
cancer. B-LOC [2.8953049182891846, -3.68713641166687]
To B-LOC [3.1700665950775146, -3.5307648181915283]
date, B-LOC [3.2876598834991455, -3.57066011428833]
26 B-LOC [3.2297329902648926, -3.430516481399536]
research B-LOC [2.8828670978546143, -3.5750904083251953]
papers B-LOC [3.0846574306488037, -3.60284161567688]
addressing B-LOC [3.3789069652557373, -3.468782424926758]
this B-LOC [3.247037172317505, -3.506226062774658]
issue B-LOC [3.091442584991455, -3.820236921310425]
have B-LOC [3.1110289096832275, -3.207031488418579]
been B-LOC [2.9715163707733154, -3.491900682449341]
published. B-LOC [3.207573652267456, -3.5051403045654297]
The B-LOC [2.1478207111358643, -2.376356840133667]
majority B-LOC [2.1789398193359375, -2.2603471279144287]
of B-LOC [2.0610461235046387, -2.3573591709136963]
studies B-LOC [2.002058267593384, -2.1180219650268555]
identified B-LOC [2.161287546157837, -2.2856974601745605]
a B-LOC [2.210167646408081, -2.55242919921875]
positive B-LOC [2.1765785217285156, -2.635079860687256]
link B-LOC [1.9207587242126465, -2.483794927597046]
between B-LOC [1.9926161766052246, -2.6242411136627197]
birthweight B-LOC [1.7019150257110596, -2.10874342918396]
and B-LOC [1.8529646396636963, -2.2261579036712646]
premenopausal, B-LOC [1.6797415018081665, -2.3019936084747314]
but B-LOC [1.7165194749832153, -1.5709021091461182]
not B-LOC [1.5012586116790771, -1.4238462448120117]
postmenopausal, B-LOC [1.6951937675476074, -2.087606430053711]
breast B-LOC [1.8188321590423584, -2.267709493637085]
cancer. B-LOC [1.7947603464126587, -2.4762392044067383]
The B-LOC [0.23755037784576416, -0.1414116621017456]
relative B-LOC [0.0855310708284378, -0.19289009273052216]
risk B-LOC [0.08438137173652649, -0.20082342624664307]
estimate B-LOC [0.104319266974926, -0.26411905884742737]
for B-LOC [0.09582741558551788, -0.009597128257155418]
breast B-LOC [0.05344280228018761, -0.055049847811460495]
cancer B-LOC [0.10505387932062149, -0.11288139969110489]
comparing B-LOC [0.037540253251791, -0.01300300844013691]
women O [-0.17708556354045868, 0.11703713238239288]
with O [-0.17659005522727966, 0.06770265102386475]
high O [-0.07384909689426422, 0.06719157099723816]
birthweight O [-0.19853167235851288, 0.3003081977367401]
to B-LOC [0.11463388055562973, 0.062502920627594]
women O [-0.1841726452112198, 0.13875405490398407]
with O [-0.23026928305625916, 0.10824529826641083]
low O [0.01689433492720127, 0.15251992642879486]
birthweight O [-0.2323589026927948, 0.32478246092796326]
combining O [-0.14759603142738342, -0.009979033842682838]
all B-LOC [0.09721951186656952, 0.047615841031074524]
studies O [-0.1740698665380478, 0.15276235342025757]
including B-LOC [0.07252088189125061, -0.02840319834649563]
both O [-0.17459316551685333, 0.14066554605960846]
pre- O [-0.2187694013118744, 0.08390530198812485]
and O [-0.16760702431201935, -0.051814887672662735]
postmenopausal O [-0.22091305255889893, 0.15519273281097412]
breast O [-0.07933470606803894, 0.07123227417469025]
cancer O [-0.12974679470062256, 0.08176872134208679]
was B-LOC [0.08615285158157349, -0.19859915971755981]
1.23 O [-0.1206631138920784, 0.06979385018348694]
(95% O [-0.1429218202829361, -0.09039395302534103]
confidence O [-0.44627276062965393, -0.08923565596342087]
interval O [-0.5715641379356384, -0.14560523629188538]
1.13-1.34). O [-0.32960960268974304, 0.06892266124486923]
The B-LOC [0.45557355880737305, -0.4913904666900635]
mechanisms B-LOC [0.04141004756093025, -0.5289869904518127]

underlying B-LOC [0.2344268262386322, -0.7904649972915649]
this B-LOC [0.4582826793193817, -0.775635302066803]
association B-LOC [0.34380510449409485, -0.8080919981002808]
likely B-LOC [0.7177219986915588, -1.145371437072754]
include B-LOC [0.44040659070014954, -0.7572144269943237]
elevated B-LOC [0.19063398241996765, -0.7762119770050049]
levels B-LOC [0.3228115737438202, -0.5940337777137756]
of B-LOC [0.17671836912631989, -0.7986451983451843]
growth B-LOC [0.2718353569507599, -0.7500528693199158]
factors B-LOC [0.24610620737075806, -0.7092282772064209]
that B-LOC [0.2519609034061432, -0.847082793712616]
may B-LOC [0.535504162311554, -1.0537724494934082]
increase B-LOC [0.21362727880477905, -0.8596833944320679]
the B-LOC [0.3410489559173584, -0.9074618816375732]
number B-LOC [0.4822915494441986, -0.9856989979743958]
of B-LOC [0.5305489897727966, -1.1041933298110962]
susceptible B-LOC [0.3297853171825409, -1.1214046478271484]
stem B-LOC [0.3599148094654083, -1.1137453317642212]
cells B-LOC [0.43316978216171265, -1.0216034650802612]
in B-LOC [0.36216190457344055, -0.7389302849769592]
the B-LOC [0.41538017988204956, -0.9014354348182678]
mammary B-LOC [0.4470510482788086, -1.1339529752731323]
gland B-LOC [0.28298598527908325, -0.8872019648551941]
or B-LOC [0.22148936986923218, -1.001201868057251]
initiate B-LOC [0.27822569012641907, -1.0411319732666016]
tumors B-LOC [0.6480903029441833, -1.087257981300354]
through B-LOC [0.34687405824661255, -1.2262330055236816]
DNA B-LOC [0.6847215294837952, -1.4903275966644287]
mutations. B-LOC [0.7177222371101379, -1.143235445022583]
Loss B-LOC [0.7053757309913635, -0.6500128507614136]
of B-LOC [0.6395125985145569, -0.720070481300354]
imprinting B-LOC [0.8545288443565369, -0.6570927500724792]
(LOI) B-LOC [0.7589056491851807, -0.9105207920074463]
of B-LOC [0.6026942729949951, -0.8413452506065369]
growth B-LOC [0.5368618369102478, -0.8161860108375549]
hormone B-LOC [0.5563743710517883, -0.861230731010437]
genes B-LOC [0.6272420287132263, -0.8486958146095276]
relevant B-LOC [0.6075835824012756, -0.8181234002113342]
for B-LOC [0.46427860856056213, -0.9294124245643616]
intrauterine B-LOC [0.6359039545059204, -0.8596157431602478]
growth, B-LOC [0.4352189600467682, -0.7027823328971863]
such B-LOC [0.9151395559310913, -0.9755241274833679]
as B-LOC [0.8606151342391968, -0.9438210129737854]
insulin-like B-LOC [0.6312257051467896, -1.0431194305419922]
growth B-LOC [0.45275095105171204, -0.7654213309288025]
factor B-LOC [0.5028102993965149, -0.9428378939628601]
2 B-LOC [0.752062201499939, -0.6776330471038818]
(IGF2), B-LOC [0.9454542398452759, -0.9857873320579529]
leads B-LOC [0.6822472214698792, -0.5853858590126038]
to B-LOC [0.5722042322158813, -0.44966256618499756]
abnormally B-LOC [0.7070677280426025, -0.7564597725868225]
high B-LOC [0.7041909098625183, -0.8918830752372742]
levels B-LOC [0.8696972727775574, -0.7530279159545898]
of B-LOC [0.804290235042572, -0.9274089932441711]
these B-LOC [0.6844942569732666, -0.9024644494056702]
hormones B-LOC [0.5939911603927612, -0.8101369738578796]
evidenced B-LOC [0.86031174659729, -0.787731945514679]
by B-LOC [0.8588704466819763, -0.7723835110664368]
high B-LOC [0.6386876702308655, -0.8618050813674927]
birthweight. B-LOC [0.782301127910614, -0.6395813822746277]
LOI B-LOC [1.4919869899749756, -1.2306668758392334]
of B-LOC [1.1454455852508545, -1.1099894046783447]
IGF2 B-LOC [1.1782619953155518, -1.3143374919891357]
has B-LOC [1.8161972761154175, -1.4790878295898438]
also B-LOC [1.801025152206421, -1.460033655166626]
been B-LOC [1.8792335987091064, -1.6532981395721436]
found B-LOC [1.6879087686538696, -1.5982475280761719]
in B-LOC [1.4605152606964111, -1.2886474132537842]
mammary B-LOC [1.412360668182373, -1.504860520362854]
tumor B-LOC [1.4642951488494873, -1.4907922744750977]
tissue. B-LOC [1.2364675998687744, -1.4160555601119995]
The B-LOC [0.9550709128379822, -1.1066265106201172]
role B-LOC [0.8803501725196838, -1.0988531112670898]
of B-LOC [0.9511248469352722, -1.1482346057891846]
environmental B-LOC [0.9462516903877258, -1.345889687538147]
factors B-LOC [0.8571255803108215, -1.2259900569915771]
that B-LOC [0.9725990295410156, -1.1061296463012695]
stimulate B-LOC [0.8861637115478516, -1.2420518398284912]
such B-LOC [1.066866397857666, -1.098799705505371]
epigenetic B-LOC [1.1766901016235352, -1.3682442903518677]
regulation B-LOC [0.8851192593574524, -1.209001064300537]
of B-LOC [0.7319188117980957, -1.2198055982589722]
gene B-LOC [0.7327813506126404, -1.3592772483825684]

expression B-LOC [1.1514976024627686, -1.3734924793243408]
remains B-LOC [1.8544788360595703, -2.0407981872558594]
to B-LOC [2.300661087036133, -2.332925796508789]
be B-LOC [2.295862913131714, -2.220207929611206]
elucidated. B-LOC [2.2019541263580322, -1.939957857131958]

To B-LOC [1.99988853931427, -2.9481818675994873]
assess B-LOC [2.859971761703491, -3.342726945877075]
the B-LOC [3.1457908153533936, -3.557497501373291]
relative B-LOC [3.0561628341674805, -3.554067850112915]
importance B-LOC [3.019425630569458, -3.497293710708618]
of B-LOC [2.8516252040863037, -3.408649444580078]
genetic B-LOC [3.0044074058532715, -3.502565622329712]
and B-LOC [2.6674444675445557, -3.295915365219116]
environmental B-LOC [2.812838315963745, -3.3079464435577393]
effects B-LOC [2.6591708660125732, -3.383612632751465]
on B-LOC [2.77813458442688, -3.211812734603882]
the B-LOC [2.5916221141815186, -3.108311891555786]
body-mass B-LOC [2.2559821605682373, -2.8790109157562256]
index B-LOC [2.3538687229156494, -3.053798198699951]
(weight B-LOC [2.7024495601654053, -2.937755823135376]
in B-LOC [2.1789634227752686, -2.447190999984741]
kilograms B-LOC [3.2184343338012695, -3.0235536098480225]
divided B-LOC [2.4670016765594482, -2.5542678833007812]
by B-LOC [2.3403537273406982, -2.5425446033477783]
the B-LOC [2.7769858837127686, -3.0032646656036377]
square B-LOC [2.6379241943359375, -3.030421018600464]
of B-LOC [2.3606200218200684, -2.6539881229400635]
the B-LOC [2.489819288253784, -2.852612257003784]
height B-LOC [1.8201136589050293, -2.654367208480835]
in B-LOC [1.879692554473877, -2.3186941146850586]
meters), B-LOC [2.5202338695526123, -2.912018060684204]
we B-LOC [2.242384433746338, -2.562314987182617]
studied B-LOC [2.6383047103881836, -2.794609308242798]
samples B-LOC [2.7200605869293213, -2.7671797275543213]
of B-LOC [2.4054808616638184, -2.629671812057495]
identical B-LOC [2.6173956394195557, -2.8308215141296387]
and B-LOC [2.582195997238159, -2.812756299972534]
fraternal B-LOC [2.6202497482299805, -2.7795276641845703]
twins, B-LOC [2.3831698894500732, -2.556666851043701]
reared B-LOC [2.535557985305786, -2.5285866260528564]
apart B-LOC [2.4158239364624023, -2.99603271484375]
or B-LOC [2.5582849979400635, -2.856313705444336]
reared B-LOC [2.54211688041687, -2.4802944660186768]
together. B-LOC [2.3873417377471924, -2.8976640701293945]
The B-LOC [2.316296100616455, -2.361752510070801]
samples B-LOC [2.1354711055755615, -2.3728671073913574]
consisted B-LOC [2.243878126144409, -2.0376148223876953]
of B-LOC [2.0483384132385254, -2.0197348594665527]
93 B-LOC [1.9929925203323364, -1.9766274690628052]
pairs B-LOC [1.5863325595855713, -1.7437959909439087]
of B-LOC [1.5974667072296143, -2.0631978511810303]
identical B-LOC [1.641943335533142, -1.9317395687103271]
twins B-LOC [1.6717133522033691, -1.7010575532913208]
reared B-LOC [2.03410267829895, -1.9577586650848389]
apart, B-LOC [1.7779114246368408, -2.191148519515991]
154 B-LOC [1.9584112167358398, -1.982267141342163]
pairs B-LOC [1.5293030738830566, -1.7359802722930908]
of B-LOC [1.5953415632247925, -2.1175618171691895]
identical B-LOC [1.5379900932312012, -1.9120310544967651]
twins B-LOC [1.554392695426941, -1.6673299074172974]
reared B-LOC [1.8475736379623413, -1.7504609823226929]
together, B-LOC [1.5939311981201172, -1.829218864440918]
218 B-LOC [2.061174154281616, -2.104257106781006]
pairs B-LOC [1.5427696704864502, -1.8086298704147339]
of B-LOC [1.7258485555648804, -2.2193334102630615]
fraternal B-LOC [1.664428949356079, -1.8273053169250488]
twins B-LOC [1.5296285152435303, -1.6514062881469727]
reared B-LOC [1.9758782386779785, -1.839595913887024]
apart, B-LOC [1.8570146560668945, -2.136833667755127]
and B-LOC [2.2781543731689453, -2.2448842525482178]
208 B-LOC [2.2629711627960205, -2.1711270809173584]
pairs B-LOC [1.761088252067566, -2.0819387435913086]
of B-LOC [1.982295274734497, -2.3408353328704834]
fraternal B-LOC [1.80060875415802, -1.9588732719421387]
twins B-LOC [1.7591981887817383, -1.9176987409591675]
reared B-LOC [2.072314500808716, -1.957029104232788]
together. B-LOC [2.0607683658599854, -2.1395516395568848]
The B-LOC [1.5906391143798828, -1.6397974491119385]
intrapair B-LOC [1.4483387470245361, -1.5368797779083252]
correlation B-LOC [1.5010998249053955, -1.6210168600082397]
coefficients B-LOC [1.3701986074447632, -1.393012523651123]
of B-LOC [1.605246901512146, -1.5367677211761475]
the B-LOC [1.6408569812774658, -1.6551358699798584]
values B-LOC [1.2819545269012451, -1.582961916923523]
for B-LOC [1.4542971849441528, -1.4790244102478027]
body-mass B-LOC [1.4934734106063843, -1.6247607469558716]
index B-LOC [1.3058561086654663, -1.348940372467041]
of B-LOC [1.355655312538147, -1.472139835357666]
identical B-LOC [1.4680051803588867, -1.6989586353302002]
twins B-LOC [1.5831489562988281, -1.576390266418457]
reared B-LOC [1.6233625411987305, -1.4586604833602905]
apart B-LOC [1.5628246068954468, -1.7309582233428955]
were B-LOC [1.4047117233276367, -1.4400086402893066]

0.70 B-LOC [0.5630245804786682, -0.9823583364486694]
for B-LOC [0.8619977235794067, -1.299635648727417]
men B-LOC [0.8622940182685852, -1.1286497116088867]
and B-LOC [0.7026150226593018, -0.6882511973381042]
0.66 B-LOC [1.3509728908538818, -1.5602483749389648]
for B-LOC [1.0090959072113037, -1.4232025146484375]
women. B-LOC [1.006435513496399, -1.1230440139770508]
These B-LOC [1.3733692169189453, -1.368157982826233]
are B-LOC [1.6170425415039062, -1.5132237672805786]
the B-LOC [1.6437876224517822, -1.5156431198120117]
most B-LOC [1.6475191116333008, -1.6315151453018188]
direct B-LOC [1.5386569499969482, -1.8044161796569824]
estimates B-LOC [1.698028564453125, -1.7503478527069092]
of B-LOC [1.6639145612716675, -1.982722282409668]
the B-LOC [1.8372366428375244, -2.077305555343628]
relative B-LOC [1.6179348230361938, -1.863555669784546]
importance B-LOC [1.5071709156036377, -1.7598989009857178]
of B-LOC [1.670837163925171, -2.1261203289031982]
genetic B-LOC [1.386712670326233, -1.8089295625686646]
influences B-LOC [1.439560890197754, -1.8097007274627686]
(heritability) B-LOC [1.8928053379058838, -1.8868581056594849]
on B-LOC [1.6565358638763428, -1.9672201871871948]
the B-LOC [1.6130577325820923, -1.9715086221694946]
body-mass B-LOC [1.0598037242889404, -1.4861019849777222]
index, B-LOC [1.146038293838501, -1.570483684539795]
and B-LOC [0.964760422706604, -0.9582709074020386]
they B-LOC [1.2888996601104736, -1.716200590133667]
were B-LOC [1.0654736757278442, -1.4734556674957275]
only B-LOC [1.1291866302490234, -1.1755576133728027]
slightly B-LOC [1.0172324180603027, -0.9963141083717346]
lower B-LOC [1.2780580520629883, -1.4449005126953125]
than B-LOC [0.9911830425262451, -1.2546486854553223]
those B-LOC [1.158074140548706, -1.3291209936141968]
for B-LOC [1.0522526502609253, -1.4928532838821411]
twins B-LOC [0.9600095152854919, -1.2046420574188232]
reared B-LOC [1.0897760391235352, -1.125691294670105]
together B-LOC [1.0047334432601929, -1.2436630725860596]
in B-LOC [0.9634050726890564, -1.3275840282440186]
this B-LOC [1.1585822105407715, -1.1985328197479248]
and B-LOC [1.1589550971984863, -1.391688585281372]
earlier B-LOC [1.0861631631851196, -1.5752496719360352]
studies. B-LOC [1.0324828624725342, -1.3778198957443237]
Similar B-LOC [2.2588281631469727, -2.7778992652893066]
estimates B-LOC [2.2662603855133057, -2.6886088848114014]
were B-LOC [2.386829376220703, -2.6992270946502686]
derived B-LOC [2.5144402980804443, -2.821932792663574]
from B-LOC [2.1388370990753174, -2.656545400619507]
maximum-likelihood B-LOC [2.4808993339538574, -3.0320522785186768]
model-fitting B-LOC [2.2436320781707764, -2.84918475151062]
analyses--0.74 B-LOC [2.216383218765259, -2.7165486812591553]
for B-LOC [2.0236995220184326, -2.6435391902923584]
men B-LOC [2.4424562454223633, -2.9427361488342285]
and B-LOC [2.065608024597168, -2.268991231918335]
0.69 B-LOC [2.3438003063201904, -2.7856626510620117]
for B-LOC [2.141417980194092, -2.7085938453674316]
women. B-LOC [2.488588809967041, -2.78706431388855]
Nonadditive B-LOC [1.5567450523376465, -1.8968050479888916]
genetic B-LOC [1.5927636623382568, -1.949572205543518]
variance B-LOC [1.3362915515899658, -1.8598591089248657]
made B-LOC [1.453899621963501, -1.961102843284607]
a B-LOC [1.6149382591247559, -2.062009334564209]
significant B-LOC [1.5941952466964722, -2.087184190750122]
contribution B-LOC [1.4757022857666016, -2.1598222255706787]
to B-LOC [1.469383716583252, -1.9701714515686035]
the B-LOC [1.6132924556732178, -2.007009744644165]
estimates B-LOC [1.638906478881836, -2.1602697372436523]
of B-LOC [1.643248200416565, -2.3212218284606934]
heritability, B-LOC [1.7733166217803955, -2.201758861541748]
particularly B-LOC [1.682141661643982, -2.0318164825439453]
among B-LOC [1.5000412464141846, -1.966549038887024]
men. B-LOC [1.5111007690429688, -1.8478882312774658]
Of B-LOC [0.8283355832099915, -0.5628691911697388]
the B-LOC [1.0272305011749268, -0.8388364911079407]
potential B-LOC [0.7237119674682617, -1.1220898628234863]
environmental B-LOC [0.5926278233528137, -0.923026442527771]
influences, B-LOC [0.7324449419975281, -0.9921762347221375]
only B-LOC [0.7051424384117126, -0.53856360912323]
those B-LOC [0.7483294606208801, -0.6717669367790222]
unique B-LOC [0.805454432964325, -0.9139220118522644]
to B-LOC [0.8761065602302551, -1.0756208896636963]
the B-LOC [0.9294902682304382, -1.1994470357894897]
individual B-LOC [0.5968384742736816, -1.2297639846801758]
and B-LOC [0.45232799649238586, -0.5916499495506287]
not B-LOC [0.5502347946166992, -0.34575891494750977]
those B-LOC [0.712969958782196, -0.7450642585754395]
shared B-LOC [0.9346631169319153, -1.0068237781524658]
by B-LOC [0.5894584655761719, -1.1551440954208374]

family B-LOC [0.5236097574234009, -0.9742360711097717]
members B-LOC [0.8520081639289856, -1.21310293674469]
were B-LOC [0.6686804890632629, -1.171003818511963]
important, B-LOC [0.7977132797241211, -1.112917184829712]
contributing B-LOC [0.9052615761756897, -1.1759122610092163]
about B-LOC [0.9422497153282166, -1.0843193531036377]
30 B-LOC [1.0925298929214478, -1.1385390758514404]
percent B-LOC [1.074323058128357, -1.2434990406036377]
of B-LOC [0.941541314125061, -1.1728311777114868]
the B-LOC [0.9604910016059875, -1.0491851568222046]
variance. B-LOC [0.8512569069862366, -1.2145273685455322]
Sharing B-LOC [0.33326172828674316, -0.1915189027786255]
the B-LOC [0.5689606070518494, -0.3225138783454895]
same B-LOC [0.4538414776325226, -0.4521024525165558]
childhood B-LOC [0.3904164135456085, -0.26451411843299866]
environment B-LOC [0.5091801881790161, -0.33904606103897095]
did B-LOC [0.04482817277312279, -0.231172114610672]
not B-LOC [0.419266015291214, -0.20254957675933838]
contribute B-LOC [0.3259155750274658, -0.4923116862773895]
to B-LOC [0.35044431686401367, -0.6263423562049866]
the B-LOC [0.3066599667072296, -0.6640176773071289]
similarity B-LOC [0.44087064266204834, -0.7260560393333435]
of B-LOC [0.372504323720932, -0.8364881277084351]
the B-LOC [0.38023778796195984, -0.7130908966064453]
body-mass B-LOC [0.27047601342201233, -0.5725515484809875]
index B-LOC [0.3002531826496124, -0.6453191637992859]
of B-LOC [0.31791022419929504, -0.7827429175376892]
twins B-LOC [0.43339598178863525, -0.5690531730651855]
later B-LOC [0.300406813621521, -0.5519537329673767]
in B-LOC [0.26135048270225525, -0.2499864101409912]
life. B-LOC [0.25993168354034424, -0.4512738287448883]
We B-LOC [0.03488795831799507, -0.3672327697277069]
conclude B-LOC [0.2625111937522888, -0.129646897315979]
that B-LOC [-0.11722876131534576, -0.30119115114212036]
genetic B-LOC [0.0669945478439331, -0.3782768249511719]
influences B-LOC [0.2608424127101898, -0.5446053743362427]
on B-LOC [0.2006760537624359, -0.4886183738708496]
body-mass B-LOC [0.03716996684670448, -0.29556387662887573]
index B-LOC [0.11923903226852417, -0.3280545473098755]
are B-LOC [0.10133513808250427, -0.3589186668395996]
substantial, B-LOC [0.28235337138175964, -0.3315504789352417]
whereas B-LOC [0.17357271909713745, -0.2286745011806488]
the B-LOC [0.31758344173431396, -0.4400581419467926]
childhood B-LOC [0.04939230903983116, -0.4094747006893158]
environment B-LOC [0.05508166924118996, -0.4784948527812958]
has B-LOC [0.5102322697639465, -0.4714524745941162]
little B-LOC [0.548229992389679, -0.35481300950050354]
or B-LOC [0.38058915734291077, -0.6435586214065552]
no B-LOC [0.38877686858177185, -0.3739868402481079]
influence. B-LOC [0.3632186949253082, -0.7391559481620789]
These B-LOC [0.99052494764328, -1.1574013233184814]
findings B-LOC [1.1117571592330933, -1.1736841201782227]
corroborate B-LOC [1.4730305671691895, -1.2098593711853027]
and B-LOC [0.9608541131019592, -1.0967365503311157]
extend B-LOC [1.2299280166625977, -1.4407812356948853]
the B-LOC [1.2304373979568481, -1.383960247039795]
results B-LOC [1.3620691299438477, -1.6726593971252441]
of B-LOC [1.1085140705108643, -1.5561797618865967]
earlier B-LOC [1.0624514818191528, -1.7217787504196167]
studies B-LOC [1.2193830013275146, -1.5029981136322021]
of B-LOC [1.3418959379196167, -1.6236704587936401]
twins B-LOC [1.3366641998291016, -1.5328967571258545]
and B-LOC [1.2247997522354126, -1.6828416585922241]
adoptees. B-LOC [1.2358136177062988, -1.3547303676605225]

PLoS B-LOC [0.7332839965820312, -1.2584517002105713]
Biology B-LOC [0.8386690020561218, -1.1914448738098145]
publishes B-LOC [0.7670228481292725, -0.8983376026153564]
today B-LOC [0.7118017077445984, -0.6181349158287048]
a B-LOC [0.45306554436683655, -0.786898672580719]
research B-LOC [0.7151101231575012, -1.0832087993621826]
article B-LOC [0.693920910358429, -1.1288633346557617]
by B-LOC [0.6096674203872681, -1.0476332902908325]
Gunther B-LOC [0.8440226912498474, -1.512738823890686]
Eysenbach B-LOC [0.9499052166938782, -1.3590600490570068]
that B-LOC [0.39144235849380493, -1.0234549045562744]
is B-LOC [0.5203356146812439, -0.5645579695701599]
not B-LOC [0.4318496882915497, -0.4377805292606354]
about B-LOC [0.9117014408111572, -1.217892050743103]
biology. B-LOC [0.9280736446380615, -1.2820568084716797]
It B-LOC [0.349555104970932, -0.7687914967536926]
is B-LOC [0.4276694357395172, -0.6896013617515564]
about B-LOC [0.8697288632392883, -1.2592322826385498]
citations. B-LOC [0.9150135517120361, -1.3014028072357178]
It B-LOC [0.157667875289917, -0.6744610667228699]
provides B-LOC [0.24647478759288788, -0.3880426287651062]
robust B-LOC [0.3216380774974823, -0.22830207645893097]
evidence B-LOC [0.353376179933548, -0.1936141848564148]
that B-LOC [0.03790914639830589, -0.574557363986969]
open-access B-LOC [0.7367832660675049, -1.0385981798171997]
articles B-LOC [0.6453115344047546, -0.9319078326225281]
(OA B-LOC [0.5701393485069275, -0.9758711457252502]
articles) B-LOC [0.6522268652915955, -0.9256499409675598]
are B-LOC [0.2644544541835785, -0.4429193139076233]
more B-LOC [0.21720394492149353, -0.182807058095932]
immediately B-LOC [0.36355677247047424, -0.6219386458396912]
recognized B-LOC [0.6337879300117493, -0.8324359655380249]
and B-LOC [0.2091132402420044, -0.45517462491989136]
cited B-LOC [0.7152418494224548, -1.0888580083847046]
than B-LOC [0.14646798372268677, -0.20235475897789001]
non-OA B-LOC [0.6526808142662048, -0.9264002442359924]
articles. B-LOC [0.6386604309082031, -1.0706923007965088]
As B-LOC [0.17005084455013275, -0.23880809545516968]
such, B-LOC [0.6520623564720154, -0.1699284464120865]
it B-LOC [0.037187930196523666, -0.45513036847114563]
adds B-LOC [0.20218871533870697, -0.34368249773979187]
objective B-LOC [0.4464523494243622, -0.7677858471870422]
support B-LOC [0.4493134915828705, -0.4415331184864044]
to B-LOC [0.5554748177528381, -0.5290907025337219]
the B-LOC [0.5347573757171631, -0.7945392727851868]
belief B-LOC [0.648090660572052, -0.6303208470344543]
we B-LOC [0.577883780002594, -0.9103261828422546]
have B-LOC [0.6935189962387085, -0.47488588094711304]
always B-LOC [0.6955766081809998, -0.6834621429443359]
held B-LOC [0.6178524494171143, -0.46662044525146484]
that B-LOC [0.24639716744422913, -0.6115253567695618]
open-access B-LOC [0.7926234602928162, -1.1132618188858032]
publication B-LOC [0.9009601473808289, -1.1793203353881836]
speeds B-LOC [0.4490388333797455, -0.6487706303596497]
up B-LOC [0.44326314330101013, -0.975303053855896]
scientific B-LOC [0.917165219783783, -1.3994371891021729]
dialog B-LOC [1.0191686153411865, -1.3338383436203003]
between B-LOC [0.9254773259162903, -1.5646759271621704]
researchers B-LOC [1.0611159801483154, -1.4935977458953857]
and, B-LOC [0.16174045205116272, -0.4731852412223816]
consequently, B-LOC [0.33621665835380554, -0.29322972893714905]
should B-LOC [0.8570306301116943, -0.9284313321113586]
be B-LOC [0.9234224557876587, -1.1965535879135132]
extended B-LOC [1.0308630466461182, -1.3432824611663818]
to B-LOC [1.1742923259735107, -1.2533737421035767]
the B-LOC [1.3472378253936768, -1.6366722583770752]
whole B-LOC [1.1067571640014648, -1.487804651260376]
scientific B-LOC [1.3731147050857544, -1.8756983280181885]
literature B-LOC [1.1943347454071045, -1.7704241275787354]
as B-LOC [0.9469921588897705, -1.313681960105896]
quickly B-LOC [0.8422642350196838, -1.5008176565170288]
as B-LOC [1.0640833377838135, -1.6005483865737915]
possible. B-LOC [0.9420614838600159, -1.338921070098877]
It B-LOC [1.8069487810134888, -1.7109622955322266]
is B-LOC [1.701338291168213, -1.701263427734375]
therefore B-LOC [1.8536428213119507, -1.5512182712554932]
fitting B-LOC [1.8738524913787842, -2.0253589153289795]
that B-LOC [1.704613447189331, -1.6304126977920532]
we B-LOC [1.4662662744522095, -1.687369704246521]
publish B-LOC [2.006196975708008, -2.217839002609253]
such B-LOC [1.690711259841919, -1.9491199254989624]
a B-LOC [1.8508880138397217, -2.5077672004699707]
paper. B-LOC [1.7557343244552612, -2.3463284969329834]
We B-LOC [0.7036163210868835, -1.0301960706710815]
have B-LOC [1.3712975978851318, -0.718718409538269]
long B-LOC [1.2818186283111572, -0.8938441872596741]
argued B-LOC [0.9287412762641907, -0.6752068996429443]
that B-LOC [0.8565149307250977, -0.839275062084198]
papers B-LOC [0.8494769930839539, -1.2565438747406006]
freely B-LOC [0.941681444644928, -1.2564023733139038]
available B-LOC [1.1102521419525146, -1.6116366386413574]
in B-LOC [1.1405404806137085, -1.7870049476623535]
a B-LOC [1.2581621408462524, -1.5426435470581055]
journal B-LOC [1.0977723598480225, -1.7886676788330078]
will B-LOC [1.034576416015625, -0.8901475071907043]
be B-LOC [0.8082309365272522, -1.1612917184829712]

more B-LOC [1.3253941535949707, -1.7906866073608398]
often B-LOC [1.7756643295288086, -2.177215814590454]
read B-LOC [1.7676174640655518, -2.3045952320098877]
and B-LOC [1.6060535907745361, -2.0041182041168213]
cited B-LOC [2.1448185443878174, -2.4202795028686523]
than B-LOC [1.6169328689575195, -1.7612550258636475]
those B-LOC [1.9299509525299072, -2.275237798690796]
behind B-LOC [2.2866485118865967, -2.5292279720306396]
a B-LOC [2.277484655380249, -2.7338614463806152]
subscription B-LOC [2.23811674118042, -2.587794065475464]
barrier. B-LOC [1.8195971250534058, -2.1618800163269043]
However, B-LOC [2.849066734313965, -3.0592238903045654]
solid B-LOC [2.7914016246795654, -3.073206663131714]
evidence B-LOC [2.7659666538238525, -3.0871829986572266]
to B-LOC [3.017887830734253, -2.996091604232788]
support B-LOC [2.8538928031921387, -3.1191494464874268]
or B-LOC [3.039299726486206, -3.295492172241211]
refute B-LOC [3.0676374435424805, -3.3401458263397217]
such B-LOC [2.8555266857147217, -3.042320966720581]
a B-LOC [2.8372089862823486, -3.243258237838745]
claim B-LOC [2.5699191093444824, -3.075106382369995]
has B-LOC [3.263880968093872, -3.170017957687378]
been B-LOC [3.079460859298706, -3.442643165588379]
surprisingly B-LOC [3.0627920627593994, -3.214538335800171]
hard B-LOC [3.385631799697876, -3.2615973949432373]
to B-LOC [3.275508165359497, -3.121537923812866]
find. B-LOC [3.092705488204956, -2.9389708042144775]
Since B-LOC [2.698817729949951, -2.336315393447876]
most B-LOC [2.694263219833374, -2.671224355697632]
open-access B-LOC [2.9458065032958984, -2.9328134059906006]
journals B-LOC [2.557100772857666, -2.934112787246704]
are B-LOC [2.9034929275512695, -2.6600794792175293]
new, B-LOC [3.107539415359497, -3.1679446697235107]
comparisons B-LOC [2.824254274368286, -3.1752851009368896]
of B-LOC [2.8660786151885986, -3.2714004516601562]
the B-LOC [3.0333220958709717, -3.218510150909424]
effects B-LOC [2.9545085430145264, -3.5160164833068848]
of B-LOC [2.6443071365356445, -3.228729486465454]
open B-LOC [2.952453374862671, -2.894883155822754]
access B-LOC [2.7384049892425537, -2.8225948810577393]
with B-LOC [2.7965383529663086, -3.2319107055664062]
established B-LOC [2.7205331325531006, -3.2120895385742188]
subscription-based B-LOC [2.8707706928253174, -2.979971170425415]
journals B-LOC [2.56215763092041, -3.0839381217956543]
are B-LOC [3.11946702003479, -2.9019062519073486]
easily B-LOC [3.124112844467163, -3.4624481201171875]
confounded B-LOC [3.130880117416382, -3.164260149002075]
by B-LOC [2.841050386428833, -3.293959379196167]
age B-LOC [3.189147472381592, -3.352149724960327]
and B-LOC [2.9610564708709717, -3.128631830215454]
reputation. B-LOC [2.9996049404144287, -3.4527628421783447]
In B-LOC [1.8777071237564087, -1.9157156944274902]
the B-LOC [2.232945680618286, -2.122319221496582]
current B-LOC [2.235581636428833, -2.315868616104126]
study, B-LOC [2.066575765609741, -2.330634832382202]
Eysenbach B-LOC [1.7199900150299072, -2.198040723800659]
compared B-LOC [2.0024373531341553, -2.281219005584717]
citations B-LOC [2.033930778503418, -2.641449213027954]
compiled B-LOC [2.48177170753479, -2.8789236545562744]
by B-LOC [2.272829532623291, -2.5244550704956055]
Thomson B-LOC [1.805213212966919, -2.5598177909851074]
Scientific B-LOC [2.1136581897735596, -2.4486424922943115]
(formerly B-LOC [2.5439019203186035, -2.6937642097473145]
Thomson B-LOC [1.7225639820098877, -2.482069253921509]
ISI) B-LOC [2.3640005588531494, -2.6150219440460205]
to B-LOC [2.0973801612854004, -2.865109443664551]
individual B-LOC [2.0398120880126953, -2.885150194168091]
articles B-LOC [1.939195990562439, -2.59639835357666]
published B-LOC [2.2370388507843018, -2.7923061847686768]
between B-LOC [2.2498245239257812, -2.697633981704712]
June B-LOC [2.74052357673645, -2.7599971294403076]
2004 B-LOC [2.302596092224121, -2.7741692066192627]
and B-LOC [2.419530153274536, -2.8869709968566895]
December B-LOC [2.5582234859466553, -2.411090135574341]
2004 B-LOC [2.3316500186920166, -2.795117139816284]
in B-LOC [1.93428635597229, -2.4816458225250244]
the B-LOC [2.248682737350464, -2.47446346282959]
same B-LOC [1.7487870454788208, -2.623044729232788]
journal—namely, B-LOC [1.9508087635040283, -2.7711119651794434]
Proceedings B-LOC [1.9921143054962158, -2.754307508468628]
of B-LOC [1.8863847255706787, -2.2395479679107666]
the B-LOC [2.042854070663452, -2.2536752223968506]
National B-LOC [1.9100290536880493, -2.572235584259033]
Academy B-LOC [1.9624148607254028, -2.7097437381744385]
of B-LOC [1.696603775024414, -2.4165639877319336]
Sciences B-LOC [2.067680597305298, -2.6045567989349365]
(PNAS), B-LOC [2.280324935913086, -2.6105117797851562]
which B-LOC [1.4698233604431152, -2.3302905559539795]
announced B-LOC [1.701747179031372, -1.7915388345718384]
its B-LOC [2.030365228652954, -2.098897933959961]
open-access B-LOC [2.2619946002960205, -2.322615146636963]

option B-LOC [1.0643434524536133, -1.74930739402771]
for B-LOC [1.3326921463012695, -1.8956280946731567]
authors B-LOC [1.5012893676757812, -2.1176679134368896]
on B-LOC [1.168362021446228, -1.8774081468582153]
June B-LOC [1.6354763507843018, -2.2114152908325195]
8 B-LOC [1.4570345878601074, -2.065795421600342]
of B-LOC [1.009577751159668, -1.9505133628845215]
that B-LOC [1.1675145626068115, -1.9788241386413574]
year, B-LOC [1.3575608730316162, -2.1736152172088623]
with B-LOC [1.4166101217269897, -1.6641206741333008]
an B-LOC [1.3307652473449707, -1.754868984222412]
associated B-LOC [1.2343897819519043, -1.9222605228424072]
publication B-LOC [1.3543754816055298, -2.1753084659576416]
charge B-LOC [1.2692201137542725, -1.8928718566894531]
of B-LOC [1.0556504726409912, -1.6718621253967285]
US$1,000. B-LOC [1.1869394779205322, -1.5534703731536865]
Non-OA B-LOC [0.9337628483772278, -1.3789005279541016]
articles B-LOC [1.0375679731369019, -1.6275582313537598]
in B-LOC [1.01779043674469, -1.5411816835403442]
PNAS B-LOC [0.965411901473999, -1.3889827728271484]
are B-LOC [1.4013737440109253, -1.394349455833435]
subject B-LOC [1.379441499710083, -1.2861305475234985]
to B-LOC [1.1749247312545776, -1.1390295028686523]
a B-LOC [0.9410448670387268, -1.0457789897918701]
six-month B-LOC [1.080228567123413, -1.2359765768051147]
“toll-access” B-LOC [0.7731960415840149, -1.0457899570465088]
delay B-LOC [0.9316937327384949, -1.2984554767608643]
before B-LOC [1.0078073740005493, -1.4540717601776123]
the B-LOC [1.0261385440826416, -1.6050835847854614]
article B-LOC [0.9153997302055359, -1.8088715076446533]
becomes B-LOC [1.5595077276229858, -1.904160976409912]
publicly B-LOC [1.4971247911453247, -1.8306773900985718]
available. B-LOC [1.4436969757080078, -1.9866106510162354]
The B-LOC [1.090156078338623, -1.1353024244308472]
results B-LOC [1.245733618736267, -1.2049164772033691]
of B-LOC [0.8472234010696411, -0.9563853740692139]
this B-LOC [0.6242911219596863, -0.942421555519104]
natural B-LOC [1.0836952924728394, -1.159409761428833]
experiment B-LOC [0.7310729622840881, -1.228269100189209]
are B-LOC [1.3256561756134033, -1.134697437286377]
clear: B-LOC [1.094793677330017, -1.1637191772460938]
in B-LOC [0.12877283990383148, -0.4981512129306793]
the B-LOC [0.4321766793727875, -0.5926849842071533]
4 B-LOC [0.40935108065605164, -0.6138952374458313]
to B-LOC [0.14750829339027405, -0.6998992562294006]
16 B-LOC [0.835179328918457, -1.1097341775894165]
months B-LOC [0.7314873933792114, -0.8567741513252258]
following B-LOC [0.5144276022911072, -0.9630171656608582]
publication, B-LOC [0.9119438529014587, -1.2647264003753662]
OA B-LOC [0.756819486618042, -0.9423676133155823]
articles B-LOC [0.6887872219085693, -0.9574940800666809]
gained B-LOC [0.23089417815208435, -0.590074896812439]
a B-LOC [0.35185447335243225, -0.6201490163803101]
significant B-LOC [0.2613333463668823, -0.5753952860832214]
citation B-LOC [0.8254584670066833, -1.0478098392486572]
advantage B-LOC [0.337490975856781, -0.8174776434898376]
over B-LOC [0.31138697266578674, -0.6243959069252014]
non-OA B-LOC [0.5919025540351868, -0.7652050852775574]
articles B-LOC [0.7519671320915222, -1.197537899017334]
during B-LOC [0.4652228057384491, -1.0092133283615112]
the B-LOC [0.8453677296638489, -0.9506926536560059]
same B-LOC [0.6180651783943176, -0.9820570349693298]
period. B-LOC [0.4852583408355713, -1.323670744895935]
They B-LOC [1.1568646430969238, -1.1972169876098633]
are B-LOC [1.1475399732589722, -1.243791103363037]
twice B-LOC [0.8139348030090332, -0.7828953266143799]
as B-LOC [0.8397495746612549, -0.601061224937439]
likely B-LOC [1.160926342010498, -1.2797703742980957]
to B-LOC [1.2239961624145508, -1.147899866104126]
be B-LOC [1.286916971206665, -1.5498369932174683]
cited B-LOC [0.9503137469291687, -1.3963310718536377]
4 B-LOC [0.5334764719009399, -0.7055906057357788]
to B-LOC [0.5807706117630005, -1.18337082862854]
10 B-LOC [0.8831865191459656, -1.1612898111343384]
months B-LOC [1.1730505228042603, -1.1460003852844238]
after B-LOC [0.9617180228233337, -0.9064913392066956]
publication B-LOC [0.9045929908752441, -1.3051912784576416]
and B-LOC [0.6228620409965515, -0.9186829924583435]
almost B-LOC [0.7255659699440002, -0.9812886118888855]
three B-LOC [0.9420933127403259, -1.0405827760696411]
times B-LOC [0.9604923129081726, -1.1762111186981201]
as B-LOC [0.8544158339500427, -0.8996227383613586]
likely B-LOC [1.258455753326416, -1.4148626327514648]
between B-LOC [0.661791980266571, -1.3223395347595215]
10 B-LOC [1.140615463256836, -1.291980266571045]
and B-LOC [0.9220557808876038, -1.4254634380340576]
16 B-LOC [1.2286324501037598, -1.4817501306533813]
months. B-LOC [1.3517013788223267, -1.583997130393982]
Given B-LOC [0.3150378167629242, -0.3113689422607422]
that B-LOC [0.2791612446308136, -0.2464480847120285]
PNAS B-LOC [0.682616651058197, -0.9898629784584045]
delays B-LOC [0.5442604422569275, -0.41674020886421204]
open B-LOC [0.59501713514328, -0.5909417867660522]
access B-LOC [0.853376567363739, -0.9015288352966309]
for B-LOC [0.528416097164154, -0.3886786997318268]
only B-LOC [0.6442991495132446, -0.5223326086997986]
six B-LOC [0.626981794834137, -0.41182413697242737]

months, B-LOC [0.9653986692428589, -1.2946690320968628]
the B-LOC [1.179068922996521, -1.5738000869750977]
disparity B-LOC [1.344698429107666, -1.7244800329208374]
between B-LOC [1.2402806282043457, -1.849037528038025]
OA B-LOC [1.3313624858856201, -1.6588362455368042]
and B-LOC [1.4625781774520874, -1.7587031126022339]
non-OA B-LOC [1.3932099342346191, -1.4875590801239014]
articles B-LOC [1.2763969898223877, -1.6972732543945312]
in B-LOC [1.346299171447754, -1.6900436878204346]
journals B-LOC [1.2606620788574219, -1.5573289394378662]
where B-LOC [1.2176945209503174, -1.7257251739501953]
the B-LOC [1.2079381942749023, -1.6086887121200562]
delay B-LOC [1.0796000957489014, -1.5202181339263916]
is B-LOC [1.3017041683197021, -1.6923322677612305]
longer B-LOC [1.2186905145645142, -1.2342605590820312]
or B-LOC [1.3103809356689453, -1.5270766019821167]
where B-LOC [1.107221007347107, -1.6333045959472656]
articles B-LOC [1.1816602945327759, -1.5692715644836426]
remain B-LOC [1.2882391214370728, -1.3493385314941406]
“toll-access” B-LOC [0.8639430403709412, -0.9408643841743469]
is B-LOC [1.3093409538269043, -1.6783701181411743]
likely B-LOC [1.3232331275939941, -1.6561317443847656]
to B-LOC [1.1836574077606201, -1.5378211736679077]
be B-LOC [1.0191597938537598, -1.7266733646392822]
even B-LOC [0.9203303456306458, -1.4321868419647217]
greater. B-LOC [1.0877580642700195, -1.3342169523239136]
Eysenbach B-LOC [1.7091352939605713, -2.109822988510132]
also B-LOC [1.9216867685317993, -2.1002609729766846]
looked B-LOC [1.9352469444274902, -1.9698258638381958]
at B-LOC [2.3439807891845703, -2.045675277709961]
the B-LOC [2.301196336746216, -2.368865728378296]
impact B-LOC [2.142606735229492, -2.4987828731536865]
of B-LOC [2.0519046783447266, -2.1841228008270264]
self-archiving B-LOC [1.8947691917419434, -1.9473822116851807]
non-OA B-LOC [2.0207598209381104, -1.984867811203003]
articles. B-LOC [2.078833818435669, -2.115739107131958]
One B-LOC [0.821856677532196, -0.8527992963790894]
route B-LOC [1.014771580696106, -1.0550413131713867]
to B-LOC [0.8772002458572388, -1.3435478210449219]
open B-LOC [1.332053542137146, -1.4525805711746216]
access, B-LOC [1.21641206741333, -1.3926291465759277]
it B-LOC [1.0351316928863525, -1.0614407062530518]
is B-LOC [1.2817552089691162, -1.1908435821533203]
argued, B-LOC [0.936323344707489, -0.8546304106712341]
is B-LOC [0.7463343739509583, -0.9541404843330383]
for B-LOC [0.7118722796440125, -1.2777652740478516]
authors B-LOC [1.3704066276550293, -1.7226407527923584]
to B-LOC [1.1349326372146606, -1.271979570388794]
archive B-LOC [1.253258228302002, -1.4386496543884277]
their B-LOC [1.4536066055297852, -1.6336948871612549]
published B-LOC [1.251310110092163, -1.734931230545044]
articles B-LOC [1.369847297668457, -1.6778990030288696]
on B-LOC [1.3722913265228271, -1.401731014251709]
their B-LOC [1.6236851215362549, -1.7176275253295898]
own B-LOC [1.224524974822998, -1.4856863021850586]
Web B-LOC [1.509474515914917, -1.858996868133545]
sites B-LOC [1.6273281574249268, -1.6877188682556152]
or B-LOC [1.1813608407974243, -1.184072494506836]
in B-LOC [1.3593473434448242, -1.403714656829834]
institutional B-LOC [1.3843467235565186, -1.8657623529434204]
repositories, B-LOC [1.3597476482391357, -1.550708293914795]
although B-LOC [0.7029790878295898, -0.7730578780174255]
this B-LOC [0.9719263315200806, -0.9117031097412109]
does B-LOC [0.9107093214988708, -0.8674497604370117]
not B-LOC [0.8998754620552063, -0.7617122530937195]
include B-LOC [0.892687976360321, -0.9459763765335083]
an B-LOC [0.9533044695854187, -1.1494956016540527]
explicit B-LOC [0.9658942222595215, -1.2123833894729614]
business B-LOC [1.4136388301849365, -1.406747579574585]
model B-LOC [1.0573503971099854, -1.3000082969665527]
to B-LOC [0.8123270869255066, -1.1309617757797241]
cover B-LOC [1.2217330932617188, -1.1179766654968262]
the B-LOC [1.2386400699615479, -1.1835041046142578]
cost B-LOC [1.0866880416870117, -1.2804064750671387]
of B-LOC [0.8999871611595154, -1.579632043838501]
peer-review B-LOC [1.5804450511932373, -1.8419573307037354]
and B-LOC [1.2272428274154663, -1.5082128047943115]
publishing. B-LOC [1.4755253791809082, -1.8734629154205322]
The B-LOC [0.3759993612766266, -0.18457910418510437]
analysis B-LOC [0.46577051281929016, -0.458153635263443]
revealed O [-0.07770131528377533, 0.10124974697828293]
that O [-0.12425205111503601, 0.022604534402489662]
self-archived B-LOC [0.7523568868637085, -0.8077988624572754]
articles B-LOC [0.7853237986564636, -0.9275102019309998]
are B-LOC [0.32464438676834106, -0.47267481684684753]
also B-LOC [0.19216421246528625, -0.19665467739105225]
cited B-LOC [0.6167753338813782, -0.8476441502571106]
less B-LOC [0.285895437002182, -0.11797291040420532]
often B-LOC [0.4595756232738495, -0.5698064565658569]
than O [-0.14348343014717102, 0.004947309847921133]

OA B-LOC [0.6296531558036804, -1.2812880277633667]
articles B-LOC [1.0499671697616577, -1.5584826469421387]
from B-LOC [1.1659762859344482, -1.5517642498016357]
the B-LOC [1.241310477256775, -1.608978509902954]
same B-LOC [0.989652156829834, -1.6063547134399414]
journal. B-LOC [1.1304600238800049, -1.6662354469299316]
Yes, B-LOC [0.2225743979215622, -0.8164864778518677]
you're B-LOC [0.4554601311683655, -1.057307481765747]
right; B-LOC [0.49780401587486267, -0.8816614747047424]
we B-LOC [0.5824142694473267, -1.1409846544265747]
do B-LOC [0.5814648270606995, -0.7669599652290344]
have B-LOC [0.9340206384658813, -0.8569112420082092]
a B-LOC [0.8510107398033142, -0.8358997106552124]
strong B-LOC [0.8905467987060547, -0.9703161120414734]
and B-LOC [0.6108759045600891, -0.9445235133171082]
vested B-LOC [1.2042226791381836, -1.1708852052688599]
interest B-LOC [1.0074355602264404, -1.0200330018997192]
in B-LOC [0.8497628569602966, -1.0434434413909912]
publishing B-LOC [1.0566504001617432, -1.4569810628890991]
results B-LOC [0.963786780834198, -1.469038486480713]
that B-LOC [0.5628646016120911, -1.3422231674194336]
so B-LOC [0.7540934085845947, -0.8586764931678772]
obviously B-LOC [0.725942075252533, -1.0913633108139038]
endorse B-LOC [0.6931652426719666, -1.2588961124420166]
our B-LOC [0.9057932496070862, -1.4404243230819702]
existence. B-LOC [1.0235769748687744, -1.4708107709884644]
Moreover, B-LOC [0.27650168538093567, -0.3967896103858948]
the B-LOC [0.5862347483634949, -1.0694146156311035]
author B-LOC [0.8779714703559875, -1.3515594005584717]
of B-LOC [0.7154051661491394, -1.3478929996490479]
the B-LOC [0.67832350730896, -1.3383578062057495]
article B-LOC [0.996713399887085, -1.65162193775177]
is B-LOC [0.6091426014900208, -0.863154947757721]
also B-LOC [0.48808008432388306, -0.6307061314582825]
an B-LOC [0.6290834546089172, -0.9150514006614685]
editor B-LOC [0.9254538416862488, -1.1946191787719727]
of B-LOC [0.788358211517334, -1.402458906173706]
an B-LOC [0.7900952696800232, -1.089638113975525]
open-access B-LOC [0.9271115660667419, -1.2637627124786377]
journal. B-LOC [0.9434579610824585, -1.5743509531021118]
But B-LOC [0.8946410417556763, -0.6987313032150269]
sometimes B-LOC [0.9517077803611755, -1.2004282474517822]
a B-LOC [0.9618991017341614, -1.3295929431915283]
potential B-LOC [1.1006062030792236, -1.4788079261779785]
conflict B-LOC [1.0646417140960693, -1.5876274108886719]
of B-LOC [1.19203519821167, -1.7866204977035522]
interest B-LOC [1.2963488101959229, -1.5175011157989502]
can B-LOC [0.9189754128456116, -1.377894639968872]
actually B-LOC [0.781915009021759, -1.200418472290039]
help B-LOC [0.8093146681785583, -1.151938557624817]
to B-LOC [1.0261704921722412, -1.1179242134094238]
ensure B-LOC [0.7264670729637146, -1.1810864210128784]
rigor. B-LOC [0.9379702806472778, -1.4687132835388184]
In B-LOC [1.1555004119873047, -1.12168550491333]
this B-LOC [1.345202088356018, -0.9707702398300171]
case, B-LOC [1.31211256980896, -0.7413699626922607]
we B-LOC [1.0699347257614136, -1.3311655521392822]
have B-LOC [1.2655181884765625, -1.2008814811706543]
an B-LOC [1.2548720836639404, -1.2429077625274658]
acute B-LOC [1.294394850730896, -1.3731361627578735]
interest B-LOC [1.5253934860229492, -1.3828128576278687]
in B-LOC [1.2914915084838867, -1.1574103832244873]
ensuring B-LOC [1.4103796482086182, -1.4322571754455566]
that B-LOC [1.3799526691436768, -1.5195847749710083]
the B-LOC [1.1318764686584473, -1.627832055091858]
article B-LOC [1.2352676391601562, -1.9966338872909546]
meets B-LOC [1.410529613494873, -1.5160785913467407]
the B-LOC [1.3516381978988647, -1.438794732093811]
same, B-LOC [1.1487364768981934, -1.530165433883667]
if B-LOC [0.9706772565841675, -1.220551609992981]
not B-LOC [1.3520050048828125, -0.9692540764808655]
higher, B-LOC [1.1279956102371216, -1.7397291660308838]
standards B-LOC [1.3482882976531982, -1.6588324308395386]
as B-LOC [0.9704722762107849, -1.6132229566574097]
any B-LOC [1.1566087007522583, -1.6242921352386475]
other B-LOC [1.094908356666565, -1.673080563545227]
research B-LOC [1.2580909729003906, -1.862107276916504]
article B-LOC [1.1667191982269287, -2.1270854473114014]
we B-LOC [1.355311632156372, -1.7391995191574097]
publish. B-LOC [1.5666149854660034, -1.7779016494750977]
Not B-LOC [-0.022762669250369072, -0.052378248423337936]
only O [-0.22329559922218323, -0.10533925145864487]
must B-LOC [0.6375939249992371, -1.0433430671691895]
the B-LOC [0.7507979869842529, -1.4166259765625]
conclusions B-LOC [0.8668441772460938, -1.5687769651412964]
provide B-LOC [0.4387768805027008, -1.3034249544143677]
a B-LOC [0.45981457829475403, -1.268959403038025]
significant B-LOC [0.658864438533783, -1.5797197818756104]
advance B-LOC [0.4667852222919464, -1.5998250246047974]
for B-LOC [1.076910138130188, -1.7584352493286133]
the B-LOC [0.958136260509491, -1.7743585109710693]
field, B-LOC [1.1058573722839355, -2.0314011573791504]
but B-LOC [0.35920313000679016, -0.5723679661750793]
the B-LOC [0.44657769799232483, -1.4018275737762451]
study B-LOC [0.9054215550422668, -1.6594793796539307]
must B-LOC [0.5959449410438538, -1.3917996883392334]
be B-LOC [0.08851558715105057, -1.2843865156173706]
technically B-LOC [0.3719842731952667, -1.0662622451782227]
sound, B-LOC [0.4730319678783417, -1.3242411613464355]
with B-LOC [0.34935328364372253, -1.199522852897644]
appropriate B-LOC [0.31349602341651917, -1.1087366342544556]

evidence B-LOC [1.8632532358169556, -2.506823778152466]
to B-LOC [2.1900217533111572, -2.557386636734009]
support B-LOC [2.3234047889709473, -2.7171292304992676]
those B-LOC [1.990862488746643, -2.3512585163116455]
conclusions. B-LOC [2.2444775104522705, -2.686109781265259]
As B-LOC [2.26021409034729, -2.5280258655548096]
with B-LOC [2.367542028427124, -2.614885091781616]
all B-LOC [2.4980533123016357, -2.622915029525757]
our B-LOC [2.101638078689575, -2.393183708190918]
research B-LOC [2.220245122909546, -2.678718328475952]
articles, B-LOC [2.394474744796753, -2.847865343093872]
we B-LOC [1.7721903324127197, -2.3258965015411377]
consulted B-LOC [2.411803722381592, -2.6925642490386963]
throughout B-LOC [2.513010263442993, -2.6313230991363525]
the B-LOC [2.494786500930786, -2.708765745162964]
evaluation B-LOC [2.409803628921509, -2.898258924484253]
process B-LOC [2.7608530521392822, -3.153251886367798]
with B-LOC [2.7687647342681885, -2.8942759037017822]
an B-LOC [2.581071615219116, -2.9318697452545166]
academic B-LOC [2.1643331050872803, -2.8219120502471924]
editor B-LOC [2.4014229774475098, -2.903212308883667]
with B-LOC [2.6872899532318115, -2.947702646255493]
appropriate B-LOC [2.3616461753845215, -2.8837549686431885]
expertise—in B-LOC [2.709130048751831, -2.7976648807525635]
this B-LOC [2.4264562129974365, -2.4575822353363037]
case, B-LOC [2.3041470050811768, -2.238922595977783]
Carol B-LOC [1.9023873805999756, -2.2968242168426514]
Tenopir, B-LOC [1.2323235273361206, -1.6290302276611328]
professor B-LOC [2.2815821170806885, -2.613887310028076]
of B-LOC [2.094557523727417, -2.8227100372314453]
information B-LOC [2.223874568939209, -2.7976324558258057]
sciences B-LOC [2.411454916000366, -2.830864191055298]
at B-LOC [2.2616899013519287, -2.439368963241577]
the B-LOC [2.26798939704895, -2.509361982345581]
University B-LOC [2.2612221240997314, -2.943748950958252]
of B-LOC [2.1299283504486084, -2.7180657386779785]
Tennessee B-LOC [1.9842627048492432, -2.3073151111602783]
(Knoxville, B-LOC [2.3487298488616943, -2.716475009918213]
Tennessee, B-LOC [2.1200942993164062, -2.3924992084503174]
United B-LOC [2.09597110748291, -2.587017774581909]
States). B-LOC [2.065612554550171, -2.570906639099121]
The B-LOC [1.6636241674423218, -2.545806407928467]
article B-LOC [1.8339353799819946, -2.3633320331573486]
was B-LOC [1.648709774017334, -2.285233736038208]
reviewed B-LOC [2.1913464069366455, -2.018529176712036]
by B-LOC [2.0974066257476807, -2.4862611293792725]
two B-LOC [2.043372631072998, -2.2160513401031494]
experts B-LOC [2.560657024383545, -2.3962621688842773]
in B-LOC [1.9197345972061157, -2.1659674644470215]
bibliometric B-LOC [2.447087049484253, -2.5771143436431885]
analyses B-LOC [2.4642860889434814, -2.5522258281707764]
and B-LOC [2.3231258392333984, -2.4294204711914062]
information B-LOC [2.5651602745056152, -2.8149096965789795]
science, B-LOC [2.520662307739258, -2.674506425857544]
and B-LOC [2.092392921447754, -2.1777939796447754]
an B-LOC [2.07822847366333, -2.1987884044647217]
experienced B-LOC [2.064032793045044, -2.32454514503479]
research B-LOC [2.377845048904419, -2.4331302642822266]
biologist B-LOC [2.2502143383026123, -2.5762622356414795]
with B-LOC [2.062730073928833, -2.290764570236206]
expertise B-LOC [2.50502872467041, -2.369792938232422]
in B-LOC [2.1578166484832764, -2.1962039470672607]
statistics. B-LOC [2.4799063205718994, -2.6490349769592285]
They B-LOC [2.1118199825286865, -2.1390764713287354]
all B-LOC [1.9309337139129639, -2.163689136505127]
enthusiastically B-LOC [2.2455196380615234, -2.1035943031311035]
supported B-LOC [2.0560152530670166, -2.1144814491271973]
publication, B-LOC [2.204298257827759, -2.653215169906616]
although B-LOC [1.9583081007003784, -1.6901540756225586]
one B-LOC [1.878515362739563, -1.792032241821289]
understandably B-LOC [2.036713123321533, -1.8362782001495361]
questioned B-LOC [2.3232219219207764, -2.1649069786071777]
the B-LOC [2.595141649246216, -2.644455909729004]
suitability B-LOC [2.5012218952178955, -2.4700229167938232]
of B-LOC [2.3710458278656006, -2.542898654937744]
PLoS B-LOC [2.6605024337768555, -2.6111972332000732]
Biology B-LOC [2.134303092956543, -2.447643756866455]
as B-LOC [2.1141574382781982, -2.5140435695648193]
the B-LOC [1.9492697715759277, -2.459343671798706]
publication B-LOC [2.02150559425354, -2.709322452545166]
venue. B-LOC [1.9614052772521973, -2.5839016437530518]
We B-LOC [1.065865159034729, -1.4361027479171753]
have B-LOC [1.509543776512146, -1.3863165378570557]
no B-LOC [1.177384853363037, -1.2466320991516113]
intention B-LOC [1.2995339632034302, -1.210547924041748]
of B-LOC [1.1689382791519165, -1.1491845846176147]
making B-LOC [1.066005825996399, -1.275403618812561]
PLoS B-LOC [1.7749433517456055, -1.817372441291809]
Biology B-LOC [1.1982753276824951, -1.5731287002563477]
a B-LOC [1.1752941608428955, -1.3581821918487549]
regular B-LOC [1.1433793306350708, -1.8229905366897583]
home B-LOC [0.5173735618591309, -1.2288304567337036]

for B-LOC [1.4327768087387085, -2.144934892654419]
bibliometric B-LOC [1.9679605960845947, -2.2430717945098877]
studies B-LOC [1.8405932188034058, -2.1468536853790283]
(even B-LOC [1.6546223163604736, -1.9416128396987915]
when B-LOC [1.3802595138549805, -1.7989625930786133]
about B-LOC [1.7750277519226074, -2.143688917160034]
open B-LOC [2.150022029876709, -2.320044994354248]
access). B-LOC [2.102997064590454, -2.3489530086517334]
What B-LOC [2.0367915630340576, -2.4762442111968994]
makes B-LOC [2.531571626663208, -2.693641185760498]
this B-LOC [2.3148930072784424, -2.73895525932312]
study B-LOC [2.25498366355896, -2.998181104660034]
worth B-LOC [2.277508020401001, -3.014209508895874]
publishing B-LOC [2.4525985717773438, -2.95615291595459]
in B-LOC [2.5796494483947754, -2.7815959453582764]
PLoS B-LOC [2.633739948272705, -2.8679473400115967]
Biology B-LOC [2.200772762298584, -2.5945088863372803]
is B-LOC [2.363297700881958, -2.3650264739990234]
not B-LOC [1.7131357192993164, -1.7817625999450684]
only B-LOC [1.8760299682617188, -1.8628411293029785]
the B-LOC [2.2917211055755615, -2.318341016769409]
relative B-LOC [2.1666390895843506, -2.628679037094116]
strength B-LOC [2.2499372959136963, -2.7042524814605713]
of B-LOC [2.4048912525177, -2.8026163578033447]
evidence B-LOC [2.4335267543792725, -2.6521427631378174]
supporting B-LOC [2.492755651473999, -2.7179126739501953]
the B-LOC [2.7316763401031494, -2.6957621574401855]
claim B-LOC [2.1516666412353516, -2.7059032917022705]
but B-LOC [2.09458327293396, -1.7758086919784546]
also B-LOC [2.2661354541778564, -2.116168737411499]
the B-LOC [2.34769868850708, -2.4982802867889404]
extent B-LOC [2.445096254348755, -2.8159725666046143]
to B-LOC [2.5852222442626953, -3.0725414752960205]
which B-LOC [2.4071085453033447, -2.6143178939819336]
many B-LOC [2.486565351486206, -2.5971105098724365]
(especially B-LOC [2.4711341857910156, -2.7185637950897217]
other B-LOC [2.3929972648620605, -2.7792820930480957]
publishers) B-LOC [2.597419261932373, -2.799727201461792]
have B-LOC [2.471571207046509, -2.4683501720428467]
anticipated B-LOC [2.461905002593994, -2.575957775115967]
such B-LOC [2.4062936305999756, -2.5365028381347656]
an B-LOC [2.316925525665283, -2.897643804550171]
analysis. B-LOC [2.0707685947418213, -2.810973882675171]
As B-LOC [2.8728737831115723, -2.3566038608551025]
far B-LOC [3.0244626998901367, -2.359034776687622]
as B-LOC [2.791137933731079, -2.4819083213806152]
we B-LOC [2.5564939975738525, -2.481652021408081]
are B-LOC [2.9207420349121094, -2.701134443283081]
aware, B-LOC [3.1978800296783447, -2.720271348953247]
no B-LOC [2.876218557357788, -2.614234447479248]
other B-LOC [2.900697946548462, -2.8720638751983643]
study B-LOC [2.7434775829315186, -2.943467140197754]
has B-LOC [3.0739123821258545, -2.9308698177337646]
compared B-LOC [2.972371816635132, -2.965790271759033]
OA B-LOC [2.8090288639068604, -2.8797056674957275]
and B-LOC [2.5980634689331055, -2.915304183959961]
non-OA B-LOC [2.831538438796997, -2.699303150177002]
articles B-LOC [2.9812562465667725, -3.176340341567993]
from B-LOC [2.9523656368255615, -3.2607948780059814]
the B-LOC [3.068375825881958, -2.961775541305542]
same B-LOC [2.8578479290008545, -2.944667339324951]
journal B-LOC [2.8502004146575928, -3.107271432876587]
and B-LOC [2.763532876968384, -2.700969696044922]
controlled B-LOC [3.035029411315918, -3.2094712257385254]
for B-LOC [3.1318442821502686, -3.054659605026245]
so B-LOC [3.127638101577759, -2.487436532974243]
many B-LOC [2.978217363357544, -3.0622456073760986]
potentially B-LOC [3.0341074466705322, -3.1487510204315186]
confounding B-LOC [3.0197856426239014, -3.2801647186279297]
factors. B-LOC [2.8101611137390137, -3.3716375827789307]
Eysenbach's B-LOC [1.214811086654663, -1.8466113805770874]
multivariate B-LOC [1.238348364830017, -1.7958403825759888]
analysis B-LOC [1.223339319229126, -1.8980945348739624]
took B-LOC [1.30104660987854, -1.9082456827163696]
into B-LOC [1.9665584564208984, -1.6357333660125732]
account B-LOC [1.8022149801254272, -2.244616746902466]
the B-LOC [1.839667797088623, -2.2493197917938232]
number B-LOC [1.518479585647583, -2.25191330909729]
of B-LOC [1.701120138168335, -2.3371479511260986]
days B-LOC [1.4333230257034302, -1.9226627349853516]
since B-LOC [1.5955499410629272, -1.970233678817749]
publication, B-LOC [1.7210098505020142, -2.0852153301239014]
number B-LOC [1.684295654296875, -2.243393659591675]
of B-LOC [1.7061350345611572, -2.3353660106658936]
authors, B-LOC [1.6033258438110352, -2.1329782009124756]
article B-LOC [1.8434853553771973, -2.2660467624664307]
type, B-LOC [2.2612011432647705, -2.2724435329437256]
country B-LOC [2.07692551612854, -2.2018282413482666]
of B-LOC [2.0552287101745605, -2.340733766555786]
the B-LOC [1.9100713729858398, -2.3104350566864014]
corresponding B-LOC [1.7966448068618774, -2.4265620708465576]
author, B-LOC [1.4440945386886597, -2.334510326385498]
funding B-LOC [1.2190409898757935, -2.0625035762786865]

type, B-LOC [2.146716356277466, -2.980470895767212]
subject B-LOC [3.0439581871032715, -3.513152837753296]
area, B-LOC [2.6252171993255615, -3.294875383377075]
submission B-LOC [2.5521457195281982, -3.1616289615631104]
track B-LOC [2.1644465923309326, -3.10467791557312]
( B-LOC [2.234008550643921, -2.893225908279419]
PNAS B-LOC [1.7542803287506104, -2.5955328941345215]
has B-LOC [2.341420888900757, -2.5126113891601562]
three B-LOC [2.325972080230713, -2.796788454055786]
different B-LOC [2.514343738555908, -3.2724111080169678]
ways B-LOC [2.206221580505371, -2.7878856658935547]
that B-LOC [1.960818886756897, -2.7821311950683594]
authors B-LOC [2.4146945476531982, -3.0502798557281494]
can B-LOC [2.4884555339813232, -3.022732973098755]
submit B-LOC [2.440723180770874, -3.020108938217163]
a B-LOC [2.3649113178253174, -3.1323816776275635]
paper), B-LOC [2.2252037525177, -3.125739574432373]
and B-LOC [2.679611921310425, -3.2127180099487305]
the B-LOC [2.872363328933716, -3.3531410694122314]
previous B-LOC [2.1301381587982178, -3.0475070476531982]
citation B-LOC [2.279130220413208, -3.1235592365264893]
record B-LOC [2.362011194229126, -3.159348964691162]
of B-LOC [2.691249370574951, -3.4158360958099365]
the B-LOC [2.651135206222534, -3.124507427215576]
first B-LOC [2.2704954147338867, -3.237717390060425]
and B-LOC [2.330721855163574, -2.8533928394317627]
last B-LOC [2.6011998653411865, -3.4073965549468994]
authors. B-LOC [2.377326726913452, -3.0380661487579346]
He B-LOC [1.9295499324798584, -2.611928701400757]
even B-LOC [2.501485586166382, -2.9162662029266357]
administered B-LOC [2.4472591876983643, -3.12326979637146]
a B-LOC [2.664454936981201, -3.265096426010132]
supplementary B-LOC [2.962432622909546, -3.6975510120391846]
questionnaire B-LOC [3.0464706420898438, -3.7007014751434326]
to B-LOC [2.7497992515563965, -3.5804195404052734]
assess B-LOC [2.97947359085083, -3.5873563289642334]
whether B-LOC [2.7283408641815186, -3.4604923725128174]
authors B-LOC [2.4999797344207764, -3.0604183673858643]
choosing B-LOC [2.5528438091278076, -3.2296249866485596]
the B-LOC [2.496065378189087, -2.9279730319976807]
OA B-LOC [2.359461545944214, -2.8175270557403564]
option B-LOC [1.7903146743774414, -2.4560885429382324]
in B-LOC [2.065317153930664, -2.5230746269226074]
PNAS B-LOC [2.2551920413970947, -2.540398359298706]
chose B-LOC [2.4054718017578125, -2.689878225326538]
to B-LOC [2.4396088123321533, -2.696603536605835]
do B-LOC [2.231529712677002, -2.71527361869812]
so B-LOC [2.551156997680664, -2.674194574356079]
for B-LOC [2.3832764625549316, -2.918148994445801]
only B-LOC [2.3917763233184814, -2.7261693477630615]
their B-LOC [2.6137430667877197, -2.849492073059082]
most B-LOC [2.494300127029419, -3.1349525451660156]
important B-LOC [2.2729079723358154, -2.902862310409546]
research B-LOC [2.079075574874878, -2.7067067623138428]
(they B-LOC [2.3086013793945312, -2.5915427207946777]
didn't). B-LOC [1.942723274230957, -2.4784390926361084]
As B-LOC [0.9138234257698059, -1.1179637908935547]
Ian B-LOC [1.4742183685302734, -1.3214588165283203]
Rowlands B-LOC [0.9184358716011047, -0.9192695617675781]
from B-LOC [1.2173521518707275, -1.2539470195770264]
the B-LOC [1.6661121845245361, -1.7839040756225586]
Centre B-LOC [1.7792168855667114, -2.3815665245056152]
for B-LOC [2.2410941123962402, -2.20757794380188]
Publishing B-LOC [1.613504409790039, -2.0509135723114014]
at B-LOC [1.7649719715118408, -1.4199790954589844]
University B-LOC [1.925560474395752, -2.076162576675415]
College B-LOC [2.1585335731506348, -1.803021788597107]
London—and B-LOC [1.7634658813476562, -1.7009005546569824]
one B-LOC [1.6319551467895508, -1.8240793943405151]
of B-LOC [1.7852436304092407, -1.9694145917892456]
the B-LOC [1.7151262760162354, -1.6913182735443115]
reviewers B-LOC [1.5069680213928223, -1.8559319972991943]
who B-LOC [1.282376766204834, -1.7390408515930176]
agreed B-LOC [1.4032641649246216, -1.6695177555084229]
to B-LOC [1.9193899631500244, -1.902359962463379]
be B-LOC [1.8118679523468018, -2.1757655143737793]
identified B-LOC [1.7463574409484863, -2.010678768157959]
in B-LOC [1.391513705253601, -1.9669246673583984]
this B-LOC [1.3740618228912354, -1.7990343570709229]
article—said B-LOC [1.2974367141723633, -2.0342442989349365]
at B-LOC [1.1972607374191284, -1.4605669975280762]
the B-LOC [1.4703633785247803, -1.6988718509674072]
start B-LOC [1.2441481351852417, -1.9106600284576416]
of B-LOC [1.3985249996185303, -1.800405740737915]
his B-LOC [1.2156152725219727, -1.619654655456543]
review: B-LOC [1.3004601001739502, -1.8634798526763916]
“Many B-LOC [0.42657172679901123, -0.9441047310829163]
(most) B-LOC [1.0577954053878784, -1.2585233449935913]
of B-LOC [0.888103187084198, -1.1913387775421143]
the B-LOC [0.9021168351173401, -1.148186445236206]
papers B-LOC [1.2686244249343872, -1.5093603134155273]
and B-LOC [1.211609959602356, -1.45682954788208]
presentations B-LOC [0.9282318949699402, -1.3879916667938232]
I B-LOC [0.394103080034256, -0.8872408270835876]

have B-LOC [1.7186992168426514, -2.124884843826294]
read/seen B-LOC [1.8830516338348389, -2.32426118850708]
on B-LOC [2.3513243198394775, -2.5045387744903564]
this B-LOC [2.0184357166290283, -2.1961801052093506]
topic B-LOC [2.5306882858276367, -2.6979281902313232]
have B-LOC [2.027555227279663, -2.3452813625335693]
completely B-LOC [2.271925687789917, -2.35952091217041]
failed B-LOC [2.1847188472747803, -2.373322010040283]
to B-LOC [2.2057688236236572, -2.3250739574432373]
address B-LOC [2.363731622695923, -2.539757251739502]
the B-LOC [2.375377893447876, -2.399712324142456]
kinds B-LOC [2.578993558883667, -2.639483690261841]
of B-LOC [2.3358078002929688, -2.461737871170044]
confounding B-LOC [2.5820860862731934, -2.8147032260894775]
issues B-LOC [2.7336864471435547, -2.6716673374176025]
that B-LOC [2.0688135623931885, -2.3301243782043457]
are B-LOC [2.4950852394104004, -2.402834892272949]
so B-LOC [2.2499759197235107, -2.1601526737213135]
convincingly B-LOC [2.4920742511749268, -2.592982292175293]
tackled B-LOC [3.0645828247070312, -2.6247613430023193]
here. B-LOC [2.1473026275634766, -2.25783634185791]
For B-LOC [2.2845489978790283, -2.454031229019165]
that B-LOC [2.5187666416168213, -2.632826566696167]
reason B-LOC [2.6250741481781006, -2.4701344966888428]
alone, B-LOC [2.852108955383301, -2.715416431427002]
this B-LOC [2.003208875656128, -2.676488161087036]
paper B-LOC [1.8784241676330566, -2.599684000015259]
deserves B-LOC [2.368170976638794, -2.7053020000457764]
to B-LOC [2.6396920680999756, -2.5432538986206055]
be B-LOC [2.546318769454956, -2.6117594242095947]
published B-LOC [2.7543869018554688, -2.862039804458618]
and B-LOC [2.3660666942596436, -2.3759241104125977]
alerted B-LOC [2.787003755569458, -2.7967374324798584]
to B-LOC [2.857205629348755, -2.7722246646881104]
the B-LOC [2.744690418243408, -2.4781930446624756]
widest B-LOC [2.984208822250366, -2.881762981414795]
possible B-LOC [2.86745548248291, -3.1273605823516846]
audience. B-LOC [2.642770767211914, -2.9651920795440674]
” B-LOC [1.8991494178771973, -1.940103530883789]
In B-LOC [2.1968863010406494, -2.253160238265991]
addition B-LOC [2.184070110321045, -2.0618093013763428]
to B-LOC [2.074636936187744, -2.1024086475372314]
providing B-LOC [2.4283134937286377, -2.7965915203094482]
evidence B-LOC [2.482699155807495, -2.915412664413452]
for B-LOC [2.6667063236236572, -2.9716217517852783]
the B-LOC [2.555000066757202, -2.762524127960205]
immediate B-LOC [2.7036542892456055, -3.08417010307312]
advantage B-LOC [2.392935037612915, -3.1320536136627197]
of B-LOC [2.3532674312591553, -2.8912103176116943]
open B-LOC [2.642265558242798, -2.791639566421509]
access, B-LOC [2.5171172618865967, -2.8007519245147705]
Eysenbach's B-LOC [1.975302815437317, -2.2452518939971924]
analysis B-LOC [2.397362232208252, -2.6576032638549805]
also B-LOC [2.541588068008423, -2.5587260723114014]
highlights B-LOC [2.740269899368286, -2.655461311340332]
several B-LOC [2.4865939617156982, -2.5590977668762207]
potential B-LOC [2.8822596073150635, -3.065516471862793]
challenges B-LOC [2.9371941089630127, -2.986037015914917]
to B-LOC [2.808945417404175, -3.0348117351531982]
its B-LOC [2.620474100112915, -3.000560998916626]
long-term B-LOC [2.7936997413635254, -2.9127771854400635]
future. B-LOC [2.86487078666687, -3.077765703201294]
Although B-LOC [1.600768804550171, -1.767350196838379]
a B-LOC [2.0913426876068115, -2.2998106479644775]
limited B-LOC [2.2879648208618164, -2.4449656009674072]
dataset, B-LOC [2.2030742168426514, -2.5847442150115967]
the B-LOC [2.117452383041382, -2.113398313522339]
citation B-LOC [1.774211049079895, -2.1976799964904785]
history B-LOC [1.9923291206359863, -2.172196626663208]
of B-LOC [1.9591774940490723, -2.1010854244232178]
the B-LOC [1.9058425426483154, -1.8361955881118774]
first B-LOC [1.3881694078445435, -1.9946231842041016]
and B-LOC [1.8822832107543945, -1.979110836982727]
last B-LOC [1.8491934537887573, -2.039111375808716]
authors B-LOC [1.901923656463623, -2.2026607990264893]
differed B-LOC [1.7626502513885498, -2.131178140640259]
between B-LOC [2.245945692062378, -2.2774980068206787]
those B-LOC [2.1121788024902344, -2.149749279022217]
who B-LOC [1.9435029029846191, -2.242581367492676]
chose B-LOC [2.087963819503784, -2.0406124591827393]
the B-LOC [2.0950047969818115, -2.1905319690704346]
open-access B-LOC [2.4272823333740234, -2.4198966026306152]
option B-LOC [2.0458765029907227, -2.3501102924346924]
and B-LOC [2.2213339805603027, -2.2144668102264404]
those B-LOC [2.0665130615234375, -2.1495540142059326]
who B-LOC [2.0023694038391113, -2.2604315280914307]
did B-LOC [1.694169044494629, -2.1076128482818604]
not. B-LOC [2.037790536880493, -2.1202852725982666]
In B-LOC [0.8511817455291748, -1.127353310585022]
the B-LOC [1.315437912940979, -1.3705583810806274]
group B-LOC [1.4024534225463867, -1.2885154485702515]
that B-LOC [1.0594384670257568, -1.6482248306274414]
chose B-LOC [1.51495361328125, -1.4414753913879395]
open B-LOC [1.384560227394104, -1.149190902709961]

access, O [-0.2986871302127838, 0.05880304053425789]
last O [-0.029722785577178, 0.11215456575155258]
authors B-LOC [0.19281616806983948, -0.383436918258667]
tended B-LOC [-0.023664845153689384, -0.1110575720667839]
to B-LOC [0.036767736077308655, -0.057833801954984665]
have O [-0.07866828888654709, -0.054904188960790634]
a O [-0.05267160385847092, 0.08440452069044113]
“stronger” B-LOC [0.15791238844394684, 0.04665428772568703]
previous O [-0.1571757048368454, -0.14431440830230713]
citation B-LOC [0.14410746097564697, -0.45205458998680115]
record, B-LOC [0.00034380200668238103, -0.1604158580303192]
whereas B-LOC [0.05391939729452133, -0.1080160140991211]
this B-LOC [0.033820707350969315, -0.33672165870666504]
situation B-LOC [0.14318212866783142, -0.5939487814903259]
was B-LOC [0.10696861147880554, -0.5678004622459412]
reversed B-LOC [0.3024539351463318, -0.5149450898170471]
among B-LOC [0.33891743421554565, -0.4530092179775238]
the B-LOC [0.5446248054504395, -0.45468276739120483]
group B-LOC [0.5711578130722046, -0.4902941882610321]
that B-LOC [0.32685133814811707, -0.6842798590660095]
declined B-LOC [0.3303300440311432, -0.3383124768733978]
the B-LOC [0.2648174464702606, -0.27384859323501587]
open-access B-LOC [0.24718402326107025, -0.4436090290546417]
option—here, B-LOC [0.20861566066741943, -0.42859578132629395]
it B-LOC [0.09530472010374069, -0.15716950595378876]
was B-LOC [0.10591523349285126, -0.1873314380645752]
the B-LOC [0.3499172627925873, -0.36474671959877014]
first B-LOC [0.2511421740055084, -0.4002290666103363]
authors B-LOC [0.429929256439209, -0.5883169770240784]
who B-LOC [0.25440773367881775, -0.4304262399673462]
tended B-LOC [0.3524927794933319, -0.34394460916519165]
to B-LOC [0.27413132786750793, -0.29997023940086365]
be B-LOC [0.1539216786623001, -0.4190487265586853]
stronger. B-LOC [0.44421061873435974, -0.13956470787525177]
This B-LOC [0.5145853757858276, -0.8548199534416199]
may B-LOC [0.6276261210441589, -1.1607764959335327]
reflect B-LOC [0.41612598299980164, -0.9372140169143677]
varying B-LOC [0.8724208474159241, -1.5236296653747559]
attitudes B-LOC [0.8680257201194763, -0.9453074336051941]
of B-LOC [0.8241878747940063, -1.4852275848388672]
authors B-LOC [0.8732268214225769, -1.1646205186843872]
at B-LOC [1.1120729446411133, -1.5766022205352783]
different B-LOC [0.8582101464271545, -1.7313886880874634]
stages B-LOC [1.1721755266189575, -1.2728734016418457]
of B-LOC [0.9749919772148132, -1.4988203048706055]
their B-LOC [1.2384592294692993, -1.5671026706695557]
career, B-LOC [0.8898341059684753, -1.1421515941619873]
a B-LOC [0.5742575526237488, -1.0592454671859741]
stronger B-LOC [0.546204686164856, -0.8087911605834961]
influence B-LOC [0.5868967175483704, -1.1638145446777344]
from B-LOC [0.8008183836936951, -1.1730848550796509]
the B-LOC [0.9464898109436035, -1.427816390991211]
leader B-LOC [0.8740057349205017, -1.2859413623809814]
of B-LOC [1.0411839485168457, -1.5784690380096436]
a B-LOC [0.8835244178771973, -1.6146105527877808]
particular B-LOC [1.0574915409088135, -1.7233107089996338]
group, B-LOC [1.0687973499298096, -1.3105121850967407]
or B-LOC [0.8203521370887756, -1.1566205024719238]
an B-LOC [0.607100784778595, -1.2739635705947876]
age- B-LOC [1.0546374320983887, -1.3021714687347412]
or B-LOC [0.8496840596199036, -1.4062899351119995]
career-related B-LOC [0.7128477096557617, -1.1046171188354492]
difference B-LOC [0.662926197052002, -1.3862799406051636]
in B-LOC [0.6933266520500183, -1.3141618967056274]
the B-LOC [0.9168505668640137, -1.2647407054901123]
ability B-LOC [0.7549688220024109, -1.1805942058563232]
to B-LOC [0.9030210375785828, -1.3792297840118408]
pay B-LOC [0.799911618232727, -1.2207841873168945]
the B-LOC [0.9127886891365051, -1.1605664491653442]
publication B-LOC [0.6649220585823059, -1.3411078453063965]
charge B-LOC [0.742447555065155, -1.255464792251587]
(e.g., B-LOC [0.87361079454422, -1.0661505460739136]
[ B-LOC [0.6447203755378723, -1.0326273441314697]
1]). B-LOC [0.6293643712997437, -0.9414665102958679]
Indeed, B-LOC [0.31591296195983887, -0.3790006935596466]
access B-LOC [0.5543491244316101, -0.31788066029548645]
to B-LOC [0.7507949471473694, -0.5667377710342407]
appropriate B-LOC [0.6857626438140869, -0.6636419892311096]
funds B-LOC [0.666835367679596, -0.5636828541755676]
may B-LOC [0.6043328642845154, -0.7518889904022217]
also B-LOC [0.46412697434425354, -0.5778759121894836]
be B-LOC [0.3279019892215729, -0.7351635694503784]
a B-LOC [0.42790475487709045, -0.5253691673278809]
reason B-LOC [0.49491456151008606, -0.6040075421333313]
why B-LOC [0.3859679400920868, -0.5828155279159546]
a B-LOC [0.46256840229034424, -0.5116713047027588]
lower B-LOC [0.33679044246673584, -0.5005983710289001]
proportion B-LOC [0.5675181746482849, -0.6867029070854187]
of B-LOC [0.5550158619880676, -0.7391616702079773]
authors B-LOC [0.6617521047592163, -0.931911826133728]
from B-LOC [0.8395162224769592, -0.7066875696182251]
European B-LOC [0.6566627621650696, -0.818117618560791]
countries B-LOC [0.7783822417259216, -0.8263815641403198]
tended B-LOC [0.4049152135848999, -0.584240734577179]
to B-LOC [0.6907367706298828, -0.6304192543029785]
choose B-LOC [0.5014599561691284, -0.6540957093238831]

the B-LOC [1.213672399520874, -1.4556902647018433]
open-access B-LOC [1.607204556465149, -1.923636794090271]
option. B-LOC [1.202423334121704, -1.6772487163543701]
In B-LOC [1.7472432851791382, -1.796701431274414]
many B-LOC [1.7658379077911377, -1.7583104372024536]
of B-LOC [2.014890432357788, -1.9700171947479248]
these B-LOC [1.7957665920257568, -1.7651581764221191]
countries, B-LOC [1.8757355213165283, -1.7222203016281128]
funds B-LOC [1.4170962572097778, -1.6165118217468262]
for B-LOC [1.5527145862579346, -1.7796728610992432]
page B-LOC [1.6037254333496094, -2.1768386363983154]
charges—and, B-LOC [1.393831491470337, -1.6324058771133423]
by B-LOC [1.8273252248764038, -1.5568352937698364]
extension, B-LOC [1.9196505546569824, -1.6739524602890015]
open-access B-LOC [1.774902105331421, -1.8926308155059814]
publication B-LOC [1.8825397491455078, -2.3749921321868896]
fees—are B-LOC [1.524289608001709, -1.7291417121887207]
often B-LOC [1.869921088218689, -1.8158888816833496]
not B-LOC [1.9746840000152588, -1.583298683166504]
included B-LOC [1.6933784484863281, -1.7239899635314941]
within B-LOC [1.841219186782837, -2.0724844932556152]
research B-LOC [1.7532215118408203, -2.1678123474121094]
grants. B-LOC [2.0090091228485107, -2.1854088306427]
PNAS B-LOC [1.518465518951416, -1.7786529064178467]
was B-LOC [1.1590886116027832, -1.198909878730774]
one B-LOC [1.4615066051483154, -1.5005255937576294]
of B-LOC [1.3720704317092896, -1.338374137878418]
the B-LOC [1.4865894317626953, -1.1830618381500244]
first B-LOC [1.5086874961853027, -1.129157543182373]
journals B-LOC [1.7946003675460815, -2.08583402633667]
to B-LOC [1.470057487487793, -1.328514814376831]
offer B-LOC [1.507088303565979, -1.3437730073928833]
an B-LOC [1.385812759399414, -1.4190552234649658]
open-access B-LOC [1.7445048093795776, -1.624287486076355]
option B-LOC [1.3844482898712158, -1.6113395690917969]
to B-LOC [1.1771001815795898, -1.7676209211349487]
its B-LOC [1.6529359817504883, -1.6932048797607422]
authors. B-LOC [1.6548271179199219, -1.9747035503387451]
However, B-LOC [2.3245961666107178, -1.9835151433944702]
such B-LOC [2.378612756729126, -2.1251652240753174]
hybrid B-LOC [2.196800470352173, -2.3542191982269287]
journals B-LOC [2.3877623081207275, -2.33152437210083]
are B-LOC [2.4152419567108154, -2.1424472332000732]
increasing: B-LOC [2.3797366619110107, -2.233948230743408]
Blackwell, B-LOC [2.156212568283081, -2.1965138912200928]
Springer, B-LOC [2.139092206954956, -2.232518196105957]
and B-LOC [2.3918097019195557, -2.1468350887298584]
Oxford B-LOC [2.4504992961883545, -2.245940923690796]
University B-LOC [2.315980911254883, -2.4604673385620117]
Press B-LOC [2.323253870010376, -2.3084490299224854]
now B-LOC [2.6390655040740967, -2.107288122177124]
provide B-LOC [2.3844778537750244, -2.1329445838928223]
this B-LOC [2.2691586017608643, -2.028179168701172]
option B-LOC [2.292243719100952, -2.356832981109619]
as B-LOC [2.51436448097229, -2.252565622329712]
well. B-LOC [2.6467807292938232, -2.334102153778076]
This B-LOC [1.627736210823059, -1.7940747737884521]
means B-LOC [1.6287412643432617, -1.3976503610610962]
that B-LOC [1.7088921070098877, -1.630460500717163]
similar B-LOC [2.1665761470794678, -2.413623094558716]
experiments B-LOC [1.848435401916504, -2.2255494594573975]
can B-LOC [2.141775369644165, -2.021367311477661]
be B-LOC [2.259969472885132, -2.3831307888031006]
replicated. B-LOC [2.118129014968872, -2.510660409927368]
Moreover, B-LOC [0.8167282938957214, -0.8758111000061035]
although B-LOC [0.5302766561508179, -0.6705034375190735]
the B-LOC [0.9066488146781921, -0.7854151129722595]
evidence B-LOC [0.5870528817176819, -0.8459110856056213]
from B-LOC [0.8986755609512329, -0.988188624382019]
the B-LOC [1.0396294593811035, -1.1866590976715088]
current B-LOC [0.8594731092453003, -1.2328228950500488]
analysis B-LOC [0.8512259125709534, -1.1796984672546387]
argues B-LOC [0.6190968751907349, -0.44837313890457153]
most B-LOC [0.7985427975654602, -0.3674390912055969]
strongly B-LOC [0.6979966163635254, -0.3579489588737488]
for B-LOC [0.6294541954994202, -0.47548285126686096]
a B-LOC [0.5131927728652954, -0.6713211536407471]
time B-LOC [0.5310547351837158, -0.8935942649841309]
advantage B-LOC [0.3023220896720886, -0.9653860926628113]
in B-LOC [0.44411006569862366, -0.8995957374572754]
citation B-LOC [0.6240100264549255, -0.9266586303710938]
for B-LOC [0.7087240815162659, -1.0614540576934814]
OA B-LOC [0.8917053937911987, -1.1071317195892334]
articles, B-LOC [0.7984666228294373, -1.0116137266159058]
a B-LOC [0.8250395059585571, -1.319199800491333]
study B-LOC [0.7262967824935913, -1.1476526260375977]
over B-LOC [0.815250813961029, -1.1658096313476562]
longer B-LOC [0.9428721070289612, -1.1938053369522095]
periods B-LOC [0.9710096120834351, -1.330036997795105]
will B-LOC [1.1671290397644043, -1.3319836854934692]
reveal B-LOC [1.2526421546936035, -1.1471889019012451]
whether B-LOC [1.2913743257522583, -1.3699203729629517]
this B-LOC [0.9055668115615845, -1.1702501773834229]
translates B-LOC [1.0841121673583984, -1.1969075202941895]
into B-LOC [0.9052824974060059, -1.1661169528961182]
a B-LOC [0.8998429775238037, -1.0485128164291382]
sustained B-LOC [0.3891907036304474, -1.2528929710388184]

increase B-LOC [0.13237348198890686, -0.4922065734863281]
in B-LOC [0.13196079432964325, -0.68215411901474]
the B-LOC [0.3152938187122345, -0.6251577734947205]
number B-LOC [0.3567734360694885, -0.8782677054405212]
of B-LOC [0.3190027177333832, -0.82877117395401]
citations. B-LOC [0.5760343074798584, -0.8488719463348389]
In B-LOC [0.7435541152954102, -0.69968181848526]
the B-LOC [0.9822496175765991, -0.373378723859787]
meantime, B-LOC [0.9893694519996643, -0.7969680428504944]
open-access B-LOC [0.8814192414283752, -0.9315266609191895]
advocates B-LOC [0.9846978783607483, -0.9443579316139221]
should B-LOC [0.9033592343330383, -0.8860666155815125]
be B-LOC [0.79283607006073, -0.8965325355529785]
emboldened B-LOC [1.1837184429168701, -0.8448041081428528]
by B-LOC [0.9071671962738037, -0.5895196795463562]
tangible B-LOC [1.1469628810882568, -0.9920737743377686]
evidence B-LOC [0.7286742329597473, -0.8866044878959656]
for B-LOC [0.8348795175552368, -0.9487003684043884]
what B-LOC [0.6373435258865356, -1.0238677263259888]
has B-LOC [0.8711869716644287, -0.9158534407615662]
seemed B-LOC [0.7708519101142883, -1.0202778577804565]
obvious B-LOC [0.9572942852973938, -1.1903033256530762]
all B-LOC [1.2312480211257935, -0.7767778038978577]
along. B-LOC [0.9936679601669312, -1.2344696521759033]

BACKGROUND B-LOC [0.37595421075820923, -0.517538845539093]
Human O [-0.588871419429779, 0.6230347752571106]
papillomavirus O [-0.27029258012771606, 0.1702657788991928]
(HPV) O [-0.4171941876411438, 0.4882015287876129]
testing O [-0.4173239469528198, 0.7470596432685852]
is O [-0.47925853729248047, 0.7716392874717712]
known O [-0.39075055718421936, 0.8260275721549988]
to O [-0.31580132246017456, 0.8707420229911804]
be O [-0.48559319972991943, 0.9445567727088928]
more O [-0.5868313908576965, 1.1178016662597656]
sensitive, O [-0.4817078709602356, 0.9355105757713318]
but O [-0.4937613308429718, 1.0202308893203735]
less O [-0.4962431490421295, 1.0823101997375488]
specific O [-0.5236616134643555, 0.9775953888893127]
than O [-0.7248497009277344, 0.8508049845695496]
cytology O [-0.4927372932434082, 0.47199851274490356]
for O [-0.6424146294593811, 0.6889544129371643]
detecting O [-0.41305217146873474, 0.5590679049491882]
cervical O [-0.4443041682243347, 0.28968921303749084]
intraepithelial O [-0.5562232136726379, 0.21594643592834473]
neoplasia O [-0.34983962774276733, 0.2824963331222534]
(CIN). O [-0.22457611560821533, 0.2512928247451782]
We B-LOC [3.0593700408935547, -3.2607247829437256]
assessed B-LOC [3.3487541675567627, -3.591310501098633]
the B-LOC [3.5340240001678467, -3.6477255821228027]
efficacy B-LOC [3.4184410572052, -3.887105941772461]
of B-LOC [3.395592212677002, -3.599508047103882]
cervical-cancer B-LOC [3.222679376602173, -3.6724307537078857]
screening B-LOC [3.2492809295654297, -3.87865948677063]
policies B-LOC [3.5570709705352783, -3.736274242401123]
that B-LOC [3.3623125553131104, -3.627596139907837]
are B-LOC [3.4920225143432617, -3.38637375831604]
based B-LOC [3.4590132236480713, -3.639927625656128]
on B-LOC [3.2477242946624756, -3.5080811977386475]
HPV B-LOC [3.4150285720825195, -3.7372353076934814]
testing. B-LOC [3.5106029510498047, -3.968264102935791]
METHODS B-LOC [1.7330840826034546, -2.484555959701538]
Between B-LOC [2.599868059158325, -3.1690919399261475]
March, B-LOC [3.1968891620635986, -3.1791322231292725]
2004, B-LOC [2.762979745864868, -3.1198370456695557]
and B-LOC [2.8749194145202637, -3.119488477706909]
December, B-LOC [3.3805043697357178, -3.304410457611084]
2004, B-LOC [2.771564245223999, -3.200993299484253]
in B-LOC [2.639962911605835, -3.1752421855926514]
two B-LOC [2.4277961254119873, -2.722223997116089]
separate B-LOC [2.4351398944854736, -2.8678672313690186]
recruitment B-LOC [2.9044997692108154, -3.073436737060547]
phases, B-LOC [3.040911912918091, -2.9987130165100098]
women B-LOC [2.7467474937438965, -3.094428777694702]
aged B-LOC [3.0227622985839844, -3.199227809906006]
25-60 B-LOC [3.3149168491363525, -2.957671880722046]
years B-LOC [3.156249761581421, -3.1868703365325928]
were B-LOC [2.819981098175049, -3.1787567138671875]
randomly B-LOC [3.2543394565582275, -3.1919758319854736]
assigned B-LOC [3.0609586238861084, -3.1339566707611084]
to B-LOC [2.6642110347747803, -3.2674214839935303]
conventional B-LOC [2.6541097164154053, -3.2721171379089355]
cytology B-LOC [3.026672601699829, -3.250526189804077]
or B-LOC [2.8260343074798584, -3.010798692703247]
to B-LOC [2.601400136947632, -3.2749688625335693]
HPV B-LOC [2.782607078552246, -2.990710973739624]
testing B-LOC [2.772554636001587, -3.2457363605499268]
in B-LOC [3.1110730171203613, -3.1465003490448]
combination B-LOC [3.0704572200775146, -2.970602512359619]
with B-LOC [2.988767623901367, -3.2227280139923096]
liquid-based B-LOC [2.875279664993286, -3.139139175415039]

cytology B-LOC [2.2361953258514404, -2.8540117740631104]
(first B-LOC [3.1928369998931885, -3.4199254512786865]
phase) B-LOC [2.9529812335968018, -3.4700424671173096]
or B-LOC [3.2961270809173584, -3.284250259399414]
alone B-LOC [3.410656690597534, -3.4813644886016846]
(second B-LOC [3.293362855911255, -3.6247971057891846]
phase). B-LOC [3.1519620418548584, -3.5294346809387207]
Randomisation B-LOC [3.5784730911254883, -3.565068483352661]
was B-LOC [3.221592426300049, -3.3064017295837402]
done B-LOC [3.5271880626678467, -3.4697890281677246]
by B-LOC [3.277928113937378, -3.4433724880218506]
computer B-LOC [3.6570467948913574, -3.64994215965271]
in B-LOC [3.4226906299591064, -3.490659475326538]
two B-LOC [3.3138957023620605, -3.563485860824585]
screening B-LOC [3.389791488647461, -3.592358350753784]
centres B-LOC [3.7110378742218018, -3.6072795391082764]
and B-LOC [3.34088397026062, -3.2603843212127686]
by B-LOC [3.4185898303985596, -3.4194998741149902]
sequential B-LOC [3.622802972793579, -3.3327479362487793]
opening B-LOC [3.551954746246338, -3.5436789989471436]
of B-LOC [3.5763142108917236, -3.3656089305877686]
numbered B-LOC [3.6679210662841797, -3.429283380508423]
sealed B-LOC [3.694740056991577, -3.3025782108306885]
envelopes B-LOC [3.696913242340088, -3.447829246520996]
in B-LOC [3.5164268016815186, -3.469451665878296]
the B-LOC [3.4515540599823, -3.219428539276123]
remaining B-LOC [3.4854159355163574, -3.3925766944885254]
seven B-LOC [3.489244222640991, -3.4130873680114746]
centres. B-LOC [3.6567928791046143, -3.5421383380889893]
During B-LOC [2.115549325942993, -2.802478551864624]
phase B-LOC [2.883957624435425, -3.064910888671875]
one, B-LOC [2.6949570178985596, -2.9072866439819336]
women B-LOC [2.6721508502960205, -3.042451858520508]
who B-LOC [2.9581806659698486, -3.0574333667755127]
were B-LOC [2.7454516887664795, -3.0837044715881348]
HPV-positive B-LOC [2.4606211185455322, -2.8883509635925293]
and B-LOC [2.42647385597229, -2.5898702144622803]
aged B-LOC [3.1135847568511963, -3.0583279132843018]
35-60 B-LOC [3.0377237796783447, -3.162447690963745]
years B-LOC [3.0415923595428467, -3.2869832515716553]
were B-LOC [2.542567729949951, -2.777883768081665]
referred B-LOC [2.713320732116699, -2.96240496635437]
to B-LOC [2.5193846225738525, -2.893484354019165]
colposcopy, B-LOC [2.7855892181396484, -2.9324679374694824]
whereas B-LOC [2.4173765182495117, -2.3929808139801025]
women B-LOC [2.6644227504730225, -2.9989709854125977]
aged B-LOC [3.119767904281616, -3.094536304473877]
25-34 B-LOC [3.16263484954834, -3.1732141971588135]
years B-LOC [3.1581366062164307, -3.301809310913086]
were B-LOC [2.485089063644409, -2.711688995361328]
referred B-LOC [2.7378337383270264, -2.879690408706665]
to B-LOC [2.521888494491577, -2.7968382835388184]
colposcopy B-LOC [2.7585458755493164, -2.729872703552246]
only B-LOC [2.6339571475982666, -2.836909532546997]
if B-LOC [2.601146697998047, -3.1405532360076904]
cytology B-LOC [2.854499101638794, -3.129535675048828]
was B-LOC [2.274214029312134, -2.833575963973999]
also B-LOC [2.5875465869903564, -3.100797176361084]
abnormal B-LOC [2.558298349380493, -3.204547643661499]
or B-LOC [2.1235101222991943, -2.859767198562622]
HPV B-LOC [2.370476245880127, -2.964341640472412]
testing B-LOC [2.414268732070923, -3.1816365718841553]
was B-LOC [2.295473337173462, -2.8997843265533447]
persistently B-LOC [2.6052794456481934, -3.009493112564087]
positive. B-LOC [2.5895049571990967, -3.2245819568634033]
During B-LOC [2.6141905784606934, -3.025236129760742]
phase B-LOC [3.201657295227051, -3.0571773052215576]
two, B-LOC [2.837477684020996, -2.9754011631011963]
women B-LOC [2.9857547283172607, -3.3951940536499023]
in B-LOC [3.0033180713653564, -3.38675856590271]
the B-LOC [3.138014554977417, -3.2548255920410156]
HPV B-LOC [2.8597240447998047, -3.270092248916626]
group B-LOC [3.0416581630706787, -3.0023982524871826]
were B-LOC [3.1259164810180664, -3.217104434967041]
referred B-LOC [3.4361660480499268, -3.348724126815796]
for B-LOC [3.0620086193084717, -3.2118618488311768]
colposcopy B-LOC [3.2921531200408936, -3.325791597366333]
if B-LOC [3.2383759021759033, -3.51822829246521]
the B-LOC [3.0083863735198975, -3.5519607067108154]
HPV B-LOC [2.8120064735412598, -3.3308143615722656]
test B-LOC [2.700432777404785, -3.662214517593384]
was B-LOC [2.8010547161102295, -3.3445587158203125]
positive. B-LOC [2.94507098197937, -3.485849142074585]
Two B-LOC [1.3226284980773926, -1.7563856840133667]
rounds B-LOC [1.8980636596679688, -1.735053539276123]
of B-LOC [1.3592345714569092, -1.4867827892303467]

screening B-LOC [2.4242303371429443, -2.982966661453247]
occurred B-LOC [2.7561254501342773, -2.862654209136963]
in B-LOC [2.8104326725006104, -3.1357667446136475]
each B-LOC [2.954684019088745, -3.0893595218658447]
phase, B-LOC [2.8546745777130127, -3.270695686340332]
and B-LOC [2.446535348892212, -2.668745279312134]
all B-LOC [2.7536652088165283, -2.8688528537750244]
women B-LOC [2.8042047023773193, -2.9827866554260254]
had B-LOC [2.6593945026397705, -2.9517982006073]
cytology B-LOC [3.1329588890075684, -3.340930700302124]
testing B-LOC [2.8838632106781006, -3.314438581466675]
only B-LOC [2.979966402053833, -3.0371193885803223]
at B-LOC [2.794640302658081, -3.1977736949920654]
the B-LOC [3.060795545578003, -2.9512155055999756]
second B-LOC [3.0200490951538086, -2.9987738132476807]
round. B-LOC [3.1246352195739746, -3.2099061012268066]
The B-LOC [2.9977352619171143, -3.307939291000366]
primary B-LOC [3.125528335571289, -3.428326368331909]
endpoint B-LOC [3.2780025005340576, -3.3594205379486084]
was B-LOC [2.69403076171875, -3.1051440238952637]
the B-LOC [2.760197401046753, -3.2941811084747314]
detection B-LOC [3.099729537963867, -3.4457833766937256]
of B-LOC [2.950643301010132, -3.439091920852661]
grade B-LOC [3.107485055923462, -3.261881113052368]
2 B-LOC [3.1563103199005127, -3.091128349304199]
and B-LOC [2.581434726715088, -2.846864938735962]
3 B-LOC [2.9889872074127197, -3.2849996089935303]
CIN, B-LOC [2.9507901668548584, -3.262390613555908]
and B-LOC [2.949965715408325, -3.2141530513763428]
of B-LOC [3.053558588027954, -3.467573404312134]
invasive B-LOC [3.2521779537200928, -3.608247756958008]
cervical B-LOC [2.88482666015625, -3.302060604095459]
cancers B-LOC [3.0583832263946533, -3.5194814205169678]
during B-LOC [2.8477835655212402, -3.433941125869751]
the B-LOC [2.905289888381958, -3.2365357875823975]
first B-LOC [2.8997514247894287, -3.37534499168396]
and B-LOC [2.7982370853424072, -3.1587798595428467]
second B-LOC [2.8942928314208984, -3.4181244373321533]
screening B-LOC [2.9901230335235596, -3.618593215942383]
rounds. B-LOC [3.3309638500213623, -3.406341075897217]
Analysis B-LOC [3.3073534965515137, -3.51049542427063]
was B-LOC [3.1471526622772217, -3.180535078048706]
done B-LOC [3.4427506923675537, -3.301764965057373]
by B-LOC [3.2472245693206787, -3.1782212257385254]
intention B-LOC [3.457218885421753, -3.472914934158325]
to B-LOC [3.3382761478424072, -3.2170209884643555]
screen. B-LOC [3.4446828365325928, -3.525907516479492]
This B-LOC [3.128875494003296, -3.2758848667144775]
trial B-LOC [3.3266024589538574, -3.460167646408081]
is B-LOC [3.4907567501068115, -3.0543086528778076]
registered, B-LOC [3.6947062015533447, -3.309253692626953]
number B-LOC [3.546154022216797, -3.302976608276367]
ISRCTN81678807. B-LOC [3.5268754959106445, -3.5452191829681396]
FINDINGS B-LOC [2.435584306716919, -2.762739896774292]
In B-LOC [2.6461219787597656, -2.680974245071411]
total B-LOC [3.383430242538452, -2.646682024002075]
for B-LOC [2.8717331886291504, -2.8634493350982666]
both B-LOC [2.6631429195404053, -2.927953004837036]
phases, B-LOC [3.1529290676116943, -3.1182825565338135]
47,001 B-LOC [3.3214540481567383, -3.2585251331329346]
women B-LOC [2.8929290771484375, -3.2348318099975586]
were B-LOC [2.992691993713379, -3.09269380569458]
randomly B-LOC [3.472230911254883, -3.346497058868408]
assigned B-LOC [3.4035916328430176, -3.3246703147888184]
to B-LOC [3.181849479675293, -3.3852555751800537]
the B-LOC [2.994450092315674, -3.1222236156463623]
cytology B-LOC [3.146979808807373, -3.2830166816711426]
group B-LOC [3.4044320583343506, -3.2320144176483154]
and B-LOC [2.9627256393432617, -3.0451149940490723]
47,369 B-LOC [3.458460569381714, -3.2462379932403564]
to B-LOC [2.7952804565429688, -3.369107723236084]
HPV B-LOC [2.8107969760894775, -3.1652348041534424]
testing. B-LOC [3.026498556137085, -3.510741949081421]
33,851 B-LOC [2.935868501663208, -2.4979052543640137]
women B-LOC [2.31657075881958, -2.5984292030334473]
from B-LOC [1.9556410312652588, -2.5730690956115723]
the B-LOC [2.505140781402588, -2.554028272628784]
cytology B-LOC [2.7778141498565674, -2.9153990745544434]
group B-LOC [2.3431689739227295, -2.0034940242767334]
and B-LOC [2.0493276119232178, -2.4366910457611084]
32,998 B-LOC [2.594866991043091, -1.9110188484191895]

from B-LOC [1.8205595016479492, -2.5552432537078857]
the B-LOC [2.2056896686553955, -2.6156466007232666]
HPV-testing B-LOC [2.3058650493621826, -2.9725449085235596]
group B-LOC [2.265634536743164, -2.8363239765167236]
had B-LOC [2.1573379039764404, -2.656663417816162]
a B-LOC [2.497974157333374, -2.8532161712646484]
second B-LOC [2.3915817737579346, -2.756692409515381]
round B-LOC [2.6296114921569824, -3.1578214168548584]
of B-LOC [2.4246795177459717, -3.0529372692108154]
screening. B-LOC [2.445634126663208, -3.083857297897339]
We B-LOC [2.082174062728882, -2.6634676456451416]
also B-LOC [2.501004934310913, -2.911071538925171]
retrieved B-LOC [2.608973264694214, -3.117642879486084]
the B-LOC [2.643477439880371, -3.0438482761383057]
histological B-LOC [3.0657124519348145, -3.4237446784973145]
diagnoses B-LOC [3.3269126415252686, -3.435966730117798]
from B-LOC [2.833890438079834, -3.286635160446167]
screening B-LOC [2.61976957321167, -3.321148157119751]
done B-LOC [2.8155834674835205, -3.263227939605713]
elsewhere. B-LOC [2.613332986831665, -3.0366647243499756]
The B-LOC [0.9582411646842957, -1.1198151111602783]
detection B-LOC [0.7949316501617432, -0.9707847237586975]
of B-LOC [1.0716840028762817, -1.011864423751831]
invasive B-LOC [0.902596116065979, -0.8993666768074036]
cervical B-LOC [0.7086090445518494, -0.887649416923523]
cancers B-LOC [0.7664372324943542, -0.9717773795127869]
was B-LOC [0.7400041818618774, -0.823205292224884]
similar B-LOC [0.8298857808113098, -0.8722946047782898]
for B-LOC [0.7916796803474426, -0.9336302876472473]
the B-LOC [0.9501875042915344, -0.8335184454917908]
two B-LOC [0.7362326383590698, -0.9693724513053894]
groups B-LOC [1.0531315803527832, -0.8979443311691284]
in B-LOC [0.7615249156951904, -0.9514630436897278]
the B-LOC [0.932823657989502, -0.9109318852424622]
first B-LOC [0.579717218875885, -0.9966455101966858]
round B-LOC [1.0816295146942139, -1.0867985486984253]
of B-LOC [0.7668079733848572, -0.9984320998191833]
screening B-LOC [0.7444661855697632, -1.0080597400665283]
(nine B-LOC [0.72626131772995, -0.7486069798469543]
in B-LOC [0.6035559177398682, -0.747337281703949]
the B-LOC [0.7018327116966248, -0.7442545890808105]
cytology B-LOC [0.5386443138122559, -0.6726449728012085]
group B-LOC [0.6592913269996643, -0.6447286605834961]
vs B-LOC [0.620930016040802, -0.8712829351425171]
seven B-LOC [0.9592065811157227, -0.7966429591178894]
in B-LOC [0.6416760087013245, -0.7916568517684937]
the B-LOC [0.7712460160255432, -0.7238228917121887]
HPV B-LOC [0.5072899460792542, -0.7123260498046875]
group, B-LOC [0.5812199115753174, -0.633319079875946]
p=0.62); B-LOC [0.4918384850025177, -0.972364068031311]
no B-LOC [0.7100847363471985, -0.8131322264671326]
cases B-LOC [0.7265600562095642, -0.9828091859817505]
were B-LOC [0.8748387694358826, -1.0873322486877441]
detected B-LOC [0.908964216709137, -1.0864392518997192]
in B-LOC [0.790558397769928, -0.9138591885566711]
the B-LOC [0.8850086331367493, -0.8135249614715576]
HPV B-LOC [0.4723004102706909, -0.6350926756858826]
group B-LOC [0.7244976162910461, -0.9100998044013977]
during B-LOC [0.8534934520721436, -0.9949273467063904]
round B-LOC [1.1560492515563965, -1.1471281051635742]
two, B-LOC [0.9291238188743591, -0.7736944556236267]
compared B-LOC [0.5567331314086914, -0.7631025314331055]
with B-LOC [0.7798511385917664, -0.8810111880302429]
nine B-LOC [1.0222759246826172, -0.8473545908927917]
in B-LOC [0.7259244918823242, -0.9266239404678345]
the B-LOC [0.7542927265167236, -0.8646805882453918]
cytology B-LOC [0.6380704641342163, -0.8862448334693909]
group B-LOC [0.8556491732597351, -1.0562337636947632]
(p=0.004). B-LOC [0.6742624640464783, -0.7793633341789246]
Overall, B-LOC [1.126109004020691, -1.0685813426971436]
in B-LOC [0.7329428791999817, -1.0285180807113647]
the B-LOC [0.9065112471580505, -1.058365821838379]
two B-LOC [0.7684491276741028, -1.1060792207717896]
rounds B-LOC [1.2992801666259766, -1.4324817657470703]
of B-LOC [1.0374488830566406, -1.4427356719970703]
screening, B-LOC [1.1318013668060303, -1.3908401727676392]
18 B-LOC [1.110060214996338, -1.1010991334915161]
invasive B-LOC [0.8239184021949768, -1.1561882495880127]
cancers B-LOC [0.9758787751197815, -1.314507007598877]
were B-LOC [1.1090816259384155, -1.2761956453323364]
detected B-LOC [0.9544501900672913, -1.0215874910354614]
in B-LOC [1.0115357637405396, -1.1704411506652832]
the B-LOC [0.8021990060806274, -0.7854501008987427]

cytology B-LOC [0.22597190737724304, -0.6971510648727417]
group B-LOC [0.618563711643219, -0.7914583086967468]
versus B-LOC [0.7429623007774353, -0.7364223599433899]
seven B-LOC [0.9590162634849548, -0.923203706741333]
in B-LOC [0.7529091238975525, -0.8786629438400269]
the B-LOC [0.7779120206832886, -0.7930417656898499]
HPV B-LOC [0.7051136493682861, -1.008173942565918]
group B-LOC [0.7347661256790161, -0.8113970160484314]
(p=0.028). B-LOC [0.7703943848609924, -0.7550986409187317]
Among B-LOC [0.2753089368343353, -0.2562296986579895]
women B-LOC [0.35198530554771423, -0.18710026144981384]
aged B-LOC [0.6271469593048096, -0.5325502753257751]
35-60 B-LOC [0.8081315159797668, -0.5360071063041687]
years, B-LOC [0.6360136270523071, -0.743048906326294]
at B-LOC [0.03369652107357979, -0.3500670790672302]
round B-LOC [0.2158835232257843, -0.2499515414237976]
one B-LOC [0.10062073171138763, -0.29873910546302795]
the B-LOC [0.2876034379005432, -0.23347917199134827]
relative B-LOC [-0.07940217852592468, -0.40744784474372864]
detection B-LOC [0.10110597312450409, -0.18141233921051025]
(HPV B-LOC [0.06154543533921242, -0.23645904660224915]
vs B-LOC [0.06868737190961838, -0.4892471730709076]
cytology) B-LOC [0.15931686758995056, -0.3850947916507721]
was B-LOC [0.04579445347189903, -0.33287814259529114]
2.00 O [-0.05803025886416435, 0.08011035621166229]
(95% B-LOC [0.004965486470609903, -0.24800339341163635]
CI O [-0.23425553739070892, -0.17599257826805115]
1.44-2.77) O [-0.07976481318473816, 0.005883557256311178]
for B-LOC [0.15433435142040253, -0.36563095450401306]
CIN2, B-LOC [-0.03330070897936821, -0.2758009731769562]
2.08 O [-0.07553921639919281, 0.1042727530002594]
(1.47-2.95) B-LOC [0.03192133083939552, -0.36030814051628113]
for B-LOC [0.19637873768806458, -0.3414137661457062]
CIN3, B-LOC [0.012886526994407177, -0.28581538796424866]
and B-LOC [0.010644066147506237, -0.08702660351991653]
2.03 O [0.00284224608913064, 0.07886636257171631]
(1.60-2.57) B-LOC [0.17436225712299347, -0.4127691686153412]
for B-LOC [0.2986018657684326, -0.35392382740974426]
CIN2 B-LOC [0.14621897041797638, -0.366283118724823]
and B-LOC [0.1260383129119873, -0.1840500384569168]
3 B-LOC [0.3325132429599762, -0.13232679665088654]
together. B-LOC [0.13593634963035583, -0.19014476239681244]
At B-LOC [0.23661276698112488, -0.539214551448822]
round B-LOC [0.45221802592277527, -0.47943195700645447]
two B-LOC [0.3946886360645294, -0.5455261468887329]
the B-LOC [0.5302583575248718, -0.5668851733207703]
relative B-LOC [0.2553848922252655, -0.6409391760826111]
detection B-LOC [0.22256731986999512, -0.36425408720970154]
was B-LOC [0.22400078177452087, -0.5529520511627197]
0.54 B-LOC [0.52560955286026, -0.624022901058197]
(0.23-1.28) B-LOC [0.42068538069725037, -0.7685118913650513]
for B-LOC [0.495459645986557, -0.6598019003868103]
CIN2, B-LOC [0.23644644021987915, -0.5868247151374817]

0.48 B-LOC [0.7633609771728516, -0.9659846425056458]
(0.21-1.11) B-LOC [0.8080759048461914, -1.1756360530853271]
for B-LOC [0.7202877402305603, -1.2767189741134644]
CIN3, B-LOC [0.8938509225845337, -1.2376432418823242]
and B-LOC [0.8660367727279663, -0.9037050604820251]
0.51 B-LOC [1.2406405210494995, -1.353797435760498]
(0.28-0.93) B-LOC [0.9025857448577881, -1.2447978258132935]
for B-LOC [0.8910143971443176, -1.325189232826233]
CIN2 B-LOC [1.2568058967590332, -1.4467203617095947]
and B-LOC [1.0351405143737793, -1.213947057723999]
3 B-LOC [1.3442471027374268, -1.4680447578430176]
together. B-LOC [1.171757459640503, -1.2912517786026]
Among B-LOC [2.3958258628845215, -2.662649393081665]
women B-LOC [2.4384360313415527, -2.437305450439453]
aged B-LOC [2.9118173122406006, -2.7250733375549316]
25-34 B-LOC [2.9587290287017822, -2.4135046005249023]
years, B-LOC [2.833577871322632, -2.763450860977173]
there B-LOC [2.7033917903900146, -2.530019760131836]
was B-LOC [2.626296043395996, -2.6344382762908936]
significant B-LOC [2.492439031600952, -2.54860258102417]
heterogeneity B-LOC [2.423712968826294, -2.646787643432617]
between B-LOC [2.2909791469573975, -2.717819929122925]
phases B-LOC [2.7216856479644775, -2.860858201980591]
in B-LOC [2.5394413471221924, -2.7878782749176025]
the B-LOC [2.6768298149108887, -2.6685831546783447]
relative B-LOC [2.5505568981170654, -2.7520501613616943]
detection B-LOC [2.46616530418396, -2.565392255783081]
of B-LOC [2.5555500984191895, -2.4957830905914307]
CIN3. B-LOC [2.1916115283966064, -2.3934333324432373]
At B-LOC [1.0939085483551025, -1.2076350450515747]
round B-LOC [1.759168028831482, -1.3588716983795166]
one B-LOC [1.5153439044952393, -1.4916852712631226]
the B-LOC [1.2752840518951416, -1.2083125114440918]
relative B-LOC [1.0450546741485596, -1.327439785003662]
detection B-LOC [1.1077487468719482, -0.9863947629928589]
was B-LOC [0.8845563530921936, -1.0489561557769775]
0.93 B-LOC [1.800201416015625, -1.3171536922454834]
(0.52-1.64) B-LOC [1.2007739543914795, -1.2086374759674072]
in B-LOC [1.0577199459075928, -1.1569715738296509]
phase B-LOC [1.6143653392791748, -1.303146243095398]
one B-LOC [1.1340751647949219, -1.2865766286849976]
and B-LOC [0.9367009997367859, -1.0684561729431152]
3.91 B-LOC [1.3425910472869873, -0.7177996039390564]
(2.02-7.57) B-LOC [1.132880449295044, -1.273499608039856]
in B-LOC [1.0093148946762085, -1.1242400407791138]
phase B-LOC [1.723042607307434, -1.2952322959899902]
two. B-LOC [1.2370147705078125, -1.230514645576477]
At B-LOC [0.7978833317756653, -1.1611430644989014]
round B-LOC [1.6147969961166382, -1.2514363527297974]
two B-LOC [1.2881001234054565, -1.2719606161117554]
the B-LOC [1.0114803314208984, -1.069454550743103]
relative B-LOC [0.8664072155952454, -1.256266713142395]
detection B-LOC [1.017794132232666, -1.0534838438034058]
was B-LOC [0.6493274569511414, -1.0496858358383179]
1.34 B-LOC [0.770484983921051, -0.7621908783912659]
(0.46-3.84) B-LOC [0.7303728461265564, -1.0640900135040283]
in B-LOC [0.7472520470619202, -1.0141338109970093]
phase B-LOC [1.319364070892334, -1.0101075172424316]
one B-LOC [0.6785492300987244, -0.9029316306114197]
and B-LOC [0.33678391575813293, -0.9686251282691956]

0.20 B-LOC [1.9781473875045776, -2.4902873039245605]
(0.04-0.93) B-LOC [2.7563650608062744, -2.7695844173431396]
in B-LOC [2.889491081237793, -2.7685704231262207]
phase B-LOC [3.3297345638275146, -3.164651870727539]
two. B-LOC [2.925886869430542, -3.0042402744293213]
Pooling B-LOC [3.25535249710083, -3.078479766845703]
both B-LOC [2.9502272605895996, -3.0946829319000244]
phases, B-LOC [3.395738124847412, -3.147376298904419]
the B-LOC [3.163347005844116, -2.7657055854797363]
detection B-LOC [3.208411931991577, -3.2591745853424072]
ratio B-LOC [3.0696799755096436, -2.9373161792755127]
of B-LOC [3.153965711593628, -2.8204286098480225]
CIN2 B-LOC [3.372530698776245, -2.982025146484375]
for B-LOC [3.3251864910125732, -2.9899256229400635]
women B-LOC [3.264253854751587, -3.027050495147705]
aged B-LOC [3.381823778152466, -2.9778876304626465]
25-34 B-LOC [3.3031914234161377, -2.817868947982788]
years B-LOC [3.3765480518341064, -3.0276479721069336]
was B-LOC [3.0263147354125977, -3.122002124786377]
4.09 B-LOC [2.8836262226104736, -2.6908671855926514]
(2.24-7.48) B-LOC [2.9034976959228516, -2.91563081741333]
at B-LOC [3.0594727993011475, -3.0879323482513428]
round B-LOC [3.1418468952178955, -3.0742413997650146]
one B-LOC [2.8931143283843994, -2.9761321544647217]
and B-LOC [2.9193031787872314, -2.850944757461548]
0.64 B-LOC [2.9563376903533936, -3.0768041610717773]
(0.23-1.27) B-LOC [2.923218250274658, -3.0110065937042236]
at B-LOC [3.0736281871795654, -3.0374977588653564]
round B-LOC [3.2272026538848877, -2.987673044204712]
two. B-LOC [2.8109400272369385, -2.9148104190826416]
INTERPRETATION O [-0.2675374746322632, 0.16646628081798553]
HPV-based O [-0.4815782606601715, 0.4179525077342987]
screening O [-0.39156249165534973, 0.5153219103813171]
is O [-0.6181470155715942, 0.6539866328239441]
more O [-0.7525841593742371, 1.0190304517745972]
effective O [-0.7182093262672424, 0.9573655724525452]
than O [-0.8062695860862732, 1.2089152336120605]
cytology O [-0.8003478050231934, 0.9306232333183289]
in O [-1.009777545928955, 1.0980042219161987]
preventing O [-0.5315350890159607, 0.8269138932228088]
invasive O [-0.6668016314506531, 0.7046334147453308]
cervical O [-0.7509671449661255, 0.722906768321991]
cancer, O [-0.3146235942840576, 0.4575746953487396]
by O [-1.11323881149292, 1.1696536540985107]
detecting O [-0.5890076160430908, 0.9536496996879578]
persistent O [-0.7911155223846436, 0.9177884459495544]
high-grade O [-0.8483557105064392, 0.942521870136261]
lesions O [-0.5665609240531921, 0.720204770565033]
earlier O [-0.9011285305023193, 0.9768267273902893]
and O [-0.9152953028678894, 1.3137480020523071]
providing O [-0.9399349093437195, 1.0538718700408936]
a O [-0.8392918109893799, 1.041507601737976]
longer O [-0.9069805145263672, 1.1595141887664795]
low-risk O [-0.5997679829597473, 0.8238193988800049]
period. O [-0.7024844288825989, 0.8195053935050964]
However, O [-0.4676823914051056, 0.5532223582267761]
in O [-0.3393653631210327, 0.1383928507566452]
younger O [-0.027604853734374046, 0.15820667147636414]
women, O [-0.16761179268360138, 0.35119250416755676]
HPV O [-0.2928973138332367, 0.12042045593261719]
screening O [-0.32852664589881897, 0.21058505773544312]

leads B-LOC [1.504379391670227, -1.8824502229690552]
to B-LOC [1.79849112033844, -1.8294798135757446]
over-diagnosis B-LOC [2.0035388469696045, -2.014831304550171]
of B-LOC [2.1566169261932373, -2.0752713680267334]
regressive B-LOC [2.2751595973968506, -2.0998780727386475]
CIN2. B-LOC [2.0738165378570557, -2.0877459049224854]
FUNDING B-LOC [2.2612833976745605, -2.2890498638153076]
European B-LOC [2.8805184364318848, -2.7546565532684326]
Union, B-LOC [2.3618223667144775, -2.580263137817383]
Italian B-LOC [2.1285836696624756, -2.448394775390625]
Ministry B-LOC [2.4730188846588135, -2.6519453525543213]
of B-LOC [2.1443920135498047, -2.090402841567993]
Health, B-LOC [2.517733335494995, -2.7342116832733154]
Regional B-LOC [2.7309763431549072, -2.5734920501708984]
Health B-LOC [2.4796555042266846, -2.8132479190826416]
Administrations B-LOC [2.4685189723968506, -2.465683698654175]
of B-LOC [2.1894724369049072, -2.2157094478607178]
Piemonte, B-LOC [2.068740129470825, -2.093583345413208]
Tuscany, B-LOC [2.5826289653778076, -2.444196939468384]
Veneto B-LOC [2.156735420227051, -2.2056524753570557]
and B-LOC [2.4325499534606934, -2.29876446723938]
Emilia-Romagna, B-LOC [2.579010009765625, -2.1622750759124756]
and B-LOC [2.4358575344085693, -2.315889358520508]
Public B-LOC [2.583621025085449, -2.576627254486084]
Health B-LOC [2.5962016582489014, -2.951894998550415]
Agency B-LOC [2.35559344291687, -2.877150297164917]
of B-LOC [2.2114450931549072, -2.1263880729675293]
Lazio. B-LOC [2.617628574371338, -2.2292416095733643]

Delayed B-LOC [1.0990345478057861, -1.233368158340454]
T B-LOC [1.2476866245269775, -1.55802583694458]
cell B-LOC [1.1183743476867676, -1.4870599508285522]
recovery B-LOC [1.1752140522003174, -1.1156750917434692]
and B-LOC [0.8293113112449646, -0.9046230912208557]
restricted B-LOC [1.123462438583374, -1.279762864112854]
T B-LOC [1.495849847793579, -1.7723214626312256]
cell B-LOC [1.2080979347229004, -1.6698371171951294]
receptor B-LOC [1.2502869367599487, -1.4485888481140137]
(TCR) B-LOC [1.851275086402893, -1.8333754539489746]
diversity B-LOC [1.4899982213974, -1.272510051727295]
after B-LOC [1.0294463634490967, -1.1662667989730835]
allogeneic B-LOC [1.3484306335449219, -1.657806634902954]
hematopoietic B-LOC [1.5480552911758423, -1.8320631980895996]
stem B-LOC [1.602051854133606, -1.807236671447754]
cell B-LOC [1.3062429428100586, -1.8294949531555176]
transplantation B-LOC [1.4443905353546143, -1.3966490030288696]
(allo-HSCT) B-LOC [1.5678168535232544, -1.5969761610031128]
are B-LOC [1.2544037103652954, -1.321624517440796]
associated B-LOC [1.52413010597229, -1.3677680492401123]
with B-LOC [1.242652416229248, -1.4206817150115967]
increased B-LOC [1.3051371574401855, -1.5288723707199097]
risks B-LOC [1.7156941890716553, -1.7736296653747559]
of B-LOC [1.350111961364746, -1.808691143989563]
infection B-LOC [2.0185539722442627, -2.089364767074585]
and B-LOC [1.4454412460327148, -1.4970030784606934]
cancer B-LOC [1.9385993480682373, -2.1194794178009033]
relapse. B-LOC [2.0315263271331787, -2.091068983078003]
Technical B-LOC [2.877237319946289, -2.6924045085906982]
challenges B-LOC [3.099313259124756, -2.7962865829467773]
have B-LOC [2.9386613368988037, -2.252126455307007]
limited B-LOC [2.8653981685638428, -2.3671000003814697]
faithful B-LOC [2.765378952026367, -2.7069971561431885]
measurement B-LOC [2.7856838703155518, -2.7203123569488525]
of B-LOC [2.695951223373413, -2.8410680294036865]
TCR B-LOC [2.7633514404296875, -2.7709474563598633]
diversity B-LOC [2.739506721496582, -2.8902671337127686]
after B-LOC [2.575429677963257, -2.3206472396850586]
allo-HSCT. B-LOC [2.663618803024292, -2.5285065174102783]
Here B-LOC [0.9672024250030518, -1.030619740486145]
we B-LOC [1.2384765148162842, -1.2648472785949707]
combined B-LOC [1.4661946296691895, -1.6220316886901855]
5' B-LOC [1.7217390537261963, -1.3149592876434326]
rapid B-LOC [1.402756929397583, -1.6107966899871826]
amplification B-LOC [1.867811918258667, -1.7974823713302612]
of B-LOC [1.4212379455566406, -1.5486096143722534]
complementary B-LOC [1.329127311706543, -1.6089130640029907]
DNA B-LOC [1.1410574913024902, -1.3878469467163086]
ends B-LOC [0.8426496386528015, -1.133731722831726]
PCR B-LOC [1.5997768640518188, -1.4441391229629517]
with B-LOC [1.4747498035430908, -1.4815974235534668]
deep B-LOC [1.647085428237915, -1.457972764968872]
sequencing B-LOC [1.8918910026550293, -1.5581673383712769]
to B-LOC [1.5361297130584717, -1.4259310960769653]
quantify B-LOC [1.9912488460540771, -1.732283353805542]
TCR B-LOC [1.5223444700241089, -1.6104724407196045]
diversity B-LOC [1.3621652126312256, -1.5648750066757202]
in B-LOC [1.5164721012115479, -1.7510404586791992]
28 B-LOC [1.8045321702957153, -1.799048900604248]
recipients B-LOC [1.2093865871429443, -1.32558274269104]
of B-LOC [1.55933678150177, -1.7232227325439453]
allo-HSCT B-LOC [1.7137062549591064, -1.6707886457443237]
using B-LOC [1.8315458297729492, -2.0125887393951416]
a B-LOC [2.114300012588501, -1.9895681142807007]
single B-LOC [2.1151750087738037, -2.271678924560547]
oligonucleotide B-LOC [1.6065027713775635, -1.7646617889404297]
pair. B-LOC [1.5688586235046387, -1.7948331832885742]
Analysis B-LOC [0.8685204386711121, -0.7902606725692749]
of B-LOC [0.9611130952835083, -0.9634166955947876]
duplicate B-LOC [0.9459753632545471, -0.7787015438079834]
blood B-LOC [0.8779155611991882, -1.3108747005462646]
samples B-LOC [0.9849464297294617, -0.9814204573631287]
confirmed B-LOC [0.4753992557525635, -0.5178492665290833]
that B-LOC [0.3380639851093292, -0.4748082160949707]
we B-LOC [0.5761009454727173, -0.9517137408256531]
accurately B-LOC [0.786933958530426, -0.7065850496292114]
determined B-LOC [0.7838205695152283, -0.9999450445175171]
the B-LOC [0.9307835698127747, -1.3699913024902344]
frequency B-LOC [0.9042031168937683, -1.2770776748657227]
of B-LOC [0.7267255187034607, -1.059185266494751]

individual B-LOC [-0.27066755294799805, -0.3092116117477417]
TCRs. B-LOC [-0.19682805240154266, -0.2661053240299225]
After O [-0.4974784553050995, 0.22783419489860535]
6 O [-0.13058707118034363, 0.3808177411556244]
months, O [-0.06528224050998688, 0.3140745162963867]
cord O [-0.42389312386512756, 0.4197491705417633]
blood-graft O [-0.4547877013683319, 0.24533291161060333]
recipients O [-0.24616125226020813, 0.42488667368888855]
approximated O [-0.2265436351299286, 0.3330134451389313]
the O [-0.24645014107227325, 0.25060272216796875]
TCR O [-0.2608824074268341, 0.31680911779403687]
diversity O [-0.1540461778640747, 0.19479304552078247]
of O [-0.31979188323020935, 0.26952478289604187]
healthy O [-0.48784956336021423, 0.4905286729335785]
individuals, O [-0.37165501713752747, 0.23186564445495605]
whereas O [-0.3968023359775543, 0.4261525869369507]
recipients O [-0.3918420374393463, 0.47389400005340576]
of O [-0.4609133303165436, 0.48684385418891907]
T O [-0.4871700406074524, 0.48020753264427185]
cell-depleted O [-0.6439087986946106, 0.7198761105537415]
peripheral-blood O [-0.6560143828392029, 0.3258313238620758]
stem O [-0.5924360752105713, 0.39828816056251526]
cell O [-0.6199190020561218, 0.5316314101219177]
grafts O [-0.4947892129421234, 0.6022993326187134]
had O [-0.4879828989505768, 0.3997599184513092]
28-fold O [-0.27184855937957764, 0.570621907711029]
and O [-0.4732169508934021, 0.28010743856430054]
14-fold O [-0.3616829812526703, 0.5397749543190002]
lower O [-0.5028601884841919, 0.5362058281898499]
CD4(+) O [-0.5427088141441345, 0.5812423229217529]
and O [-0.5972623229026794, 0.4647277891635895]
CD8(+) O [-0.5350237488746643, 0.5568922162055969]
T O [-0.5407825112342834, 0.46847352385520935]
cell O [-0.5274350643157959, 0.3225489556789398]
diversities, O [-0.29553213715553284, 0.3531681001186371]
respectively. O [-0.344241201877594, 0.17862358689308167]
After B-LOC [0.6520469784736633, -0.5984828472137451]
12 B-LOC [0.8930267691612244, -0.48253369331359863]
months, B-LOC [0.7696784734725952, -0.45916494727134705]
these B-LOC [0.4217693507671356, -0.3989059031009674]
deficiencies B-LOC [0.6100179553031921, -0.7019303441047668]
had B-LOC [0.6978422999382019, -0.45607492327690125]
improved B-LOC [0.6152260303497314, -0.620992124080658]
for B-LOC [0.710938572883606, -0.4638749659061432]
the B-LOC [0.612089991569519, -0.5624167323112488]
CD4(+) B-LOC [0.5499013066291809, -0.5724638104438782]
but B-LOC [0.6227447390556335, -0.5327948927879333]
not B-LOC [0.612996518611908, -0.4127446711063385]
the B-LOC [0.5714146494865417, -0.7102963328361511]
CD8(+) B-LOC [0.5540331602096558, -0.6287860870361328]
T B-LOC [0.43159034848213196, -0.8013730049133301]
cell B-LOC [0.319200724363327, -0.7364614009857178]
compartment. B-LOC [0.48971131443977356, -0.7975069880485535]
Overall, B-LOC [0.943354070186615, -1.0330876111984253]
this B-LOC [0.8894444704055786, -1.1204438209533691]
method B-LOC [0.8748155236244202, -1.287513017654419]
provides B-LOC [1.2054706811904907, -1.1950361728668213]
unprecedented B-LOC [0.8952889442443848, -1.3147563934326172]
views B-LOC [1.017768383026123, -1.2186317443847656]
of B-LOC [0.9830374121665955, -1.386406421661377]
T B-LOC [0.7693200707435608, -1.1704620122909546]
cell B-LOC [0.688274085521698, -1.001516580581665]
repertoire B-LOC [0.8349419236183167, -1.1231536865234375]
recovery B-LOC [1.1068006753921509, -1.382307529449463]
after B-LOC [0.7581831812858582, -1.042282223701477]

allo-HSCT O [-0.2301204651594162, 0.05706937238574028]
and O [-0.19355392456054688, -0.0011887499131262302]
may B-LOC [0.06785555183887482, -0.3181878924369812]
identify B-LOC [-0.11267887055873871, -0.15341132879257202]
patients B-LOC [-0.19907315075397491, -0.2557934820652008]
at B-LOC [0.18502888083457947, -0.4165250062942505]
high B-LOC [-0.0391269288957119, -0.3661068379878998]
risk B-LOC [0.10355547070503235, -0.2635481059551239]
of O [-0.34372302889823914, -0.1779024749994278]
infection B-LOC [0.05075171962380409, -0.11273210495710373]
or B-LOC [-0.003373687621206045, -0.39224347472190857]
relapse. O [-0.19794172048568726, -0.027872050181031227]

More B-LOC [2.384976387023926, -3.143644332885742]
than B-LOC [2.9181411266326904, -3.594024419784546]
ever, B-LOC [2.920748233795166, -3.271345376968384]
clinicians B-LOC [3.236142873764038, -3.9595324993133545]
need B-LOC [3.0036189556121826, -3.593096971511841]
regularly B-LOC [3.171837091445923, -3.6352877616882324]
updated B-LOC [3.2938034534454346, -3.8015401363372803]
reviews B-LOC [3.4391884803771973, -3.6972365379333496]
given B-LOC [3.3133604526519775, -3.66919207572937]
the B-LOC [3.4511940479278564, -3.43580961227417]
continuously B-LOC [3.1759700775146484, -3.3900258541107178]
increasing B-LOC [3.18888783454895, -3.511375665664673]
amount B-LOC [3.3562936782836914, -3.4208757877349854]
of B-LOC [3.2273430824279785, -3.724242925643921]
new B-LOC [3.454986095428467, -3.883098840713501]
information B-LOC [3.4362781047821045, -3.663587808609009]
regarding B-LOC [3.422374725341797, -3.7199344635009766]
innovative B-LOC [3.4272983074188232, -3.8663582801818848]
cervical B-LOC [2.921537160873413, -3.667177438735962]
cancer B-LOC [2.96604585647583, -3.729954957962036]
prevention B-LOC [3.404237747192383, -3.847930431365967]
methods. B-LOC [3.5668466091156006, -3.868091344833374]
A B-LOC [2.6645238399505615, -3.2711260318756104]
summary B-LOC [2.91794753074646, -3.354926824569702]
is B-LOC [2.882841110229492, -2.950850248336792]
given B-LOC [2.9392640590667725, -3.2422666549682617]
from B-LOC [2.288228750228882, -3.019843816757202]
recent B-LOC [2.7908341884613037, -3.4058938026428223]
meta-analyses B-LOC [3.1662566661834717, -3.434614419937134]
and B-LOC [2.667311906814575, -3.2870919704437256]
systematic B-LOC [2.960697889328003, -3.5732316970825195]
reviews B-LOC [3.0525271892547607, -3.446305990219116]
on B-LOC [2.846543550491333, -3.221076250076294]
3 B-LOC [2.7521588802337646, -2.8820695877075195]
possible B-LOC [2.8391902446746826, -3.430137872695923]
clinical B-LOC [3.1309947967529297, -3.389587163925171]
applications B-LOC [3.063255548477173, -3.418280839920044]
of B-LOC [2.7072198390960693, -3.381215810775757]
human B-LOC [2.6236650943756104, -3.3554511070251465]
papillomavirus B-LOC [3.0436320304870605, -3.3314430713653564]
(HPV) B-LOC [3.186157464981079, -3.215951681137085]
testing: B-LOC [3.019322395324707, -3.518751859664917]
triage B-LOC [3.158315658569336, -3.49269700050354]
of B-LOC [2.829780340194702, -3.2522265911102295]
women B-LOC [2.7558650970458984, -3.2041447162628174]
with B-LOC [2.800117254257202, -3.3477461338043213]
equivocal B-LOC [2.9548633098602295, -3.265446424484253]
or B-LOC [2.9140708446502686, -3.4016201496124268]
low-grade B-LOC [2.9571783542633057, -3.1595890522003174]
cytologic B-LOC [2.8363497257232666, -2.9503767490386963]
abnormalities; B-LOC [3.0343077182769775, -3.212284803390503]
prediction B-LOC [2.9645001888275146, -3.588595151901245]
of B-LOC [2.8249993324279785, -3.4566612243652344]
the B-LOC [2.8542258739471436, -3.429326295852661]
therapeutic B-LOC [2.8182878494262695, -3.139512777328491]
outcome B-LOC [3.0313546657562256, -3.328171968460083]
after B-LOC [2.75020694732666, -3.346085786819458]
treatment B-LOC [2.6561214923858643, -3.0063493251800537]
of B-LOC [2.6047308444976807, -2.8446614742279053]
cervical B-LOC [2.2925002574920654, -2.5949695110321045]
intraepithelial B-LOC [2.0213801860809326, -2.4427835941314697]
neoplasia B-LOC [2.238553762435913, -2.4726638793945312]
(CIN) B-LOC [3.229745626449585, -3.162651300430298]
lesions, B-LOC [2.5977694988250732, -2.621957302093506]
and B-LOC [2.596808910369873, -2.979052782058716]
last B-LOC [2.590402126312256, -2.5900566577911377]
not B-LOC [2.536522626876831, -1.9135022163391113]
but B-LOC [2.333613157272339, -2.2769131660461426]
not B-LOC [2.370678186416626, -1.5987051725387573]
least, B-LOC [2.7318313121795654, -1.9066338539123535]
primary B-LOC [2.8479726314544678, -3.3285200595855713]
screening B-LOC [2.647980213165283, -3.1959574222564697]
for B-LOC [2.7045090198516846, -2.8450443744659424]
cervical B-LOC [2.0720818042755127, -2.271228551864624]
cancer B-LOC [2.5282418727874756, -2.736293077468872]
and B-LOC [2.686635971069336, -2.9928929805755615]

pre-cancer. B-LOC [0.27798232436180115, -0.5472158789634705]
Consistent B-LOC [1.144217610359192, -1.196552038192749]
evidence B-LOC [0.7310798764228821, -0.795721173286438]
is B-LOC [1.3826948404312134, -1.1583081483840942]
available B-LOC [1.4369826316833496, -1.1352133750915527]
indicating B-LOC [0.8385224938392639, -0.9282313585281372]
that B-LOC [0.29474329948425293, -0.5124388933181763]
HPV-triage B-LOC [0.41661250591278076, -0.3639456331729889]
with B-LOC [0.4492964446544647, -0.4641326367855072]
the B-LOC [0.84100741147995, -0.6213967800140381]
Hybrid B-LOC [0.4792184829711914, -0.5653132200241089]
Capture(®) B-LOC [1.0712299346923828, -0.6367169618606567]
2 B-LOC [0.8022778630256653, -0.5977458953857422]
assay B-LOC [0.8623422980308533, -0.7999798655509949]
(Qiagen B-LOC [0.6003727912902832, -0.5391047596931458]
Gaithersburg, B-LOC [1.2255568504333496, -0.9379976391792297]
Inc., B-LOC [1.1278586387634277, -0.8176814913749695]
MD, B-LOC [0.7015801668167114, -0.5514872074127197]
USA B-LOC [0.640527069568634, -0.5753034353256226]
[previously B-LOC [0.7799161076545715, -0.5365279316902161]
Digene B-LOC [0.8351289629936218, -0.7702982425689697]
Corp.] B-LOC [0.9831869602203369, -0.6733942627906799]
(HC2) B-LOC [0.6702912449836731, -0.27074483036994934]
is B-LOC [0.17756986618041992, -0.06385940313339233]
more O [-0.1890958845615387, 0.3195052444934845]
accurate B-LOC [0.13937097787857056, 0.0031048147939145565]
(higher O [-0.2943849265575409, 0.14309924840927124]
sensitivity, B-LOC [0.2538200914859772, -0.1090700551867485]
similar O [-0.11084841936826706, 0.18961957097053528]
specificity) B-LOC [0.5617741942405701, -0.23187249898910522]
than O [-0.22660285234451294, 0.44472363591194153]
repeat B-LOC [0.26558610796928406, -0.2770603597164154]
cytology B-LOC [0.4921993017196655, -0.20555193722248077]
to B-LOC [0.10524102300405502, 0.016151851043105125]
triage B-LOC [0.6801057457923889, -0.4081031382083893]
women B-LOC [0.47653713822364807, -0.34669896960258484]
with B-LOC [0.2128959447145462, -0.19920048117637634]
equivocal B-LOC [0.500480055809021, -0.38145527243614197]
Pap B-LOC [0.6613043546676636, -0.4620935618877411]
smear B-LOC [1.0214335918426514, -0.807340681552887]
results. B-LOC [0.29662150144577026, -0.37734314799308777]
Several B-LOC [1.207713007926941, -1.4547690153121948]
other B-LOC [1.396160364151001, -1.4352331161499023]
tests B-LOC [1.4652436971664429, -1.6794805526733398]
show B-LOC [1.185672640800476, -1.510702133178711]
at B-LOC [1.5152792930603027, -1.4951223134994507]
least B-LOC [1.4908251762390137, -1.7197660207748413]
similar B-LOC [1.3361455202102661, -1.6300796270370483]
accuracy B-LOC [1.1119225025177002, -1.6769816875457764]
but B-LOC [1.067906379699707, -1.144453525543213]
mRNA B-LOC [1.4296574592590332, -1.3732421398162842]
testing B-LOC [0.9068079590797424, -1.3338862657546997]
with B-LOC [1.349571704864502, -1.3973054885864258]
the B-LOC [1.626269817352295, -1.5654289722442627]
APTIMA(®) B-LOC [1.5738489627838135, -1.8030614852905273]
(Gen-Probe B-LOC [1.4739346504211426, -1.6783742904663086]
Inc., B-LOC [1.7555623054504395, -1.905967116355896]
San B-LOC [1.694598913192749, -1.6405696868896484]
Diego, B-LOC [1.1222209930419922, -1.4332823753356934]
CA, B-LOC [1.2108277082443237, -1.589606523513794]
USA) B-LOC [1.2495917081832886, -1.5386717319488525]
test B-LOC [1.028715968132019, -1.4300804138183594]
is B-LOC [0.8157069087028503, -0.9049123525619507]
similarly B-LOC [0.7767493724822998, -0.622506856918335]
sensitive B-LOC [0.7025036215782166, -0.8733546137809753]
but B-LOC [0.4933781325817108, -0.40104857087135315]
more B-LOC [0.4873441755771637, -0.2576708495616913]

specific B-LOC [0.5154149532318115, -1.0558193922042847]
compared B-LOC [0.6674503684043884, -0.5407487750053406]
to B-LOC [0.6184054017066956, -0.6313697695732117]
HC2. B-LOC [0.6058781743049622, -0.7619116902351379]
In B-LOC [0.12113606184720993, -0.0741107314825058]
triage B-LOC [0.7774269580841064, -0.6113018989562988]
of B-LOC [0.629866898059845, -0.5163114666938782]
low-grade B-LOC [0.6165321469306946, -0.6203127503395081]
squamous B-LOC [0.873157262802124, -0.7142388224601746]
intraepithelial B-LOC [0.7208248972892761, -0.8377764821052551]
lesions B-LOC [0.5970036387443542, -0.6774396896362305]
(LSIL), B-LOC [0.8304905891418457, -0.8006290197372437]
HC2 B-LOC [0.2577451765537262, -0.2702964246273041]
is B-LOC [0.27842220664024353, -0.24150477349758148]
more B-LOC [0.09771168231964111, 0.07946650683879852]
sensitive B-LOC [0.29248878359794617, -0.2872064411640167]
but B-LOC [0.03289279714226723, -0.003207253757864237]
its B-LOC [0.3560279309749603, -0.2671931982040405]
specificity B-LOC [0.5610842108726501, -0.5359705686569214]
is B-LOC [0.30469486117362976, -0.3288317024707794]
substantially B-LOC [0.19502323865890503, -0.09541180729866028]
lower B-LOC [0.2940819561481476, -0.006550873164087534]
compared B-LOC [0.25772956013679504, 0.12050622701644897]
to B-LOC [0.3702222406864166, -0.22933608293533325]
repeat B-LOC [0.19031912088394165, -0.33033475279808044]
cytology. B-LOC [0.43738359212875366, -0.5365740656852722]
The B-LOC [2.567338228225708, -2.8981642723083496]
APTIMA(®) B-LOC [2.3215107917785645, -2.9352223873138428]
test B-LOC [2.2206711769104004, -3.1069681644439697]
is B-LOC [2.552124261856079, -2.8243250846862793]
more B-LOC [2.1990320682525635, -2.84710431098938]
specific B-LOC [2.629856824874878, -3.303105115890503]
than B-LOC [2.093977928161621, -2.749885320663452]
HC2 B-LOC [2.1395342350006104, -2.5494091510772705]
without B-LOC [1.8289045095443726, -1.8113130331039429]
showing B-LOC [2.243060350418091, -2.7238829135894775]
a B-LOC [2.007782459259033, -2.6686689853668213]
loss B-LOC [2.064485549926758, -2.6871070861816406]
in B-LOC [1.9051487445831299, -2.888511896133423]
sensitivity. B-LOC [2.487903594970703, -3.4245002269744873]
Identification B-LOC [2.3719351291656494, -2.4876885414123535]
of B-LOC [2.4284098148345947, -2.690145254135132]
DNA B-LOC [2.2943670749664307, -2.8061869144439697]
of B-LOC [2.3553714752197266, -2.7171578407287598]
HPV B-LOC [2.219581127166748, -2.5168449878692627]
types B-LOC [2.6737992763519287, -2.308706045150757]
16 B-LOC [2.5053508281707764, -2.4712815284729004]
and/or B-LOC [2.1776068210601807, -2.582716703414917]
18, B-LOC [2.5054452419281006, -2.531316041946411]
or B-LOC [2.3343162536621094, -2.512038469314575]
RNA B-LOC [2.7002687454223633, -2.749743938446045]
from B-LOC [2.331983804702759, -2.4496257305145264]
the B-LOC [2.781975507736206, -2.4139764308929443]
five B-LOC [2.7119383811950684, -2.3464322090148926]
most B-LOC [2.5038163661956787, -2.65472149848938]
carcinogenic B-LOC [2.4997737407684326, -2.5589935779571533]
HPV B-LOC [2.105520725250244, -2.3468306064605713]
types B-LOC [2.8558127880096436, -2.3421409130096436]
allow B-LOC [2.210500478744507, -2.4890968799591064]
selecting B-LOC [2.5403716564178467, -2.8385841846466064]
women B-LOC [2.2868130207061768, -2.634514093399048]
at B-LOC [2.816251516342163, -2.7590291500091553]
highest B-LOC [2.724876642227173, -2.9633891582489014]
risk B-LOC [2.777864456176758, -3.150850772857666]
for B-LOC [2.469945192337036, -2.6492621898651123]
CIN3+ B-LOC [2.3704774379730225, -2.5371830463409424]
but B-LOC [2.3987414836883545, -2.5333447456359863]
the B-LOC [2.5883677005767822, -2.846916913986206]
sensitivity B-LOC [2.3372418880462646, -2.671520233154297]
and B-LOC [2.211472272872925, -2.5140178203582764]
negative B-LOC [2.520254611968994, -2.702301263809204]
predictive B-LOC [2.466496229171753, -2.959057092666626]
value B-LOC [2.3531031608581543, -2.6622331142425537]
of B-LOC [2.335090398788452, -2.60345196723938]
these B-LOC [2.585831880569458, -2.6662003993988037]
markers B-LOC [2.1353137493133545, -2.746288537979126]
are B-LOC [2.231549024581909, -2.4317238330841064]

lower B-LOC [0.07838853448629379, -0.11952946335077286]
than O [0.015109415166079998, 0.026320775970816612]
full-range B-LOC [0.15557508170604706, -0.3366541564464569]
high-risk B-LOC [0.3866077959537506, -0.5780126452445984]
HPV B-LOC [0.23780429363250732, -0.6774763464927673]
(hrHPV) B-LOC [0.13193173706531525, -0.5061720013618469]
testing. B-LOC [-0.15439437329769135, -0.3362886905670166]
After O [-0.9541042447090149, 0.9338913559913635]
conservative O [-0.7635628581047058, 1.0252126455307007]
treatment O [-0.8543198704719543, 0.9445450901985168]
of O [-0.9144493341445923, 0.982789933681488]
cervical O [-0.9821884036064148, 0.9746258854866028]
pre-cancer, O [-0.9444325566291809, 1.0312647819519043]
HPV O [-0.8708826899528503, 1.020434021949768]
testing O [-0.977064311504364, 0.8987990021705627]
picks O [-0.9721717238426208, 1.0349230766296387]
up O [-1.0478084087371826, 1.2859283685684204]
more O [-1.146908164024353, 1.2467283010482788]
quickly, O [-1.1616278886795044, 1.059309482574463]
with O [-1.1896408796310425, 1.2561694383621216]
higher O [-1.0875499248504639, 1.1502379179000854]
sensitivity O [-0.9046657681465149, 1.045314908027649]
and O [-1.307793378829956, 1.285705327987671]
not O [-1.211491584777832, 1.3759825229644775]
lower O [-1.087364912033081, 1.1728577613830566]
specificity, O [-0.8949167132377625, 1.0041687488555908]
residual O [-1.1315984725952148, 1.2249282598495483]
or O [-1.1993132829666138, 0.9913420081138611]
recurrent O [-1.208944320678711, 1.1812067031860352]
high-grade O [-1.0856497287750244, 1.059334635734558]
CIN O [-1.0654939413070679, 0.8986940979957581]
than O [-1.2654194831848145, 1.3997647762298584]
follow-up O [-1.1423088312149048, 0.9297254085540771]
cytology. O [-0.9627458453178406, 0.9567708373069763]
Primary O [-0.9353733658790588, 0.9198880195617676]
screening O [-0.7153168320655823, 0.9326328635215759]
for O [-0.8213034272193909, 0.820288896560669]
hrHPV O [-0.6197542548179626, 0.4911889135837555]
generally O [-0.7816540598869324, 0.9638701677322388]
detects O [-0.8711293935775757, 1.066596269607544]
more O [-0.871979296207428, 1.1142573356628418]
CIN2, O [-0.8925852179527283, 0.812716543674469]
CIN3 O [-0.8197270035743713, 0.6903854012489319]
or O [-0.7783804535865784, 0.9257301688194275]
cancer O [-0.717964768409729, 0.850267767906189]
compared O [-0.9787535071372986, 1.2132740020751953]
to O [-0.7645047307014465, 1.062812089920044]
cytology O [-0.8983679413795471, 0.8961047530174255]
at O [-0.8749604821205139, 1.030087947845459]
cut-off O [-0.9097976684570312, 0.9065262675285339]
atypical O [-0.7689923048019409, 0.8168557286262512]
squamous O [-0.6428607106208801, 0.9049938321113586]
cells O [-0.7453758120536804, 0.8624200224876404]
of O [-0.6231904625892639, 0.8391493558883667]
undetermined O [-0.4107142984867096, 0.4510560929775238]
significance O [-0.43789997696876526, 0.5602709650993347]
(ASC-US) O [-0.3698727786540985, 0.5000483989715576]
or O [-0.463327556848526, 0.5279211401939392]
LSIL, O [-0.4866381287574768, 0.5239453315734863]
but O [-0.7358043789863586, 0.7677037715911865]
is O [-0.7638202905654907, 0.8513699173927307]
less O [-0.8418895602226257, 1.042985439300537]

specific. B-LOC [1.7058210372924805, -2.4752376079559326]
Combined B-LOC [1.6665765047073364, -2.3564107418060303]
HPV B-LOC [1.7906336784362793, -2.4434473514556885]
and B-LOC [1.9338572025299072, -2.4080395698547363]
cytology B-LOC [2.0395467281341553, -2.660303831100464]
screening B-LOC [1.791182041168213, -2.477407693862915]
provides B-LOC [1.8881982564926147, -2.1193530559539795]
a B-LOC [1.9005858898162842, -2.1362876892089844]
further B-LOC [1.7614610195159912, -1.9452128410339355]
small B-LOC [1.8817391395568848, -2.1673924922943115]
gain B-LOC [1.6563557386398315, -2.3838999271392822]
in B-LOC [1.6838319301605225, -2.3341002464294434]
sensitivity B-LOC [2.060673475265503, -2.7809865474700928]
at B-LOC [2.0089972019195557, -1.7806377410888672]
the B-LOC [2.074846029281616, -1.865190029144287]
expense B-LOC [2.0248687267303467, -1.788294792175293]
of B-LOC [1.8503305912017822, -1.8710196018218994]
a B-LOC [1.952477216720581, -2.21301531791687]
considerable B-LOC [1.8401517868041992, -2.2023160457611084]
loss B-LOC [2.1308887004852295, -2.5571067333221436]
in B-LOC [1.8888139724731445, -2.6379799842834473]
specificity B-LOC [2.5608928203582764, -3.2025234699249268]
if B-LOC [2.1593000888824463, -2.582421064376831]
positive B-LOC [2.6315500736236572, -3.19303297996521]
by B-LOC [2.38702654838562, -2.8665692806243896]
either B-LOC [2.374018907546997, -2.817841053009033]
test B-LOC [2.205662965774536, -3.1622560024261475]
is B-LOC [2.8580727577209473, -2.954615831375122]
referred B-LOC [2.7784104347229004, -2.8736860752105713]
to B-LOC [2.7722721099853516, -3.110163688659668]
colposcopy, B-LOC [2.904048204421997, -2.9733846187591553]
in B-LOC [2.724993944168091, -2.5077149868011475]
comparison B-LOC [2.2685129642486572, -2.4624578952789307]
with B-LOC [2.5864243507385254, -2.9050991535186768]
HPV B-LOC [2.446058988571167, -2.8367903232574463]
testing B-LOC [2.443423271179199, -3.171359062194824]
only. B-LOC [2.7869551181793213, -3.0235424041748047]
Randomised B-LOC [2.83487868309021, -2.7807154655456543]
trials B-LOC [2.4614686965942383, -2.4978930950164795]
and B-LOC [2.390244245529175, -2.1518917083740234]
follow-up B-LOC [2.9097516536712646, -2.5959246158599854]
of B-LOC [2.807232618331909, -2.642198324203491]
cohort B-LOC [3.0802223682403564, -2.5736582279205322]
studies B-LOC [2.5261528491973877, -2.4387736320495605]
consistently B-LOC [2.359219789505005, -2.2254536151885986]
demonstrate B-LOC [2.4326860904693604, -2.243788957595825]
a B-LOC [2.418012857437134, -2.397042989730835]
significantly B-LOC [2.3173983097076416, -2.4156463146209717]
lower B-LOC [2.300041913986206, -2.589038133621216]
cumulative B-LOC [2.696068048477173, -2.908493757247925]
incidence B-LOC [2.4638354778289795, -2.6579158306121826]
of B-LOC [2.4728591442108154, -2.5215251445770264]
CIN3+ B-LOC [2.0303614139556885, -2.2708756923675537]
and B-LOC [1.9913451671600342, -2.068894624710083]
even B-LOC [2.264538049697876, -2.3077609539031982]
of B-LOC [2.627171516418457, -2.641850709915161]
cancer, B-LOC [2.4534366130828857, -2.6430060863494873]
in B-LOC [2.40122127532959, -2.520881175994873]
women B-LOC [2.6868488788604736, -2.6109297275543213]
aged B-LOC [3.1570944786071777, -3.0396640300750732]
30 B-LOC [3.011556386947632, -2.9913575649261475]
years B-LOC [3.217822790145874, -2.958658456802368]
or B-LOC [2.8809235095977783, -2.9252822399139404]
older, B-LOC [3.2076456546783447, -2.762468099594116]
who B-LOC [2.719285249710083, -2.7347352504730225]
were B-LOC [2.605067014694214, -2.5957014560699463]
at B-LOC [2.12857723236084, -2.052830934524536]
enrollment B-LOC [1.70163893699646, -1.4033453464508057]
hrHPV B-LOC [2.728755474090576, -2.7618472576141357]
DNA B-LOC [2.124854326248169, -2.6141562461853027]
negative B-LOC [2.531034231185913, -2.5967671871185303]
compared B-LOC [1.9269394874572754, -2.164252519607544]
to B-LOC [2.33760142326355, -2.539355516433716]
those B-LOC [2.3995254039764404, -2.4796435832977295]
who B-LOC [2.4604153633117676, -2.466299295425415]
were B-LOC [2.378865957260132, -2.4336349964141846]
cytologically B-LOC [2.3775012493133545, -2.622023105621338]
negative. B-LOC [2.464407205581665, -2.7312095165252686]
The B-LOC [0.6794252395629883, -0.7237992882728577]
difference B-LOC [0.42633166909217834, -0.9812020659446716]
in B-LOC [0.6875999569892883, -1.148228645324707]
cumulative B-LOC [0.7455936074256897, -0.9028694033622742]
risk B-LOC [0.5721158981323242, -0.976219117641449]
of B-LOC [0.4793335497379303, -0.9914464354515076]
CIN3+ B-LOC [0.6289995312690735, -1.0670411586761475]
or B-LOC [0.6914898157119751, -0.9978967308998108]
cancer B-LOC [0.6315634846687317, -1.055528998374939]
for B-LOC [0.4697169363498688, -0.9792659282684326]

double B-LOC [1.927532434463501, -2.28194260597229]
negative B-LOC [2.1601035594940186, -2.4915435314178467]
(cytology B-LOC [1.9097907543182373, -2.3047728538513184]
& B-LOC [1.5703065395355225, -2.3010785579681396]
HPV) B-LOC [2.0143346786499023, -2.5508172512054443]
versus B-LOC [1.8747010231018066, -2.1762278079986572]
only B-LOC [1.8467248678207397, -2.1143481731414795]
HPV-negative B-LOC [1.9822479486465454, -2.498002290725708]
women B-LOC [1.861680269241333, -2.2681639194488525]
is B-LOC [2.2074737548828125, -2.398691415786743]
small. B-LOC [2.28595232963562, -2.4458353519439697]
HC2, B-LOC [2.5125091075897217, -2.366661787033081]
GP5+/6+ B-LOC [2.2361180782318115, -2.2133147716522217]
PCR B-LOC [2.4059159755706787, -2.8704400062561035]
(polymerase B-LOC [2.848942518234253, -2.917707681655884]
chain B-LOC [2.807025194168091, -2.8225650787353516]
reaction), B-LOC [2.693437337875366, -3.0429704189300537]
cobas(®) B-LOC [2.6818385124206543, -2.5712316036224365]
4800 B-LOC [3.1169776916503906, -3.050567388534546]
PCR B-LOC [2.856706142425537, -3.184882402420044]
(Roche B-LOC [2.9273416996002197, -2.8934643268585205]
Molecular B-LOC [2.870579481124878, -2.9736006259918213]
Systems B-LOC [2.868163585662842, -2.560023546218872]
Inc., B-LOC [3.3163392543792725, -2.5609524250030518]
Alameda, B-LOC [3.2248854637145996, -2.8133907318115234]
CA, B-LOC [3.1132194995880127, -2.852590322494507]
USA) B-LOC [3.2158782482147217, -2.8497321605682373]
and B-LOC [3.3446569442749023, -3.0249171257019043]
Real B-LOC [3.3918793201446533, -3.4269206523895264]
Time B-LOC [3.1334667205810547, -3.2552616596221924]
PCR B-LOC [3.0282323360443115, -3.313176393508911]
(Abbott B-LOC [3.0604100227355957, -2.837379217147827]
Molecular, B-LOC [3.2011053562164307, -3.0532331466674805]
Des B-LOC [3.254793405532837, -3.13521409034729]
Plaines, B-LOC [3.305271863937378, -2.531836748123169]
IL, B-LOC [3.3928258419036865, -3.122342348098755]
USA) B-LOC [3.372840404510498, -3.0410215854644775]
can B-LOC [3.5220143795013428, -3.1461474895477295]
be B-LOC [3.4053642749786377, -3.3433642387390137]
considered B-LOC [3.6367995738983154, -3.150071144104004]
as B-LOC [3.567758083343506, -3.1133549213409424]
clinically B-LOC [3.674333333969116, -3.5085747241973877]
validated B-LOC [3.509323835372925, -3.3577373027801514]
for B-LOC [3.4523465633392334, -3.027196168899536]
use B-LOC [3.304194688796997, -3.111741781234741]
in B-LOC [3.2669742107391357, -3.3681089878082275]
primary B-LOC [3.272169351577759, -3.6155288219451904]
screening. B-LOC [3.2992947101593018, -3.514232873916626]
The B-LOC [2.5911221504211426, -3.165940523147583]
loss B-LOC [2.429112195968628, -3.2144951820373535]
in B-LOC [2.4177112579345703, -2.969066858291626]
specificity B-LOC [2.944478750228882, -3.360513210296631]
associated B-LOC [2.4754440784454346, -2.761213541030884]
with B-LOC [2.4633400440216064, -2.893618583679199]
primary B-LOC [2.443601369857788, -3.2327301502227783]
HPV-based B-LOC [2.2531216144561768, -2.466972589492798]
screening B-LOC [2.4376142024993896, -3.225623607635498]
can B-LOC [2.8552839756011963, -3.1327850818634033]
be B-LOC [2.848588705062866, -3.3078787326812744]
compensated B-LOC [2.669855833053589, -3.292990207672119]
by B-LOC [2.7571277618408203, -3.23392653465271]
appropriate B-LOC [2.7593140602111816, -3.3342702388763428]
algorithms B-LOC [2.8212764263153076, -3.315566301345825]
involving B-LOC [2.3476850986480713, -2.680051565170288]
reflex B-LOC [2.3265812397003174, -3.5033514499664307]
cytology B-LOC [2.835637331008911, -3.2193784713745117]
and/or B-LOC [2.7354936599731445, -3.0051629543304443]
HPV B-LOC [2.344022512435913, -2.8574130535125732]
genotyping B-LOC [3.0477986335754395, -3.0163495540618896]

for B-LOC [1.2031294107437134, -1.6115713119506836]
HPV16 B-LOC [1.2578175067901611, -1.744367003440857]
or B-LOC [1.3539543151855469, -1.8715546131134033]
18. B-LOC [1.841217279434204, -1.9843754768371582]
There B-LOC [1.869225263595581, -1.9037705659866333]
exists B-LOC [2.019286632537842, -1.9384193420410156]
a B-LOC [1.7926729917526245, -1.8692612648010254]
substantial B-LOC [1.777660608291626, -1.769639015197754]
evidence B-LOC [1.7960572242736816, -1.7316114902496338]
base B-LOC [2.017242670059204, -2.149461030960083]
to B-LOC [2.146472692489624, -1.9688016176223755]
support B-LOC [1.444286823272705, -1.585907220840454]
that B-LOC [1.187464714050293, -1.7824351787567139]
HPV B-LOC [1.4495476484298706, -1.6695908308029175]
testing B-LOC [1.2147092819213867, -1.761022925376892]
is B-LOC [1.4899214506149292, -1.8377134799957275]
advantageous B-LOC [1.204068899154663, -1.6283845901489258]
both B-LOC [1.2095704078674316, -1.6659945249557495]
in B-LOC [0.9831395745277405, -1.5289525985717773]
triage B-LOC [1.7140660285949707, -1.9473410844802856]
of B-LOC [1.4794094562530518, -1.8810547590255737]
women B-LOC [1.4724757671356201, -1.793279767036438]
with B-LOC [1.4002424478530884, -1.7042449712753296]
equivocal B-LOC [1.2852702140808105, -1.5458314418792725]
abnormal B-LOC [1.3157150745391846, -1.5553442239761353]
cytology, B-LOC [1.4877583980560303, -1.6780304908752441]
in B-LOC [0.8927401304244995, -1.466590404510498]
surveillance B-LOC [1.3011667728424072, -1.461841344833374]
after B-LOC [1.3817284107208252, -1.8710451126098633]
treatment B-LOC [1.411069393157959, -1.6270626783370972]
of B-LOC [1.36421799659729, -1.6724236011505127]
CIN B-LOC [1.3072879314422607, -1.6392872333526611]
lesions B-LOC [0.9720563292503357, -1.2170336246490479]
and B-LOC [1.3036904335021973, -1.4387056827545166]
in B-LOC [0.9489970207214355, -1.5235850811004639]
primary B-LOC [1.4336093664169312, -1.829850196838379]
screening B-LOC [1.4926042556762695, -1.7220760583877563]
of B-LOC [1.836228370666504, -2.103036642074585]
women B-LOC [1.7858295440673828, -2.020190954208374]
aged B-LOC [2.40659236907959, -2.4603028297424316]
30 B-LOC [2.189077377319336, -2.2592084407806396]
years B-LOC [2.3007185459136963, -2.3014068603515625]
or B-LOC [2.3919389247894287, -2.825324058532715]
older. B-LOC [2.4643702507019043, -2.165935754776001]
However, B-LOC [2.850201368331909, -2.750818967819214]
the B-LOC [3.2397305965423584, -3.3001112937927246]
possible B-LOC [3.2500240802764893, -3.4931588172912598]
advantages B-LOC [3.048389196395874, -3.5483124256134033]
offered B-LOC [3.216301202774048, -3.329738140106201]
by B-LOC [3.2433297634124756, -3.351320505142212]
HPV-based B-LOC [2.9099204540252686, -3.13096022605896]
screening B-LOC [3.123746871948242, -3.5858423709869385]
require B-LOC [2.9324376583099365, -3.242354393005371]
a B-LOC [3.124711275100708, -3.325988531112671]
well B-LOC [3.156337022781372, -3.3430964946746826]
organised B-LOC [3.1826977729797363, -3.454157590866089]
program B-LOC [3.111480951309204, -3.6166880130767822]
with B-LOC [3.1174662113189697, -3.463528871536255]
good B-LOC [3.0431342124938965, -3.478032350540161]
compliance B-LOC [3.202035665512085, -3.526362180709839]
with B-LOC [3.1216437816619873, -3.489173173904419]
screening B-LOC [3.339345693588257, -3.7790169715881348]
and B-LOC [3.256406545639038, -3.4347400665283203]
triage B-LOC [3.3288726806640625, -3.5792298316955566]
policies. B-LOC [3.3388431072235107, -3.476958990097046]
This B-LOC [1.9915828704833984, -2.2121951580047607]
article B-LOC [2.1610324382781982, -2.37924861907959]
forms B-LOC [2.278270721435547, -2.221951961517334]
part B-LOC [2.3892297744750977, -2.3871335983276367]
of B-LOC [2.3359320163726807, -2.130756139755249]
a B-LOC [2.4956302642822266, -2.287792444229126]
special B-LOC [2.4624710083007812, -2.751059055328369]
supplement B-LOC [2.130614995956421, -2.705571174621582]
entitled B-LOC [2.416078567504883, -2.4734702110290527]
"Comprehensive B-LOC [2.2887496948242188, -2.716731548309326]
Control B-LOC [2.804964780807495, -3.022763967514038]
of B-LOC [2.4110748767852783, -2.76676082611084]
HPV B-LOC [2.0809099674224854, -2.518792152404785]
Infections B-LOC [2.5390465259552, -2.8521955013275146]
and B-LOC [2.5973029136657715, -2.6452279090881348]
Related B-LOC [2.5110673904418945, -2.7074241638183594]
Diseases" B-LOC [2.876633882522583, -2.9622693061828613]
Vaccine B-LOC [1.8452881574630737, -2.2781763076782227]
Volume B-LOC [2.0866687297821045, -2.566879987716675]
30, B-LOC [2.6053993701934814, -2.7145018577575684]
Supplement B-LOC [2.2520015239715576, -2.494459867477417]
5, B-LOC [2.5592610836029053, -2.4618101119995117]
2012. B-LOC [2.1194260120391846, -2.3231520652770996]

The B-LOC [1.7410567998886108, -2.1050665378570557]
Sir2 B-LOC [1.7998085021972656, -2.109025716781616]
deacetylase B-LOC [1.9041054248809814, -2.164447546005249]
modulates B-LOC [2.7904367446899414, -2.477484941482544]
organismal B-LOC [2.5135958194732666, -3.0935137271881104]
life-span B-LOC [2.4732143878936768, -2.6581268310546875]
in B-LOC [2.293844699859619, -2.6369736194610596]
various B-LOC [2.6413166522979736, -2.888684034347534]
species. B-LOC [2.626497507095337, -2.577353000640869]
However, B-LOC [3.1241397857666016, -2.814810276031494]
the B-LOC [3.0259974002838135, -2.851830244064331]
molecular B-LOC [2.9043776988983154, -2.6981797218322754]
mechanisms B-LOC [2.8733723163604736, -2.823272228240967]
by B-LOC [3.0252420902252197, -3.062636375427246]
which B-LOC [2.694622755050659, -2.9532527923583984]
Sir2 B-LOC [2.0070457458496094, -2.2987115383148193]
increases B-LOC [2.277026414871216, -2.6108040809631348]
longevity B-LOC [2.518378496170044, -2.8232641220092773]
are B-LOC [3.3431921005249023, -2.7002017498016357]
largely B-LOC [3.29667592048645, -2.7514824867248535]
unknown. B-LOC [3.1900033950805664, -2.7425639629364014]
We B-LOC [0.4627256691455841, -0.3671925365924835]
show B-LOC [0.5394701361656189, -0.41240614652633667]
that B-LOC [0.46309441328048706, -0.7783483862876892]
in B-LOC [0.7076224088668823, -0.8213594555854797]
mammalian B-LOC [1.1643540859222412, -0.9591963887214661]
cells, B-LOC [0.8125588297843933, -0.9040604829788208]
the B-LOC [0.9370647072792053, -0.8022446036338806]
Sir2 B-LOC [1.08303964138031, -1.0320980548858643]
homolog B-LOC [0.9797507524490356, -0.895453155040741]
SIRT1 B-LOC [0.7839128375053406, -1.0273298025131226]
appears B-LOC [0.9720017910003662, -0.9013182520866394]
to B-LOC [0.9064905643463135, -0.9182537198066711]
control B-LOC [0.7455620765686035, -1.0331528186798096]
the B-LOC [0.9293453097343445, -0.964858889579773]
cellular B-LOC [0.7541362047195435, -1.0654810667037964]
response B-LOC [1.0083250999450684, -1.1716126203536987]
to B-LOC [1.1550854444503784, -1.1811716556549072]
stress B-LOC [1.0062748193740845, -0.9630860686302185]
by B-LOC [0.444440096616745, -0.659492015838623]
regulating B-LOC [0.7819767594337463, -0.844793975353241]
the B-LOC [1.0277427434921265, -0.7289820313453674]
FOXO B-LOC [0.7804874777793884, -0.776791512966156]
family B-LOC [0.9979285597801208, -1.0227766036987305]
of B-LOC [0.8270201086997986, -0.8851853609085083]
Forkhead B-LOC [0.6608553528785706, -0.8893242478370667]
transcription B-LOC [0.5836743116378784, -0.8612745404243469]
factors, B-LOC [0.5809862017631531, -0.8940696716308594]
a B-LOC [0.8273599147796631, -0.8279648423194885]
family B-LOC [1.124457597732544, -1.1890053749084473]
of B-LOC [0.8815400004386902, -1.0706605911254883]
proteins B-LOC [0.8795607686042786, -0.8983404636383057]
that B-LOC [0.7313907742500305, -0.9076518416404724]
function B-LOC [0.907528817653656, -0.859009325504303]
as B-LOC [0.5614925026893616, -0.7320590019226074]
sensors B-LOC [0.9663121104240417, -0.9614779949188232]
of B-LOC [0.7349897027015686, -0.8662518858909607]
the B-LOC [0.9272496104240417, -0.8275810480117798]
insulin B-LOC [0.7418137192726135, -1.0396099090576172]
signaling B-LOC [0.5408739447593689, -0.9808416962623596]
pathway B-LOC [0.5735496878623962, -1.0395965576171875]
and B-LOC [0.7771414518356323, -0.6440662145614624]
as B-LOC [0.6682884097099304, -0.8903467655181885]
regulators B-LOC [0.8181762099266052, -1.0885329246520996]
of B-LOC [0.7797033190727234, -1.231757402420044]
organismal B-LOC [0.9214956760406494, -1.456008791923523]
longevity. B-LOC [1.09889817237854, -1.156152367591858]
SIRT1 B-LOC [0.2883888781070709, -0.7325702905654907]
and B-LOC [0.13931891322135925, -0.46015796065330505]
the B-LOC [0.18487000465393066, -0.4278869032859802]
FOXO B-LOC [-0.09297062456607819, -0.35369133949279785]
transcription B-LOC [-0.09388664364814758, -0.36460575461387634]
factor B-LOC [-0.1347799301147461, -0.42657119035720825]
FOXO3 B-LOC [-0.10510251671075821, -0.3847951591014862]
formed B-LOC [0.08313090354204178, -0.4535050690174103]
a B-LOC [0.046222101897001266, -0.4288698732852936]
complex B-LOC [0.00042776259942911565, -0.49498042464256287]
in B-LOC [-0.12285127490758896, -0.4253036081790924]
cells B-LOC [-0.2005157172679901, -0.36772534251213074]
in B-LOC [-0.11542566120624542, -0.5173827409744263]
response B-LOC [0.101778045296669, -0.3479333817958832]
to B-LOC [0.166805237531662, -0.48412710428237915]
oxidative B-LOC [0.03165619447827339, -0.3771428167819977]

stress, B-LOC [-0.13856399059295654, -0.1799546331167221]
and O [-0.259080708026886, 0.18573300540447235]
SIRT1 O [-0.14062656462192535, -0.006843032781034708]
deacetylated O [-0.09363900125026703, 0.09472678601741791]
FOXO3 B-LOC [-0.11369585245847702, -0.11896657198667526]
in B-LOC [0.007767158094793558, -0.2995827794075012]
vitro B-LOC [0.20996470749378204, -0.39173004031181335]
and B-LOC [0.18637801706790924, -0.29800665378570557]
within B-LOC [0.09915528446435928, -0.2634192407131195]
cells. B-LOC [0.07008524984121323, -0.33194997906684875]
SIRT1 O [-0.4059032201766968, 0.3399343192577362]
had O [-0.3874942362308502, 0.5099256634712219]
a O [-0.3429405391216278, 0.5575956702232361]
dual O [-0.03352842479944229, 0.17074647545814514]
effect O [-0.3929777443408966, 0.2585613429546356]
on O [-0.35203251242637634, 0.3012235164642334]
FOXO3 O [-0.6453902721405029, 0.5389620661735535]
function: O [-0.7440521121025085, 0.7724274396896362]
SIRT1 O [-0.9335736036300659, 1.075714111328125]
increased O [-1.1500108242034912, 1.2010194063186646]
FOXO3's O [-1.0172480344772339, 0.990365207195282]
ability O [-1.2103981971740723, 1.2387616634368896]
to O [-1.3095157146453857, 1.1987147331237793]
induce O [-1.319969654083252, 1.2974669933319092]
cell O [-1.2593318223953247, 1.2614073753356934]
cycle O [-1.3844091892242432, 1.3094788789749146]
arrest O [-1.0649476051330566, 1.2563111782073975]
and O [-1.3813817501068115, 1.410683274269104]
resistance O [-1.0806267261505127, 1.2264747619628906]
to O [-1.047005534172058, 1.02947199344635]
oxidative O [-1.0875749588012695, 1.309569239616394]
stress O [-0.8790172934532166, 1.1399348974227905]
but O [-1.035750389099121, 1.2352218627929688]
inhibited O [-1.282899260520935, 1.4163154363632202]
FOXO3's O [-0.945563018321991, 1.0011335611343384]
ability O [-1.131173014640808, 1.244591236114502]
to O [-1.103735089302063, 1.1661187410354614]
induce O [-1.187477946281433, 1.2482999563217163]
cell O [-1.0350421667099, 0.8454414010047913]
death. O [-0.7932085990905762, 0.9469208717346191]
Thus, O [-0.23886063694953918, 0.351244181394577]
one B-LOC [0.17994087934494019, -0.18738040328025818]
way B-LOC [0.09070773422718048, -0.22597870230674744]
in O [-0.16819024085998535, -0.1506272256374359]
which B-LOC [0.08105827122926712, -0.2552797198295593]
members B-LOC [0.47160378098487854, -0.19844520092010498]
of B-LOC [0.3250330090522766, -0.2205522656440735]
the B-LOC [0.4265190064907074, -0.2694217264652252]
Sir2 B-LOC [0.13047188520431519, -0.37382617592811584]
family B-LOC [0.4402845799922943, -0.5124213099479675]
of B-LOC [0.3152841627597809, -0.37832316756248474]
proteins B-LOC [0.2500718832015991, -0.2772352695465088]
may B-LOC [0.26021045446395874, -0.3852347135543823]
increase B-LOC [-0.14538925886154175, -0.28199663758277893]
organismal B-LOC [0.10067641735076904, -0.5867459177970886]
longevity B-LOC [0.03927616775035858, -0.11143310368061066]
is B-LOC [0.1672360897064209, -0.3892051875591278]
by O [-0.37809446454048157, -0.02128462679684162]
tipping O [-0.1474861204624176, -0.052885305136442184]
FOXO-dependent O [-0.313987672328949, -0.06072644516825676]
responses O [-0.3588685393333435, 0.22109469771385193]
away O [-0.1573570966720581, 0.3606416583061218]
from O [-0.2614019811153412, 0.3619256317615509]
apoptosis O [-0.5560674071311951, 0.26804298162460327]
and O [-0.17822493612766266, 0.2908952534198761]
toward O [-0.2801201641559601, 0.1212565153837204]
stress O [-0.09364542365074158, 0.04781169444322586]
resistance. O [-0.22693756222724915, -0.04352972283959389]

We B-LOC [1.3650966882705688, -1.7747312784194946]
examined B-LOC [2.3211896419525146, -2.4477317333221436]
the B-LOC [2.5910916328430176, -2.5661542415618896]
contributions B-LOC [2.228804588317871, -2.523792028427124]
of B-LOC [2.1312448978424072, -2.4332966804504395]
genetic B-LOC [2.3050596714019775, -2.484764337539673]
factors B-LOC [2.3000972270965576, -2.526789426803589]
and B-LOC [2.315589666366577, -2.5702664852142334]
the B-LOC [2.5929148197174072, -2.613128185272217]
family B-LOC [2.1257596015930176, -2.200427293777466]
environment B-LOC [2.416966438293457, -2.5189568996429443]
to B-LOC [2.37640643119812, -2.8436200618743896]
human B-LOC [2.1453444957733154, -2.4825074672698975]
fatness B-LOC [1.9988737106323242, -2.2490322589874268]
in B-LOC [2.330186128616333, -2.320399761199951]
a B-LOC [2.2902286052703857, -2.3302388191223145]
sample B-LOC [2.246335744857788, -2.355363607406616]
of B-LOC [2.033298969268799, -2.1786530017852783]
540 B-LOC [2.3225343227386475, -2.222193956375122]
adult B-LOC [2.1899964809417725, -2.2890944480895996]
Danish B-LOC [1.721717119216919, -2.110802412033081]
adoptees B-LOC [1.9380155801773071, -1.8069202899932861]
who B-LOC [2.0941505432128906, -2.224867105484009]
were B-LOC [2.2067363262176514, -2.1770081520080566]
selected B-LOC [2.1843631267547607, -2.265371561050415]
from B-LOC [2.281365394592285, -2.221143960952759]
a B-LOC [2.2872374057769775, -2.3183181285858154]
population B-LOC [2.347583055496216, -2.302992820739746]
of B-LOC [1.9901484251022339, -2.25152850151062]
3580 B-LOC [2.559800863265991, -2.3355391025543213]
and B-LOC [2.1950626373291016, -2.4755842685699463]
divided B-LOC [2.5775952339172363, -2.4939401149749756]
into B-LOC [2.396984338760376, -2.4172956943511963]
four B-LOC [2.306208372116089, -2.316669225692749]
weight B-LOC [1.9890040159225464, -2.2909538745880127]
classes: B-LOC [2.4138402938842773, -2.4069035053253174]
thin, B-LOC [2.034701108932495, -2.1644065380096436]
median B-LOC [1.8866053819656372, -2.236292600631714]
weight, B-LOC [1.8449938297271729, -2.0792429447174072]
overweight, B-LOC [1.9524595737457275, -2.282034397125244]
and B-LOC [1.7612687349319458, -1.8589565753936768]
obese. B-LOC [2.141087770462036, -2.4242429733276367]
There B-LOC [0.9026859998703003, -0.9993435740470886]
was B-LOC [0.8914412260055542, -1.121663212776184]
a B-LOC [0.8572737574577332, -0.9793577194213867]
strong B-LOC [0.8788782358169556, -1.1060144901275635]
relation B-LOC [0.7243519425392151, -1.0798215866088867]
between B-LOC [0.8617083430290222, -1.4681286811828613]
the B-LOC [1.1677038669586182, -1.3566495180130005]
weight B-LOC [0.9466850161552429, -0.7112228274345398]
class B-LOC [0.8759109377861023, -0.8368245959281921]
of B-LOC [0.8409780263900757, -1.1940271854400635]
the B-LOC [0.9670919179916382, -0.8420819640159607]
adoptees B-LOC [1.052269458770752, -0.784902036190033]
and B-LOC [1.1525940895080566, -1.4562112092971802]
the B-LOC [1.161412239074707, -1.4108216762542725]
body-mass B-LOC [0.6503891348838806, -0.8411718010902405]
index B-LOC [0.7906047105789185, -1.0815322399139404]
of B-LOC [0.8589795231819153, -1.2881627082824707]
their B-LOC [0.965088427066803, -0.9937629103660583]
biologic B-LOC [0.9587975144386292, -1.1335649490356445]
parents B-LOC [0.6845663189888, -0.769825279712677]
- B-LOC [0.5296604633331299, -0.8675553798675537]
for B-LOC [0.4147888720035553, -0.8999045491218567]
the B-LOC [0.950750470161438, -0.9052449464797974]
mothers, B-LOC [0.6855628490447998, -0.7721129655838013]
P B-LOC [0.5765830278396606, -0.9678186774253845]
less B-LOC [0.849093496799469, -0.889396607875824]
than B-LOC [0.76725172996521, -0.9301568865776062]
0.0001; B-LOC [0.8622228503227234, -1.105452537536621]
for B-LOC [0.47889307141304016, -0.656186044216156]
the B-LOC [0.8076612949371338, -0.7240243554115295]
fathers, B-LOC [0.4388534426689148, -0.7642653584480286]
P B-LOC [0.5274574160575867, -0.7710254192352295]
less B-LOC [0.7403868436813354, -0.7470822930335999]
than B-LOC [0.6336535215377808, -0.879051148891449]
0.02. B-LOC [0.7460917830467224, -1.0993403196334839]
There B-LOC [0.7510551810264587, -0.9936830401420593]
was B-LOC [0.8537834286689758, -1.1763496398925781]
no B-LOC [0.8424156904220581, -1.0976181030273438]
relation B-LOC [0.7244798541069031, -1.2420213222503662]
between B-LOC [0.9235321879386902, -1.5744295120239258]
the B-LOC [1.0718297958374023, -1.4789910316467285]
weight B-LOC [1.027587652206421, -1.0366103649139404]
class B-LOC [0.8873147964477539, -1.133679747581482]
of B-LOC [0.8820934891700745, -1.3344016075134277]
the B-LOC [0.7981119155883789, -1.0652726888656616]
adoptees B-LOC [0.9493894577026367, -0.7623835206031799]
and B-LOC [1.074910044670105, -1.4935870170593262]
the B-LOC [1.0991407632827759, -1.514177680015564]
body-mass B-LOC [0.7417376041412354, -1.0442094802856445]
index B-LOC [0.8078374266624451, -1.2323472499847412]
of B-LOC [0.8237701058387756, -1.4138563871383667]
their B-LOC [0.834845244884491, -1.064483880996704]
adoptive B-LOC [0.972955048084259, -0.90973961353302]
parents. B-LOC [0.6966227293014526, -0.9083928465843201]

Cumulative B-LOC [0.7054634094238281, -0.8063979148864746]
distributions B-LOC [1.1024203300476074, -0.9005342125892639]
of B-LOC [0.9715770483016968, -1.1628528833389282]
the B-LOC [1.1430294513702393, -1.255629301071167]
body-mass B-LOC [0.6330471634864807, -0.8380703926086426]
index B-LOC [0.8809465765953064, -1.0996710062026978]
of B-LOC [0.9287621378898621, -1.3172229528427124]
parents B-LOC [0.7841195464134216, -0.7957887053489685]
showed B-LOC [0.6956442594528198, -0.9208511114120483]
similar B-LOC [0.943683922290802, -1.2421939373016357]
results; B-LOC [0.7451412677764893, -1.0852478742599487]
there B-LOC [0.3416873812675476, -0.07690668106079102]
was B-LOC [0.2630879878997803, -0.20575003325939178]
a B-LOC [0.3394651710987091, -0.17971713840961456]
strong B-LOC [0.3273935616016388, -0.28351181745529175]
relation B-LOC [0.4067409336566925, -0.5767218470573425]
between B-LOC [0.5816085338592529, -0.8893006443977356]
the B-LOC [0.6012435555458069, -0.7949967384338379]
body-mass B-LOC [0.32914218306541443, -0.4120994508266449]
index B-LOC [0.2520376145839691, -0.5703482031822205]
of B-LOC [0.3927617073059082, -0.9626737833023071]
biologic B-LOC [0.3659663498401642, -0.5924816727638245]
parents B-LOC [0.4381970763206482, -0.4872247278690338]
and B-LOC [0.664618194103241, -0.8345386385917664]
adoptee B-LOC [0.4260573089122772, -0.32732954621315]
weight B-LOC [0.4231936037540436, -0.5136528611183167]
class B-LOC [0.3981672525405884, -0.5539495944976807]
and B-LOC [0.3319719135761261, -0.18515849113464355]
no B-LOC [0.4652463495731354, -0.2812991142272949]
relation B-LOC [0.4716784656047821, -0.6827625632286072]
between B-LOC [0.6640345454216003, -1.010118842124939]
the B-LOC [0.6113709807395935, -0.9011805653572083]
index B-LOC [0.28617146611213684, -0.6847108006477356]
of B-LOC [0.422123521566391, -1.0299196243286133]
adoptive B-LOC [0.44722506403923035, -0.40651935338974]
parents B-LOC [0.43120837211608887, -0.4876752197742462]
and B-LOC [0.7110142707824707, -0.9402549266815186]
adoptee B-LOC [0.4859655797481537, -0.4369616210460663]
weight B-LOC [0.4412606358528137, -0.6040545105934143]
class. B-LOC [0.5027481317520142, -0.6436493396759033]
Furthermore, B-LOC [0.6803810000419617, -0.6125766038894653]
the B-LOC [1.2321436405181885, -1.294235348701477]
relation B-LOC [1.0879390239715576, -1.3848295211791992]
between B-LOC [1.2143012285232544, -1.6273720264434814]
biologic B-LOC [0.9140673279762268, -1.4126670360565186]
parents B-LOC [0.817358672618866, -1.0713679790496826]
and B-LOC [1.1365563869476318, -1.5629323720932007]
adoptees B-LOC [1.0688056945800781, -0.9811027646064758]
was B-LOC [0.8886652588844299, -1.0730252265930176]
not B-LOC [0.644119918346405, -0.6975070238113403]
confined B-LOC [1.1033309698104858, -1.229448914527893]
to B-LOC [1.2300992012023926, -1.1689904928207397]
the B-LOC [1.1991631984710693, -1.276768684387207]
obesity B-LOC [0.8504238724708557, -1.3248498439788818]
weight B-LOC [1.1030679941177368, -1.2742016315460205]
class, B-LOC [1.0182033777236938, -1.286047101020813]
but B-LOC [0.5974803566932678, -0.9693856835365295]
was B-LOC [0.8113554120063782, -1.064239501953125]
present B-LOC [0.9226323962211609, -1.2876008749008179]
across B-LOC [0.9819103479385376, -1.371150255203247]
the B-LOC [1.1845614910125732, -1.373748540878296]
whole B-LOC [1.093041181564331, -1.2681666612625122]
range B-LOC [1.2272483110427856, -1.7351542711257935]
of B-LOC [1.0294278860092163, -1.5515100955963135]
body B-LOC [0.7538937330245972, -1.1804871559143066]
fatness B-LOC [0.8125701546669006, -1.140019416809082]
- B-LOC [0.5567553639411926, -1.0379951000213623]
from B-LOC [0.7760255336761475, -1.0500824451446533]
very B-LOC [0.6831998825073242, -1.2372822761535645]
thin B-LOC [0.997283399105072, -1.0729796886444092]
to B-LOC [0.7308681607246399, -1.0727941989898682]
very B-LOC [0.7544973492622375, -1.2798622846603394]
fat. B-LOC [0.7492010593414307, -1.0506175756454468]
We B-LOC [-0.01936955563724041, -0.4030110239982605]
conclude B-LOC [0.482681542634964, -0.24926340579986572]
that B-LOC [0.14920999109745026, -0.5038050413131714]
genetic B-LOC [0.5503495931625366, -0.8405647277832031]
influences B-LOC [0.5036934018135071, -0.819730281829834]
have B-LOC [0.7768844962120056, -0.8493690490722656]
an B-LOC [0.7188245058059692, -0.7593421339988708]
important B-LOC [0.6624243855476379, -0.7522706389427185]
role B-LOC [0.5560187697410583, -0.9467422962188721]
in B-LOC [0.587274968624115, -0.8947761654853821]
determining B-LOC [0.5615338087081909, -0.952893078327179]
human B-LOC [0.3432014584541321, -0.7973635792732239]
fatness B-LOC [0.4740144908428192, -0.6471970081329346]
in B-LOC [0.32788512110710144, -0.7364598512649536]
adults, B-LOC [0.4358740448951721, -0.5291152000427246]
whereas B-LOC [0.3303387761116028, -0.4827632009983063]
the B-LOC [0.7593781352043152, -0.6837613582611084]
family B-LOC [0.404409259557724, -0.6698753237724304]
environment B-LOC [0.3259989321231842, -0.8602824211120605]
alone B-LOC [0.5087136626243591, -0.7971042394638062]
has B-LOC [0.9566125273704529, -0.9229384064674377]
no B-LOC [0.8042634129524231, -0.7413185834884644]
apparent B-LOC [0.7802063822746277, -1.0130078792572021]
effect. B-LOC [0.5720639824867249, -1.1305525302886963]

IMPORTANCE B-LOC [2.449979543685913, -2.9738194942474365]
Exacerbations B-LOC [2.9515955448150635, -3.1128430366516113]
of B-LOC [3.048875331878662, -3.190908670425415]
respiratory B-LOC [3.178217649459839, -3.4365639686584473]
symptoms B-LOC [3.532468557357788, -3.14788818359375]
in B-LOC [2.946415662765503, -3.079055070877075]
chronic B-LOC [3.434692621231079, -3.3132424354553223]
obstructive B-LOC [3.0704948902130127, -2.98832106590271]
pulmonary B-LOC [3.093024969100952, -3.479773759841919]
disease B-LOC [3.4345929622650146, -3.112492561340332]
(COPD) B-LOC [3.3523001670837402, -3.0273354053497314]
have B-LOC [3.132889747619629, -3.160888433456421]
profound B-LOC [3.343733549118042, -3.2587316036224365]
and B-LOC [2.8345463275909424, -2.8869240283966064]
long-lasting B-LOC [3.108752965927124, -3.2668888568878174]
adverse B-LOC [3.5589499473571777, -3.5588858127593994]
effects B-LOC [3.4998013973236084, -3.3058509826660156]
on B-LOC [3.1091527938842773, -3.31709361076355]
patients. B-LOC [3.5200369358062744, -3.430976152420044]
OBJECTIVE B-LOC [3.002861261367798, -3.4174187183380127]
To B-LOC [3.264913320541382, -3.473935842514038]
test B-LOC [3.305729389190674, -3.628617525100708]
the B-LOC [3.5272791385650635, -3.43750262260437]
hypothesis B-LOC [3.4401395320892334, -3.602691888809204]
that B-LOC [2.9982120990753174, -3.456467628479004]
elevated B-LOC [3.0397346019744873, -3.465654134750366]
levels B-LOC [3.2709739208221436, -3.2838704586029053]
of B-LOC [3.0590035915374756, -3.328490734100342]
inflammatory B-LOC [3.2258570194244385, -3.486217498779297]
biomarkers B-LOC [3.1015121936798096, -3.498762607574463]
in B-LOC [2.9743399620056152, -3.369929790496826]
individuals B-LOC [3.3316547870635986, -3.4790875911712646]
with B-LOC [3.247408628463745, -3.554694414138794]
stable B-LOC [2.958597183227539, -3.510406017303467]
COPD B-LOC [2.938127279281616, -3.2816073894500732]
are B-LOC [3.147670269012451, -3.303703546524048]
associated B-LOC [3.123915672302246, -3.4497830867767334]
with B-LOC [2.9710779190063477, -3.3170547485351562]
an B-LOC [3.191118001937866, -3.5025877952575684]
increased B-LOC [2.99898362159729, -3.6469197273254395]
risk B-LOC [3.399735689163208, -3.6591546535491943]
of B-LOC [3.0100557804107666, -3.1914799213409424]
having B-LOC [3.2641046047210693, -3.670475959777832]
exacerbations. B-LOC [3.3122217655181885, -3.544710636138916]
DESIGN, B-LOC [2.975273609161377, -3.187976837158203]
SETTING, B-LOC [2.47652530670166, -2.8176333904266357]
AND B-LOC [2.8213050365448, -3.1226131916046143]
PARTICIPANTS B-LOC [2.661578893661499, -2.937248468399048]
Prospective B-LOC [3.0377557277679443, -3.378117561340332]
cohort B-LOC [3.12508225440979, -2.9827358722686768]
study B-LOC [2.5892252922058105, -2.930534601211548]
examining B-LOC [2.865307569503784, -3.017719030380249]
61,650 B-LOC [3.202195882797241, -3.2267115116119385]
participants B-LOC [3.003406286239624, -3.4728469848632812]
with B-LOC [3.073582887649536, -3.096076726913452]
spirometry B-LOC [3.3664133548736572, -3.2538845539093018]
measurements B-LOC [3.1779375076293945, -3.190467357635498]
from B-LOC [3.107950448989868, -3.076918363571167]
the B-LOC [3.156245708465576, -2.8841402530670166]
Copenhagen B-LOC [2.982048511505127, -3.2262628078460693]
City B-LOC [3.3527674674987793, -3.333347797393799]
Heart B-LOC [3.112180471420288, -3.4947495460510254]
Study B-LOC [3.0689425468444824, -3.2670531272888184]

(2001-2003) B-LOC [2.717353343963623, -3.112943649291992]
and B-LOC [3.1004252433776855, -3.195297956466675]
the B-LOC [3.2497775554656982, -3.1671483516693115]
Copenhagen B-LOC [3.5467240810394287, -3.439880609512329]
General B-LOC [3.417724370956421, -3.625009298324585]
Population B-LOC [3.220543146133423, -3.2332193851470947]
Study B-LOC [3.2579729557037354, -3.3619954586029053]
(2003-2008). B-LOC [3.205481767654419, -3.2099223136901855]
Of B-LOC [3.0594711303710938, -2.8179752826690674]
these, B-LOC [3.294865369796753, -2.7022247314453125]
6574 B-LOC [3.199502468109131, -3.1079885959625244]
had B-LOC [3.1322438716888428, -2.849656343460083]
COPD, B-LOC [2.8202240467071533, -2.9559643268585205]
defined B-LOC [3.5098636150360107, -3.166355848312378]
as B-LOC [3.104810953140259, -3.0045089721679688]
a B-LOC [3.1104776859283447, -3.132517099380493]
ratio B-LOC [2.8785150051116943, -3.1338775157928467]
between B-LOC [3.007581949234009, -3.2673609256744385]
forced B-LOC [2.866084575653076, -3.1660587787628174]
expiratory B-LOC [2.8966333866119385, -3.1567862033843994]
volume B-LOC [3.050734758377075, -3.0763261318206787]
in B-LOC [3.036020040512085, -2.886200189590454]
1 B-LOC [3.0435216426849365, -2.7934634685516357]
second B-LOC [2.8256137371063232, -3.256540060043335]
(FEV1) B-LOC [3.300354242324829, -3.118056535720825]
and B-LOC [2.980182647705078, -2.9949800968170166]
forced B-LOC [2.8325939178466797, -3.231154680252075]
vital B-LOC [2.942423105239868, -3.2216780185699463]
capacity B-LOC [2.8105721473693848, -3.103933334350586]
below B-LOC [2.993239402770996, -3.0213983058929443]
0.7. B-LOC [3.033686399459839, -2.9949562549591064]
MAIN B-LOC [2.453212261199951, -2.86220383644104]
OUTCOMES B-LOC [2.74863862991333, -2.7794241905212402]
AND B-LOC [2.7354085445404053, -3.0332629680633545]
MEASURES B-LOC [2.9044415950775146, -3.063103437423706]
Baseline B-LOC [2.883488416671753, -2.7024929523468018]
levels B-LOC [2.8254706859588623, -3.057751417160034]
of B-LOC [2.616492509841919, -2.8913321495056152]
C-reactive B-LOC [2.1849658489227295, -2.502237558364868]
protein B-LOC [2.498723030090332, -2.5544955730438232]
(CRP) B-LOC [2.9203245639801025, -2.9027140140533447]
and B-LOC [2.7226920127868652, -2.841830015182495]
fibrinogen B-LOC [2.5363147258758545, -2.443010091781616]
and B-LOC [2.821786880493164, -2.774355411529541]
leukocyte B-LOC [2.573673725128174, -2.4779655933380127]
count B-LOC [2.9072484970092773, -3.0336720943450928]
were B-LOC [2.68512225151062, -2.7294182777404785]
measured B-LOC [3.0228872299194336, -3.078900098800659]
in B-LOC [2.5635340213775635, -2.90165114402771]
participants B-LOC [2.672175645828247, -3.001781702041626]
at B-LOC [2.864300489425659, -2.9538028240203857]
a B-LOC [2.873749256134033, -2.6811022758483887]
time B-LOC [2.515641450881958, -3.1225101947784424]
when B-LOC [2.2147409915924072, -2.922893762588501]
they B-LOC [2.854008913040161, -2.7719480991363525]
were B-LOC [2.7371931076049805, -2.5745341777801514]
not B-LOC [2.760361433029175, -2.7023508548736572]
experiencing B-LOC [2.7014005184173584, -3.0610804557800293]
symptoms B-LOC [2.955596685409546, -3.0911219120025635]
of B-LOC [2.751936912536621, -2.9940245151519775]
exacerbations. B-LOC [2.655327558517456, -3.031409502029419]
Exacerbations B-LOC [2.7979464530944824, -2.9809253215789795]
were B-LOC [3.2470431327819824, -2.878631830215454]
recorded B-LOC [3.19245982170105, -3.1896281242370605]
and B-LOC [2.9034039974212646, -2.9422240257263184]
defined B-LOC [3.548513174057007, -3.2831122875213623]
as B-LOC [2.9764626026153564, -3.0278618335723877]
short-course B-LOC [2.917579174041748, -3.1803903579711914]
treatment B-LOC [2.8390467166900635, -3.103058338165283]
with B-LOC [2.6963770389556885, -2.88547420501709]

oral B-LOC [0.858667254447937, -1.5066677331924438]
corticosteroids B-LOC [1.2905430793762207, -1.745622158050537]
alone B-LOC [1.2409896850585938, -1.581650972366333]
or B-LOC [1.4845006465911865, -2.1016123294830322]
in B-LOC [1.5133548974990845, -2.114407777786255]
combination B-LOC [1.6145073175430298, -1.997785210609436]
with B-LOC [1.4895060062408447, -1.836670160293579]
an B-LOC [1.603166103363037, -2.0358211994171143]
antibiotic B-LOC [1.7665424346923828, -2.226518392562866]
or B-LOC [1.4915125370025635, -2.0129988193511963]
as B-LOC [1.3002159595489502, -2.0823864936828613]
a B-LOC [1.678165316581726, -2.243748664855957]
hospital B-LOC [1.6932389736175537, -2.2454349994659424]
admission B-LOC [1.4091100692749023, -2.0593185424804688]
due B-LOC [1.5061724185943604, -2.012145519256592]
to B-LOC [1.4739868640899658, -1.9773260354995728]
COPD. B-LOC [1.2587547302246094, -1.7223137617111206]
Levels B-LOC [2.576443910598755, -3.0185651779174805]
of B-LOC [2.288408041000366, -2.935274839401245]
CRP B-LOC [2.2445790767669678, -3.0021331310272217]
and B-LOC [2.356139898300171, -2.744541645050049]
fibrinogen B-LOC [2.1902098655700684, -2.6625168323516846]
and B-LOC [2.423295259475708, -2.7892725467681885]
leukocyte B-LOC [2.3584721088409424, -2.7592837810516357]
count B-LOC [2.2796471118927, -2.955301284790039]
were B-LOC [2.5138890743255615, -2.9751620292663574]
defined B-LOC [2.685032606124878, -3.0803959369659424]
as B-LOC [2.6745340824127197, -2.830749273300171]
high B-LOC [2.532665967941284, -3.1050360202789307]
or B-LOC [2.583465814590454, -2.9616777896881104]
low B-LOC [2.690213918685913, -3.0223519802093506]
according B-LOC [2.5748207569122314, -2.822990655899048]
to B-LOC [2.6413869857788086, -2.8157474994659424]
cut B-LOC [2.7953684329986572, -3.2114834785461426]
points B-LOC [2.4976704120635986, -3.052110195159912]
of B-LOC [2.35093092918396, -2.8693010807037354]
3 B-LOC [2.2781527042388916, -2.407351493835449]
mg/L, B-LOC [2.5330140590667725, -3.1026012897491455]
14 B-LOC [2.3159945011138916, -2.638788938522339]
μmol/L, B-LOC [2.0020251274108887, -2.8220372200012207]
and B-LOC [2.489610433578491, -2.91474986076355]
9 B-LOC [2.523219347000122, -2.7775800228118896]
×10(9)/L, B-LOC [2.398404121398926, -2.6994693279266357]
respectively. B-LOC [2.5229861736297607, -3.2773115634918213]
RESULTS B-LOC [1.537537693977356, -2.1715996265411377]
During B-LOC [2.108318328857422, -2.364794969558716]
follow-up, B-LOC [1.9175227880477905, -2.2198257446289062]
3083 B-LOC [2.8255932331085205, -2.530945062637329]
exacerbations B-LOC [2.3705928325653076, -2.5803680419921875]
were B-LOC [2.3051071166992188, -2.544074296951294]
recorded B-LOC [2.4895684719085693, -2.54872989654541]
(mean, B-LOC [2.3756940364837646, -2.3582866191864014]
0.5/participant). B-LOC [2.1833488941192627, -2.7088754177093506]
In O [-0.2770760953426361, 0.008713509887456894]
the B-LOC [0.018367880955338478, -0.1684364527463913]
first O [-0.2231699675321579, -0.12025628983974457]
year B-LOC [0.21216470003128052, -0.2306993156671524]
of B-LOC [-0.13836008310317993, -0.14066268503665924]
follow-up, B-LOC [0.41401833295822144, -0.6316032409667969]
multivariable-adjusted B-LOC [-0.06302299350500107, -0.0857677087187767]
odds O [-0.038676917552948, 0.10196292400360107]
ratios O [-0.030612869188189507, 0.06870132684707642]
for O [-0.19620835781097412, 0.17358176410198212]
having O [-0.11266373097896576, 0.14586123824119568]
frequent O [-0.2026878297328949, 0.07013976573944092]

exacerbations O [-0.5983487367630005, 0.6277641654014587]
were O [-0.5226404666900635, 0.6140993237495422]
1.2 O [-0.527978777885437, 0.7454137802124023]
(95% O [-0.7319190502166748, 0.5447981953620911]
CI, O [-0.8152943253517151, 0.5908464789390564]
0.7-2.2; O [-0.5618788599967957, 0.7742075324058533]
17 O [-0.3666871190071106, 0.6269659399986267]
events/1000 O [-0.780802309513092, 0.5892322659492493]
person-years) O [-0.852508008480072, 0.5187250971794128]
for O [-0.8355181217193604, 0.852497935295105]
individuals O [-0.9486280083656311, 0.9458740949630737]
with O [-0.8566969037055969, 0.9336281418800354]
1 O [-0.8076918721199036, 1.1182669401168823]
high O [-0.7691181302070618, 0.9098849892616272]
biomarker, O [-0.7951923608779907, 0.9233489632606506]
1.7 O [-0.796629011631012, 1.0935187339782715]
(95% O [-0.8408480286598206, 0.7618746161460876]
CI, O [-0.9700927734375, 0.8750023245811462]
0.9-3.2; O [-0.8469410538673401, 1.1121058464050293]
32 O [-0.5888055562973022, 1.0408990383148193]
events/1000 O [-0.9387075901031494, 0.8980588912963867]
person-years) O [-0.996782124042511, 0.7683227062225342]
for O [-0.9020200371742249, 1.0299830436706543]
individuals O [-0.92973393201828, 0.9953582286834717]
with O [-0.8683099150657654, 0.976744532585144]
2 O [-0.7070562243461609, 1.106024980545044]
high O [-0.7791057229042053, 0.9534967541694641]
biomarkers, O [-0.8124049305915833, 0.9383015632629395]
and O [-0.8033406138420105, 0.8954183459281921]
3.7 O [-0.7495688796043396, 1.1992485523223877]
(95% O [-0.7772926688194275, 0.6931609511375427]
CI, O [-0.9200426340103149, 0.7539653778076172]
1.9-7.4; O [-0.7348673939704895, 0.8041736483573914]
81 O [-0.6297346949577332, 0.7322179675102234]
events/1000 O [-0.9000276327133179, 0.6670721769332886]
person-years) O [-0.9161129593849182, 0.5884895920753479]
for O [-0.8266087174415588, 0.9466169476509094]
individuals O [-0.9146525859832764, 0.9305290579795837]
with O [-0.8698587417602539, 0.84661465883255]
3 O [-0.626772403717041, 0.9232624173164368]
high O [-0.7555491328239441, 0.8135550022125244]
biomarkers O [-0.7044420838356018, 0.7114196419715881]
compared O [-0.9938548803329468, 1.0030118227005005]
with O [-0.6650183200836182, 0.7875023484230042]
individuals O [-0.8699547052383423, 0.8156233429908752]
who O [-0.8658410906791687, 0.6440322995185852]
had O [-0.8152509927749634, 0.8449438810348511]
no O [-0.6009846329689026, 0.8496605753898621]
elevated O [-0.6825767159461975, 0.766549825668335]
biomarkers O [-0.6901613473892212, 0.6200208067893982]
(9 O [-0.7727607488632202, 0.8023534417152405]
events/1000 O [-0.7644457221031189, 0.6293178796768188]
person-years; O [-0.849401593208313, 0.5287041664123535]

trend: B-LOC [0.2726691663265228, -0.7836752533912659]
P B-LOC [0.1348029226064682, -0.6253690719604492]
= B-LOC [0.18587279319763184, -0.5928323268890381]
2 B-LOC [0.4524122178554535, -0.4604349732398987]
× B-LOC [0.1839975118637085, -0.367434024810791]
10(-5)). B-LOC [0.34558042883872986, -0.5151424407958984]
Corresponding B-LOC [1.188062310218811, -1.0944639444351196]
hazard B-LOC [0.7482059001922607, -0.8215180039405823]
ratios B-LOC [0.8756864666938782, -0.8931419253349304]
using B-LOC [0.7473349571228027, -0.9548372030258179]
maximum B-LOC [0.8409215807914734, -0.9846228361129761]
follow-up B-LOC [0.836698591709137, -1.1211071014404297]
time B-LOC [0.668146014213562, -0.7282459735870361]
were B-LOC [0.6349876523017883, -0.8686050176620483]
1.4 B-LOC [0.4841850697994232, -0.49600350856781006]
(95% B-LOC [0.4619332551956177, -0.9135516881942749]
CI, B-LOC [-0.16936683654785156, -0.31520771980285645]
1.1-1.8), B-LOC [0.06219560280442238, -0.2885015308856964]
1.6 B-LOC [0.2070227712392807, -0.2672071158885956]
(95% B-LOC [0.3199315369129181, -0.7980100512504578]
CI, O [-0.26459699869155884, -0.1668316274881363]
1.3-2.2), B-LOC [0.013256109319627285, -0.1869608759880066]
and B-LOC [0.571437656879425, -0.8416355848312378]
2.5 B-LOC [0.44468554854393005, -0.37243595719337463]
(95% B-LOC [0.5164988040924072, -1.0038460493087769]
CI, B-LOC [-0.2182941436767578, -0.23982715606689453]
1.8-3.4), B-LOC [0.12407198548316956, -0.19918784499168396]
respectively B-LOC [0.7238520383834839, -1.1807005405426025]
(trend: B-LOC [0.779323399066925, -1.0491013526916504]
P B-LOC [0.5366841554641724, -1.1451315879821777]
= B-LOC [0.36553147435188293, -0.6470386385917664]
1 B-LOC [0.99783855676651, -1.1298366785049438]
× B-LOC [0.46392199397087097, -0.4756089150905609]
10(-8)). B-LOC [1.0658650398254395, -1.3083162307739258]
The B-LOC [1.060936450958252, -1.2324872016906738]
addition B-LOC [1.0139052867889404, -1.4489363431930542]
of B-LOC [1.2359848022460938, -1.5669138431549072]
inflammatory B-LOC [1.1440082788467407, -1.423110008239746]
biomarkers B-LOC [1.2326388359069824, -1.5532739162445068]
to B-LOC [1.1761764287948608, -1.476725697517395]
a B-LOC [1.4134464263916016, -1.5631556510925293]
basic B-LOC [1.2005329132080078, -1.5498979091644287]
model B-LOC [1.1247974634170532, -1.3780187368392944]
including B-LOC [1.3962175846099854, -1.4601800441741943]
age, B-LOC [1.3091094493865967, -1.4768998622894287]
sex, B-LOC [0.9804750084877014, -1.3757984638214111]
FEV1 B-LOC [1.2701101303100586, -1.3400893211364746]
percent B-LOC [1.293399453163147, -1.330649971961975]
predicted, B-LOC [0.9842986464500427, -1.1845757961273193]

smoking, B-LOC [0.5770261883735657, -0.9678729176521301]
use B-LOC [0.7995643019676208, -1.2490699291229248]
of B-LOC [1.0868712663650513, -1.4026780128479004]
any B-LOC [1.135098934173584, -1.4442923069000244]
inhaled B-LOC [0.8618824481964111, -1.2776267528533936]
medication, B-LOC [0.7147967219352722, -1.2718862295150757]
body B-LOC [0.8070746660232544, -1.08907949924469]
mass B-LOC [0.9033462405204773, -1.1150912046432495]
index, B-LOC [0.8059472441673279, -1.2244880199432373]
history B-LOC [1.1194126605987549, -1.4233276844024658]
of B-LOC [1.4693708419799805, -1.7510249614715576]
previous B-LOC [0.9302440285682678, -1.3869539499282837]
exacerbations, B-LOC [1.226676344871521, -1.670530080795288]
and B-LOC [1.3849343061447144, -1.5801591873168945]
time B-LOC [1.205702543258667, -1.6211037635803223]
since B-LOC [1.4115724563598633, -1.460600733757019]
most B-LOC [1.627400279045105, -1.7479889392852783]
recent B-LOC [1.6128039360046387, -1.5003749132156372]
prior B-LOC [1.26168954372406, -1.6480498313903809]
exacerbation B-LOC [1.5276861190795898, -1.8060534000396729]
improved B-LOC [1.1273243427276611, -1.3280246257781982]
the B-LOC [1.202746033668518, -1.4732534885406494]
C B-LOC [0.7933884859085083, -1.48393976688385]
statistics B-LOC [1.0100128650665283, -1.3698515892028809]
from B-LOC [0.9997503161430359, -1.2338604927062988]
0.71 B-LOC [1.2570974826812744, -1.5862172842025757]
to B-LOC [0.9286341071128845, -1.290755271911621]
0.73 B-LOC [1.2368812561035156, -1.7307790517807007]
(comparison: B-LOC [1.280723214149475, -1.3839426040649414]
P B-LOC [0.6610619425773621, -1.3356660604476929]
= B-LOC [0.7796555161476135, -1.234601616859436]
9 B-LOC [1.0018789768218994, -1.1376078128814697]
× B-LOC [0.565675675868988, -1.1256548166275024]
10(-5)). B-LOC [0.9725645184516907, -1.2762264013290405]
Relative B-LOC [2.3497018814086914, -2.2132365703582764]
risks B-LOC [2.4997048377990723, -2.361621856689453]
were B-LOC [2.1624886989593506, -2.208306312561035]
consistent B-LOC [2.4092984199523926, -2.362990617752075]
in B-LOC [2.2102878093719482, -2.2704951763153076]
those B-LOC [2.222134828567505, -1.934175729751587]
with B-LOC [2.0604360103607178, -2.049534320831299]
milder B-LOC [2.527270793914795, -2.3307528495788574]
COPD, B-LOC [1.8246476650238037, -2.1340525150299072]
in B-LOC [2.0894439220428467, -2.224566698074341]
those B-LOC [2.2172963619232178, -2.036811351776123]
with B-LOC [2.369039297103882, -2.329061508178711]
no B-LOC [2.438568592071533, -2.3517649173736572]
history B-LOC [2.4741227626800537, -2.3981611728668213]
of B-LOC [2.6245386600494385, -2.591423273086548]
frequent B-LOC [2.494365930557251, -2.6002252101898193]
exacerbations, B-LOC [2.820216178894043, -2.6136186122894287]
and B-LOC [2.4564743041992188, -2.575695037841797]
in B-LOC [2.429325580596924, -2.4578797817230225]
the B-LOC [2.6436767578125, -2.226969003677368]
2 B-LOC [2.409376382827759, -2.2466542720794678]
studies B-LOC [2.619276762008667, -2.515226125717163]
separately. B-LOC [2.6444966793060303, -2.7279462814331055]
The B-LOC [0.6995097994804382, -0.6304482817649841]
highest B-LOC [0.4568198323249817, -0.6376262307167053]
5-year B-LOC [0.37559667229652405, -0.5426300764083862]
absolute B-LOC [0.5131564140319824, -0.8804302215576172]
risks B-LOC [0.24800431728363037, -0.5173216462135315]
of B-LOC [0.3174643814563751, -0.4149535000324249]
having B-LOC [0.36849096417427063, -0.5566555261611938]
frequent B-LOC [0.32247763872146606, -0.5289720892906189]
exacerbations B-LOC [0.6398352980613708, -0.8976544141769409]
in B-LOC [0.3837534487247467, -0.27317488193511963]
those B-LOC [0.19174985587596893, -0.21141770482063293]
with B-LOC [0.14875461161136627, -0.4388748109340668]
3 B-LOC [0.39460644125938416, -0.13108491897583008]
high B-LOC [0.2630716860294342, -0.5603420734405518]
biomarkers B-LOC [0.1569402813911438, -0.5814675092697144]
(vs B-LOC [0.41272541880607605, -0.22544041275978088]
no B-LOC [0.28590598702430725, -0.1576051414012909]
high B-LOC [0.3107512295246124, -0.5434951782226562]
biomarkers) B-LOC [0.175360769033432, -0.5583339929580688]
were B-LOC [0.3706963360309601, -0.6152994632720947]
62% B-LOC [0.4252682030200958, -0.43495985865592957]

(vs B-LOC [1.0017368793487549, -1.4522236585617065]
24%) B-LOC [1.3445285558700562, -1.6616240739822388]
for B-LOC [1.2578582763671875, -1.4200071096420288]
those B-LOC [1.3937153816223145, -1.7312475442886353]
with B-LOC [1.8721904754638672, -1.9498872756958008]
Global B-LOC [1.9202760457992554, -2.137915849685669]
Initiative B-LOC [2.057060956954956, -2.2414724826812744]
for B-LOC [2.4968020915985107, -2.571475028991699]
Chronic B-LOC [2.4196717739105225, -2.3550703525543213]
Obstructive B-LOC [2.6018431186676025, -2.610309600830078]
Lung B-LOC [2.3402273654937744, -2.4843389987945557]
Disease B-LOC [2.0557520389556885, -2.429857015609741]
(GOLD) B-LOC [2.483778238296509, -2.312023401260376]
grades B-LOC [1.2948095798492432, -1.695561408996582]
C-D B-LOC [1.1755554676055908, -1.6129484176635742]
(n B-LOC [1.6954309940338135, -1.7994394302368164]
= B-LOC [0.7442919611930847, -1.4182997941970825]
558), B-LOC [1.6887702941894531, -1.6793346405029297]
98% B-LOC [1.257045030593872, -1.5952446460723877]
(vs B-LOC [1.477475643157959, -1.6938763856887817]
64%) B-LOC [1.2911152839660645, -1.1857337951660156]
in B-LOC [1.2977039813995361, -1.5184508562088013]
those B-LOC [1.4954407215118408, -1.747218370437622]
with B-LOC [1.813864827156067, -1.9324690103530884]
a B-LOC [1.718492865562439, -1.732218623161316]
history B-LOC [1.483742117881775, -1.6555923223495483]
of B-LOC [1.7006820440292358, -2.022937774658203]
frequent B-LOC [1.602593183517456, -1.8533536195755005]
exacerbations B-LOC [1.7485417127609253, -2.010244131088257]
(n B-LOC [1.519605040550232, -1.8153605461120605]
= B-LOC [0.7892062664031982, -1.5210258960723877]
127), B-LOC [1.538351058959961, -1.9154177904129028]
and B-LOC [1.1712822914123535, -1.4762935638427734]
52% B-LOC [1.3311989307403564, -1.2911856174468994]
(vs B-LOC [1.4611127376556396, -1.7181587219238281]
15%) B-LOC [1.2716853618621826, -1.2818447351455688]
for B-LOC [1.4303877353668213, -1.471726655960083]
those B-LOC [1.4934512376785278, -1.7005046606063843]
with B-LOC [1.6167702674865723, -1.6875500679016113]
GOLD B-LOC [1.530200719833374, -1.6180391311645508]
grades B-LOC [1.2971041202545166, -1.5276849269866943]
3-4 O [-0.8773491978645325, 0.6732047200202942]
(n B-LOC [1.3166296482086182, -1.433354377746582]
= B-LOC [0.6822988390922546, -1.3399854898452759]
465). B-LOC [1.0858346223831177, -0.9519081711769104]
CONCLUSIONS O [-1.2128043174743652, 0.8897831439971924]
AND O [-1.1136904954910278, 0.9203643202781677]
RELEVANCE O [-1.1815516948699951, 0.8589443564414978]
Simultaneously O [-1.1942615509033203, 1.1199908256530762]
elevated O [-1.3192616701126099, 1.1780166625976562]
levels O [-1.2312798500061035, 1.2063016891479492]
of O [-1.4570180177688599, 1.2532155513763428]
CRP O [-1.183665156364441, 1.2745039463043213]
and O [-1.5122398138046265, 1.2984018325805664]
fibrinogen O [-1.1361407041549683, 1.286020040512085]
and O [-1.5372451543807983, 1.3919084072113037]
leukocyte O [-1.090064287185669, 1.3224470615386963]
count O [-1.2580862045288086, 1.5064189434051514]
in O [-1.4701519012451172, 1.302419900894165]
individuals O [-1.4204051494598389, 1.2788734436035156]
with O [-1.558836579322815, 1.2179447412490845]
COPD O [-1.2730722427368164, 1.207169532775879]
were O [-1.5155117511749268, 1.3175427913665771]
associated O [-1.508608102798462, 1.276750922203064]
with O [-1.4485788345336914, 1.2369098663330078]
increased O [-1.4320106506347656, 1.158231496810913]
risk O [-1.3774601221084595, 1.226407766342163]
of O [-1.4351094961166382, 1.2258739471435547]
having O [-1.2665927410125732, 1.206017017364502]

exacerbations, O [-0.1986190527677536, -0.04296484962105751]
even O [-0.24486076831817627, 0.07333444058895111]
in O [-0.19194285571575165, 0.2386249303817749]
those O [-0.2658788859844208, 0.33020010590553284]
with O [-0.173247829079628, 0.1794002801179886]
milder O [-0.3008477985858917, 0.41892072558403015]
COPD O [-0.27305135130882263, 0.2537197172641754]
and O [-0.13309791684150696, 0.135636568069458]
in O [-0.19447724521160126, 0.25022459030151367]
those O [-0.19859234988689423, 0.26681771874427795]
without O [-0.07855787873268127, 0.229506254196167]
previous O [-0.2750318944454193, -0.16207018494606018]
exacerbations. O [-0.11903616040945053, -0.054876770824193954]
Further B-LOC [2.617600202560425, -3.0033934116363525]
investigation B-LOC [2.6260616779327393, -2.9967896938323975]
is B-LOC [2.82552170753479, -2.7917697429656982]
needed B-LOC [2.8062777519226074, -2.9085028171539307]
to B-LOC [3.003999710083008, -3.1323254108428955]
determine B-LOC [2.8149144649505615, -3.112762212753296]
the B-LOC [2.7600603103637695, -3.0631120204925537]
clinical B-LOC [2.5965588092803955, -3.1342649459838867]
value B-LOC [2.5288479328155518, -3.157338857650757]
of B-LOC [2.473093271255493, -2.950392484664917]
these B-LOC [2.3235316276550293, -2.681772232055664]
biomarkers B-LOC [2.0910890102386475, -2.9604203701019287]
for B-LOC [2.349538564682007, -2.907244920730591]
risk B-LOC [2.6053388118743896, -3.323133707046509]
stratification. B-LOC [2.374011278152466, -2.8636996746063232]

Excitation-transcription B-LOC [1.9313406944274902, -3.0193662643432617]
coupling, B-LOC [2.3891773223876953, -3.094036817550659]
linking B-LOC [2.6688883304595947, -3.1105833053588867]
stimulation B-LOC [2.0457968711853027, -2.9212310314178467]
at B-LOC [2.4478561878204346, -2.9669296741485596]
the B-LOC [2.34869384765625, -3.0620291233062744]
cell B-LOC [2.154447317123413, -3.012868881225586]
surface B-LOC [2.5047800540924072, -3.3860766887664795]
to B-LOC [2.515533208847046, -3.256723403930664]
changes B-LOC [2.482970952987671, -3.2577626705169678]
in B-LOC [2.3161916732788086, -3.413238525390625]
nuclear B-LOC [2.3816187381744385, -3.2382171154022217]
gene B-LOC [2.324690818786621, -3.2349793910980225]
expression, B-LOC [2.590369939804077, -3.171201705932617]
is B-LOC [3.1409528255462646, -2.9999940395355225]
conserved B-LOC [2.945390462875366, -3.2005627155303955]
throughout B-LOC [2.7345516681671143, -2.9808332920074463]
eukaryotes. B-LOC [2.663808584213257, -2.7040884494781494]
How B-LOC [2.7672343254089355, -3.4885990619659424]
closely B-LOC [3.023911237716675, -3.4234092235565186]
related B-LOC [2.934563159942627, -3.3021600246429443]
coexpressed B-LOC [2.7955191135406494, -3.187769889831543]
transcription B-LOC [2.370567560195923, -3.2039883136749268]
factors B-LOC [2.313481569290161, -2.996377468109131]
are B-LOC [3.118227958679199, -3.069420576095581]
differentially B-LOC [3.056178331375122, -3.438181161880493]
activated B-LOC [2.760133743286133, -3.1156888008117676]
remains B-LOC [3.222630739212036, -3.120933771133423]
unclear. B-LOC [3.133842706680298, -3.114006519317627]
Here, O [-0.29056671261787415, -0.016077794134616852]
we O [-0.4627836048603058, 0.1640523374080658]
show O [-0.30162331461906433, 0.1802474856376648]
that O [-0.46562710404396057, -0.10366957634687424]
two B-LOC [0.19480827450752258, -0.4820258319377899]
Ca2+-dependent B-LOC [0.9601402878761292, -1.4129842519760132]
transcription B-LOC [0.007845559157431126, -0.39610856771469116]
factor B-LOC [-0.19268053770065308, -0.40329453349113464]
isoforms, B-LOC [0.18119840323925018, -0.40916258096694946]
NFAT1 B-LOC [0.004352340940386057, -0.4646056890487671]
and B-LOC [0.026228317990899086, -0.28449705243110657]
NFAT4, B-LOC [0.045276474207639694, -0.5088461637496948]
require B-LOC [0.03880329430103302, -0.3421015739440918]
distinct B-LOC [0.2384406328201294, -0.687504231929779]
sub-cellular B-LOC [0.17207834124565125, -0.3988468050956726]
InsP3 B-LOC [-0.156697079539299, -0.3604869842529297]
and B-LOC [-0.034021131694316864, -0.24200224876403809]
Ca2+ B-LOC [-0.07126030325889587, -0.4537978172302246]
signals B-LOC [0.04373503103852272, -0.21843911707401276]
for B-LOC [-0.1214003935456276, -0.18952251970767975]
physiologically B-LOC [0.0006826692842878401, -0.1306619942188263]
sustained B-LOC [-0.04507158696651459, -0.390196293592453]
activation. B-LOC [0.04762094095349312, -0.19989031553268433]
NFAT1 O [-0.33261340856552124, 0.20599734783172607]
is O [-0.3069840967655182, 0.18734784424304962]
stimulated O [-0.3571285605430603, 0.3001970648765564]
by O [-0.39836305379867554, 0.3094397783279419]
sub-plasmalemmal O [-0.1167205274105072, 0.22613561153411865]
Ca2+ O [-0.4287143051624298, 0.2089216709136963]
microdomains, O [-0.4184187948703766, 0.3655804693698883]
whereas O [-0.2952113449573517, 0.32208284735679626]
NFAT4 O [-0.3880440294742584, 0.20139065384864807]
additionally O [-0.2655855715274811, 0.14283624291419983]
requires O [-0.22613415122032166, 0.18059691786766052]
Ca2+ O [-0.39225852489471436, 0.10711555182933807]
mobilization O [-0.3011654317378998, 0.29916855692863464]

from B-LOC [0.6097318530082703, -1.0467898845672607]
the B-LOC [0.6120617389678955, -0.9124323725700378]
inner B-LOC [0.6683374643325806, -1.1015509366989136]
nuclear B-LOC [0.814279317855835, -1.1658800840377808]
envelope B-LOC [0.5956504940986633, -1.0751501321792603]
by B-LOC [0.4648241102695465, -0.9040032625198364]
nuclear B-LOC [0.7764376997947693, -0.992775022983551]
InsP3 B-LOC [0.4354625642299652, -1.0260497331619263]
receptors. B-LOC [0.6697931289672852, -1.1039605140686035]
NFAT1 B-LOC [-0.006786228623241186, -0.022074643522500992]
is B-LOC [0.08680497854948044, 0.035876695066690445]
rephosphorylated O [0.12307512015104294, 0.13027536869049072]
(deactivated) B-LOC [0.21436837315559387, -0.06068439409136772]
more O [-0.1200171634554863, 0.2771882712841034]
slowly O [-0.029303042218089104, 0.1537177711725235]
than O [-0.14155326783657074, 0.30071696639060974]
NFAT4 O [-0.07297586649656296, 0.1010577380657196]
in O [-0.30498218536376953, 0.1823224127292633]
both O [-0.25112807750701904, 0.2713353931903839]
cytoplasm O [-0.242176353931427, 0.23415973782539368]
and O [-0.07762625813484192, 0.34940770268440247]
nucleus, B-LOC [0.03899508714675903, -0.09689648449420929]
enabling O [-0.30575406551361084, 0.31706997752189636]
a O [-0.188754141330719, 0.25125259160995483]
more O [-0.3060894310474396, 0.3077535927295685]
prolonged O [-0.04637503996491432, 0.039018627256155014]
activation B-LOC [0.13701370358467102, 0.008947556838393211]
phase. O [-0.095734141767025, 0.11291389167308807]
Oscillations B-LOC [0.49664807319641113, -0.8506835699081421]
in B-LOC [0.837618350982666, -0.9318767189979553]
cytoplasmic B-LOC [0.6773918867111206, -0.8240651488304138]
Ca2+, B-LOC [0.3231140077114105, -0.7862931489944458]
long B-LOC [1.4756594896316528, -1.0883501768112183]
considered B-LOC [1.390079379081726, -0.981624960899353]
the B-LOC [1.2690064907073975, -1.0803182125091553]
physiological B-LOC [0.8903244137763977, -1.151869297027588]
form B-LOC [0.8596288561820984, -1.0280749797821045]
of B-LOC [0.9536904692649841, -1.2891854047775269]
Ca2+ B-LOC [0.38387200236320496, -0.9441404938697815]
signaling, B-LOC [0.6507907509803772, -0.8630265593528748]
play B-LOC [1.1882210969924927, -1.0126811265945435]
no B-LOC [1.2739726305007935, -1.097359299659729]
role B-LOC [0.9726752638816833, -1.3774356842041016]
in B-LOC [1.082930564880371, -1.1528966426849365]
activating B-LOC [0.8293887376785278, -0.992247998714447]
either B-LOC [0.8209230303764343, -1.3505103588104248]
NFAT B-LOC [0.6449647545814514, -1.0082364082336426]
protein. B-LOC [0.5838606953620911, -1.023516297340393]
Instead, B-LOC [1.1383495330810547, -0.9001023769378662]
effective B-LOC [0.7888290286064148, -1.0502243041992188]
sustained B-LOC [0.7574270367622375, -1.1808353662490845]
physiological B-LOC [0.6034614443778992, -0.9539421796798706]
activation B-LOC [0.5493090748786926, -0.9323639273643494]
of B-LOC [0.6430498957633972, -0.9695140719413757]
NFAT4 B-LOC [0.5844115614891052, -0.8967400789260864]
is B-LOC [1.2345207929611206, -1.1335136890411377]
tightly B-LOC [1.1940240859985352, -1.242124319076538]
linked B-LOC [1.1109585762023926, -1.2030314207077026]
to B-LOC [0.8271122574806213, -1.205193042755127]
oscillations B-LOC [0.8881322741508484, -1.2118432521820068]
in B-LOC [0.87428218126297, -1.250583291053772]
nuclear B-LOC [0.9101249575614929, -1.2114721536636353]
Ca2+. B-LOC [0.44073107838630676, -0.9531431794166565]
Our B-LOC [0.5249819159507751, -0.7407130599021912]
results B-LOC [0.7710232734680176, -0.9290257096290588]
show B-LOC [0.7703921794891357, -0.8503780961036682]
how B-LOC [0.7958983778953552, -1.4941706657409668]
gene B-LOC [0.6861392855644226, -1.3351911306381226]
expression B-LOC [0.6918883323669434, -1.1264114379882812]
can B-LOC [0.8484247326850891, -1.4017341136932373]

be B-LOC [0.2881346046924591, -0.45536014437675476]
controlled B-LOC [0.20978137850761414, -0.40894997119903564]
by B-LOC [0.17013949155807495, -0.5590769648551941]
coincident B-LOC [0.3964832127094269, -0.6127171516418457]
yet B-LOC [0.5035915374755859, -0.473447322845459]
geographically B-LOC [0.4386340081691742, -0.5740602016448975]
distinct B-LOC [0.3284338414669037, -0.7103989720344543]
Ca2+ B-LOC [-0.019263001158833504, -0.4018458127975464]
signals, B-LOC [0.14808663725852966, -0.28384339809417725]
generated B-LOC [0.3541586697101593, -0.4364556670188904]
by B-LOC [0.20563797652721405, -0.3546672761440277]
a B-LOC [0.3163258731365204, -0.3445552885532379]
freely B-LOC [0.1963837593793869, -0.3761068284511566]
diffusible B-LOC [0.36384275555610657, -0.33568498492240906]
InsP3 B-LOC [-0.014973093755543232, -0.30572274327278137]
message. B-LOC [-0.054614271968603134, -0.2926119267940521]

The B-LOC [0.9781548380851746, -1.0756474733352661]
RIG-I-like B-LOC [0.9394047856330872, -1.3166656494140625]
receptors B-LOC [0.960037112236023, -1.3501969575881958]
(RLRs) B-LOC [1.3929529190063477, -1.2717218399047852]
RIG-I, B-LOC [0.8571727871894836, -1.1434056758880615]
MDA5, B-LOC [0.8882525563240051, -0.9761383533477783]
and B-LOC [1.0740190744400024, -0.9688004851341248]
LGP2 B-LOC [1.107053518295288, -1.1848628520965576]
play B-LOC [1.3732995986938477, -1.2436599731445312]
a B-LOC [1.2227662801742554, -1.0924382209777832]
major B-LOC [1.1844606399536133, -1.1420491933822632]
role B-LOC [1.0408391952514648, -1.2152466773986816]
in B-LOC [1.060981273651123, -1.2521865367889404]
pathogen B-LOC [1.5676579475402832, -1.694695234298706]
sensing B-LOC [1.0393041372299194, -1.0549958944320679]
of B-LOC [1.105011224746704, -1.3416723012924194]
RNA B-LOC [1.5512665510177612, -1.8248863220214844]
virus B-LOC [1.3333392143249512, -1.7168289422988892]
infection B-LOC [1.3560748100280762, -1.328592300415039]
to B-LOC [0.9371321797370911, -1.2059694528579712]
initiate B-LOC [1.2422444820404053, -1.3386600017547607]
and B-LOC [1.0914671421051025, -1.0997145175933838]
modulate B-LOC [1.5445133447647095, -1.3762760162353516]
antiviral B-LOC [1.6025431156158447, -1.6466997861862183]
immunity. B-LOC [1.4794673919677734, -1.5770056247711182]
The B-LOC [0.6244903206825256, -0.5599584579467773]
RLRs B-LOC [0.6011834740638733, -0.7041136622428894]
detect B-LOC [0.45457011461257935, -0.49551624059677124]
viral B-LOC [0.5226514935493469, -0.6372970342636108]
RNA B-LOC [0.48211678862571716, -0.6722068786621094]
ligands B-LOC [0.4784150719642639, -0.48309680819511414]
or B-LOC [0.451302170753479, -0.6491373181343079]
processed B-LOC [0.33556947112083435, -0.46985557675361633]
self B-LOC [0.33316323161125183, -0.5738894939422607]
RNA B-LOC [0.5032383799552917, -0.7403368949890137]
in B-LOC [0.22493727505207062, -0.3552717864513397]
the B-LOC [0.4765514135360718, -0.4497127830982208]
cytoplasm B-LOC [0.3898063600063324, -0.4956663250923157]
to B-LOC [0.19534267485141754, -0.5901386141777039]
trigger B-LOC [0.3353705108165741, -0.612575113773346]
innate B-LOC [0.4936899244785309, -0.6238900423049927]
immunity B-LOC [0.4743586480617523, -0.5488172173500061]
and B-LOC [0.31837746500968933, -0.5272715091705322]
inflammation B-LOC [0.5076500177383423, -0.6245537400245667]
and B-LOC [0.41239801049232483, -0.4445433020591736]
to B-LOC [0.3879848122596741, -0.5482921600341797]
impart B-LOC [0.35824891924858093, -0.4201420247554779]
gene B-LOC [0.3591334819793701, -0.5479676127433777]
expression B-LOC [0.37717899680137634, -0.23541700839996338]
that B-LOC [0.30374059081077576, -0.7140511274337769]
serves B-LOC [0.6788755059242249, -0.5311610102653503]
to B-LOC [0.5448353886604309, -0.5731768608093262]
control B-LOC [0.520194947719574, -0.7040135264396667]
infection. B-LOC [0.7099522352218628, -0.8072217702865601]
Importantly, B-LOC [1.0354526042938232, -0.7976748943328857]
RLRs B-LOC [0.7288616895675659, -0.9536332488059998]
cooperate B-LOC [0.9886893630027771, -0.8321713209152222]
in B-LOC [1.0578683614730835, -0.9556151628494263]
signaling B-LOC [1.003501534461975, -0.809451162815094]
crosstalk B-LOC [0.9933172464370728, -1.084612488746643]
networks B-LOC [1.0741621255874634, -0.9716814160346985]
with B-LOC [0.9544404149055481, -1.2410528659820557]
Toll-like B-LOC [0.9279740452766418, -1.078632116317749]
receptors B-LOC [0.9498226046562195, -1.2041245698928833]
and B-LOC [1.1179022789001465, -1.2062968015670776]
other B-LOC [1.3905010223388672, -1.3611016273498535]
factors B-LOC [1.0684921741485596, -1.4263678789138794]
to B-LOC [0.606483519077301, -1.0190082788467407]

impart B-LOC [1.0136692523956299, -1.5528361797332764]
innate B-LOC [1.2526795864105225, -1.5955733060836792]
immunity B-LOC [1.1040468215942383, -1.3651572465896606]
and B-LOC [1.1054346561431885, -1.4318227767944336]
to B-LOC [1.0647177696228027, -1.4921941757202148]
modulate B-LOC [1.5317158699035645, -1.7729856967926025]
the B-LOC [1.176764726638794, -1.4254918098449707]
adaptive B-LOC [1.324859380722046, -1.8612250089645386]
immune B-LOC [1.250056505203247, -1.5688704252243042]
response. B-LOC [1.2934856414794922, -1.6942152976989746]
RLR B-LOC [1.3798578977584839, -1.8066483736038208]
regulation B-LOC [1.4961097240447998, -1.6114643812179565]
occurs B-LOC [1.8371212482452393, -1.946821928024292]
at B-LOC [1.8096330165863037, -1.887341022491455]
a B-LOC [2.0060741901397705, -1.9441194534301758]
variety B-LOC [2.0370194911956787, -2.235996961593628]
of B-LOC [1.895132064819336, -2.200009346008301]
levels B-LOC [1.8643498420715332, -2.2432796955108643]
ranging B-LOC [1.942288875579834, -2.159928798675537]
from B-LOC [1.9392435550689697, -2.0197560787200928]
autoregulation B-LOC [1.9976081848144531, -2.5547268390655518]
to B-LOC [1.9216901063919067, -2.2265617847442627]
ligand B-LOC [1.9141263961791992, -2.1816775798797607]
and B-LOC [1.6181213855743408, -2.020684242248535]
cofactor B-LOC [1.6537692546844482, -2.0971288681030273]
interactions B-LOC [1.8268004655838013, -2.0415899753570557]
and B-LOC [1.8226183652877808, -2.0909714698791504]
posttranslational B-LOC [1.738830804824829, -1.9857754707336426]
modifications. B-LOC [1.8895022869110107, -2.17539381980896]
Abberant B-LOC [1.2521774768829346, -1.1549956798553467]
RLR B-LOC [1.02542245388031, -1.3253908157348633]
signaling B-LOC [1.245815634727478, -1.2037887573242188]
or B-LOC [1.5389658212661743, -1.2851896286010742]
dysregulation B-LOC [1.523008108139038, -1.5252768993377686]
of B-LOC [1.4626832008361816, -1.4478518962860107]
RLR B-LOC [1.1078457832336426, -1.4174884557724]
expression B-LOC [1.2034409046173096, -1.1303093433380127]
is B-LOC [2.076166868209839, -1.6238350868225098]
now B-LOC [2.1963655948638916, -1.7462636232376099]
implicated B-LOC [1.9630112648010254, -1.8288949728012085]
in B-LOC [1.9475255012512207, -1.847366452217102]
the B-LOC [1.9802957773208618, -1.6778392791748047]
development B-LOC [2.1567986011505127, -1.7935612201690674]
of B-LOC [2.1671152114868164, -2.170964479446411]
autoimmune B-LOC [2.1619811058044434, -2.152418375015259]
diseases. B-LOC [2.2402584552764893, -2.126488447189331]
Understanding B-LOC [2.3246171474456787, -2.563539505004883]
the B-LOC [2.4925506114959717, -2.6613481044769287]
processes B-LOC [2.475734233856201, -2.7830560207366943]
of B-LOC [2.1486315727233887, -2.542546510696411]
RLR B-LOC [1.705365777015686, -2.0031604766845703]
signaling B-LOC [2.04370379447937, -2.2165610790252686]
and B-LOC [2.343135118484497, -2.515429735183716]
response B-LOC [2.2416884899139404, -2.5228917598724365]
will B-LOC [2.3621599674224854, -2.6686110496520996]
provide B-LOC [2.4012012481689453, -2.730231523513794]
insights B-LOC [2.3309390544891357, -2.751035690307617]
to B-LOC [2.33785080909729, -2.74971079826355]
guide B-LOC [2.2790706157684326, -2.7739791870117188]
RLR-targeted B-LOC [1.8491089344024658, -2.1257410049438477]
therapeutics B-LOC [2.2865443229675293, -2.68632435798645]
for B-LOC [2.3480920791625977, -2.9315755367279053]
antiviral B-LOC [2.2777726650238037, -2.7569735050201416]
and B-LOC [2.1861934661865234, -2.6042582988739014]
immune-modifying B-LOC [2.2929980754852295, -2.7179620265960693]
applications. B-LOC [2.5590145587921143, -2.798914670944214]

CONTEXT B-LOC [0.7079662680625916, -1.1093499660491943]
Increasing B-LOC [1.116823673248291, -1.3549519777297974]
evidence B-LOC [1.0221105813980103, -1.0687448978424072]
supports B-LOC [1.272281527519226, -1.2833659648895264]
the B-LOC [1.4427318572998047, -1.4615620374679565]
hypothesis B-LOC [1.1435277462005615, -1.2827985286712646]
of B-LOC [1.0709869861602783, -1.3784599304199219]
a B-LOC [1.0049234628677368, -1.191746711730957]
causal B-LOC [1.1502203941345215, -1.2605926990509033]
association B-LOC [1.0214684009552002, -1.3382010459899902]
between B-LOC [1.1218599081039429, -1.6166021823883057]
certain B-LOC [1.159672737121582, -1.5435341596603394]
bacterial B-LOC [1.3070404529571533, -1.5337855815887451]
infections B-LOC [1.302706003189087, -1.3267171382904053]
and B-LOC [1.1377832889556885, -1.2652294635772705]
increased B-LOC [0.8560774326324463, -1.279832124710083]
risk B-LOC [1.01017427444458, -1.255598783493042]
of B-LOC [0.7967713475227356, -1.1669762134552002]
developing B-LOC [0.8958101868629456, -1.1775305271148682]
acute B-LOC [1.0192627906799316, -1.479374647140503]
myocardial B-LOC [0.8745468258857727, -1.263339877128601]
infarction. B-LOC [0.9664930701255798, -1.261932134628296]
If B-LOC [0.7517849206924438, -0.8853932619094849]
such B-LOC [1.052592396736145, -0.9229791760444641]
a B-LOC [1.0769250392913818, -1.0855705738067627]
causal B-LOC [1.1608569622039795, -1.1037216186523438]
association B-LOC [0.8802952170372009, -1.2047808170318604]
exists, B-LOC [1.3627216815948486, -1.0608277320861816]
subjects B-LOC [0.893558919429779, -1.0451061725616455]
who B-LOC [0.7089797258377075, -1.132272720336914]
used B-LOC [0.5574353337287903, -0.7986864447593689]
antibiotics B-LOC [0.8467957973480225, -1.0182651281356812]
active B-LOC [0.7491018176078796, -0.5736275315284729]
against B-LOC [0.8923520445823669, -0.6782206892967224]
the B-LOC [0.7380205988883972, -0.6995591521263123]
bacteria, B-LOC [0.8552246689796448, -1.2227504253387451]
regardless B-LOC [0.9733608365058899, -1.0723743438720703]
of B-LOC [1.3819479942321777, -1.4503599405288696]
indication, B-LOC [0.6863911151885986, -1.1731853485107422]
might B-LOC [0.8366181254386902, -0.9244797825813293]
be B-LOC [0.8389279842376709, -1.048365592956543]
at B-LOC [1.1168426275253296, -1.0286256074905396]
lower B-LOC [0.89168781042099, -0.8303731679916382]
risk B-LOC [1.0708521604537964, -0.9578492045402527]
of B-LOC [0.6309131979942322, -0.7426519393920898]
developing B-LOC [0.7937707304954529, -0.9206114411354065]
acute B-LOC [0.7908884882926941, -1.235299825668335]
myocardial B-LOC [0.8297421336174011, -1.128317952156067]
infarction B-LOC [0.9862224459648132, -1.0738722085952759]
than B-LOC [0.56146240234375, -0.7983258366584778]
nonusers. B-LOC [0.9998617768287659, -1.3056659698486328]
OBJECTIVE B-LOC [3.1299259662628174, -3.1405937671661377]
To B-LOC [3.34236741065979, -3.2745203971862793]
determine B-LOC [3.6073684692382812, -3.291077136993408]
whether B-LOC [3.573870897293091, -3.4567506313323975]
previous B-LOC [3.300921678543091, -3.714132785797119]
use B-LOC [3.3539860248565674, -3.7285892963409424]
of B-LOC [3.2136144638061523, -3.163938522338867]
antibiotics B-LOC [3.5422658920288086, -3.5399208068847656]
decreases B-LOC [3.363921880722046, -3.8026933670043945]
the B-LOC [3.4527642726898193, -3.4507896900177]
risk B-LOC [3.5921497344970703, -3.6435158252716064]
of B-LOC [3.0493557453155518, -3.2040977478027344]
developing B-LOC [3.47274112701416, -3.4061365127563477]
a B-LOC [3.4030473232269287, -3.4028666019439697]
first-time B-LOC [3.3247904777526855, -3.7254326343536377]
acute B-LOC [3.5551257133483887, -3.7470552921295166]
myocardial B-LOC [3.214083194732666, -2.9760491847991943]
infarction. B-LOC [3.447774648666382, -3.201669454574585]
DESIGN B-LOC [3.4622092247009277, -3.3303301334381104]
Population-based B-LOC [3.212108850479126, -3.2324349880218506]
case-control B-LOC [3.5589981079101562, -3.3947222232818604]
analysis. B-LOC [3.3437275886535645, -3.2979509830474854]

SETTING B-LOC [2.4497921466827393, -3.1922855377197266]
The B-LOC [2.8643243312835693, -3.1717443466186523]
United B-LOC [3.353576421737671, -3.220374345779419]
Kingdom-based B-LOC [3.44096302986145, -3.000939130783081]
General B-LOC [3.545078992843628, -3.6272165775299072]
Practice B-LOC [3.2913596630096436, -3.357917547225952]
Research B-LOC [3.2179763317108154, -3.474484920501709]
Database B-LOC [3.311685085296631, -3.267068386077881]
comprising B-LOC [3.6293587684631348, -3.1077754497528076]
350 B-LOC [3.699751138687134, -3.2993826866149902]
general B-LOC [3.5511605739593506, -3.622174024581909]
practices. B-LOC [3.4911091327667236, -3.3438854217529297]
PATIENTS B-LOC [2.9022576808929443, -3.193908452987671]
A B-LOC [3.3313210010528564, -3.0332190990448]
total B-LOC [3.7960872650146484, -2.8728089332580566]
of B-LOC [3.4662697315216064, -2.7009503841400146]
3315 B-LOC [3.5519587993621826, -2.8646090030670166]
case B-LOC [3.1849918365478516, -2.91363525390625]
patients B-LOC [3.4522109031677246, -2.9545066356658936]
aged B-LOC [3.588937759399414, -2.867619752883911]
75 B-LOC [3.3801209926605225, -2.7293784618377686]
years B-LOC [3.4446539878845215, -2.583420991897583]
or B-LOC [2.999906301498413, -2.6498212814331055]
younger B-LOC [3.552649974822998, -2.783020257949829]
with B-LOC [3.500948667526245, -2.890805721282959]
a B-LOC [3.2895052433013916, -2.7994322776794434]
diagnosis B-LOC [3.5583996772766113, -3.011887311935425]
of B-LOC [3.3908374309539795, -2.72990083694458]
first-time B-LOC [3.105292797088623, -2.9842584133148193]
acute B-LOC [3.222459077835083, -2.920093297958374]
myocardial B-LOC [2.9485390186309814, -2.534290075302124]
infarction B-LOC [3.267521619796753, -2.700308322906494]
between B-LOC [3.5002901554107666, -2.9151060581207275]
1992 B-LOC [3.317431926727295, -2.794386863708496]
and B-LOC [3.3664093017578125, -2.7292072772979736]
1997 B-LOC [3.348931074142456, -3.1249513626098633]
and B-LOC [3.3101155757904053, -3.0715911388397217]
13139 B-LOC [3.6425321102142334, -3.101501226425171]
controls B-LOC [3.394233465194702, -2.902881383895874]
without B-LOC [3.5411620140075684, -2.9083454608917236]
myocardial B-LOC [3.1677019596099854, -2.590996503829956]
infarction B-LOC [3.42779803276062, -3.0537941455841064]
matched B-LOC [3.5428836345672607, -3.013476610183716]
to B-LOC [3.2485878467559814, -3.176813840866089]
cases B-LOC [3.7072765827178955, -3.131239175796509]
for B-LOC [3.29785418510437, -3.0755903720855713]
age, B-LOC [3.582911491394043, -2.8748514652252197]
sex, B-LOC [3.568359613418579, -3.1668171882629395]
general B-LOC [3.616818428039551, -3.431791305541992]
practice B-LOC [3.4512827396392822, -3.320385694503784]
attended, B-LOC [3.4303507804870605, -3.3737950325012207]
and B-LOC [3.339125871658325, -3.134469747543335]
calendar B-LOC [3.4776971340179443, -3.3299577236175537]
time. B-LOC [3.516348123550415, -3.386004686355591]
MAIN B-LOC [3.284705400466919, -3.226510763168335]
OUTCOME B-LOC [3.082045316696167, -2.8363747596740723]
MEASURES B-LOC [3.2232046127319336, -2.9272854328155518]
Use B-LOC [3.050330638885498, -2.7370946407318115]
of B-LOC [3.0934934616088867, -2.6880099773406982]
antibiotics B-LOC [3.3932619094848633, -3.075446605682373]
among B-LOC [3.252345561981201, -2.8701696395874023]
those B-LOC [3.305210590362549, -2.6732447147369385]
who B-LOC [2.9919488430023193, -2.876220464706421]
did B-LOC [3.1816232204437256, -2.461155652999878]
or B-LOC [2.511035203933716, -2.5030784606933594]
did B-LOC [2.9150946140289307, -2.5720040798187256]
not B-LOC [2.910386800765991, -2.3364861011505127]
have B-LOC [3.297502040863037, -2.6530416011810303]
a B-LOC [3.179861068725586, -2.7062413692474365]
first-time B-LOC [3.0235464572906494, -3.065687894821167]
acute B-LOC [3.4013588428497314, -3.1866371631622314]
myocardial B-LOC [3.1820573806762695, -2.555588483810425]
infarction. B-LOC [3.368417978286743, -2.9967098236083984]
RESULTS B-LOC [0.7011815905570984, -1.6828196048736572]
Cases B-LOC [1.6240068674087524, -1.7647393941879272]
were B-LOC [1.1120703220367432, -1.8928954601287842]
significantly B-LOC [1.0510497093200684, -1.7592542171478271]

less O [-0.16785097122192383, 0.18660931289196014]
likely O [0.031781699508428574, 0.18291005492210388]
to B-LOC [0.06621378660202026, 0.013341037556529045]
have O [0.0077137150801718235, 0.06318193674087524]
used O [-0.1940022110939026, 0.09738937020301819]
tetracycline O [-0.06157650426030159, 0.16175700724124908]
antibiotics O [-0.1967296302318573, 0.18217402696609497]
(adjusted O [-0.30756285786628723, 0.33246833086013794]
odds O [-0.29603198170661926, 0.30353620648384094]
ratio O [-0.38051900267601013, 0.25291112065315247]
[OR], O [-0.30529406666755676, 0.22920332849025726]
0.70; O [-0.12313908338546753, 0.38346976041793823]
95% O [-0.40339958667755127, 0.47780585289001465]
confidence O [-0.3928903043270111, 0.3588501214981079]
interval O [-0.49350714683532715, 0.3259396255016327]
[CI], O [-0.29163989424705505, 0.2575679421424866]
0.55-0.90) O [-0.1855817437171936, 0.28922200202941895]
or O [-0.051057588309049606, 0.260501891374588]
quinolones O [-0.09004349261522293, 0.19314663112163544]
(adjusted O [-0.20713576674461365, 0.21252870559692383]
OR, O [-0.28168123960494995, 0.48437127470970154]
0.45; O [-0.14842242002487183, 0.19764068722724915]
95% O [-0.3885127305984497, 0.2634475529193878]
CI, O [-0.44232630729675293, 0.05565363168716431]
0.21-0.95). B-LOC [0.10442949831485748, -0.0894843339920044]
No B-LOC [0.8868680000305176, -1.1805851459503174]
effect B-LOC [0.7425124645233154, -1.2606310844421387]
was B-LOC [0.8371675610542297, -1.1742634773254395]
found B-LOC [0.8600307106971741, -1.2622483968734741]
for B-LOC [0.8674502372741699, -1.2034934759140015]
previous B-LOC [0.7066585421562195, -1.190976858139038]
use B-LOC [0.7344667911529541, -1.0898692607879639]
of B-LOC [0.9237372279167175, -1.1057634353637695]
macrolides B-LOC [1.0462709665298462, -1.1158051490783691]
(primarily B-LOC [1.1727286577224731, -1.2981226444244385]
erythromycin), B-LOC [0.6145185828208923, -1.138263463973999]
sulfonamides, B-LOC [0.9672211408615112, -1.2656941413879395]
penicillins, B-LOC [0.7983934283256531, -1.2987126111984253]
or B-LOC [1.1777360439300537, -1.4134619235992432]
cephalosporins. B-LOC [0.7121387124061584, -0.9390826225280762]
CONCLUSIONS O [-0.35063913464546204, 0.10048927366733551]
The B-LOC [0.7981224656105042, -0.822523295879364]
findings B-LOC [0.9726558327674866, -0.9900718331336975]
from B-LOC [0.9035195708274841, -1.0206637382507324]
this B-LOC [0.7204779982566833, -0.6814389228820801]
large B-LOC [0.8515874743461609, -1.1866588592529297]
case-control B-LOC [1.3013229370117188, -1.3255994319915771]
analysis B-LOC [0.9712750911712646, -1.3859155178070068]
provide B-LOC [0.8715127110481262, -0.863004744052887]
further, B-LOC [0.8329299092292786, -0.8808184266090393]

albeit O [0.05714504420757294, 0.06577008962631226]
indirect, B-LOC [0.22248420119285583, -0.015060009434819221]
evidence O [0.018328016623854637, 0.06983868777751923]
for B-LOC [0.06857334822416306, -0.10480521619319916]
an B-LOC [0.10502421855926514, -0.1738361120223999]
association B-LOC [0.19350072741508484, -0.1655348837375641]
between B-LOC [0.11897078156471252, -0.3207184970378876]
bacterial B-LOC [0.20225852727890015, -0.1853981614112854]
infections B-LOC [0.423147976398468, -0.18828251957893372]
with B-LOC [0.23061585426330566, -0.43374860286712646]
organisms B-LOC [0.21374750137329102, -0.24774552881717682]
susceptible B-LOC [0.2972854673862457, -0.20224477350711823]
to B-LOC [0.07540232688188553, -0.19846059381961823]
tetracycline B-LOC [0.26070091128349304, -0.27448326349258423]
or B-LOC [0.1982341855764389, -0.3110092878341675]
quinolone B-LOC [0.21213141083717346, -0.1934032291173935]
antibiotics B-LOC [0.1680942326784134, -0.14365944266319275]
and B-LOC [0.39629310369491577, -0.4232686460018158]
the B-LOC [0.3080180287361145, -0.49192172288894653]
risk B-LOC [0.15259189903736115, -0.3547786772251129]
of B-LOC [-0.011924461461603642, -0.349908709526062]
acute B-LOC [0.11476265639066696, -0.298545777797699]
myocardial B-LOC [-0.06533073633909225, -0.23012369871139526]
infarction. B-LOC [0.17327940464019775, -0.37511858344078064]
These B-LOC [1.6621038913726807, -1.685217022895813]
results B-LOC [1.909456491470337, -2.135725736618042]
of B-LOC [1.8859968185424805, -2.099519968032837]
preliminary B-LOC [1.9870386123657227, -2.3377530574798584]
nature B-LOC [2.0067994594573975, -2.381824493408203]
should B-LOC [1.7979116439819336, -2.0439765453338623]
stimulate B-LOC [1.8713310956954956, -2.255647897720337]
more B-LOC [1.9471192359924316, -2.562347650527954]
research B-LOC [2.0214154720306396, -2.4620611667633057]
to B-LOC [2.208111524581909, -2.313155174255371]
further B-LOC [2.205404043197632, -2.615382432937622]
explore B-LOC [2.276376485824585, -2.5301034450531006]
the B-LOC [2.3200180530548096, -2.5996596813201904]
role B-LOC [2.191800355911255, -2.7221477031707764]
of B-LOC [2.0167486667633057, -2.5860707759857178]
infections B-LOC [2.172163248062134, -2.4302818775177]
in B-LOC [2.143636465072632, -2.7707083225250244]
the B-LOC [2.2797091007232666, -2.6206486225128174]
etiology B-LOC [2.2849786281585693, -2.568718194961548]
of B-LOC [2.021296262741089, -2.355290651321411]
acute B-LOC [2.100821018218994, -2.3965137004852295]
myocardial B-LOC [1.675816297531128, -1.9533363580703735]
infarction. B-LOC [1.911060094833374, -1.9782114028930664]

T B-LOC [0.27638325095176697, -0.8860389590263367]
cell B-LOC [0.19994384050369263, -0.8952800631523132]
receptor B-LOC [0.4277612268924713, -0.9350887537002563]
(TCR-CD3) B-LOC [0.4837394654750824, -0.9378663301467896]
triggering B-LOC [0.32853004336357117, -0.8298113346099854]
involves B-LOC [0.24213731288909912, -0.7791721224784851]
both B-LOC [0.21309155225753784, -0.7164616584777832]
receptor B-LOC [0.28958627581596375, -0.6230508685112]
clustering B-LOC [0.5484653115272522, -0.7059652805328369]
and B-LOC [0.39841586351394653, -0.6543781757354736]
conformational B-LOC [0.6373306512832642, -0.9767633080482483]
changes B-LOC [0.36494603753089905, -0.9321916699409485]
at B-LOC [0.489722341299057, -0.9460916519165039]
the B-LOC [0.47455236315727234, -0.8449053168296814]
cytoplasmic B-LOC [0.45037713646888733, -0.9937376379966736]
tails B-LOC [0.7005104422569275, -0.8322625160217285]
of B-LOC [0.5667744874954224, -0.9991494417190552]
the B-LOC [0.6787843108177185, -0.8367639780044556]
CD3 B-LOC [0.5603414177894592, -0.7176530957221985]
subunits. B-LOC [0.5527964234352112, -0.9687650203704834]
The B-LOC [2.7221388816833496, -2.564854383468628]
mechanism B-LOC [2.4787216186523438, -2.480149030685425]
by B-LOC [2.508352518081665, -2.5428764820098877]
which B-LOC [2.5749261379241943, -2.6320912837982178]
TCRalphabeta B-LOC [1.7621264457702637, -1.9881480932235718]
ligand B-LOC [2.0791614055633545, -2.319669485092163]
binding B-LOC [2.1816792488098145, -2.2231862545013428]
confers B-LOC [2.4778478145599365, -2.6218671798706055]
conformational B-LOC [2.5178310871124268, -2.7461395263671875]
changes B-LOC [2.2725095748901367, -2.61955189704895]
to B-LOC [2.227775812149048, -2.46708607673645]
CD3 B-LOC [2.0738375186920166, -2.1446115970611572]
is B-LOC [3.1368935108184814, -2.428609609603882]
unknown. B-LOC [2.9766478538513184, -2.506815195083618]
By B-LOC [0.07300197333097458, -0.031632035970687866]
using B-LOC [0.30549684166908264, -0.12008460611104965]
well-defined B-LOC [0.6160606145858765, -0.4195215404033661]
ligands, B-LOC [0.5410004258155823, -0.35586994886398315]
we B-LOC [-0.05430658161640167, -0.10620227456092834]
showed O [-0.0007534711039625108, 0.08951804041862488]
that O [-0.15960636734962463, -0.15300486981868744]
induction B-LOC [0.20044319331645966, -0.2911514639854431]
of B-LOC [0.24319255352020264, -0.36176997423171997]
the B-LOC [0.2703499495983124, -0.41388705372810364]
conformational B-LOC [0.3568210005760193, -0.5493119955062866]
change B-LOC [0.1188683733344078, -0.6201543211936951]
requires B-LOC [0.05677236244082451, -0.24378788471221924]
both B-LOC [0.029032619670033455, -0.08952197432518005]
multivalent B-LOC [0.25390955805778503, -0.24117174744606018]
engagement B-LOC [0.2871681749820709, -0.26065146923065186]
and B-LOC [0.310896635055542, -0.03694343939423561]
the B-LOC [0.08991050720214844, -0.13257534801959991]
mobility B-LOC [0.2694171071052551, -0.16141988337039948]
restriction B-LOC [0.32089683413505554, -0.25637087225914]
of B-LOC [0.26145175099372864, -0.27774778008461]
the B-LOC [0.2801361083984375, -0.22316592931747437]
TCR-CD3 B-LOC [0.37593236565589905, -0.6282562017440796]
imposed B-LOC [0.29168060421943665, -0.36047831177711487]
by B-LOC [0.23700779676437378, -0.36931920051574707]
the B-LOC [0.2784792482852936, -0.3716677129268646]
plasma B-LOC [0.3038887083530426, -0.475053608417511]
membrane. B-LOC [0.22549569606781006, -0.4060268700122833]
The B-LOC [0.32406681776046753, -0.7440938353538513]
conformational B-LOC [0.7009369730949402, -0.8805434107780457]
change B-LOC [0.32516738772392273, -1.0616766214370728]
is B-LOC [0.6593897938728333, -0.8146447539329529]
elicited B-LOC [0.638096272945404, -0.7446961998939514]
by B-LOC [0.2508736848831177, -0.5796099901199341]
cooperative B-LOC [0.33092913031578064, -0.527534544467926]
rearrangements B-LOC [0.7953861355781555, -0.7365289330482483]
of B-LOC [0.6735929846763611, -0.9070541858673096]
two B-LOC [0.578796923160553, -0.9847062826156616]

TCR-CD3 B-LOC [0.08894647657871246, -0.6877260804176331]
complexes B-LOC [0.15097813308238983, -0.5382847189903259]
and B-LOC [-0.044617969542741776, -0.24137766659259796]
does B-LOC [0.1732480227947235, -0.2689775228500366]
not B-LOC [0.15146547555923462, -0.2201801836490631]
require B-LOC [0.01566375233232975, -0.5614935755729675]
accompanying B-LOC [0.14997580647468567, -0.40122953057289124]
changes B-LOC [-0.02029305137693882, -0.5177845358848572]
in B-LOC [-0.11425299942493439, -0.6252792477607727]
the B-LOC [0.062019798904657364, -0.4974694848060608]
structure B-LOC [0.38842594623565674, -0.4151434600353241]
of B-LOC [0.14138564467430115, -0.649707019329071]
the B-LOC [0.309144526720047, -0.4761843681335449]
TCRalphabeta B-LOC [0.21896223723888397, -0.47562211751937866]
ectodomains. B-LOC [0.01122387032955885, -0.3494153618812561]
This O [-0.16858306527137756, 0.07105860114097595]
conformational O [-0.034683406352996826, 0.022546319290995598]
change O [-0.23658707737922668, -0.10106848180294037]
at O [-0.33098211884498596, -0.07587248831987381]
CD3 O [-0.0717422217130661, 0.2969527542591095]
reverts O [-0.28211796283721924, 0.18176300823688507]
upon O [-0.2627085745334625, -0.06318577378988266]
ligand O [-0.10648570954799652, -0.0894922986626625]
dissociation O [-0.06431256234645844, 0.007727546151727438]
and O [-0.45772165060043335, 0.25416299700737]
is O [-0.2847868502140045, 0.20442579686641693]
required O [-0.28571680188179016, 0.13829673826694489]
for O [-0.32980504631996155, -0.03914586827158928]
T O [-0.08427631855010986, 0.05410311743617058]
cell O [-0.35153475403785706, 0.0122078787535429]
activation. O [-0.10971292108297348, 0.07470375299453735]
Thus, B-LOC [1.1688635349273682, -0.9598485827445984]
our B-LOC [1.026468276977539, -1.021602749824524]
permissive B-LOC [1.488396406173706, -1.8225432634353638]
geometry B-LOC [1.3854491710662842, -1.7137799263000488]
model B-LOC [1.335922360420227, -1.5969176292419434]
provides B-LOC [1.4230455160140991, -1.4935234785079956]
a B-LOC [1.4359800815582275, -1.5965632200241089]
molecular B-LOC [1.584688425064087, -1.7354811429977417]
mechanism B-LOC [1.3841224908828735, -1.8701438903808594]
that B-LOC [1.338038682937622, -1.6539561748504639]
rationalizes B-LOC [1.6381052732467651, -1.98624849319458]
how B-LOC [1.5299917459487915, -1.904297113418579]
the B-LOC [1.8286265134811401, -1.9681556224822998]
information B-LOC [1.4505022764205933, -1.8669054508209229]
of B-LOC [1.5319228172302246, -1.9075608253479004]
ligand B-LOC [1.638049840927124, -1.9609956741333008]
binding B-LOC [1.6766514778137207, -1.7104889154434204]
to B-LOC [1.6683861017227173, -1.6351685523986816]
TCRalphabeta B-LOC [1.1783485412597656, -1.482943058013916]
is B-LOC [2.089543104171753, -2.0540308952331543]
transmitted B-LOC [1.7985352277755737, -2.1002705097198486]
to B-LOC [1.6680917739868164, -2.1566810607910156]
the B-LOC [1.7637096643447876, -1.89530611038208]
CD3 B-LOC [1.3606488704681396, -1.446397304534912]
subunits B-LOC [1.3087050914764404, -1.7833118438720703]
and B-LOC [1.630799651145935, -1.8339014053344727]
to B-LOC [1.753196120262146, -2.2759687900543213]
the B-LOC [1.9901323318481445, -2.222923517227173]
intracellular B-LOC [1.4681463241577148, -1.8182297945022583]
signaling B-LOC [1.4355071783065796, -1.9482179880142212]
machinery. B-LOC [1.6720982789993286, -2.004612922668457]

CONTEXT B-LOC [1.8843307495117188, -2.5391199588775635]
Bioterrorist B-LOC [2.9419052600860596, -3.1401193141937256]
attacks B-LOC [2.5865485668182373, -2.684748888015747]
involving B-LOC [2.8845417499542236, -2.879709005355835]
letters B-LOC [2.3315703868865967, -2.767059564590454]
and B-LOC [2.7698824405670166, -2.983422040939331]
mail-handling B-LOC [2.5249135494232178, -2.889655590057373]
systems B-LOC [2.456629514694214, -3.016925096511841]
in B-LOC [2.83876895904541, -2.720794200897217]
Washington, B-LOC [2.9982314109802246, -2.953836441040039]
DC, B-LOC [3.018017292022705, -3.0342648029327393]
resulted B-LOC [2.6105172634124756, -2.6836156845092773]
in B-LOC [2.5059444904327393, -2.675518274307251]
Bacillus B-LOC [2.3135132789611816, -2.738088846206665]
anthracis B-LOC [2.6878440380096436, -2.8371429443359375]
(anthrax) B-LOC [2.5622525215148926, -2.6436338424682617]
spore B-LOC [2.682842493057251, -2.763566255569458]
contamination B-LOC [2.469913959503174, -2.7108983993530273]
in B-LOC [2.647264003753662, -2.64487624168396]
the B-LOC [2.878147840499878, -2.687459945678711]
Hart B-LOC [2.034104347229004, -2.6522772312164307]
Senate B-LOC [2.431230306625366, -2.924647569656372]
Office B-LOC [2.851543426513672, -3.1459286212921143]
Building B-LOC [2.455261468887329, -2.9340856075286865]
and B-LOC [2.68746018409729, -3.1027166843414307]
other B-LOC [2.8591885566711426, -2.902132272720337]
facilities B-LOC [2.631641149520874, -3.0696518421173096]
in B-LOC [3.1887638568878174, -2.9259254932403564]
the B-LOC [3.200071334838867, -2.894719362258911]
US B-LOC [2.6982734203338623, -3.1370792388916016]
Capitol's B-LOC [2.6141114234924316, -3.105274200439453]
vicinity. B-LOC [2.84670090675354, -2.9974467754364014]
OBJECTIVE B-LOC [3.207221746444702, -3.0862767696380615]
To B-LOC [3.3487865924835205, -3.0590126514434814]
provide B-LOC [3.3277037143707275, -3.081883192062378]
information B-LOC [3.429649591445923, -3.119781255722046]
about B-LOC [3.5774364471435547, -3.042752742767334]
the B-LOC [3.6639082431793213, -3.078782320022583]
nature B-LOC [3.5833370685577393, -3.218346357345581]
and B-LOC [3.3896636962890625, -2.733520984649658]
extent B-LOC [3.6195149421691895, -3.385704278945923]
of B-LOC [3.469755172729492, -2.99143648147583]
indoor B-LOC [3.3261704444885254, -3.2479846477508545]
secondary B-LOC [3.5043492317199707, -3.24316668510437]
aerosolization B-LOC [3.3901822566986084, -3.064875364303589]
of B-LOC [3.456434965133667, -2.905149459838867]
B B-LOC [3.1552937030792236, -3.3232343196868896]
anthracis B-LOC [3.310861587524414, -2.9246151447296143]
spores. B-LOC [3.464106321334839, -2.937011480331421]
DESIGN B-LOC [3.450843095779419, -3.029352903366089]
Stationary B-LOC [3.2325010299682617, -3.076117753982544]
and B-LOC [3.0742313861846924, -3.024099826812744]
personal B-LOC [3.4344775676727295, -3.3053181171417236]
air B-LOC [3.1584041118621826, -3.4325814247131348]
samples, B-LOC [3.3952739238739014, -3.17938232421875]
surface B-LOC [3.2782530784606934, -3.317838668823242]
dust, B-LOC [3.384612798690796, -3.2709479331970215]
and B-LOC [3.1678555011749268, -3.091050624847412]
swab B-LOC [3.325505495071411, -2.9887168407440186]
samples B-LOC [3.475552558898926, -3.2639238834381104]
were B-LOC [3.422466278076172, -2.8427257537841797]
collected B-LOC [3.5822129249572754, -3.186108350753784]
under B-LOC [3.461071014404297, -3.0823795795440674]
semiquiescent B-LOC [3.3276426792144775, -2.751399040222168]
(minimal B-LOC [3.314080238342285, -3.109269857406616]
activities) B-LOC [3.2169840335845947, -3.064174175262451]
and B-LOC [2.913184642791748, -2.9551424980163574]
then B-LOC [3.2804276943206787, -2.752598762512207]
simulated B-LOC [3.3059544563293457, -3.099064826965332]
active B-LOC [3.231426954269409, -3.388242244720459]
office B-LOC [3.2255396842956543, -3.367133855819702]
conditions B-LOC [3.4180781841278076, -3.1578762531280518]
to B-LOC [3.522106409072876, -2.8672192096710205]
estimate B-LOC [3.6440107822418213, -3.1957597732543945]
secondary B-LOC [3.4621570110321045, -2.872560501098633]

aerosolization B-LOC [2.534140110015869, -3.0507333278656006]
of B-LOC [2.8121707439422607, -3.2849462032318115]
B B-LOC [2.573421001434326, -3.0899658203125]
anthracis B-LOC [2.591480255126953, -3.1932296752929688]
spores. B-LOC [3.0920305252075195, -3.3985793590545654]
Nominal B-LOC [3.3963663578033447, -3.832575798034668]
size B-LOC [3.406310796737671, -3.6958401203155518]
characteristics, B-LOC [3.374532461166382, -3.7695322036743164]
airborne B-LOC [3.4812347888946533, -3.754047155380249]
concentrations, B-LOC [3.5089352130889893, -3.529163360595703]
and B-LOC [3.1952528953552246, -3.828662157058716]
surface B-LOC [3.5270583629608154, -3.857048273086548]
contamination B-LOC [3.3765952587127686, -3.7657206058502197]
of B-LOC [3.2468836307525635, -3.6486337184906006]
B B-LOC [3.1249630451202393, -3.5894551277160645]
anthracis B-LOC [3.0966694355010986, -3.6648120880126953]
particles B-LOC [3.348830461502075, -3.621669054031372]
(colony-forming B-LOC [3.4372105598449707, -3.7660441398620605]
units) B-LOC [3.425438642501831, -3.541553258895874]
were B-LOC [3.3638784885406494, -3.749382495880127]
evaluated. B-LOC [3.6098954677581787, -3.754678726196289]
RESULTS B-LOC [1.4491361379623413, -1.9679385423660278]
Viable B-LOC [1.6757432222366333, -1.761053204536438]
B B-LOC [2.0147547721862793, -2.3797314167022705]
anthracis B-LOC [1.9757746458053589, -2.262887716293335]
spores B-LOC [1.971068263053894, -2.14776349067688]
reaerosolized B-LOC [1.7822097539901733, -2.1224939823150635]
under B-LOC [2.094574451446533, -2.195342779159546]
semiquiescent B-LOC [1.9416604042053223, -2.1376538276672363]
conditions, B-LOC [1.907808542251587, -2.1341307163238525]
with B-LOC [1.5804287195205688, -1.827329397201538]
a B-LOC [1.6563844680786133, -1.9262585639953613]
marked B-LOC [1.5695834159851074, -1.8746967315673828]
increase B-LOC [1.5662567615509033, -2.0635266304016113]
in B-LOC [1.332209587097168, -1.9665297269821167]
reaerosolization B-LOC [1.5192975997924805, -2.0876095294952393]
during B-LOC [1.883019208908081, -2.22369122505188]
simulated B-LOC [1.8698099851608276, -2.337712049484253]
active B-LOC [1.9910240173339844, -2.3150832653045654]
office B-LOC [1.7782806158065796, -2.290442705154419]
conditions. B-LOC [1.8909645080566406, -2.2232234477996826]
Increases B-LOC [2.459932565689087, -2.371290445327759]
were B-LOC [2.4711251258850098, -2.390939950942993]
observed B-LOC [2.4443488121032715, -2.395556688308716]
for B-LOC [2.3838088512420654, -2.3389151096343994]
B B-LOC [2.005983829498291, -2.2487945556640625]
anthracis B-LOC [2.6621832847595215, -2.590402126312256]
collected B-LOC [2.5391733646392822, -2.4383933544158936]
on B-LOC [2.3476359844207764, -2.212796926498413]
open B-LOC [2.550612688064575, -2.8807432651519775]
sheep B-LOC [2.402174711227417, -2.6410255432128906]
blood B-LOC [2.4300878047943115, -2.803558588027954]
agar B-LOC [2.789170980453491, -2.734956979751587]
plates B-LOC [2.7093138694763184, -2.7649009227752686]
(P<.001) B-LOC [2.489945411682129, -2.3000316619873047]
and B-LOC [2.3217852115631104, -2.3697469234466553]
personal B-LOC [2.4377267360687256, -2.7405176162719727]
air B-LOC [2.2608587741851807, -2.9783918857574463]
monitors B-LOC [2.6729767322540283, -2.784304141998291]
(P B-LOC [2.518505334854126, -2.465306043624878]
=.01) B-LOC [1.6809706687927246, -1.978844165802002]
during B-LOC [2.2334773540496826, -2.583904981613159]
active B-LOC [2.380643606185913, -2.56581974029541]
office B-LOC [1.8437933921813965, -2.3256893157958984]
conditions. B-LOC [2.26444935798645, -2.496675729751587]
More B-LOC [1.3730404376983643, -1.3773657083511353]
than B-LOC [1.2190419435501099, -1.1689742803573608]

80% O [-0.5166910290718079, 0.2855563461780548]
of O [-0.5164587497711182, 0.553602397441864]
the O [-0.520272433757782, 0.531008780002594]
B O [-0.5497284531593323, 0.4153101146221161]
anthracis O [-0.44730111956596375, 0.06258387863636017]
particles O [-0.42119699716567993, 0.3538753092288971]
collected O [-0.2103690505027771, 0.25865545868873596]
on O [-0.274814248085022, 0.3255852460861206]
stationary O [-0.2975529134273529, 0.2909771800041199]
monitors O [-0.2941419780254364, 0.33271658420562744]
were O [-0.47298920154571533, 0.4777029752731323]
within O [-0.4155586063861847, 0.47226282954216003]
an O [-0.6709137558937073, 0.5781117677688599]
alveolar O [-0.4838087856769562, 0.36500221490859985]
respirable O [-0.5367366671562195, 0.7177906036376953]
size O [-0.439247727394104, 0.6670284867286682]
range O [-0.713714063167572, 0.520757794380188]
of O [-0.7281611561775208, 0.4310548007488251]
0.95 O [-0.3994792699813843, 0.44387713074684143]
to O [-0.7132006287574768, 0.13289424777030945]
3.5 O [-0.32506898045539856, 0.641671359539032]
micro O [-0.6440409421920776, 0.23990754783153534]
m. O [-0.6213223934173584, 0.08924144506454468]
CONCLUSIONS O [-0.8087491393089294, 0.5342381596565247]
Bacillus O [-0.618092954158783, 0.4687044620513916]
anthracis O [-0.5907784104347229, 0.46664658188819885]
spores O [-0.6148303151130676, 0.6343346834182739]
used O [-0.5825895667076111, 0.5245247483253479]
in O [-0.48414990305900574, 0.4934932589530945]
a O [-0.4415971040725708, 0.4680149257183075]
recent O [-0.44281911849975586, 0.46801188588142395]
terrorist O [-0.28045228123664856, 0.36434897780418396]
incident O [-0.3752969205379486, 0.4357580244541168]
reaerosolized O [-0.7014558911323547, 0.5984951853752136]
under O [-0.40284493565559387, 0.4332633316516876]
common O [-0.5505841374397278, 0.3773631155490875]
office O [-0.42126336693763733, 0.26617977023124695]
activities. O [-0.4448639452457428, 0.5034499168395996]
These B-LOC [1.9169338941574097, -2.010845184326172]
findings B-LOC [1.9323464632034302, -2.109499216079712]
have B-LOC [2.373339891433716, -2.2809994220733643]
important B-LOC [2.0955779552459717, -2.1623799800872803]
implications B-LOC [2.1961050033569336, -2.38716721534729]
for B-LOC [1.9707112312316895, -2.2829926013946533]
appropriate B-LOC [2.0104758739471436, -2.239927291870117]
respiratory B-LOC [1.981026530265808, -2.411020040512085]
protection, B-LOC [2.186335325241089, -2.3035006523132324]
remediation, B-LOC [2.438025951385498, -2.2228124141693115]
and B-LOC [2.188265323638916, -2.281104564666748]
reoccupancy B-LOC [2.27311110496521, -2.2245497703552246]
of B-LOC [2.0737991333007812, -1.9501017332077026]
contaminated B-LOC [1.9726016521453857, -2.2593204975128174]
office B-LOC [1.6479307413101196, -2.0483357906341553]
environments. B-LOC [1.9018447399139404, -2.0381906032562256]

OBJECTIVE B-LOC [3.35259747505188, -3.6780526638031006]
To B-LOC [3.3875436782836914, -3.667527198791504]
obtain B-LOC [3.5619397163391113, -3.5231006145477295]
summary B-LOC [3.668724536895752, -3.659433603286743]
estimates B-LOC [3.6626169681549072, -3.641225576400757]
of B-LOC [3.5762784481048584, -3.4312524795532227]
the B-LOC [3.722963809967041, -3.350475549697876]
accuracy B-LOC [3.5318312644958496, -3.5751049518585205]
of B-LOC [3.5298686027526855, -3.443450450897217]
a B-LOC [3.427225351333618, -3.3226840496063232]
single B-LOC [3.507024049758911, -3.549703359603882]
baseline B-LOC [3.7058677673339844, -3.596543550491333]
measurement B-LOC [3.730313777923584, -3.7406270503997803]
of B-LOC [3.6573617458343506, -3.438185453414917]
the B-LOC [3.791203260421753, -3.3596460819244385]
Elecsys B-LOC [3.610626697540283, -3.534553289413452]
Troponin B-LOC [3.714470624923706, -3.422452688217163]
T B-LOC [3.6142804622650146, -3.416672945022583]
high-sensitive B-LOC [3.6083006858825684, -3.3193745613098145]
assay B-LOC [3.679187536239624, -3.5549051761627197]
(Roche B-LOC [3.7570791244506836, -3.3756392002105713]
Diagnostics) B-LOC [3.4096858501434326, -3.399345636367798]
for B-LOC [3.68713116645813, -3.3533554077148438]
the B-LOC [3.583319664001465, -3.2660584449768066]
diagnosis B-LOC [3.913869619369507, -3.487011432647705]
of B-LOC [3.7074358463287354, -3.372917652130127]
acute B-LOC [3.6655385494232178, -3.4329774379730225]
myocardial B-LOC [3.56691837310791, -3.1747782230377197]
infarction B-LOC [3.685081720352173, -3.2529795169830322]
in B-LOC [3.590358018875122, -3.3688085079193115]
patients B-LOC [3.7801058292388916, -3.4135565757751465]
presenting B-LOC [3.8094308376312256, -3.5281131267547607]
to B-LOC [3.3754632472991943, -3.233614921569824]
the B-LOC [3.516536235809326, -3.1303603649139404]
emergency B-LOC [3.7613234519958496, -3.516169309616089]
department. B-LOC [3.591562032699585, -3.579909324645996]
DESIGN B-LOC [3.5748655796051025, -3.5224082469940186]
Systematic B-LOC [3.399127244949341, -2.988793134689331]
review B-LOC [3.414210319519043, -3.1361334323883057]
and B-LOC [3.41125750541687, -3.0950887203216553]
meta-analysis B-LOC [3.485905170440674, -3.224438428878784]
of B-LOC [3.4595062732696533, -3.270843505859375]
diagnostic B-LOC [3.641465663909912, -3.6708691120147705]
test B-LOC [3.6014254093170166, -3.699276924133301]
accuracy B-LOC [3.5500500202178955, -3.7128498554229736]
studies. B-LOC [3.645670175552368, -3.4424686431884766]
DATA B-LOC [3.595384359359741, -3.3657922744750977]
SOURCES B-LOC [3.2637288570404053, -3.0639073848724365]
Medline, B-LOC [3.2513673305511475, -2.9480836391448975]
Embase, B-LOC [3.1911890506744385, -3.070812463760376]
and B-LOC [3.1342296600341797, -3.130626916885376]
other B-LOC [3.2691657543182373, -2.9940054416656494]
relevant B-LOC [3.2911970615386963, -3.2913575172424316]
electronic B-LOC [3.346844434738159, -3.2590205669403076]
databases B-LOC [3.2697603702545166, -3.145674228668213]
were B-LOC [3.526430130004883, -3.1861963272094727]
searched B-LOC [3.5689470767974854, -3.005505084991455]
for B-LOC [3.447735071182251, -3.2743442058563232]
papers B-LOC [3.349978446960449, -3.349827527999878]
published B-LOC [3.552948474884033, -3.1896579265594482]
between B-LOC [3.4189817905426025, -2.9244954586029053]
January B-LOC [3.533153772354126, -2.940070390701294]
2006 B-LOC [3.548358201980591, -2.9866132736206055]
and B-LOC [3.505744695663452, -2.9484407901763916]
December B-LOC [3.5857746601104736, -2.8899240493774414]
2013. B-LOC [3.490225076675415, -3.174234390258789]
STUDY B-LOC [2.518442392349243, -2.8683857917785645]
SELECTION B-LOC [2.1484248638153076, -2.661583185195923]
Studies B-LOC [2.7440383434295654, -3.0332300662994385]
were B-LOC [3.1593210697174072, -2.96187424659729]
included B-LOC [3.538522720336914, -3.381530523300171]
if B-LOC [3.1626601219177246, -3.207153081893921]
they B-LOC [2.9232044219970703, -2.96492075920105]
evaluated B-LOC [3.123464584350586, -3.0352137088775635]
the B-LOC [3.424269676208496, -3.1135342121124268]
diagnostic B-LOC [3.3944122791290283, -3.4043924808502197]
accuracy B-LOC [3.222773790359497, -3.4391746520996094]
of B-LOC [3.051295042037964, -2.9937446117401123]
a B-LOC [3.0941450595855713, -2.981753349304199]

single B-LOC [2.854504108428955, -3.361332654953003]
baseline B-LOC [3.135619640350342, -3.803036689758301]
measurement B-LOC [2.861879587173462, -3.593773603439331]
of B-LOC [2.8906443119049072, -3.4131364822387695]
Elecsys B-LOC [2.9377615451812744, -3.320939064025879]
Troponin B-LOC [2.9112443923950195, -3.266047716140747]
T B-LOC [2.8033969402313232, -3.2831127643585205]
high-sensitive B-LOC [3.0340206623077393, -3.353872299194336]
assay B-LOC [3.1755871772766113, -3.613826036453247]
for B-LOC [3.2611756324768066, -3.614452362060547]
the B-LOC [3.294647216796875, -3.609835624694824]
diagnosis B-LOC [3.383497953414917, -3.6148505210876465]
of B-LOC [3.345266103744507, -3.559265375137329]
acute B-LOC [3.3552496433258057, -3.623018741607666]
myocardial B-LOC [3.013014793395996, -3.306013584136963]
infarction B-LOC [3.368530511856079, -3.444753885269165]
in B-LOC [3.2888848781585693, -3.5432956218719482]
patients B-LOC [3.4309113025665283, -3.455984354019165]
presenting B-LOC [3.4907209873199463, -3.609368085861206]
to B-LOC [3.3727519512176514, -3.6473727226257324]
the B-LOC [3.3416996002197266, -3.4485366344451904]
emergency B-LOC [3.3828327655792236, -3.5663957595825195]
department B-LOC [3.3191611766815186, -3.7308690547943115]
with B-LOC [3.3899693489074707, -3.48801589012146]
suspected B-LOC [3.397902727127075, -3.572654962539673]
acute B-LOC [3.4428493976593018, -3.5739622116088867]
coronary B-LOC [3.0973169803619385, -3.28487229347229]
syndrome. B-LOC [3.4032790660858154, -3.5539209842681885]
STUDY B-LOC [2.372040033340454, -2.97832989692688]
APPRAISAL B-LOC [2.7531521320343018, -3.3176591396331787]
AND B-LOC [2.7535412311553955, -3.5089516639709473]
DATA B-LOC [2.9435348510742188, -3.3538336753845215]
SYNTHESIS B-LOC [2.3179070949554443, -2.8674943447113037]
The B-LOC [2.547450542449951, -2.9558756351470947]
first B-LOC [2.6542909145355225, -3.122497797012329]
author B-LOC [2.9153294563293457, -3.4106218814849854]
screened B-LOC [2.9568607807159424, -3.5176961421966553]
all B-LOC [3.0677852630615234, -3.598917245864868]
titles B-LOC [3.2335026264190674, -3.659571647644043]
and B-LOC [2.920769214630127, -3.455416202545166]
abstracts B-LOC [3.42268443107605, -3.500927209854126]
identified B-LOC [3.473021984100342, -3.8360283374786377]
through B-LOC [3.218576669692993, -3.723710775375366]
the B-LOC [3.124537467956543, -3.4321353435516357]
searches B-LOC [3.527040481567383, -3.5440378189086914]
and B-LOC [3.048617124557495, -3.4587981700897217]
selected B-LOC [3.3260881900787354, -3.6963751316070557]
all B-LOC [3.245469331741333, -3.7076590061187744]
potentially B-LOC [3.303492546081543, -3.7178614139556885]
relevant B-LOC [3.2454826831817627, -3.771419048309326]
papers. B-LOC [3.4281294345855713, -3.6002562046051025]
The B-LOC [2.3755133152008057, -2.897975444793701]
screening B-LOC [2.9130804538726807, -3.2780416011810303]
of B-LOC [2.872952938079834, -3.1901626586914062]
the B-LOC [2.779625177383423, -3.160921812057495]
full B-LOC [2.8785181045532227, -3.4430348873138428]
texts, B-LOC [2.952423572540283, -3.335134744644165]
the B-LOC [2.6934192180633545, -3.1960411071777344]
data B-LOC [3.1178324222564697, -3.5235750675201416]
extraction, B-LOC [2.9905450344085693, -3.5411298274993896]
and B-LOC [2.9507646560668945, -3.0445737838745117]
the B-LOC [2.8423869609832764, -3.189491033554077]
methodological B-LOC [3.0366551876068115, -3.5940535068511963]
quality B-LOC [2.949368715286255, -3.549987316131592]
assessment, B-LOC [3.1883671283721924, -3.5432145595550537]
using B-LOC [3.150984764099121, -3.5394539833068848]
the B-LOC [3.1990509033203125, -3.179227828979492]
adapted B-LOC [2.863832950592041, -3.1494688987731934]
QUADAS-2 B-LOC [3.083984375, -2.9905130863189697]
tool, B-LOC [3.099419116973877, -3.315735340118408]
were B-LOC [2.6528866291046143, -2.8155710697174072]
conducted B-LOC [2.8849639892578125, -3.051299810409546]
independently B-LOC [2.8542988300323486, -3.1006832122802734]
by B-LOC [2.738863706588745, -3.125532865524292]
two B-LOC [2.603583574295044, -3.0056140422821045]
reviewers B-LOC [3.2057864665985107, -3.3008978366851807]
with B-LOC [2.773907423019409, -2.699209690093994]
disagreements B-LOC [2.9679372310638428, -3.017913579940796]
being B-LOC [3.128190755844116, -3.21708083152771]
resolved B-LOC [3.1600522994995117, -2.9212586879730225]
through B-LOC [3.113920211791992, -3.166778326034546]
discussion B-LOC [3.01613187789917, -2.858510732650757]

or B-LOC [2.7815535068511963, -3.5879690647125244]
arbitration. B-LOC [3.1416850090026855, -3.8085134029388428]
If B-LOC [3.320432424545288, -3.8824374675750732]
appropriate, B-LOC [3.362273931503296, -3.7095794677734375]
meta-analysis B-LOC [3.4340550899505615, -4.011859893798828]
was B-LOC [3.2664177417755127, -3.772913694381714]
conducted B-LOC [3.4616360664367676, -3.9172263145446777]
using B-LOC [3.430150270462036, -4.005964279174805]
the B-LOC [3.5320022106170654, -3.7634174823760986]
hierarchical B-LOC [3.353745937347412, -3.736787796020508]
bivariate B-LOC [3.326977014541626, -3.817927837371826]
model. B-LOC [3.339900493621826, -3.9910173416137695]
RESULTS B-LOC [1.9650248289108276, -2.7057316303253174]
Twenty B-LOC [3.270604372024536, -3.151475667953491]
three B-LOC [3.052510976791382, -3.336921453475952]
studies B-LOC [2.945324420928955, -3.2787797451019287]
reported B-LOC [2.9417240619659424, -3.3330557346343994]
the B-LOC [3.1212308406829834, -3.4391121864318848]
performance B-LOC [3.097450017929077, -3.6902811527252197]
of B-LOC [3.0409703254699707, -3.387734889984131]
the B-LOC [3.2254128456115723, -3.3558335304260254]
evaluated B-LOC [3.2312963008880615, -3.6100473403930664]
assay B-LOC [3.4441092014312744, -3.563530206680298]
at B-LOC [2.907083749771118, -3.2950150966644287]
presentation. B-LOC [3.1500089168548584, -3.620466709136963]
The B-LOC [2.833282947540283, -3.2260220050811768]
results B-LOC [2.7141916751861572, -3.2958831787109375]
for B-LOC [2.841305732727051, -2.874114751815796]
14 B-LOC [2.9882113933563232, -3.2404849529266357]
ng/L B-LOC [2.8489131927490234, -3.5314645767211914]
and B-LOC [2.844026803970337, -3.1603639125823975]
3-5 B-LOC [2.5741374492645264, -2.9570233821868896]
ng/L B-LOC [2.9575581550598145, -3.594905376434326]
cut-off B-LOC [3.2610952854156494, -3.6489250659942627]
values B-LOC [2.9733335971832275, -3.4871251583099365]
were B-LOC [3.126150369644165, -3.27287220954895]
pooled B-LOC [3.2130510807037354, -3.3684685230255127]
separately. B-LOC [3.1903908252716064, -3.4768660068511963]
At O [-0.21589034795761108, 0.06395899504423141]
14 B-LOC [0.10544241964817047, -0.07487113028764725]
ng/L B-LOC [0.3725966513156891, -0.2407267540693283]
(20 B-LOC [0.4088291823863983, -0.5160805583000183]
papers), B-LOC [0.6348621845245361, -0.6119285225868225]
the B-LOC [-0.0059495954774320126, -0.07624948024749756]
summary B-LOC [0.08120495826005936, -0.2248172163963318]
sensitivity O [-0.12709519267082214, 0.002258769702166319]
was B-LOC [0.06698909401893616, -0.17514371871948242]
89.5% O [-0.4107842743396759, 0.07295580208301544]
(95% O [-0.32865795493125916, -0.049508966505527496]
confidence O [-0.3067731559276581, 0.12330327928066254]
interval O [-0.523815393447876, 0.030882595106959343]
86.3% O [-0.6235230565071106, 0.4239019453525543]
to O [-0.4871542155742645, -0.040664080530405045]
92.1%) O [-0.5344032645225525, 0.3507760763168335]
and O [-0.548210620880127, -0.044372498989105225]
the O [-0.1423151195049286, -0.0344250313937664]
summary B-LOC [-0.11537962406873703, -0.15702179074287415]
specificity O [-0.21411600708961487, -0.027754629030823708]
was O [-0.20610922574996948, -0.07738184183835983]
77.1% O [-0.5281098484992981, 0.349332720041275]
(68.7% O [-0.4113568961620331, -0.0008569047204218805]
to O [-0.5410535335540771, -0.031414929777383804]
83.7%). O [-0.47823366522789, 0.2536815106868744]
At B-LOC [-0.05324080213904381, -0.17682316899299622]

3-5 O [-0.38883689045906067, 0.027345983311533928]
ng/L O [-0.27686044573783875, 0.095511294901371]
(six B-LOC [-0.1424834132194519, -0.14952480792999268]
papers), O [-0.16961988806724548, 0.09518297016620636]
the O [-0.39296868443489075, 0.0299850944429636]
summary O [-0.2865225672721863, -0.04424389451742172]
sensitivity O [-0.3683414161205292, 0.06068580225110054]
was O [-0.3938865065574646, 0.0008976287790574133]
97.4% O [-0.4804592430591583, 0.4294497072696686]
(94.9% O [-0.4071015417575836, -0.03515434265136719]
to O [-0.5053359270095825, -0.17966978251934052]
98.7%) O [-0.41690149903297424, 0.4941549003124237]
and O [-0.5106118321418762, 0.14122708141803741]
the O [-0.26712751388549805, -0.04672406613826752]
summary O [-0.26636460423469543, -0.12717370688915253]
specificity O [-0.3021746873855591, -0.0815940871834755]
was O [-0.33854588866233826, -0.011066460981965065]
42.4% O [-0.29887863993644714, 0.4321112334728241]
(31.2% O [-0.38595667481422424, -0.09422353655099869]
to O [-0.5080171227455139, -0.1326872557401657]
54.5%). O [-0.4466336667537689, 0.42350977659225464]
This O [-0.42141783237457275, 0.24310986697673798]
means O [-0.4890138804912567, 0.44148436188697815]
that O [-0.6160011887550354, 0.3649085760116577]
if O [-0.6388904452323914, 0.22998417913913727]
21 O [-0.16828586161136627, 0.4952729642391205]
of O [-0.4944206178188324, 0.5431408882141113]
100 O [-0.2833958566188812, 0.44797903299331665]
consecutive O [-0.4964519739151001, 0.29059651494026184]
patients O [-0.574430525302887, 0.39536240696907043]
have O [-0.3143843412399292, 0.19464217126369476]
the O [-0.2799476981163025, 0.29664888978004456]
target O [-0.4949972629547119, 0.5305356979370117]
condition O [-0.48253121972084045, 0.525036096572876]
(21%, O [-0.4201374650001526, 0.32390275597572327]
the O [-0.3087060749530792, 0.2412375658750534]
median O [-0.5518677830696106, 0.4643777310848236]
prevalence O [-0.4315207898616791, 0.3622463643550873]
across O [-0.17481055855751038, 0.007689160760492086]
the O [-0.026103636249899864, 0.07794129103422165]
studies), O [-0.3329555094242096, 0.12102250754833221]
2 O [-0.4741162359714508, 0.773234486579895]
(95% O [-0.4745408296585083, 0.37588080763816833]
confidence O [-0.6825487017631531, 0.49396100640296936]
interval O [-0.6030601859092712, 0.3282613754272461]
2 O [-0.5557374358177185, 0.5173215866088867]
to O [-0.4253932535648346, 0.08418464660644531]
3) O [-0.3501453995704651, 0.47045519948005676]
of O [-0.610867440700531, 0.4274531304836273]
21 O [-0.2523432672023773, 0.5005977153778076]
patients O [-0.6240389943122864, 0.4970514476299286]
with O [-0.47711923718452454, 0.3021981418132782]
acute O [-0.5936848521232605, 0.40006282925605774]
myocardial O [-0.7199329733848572, 0.4939498007297516]
infarction O [-0.5123447775840759, 0.3297964036464691]
will O [-0.33480530977249146, 0.2962026298046112]
be O [-0.29980653524398804, 0.1471564769744873]
missed O [-0.14024218916893005, 0.3138384521007538]
(false O [-0.2195725291967392, 0.14855682849884033]
negatives) O [-0.1876297891139984, -0.03563103452324867]
if O [-0.6153906583786011, 0.12681084871292114]
14 O [-0.17258384823799133, 0.16192962229251862]
ng/L O [-0.44796815514564514, 0.22007106244564056]
is O [-0.19250792264938354, 0.15107876062393188]
used O [-0.1936967968940735, 0.12166349589824677]
as O [-0.17601294815540314, 0.14337360858917236]
a O [-0.2810315191745758, 0.24091431498527527]
cut-off O [-0.21586601436138153, 0.118727907538414]
value O [-0.304097980260849, 0.17333781719207764]
and O [-0.4247386157512665, 0.22791443765163422]
18 O [-0.28119343519210815, 0.25843650102615356]

(13 B-LOC [0.5224149227142334, -1.0470991134643555]
to B-LOC [0.598577082157135, -1.0683096647262573]
25) B-LOC [1.0224547386169434, -1.1897892951965332]
of B-LOC [0.5853638052940369, -1.0055477619171143]
79 B-LOC [0.9076139330863953, -0.9463056325912476]
patients B-LOC [0.5877929329872131, -1.2167165279388428]
without B-LOC [0.6056377291679382, -1.0433664321899414]
acute B-LOC [0.5477975010871887, -1.1920549869537354]
myocardial B-LOC [0.4910925030708313, -1.129503607749939]
infarction B-LOC [0.7015106081962585, -1.203193187713623]
will B-LOC [0.6514598727226257, -1.017592430114746]
test B-LOC [0.6974229216575623, -1.2891756296157837]
positive B-LOC [0.8239161372184753, -1.1850862503051758]
(false B-LOC [0.915707528591156, -1.2814688682556152]
positives). B-LOC [0.8372496366500854, -1.3622794151306152]
If B-LOC [0.20348230004310608, -0.682966411113739]
the B-LOC [0.4672166407108307, -0.5925949215888977]
3-5 B-LOC [0.33052220940589905, -0.5310004949569702]
ng/L B-LOC [0.2524779736995697, -0.8443838953971863]
cut-off B-LOC [0.3383198380470276, -0.7006936073303223]
value B-LOC [0.3177599012851715, -0.8090286254882812]
is B-LOC [0.5450864434242249, -0.714649498462677]
used, B-LOC [0.526423990726471, -0.715333878993988]
<1 B-LOC [0.3487626612186432, -0.6899334192276001]
(0 B-LOC [0.4779109060764313, -0.7118126749992371]
to B-LOC [0.3689709007740021, -0.8851084113121033]
1) B-LOC [0.6492493748664856, -0.6466522812843323]
patient B-LOC [0.2930382192134857, -0.9125068187713623]
with B-LOC [0.5160946249961853, -0.8956438899040222]
acute B-LOC [0.29462122917175293, -0.837017834186554]
myocardial B-LOC [0.28298139572143555, -0.7433907389640808]
infarction B-LOC [0.49001163244247437, -0.8309649229049683]
will B-LOC [0.36204299330711365, -0.6872954368591309]
be B-LOC [0.5125129818916321, -0.7853951454162598]
missed B-LOC [0.7190421223640442, -0.7831965684890747]
and B-LOC [0.18262282013893127, -0.6299132704734802]
46 B-LOC [0.6796488761901855, -0.7571614384651184]
(36 B-LOC [0.5717951655387878, -0.9751865267753601]
to B-LOC [0.28420132398605347, -0.9531405568122864]
54) B-LOC [0.7838639616966248, -0.9678956866264343]
patients B-LOC [0.4799032211303711, -1.0893590450286865]
without B-LOC [0.4931219816207886, -0.8011506199836731]
acute B-LOC [0.32921352982521057, -1.0113097429275513]
myocardial B-LOC [0.36788174510002136, -0.8334111571311951]
infarction B-LOC [0.5699923634529114, -0.9257513880729675]
will B-LOC [0.40081679821014404, -0.7765378952026367]
test B-LOC [0.4647168815135956, -1.2133355140686035]
positive. B-LOC [0.5315350890159607, -1.0840989351272583]
CONCLUSIONS O [-0.5301416516304016, 0.1378004103899002]
The B-LOC [0.7581294178962708, -0.7257871031761169]
results B-LOC [0.7658676505088806, -0.8985471129417419]
indicate B-LOC [0.5556837916374207, -0.6382233500480652]
that B-LOC [0.6155361533164978, -0.8141995072364807]
a B-LOC [1.2562363147735596, -1.0631159543991089]
single B-LOC [1.5786700248718262, -1.2754619121551514]
baseline B-LOC [1.405334234237671, -1.5234627723693848]
measurement B-LOC [1.1517548561096191, -1.334910273551941]
of B-LOC [1.1635653972625732, -1.398148775100708]
the B-LOC [1.4833375215530396, -1.4630910158157349]
Elecsys B-LOC [1.2812139987945557, -1.1811516284942627]
Troponin B-LOC [1.3408851623535156, -1.227455973625183]
T B-LOC [1.0534621477127075, -1.1791269779205322]
high-sensitive B-LOC [1.1005291938781738, -1.1652196645736694]
assay B-LOC [1.362912893295288, -1.486018419265747]
could B-LOC [1.0109834671020508, -1.0539876222610474]
be B-LOC [1.2887206077575684, -1.4543198347091675]
used B-LOC [1.3485491275787354, -1.4565051794052124]
to B-LOC [1.53904390335083, -1.3824098110198975]
rule B-LOC [1.4326289892196655, -1.3795745372772217]
out B-LOC [1.4407069683074951, -1.5356136560440063]
acute B-LOC [1.1157879829406738, -1.416940689086914]
myocardial B-LOC [0.7338690757751465, -0.9512577652931213]
infarction B-LOC [1.2132010459899902, -1.3257761001586914]
if B-LOC [0.754302978515625, -1.199554681777954]

lower B-LOC [0.4239853620529175, -0.5994592905044556]
cut-off B-LOC [0.590752363204956, -0.6909633278846741]
values B-LOC [0.5701399445533752, -0.7648380398750305]
such B-LOC [0.5611984729766846, -0.7757577300071716]
as B-LOC [0.4817593991756439, -0.7461302876472473]
3 B-LOC [0.34568077325820923, -0.5215482115745544]
ng/L B-LOC [0.43425455689430237, -0.8089446425437927]
or B-LOC [0.5157299637794495, -0.8366491794586182]
5 B-LOC [0.4382566511631012, -0.5852473378181458]
ng/L B-LOC [0.4431668817996979, -0.8159539103507996]
are B-LOC [0.730690598487854, -0.8923243880271912]
used. B-LOC [0.6355763077735901, -0.7095332741737366]
However, B-LOC [1.2453975677490234, -1.3397834300994873]
this B-LOC [1.0341805219650269, -1.2400407791137695]
method B-LOC [0.8974030017852783, -1.31759774684906]
should B-LOC [1.4644719362258911, -1.4609746932983398]
be B-LOC [1.3094052076339722, -1.6174981594085693]
part B-LOC [1.634667158126831, -1.386777639389038]
of B-LOC [1.3849434852600098, -1.64644193649292]
a B-LOC [1.3742343187332153, -1.7128784656524658]
comprehensive B-LOC [1.263987421989441, -1.6214861869812012]
triage B-LOC [1.4472298622131348, -1.6897931098937988]
strategy B-LOC [1.3635703325271606, -1.6448628902435303]
and B-LOC [0.6816311478614807, -0.972809374332428]
may B-LOC [1.435178518295288, -1.5316002368927002]
not B-LOC [1.3033021688461304, -1.2100087404251099]
be B-LOC [1.0962117910385132, -1.6225560903549194]
appropriate B-LOC [1.1076958179473877, -1.3809418678283691]
for B-LOC [1.2512716054916382, -1.605581283569336]
patients B-LOC [1.1998294591903687, -1.549909234046936]
who B-LOC [1.0872782468795776, -1.5233588218688965]
present B-LOC [1.0460219383239746, -1.3811869621276855]
less B-LOC [0.8959376215934753, -1.3582184314727783]
than B-LOC [0.7600721716880798, -1.3179184198379517]
three B-LOC [0.7506718635559082, -1.005944013595581]
hours B-LOC [1.0497045516967773, -1.4111818075180054]
after B-LOC [0.9996827244758606, -1.3165165185928345]
symptom B-LOC [1.2226314544677734, -1.675022840499878]
onset. B-LOC [0.8074416518211365, -1.3458101749420166]
Care B-LOC [2.440633535385132, -2.6619985103607178]
must B-LOC [2.4189465045928955, -2.5516703128814697]
also B-LOC [2.549548864364624, -2.5254220962524414]
be B-LOC [2.5939571857452393, -2.7095978260040283]
exercised B-LOC [2.7403476238250732, -2.7638885974884033]
because B-LOC [2.137760877609253, -1.7323228120803833]
of B-LOC [2.067415714263916, -1.824193000793457]
the B-LOC [2.096452474594116, -2.0090882778167725]
higher B-LOC [1.2409864664077759, -1.5987324714660645]
imprecision B-LOC [2.3546693325042725, -2.238736391067505]
of B-LOC [2.363448143005371, -2.3010811805725098]
the B-LOC [2.582948684692383, -2.4442622661590576]
evaluated B-LOC [2.391486406326294, -2.4767673015594482]
assay B-LOC [2.885417938232422, -2.5805633068084717]
and B-LOC [1.5255826711654663, -1.3061017990112305]
the B-LOC [1.7312042713165283, -1.750328540802002]
greater B-LOC [1.2926679849624634, -1.5215880870819092]
effect B-LOC [2.0912692546844482, -2.2335093021392822]
of B-LOC [1.9195810556411743, -2.046513080596924]
lot-to-lot B-LOC [2.4897754192352295, -2.7422921657562256]
reagent B-LOC [2.6315996646881104, -2.425142765045166]
variation B-LOC [2.041081666946411, -2.1955325603485107]
at B-LOC [1.8788150548934937, -1.8700668811798096]
low B-LOC [1.7219427824020386, -1.8979334831237793]
troponin B-LOC [2.5311660766601562, -2.31369686126709]
concentrations. B-LOC [2.304605722427368, -2.0603725910186768]
SYSTEMATIC B-LOC [1.897938847541809, -2.149273157119751]
REVIEW B-LOC [2.0060644149780273, -2.160433292388916]
REGISTRATION B-LOC [1.8141958713531494, -1.8629062175750732]
PROSPERO B-LOC [1.9579377174377441, -2.0305159091949463]
registration B-LOC [2.3608057498931885, -2.0136358737945557]
number B-LOC [2.1116998195648193, -1.8415625095367432]
CRD42013003926. B-LOC [2.36154842376709, -2.1857619285583496]

OBJECTIVE B-LOC [3.080274820327759, -3.6481611728668213]
To B-LOC [3.2433319091796875, -3.8119163513183594]
describe B-LOC [3.3541455268859863, -3.800342559814453]
the B-LOC [3.5351157188415527, -3.71496844291687]
efficacy B-LOC [3.4288136959075928, -3.9850854873657227]
of B-LOC [3.467836380004883, -3.706420660018921]
the B-LOC [3.521754503250122, -3.6595778465270996]
Finnish B-LOC [3.217327833175659, -4.019864082336426]
mass B-LOC [3.3650569915771484, -3.966892719268799]
screening B-LOC [3.2653005123138428, -3.974418878555298]
program B-LOC [3.5571577548980713, -3.9357540607452393]
for B-LOC [3.597278594970703, -3.7175488471984863]
cervical B-LOC [3.3390746116638184, -3.6143877506256104]
squamous B-LOC [3.497105836868286, -3.4187886714935303]
carcinoma B-LOC [3.358203172683716, -3.6273488998413086]
and B-LOC [3.390639543533325, -3.5695037841796875]
adenocarcinoma, B-LOC [3.527111768722534, -3.588685989379883]
as B-LOC [3.5471513271331787, -3.587920904159546]
reflected B-LOC [3.5072414875030518, -3.7947232723236084]
by B-LOC [3.308030366897583, -3.545954704284668]
changes B-LOC [3.433126926422119, -3.9247331619262695]
of B-LOC [3.2874298095703125, -3.635312557220459]
incidence B-LOC [3.561978578567505, -3.812798500061035]
and B-LOC [3.1500320434570312, -3.5327022075653076]
mortality B-LOC [3.7330098152160645, -3.819272994995117]
rate. B-LOC [3.6238009929656982, -3.9587013721466064]
METHODS B-LOC [2.9309489727020264, -3.5417959690093994]
Cervical B-LOC [3.2392823696136475, -3.440638780593872]
cancer B-LOC [3.3018627166748047, -3.751272201538086]
incidence B-LOC [3.4135475158691406, -3.5992114543914795]
and B-LOC [3.0321602821350098, -3.382610559463501]
mortality B-LOC [3.458080530166626, -3.735222816467285]
data B-LOC [3.3307082653045654, -3.547910213470459]
were B-LOC [3.2768771648406982, -3.334841251373291]
obtained B-LOC [3.47444748878479, -3.376534938812256]
from B-LOC [3.361881971359253, -3.319566249847412]
the B-LOC [3.4189541339874268, -3.2912063598632812]
Finnish B-LOC [2.935697078704834, -3.8613669872283936]
Cancer B-LOC [3.1512622833251953, -3.7693045139312744]
Registry. B-LOC [3.5605883598327637, -3.5699002742767334]
Data B-LOC [3.323496103286743, -3.7014834880828857]
were B-LOC [3.4009015560150146, -3.5484049320220947]
available B-LOC [3.526266574859619, -3.408176898956299]
from B-LOC [3.405724287033081, -3.2952873706817627]
the B-LOC [3.3167903423309326, -3.3830363750457764]
year B-LOC [3.403707504272461, -3.6639645099639893]
1953, B-LOC [3.1952438354492188, -3.742948293685913]
when B-LOC [3.1233837604522705, -3.639866590499878]
the B-LOC [3.33880352973938, -3.6488449573516846]
registry B-LOC [3.4500300884246826, -3.930149555206299]
was B-LOC [3.397878885269165, -3.5617003440856934]
established. B-LOC [3.571272134780884, -3.8040194511413574]
The B-LOC [3.1668951511383057, -3.485260009765625]
nationwide B-LOC [3.1476492881774902, -3.596287488937378]
mass B-LOC [2.9373104572296143, -3.587366819381714]
screening B-LOC [3.0032413005828857, -3.569746255874634]
program B-LOC [3.2275168895721436, -3.634183645248413]
in B-LOC [3.1407766342163086, -3.2088077068328857]
Finland B-LOC [2.6923105716705322, -3.3443877696990967]
was B-LOC [3.167912006378174, -3.3813154697418213]
started B-LOC [3.3165557384490967, -3.558259963989258]
in B-LOC [3.0216734409332275, -3.4292993545532227]
the B-LOC [3.073652744293213, -3.3512203693389893]
mid-1960s. B-LOC [3.0422775745391846, -3.427014112472534]
A B-LOC [3.153092384338379, -3.2863571643829346]
centralized B-LOC [3.241088390350342, -3.481663465499878]
organization B-LOC [3.3742997646331787, -3.4167885780334473]
administers B-LOC [3.422429084777832, -3.1337127685546875]
this B-LOC [2.9920787811279297, -3.2506520748138428]
program. B-LOC [3.129828691482544, -3.459460973739624]
Women B-LOC [2.923332452774048, -3.0122623443603516]
age B-LOC [3.2998383045196533, -3.0231823921203613]
30-60 B-LOC [3.1623616218566895, -2.8950202465057373]
years B-LOC [3.1669957637786865, -3.0580837726593018]
are B-LOC [3.183961868286133, -2.92983078956604]
notified B-LOC [3.319658041000366, -3.193082571029663]
for B-LOC [3.053075075149536, -2.888320207595825]
screening B-LOC [2.9101369380950928, -3.1016666889190674]
every B-LOC [2.7563893795013428, -3.138263463973999]
5 B-LOC [2.338489294052124, -3.017467737197876]

years. B-LOC [1.253361701965332, -1.9590895175933838]
RESULTS B-LOC [0.5941793322563171, -1.388418197631836]
The B-LOC [0.8379541039466858, -1.2446595430374146]
mean B-LOC [0.57358318567276, -1.1223936080932617]
incidence B-LOC [0.5641174912452698, -1.0772264003753662]
of B-LOC [0.6070516705513, -1.01156485080719]
cervical B-LOC [0.5275964140892029, -0.9893882870674133]
carcinoma B-LOC [0.5206312537193298, -1.1452800035476685]
in B-LOC [0.7248564958572388, -1.1530261039733887]
the B-LOC [0.7583920359611511, -1.0902587175369263]
early B-LOC [0.7614690661430359, -1.233252763748169]
1960s B-LOC [0.789446234703064, -1.236964464187622]
was B-LOC [0.4746774733066559, -1.1311454772949219]
15.4 B-LOC [0.6909921169281006, -0.8918508887290955]
per B-LOC [0.5042373538017273, -1.0183002948760986]
10(5) B-LOC [0.8993275761604309, -1.2591142654418945]
woman-years. B-LOC [0.5289925336837769, -1.0398894548416138]
In B-LOC [1.393865942955017, -1.5624620914459229]
1991, B-LOC [1.8999472856521606, -1.8323297500610352]
it B-LOC [0.993487536907196, -1.4651761054992676]
was B-LOC [1.2074165344238281, -1.5244911909103394]
only B-LOC [1.4648220539093018, -1.5436286926269531]
2.7 B-LOC [1.5136313438415527, -1.6077011823654175]
per B-LOC [0.9968152642250061, -1.466353178024292]
10(5) B-LOC [1.6705600023269653, -2.03312611579895]
woman-years. B-LOC [1.1746855974197388, -1.6673834323883057]
The B-LOC [1.6388373374938965, -1.971177101135254]
mortality B-LOC [2.0403385162353516, -2.279231548309326]
rate B-LOC [1.884904384613037, -2.4087414741516113]
has B-LOC [2.089721918106079, -2.038255453109741]
decreased B-LOC [2.0772507190704346, -2.238999366760254]
in B-LOC [1.8565592765808105, -1.885859489440918]
the B-LOC [1.8993861675262451, -1.8859754800796509]
same B-LOC [1.8538615703582764, -2.3268892765045166]
proportion B-LOC [1.8887094259262085, -2.243757486343384]
since B-LOC [1.9980875253677368, -2.0164108276367188]
the B-LOC [1.7005057334899902, -1.9039080142974854]
mass B-LOC [1.5835843086242676, -2.113330125808716]
screening B-LOC [1.7856050729751587, -2.280924081802368]
program. B-LOC [1.6832643747329712, -2.0884151458740234]
In B-LOC [0.7511947751045227, -0.932498037815094]
the B-LOC [1.0693227052688599, -1.0466217994689941]
early B-LOC [0.8800228238105774, -1.1607613563537598]
1960s, B-LOC [1.0229101181030273, -1.1395142078399658]
the B-LOC [0.8126266598701477, -0.9738494753837585]
mortality B-LOC [0.7828903198242188, -1.1402294635772705]
was B-LOC [0.4924558699131012, -0.878427267074585]
6.6 B-LOC [0.6088923215866089, -0.6989657282829285]
and B-LOC [0.6012234091758728, -0.853884756565094]
in B-LOC [0.9725275635719299, -0.8082981109619141]
1991 B-LOC [1.1070451736450195, -0.9307429194450378]
1.4 B-LOC [0.6125511527061462, -0.8487540483474731]
per B-LOC [0.4618387222290039, -0.9774371385574341]
10(5) B-LOC [1.1751623153686523, -1.3239351511001587]
woman-years. B-LOC [0.9150873422622681, -1.2864508628845215]
However, B-LOC [1.3438853025436401, -1.3464879989624023]
the B-LOC [1.4717881679534912, -1.2273801565170288]
decrease B-LOC [1.4020253419876099, -1.521821141242981]
of B-LOC [1.6056921482086182, -1.4700829982757568]
the B-LOC [1.4637184143066406, -1.4767069816589355]
incidence B-LOC [1.1126395463943481, -1.5058889389038086]
is B-LOC [1.7642645835876465, -1.3707027435302734]
seen B-LOC [1.4099041223526, -1.250849962234497]
almost B-LOC [1.606571912765503, -1.137866497039795]
exclusively B-LOC [1.4242653846740723, -1.2357573509216309]
in B-LOC [1.119265079498291, -1.3538066148757935]
squamous B-LOC [1.4313287734985352, -1.3521759510040283]
cell B-LOC [1.2118871212005615, -1.4331812858581543]
carcinomas. B-LOC [1.3607118129730225, -1.6406540870666504]
The B-LOC [0.32755330204963684, -0.829703152179718]
mortality B-LOC [0.4212626516819, -0.7850779891014099]
caused B-LOC [0.4754207730293274, -0.9312290549278259]
by B-LOC [0.19967128336429596, -0.6632822155952454]

adenocarcinoma B-LOC [0.6975319981575012, -1.0395891666412354]
has B-LOC [1.2403028011322021, -1.4218910932540894]
decreased B-LOC [1.2363256216049194, -1.4080779552459717]
in B-LOC [1.166231632232666, -1.4732801914215088]
screened B-LOC [1.0038514137268066, -1.3597691059112549]
birth B-LOC [1.0733708143234253, -1.6686797142028809]
cohorts, B-LOC [1.3427613973617554, -1.7031625509262085]
but B-LOC [1.1824277639389038, -1.499063491821289]
the B-LOC [1.3604910373687744, -1.685560941696167]
incidence B-LOC [1.3717265129089355, -1.8127295970916748]
rate B-LOC [1.4356552362442017, -1.9832336902618408]
has B-LOC [1.5863885879516602, -1.576019525527954]
remained B-LOC [1.4601527452468872, -1.5525391101837158]
the B-LOC [1.4605200290679932, -1.627760648727417]
same. B-LOC [1.335977554321289, -1.9366145133972168]
CONCLUSIONS O [-0.2869706451892853, -0.1915171593427658]
The B-LOC [1.5411827564239502, -1.9001013040542603]
Finnish B-LOC [1.226480484008789, -2.0350940227508545]
mass B-LOC [1.5662864446640015, -2.297088146209717]
screening B-LOC [1.6730345487594604, -2.2425832748413086]
program B-LOC [1.7770596742630005, -2.302945137023926]
has B-LOC [1.8034868240356445, -1.823143720626831]
been B-LOC [1.6278259754180908, -2.060734272003174]
effective B-LOC [1.6665637493133545, -1.9403488636016846]
and B-LOC [1.28633713722229, -1.6616132259368896]
its B-LOC [1.8576765060424805, -2.388742685317993]
continuation B-LOC [1.9085290431976318, -2.0721452236175537]
is B-LOC [2.0039336681365967, -2.0097339153289795]
of B-LOC [1.7491028308868408, -1.949562668800354]
utmost B-LOC [1.8062536716461182, -1.9842408895492554]
importance. B-LOC [1.9545011520385742, -1.9720265865325928]
In B-LOC [0.9057254195213318, -1.027200698852539]
the B-LOC [1.2080692052841187, -0.9831318259239197]
future B-LOC [1.2213091850280762, -1.23173189163208]
more B-LOC [0.6304572224617004, -0.8900769352912903]
attention B-LOC [0.7928654551506042, -0.6828900575637817]
should B-LOC [1.121908187866211, -1.0240182876586914]
be B-LOC [1.0615019798278809, -1.1233254671096802]
given B-LOC [0.9782162308692932, -1.0052605867385864]
to B-LOC [0.9111369252204895, -0.7649849057197571]
glandular B-LOC [0.3444964289665222, -0.4526248276233673]
cell B-LOC [0.06009441986680031, -0.36835917830467224]
atypias B-LOC [0.3239741027355194, -0.46791788935661316]
in B-LOC [0.45604878664016724, -0.5430193543434143]
cervical B-LOC [0.2534816563129425, -0.5768423676490784]
smears. B-LOC [0.44303569197654724, -0.5623425841331482]
Thus, B-LOC [0.5205768346786499, -0.6891008019447327]
it B-LOC [0.614673912525177, -0.9876472353935242]
might B-LOC [0.9673839807510376, -0.9952419996261597]
be B-LOC [0.84413081407547, -1.0652523040771484]
possible B-LOC [0.6187905073165894, -1.0231434106826782]
to B-LOC [0.8098393082618713, -0.9201436638832092]
decrease B-LOC [0.6334050297737122, -0.9361933469772339]
the B-LOC [0.630163848400116, -0.9750544428825378]
incidence B-LOC [0.402174174785614, -0.6903857588768005]
of B-LOC [0.3723728358745575, -0.5865680575370789]
cervical B-LOC [0.18159431219100952, -0.5997896194458008]
adenocarcinoma. B-LOC [0.18143081665039062, -0.36981549859046936]

Blood B-LOC [1.5561249256134033, -2.368995428085327]
monocytes B-LOC [1.8429834842681885, -2.249587059020996]
are B-LOC [2.2969086170196533, -2.4730236530303955]
well-characterized B-LOC [2.628251791000366, -2.737733840942383]
precursors B-LOC [2.3210175037384033, -2.474346399307251]
for B-LOC [1.9865303039550781, -2.413839101791382]
macrophages B-LOC [2.248872995376587, -2.3142292499542236]
and B-LOC [2.0796329975128174, -2.205155849456787]
dendritic B-LOC [2.0591516494750977, -2.2302305698394775]
cells. B-LOC [1.8688368797302246, -2.2630317211151123]
Subsets B-LOC [3.0132596492767334, -2.960101842880249]
of B-LOC [2.6334517002105713, -2.946492910385132]
human B-LOC [2.4364495277404785, -2.777658700942993]
monocytes B-LOC [2.3458781242370605, -2.5487711429595947]
with B-LOC [3.1006875038146973, -3.182368278503418]
differential B-LOC [3.0352282524108887, -3.2184031009674072]
representation B-LOC [2.9553301334381104, -2.955213785171509]
in B-LOC [3.1056694984436035, -3.16986346244812]
various B-LOC [3.144789934158325, -3.1782965660095215]
disease B-LOC [3.0693681240081787, -3.1482231616973877]
states B-LOC [3.1693127155303955, -3.1258645057678223]
are B-LOC [3.4001457691192627, -3.045456886291504]
well B-LOC [3.4817209243774414, -3.1902287006378174]
known. B-LOC [3.387977361679077, -3.0321390628814697]
In B-LOC [2.8052268028259277, -2.593693494796753]
contrast, B-LOC [2.8036022186279297, -2.569343328475952]
mouse B-LOC [2.0828380584716797, -2.4984729290008545]
monocyte B-LOC [2.3386306762695312, -2.4879376888275146]
subsets B-LOC [2.964550256729126, -2.761522054672241]
have B-LOC [3.177405595779419, -2.9927170276641846]
been B-LOC [3.0419986248016357, -3.177839994430542]
characterized B-LOC [3.030941963195801, -2.9452197551727295]
minimally. B-LOC [3.068999767303467, -3.0367259979248047]
In B-LOC [1.354241967201233, -1.4290320873260498]
this B-LOC [1.5549530982971191, -1.4061371088027954]
study B-LOC [1.4816830158233643, -1.7598448991775513]
we B-LOC [1.1586461067199707, -1.0210368633270264]
identify B-LOC [1.6356396675109863, -1.3470866680145264]
three B-LOC [1.7893121242523193, -1.476254940032959]
subpopulations B-LOC [1.914069414138794, -1.7191673517227173]
of B-LOC [1.515936255455017, -1.6025166511535645]
mouse B-LOC [1.4130033254623413, -1.6304796934127808]
monocytes B-LOC [1.3681155443191528, -1.5322093963623047]
that B-LOC [1.7549045085906982, -1.7759644985198975]
can B-LOC [2.344393014907837, -2.103900671005249]
be B-LOC [2.1398746967315674, -2.205875873565674]
distinguished B-LOC [2.1076903343200684, -2.059795379638672]
by B-LOC [1.6754512786865234, -1.8902405500411987]
differential B-LOC [1.7234482765197754, -2.1744930744171143]
expression B-LOC [1.5909795761108398, -1.5744099617004395]
of B-LOC [1.3538507223129272, -1.6171035766601562]
Ly-6C, B-LOC [1.6888322830200195, -1.569847822189331]
CD43, B-LOC [1.4851959943771362, -1.579712986946106]
CD11c, B-LOC [1.4482473134994507, -1.535539150238037]
MBR, B-LOC [1.1801261901855469, -1.582728624343872]
and B-LOC [1.718759536743164, -1.851940393447876]
CD62L. B-LOC [1.4719526767730713, -1.4089252948760986]
The B-LOC [0.7888402342796326, -1.0372345447540283]
subsets B-LOC [1.3427833318710327, -1.074764370918274]
share B-LOC [0.7864983081817627, -0.6761437058448792]
the B-LOC [0.5826183557510376, -0.5581335425376892]
characteristics B-LOC [0.46703195571899414, -0.6545263528823853]
of B-LOC [0.3723081946372986, -0.4599267840385437]
extensive B-LOC [0.3609394431114197, -0.6416431069374084]
phagocytosis, B-LOC [0.17828874289989471, -0.6119100451469421]
similar B-LOC [0.47333505749702454, -0.6578904986381531]
expression B-LOC [0.41905876994132996, -0.3562370538711548]
of B-LOC [0.3407926857471466, -0.5617378354072571]
M-CSF B-LOC [0.16272786259651184, -0.2366378903388977]
receptor B-LOC [0.10475938022136688, -0.34669676423072815]

(CD115), B-LOC [0.4002135396003723, -0.965785026550293]
and B-LOC [0.7337813377380371, -1.0114190578460693]
development B-LOC [0.7332609295845032, -0.8639740943908691]
into B-LOC [0.5511042475700378, -0.8445464968681335]
macrophages B-LOC [0.7524847388267517, -0.8719038367271423]
upon B-LOC [0.46958890557289124, -0.931988537311554]
M-CSF B-LOC [0.7051374316215515, -1.039730429649353]
stimulation. B-LOC [0.6008841395378113, -0.99676913022995]
By B-LOC [1.7871840000152588, -2.2307605743408203]
eliminating B-LOC [2.0679571628570557, -2.2616982460021973]
blood B-LOC [1.7109498977661133, -2.2258896827697754]
monocytes B-LOC [2.308624267578125, -2.4526734352111816]
with B-LOC [2.0367746353149414, -2.1202783584594727]
dichloromethylene-bisphosphonate-loaded B-LOC [2.0231077671051025, -2.0301249027252197]
liposomes B-LOC [2.174340009689331, -2.3968207836151123]
and B-LOC [2.5436594486236572, -2.444453001022339]
monitoring B-LOC [2.617418050765991, -2.77986216545105]
their B-LOC [2.6122825145721436, -2.6410536766052246]
repopulation, B-LOC [2.7439422607421875, -2.741286516189575]
we B-LOC [1.937441110610962, -2.022035837173462]
showed B-LOC [2.2712910175323486, -2.259119987487793]
a B-LOC [2.605466365814209, -2.837470293045044]
developmental B-LOC [2.8857522010803223, -2.8096158504486084]
relationship B-LOC [2.6304986476898193, -2.9091367721557617]
between B-LOC [2.7374379634857178, -3.0017149448394775]
the B-LOC [2.7679338455200195, -2.7071030139923096]
subsets. B-LOC [2.781088352203369, -2.727236270904541]
Monocytes B-LOC [1.2974871397018433, -1.6440341472625732]
were B-LOC [1.8962924480438232, -1.6086112260818481]
maximally B-LOC [2.225770950317383, -1.9156912565231323]
depleted B-LOC [1.9344180822372437, -1.7620775699615479]
18 B-LOC [1.4744646549224854, -1.486344575881958]
h B-LOC [1.3945682048797607, -1.6308143138885498]
after B-LOC [1.2673332691192627, -1.3711434602737427]
liposome B-LOC [1.6104791164398193, -1.8426704406738281]
application B-LOC [1.4961575269699097, -1.3638192415237427]
and B-LOC [1.5298576354980469, -1.537065029144287]
subsequently B-LOC [2.104268789291382, -1.6474190950393677]
reappeared B-LOC [1.7970573902130127, -1.6316182613372803]
in B-LOC [1.8813101053237915, -1.6715539693832397]
the B-LOC [1.865154504776001, -1.8730032444000244]
circulation. B-LOC [1.454772710800171, -1.9966672658920288]
These B-LOC [1.8476238250732422, -1.7021923065185547]
cells B-LOC [1.5895628929138184, -1.5667296648025513]
were B-LOC [2.0613834857940674, -1.421717882156372]
exclusively B-LOC [2.0832746028900146, -1.6318106651306152]
of B-LOC [1.613030195236206, -1.0889924764633179]
the B-LOC [1.6442346572875977, -1.0334805250167847]
Ly-6C(high) B-LOC [1.544304609298706, -1.2778631448745728]
subset, B-LOC [1.712280511856079, -1.5158929824829102]
resembling B-LOC [1.691428303718567, -1.4224576950073242]
bone B-LOC [1.5361170768737793, -1.6306612491607666]
marrow B-LOC [1.622933268547058, -1.401405692100525]
monocytes. B-LOC [1.4755449295043945, -1.5988494157791138]
Serial B-LOC [1.6957552433013916, -2.016244411468506]
flow B-LOC [1.3587462902069092, -1.678078293800354]
cytometric B-LOC [1.6653060913085938, -1.7039239406585693]
analyses B-LOC [1.3692810535430908, -1.4728918075561523]

of O [-0.2307107150554657, 0.22348010540008545]
newly O [-0.13844794034957886, 0.193633571267128]
released O [-0.06874756515026093, 0.16098767518997192]
Ly-6C(high) O [-0.08260773122310638, 0.18044590950012207]
monocytes O [-0.07654643058776855, -0.002980621997267008]
showed O [-0.22279727458953857, 0.2298761010169983]
that O [-0.30969861149787903, 0.17748218774795532]
Ly-6C O [-0.1284562051296234, 0.08654648065567017]
expression O [-0.001445529400371015, 0.05418388545513153]
on O [-0.11268021166324615, 0.03503522649407387]
these O [-0.0396261103451252, 0.0752246081829071]
cells O [-0.11054997146129608, 0.012375039979815483]
was O [-0.03943021968007088, 0.016724897548556328]
down-regulated O [0.029665658250451088, 0.08711449801921844]
while O [-0.11061718314886093, 0.09656931459903717]
in B-LOC [0.16338756680488586, -0.11241605877876282]
circulation. O [-0.058142345398664474, 0.08681497722864151]
Under O [-0.8118738532066345, 0.38562652468681335]
inflammatory O [-0.43442824482917786, 0.40345892310142517]
conditions O [-0.5236558318138123, 0.4785837233066559]
elicited O [-0.6406788229942322, 0.5687865614891052]
either O [-0.6512421369552612, 0.267795592546463]
by O [-0.7927690148353577, 0.38130563497543335]
acute O [-0.8174555897712708, 0.43948397040367126]
infection O [-0.5348776578903198, 0.34226951003074646]
with O [-0.6980802416801453, 0.3062991201877594]
Listeria O [-0.33520397543907166, 0.17628559470176697]
monocytogenes O [-0.7116499543190002, 0.4335334599018097]
or O [-0.5480252504348755, 0.2497285008430481]
chronic O [-0.8332364559173584, 0.5376092791557312]
infection O [-0.5365594029426575, 0.3701748549938202]
with O [-0.6954758763313293, 0.34963035583496094]
Leishmania O [-0.3182998597621918, 0.3321039080619812]
major, O [-0.8645732998847961, 0.5732428431510925]
there O [-0.7716923356056213, 0.43671783804893494]
was O [-0.7809306979179382, 0.25400298833847046]
a O [-0.6571787595748901, 0.3653605282306671]
significant O [-0.693030059337616, 0.35285475850105286]
increase O [-0.6571216583251953, 0.2218167930841446]
in O [-0.639092206954956, 0.3814391791820526]
immature O [-0.5831177830696106, 0.5852842926979065]
Ly-6C(high) O [-0.4839157164096832, 0.2918888032436371]
monocytes, O [-0.5296154022216797, 0.2530328333377838]
resembling O [-0.2730644643306732, 0.21250012516975403]
the O [-0.4073283076286316, 0.2455623745918274]
inflammatory O [-0.46423885226249695, 0.20969676971435547]
left O [-0.3844231069087982, 0.536369264125824]
shift O [-0.5517726540565491, 0.06666219234466553]
of O [-0.29242977499961853, 0.07178349792957306]
granulocytes. O [-0.43410971760749817, 0.20956049859523773]
In O [-0.2984045147895813, -0.054478686302900314]
addition, O [-0.46423304080963135, 0.08933194726705551]
acute O [-0.3290683627128601, 0.008297162130475044]
peritoneal O [-0.2913563847541809, -0.14300699532032013]
inflammation O [-0.23031553626060486, 0.08040197193622589]
recruited O [-0.2525298595428467, 0.022878160700201988]
preferentially B-LOC [-0.061627183109521866, -0.10985001921653748]
Ly-6C(med-high) B-LOC [-0.10255037248134613, -0.11122307181358337]

monocytes. B-LOC [0.39331740140914917, -0.816283106803894]
Taken B-LOC [1.5086300373077393, -1.1556580066680908]
together, B-LOC [1.3790216445922852, -1.2995249032974243]
these B-LOC [0.982530415058136, -1.0711396932601929]
data B-LOC [0.964060366153717, -1.093573808670044]
identify B-LOC [1.1697359085083008, -1.0318388938903809]
distinct B-LOC [1.2147905826568604, -1.473822832107544]
subpopulations B-LOC [1.2702524662017822, -1.2670937776565552]
of B-LOC [0.8178371787071228, -1.1832373142242432]
mouse B-LOC [0.6478258967399597, -1.2545106410980225]
blood B-LOC [0.26138851046562195, -1.2428927421569824]
monocytes B-LOC [0.49421435594558716, -0.9711249470710754]
that B-LOC [0.9215989708900452, -1.356191873550415]
differ B-LOC [1.2123496532440186, -1.4513113498687744]
in B-LOC [0.826237678527832, -1.591800570487976]
maturation B-LOC [0.8313791155815125, -0.7961992025375366]
stage B-LOC [0.7021970152854919, -1.1036025285720825]
and B-LOC [1.1343748569488525, -1.2476203441619873]
capacity B-LOC [0.5910335183143616, -1.1813726425170898]
to B-LOC [0.9438292384147644, -1.3278241157531738]
become B-LOC [0.6545969843864441, -1.0613113641738892]
recruited B-LOC [0.5976415276527405, -0.7430380582809448]
to B-LOC [0.4848881661891937, -1.0424301624298096]
inflammatory B-LOC [0.5868303179740906, -0.9720429182052612]
sites. B-LOC [0.4902873933315277, -0.9230784773826599]

Many B-LOC [2.8044705390930176, -3.1674563884735107]
fundamental B-LOC [3.0767362117767334, -3.234471559524536]
aspects B-LOC [2.9256742000579834, -3.2113986015319824]
of B-LOC [2.7365479469299316, -3.1504666805267334]
DNA B-LOC [2.5168211460113525, -3.0780112743377686]
replication, B-LOC [2.825068473815918, -3.0924131870269775]
such B-LOC [3.128284215927124, -3.1759681701660156]
as B-LOC [3.057213068008423, -3.1574180126190186]
the B-LOC [3.092113494873047, -3.1928539276123047]
exact B-LOC [3.1778831481933594, -3.2657470703125]
locations B-LOC [2.750898599624634, -2.85103440284729]
where B-LOC [2.5219836235046387, -3.0044291019439697]
DNA B-LOC [2.3362836837768555, -2.784282922744751]
synthesis B-LOC [2.1373138427734375, -2.5200493335723877]
is B-LOC [2.707379102706909, -2.7253968715667725]
initiated B-LOC [2.403892755508423, -2.7438764572143555]
and B-LOC [2.44163179397583, -2.5178656578063965]
terminated, B-LOC [2.5233023166656494, -2.7953643798828125]
how B-LOC [2.720566511154175, -3.1462223529815674]
frequently B-LOC [2.4903409481048584, -3.0755269527435303]
origins B-LOC [2.58621883392334, -3.000840425491333]
are B-LOC [3.2155439853668213, -3.2638213634490967]
used, B-LOC [2.7512660026550293, -3.056034564971924]
and B-LOC [3.047773838043213, -3.1851067543029785]
how B-LOC [2.778071165084839, -3.374671697616577]
fork B-LOC [2.5309574604034424, -3.279989004135132]
progression B-LOC [2.365300178527832, -3.0779495239257812]
is B-LOC [3.297802209854126, -3.3050591945648193]
influenced B-LOC [2.899010181427002, -3.1308610439300537]
by B-LOC [2.7136189937591553, -3.1385653018951416]
transcription, B-LOC [2.7899057865142822, -3.254945993423462]
are B-LOC [3.3406248092651367, -3.1946699619293213]
poorly B-LOC [3.3762030601501465, -3.1858925819396973]
understood. B-LOC [3.2811319828033447, -3.113328456878662]
Via B-LOC [2.3965706825256348, -2.6677558422088623]
the B-LOC [2.6127097606658936, -2.5978646278381348]
deep B-LOC [2.433727979660034, -2.7184231281280518]
sequencing B-LOC [2.8472931385040283, -2.71108341217041]
of B-LOC [2.7199904918670654, -2.6637697219848633]
Okazaki B-LOC [2.169872283935547, -2.6671104431152344]
fragments, B-LOC [2.6704065799713135, -2.760291337966919]
we B-LOC [2.473578691482544, -2.5496151447296143]
comprehensively B-LOC [2.9612081050872803, -2.9689056873321533]
document B-LOC [2.6805951595306396, -2.8063485622406006]
replication B-LOC [2.507746458053589, -2.8167240619659424]
fork B-LOC [2.4971444606781006, -3.1771037578582764]
directionality B-LOC [2.7871944904327393, -3.0747334957122803]
throughout B-LOC [2.581326723098755, -2.7906887531280518]
the B-LOC [2.7130672931671143, -2.670635938644409]
S. B-LOC [2.2700140476226807, -2.579130172729492]
cerevisiae B-LOC [2.369446039199829, -2.644439458847046]
genome, B-LOC [2.471118211746216, -3.008413076400757]
which B-LOC [2.6729071140289307, -3.1844141483306885]
permits B-LOC [2.5245726108551025, -2.851351022720337]
the B-LOC [2.7178990840911865, -2.9349634647369385]
systematic B-LOC [2.894325017929077, -3.162620782852173]
analysis B-LOC [2.6783447265625, -3.0372910499572754]
of B-LOC [2.688446283340454, -3.062250852584839]
initiation, B-LOC [2.7289044857025146, -3.356966733932495]
origin B-LOC [2.5961391925811768, -3.058580160140991]
efficiency, B-LOC [2.599081039428711, -3.2591421604156494]
fork B-LOC [2.399996757507324, -3.1607472896575928]
progression, B-LOC [2.623197078704834, -3.1241068840026855]
and B-LOC [2.8150265216827393, -3.047881841659546]
termination. B-LOC [2.6915512084960938, -3.2141940593719482]
We B-LOC [0.13640429079532623, -0.36044734716415405]
show B-LOC [0.2122764140367508, -0.14840035140514374]
that B-LOC [-0.11629312485456467, -0.25015780329704285]
leading-strand B-LOC [0.3272880017757416, -0.7742242217063904]
initiation B-LOC [0.3498821556568146, -0.720927894115448]
preferentially B-LOC [0.1915540099143982, -0.38802215456962585]
occurs B-LOC [0.29377779364585876, -0.5476757884025574]
within B-LOC [0.46430423855781555, -0.5055970549583435]
a B-LOC [0.39673182368278503, -0.3271964490413666]
nucleosome-free B-LOC [0.342292845249176, -0.3646169602870941]
region B-LOC [0.16539186239242554, -0.6202442049980164]
at B-LOC [0.2128351330757141, -0.6837353110313416]
replication B-LOC [0.5014225244522095, -0.6788678169250488]
origins. B-LOC [0.48152050375938416, -0.7495925426483154]
Using B-LOC [0.1394040584564209, -0.31427502632141113]
a B-LOC [0.3710504472255707, -0.36448556184768677]
strain B-LOC [0.3012850284576416, -0.5303239226341248]
in B-LOC [0.3607265055179596, -0.4632156193256378]
which B-LOC [0.19790878891944885, -0.372977077960968]

late O [-0.7339134216308594, 0.7602226734161377]
origins O [-0.37430211901664734, 0.4007861614227295]
can O [-0.5661359429359436, 0.6110697984695435]
be O [-0.5687846541404724, 0.5126982927322388]
induced O [-0.3715685307979584, 0.6186025738716125]
to O [-0.49012377858161926, 0.5667690634727478]
fire O [-0.3626789152622223, 0.32760506868362427]
early, O [-0.573505163192749, 0.7438416481018066]
we O [-0.6840602159500122, 0.8012352585792542]
show O [-0.6827594637870789, 0.6307967901229858]
that O [-0.9222379922866821, 0.5208930373191833]
replication O [-0.3288861811161041, 0.3424108624458313]
termination O [-0.42500540614128113, 0.3656473457813263]
is O [-0.6221795082092285, 0.6485694050788879]
a O [-0.5973538756370544, 0.7446733117103577]
largely O [-0.3695982098579407, 0.5921173095703125]
passive O [-0.40238675475120544, 0.5402067303657532]
phenomenon O [-0.4451535940170288, 0.27863845229148865]
that O [-0.7701455354690552, 0.42954379320144653]
does O [-0.5928308963775635, 0.7620376944541931]
not O [-0.4463898837566376, 0.735998809337616]
rely O [-0.6140270829200745, 0.5892004370689392]
on O [-0.361607164144516, 0.6667577624320984]
cis-acting O [-0.6134226322174072, 0.5493660569190979]
sequences O [-0.31431642174720764, 0.30047446489334106]
or O [-0.32781314849853516, 0.5618981719017029]
replication O [-0.1178337037563324, 0.3009278178215027]
fork O [-0.6813787817955017, 0.31202438473701477]
pausing. O [-0.29489901661872864, 0.32808247208595276]
The B-LOC [0.2306390404701233, -0.4276786744594574]
replication B-LOC [0.3637530207633972, -0.5234012007713318]
profile B-LOC [0.3467140793800354, -0.7116300463676453]
is B-LOC [0.3834889233112335, -0.427814781665802]
predominantly B-LOC [0.2784879803657532, -0.20108017325401306]
determined B-LOC [0.4228845536708832, -0.6816785335540771]
by B-LOC [0.41039103269577026, -0.49834612011909485]
the B-LOC [0.5324380993843079, -0.6820350885391235]
kinetics B-LOC [0.3722354769706726, -0.5615452527999878]
of B-LOC [0.3008512258529663, -0.7196471095085144]
origin B-LOC [0.2627579867839813, -0.558495819568634]
firing, B-LOC [0.325237900018692, -0.621262788772583]
allowing B-LOC [0.16715073585510254, -0.39159563183784485]
us B-LOC [0.20755141973495483, -0.47084227204322815]
to B-LOC [0.24537703394889832, -0.4889938533306122]
reconstruct B-LOC [0.38321468234062195, -0.45699313282966614]
chromosome-wide B-LOC [0.28500181436538696, -0.6827095746994019]
timing B-LOC [0.25123265385627747, -0.6302226781845093]
profiles B-LOC [0.2981144189834595, -0.5857670307159424]
from B-LOC [0.31855061650276184, -0.5246690511703491]
an B-LOC [0.2866016626358032, -0.5499283671379089]
asynchronous B-LOC [0.11617814004421234, -0.3862726092338562]
culture. B-LOC [0.23030135035514832, -0.7137393355369568]

CONTEXT B-LOC [1.1813137531280518, -2.20414662361145]
During B-LOC [1.6309409141540527, -2.3407509326934814]
pregnancy, B-LOC [2.0723464488983154, -2.392446279525757]
serum B-LOC [1.9151363372802734, -2.6928584575653076]
levels B-LOC [2.2964909076690674, -2.5521202087402344]
of B-LOC [1.8678617477416992, -2.558258056640625]
estrogen, B-LOC [2.362870216369629, -2.5182480812072754]
progesterone, B-LOC [1.9310083389282227, -2.548835515975952]
and B-LOC [2.0945818424224854, -2.73673152923584]
other B-LOC [2.598134756088257, -2.8827269077301025]
hormones B-LOC [2.2504189014434814, -2.7193665504455566]
are B-LOC [2.038322687149048, -2.4366941452026367]
markedly B-LOC [1.8668032884597778, -2.3328869342803955]
higher B-LOC [1.9168490171432495, -2.4625422954559326]
than B-LOC [1.7234832048416138, -2.2295734882354736]
during B-LOC [1.6373555660247803, -2.290923833847046]
other B-LOC [1.7509486675262451, -2.328015089035034]
periods B-LOC [2.036027669906616, -2.518333673477173]
of B-LOC [2.057300329208374, -2.6427314281463623]
life. B-LOC [2.0087897777557373, -2.5837767124176025]
Pregnancy B-LOC [0.9476305246353149, -1.2949422597885132]
hormones B-LOC [1.3616867065429688, -1.6925709247589111]
primarily B-LOC [1.259629487991333, -1.3913304805755615]
are B-LOC [1.4651777744293213, -1.8462107181549072]
produced B-LOC [1.1488232612609863, -1.5648939609527588]
in B-LOC [0.9656856060028076, -1.2190120220184326]
the B-LOC [1.0629582405090332, -1.3412647247314453]
placenta, B-LOC [1.4694578647613525, -2.2787435054779053]
and B-LOC [1.1105090379714966, -1.5310090780258179]
signs B-LOC [1.624906063079834, -1.8885754346847534]
of B-LOC [1.3631409406661987, -2.0223052501678467]
placental B-LOC [1.7757153511047363, -2.380720376968384]
impairment B-LOC [1.6272642612457275, -2.129542112350464]
may B-LOC [1.557614803314209, -2.019303798675537]
serve B-LOC [1.5708361864089966, -2.032470703125]
as B-LOC [1.529954433441162, -1.9139928817749023]
indirect B-LOC [1.848619818687439, -2.136672258377075]
markers B-LOC [1.7197184562683105, -2.0832998752593994]
of B-LOC [1.5279234647750854, -2.1399500370025635]
hormone B-LOC [1.693834662437439, -2.5493946075439453]
exposures B-LOC [1.968765139579773, -2.429450035095215]
during B-LOC [1.6590406894683838, -1.920820713043213]
pregnancy. B-LOC [1.909369945526123, -2.336860418319702]
During B-LOC [2.5144765377044678, -2.555495023727417]
pregnancy, B-LOC [2.6836230754852295, -2.6282315254211426]
these B-LOC [2.4617578983306885, -2.6126821041107178]
markers B-LOC [2.705704927444458, -2.8460257053375244]
have B-LOC [3.070263624191284, -2.496570348739624]
been B-LOC [2.895930290222168, -2.741401433944702]
inconsistently B-LOC [2.828080892562866, -2.692286252975464]
associated B-LOC [3.0351927280426025, -2.666557550430298]
with B-LOC [2.9051687717437744, -2.672578811645508]
subsequent B-LOC [2.6854746341705322, -2.824796438217163]
risk B-LOC [2.970576524734497, -2.9360811710357666]
of B-LOC [2.6297690868377686, -2.735246419906616]
breast B-LOC [2.6945645809173584, -2.680168390274048]
cancer B-LOC [2.9730589389801025, -3.0592753887176514]
in B-LOC [2.7917354106903076, -2.847116231918335]
the B-LOC [2.749424934387207, -2.6983067989349365]
mother. B-LOC [2.578892707824707, -2.8914453983306885]
OBJECTIVE B-LOC [2.6944820880889893, -2.8082635402679443]
To B-LOC [2.5360281467437744, -2.6588282585144043]
examine B-LOC [2.9361562728881836, -2.798748731613159]
associations B-LOC [2.6412410736083984, -2.7679812908172607]
between B-LOC [2.5687758922576904, -2.9473280906677246]
indirect B-LOC [2.7304773330688477, -2.9120466709136963]
markers B-LOC [2.4588398933410645, -2.764719009399414]
of B-LOC [2.2735483646392822, -2.736128568649292]
hormonal B-LOC [2.4533286094665527, -2.7151644229888916]
exposures, B-LOC [2.646503448486328, -2.846759557723999]
such B-LOC [2.829725980758667, -2.5716347694396973]
as B-LOC [2.566218614578247, -2.718878984451294]
placental B-LOC [2.8613412380218506, -2.900223970413208]
weight B-LOC [2.6664905548095703, -2.732271909713745]
and B-LOC [2.5132806301116943, -2.6874265670776367]
other B-LOC [2.781085729598999, -2.7848737239837646]
pregnancy B-LOC [2.657555103302002, -2.8366565704345703]
characteristics, B-LOC [2.279059648513794, -2.7878944873809814]

and B-LOC [3.1290290355682373, -3.79309344291687]
maternal B-LOC [3.338308572769165, -3.825836420059204]
risk B-LOC [3.3608200550079346, -3.9177682399749756]
of B-LOC [3.0810039043426514, -3.751458168029785]
developing B-LOC [3.3735387325286865, -3.721686601638794]
breast B-LOC [3.2891314029693604, -3.680835485458374]
cancer. B-LOC [3.4058244228363037, -3.7690627574920654]
DESIGN B-LOC [3.417623996734619, -3.7984769344329834]
AND B-LOC [3.3489952087402344, -3.8068203926086426]
SETTING B-LOC [3.170414924621582, -3.7002456188201904]
Population-based B-LOC [3.3353431224823, -3.703958749771118]
cohort B-LOC [3.4681761264801025, -3.776623487472534]
study B-LOC [3.1784608364105225, -3.7723388671875]
using B-LOC [3.028517246246338, -3.8505823612213135]
data B-LOC [3.4495861530303955, -3.680061101913452]
from B-LOC [3.4608314037323, -3.5642964839935303]
the B-LOC [3.4732093811035156, -3.3501808643341064]
Swedish B-LOC [3.0549280643463135, -3.8808887004852295]
Birth B-LOC [3.230400800704956, -3.74747633934021]
Register, B-LOC [3.550680160522461, -3.8990280628204346]
the B-LOC [3.525125741958618, -3.393829345703125]
Swedish B-LOC [3.0552217960357666, -3.8491594791412354]
Cancer B-LOC [3.3344976902008057, -3.924036979675293]
Register, B-LOC [3.5807559490203857, -3.901836633682251]
the B-LOC [3.591643810272217, -3.4318735599517822]
Swedish B-LOC [3.1592519283294678, -3.849118947982788]
Cause B-LOC [3.5132763385772705, -3.887692451477051]
of B-LOC [3.476729393005371, -3.6593284606933594]
Death B-LOC [3.4475748538970947, -3.7294888496398926]
Register, B-LOC [3.606050968170166, -3.8326399326324463]
and B-LOC [3.4530160427093506, -3.5529675483703613]
the B-LOC [3.561173677444458, -3.400449752807617]
Swedish B-LOC [3.1942875385284424, -3.8866336345672607]
Register B-LOC [3.6488306522369385, -3.915435314178467]
of B-LOC [3.34717059135437, -3.546321153640747]
Population B-LOC [3.568671464920044, -3.611196279525757]
and B-LOC [3.3017873764038086, -3.4770097732543945]
Population B-LOC [3.48140549659729, -3.5735135078430176]
Changes. B-LOC [3.5045671463012695, -3.896113634109497]
PARTICIPANTS B-LOC [2.9527454376220703, -3.120181083679199]
Women B-LOC [3.239779233932495, -3.433647871017456]
included B-LOC [3.375321626663208, -3.3926804065704346]
in B-LOC [2.9514920711517334, -3.3065268993377686]
the B-LOC [3.1174540519714355, -3.162580966949463]
Sweden B-LOC [3.0615880489349365, -3.5855774879455566]
Birth B-LOC [3.1701529026031494, -3.3891236782073975]
Register B-LOC [3.43337082862854, -3.527087450027466]
who B-LOC [3.0741946697235107, -3.2937538623809814]
delivered B-LOC [3.1031129360198975, -3.210890054702759]
singletons B-LOC [3.3392131328582764, -3.3440489768981934]
between B-LOC [3.2525432109832764, -3.172380208969116]
1982 B-LOC [3.349073648452759, -3.1884896755218506]
and B-LOC [3.306614398956299, -2.963164806365967]
1989, B-LOC [3.1640422344207764, -3.445666551589966]
with B-LOC [3.3370211124420166, -3.3954460620880127]
complete B-LOC [3.411654233932495, -3.5575010776519775]
information B-LOC [3.394390106201172, -3.4442803859710693]
on B-LOC [3.359257221221924, -3.3676822185516357]
date B-LOC [3.512418508529663, -3.6617605686187744]
of B-LOC [3.269584894180298, -3.3720076084136963]
birth B-LOC [3.4243037700653076, -3.5384085178375244]
and B-LOC [3.391049861907959, -3.2341666221618652]
gestational B-LOC [3.5359013080596924, -3.482365369796753]
age. B-LOC [3.5623130798339844, -3.5639426708221436]
Women B-LOC [3.380924701690674, -3.5707199573516846]
were B-LOC [3.3533966541290283, -3.6419289112091064]
followed B-LOC [3.3219242095947266, -3.731806516647339]
up B-LOC [3.278656482696533, -3.401604413986206]
until B-LOC [3.417806625366211, -3.4727485179901123]
the B-LOC [3.176543951034546, -3.4631187915802]
occurrence B-LOC [3.362382173538208, -3.6414875984191895]
of B-LOC [3.211440324783325, -3.4105474948883057]
breast B-LOC [3.3513400554656982, -3.6237642765045166]
cancer, B-LOC [3.356499433517456, -3.522636651992798]
death, B-LOC [3.376763105392456, -3.5922739505767822]
or B-LOC [3.2335681915283203, -3.5104691982269287]
end B-LOC [3.20508074760437, -3.5013339519500732]
of B-LOC [3.046434164047241, -3.409818172454834]
follow-up B-LOC [3.211723566055298, -3.524576425552368]
(December B-LOC [3.4223873615264893, -3.319010019302368]
31, B-LOC [3.4631264209747314, -3.208125114440918]
2001). B-LOC [3.2635245323181152, -3.4307339191436768]
Cox B-LOC [2.7147624492645264, -2.855562925338745]
proportional B-LOC [2.4413280487060547, -2.789081335067749]
hazards B-LOC [2.3474228382110596, -2.807976007461548]
models B-LOC [2.662623643875122, -2.8994228839874268]
were B-LOC [2.7717950344085693, -2.7549493312835693]
used B-LOC [2.8993520736694336, -3.1563780307769775]
to B-LOC [2.759707450866699, -2.904487371444702]
estimate B-LOC [2.6103172302246094, -2.8549840450286865]

associations B-LOC [3.3575198650360107, -3.5492734909057617]
between B-LOC [3.5511271953582764, -3.5658061504364014]
hormone B-LOC [3.5581090450286865, -3.8425629138946533]
exposures B-LOC [3.849419355392456, -3.4129464626312256]
and B-LOC [3.3361592292785645, -3.263378143310547]
risks B-LOC [3.9016640186309814, -3.6713311672210693]
of B-LOC [3.5338521003723145, -3.454902410507202]
breast B-LOC [3.485224962234497, -3.6074488162994385]
cancer. B-LOC [3.7738823890686035, -3.5197997093200684]
MAIN B-LOC [3.4200212955474854, -3.3182289600372314]
OUTCOME B-LOC [3.312126636505127, -3.2654683589935303]
MEASURE B-LOC [3.31680965423584, -3.2604501247406006]
Incidence B-LOC [3.444870710372925, -3.407569169998169]
of B-LOC [3.561455488204956, -3.1865298748016357]
invasive B-LOC [3.402484893798828, -3.427262544631958]
breast B-LOC [3.2233433723449707, -3.3752448558807373]
cancer. B-LOC [3.673198699951172, -3.345210552215576]
RESULTS B-LOC [2.3926398754119873, -2.7331254482269287]
Of B-LOC [2.969405174255371, -2.5418992042541504]
314,019 B-LOC [3.4305965900421143, -2.7764995098114014]
women B-LOC [3.286961793899536, -2.9864773750305176]
in B-LOC [3.121157169342041, -2.8189146518707275]
the B-LOC [3.0568912029266357, -2.6420652866363525]
cohort, B-LOC [3.148848295211792, -2.906461477279663]
2216 B-LOC [3.295957088470459, -3.038987874984741]
(0.7%) B-LOC [3.127794027328491, -2.97316312789917]
developed B-LOC [3.1565911769866943, -2.8737146854400635]
breast B-LOC [3.072463274002075, -2.98481822013855]
cancer B-LOC [3.211193799972534, -3.0797080993652344]
during B-LOC [2.971073627471924, -2.782968282699585]
the B-LOC [3.091982364654541, -2.6966469287872314]
follow-up B-LOC [3.1029694080352783, -3.163933515548706]
through B-LOC [3.4520785808563232, -2.843477964401245]
2001, B-LOC [3.3802011013031006, -3.064195394515991]
of B-LOC [3.0630874633789062, -2.9866769313812256]
whom B-LOC [3.188986301422119, -2.889613389968872]
2100 B-LOC [3.14841365814209, -3.0495526790618896]
(95%) B-LOC [3.0872676372528076, -2.910630941390991]
were B-LOC [3.2416882514953613, -2.956306219100952]
diagnosed B-LOC [3.412266492843628, -3.187586545944214]
before B-LOC [3.162884473800659, -2.655654191970825]
age B-LOC [3.5456721782684326, -2.92299485206604]
50 B-LOC [3.348191976547241, -3.0275824069976807]
years. B-LOC [3.485677480697632, -3.1320178508758545]
Compared O [-0.8633574843406677, 0.8170377612113953]
with O [-0.5638856291770935, 0.6189138889312744]
women O [-0.6064581871032715, 0.4870830774307251]
who O [-0.7364228367805481, 0.30577632784843445]
had O [-0.6903023719787598, 0.5318564772605896]
placentas O [-0.4847539961338043, 0.42584428191185]
weighing O [-0.5075753927230835, 0.6051980257034302]
less O [-0.5112784504890442, 0.8534194827079773]
than O [-0.5594647526741028, 0.4001106321811676]
500 O [-0.11065609008073807, 0.42916253209114075]
g O [-0.5689771175384521, 0.45664122700691223]
in O [-0.5704258680343628, 0.2221250832080841]
2 O [-0.3397972583770752, 0.5367741584777832]
consecutive O [-0.49096447229385376, 0.45756301283836365]
pregnancies, O [-0.47135618329048157, 0.4302872121334076]
the O [-0.8087207078933716, 0.4687522351741791]
risk O [-0.702150285243988, 0.4951836168766022]
of O [-0.917124330997467, 0.6621977686882019]
breast O [-0.4562797248363495, 0.5212764739990234]
cancer O [-0.568771243095398, 0.3936425745487213]
was O [-0.766261637210846, 0.3587181866168976]
increased O [-0.6833570003509521, 0.4970088303089142]
among O [-0.6152560710906982, 0.6378313899040222]
women O [-0.6891659498214722, 0.4811064898967743]
whose O [-0.8049842119216919, 0.4517402648925781]
placentas O [-0.6494609117507935, 0.5159532427787781]
weighed O [-0.5715101361274719, 0.5357714295387268]
between O [-0.7497782111167908, 0.40779998898506165]
500 O [-0.22284340858459473, 0.47737595438957214]
and O [-0.7735704183578491, 0.15362794697284698]
699 O [-0.2420409917831421, 0.6742123365402222]
g O [-0.8300741314888, 0.5673869252204895]
in O [-0.5806232690811157, 0.33260491490364075]
their O [-0.5914550423622131, 0.6659790277481079]
first O [-0.6309323310852051, 0.6803358197212219]
pregnancy O [-0.4672871530056, 0.6058698296546936]
and O [-0.8093928694725037, 0.4674454927444458]
at O [-0.7449466586112976, 0.2146207094192505]

least O [-0.46425819396972656, -0.046274010092020035]
700 O [-0.12411496043205261, 0.13740086555480957]
g O [-0.3176557719707489, -0.0952392965555191]
in O [-0.4638834297657013, -0.11734730005264282]
their O [-0.28235799074172974, 0.07330644130706787]
second O [-0.3186472952365875, 0.08730116486549377]
pregnancy O [-0.22125670313835144, 0.09802840650081635]
(or B-LOC [0.024042846634984016, -0.0014665224589407444]
vice O [-0.028375228866934776, 0.0169257503002882]
versa) O [-0.23643305897712708, -0.09077814221382141]
(adjusted O [-0.1942460536956787, 0.004068938549607992]
hazard O [-0.3483082354068756, 0.14967899024486542]
ratio, O [-0.43730562925338745, 0.11848162859678268]
1.82; O [-0.40147244930267334, 0.33767080307006836]
95% O [-0.5170405507087708, 0.31039854884147644]
confidence O [-0.5218822360038757, 0.13914582133293152]
interval O [-0.5267624855041504, 0.16733790934085846]
[CI], O [-0.30804798007011414, -0.03621816262602806]
1.07-3.08), O [-0.4084495007991791, 0.35886991024017334]
and O [-0.45401713252067566, 0.10201961547136307]
the O [-0.23390693962574005, -0.02519485540688038]
corresponding O [-0.2461196780204773, -0.011495502665638924]
risk O [-0.3632573187351227, 0.010493023321032524]
was O [-0.2614152729511261, -0.15639598667621613]
doubled O [-0.11430586874485016, 0.09261192381381989]
among O [-0.19340267777442932, -0.11602307111024857]
women B-LOC [-0.11902827769517899, -0.1541026532649994]
whose O [-0.1220012903213501, -0.11718294769525528]
placentas O [-0.17196978628635406, -0.12718228995800018]
weighed O [-0.22067216038703918, -0.006071573588997126]
at O [-0.2635081112384796, 0.009065156802535057]
least O [-0.23350003361701965, -0.13378217816352844]
700 B-LOC [0.08717867732048035, 0.04762275889515877]
g O [-0.29246535897254944, -0.1938837319612503]
in O [-0.3012884557247162, -0.2850976884365082]
both O [-0.32246720790863037, -0.18046991527080536]
pregnancies O [-0.148408904671669, -0.12638874351978302]
(adjusted B-LOC [0.09461669623851776, -0.12488441169261932]
hazard O [-0.1746951937675476, 0.024105913937091827]
ratio, O [-0.25255846977233887, -0.11224544793367386]
2.05; O [-0.3033221662044525, 0.24853798747062683]
95% O [-0.43729913234710693, 0.1625601053237915]
CI, O [-0.45258525013923645, -0.17107833921909332]
1.15-3.64). O [-0.2328740954399109, 0.1877075880765915]
A O [-0.8043742179870605, 0.3559214174747467]
high O [-0.6354590058326721, 0.2523610293865204]
birth O [-0.5711204409599304, 0.4055982530117035]
weight O [-0.350895494222641, 0.5089647173881531]
(> O [-0.561339795589447, 0.24244356155395508]
or O [-0.6057555079460144, -0.15244892239570618]
=4000 O [-0.6381610035896301, -0.21522630751132965]
g) O [-0.49236613512039185, -0.037565018981695175]
in O [-0.818213164806366, 0.20887228846549988]
2 O [-0.48136618733406067, 0.31125810742378235]
successive O [-0.6132538914680481, 0.24169202148914337]
births O [-0.4167802631855011, 0.19181138277053833]
was O [-0.6239575743675232, 0.17715276777744293]
associated O [-0.6997595429420471, 0.4011971950531006]
with O [-0.7331551313400269, 0.2716241478919983]
an O [-0.7389939427375793, 0.23726922273635864]
increased O [-0.6860780119895935, 0.24051958322525024]
risk O [-0.629467785358429, 0.28453394770622253]
of O [-0.8728843331336975, 0.480970174074173]
breast O [-0.5555921792984009, 0.3401322066783905]
cancer O [-0.4925418198108673, 0.11672840267419815]
before O [-0.5605458617210388, 0.19193878769874573]
but O [-0.3521028459072113, 0.11065702885389328]
not O [-0.12149706482887268, 0.2245960533618927]
after O [-0.389719694852829, 0.14291252195835114]
adjusting O [-0.6401790976524353, 0.03358573094010353]
for O [-0.4766506254673004, 0.056499432772397995]
placental O [-0.20033994317054749, 0.06246514245867729]
weight O [-0.36089828610420227, 0.16163484752178192]

and B-LOC [0.02265309728682041, -0.2828369438648224]
other B-LOC [0.19707787036895752, -0.3553236126899719]
covariates B-LOC [0.12748099863529205, -0.2944928705692291]
(adjusted B-LOC [0.156433567404747, -0.12600046396255493]
hazard B-LOC [0.09472374618053436, -0.2850710451602936]
ratio, B-LOC [-0.03335380181670189, -0.2454022765159607]
1.10; B-LOC [0.0588904432952404, -0.16920943558216095]
95% O [-0.4198354184627533, 0.12157023698091507]
CI, O [-0.3082382082939148, -0.18583036959171295]
0.76-1.59). B-LOC [0.0003752807097043842, -0.09067240357398987]
CONCLUSIONS O [-0.7051424384117126, 0.5277619957923889]
Placental O [-0.32311251759529114, 0.19918130338191986]
weight O [-0.10214082896709442, 0.39824816584587097]
is O [-0.3349258005619049, 0.04303237423300743]
positively O [-0.2547049820423126, 0.22421129047870636]
associated O [-0.3047884702682495, 0.2242891937494278]
with O [-0.38983768224716187, 0.028325488790869713]
maternal O [-0.2453281432390213, 0.063213050365448]
risk O [-0.3439524471759796, 0.18214286863803864]
of O [-0.46979543566703796, 0.14962521195411682]
breast B-LOC [-0.003314667847007513, -0.16320586204528809]
cancer. B-LOC [-0.02189466543495655, -0.2845584452152252]
These B-LOC [0.7070430517196655, -0.8356499075889587]
results B-LOC [0.844510555267334, -0.7131019234657288]
further B-LOC [1.0714309215545654, -0.9285268187522888]
support B-LOC [1.2801709175109863, -0.7842512726783752]
the B-LOC [1.1793748140335083, -0.8644362092018127]
hypothesis B-LOC [0.9281620979309082, -0.9192262887954712]
that B-LOC [0.637835681438446, -0.96245938539505]
pregnancy B-LOC [0.6036213040351868, -1.021491289138794]
hormones B-LOC [0.5207407474517822, -0.8938146829605103]
are B-LOC [0.6112071871757507, -1.0277085304260254]
important B-LOC [0.5500034093856812, -1.0519428253173828]
modifiers B-LOC [1.019657015800476, -1.0971407890319824]
of B-LOC [0.5436304211616516, -1.064502239227295]
subsequent B-LOC [0.4667692482471466, -1.2209336757659912]
maternal B-LOC [0.4732200503349304, -1.1264655590057373]
breast B-LOC [0.5216154456138611, -0.9661741852760315]
cancer B-LOC [0.582948625087738, -1.2088030576705933]
risk. B-LOC [0.5851182341575623, -0.8835970759391785]

Resistance B-LOC [1.8123096227645874, -2.2663285732269287]
to B-LOC [1.9822046756744385, -2.0692875385284424]
apoptosis, B-LOC [1.5547218322753906, -1.8781325817108154]
often B-LOC [2.075467586517334, -2.103789806365967]
achieved B-LOC [1.6168380975723267, -1.9308580160140991]
by B-LOC [1.6591424942016602, -1.8130505084991455]
the B-LOC [1.6686893701553345, -1.640205979347229]
overexpression B-LOC [1.8187273740768433, -2.087925672531128]
of B-LOC [1.6762551069259644, -2.0571305751800537]
antiapoptotic B-LOC [1.83026921749115, -2.20349383354187]
proteins, B-LOC [1.852534532546997, -2.1600992679595947]
is B-LOC [2.6805827617645264, -2.769030809402466]
common B-LOC [2.3847243785858154, -2.52489972114563]
and B-LOC [2.2905075550079346, -2.6792705059051514]
perhaps B-LOC [2.6521666049957275, -2.914604902267456]
required B-LOC [2.404672384262085, -2.8456509113311768]
in B-LOC [2.360776662826538, -2.8747718334198]
the B-LOC [2.4597103595733643, -2.6835029125213623]
genesis B-LOC [2.7561023235321045, -3.10026478767395]
of B-LOC [2.508300542831421, -3.014981269836426]
cancer. B-LOC [2.683323860168457, -3.1693668365478516]
However, B-LOC [3.132758855819702, -3.2506844997406006]
it B-LOC [3.1882784366607666, -3.377329111099243]
remains B-LOC [3.325399160385132, -3.306344747543335]
uncertain B-LOC [3.164595127105713, -3.2345874309539795]
whether B-LOC [2.908137321472168, -3.5072553157806396]
apoptotic B-LOC [2.812124252319336, -3.2873194217681885]
defects B-LOC [2.8833682537078857, -3.2135818004608154]
are B-LOC [3.0825202465057373, -3.5430548191070557]
essential B-LOC [2.932232141494751, -3.5113773345947266]
for B-LOC [2.8221075534820557, -3.3668901920318604]
tumor B-LOC [2.8426506519317627, -3.332977533340454]
maintenance. B-LOC [2.861034631729126, -3.293405771255493]
To B-LOC [1.272965431213379, -1.506304383277893]
test B-LOC [1.6259626150131226, -1.6416261196136475]
this, B-LOC [1.8745946884155273, -2.0256354808807373]
we B-LOC [1.1477546691894531, -0.8883948922157288]
generated B-LOC [1.1348978281021118, -0.7796988487243652]
mice B-LOC [0.9163662195205688, -1.0409451723098755]
expressing B-LOC [1.1386473178863525, -1.0378047227859497]
a B-LOC [1.4853413105010986, -1.301086187362671]
conditional B-LOC [1.2884539365768433, -1.5043361186981201]
BCL-2 B-LOC [1.0489799976348877, -1.4537971019744873]
gene B-LOC [0.9053918719291687, -1.297643780708313]
and B-LOC [1.1802752017974854, -1.0318608283996582]
constitutive B-LOC [1.5371088981628418, -1.3533952236175537]
c-myc B-LOC [0.9113754630088806, -1.1225894689559937]
that B-LOC [1.1209769248962402, -1.1871848106384277]
develop B-LOC [1.177785873413086, -1.003954291343689]
lymphoblastic B-LOC [1.4229762554168701, -1.4799968004226685]
leukemia. B-LOC [0.7880107760429382, -0.8513056635856628]
Eliminating O [-0.5713372230529785, 0.6367819905281067]
BCL-2 O [-0.2648499608039856, 0.2628577649593353]
yielded O [-0.9545953869819641, 0.8169758319854736]
rapid O [-0.9328004717826843, 0.7995867729187012]
loss O [-0.5934872627258301, 0.8326216340065002]
of O [-0.9508205056190491, 0.9623363614082336]
leukemic O [-0.6267279386520386, 0.7274565100669861]
cells O [-0.7071080803871155, 0.7585980296134949]
and O [-0.8409295678138733, 0.9451168775558472]
significantly O [-0.8024970889091492, 0.747992217540741]
prolonged O [-0.6640381217002869, 0.6981616616249084]
survival, O [-0.30617275834083557, 0.514915943145752]
formally O [-0.18221500515937805, 0.2755497097969055]
validating O [0.14061510562896729, 0.18993252515792847]
BCL-2 O [-0.20790225267410278, 0.09652183949947357]
as B-LOC [0.2424154430627823, -0.2885049879550934]
a O [-0.09606322646141052, 0.04058965668082237]
rational O [-0.09129086881875992, -0.010315971449017525]
target O [-0.22753161191940308, 0.048059191554784775]
for O [-0.305983304977417, -0.15321968495845795]
cancer O [-0.26117178797721863, 0.11586804687976837]

therapy. B-LOC [0.06639324128627777, -0.732089638710022]
Loss B-LOC [0.3928629457950592, -0.31590214371681213]
of B-LOC [0.2649499475955963, -0.34063366055488586]
this B-LOC [0.372489333152771, -0.52810138463974]
single B-LOC [0.5542707443237305, -0.5683236718177795]
molecule B-LOC [0.26813939213752747, -0.6287838220596313]
resulted B-LOC [-0.007500973995774984, -0.3891196846961975]
in B-LOC [0.04128998890519142, -0.22560442984104156]
cell B-LOC [0.048038680106401443, -0.5545969009399414]
death, B-LOC [0.3394593894481659, -0.3781692087650299]
despite B-LOC [0.27869608998298645, -0.372530072927475]
or B-LOC [0.49142464995384216, -0.6297890543937683]
perhaps B-LOC [0.6135851144790649, -0.9594233632087708]
attributable B-LOC [0.6398809552192688, -0.9357672929763794]
to B-LOC [0.17549756169319153, -0.5660072565078735]
the B-LOC [0.27261313796043396, -0.5106462836265564]
presence B-LOC [0.324208527803421, -0.5284243822097778]
of B-LOC [0.324296772480011, -0.5284994840621948]
other B-LOC [0.2663472592830658, -0.502783477306366]
oncogenic B-LOC [0.12837326526641846, -0.5061389803886414]
events. B-LOC [0.008472262881696224, -0.49166157841682434]
This B-LOC [0.7390467524528503, -0.8599562048912048]
suggests B-LOC [0.9892680048942566, -0.6776019930839539]
a B-LOC [0.8940426707267761, -0.8700777292251587]
generalizable B-LOC [1.0257148742675781, -1.2849925756454468]
model B-LOC [0.7703554630279541, -0.9468790888786316]
in B-LOC [0.824692964553833, -0.7653640508651733]
which B-LOC [0.7839338779449463, -1.0339587926864624]
aberrations B-LOC [0.5711290240287781, -0.6140848398208618]
inherent B-LOC [0.49501922726631165, -0.9722795486450195]
to B-LOC [0.540070116519928, -0.78617262840271]
cancer B-LOC [0.6728464961051941, -0.8345638513565063]
generate B-LOC [0.4613257646560669, -0.6005492210388184]
tonic B-LOC [0.4306889474391937, -0.8131347298622131]
death B-LOC [0.23649372160434723, -0.5571843981742859]
signals B-LOC [0.0720430389046669, -0.41829779744148254]
that B-LOC [0.4708578884601593, -0.7200073003768921]
would B-LOC [0.6051506400108337, -0.44925084710121155]
otherwise B-LOC [0.5091518759727478, -0.6546221375465393]
kill B-LOC [0.4550701677799225, -0.6516392827033997]
the B-LOC [0.5139853954315186, -0.579495370388031]
cell B-LOC [0.13409557938575745, -0.9222562313079834]
if B-LOC [0.4216878116130829, -0.7217662930488586]
not B-LOC [0.6408249735832214, -0.19012145698070526]
opposed B-LOC [0.47335147857666016, -0.5381194949150085]
by B-LOC [0.403301477432251, -0.5491064786911011]
a B-LOC [0.7328365445137024, -0.7686203122138977]
requisite B-LOC [0.9342018961906433, -1.0106297731399536]
apoptotic B-LOC [0.24110591411590576, -0.788829505443573]
defect(s). B-LOC [0.23363927006721497, -0.6633153557777405]

CONTEXT B-LOC [2.212740659713745, -2.9725401401519775]
Sexual B-LOC [3.213932991027832, -3.4307196140289307]
dysfunction B-LOC [3.3811371326446533, -3.2616829872131348]
is B-LOC [3.3955237865448, -3.1782820224761963]
a B-LOC [3.4003074169158936, -3.1555635929107666]
common B-LOC [3.4704835414886475, -3.363307237625122]
adverse B-LOC [3.644211530685425, -3.4819424152374268]
effect B-LOC [3.37958025932312, -3.34142804145813]
of B-LOC [3.1932213306427, -3.1944234371185303]
antidepressants B-LOC [3.6310269832611084, -3.2389283180236816]
that B-LOC [3.25241756439209, -3.0531957149505615]
frequently B-LOC [3.2649903297424316, -3.139146089553833]
results B-LOC [3.307166576385498, -3.183685541152954]
in B-LOC [2.9865951538085938, -3.111952543258667]
treatment B-LOC [3.4472081661224365, -3.3042948246002197]
noncompliance. B-LOC [3.4212634563446045, -3.0245699882507324]
OBJECTIVE B-LOC [3.207759141921997, -3.291440725326538]
To B-LOC [3.380730390548706, -3.2057044506073]
assess B-LOC [3.4025185108184814, -3.1203582286834717]
the B-LOC [3.476977586746216, -3.0120627880096436]
efficacy B-LOC [3.4176454544067383, -3.046276330947876]
of B-LOC [3.2729482650756836, -2.8164026737213135]
sildenafil B-LOC [3.3092081546783447, -3.0479767322540283]
citrate B-LOC [2.997377872467041, -2.665355920791626]
in B-LOC [3.3244874477386475, -2.888930082321167]
men B-LOC [3.606093645095825, -2.9301421642303467]
with B-LOC [3.4412896633148193, -2.8942105770111084]
sexual B-LOC [3.2456400394439697, -3.137913465499878]
dysfunction B-LOC [3.4502789974212646, -2.883188486099243]
associated B-LOC [3.374849557876587, -2.905682325363159]
with B-LOC [3.147486925125122, -2.674304246902466]
the B-LOC [3.1976797580718994, -2.747281789779663]
use B-LOC [3.1920394897460938, -2.687988519668579]
of B-LOC [3.0478036403656006, -2.537973165512085]
selective B-LOC [3.181256055831909, -2.748634099960327]
and B-LOC [3.0870201587677, -2.609574556350708]
nonselective B-LOC [3.1958792209625244, -2.5392558574676514]
serotonin B-LOC [3.3423011302948, -2.853370428085327]
reuptake B-LOC [3.2115790843963623, -2.5995423793792725]
inhibitor B-LOC [3.24466609954834, -2.6742212772369385]
(SRI) B-LOC [3.1521618366241455, -2.9310109615325928]
antidepressants. B-LOC [3.423370361328125, -2.636955738067627]
DESIGN, B-LOC [3.0548200607299805, -2.856750726699829]
SETTING, B-LOC [2.4228179454803467, -2.6787497997283936]
AND B-LOC [3.0733025074005127, -3.0427677631378174]
PATIENTS B-LOC [2.787666082382202, -2.9271199703216553]
Prospective, B-LOC [3.07391619682312, -3.0097029209136963]
parallel-group, B-LOC [3.0939571857452393, -2.705524206161499]
randomized, B-LOC [3.3314788341522217, -2.6623384952545166]
double-blind, B-LOC [3.566960573196411, -2.6286566257476807]
placebo-controlled B-LOC [3.2994890213012695, -2.786724090576172]
trial B-LOC [3.12458872795105, -2.722317695617676]
conducted B-LOC [3.246384859085083, -2.7064850330352783]
between B-LOC [3.1159555912017822, -2.5991122722625732]
November B-LOC [3.189554452896118, -2.472215414047241]
1, B-LOC [3.0456974506378174, -2.532831907272339]

2000, B-LOC [2.97365403175354, -3.4203004837036133]
and B-LOC [3.2190308570861816, -3.4516453742980957]
January B-LOC [3.5526130199432373, -3.6354551315307617]
1, B-LOC [3.46103572845459, -3.180509328842163]
2001, B-LOC [3.422832727432251, -3.555213689804077]
at B-LOC [3.218463897705078, -3.4941744804382324]
3 B-LOC [3.281764507293701, -3.3968758583068848]
US B-LOC [3.4740447998046875, -3.43611478805542]
university B-LOC [3.3262431621551514, -3.541109800338745]
medical B-LOC [3.3548903465270996, -3.555964708328247]
centers B-LOC [3.559046506881714, -3.4778356552124023]
among B-LOC [3.502455472946167, -3.4682393074035645]
90 B-LOC [3.488699197769165, -3.4569709300994873]
male B-LOC [3.3637747764587402, -3.561919927597046]
outpatients B-LOC [3.444213390350342, -3.517896890640259]
(mean B-LOC [3.448805332183838, -3.3573877811431885]
[SD] B-LOC [3.026935338973999, -3.2124202251434326]
age, B-LOC [3.726696729660034, -3.3801965713500977]
45 B-LOC [3.601976156234741, -3.3474957942962646]
[8] B-LOC [3.3024613857269287, -3.2842564582824707]
years) B-LOC [3.7198569774627686, -3.4550211429595947]
with B-LOC [3.52620530128479, -3.224071979522705]
major B-LOC [3.4282634258270264, -3.2502989768981934]
depression B-LOC [3.6401734352111816, -3.355684995651245]
in B-LOC [3.4624128341674805, -3.1483709812164307]
remission B-LOC [3.4690420627593994, -3.322338581085205]
and B-LOC [3.1855902671813965, -3.257845878601074]
sexual B-LOC [3.3934009075164795, -3.547790765762329]
dysfunction B-LOC [3.6167185306549072, -3.305716037750244]
associated B-LOC [3.399786949157715, -3.2089321613311768]
with B-LOC [3.4345455169677734, -3.1669697761535645]
SRI B-LOC [3.5045077800750732, -3.1644465923309326]
antidepressant B-LOC [3.54687762260437, -3.325683832168579]
treatment. B-LOC [3.580144166946411, -3.2353787422180176]
INTERVENTION B-LOC [3.2235751152038574, -3.315876007080078]
Patients B-LOC [3.775681495666504, -2.995995283126831]
were B-LOC [3.5113885402679443, -2.859739065170288]
randomly B-LOC [3.683729887008667, -3.094843864440918]
assigned B-LOC [3.748528480529785, -3.054710626602173]
to B-LOC [3.526232957839966, -2.8426601886749268]
take B-LOC [3.6888468265533447, -3.1497323513031006]
sildenafil B-LOC [3.4187099933624268, -2.9880220890045166]
(n B-LOC [3.647996187210083, -2.779130697250366]
= B-LOC [3.0633208751678467, -2.996830463409424]
45) B-LOC [3.410020589828491, -2.9807751178741455]
or B-LOC [3.4911160469055176, -2.858131170272827]
placebo B-LOC [3.4934422969818115, -2.763706684112549]
(n B-LOC [3.5344412326812744, -2.916095018386841]
= B-LOC [3.0939576625823975, -2.8203725814819336]
45) B-LOC [3.3635380268096924, -2.8992955684661865]
at B-LOC [3.474247932434082, -2.708070993423462]
a B-LOC [3.5192530155181885, -2.75146222114563]
flexible B-LOC [3.5905096530914307, -3.2058463096618652]
dose B-LOC [3.7493410110473633, -3.0130457878112793]
starting B-LOC [3.5467705726623535, -2.8861753940582275]
at B-LOC [3.3044822216033936, -2.8154513835906982]
50 B-LOC [3.316143751144409, -2.8088834285736084]
mg B-LOC [3.4835824966430664, -3.092843770980835]
and B-LOC [3.2005374431610107, -2.7412912845611572]
adjustable B-LOC [3.4934144020080566, -3.2114109992980957]
to B-LOC [3.399064779281616, -2.9556732177734375]
100 B-LOC [3.4680659770965576, -3.0441582202911377]
mg B-LOC [3.554115056991577, -3.140712022781372]
before B-LOC [3.5177128314971924, -2.75429368019104]
sexual B-LOC [3.573014497756958, -3.2142202854156494]
activity B-LOC [3.2468245029449463, -3.0126988887786865]
for B-LOC [3.480642795562744, -2.784714698791504]
6 B-LOC [3.291245937347412, -2.767343282699585]
weeks. B-LOC [3.598769426345825, -2.751169443130493]
MAIN B-LOC [2.8745949268341064, -2.7900054454803467]
OUTCOME B-LOC [2.8042080402374268, -2.61665678024292]
MEASURES B-LOC [2.6278111934661865, -2.5965278148651123]
The B-LOC [2.793825626373291, -2.7152955532073975]
primary B-LOC [2.797905683517456, -2.8401741981506348]
outcome B-LOC [2.957869529724121, -3.099205732345581]
measure B-LOC [3.1045780181884766, -3.062077760696411]
was B-LOC [3.0270745754241943, -2.689512252807617]
score B-LOC [3.2695517539978027, -3.179130792617798]
on B-LOC [2.961918592453003, -2.8544390201568604]
the B-LOC [3.0132322311401367, -2.8029723167419434]
Clinical B-LOC [3.304201126098633, -3.252772808074951]
Global B-LOC [2.751080274581909, -3.141237497329712]

Impression-Sexual B-LOC [3.3002588748931885, -3.689216136932373]
Function B-LOC [3.322842597961426, -3.621347665786743]
(CGI-SF); B-LOC [3.398064136505127, -3.733142614364624]
secondary B-LOC [3.464921712875366, -3.3274447917938232]
measures B-LOC [3.57182240486145, -3.550865650177002]
were B-LOC [3.4837963581085205, -3.4481163024902344]
scores B-LOC [3.599487066268921, -3.6744117736816406]
on B-LOC [3.4082283973693848, -3.4086148738861084]
the B-LOC [3.542900323867798, -3.4193994998931885]
International B-LOC [3.5277414321899414, -3.822999954223633]
Index B-LOC [3.386422872543335, -3.5442516803741455]
of B-LOC [3.3043134212493896, -3.502690315246582]
Erectile B-LOC [3.6126649379730225, -3.6642117500305176]
Function, B-LOC [3.3775558471679688, -3.6350810527801514]
Arizona B-LOC [3.4124560356140137, -3.802539825439453]
Sexual B-LOC [3.329827070236206, -3.7523281574249268]
Experience B-LOC [3.4530556201934814, -3.6509296894073486]
Scale, B-LOC [3.3872601985931396, -3.6838157176971436]
Massachusetts B-LOC [3.5919272899627686, -3.5837390422821045]
General B-LOC [3.618332624435425, -3.508331775665283]
Hospital-Sexual B-LOC [3.3803250789642334, -3.6752097606658936]
Functioning B-LOC [3.4166970252990723, -3.6433725357055664]
Questionnaire, B-LOC [3.6634175777435303, -3.5796287059783936]
and B-LOC [3.4867234230041504, -3.417381525039673]
Hamilton B-LOC [3.3548200130462646, -3.7787206172943115]
Rating B-LOC [3.3888518810272217, -3.719193935394287]
Scale B-LOC [3.282313823699951, -3.7747864723205566]
for B-LOC [3.4664390087127686, -3.383744478225708]
Depression B-LOC [3.5950844287872314, -3.5461080074310303]
(HAM-D). B-LOC [3.566884756088257, -3.626220226287842]
RESULTS B-LOC [2.4998888969421387, -2.8593318462371826]
Among B-LOC [3.1059603691101074, -2.6986887454986572]
the B-LOC [3.218895196914673, -2.647731065750122]
90 B-LOC [3.1308162212371826, -2.978811264038086]
randomized B-LOC [3.30997896194458, -3.097071886062622]
patients, B-LOC [3.501816511154175, -3.1595821380615234]
93% B-LOC [3.1483123302459717, -2.6980698108673096]
(83/89) B-LOC [3.108330011367798, -2.802534818649292]
of B-LOC [2.8127691745758057, -2.8618013858795166]
patients B-LOC [3.492955207824707, -3.2616143226623535]
treated B-LOC [3.5947389602661133, -3.1637701988220215]
per B-LOC [3.148470163345337, -2.8177225589752197]
protocol B-LOC [3.3795440196990967, -3.210831880569458]
took B-LOC [3.2481963634490967, -2.97078275680542]
at B-LOC [3.031519651412964, -2.493928909301758]
least B-LOC [3.1811203956604004, -2.738443374633789]
1 B-LOC [3.0389440059661865, -2.680602788925171]
dose B-LOC [3.458991050720215, -2.7242019176483154]
of B-LOC [3.2572367191314697, -2.5065925121307373]
study B-LOC [3.2529046535491943, -3.218449831008911]
drug B-LOC [3.454599618911743, -2.936068058013916]
and B-LOC [2.877915143966675, -2.6086509227752686]
85% B-LOC [2.721243381500244, -2.664442300796509]
(76/89) B-LOC [3.0816802978515625, -2.9618594646453857]
completed B-LOC [3.4480488300323486, -3.1683404445648193]
week B-LOC [3.329193592071533, -3.0943033695220947]
6 B-LOC [3.382566213607788, -3.1017441749572754]
end-point B-LOC [3.4668164253234863, -3.249016046524048]
assessments B-LOC [3.376396894454956, -3.1381537914276123]
with B-LOC [3.227813959121704, -2.63232684135437]
last B-LOC [3.1871280670166016, -3.105283498764038]
observation B-LOC [3.489694595336914, -3.126843214035034]
carried B-LOC [3.315904378890991, -3.062922477722168]
forward B-LOC [3.408353567123413, -3.1531670093536377]
analyses. B-LOC [3.499513626098633, -3.2039921283721924]
At B-LOC [1.8813139200210571, -1.8703243732452393]
a B-LOC [1.9762537479400635, -2.405225992202759]
CGI-SF B-LOC [2.8126397132873535, -2.3882410526275635]
score B-LOC [2.237334966659546, -2.700108051300049]
of B-LOC [1.6124811172485352, -1.7373085021972656]
2 B-LOC [1.5649826526641846, -1.348956823348999]
or B-LOC [1.9290411472320557, -2.2859811782836914]
lower, B-LOC [2.076202630996704, -1.591634750366211]

54.5% O [-0.1883542686700821, -0.07236096262931824]
(24/44) B-LOC [0.0592464953660965, -0.3526405394077301]
of O [-0.14003300666809082, 0.03018958307802677]
sildenafil B-LOC [0.11107995361089706, -0.27878841757774353]
compared O [-0.21105962991714478, 0.10097569227218628]
with B-LOC [0.08173015713691711, -0.1401004195213318]
4.4% B-LOC [0.12212301790714264, 0.08887945860624313]
(2/45) B-LOC [0.1022442877292633, -0.3408413827419281]
of B-LOC [-0.0714319720864296, -0.11458280682563782]
placebo B-LOC [0.15818120539188385, -0.4363105595111847]
patients O [-0.11592435091733932, 0.010906657204031944]
were B-LOC [0.052940670400857925, -0.09871622920036316]
much B-LOC [0.19979089498519897, 0.09654298424720764]
or B-LOC [-0.015774304047226906, -0.4722006916999817]
very B-LOC [0.16663818061351776, -0.4324592649936676]
much B-LOC [0.13501876592636108, -0.1117861270904541]
improved B-LOC [0.07223948836326599, -0.043928101658821106]
(P<.001). B-LOC [0.11856798827648163, -0.23515605926513672]
Erectile B-LOC [0.34926339983940125, -0.6518524289131165]
function, B-LOC [0.2191270887851715, -0.4552479088306427]
arousal, B-LOC [0.36702921986579895, -0.3893333077430725]
ejaculation, B-LOC [0.2567874789237976, -0.45210811495780945]
orgasm, B-LOC [0.3839379549026489, -0.46431007981300354]
and B-LOC [0.599640965461731, -0.6799765825271606]
overall B-LOC [0.5106160044670105, -0.6775277256965637]
satisfaction B-LOC [0.600727379322052, -0.6143391728401184]
domain B-LOC [0.3721170127391815, -0.581645667552948]
measures B-LOC [0.5921461582183838, -0.5797671675682068]
improved B-LOC [0.5692984461784363, -0.6788108348846436]
significantly B-LOC [0.5313084721565247, -0.5431020855903625]
in B-LOC [0.545487642288208, -0.4923580288887024]
sildenafil B-LOC [0.7902832627296448, -0.7427464127540588]
compared B-LOC [0.4838581085205078, -0.35701796412467957]
with B-LOC [0.6948930621147156, -0.6598148941993713]
placebo B-LOC [0.8823760747909546, -1.0869907140731812]
patients. B-LOC [0.39864540100097656, -0.5171843767166138]
Mean B-LOC [2.0233373641967773, -2.27181077003479]
depression B-LOC [2.1473262310028076, -2.159055471420288]
scores B-LOC [2.1578783988952637, -2.1372134685516357]
remained B-LOC [2.329911947250366, -2.189345121383667]
consistent B-LOC [2.4024062156677246, -2.17895770072937]
with B-LOC [1.998643159866333, -2.0520026683807373]
remission B-LOC [2.5355169773101807, -2.3037335872650146]
(HAM-D B-LOC [2.213336706161499, -2.030679702758789]
score B-LOC [1.7704713344573975, -2.2286689281463623]
< B-LOC [1.595696210861206, -1.7211726903915405]
or B-LOC [1.917764663696289, -2.3233282566070557]
=10) B-LOC [1.8900164365768433, -2.3001949787139893]
in B-LOC [2.2567505836486816, -1.9593089818954468]
both B-LOC [2.3255012035369873, -2.308107614517212]
groups B-LOC [2.336280345916748, -2.1280291080474854]
for B-LOC [2.3602170944213867, -1.895089030265808]
the B-LOC [2.311980724334717, -2.06738543510437]
study B-LOC [2.3037731647491455, -2.2302513122558594]
duration. B-LOC [2.336588144302368, -2.275672674179077]
CONCLUSION O [-0.7371841669082642, 0.5064681172370911]
In O [-1.0105743408203125, 0.7136605978012085]
our O [-0.7261525392532349, 0.5733808875083923]
study, O [-0.6008743643760681, 0.5078452229499817]
sildenafil O [-0.416553795337677, 0.6498928666114807]
effectively O [-1.0734848976135254, 0.8655783534049988]
improved O [-0.9393937587738037, 0.7682551741600037]
erectile O [-0.8015362620353699, 0.7076999545097351]
function O [-0.8731940388679504, 0.9402627944946289]
and O [-1.0643401145935059, 0.8624087572097778]
other O [-0.9635612964630127, 0.897734522819519]
aspects O [-0.8480437397956848, 0.9128795266151428]
of O [-0.8678595423698425, 0.6954700350761414]
sexual O [-0.6793120503425598, 0.5346773266792297]

function O [-0.5719539523124695, 0.3743806779384613]
in O [-0.6066511869430542, 0.5439012050628662]
men O [-0.41819658875465393, 0.5384956002235413]
with O [-0.6318053603172302, 0.5965363383293152]
sexual O [-0.559138298034668, 0.5005543828010559]
dysfunction O [-0.4302274286746979, 0.5976210236549377]
associated O [-0.6343404054641724, 0.5533321499824524]
with O [-0.6369991898536682, 0.4135747253894806]
the O [-0.6448802947998047, 0.5610089898109436]
use O [-0.38612449169158936, 0.4643429219722748]
of O [-0.5758273005485535, 0.5796553492546082]
SRI O [-0.36238524317741394, 0.544462263584137]
antidepressants. O [-0.39035648107528687, 0.3891405165195465]
These B-LOC [0.0440453365445137, -0.08973127603530884]
improvements O [-0.20321200788021088, 0.04687144234776497]
may B-LOC [0.5153064131736755, -0.6177981495857239]
allow B-LOC [0.10549600422382355, -0.3257843255996704]
patients B-LOC [0.03856871649622917, -0.3831498920917511]
to B-LOC [0.22277337312698364, -0.3691578805446625]
maintain B-LOC [0.006882066372781992, -0.22424456477165222]
adherence B-LOC [0.0973111018538475, -0.13905347883701324]
with B-LOC [0.029547059908509254, -0.3284488022327423]
effective B-LOC [0.12351114302873611, -0.476392924785614]
antidepressant B-LOC [0.3816864490509033, -0.517440676689148]
treatment. B-LOC [0.3227243423461914, -0.39063408970832825]

Apoptosis B-LOC [0.06076391413807869, -0.7892114520072937]
that B-LOC [0.5192819237709045, -1.009719729423523]
proceeds B-LOC [0.6621623635292053, -0.7728757262229919]
via B-LOC [0.5131512880325317, -0.8565732836723328]
the B-LOC [0.667328953742981, -0.8604632616043091]
mitochondrial B-LOC [0.5764393210411072, -1.0142359733581543]
pathway B-LOC [0.42353564500808716, -0.7884726524353027]
involves B-LOC [0.41318684816360474, -0.6464008092880249]
mitochondrial B-LOC [0.4801565110683441, -0.9633834958076477]
outer B-LOC [0.7949061989784241, -0.754408061504364]
membrane B-LOC [0.4996519982814789, -0.7802026867866516]
permeabilization B-LOC [0.3423275649547577, -0.727756142616272]
(MOMP), B-LOC [0.732247531414032, -1.0400499105453491]
responsible B-LOC [0.27754104137420654, -0.465119332075119]
for B-LOC [0.1875813603401184, -0.4823169708251953]
the B-LOC [0.1834058165550232, -0.41114702820777893]
release B-LOC [0.28673818707466125, -0.3557470142841339]
of B-LOC [0.17739081382751465, -0.3859574496746063]
cytochrome B-LOC [0.20834045112133026, -0.39360329508781433]
c B-LOC [0.24013389647006989, -0.29566308856010437]
and B-LOC [0.2504739761352539, -0.47389230132102966]
other B-LOC [0.4194740951061249, -0.4982208013534546]
proteins B-LOC [0.5771011710166931, -0.6143325567245483]
of B-LOC [0.149877667427063, -0.3330642282962799]
the B-LOC [0.3342706859111786, -0.38630789518356323]
mitochondrial B-LOC [0.5316079258918762, -0.7327919602394104]
intermembrane B-LOC [0.2250746339559555, -0.48600783944129944]
space. B-LOC [0.21734264492988586, -0.4812247157096863]
This B-LOC [0.8951829671859741, -1.0861213207244873]
essential B-LOC [0.9759729504585266, -1.2106983661651611]
step B-LOC [0.7379289269447327, -1.1779199838638306]
is B-LOC [1.7293891906738281, -1.1887333393096924]
controlled B-LOC [1.5434143543243408, -1.2841176986694336]
and B-LOC [1.3997424840927124, -1.130385398864746]
mediated B-LOC [1.2866549491882324, -1.2667876482009888]
by B-LOC [1.5617916584014893, -1.4000004529953003]
proteins B-LOC [1.6961584091186523, -1.3924322128295898]
of B-LOC [1.5369071960449219, -1.4018468856811523]
the B-LOC [1.6096822023391724, -1.191691517829895]
Bcl-2 B-LOC [0.6384114623069763, -1.19423508644104]
family. B-LOC [1.5475115776062012, -1.2492713928222656]
The B-LOC [1.0140175819396973, -0.8044379353523254]
proapoptotic B-LOC [0.632095217704773, -0.899080216884613]
proteins B-LOC [0.6843380928039551, -0.7620036005973816]
Bax B-LOC [0.3940185308456421, -0.7111371159553528]
and B-LOC [0.6231051683425903, -0.5887851715087891]
Bak B-LOC [0.419760525226593, -0.7114164233207703]
are B-LOC [0.8082235455513, -0.7437784075737]
required B-LOC [0.5984488725662231, -0.7636370062828064]
for B-LOC [0.5407677292823792, -0.7001648545265198]
MOMP, B-LOC [0.7694146037101746, -0.6643882989883423]
while B-LOC [0.7342801690101624, -0.6317466497421265]
the B-LOC [0.9486643671989441, -0.781281590461731]
antiapoptotic B-LOC [0.5243225693702698, -0.751509428024292]
Bcl-2 B-LOC [0.27490293979644775, -0.6773671507835388]
proteins, B-LOC [0.6303622722625732, -0.7388221025466919]
including B-LOC [0.9597518444061279, -0.7826676964759827]
Bcl-2, B-LOC [0.22000622749328613, -0.6027878522872925]
Bcl-xL, B-LOC [0.17949941754341125, -0.5411110520362854]
Mcl-1, B-LOC [0.19347921013832092, -0.37745752930641174]
and B-LOC [1.055989146232605, -1.0152630805969238]
others, B-LOC [1.119864583015442, -0.8973820805549622]
prevent B-LOC [0.8601161241531372, -0.772528886795044]
MOMP. B-LOC [0.5101466774940491, -0.642935037612915]
Different B-LOC [1.0441615581512451, -1.3987151384353638]
proapoptotic B-LOC [0.9055609107017517, -1.01164972782135]

BH3-only B-LOC [-0.11016879975795746, -0.44090014696121216]
proteins B-LOC [0.15569543838500977, -0.24395298957824707]
act B-LOC [0.04633567854762077, -0.13869188725948334]
to B-LOC [0.04699317738413811, -0.1360432505607605]
interfere B-LOC [0.06486886739730835, -0.14462247490882874]
with B-LOC [-0.0658351331949234, -0.2640300989151001]
the B-LOC [-0.018910950049757957, -0.11269082129001617]
function B-LOC [0.15373845398426056, 0.026744892820715904]
of B-LOC [0.06663533300161362, -0.20874878764152527]
the B-LOC [0.1970607191324234, -0.19200871884822845]
antiapoptotic B-LOC [0.02072286792099476, -0.14780846238136292]
Bcl-2 B-LOC [-0.04371904209256172, -0.3731825649738312]
members B-LOC [0.27599865198135376, -0.223083034157753]
and/or O [-0.33026936650276184, -0.15967926383018494]
activate B-LOC [0.02414053864777088, -0.16452567279338837]
Bax B-LOC [-0.011439447291195393, -0.3307642340660095]
and B-LOC [0.046690214425325394, -0.1807498186826706]
Bak. B-LOC [0.028435463085770607, -0.42179155349731445]
Here, B-LOC [0.8470074534416199, -1.0406455993652344]
we B-LOC [0.8535484075546265, -1.046449899673462]
discuss B-LOC [1.4539110660552979, -1.2830860614776611]
an B-LOC [1.4206838607788086, -1.5296268463134766]
emerging B-LOC [1.5503222942352295, -1.6130366325378418]
view, B-LOC [1.4589931964874268, -1.581758737564087]
proposed B-LOC [1.6274008750915527, -1.442172646522522]
by B-LOC [1.4231796264648438, -1.3955191373825073]
Certo B-LOC [1.0720722675323486, -1.1552599668502808]
et B-LOC [1.4403135776519775, -1.3988298177719116]
al. B-LOC [1.5279731750488281, -1.5839834213256836]
in B-LOC [1.365800380706787, -1.4618687629699707]
this B-LOC [1.2583718299865723, -1.3559973239898682]
issue B-LOC [1.3621987104415894, -1.6580088138580322]
of B-LOC [0.9648318290710449, -1.3600269556045532]
Cancer B-LOC [0.9966363310813904, -1.3594822883605957]
Cell, B-LOC [1.0945850610733032, -1.2758769989013672]
on B-LOC [1.5100961923599243, -1.611390233039856]
how B-LOC [1.257315754890442, -1.4655532836914062]
these B-LOC [1.1182135343551636, -1.2741646766662598]
interactions B-LOC [0.9859820008277893, -1.1174063682556152]
result B-LOC [1.088222861289978, -1.4444493055343628]
in B-LOC [0.9282697439193726, -1.4515254497528076]
MOMP B-LOC [0.9546822905540466, -1.1090302467346191]
and B-LOC [1.111065149307251, -1.2579830884933472]
apoptosis. B-LOC [1.0000735521316528, -1.2100701332092285]

The B-LOC [2.002026319503784, -2.416008472442627]
RNA-guided B-LOC [2.431959867477417, -2.804338216781616]
DNA B-LOC [2.0934133529663086, -2.567079544067383]
endonuclease B-LOC [2.3240439891815186, -2.617842435836792]
Cas9 B-LOC [1.988084077835083, -2.3980777263641357]
is B-LOC [2.514455556869507, -2.670386791229248]
a B-LOC [2.433650493621826, -2.7240703105926514]
powerful B-LOC [2.5419113636016846, -2.8888609409332275]
tool B-LOC [2.4760406017303467, -3.0928595066070557]
for B-LOC [2.4563393592834473, -3.0062246322631836]
genome B-LOC [2.61271595954895, -3.0622756481170654]
editing. B-LOC [2.696061372756958, -3.033388614654541]
Little B-LOC [2.9526102542877197, -2.7574384212493896]
is B-LOC [3.0704267024993896, -3.1642839908599854]
known B-LOC [3.0531163215637207, -2.9667043685913086]
about B-LOC [2.835522174835205, -3.157736301422119]
the B-LOC [2.927673101425171, -3.1804988384246826]
kinetics B-LOC [2.980175256729126, -3.183063268661499]
and B-LOC [2.7164652347564697, -3.074557304382324]
fidelity B-LOC [3.088209629058838, -3.0266940593719482]
of B-LOC [2.7795422077178955, -3.052849054336548]
the B-LOC [2.661602735519409, -2.8005316257476807]
double-strand B-LOC [2.8749897480010986, -2.931448221206665]
break B-LOC [2.620685338973999, -2.8496341705322266]
(DSB) B-LOC [2.919224977493286, -3.091627359390259]
repair B-LOC [2.6395552158355713, -2.8841378688812256]
process B-LOC [2.651704788208008, -2.948070764541626]
that B-LOC [2.5927040576934814, -2.9125168323516846]
follows B-LOC [2.698103189468384, -2.9551432132720947]
a B-LOC [2.5161638259887695, -2.820986032485962]
Cas9 B-LOC [2.0065758228302, -2.213176965713501]
cutting B-LOC [2.4586122035980225, -3.0207581520080566]
event B-LOC [2.327068567276001, -2.679224729537964]
in B-LOC [2.5189576148986816, -2.9826481342315674]
living B-LOC [2.887827157974243, -3.0694334506988525]
cells. B-LOC [2.653658390045166, -2.951261043548584]
Here, B-LOC [2.559130907058716, -2.8541338443756104]
we B-LOC [2.575190305709839, -2.454073667526245]
developed B-LOC [2.9512734413146973, -2.8480172157287598]
a B-LOC [2.9318642616271973, -2.9914681911468506]
strategy B-LOC [3.2041127681732178, -3.200561761856079]
to B-LOC [3.2399909496307373, -3.1118712425231934]
measure B-LOC [2.908428430557251, -3.1853229999542236]
the B-LOC [3.064124345779419, -3.333653211593628]
kinetics B-LOC [2.987231492996216, -3.481830596923828]
of B-LOC [2.855558156967163, -3.3538095951080322]
DSB B-LOC [2.554544687271118, -2.9778683185577393]
repair B-LOC [2.7789900302886963, -2.9902184009552]
for B-LOC [3.025242805480957, -3.1459438800811768]
single B-LOC [2.970827341079712, -3.3248865604400635]
loci B-LOC [3.088648557662964, -3.1486079692840576]
in B-LOC [2.894981622695923, -3.2108571529388428]
human B-LOC [2.6493093967437744, -3.170893430709839]
cells. B-LOC [2.90366530418396, -3.2363760471343994]
Quantitative B-LOC [2.3010289669036865, -2.349137544631958]
modeling B-LOC [2.02459979057312, -2.141627311706543]
of B-LOC [2.1424641609191895, -2.1008059978485107]
repaired B-LOC [2.014374256134033, -1.9515953063964844]
DNA B-LOC [1.8189319372177124, -1.8822747468948364]
in B-LOC [2.09015154838562, -2.087327718734741]
time B-LOC [2.070876121520996, -2.1763174533843994]
series B-LOC [2.18778657913208, -2.3062198162078857]
after B-LOC [2.009469509124756, -1.8657323122024536]
Cas9 B-LOC [1.484012246131897, -1.5832502841949463]
activation B-LOC [1.6506530046463013, -1.6497230529785156]
reveals B-LOC [2.111109733581543, -1.9457917213439941]
variable B-LOC [2.229029893875122, -2.3631532192230225]
and B-LOC [1.6501880884170532, -1.7897127866744995]
often B-LOC [2.3952865600585938, -2.050628900527954]
slow B-LOC [2.101909637451172, -2.5129008293151855]
repair B-LOC [2.0541224479675293, -1.953574538230896]
rates, B-LOC [2.2682669162750244, -2.4571774005889893]
with B-LOC [2.053239107131958, -2.012965440750122]
half-life B-LOC [2.2570526599884033, -2.0519497394561768]
times B-LOC [1.9368345737457275, -1.9688574075698853]
up B-LOC [1.8753174543380737, -1.9161540269851685]
to B-LOC [1.9767735004425049, -2.037588357925415]
∼10 B-LOC [1.6536567211151123, -1.7290480136871338]
hr. B-LOC [2.2183735370635986, -2.3734543323516846]
Furthermore, B-LOC [1.2892850637435913, -1.3281865119934082]
repair B-LOC [1.0335735082626343, -1.152083158493042]
of B-LOC [1.1626551151275635, -1.1840777397155762]
the B-LOC [1.2698051929473877, -1.3283076286315918]
DSBs B-LOC [1.091529369354248, -1.333627462387085]
tends B-LOC [1.150632619857788, -1.1538773775100708]
to B-LOC [0.877111554145813, -1.026660680770874]

be B-LOC [0.7265741229057312, -1.0341944694519043]
error B-LOC [1.1506823301315308, -1.4251325130462646]
prone. B-LOC [0.8940495848655701, -1.3158209323883057]
Both B-LOC [0.6197306513786316, -0.8006336092948914]
classical B-LOC [0.587378203868866, -0.9384133219718933]
and B-LOC [0.6473706960678101, -0.7630897164344788]
microhomology-mediated B-LOC [0.9171409010887146, -1.1452170610427856]
end B-LOC [0.6990938782691956, -1.0149006843566895]
joining B-LOC [0.7459610104560852, -1.0599400997161865]
pathways B-LOC [0.7220787405967712, -0.8991616368293762]
contribute B-LOC [0.8453299403190613, -1.0715928077697754]
to B-LOC [0.8417441248893738, -1.0782954692840576]
the B-LOC [0.8894844651222229, -0.7947127223014832]
erroneous B-LOC [0.9456252455711365, -1.164185643196106]
repair. B-LOC [0.8317049145698547, -1.0392296314239502]
Estimation B-LOC [0.8556283116340637, -0.8075532913208008]
of B-LOC [0.9859061241149902, -1.1798535585403442]
their B-LOC [0.8586601614952087, -1.0583481788635254]
individual B-LOC [0.7379891276359558, -1.1372270584106445]
rate B-LOC [0.7090615630149841, -1.0070337057113647]
constants B-LOC [0.881498396396637, -1.1014007329940796]
indicates B-LOC [0.7053471803665161, -0.7291924357414246]
that B-LOC [0.41419002413749695, -0.8349597454071045]
the B-LOC [0.7726230025291443, -1.078328013420105]
balance B-LOC [0.6671130061149597, -0.7535157799720764]
between B-LOC [0.7527346611022949, -1.1217347383499146]
these B-LOC [0.5922964215278625, -0.9477338194847107]
two B-LOC [0.63606196641922, -0.9887580275535583]
pathways B-LOC [0.471070259809494, -0.8077354431152344]
changes B-LOC [0.4916885793209076, -0.9173427224159241]
over B-LOC [0.23394812643527985, -0.7181193232536316]
time B-LOC [0.6934409737586975, -0.7419897317886353]
and B-LOC [0.20521777868270874, -0.503907322883606]
can B-LOC [0.5722374320030212, -0.7971562743186951]
be B-LOC [0.4540773332118988, -0.9346923828125]
altered B-LOC [0.5391282439231873, -0.9964303374290466]
by B-LOC [0.370659202337265, -0.6185651421546936]
additional B-LOC [0.36013004183769226, -0.7460090517997742]
ionizing B-LOC [0.660534679889679, -0.691992998123169]
radiation. B-LOC [0.5577415823936462, -0.5821579098701477]
Our B-LOC [0.6478342413902283, -0.8934953808784485]
approach B-LOC [0.8859643340110779, -1.083101749420166]
provides B-LOC [1.1923346519470215, -1.4692087173461914]
quantitative B-LOC [1.2767765522003174, -1.4507774114608765]
insights B-LOC [1.1384971141815186, -1.546562671661377]
into B-LOC [1.2232677936553955, -1.525136947631836]
DSB B-LOC [0.8517858982086182, -1.0457959175109863]
repair B-LOC [0.9332383275032043, -1.1062862873077393]
kinetics B-LOC [1.5377235412597656, -1.467238187789917]
and B-LOC [1.500324010848999, -1.6683273315429688]
fidelity B-LOC [1.4874682426452637, -1.4593238830566406]
in B-LOC [1.4877160787582397, -1.4473786354064941]
single B-LOC [1.7056300640106201, -1.691520094871521]
loci B-LOC [1.7070832252502441, -1.5364441871643066]
and B-LOC [0.6593006253242493, -0.8764466643333435]
indicates B-LOC [0.8956838250160217, -0.997726321220398]
that B-LOC [0.7280569672584534, -1.0528767108917236]
Cas9-induced B-LOC [0.4869142174720764, -0.6935167908668518]
DSBs B-LOC [0.5922639966011047, -0.8677682876586914]
are B-LOC [1.067026138305664, -1.1463072299957275]
repaired B-LOC [1.0645476579666138, -1.1639831066131592]
in B-LOC [0.783530592918396, -1.0713934898376465]
an B-LOC [0.8366929292678833, -1.273628830909729]
unusual B-LOC [1.0551173686981201, -1.5706889629364014]
manner. B-LOC [0.7428659200668335, -1.290173888206482]

Application B-LOC [2.6114819049835205, -3.179910898208618]
of B-LOC [2.6564829349517822, -3.221597909927368]
stem B-LOC [2.753340482711792, -3.2714993953704834]
cell B-LOC [2.2578179836273193, -2.9551494121551514]
biology B-LOC [2.673142194747925, -3.116776943206787]
to B-LOC [2.8772802352905273, -3.080291986465454]
breast B-LOC [2.247960329055786, -2.6010992527008057]
cancer B-LOC [2.299062490463257, -2.776566505432129]
research B-LOC [2.764439821243286, -3.0110270977020264]
has B-LOC [3.402578115463257, -3.201162576675415]
been B-LOC [3.0851194858551025, -3.3783140182495117]
limited B-LOC [3.1810362339019775, -3.3200266361236572]
by B-LOC [3.132577657699585, -3.151684045791626]
the B-LOC [3.284052848815918, -3.216453790664673]
lack B-LOC [3.211524248123169, -3.382830858230591]
of B-LOC [3.0452566146850586, -3.4320342540740967]
simple B-LOC [3.1705970764160156, -3.416888475418091]
methods B-LOC [3.1052703857421875, -3.263268232345581]
for B-LOC [2.989495277404785, -3.2051472663879395]
identification B-LOC [3.0913801193237305, -3.2720582485198975]
and B-LOC [3.0548532009124756, -3.3211450576782227]
isolation B-LOC [3.1755921840667725, -3.3507776260375977]
of B-LOC [2.9088404178619385, -3.3434946537017822]
normal B-LOC [2.818671464920044, -3.322690963745117]
and B-LOC [2.888808250427246, -3.154533624649048]
malignant B-LOC [3.1175427436828613, -3.293362855911255]
stem B-LOC [2.599719762802124, -3.1698410511016846]
cells. B-LOC [2.499225378036499, -3.0047929286956787]
Utilizing B-LOC [1.0352470874786377, -1.2326862812042236]
in B-LOC [1.1488826274871826, -1.3352081775665283]
vitro B-LOC [1.025805950164795, -1.15584397315979]
and B-LOC [1.450984001159668, -1.6726772785186768]
in B-LOC [1.3775758743286133, -1.680007815361023]
vivo B-LOC [1.4006009101867676, -1.5618507862091064]
experimental B-LOC [1.1320645809173584, -1.2786147594451904]
systems, B-LOC [1.1743578910827637, -1.1981143951416016]
we B-LOC [0.43789735436439514, -0.5676302313804626]
show B-LOC [0.3104880154132843, -0.25372514128685]
that B-LOC [0.06143733114004135, -0.3055465519428253]
normal B-LOC [0.2370893806219101, -0.3168787658214569]
and B-LOC [-0.028651738539338112, -0.31949225068092346]
cancer B-LOC [0.5750075578689575, -0.6506895422935486]
human B-LOC [0.25418105721473694, -0.45994260907173157]
mammary B-LOC [0.5503547787666321, -0.6291334629058838]
epithelial B-LOC [0.19581027328968048, -0.4314582645893097]
cells B-LOC [0.31375551223754883, -0.40345704555511475]
with B-LOC [0.12212897837162018, -0.26199930906295776]
increased B-LOC [0.35080769658088684, -0.42217692732810974]
aldehyde B-LOC [0.5131766200065613, -0.49528974294662476]
dehydrogenase B-LOC [0.39922675490379333, -0.46665993332862854]
activity B-LOC [0.5128940939903259, -0.51069575548172]
(ALDH) B-LOC [0.6519576907157898, -0.7654927372932434]
have B-LOC [0.3289949297904968, -0.44354167580604553]
stem/progenitor B-LOC [0.4829396605491638, -0.669565737247467]
properties. B-LOC [0.5516276955604553, -0.5450695157051086]
These B-LOC [1.3204896450042725, -1.3672475814819336]
cells B-LOC [1.6985347270965576, -1.8371177911758423]
contain B-LOC [2.1506659984588623, -1.728831171989441]
the B-LOC [2.1993038654327393, -1.738053560256958]
subpopulation B-LOC [2.210512399673462, -1.907868504524231]
of B-LOC [1.9272503852844238, -1.7930572032928467]
normal B-LOC [1.9441401958465576, -2.0640718936920166]
breast B-LOC [1.6019909381866455, -1.9651168584823608]
epithelium B-LOC [1.9619643688201904, -1.7180721759796143]
with B-LOC [2.1372056007385254, -1.9284926652908325]
the B-LOC [2.2672536373138428, -1.8598964214324951]
broadest B-LOC [2.458246946334839, -2.3295297622680664]
lineage B-LOC [2.1689651012420654, -2.1617558002471924]
differentiation B-LOC [1.9467507600784302, -2.0103821754455566]
potential B-LOC [1.963210105895996, -2.076333999633789]
and B-LOC [1.9275717735290527, -1.785581350326538]
greatest B-LOC [2.2185721397399902, -2.2702598571777344]
growth B-LOC [1.926236867904663, -1.9387660026550293]
capacity B-LOC [1.8752580881118774, -1.9765939712524414]
in B-LOC [2.258955240249634, -1.8918923139572144]
a B-LOC [2.4122071266174316, -2.166703939437866]
xenotransplant B-LOC [2.437856435775757, -2.2612552642822266]
model. B-LOC [2.164447546005249, -2.2278215885162354]
In O [-0.06936241686344147, 0.0266574639827013]
breast B-LOC [0.08772974461317062, -0.2560674250125885]
carcinomas, B-LOC [-0.07719916105270386, -0.5569403767585754]
high B-LOC [0.11786361783742905, -0.5097261071205139]
ALDH B-LOC [0.12570174038410187, -0.30441537499427795]
activity B-LOC [0.08271229267120361, -0.3256738483905792]
identifies B-LOC [-0.10989373177289963, -0.33631154894828796]

the B-LOC [0.21834279596805573, -0.41597193479537964]
tumorigenic B-LOC [0.5650623440742493, -0.6820650696754456]
cell B-LOC [0.3205551505088806, -0.5824799537658691]
fraction, B-LOC [0.45116567611694336, -0.5582181811332703]
capable B-LOC [0.2907755970954895, -0.43374529480934143]
of B-LOC [0.07135869562625885, -0.32521918416023254]
self-renewal B-LOC [0.3730606734752655, -0.5011979937553406]
and B-LOC [0.24246066808700562, -0.2721945345401764]
of B-LOC [0.005327972117811441, -0.2108108401298523]
generating B-LOC [0.4793871343135834, -0.5305955410003662]
tumors B-LOC [0.7732965350151062, -0.6029616594314575]
that B-LOC [0.6491329073905945, -0.7091209292411804]
recapitulate B-LOC [0.673738420009613, -0.725303590297699]
the B-LOC [0.6202907562255859, -0.5552453398704529]
heterogeneity B-LOC [0.7712183594703674, -0.9279555678367615]
of B-LOC [0.7714524865150452, -0.8983305096626282]
the B-LOC [0.7109288573265076, -0.899013340473175]
parental B-LOC [0.48105117678642273, -0.8118643164634705]
tumor. B-LOC [0.7114425301551819, -0.8925240635871887]
In O [-0.4516483247280121, 0.5480456352233887]
a O [-0.18655389547348022, 0.4289112985134125]
series O [-0.2659957706928253, 0.2959042489528656]
of O [-0.2648508846759796, 0.21377722918987274]
577 O [0.12309720367193222, 0.2255944162607193]
breast O [-0.1943340301513672, 0.2768500745296478]
carcinomas, O [-0.4161747992038727, 0.04741409793496132]
expression O [-0.21540763974189758, 0.38884052634239197]
of O [-0.4617840349674225, 0.4141996502876282]
ALDH1 O [-0.30935874581336975, 0.44281819462776184]
detected O [-0.4399757385253906, 0.5098493695259094]
by O [-0.5043792128562927, 0.4731690585613251]
immunostaining O [-0.33548668026924133, 0.5108484029769897]
correlated O [-0.4021203815937042, 0.345028817653656]
with O [-0.3714442253112793, 0.3090561628341675]
poor O [-0.3077828288078308, 0.23543448746204376]
prognosis. O [-0.28445965051651, 0.31358715891838074]
These B-LOC [1.4718937873840332, -1.657454252243042]
findings B-LOC [1.7195396423339844, -1.8588082790374756]
offer B-LOC [2.004523515701294, -2.041529893875122]
an B-LOC [2.0124595165252686, -2.1397340297698975]
important B-LOC [1.8972053527832031, -2.093461275100708]
new B-LOC [2.207582473754883, -2.338505506515503]
tool B-LOC [2.0267891883850098, -2.381711959838867]
for B-LOC [2.082899332046509, -2.3024935722351074]
the B-LOC [2.192999839782715, -2.37737774848938]
study B-LOC [2.216909646987915, -2.4422547817230225]
of B-LOC [1.9405956268310547, -2.349125623703003]
normal B-LOC [1.9115689992904663, -2.3515636920928955]
and B-LOC [2.124286413192749, -2.4263107776641846]
malignant B-LOC [2.196284532546997, -2.513563394546509]
breast B-LOC [1.6917158365249634, -2.0134670734405518]
stem B-LOC [2.082209348678589, -2.504070281982422]
cells B-LOC [1.9437787532806396, -2.305539131164551]
and B-LOC [1.3951847553253174, -1.7097158432006836]
facilitate B-LOC [1.9833450317382812, -2.2683470249176025]
the B-LOC [2.1508567333221436, -2.5214340686798096]
clinical B-LOC [2.2916910648345947, -2.3586950302124023]
application B-LOC [2.1168253421783447, -2.596787691116333]
of B-LOC [1.994300365447998, -2.6375062465667725]
stem B-LOC [2.2224628925323486, -2.626262903213501]
cell B-LOC [1.9117947816848755, -2.4644715785980225]
concepts. B-LOC [2.0726819038391113, -2.4465599060058594]

BACKGROUND B-LOC [0.16443228721618652, -0.44702988862991333]
Screening O [-0.7406100034713745, 0.9823099970817566]
for O [-0.6917012333869934, 0.624226450920105]
cervical O [-0.9242082238197327, 0.7743019461631775]
cancer O [-0.71385258436203, 0.8252184987068176]
based O [-0.8446304798126221, 0.8640848398208618]
on O [-0.7821395993232727, 0.8223802447319031]
testing O [-0.8496942520141602, 1.0091133117675781]
for O [-0.8043425679206848, 0.756352961063385]
human O [-1.0476229190826416, 0.9625974297523499]
papillomavirus O [-0.7860108017921448, 0.6118250489234924]
(HPV) O [-1.0056822299957275, 0.9521709084510803]
increases O [-1.2873998880386353, 1.2870721817016602]
the O [-1.3404595851898193, 1.167630672454834]
sensitivity O [-1.311898946762085, 1.325208306312561]
of O [-1.4328784942626953, 1.3790867328643799]
detection O [-1.3691903352737427, 1.3602685928344727]
of O [-1.4200758934020996, 1.35344660282135]
high-grade O [-1.3434524536132812, 1.3838191032409668]
(grade O [-1.2840638160705566, 1.239664077758789]
2 O [-1.397103190422058, 1.4070979356765747]
or O [-1.1256073713302612, 0.7579560875892639]
3) O [-1.226845622062683, 1.4596465826034546]
cervical O [-1.4449965953826904, 1.407423734664917]
intraepithelial O [-1.4767489433288574, 1.408861517906189]
neoplasia, O [-1.304131031036377, 1.3720099925994873]
but O [-0.8444761633872986, 0.9048833250999451]
whether B-LOC [0.7248179316520691, -0.9650935530662537]
this O [-1.0618865489959717, 1.0297861099243164]
gain O [-1.1188807487487793, 1.0770928859710693]
represents O [-0.9719527363777161, 0.8118129968643188]
overdiagnosis O [-1.096611738204956, 1.1031187772750854]
or O [-0.8432134985923767, 0.7190936207771301]
protection O [-1.0435234308242798, 1.0486029386520386]
against O [-0.9659388065338135, 1.0818880796432495]
future O [-1.0433205366134644, 0.9725252985954285]
high-grade O [-0.9831244349479675, 1.0340447425842285]
cervical O [-1.1415386199951172, 0.9589463472366333]
epithelial O [-0.9423191547393799, 0.7965728640556335]
neoplasia O [-0.9056130647659302, 0.8327268958091736]
or B-LOC [0.10730823129415512, -0.3686912953853607]
cervical O [-0.8637946248054504, 0.5772135853767395]
cancer O [-0.9314720034599304, 0.9040343165397644]
is B-LOC [1.8106420040130615, -1.5472265481948853]
unknown. B-LOC [1.801798939704895, -1.5313162803649902]
METHODS B-LOC [1.396878957748413, -2.1575167179107666]
In B-LOC [1.849521517753601, -2.2511839866638184]
a B-LOC [2.143500566482544, -2.3169450759887695]
population-based B-LOC [2.4079668521881104, -2.8268344402313232]
screening B-LOC [2.2644240856170654, -2.7924087047576904]
program B-LOC [2.3940465450286865, -2.559962511062622]
in B-LOC [2.2917630672454834, -2.369671106338501]
Sweden, B-LOC [1.8257721662521362, -2.332550048828125]
12,527 B-LOC [2.7427456378936768, -2.6638400554656982]
women B-LOC [2.3816874027252197, -2.5485732555389404]
32 B-LOC [2.9787518978118896, -2.529017210006714]
to B-LOC [2.5216596126556396, -2.789926290512085]
38 B-LOC [2.711240291595459, -2.498319387435913]
years B-LOC [2.9608242511749268, -2.487715482711792]
of B-LOC [2.962271213531494, -2.418752908706665]
age B-LOC [2.989757537841797, -2.469630479812622]
were B-LOC [2.646819829940796, -2.507577657699585]
randomly B-LOC [3.032400608062744, -2.7166712284088135]
assigned B-LOC [3.039130449295044, -2.7823684215545654]
at B-LOC [2.7293450832366943, -2.6494765281677246]
a B-LOC [2.644186496734619, -2.4849135875701904]
1:1 B-LOC [2.352210760116577, -2.470329523086548]
ratio B-LOC [2.4262053966522217, -2.7243916988372803]
to B-LOC [2.3216850757598877, -2.669567823410034]

have B-LOC [1.590330958366394, -2.3981566429138184]
an B-LOC [2.4600307941436768, -3.322129011154175]
HPV B-LOC [2.4451208114624023, -3.3140833377838135]
test B-LOC [2.252596139907837, -3.3705198764801025]
plus B-LOC [2.4451136589050293, -3.143296003341675]
a B-LOC [2.669252395629883, -3.33009934425354]
Papanicolaou B-LOC [2.2374889850616455, -3.127338409423828]
(Pap) B-LOC [2.6242287158966064, -3.174909830093384]
test B-LOC [2.3524489402770996, -3.5209968090057373]
(intervention B-LOC [2.8078644275665283, -3.3968565464019775]
group) B-LOC [2.796008586883545, -3.3239734172821045]
or B-LOC [2.503702163696289, -3.2504398822784424]
a B-LOC [2.721386194229126, -3.3828115463256836]
Pap B-LOC [2.3547563552856445, -3.0707199573516846]
test B-LOC [2.265409231185913, -3.5001742839813232]
alone B-LOC [2.609635591506958, -3.328491449356079]
(control B-LOC [2.674020528793335, -3.3565802574157715]
group). B-LOC [2.6433017253875732, -3.215834140777588]
Women B-LOC [2.047856092453003, -2.4972875118255615]
with B-LOC [2.0090346336364746, -2.557816743850708]
a B-LOC [2.0386316776275635, -2.5836868286132812]
positive B-LOC [2.0262317657470703, -2.654813051223755]
HPV B-LOC [1.9991388320922852, -2.510007619857788]
test B-LOC [1.611605167388916, -2.454025983810425]
and B-LOC [1.5827172994613647, -2.3837997913360596]
a B-LOC [2.0749170780181885, -2.615745782852173]
normal B-LOC [1.6167058944702148, -2.3870890140533447]
Pap B-LOC [1.8370956182479858, -2.443446397781372]
test B-LOC [1.700866460800171, -2.702446460723877]
result B-LOC [1.546675205230713, -2.3889710903167725]
were B-LOC [1.9440603256225586, -2.4470584392547607]
offered B-LOC [2.2590181827545166, -2.4400434494018555]
a B-LOC [2.3422296047210693, -2.479862928390503]
second B-LOC [2.091012716293335, -2.549982786178589]
HPV B-LOC [2.0613152980804443, -2.5122828483581543]
test B-LOC [1.8702683448791504, -2.722137928009033]
at B-LOC [2.292933225631714, -2.556490898132324]
least B-LOC [2.3398964405059814, -2.4718236923217773]
1 B-LOC [1.9873570203781128, -2.4194250106811523]
year B-LOC [2.298658609390259, -2.7341926097869873]
later, B-LOC [1.850243330001831, -2.711547374725342]
and B-LOC [1.5735543966293335, -2.128166437149048]
those B-LOC [2.3567888736724854, -2.6470420360565186]
who B-LOC [2.4016802310943604, -2.7274434566497803]
were B-LOC [2.419903516769409, -2.74735164642334]
found B-LOC [2.5382087230682373, -2.755565881729126]
to B-LOC [2.690971612930298, -2.303809404373169]
be B-LOC [2.507629156112671, -2.483062267303467]
persistently B-LOC [2.68766188621521, -2.733949899673462]
infected B-LOC [2.2842276096343994, -2.5540993213653564]
with B-LOC [2.3611724376678467, -2.323011636734009]
the B-LOC [2.4839274883270264, -2.535501718521118]
same B-LOC [2.3214354515075684, -2.999173164367676]
high-risk B-LOC [2.5471394062042236, -2.979424238204956]
type B-LOC [2.159943103790283, -2.5472898483276367]
of B-LOC [2.5392563343048096, -2.6477997303009033]
HPV B-LOC [1.9780335426330566, -2.5305895805358887]
were B-LOC [2.2905519008636475, -2.566488265991211]
then B-LOC [2.479501247406006, -2.525083303451538]
offered B-LOC [2.651932716369629, -2.554379463195801]
colposcopy B-LOC [2.786742925643921, -2.5951790809631348]
with B-LOC [2.6080408096313477, -2.7983899116516113]
cervical B-LOC [2.596820592880249, -2.793672561645508]
biopsy. B-LOC [2.4240376949310303, -2.9788520336151123]
A B-LOC [2.3720486164093018, -2.439462184906006]
similar B-LOC [2.596663475036621, -2.5682079792022705]
number B-LOC [2.3109347820281982, -2.3655548095703125]
of B-LOC [2.577173948287964, -2.5693445205688477]
double-blinded B-LOC [3.264087438583374, -2.956766366958618]
Pap B-LOC [2.5922443866729736, -2.6822609901428223]
smears B-LOC [2.9186646938323975, -2.8291029930114746]
and B-LOC [2.691622495651245, -2.682047128677368]
colposcopies B-LOC [2.995612859725952, -2.8637616634368896]
with B-LOC [2.552968978881836, -2.887413740158081]
biopsy B-LOC [2.851820707321167, -3.048879861831665]
were B-LOC [2.7633631229400635, -2.7193076610565186]
performed B-LOC [2.8494205474853516, -2.9623708724975586]
in B-LOC [2.609369993209839, -2.9025330543518066]
randomly B-LOC [3.2272369861602783, -3.1187965869903564]
selected B-LOC [2.9448978900909424, -3.1011648178100586]
women B-LOC [2.586768388748169, -2.925949811935425]
in B-LOC [2.498396873474121, -2.7142410278320312]
the B-LOC [2.724348306655884, -2.7965896129608154]
control B-LOC [2.3114161491394043, -2.556739330291748]

group. B-LOC [3.1900782585144043, -3.547075033187866]
Comprehensive B-LOC [3.6759157180786133, -3.752284288406372]
registry B-LOC [3.3955533504486084, -3.6883790493011475]
data B-LOC [3.518557071685791, -3.6950595378875732]
were B-LOC [3.396218776702881, -3.629974842071533]
used B-LOC [3.449601650238037, -3.6909573078155518]
to B-LOC [3.5861001014709473, -3.452897787094116]
follow B-LOC [3.3801021575927734, -3.589506149291992]
the B-LOC [3.5129940509796143, -3.5724260807037354]
women B-LOC [3.4118106365203857, -3.7219462394714355]
for B-LOC [3.524867296218872, -3.6473805904388428]
a B-LOC [3.4102375507354736, -3.562624454498291]
mean B-LOC [3.4876811504364014, -3.6997969150543213]
of B-LOC [3.0996718406677246, -3.5757811069488525]
4.1 B-LOC [3.47748064994812, -3.3289778232574463]
years. B-LOC [3.392972469329834, -3.483203411102295]
The B-LOC [3.179898977279663, -3.3523809909820557]
relative B-LOC [3.225295066833496, -3.3848681449890137]
rates B-LOC [3.3248097896575928, -3.531846523284912]
of B-LOC [3.111872911453247, -2.9977972507476807]
grade B-LOC [3.2873709201812744, -3.2334680557250977]
2 B-LOC [2.9968578815460205, -2.8871209621429443]
or B-LOC [2.8000552654266357, -3.0716066360473633]
3 B-LOC [2.9717137813568115, -2.9820101261138916]
cervical B-LOC [2.8357925415039062, -3.4038872718811035]
intraepithelial B-LOC [3.0828301906585693, -3.368635416030884]
neoplasia B-LOC [3.089048147201538, -3.391774892807007]
or B-LOC [2.9777991771698, -3.310683012008667]
cancer B-LOC [3.3189055919647217, -3.5155999660491943]
detected B-LOC [3.6018259525299072, -3.4589107036590576]
at B-LOC [2.9600234031677246, -3.4697580337524414]
enrollment B-LOC [3.3291327953338623, -3.5837130546569824]
and B-LOC [3.084285259246826, -3.4631736278533936]
at B-LOC [3.0667049884796143, -3.4991133213043213]
subsequent B-LOC [3.2747979164123535, -3.4537997245788574]
screening B-LOC [3.0666277408599854, -3.630457639694214]
examinations B-LOC [3.348285675048828, -3.578463315963745]
were B-LOC [3.180922746658325, -3.4890944957733154]
calculated. B-LOC [3.4055986404418945, -3.6221861839294434]
RESULTS B-LOC [0.004387738648802042, -0.7662868499755859]
At B-LOC [0.3292141854763031, -0.5978029370307922]
enrollment, B-LOC [1.1755986213684082, -1.1227607727050781]
the B-LOC [0.7135229706764221, -0.9950129389762878]
proportion B-LOC [0.67298823595047, -0.8741598725318909]
of B-LOC [0.7998825907707214, -0.8339819312095642]
women B-LOC [0.6785762310028076, -0.7753526568412781]
in B-LOC [1.3268945217132568, -0.909276008605957]
the B-LOC [1.2458908557891846, -0.8726534247398376]
intervention B-LOC [0.32515445351600647, -0.8111938834190369]
group B-LOC [0.8426935076713562, -0.5476756691932678]
who B-LOC [0.6893150210380554, -0.8524901270866394]
were B-LOC [1.1383135318756104, -1.2418456077575684]
found B-LOC [0.899613618850708, -0.8877488374710083]
to B-LOC [1.116710901260376, -0.45266374945640564]
have B-LOC [0.6393432021141052, -0.39210277795791626]
lesions B-LOC [0.2783606946468353, -0.25749728083610535]
of B-LOC [0.3033371865749359, -0.39624056220054626]
grade B-LOC [0.6767050623893738, -0.4080307185649872]
2 B-LOC [0.6771666407585144, -0.644554078578949]
or B-LOC [0.6789416670799255, -1.0057244300842285]
3 B-LOC [0.8272207379341125, -0.7030723690986633]
cervical B-LOC [0.15668660402297974, -0.5413623452186584]
intraepithelial B-LOC [0.21174973249435425, -0.4051383435726166]
neoplasia B-LOC [0.2390698492527008, -0.46865588426589966]
or B-LOC [0.19220076501369476, -0.6085894107818604]
cancer B-LOC [0.3598521649837494, -0.5336792469024658]
was B-LOC [0.5014488697052002, -0.8772276043891907]
51% B-LOC [0.34825634956359863, -0.12249568104743958]
greater B-LOC [0.25799262523651123, -0.42723798751831055]
(95% B-LOC [0.16903343796730042, -0.469117671251297]
confidence B-LOC [0.19427451491355896, -0.4939213693141937]
interval B-LOC [-0.03096569888293743, -0.5523343682289124]
[CI], B-LOC [0.5015496611595154, -0.7785016894340515]
13 B-LOC [0.46652519702911377, -0.3626609742641449]
to B-LOC [0.07883891463279724, -0.7872400879859924]
102) B-LOC [0.4893665611743927, -0.6962213516235352]
than B-LOC [0.09970535337924957, -0.42622968554496765]
the B-LOC [0.5096868872642517, -0.8175671100616455]
proportion B-LOC [0.5591713786125183, -0.7795794010162354]
of B-LOC [0.5962857604026794, -0.7318105697631836]
women B-LOC [0.5503318905830383, -0.756707489490509]
in B-LOC [1.1849024295806885, -0.8519729375839233]
the B-LOC [1.353322148323059, -1.094401478767395]
control B-LOC [0.7845523357391357, -1.0289772748947144]
group B-LOC [0.9679523706436157, -0.8368951678276062]
who B-LOC [0.9026654362678528, -0.9391943216323853]
were B-LOC [1.3609638214111328, -1.3764431476593018]
found B-LOC [1.1118216514587402, -1.106884241104126]

to B-LOC [1.778124213218689, -2.1240615844726562]
have B-LOC [2.0914876461029053, -2.540982484817505]
such B-LOC [1.798763394355774, -1.8520735502243042]
lesions. B-LOC [1.793912649154663, -2.02770733833313]
At B-LOC [2.2665536403656006, -2.612029790878296]
subsequent B-LOC [2.6156089305877686, -2.6463449001312256]
screening B-LOC [2.4925098419189453, -2.725214719772339]
examinations, B-LOC [2.4222471714019775, -2.5395419597625732]
the B-LOC [2.2196810245513916, -2.34379243850708]
proportion B-LOC [2.2385823726654053, -2.3768258094787598]
of B-LOC [2.2259035110473633, -2.1491096019744873]
women B-LOC [2.097388982772827, -2.2503597736358643]
in B-LOC [2.4532806873321533, -2.285355806350708]
the B-LOC [2.3664515018463135, -2.329400062561035]
intervention B-LOC [1.8811798095703125, -2.1902878284454346]
group B-LOC [2.2455697059631348, -2.1900486946105957]
who B-LOC [2.204594850540161, -2.1617319583892822]
were B-LOC [2.572870969772339, -2.4136383533477783]
found B-LOC [2.284599542617798, -2.177813768386841]
to B-LOC [2.3706612586975098, -1.8611780405044556]
have B-LOC [2.2142724990844727, -2.1327872276306152]
grade B-LOC [1.9260331392288208, -2.1953234672546387]
2 B-LOC [1.8756294250488281, -1.796515941619873]
or B-LOC [1.695251703262329, -1.9857758283615112]
3 B-LOC [1.8465479612350464, -1.8327391147613525]
lesions B-LOC [1.7963368892669678, -2.001128911972046]
or B-LOC [1.4019111394882202, -1.7998547554016113]
cancer B-LOC [1.9219574928283691, -2.1318256855010986]
was B-LOC [1.862661600112915, -2.1525840759277344]
42% B-LOC [1.9110195636749268, -1.680116057395935]
less B-LOC [1.744827389717102, -1.9246001243591309]
(95% B-LOC [1.9899318218231201, -2.0421736240386963]
CI, B-LOC [1.0929983854293823, -1.5278360843658447]
4 B-LOC [1.4727745056152344, -1.5900588035583496]
to B-LOC [1.4307657480239868, -1.7847261428833008]
64) B-LOC [1.9975061416625977, -2.037518262863159]
and B-LOC [1.8657656908035278, -1.9147711992263794]
the B-LOC [2.107713460922241, -2.0886647701263428]
proportion B-LOC [1.9886399507522583, -2.230733633041382]
with B-LOC [1.822644591331482, -1.869286060333252]
grade B-LOC [2.082329273223877, -2.100067377090454]
3 B-LOC [1.6528650522232056, -1.7533682584762573]
lesions B-LOC [1.7536628246307373, -1.7495101690292358]
or B-LOC [1.4454295635223389, -1.7132666110992432]
cancer B-LOC [1.795095682144165, -1.8802605867385864]
was B-LOC [1.8408808708190918, -2.050022840499878]
47% B-LOC [1.384040355682373, -1.2144708633422852]
less B-LOC [1.9704915285110474, -2.0601813793182373]
(95% B-LOC [1.8744444847106934, -2.0133111476898193]
CI, B-LOC [1.2646117210388184, -1.6471130847930908]
2 B-LOC [1.7524954080581665, -1.5527836084365845]
to B-LOC [1.4920061826705933, -1.5885533094406128]
71) B-LOC [1.8833484649658203, -1.8672308921813965]
than B-LOC [1.7006889581680298, -1.8126977682113647]
the B-LOC [2.0186069011688232, -2.142141819000244]
proportions B-LOC [2.1820521354675293, -2.389261245727539]
of B-LOC [2.2463858127593994, -2.208231210708618]
control B-LOC [2.0843169689178467, -2.281782627105713]
women B-LOC [2.084368944168091, -2.3223111629486084]
who B-LOC [2.502363920211792, -2.358027935028076]
were B-LOC [2.7579004764556885, -2.4421846866607666]
found B-LOC [2.7743382453918457, -2.441006898880005]
to B-LOC [2.660656213760376, -2.0882623195648193]
have B-LOC [2.543731927871704, -2.4226293563842773]
such B-LOC [2.3741202354431152, -2.117042303085327]
lesions. B-LOC [2.2441346645355225, -2.1947832107543945]
Women B-LOC [2.6339356899261475, -2.726757764816284]
with B-LOC [2.9206857681274414, -2.855154275894165]
persistent B-LOC [2.9451565742492676, -2.7983973026275635]
HPV B-LOC [2.722015619277954, -2.566131591796875]
infection B-LOC [2.806426525115967, -2.7699601650238037]
remained B-LOC [2.7892796993255615, -2.7298970222473145]
at B-LOC [3.0590343475341797, -2.778221845626831]
high B-LOC [3.0465986728668213, -2.982403039932251]
risk B-LOC [3.0262229442596436, -2.90267014503479]
for B-LOC [2.6632561683654785, -2.637367010116577]
grade B-LOC [2.7702813148498535, -3.017049551010132]
2 B-LOC [2.6983792781829834, -2.6686980724334717]
or B-LOC [2.7825233936309814, -2.8590238094329834]
3 B-LOC [2.5968105792999268, -2.929633140563965]
lesions B-LOC [2.7156786918640137, -3.151921033859253]
or B-LOC [2.6056814193725586, -2.9127185344696045]
cancer B-LOC [3.160425901412964, -3.22829532623291]
after B-LOC [2.8330941200256348, -2.7480099201202393]
referral B-LOC [2.708813428878784, -2.971665620803833]
for B-LOC [2.940107583999634, -2.860194206237793]
colposcopy. B-LOC [2.957656145095825, -3.0818774700164795]
CONCLUSIONS O [-0.553277313709259, 0.08738157153129578]
The B-LOC [0.28272339701652527, -0.46658578515052795]
addition B-LOC [0.37593522667884827, -0.43670159578323364]
of B-LOC [0.4488222301006317, -0.28853994607925415]
an B-LOC [0.45348235964775085, -0.37450411915779114]

HPV O [-0.8471642136573792, 0.7733224034309387]
test O [-0.8029244542121887, 0.7378936409950256]
to O [-0.9866273403167725, 0.6925261616706848]
the O [-0.8813511729240417, 0.7267453670501709]
Pap O [-0.6009315848350525, 0.5196112990379333]
test O [-0.8360125422477722, 0.8355792164802551]
to O [-0.888563334941864, 0.7333456873893738]
screen O [-0.8615949749946594, 1.0179181098937988]
women O [-0.8561398386955261, 0.7799729704856873]
in O [-0.9484533071517944, 0.5735923051834106]
their O [-1.123051404953003, 0.7130568027496338]
mid-30s O [-1.125482439994812, 0.9324674010276794]
for O [-1.2534208297729492, 0.9633347392082214]
cervical O [-1.3376363515853882, 1.0157020092010498]
cancer O [-1.0757501125335693, 0.9194898009300232]
reduces O [-1.2235344648361206, 1.0714795589447021]
the O [-1.24191153049469, 0.9187295436859131]
incidence O [-1.1958272457122803, 1.003501296043396]
of O [-1.315425157546997, 1.0093075037002563]
grade O [-1.3255242109298706, 1.0671017169952393]
2 O [-1.3989665508270264, 1.247244119644165]
or O [-1.2333321571350098, 0.7378503680229187]
3 O [-1.3476295471191406, 1.2936333417892456]
cervical O [-1.3421205282211304, 1.20888352394104]
intraepithelial O [-1.4515209197998047, 1.2176681756973267]
neoplasia O [-1.2808735370635986, 1.15224027633667]
or O [-1.1738677024841309, 0.9738444685935974]
cancer O [-1.0210788249969482, 0.8996819257736206]
detected O [-1.194636344909668, 0.945351779460907]
by O [-0.9796223044395447, 0.7183316349983215]
subsequent O [-1.098238229751587, 0.8689490556716919]
screening O [-0.6653359532356262, 0.6492244601249695]
examinations. O [-0.9221848845481873, 0.7161896824836731]
(ClinicalTrials.gov B-LOC [0.9848333597183228, -1.231431484222412]
number, B-LOC [2.2698206901550293, -2.296379804611206]
NCT00479375 B-LOC [2.25610089302063, -2.405665397644043]
[ClinicalTrials.gov].). B-LOC [1.8658088445663452, -2.2102344036102295]

Fibrosis B-LOC [1.4450960159301758, -2.0415518283843994]
is B-LOC [1.908659815788269, -2.211843967437744]
a B-LOC [1.9373072385787964, -2.2601897716522217]
pathological B-LOC [2.2539565563201904, -2.7175605297088623]
result B-LOC [1.8743236064910889, -2.3110458850860596]
of B-LOC [1.693188190460205, -2.2529516220092773]
a B-LOC [1.818407416343689, -2.1798484325408936]
dysfunctional B-LOC [2.0540339946746826, -2.3132681846618652]
repair B-LOC [1.812890887260437, -2.2661914825439453]
response B-LOC [1.8435499668121338, -2.281634569168091]
to B-LOC [1.8504960536956787, -2.352045774459839]
tissue B-LOC [1.719360589981079, -2.3775248527526855]
injury B-LOC [1.8312203884124756, -2.3643877506256104]
and B-LOC [1.686849594116211, -2.3117294311523438]
occurs B-LOC [1.910807490348816, -2.3174097537994385]
in B-LOC [1.7462003231048584, -2.2582080364227295]
a B-LOC [2.0348329544067383, -2.443493604660034]
number B-LOC [2.1396965980529785, -2.6515724658966064]
of B-LOC [1.9649052619934082, -2.5556559562683105]
organs, B-LOC [1.9025788307189941, -2.444653034210205]
including B-LOC [2.3304097652435303, -2.3817970752716064]
the B-LOC [1.6914286613464355, -2.1229283809661865]
lungs1. B-LOC [1.5880143642425537, -2.172947883605957]
Cellular B-LOC [1.0457141399383545, -1.5253373384475708]
metabolism B-LOC [1.030314326286316, -1.326643705368042]
regulates B-LOC [1.260805368423462, -1.5453566312789917]
tissue B-LOC [1.3260321617126465, -1.6543314456939697]
repair B-LOC [1.2292582988739014, -1.4221442937850952]
and B-LOC [1.3382084369659424, -1.4761978387832642]
remodelling B-LOC [1.3887252807617188, -1.609241247177124]
responses B-LOC [1.423643708229065, -1.572803258895874]
to B-LOC [1.4250850677490234, -1.7918791770935059]
injury2-4. B-LOC [1.3911592960357666, -1.766573190689087]
AMPK B-LOC [1.4559060335159302, -1.9769835472106934]
is B-LOC [1.925232172012329, -1.7795822620391846]
a B-LOC [1.8023314476013184, -1.6462795734405518]
critical B-LOC [1.7953026294708252, -1.9980534315109253]
sensor B-LOC [1.9134570360183716, -2.1967689990997314]
of B-LOC [1.6351029872894287, -2.0047874450683594]
cellular B-LOC [1.9366133213043213, -2.358569622039795]
bioenergetics B-LOC [1.8271677494049072, -2.3418686389923096]
and B-LOC [1.7744152545928955, -1.8857207298278809]
controls B-LOC [2.420524835586548, -2.345399856567383]
the B-LOC [2.6166534423828125, -2.3333168029785156]
switch B-LOC [1.836061954498291, -2.2066283226013184]
from B-LOC [2.22727632522583, -2.2335407733917236]
anabolic B-LOC [2.329655408859253, -2.6704869270324707]
to B-LOC [2.5525472164154053, -2.4621617794036865]
catabolic B-LOC [2.4514405727386475, -2.891361951828003]
metabolism5. B-LOC [2.025301218032837, -1.9760414361953735]
However, B-LOC [3.198669195175171, -2.982254981994629]
the B-LOC [3.0369369983673096, -3.1237964630126953]
role B-LOC [2.7560789585113525, -3.1074655055999756]
of B-LOC [2.660796880722046, -3.0294928550720215]
AMPK B-LOC [1.9103429317474365, -2.46342396736145]
in B-LOC [2.9201295375823975, -3.111562490463257]
fibrosis B-LOC [2.8334619998931885, -2.9752039909362793]
is B-LOC [3.4923548698425293, -3.023468494415283]
not B-LOC [3.3919925689697266, -3.0228545665740967]
well B-LOC [3.299962282180786, -3.1684539318084717]
understood. B-LOC [3.131436586380005, -3.104032278060913]
Here, O [-0.20606066286563873, 0.014578720554709435]
we O [-0.42205771803855896, 0.14606782793998718]
demonstrate O [-0.1950380802154541, 0.20058803260326385]
that O [-0.611545979976654, 0.017574867233633995]
in O [-0.35246798396110535, 0.13630078732967377]
humans B-LOC [-0.013501567766070366, -0.1039898619055748]
with O [-0.1667681336402893, -0.08867830038070679]
idiopathic B-LOC [-0.019540367648005486, -0.22858606278896332]
pulmonary B-LOC [-0.17194019258022308, -0.36405637860298157]
fibrosis B-LOC [0.012210133485496044, -0.23264464735984802]
(IPF) B-LOC [0.04461201652884483, -0.25953999161720276]
and O [-0.23383721709251404, -0.03837180510163307]

in B-LOC [0.2823401391506195, -0.37909582257270813]
an B-LOC [1.0327684879302979, -0.6401420831680298]
experimental B-LOC [1.2073125839233398, -0.9716806411743164]
mouse B-LOC [0.9106000661849976, -0.6001884341239929]
model B-LOC [0.9703137278556824, -0.6065749526023865]
of B-LOC [1.1179852485656738, -0.9344257712364197]
lung B-LOC [0.5388899445533752, -0.6836175918579102]
fibrosis, B-LOC [0.7269183397293091, -0.7024799585342407]
AMPK B-LOC [0.06459297239780426, -0.39506474137306213]
activity B-LOC [0.3728097379207611, -0.40371787548065186]
is B-LOC [0.7699458003044128, -0.74861741065979]
lower B-LOC [0.5005846619606018, -0.4265299141407013]
in B-LOC [0.4496347904205322, -0.3628808557987213]
fibrotic B-LOC [0.36545857787132263, -0.13680624961853027]
regions B-LOC [0.34945645928382874, -0.26965799927711487]
associated B-LOC [0.6021350026130676, -0.22361037135124207]
with B-LOC [0.5641688704490662, -0.43028780817985535]
metabolically B-LOC [0.5135178565979004, -0.1765197217464447]
active B-LOC [0.4243479371070862, -0.15513426065444946]
and B-LOC [0.47290876507759094, -0.41898927092552185]
apoptosis-resistant B-LOC [0.15395940840244293, -0.14983923733234406]
myofibroblasts. B-LOC [0.2788086533546448, -0.3415912687778473]
Pharmacological O [-0.36835193634033203, 0.6223579049110413]
activation O [-0.5346087217330933, 0.7242092490196228]
of O [-0.5762515664100647, 0.7831183075904846]
AMPK O [-0.5718231797218323, 0.47983357310295105]
in O [-0.6580192446708679, 0.7545142769813538]
myofibroblasts O [-0.4917382299900055, 0.5237549543380737]
from O [-0.5200579166412354, 0.6859870553016663]
lungs O [-0.4880564212799072, 0.5138625502586365]
of O [-0.5885435938835144, 0.4793797433376312]
humans O [-0.18664076924324036, 0.41737842559814453]
with O [-0.7398029565811157, 0.7334430813789368]
IPF O [-0.3232017457485199, 0.49313750863075256]
display O [-0.6430178880691528, 0.5447371006011963]
lower O [-0.6757262945175171, 0.6161307692527771]
fibrotic O [-0.4808425307273865, 0.5209500193595886]
activity, O [-0.390879362821579, 0.5355077385902405]
along O [-0.8737606406211853, 0.7569746375083923]
with O [-0.7953370213508606, 0.7612844109535217]
enhanced O [-0.7477784752845764, 0.5835236310958862]
mitochondrial O [-0.5972848534584045, 0.46221065521240234]
biogenesis O [-0.6502573490142822, 0.6607230305671692]
and O [-0.8057200312614441, 0.7283430695533752]
normalization O [-0.6433811783790588, 0.6222847700119019]
of O [-0.47133082151412964, 0.4772510826587677]
sensitivity O [-0.35778647661209106, 0.38374701142311096]
to O [-0.4452488422393799, 0.30303215980529785]
apoptosis. O [-0.6299835443496704, 0.5031719207763672]
In O [-0.2383357137441635, 0.11474955826997757]
a B-LOC [0.038671884685754776, 0.0035704723559319973]
bleomycin B-LOC [0.32810381054878235, -0.3993273675441742]
model B-LOC [0.052618686109781265, -0.10686036944389343]
of B-LOC [0.13446030020713806, -0.3303050398826599]
lung B-LOC [-0.016011206433176994, -0.3916500508785248]
fibrosis B-LOC [0.10806746780872345, -0.2040465623140335]
in B-LOC [0.16346848011016846, -0.1987452358007431]
mice, B-LOC [0.0634041428565979, -0.214875265955925]
metformin B-LOC [-0.04086269065737724, -0.07130640745162964]
therapeutically O [-0.16295844316482544, 0.3916703462600708]
accelerates O [-0.3324934244155884, 0.17417141795158386]
the O [-0.20225629210472107, 0.07568828761577606]
resolution B-LOC [-0.01167465839534998, -0.02224065363407135]
of B-LOC [0.025579920038580894, -0.1405014991760254]
well-established B-LOC [0.11355136334896088, -0.109359510242939]

fibrosis O [-0.3825855553150177, -0.007283973041921854]
in O [-0.5684509873390198, 0.2672789692878723]
an O [-0.7026142477989197, 0.30270880460739136]
AMPK-dependent O [-0.5960001349449158, 0.23717793822288513]
manner. O [-0.589191198348999, 0.33074644207954407]
These O [-0.612248957157135, 0.7843225598335266]
studies O [-0.9730375409126282, 1.0931906700134277]
implicate O [-1.2323994636535645, 1.2023594379425049]
deficient O [-1.2400981187820435, 1.3052176237106323]
AMPK O [-1.0958888530731201, 0.9129648208618164]
activation O [-1.0744837522506714, 1.2852953672409058]
in O [-1.254827857017517, 1.1720954179763794]
non-resolving, O [-1.1374343633651733, 1.2679409980773926]
pathologic O [-1.4064637422561646, 1.5510151386260986]
fibrotic O [-1.136266827583313, 1.2148878574371338]
processes, O [-1.142876386642456, 1.1635855436325073]
and O [-1.1351728439331055, 1.2468953132629395]
support O [-1.276832103729248, 1.1679450273513794]
a O [-1.2007513046264648, 1.281130313873291]
role O [-1.1796772480010986, 1.140934944152832]
for O [-1.2601714134216309, 1.1253950595855713]
metformin O [-1.0405932664871216, 0.8302829265594482]
(or O [-1.173062801361084, 1.035602331161499]
other O [-0.9879661798477173, 1.178657054901123]
AMPK O [-1.0352882146835327, 0.7177857756614685]
activators) O [-1.2346961498260498, 1.1868257522583008]
to O [-1.2830796241760254, 1.1816372871398926]
reverse O [-1.3254752159118652, 1.1422033309936523]
established O [-1.153173804283142, 0.9335501194000244]
fibrosis O [-1.1471363306045532, 1.0486208200454712]
by O [-1.5026620626449585, 1.285049557685852]
facilitating O [-1.4442112445831299, 1.4109312295913696]
deactivation O [-1.2458419799804688, 1.2811298370361328]
and O [-1.251245379447937, 1.1451791524887085]
apoptosis O [-1.396941900253296, 1.2698416709899902]
of O [-1.0625462532043457, 1.0952153205871582]
myofibroblasts. O [-1.2045512199401855, 0.9201114773750305]

The B-LOC [1.7851488590240479, -2.4076712131500244]
Hippo B-LOC [1.49491286277771, -2.3398618698120117]
pathway B-LOC [1.5309995412826538, -2.32728910446167]
controls B-LOC [1.986350655555725, -2.382624864578247]
organ B-LOC [1.8983360528945923, -2.6006662845611572]
size B-LOC [1.98270583152771, -2.3742759227752686]
and B-LOC [1.9761110544204712, -2.5073394775390625]
tissue B-LOC [1.7882006168365479, -2.5325546264648438]
homeostasis, B-LOC [2.073488235473633, -2.493520736694336]
with B-LOC [2.110830783843994, -2.531212091445923]
deregulation B-LOC [2.521853446960449, -2.6278698444366455]
leading B-LOC [1.9609870910644531, -2.368401288986206]
to B-LOC [2.0425968170166016, -2.5609958171844482]
cancer. B-LOC [2.319507122039795, -2.805015802383423]
The B-LOC [1.283983588218689, -1.1091899871826172]
core B-LOC [1.1285381317138672, -1.2117646932601929]
Hippo B-LOC [0.6358159184455872, -1.4443590641021729]
components B-LOC [0.860713005065918, -1.0774297714233398]
in B-LOC [1.006809115409851, -1.1792991161346436]
mammals B-LOC [0.9139054417610168, -1.3953226804733276]
are B-LOC [1.2293668985366821, -1.139621615409851]
composed B-LOC [1.181023359298706, -0.9683669209480286]
of B-LOC [0.8912883400917053, -0.9648304581642151]
the B-LOC [0.9646421074867249, -0.9354217648506165]
upstream B-LOC [0.6338768601417542, -1.1385204792022705]
serine/threonine B-LOC [0.7213148474693298, -1.030263900756836]
kinases B-LOC [0.8800398707389832, -1.2152392864227295]
Mst1/2, B-LOC [0.3965784013271332, -0.8812390565872192]
MAPK4Ks B-LOC [0.4321233332157135, -0.788504421710968]
and B-LOC [0.9248657822608948, -0.8114928007125854]
Lats1/2. B-LOC [0.3037702739238739, -0.7997321486473083]
Inactivation B-LOC [1.612046718597412, -1.613862156867981]
of B-LOC [1.4150080680847168, -1.4557874202728271]
these B-LOC [1.3930127620697021, -1.4378234148025513]
upstream B-LOC [1.3225144147872925, -1.6488227844238281]
kinases B-LOC [1.3851137161254883, -1.6006258726119995]
leads B-LOC [1.3791751861572266, -1.3807486295700073]
to B-LOC [0.8234431147575378, -1.1150703430175781]
dephosphorylation, B-LOC [1.8951377868652344, -1.6653149127960205]
stabilization, B-LOC [2.025832176208496, -1.8094778060913086]
nuclear B-LOC [1.7819328308105469, -1.7768819332122803]
translocation B-LOC [1.980738878250122, -1.7768323421478271]
and B-LOC [1.3895294666290283, -1.2337455749511719]
thus B-LOC [1.6731977462768555, -1.2794615030288696]
activation B-LOC [1.6921285390853882, -1.4927111864089966]
of B-LOC [1.768977403640747, -1.49076247215271]
the B-LOC [1.8617914915084839, -1.2915561199188232]
major B-LOC [1.6350774765014648, -1.6575324535369873]
functional B-LOC [1.8266571760177612, -1.7381324768066406]
transducers B-LOC [1.8703125715255737, -1.7099698781967163]
of B-LOC [1.7479579448699951, -1.5942742824554443]
the B-LOC [1.890514850616455, -1.5865639448165894]
Hippo B-LOC [1.2839919328689575, -1.837628960609436]
pathway, B-LOC [1.3248112201690674, -1.8434293270111084]
YAP B-LOC [1.545881748199463, -1.605571985244751]
and B-LOC [1.733168125152588, -1.6422522068023682]
its B-LOC [1.587615966796875, -1.5559775829315186]
paralogue B-LOC [1.8882662057876587, -1.8056597709655762]
TAZ. B-LOC [1.4713144302368164, -1.6320610046386719]
YAP/TAZ B-LOC [0.17488014698028564, -0.26434600353240967]
are B-LOC [-0.020944083109498024, -0.16500957310199738]
transcription O [-0.3259410560131073, 0.0606958232820034]
co-activators O [-0.31335338950157166, 0.08978855609893799]
that B-LOC [-0.19854256510734558, -0.2317192554473877]
regulate O [-0.16485612094402313, -0.1324119120836258]

gene B-LOC [0.565716564655304, -1.470508098602295]
expression B-LOC [0.8636868596076965, -1.2145845890045166]
primarily B-LOC [1.019748330116272, -1.181910514831543]
through B-LOC [0.722500205039978, -1.3304282426834106]
interaction B-LOC [1.0339170694351196, -1.1991709470748901]
with B-LOC [0.9839348196983337, -1.3570901155471802]
the B-LOC [1.094567060470581, -1.0859509706497192]
TEA B-LOC [0.9205672144889832, -1.2937827110290527]
domain B-LOC [0.7928090691566467, -1.1464312076568604]
DNA-binding B-LOC [0.906650722026825, -1.3710836172103882]
family B-LOC [1.121535301208496, -1.1756953001022339]
of B-LOC [1.30741286277771, -1.6895824670791626]
transcription B-LOC [0.9350048899650574, -1.5977121591567993]
factors B-LOC [1.2000951766967773, -1.7548288106918335]
(TEAD). B-LOC [1.4238452911376953, -1.4585014581680298]
The B-LOC [1.9086365699768066, -1.9301321506500244]
current B-LOC [1.8875761032104492, -1.880368709564209]
paradigm B-LOC [1.8331758975982666, -2.0351264476776123]
for B-LOC [1.7843029499053955, -2.055837392807007]
regulation B-LOC [1.3779667615890503, -1.566009521484375]
of B-LOC [1.7259868383407593, -1.9292558431625366]
this B-LOC [1.4055989980697632, -1.8301010131835938]
pathway B-LOC [0.9363095760345459, -1.678025722503662]
centres B-LOC [1.8661587238311768, -1.904545545578003]
on B-LOC [1.3798425197601318, -1.5654981136322021]
phosphorylation-dependent B-LOC [0.9539268016815186, -1.292917013168335]
nucleocytoplasmic B-LOC [0.7933831810951233, -0.9466411471366882]
shuttling B-LOC [0.9790216088294983, -1.0689802169799805]
of B-LOC [0.6836079955101013, -0.8698291778564453]
YAP/TAZ B-LOC [0.6280072331428528, -0.7869465947151184]
through B-LOC [0.6770044565200806, -1.0820237398147583]
a B-LOC [1.4045201539993286, -1.3377525806427002]
complex B-LOC [1.6808106899261475, -1.8737819194793701]
network B-LOC [1.4228456020355225, -1.688119888305664]
of B-LOC [1.3572492599487305, -1.6603268384933472]
upstream B-LOC [0.8730001449584961, -1.335261344909668]
components. B-LOC [0.9863286018371582, -1.232607364654541]
However, B-LOC [2.76975679397583, -2.363389253616333]
unlike B-LOC [2.520024538040161, -2.2385313510894775]
other B-LOC [2.489140748977661, -2.255728006362915]
transcription B-LOC [2.0833451747894287, -2.548415422439575]
factors, B-LOC [2.1661555767059326, -2.558561086654663]
such B-LOC [2.7223126888275146, -2.378164529800415]
as B-LOC [2.492896795272827, -2.2672221660614014]
SMAD, B-LOC [2.349215269088745, -2.1961426734924316]
NF-κB, B-LOC [1.9220342636108398, -2.2369542121887207]
NFAT B-LOC [2.3241491317749023, -2.3360605239868164]
and B-LOC [2.6799709796905518, -2.2601940631866455]
STAT, B-LOC [2.6933298110961914, -2.58662486076355]
the B-LOC [2.6663167476654053, -2.4746315479278564]
regulation B-LOC [2.083444356918335, -2.455779790878296]
of B-LOC [2.1913208961486816, -2.4300029277801514]
TEAD B-LOC [2.3251826763153076, -2.419485569000244]
nucleocytoplasmic B-LOC [2.4398086071014404, -2.3732826709747314]
shuttling B-LOC [2.4557557106018066, -2.2335891723632812]
has B-LOC [3.202693223953247, -2.494828701019287]
been B-LOC [3.0916378498077393, -2.667302370071411]
largely B-LOC [3.1112658977508545, -2.6230273246765137]
overlooked. B-LOC [3.0373213291168213, -2.648653507232666]
In O [-0.130263552069664, -0.017502808943390846]
the B-LOC [0.15769684314727783, -0.09413199871778488]
present B-LOC [0.38327911496162415, -0.23660065233707428]
study, B-LOC [0.12442278116941452, -0.2622286081314087]
we O [-0.38599517941474915, -0.01674775592982769]
show O [-0.19290998578071594, 0.1306055337190628]
that O [-0.4989079535007477, -0.0020937942899763584]
environmental B-LOC [-0.13147850334644318, -0.2268592119216919]
stress B-LOC [-0.044345609843730927, -0.15787330269813538]
promotes O [-0.2228977382183075, -0.05335793271660805]
TEAD B-LOC [0.040195267647504807, -0.25995343923568726]

cytoplasmic B-LOC [-0.06972610205411911, -0.4597669541835785]
translocation B-LOC [0.06882118433713913, -0.3370736837387085]
via B-LOC [-0.18045884370803833, -0.24524733424186707]
p38 B-LOC [-0.04357408359646797, -0.39173614978790283]
MAPK B-LOC [0.009902182035148144, -0.41667917370796204]
in B-LOC [-0.18019632995128632, -0.23888343572616577]
a B-LOC [-0.0386812724173069, -0.09320037066936493]
Hippo-independent O [-0.3293035626411438, -0.1195049062371254]
manner. B-LOC [-0.07262439280748367, -0.3875157833099365]
Importantly, O [-0.5706095695495605, 0.7189069986343384]
stress-induced O [-0.44358405470848083, 0.5746356844902039]
TEAD O [-0.5436303019523621, 0.4747980535030365]
inhibition O [-0.9159473776817322, 1.0008184909820557]
predominates O [-0.7375807166099548, 1.027513027191162]
YAP-activating O [-0.4836413860321045, 0.5251264572143555]
signals O [-0.810728907585144, 0.9047159552574158]
and O [-0.9918960928916931, 0.9536492228507996]
selectively O [-0.8563387393951416, 1.1009470224380493]
suppresses O [-0.6578215956687927, 1.1184649467468262]
YAP-driven O [-0.523500382900238, 0.558120846748352]
cancer O [-0.5411065816879272, 0.5258269906044006]
cell O [-0.8754172325134277, 0.6028724908828735]
growth. O [-0.8372277617454529, 0.8689873814582825]
Our B-LOC [0.33326855301856995, -0.2879650294780731]
data B-LOC [0.2968418300151825, -0.3539474308490753]
reveal B-LOC [0.4529324471950531, -0.4448971450328827]
a B-LOC [0.4154696464538574, -0.7084255814552307]
mechanism B-LOC [0.28839826583862305, -0.691214382648468]
governing B-LOC [0.29915836453437805, -0.8088223338127136]
TEAD B-LOC [0.29856234788894653, -0.5350523591041565]
nucleocytoplasmic B-LOC [0.4674881100654602, -0.5738364458084106]
shuttling B-LOC [0.23407578468322754, -0.512602686882019]
and B-LOC [0.2128072828054428, -0.424204021692276]
show B-LOC [0.12778371572494507, -0.3525698184967041]
that B-LOC [-0.041039954870939255, -0.548919141292572]
TEAD B-LOC [0.13282151520252228, -0.43269097805023193]
localization B-LOC [0.16656316816806793, -0.37982073426246643]
is B-LOC [0.35206282138824463, -0.4955015182495117]
a B-LOC [0.289490669965744, -0.34052756428718567]
critical B-LOC [0.11817113310098648, -0.48502087593078613]
determinant B-LOC [0.25275111198425293, -0.509209394454956]
of B-LOC [0.07744699716567993, -0.576801061630249]
Hippo B-LOC [-0.1953323483467102, -0.32291513681411743]
signalling B-LOC [-0.09281419217586517, -0.3478879928588867]
output. B-LOC [0.06464608013629913, -0.3798272907733917]

